<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
     xmlns:dc="http://purl.org/dc/elements/1.1/"
     xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
     xmlns:admin="http://webns.net/mvcb/"
     xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
     xmlns:content="http://purl.org/rss/1.0/modules/content/"
     xmlns:media="http://search.yahoo.com/mrss/">
<channel>
<title>Bersama Kita Sehat &#45; : Pharmaceutical</title>
<link>https://edusehat.com/en/rss/category/Pharmaceutical</link>
<description>Bersama Kita Sehat &#45; : Pharmaceutical</description>
<dc:language>en</dc:language>
<dc:rights>2025&#45;2055 PS Global Media &#45; Hak Cipta</dc:rights>

<item>
<title>Photonence expands its medical aesthetics portfolio</title>
<link>https://edusehat.com/en/photonence-expands-its-medical-aesthetics-portfolio</link>
<guid>https://edusehat.com/en/photonence-expands-its-medical-aesthetics-portfolio</guid>
<description><![CDATA[ 
Photonence is strengthening its market presence and expanding its portfolio across emerging segments of the medical aesthetics and wellness industry. Building on its strong position in skin lifting and tightening, the company is now looking to tap into newer opportunities in post-procedure care, stretch mark treatments and gynaecological aesthetics. The company currently has a presence […]
The post Photonence expands its medical aesthetics portfolio appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/20154509/Medical-Aesthetics.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 20 Nov 2026 18:15:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Photonence, expands, its, medical, aesthetics, portfolio</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/20154509/Medical-Aesthetics.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/20154509/Medical-Aesthetics.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/20154509/Medical-Aesthetics-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p align="LEFT"><a name="Bookmark"></a> <span><span><span>Photonence is strengthening its market presence and expanding its portfolio across emerging segments of the medical aesthetics and wellness industry. Building on its strong position in skin lifting and tightening, the company is now looking to tap into newer opportunities in post-procedure care, stretch mark treatments and gynaecological aesthetics.</span></span></span></p>
<p><span><span><span>The company currently has a presence in skin lifting and tightening, as well as body contouring. According to the company, skin lifting and tightening accounts for its largest share of business in India. Demand for body contouring treatments has also increased over the past few years, driven by interest in non-invasive and minimally invasive procedures.</span></span></span></p>
<p><span><span><span>In terms of geographical distribution, North India contributes approximately 40 per cent of the company’s market presence, followed by West and South India at around 25 per cent each. East India accounts for the remaining 10 per cent.</span></span></span></p>
<p><span><span><span>The medical aesthetics market has traditionally seen demand for procedures such as laser hair reduction and medi-facials. However, the range of treatments being considered by clinics and practitioners is expanding, with greater attention being paid to post-procedure recovery, skin health and patient outcomes.</span></span></span></p>
<p><span><span><span>Against this backdrop, Photonence is evaluating opportunities in post-procedure care, including technologies and solutions aimed at supporting recovery and reducing downtime following aesthetic procedures.</span></span></span></p>
<p align="LEFT"><span><span><span>Ashish Jha, Director-Marketing, Photonence India said, “The company is also evaluating expansion into stretch mark treatments and gynaecological aesthetics, including solutions addressing concerns such as post-menopausal vaginal dryness and intimate wellness”.</span></span></span></p>
<p align="LEFT"><span><span><span>With these strategic initiatives, Photonence aims to evolve from being an equipment provider in established aesthetics categories to a broader technology partner for clinics and medical practitioners. Its focus will remain on bringing advanced global technologies to India, enabling practitioners to expand their treatment offerings and making newer aesthetic and wellness solutions more accessible to the Indian market.</span></span></span></p>
<p>The post <a href="https://www.expresspharma.in/photonence-expands-its-medical-aesthetics-portfolio/">Photonence expands its medical aesthetics portfolio</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Advancing skin longevity through research and clinical validation</title>
<link>https://edusehat.com/en/advancing-skin-longevity-through-research-and-clinical-validation</link>
<guid>https://edusehat.com/en/advancing-skin-longevity-through-research-and-clinical-validation</guid>
<description><![CDATA[ 
What will the fresh investment enable in terms of research priorities, formulation development and clinical validation? The investment allows us to deepen our research capabilities, particularly in photobiology: understanding how different wavelengths of light interact with skin, and translating that knowledge into better photoprotection and care for pigmentation and skin ageing. We also want to […]
The post Advancing skin longevity through research and clinical validation appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/20160043/Dr-Renita-Rajan-Founder-CHOSEN.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 20 Nov 2026 18:15:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Advancing, skin, longevity, through, research, and, clinical, validation</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/20160043/Dr-Renita-Rajan-Founder-CHOSEN.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/20160043/Dr-Renita-Rajan-Founder-CHOSEN.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/20160043/Dr-Renita-Rajan-Founder-CHOSEN-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p align="LEFT"><span><span><span><b>What will the fresh investment enable in terms of research priorities, formulation development and clinical validation?</b></span></span></span></p>
<p align="LEFT"><span><span><span>The investment allows us to deepen our research capabilities, particularly in photobiology: understanding how different wavelengths of light interact with skin, and translating that knowledge into better photoprotection and care for pigmentation and skin ageing.</span></span></span></p>
<p align="LEFT"><span><span><span>We also want to strengthen the exchange of knowledge between CHOSEN and our partner clinics. Dermatologists bring observations from everyday practice, including unmet needs, treatment responses and the difficulties people have in sustaining a routine. Our research can investigate these questions and bring the findings back into clinical practice.</span></span></span></p>
<p align="LEFT"><span><span><span>The funding gives us greater capacity to connect these observations with formulation development and clinical validation. The Centre of Excellence is an important next step in making that exchange more systematic.</span></span></span></p>
<p align="LEFT"><span><span><span><b>How will the Centre of Excellence strengthen your R&D capabilities and support clinically validated formulations?</b></span></span></span></p>
<p align="LEFT"><span><span><span>The Centre of Excellence is intended to bring dermatologists more deeply into the research and development process, beginning with the questions we choose to investigate.</span></span></span></p>
<p align="LEFT"><span><span><span>A dermatologist’s contribution extends well beyond evaluating a finished product. It includes identifying a clinical need, helping define the formulation brief, selecting meaningful study outcomes and interpreting whether the benefit is useful in practice.</span></span></span></p>
<p align="LEFT"><span><span><span>We see this as a continuing exchange. Observations from partner clinics can inform our research priorities, while findings from our studies can support better informed product use and clinical protocols. It also creates opportunities to learn across different settings and populations.</span></span></span></p>
<p align="LEFT"><span><span><span>For CHOSEN, the aim is to build on our clinical foundation and develop more Indian authored research, with formulations shaped by the needs of the people who use them.</span></span></span></p>
<p align="LEFT"><span><span><span><b>How is the Indian cosmeceutical industry evolving in skin ageing, pigmentation and preventive skincare?</b></span></span></span></p>
<p align="LEFT"><span><span><span>The conversation is expanding from addressing an existing concern to understanding how skin changes over time and what we can do earlier. Prejuvenation is part of this shift: taking sensible preventive steps before changes become more established.</span></span></span></p>
<p align="LEFT"><span><span><span>An exposome lens makes this approach more relevant. Sun exposure, climate, pollution, sleep, stress and other influences form the context in which a skincare routine has to work. For Indian skin, this also means giving pigmentation, barrier health and tolerability greater attention within the ageing conversation.</span></span></span></p>
<p align="LEFT"><span><span><span>There is also a need for better options between everyday skincare and procedures. People may notice changes in firmness or facial contours and want to begin addressing them at home before they feel ready for a procedure. That is the space we are exploring with CHOSEN Sculpt. It gives people an earlier point of entry into care, with expectations driven from actual clinical studies.</span></span></span></p>
<p align="LEFT"><span><span><span><b>How is skin longevity changing R&D in active ingredients, formulation technologies and efficacy assessment?</b></span></span></span></p>
<p align="LEFT"><span><span><span>Skin longevity requires us to think about both the benefit and duration of exposure. If we are developing products that people may use for years, we need to ask how effectively they work now and how appropriate they are for sustained use.</span></span></span></p>
<p align="LEFT"><span><span><span>That brings safety over the long term, including the potential for endocrine disruption, into the research conversation. Ingredient selection needs to consider concentration, absorption, patterns of exposure and the available toxicological evidence, alongside efficacy. Formulation technologies should help us achieve a meaningful benefit with an appropriate exposure and tolerability profile.</span></span></span></p>
<p align="LEFT"><span><span><span>Our ambition is care that is effective today and remains safe throughout its intended use. That requires continuing assessment as evidence develops.</span></span></span></p>
<p align="LEFT"><span><span><span>Skinspan (the years skin remains healthy and functions well) only matters when lifespan (the total length of a person’s life) is factored into the thinking. It makes little sense for skin to look younger if the health of the rest of the body is being compromised. Maintaining the appearance and function of skin has to support the health of the whole person. That is the essence of the youthful <b>and</b> holistic longevity we pursue at CHOSEN.</span></span></span></p>
<p align="LEFT"><span><span><span><b>Which advanced actives have the potential to make a meaningful difference?</b></span></span></span></p>
<p align="LEFT"><span><span><span>Our work spans signalling peptides, plant extracts such as Pycnogenol®, DMAE and advances in photoprotection, including bemotrizinol. What interests me is how we can translate these ingredients into formulations that meet a specific clinical need.</span></span></span></p>
<p align="LEFT"><span><span><span>We introduced Pycnogenol® into India and have built the widest range of oral and topical formulations containing it, including several first and only offerings. This reflects our interest in taking well characterised molecules through thoughtful formulation development, to serve outcomes relevant to the Indian exposome.</span></span></span></p>
<p align="LEFT"><span><span><span>Innovation also comes from understanding where an established ingredient needs a different formulation. Even a familiar active such as tranexamic acid requires a distinct approach when we are developing a serum for pigmentation in sensitive skin damaged by steroid and skin lightening cream use. The formulation has to account for the compromised barrier, tolerability and the other ingredients that skin can comfortably accommodate. That is a different brief from using the same tranexamic acid in a multipurpose pigmentation serum.</span></span></span></p>
<p align="LEFT"><span><span><span>As a doctor, you begin with the person in front of you. Their needs guide the choice of ingredient, the formulation and how you assess its benefit. Everything we develop has to serve that person. The same thinking guides our work with signalling peptides, DMAE and sunscreen filters.</span></span></span></p>
<p align="LEFT"><span><span><span><b>What are the challenges in validating cosmeceuticals, and how can the industry strengthen evidence and safety?</b></span></span></span></p>
<p align="LEFT"><span><span><span>Clinical studies are one of CHOSEN’s strengths, and an area in which we intend to keep investing as a point of differentiation.</span></span></span></p>
<p align="LEFT"><span><span><span>Consumer research tells us whether a product is acceptable: whether people like its texture, find it comfortable and are willing to continue using it. Those findings matter because even a well designed formulation needs to fit into daily life. Clinical studies answer a further question: does the product deliver a meaningful, measurable benefit?</span></span></span></p>
<p align="LEFT"><span><span><span>That requires relevant endpoints, appropriate study parameters and a duration suited to the claim. A pigmentation claim needs pigmentation assessment; a firmness claim needs measures that can substantiate changes in firmness. Satisfaction alone cannot establish either.</span></span></span></p>
<p align="LEFT"><span><span><span>The industry can strengthen confidence by making the relationship between the study and the claim clearer, while assessing safety and tolerability with equal care. For us, clinical validation is part of product development, informing what we make, how we improve it and what we can responsibly say about it.</span></span></span></p>
<p>The post <a href="https://www.expresspharma.in/advancing-skin-longevity-through-research-and-clinical-validation/">Advancing skin longevity through research and clinical validation</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>SkinBB develops Vybie skin intelligence platform in India</title>
<link>https://edusehat.com/en/skinbb-develops-vybie-skin-intelligence-platform-in-india</link>
<guid>https://edusehat.com/en/skinbb-develops-vybie-skin-intelligence-platform-in-india</guid>
<description><![CDATA[ 
Platform combines environmental data, AI-led skin analysis and skincare tools to help consumers understand their skin and make informed choices
The post SkinBB develops Vybie skin intelligence platform in India appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2020/04/30183622/GettyImages-1179214915-e1763466693590.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 20 Nov 2026 18:15:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>SkinBB, develops, Vybie, skin, intelligence, platform, India</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="338" src="https://cdn.expresspharma.in/wp-content/uploads/2020/04/30183622/GettyImages-1179214915-e1763466693590.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async"></div><p><span>Skin Beyond Borders (SkinBB) is positioning Vybie, The Living Skin Intelligence<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley">, as a technology platform developed in India to help consumers understand their skin in relation to their individual characteristics and surrounding environment.</span></p>
<p><span>The platform brings together environmental intelligence, AI-led skin insights and skincare tools. It has been developed with Indian skin and local conditions in mind.</span></p>
<p><span>The launch comes amid an increase in demand for skincare products, treatments and routines during the wedding season. From brides and grooms preparing for their wedding to families seeking skincare recommendations, skin preparation often involves last-minute experimentation, trending products and advice from multiple sources, rather than an understanding of individual skin needs.</span></p>
<p><span>Through its Hyper Local-Hyper Personalised (HLHP) approach, Vybie connects environmental factors such as UV levels, humidity, temperature and air quality with individual skin information. Its selfie-based face analysis provides users with insights into their skin, while a 30-second daily skin log allows them to record changes and track their skin journey over time. The platform aims to help consumers move beyond generic skincare advice and make decisions based on their skin and location.</span></p>
<p><span>“Skin intelligence needs to go beyond identifying a skin concern or recommending a product. It is about understanding the relationship between an individual’s skin, the environment and the choices they make every day. With Vybie, we are bringing these elements together through an indigenous technology platform that aims to make skin understanding more contextual and personalised. Our larger vision is to build an ecosystem that helps consumers engage with their skin continuously, rather than only when a particular concern arises,” said Ajit Marathe, Founder and Chief Innovation Officer, Skin Beyond Borders (SkinBB).</span></p>
<p><span>Vybie’s ecosystem includes tools that address different aspects of the consumer skincare journey. The Skin Friendliness Index (SFI) uses environmental parameters to help users understand prevailing conditions and their potential relevance to skin health. LabelLooker enables consumers to examine skincare product ingredients, while Ingredipedia provides information on skincare ingredients.</span></p>
<p><span>These tools are complemented by SkinBB’s Product Review and Approval Committee (PRAC), which provides a product review layer, and a network of registered dermatologists who can offer guidance.</span></p>
<p><span>The technology is also being applied to consumer needs through initiatives such as the Vybie Glow Plus Plan, developed around the wedding journey. The plan aims to encourage couples to begin skin preparation early and access guidance from registered dermatologists. It is intended to help them make informed choices about routines, products and skincare concerns before the wedding and beyond.</span></p>
<p><span>SkinBB is also using Vybie as a foundation for consumer education and awareness initiatives. Its wedding-season campaign, ‘Haan Se, Honeymoon Tak’, uses three AI-animated films featuring a fictional couple, Riya and Kabir, to address the pressures and confusion surrounding wedding-related skin preparation.</span></p>
<p><span>Through humour and wedding situations, the films address last-minute skincare experimentation, advice from relatives and the pressure to achieve camera-ready skin. They also encourage consumers to seek informed guidance.</span></p>
<p><span>“Our focus is to make skin intelligence accessible and relevant to everyday consumers. With Vybie, we want people to look beyond products and understand the factors that influence their skin, from their immediate environment to their individual skin needs. Wedding season provides an opportunity to bring this conversation to the forefront, as people become more conscious of their appearance and skin preparation. Through our digital campaigns and experiential initiatives, we aim to simplify skin education and encourage consumers to make more informed choices. We see technology not just as a tool for personalisation, but also as a powerful way to build awareness and change how people engage with skincare,” said Supriya Marathe, Chief Marketing Officer, Skin Beyond Borders (SkinBB).</span></p>
<p><span>SkinBB’s vision is to develop Vybie into a Skin Intelligence Ecosystem connecting environmental data, individual skin insights, ingredient information, product evaluation and expert guidance. As the platform evolves, the focus is on building an understanding of skin over time and helping consumers make informed choices at different stages of their skincare journey.</span></p>
<p><span>By combining technology, expert inputs and consumer awareness, SkinBB aims to make skin intelligence part of everyday skincare and move the conversation from product-led experimentation towards an understanding of skin.</span></p>
<p>The post <a href="https://www.expresspharma.in/skinbb-develops-vybie-skin-intelligence-platform-in-india/">SkinBB develops Vybie skin intelligence platform in India</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Health Ministry proposes Good Storage and Distribution Practices under Drugs Rules, 1945</title>
<link>https://edusehat.com/en/health-ministry-proposes-good-storage-and-distribution-practices-under-drugs-rules-1945</link>
<guid>https://edusehat.com/en/health-ministry-proposes-good-storage-and-distribution-practices-under-drugs-rules-1945</guid>
<description><![CDATA[ 
Proposed GSDP framework aims to strengthen regulatory oversight, accountability and quality assurance across the pharmaceutical supply chain
The post Health Ministry proposes Good Storage and Distribution Practices under Drugs Rules, 1945 appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 20 Nov 2026 14:40:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Health, Ministry, proposes, Good, Storage, and, Distribution, Practices, under, Drugs, Rules, 1945</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>The Union Ministry of Health and Family Welfare has proposed the incorporation of Good Storage and Distribution Practices (GSDP) guidelines for pharmaceutical products into the Drugs Rules, 1945. The proposal aims to ensure that the quality, safety, efficacy and integrity of pharmaceutical products are maintained throughout the distribution chain, from the manufacturer or importer to the point of supply to the patient.</span></p>
<p><span>The proposed framework builds on the GSDP guidance developed by the Central Drugs Standard Control Organisation (CDSCO). The guidelines aim to ensure the quality and identity of pharmaceutical products at every stage of the distribution process, including procurement, purchasing, storage, distribution, transportation, documentation and record-keeping.</span></p>
<p><span>Maintaining appropriate storage and distribution conditions is essential to preserving the quality and integrity of pharmaceutical products beyond the manufacturing stage. The proposed GSDP framework seeks to address potential risks associated with their handling and movement across the supply chain, including deterioration, contamination, mix-ups, falsification, diversion and unauthorised distribution.</span></p>
<p><span>The incorporation of GSDP requirements into the Drugs Rules, 1945, is expected to strengthen the regulatory framework governing pharmaceutical distribution and support regulatory oversight, inspection and enforcement by the Central and State drug-control authorities. It will also promote documentation, record-keeping and traceability, while enhancing accountability among manufacturers, importers, wholesalers, distributors, stockists and other entities involved in the distribution process.</span></p>
<p><span>The proposed guidelines will further strengthen assurance that pharmaceutical products remain within specified quality and environmental conditions during storage and transportation. This is expected to reduce the risk of deterioration, contamination, mix-ups, falsification, diversion and unauthorised distribution, supporting the availability of pharmaceutical products of assured quality to patients and healthcare providers.</span></p>
<p><span>The proposed amendment represents a step towards strengthening India’s pharmaceutical quality-management system and ensuring that the quality established at the manufacturing stage is maintained throughout the supply chain until the product reaches the patient.</span></p>
<p><span>Stakeholders and members of the public have been invited to submit their objections and suggestions, if any, to the Under Secretary (Drugs Regulation), Ministry of Health and Family Welfare, Government of India, U-6, Work Hall, C Wing, First Floor, Kartavya Bhawan-1, New Delhi – 110001, or via email at drugsdiv-mohfw[at]gov[dot]in.</span></p>
<p>The post <a href="https://www.expresspharma.in/health-ministry-proposes-good-storage-and-distribution-practices-under-drugs-rules-1945/">Health Ministry proposes Good Storage and Distribution Practices under Drugs Rules, 1945</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Capitalism at the cost of healthcare</title>
<link>https://edusehat.com/en/capitalism-at-the-cost-of-healthcare</link>
<guid>https://edusehat.com/en/capitalism-at-the-cost-of-healthcare</guid>
<description><![CDATA[ 
Dr Suresh Saravdekar, Consultant – Healthcare and Pharmaceuticals highlights the Supreme Court&#039;s observations on medicine prices and examines Norway&#039;s National Health and Drug Policy as a model for India&#039;s drug pricing framework.
The post Capitalism at the cost of healthcare appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2022/06/07141645/Dr-Suresh-Saravdekar.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 20 Nov 2026 14:40:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Capitalism, the, cost, healthcare</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2022/06/07141645/Dr-Suresh-Saravdekar.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2022/06/07141645/Dr-Suresh-Saravdekar.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2022/06/07141645/Dr-Suresh-Saravdekar-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>The Supreme Court recently slammed the Union Government over steep mark-ups on essential medicines in India. The apex court bench comprising Justices Vikram Nath and Sandeep Mehta described such excessive hospital margins as “loot” and “dacoity”. The Court also questioned why the Union Government was reluctant to bring a wider range of medicines under price control. It observed that the Centre’s reliance on market forces and concerns regarding the growth of the pharma industry cannot justify leaving patients exposed to medicine prices that may be hundreds of times higher than the cost at which they were procured.</span></p>
<p><span>It is interesting to look at the arguments between the Court and the Union Government. The following are a few examples of these arguments, which reveal how casual and callous the government has been in taking action against firms and hospitals in this regard.</span></p>
<p><b>Supreme Court’s arguments</b></p>
<p><span>During the proceedings, the Supreme Court questioned the government’s approach towards medicine pricing and its emphasis on commerce and economic policy over the lives of citizens.</span></p>
<ul>
<li aria-level="1"><span>“You are talking only in the terms of commerce, economic policy, this is a matter in which economic policy will be supreme as compared to the life of the citizens at large?”</span></li>
<li aria-level="1"><span>“You are dealing with the lives of people, Don’t take it as a commerce. Treat it as a life of the poorest person of this country.”</span></li>
<li aria-level="1"><span>The bench also questioned the government’s reliance on innovation as a justification for allowing market forces to operate. A Justice asked, “to name a few molecules developed by the Indian Pharmaceutical industry in the preceding 30 years???”</span></li>
<li aria-level="1"><span>“You at the initial level fix the MRP right up to the moon. Then you increase by 10%. How does that make a difference?”</span></li>
<li aria-level="1"><span>He further questioned, “Your calibration is too wayward. Rs 11,000 to Rs 1,30,000 for cancer drug is no calibration… When you talk of patients and life, should we have such capitalistic thinking?”</span></li>
<li aria-level="1"><span>Further, the Court sought to know whether these considerations justified MRPs hundreds of times higher than procurement prices in tenders.</span></li>
</ul>
<p><span>Referring to the Centre’s recent decision in October 2026 to cap trade margins on anti-cancer drugs, the Court pointed out that the 30 per cent cap covered only a limited portion of the market, while nearly 90 per cent remained outside the price control mechanism.</span></p>
<p><span>The Court also questioned the government, asking, “Why is the DPCO not in place at all? Why the government is allowing this to happen. There have been three parliamentary committees on this. And their outcome is not very convenient to people who pull the strings.”</span></p>
<p><span>To put it succinctly, the Court has clearly concluded that there is a total failure on the part of regulatory control in two areas:</span></p>
<ol>
<li aria-level="1"><span>Proper selection of medicines for price control.</span></li>
<li aria-level="1"><span>Fixing of MRP by the manufacturer.</span></li>
</ol>
<p><span>The Court has also concluded that the reasons for this include a totally callous and casual attitude and a “not pro people but pro-industry approach” on the part of Indian regulatory authorities.</span></p>
<p><span>In this context, it is worthwhile to understand the world’s most successful National Health and Drug Policy of Norway.</span></p>
<p><b>National Health and Drug Policy of Norway – Role model for WHO</b></p>
<p><b>Basic concept – The Medical Need Clause: “Less is More” policy</b></p>
<p><span>This policy has been in place since 1938. In Norway, a new drug can only be registered if there is a “clear-cut medical need for any new product” and “new drugs should represent better therapeutic alternatives than those already on the market”.</span></p>
<p><span>This was called Behovsparagrafen – the Medical Need Clause (MNC). It still continues. The Director of Health could reject a drug even if it was approved in European countries such as the UK, France and Germany.</span></p>
<p><span>Although the industry describes this policy as a “dictatorship” model, it kept industry lobbying out.</span></p>
<p><span>Consequently, Norway had only around 1,800 drugs on the market, compared with more than 10,000 in Germany and France, which is ten times the number in Norway.</span></p>
<p><b>Salient features of Norway’s drug policy</b></p>
<ol>
<li aria-level="1"><b>Essentiality:</b><span> The selection of new drugs is based on “Public health need” and Health Technology Assessment, and not on the claims made by the industry.</span></li>
<li aria-level="1"><b>Changing disease burden:</b><span> The selection changes as healthcare needs change. For example, initially the focus was on TB, while now it includes cancer and diabetes.</span></li>
<li aria-level="1"><b>Efficacy and safety:</b><span> There must be unequivocal evidence regarding the quality of medicines, with global cGMP standards.</span></li>
<li aria-level="1"><b>Cost-effectiveness:</b><span> The total treatment cost, and not just the unit price, is compared with the tender price.</span></li>
<li aria-level="1"><b>Strict FDC policy:</b><span> Fixed-dose combinations (FDCs) are allowed only if they demonstrate a proven therapeutic advantage over a single drug. Combination drugs, for example antibiotics and vitamins, were rejected as “at best fraudulent and at worst dangerous”. FDCs of antimicrobials were kept off the market. Broad-spectrum antibiotics were viewed with suspicion from the late 1960s. That is why Norway still uses narrow-spectrum penicillin (phenoxymethyl-penicillin) as first-line treatment today and has the lowest antimicrobial resistance in Europe.</span></li>
</ol>
<p><span>Thus, for its Essential Medicines Policy, Norway has one of the oldest and most unique price control mechanisms. It introduced one of the strictest models in the world. This model was praised by WHO as an ideal rational drug policy and became a role model for the WHO Essential Medicines List from 1977. The WHO Essential Drug concept was actually inspired by Norway.</span></p>
<p><b>Comparison – India vs Norway</b></p>
<p><b>India</b></p>
<p><span>India has some of the cheapest generics in the world and uses the WHO model of Essential Medicines. However, it separates the framework into two parts.</span></p>
<p><b>NLEM List:</b><span> This is a list of essential medicines for public health, for which prices are controlled. However, availability is not controlled. As a result, many generic manufacturers stop manufacturing essential medicines because of low profit margins.</span></p>
<p><span>Ultimately, hospitals suffer because of the non-availability of life-saving medicines such as penicillins, tetracyclines, adrenaline and oxytocin.</span></p>
<p><span>In India, these medicines were once made available through government-run companies such as Hindustan Antibiotics, IDPL and Bengal Immunity, which are now non-functioning because of a lack of government support. Paradoxically, it is not surprising that the idle and unused space at IDPL is now used for the NPPA office.</span></p>
<p><b>Non-NLEM List:</b><span> The philosophy followed since 1970 has been, “You can sell, we will not fix price but monitor”. The approach is to promote competition and let the market decide prices for non-essential medicines. The idea was that more brands would automatically lead to lower prices.</span></p>
<p><span>However, in practice, this created brand proliferation because non-scheduled pricing is loosely controlled.</span></p>
<p><b>With the result:</b><span> Currently, there are only 935 scheduled formulations under ceiling price, covering 384 NLEM molecules, while a vast number of 85,000 to 100,000 formulations are actually in the market, often quoted at prices 60 to 100 times higher.</span></p>
<p><b>Norway</b></p>
<p><span>Norway does not separate medicines into NLEM and non-NLEM categories. The total number of medicines was only around 1,800 in the 1970s. Now, there are around 5,200 authorisations, but only around 1,200 to 1,500 are allowed for active marketing after tendering and substitution.</span></p>
<p><span>Price control is implemented through a national-level tendering system.</span></p>
<p><span>Norway follows the “Less is More” legacy. Until 1994, its law stated: “If there is already a drug that does same job, new one has NO medical need, it is, rejected”.</span></p>
<p><span>As a result, me-too drugs never entered the market. Even after 1994, the reimbursement rule states: “If we already have 3 ACE inhibitors, we will tender and only cheapest 1-2 will be reimbursed.” Therefore, effectively, all actively used drugs are under price control.</span></p>
<p><span>Secondly, Norway follows the WHO’s Aware antibiotic classification strictly. The goal is to achieve the lowest antibiotic resistance and high access with low spending.</span></p>
<p><b>India – Two gates: State and Central dual system</b></p>
<p><span>In India, CDSCO approves new drugs, but State FDA issues manufacturing licences.</span></p>
<p><span>Until 2022, states could approve generics without checking whether the same drug had already been approved centrally. As a result, the same molecule, such as paracetamol 650 mg, could receive licences in 28 states with 20 manufacturers in each state, resulting in 560 licences. Each could have a different brand name.</span></p>
<p><span>Data placed by DCGI in an affidavit in 2023 showed that there were more than 14,000 licences for paracetamol combinations.</span></p>
<p><span>Consequently, only 35 per cent of drugs are covered by public procurement through Jan Aushadhi and state medical corporations. The remaining 65 per cent is the private, out-of-pocket market, where the patient buys the brand prescribed by the doctor.</span></p>
<p><span>Therefore, price control is not on the MRP sticker.</span></p>
<p><b>Norway – One gate</b></p>
<p><span>Norway follows a single-agency system through NOMA. If EMA (European Medicines Agency) rejects a drug or NOMA says there is no therapeutic need, the drug cannot be sold anywhere in Norway. There is no state-level bypass.</span></p>
<p><span>Until 1994, the Medical Need Clause actively rejected all me-too drugs.</span></p>
<p><b>India – Quality of medicines</b></p>
<p><span>In India, all medicines are manufactured under the following two criteria:</span></p>
<ol>
<li><b> Three types of GMP (Good Manufacturing Practices):</b></li>
</ol>
<ol>
<li aria-level="1"><span>cGMP standards for marketing to developed countries such as the US and EU.</span></li>
<li aria-level="1"><span>WHO-GMP standards for marketing to developing countries.</span></li>
<li aria-level="1"><span>Domestic GMP, which has not been updated in line with current international standards and is intended to favour small and medium-scale industries.</span></li>
</ol>
<ol start="2">
<li><b> Three types of licences:</b></li>
<li><span>a) Own manufacturing and marketing licence.</span></li>
<li><span>b) Only marketing licence, with manufacturing outsourced under a loan licence.</span></li>
<li><span>c) Third-party licence.</span></li>
</ol>
<p><span>Consequently, the price of a particular medicine will vary with these three manufacturing standards and three types of licences.</span></p>
<p><b>Norway</b></p>
<p><span>All medicines are imported only if they meet cGMP manufacturing standards and have their own manufacturing licence.</span></p>
<p><b>3. India – DPCO market-based price</b></p>
<p><span>The formula is based on the average price of all brands with more than one per cent market share.</span></p>
<p><span>The incentive for the industry is to launch many brands at higher prices to increase the average. If there are 20 brands, the average price goes up and the ceiling price also increases.</span></p>
<p><span>The Supreme Court observed in 2013 that “DPCO incentivizes proliferation”.</span></p>
<p><b>Norway – Trinnpris</b></p>
<p><span>The prices of all medicines, irrespective of whether they are essential or non-essential, are controlled by comparing them with prices determined through the national-level tendering system.</span></p>
<p><b>Equity of access</b></p>
<p><span>Norway introduced Rural Availability Regulation 2023. According to this law, pharmaceutical companies must ensure that essential medicines are available in all regions, especially rural North Norway, and not just in the capital, Oslo.</span></p>
<p><b>Failure of Norway’s price control policy and lessons for India</b></p>
<p><span>Currently, a very specific problem is being faced in Sweden and Norway. It is not because the drugs do not work. It is because the drugs work too well and are too cheap.</span></p>
<p><span>Sweden and Norway are unique in that they have some of the lowest antibiotic resistance levels in Europe. Therefore, they still rely on old, narrow-spectrum penicillins such as phenoxymethylpenicillin (Penicillin V) and pivmecillinam as first-line treatments.</span></p>
<p><span>Phenoxymethylpenicillin is Norway’s most consumed antibiotic. However, these exact drugs are disappearing from the market.</span></p>
<p><span>The main reason is that the market is too small and too unprofitable. These are old, off-patent generics.</span></p>
<p><span>The second reason is dependence on external suppliers for essential medicines, as well as the vulnerability of supply chains in the event of economic or geopolitical crises.</span></p>
<p><span>Currently, up to 90 per cent of the antibiotics used globally are produced outside Europe, primarily in China and India. In India, some production also depends on chemical raw materials sourced from China.</span></p>
<p><b>Proposed model</b></p>
<p><span>To conclude, the current exorbitant and unaffordable prices of medicines in the Indian market can be controlled only if regulators think of a “Pro Public rather than Pro-Industry Policy”, based on the following principles:</span></p>
<ol>
<li aria-level="1"><b>Proper selection of both essential and non-essential medicines:</b><span> Selection should be based on “Real Health Needs” and not on “Artificial Market needs”. There should not be a dual price policy for these two classes.</span></li>
<li aria-level="1"><b>Price comparison:</b><span> Price comparison should be with international manufacturing standards such as WHO-GMP and own licences, and not with outsourced manufacturing.</span></li>
<li aria-level="1"><b>Sustaining production capacity:</b><span> While deciding the prices of essential medicines such as old antibiotics, low margins, unpredictable purchasing volumes and limited market opportunities should be considered positively for manufacturers. This will help them maintain and sustain their production capacity and invest in supply security.</span></li>
</ol>
<p>The post <a href="https://www.expresspharma.in/capitalism-at-the-cost-of-healthcare/">Capitalism at the cost of healthcare</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Schedule M: Govt proposes regulatory flexibility under three drug categories</title>
<link>https://edusehat.com/en/schedule-m-govt-proposes-regulatory-flexibility-under-three-drug-categories</link>
<guid>https://edusehat.com/en/schedule-m-govt-proposes-regulatory-flexibility-under-three-drug-categories</guid>
<description><![CDATA[ 
The Ministry clarified that the proposal does not dilute quality or safety standards or regulatory oversight.
The post Schedule M: Govt proposes regulatory flexibility under three drug categories appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/19162202/compliance.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 19 Nov 2026 20:45:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Schedule, Govt, proposes, regulatory, flexibility, under, three, drug, categories</media:keywords>
<content:encoded><![CDATA[<div><img width="800" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/19162202/compliance.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/19162202/compliance.jpg 800w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/19162202/compliance-300x150.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/19162202/compliance-768x384.jpg 768w" sizes="auto, (max-width: 800px) 100vw, 800px"></div><p data-pm-slice="1 1 []">The Union Ministry of Health and Family Welfare has proposed changes to the Drugs Rules, 1945, to provide regulatory flexibility under revised Schedule M for medicinal gases, empty gelatin capsules and disinfectant fluids.</p>
<p>The draft amendment, published as G.S.R. 985 (E) dated November 6, seeks to continue exemptions available to these products under Schedule M before its revision.</p>
<p>The proposal follows stakeholder representations on the applicability of revised Schedule M, notified through G.S.R. 922 (E) on December 28, 2023.</p>
<p>At its 93rd meeting on February 16, 2026, the Drugs Technical Advisory Board (DTAB) observed that some revised Schedule M requirements may not be relevant to the manufacturing processes of these products. It recommended continuing the exemptions available under the earlier Schedule M.</p>
<p>The proposed changes would allow Licensing Authorities to take product-specific decisions based on scientific and practical considerations, while aligning regulatory requirements with the nature of the products and their manufacturing processes.</p>
<p>The Ministry clarified that the proposal does not dilute quality or safety standards or regulatory oversight.</p>
<p>Stakeholders and members of the public can submit objections and suggestions within the prescribed period from the date of publication of the draft notification in the Official Gazette.</p>
<p>Submissions can be sent to the Under Secretary (Drugs), MoHFW, Kartavya Bhawan-1, New Delhi – 110011, or emailed to <a href="mailto:drugsdiv-mohfw@gov.in">drugsdiv-mohfw@gov.in</a>.</p>
<p>The post <a href="https://www.expresspharma.in/schedule-m-govt-proposes-regulatory-flexibility-under-three-drug-categories/">Schedule M: Govt proposes regulatory flexibility under three drug categories</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>From GMP compliance to workforce compliance: Why digital HR systems matter for pharma manufacturers</title>
<link>https://edusehat.com/en/from-gmp-compliance-to-workforce-compliance-why-digital-hr-systems-matter-for-pharma-manufacturers</link>
<guid>https://edusehat.com/en/from-gmp-compliance-to-workforce-compliance-why-digital-hr-systems-matter-for-pharma-manufacturers</guid>
<description><![CDATA[ 
As pharma operations become more complex, managing employee records, training, attendance and statutory requirements calls for greater accuracy and accountability. Sonali Chowdhry, CEO, OfficeNet, highlights how technology can bring greater visibility, consistency and control to workforce management
The post From GMP compliance to workforce compliance: Why digital HR systems matter for pharma manufacturers appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/19165236/Ms._Sonali_Chowdhry_-_CEO_-_Officenet-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 19 Nov 2026 20:45:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>From, GMP, compliance, workforce, compliance:, Why, digital, systems, matter, for, pharma, manufacturers</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/19165236/Ms._Sonali_Chowdhry_-_CEO_-_Officenet-1.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/19165236/Ms._Sonali_Chowdhry_-_CEO_-_Officenet-1.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/19165236/Ms._Sonali_Chowdhry_-_CEO_-_Officenet-1-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p align="JUSTIFY"><span><span><span lang="en-IN">Pharmaceutical manufacturing is among the most tightly regulated industries in the world. Quality, consistency and accountability define every stage of production. A single lapse can compromise patient safety, so nothing is left to chance. Cleanroom standards, process monitoring, documentation and batch traceability all sit within strict Good Manufacturing Practices (GMP). Yet while product quality commands most of the attention, workforce compliance deserves the same rigour.</span></span></span></p>
<p align="JUSTIFY"><span><span><span lang="en-IN">Pharma manufacturing runs on people as much as on processes and technology. Employees across production, quality control, packaging, warehousing and maintenance must follow defined protocols, hold the right training and work to approved procedures. People are as much a part of the control environment as any validated equipment. A gap in workforce management, whether in attendance records, training documentation, shift allocation or statutory compliance, does not stay contained. It creates operational friction and can weaken the wider compliance framework.</span></span></span></p>
<p align="JUSTIFY"><span><span><span lang="en-IN">That makes workforce compliance a natural extension of GMP. The right people must hold the right roles. Their working hours must be recorded accurately. Every employee record must be maintained systematically. Regulators expect this to be demonstrable, not assumed. The challenge grows sharply for organisations running multiple facilities, managing large workforces or engaging contract labour across production units.</span></span></span></p>
<p align="JUSTIFY"><span><span><span lang="en-IN">Manual HR processes were not built for this. Attendance registers, spreadsheets and disconnected systems produce inaccurate records, delayed reporting and limited visibility. Multiple shifts, overtime, leave, contractor attendance and payroll across sites only add to the complexity. Each gap is a potential point of exposure. Most important, fragmented documentation makes accurate workforce data hard to retrieve when an internal review or regulatory inspection demands it.</span></span></span></p>
<p align="JUSTIFY"><span><span><span lang="en-IN">Digital HR systems close these gaps by bringing workforce processes onto a single platform. Automated attendance tracking, shift scheduling, leave management and payroll processing deliver accuracy and consistency in employee records. Integrated contractor management and statutory compliance workflows give organisations firmer oversight of their extended workforce. Records stay current, consistent and ready for scrutiny.</span></span></span></p>
<p align="JUSTIFY"><span><span><span lang="en-IN">Training and skill management is equally critical. In a GMP setting, an untrained employee is a compliance risk. Employees must be competent to handle equipment, follow safety protocols and comply with standard operating procedures. Digital systems maintain training records, track certifications and surface training requirements. Gaps become easier to spot, and employees are better prepared for their responsibilities.</span></span></span></p>
<p align="JUSTIFY"><span><span><span lang="en-IN">The value extends beyond documentation. Real-time visibility into availability, shift allocation and labour deployment lets plant managers respond faster to production demands. Administrative bottlenecks shrink, departments coordinate better and workforce resources are used more efficiently. That efficiency compounds across shifts and sites.</span></span></span></p>
<p align="JUSTIFY"><span><span><span lang="en-IN">As manufacturers expand and regulatory expectations grow more complex, compliance can no longer stop at production and product quality. The systems that support the workforce must be accurate, transparent and accountable. Digital HR platforms provide the structure to deliver that, connecting people, processes and compliance in one framework. Strong compliance begins with the people who deliver it.</span></span></span></p>
<p align="JUSTIFY">
</p><p>The post <a href="https://www.expresspharma.in/from-gmp-compliance-to-workforce-compliance-why-digital-hr-systems-matter-for-pharma-manufacturers/">From GMP compliance to workforce compliance: Why digital HR systems matter for pharma manufacturers</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Indegene joins C&#45;CAMP&#45;Imperial Indo&#45;UK Life Science Corridor as first industry partner</title>
<link>https://edusehat.com/en/indegene-joins-c-camp-imperial-indo-uk-life-science-corridor-as-first-industry-partner</link>
<guid>https://edusehat.com/en/indegene-joins-c-camp-imperial-indo-uk-life-science-corridor-as-first-industry-partner</guid>
<description><![CDATA[ 
The partnership will focus on connecting research, entrepreneurship and industry, with initial priority areas including antimicrobial resistance, diagnostics, digital health, agritech, brain science and mental health.
The post Indegene joins C-CAMP-Imperial Indo-UK Life Science Corridor as first industry partner appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/19135738/Indegene-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 19 Nov 2026 17:10:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Indegene, joins, C-CAMP-Imperial, Indo-UK, Life, Science, Corridor, first, industry, partner</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/19135738/Indegene-1.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/19135738/Indegene-1.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/19135738/Indegene-1-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p>The Centre for Cellular and Molecular Platforms (C-CAMP) and Imperial College London have announced Indegene as the first industry partner of the Indo-UK Life Science Corridor, an initiative aimed at connecting research, entrepreneurship and industry to accelerate life sciences innovation between India and the UK.</p>
<p>Supported through the Imperial Global India initiative, the Corridor seeks to facilitate knowledge exchange, strengthen innovation ecosystems and create pathways for translating research into real-world applications. Under the partnership, Indegene, C-CAMP and Imperial College London will co-develop entrepreneurship programmes and support the exchange of knowledge and talent between the two countries.</p>
<p>As part of the collaboration, Indegene will help define industry challenges and support startup exchanges and ecosystem immersion programmes. The initial focus areas include antimicrobial resistance, diagnostics, digital health, agritech, brain science and mental health.</p>
<p>The announcement was made at the C-CAMP–Imperial joint roundtable on International Partnerships for AI Discovery and Innovation, convened under the Government of Karnataka’s Global Innovation Alliance initiative as part of the Bengaluru Tech Summit 2026.</p>
<p>“Global health challenges cannot be solved in isolation”, said Dr. Taslimarif Saiyed, CEO, C-CAMP. “This understanding was central to our vision for the Indo-UK Life Science Corridor, which connects the complementary innovation ecosystems of Imperial College London and C-CAMP to enable cross-border problem-solving. Exposure to both ecosystems will produce smarter, more scalable, and more accessible innovations relevant to both populations.”</p>
<p>Amanda Wolthuizen, Vice-President (Strategy), Imperial College London, said: “Welcoming Indegene as the first industry partner of the Indo-UK Life Sciences Innovation Corridor is an important moment for this partnership. When we launched the initiative with C-CAMP earlier this year, we wanted to create a platform where research, talent and industry could come together to accelerate new technologies and solve shared global challenges. Indegene’s expertise in life sciences make them an ideal first partner as we strengthen India-UK links and grow our network of industry collaborators.”</p>
<p>Dr. Saurabh Jain, Vice President – Global Delivery Centers, CSR, and Advocacy, Indegene, said, “The next decade of life sciences innovation will be defined by how well we connect science, talent, and industry across borders. This Corridor brings together the strengths of India and the UK, giving promising ideas a clearer path from discovery to real-world impact. The partnership reflects our continued commitment to support deep science, strengthen translation pathways, and help promising innovation reach scale.”</p>
<p>C-CAMP has supported more than 700 startups, which have collectively raised over $720 million and have a cumulative valuation of approximately $2.7 billion. It has enabled more than 6,000 research projects and trained over 2,200 scientific personnel. More than 420 life sciences products are in the market, while C-CAMP startups have filed 1,000 patents and supported over 300 publications. The technologies have reportedly reached more than 70 million lives.</p>
<p>Imperial College London launched Imperial Global India in 2025 to drive science and technology programmes through academic, industrial and innovation partnerships, facilitate two-way STEM talent exchange between India and the UK, and support its growing alumni network in India.</p>
<p>Indegene works across commercial, medical, R&D and safety operations for the life sciences industry. It combines life sciences expertise with AI-embedded platforms and operating models to support complex, regulated workflows for global biopharma companies.</p>
<p>The post <a href="https://www.expresspharma.in/indegene-joins-c-camp-imperial-indo-uk-life-science-corridor-as-first-industry-partner/">Indegene joins C-CAMP-Imperial Indo-UK Life Science Corridor as first industry partner</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Piramal Pharma moves to take full ownership of Yapan Bio</title>
<link>https://edusehat.com/en/piramal-pharma-moves-to-take-full-ownership-of-yapan-bio</link>
<guid>https://edusehat.com/en/piramal-pharma-moves-to-take-full-ownership-of-yapan-bio</guid>
<description><![CDATA[ 
The acquisition will take Piramal Pharma’s shareholding from 74 per cent to 100 per cent, subject to completion
The post Piramal Pharma moves to take full ownership of Yapan Bio appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2020/08/17145457/MA-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 19 Nov 2026 17:10:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Piramal, Pharma, moves, take, full, ownership, Yapan, Bio</media:keywords>
<content:encoded><![CDATA[<div><img width="888" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2020/08/17145457/MA-1.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2020/08/17145457/MA-1.jpg 888w, https://cdn.expresspharma.in/wp-content/uploads/2020/08/17145457/MA-1-300x135.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2020/08/17145457/MA-1-768x346.jpg 768w" sizes="(max-width: 888px) 100vw, 888px"></div><p>Piramal Pharma is moving towards full ownership of Yapan Bio. It has exercised its call option to acquire the remaining 26 per cent stake in the company.</p>
<p>The acquisition will take Piramal Pharma’s shareholding from 74 per cent to 100 per cent, subject to completion. The decision has been approved by the Administrative Committee of the Board of Directors.</p>
<p>Yapan Bio provides process development, characterisation and Phase I/II GMP manufacturing services for vaccines and biologics.</p>
<p>Piramal Pharma is in talks with the existing shareholders to complete the acquisition. The deal value and share transfer date are yet to be finalised.</p>
<p>The post <a href="https://www.expresspharma.in/piramal-pharma-moves-to-take-full-ownership-of-yapan-bio/">Piramal Pharma moves to take full ownership of Yapan Bio</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Pfizer, Starna Therapeutics enter exclusive licensing agreement for autoimmune diseases</title>
<link>https://edusehat.com/en/pfizer-starna-therapeutics-enter-exclusive-licensing-agreement-for-autoimmune-diseases</link>
<guid>https://edusehat.com/en/pfizer-starna-therapeutics-enter-exclusive-licensing-agreement-for-autoimmune-diseases</guid>
<description><![CDATA[ 
Starna to receive upfront payment of $330 million, eligible to receive up to $2.3 billion in milestone payments associated with certain development and commercial milestones, plus royalties on net sales of approved products
The post Pfizer, Starna Therapeutics enter exclusive licensing agreement for autoimmune diseases appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2020/02/12143653/agreement-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 19 Nov 2026 13:30:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Pfizer, Starna, Therapeutics, enter, exclusive, licensing, agreement, for, autoimmune, diseases</media:keywords>
<content:encoded><![CDATA[<div><img width="888" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2020/02/12143653/agreement-1.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2020/02/12143653/agreement-1.jpg 888w, https://cdn.expresspharma.in/wp-content/uploads/2020/02/12143653/agreement-1-300x135.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2020/02/12143653/agreement-1-768x346.jpg 768w" sizes="(max-width: 888px) 100vw, 888px"></div><p><span>Pfizer has entered into an exclusive licensing agreement with Starna Therapeutics, a biotechnology company developing RNA medicines designed to enable in vivo therapeutics. </span></p>
<p><span>Starna will receive an upfront payment of $330 million, and is eligible to receive up to $2.3 billion in milestone payments associated with certain development and commercial milestones, plus royalties on net sales of approved products.</span></p>
<p><span>Under the agreement, Pfizer obtains exclusive rights outside Greater China to develop, manufacture and commercialise three pre-IND in vivo chimeric antigen receptor T-cell (CAR-T) programmes that are focused on treating autoimmune diseases. </span></p>
<p><span>Pfizer will lead clinical development outside Greater China and plans to manufacture the finished drug product for the initial clinical trials using its facilities in theUS .</span></p>
<p><span>Pfizer will have sole and exclusive control over commercialisation outside of Greater China for all products. Pfizer holds options to expand its territory to include Greater China.</span></p>
<p><span>Pfizer also receives rights to use Starna’s proprietary in vivo CAR-T technology in inflammation and immunology, and in oncology, as well as options to exclusively license compounds created under a separate research collaboration and an option to expand the territory to include exclusive rights to develop and commercialise each exclusively licensed compound and product in Greater China.</span></p>
<p>The post <a href="https://www.expresspharma.in/pfizer-starna-therapeutics-enter-exclusive-licensing-agreement-for-autoimmune-diseases/">Pfizer, Starna Therapeutics enter exclusive licensing agreement for autoimmune diseases</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>AI and the future of pharmacy education</title>
<link>https://edusehat.com/en/ai-and-the-future-of-pharmacy-education</link>
<guid>https://edusehat.com/en/ai-and-the-future-of-pharmacy-education</guid>
<description><![CDATA[ 
Prof. (Dr) Satish Sardana, Director, Amity Institute of Pharmacy, Amity University Haryana speaks to Kalyani Sharma about how AI is shaping pharmacy education and the skills future pharmacists will need in an evolving healthcare landscape
The post AI and the future of pharmacy education appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/18143628/EP_GB_Satish_Sardana_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 19:30:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>and, the, future, pharmacy, education</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/18143628/EP_GB_Satish_Sardana_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/18143628/EP_GB_Satish_Sardana_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/18143628/EP_GB_Satish_Sardana_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><b>AI is moving beyond drug discovery into areas such as clinical decision-making and pharmacy practice. How is this changing the skill sets expected from the next generation of pharmacists? </b></p>
<p><span>AI is shifting the pharmacist’s role from someone who mainly dispenses and checks to someone who interprets, verifies, and takes responsibility for what automated systems recommend. Pharmacists will use tools that flag interactions, predict adverse events, and suggest dosing. Basic biostatistics and the ability to assess a validation study could become routine </span></p>
<p><span>When systems can recall interactions instantly, need for memorisation will be reduced. Deciding when to trust an alert, when to override it, and when a recommendation doesn’t suit a particular patient matters more. Overreliance on it can cause errors, so pharmacists must verify AI outputs. As routine verification is automated, pharmacists move toward medication therapy management, deprescribing, polypharmacy review, and comanaging chronic disease. This needs strong pharmacology and therapeutics, since they must explain why a recommendation makes sense. </span></p>
<p><span>New questions may arise specially, when an AI-informed recommendation harms a patient. More concerns will be about how data is protected, whether algorithms are biased, and how AI use is disclosed. Knowledge of privacy, consent, and regulation will be essential. Communication, empathy, and trust-building cannot be replaced by AI. With less time on dispensing, pharmacists will counsel more, improve adherence, and address misinformation. </span></p>
<p><b>As precision therapeutics and personalised medicine gain ground, what changes are needed in pharmacy education to prepare students for more individualised approaches to treatment? </b></p>
<p><span>Precision medicine is shifting healthcare from a one-sizefits-all approach to treatments tailored to a patient’s genetic, clinical, and lifestyle profile. To prepare students for this shift, pharmacy education must strengthen training in pharmacogenomics, genetic variation, biomarkers, epigenetics, and tumor genomics, particularly in areas where precision therapies are advancing rapidly.</span></p>
<p><span>Students should learn how gene-drug interactions influence treatment outcomes and gain experience interpreting pharmacogenomic reports to support therapy decisions. </span></p>
<p><span>The curriculum should also build skills in biostatistics, data analytics, evidence appraisal, and the use of EHRs and clinical decision-support tools, while encouraging consideration of factors such as genetics, age, comorbidities, and patient preferences. Equally important are topics such as ethics, patient privacy, informed consent, and the limitations of genomic data, particularly in a diverse country like India. Regular faculty upskilling and curriculum updates will be essential to prepare graduates to deliver personalised, evidence-based care. </span></p>
<p><b>How is AI being integrated into pharmacy curricula today, particularly in areas such as drug discovery, pharmacovigilance, formulation development, and clinical pharmacy? </b></p>
<p><span>AI is becoming an integral part of pharmacy education through the revised Pharmacy Council of India (PCI) curriculum, which introduces students to programming, data analytics, machine learning, AI applications, and ethical considerations. The learning progresses semesterwise, beginning with Python programming and pharmaceutical data analysis in Semester I, followed by biostatistics and data analytics in Semester II, machine learning applications in Semester III, AI applications in pharma sciences in Semester VI, AI in clinical practice in Semester VII, and ethical and translational aspects of AI in Semester VIII. </span></p>
<p><span>This structured approach equips students to apply AI in drug discovery, formulation development, pharmacovigilance, pharma manufacturing, and clinical pharmacy, while developing the skills needed for evidence based decision-making and the responsible use of emerging technologies in healthcare. </span></p>
<p><b>What gaps do you see between the skills being taught in pharmacy institutions and what the pharma industry now expects from graduates? </b></p>
<p><span>With the growing adoption of AI, automation, and digital technologies, the gap between pharmacy education and industry expectations is becoming more evident. While institutions provide strong theoretical knowledge, the pharma industry increasingly seeks graduates who can apply this knowledge in realworld settings. </span></p>
<p><span>Key gaps include limited exposure to industry practices such as Good Manufacturing Practices (GMP), regulatory compliance, quality systems, and digital tools used in manufacturing, research, and clinical operations. Employers also expect skills in data analytics, problem-solving, critical thinking, and the use of emerging technologies like AI. </span></p>
<p><span>In addition, graduates often need stronger training in clinical application, pharmacovigilance, and patient-centered decisionmaking. For example, students may know the names of regulatory guidelines but struggle to interpret them or apply them to real documentation, inspections, and compliance scenarios; students may be trained to reproduce known results rather than independently solve complex scientific and technical problems, or they may know how to perform an analytical test but lack the investigative and documentation skills required when results deviate from specifications or a quality system fails. </span></p>
<p><span>Bridging these gaps will require greater emphasis on practical training, industry internships, digital literacy, interdisciplinary learning, and hands-on experience with modern pharma processes. This will help ensure graduates are workforce ready and equipped for the evolving needs of the industry.</span></p>
<p><b>With pharma becoming increasingly interdisciplinary, how can universities strengthen collaboration between pharmacy, biotechnology, data science and other technology disciplines? </b></p>
<p><span>Universities can strengthen interdisciplinary collaboration by integrating crossdisciplinary courses, joint projects, and problem-based learning into the curriculum. They should establish shared research centres and laboratories, encourage partnerships with pharma and technology companies, and provide industry internships. </span></p>
<p><span>Universities can also pair an academic supervisor with an industry scientist or technology specialist, giving students experience with pharma R&D, biotech startups, clinical research organisations, health-tech firms, and AI companies. </span></p>
<p><span>Creating incentives for collaborative research and innovation will further help students and faculty work across disciplines to address real-world healthcare challenges. </span></p>
<p><b>What role can academic institutions play in preparing pharmacists to work with emerging technologies while ensuring that scientific rigour and ethical considerations remain central? </b></p>
<p><span>Academic institutions have a critical role in preparing future pharmacists for a technology-driven healthcare landscape. They must equip students with knowledge of AI, precision medicine, genetic testing, and digital health tools, while fostering critical thinking to evaluate technology-driven insights. </span></p>
<p><span>Pharmacy education should also emphasize ethics, patient privacy, interdisciplinary collaboration, and practical industry exposure. Ultimately, the goal is to develop pharmacists who can responsibly leverage emerging technologies to improve patient outcomes and drive healthcare innovation. </span></p>
<p><b>Looking ahead, which areas of pharma research and practice do you believe will see the biggest impact from AI, precision medicine and other emerging technologies, and how should pharmacy education prepare for this shift? </b></p>
<p><span>AI, precision medicine, and emerging technologies will significantly impact areas such as drug discovery and design, clinical trials, pharmacovigilance, regulatory compliance, and personalised medicine. These innovations can help accelerate research, improve diagnosis, reduce medication errors, and enable more targeted and effective patient care. </span></p>
<p><span>To prepare for this shift, pharmacy education should incorporate foundational knowledge of AI, digital health, and data analytics, along with practical exposure through hospital training, laboratory work, and industry training and real-world examples. Students must also learn to critically assess AI-generated information, protect patient privacy, and use technology ethically. Regular curriculum updates and faculty training will be essential to ensure graduates are equipped to use these technologies confidently and deliver safer, better patient care. </span></p>
<p><b><i>Kalyani.sharma@expressindia.com</i></b></p>
<p><b><i>journokalyani@gmail.com</i></b></p>
<p>The post <a href="https://www.expresspharma.in/ai-and-the-future-of-pharmacy-education/">AI and the future of pharmacy education</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Senores Pharmaceuticals secures PIC/S GMP certification for Gujarat facility</title>
<link>https://edusehat.com/en/senores-pharmaceuticals-secures-pics-gmp-certification-for-gujarat-facility</link>
<guid>https://edusehat.com/en/senores-pharmaceuticals-secures-pics-gmp-certification-for-gujarat-facility</guid>
<description><![CDATA[ 
The certification covers injectable and oral solid manufacturing at its subsidiary Ratnatris Pharmaceuticals’ Mehsana facility and supports the company’s plans to pursue approvals across semi-regulated markets
The post Senores Pharmaceuticals secures PIC/S GMP certification for Gujarat facility appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 19:30:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Senores, Pharmaceuticals, secures, PICS, GMP, certification, for, Gujarat, facility</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>Senores Pharmaceuticals has secured Pharmaceutical Inspection Co-operation Scheme (PIC/S) Good Manufacturing Practices (GMP) certification for the manufacturing facility of its subsidiary, Ratnatris Pharmaceuticals Private Limited, in Mehsana, Gujarat.</span></p>
<p><span>Issued by Ukraine’s State Service on Medicines and Drugs Control (SMDC), the certification expands the company’s pathway to pursue regulatory approvals across semi-regulated pharmaceutical markets.</span></p>
<p><span>Commenting on the development, Swapnil Shah, Managing Director, Senores Pharmaceuticals, said, “The PIC/s approval will open many strategic markets that we couldn’t serve so far. With approval of both, injectable and oral solids, our diverse and strategic portfolio’s reach will be further enhanced, and will continue to give long term growth and sustained profitability”.</span></p>
<p><span>The certificate of GMP compliance was issued by SMDC on November 16, 2026, and received by the company on November 17, 2026.</span></p>
<p>The post <a href="https://www.expresspharma.in/senores-pharmaceuticals-secures-pic-s-gmp-certification-for-gujarat-facility/">Senores Pharmaceuticals secures PIC/S GMP certification for Gujarat facility</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Ministry of Ayush to observe 9th Naturopathy Day on November 18</title>
<link>https://edusehat.com/en/ministry-of-ayush-to-observe-9th-naturopathy-day-on-november-18</link>
<guid>https://edusehat.com/en/ministry-of-ayush-to-observe-9th-naturopathy-day-on-november-18</guid>
<description><![CDATA[ 
The event in Karnataka will focus on preventive healthcare, healthy lifestyles and addressing obesity and lifestyle-related disorders under the theme ‘Prakritik Chikitsa, Swasth Bharat’.
The post Ministry of Ayush to observe 9th Naturopathy Day on November 18 appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2022/08/29115711/events.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 15:55:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Ministry, Ayush, observe, 9th, Naturopathy, Day, November</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2022/08/29115711/events.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2022/08/29115711/events.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2022/08/29115711/events-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>The Ministry of Ayush will observe the 9th Naturopathy Day on November 18, 2026, at the Central Research Institute of Yoga and Naturopathy (CRIYN), Nagamangala, Karnataka, under the theme ‘Prakritik Chikitsa, Swasth Bharat’. The observance will highlight the role of naturopathy in promoting preventive healthcare, healthy lifestyles and overall well-being, with a focus on addressing obesity and lifestyle-related disorders.</span></p>
<p><span>The inaugural session of the main event at Nagamangala will feature several initiatives, including a community health initiative and programmes aimed at promoting well-being and community development. The programmes are designed to engage participants from different sections of society and encourage public welfare and inclusive progress.</span></p>
<p><span>This year’s theme highlights the importance of adopting healthy lifestyles through dietary practices, physical activity, yoga, stress management and other evidence-informed naturopathic approaches. It seeks to strengthen public awareness about prevention and encourage individuals and communities to take an active role in maintaining their health and well-being. The observance also aligns with the Prime Minister’s vision for a Fit and Healthy India, emphasising preventive healthcare and healthy living.</span></p>
<p><span>As part of its nationwide outreach, the observance will feature ten sub-themes focusing on different sections of society and areas of public health. These include ‘Mother Nature – Healthy Mother, Healthy Family’, ‘Swastha Mahila – Fit & Healthy Women’, ‘Fit Force – Strong, Lean & Healthy Force’, ‘Healthy Campus – Fit Students, Healthy Nation’, ‘Healthy Workplace – Fit Workforce’ and ‘Safe Journey – Fit Driver, Safe Journey’.</span></p>
<p><span>The other sub-themes are ‘Golden Wellness – Active Ageing, Healthy Ageing’, ‘Prakriti se Samarth – Healthy & Active Living’, ‘Natural Strength for Sporting Excellence’ and ‘Prakriti Kisan – Fit Farmer, Healthy Nation’.</span></p>
<p><span>Through these initiatives, the Ministry aims to extend the message of naturopathy to families, women, students, working professionals, armed forces personnel, senior citizens, sportspersons and farmers, encouraging healthy practices across communities.</span></p>
<p><span>The observance will also highlight the Ministry of Ayush’s efforts to strengthen the institutional, research and healthcare infrastructure for yoga and naturopathy in the country. Through its research institutions and initiatives, the Ministry is working to advance scientific research, education and the integration of naturopathy into preventive and promotive healthcare.</span></p>
<p><span>The 9th Naturopathy Day will serve as a platform to strengthen public engagement with naturopathy and highlight the importance of healthy lifestyles, preventive healthcare and community participation in building a Swasth Bharat.</span></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/ministry-of-ayush-to-observe-9th-naturopathy-day-on-november-18/">Ministry of Ayush to observe 9th Naturopathy Day on November 18</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>DALPL: Building India’s next&#45;gen of specialised testing capabilities </title>
<link>https://edusehat.com/en/dalpl-building-indias-next-gen-of-specialised-testing-capabilities</link>
<guid>https://edusehat.com/en/dalpl-building-indias-next-gen-of-specialised-testing-capabilities</guid>
<description><![CDATA[ 
From a food and agricultural testing laboratory to a specialised pharma testing facility, the company’s journey reflects the evolution of India’s analytical testing industry. In this conversation, Ashay Mehta, Founder &amp; Managing Director of Doctors’ Analytical Laboratories Pvt Ltd (DALPL) discusses regulatory compliance, data integrity, emerging testing requirements, talent challenges and plans to expand into peptides, topical products and medical device testing with Swati Rana 
The post DALPL: Building India’s next-gen of specialised testing capabilities  appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17170457/Ashay-Mehta.jpg.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 12:20:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>DALPL:, Building, India’s, next-gen, specialised, testing, capabilities </media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17170457/Ashay-Mehta.jpg.jpeg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17170457/Ashay-Mehta.jpg.jpeg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/17170457/Ashay-Mehta.jpg-300x160.jpeg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><b>DALPL was established in 2006 with a food and agricultural testing laboratory and has since expanded into pharmaceutical testing and other verticals. How has the journey been, and what have been the key milestones?</b></p>
<p><span>We started in 2006 in Pune as a food and general testing laboratory, when food regulations in India were still developing. At the time, regulatory requirements were largely linked to exports of certain commodities to Europe. I joined the business in 2008. It was a family investment that we subsequently spearheaded and developed into what it is today.</span></p>
<p><span>In 2011–12, we decided to move the facility from Pune to Mumbai. Since we were based in Mumbai, the move offered better operational control and opportunities for expansion. Mumbai also provided a strategic advantage because of its connectivity to ports and its accessibility to customers and sample sources across Gujarat, Goa and other regions. We re-established our operations in Mumbai in 2012.</span></p>
<p><span>Although India’s food safety law had been enacted earlier and came into effect in 2011, awareness remained limited. The Maggi controversy in 2015 brought food safety and testing into sharper public focus, and the industry has continued to develop since then, although growth has been uneven.</span></p>
<p><span>Around 2012–13, we also began exploring pharmaceutical testing. We entered the segment gradually, starting with one area where regulatory requirements were still evolving.</span></p>
<p><span>In 2016, we underwent our first US FDA inspection at a facility where we were conducting both food and pharmaceutical testing. The experience made us realise that if we wanted to pursue pharmaceutical testing seriously, we needed a dedicated facility, team, standard operating procedures (SOPs) and quality management systems (QMS). Food and pharmaceutical testing require different operating environments and approaches, and we felt that both could not be managed effectively within the same facility.</span></p>
<p><span>We therefore took the decision to shut down our pharmaceutical testing operations temporarily and invest in a dedicated facility, even though it meant losing the business we had built in that segment. We developed the new facility and opened it in September 2017.</span></p>
<p><span>In May 2018, we received our first US FDA Establishment Inspection Report (EIR), following an inspection conducted shortly after we moved to the new premises. We were inspected again in 2022. During the COVID-19 period, one of our clients was facing delays in securing approvals because our facility had not been reinspected. We approached the FDA, explained the situation and requested an inspection on our client’s behalf. The agency conducted the inspection, and we received a Form 483 with observations.</span></p>
<p><span>We have since continued to strengthen our compliance capabilities. Our facility has undergone audits supporting work for clients in Canada and Europe, including an audit by a Qualified Person (QP) representing a client. Our regulatory experience spans the US, European and Canadian markets, as well as Australia.</span></p>
<p><b>How has India’s analytical testing ecosystem evolved over the past two decades?</b></p>
<p><span>When we entered the market, there were very few laboratories serving the highly regulated pharmaceutical testing segment. In 2017, there were only around six or seven laboratories in India with US FDA approval, based on our understanding at the time.</span></p>
<p><span>Today, the landscape has changed considerably. There has been a substantial increase in the number of testing laboratories, particularly in pharmaceutical hubs such as Hyderabad. Food testing has also expanded rapidly, with new laboratories entering the market regularly.</span></p>
<p><span>However, the growth of laboratory infrastructure has not always been matched by the development of specialised talent. The industry needs experienced professionals who understand complex analytical techniques, regulatory expectations, quality systems and the demands of international inspections.</span></p>
<p><span>Regulatory compliance is another important consideration. Establishing a laboratory is one thing; sustaining compliance through inspections and consistently meeting regulatory expectations is another. Laboratories must invest continuously in people, systems, equipment and processes.</span></p>
<p><span>The ecosystem is developing rapidly, and I believe the availability of specialised talent and expertise will improve over time. For now, however, workforce development remains an important area of focus.</span></p>
<p><b>What are the biggest challenges pharmaceutical companies face when it comes to analytical testing in India?</b></p>
<p><span>The encouraging development is that Indian laboratories can now provide a wide range of specialised testing services that companies previously had to seek from laboratories in Europe or the US. These include in vitro release testing (IVRT), in vitro permeation testing (IVPT), nitrosamine analysis, extractables and leachables studies, and peptide-related testing.</span></p>
<p><span>Companies no longer need to depend as heavily on overseas laboratories or face the same waiting periods for many of these services. The domestic ecosystem has developed the infrastructure and expertise needed to support increasingly complex testing requirements.</span></p>
<p><span>The industry is also seeing greater government participation in laboratory development. Support schemes and subsidies for setting up testing infrastructure can help expand capacity in areas where specialised facilities are required.</span></p>
<p><span>The opportunity now is to ensure that this infrastructure continues to evolve alongside regulatory requirements, emerging technologies and the growing complexity of pharmaceutical products.</span></p>
<p><b>With increasing regulatory scrutiny, what changes are you seeing in documentation and quality systems across pharmaceutical testing laboratories?</b></p>
<p><span>We began seeing a significant shift in 2016–17, which was one of the reasons we decided to establish a dedicated pharmaceutical testing facility.</span></p>
<p><span>Regulatory testing requires extensive documentation, whether in food or pharmaceuticals. In pharmaceutical testing, traceability must be maintained throughout the process, from sample receipt and registration to testing, reporting and eventual sample disposal.</span></p>
<p><span>Our systems are designed to maintain complete traceability. The analytical instruments and associated systems are configured with appropriate user access controls and privileges. These controls help prevent unauthorised deletion or manipulation of records and chromatographic data.</span></p>
<p><span>Regulatory expectations have become increasingly stringent, but customer expectations have evolved as well. A decade ago, laboratories could encounter resistance when they explained that a particular request could not be accommodated because of regulatory requirements. Customers might point to another laboratory that was willing to do it differently.</span></p>
<p><span>Today, customers increasingly recognise the importance of compliance, data integrity and reliable testing, particularly given the investment involved in pharmaceutical development and regulatory approvals. Responsible customers understand that compromising testing integrity can create significant risks for their products and businesses.</span></p>
<p><span>Overall, regulatory expectations and customer awareness are moving in the same direction, encouraging better practices across the ecosystem.</span></p>
<p><b>Are Indian testing laboratories keeping pace with global regulatory standards?</b></p>
<p><span>Yes, India is keeping pace with global regulatory standards, and the development of the domestic testing ecosystem reflects that progress.</span></p>
<p><span>Regulatory requirements should not be viewed simply as a burden on the industry. They ultimately help ensure product quality and patient safety. The challenge is to develop the capabilities, infrastructure and expertise needed to meet those requirements consistently.</span></p>
<p><span>India continues to face competitive pressures, including from China, which has significant manufacturing scale and an established industrial ecosystem. However, Indian laboratories are strengthening their capabilities and working to meet international expectations.</span></p>
<p><span>Continued investment in infrastructure, technology and skilled professionals will be essential to sustaining this progress.</span></p>
<p><b>Pharmaceutical companies often have their own analytical testing laboratories. What role do independent testing laboratories play?</b></p>
<p><span>Pharmaceutical companies generally use their in-house laboratories for routine quality control testing. Independent laboratories complement these capabilities by providing specialised services, particularly method development and method validation.</span></p>
<p><span>Developing and validating an analytical method can be time-consuming and requires specialised expertise and equipment. Once the method has been developed and validated, companies may send their samples to an independent laboratory for testing, allowing them to focus their internal resources on other activities.</span></p>
<p><span>Some analytical instruments are also extremely expensive, and it may not be practical for every pharmaceutical company to invest in multiple systems for specialised testing. As commercial laboratories, we can make these investments across a broader client base.</span></p>
<p><span>Our work is not limited to Indian companies. We serve international customers from markets including Turkey, Bangladesh, Saudi Arabia and Canada.</span></p>
<p><span>Customer audits are another important part of the relationship. In addition to regulatory inspections, customers typically audit our facility before starting work with us and may conduct periodic audits thereafter. This provides an additional layer of oversight and helps maintain confidence in the laboratory’s systems and capabilities.</span></p>
<p><b>Data integrity is a major regulatory concern. What does maintaining data integrity mean in practical terms for a testing laboratory?</b></p>
<p><span>Data integrity can be compromised in different circumstances. Sometimes, an employee makes an honest mistake and attempts to conceal it out of fear of reprimand. In other cases, data may be deliberately manipulated.</span></p>
<p><span>We address the first situation by creating an environment in which employees are encouraged to report mistakes immediately. We tell our teams that making a mistake is not necessarily the biggest problem; concealing it can create a much greater risk.</span></p>
<p><span>If an employee reports an error, we can investigate it, assess its impact, implement corrective measures and prevent it from recurring. If people feel pressured to hide mistakes, neither the individual nor the organisation can learn from the incident or mitigate the risk effectively.</span></p>
<p><span>Our approach is to encourage transparency and make employees understand that reporting an error is the right thing to do. We take responsibility for investigating the issue and determining the appropriate corrective action.</span></p>
<p><span>At the same time, deliberate manipulation must be prevented through robust quality systems, appropriate access controls, traceable records and a culture of accountability. Technology and procedures are important, but the right organisational culture is equally essential to maintaining data integrity.</span></p>
<p><b>What will pharmaceutical companies expect from analytical testing laboratories over the next five years?</b></p>
<p><span>Customers will increasingly expect laboratories to provide a broader range of services under one roof, along with stronger regulatory credentials and expertise across different markets.</span></p>
<p><span>As pharmaceutical companies expand internationally, they must comply with the requirements of individual countries and regulatory authorities. These requirements may differ, and companies need laboratory partners that understand the relevant standards and can support their testing needs.</span></p>
<p><span>Consequently, laboratories will need to expand their service portfolios, invest in specialised equipment, strengthen their regulatory capabilities and provide more comprehensive technical support.</span></p>
<p><span>The ability to respond to evolving requirements quickly and consistently will become an important differentiator.</span></p>
<p><b>Which areas should India’s pharmaceutical testing ecosystem prioritise over the next five to ten years?</b></p>
<p><span>Medical devices, peptides and topical products are three important areas.</span></p>
<p><span>Medical device manufacturing is receiving greater attention in India, but there is a need for more specialised testing infrastructure. Many existing laboratories offer routine testing services, while advanced and specialised requirements will call for dedicated capabilities.</span></p>
<p><span>Peptides also have significant potential because of their applications across pharmaceuticals and nutraceuticals. As the market develops, laboratories will need to strengthen their expertise and infrastructure to support the associated analytical and regulatory requirements.</span></p>
<p><span>Topical products represent another important growth area. Specialised studies, including IVRT and IVPT, help assess drug release from formulations and the permeation of active ingredients through the skin. These capabilities are important for the development and evaluation of topical pharmaceutical products.</span></p>
<p><span>Building specialised services around these three areas will be important to meeting future industry demand.</span></p>
<p><b>What are your company’s expansion plans for the coming years? How do you see the company’s growth trajectory over the next five years?</b></p>
<p><span>We are planning to expand both our food and pharmaceutical testing capabilities.</span></p>
<p><span>In 2027, we intend to move our food testing division into a larger facility next door. The additional space will allow us to introduce RT-PCR testing for genetically modified organisms (GMOs) and animal species identification.</span></p>
<p><span>In pharmaceutical testing, we plan to expand our work in peptides. We have already established facilities for specialised in vitro testing of topical products, including IVRT and IVPT.</span></p>
<p><span>We are also keen to establish a dedicated medical device testing division. However, that investment is likely to form part of a longer-term plan, potentially in the third or fourth year of our expansion programme.</span></p>
<p><span>Our focus remains on the life sciences, food testing and pharmaceutical testing sectors, with medical devices representing a potential future area of diversification.</span></p>
<p><span>We have been growing at approximately 25–30% year on year. For the 2026–27 financial year, we are targeting growth of at least 50–60%.</span></p>
<p><span>Given the changes taking place in food safety requirements and pharmaceutical testing, we see opportunities to expand our business. Our planned investments in additional infrastructure and specialised services are intended to support this growth.</span></p>
<p><span>The objective is to build on our existing capabilities while entering areas where we can offer specialised expertise and differentiated services.</span></p>
<p><b>Could you elaborate on the specialised pharmaceutical testing services you currently offer?</b></p>
<p><span>Our pharmaceutical testing portfolio covers active pharmaceutical ingredients (APIs), intermediates, finished formulations and packaging materials.</span></p>
<p><span>One important area is the development and validation of analytical methods for nitrosamines and nitrosamine drug substance-related impurities (NDSRIs), which are potential carcinogenic impurities that require careful assessment. We also undertake elemental impurity testing and extractables and leachables studies, which evaluate substances that may migrate from packaging materials into pharmaceutical products.</span></p>
<p><span>For topical products, we conduct IVRT and IVPT studies to assess drug release from formulations and the permeation of active ingredients through the skin.</span></p>
<p><span>We also undertake gastric and feeding-tube studies for medicines administered through feeding tubes, which may be used by post-operative patients and others who cannot take medication orally in the usual manner. These studies help evaluate drug recovery and the amount of medicine delivered through the tube. Our work can include particle-size evaluation and high-performance liquid chromatography (HPLC) assays.</span></p>
<p><span>Another area involves in vitro binding studies for certain gastrointestinal medicines, including products such as sucralfate and phosphate binders. These studies help assess interactions between medicines under specified conditions.</span></p>
<p><span>We also conduct particle-size evaluations and other specialised analytical assessments. Several of these services support product development and bioequivalence-related investigations where appropriate in vitro methods can provide useful evidence without requiring a clinical study for that particular assessment.</span></p>
<p><span>Our approach is not to compete purely on the number of instruments we operate. We invest in the equipment, expertise and infrastructure needed to deliver specialised projects that meet our technical and commercial requirements. We focus on areas where we can provide meaningful value rather than attempting to handle every project regardless of its complexity or commercial viability.</span></p>
<p> </p>
<p><em><strong>swati.rana@expressindia.com<br>
Swatirana.express@gmail.com </strong></em></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/dalpl-building-indias-next-gen-of-specialised-testing-capabilities/">DALPL: Building India’s next-gen of specialised testing capabilities </a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Biocon secures EC marketing authorisation for pertuzumab biosimilar Pebrilzo</title>
<link>https://edusehat.com/en/biocon-secures-ec-marketing-authorisation-for-pertuzumab-biosimilar-pebrilzo</link>
<guid>https://edusehat.com/en/biocon-secures-ec-marketing-authorisation-for-pertuzumab-biosimilar-pebrilzo</guid>
<description><![CDATA[ 
The approval makes Pebrilzo the first biosimilar to receive EC marketing authorisation under the EMA’s new tailored clinical approach
The post Biocon secures EC marketing authorisation for pertuzumab biosimilar Pebrilzo appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 12:20:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Biocon, secures, marketing, authorisation, for, pertuzumab, biosimilar, Pebrilzo</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>Biocon has announced that the European Commission (EC) has granted marketing authorisation for Pebrilzo, its biosimilar pertuzumab, for the treatment of HER2-positive breast cancer across multiple disease stages in the European Union (EU).</span></p>
<p><span>Biocon’s pertuzumab biosimilar is the first biosimilar to receive EC marketing authorisation under the European Medicines Agency’s (EMA) new tailored clinical approach. The approval follows the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) on September 17, 2026.</span></p>
<p><span>Commenting on the approval, Shreehas Tambe, CEO and Managing Director, Biocon, said, “The European Commission’s approval of Pebrilzo, our pertuzumab biosimilar, the first under its new tailored clinical pathway, marks a significant regulatory milestone for Biocon. With this approval, pertuzumab becomes our fifth oncology biosimilar approved in both Europe and the United States, strengthening our global oncology portfolio and reinforcing our commitment to expanding access to high-quality, affordable biologic therapies for patients with HER2-positive breast cancer.”</span></p>
<p><span>Biocon’s pertuzumab biosimilar has been approved as a 420 mg concentrate for solution for infusion. Its active substance, pertuzumab, is a monoclonal antibody that binds with high affinity and specificity to the human epidermal growth factor receptor 2 (HER2), inhibiting the proliferation of tumour cells that overexpress HER2.</span></p>
<p><span>The biosimilar is indicated for use in combination with trastuzumab and chemotherapy in the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory or early-stage breast cancer at high risk of recurrence. It is also indicated for the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence.</span></p>
<p><span>In addition, the biosimilar is indicated for use in combination with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.</span></p>
<p><span>According to Biocon, extensive orthogonal, state-of-the-art structural and functional analytical characterisation, together with comparative clinical pharmacokinetic data, demonstrated that its pertuzumab biosimilar is highly similar to the reference product, with no clinically meaningful differences in quality, safety or efficacy.</span></p>
<p>The post <a href="https://www.expresspharma.in/biocon-secures-ec-marketing-authorisation-for-pertuzumab-biosimilar-pebrilzo/">Biocon secures EC marketing authorisation for pertuzumab biosimilar Pebrilzo</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Litmys and PharmaACE partner on pharma commercial forecasting</title>
<link>https://edusehat.com/en/litmys-and-pharmaace-partner-on-pharma-commercial-forecasting</link>
<guid>https://edusehat.com/en/litmys-and-pharmaace-partner-on-pharma-commercial-forecasting</guid>
<description><![CDATA[ The partnership links real-world product adoption analytics with commercial modelling to assist companies in making clinical development, investment, and commercialisation choices. The companies will combine their respective analytical 
The post Litmys and PharmaACE partner on pharma commercial forecasting appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/11/PT-12-11-2026-shutterstock_1884612916.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 08:45:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Litmys, and, PharmaACE, partner, pharma, commercial, forecasting</media:keywords>
<content:encoded><![CDATA[<p>The partnership links real-world product adoption analytics with commercial modelling to assist companies in making clinical development, investment, and commercialisation choices.</p>
<p>The companies will combine their respective analytical tools to generate market projections based on customer behaviour rather than standard assumptions.</p>
<p>Conventional industry forecasts frequently depend on clinical profiles, total market scale, and expected market share.</p>
<p>The joint initiative instead evaluates how interactions between healthcare providers, payers, and patients drive uptake, helping companies identify commercial risks before finalising major development decisions.</p>
<p>Litmys managing partner Harris Kaplan said: “Approval does not equal adoption, and a forecast is only as good as the assumptions behind it. Our work focuses on understanding what will actually drive physicians, payers, and patients to embrace a new product.</p>
<p>“Combining that perspective with PharmaACE’s sophisticated forecasting and analytics capabilities allows us to connect the drivers of adoption more directly to commercial expectations and help clients make better decisions while they still have time to influence the outcome.”</p>
<p>Litmys uses its Realistic Assessment of Market Potential (RAMPx) methodology to assess product advantages, uptake barriers, and stakeholder willingness to alter current behaviours.</p>
<p>PharmaACE then applies forecasting models, commercial analytics, and consulting expertise to translate these findings into market projections.</p>
<p>Together, the firms intend to offer complementary services throughout the product lifecycle, from clinical development through to launch, while establishing an assessment framework to evaluate assets and allocate resources across international portfolios.</p>
<p>Litmys is headquartered in Santa Fe, New Mexico, US, with an additional site in Minneapolis, Minnesota focusing on commercial readiness analytics and development risk assessment for medicines and medical devices.</p>
<p>Established in 2013, PharmaACE is based in Princeton, New Jersey, and maintains offices in Canada, Germany, India, and Portugal.</p>
<p>The consultancy provides analytics, forecasting, and advisory services across therapy areas including cardiometabolic conditions, central nervous system disorders, immunology, oncology, and rare diseases.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/news/litmys-pharmaace-pharma-commercial-forecasting/">Litmys and PharmaACE partner on pharma commercial forecasting</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>ProBio signs global antibody licensing deal with AbTis</title>
<link>https://edusehat.com/en/probio-signs-global-antibody-licensing-deal-with-abtis</link>
<guid>https://edusehat.com/en/probio-signs-global-antibody-licensing-deal-with-abtis</guid>
<description><![CDATA[ The asset was developed via ProBio’s biologics discovery and development operations and is directed against an oncology target. ProBio is set to receive an upfront payment, alongside eligibility 
The post ProBio signs global antibody licensing deal with AbTis appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/11/PT-2-12-11-2026-ProBio-Inc-AbTis-discovery-stage-therapeutic-antibody.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 08:45:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>ProBio, signs, global, antibody, licensing, deal, with, AbTis</media:keywords>
<content:encoded><![CDATA[<p>The asset was developed via ProBio’s biologics discovery and development operations and is directed against an oncology target.</p>
<p>ProBio is set to receive an upfront payment, alongside eligibility for potential payments tied to developmental and commercial milestones. Financial figures of the deal were not disclosed.</p>
<p>The agreement additionally entitles the company to receive royalties on future product sales generated by the candidate.</p>
<p>AbTis, a subsidiary of Dong-A ST, plans to incorporate the licensed antibody into its portfolio of bispecific antibody-drug conjugates (ADCs).</p>
<p>The company will apply its AbClick site-specific conjugation technology to develop the candidate into a next-generation ADC.</p>
<p>The AbClick linker platform enables controlled, site-specific antibody conjugation, designed to progress conjugate consistency and characteristics relative to conventional non-specific conjugation methods across oncology applications.</p>
<p>ProBio CEO Allen Guo said: “This agreement demonstrates the value of ProBio’s strategy to not only support our partners’ programmes, but also generate differentiated assets that can advance into innovative therapeutic development.</p>
<p>“By combining ProBio’s biologics discovery capabilities with AbTis’ site-specific ADC technology, we have the opportunity to accelerate the development of a promising oncology asset and create additional value for patients and our partners.”</p>
<p>The transaction aligns with ProBio’s role as a global contract research, development, and manufacturing organisation (CRDMO), providing partners with an integrated pathway that links scientific research directly with manufacturing capabilities.</p>
<p>Operating across biologics, cell therapy, and gene therapy, ProBio maintains scalable, good manufacturing practice (GMP)-compliant facilities designed to de-risk development schedules and shorten production timelines.</p>
<p>AbTis remains focused on advancing bioconjugate therapeutics, seeking to improve clinical outcomes for individuals treated for cancer and other serious diseases.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/news/probio-global-antibody-licensing-deal-abtis/">ProBio signs global antibody licensing deal with AbTis</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Lilly&#45;backed Oyster Therapeutics raises $60m for neurological degraders</title>
<link>https://edusehat.com/en/lilly-backed-oyster-therapeutics-raises-60m-for-neurological-degraders</link>
<guid>https://edusehat.com/en/lilly-backed-oyster-therapeutics-raises-60m-for-neurological-degraders</guid>
<description><![CDATA[ London-based life science venture capital fund 4BIO Capital led the investment. New participants in the round included Actium Group, CE Ventures, Eli Lilly, and TOHO Ventures, managed by 
The post Lilly-backed Oyster Therapeutics raises $60m for neurological degraders appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/11/PT-12-11-2026-shutterstock_2271147415.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 08:45:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Lilly-backed, Oyster, Therapeutics, raises, 60m, for, neurological, degraders</media:keywords>
<content:encoded><![CDATA[<p>London-based life science venture capital fund 4BIO Capital led the investment. New participants in the round included Actium Group, CE Ventures, Eli Lilly, and TOHO Ventures, managed by Global Brain.</p>
<p>Existing backers MGB Ventures, Mission BioCapital, Oxford Science Enterprises (OSE), and Syncona also took part. Alongside the fundraise, the business adopted its new trading identity as Oyster Therapeutics.</p>
<div>
<p>Oyster Therapeutics CEO Rob Johnson said: “This financing accelerates our progress towards the clinic and enables us to validate a new approach to targeted protein degradation, or TPD, that solves some of its major limitations through the use of smaller molecules.</p>
<p>“Millions of people living with diseases such as Alzheimer’s need new approaches such as TPD to address the root cause of disease. At Oyster we are defining next-generation TPD medicines that can reliably reach the brain and are orally available to better meet the needs of global patient populations.</p>
<p>“We welcome this support from both new and existing investors for our vision of building the world’s leading neuroscience TPD company.”</p>
<p>The proceeds will help advance the company’s lead programme that centres on an oral degrader directed at tau, a protein whose abnormal accumulation defines tauopathies such as Alzheimer’s disease.</p>
<p>This tau degrader is designed to enter the central nervous system (CNS) to eliminate pathological tau whilst preserving healthy forms of the protein.</p>
<p>Oyster Therapeutics selected an oral formulation to allow room-temperature storage, lower production expenses, and provide ease of administration for large patient populations.</p>
<p>In tandem with the programme, the company has agreed a sponsored research partnership with Massachusetts General Hospital.</p>
<p>The project is supervised by Mass General Brigham Neuroscience Institute investigator and Harvard Medical School neurology assistant professor Dr Catarina Silva.</p>
<p>It gives the company access to patient-derived neuronal cell lines and advanced methods for detecting neurotoxic oligomeric tau.</p>
<p>Additionally, the financing supports development of Oyster Therapeutics’ SELFTAC platform to generate targeted protein degraders with improved drug-like properties.</p>
</div>
<p>The post <a href="https://www.pharmaceutical-business-review.com/news/oyster-60m-neurological-degraders-pipeline/">Lilly-backed Oyster Therapeutics raises $60m for neurological degraders</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>BMS sets unified research and development structure for 2027</title>
<link>https://edusehat.com/en/bms-sets-unified-research-and-development-structure-for-2027</link>
<guid>https://edusehat.com/en/bms-sets-unified-research-and-development-structure-for-2027</guid>
<description><![CDATA[ The company’s executive vice president and chief medical officer Cristian Massacesi will lead the unified, end-to-end R&amp;D organisation. The planned structure will place the company’s scientific and clinical 
The post BMS sets unified research and development structure for 2027 appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/11/PT-2-13-11-2026-shutterstock_2394208173.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 08:45:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>BMS, sets, unified, research, and, development, structure, for, 2027</media:keywords>
<content:encoded><![CDATA[<p>The company’s executive vice president and chief medical officer Cristian Massacesi will lead the unified, end-to-end R&D organisation.</p>
<p>The planned structure will place the company’s scientific and clinical expertise within one group, spanning discovery and development.</p>
<p>BMS executive vice president and chief research officer Robert Plenge will remain at the company in an advisory role through March 2027 before departing.</p>
<p>Plenge’s continued involvement is intended to support the transition to the new organisational model.</p>
<p>BMS board chair and CEO Christopher Boerner said: “Bringing Research and Development together as one organisation is an important step in our work to position BMS for long-term growth.</p>
<p>“Under Cristian’s leadership, this new structure will more closely connect our scientific and clinical expertise across R&D, accelerate decision making and ultimately enhance portfolio execution. Increasingly, traditional boundaries between research and development are collapsing.</p>
<p>“This combined R&D organisation sets us up to attract and retain the best talent, build critical capabilities, and better integrate new technology. I want to sincerely thank Robert for his extraordinary and lasting contributions to Bristol Myers Squibb, and his support on evolving the organisation.”</p>
<p>As part of its core operations, BMS works to discover, develop, and deliver medicines intended to help patients address serious diseases.</p>
<p>Massacesi said: “This is an exciting time at BMS, with immense scientific potential and an important opportunity to deliver on the promise of our pipeline while building what comes next. I’m grateful to Robert for his partnership, all he has contributed and the organisation he has built.</p>
<p>“Our Research & Development teams are advancing exceptional science and uniting them as one team will enable us to translate our most promising discoveries into medicines for patients with greater speed and focus.”</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/news/bms-unified-research-and-development-structure-2027/">BMS sets unified research and development structure for 2027</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>FDA and EMA waive paediatric studies for Shanton’s gout candidate</title>
<link>https://edusehat.com/en/fda-and-ema-waive-paediatric-studies-for-shantons-gout-candidate</link>
<guid>https://edusehat.com/en/fda-and-ema-waive-paediatric-studies-for-shantons-gout-candidate</guid>
<description><![CDATA[ Under an agreement reached with the EMA on a paediatric investigation plan (PIP), the clinical-stage biotechnology company received a full, product-specific waiver. The decision applies across all paediatric 
The post FDA and EMA waive paediatric studies for Shanton’s gout candidate appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/11/PT-2-12-11-2026-shutterstock_2159556759.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 08:45:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>FDA, and, EMA, waive, paediatric, studies, for, Shanton’s, gout, candidate</media:keywords>
<content:encoded><![CDATA[<p>Under an agreement reached with the EMA on a paediatric investigation plan (PIP), the clinical-stage biotechnology company received a full, product-specific waiver.</p>
<p>The decision applies across all paediatric age groups diagnosed with hyperuricemia, except for conditions arising from obesity or chronic kidney disease.</p>
<p>The European determination follows an agreed initial paediatric study plan (PSP) submitted in May of this year to the FDA.</p>
<p>Regulators at the FDA similarly exempted SAP-001 from paediatric study requirements because gout occurs with extremely low frequency in children.</p>
<p>Shanton Pharma CEO Bing Li said: “We are pleased that the EMA and FDA have determined that paediatric clinical studies evaluating SAP-001 are not needed to support market authorisation applications for hyperuricemia and gout.</p>
<p>“The EMA and FDA waivers significantly lessen the administrative and regulatory burden and lower the overall cost of clinical development of SAP-001.”</p>
<p>SAP-001 is an investigational, once-daily oral urate-lowering therapy designed to treat uncontrolled and refractory gout in adult patients.</p>
<p>In a recent Phase IIb study (NCT05690204), the compound demonstrated efficacy and safety in individuals whose hyperuricemia failed to respond to standard-of-care xanthine oxidase inhibitor treatments.</p>
<p>Last year, the FDA granted fast track designation (FTD) to the drug candidate, supported in part by the Phase IIb results indicating its potential to improve upon existing urate-lowering therapies for patients facing unmet medical needs.</p>
<p>Established in 2016 by pharmaceutical entrepreneurs, Shanton Pharma is a privately held business focused on developing treatments for adults with gout and hyperuricemia.</p>
<p>The company maintains its corporate headquarters in Singapore, alongside research and development activities based in China, Singapore, and the US.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/news/shanton-ema-fda-paediatric-waivers-gout/">FDA and EMA waive paediatric studies for Shanton’s gout candidate</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Lilly agrees to acquire Calytrix Bio for $1.5bn</title>
<link>https://edusehat.com/en/lilly-agrees-to-acquire-calytrix-bio-for-15bn</link>
<guid>https://edusehat.com/en/lilly-agrees-to-acquire-calytrix-bio-for-15bn</guid>
<description><![CDATA[ Under the terms of the definitive agreement, Calytrix Bio shareholders could receive the total cash, including an initial upfront payment followed by subsequent payouts contingent on reaching specified 
The post Lilly agrees to acquire Calytrix Bio for $1.5bn appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/11/PT-17-11-2026-shutterstock_2641777219.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 08:45:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Lilly, agrees, acquire, Calytrix, Bio, for, 1.5bn</media:keywords>
<content:encoded><![CDATA[<p>Under the terms of the definitive agreement, Calytrix Bio shareholders could receive the total cash, including an initial upfront payment followed by subsequent payouts contingent on reaching specified clinical and regulatory milestones.</p>
<p>Engineered to provide pan-mutant activity, the antibody binds both Type 1 and Type 2 (mCALR) expressed on tumour-specific cell surfaces.</p>
<p>This targeted mechanism is intended to eradicate disease-driving mutant clones while avoiding damage to healthy tissues and preserving normal haematopoiesis.</p>
<p>The antibody also features a convenience and safety profile aimed at supporting initial therapeutic intervention alongside extended, long-term administration.</p>
<p>The biological profile addresses an unmet therapeutic need in the management of myeloproliferative neoplasms (MPNs).</p>
<p>By focusing directly on the genetic alterations driving disease progression, the Calytrix Bio candidate is intended to provide a targeted, disease-modifying alternative.</p>
<p>Calytrix Bio president and CEO Brad Prosek said: “Calytrix was founded on the belief that patients with MPNs deserve therapies that do more than manage symptoms. From the beginning, our goal has been to alter the disease course in mCALR-driven ET and MF.</p>
<p>“This transaction represents an important step toward accelerating that vision. We look forward to Lilly advancing the programme through the clinic and exploring its potential to benefit patients across the disease spectrum.</p>
<p>“I am deeply grateful to our team, scientific advisors, and committed investors, each of whom has supported delivery of Calytrix’s programme to the starting line for clinical development.”</p>
<p>Based in Wellesley Hills, Massachusetts, Calytrix Bio was established in 2025 by J.P. Morgan Life Sciences Private Capital, the life sciences venture capital division of J.P. Morgan Asset Management.</p>
<p>Last month, Lilly expanded its partnership and licensing agreement with California-based biotech, Gate Bioscience, to develop molecular gate therapies targeting difficult-to-drug proteins. Lilly has been the most prolific dealmaking company in big pharma so far this year.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/news/lilly-to-acquire-calytrix-bio-1-5bn/">Lilly agrees to acquire Calytrix Bio for $1.5bn</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>AstraZeneca secures FDA approval for Imfinzi combo in MIBC</title>
<link>https://edusehat.com/en/astrazeneca-secures-fda-approval-for-imfinzi-combo-in-mibc</link>
<guid>https://edusehat.com/en/astrazeneca-secures-fda-approval-for-imfinzi-combo-in-mibc</guid>
<description><![CDATA[ The therapeutic schedule for Imfinzi with Astellas Pharma and Pfizer’s drug involves neoadjuvant treatment prior to radical cystectomy, followed by single-agent Imfinzi as adjuvant therapy. The FDA granted 
The post AstraZeneca secures FDA approval for Imfinzi combo in MIBC appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/11/PT-2-16-11-2026-original.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 08:45:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>AstraZeneca, secures, FDA, approval, for, Imfinzi, combo, MIBC</media:keywords>
<content:encoded><![CDATA[<p>The therapeutic schedule for Imfinzi with Astellas Pharma and Pfizer’s drug involves neoadjuvant treatment prior to radical cystectomy, followed by single-agent Imfinzi as adjuvant therapy.</p>
<p>The FDA granted the clearance under priority review based on findings from the multi-centre VOLGA Phase III clinical study (NCT04960709), published in <em>The New England Journal of Medicine</em> and presented at the 2026 European Society for Medical Oncology Congress.</p>
<p>In the trial, the perioperative regimen reduced the risk of disease progression, recurrence, omitted surgery, or death by 49% compared with radical cystectomy with or without approved adjuvant treatment.</p>
<p>Two-year event-free survival reached an estimated 64% with the regimen, compared with 45% in the control arm, where median event-free survival was 12.1 months.</p>
<p>Overall survival results demonstrated a 42% decrease in the risk of death, with two-year survival rates estimated at 78% versus 69%.</p>
<p>Grade 3 and 4 adverse events arising from any cause occurred in 64% of individuals treated with the combination, compared with 44% in the comparator arm, with no new safety signals reported.</p>
<p>Patient-reported quality of life was maintained following surgical intervention.</p>
<p>AstraZeneca oncology haematology business unit executive vice president Dave Fredrickson said: “Today’s approval offers a novel Imfinzi-based regimen that almost halved the risk of disease recurrence and reduced the risk of death by 42% in the VOLGA trial, allowing physicians to optimise treatment for patients in this curative-intent setting.</p>
<p>“As our third bladder cancer indication in two years, this approval reinforces Imfinzi as an immunotherapy backbone across muscle-invasive and non-muscle-invasive disease.”</p>
<p>Muscle-invasive tumours account for roughly one-quarter of all bladder cancer cases, with approximately 16,000 individuals in the US expected to receive treatment in 2026.</p>
<p>Impaired renal function or other comorbidities prevent up to 50% of patients from tolerating cisplatin-based chemotherapy, leaving radical cystectomy alone as the historical standard despite frequent recurrences.</p>
<p>Outside the US, regulatory applications based on the 695-patient trial remain under review in the European Union, Japan, and other territories.</p>
<p>In May this year, AstraZeneca received approval from the US FDA for Imfinzi in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy for adult patients with BCG-naïve, high-risk non-MIBC. Imfinzi holds multiple approvals in the US across lung, bladder, gastrointestinal, and gynecological cancers.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/news/astrazeneca-fda-approval-imfinzi-combo-mibc/">AstraZeneca secures FDA approval for Imfinzi combo in MIBC</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>FDA rejects Summit’s ivonescimab application for lung cancer</title>
<link>https://edusehat.com/en/fda-rejects-summits-ivonescimab-application-for-lung-cancer</link>
<guid>https://edusehat.com/en/fda-rejects-summits-ivonescimab-application-for-lung-cancer</guid>
<description><![CDATA[ The regulator notified the company of its decision in a complete response letter (CRL). Summit Therapeutics had sought approval for the investigational drug, in combination with platinum-containing chemotherapy, 
The post FDA rejects Summit’s ivonescimab application for lung cancer appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/11/PT-16-11-2026-shutterstock_2022905333.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 08:45:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>FDA, rejects, Summit’s, ivonescimab, application, for, lung, cancer</media:keywords>
<content:encoded><![CDATA[<p>The regulator notified the company of its decision in a complete response letter (CRL).</p>
<p>Summit Therapeutics had sought approval for the investigational drug, in combination with platinum-containing chemotherapy, to treat patients whose NSCLC had progressed after epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor therapy.</p>
<p>The FDA said the application could not be approved in its current form, concluding that Summit had not established substantial evidence of effectiveness without a statistically significant improvement in overall survival.</p>
<p>Although ivonescimab achieved a progression-free survival (PFS) benefit in the global Phase III HARMONi clinical trial (NCT06396065), the FDA determined that this finding did not support a favourable benefit-risk balance without a survival gain.</p>
<p>The primary overall survival analysis showed a positive trend but did not achieve statistical significance. Currently, no treatments approved by the FDA have demonstrated a statistically significant overall survival benefit in this subset of NSCLC patients.</p>
<p>Summit Therapeutics president and co-CEO Maky Zanganeh said: “As a cancer survivor, I understand firsthand how important it is for patients to have access to multiple treatment options, particularly when they are facing diseases with significant unmet medical needs.</p>
<p>“Behind every diagnosis is a person, a family, and a community hoping for more time, more possibilities, and a better future. I know that hope is not simply an emotion; it is the possibility that another treatment, another scientific breakthrough, or another therapeutic option may make a meaningful difference in someone’s life.</p>
<p>“Every additional treatment option matters. It represents another opportunity for patients and their families, especially those who have exhausted existing therapies or have limited alternatives.”</p>
<p>Safety findings from the Phase III study showed that 16 patients (7.3%) discontinued ivonescimab due to treatment-related adverse events, compared with 11 patients (5.0%) who discontinued placebo.</p>
<p>Deaths resulting from treatment-related adverse events occurred in four patients (1.8%) receiving ivonescimab with chemotherapy and five patients (2.3%) receiving chemotherapy alone.</p>
<p>Ivonescimab was developed by Akeso and received marketing authorisation for NSCLC patients with EGFR gene mutations that progressed after EGFR-TKI treatment in China in May 2024.</p>
<p>The programmed cell death protein-1 (PD-1) x vascular endothelial growth factor (VEGF) bispecific antibody remains investigational and unapproved across Summit’s licence territories, which include Europe and the US.</p>
<p>To date, the FDA has not approved any PD-1 x VEGF bispecific antibodies.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/news/fda-rejects-summits-ivonescimab-application/">FDA rejects Summit’s ivonescimab application for lung cancer</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Takeda begins US distribution of narcolepsy type 1 drug Orzeyful</title>
<link>https://edusehat.com/en/takeda-begins-us-distribution-of-narcolepsy-type-1-drug-orzeyful</link>
<guid>https://edusehat.com/en/takeda-begins-us-distribution-of-narcolepsy-type-1-drug-orzeyful</guid>
<description><![CDATA[ The therapy is an oral orexin receptor 2 agonist, formulated to target the orexin deficiency that causes the chronic neurological condition. Following approval by the US Food and 
The post Takeda begins US distribution of narcolepsy type 1 drug Orzeyful appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/11/PT-13-11-2026-shutterstock_2516166199.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 08:45:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Takeda, begins, distribution, narcolepsy, type, drug, Orzeyful</media:keywords>
<content:encoded><![CDATA[<p>The therapy is an oral orexin receptor 2 agonist, formulated to target the orexin deficiency that causes the chronic neurological condition.</p>
<p>Following approval by the US Food and Drug Administration (FDA) in August 2026, the drug received a Schedule IV controlled substance (CIV) classification.</p>
<p>Distribution across the country is being managed through Accredo Specialty Pharmacy, a division of Evernorth Health Services, with licensed healthcare practitioners able to prescribe the treatment.</p>
<p>Takeda is also offering patient support programmes to assist eligible adults with treatment initiation and healthcare coverage navigation.</p>
<p>Takeda US business unit president Rhonda Pacheco said: “We work for decades toward the defining moments that have the potential to make a real difference for patients.</p>
<p>“Bringing Orzeyful, a first-in-class medicine, to people living with narcolepsy type 1 in the US is one of those moments.</p>
<p>“We’re incredibly proud to be here, and equally focused on what comes next: supporting care and access for patients prescribed Orzeyful.”</p>
<p>Narcolepsy type 1 is described as a rare disorder caused by the loss of orexin-producing neurons. The condition leads to fragmented nocturnal sleep, excessive daytime sleepiness, cognitive difficulties, and cataplexy, which involves sudden and temporary muscle tone loss.</p>
<p>Orzeyful functions by selectively activating orexin receptor 2 pathways to restore signalling, thereby promoting daytime wakefulness and reducing abnormal rapid eye movement sleep phenomena.</p>
<p>In clinical evaluations, the most frequently reported adverse effects included insomnia, excessive saliva production, increased urinary urgency, and urinary frequency.</p>
<p>Regulatory authorities in China and Japan have also approved Orzeyful for adult patients with narcolepsy type 1.</p>
<p>The compound serves as the lead asset in Takeda’s pipeline of orexin-focused treatments.</p>
<p>Alongside Orzeyful, the company is advancing other investigational oral orexin agonists, including TAK-360, which is in clinical development for idiopathic hypersomnia, narcolepsy type 1, and narcolepsy type 2, as well as TAK-495.</p>
<p>Takeda is also creating digital tools and biomarker diagnostic solutions designed to identify and differentiate narcolepsy type 1 earlier.</p>
<p>Jazz Pharmaceuticals’ flagship oxybate blockbuster brands Xywav and Xyrem have traditionally been the top-selling narcolepsy drugs in the US.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/news/takeda-us-distribution-orzeyful/">Takeda begins US distribution of narcolepsy type 1 drug Orzeyful</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Seawolf Therapeutics and Sanofi agree $1.2bn drug deal</title>
<link>https://edusehat.com/en/seawolf-therapeutics-and-sanofi-agree-12bn-drug-deal</link>
<guid>https://edusehat.com/en/seawolf-therapeutics-and-sanofi-agree-12bn-drug-deal</guid>
<description><![CDATA[ Under the terms of the partnership, Seawolf could receive the funds upon reaching research, development, and commercial milestone payments, alongside tiered royalties on future sales of any therapies 
The post Seawolf Therapeutics and Sanofi agree $1.2bn drug deal appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/11/PT-2-17-11-2026-shutterstock_2556717719.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 08:45:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Seawolf, Therapeutics, and, Sanofi, agree, 1.2bn, drug, deal</media:keywords>
<content:encoded><![CDATA[<p>Under the terms of the partnership, Seawolf could receive the funds upon reaching research, development, and commercial milestone payments, alongside tiered royalties on future sales of any therapies resulting from the collaboration.</p>
<p>The alliance coincides with Seawolf emerging from stealth mode with $100m in financing to advance its pipeline of deoxyribonucleic acid (DNA)-based medicines.</p>
<p>This funding total includes seed financing led by founding investor Versant Ventures, followed by a Series A round supported by MPM BioImpact, Novartis Venture Fund, and Versant Ventures.</p>
<p>Other participants in the financing included Alexandria Venture Investments, CRISPR Therapeutics, Eli Lilly and Company, Pathway to Cures, which is the philanthropic venture arm of the National Bleeding Disorders Foundation, and Sixty Degree Capital.</p>
<p>Seawolf Therapeutics president and CEO Elizabeth Alcamo said: “Seawolf is charting a new course in patient care through LNP-based DNA medicines.</p>
<p>“With a strong syndicate of investors and our collaboration with Sanofi, we are well-positioned to execute on our next stage of growth, which will include advancing our lead programme for metabolic diseases and collaborating with Sanofi in its mission to develop therapies for patient unmet needs.”</p>
<p>Seawolf will use the capital to progress candidates built upon its Targeted RNA-Induced DNA Expression via Nuclear Translocation (TRIDENT) platform.</p>
<p>The technology uses lipid nanoparticles to transport immune-quiet DNA encoding a therapeutic transgene directly into cell nuclei, aided by an auxiliary factor.</p>
<p>This nuclear delivery aims to achieve stable, long-term therapeutic protein expression, overcoming the transient activity associated with standard RNA-based therapies.</p>
<p>Unlike viral vectors, the nanoparticle delivery system allows repeated administration to adjust or supplement dosing over time.</p>
<p>Seawolf showed proof of concept for the approach in preclinical murine and non-human primate models of metabolic and rare diseases.</p>
<p>In addition to collaborating with Sanofi, the company is advancing an internal lead programme targeting metabolic diseases.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/news/seawolf-sanofi-agree-drug-deal/">Seawolf Therapeutics and Sanofi agree $1.2bn drug deal</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>PLI 2.0: Can MSMEs catch up?</title>
<link>https://edusehat.com/en/pli-20-can-msmes-catch-up</link>
<guid>https://edusehat.com/en/pli-20-can-msmes-catch-up</guid>
<description><![CDATA[ 
Is the scheme translating manufacturing investments into global competitiveness for pharma MSMEs, or does the next phase need to do more to bridge the gap between smaller manufacturers and larger exporters?
The post PLI 2.0: Can MSMEs catch up? appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17190138/EP_DigiMag_CS_Nov_2026_Ft_Image_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 17 Nov 2026 22:00:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>PLI, 2.0:, Can, MSMEs, catch, up</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17190138/EP_DigiMag_CS_Nov_2026_Ft_Image_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17190138/EP_DigiMag_CS_Nov_2026_Ft_Image_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/17190138/EP_DigiMag_CS_Nov_2026_Ft_Image_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>India’s Pharmaceutical Production Linked Incentive (PLI) scheme was designed to strengthen domestic manufacturing, attract investment and encourage companies to move towards higher-value pharmaceutical products. With a financial outlay of ₹15,000 crore, the scheme has supported manufacturing expansion across the pharmaceutical sector. But for India’s micro, small and medium enterprises (MSMEs), the bigger question is whether this investment is translating into stronger technological capabilities, improved quality systems and sustainable export growth.</span></p>
<p><span>The challenge is significant. Smaller pharma manufacturers play an important role in domestic medicine supplies, contract manufacturing, employment generation and exports. However, they often operate with tighter budgets and have less access to capital, research facilities, advanced technology and specialist regulatory expertise. This can make it difficult for them to compete with larger Indian companies and international manufacturers.</span></p>
<p><span>The government has recognised these differences in the design of the pharma PLI scheme. Of the 55 applicants selected, 20 are MSMEs, accommodated within Group C, which has a dedicated framework for smaller manufacturers.</span></p>
<p><span>However, industry representatives argue that a separate framework is only the starting point. Smaller companies need practical access to finance, technology, quality expertise and export markets if they are to turn manufacturing investment into sustainable growth.</span></p>
<p><span>Ajay Singh Dassundi, Secretary of the MP Small and Medium Drugs Manufacturers Association, says the scheme is a positive initiative, but its benefits have been relatively limited for MSMEs compared with companies that have the financial strength and scale to make large investments.</span></p>
<p><span>“The next phase must ensure that the benefits of the PLI Scheme reach not only large manufacturers but also the thousands of MSMEs that form the backbone of India’s pharmaceutical industry,” he says.</span></p>
<p><b>Investment, but for whom? </b></p>
<p><span>A government update published in January 2026, reporting progress through September 2025, said the scheme had attracted investment of ₹40,294 crore against a targeted ₹17,275 crore. Cumulative sales stood at ₹3,08,408.60 crore, including exports of ₹1,98,509.49 crore. The government also reported an employment generation of approximately 97,000 people, including contractual and apprentice workers.</span></p>
<p><span>For Namit Joshi, Chairman of Pharmexcil, this distinction is crucial.</span></p>
<p><span>“The impact of the scheme is more clearly visible in terms of manufacturing investment and capacity creation,” he says, cautioning that it would be premature to attribute a substantial expansion in international market presence specifically to PLI-supported MSMEs without more detailed data.</span></p>
<p><span>“Investment and production figures indicate whether manufacturing activity is expanding. They do not necessarily show whether smaller companies are adopting advanced technologies, entering new markets or developing higher-value products. The next phase should focus on helping these businesses convert manufacturing capabilities into tangible and sustained export outcomes,” Joshi adds.</span></p>
<p><span>“The ultimate test is whether MSMEs are becoming stronger businesses that can invest independently, create employment, develop better products, enter new markets, and sustain their growth beyond the incentive period,” he says.</span></p>
<p><b>Group C: A step towards a level playing field?</b></p>
<p><span>The creation of a dedicated MSME framework within Group C reflects the government’s recognition that smaller manufacturers cannot always meet investment requirements designed for large pharmaceutical companies.</span></p>
<p><span>The changes introduced to the scheme’s operational guidelines in 2024 were intended to improve access for MSMEs. However, a separate eligibility framework does not automatically eliminate the financial and administrative challenges of participating.</span></p>
<p><span>Suveer Shrivastava, former Chief Quality Officer and Sr VP of Regulatory Affairs, believes the changes are a positive step, but their effectiveness will depend on implementation.</span></p>
<p><span>“Introducing a separate framework is only the first step. Its effectiveness will depend on how well the provisions are implemented and monitored,” he says.</span></p>
<p><span>Shrivastava argues that eligible MSMEs need to receive the intended benefits without being disadvantaged by limited financial resources or administrative capabilities. He also recommends greater involvement of independent third-party experts and relevant State Food and Drug Administrations in monitoring implementation and assessing outcomes.</span></p>
<p><span>For Bhavin Mehta, Whole-Time Director of Kilitch Drugs (India) and Vice-Chairman of Pharmexcil, accessibility and predictability are equally important.</span></p>
<p><span>“Clear eligibility criteria, streamlined documentation, transparent evaluation processes and predictable timelines for incentive disbursement can help businesses plan investments with greater confidence,” he says.</span></p>
<p><span>Dassundi welcomes the separate framework but stresses that the eligibility criteria, investment thresholds, incentive structure and application procedures must be realistic for smaller manufacturers.</span></p>
<p><span>“For a small or medium manufacturer, even an investment of a few crores can be a significant financial commitment,” he says.</span></p>
<p><span>Mehta says the framework should be practical enough for eligible companies to navigate while retaining performance requirements to ensure that public incentives support genuine manufacturing activity. He recommends clear guidance, efficient administration and regular assessment of the capabilities being developed.</span></p>
<p><span>As Dassundi puts it, “MSMEs do not necessarily need protection from competition; they need the financial and technological capabilities to compete.”</span></p>
<p><img decoding="async" class="wp-image-460184 alignleft" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17185704/EP_DigiMag_CS_nov_2026_Inside_Image_01_1000-209x300.jpg" alt="" width="360" height="517" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17185704/EP_DigiMag_CS_nov_2026_Inside_Image_01_1000-209x300.jpg 209w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/17185704/EP_DigiMag_CS_nov_2026_Inside_Image_01_1000-714x1024.jpg 714w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/17185704/EP_DigiMag_CS_nov_2026_Inside_Image_01_1000-768x1101.jpg 768w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/17185704/EP_DigiMag_CS_nov_2026_Inside_Image_01_1000.jpg 1000w" sizes="(max-width: 360px) 100vw, 360px"><b>The cost of catching up</b></p>
<p><span>One of the biggest challenges facing pharma MSMEs is the cost of upgrading existing manufacturing facilities.</span></p>
<p><span>Pharma production requires qualified equipment, validated processes, reliable documentation and effective quality management systems. Companies seeking to supply regulated international markets must also meet the requirements of their target markets, which can require substantial investment in infrastructure, technology and personnel.</span></p>
<p><span>For a smaller manufacturer, such investment can be difficult to finance alongside day-to-day operations.</span></p>
<p><span>Narotam Juneja, Technical Advisor at Uniserum Lifesciences, identifies infrastructure modernisation as a major concern, particularly for businesses operating older facilities. Upgrading these plants to meet current good manufacturing practice (GMP) requirements and international regulatory standards requires substantial capital expenditure.</span></p>
<p><span>Companies unable to make the necessary changes may face regulatory action, including suspension of operations or cancellation of manufacturing licences. The result is a difficult investment choice: a company may need to spend heavily simply to maintain its existing manufacturing capabilities, leaving fewer resources for new products, automation or export expansion.</span></p>
<p><span>Dassundi identifies high investment requirements as one of the principal barriers to MSME participation. Modern pharmaceutical manufacturing requires spending on plant and machinery, laboratory facilities, automation, validation and regulatory compliance. At the same time, high borrowing costs, collateral requirements, working-capital constraints and long payment cycles can prevent smaller companies from financing expansion.</span></p>
<p><span>The challenges extend beyond capital expenditure. Smaller businesses may not have dedicated teams to manage incentive applications, compliance requirements and the documentation needed for international markets. Many also lack the resources to establish sophisticated research facilities or maintain specialised research and development teams.</span></p>
<p><span>Juneja also points to the challenges MSMEs face when attempting to enter higher-value product categories.</span></p>
<p><span>Developing complex generics and other advanced pharmaceutical products can require significant expenditure on research and development, specialised equipment, regulatory documentation and compliance. For a smaller company, the financial risk can be considerably higher than for a large manufacturer with a broader portfolio and greater access to capital.</span></p>
<p><span>Research-driven MSMEs may also face a first-mover disadvantage when they have to finance trials and generate regulatory data before commercial returns become visible. These challenges suggest that the next phase of PLI should pay closer attention to the quality and purpose of investment, rather than focusing primarily on the amount committed.</span></p>
<p><span>Shrivastava argues that MSMEs need to move beyond a narrow focus on production volumes and short-term financial performance.</span></p>
<p><span>“Investments in quality, innovation, and digitalisation are not merely compliance expenses; they are essential to sustainable growth and access to higher-value markets,” he says.</span></p>
<p><span>He identifies automation, data integrity, robust quality management and workforce development as important areas for improvement. For smaller manufacturers, however, adopting these capabilities may require technical expertise that is difficult to recruit or retain in-house.</span></p>
<p><span>Shrivastava therefore proposes a structured technical guidance and mentoring programme involving experienced pharmaceutical professionals. Such a programme could help companies identify compliance gaps, develop improvement plans and implement stronger manufacturing and quality systems. Shared technical infrastructure, specialised training and independent assessments could also help smaller businesses address capability gaps without bearing the full cost of developing every resource independently.</span></p>
<p><span>Dassundi recommends a more integrated support system. Alongside incentives, he wants government-backed credit guarantees, interest subvention and concessional financing to help MSMEs fund technology upgrades and capacity expansion.</span></p>
<p><span>He also proposes affordable research and development facilities, common testing laboratories, pilot-scale manufacturing facilities and technology-transfer programmes developed in collaboration with government-supported research institutions.</span></p>
<p><img decoding="async" class="wp-image-460185 alignright" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17185708/EP_DigiMag_CS_nov_2026_Inside_Image_02_1000-300x288.jpg" alt="" width="463" height="444" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17185708/EP_DigiMag_CS_nov_2026_Inside_Image_02_1000-300x288.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/17185708/EP_DigiMag_CS_nov_2026_Inside_Image_02_1000-768x737.jpg 768w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/17185708/EP_DigiMag_CS_nov_2026_Inside_Image_02_1000.jpg 1000w" sizes="(max-width: 463px) 100vw, 463px"></p>
<p><b>Opportunity comes with risk</b></p>
<p><span>Moving towards higher-value pharma products is a key ambition of the PLI scheme. It offers Indian manufacturers an opportunity to develop specialised capabilities and compete in segments where technology, quality and regulatory expertise are critical.</span></p>
<p><span>For MSMEs, however, entering these categories is not simply a matter of installing new equipment.</span></p>
<p><span>Depending on the product, companies may need to invest in research, process development, specialised analytical capabilities, validation, regulatory submissions and skilled personnel. These investments can take time to generate revenue and may not always lead to commercial success.</span></p>
<p><span>Juneja argues that smaller manufacturers can be structurally disadvantaged because of the higher capital and compliance costs associated with developing complex products. He also highlights the difficulty of funding innovation when the first applicant bears substantial costs for trials and regulatory data, while subsequent entrants may have access to less expensive regulatory pathways.</span></p>
<p><span>The next phase of PLI could address this challenge by encouraging product diversification alongside targeted technical and regulatory support.</span></p>
<p><span>Mehta believes the long-term impact of PLI will depend on whether manufacturing investment translates into sustainable business growth.</span></p>
<p><span>“In segments such as sterile injectables, this requires more than production capacity alone,” he says. “Companies must build strong process validation systems, maintain consistent product quality, secure regulatory approvals and establish dependable supply relationships with customers across markets.”</span></p>
<p><span>Dassundi also believes that the next phase should support MSMEs in moving up the value chain, developing differentiated products and building sustainable export businesses rather than simply increasing the volume of conventional products.</span></p>
<p><img loading="lazy" decoding="async" class="wp-image-460186 aligncenter" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17185917/EP_DigiMag_CS_nov_2026_Inside_Image_03_1000-300x241.jpg" alt="" width="662" height="532" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17185917/EP_DigiMag_CS_nov_2026_Inside_Image_03_1000-300x241.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/17185917/EP_DigiMag_CS_nov_2026_Inside_Image_03_1000-768x617.jpg 768w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/17185917/EP_DigiMag_CS_nov_2026_Inside_Image_03_1000.jpg 1000w" sizes="auto, (max-width: 662px) 100vw, 662px"></p>
<p><b>Can MSMEs crack exports? </b></p>
<p><span>India’s pharma industry has an established presence in international markets. According to the Ministry of Commerce and Industry, pharmaceutical exports reached approximately $30.47 billion in FY2024-25, registering growth of 9.4 per cent over the previous financial year.</span></p>
<p><span>For smaller manufacturers, moving from domestic production to international sales requires capabilities that extend beyond manufacturing.</span></p>
<p><span>Companies must secure the necessary product registrations, meet the regulatory requirements of their target markets, maintain consistent quality and supply, and develop distribution or customer relationships overseas. These activities require time, money and specialised knowledge. Smaller exporters may struggle to absorb the costs, particularly when they have a limited product portfolio.</span></p>
<p><span>Joshi says Indian MSMEs must compete on cost, quality, consistency of supply and compliance with international regulatory standards.</span></p>
<p><span>“Manufacturing competitiveness and export competitiveness are not the same,” he emphasises.</span></p>
<p><span>He points to the advantages enjoyed by countries such as China in manufacturing scale, supply-chain integration and access to raw materials. For smaller Indian companies, technology upgrades, regulatory approvals, product development and market entry can create substantial additional costs.</span></p>
<p><span>“Tariff and non-tariff barriers add to the challenge. Changes in regulatory requirements, product-registration procedures and market-access conditions can make exporting more expensive and time-consuming for businesses with limited resources. Larger exporters are generally better placed to spread these costs across multiple products and markets. MSMEs often have less flexibility,” Joshi says.</span></p>
<p><span>“Manufacturing investment and production remain important, but they should be viewed as intermediate outcomes rather than the ultimate measure of success,” he says.</span></p>
<p><span>Joshi recommends greater emphasis on incremental exports, international product registrations, technology adoption, productivity improvements and the development of higher-value products. These measures, he argues, would help determine whether PLI-supported businesses are developing the capabilities required to compete internationally, rather than simply expanding domestic capacity.</span></p>
<p><span>Dassundi agrees that MSMEs can play a larger role in pharmaceutical exports, but says growth requires regulatory preparedness, consistent quality, product development, international marketing and reliable working capital.</span></p>
<p><span>“The next phase should help MSMEs move up the value chain, develop differentiated products, and build sustainable export businesses rather than simply increase the volume of conventional products,” he says.</span></p>
<p><span>Mehta also stresses the need to align manufacturing investments with international demand. Companies must understand the requirements of their intended markets and ensure that their products, facilities and supply systems can meet them.</span></p>
<p><b>Quality is non-negotiable </b></p>
<p><span>For pharma companies, quality is central to market access and commercial credibility.</span></p>
<p><span>Manufacturers must maintain effective quality management systems, validate processes, qualify equipment, preserve reliable records and ensure that employees are trained to perform their responsibilities. For MSMEs seeking to enter highly regulated markets, gaps in documentation, data integrity or process control can become significant obstacles.</span></p>
<p><span>Shrivastava believes one of the biggest challenges is translating regulatory requirements into consistent practice on the manufacturing floor. He identifies quality management, documentation, data integrity, process validation, equipment qualification, automation and workforce competence as areas requiring attention.</span></p>
<p><span>Dassundi proposes common skill-development centres that provide practical training in advanced manufacturing, automation, quality assurance, regulatory compliance and modern pharmaceutical technologies. Such shared facilities could give smaller businesses access to training and expertise that may be difficult to fund independently.</span></p>
<p><span>Mehta similarly argues that modern infrastructure, automation and robust quality systems are essential if Indian manufacturers are to remain competitive. For MSMEs, quality improvements should not be treated as a one-time exercise. They must become part of everyday manufacturing practice.</span></p>
<p><b>Is the framework tilted towards larger companies?</b></p>
<p><span>A central concern among industry representatives is whether companies with greater financial strength are better positioned to benefit from incentive-linked manufacturing schemes.</span></p>
<p><span>Large pharma companies generally have more resources to fund capital expenditure, recruit specialist teams and manage complex documentation and reporting requirements. Smaller businesses may struggle to make substantial upfront investments while continuing to finance routine operations.</span></p>
<p><span>Juneja argues that qualifying thresholds and investment commitments need to reflect the practical realities of smaller manufacturers. MSMEs may find it difficult to fund eligible greenfield projects or major expansions and wait through prolonged gestation periods before the investment begins generating returns.</span></p>
<p><span>His recommendation is for a more MSME-focused assessment of eligibility thresholds, qualifying investments and performance measures. The objective should be to help smaller companies upgrade existing facilities, meet higher regulatory standards, invest in product development and progressively increase the share of higher-value products in their portfolios.</span></p>
<p><span>Shrivastava also believes that the framework should focus more on technical capability, quality performance and the potential for sustainable growth.</span></p>
<p><span>“The objective should not be to give smaller companies an advantage simply because they are small, but to ensure that technically capable MSMEs are not excluded because they lack the financial and administrative resources of larger competitors,” he says.</span></p>
<p><span>Dassundi calls for a dedicated MSME incentive window with a defined allocation and proportionate eligibility criteria. He believes this would help ensure that eligible smaller manufacturers receive meaningful access to the scheme.</span></p>
<p><span>He also recommends simpler application procedures, predictable incentive payments and dedicated facilitation mechanisms. For MSMEs with limited administrative resources, a complicated application process can become an additional barrier even when a project is technically suitable.</span></p>
<p><span>The policy challenge is to balance accountability for public spending with a process that smaller companies can realistically navigate.</span></p>
<p><img loading="lazy" decoding="async" class="wp-image-460187 aligncenter" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17185921/EP_DigiMag_CS_nov_2026_Inside_Image_04_1000-300x120.jpg" alt="" width="698" height="279" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17185921/EP_DigiMag_CS_nov_2026_Inside_Image_04_1000-300x120.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/17185921/EP_DigiMag_CS_nov_2026_Inside_Image_04_1000-768x307.jpg 768w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/17185921/EP_DigiMag_CS_nov_2026_Inside_Image_04_1000.jpg 1000w" sizes="auto, (max-width: 698px) 100vw, 698px"></p>
<p><b>What should PLI 2.0 measure?</b></p>
<p><span>Joshi wants the next phase to place greater emphasis on incremental exports, international registrations, technology adoption, productivity and higher-value products.</span></p>
<p><span>Mehta highlights sustainable business growth, modern manufacturing infrastructure, quality systems and export readiness. Juneja stresses the need to address investment barriers, facility upgrades and the costs of developing higher-value products.</span></p>
<p><span>Shrivastava calls for a robust and transparent mechanism to measure the scheme’s actual benefits, including independent impact assessments comparing companies’ performance before and after receiving support.</span></p>
<p><span>Dassundi recommends evaluating a wider range of outcomes, including investment in infrastructure, incremental production, technology adoption, research and development, API manufacturing, exports, employment, quality and compliance, financial sustainability, MSME participation and movement towards higher-value products.</span></p>
<p><span>“I would particularly emphasise incremental exports, technology adoption, innovation, and sustainable financial performance,” he says.</span></p>
<p><span>Together, these recommendations suggest several areas for a more comprehensive assessment such as : </span></p>
<p><b>Investment and production</b><span>: Has the scheme encouraged additional manufacturing investment and eligible sales, and how much of that activity is attributable to participating MSMEs?</span></p>
<p><b>Technology and productivity</b><span>: Have MSMEs adopted modern equipment, automation or digital systems, and have these changes improved manufacturing performance?</span></p>
<p><b>Quality and compliance</b><span>: Have companies strengthened quality management, data integrity, process validation and workforce competence?</span></p>
<p><b>Product development and exports</b><span>: Have manufacturers introduced higher-value products, obtained international registrations, entered new markets or expanded repeat export business?</span></p>
<p><b>Financial sustainability</b><span>: Can businesses maintain upgraded facilities, finance future investment and compete commercially after the incentive period ends?</span></p>
<p><b>MSME participation and employment</b><span>: How many eligible MSMEs have received incentives and completed their projects? Have the investments generated skilled jobs and improved workforce capabilities?</span></p>
<p><b>Beyond incentives  </b></p>
<p><span>India’s pharma PLI scheme has helped stimulate manufacturing investment and create opportunities for domestic producers. Its dedicated framework for MSMEs recognises that smaller companies face different financial and operational constraints from larger manufacturers.</span></p>
<p><span>But the industry’s challenge now is to translate participation into capability.</span></p>
<p><span>Dassundi’s recommendations include government-backed credit guarantees, interest subvention and concessional financing; affordable research and development facilities; common testing and skill-development centres; technology upgrades; support for API manufacturing; and stronger export facilitation. He also calls for closer collaboration between MSMEs and research institutions to make advanced technologies and product-development capabilities more accessible.</span></p>
<p><span>For Joshi, the priority is to link manufacturing support more closely with export readiness and measurable improvements in competitiveness. Mehta similarly sees the opportunity in helping manufacturers develop more specialised capabilities and participate more meaningfully in global value chains.</span></p>
<p><span>For Shrivastava, the ultimate measure is whether the scheme creates stronger, more innovative and quality-driven businesses. Juneja’s recommendations underline the need to ensure that investment requirements and eligibility criteria reflect the circumstances of smaller manufacturers.</span></p>
<p><span>As Dassundi concludes, the objective should not simply be to create a few large manufacturing capacities. It should be to build a broad base of technologically advanced, financially sustainable and globally competitive Indian pharma manufacturers.</span></p>
<p>The post <a href="https://www.expresspharma.in/pli-2-0-can-msmes-catch-up/">PLI 2.0: Can MSMEs catch up?</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>From lab to market: Bridging India’s pharma innovation gap </title>
<link>https://edusehat.com/en/from-lab-to-market-bridging-indias-pharma-innovation-gap</link>
<guid>https://edusehat.com/en/from-lab-to-market-bridging-indias-pharma-innovation-gap</guid>
<description><![CDATA[ 
Dr Richa Dayaramani, Scientist Grade F at NIPER Ahmedabad, discusses the gaps between academia and industry, the challenges of scaling research, and how stronger industry partnerships, quality systems and commercialisation pathways can help India build its innovation ecosystem, in an interview with Lakshmipriya Nair 
The post From lab to market: Bridging India’s pharma innovation gap  appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17133159/Dr-Richa-Dayaramani.jpg.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 17 Nov 2026 18:20:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>From, lab, market:, Bridging, India’s, pharma, innovation, gap </media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17133159/Dr-Richa-Dayaramani.jpg.jpeg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17133159/Dr-Richa-Dayaramani.jpg.jpeg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/17133159/Dr-Richa-Dayaramani.jpg-300x160.jpeg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><strong>India wants to move from being a global generics hub to a leader in pharma innovation. From your vantage point in academia, what is holding that transition back? </strong></p>
<p><span>With our vast talent base and premium manufacturing capacities we can accelerate our path to global leadership by actively tackling four foundational pillars in research and academia. A seamless, trust-based collaboration between industry and research institutions to fund frontier innovation, synergistic partnerships where industry confidently backs early-stage, visionary academic research is the need of hour. Simultaneously, academia can evolve its metrics of successmoving beyond publication counts to celebrate tangible outcomes like patent commercialisation, technology transfers, and thriving spin-offs that reward every contributor. We have a tremendous opportunity to scale up our R&D investment from the current 0.6 per cent to 0.7 per cent of GDP toward the two to three per cent benchmarks seen in nations like the US, China, and South Korea. Our academic laboratories are equipped with world-class capabilities in pharma, biopharma and molecular research. The next vital step is to surround our scientists with a robust translational ecosystem while simultaneously empowering senior faculty and institutional leaders to embrace this new era of commercialisation using industry norms of quality management system establishment in research laboratories. By pairing this infrastructure with more agile, modern regulatory pathways for advanced therapeutics and biologics, we can match the velocity of global innovation hubs like Boston or San Francisco and dramatically shorten the journey from the lab bench to the patient. This will develop a mature network of scientist-entrepreneurs who can successfully take a novel drug to market and can mentor the next generation so as to channel this immense intellectual capital into our own rapidly evolving innovation ecosystem. </span></p>
<p><strong>Pharma companies are under pressure to innovate faster and manage R&D costs. What can academia realistically do to help industry solve problems faster? </strong></p>
<p><span>To accelerate innovation and curb soaring R&D costs, academia and pharma companies can function as dynamic, agile research partners. Although, in realistic terms, universities may not keep up the pace and match the scale of industrial development, but they can fundamentally derisk the early stages of discovery. Embracing a culture of open innovation and pre competitive consortia academia can work with multiple pharma companies on shared, nonproprietary challenges. Implementing clear, prenegotiated, and industryfriendly licensing frameworks allows companies to quickly pick up academic discoveries and move them into pipeline development without legal friction. Replacing a publication first mindset to a patent and proof of concept validation will reduce target failure rates. </span></p>
<p><span>Instead of every pharma company investing in niche, expensive equipment universities can operate as centralised, state-of-the-art “core facilities” providing rapid testing services to industry partners at a fraction of the cost. Academia can co-design curriculum and PhD programs with industry inputs. Creating seamless pathways for academic faculty to spend sabbaticals inside pharma R&D labs-and vice versa-ensures that academic research stays aligned with actual, practical commercial bottlenecks. </span></p>
<p><strong>There is still a gap between a promising academic discovery and something industry can develop at scale. Where does that gap usually emerge? </strong></p>
<p><span>academic discovery and a scalable industrial product is known as the “Translational Valley of Death”. For instance, an academic lab might successfully synthesise milligrams of a complex molecule using expensive, lowyield, or highly toxic chemical steps while the industry requirement is in kilograms or tons produced via highly reproducible, safe, and costeffective processes. A compound that successfully kills cancer cells in a petri dish frequently fails inside a complex living organism. Academic researchers in India often lack the specialised resources to test Pharmacokinetics and Pharmacodynamics.</span></p>
<p><span>Industry requires data generated under strict Good Laboratory Practice (GLP) standards. When pharma companies attempt to replicate breakthrough academic findings under rigid industrial conditions, a startlingly high percentage of the results cannot be reproduced, killing the project instantly. While academia rewards novelty industry rewards clinical utility for a drug that is safer, cheaper, or easier to administer than what is already on the pharmacy shelf. The IP blind spot further gaps this valley because academic scientists often publish their findings too early and without an airtight patent protection, industry cannot justify spending hundreds of millions of dollars to bring the discovery to market. </span></p>
<p><strong>NIPER was created to strengthen specialised pharma education and research. How do you see its role evolving as the industry moves towards complex generics, biologics, advanced drug delivery and other newer technologies? </strong></p>
<p><span>As the Indian pharma sector transitions from volume-based traditional generics to a highvalue, innovation-driven biopharma powerhouse, the National Institute of Pharmaceutical Education and Research (NIPER) is shifting its core focus toward specialised R&D, advanced therapeutics, and industry collaboration. With national initiatives like the `10,000-crore biopharma manufacturing push, NIPER campuses are expanding infrastructure for noncommunicable diseases (such as cancer, diabetes, and autoimmune disorders) to build domestic expertise in biologics. Responding to specialised industrial demand, NIPER has integrated dedicated streams and testing infrastructure for medical device engineering and regulatory compliance. Moving away from routine manufacturing support, NIPER acts as an incubation and grantsupport hub for faculty-led and student-led deep-tech pharma startups. To catalyse the transition of NIPERs and the wider ecosystem toward complex therapeutics, the Government of India has deployed a multi-layered support architecture. These flagship initiatives directly bridge the gap between academic research, regulatory compliance, and commercial market entry. With a `5,000 crore total financial outlay, the PRIP scheme managed by the Department of Pharmaceuticals is the cornerstone of India’s innovation push. Allocates `700 crores to establish dedicated Centres of Excellence (CoEs) across all seven NIPER campuses. Each campus focuses on a specialised domain. A newly formed institutional bridge led by the Secretary of the Department of Pharmaceuticals. It brings together all major industry associations and NIPER heads to ensure academic curricula and research directly match the industry’s shift toward biologics and advanced engineering. By intentionally linking financial backing, infrastructure building, regulatory handholding, and intellectual property support, the framework targets the historical bottlenecks that previously slowed down Indian pharma innovation. </span></p>
<p><strong>Coming to your own work, what is the specific problem your research is trying to solve, and why does it matter to patients or the pharma industry today? </strong></p>
<p><span>My research focuses directly on bridging the gap between advanced formulation science and real-world execution, specifically within injectables and specialty formulations. In the current landscape, formulation is becoming the primary value driver and differentiator. My work focuses on designing future formulations that support selfadministration through wearable injectors, pre-filled syringes, and next-generation delivery systems. My dual role as a Scientist & Project Manager for the PRIP Centre of Excellence (CoE) in Medical Devices, combined with my credentials as an ISO 13485 Lead Assessor, allows me to bridge the critical gap between academic prototyping and global commercialisation under the guidance and visionary leadership at institute level. The primary reason many innovative medical device prototypes fail to reach the market is a lack of compliance with international Quality Management Systems (QMS). As a certified ISO 13485 Lead Assessor, I embed global compliance requirements directly into our scientific workflows. Establishing a Quality Management System (QMS) and securing NABL accreditation (ISO/IEC 17025:2017) for specialised testing laboratories is the definitive step in transforming a research laboratory into a globally recognised conformity assessment body. At the PRIP Centre of Excellence in Medical Devices at NIPER Ahmedabad, we executed this exact roadmap. The NIPER-A Testing Laboratory (NTL) achieved national milestone status as India’s first NABL-accredited facility for specialised mechanical orthopedic implant testing. I spearhead the establishment of our Quality Management System (QMS) and direct the end-to-end documentation pipeline required to secure NABL accreditations across our specialised mechanical, analytical, and biocompatibility testing laboratories. Ultimately, our goal at the CoE is to prove that when academic research embraces a rigorous, regulatoryfirst approach, it creates intellectual property that the pharma and MedTech industries can rapidly scale, commercialise, and bring directly to patients. </span></p>
<p><strong>When research moves closer to commercialisation, what tends to become the biggest challenge-funding, scale-up, validation, regulatory requirements or finding the right industry partner? </strong></p>
<p><span>Moving research out of the lab and into the market-a risky transition known as the “Valley of Death”-presents a complex web of hurdles rather than a single isolated challenge. While the exact bottleneck varies by sector, deep-tech and science-based innovations are primarily choked by regulatory compliance and validation, where navigating rigorous FDA/EMA approvals and multi-phase clinical trials requires years of effort and carries the highest risk of failure. Furthermore, companies must conquer industrial scale-up by translating delicate lab protocols into stable, costeffective manufacturing processes, while simultaneously achieving market validation by securing channel partners or enterprise customers to prove the scientific breakthrough solves a genuine, profitable problem. </span></p>
<p><span>If you could change one thing about the way Indian academia and pharma industry work together today, what would you change-and what difference could that make to India’s innovation ambitions? </span></p>
<p><span>Evolve a co-owned, codelivered, and co-evaluated translation models by expanding the policies that allow academic researchers and professors to actively spin off or lead commercial ventures while retaining institutional ties. By implementing flexible, tiered licensing agreements allows industry partners to take commercial risks while ensuring universities receive fair royalties and empowering scientists to transition smoothly between teaching and industry roles creates a dynamic exchange of ideas and upskilling. </span></p>
<p> </p>
<p><em><strong>lakshmipriya.nair@expressindia.com </strong></em></p>
<p><em><strong>laxmipriyanair@gmail.com </strong></em></p>
<p>The post <a href="https://www.expresspharma.in/from-lab-to-market-bridging-indias-pharma-innovation-gap/">From lab to market: Bridging India’s pharma innovation gap </a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>When patient burden becomes a regulatory risk </title>
<link>https://edusehat.com/en/when-patient-burden-becomes-a-regulatory-risk</link>
<guid>https://edusehat.com/en/when-patient-burden-becomes-a-regulatory-risk</guid>
<description><![CDATA[ 
Ian Fisher, Head of Development Analytics at IQVIA, explains how assessing patient burden early in clinical trial design can help sponsors improve trial execution, preserve data quality and support regulatory decisions 
The post When patient burden becomes a regulatory risk  appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17162759/Ian-Fisher-Head-of-Development-Analytics-at-IQVIA.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 17 Nov 2026 18:20:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>When, patient, burden, becomes, regulatory, risk </media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17162759/Ian-Fisher-Head-of-Development-Analytics-at-IQVIA.jpeg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17162759/Ian-Fisher-Head-of-Development-Analytics-at-IQVIA.jpeg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/17162759/Ian-Fisher-Head-of-Development-Analytics-at-IQVIA-300x160.jpeg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>New drug development typically takes close to nine years from first inhuman trials to regulatory approval, although with pre-clinical development and launch activities, the total time commitment is around 15 years. The pressure of this lengthy and costly development process on drug developers is compounded by increasingly segmented disease populations and increased challenge in proving value over existing therapies, which potentially reduces success rates. </span></p>
<p><span>To alleviate these pressures, sponsors often seek to highly tune their trial designs and protocols to the precise needs and expectations of regulators, with approval the ultimate goal. Though meant to maximise probability of success, unnecessarily complex trial designs can easily work against that goal. Frequent visits, invasive procedures and specialised assessments can make sustained participation difficult, even when patients have a strong motivation to participate. </span></p>
<p><span>When these demands begin to complicate trial execution, increased patient burden becomes more than a recruitment concern; it can undermine the robustness and quality of registrational trial data and evidence. By evaluating and enhancing the relationship between patient burden, enrollment and retention, trial timelines and trial execution, sponsors can secure and retain patients and preserve the critical data they generate for regulatory review. </span></p>
<p><strong>Patient burden does not end with recruitment </strong></p>
<p><span>Before clinical trials begin, the trial and protocol design phases determine the procedures patients will undertake and the number of patients needed for success. These procedures can impact a patient’s willingness to participate. Sponsors can improve successful trial execution by rethinking how they approach recruitment. </span></p>
<p><span>Rather than viewing recruitment as the primary issue, sponsors can consider and plan for recruitment challenges that could be warning signs that assumptions made during protocol development might not reflect operational reality. A trial that looks feasible on paper can become difficult to execute once patients and sites encounter its real-world demands. </span></p>
<p><span>When those challenges emerge after enrollment commences, sponsors often need to revisit assumptions built into the original protocol. Changes intended to make the study more executable can create new detrimental consequences of their own. Late amendments introduce delays, inflate costs and risk the interpretability of the data. At that point, unnecessary patient burden becomes a threat to the study and therapy success. </span></p>
<p><strong>When operational burden weakens the evidence </strong></p>
<p><span>The purpose of a clinical trial is to generate compelling and robust evidence of clinical benefit and safety. To ensure that clinical trials remain centered on that goal, sponsors should establish checkpoints within the design phase to prevent overly burdensome protocol changes during the trial. These checkpoints include: </span></p>
<p><span>Endpoints: Sponsors must liaise with regulators, patients, physicians and payers to establish lean yet truly meaningful, validated and reliable endpoints needed to evaluate benefit and safety. Any ambiguity in potential acceptance or utility of the trial’s endpoints represents a clear risk to success. </span></p>
<p><span>Patient populations: A realistic and appropriately generalisable set of eligibility criteria, which evolves over the duration of the development program, is a critical component of program and trial design. Confidence that the right information has been gathered from the right patients over time is key to regulatory and commercial success. </span></p>
<p><span>Follow-ups: Clinical trials need sufficient timelines to capture initial results and time to conduct follow-up assessments of the durability of clinical benefits. Information capturing periods that end prematurely may fail to establish the benefits of a slow-acting or disease-modifying therapy.</span></p>
<p><span>If operational difficulties prevent critical design choices from being executed as intended, sponsors risk reaching the end of the study without the clarity needed to make confident development and regulatory decisions. </span></p>
<p><strong>Missing or difficult-to-interpret data can change what the study can prove </strong></p>
<p><span>Even when a trial is completed, the collected data must still support a clear assessment of clinical benefits. Sponsors should plan for gaps in data and stress-test alternative interpretations so that conclusions hold up under different assumptions. This becomes important when challenges in participation or protocol modifications affect how a study unfolds, since late changes can compromise data interpretability.</span></p>
<p><span>Therefore, clear, robust evidence that persuades regulators that the therapy under study delivers meaningful clinical benefits. </span></p>
<p><strong>Assess burden before the protocol is locked </strong></p>
<p><span>Trial sponsors can resolve protocol problems by critically evaluating patient burden and willingness to participate early enough for that information to influence trial design. These feasibility assessments can incorporate valuable input from patients, trial sites and clinical operations teams. Sponsors can strengthen those insights by integrating evidence from comparable trials and actual site performance. </span></p>
<p><span>Historical data can also reveal feasibility risks that may not have been apparent through expert-led protocol planning. These perspectives can clarify whether eligibility criteria, endpoints and assessment schedules may create practical challenges before those requirements are finalised. </span></p>
<p><span>Sponsors who delay this evaluation until enrollment begins risk discovering feasibility problems when changes are far more disruptive. Technology is also providing clinical teams with new opportunities to identify risks faster, with advanced analytics increasingly supporting trial planning and even helping predict patient dropouts. Evaluating participation and retention risks before finalising protocols allows feasibility to shape the study rather than forcing the study to react to feasibility later. </span></p>
<p><strong>Patient-centered design should also be decision centered </strong></p>
<p><span>Addressing the overall patient burden before adopting protocols is only one piece of building a trial that can support a regulatory decision. Sponsors must also establish early alignment with regulators on what the study must demonstrate. All regulatory feedback must be leveraged to guide the evidence-generation strategy before a program advances to a point where significant changes become difficult and costly. If sponsors gain little insight from that feedback, they’ll fail to translate regulatory concerns into the study itself. </span></p>
<p><span>Sponsors must also consider that scientific validity alone does not guarantee that a study will answer the questions regulators need resolved. Even the most meaningful results may miss the mark if the trial was not designed around the regulatory conclusions it ultimately set out to support. Sponsors should prioritise maintaining ongoing regulatory engagement throughout development, particularly when existing guidance does not adequately address the circumstances of a program. This line of communication and alignment helps ensure that evidence generated can answer any regulatory questions the study was designed to resolve. </span></p>
<p><strong>Patient experience should shape trial design </strong></p>
<p><span>Patient experience should influence more than how sponsors can recruit and retain patients. </span></p>
<p><span>It should be the source of truth as to whether the study can realistically be accomplished to the degree that sponsors require. Bringing this viewpoint into the development stage gives sponsors an opportunity to pinpoint assumptions that may not withstand the realities of participation. </span></p>
<p><span>From there, patient centeredness becomes part of building a clinical trial that can generate meaningful evidence for regulators to confidently evaluate a therapy. </span></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/when-patient-burden-becomes-a-regulatory-risk/">When patient burden becomes a regulatory risk </a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Beyond expiry dates: Building a more transparent and traceable medicine supply chain </title>
<link>https://edusehat.com/en/beyond-expiry-dates-building-a-more-transparent-and-traceable-medicine-supply-chain</link>
<guid>https://edusehat.com/en/beyond-expiry-dates-building-a-more-transparent-and-traceable-medicine-supply-chain</guid>
<description><![CDATA[ 
Devashish Singh, Co-founder and CEO of MrMed, highlights how end-to-end medicine traceability can strengthen supply-chain accountability, improve medicine safety and ensure critical medicines can be tracked from manufacturer to patient 
The post Beyond expiry dates: Building a more transparent and traceable medicine supply chain  appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17163154/Devashish-Singh.jpg.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 17 Nov 2026 18:20:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Beyond, expiry, dates:, Building, more, transparent, and, traceable, medicine, supply, chain </media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17163154/Devashish-Singh.jpg.jpeg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17163154/Devashish-Singh.jpg.jpeg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/17163154/Devashish-Singh.jpg-300x160.jpeg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>A medicine does not become a patient-safety risk only when it crosses its expiry date. The risk can begin much earlier, when its source cannot be verified, when a batch cannot be traced, when storage conditions are unknown, or when a product recalled by the manufacturer cannot be reliably located across the supply chain. </span></p>
<p><span>India has made significant progress in putting systems in place to address some of these challenges. QR and barcode based identification have been part of the regulatory framework for several years, and the government has recently expanded the traceability framework to cover critical categories including anti-cancer medicines, vaccines and antimicrobials. Under the amended framework, these products will carry QR or barcodes containing key information such as product identification, manufacturer, batch number, manufacturing and expiry dates, and licensing details. </span></p>
<p><span>The next challenge is not creating more traceability infrastructure. It is ensuring that the information captured at the manufacturing stage remains usable and verifiable all the way to the point where a medicine reaches a patient. </span></p>
<p><span>That distinction matters. A medicine may pass through manufacturers, distributors, warehouses, pharmacies and hospitals before it is finally dispensed. At each stage, its identity, batch, expiry, storage conditions and ownership can potentially become less visible. When that happens, even a well-regulated product can become difficult to track when something goes wrong. </span></p>
<p><span>For ordinary medicines, this can lead to avoidable wastage, stock-outs or inefficient inventory management. For oncology, biologics, transplant and rare-disease therapies, the consequences can be considerably more serious. India has the technology to track medicines. The open question is whether the industry can make traceability a continuous responsibility, from manufacturer to patient, rather than a set of checkpoints along the way. </span></p>
<p><strong>Where batch-level tracking breaks down </strong></p>
<p><span>Most pharmacies, hospitals and distributors record a purchase and a sale. Far fewer consistently capture the batch number and expiry date at both ends of that transaction, and fewer still reconcile the two.</span></p>
<p><span>A medicine is a traceable unit with a specific manufacturing history, shelf life and chain of custody, not just a product. Once batch identity is lost at any point, everything downstream becomes harder to verify. A recall cannot be executed with precision, nearexpiry stock cannot be proactively moved or removed, and a suspicious pack becomes difficult to distinguish from a genuine one. </span></p>
<p><span>Strengthening this does not necessarily require another layer of complexity. It requires making existing practices non-negotiable. </span></p>
<p><span>Batch number and expiry should be captured when goods are received rather than reconstructed later from invoices. Inventory should follow a strict first-expiry-first-out principle, with systems preventing a dispense that violates it rather than merely flagging the issue afterwards. Physical stock should be reconciled against digital records at defined intervals, and discrepancies should trigger investigation. </span></p>
<p><span>Procurement is equally important. Pharmacies and hospitals should source medicines only from manufacturers or authorised distributors, with invoices and batch details that can be traced back through the supply chain. </span></p>
<p><span>For hospitals, this discipline needs to extend beyond the central pharmacy. Ward-level inventories, emergency stocks and crash carts also need the same level of visibility, because a medicine that is correctly tracked in a warehouse can still become a patient-safety risk if its expiry is not monitored once it reaches the point of care. </span></p>
<p><strong>Authenticity is only one part of the equation </strong></p>
<p><span>Traceability is often discussed in the context of counterfeit medicines, but authenticity is only one part of the problem. A medicine can be genuine when it leaves the manufacturer and still become unsuitable for use if it is improperly stored, mishandled or allowed to cross its expiry date. </span></p>
<p><span>This is particularly important for temperature-sensitive therapies. A product that has been exposed to conditions outside its prescribed cold chain may look no different from a properly stored product. The packaging does not necessarily tell the patient what happened to the medicine between manufacturing and dispensing. </span></p>
<p><span>That is why end-to-end traceability needs to include more than a batch number. Where storage conditions are critical, temperature and handling records should also form part of the chain of custody and be available when required. </span></p>
<p><span>For the patient, the question should ultimately be simple. Can the authenticity, provenance, storage history and expiry status of a critical medicine be established with confidence? Today, that answer is not always yes. </span></p>
<p><strong>Why expiry management matters even more for super-specialty medicines </strong></p>
<p><span>Expiry management becomes particularly consequential when dealing with super-specialty and life-saving therapies. </span></p>
<p><span>Oncology medicines, biologics, transplant therapies and rare-disease treatments can be extremely expensive, temperature-sensitive and clinically critical. They are also often prescribed as part of tightly sequenced treatment regimens where delays or interruptions can have serious consequences. </span></p>
<p><span>For these medicines, the issue is not simply financial wastage. A medicine nearing expiry may technically remain within its labelled shelf life, but that does not necessarily make it appropriate for every patient or treatment schedule. A patient beginning a long term therapy should not be handed stock with an impractically short remaining shelf life. </span></p>
<p><span>The industry needs to move from asking whether a medicine is expired to asking whether it is fit, authentic, properly stored and appropriate for the intended treatment window. </span></p>
<p><span>This is where minimum remaining-shelf-life thresholds can play a role, particularly for high-value and critical therapies. Cold-chain compliance should also be demonstrable rather than assumed simply because a shipment arrived cold. </span></p>
<p><span>For patients and caregivers, these may appear to be backend supply-chain issues. In reality, they directly influence treatment continuity and patient safety.</span></p>
<p><strong>The gaps in the current medicine supply chain </strong></p>
<p><span>Three gaps require particular attention. </span></p>
<p><span>The first is reverse logistics. Medicines move down the supply chain with relatively detailed documentation, but expired, damaged and returned stock can move back with considerably less visibility. That creates an opportunity for diversion, repackaging and reentry into the legitimate market. The answer is to treat reverse logistics with the same seriousness as forward distribution. Every returned or expired batch should have a documented status, location and final disposition. </span></p>
<p><span>The second is the last mile. Unlicensed sellers, unverified online listings and retailers sourcing from unknown channels create points in the system where the provenance of medicines becomes difficult to establish. Stronger procurement controls and more frequent verification are required at these points. </span></p>
<p><span>The third is fragmented use of traceability infrastructure. India is now expanding QR-based traceability to more critical medicine categories, but the value of such infrastructure will ultimately depend on how consistently the information is accessed and acted upon across the supply chain. A traceability system that records information but does not use it to make decisions is only partially solving the problem. </span></p>
<p><strong>What pharmacies, hospitals and distributors can do </strong></p>
<p><span>The industry does not need to wait for every regulatory requirement to take effect. </span></p>
<p><span>Pharmacies can strengthen batch-level inventory by recording batch and expiry information at inward and dispensing stages, implementing first-expiry-first-out systems and conducting regular physical reconciliation. Distributors can improve visibility by maintaining batchlevel records through both forward and reverse logistics, ensuring that returned or damaged stock is appropriately quarantined and disposed of, and limiting procurement to verified channels. Hospitals can extend these practices into wards, emergency departments and other locations where medicines may be stored outside the central pharmacy. </span></p>
<p><span>For critical therapies, the ability to establish not only where a product came from but also how it was stored can be particularly important. These are operational changes, but they can have a direct impact on patient safety. </span></p>
<p><strong>What regulators can do next </strong></p>
<p><span>The recent expansion of QRbased traceability is an important step. The government has now brought vaccines, antimicrobials, anti-cancer medicines and specified narcotic and psychotropic drugs under the expanded framework, with phased implementation timelines beginning in 2027. </span></p>
<p><span>The next step is ensuring that this infrastructure creates an actionable, connected system rather than another compliance requirement. </span></p>
<p><span>First, QR-based traceability should progressively cover more medicines, with priority given to high-value, temperature-sensitive and clinically critical therapies. </span></p>
<p><span>Second, verification should happen at meaningful points in the supply chain. Pharmacies, hospitals and other licensed dispensing points should be encouraged, and for higher-risk categories, potentially required, to scan and verify medicines before dispensing. A code that exists on a package but is never checked provides limited protection. </span></p>
<p><span>Third, India needs a more centralised and real-time recall mechanism. When a particular batch is found to be defective, spurious or unsafe, information should reach licensed pharmacies, hospitals and distributors quickly and in a standardised format. Batch level alerts can help reduce the dependence on information moving manually through multiple layers of the supply chain.</span></p>
<p><span>Fourth, the disposal loop needs to be closed. Expired medicines should move through authorised disposal channels, with destruction or disposal documented against the original batch. This matters because expired and returned stock can otherwise become a source of material for fraudulent repackaging. </span></p>
<p><span>Finally, enforcement needs to focus on vulnerable points in the chain. Warehouses, distribution facilities and other high-risk nodes need appropriate licensing checks, audit mechanisms and inspection frequency. The objective should not only be to identify violations after they occur, but to make diversion and reentry increasingly difficult.</span></p>
<p><strong>From compliance to accountability </strong></p>
<p><span>None of these interventions depends on technology that does not yet exist. The infrastructure for barcoding, digital inventory management, batchlevel tracking and QR-based verification is already available, and its regulatory scope is expanding.</span></p>
<p><span>The larger shift required is operational. The industry needs to treat batch and expiry information as a living part of a medicine’s identity, not data recorded once and forgotten. Pharmacies need to verify what they receive, hospitals need visibility beyond their central stores, and distributors need stronger controls over forward and reverse movement. Manufacturers need greater visibility into where products ultimately travel, and regulators need systems that connect these individual points into a more coherent chain. </span></p>
<p><span>Medicine safety is not determined only at the point of manufacture. It is protected, or compromised, at every handover that follows. </span></p>
<p><span>The goal should be bigger than preventing the sale of expired medicine. It should be a supply chain where every critical medicine can be authenticated, its batch and expiry can be verified, its handling can be traced, and its movement can be accounted for from manufacturer to patient. That is the level of transparency and accountability that patient safety demands. </span></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/beyond-expiry-dates-building-a-more-transparent-and-traceable-medicine-supply-chain/">Beyond expiry dates: Building a more transparent and traceable medicine supply chain </a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>From making vaccines to inventing them: India’s next challenge </title>
<link>https://edusehat.com/en/from-making-vaccines-to-inventing-them-indias-next-challenge</link>
<guid>https://edusehat.com/en/from-making-vaccines-to-inventing-them-indias-next-challenge</guid>
<description><![CDATA[ 
Ajay Mahipal, Co-Founder and General Partner, HealthKois, examines what it will take to bridge this gap, from patient capital and industry-academia collaboration to regulatory predictability, and build a globally competitive vaccine discovery ecosystem 
The post From making vaccines to inventing them: India’s next challenge  appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17163612/Ajay-Mahipal.jpg.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 17 Nov 2026 18:20:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>From, making, vaccines, inventing, them:, India’s, next, challenge </media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17163612/Ajay-Mahipal.jpg.jpeg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17163612/Ajay-Mahipal.jpg.jpeg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/17163612/Ajay-Mahipal.jpg-300x160.jpeg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>When a country accounts for 60 per cent of the world’s vaccine production, the statistic is usually interpreted as an indication of manufacturing scale. But there is another way to look at it. This scale represents decades of scientific knowledge, development expertise, specialised infrastructure, regulatory experience, and an understanding of how vaccines move from laboratories to large-scale delivery. </span></p>
<p><span>That makes India’s position in global vaccines more than a manufacturing achievement, representing an ecosystem built around one of the most complex areas of healthcare. The question now is how far that ecosystem can extend upstream, towards the discovery and development of the next generation of vaccines. </span></p>
<p><span>This requires recongising that the manufacturing capabilities can create a strong foundation for scientific origination, while also creating the conditions for capital to participate much earlier in the value chain. </span></p>
<p><strong>The advantage of an ecosystem built around vaccines </strong></p>
<p><span>Vaccine discovery does not happen in isolation. It depends on a network of scientific research, clinical development, regulatory expertise, manufacturing capabilities, and an understanding of population-level healthcare needs. India’s experience across these areas gives it a distinctive base for exploring the next phase of vaccine innovation.</span></p>
<p><span>There are already indications of a broader shift in Indian life sciences. Over the past decade, the country has witnessed significant growth on many fronts, including its innovation pipeline, biotech ecosystem, and patent activity. Alongside this, Indian corporations and institutes have witnessed the emergence of novel therapeutic assets. </span></p>
<p><span>For vaccines specifically, this evolution is important because the distance between discovery and scale can be shorter when capabilities across the value chain exist within the same ecosystem. Scientific ideas can be developed with a clearer understanding of manufacturability, cost, access, and eventual deployment. These considerations are important for vaccines, where global impact depends as much on reach as scientific efficacy. </span></p>
<p><span>It also changes the economics of innovation. When research, development, manufacturing and distribution capabilities are closer together, companies can potentially move from scientific validation to commercial scale with fewer structural gaps. That can make the ecosystem more efficient at converting scientific opportunity into economic and societal value. </span></p>
<p><strong>Moving further upstream </strong></p>
<p><span>The next opportunity, therefore, may lie in moving further upstream without moving away from the strengths India has already developed. </span></p>
<p><span>Discovery requires a different investment horizon from manufacturing. Early scientific programs can take years to demonstrate proof of concept, Many will not progress to a market-ready product. This makes patient capital important, alongside investors and institutions that understand scientific risk and can support companies through long development cycles. </span></p>
<p><span>It also calls for a different approach to risk. Not every discovery program will lead to a successful vaccine. Early-stage investments come with inherent uncertainty and long timelines, making predictable short-term returns an unrealistic expectation. A stronger ecosystem is one where multiple scientific bets can be made, the strongest programmes can attract followon capital, and successful platforms can generate value beyond a single product. </span></p>
<p><span>Similarly, stronger connections between academic research and industry can help promising discoveries move beyond the laboratory, while shared infrastructure will enable early-stage companies to access capabilities that would otherwise be difficult to build independently. India has already begun developing such mechanisms through industry-academia programs, technology transfer networks, and research initiatives spanning the innovation lifecycle. </span></p>
<p><span>For vaccine discovery, these connections become especially valuable. The ability to understand a scientific problem, validate it clinically, develop the technology, and eventually manufacture at scale needs to function as a connected pathway rather than as separate capabilities. The stronger that pathway becomes, the more efficiently capital, talent, and scientific expertise can move through it. </span></p>
<p><span>Regulatory predictability will be equally important as India moves further upstream. For companies investing in novel vaccine platforms and early-stage discovery, the regulatory pathway needs to be sufficiently clear from the outset, with well-defined guidelines, predictable review processes, and reasonable timelines for approvals. The objective should not be to lower the regulatory bar, but to provide greater clarity on the path to meeting it. This is particularly important for emerging technologies, where uncertainty around applicable guidelines or prolonged processing timelines can add significant cost and delay to programmes that are already exposed to scientific risk. </span></p>
<p><span>A more predictable regulatory environment can also improve the ability of investors to underwrite early-stage innovation. When companies and investors have greater visibility on the evidence required, approval pathway and expected timelines, they can make better informed decisions on capital allocation and development milestones. Clear regulatory pathways can therefore become an important part of the innovation infrastructure—helping ensure that scientific breakthroughs are not held back by avoidable uncertainty between discovery, clinical development and eventual deployment. </span></p>
<p><strong>From manufacturing strength to discovery potential </strong></p>
<p><span>The most interesting question for India is not whether it can replicate established global models of pharmaceutical innovation. It is whether it can build on what is already distinctive about its own ecosystem. </span></p>
<p><span>India currently has over 10,000 pharmaceutical manufacturing facilities and more than 650 USFDA-compliant plants, the highest number outside the US. Its combination of scientific talent, development capabilities, cost efficiency, a large and diverse population, and established manufacturing depth creates the possibility of connecting discovery with scale for global relevance. That possibility should also be viewed with a long-term lens. </span></p>
<p><span>The emergence of a discovery ecosystem is unlikely to be defined by one breakthrough or one company. Its real measure will be whether scientific ideas originating in India can move through a consistent pathway from research to global deployment. </span></p>
<p><span>This is where the opportunity becomes larger than any individual vaccine. A mature discovery ecosystem can create intellectual property, technology platforms, specialised talent and companies capable of generating multiple innovations over time. The resulting value is not limited to the product that eventually reaches the market; it also lies in the capabilities and assets created along the journey. India’s vaccine manufacturing leadership has already demonstrated what becomes possible when scientific capability, entrepreneurship, infrastructure, and scale converge around a healthcare need. The next opportunity is to build further on that foundation by creating an environment where scientific risk can be taken earlier, capital can stay invested longer, and successful innovation can scale globally. </span></p>
<p><span>The aspiration, then, need not be to move from “made in India” to “discovered in India” as though one replaces the other. It is to make the two increasingly connected. </span></p>
<p><span>The larger opportunity is to build an ecosystem where India not only participates in the final stages of global vaccine value creation but increasingly captures value from the ideas, technologies, and companies that shape those products from the beginning. </span></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/from-making-vaccines-to-inventing-them-indias-next-challenge/">From making vaccines to inventing them: India’s next challenge </a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>When health data crosses borders, trust must travel with it </title>
<link>https://edusehat.com/en/when-health-data-crosses-borders-trust-must-travel-with-it</link>
<guid>https://edusehat.com/en/when-health-data-crosses-borders-trust-must-travel-with-it</guid>
<description><![CDATA[ 
Pradeep Gupta, Partner, Deloitte India, explores how the DPDP Act, 2023, and DPDP Rules, 2025, are reshaping health data governance and why building trust must go hand in hand with enabling cross-border healthcare and research 
The post When health data crosses borders, trust must travel with it  appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17101930/Pradeep-Gupta.jpg.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 17 Nov 2026 14:45:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>When, health, data, crosses, borders, trust, must, travel, with, it </media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17101930/Pradeep-Gupta.jpg.jpeg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/17101930/Pradeep-Gupta.jpg.jpeg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/17101930/Pradeep-Gupta.jpg-300x160.jpeg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>The framework of India’s Digital Personal Data Protection (DPDP) is currently reshaping how hospitals, pharmaceutical companies, Clinical Research Organisations (CROs), insurers and research institutions collect, process and share health data, making governance and accountability integral to healthcare and clinical research. This happens in parallel to raising the stakes for inadequate data protection and breach preparedness. </span></p>
<p><span>Health records travel with patients as they cross national borders, and accordingly, Personally Identifiable Information (PII) is also shared with overseas healthcare stakeholders. </span></p>
<p><span>The digital health database in India shows a rise in Medical Value Travel (MVT), which is about 5.5 per cent of all foreign tourist arrivals. As more than 450,000 patients from other countries travel to India each year, the medical tourism industry is projected to grow by $16.21 billion by 2030, posting a CAGR of 13.23 per cent. The AYUSH market is also poised to grow and is expected to reach $200 billion. Concurrently, the rising trends in the medical tourism industry reflect the growing demand for advanced clinical care and preventive wellness in India. </span></p>
<p><span>Such dynamic expansion of the digital health ecosystems results in the exchange of large volumes of health information among patients, healthcare providers, insurers, CROs, pharma companies and international partners. </span></p>
<p><span>The growth of medical tourism, cross-border healthcare services and global clinical research also increases the movement of sensitive personal health data across jurisdictions, highlighting the importance of resilient privacy, security and governance safeguards. </span></p>
<p><span>This is where India’s DPDP Act, 2023 and the DPDP Rules, 2025 come into the picture by providing a legal and operational framework to process digital personal data and protect the information of domestic and international patients. </span></p>
<p><span>As healthcare moves towards interoperable digital records, privacy, security and informed consent become the primary concerns of hospitals, health-tech firms, insurers, labs and pharma companies for the responsible use of patient centric health information. This is done by implementing access controls, consent tools and breach response plans. Penalties of $2.5 billion for failure to implement security safeguards and $2 billion for failure to report a breach in India are consequences of the DPDP Act’s robust implementation framework. </span></p>
<p><span>Anonymised health data supports disease tracking, monitoring of public health trends and the design of targeted health programmes. The scale is massive with over 1.2 billion linked health records, over 980 million ABHA IDs, over 1.2 million Healthcare Professionals Registries (HPRs) of medical professionals and over 500,000 verified Health Facility Registries (HFRs) as of October 2026, showing the growing digital footprint of India’s domestic healthcare ecosystem. </span></p>
<p><span>This showcases the government’s shift from policymaking to establishing an environment of trust and accountability to operationalise digital personal data governance at scale. A critical component of this trust is to make sure that data subjects can participate meaningfully in the ecosystem through accessible and inclusive engagement. </span></p>
<p><strong>Inclusivity </strong></p>
<p><span>While inclusivity drives engagement, strict adherence to jurisdictional boundaries ensures that this expanded access does not compromise national data sovereignty. Privacy notices and consent mechanisms need to be accessible in vernacular languages as an important part of the DPDP compliance. The BHASHINI app, for instance, supports 36+ Indian languages, 350+ AI models and 23+ language services. This helps to make privacy information and consent processes more accessible and inclusive for India’s citizens. </span></p>
<p><strong>Cross-border transfer responsibility </strong></p>
<p><span>Organisations should proactively map cross-border data flows, conduct Data Protection Impact Assessments (DPIAs) and strengthen contractual safeguards to ensure that every international transfer is necessary, secure and compliant. DPDP Rules permit the government to restrict transfers of personal data to specified foreign states. DPIA can help identify and share essential datasets for clinical research. Contracts with pharmaceutical companies and CROs, sponsors, insurers, cloud providers, etc., should govern secondary use, onward transfers, security standards, subprocessors and timely incident reporting. </span></p>
<p><strong>Breach preparedness</strong></p>
<p><span>Organisations should move beyond reactive breach management by strengthening incident response readiness and investing strategically in Privacy Enhancing Technologies (PETs). This will help build resilience, reduce privacy risks and embed privacy by design into their data ecosystem. The DPDP Rules, 2025, establish clear requirements for breach notification, with Rule 7 requiring data fiduciaries to notify the Data Protection Board within 72 hours, unless an extension is permitted. This highlights the necessity for organisations to establish and operationalise robust breachresponse mechanisms well in advance. </span></p>
<p><strong>Compliance obligation </strong></p>
<p><span>Healthcare organisations should treat data protection as a strategic priority, implementing privacy, security and responsible data governance into digital healthcare initiatives from the outset to build trust and unlock sustainable growth. Rapid expansion of India’s digital infrastructure adds urgency to this transition since the scale and sensitivity of personal health data requires protection, as Internet subscriptions surpass one billion, mobile connectivity in 98 per cent of villages, covering more than 470,000 5G towers in 99.6 per cent of districts.  </span></p>
<p><span>For clinical research, medical tourism and cross-border health data exchange, the DPDP Act, 2023, and the DPDP Rules, 2025, provide the guardrails for how personal health data should be handled, protected and shared. Their impact, however, will be determined by how consistently hospitals, pharmaceutical companies, CROs, insurers and research institutions translate these requirements into everyday decisions on consent, access, security and accountability. When health data crosses borders, trust cannot be assumed; it must be demonstrated at every stage of the data journey.</span></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/when-health-data-crosses-borders-trust-must-travel-with-it/">When health data crosses borders, trust must travel with it </a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Mankind Pharma enters into in&#45;licensing agreement with Betta Pharmaceuticals for Ensartinib</title>
<link>https://edusehat.com/en/mankind-pharma-enters-into-in-licensing-agreement-with-betta-pharmaceuticals-for-ensartinib</link>
<guid>https://edusehat.com/en/mankind-pharma-enters-into-in-licensing-agreement-with-betta-pharmaceuticals-for-ensartinib</guid>
<description><![CDATA[ 
Strategic agreement to strengthen Mankind Pharma’s oncology portfolio with a US FDA-approved targeted therapy for ALK-positive non-small cell lung cancer
The post Mankind Pharma enters into in-licensing agreement with Betta Pharmaceuticals for Ensartinib appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2019/09/11121123/agreement-e1724903886928.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 16 Nov 2026 20:45:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Mankind, Pharma, enters, into, in-licensing, agreement, with, Betta, Pharmaceuticals, for, Ensartinib</media:keywords>
<content:encoded><![CDATA[<div><img width="749" height="397" src="https://cdn.expresspharma.in/wp-content/uploads/2019/09/11121123/agreement-e1724903886928.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2019/09/11121123/agreement-e1724903886928.jpg 749w, https://cdn.expresspharma.in/wp-content/uploads/2019/09/11121123/agreement-e1724903886928-300x159.jpg 300w" sizes="(max-width: 749px) 100vw, 749px"></div><p><span>Mankind Pharma, one of India’s leading pharmaceutical companies, has entered into an in-licensing agreement with Betta Pharmaceuticals for Ensartinib, a novel, patented oncology drug approved by the US Food and Drug Administration (US FDA) and China’s National Medical Products Administration (NMPA). The drug is indicated for adult patients with anaplastic lymphoma kinase (ALK)-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK inhibitor.</span></p>
<p><span>Under the terms of the license agreement, Mankind Pharma will pay Betta Pharmaceuticals an upfront payment, potential development and sales milestone payments, and royalty payments on the annual net sales of Ensartinib in India. Mankind Pharma will be granted an exclusive license to develop, manufacture, register, and commercialize Ensartinib in India, subject to the terms and conditions of the license agreement.</span></p>
<p><span>The agreement marks another step in Mankind Pharma’s efforts to strengthen its oncology portfolio through strategic collaborations with global pharmaceutical innovators and expand its presence in specialised therapies.</span></p>
<p><span>Ensartinib is a targeted therapy designed to inhibit ALK, a protein that can drive cancer growth in a subset of patients with NSCLC. ALK-positive lung cancer represents a distinct molecular subtype of the disease, for which targeted therapies play an important role in treatment.</span></p>
<p><span>This move aligns with Mankind Pharma’s broader strategy of expanding its portfolio through a combination of in-house capabilities and external partnerships, with a focus on innovative therapies addressing significant unmet medical needs.</span></p>
<p><span>Atish Majumdar, Senior President, Mankind Pharma, said:  “Our ambition is to build a differentiated oncology portfolio that brings innovative therapies to the forefront of our growth strategy. The in-licensing of Ensartinib marks a significant step in this journey, strengthening our focus on specialised therapies and reinforcing our commitment to strategic partnerships that complement our capabilities. We see this as an opportunity to accelerate our presence in oncology, expand our therapeutic capabilities and build a stronger foundation for bringing advanced treatment options to patients in India.”</span></p>
<p><span>Together, Mankind Pharma’s pharmaceutical capabilities and Betta Pharmaceuticals’ expertise in oncology innovation, reflect a shared commitment to advancing targeted treatment options and addressing evolving patient needs.</span></p>
<p><span>Shizhe Ding, Chairman Assistant and Head of Business Development, Betta Pharmaceuticals said: “Ensartinib represents an important advancement in targeted therapy for patients with ALK-positive non-small cell lung cancer. Our partnership with Mankind Pharma brings together complementary strengths and a shared commitment to expanding therapeutic options towards a more global patient base. We see this collaboration as an opportunity to extend the reach of Ensartinib and to expand upon its clinical potential. We hope this collaboration indicates a strong start of actualizing the fruition of oncology research into meaningful progress for patients around the world.”</span></p>
<p><span>The introduction of Ensartinib in India will be subject to applicable regulatory approvals and the completion of relevant commercial and operational requirements. Further details on the agreement will be announced in due course.</span></p>
<p>The post <a href="https://www.expresspharma.in/mankind-pharma-enters-into-in-licensing-agreement-with-betta-pharmaceuticals-for-ensartinib/">Mankind Pharma enters into in-licensing agreement with Betta Pharmaceuticals for Ensartinib</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Biocon receives US FDA approval for Pebrilzo injection</title>
<link>https://edusehat.com/en/biocon-receives-us-fda-approval-for-pebrilzo-injection</link>
<guid>https://edusehat.com/en/biocon-receives-us-fda-approval-for-pebrilzo-injection</guid>
<description><![CDATA[ 
PEBRILZO further strengthens Biocon’s oncology portfolio, now totaling five biosimilar therapies for cancer in the United States
The post Biocon receives US FDA approval for Pebrilzo injection appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/06/25113229/us-fda-approval-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 16 Nov 2026 17:10:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Biocon, receives, FDA, approval, for, Pebrilzo, injection</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/06/25113229/us-fda-approval-1.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/06/25113229/us-fda-approval-1.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/06/25113229/us-fda-approval-1-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p>Biocon, an innovation‑led global biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) has approved Pebrilzo (pertuzumab-qcay), a biosimilar of the reference product Perjeta (pertuzumab). PEBRILZO is a monoclonal antibody used to treat HER2-positive breast cancer by blocking HER2 receptors on cancer cells. The FDA approval further strengthens Biocon’s oncology portfolio.</p>
<p>Shreehas Tambe, CEO & Managing Director, Biocon said, “The US FDA approval of PEBRILZO, our biosimilar pertuzumab, marks another significant milestone in Biocon’s journey to expand access to high-quality biosimilars. For patients diagnosed with HER2-positive breast cancer, the burden of the disease extends well beyond the physical challenges, often placing considerable financial strain on patients and their families. As our fifth oncology biosimilar to receive U.S. FDA approval, PEBRILZO strengthens our anti-cancer portfolio and advances our commitment to expanding access to high-quality, affordable biologic medicines.”</p>
<p>In September, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had given a positive opinion<a href="https://www.biocon.com/biocons-pertuzumab-becomes-first-biosimilar-to-secure-ema-chmp-approval-recommendation-under-new-tailored-clinical-approach/"> recommending the granting of a marketing authorization for Biocon’s Pertuzumab biosimilar</a> as 420 mg/14 mL concentrate solution for infusion, under the brand name Pebrilzo, for the treatment of HER2‑positive breast cancer across multiple disease stages in Europe.</p>
<p>Biocon also announced a <a href="https://www.biocon.com/biocon-secures-earliest-licensed-launch-dates-for-pebrilzo-bpertuzumab-following-global-patent-settlement-with-genentech/">global settlement and license agreement with Genentech</a> securing the earliest licensed launch date for PEBRILZO in the United States in Q3 of calendar year 2028.</p>
<p>The post <a href="https://www.expresspharma.in/biocon-receives-us-fda-approval-for-pebrilzo-injection/">Biocon receives US FDA approval for Pebrilzo injection</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>From product knowledge to responsible engagement: What pharma’s frontline workforce needs today? </title>
<link>https://edusehat.com/en/from-product-knowledge-to-responsible-engagement-what-pharmas-frontline-workforce-needs-today</link>
<guid>https://edusehat.com/en/from-product-knowledge-to-responsible-engagement-what-pharmas-frontline-workforce-needs-today</guid>
<description><![CDATA[ 
Anindita Banik, Co-Founder &amp; CEO, SmartWinnr, discusses why pharmaceutical companies need to move beyond product knowledge and equip medical representatives to handle doctor interactions with accuracy, confidence and compliance 
The post From product knowledge to responsible engagement: What pharma’s frontline workforce needs today?  appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/16102758/Anindita-Banik.jpg.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 16 Nov 2026 13:35:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>From, product, knowledge, responsible, engagement:, What, pharma’s, frontline, workforce, needs, today </media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/16102758/Anindita-Banik.jpg.jpeg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/16102758/Anindita-Banik.jpg.jpeg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/16102758/Anindita-Banik.jpg-300x160.jpeg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>In a crowded OPD, a medical representative (MR) gets a few minutes with the doctor. The MR knows the brand’s data cold. The doctor asks, “Is this safe for my elderly patients?” </span></p>
<p><span>The quickest reply perhaps is “Completely safe, doctor.” That answer can land the pharmaceutical company in trouble. Under the Uniform Code for Pharmaceutical Marketing Practices (UCPMP 2024), the word “safe” must not be used without qualification. The code holds companies responsible for their MRs’ conduct. The CEO answers for adherence, and the company’s executive head files an annual disclosure and compliance declaration. </span></p>
<p><span>The scrutiny is growing. In September, the Supreme Court reserved its order on a plea to regulate pharma marketing. The Centre proposed a three-member committee to examine whether a law is needed, and the code applies until then. Since May 2025, as per the DGHS order, MRs are not permitted in central government hospitals. It says they may share updates “by email or other digital media”. </span></p>
<p><span>Product knowledge gets an MR initial access, but what the MR says next determines whether the doctor trusts the brand or not. Those few minutes have to be accurate, compliant, and useful to the doctor. </span></p>
<p><span>Too much field training is still judged by completion rates and quiz scores. Both show what an MR remembers, not how they handle a doctor who pushes back.</span></p>
<p><span>That gap shows up in a handful of moments: a safety question, a query about an unapproved use, a comparison with a competitor, or a request that crosses a line, such as a doctor asking the company to sponsor a conference trip. The code bars that unless the doctor is speaking at a CME or CPD program.</span></p>
<p><span>On safety, the evidence is sobering. When doctors in Canada, France and the US reported on 1,692 sales-rep promotions, serious side effects came up in only 5 to 6% of them, according to a 2013 study in the Journal of General Internal Medicine. Managers can’t hear most calls, so moments like these rarely get coached.</span></p>
<p><span>Imagine the same MR in a team that gets trained for these scenarios. The safety question would not be a surprise. </span></p>
<p><span>Weeks earlier, at the cycle meeting, the brand, medical affairs and compliance teams list the questions MRs are most likely to fumble and agree on what good answers sound like. “Is it safe for my elderly patients?” is on the list. So is the doctor who asks about an unapproved use, and the one who wants a conference trip sponsored. The list keeps changing. When the prescribing information is updated, or a new question starts coming up in the field, the scenarios change with it. </span></p>
<p><span>The MR rehearses each scenario with an AI-simulated doctor on the phone and gets scored every time. The feedback is specific: “You called it safe without qualifying it.” “You skipped the side effects in the prescribing information.” “You didn’t offer the leaflet. </span></p>
<p><span>The bar is agreed in advance with medical and compliance. The answer has to be accurate, every safety statement has to be qualified, and the MR has to recognize when a question belongs with the medical team. Every MR is held to the same bar. A new joiner may simply need more attempts to reach it than a veteran. </span></p>
<p><span>The area manager watches a couple of those attempts before joint field work, coaches the one habit that matters, and signs off only when the MR clears the bar. In the field, the manager checks the same things. </span></p>
<p><span>The manager stays in the loop for a reason. A randomized field experiment with sales agents outside pharma, published in the Journal of Marketing, found that AI coaching combined with a manager’s coaching beat either one alone. </span></p>
<p><span>This does not make the doctor’s question easier. It means the MR has practiced it and is better prepared for the actual conversation with the doctor. </span></p>
<p><span>When the DGHS order came out last year, the Indian Pharmaceutical Alliance asked for “a balanced, structured and transparent engagement model”. The government may yet write one into law. Companies don’t need to wait. The model can start inside the field force: a short list of scenarios that matter, practice before the first call, and managers who coach from what they’ve seen. For a sales head, the test is simple. Before an MR walks into a doctor’s chamber, can you show they can handle the questions most likely to go wrong? If the only evidence is a quiz score, it’s time to measure something else. </span></p>
<p>The post <a href="https://www.expresspharma.in/from-product-knowledge-to-responsible-engagement-what-pharmas-frontline-workforce-needs-today/">From product knowledge to responsible engagement: What pharma’s frontline workforce needs today? </a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Indian pharma needs to balance innovation, scale and integration for sustained growth </title>
<link>https://edusehat.com/en/indian-pharma-needs-to-balance-innovation-scale-and-integration-for-sustained-growth</link>
<guid>https://edusehat.com/en/indian-pharma-needs-to-balance-innovation-scale-and-integration-for-sustained-growth</guid>
<description><![CDATA[ 
Dr Simta Jadhav, VP, Raay Neopharma, highlights how AI, formulation-led research and backward integration could shape the next phase of Indian pharma’s growth, and discusses why companies need to rethink R&amp;D investment, risk and long-term planning, in an in-person interaction with Neha Aathavale 
The post Indian pharma needs to balance innovation, scale and integration for sustained growth  appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/16105021/Dr-Simta-Jadhav.jpg.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 16 Nov 2026 13:35:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Indian, pharma, needs, balance, innovation, scale, and, integration, for, sustained, growth </media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/16105021/Dr-Simta-Jadhav.jpg.jpeg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/16105021/Dr-Simta-Jadhav.jpg.jpeg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/16105021/Dr-Simta-Jadhav.jpg-300x160.jpeg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p dir="ltr"><span><strong>India built much of its global pharmaceutical position on the ability to manufacture affordable generics. But as competition increases and the economics of conventional generics come under pressure, is formulation-led innovation becoming the next logical growth engine for Indian pharma? </strong></span></p>
<p></p>
<p dir="ltr"><span>Absolutely yes, considering the current market dynamics and geopolitical uncertainties, I believe formulation-led research is no longer just a logical progression for the Indian pharmaceutical industry; it has become a strategic necessity.</span></p>
<p></p>
<p dir="ltr"><span>There are two major reasons driving this shift. First, the increasing price competition and commoditisation of generics are making it difficult for companies to sustain profitability by relying on volume alone. To remain competitive, companies need to differentiate their products through advanced formulations, improved drug delivery systems and complex generics that offer greater value.</span></p>
<p></p>
<p dir="ltr"><span>Second, government support and enabling policies are becoming increasingly important in encouraging innovation. Initiatives such as the Promotion of Research and Innovation in PharmaMedTech Sector (PRIP) scheme have created opportunities for pharmaceutical companies, including established industry players, to strengthen their R&D capabilities and participate in innovation.</span></p>
<p></p>
<p dir="ltr"><span>Given the substantial investment and risk associated with developing new chemical entities, formulation-led research offers Indian companies a more practical pathway to build on their existing expertise while developing differentiated, commercially viable products.</span></p>
<p></p>
<p dir="ltr"><span>Therefore, I believe we will see a stronger shift towards formulation-led innovation in the coming years. This is not to say that new chemical entity research is unimportant, but rather that formulation-led research aligns more closely with the capabilities and commercial realities of many Indian pharmaceutical companies today.</span></p>
<p></p>
<p dir="ltr"><span>Ultimately, formulation led innovation is no longer simply an opportunity for growth; it is becoming essential for competitiveness, sustainability and the long term survival of Indian pharmaceutical companies. </span></p>
<p dir="ltr"><span>India is increasingly being spoken about as a potential innovation hub rather than only the ‘pharmacy of the world’.</span></p>
<p><strong>What, in your view, needs to change within pharma companies themselves for that transition to happen, particularly in how R&D is funded, evaluated and given room to take risks? </strong></p>
<p></p>
<p dir="ltr"><span>Speaking from my experience in R&D, I believe Indian pharma needs to strike the right balance between its traditional strengths and the changing demands of the industry.</span></p>
<p></p>
<p dir="ltr"><span>Since 2010, Indian pharmaceutical companies have largely built their growth on the generics business, particularly exports to the US. However, with changing trade policies, increasing competition and saturation in several generic segments, the industry is now moving towards complex generics and more differentiated products.</span></p>
<p></p>
<p dir="ltr"><span>In this scenario, I believe Indian companies should increasingly focus on formulation-led innovation rather than immediately moving towards new chemical entities (NCEs), which require significantly higher R&D investments and involve greater financial risks. By leveraging our existing strengths in formulation development, drug delivery systems and complex generics, we can build differentiated products without necessarily taking on the investment burden associated with developing a completely new molecule.</span></p>
<p></p>
<p dir="ltr"><span>However, beyond investment, one of the most important changes required is to build a culture of innovation within Indian pharmaceutical companies. Innovation should not be viewed as an occasional initiative but as an integral part of the organisation’s R&D strategy.</span></p>
<p></p>
<p dir="ltr"><span>Equally important is developing a culture that accepts risk and failure as part of the innovation process. In research, not every project will succeed, and not every investment will translate into a commercial product. A project that fails can still provide valuable scientific insights and learning for future development. Instead of treating failure as a reason to terminate the innovation journey, companies should view it as an opportunity to learn, reassess and improve their approach.</span></p>
<p></p>
<p dir="ltr"><span>Ultimately, the future of Indian pharma will depend not only on how much we invest in R&D, but also on how effectively we innovate, differentiate our products and learn from our experiences. We need to move from being purely volume-driven generic players to innovation-led companies, while continuing to leverage our existing strengths in manufacturing, affordability and formulation expertise.</span></p>
<p></p>
<p dir="ltr"><span><strong>What do you think might be the major reasons for many companies to downsize their R&D? </strong></span></p>
<p></p>
<p dir="ltr"><span>From what I have observed, the current downsizing across several pharmaceutical companies is closely linked to the challenges in their export businesses in specific US market. Traditionally, companies have followed a growth trajectory that begins with the domestic market, expands into the emerging markets, and eventually moves into highly regulated markets such as the US and Europe.</span></p>
<p></p>
<p dir="ltr"><span>Since around 2010, India has established itself as a major player in the global generics market. However, entering and sustaining a presence in US regulated markets has also meant dealing with increasing scrutiny around manufacturing practices, GMP compliance and product quality, particularly from the US FDA. In highly competitive segments, especially where generic products compete directly with innovator brands, regulatory compliance and manufacturing quality become critical factors. At the same time, the market has continued to operate under complex commercial and regulatory dynamics.</span></p>
<p></p>
<p dir="ltr"><span>In my view, one of the major reasons for the current shift is the increasing saturation of the US generics market. Changing US trade policies, tariff-related uncertainties and intensifying competition are putting pressure on the traditional export-driven business model. Since export revenues have historically supported a significant portion of Indian pharmaceutical companies’ growth and R&D investments, any slowdown in this business directly affects their ability to sustain those investments.</span></p>
<p></p>
<p dir="ltr"><span>The domestic market presents a different set of challenges. Price controls under the DPCO and regulation by the NPPA can limit the commercial returns companies achieve on certain formulations. Consequently, even when a company invests in formulation-led or innovation-led research, it may not be able to realise the same value from the product in India as it could in international markets. This creates a fundamental challenge: companies are expected to invest in innovation, but the commercial environment does not always allow them to recover those investments adequately.</span></p>
<p></p>
<p dir="ltr"><span>Another important factor is the evolving regulatory landscape in Europe and the UK following Brexit. Regulatory requirements and submission pathways have changed, and companies may need to reassess their existing regulatory strategies, documentation and dossiers to meet the respective requirements. For example, a regulatory dossier or marketing authorisation approach previously used for the EU may not automatically be sufficient for the UK. Such changes can increase compliance costs, development timelines and the resources required to maintain market access.</span></p>
<p></p>
<p dir="ltr"><span>Therefore, I believe the current reduction in R&D investment is not attributable to a single factor. It reflects a combination of saturation in the US generics market, changing trade policies, domestic price controls and evolving regulatory requirements across international markets.</span></p>
<p></p>
<p dir="ltr"><span>Ultimately, the key challenge for Indian pharma is that the traditional exportdriven model, which helped fund growth and R&D for many years, is becoming more difficult to sustain. Companies now need to reassess their market strategies, diversify their revenue streams and focus on differentiated products and innovation, while ensuring that the commercial returns justify the investments required.</span></p>
<p></p>
<p dir="ltr"><span><strong>There is now a lot of talk about complex generics, differentiated drug delivery and reformulation as the middle ground between conventional generics and discovering a completely new molecule. Do you think Indian pharma is sufficiently willing to invest in this space, or is the industry still too focused on volume and speed to market? </strong></span></p>
<p></p>
<p dir="ltr"><span>Here, I believe Indian pharma needs to strike the right balance between volume and innovation. Our traditional strength has been large-scale manufacturing and the ability to provide affordable medicines. However, with the US increasingly focusing on strengthening domestic manufacturing under its Make in America agenda, relying solely on scale and volume may not be a sustainable long-term strategy. We need to move up the value chain by investing more in innovation.</span></p>
<p></p>
<p dir="ltr"><span>While India is making progress in this direction, the challenge lies in generating adequate returns on R&D investments, particularly when the domestic market alone may not be sufficient to justify the cost and risk involved. Developing a niche product does not necessarily translate into commercial success, and this uncertainty can act as a significant barrier to innovation.</span></p>
<p></p>
<p dir="ltr"><span>At the same time, ensuring access to affordable medicines remains critical. The question is how we balance affordability with the need to create a commercially viable environment for innovation. This is where government policy becomes important— not just in encouraging R&D investments, but also in creating mechanisms that enable companies to recover those investments and generate sustainable returns.</span></p>
<p></p>
<p dir="ltr"><span>Ultimately, we should not move away from our strength in generics and manufacturing scale; rather, we need to build on it by strengthening our innovation capabilities.</span></p>
<p></p>
<p dir="ltr"><span><strong>For a company trying to move beyond the conventional generics playbook, the challenge is not just developing a different product but deciding which problems are actually worth solving. From a leadership perspective, how do you decide where to take an R&D bet and where not to? </strong></span></p>
<p></p>
<p dir="ltr"><span>From an R&D and leadership perspective, I believe the first step is to clearly understand an organisation’s core capabilities and strengths. Every company has its own areas of expertise, and strategic decisions should be built around those strengths rather than driven purely by industry trends. For instance, biologics and biosimilars are receiving significant attention today, but that does not necessarily mean every company should enter these segments without first assessing its capabilities and preparedness.</span></p>
<p></p>
<p dir="ltr"><span>One of the key challenges is the availability of skilled talent. While biotechnology is gaining momentum in India, the pool of professionals with deep, hands-on experience in biologics and biosimilars remains relatively limited compared with the established expertise available in conventional formulation development. Some companies have already invested in these areas, but building the necessary technical capabilities and developing a skilled workforce takes time.</span></p>
<p></p>
<p dir="ltr"><span>Therefore, as leaders, we need to take a two-pronged approach. First, we should strengthen our existing core competencies through innovation, platform technologies and formulation-led research that can create differentiation and establish a sustainable competitive advantage. Second, if we want to enter emerging areas such as biologics and biosimilars, we must invest in the right talent, technical expertise and infrastructure required to succeed.</span></p>
<p></p>
<p dir="ltr"><span>Equally important is the need to evaluate the commercial viability of every R&D investment right from the beginning. We must assess the investment required, the development timelines, the market potential, the expected returns and the competitive landscape. In the generics business, for example, understanding the market forecast, anticipated price erosion and the likely entry of other generic players is critical to making informed decisions.</span></p>
<p></p>
<p dir="ltr"><span>We often see projects being put on hold or discontinued after substantial investments have already been made. This can happen when the initial assessment does not adequately account for development costs, commercial risks or changes in market dynamics. By the time a product is ready for launch, the market opportunity may have diminished significantly.</span></p>
<p></p>
<p dir="ltr"><span>Ultimately, leadership in R&D is not just about deciding what to develop; it is about deciding where to invest, when to invest and whether the investment can deliver sustainable value. A thorough assessment of technical capabilities, talent, timelines, financial commitments and market potential is essential to ensure that innovation is not only scientifically successful but also commercially viable. This is how companies can protect their resources, minimise risks and build a sustainable R&D pipeline for long-term growth.</span></p>
<p></p>
<p dir="ltr"><strong><span>If you look five to ten years ahead, what do you think will distinguish the Indian pharma companies that successfully move up the value chain from those that remain dependent on the traditional generics model? And what leadership choices need to be made now to get there?</span></strong></p>
<p></p>
<p dir="ltr"><span>Looking ahead over the next five to ten years, I believe AI will play a transformative role in the pharmaceutical industry, much like the impact we have already witnessed in the software sector.</span></p>
<p></p>
<p dir="ltr"><span>We are already seeing a shift in how AI platforms are being developed and applied across pharmaceutical R&D. Initially, the focus was largely on compatibility, but today, these platforms are expanding into areas such as formulation stability prediction, clinical study outcomes and biopredictability. For instance, in formulation development, AI-driven platforms have the potential to significantly reduce the number of experimental trials required. What might traditionally take 10 to 15 trials could potentially be narrowed down to just two or three targeted experiments, depending on the formulation and the complexity of the product. Several excipient companies are also developing platforms based on Biopharmaceutics Classification System (BCS) principles, offering ready-to-use formulation approaches that companies can further optimise for their specific requirements. Similar advancements are taking place in predicting in-vivo performance and biopredictability.</span></p>
<p></p>
<p dir="ltr"><span>Therefore, adopting AI will increasingly become a strategic necessity rather than simply a technological advantage. However, successful adoption will depend not only on the availability of these platforms but also on hiring the right talent, building internal capabilities and integrating AI effectively into existing R&D workflows. </span></p>
<p dir="ltr"><span>Another major challenge for pharmaceutical innovation is backward integration and the security of the supply chain, particularly for active pharmaceutical ingredients (APIs), key starting materials and other critical raw materials. Geopolitical disruptions, including conflicts in regions such as West Asia, have highlighted how vulnerable supply chains can be. In some cases, sourcing APIs, raw materials or even specific impurities can take three to four months, potentially delaying development timelines and product launches.</span></p>
<p></p>
<p dir="ltr"><span>Therefore, going forward, pharmaceutical companies need to focus on two critical priorities: leveraging AI to improve the speed and efficiency of R&D, and strengthening supply-chain resilience through better sourcing strategies and backward integration wherever commercially viable. Ultimately, the future competitiveness of Indian pharma will depend on how effectively we combine technology-driven innovation with supply-chain security. AI can help us develop products faster and more efficiently, while stronger control over critical raw materials can help ensure that these innovations reach the market without unnecessary delays. </span></p>
<p dir="ltr"><span><br>
</span><span><br>
</span><b><span>neha.aathavale@expressindia.com<br>
</span><span>nehaaathavale75@gmail.com</span></b></p>
<p><span> </span></p>
<p>The post <a href="https://www.expresspharma.in/indian-pharma-needs-to-balance-innovation-scale-and-integration-for-sustained-growth/">Indian pharma needs to balance innovation, scale and integration for sustained growth </a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>NPPA directs monitoring of trade margin rationalisation on 137 anti&#45;cancer drugs</title>
<link>https://edusehat.com/en/nppa-directs-monitoring-of-trade-margin-rationalisation-on-137-anti-cancer-drugs</link>
<guid>https://edusehat.com/en/nppa-directs-monitoring-of-trade-margin-rationalisation-on-137-anti-cancer-drugs</guid>
<description><![CDATA[ 
State Drug Controllers asked to monitor revised prices and submit action taken reports by 16 November
The post NPPA directs monitoring of trade margin rationalisation on 137 anti-cancer drugs appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 13 Nov 2026 19:35:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>NPPA, directs, monitoring, trade, margin, rationalisation, 137, anti-cancer, drugs</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, has directed monitoring of the implementation of Trade Margin Rationalisation (TMR) on 137 non-scheduled anti-cancer drugs, notified through a Gazette Order dated 17 October 2026. The revised prices came into effect on 9 November 2026.</span></p>
<p><span>The latest revised price lists, based on submissions received from companies up to 11 November 2026, are available on the NPPA website and the Pharma Sahi Daam app/portal. Manufacturers, retailers, dealers, stockists, hospitals and medical institutions have been directed to comply with the revised prices and display the updated price lists at their premises and websites.</span></p>
<p><span>State Drug Controllers (SDCs) have been directed to monitor compliance by manufacturers, dealers, hospitals and medical institutions to ensure that the benefits of revised maximum retail prices (MRPs) are passed on to patients. Any violation may attract overcharging proceedings under the provisions of the Drugs (Prices Control) Order (DPCO), 2013.</span></p>
<p><span>Complaints regarding overcharging, shortage or non-availability of medicines can be reported through the Pharma Sahi Daam app/portal, NPPA helpline (1800-111-255) or email (monitoring-nppa[at]gov[dot]in).</span></p>
<p><span>State Drug Controllers have been asked to submit their Action Taken Reports to NPPA by 16 November 2026.</span></p>
<p>The post <a href="https://www.expresspharma.in/nppa-directs-monitoring-of-trade-margin-rationalisation-on-137-anti-cancer-drugs/">NPPA directs monitoring of trade margin rationalisation on 137 anti-cancer drugs</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>From volume to value: How India’s pharma industry can move up the global value chain</title>
<link>https://edusehat.com/en/from-volume-to-value-how-indias-pharma-industry-can-move-up-the-global-value-chain</link>
<guid>https://edusehat.com/en/from-volume-to-value-how-indias-pharma-industry-can-move-up-the-global-value-chain</guid>
<description><![CDATA[ 
 Arun Patel, Founder and Partner, Arunasset Investment Services, explains how India’s pharma industry can move beyond volume-led growth and strengthen its position in the global value chain
The post From volume to value: How India’s pharma industry can move up the global value chain appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/13170953/EP_GB_Arun_Patel_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 13 Nov 2026 19:35:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>From, volume, value:, How, India’s, pharma, industry, can, move, the, global, value, chain</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/13170953/EP_GB_Arun_Patel_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/13170953/EP_GB_Arun_Patel_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/13170953/EP_GB_Arun_Patel_750-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>India’s pharma exports reached $31.13 billion in FY2025-26, against $30.47 billion a year earlier. Growth has continued, but not accelerated: exports rose 4.9 per cent to $16.14 billion in April–September 2026, with July–September shipments up just 3.05 per cent to $8.04 billion. Europe expanded 9.66 per cent, ASEAN 21.54 per cent, and Latin America and the Caribbean 16.58 per cent in the first half. Formulations and biologicals still account for 73.84 per cent of shipments. About 35 per cent of formulation exports go to the US and 17 per cent to Europe, according to Crisil. Geographic diversification is progressing, but the American market remains too large to ignore.</span></p>
<p><span>The latest US tariff framework is more selective than the headline 100 per cent rate suggests. Under the April 2026 Section 232 proclamation, the 100 per cent duty applies to specified patented medicines and their ingredients, with concessions linked to US manufacturing commitments. The standard rate for imports from the EU, Japan, South Korea and Switzerland is 15 per cent, creating a substantial difference from the baseline treatment of other patented imports. Generic medicines, biosimilars and their ingredients are currently exempt, although Washington plans to reassess that treatment by April 2027. This protects the largest portion of India’s US pharma exports for now. It does not protect manufacturers from fierce generic competition, price erosion or the costs of developing alternatives to high-volume products.</span></p>
<p><span>The domestic market is in considerably better shape. Indian pharma sales grew 14.7 per cent to approximately </span><span>₹</span><span>74,610 crore in July–September, according to Equirus Securities, while September alone recorded 17.1 per cent growth and 5.4 per cent unit expansion. Quarterly volume growth was 3 per cent. Anti-diabetic medicines grew 21.2 per cent in September, cardiac therapies 20.4 per cent, and oncology 29.4 per cent. Chronic treatments grew 16.8 per cent on a trailing-year basis, compared with 10.9 per cent for acute therapies. Higher prices and new launches still contribute to growth, but the recovery in volumes makes the latest domestic numbers more substantial than a price-led expansion. Nifty Pharma gained 6.1 per cent in the final week of October, compared with 2.59 per cent for Nifty 50, despite mixed company earnings.</span></p>
<p><span>September-quarter earnings illustrate how sharply domestic strength and US weakness can diverge. Sun Pharma’s sales rose 11.8 per cent to </span><span>₹</span><span>16,100 crore, with Indian formulations up 17.3 per cent, while US formulations declined 8.2 per cent to $455 million. Its innovative-medicines portfolio generated $356 million, up 6.9 per cent, and represented 21.1 per cent of sales. Reported net profit fell to </span><span>₹</span><span>1,989 crore, largely reflecting exceptional acquisition-related and other charges; adjusted profit was </span><span>₹</span><span>3,162 crore. The distinction matters because an exceptional expense should not be confused with deterioration in the underlying formulations business.</span></p>
<p><span>Dr Reddy’s reported revenue of </span><span>₹</span><span>8,671 crore, down 1.5 per cent, with North American sales dropping 23 per cent to </span><span>₹</span><span>2,489 crore as revenues from lenalidomide normalised. Its India business grew 17 per cent and emerging markets 24 per cent, but gross margin still fell from 54.7 per cent to 52.1 per cent. Cipla’s revenue declined 2.4 per cent to </span><span>₹</span><span>7,404 crore, and profit dropped 35 per cent to </span><span>₹</span><span>878 crore. Its Indian business grew 12 per cent, while North American revenue fell 19 per cent to $172 million. Strong prescription growth at home has not been enough to replace the profitability of earlier, limited-competition US opportunities.</span></p>
<p><span>Lupin’s net sales rose 14 per cent to </span><span>₹</span><span>7,786 crore, helped by 14.7 per cent growth in India. However, profit fell 22 per cent to </span><span>₹</span><span>1,155 crore and its reported EBITDA margin contracted to 27.9 per cent from 35.6 per cent, including foreign-exchange and other income. Torrent Pharma’s 50.8 per cent revenue jump to </span><span>₹</span><span>4,979 crore partly reflected its expanded business following the JB Chemicals acquisition; net profit nevertheless declined 9.6 per cent to </span><span>₹</span><span>534 crore as depreciation and financing costs increased. Revenue growth alone therefore gives an incomplete account of sector performance.</span></p>
<p><span>Currency provides a partial cushion. Sun Pharma’s disclosed average exchange rate was </span><span>₹</span><span>95.58 to the dollar this September quarter, versus </span><span>₹</span><span>87.35 a year earlier. Lupin’s US sales were approximately 1 per cent higher in dollars but 9.3 per cent higher in rupees. Depreciation supports exporters’ reported revenue, yet imported inputs, equipment and dollar-linked freight can absorb some of that benefit. Dr Reddy’s specifically cited higher freight expenses linked to disruption in the Middle East. India also imported approximately $4.35 billion of specified APIs, bulk drugs and intermediates in FY2024-25, of which China supplied 73.7 per cent, according to Parliament data.</span></p>
<p><span>Complex development and contract manufacturing are providing measurable examples of higher-value business. Laurus Labs reported a 33 per cent rise in quarterly revenue to </span><span>₹</span><span>2,206 crore and 78 per cent EBITDA growth to </span><span>₹</span><span>762 crore. Its contract development and manufacturing revenue rose 77 per cent in the first half, supported by small-molecule projects and investment in peptides. India has established annual domestic capacity of around 56,800 tonnes for 28 of 41 identified critical bulk-drug products under its production-linked incentive programme, although capacity creation does not by itself eliminate import dependence. Moving from commodity generics to peptides, biosimilars and complex inhalation products increases development costs but can also reduce the number of direct competitors.</span></p>
<p><span>For October–December, domestic chronic therapies should remain the main support, while respiratory and anti-infective demand will depend on seasonal incidence and last year’s comparison base. Cipla expects to introduce generic Advair in the US during the quarter, but launch timing and competitive pricing will determine the contribution. Lower lenalidomide revenue remains a comparison challenge for other exporters. Crisil projects 11–13 per cent sector revenue growth for FY27, but warns that raw-material, energy and freight costs could reduce operating margins by 150–200 basis points. The critical indicators in December-quarter results will be US product-level price realisations, margins excluding currency gains, domestic prescription volumes and how quickly new complex products contribute revenue.</span></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/from-volume-to-value-how-indias-pharma-industry-can-move-up-the-global-value-chain/">From volume to value: How India’s pharma industry can move up the global value chain</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>CCRAS&#45;CARI, DU signs MoU to document medicinal plant diversity of North Campus</title>
<link>https://edusehat.com/en/ccras-cari-du-signs-mou-to-document-medicinal-plant-diversity-of-north-campus</link>
<guid>https://edusehat.com/en/ccras-cari-du-signs-mou-to-document-medicinal-plant-diversity-of-north-campus</guid>
<description><![CDATA[ 
The project aims to systematically document, identify and conserve the medicinal plant diversity available across the 250-300 acres of the University of Delhi&#039;s North Campus.
The post CCRAS-CARI, DU signs MoU to document medicinal plant diversity of North Campus appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/13111517/EP_DU.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 13 Nov 2026 16:00:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>CCRAS-CARI, signs, MoU, document, medicinal, plant, diversity, North, Campus</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/13111517/EP_DU.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/13111517/EP_DU.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/13111517/EP_DU-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>The Central Council for Research in Ayurvedic Sciences (CCRAS) – Central Ayurveda Research Institute (CARI), New Delhi and the University of Delhi signed a Memorandum of Understanding (MoU) on 10 November 2026 to undertake a collaborative project titled “Inventory of Phyto-diversity of Medicinal Importance Used in Ayurveda of North Campus of Delhi University.”</span></p>
<p><span>The MoU was formally signed by Prof. (Vd.) Rabinarayan Acharya, Director General, CCRAS, and Dr. Vikas Gupta, Registrar, University of Delhi, at the VC Office, North Campus, New Delhi.</span></p>
<p><span>The project aims to systematically document, identify and conserve the medicinal plant diversity available across the 250-300 acres of the University of Delhi’s North Campus. The initiative seeks to explore the rich botanical heritage of the campus and document plant species of medicinal importance described in Ayurveda.</span></p>
<p><span>The major activities under the project will include comprehensive field surveys, identification and documentation of medicinal plant species, preparation of herbarium specimens, and installation of QR-code-enabled name boards across the campus to facilitate easy identification and access to information about medicinal plants.</span></p>
<p><span>The project will also result in the preparation of an illustrated pictorial book documenting the medicinal flora of the North Campus, along with joint research publications to disseminate the scientific findings.</span></p>
<p><span>Prof. K. Ratnabali, Dean of Academic Affairs, Delhi University; Prof. (Dr.) Shobha Bagai, Director of the Cluster Innovation Centre (CIC), Delhi; Dr. Hemanta Panigrahi, Director in Charge, CARI, New Delhi; Dr. Sakshi Sharma, Research Officer and PI of the Project, CARI, New Delhi; Prof. (Dr.) Suresh Kumar, PI of the Project, Cluster Innovation Centre (CIC), University of Delhi; and Prof. (Dr.) Vandana, Department of  Chemistry, Dyal Singh College, Delhi University, were also present on the occasion.</span></p>
<p><span>This collaborative initiative represents an important step towards strengthening institutional cooperation in the fields of Ayurveda, biodiversity conservation, medicinal plant research and scientific documentation. It is expected to contribute significantly to raising awareness about the medicinal wealth of the university campus and promoting the conservation and sustainable utilisation of medicinal plant resources.</span></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/ccras-cari-du-signs-mou-to-document-medicinal-plant-diversity-of-north-campus/">CCRAS-CARI, DU signs MoU to document medicinal plant diversity of North Campus</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Lupin launches biosimilar Ranibizumab in European market</title>
<link>https://edusehat.com/en/lupin-launches-biosimilar-ranibizumab-in-european-market</link>
<guid>https://edusehat.com/en/lupin-launches-biosimilar-ranibizumab-in-european-market</guid>
<description><![CDATA[ 
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A.
The post Lupin launches biosimilar Ranibizumab in European market appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/06/18094312/IV-injection.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 12 Nov 2026 18:30:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Lupin, launches, biosimilar, Ranibizumab, European, market</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/06/18094312/IV-injection.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/06/18094312/IV-injection.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/06/18094312/IV-injection-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p>Lupin announced that its commercial partner, Sandoz has launched Ranluspec, Lupin’s biosimilar Ranibizumab, across Europe, excluding Germany.</p>
<p>The launch follows the European Commission approval of Ranluspec in vial and pre-filled syringe presentations and marks an important step in expanding access to high-quality biologic treatment options for retinal diseases.</p>
<p>Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A. The indications of Ranluspec encompass the treatment of patients with neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, proliferative diabetic retinopathy, and choroidal neovascularization.</p>
<p>Thierry Volle, President EMEA and Emerging Markets, Lupin, said, “The launch of Ranluspec in Europe advances Lupin’s strategy of bringing high-quality biosimilars to more patients suffering from retinal and choroidal vascular diseases. Together with Sandoz, we will expand access to this important treatment across the region.”</p>
<p>“The launch of Ranluspec reinforces our growing capabilities in biosimilars as it brings together our scientific expertise and manufacturing capabilities in biologics. It underscores our commitment to addressing unmet needs while supporting more sustainable healthcare systems,” said Dr Cyrus Karkaria, President – Biotech Business, Lupin.</p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/lupin-launches-biosimilar-ranibizumab-in-european-market/">Lupin launches biosimilar Ranibizumab in European market</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Biodeal Pharmaceuticals receives CDSCO approval for Midazolam nasal spray</title>
<link>https://edusehat.com/en/biodeal-pharmaceuticals-receives-cdsco-approval-for-midazolam-nasal-spray</link>
<guid>https://edusehat.com/en/biodeal-pharmaceuticals-receives-cdsco-approval-for-midazolam-nasal-spray</guid>
<description><![CDATA[ 
Indigenously developed through in-house R&amp;D, the product marks a significant milestone in Biodeal’s evolution from a manufacturing-led CDMO to an innovation-driven pharmaceutical company.
The post Biodeal Pharmaceuticals receives CDSCO approval for Midazolam nasal spray appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/12162847/EP_Biodeal.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 12 Nov 2026 18:30:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Biodeal, Pharmaceuticals, receives, CDSCO, approval, for, Midazolam, nasal, spray</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/12162847/EP_Biodeal.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/12162847/EP_Biodeal.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/12162847/EP_Biodeal-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Biodeal Pharmaceuticals, an Indian Contract Development and Manufacturing Organisation (CDMO), announced a significant regulatory milestone for its indigenously developed Midazolam Nasal Spray 1.25% w/v, which has received New Drug Permission from India’s Central Drugs Standard Control Organisation (CDSCO). This is the first approval of this product and strength in India.</span></p>
<p><span>Further recognising its innovation, the National Pharmaceutical Pricing Authority’s (NPPA) Multidisciplinary Committee of Experts has recommended a five-year exemption under Para 32(iii) of the Drug Price Control Order (DPCO), 2013, recognising the product as a genuinely new, indigenously developed drug delivery system rather than a reformulation of an existing medicine.</span></p>
<p><span>Midazolam is an established medicine used in the rapid management of emergency situations, primarily acute seizures. Traditionally administered through injection, its nasal delivery offers a new well established delivery system innovated in the US, through the nasal route, particularly in emergency and out-of-hospital settings where intravenous access may not be readily available.</span></p>
<p><span>The product has been developed primarily at Biodeal’s Department of Scientific and Industrial Research (DSIR)-accredited R&D facility. The development involved formulation science, device engineering, dosing precision and manufacturing expertise, reflecting the company’s growing focus on differentiated pharmaceutical products and specialised drug delivery.</span></p>
<p><span>Commenting on the development, Anurag Kumar, Chairman & Managing Director, Biodeal Pharmaceuticals said, “This is a particularly meaningful milestone for Biodeal because it represents recognition of our ability to develop and innovate, beyond our established strengths in pharmaceutical manufacturing. Our teams have worked extensively on the formulation, device engineering and scientific development behind Midazolam Nasal Spray. The recognition by India’s drug regulatory and pricing authorities validates the investment we have made in building indigenous R&D capabilities over the years.</span></p>
<p><span>India has established a strong position in global pharmaceutical manufacturing. The next phase of growth will increasingly depend on our ability to develop differentiated products, build specialised delivery systems and create intellectual and technical capabilities within the country. This milestone reinforces our belief that Indian CDMOs can play a much larger role in that transition.”</span></p>
<p><span>The development marks an important step in Biodeal’s broader evolution towards becoming a specialised, innovation-led CDMO. Building on more than two decades of expertise in nasal drug delivery, the company continues to strengthen its capabilities across complex formulations and specialised pharmaceutical manufacturing, with a focus on serving evolving healthcare requirements in India and international markets.</span></p>
<p>The post <a href="https://www.expresspharma.in/biodeal-pharmaceuticals-receives-cdsco-approval-for-midazolam-nasal-spray/">Biodeal Pharmaceuticals receives CDSCO approval for Midazolam nasal spray</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Carrier Transicold launches X4 7300 trailer refrigeration unit in India</title>
<link>https://edusehat.com/en/carrier-transicold-launches-x4-7300-trailer-refrigeration-unit-in-india</link>
<guid>https://edusehat.com/en/carrier-transicold-launches-x4-7300-trailer-refrigeration-unit-in-india</guid>
<description><![CDATA[ 
New single-temperature unit delivers advanced cooling performance and precise temperature control in ambient conditions up to 50°C
The post Carrier Transicold launches X4 7300 trailer refrigeration unit in India appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/12161422/EP_Carrier-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 12 Nov 2026 18:30:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Carrier, Transicold, launches, 7300, trailer, refrigeration, unit, India</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/12161422/EP_Carrier-1.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/12161422/EP_Carrier-1.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/12161422/EP_Carrier-1-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p>Carrier Transicold has launched the X4 7300 single-temperature trailer refrigeration unit in India, where it is now commercially available, expanding its portfolio for fleets transporting temperature-sensitive food, pharmaceuticals and other perishable cargo. Carrier Transicold is part of Carrier Global Corporation (NYSE: CARR), global leader in intelligent climate and energy solutions.</p>
<p>Designed for demanding temperature-controlled transport applications, the X4 7300 combines strong refrigeration performance with precise temperature control and an efficient operating platform to help fleet operators maintain the conditions required to protect temperature-sensitive cargo across increasingly complex distribution routes.</p>
<p>“As India strengthens the infrastructure connecting producers, distribution centers and end markets, fleets need refrigeration equipment that can protect temperature-sensitive cargo efficiently across longer and more demanding routes,” said Pankaj Mehta, Managing Director, Truck Trailer India, Carrier Transicold. “We see trailer refrigeration emerging as an important new category for temperature-controlled transportation. The X4 7300 is designed to help operators meet these evolving demands while managing operating costs, and it underscores our commitment to supporting the continued development of India’s cold chain with advanced, efficient refrigeration solutions.”</p>
<p>Engineered with EcoFORWARD technologies, the X4 7300 delivers dependable refrigeration performance in ambient temperatures of up to 50°C, making it well suited to the demanding conditions of India’s temperature-controlled distribution network. Reduced engine run hours and lower maintenance costs compared to legacy units can also help lower the total cost of ownership for fleet operators.</p>
<p>The X4 7300 features Carrier Transicold’s APX Control System, which coordinates refrigeration components to help optimize performance and fuel efficiency while supporting precise temperature control, system reliability and ease of operation.</p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/carrier-transicold-launches-x4-7300-trailer-refrigeration-unit-in-india/">Carrier Transicold launches X4 7300 trailer refrigeration unit in India</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>IIT Kanpur scientists discover how immune cells silence insulin</title>
<link>https://edusehat.com/en/iit-kanpur-scientists-discover-how-immune-cells-silence-insulin</link>
<guid>https://edusehat.com/en/iit-kanpur-scientists-discover-how-immune-cells-silence-insulin</guid>
<description><![CDATA[ 
Breakthrough at IIT Kanpur opens a new direction in diabetes research, discovers a new path of communication between immune cells and insulin-producing cells
The post IIT Kanpur scientists discover how immune cells silence insulin appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/12165319/EP_IIT-Kanpur.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 12 Nov 2026 18:30:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>IIT, Kanpur, scientists, discover, how, immune, cells, silence, insulin</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/12165319/EP_IIT-Kanpur.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/12165319/EP_IIT-Kanpur.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/12165319/EP_IIT-Kanpur-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>In a breakthrough that changes our understanding of how diabetes develops, researchers at the Indian Institute of Technology Kanpur (IIT Kanpur) have found that immune cells inside the pancreas can switch off insulin release within minutes and have identified the molecular switch that allows them to do it. The study published in the Journal of Clinical Investigation, one of the leading biomedical journals in the world, was jointly led by Simran Singh and Ashish Kumar, who are the co-first authors of the research, under the supervision of Dr Sai Prasad Pydi at the Department of Biological Sciences and Bioengineering, IIT Kanpur.</span></p>
<p><span>The team has also confirmed that the same pathway is present and active in human pancreatic tissue, which makes it a target for drugs meant to protect insulin production in people with obesity and type 2 diabetes.</span></p>
<p><span>The human  pancreas contains several types of cells, including insulin-producing beta cells and immune cells called macrophages. While beta cells regulate blood glucose by secreting insulin, macrophages help maintain tissue health and immune balance. This study reveals how macrophages directly communicate with neighbouring beta cells to regulate insulin secretion.</span></p>
<p><span>The understanding till now was that obesity triggers low grade inflammation which damages beta cells slowly, over months and years. Now, the IIT Kanpur research has revealed a much faster and more direct exchange of signals.</span></p>
<p>“We discovered that immune cells that are present next to beta cells can switch off insulin release within minutes,” said Dr Sai Prasad Pydi, Assistant Professor in the Department of Biological Sciences and Bioengineering at IIT Kanpur who led the study. “And they do it without giving any of the classical inflammation signals we have been studying for decades. The findings change our fundamental understanding of how immune cells influence insulin production. The effect is not slow damage from inflammation but instruction that is delivered in minutes. The fact that this works the same way in human tissue is what makes it exciting, It is not just a finding in tissues of laboratory mice, but a real biological circuit that could be targeted with a drug ”</p>
<p><span>The team used a precision genetic technique that allowed them to switch a single signalling pathway on or off inside immune cells. Activating this pathway in macrophages caused a sharp reduction in insulin release in mouse models. Conversely, switching the same pathway off had the opposite effect, with insulin secretion improving.</span></p>
<p><span>The messengers were fats, a class of lipids called sphingolipids, and not inflammatory proteins. Once activated, the macrophages rapidly released these fats that the neighbouring beta cells took up through a transporter on their surface. These then interfered with the internal insulin machinery of the beta cells.</span></p>
<p><span>The team traced the trigger to GPR18, a receptor on macrophages that sits at the top of the chain. Blocking GPR18, or any of the steps below it, restored normal insulin release. The pathway therefore has three points at which a potential drug could act: the receptor, the lipid signal and the uptake step.</span></p>
<p><span>The part of the work with the most consequence for patients was carried out on human tissue. Working with the Indiana Biosciences Research Institute in the United States, the IIT Kanpur team confirmed that GPR18 is heavily concentrated in the immune cells of human pancreatic islets. When the researchers activated the pathway in donated human pancreatic tissue, insulin secretion was blocked there as well.</span></p>
<p><span>While the study does not offer a treatment for diabetes, the validation establishes a foundation for further research into how disrupting the pathway can help preserve insulin secretion in people with obesity and type 2 diabetes.</span></p>
<p>The post <a href="https://www.expresspharma.in/iit-kanpur-scientists-discover-how-immune-cells-silence-insulin/">IIT Kanpur scientists discover how immune cells silence insulin</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Slotorado casino account verification</title>
<link>https://edusehat.com/en/slotorado-casino-account-verification</link>
<guid>https://edusehat.com/en/slotorado-casino-account-verification</guid>
<description><![CDATA[ Slotorado Casino: A Practical Guide for Canadian Players If you’re searching for a fresh online casino that feels built for Canadians, you’ve probably landed on Casino Slotorado. This 
The post Slotorado casino account verification appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/A6ZIlFbiXto/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 12 Nov 2026 14:55:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Slotorado, casino, account, verification</media:keywords>
<content:encoded><![CDATA[<figure data-affgun-media="hero"><img decoding="async" src="https://i.ytimg.com/vi/A6ZIlFbiXto/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<h1>Slotorado Casino: A Practical Guide for Canadian Players</h1>
<p>If you’re searching for a fresh online casino that feels built for Canadians, you’ve probably landed on <a href="https://casino-slotorado.com/">Casino Slotorado</a>. This guide walks you through the most useful details – from signing up to cashing out – so you can decide whether Slotorado matches your style of play.</p>
<h2>1. Getting Started – Registration & Account Setup</h2>
<div data-affgun-media="video"></div>
<p>The registration process at Slotorado casino is deliberately simple. You’ll be asked for a valid email address, a password, and a few personal details (name, date of birth, and province). Because Canadian law requires age verification, you’ll need to confirm you’re at least 19 years old (or 18 in Alberta).</p>
<p>After you submit the form, an activation link is sent to your inbox. Click the link, set up a security question, and you’re ready to make your first deposit. The platform also offers a “guest” mode where you can explore the game lobby without logging in, but you won’t be able to claim any bonuses until the account is fully verified.</p>
<h2>2. Welcome Bonuses and Ongoing Promotions</h2>
<p>Slotorado casino greets new players with a multi‑tiered welcome package. The first deposit usually unlocks a 100 % match up to CAD 200 plus 50 free spins. Subsequent deposits bring smaller matches and extra spins, creating a stair‑step bonus structure that lasts for the first four deposits.</p>
<p>Wagering requirements are a key factor: the initial match comes with a 30× playthrough, while later bonuses are usually 25×. These figures are fairly typical for Canadian online casinos, but always read the fine print before you claim.</p>
<table border="1" cellpadding="5" cellspacing="0">
<thead>
<tr>
<th>Deposit Tier</th>
<th>Bonus Offer</th>
<th>Wagering Requirement</th>
<th>Free Spins</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st Deposit (up to CAD 200)</td>
<td>100 % match</td>
<td>30×</td>
<td>50</td>
</tr>
<tr>
<td>2nd Deposit (up to CAD 100)</td>
<td>50 % match</td>
<td>25×</td>
<td>30</td>
</tr>
<tr>
<td>3rd Deposit (up to CAD 100)</td>
<td>25 % match</td>
<td>25×</td>
<td>20</td>
</tr>
<tr>
<td>4th Deposit (up to CAD 100)</td>
<td>25 % match</td>
<td>25×</td>
<td>20</td>
</tr>
</tbody>
</table>
<h2>3. Payment Methods & Deposit Options</h2>
<p>Canadian players have a decent selection of trusted deposit methods. Most major credit and debit cards are accepted, as well as Interac e‑Transfer – a favourite for its instant processing. Below is a quick rundown of the most popular options.</p>
<ul>
<li><strong>Interac e‑Transfer:</strong> Zero‑fee, instant credit to your casino balance.</li>
<li><strong>Visa/Mastercard:</strong> Instant, but some banks may apply a small processing fee.</li>
<li><strong>PayPal:</strong> Fast and secure, though not every Canadian bank links directly.</li>
<li><strong>Bank Transfer (EFT):</strong> Takes 1‑2 business days but useful for large sums.</li>
</ul>
<p>All deposits are processed in Canadian dollars, which protects you from hidden conversion fees. Minimum deposit amounts start at CAD 10, making it easy for casual players to test the waters.</p>
<h2>4. Withdrawal Process & Speed</h2>
<p>When it’s time to cash out, Slotorado follows a standard verification step: you’ll need to upload a government‑issued ID, a recent utility bill, and a copy of the card used for the deposit. This KYC (Know Your Customer) check is mandatory before the first withdrawal.</p>
<p>After verification, withdrawal speed depends on the method you choose. Here’s what you can typically expect:</p>
<ul>
<li><strong>Interac e‑Transfer:</strong> 1‑2 business days (most players report same‑day if requested early).</li>
<li><strong>PayPal:</strong> 24‑48 hours.</li>
<li><strong>Bank Transfer:</strong> 3‑5 business days.</li>
</ul>
<p>Most Canadian players appreciate the “instant payouts” promise advertised by Slotorado, though it really applies only to e‑Transfer withdrawals.</p>
<h2>5. Mobile Experience – App & Browser Play</h2>
<p>Slotorado casino offers a responsive web design that works smoothly on iOS and Android browsers. No separate download is required, but the brand also provides a lightweight Android app for those who prefer a dedicated icon on their home screen.</p>
<p>The mobile interface mirrors the desktop lobby, giving you access to slots, live casino tables, and the sportsbook. Load times are quick, and the touch‑optimized controls make it easy to place bets on the go. Canadian players with limited data plans will notice the site’s efficient compression, which reduces bandwidth without sacrificing graphics quality.</p>
<h2>6. Game Selection – Slots, Live Casino, Sports Betting</h2>
<p>The core of Slotorado casino is its slot library. You’ll find titles from industry giants like NetEnt, Microgaming, and Play’n GO, covering a range of RTPs (usually 96‑98 %) and volatility levels. Whether you enjoy high‑risk, high‑reward games or prefer steadier returns, there’s a slot that fits.</p>
<p>Beyond slots, the live casino section streams real‑time dealers for blackjack, roulette, and baccarat. The video quality is HD, and the chat function lets you interact with the dealer – a nice touch for those who miss the brick‑and‑mortar vibe.</p>
<p>Sports‑betting enthusiasts can also place wagers on major North American leagues (NHL, CFL, NFL) and international events. The sportsbook runs on the same account, so you can switch between casino games and sports bets without logging out.</p>
<h2>7. Security, Licensing & Responsible Gambling</h2>
<p>Slotorado operates under a license from the Malta Gaming Authority, a jurisdiction known for strong player protection standards. All data traffic is encrypted with 128‑bit SSL, and the platform undergoes regular third‑party audits to ensure fairness.</p>
<p>The casino promotes responsible gambling through tools such as deposit limits, self‑exclusion, and “time‑out” reminders. If you ever feel you need a break, a simple request to customer support can trigger a temporary lock on your account.</p>
<h2>8. Customer Support & Help Resources</h2>
<p>Help is available 24/7 via live chat and email, with an average response time of under two minutes for chat. The support team is fluent in English (Canadian spelling) and can guide you through everything from bonus activation to withdrawal troubleshooting.</p>
<p>For quick answers, the FAQ section contains articles on common topics like “How to verify my account?” and “Why is my withdrawal pending?” The knowledge base is searchable and organized by category, making it easy to find what you need without waiting for a live agent.</p>
<h2>9. Frequently Asked Questions</h2>
<ul>
<li><strong>Is Slotorado legal for Canadian players?</strong> Yes – the Malta license is accepted in Canada, and the site complies with local gambling regulations.</li>
<li><strong>Can I play on my iPhone?</strong> Absolutely. The responsive website works flawlessly on Safari, and there’s an Android app for Android devices.</li>
<li><strong>What’s the fastest way to withdraw?</strong> Interac e‑Transfer, usually completed within 1‑2 business days after verification.</li>
<li><strong>Are there any hidden fees?</strong> No. All fees are disclosed during the deposit and withdrawal processes.</li>
</ul>
<p>With a solid bonus structure, a wide selection of games, and transparent banking options, Slotorado casino stands as a competitive choice for Canadian players looking for both entertainment and reliability.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/uncategorized/slotorado-casino-account-verification/">Slotorado casino account verification</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Emperia app account verification guide for Canadian players</title>
<link>https://edusehat.com/en/emperia-app-account-verification-guide-for-canadian-players</link>
<guid>https://edusehat.com/en/emperia-app-account-verification-guide-for-canadian-players</guid>
<description><![CDATA[ Emperia App – Complete Guide for Canadian Players Getting Started: Registration and First Steps When you land on the Emperia homepage, the first thing you’ll notice is the 
The post Emperia app account verification guide for Canadian players appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/anUyZ2ml6EM/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 12 Nov 2026 14:55:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Emperia, app, account, verification, guide, for, Canadian, players</media:keywords>
<content:encoded><![CDATA[<figure data-affgun-media="hero"><img decoding="async" src="https://i.ytimg.com/vi/anUyZ2ml6EM/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<h1>Emperia App – Complete Guide for Canadian Players</h1>
<p><!-- Hero image / video will be injected automatically --></p>
<h2>Getting Started: Registration and First Steps</h2>
<div data-affgun-media="video"></div>
<p>When you land on the Emperia homepage, the first thing you’ll notice is the bright “Sign Up” button. Canadian players can create an account in just a few minutes by filling out name, email, and a password. The form also asks for your province to make sure the service is legal where you live, which most of us in Canada appreciate.</p>
<p>After you confirm the verification email, the system will prompt you to set a deposit limit – a handy responsible‑gambling tool. If you’re new to online casinos, take a moment to read the short tutorial that explains how points turn into bonus credits. That way you won’t be surprised when a welcome bonus pops up on your dashboard.</p>
<h2>Downloading and Installing the Emperia App</h2>
<p>The Emperia app is available for both iOS and Android. For iPhone users, head to the Apple App Store and search “Emperia Casino”. Android players need to download the APK from the official Emperia site – the site will check your device compatibility before the file starts.</p>
<p>Installation is straightforward: tap the file, allow “unknown sources” temporarily, and the app will appear on your home screen. Once opened, the app asks you to log in with the credentials you just created. You’ll notice the interface mirrors the desktop site, but with larger buttons that are easier to tap on a phone.</p>
<h2>Bonuses and Promotions – What You Can Claim</h2>
<p>Emperia loves to greet newcomers with a solid welcome bonus. The typical offer is a 100 % match on your first deposit up to CAD 200, plus 50 free spins on a popular slot. Remember, the free spins come with a 30× wagering requirement, so you’ll need to play enough to cash out.</p>
<p>Beyond the starter pack, the app rolls out weekly reload bonuses, cash‑back on losses, and a loyalty program that awards “Emperia points”. Points can be swapped for bonus cash or tournament entries. Keep an eye on the “Promotions” tab inside the app – they update every Monday.</p>
<ul>
<li>Welcome bonus – 100 % match + 50 free spins</li>
<li>Weekly reload – 50 % up to CAD 100</li>
<li>Cash‑back – 10 % of net losses every weekend</li>
<li>Loyalty points – earn 1 point per CAD 1 wagered</li>
</ul>
<h2>Payment Methods, Deposits and Withdrawal Speed</h2>
<p>Canadian players have a decent selection of deposit and withdrawal options. Below is a quick glance at the most common methods, their minimum amounts and typical processing times.</p>
<table border="1" cellpadding="5" cellspacing="0">
<thead>
<tr>
<th>Method</th>
<th>Type</th>
<th>Minimum</th>
<th>Processing Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interac e‑Transfer</td>
<td>Deposit</td>
<td>CAD 10</td>
<td>Instant</td>
</tr>
<tr>
<td>Visa / MasterCard</td>
<td>Deposit</td>
<td>CAD 20</td>
<td>Instant</td>
</tr>
<tr>
<td>PayPal</td>
<td>Deposit / Withdrawal</td>
<td>CAD 20</td>
<td>Instant / 24‑48 h</td>
</tr>
<tr>
<td>Bank</td>
</tr>
</tbody>
</table>
<p>Ready to start playing? Visit <a href="https://casino-emperia.com/">casino-emperia.com</a> now and verify your Emperia app account today!</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/uncategorized/emperia-app-account-verification-guide-for-canadian-players/">Emperia app account verification guide for Canadian players</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Spin Aura review: compleet overzicht voor Nederlandse spelers</title>
<link>https://edusehat.com/en/spin-aura-review-compleet-overzicht-voor-nederlandse-spelers</link>
<guid>https://edusehat.com/en/spin-aura-review-compleet-overzicht-voor-nederlandse-spelers</guid>
<description><![CDATA[ Spin Aura: praktische gids voor Nederlandse spelers Wat is Spin Aura? Spin Aura is een relatief nieuw online casino dat zich richt op de Nederlandse markt. Het platform 
The post Spin Aura review: compleet overzicht voor Nederlandse spelers appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/_tSdSgoyAMQ/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 12 Nov 2026 14:55:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Spin, Aura, review:, compleet, overzicht, voor, Nederlandse, spelers</media:keywords>
<content:encoded><![CDATA[<figure data-affgun-media="hero"><img decoding="async" src="https://i.ytimg.com/vi/_tSdSgoyAMQ/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<h1>Spin Aura: praktische gids voor Nederlandse spelers</h1>
<h2>Wat is Spin Aura?</h2>
<div data-affgun-media="video"></div>
<p>Spin Aura is een relatief nieuw online casino dat zich richt op de Nederlandse markt. Het platform biedt een breed scala aan slots, live casino‑spellen en een geïntegreerde sportsbook, waardoor zowel casinofans als sportliefhebbers zich thuis voelen. De website is volledig vertaald naar het Nederlands en werkt met een Nederlandse licentie, zodat je als speler zeker bent van een eerlijk en gecontroleerd spelklimaat. Naast de standaardgames kun je bij Spin Aura ook exclusieve releases vinden die je niet overal tegenkomt.</p>
<p>De naam “Spin Aura” verwijst naar de dynamiek van het draaien van de rollen en de sfeer (aura) die ontstaat als je een grote winst behaalt. Voor Nederlandse spelers betekent dit een combinatie van lokale betaalmethoden, Nederlands‑sprekende klantenservice en promoties die aansluiten bij onze speelgewoonten. Het casino claimt snelle uitbetalingen, een gebruiksvriendelijke interface en een mobiel geoptimaliseerde ervaring.</p>
<h2>Registratie en eerste stappen</h2>
<p>De eerste stap om te kunnen spelen is natuurlijk het aanmaken van een account. Ga naar de startpagina, klik op “Registreren” en vul je e‑mail, een wachtwoord en een mobiel telefoonnummer in. Het proces is simpel en duurt meestal minder dan twee minuten. Na de registratie ontvang je een bevestigingsmail; klik op de link om je account te activeren.</p>
<p>Voor de veiligheid vraagt Spin Aura daarna om een korte verificatie. Je moet een kopie van een legitimatiebewijs (paspoort of identiteitskaart) en een recent bankafschrift uploaden. Deze KYC‑stappen zorgen ervoor dat je geen problemen krijgt bij later geld opnemen. Zodra je documenten zijn goedgekeurd, kun je direct een eerste storting doen en profiteren van de welkomstbonus.</p>
<h2>Welkomstbonus en andere promoties</h2>
<p>Spin Aura biedt een royale welkomstbonus die bestaat uit een matchbonus op je eerste drie stortingen plus een aantal gratis spins. De exacte voorwaarden verschillen per promotieperiode, maar over het algemeen krijg je 100 % extra tot €300 en 50 gratis spins op een populaire slot. Let wel op de bijbehorende inzetvereisten – meestal 35× de bonuswaarde – voordat je winsten kunt opnemen.</p>
<p>Naast de welkomstbonus heeft Spin Aura een doorlopend promotie‑programma met reload‑bonussen, cashback en een loyaliteitsprogramma. Alles staat overzichtelijk in het “Promoties” menu, zodat je nooit een aanbieding mist.</p>
<table border="1" cellpadding="5" cellspacing="0">
<thead>
<tr>
<th>Bonus type</th>
<th>Percentage</th>
<th>Max. bonus</th>
<th>Inzetvereiste</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welkomstbonus 1e storting</td>
<td>100 %</td>
<td>€200</td>
<td>35×</td>
</tr>
<tr>
<td>Welkomstbonus 2e & 3e storting</td>
<td>50 %</td>
<td>€100</td>
<td>30×</td>
</tr>
<tr>
<td>Maandelijkse reload</td>
<td>25 %</td>
<td>€50</td>
<td>20×</td>
</tr>
</tbody>
</table>
<h2>Betaalmethoden en opname snelheid</h2>
<p>Spin Aura ondersteunt een reeks populaire betaalopties die in Nederland gangbaar zijn. Je kunt kiezen uit iDEAL, Bancontact, creditcards (Visa, Mastercard), en verschillende e‑wallets zoals Skrill en Neteller. Stortingen worden vrijwel direct verwerkt, waardoor je meteen kunt beginnen met spelen.</p>
<p>Opnames zijn iets langzamer, maar nog steeds redelijk snel. Met iDEAL kun je binnen 24 uur je geld op je bankrekening hebben, terwijl e‑wallets vaak binnen een paar uur klaar zijn. Creditcardopnames duren meestal 2‑3 werkdagen. Hieronder een overzicht van de gemiddelde verwerkingstijden:</p>
<ul>
<li><strong>iDEAL:</strong> 24 uur</li>
<li><strong>Skrill/Neteller:</strong> 1‑3 uur</li>
<li><strong>Visa/Mastercard:</strong> 2‑3 werkdagen</li>
<li><strong>Bankoverschrijving:</strong> 3‑5 werkdagen</li>
</ul>
<h2>Mobiele ervaring en app</h2>
<p>Voor spelers die graag onderweg zijn, biedt Spin Aura een responsieve mobiele website die werkt op zowel Android‑ als iOS‑apparaten. Het ontwerp past zich automatisch aan de schermgrootte aan, zodat knoppen en menu’s niet te klein worden. Daarnaast kun je de officiële Spin Aura‑app downloaden vanuit de Google Play Store of de Apple App Store.</p>
<p>De app biedt dezelfde functionaliteit als de desktopversie: je kunt storten, uitbetalen, bonussen claimen en zelfs live dealer‑spellen spelen met een enkele tik. De laadtijden zijn kort, en de app maakt gebruik van push‑notificaties om je te informeren over nieuwe promoties of aankomende sportwedstrijden.</p>
<h2>Live casino en sportweddenschappen</h2>
<p>Spin Aura heeft een uitgebreid live casino‑gedeelte met spellen zoals live roulette, baccarat, blackjack en een aantal unieke “Lightning” varianten. De dealers zijn professioneel en spreken Engels, maar er zijn ook Nederlandse tafels beschikbaar. De streams zijn van hoge kwaliteit en bieden een authentieke casino‑sfeer zonder dat je je huis hoeft te verlaten.</p>
<p>Naast het casino kun je bij Spin Aura ook sportweddenschappen plaatsen. Het aanbod omvat voetbal, tennis, basketball en niche‑evenementen zoals e‑sports. De odds zijn competitief en er zijn regelmatig “Boosted odds” en “Parlay” promoties. Als je zowel van gokken als van sport houdt, is dit een handige één‑stop‑shop.</p>
<h2>Veiligheid, licenties en verantwoord spelen</h2>
<p>Spin Aura opereert onder een licentie van de Kansspelautoriteit (KSA) in Nederland, wat betekent dat het voldoet aan strenge eisen op het gebied van eerlijk spel, financiële transparantie en spelersbescherming. Alle transacties worden versleuteld met SSL‑technologie, zodat je persoonlijke en financiële gegevens veilig zijn.</p>
<p>Verantwoord gokken staat centraal: er zijn tools voor limietinstellingen, zelfuitsluiting en real‑time spelgedrag‑monitoring. Mocht je merken dat je problemen krijgt, kun je direct contact opnemen met de supportafdeling of gebruikmaken van externe hulporganisaties zoals Gamblers Anonymous.</p>
<h2>Klantenservice en support</h2>
<p>De klantenservice van Spin Aura is 24/7 bereikbaar via live chat, e‑mail en telefoon. Het supportteam spreekt Nederlands, Engels en verschillende andere talen, zodat je altijd een duidelijk antwoord kunt krijgen. De meeste vragen worden binnen enkele minuten afgehandeld via de chat.</p>
<p>Naast directe ondersteuning heeft Spin Aura een uitgebreide FAQ‑sectie met antwoorden op veelvoorkomende vragen over registratie, bonussen, betalingen en technische problemen. Deze zelfhulp‑optie is handig als je buiten kantooruren toch snel een oplossing zoekt.</p>
<h2>Veelgestelde vragen (FAQ)</h2>
<ul>
<li><strong>Is Spin Aura legaal voor spelers uit Nederland?</strong> Ja, het casino beschikt over een KSA‑licentie en voldoet aan alle Nederlandse regelgeving.</li>
<li><strong>Welke betaalmethoden kan ik gebruiken?</strong> iDEAL, Bancontact, Visa, Mastercard, Skrill, Neteller en bankoverschrijving.</li>
<li><strong>Hoe snel kan ik mijn winst opnemen?</strong> Met iDEAL binnen 24 uur; e‑wallets vaak binnen enkele uren.</li>
<li><strong>Kan ik spelen op mijn mobiel?</strong> Ja, via een responsive website of de gratis Spin Aura‑app.</li>
<li><strong>Hoe werkt de welkomstbonus?</strong> Je krijgt 100 % match tot €200 op je eerste storting plus 50 gratis spins, onder een inzetvereiste van 35×.</li>
</ul>
<p>Ben je klaar om zelf te ervaren wat Spin Aura te bieden heeft? Bezoek <a href="https://casino-spin-aura.net/nl/">Spin Aura Casino Nederland</a> en begin vandaag nog met spelen.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/uncategorized/spin-aura-review-compleet-overzicht-voor-nederlandse-spelers/">Spin Aura review: compleet overzicht voor Nederlandse spelers</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>OzzyBet bonus guide – Canada welcome offer, free spins &amp;amp; wagering details</title>
<link>https://edusehat.com/en/ozzybet-bonus-guide-canada-welcome-offer-free-spins-wagering-details</link>
<guid>https://edusehat.com/en/ozzybet-bonus-guide-canada-welcome-offer-free-spins-wagering-details</guid>
<description><![CDATA[ OzzyBet – Your Practical Guide to Canada’s Online Casino &amp; Sportsbook Welcome to the definitive walkthrough for anyone in Canada curious about OzzyBet. This page isn’t a generic 
The post OzzyBet bonus guide – Canada welcome offer, free spins &amp; wagering details appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/IC5WC0iAvRI/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 12 Nov 2026 14:55:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>OzzyBet, bonus, guide, –, Canada, welcome, offer, free, spins, wagering, details</media:keywords>
<content:encoded><![CDATA[<figure data-affgun-media="hero"><img decoding="async" src="https://i.ytimg.com/vi/IC5WC0iAvRI/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<article>
<h1>OzzyBet – Your Practical Guide to Canada’s Online Casino & Sportsbook</h1>
<p>Welcome to the definitive walkthrough for anyone in Canada curious about OzzyBet. This page isn’t a generic sales pitch; it’s a hands‑on manual that shows exactly what you’ll see, click and experience when you sign up. From the moment you hit the “Register” button to the first withdrawal, you’ll know the steps, the pitfalls and the little tricks that make the difference. If you’re looking for a trustworthy place to play slots, table games or bet on the NHL, keep reading – the details below are built for real‑world decisions. For the full site, you can visit <a href="https://casino-ozzybet.com/">casino-ozzybet.com</a> and explore the offers yourself.</p>
<h2>1. Getting Started: Registration and First Steps</h2>
<div data-affgun-media="video"></div>
<p>Creating an OzzyBet account is intentionally straightforward, but a few fields can trip up newcomers. You’ll need a valid Canadian email address, a password that meets the usual complexity rules, and your date of birth – the platform checks you’re 19 or older, the legal gambling age in most provinces. After submitting the form, an activation link lands in your inbox; clicking it confirms your address and unlocks the dashboard.</p>
<p>One practical tip: keep a copy of the confirmation email before you delete it. OzzyBet sometimes asks for that reference when you contact support about KYC (Know Your Customer) verification. If you plan to use the mobile app later, you can skip the optional “promo code” field – you’ll be able to claim any welcome bonus from the promotions tab after logging in.</p>
<h2>2. Welcome Bonuses and What They Really Mean</h2>
<p>OzzyBet’s headline offer is a “100% match up to $500” plus 50 free spins on a popular slot. That sounds generous, but the real value lies in the wagering requirements. In most Canadian online casinos, a 30x playthrough on the bonus amount is common; OzzyBet follows that standard, meaning you’ll need to bet $15,000 before you can cash out the $500 bonus.</p>
<p>Below is a quick snapshot of the current welcome package and its key terms:</p>
<table border="1" cellpadding="5" cellspacing="0">
<thead>
<tr>
<th>Component</th>
<th>Amount</th>
<th>Wagering Requirement</th>
<th>Expiry</th>
</tr>
</thead>
<tbody>
<tr>
<td>Match Bonus</td>
<td>$500</td>
<td>30x bonus</td>
<td>30 days</td>
</tr>
<tr>
<td>Free Spins</td>
<td>50 spins</td>
<td>20x winnings</td>
<td>7 days</td>
</tr>
</tbody>
</table>
<p>When you claim the offer, the bonus funds land in a separate “bonus balance”. You can still play your favorite slots or table games, but any winnings from that balance are locked until the wagering is satisfied. If you prefer lower‑risk play, look for the “low‑volatility” slots in the catalogue – they tend to meet requirements more predictably.</p>
<h2>3. Payment Methods: Deposits and Withdrawals in Canada</h2>
<p>OzzyBet supports the most common Canadian banking options, which is a relief for players wary of foreign e‑wallets. You can fund your account with Interac e‑Transfer, Visa/Mastercard, and major e‑wallets like PayPal. Deposits are instant, and the minimum amount is typically $10, which fits a cautious starter’s budget.</p>
<p>Withdrawals are a bit slower, but still reasonable. The platform processes e‑Transfer payouts within 24‑48 hours, while card withdrawals may take up to five business days due to bank processing. For faster cash‑out, use the “Instant Pay” option with PayPal – it usually lands in your wallet within a few hours, provided you’ve cleared the KYC step.</p>
<h2>4. Game Selection: Casino, Live Dealer, and Sports Betting</h2>
<p>OzzyBet’s library is supplied by several leading software providers, giving you access to over 2,000 slot titles, classic table games, and a robust live dealer section. If you enjoy the ambience of a real casino, the live studio hosts dealers for blackjack, roulette and baccarat, streamed in high definition. The live games have a higher RTP (return‑to‑player) than many stand‑alone slots, often hovering around 97%.</p>
<p>Sports betting is integrated on the same account, so you can flip from a slot spin to a live NHL game without logging out. The sportsbook panel offers typical North‑American markets – hockey, football, basketball and baseball – with competitive odds and occasional “money‑back” promos on big matches. Keep an eye on the “Bet Builder” tool; it lets you combine several selections into a single wager, which can boost potential payouts.</p>
<h2>5. Mobile Experience: App and Browser Play</h2>
<p>For Canadians who favour on‑the‑go gambling, OzzyBet provides a native iOS/Android app that mirrors the desktop experience. The download size is modest (around 50 MB) and the installation process follows the usual app‑store steps. Once logged in, the app remembers your last game, so you can pick up exactly where you left off.</p>
<p>If you prefer not to install anything, the mobile‑optimized website works smoothly in any modern browser. Touch‑friendly menus, auto‑scaling graphics, and quick‑load times make it practical for commuting or quick coffee‑break sessions. Both platforms use the same secure encryption, so your funds and data stay protected whether you’re on a phone or laptop.</p>
<h2>6. Security, Licensing, and Responsible Gambling</h2>
<p>OzzyBet operates under a licence from the Malta Gaming Authority, a reputable regulator that enforces strict player protection rules. All data transmissions are encrypted with 128‑bit SSL, the same standard used by major banks. For added peace of mind, the site undergoes regular audits by independent testing houses that verify RNG fairness.</p>
<p>Responsible gambling tools are built into the user dashboard. You can set daily deposit limits, self‑exclude for a chosen period, or request a “cool‑off” pause. If you ever feel that gambling is affecting your life, the “Help” section links to Canadian support organisations such as the Responsible Gambling Council.</p>
<h2>7. Customer Support: How to Get Help When You Need It</h2>
<p>OzzyBet offers 24/7 live chat, which is the fastest way to resolve account questions. The chat agents are English‑speaking Canadians, so you won’t get lost in translation. For issues outside chat hours, there’s an email ticketing system and an extensive FAQ database that covers topics from bonus clarification to withdrawal troubleshooting.</p>
<p>When you contact support, have the following information ready: your username, the last four digits of the payment method used, and any reference numbers from previous tickets. Providing these details up front usually cuts the response time in half, especially for verification‑related queries.</p>
<h2>8. Frequently Asked Questions</h2>
<ul>
<li><strong>Is OzzyBet legal for players in Canada?</strong> Yes – the MGA licence is accepted by Canadian regulators, and the platform adheres to provincial gambling laws.</li>
<li><strong>What is the minimum withdrawal amount?</strong> The smallest cash‑out is $20, which applies to all supported methods.</li>
<li><strong>Can I play on a Mac?</strong> Absolutely – the web version runs on any modern browser, and the iOS app works on iPhone and iPad.</li>
<li><strong>How long does verification take?</strong> Typically 24 hours if you submit a clear photo ID and proof of address.</li>
</ul>
<p>With this practical roadmap, you should feel equipped to decide whether OzzyBet matches your gambling style. Remember, the best choice balances exciting games, fair bonuses and reliable support – and OzzyBet ticks most of those boxes for Canadian players.</p>
</article>
<p>The post <a href="https://www.pharmaceutical-business-review.com/uncategorized/ozzybet-bonus-guide-canada-welcome-offer-free-spins-wagering-details/">OzzyBet bonus guide – Canada welcome offer, free spins & wagering details</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Kazeeno Bonus Guide for Canadian Players – Welcome Offers, Wagering Requirements &amp;amp; Claim Steps</title>
<link>https://edusehat.com/en/kazeeno-bonus-guide-for-canadian-players-welcome-offers-wagering-requirements-claim-steps</link>
<guid>https://edusehat.com/en/kazeeno-bonus-guide-for-canadian-players-welcome-offers-wagering-requirements-claim-steps</guid>
<description><![CDATA[ kazeeno: Practical Guide for Canadian Players What is kazeeno and Why It Matters for Canadian Gamblers? kazeeno is an online casino platform that has been gaining traction among 
The post Kazeeno Bonus Guide for Canadian Players – Welcome Offers, Wagering Requirements &amp; Claim Steps appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/nAHEh2zHjSk/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 12 Nov 2026 14:55:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Kazeeno, Bonus, Guide, for, Canadian, Players, –, Welcome, Offers, Wagering, Requirements, Claim, Steps</media:keywords>
<content:encoded><![CDATA[<figure data-affgun-media="hero"><img decoding="async" src="https://i.ytimg.com/vi/nAHEh2zHjSk/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<h1>kazeeno: Practical Guide for Canadian Players</h1>
<h2>What is kazeeno and Why It Matters for Canadian Gamblers?</h2>
<div data-affgun-media="video"></div>
<p>kazeeno is an online casino platform that has been gaining traction among Canadian players looking for a mix of slots, live dealer tables, and sports betting. The brand promotes itself as a one‑stop entertainment hub, offering a welcome bonus that can stretch a modest deposit into a sizeable playing balance. For newcomers, the biggest draw is the smooth onboarding process paired with a modern website design that works well on both desktop and mobile.</p>
<p>Beyond the flashy marketing, what really matters is how kazeeno handles key concerns: licensing, payment options, and responsible gambling tools. Canadian users will want to know if the casino holds a reputable licence, whether popular Canadian banking methods are accepted, and how fast withdrawals are processed. This guide walks you through each of those practical points so you can decide if kazeeno fits your style.</p>
<h2>How to Register and Verify Your Account</h2>
<p>The registration on kazeeno is intentionally simple. You start by clicking the “Sign Up” button, filling in your name, email, and a strong password. After submitting, you’ll receive a verification email that you must confirm before you can make a deposit. The whole process typically takes under five minutes, unless you run into email filters.</p>
<p>Verification (often called KYC) becomes necessary once you request a withdrawal that exceeds the initial bonus amount. You’ll be asked to upload a government‑issued ID and a proof‑of‑address document, such as a utility bill. The casino’s support team usually reviews these files within 24‑48 hours, meaning you can expect your first payout to clear shortly after verification.</p>
<h2>Bonuses, Welcome Offers, and Wagering Requirements</h2>
<p>kazeeno’s headline attraction is its welcome bonus package. New players can claim a 100 % match on the first deposit up to $200, plus 50 free spins on a popular slot. The bonus is credited instantly, but note the wagering requirement: you must bet 30 × the bonus amount before any winnings can be withdrawn. This is fairly standard, yet it’s essential to calculate how much play you’ll need.</p>
<p>Beyond the welcome package, there are weekly reload promotions, cash‑back on losses, and a loyalty program that awards points for each wager. These points can be swapped for bonus credits or free spins, adding extra value for frequent players. Always read the terms for each promotion; some may exclude certain game types or have lower wagering multiples.</p>
<h2>Payment Methods and Withdrawal Speed</h2>
<p>Canadian players have a decent selection of deposit options at kazeeno. The most common include Interac e‑Transfer, Visa/Mastercard, and several e‑wallets like PayPal and Skrill. Deposits are processed instantly, allowing you to start playing without delay. Most e‑wallets also support rapid withdrawals, often credited to your account within a few hours.</p>
<p>Bank‑card withdrawals typically take 2‑5 business days, while Interac transfers can be as quick as the next business day. The casino does not charge a fee for standard withdrawals, but some e‑wallet providers may apply their own small charge. Below is a quick comparison of the main payment routes:</p>
<table border="1" cellpadding="5" cellspacing="0">
<thead>
<tr>
<th>Payment Method</th>
<th>Deposit Speed</th>
<th>Withdrawal Speed</th>
<th>Typical Fees</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interac e‑Transfer</td>
<td>Instant</td>
<td>1‑2 business days</td>
<td>None</td>
</tr>
<tr>
<td>Visa / Mastercard</td>
<td>Instant</td>
<td>2‑5 business days</td>
<td>None</td>
</tr>
<tr>
<td>PayPal</td>
<td>Instant</td>
<td>Within 24 hours</td>
<td>Potential e‑wallet fee</td>
</tr>
<tr>
<td>Skrill</td>
<td>Instant</td>
<td>Same‑day</td>
<td>Potential e‑wallet fee</td>
</tr>
</tbody>
</table>
<h2>Game Selection: Slots, Live Casino, and Sports Betting</h2>
<p>kazeeno hosts a library that runs into the thousands, supplied by big providers such as NetEnt, Microgaming, and Evolution Gaming. Slot enthusiasts will find high‑RTP titles, progressive jackpots, and a range of volatility levels to match any risk appetite. For those craving a more authentic feel, the live casino section offers real‑time dealers on blackjack, roulette, and baccarat.</p>
<p>The sportsbook is a newer addition but already covers major Canadian sports like NHL, CFL, and MLS, plus international leagues. Betting markets include typical spreads, totals, and money‑line options, as well as live in‑play wagering. If you enjoy switching between casino games and sports action, kazeeno’s single‑sign‑on system makes the transition seamless.</p>
<h2>Mobile Experience and App Availability</h2>
<p>The website is fully responsive, meaning you can play directly in a mobile browser without needing a separate app. However, kazeeno also offers a downloadable app for Android and iOS users. The app mirrors the desktop layout, delivering fast load times and push notifications for bonus alerts.</p>
<p>If you prefer not to install anything, the mobile browser version still supports most slots, live dealer streams, and the sports betting interface. All payment methods work on the go, though some banks may require an extra security step when you log in from a new device.</p>
<h2>Security, Licensing, and Responsible Gambling</h2>
<p>kazeeno operates under a licence from the Malta Gaming Authority, a well‑regarded regulator that enforces strict player protection standards. All data transmissions are encrypted with SSL 128‑bit technology, safeguarding personal and financial information against interception.</p>
<p>For responsible gambling, the platform provides tools such as deposit limits, session timers, and self‑exclusion options. If you ever feel that gambling is affecting your life, you can request a temporary or permanent ban through the “Responsible Gaming” section of your account. These features are in line with Canadian best practices for safe play.</p>
<h2>Customer Support and Common Questions</h2>
<p>Support at kazeeno is available 24/7 via live chat and email. The live chat response time is typically under a minute, and the support staff are fluent in English, which is helpful for Canadian players. A comprehensive FAQ covers topics ranging from bonus redemption to verification requirements, reducing the need to wait for an agent.</p>
<p>When you have a question that isn’t answered instantly, you can also reach out through a ticket system. Most users report that the resolution time for payment‑related inquiries is within 24 hours, provided you’ve submitted all required documents.</p>
<h2>Final Thoughts: Should You Choose kazeeno?</h2>
<p>If you value a solid welcome bonus, a wide variety of games, and quick deposit options, kazeeno is worth a look. Its licensing, security measures, and responsible gambling tools meet the expectations of Canadian players seeking a trustworthy environment. The mobile experience is smooth, and the sportsbook adds a nice extra dimension for those who like to bet on NHL or CFL matches.</p>
<p>For the latest offers and to start your registration, visit the official site at <a href="https://casino-kazeeno.net/">casino-kazeeno.net</a>. Remember to read the fine print on any promotion, set realistic bankroll limits, and enjoy the entertainment responsibly.</p>
<ul>
<li>Check the bonus wagering requirements before you claim.</li>
<li>Use Interac for the fastest withdrawals.</li>
<li>Take advantage of the live casino for an authentic feel.</li>
<li>Set daily deposit limits via the responsible gambling tools.</li>
<li>Contact support via live chat for immediate assistance.</li>
</ul>
<p>The post <a href="https://www.pharmaceutical-business-review.com/uncategorized/kazeeno-bonus-guide-for-canadian-players-welcome-offers-wagering-requirements-claim-steps/">Kazeeno Bonus Guide for Canadian Players – Welcome Offers, Wagering Requirements & Claim Steps</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Hypp1s Suomi rekisteröitymisvaiheet – helppo opas aloittelijoille</title>
<link>https://edusehat.com/en/hypp1s-suomi-rekisteroeitymisvaiheet-helppo-opas-aloittelijoille</link>
<guid>https://edusehat.com/en/hypp1s-suomi-rekisteroeitymisvaiheet-helppo-opas-aloittelijoille</guid>
<description><![CDATA[ Hypp1s Suomi – Käytännöllinen opas suomalaisille pelaajille Miksi valita Hypp1s Suomi? Suomessa kasinopelaaminen on kasvussa, ja jokainen uusi pelaaja etsii luotettavaa kumppania. Hypp1s Suomi erottuu edukseen erityisesti selkeillä 
The post Hypp1s Suomi rekisteröitymisvaiheet – helppo opas aloittelijoille appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/4uSPFIBpTtM/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 12 Nov 2026 14:55:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Hypp1s, Suomi, rekisteröitymisvaiheet, –, helppo, opas, aloittelijoille</media:keywords>
<content:encoded><![CDATA[<figure data-affgun-media="hero"><img decoding="async" src="https://i.ytimg.com/vi/4uSPFIBpTtM/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<h1>Hypp1s Suomi – Käytännöllinen opas suomalaisille pelaajille</h1>
<h2>Miksi valita Hypp1s Suomi?</h2>
<div data-affgun-media="video"></div>
<p>Suomessa kasinopelaaminen on kasvussa, ja jokainen uusi pelaaja etsii luotettavaa kumppania. Hypp1s Suomi erottuu edukseen erityisesti selkeillä bonusehdoilla ja suomalaisille suunnatulla maksupalveluvalikoimalla. Sivusto on lisensoitu Maltan viranomaisen toimesta, mikä takaa EU-tason turvallisuuden ja läpinäkyvyyden. Lisäksi käyttöliittymä on suomenkielinen, eikä kielimuuri estä pelaamista tai tukea. Jos haluat sekä viihdyttävän että vastuullisen pelikokemuksen, tämä on yksi parhaista vaihtoehdoista.</p>
<p>Hypp1s Suomi tarjoaa myös laajan valikoiman live‑casinopöytiä, urheiluvedonlyöntiä ja mobiilisovelluksen, joka toimii sujuvasti sekä iOS- että Android-laitteilla. Monipuolinen pelivalikoima tarkoittaa, että voit siirtyä pokeripöydästä vedonlyöntiin ilman, että sinun tarvitsee vaihtaa sivustoja. Tämä yhden luukun konsepti säästää aikaa ja pitää pelikokemuksen yhtenäisenä.</p>
<h2>Rekisteröityminen ja tervetulobonus</h2>
<p>Rekisteröityminen Hypp1s Suomi -sivustolle vie vain muutaman minuutin. Täytä perus tiedot, vahvista sähköpostiosoite ja tee ensimmäinen talletus – ja bonuksesi on jo matkalla. Tervetulobonus koostuu 100 % talletusbonuksesta, enintään 200 € ja 50 ilmaiskierroksesta, jotka aktivoituvat heti ensimmäisen talletuksen jälkeen.</p>
<p>Bonuksen kierrätysvaatimus on 30×, mutta se jakautuu tasaisesti sekä bonuksen että talletuksen määrään, mikä tekee kierrättämisestä vähemmän rasittavaa. Jos olet aloittelija, kannattaa aloittaa pienemmällä talletuksella ja tarkistaa kierrätysvaatimukset ennen isompien sumien panostamista. Bonuskoodia ei enää tarvita – se lisätään automaattisesti rekisteröitymisen yhteydessä.</p>
<h2>Maksutavat ja talletus – Helppoa ja turvallista</h2>
<p>Suomalaiset pelaajat arvostavat nopeita ja turvallisia maksutapoja. Hypp1s Suomi tukee suosituimpia suomalaisia maksutapoja, kuten verkkopankkia (Siirto, Trustly), e-lompakoita (Skrill, Neteller) sekä perinteisiä luottokortteja (Visa, MasterCard). Kaikki talletukset prosessoidaan välittömästi, joten voit heti siirtyä pelaamaan.</p>
<p>Talletusmaksimissa on 5 000 € per transaktio, mutta useimmat suomalaiset pelaajat käyttävät 100–500 € välisiä summia. Jos talletus ei onnistu, tarkista, että korttisi on aktivoinut internet‑ostokset tai että verkkopankin turvatunnus on oikein syötetty. Maksutapa valitsee myös mahdollisesti kierrätysvaatimusten täyttämisen – osa maksutavoista voi sulkea bonuksen vastaanottamisen.</p>
<h2>Nostot ja maksunopeus – Mitä odottaa?</h2>
<p>Nostojen käsittelyaika on yksi tärkeimmistä tekijöistä, kun valitsee online‑kasinoa. Hypp1s Suomi pyrkii tarjoamaan “instant payouts” –tavalla, jossa suosituimmat maksutavat, kuten Trustly ja Skrill, saavat varat tilillesi 15–30 minuutissa. Perinteisemmät menetelmät, kuten pankkisiirto, voivat viedä 1–3 arkipäivää.</p>
<p>Nostomaksimissa on 5 000 € päivässä, ja nostoa voi tehdä enintään 3 kertaa per viikko. Kaikki nostot käyvät läpi KYC‑vahvistuksen – henkilötodistus ja osoitteesi täytyy olla tarkistettu ennen ensimmäistä nostoa. Tämä turvatoimi ehkäisee petoksia ja suojaa sekä sinua että kasinoa.</p>
<h2>Live casino ja urheiluvedonlyönti – Pelivalikoima</h2>
<p>Hypp1s Suomi panostaa sekä live‑casinoon että urheiluvedonlyöntiin. Live‑casinossa voit pelata reaaliaikaisia pelejä, kuten blackjackia, rulettia ja baccaratia, oikeiden jakajien kanssa. Pelien RTG (Return to Player) on keskimäärin 96 % – 98 %, mikä on kilpailukykyistä alan tasossa.</p>
<p>Urheiluvedonlyönti kattaa kaikki suuret urheilulajit: jalkapallo, jääkiekko, koripallo, sekä e-urheilu. Vedonlyöntikohteita on yli 2 000 päivittäin, ja live‑vedonlyönti käynnistyy ottelun alkaessa. Kertoimet ovat lähellä markkinoiden parhaita, ja vedonlyönti on helppo yhdistää casino‑tiliisi ilman erillistä rekisteröitymistä.</p>
<h2>Mobiilisovellus ja mobiilikokemus</h2>
<p>Suomalaiset käyttävät yhä enemmän puhelimia pelaamiseen, ja Hypp1s Suomi on ottanut tämän huomioon. Sovellus on saatavilla sekä Google Play -kaupasta että Applen App Storesta, eikä vaadi erillistä latausta – se toimii myös suoraan selaimessa. Mobiiliversio tarjoaa täyden pääsyn kaikkiin peleihin, bonuksiin ja talletusmenetelmiin.</p>
<p>Sovelluksen käyttöliittymä on optimoitu pienemmille näytöille: suuri fontti, selkeät napit ja nopea navigointi. Mobiilisovellus tukee myös push‑ilmoituksia, joilla saat tiedon uusista bonuksista tai tapahtumista juuri silloin, kun ne ovat merkityksellisiä. Tämä tekee pelaamisesta sujuvaa myös liikkeellä ollessa.</p>
<h2>Turvallisuus, lisenssi ja vastuullinen pelaaminen</h2>
<p>Hypp1s Suomi toimii Maltan Gaming Authorityn myöntämän lisenssin alaisena, mikä takaa, että sivusto noudattaa EU‑standardien tiukkoja turvallisuusvaatimuksia. Kaikki tiedonsiirto on suojattu 128‑bit SSL‑salauksella, eikä henkilökohtaisia tietoja jaeta kolmansille osapuolille ilman suostumusta.</p>
<p>Vastuullinen pelaaminen on keskeinen osa Hypp1s Suomi -filosofiaa. Sivustolta löytyy itsearviointityökalu, talletusrajoitukset, sekä mahdollisuus sulkea oma tili tilapäisesti. Jos pelaaminen alkaa tuntua hallitsemattomalta, voit helposti ottaa yhteyttä tukitiimiin, joka tarjoaa myös linkin erikoisjärjestöihin, kuten Peliriskit.</p>
<h2>Asiakaspalvelu ja tuki – Kuinka saada apua?</h2>
<p>Hypp1s Suomi tarjoaa asiakaspalvelua 24/7. Live‑chat on nopein tapa saada apua, ja vastausaika on yleensä alle 30 sekuntia. Sähköpostituki on saatavilla myös, ja vastaukset tulevat yleensä kahden tunnin sisällä. Jos puhut suomeksi, voit valita kielen chat‑ikkunassa – tuki on paikallisesti koulutettua.</p>
<p>Yleisiä kysymyksiä käsitellään kattavassa FAQ‑osiosta, joka kattaa rekisteröitymisen, bonukset, maksut ja turvallisuus. Jos ongelma jatkuu, voit pyytää puhelintukea, jossa asiakasneuvoja voi tarkistaa tilisi tiedot suoraan puhelimen kautta.</p>
<h2>Vertailutaulukko – Hypp1s Suomi vs. muut suomalaiset kasinot</h2>
<table border="1" cellpadding="5" cellspacing="0">
<thead>
<tr>
<th>Ominaisuus</th>
<th>Hypp1s Suomi</th>
<th>Kilpailija A</th>
<th>Kilpailija B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lisenssi</td>
<td>Maltan Gaming Authority</td>
<td>UK Gambling Commission</td>
<td>Estonia Gaming Board</td>
</tr>
<tr>
<td>Tervetulobonus</td>
<td>100 % / 200 € + 50 kiera</td>
<td>150 % / 300 €</td>
<td>200 % / 250 €</td>
</tr>
<tr>
<td>Kierrätysvaatimus</td>
<td>30×</td>
<td>40×</td>
<td>35×</td>
</tr>
<tr>
<td>Instant payout</td>
<td>Kyllä (Trustly, Skrill)</td>
<td>Ei</td>
<td>Kyllä (Neteller)</td>
</tr>
<tr>
<td>Maksutavat</td>
<td>Verkkomaksu, kortit, e‑lompakot</td>
<td>Vain kortit</td>
<td>Verkkomaksu, kortit</td>
</tr>
<tr>
<td>Mobiilisovellus</td>
<td>Kyllä (iOS & Android)</td>
<td>Kyllä (iOS)</td>
<td>Ei</td>
</tr>
</tbody>
</table>
<h2>Lopuksi – Onko Hypp1s Suomi sinulle?</h2>
<p>Jos arvostat nopeita talletuksia, selkeää bonuksia ja suomenkielistä tukea, Hypp1s Suomi on erinomainen valinta. Sivusto tarjoaa kattavan pelivalikoiman sekä casino‑ että sportsbook</p>
<p>Liity nyt Hypp1s Suomi -kasinolle ja aloita pelaaminen heti <a href="https://hypp1s.com/">https://hypp1s.com/</a>!</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/uncategorized/hypp1s-suomi-rekisteroitymisvaiheet-helppo-opas-aloittelijoille/">Hypp1s Suomi rekisteröitymisvaiheet – helppo opas aloittelijoille</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Pike login review overview – Canadian guide to quick access</title>
<link>https://edusehat.com/en/pike-login-review-overview-canadian-guide-to-quick-access</link>
<guid>https://edusehat.com/en/pike-login-review-overview-canadian-guide-to-quick-access</guid>
<description><![CDATA[ Pike Login: Practical Guidance for Canadian Players What is Pike and Why You Need a Pike Login If you’ve been browsing the Canadian gambling scene, you’ve probably seen 
The post Pike login review overview – Canadian guide to quick access appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/iaoZS7206Mc/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 12 Nov 2026 14:55:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Pike, login, review, overview, –, Canadian, guide, quick, access</media:keywords>
<content:encoded><![CDATA[<figure data-affgun-media="hero"><img decoding="async" src="https://i.ytimg.com/vi/iaoZS7206Mc/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<h1>Pike Login: Practical Guidance for Canadian Players</h1>
<h2>What is Pike and Why You Need a Pike Login</h2>
<div data-affgun-media="video"></div>
<p>If you’ve been browsing the Canadian gambling scene, you’ve probably seen the name “Pike” pop up alongside big‑ticket bonuses and live‑dealer tables. Pike is an online casino and sportsbook that targets North‑American players with a mix of slots, table games and a full‑featured sports betting platform. To enjoy any of that, a <strong>pike login</strong> is mandatory – it’s the gateway that ties your personal details, payment methods and bonus entitlements together.</p>
<p>For most newcomers, the biggest hurdle isn’t the games, it’s simply figuring out how to log in the first time. This guide cuts through the fluff and walks you through every step, from registration to troubleshooting, with a focus on what matters to Canadian users: fast deposits, responsible gambling tools and solid customer support.</p>
<h2>How to Create a Pike Account – Step‑by‑Step</h2>
<p>Before you can even think about a <em>pike login</em>, you need a registered account. The registration flow is intentionally short, but it still asks for a few pieces of information that can trip up first‑timers.</p>
<ul>
<li>Navigate to the official homepage and click “Register”.</li>
<li>Enter your full name, a valid Canadian email address and a strong password (mix letters, numbers and a symbol).</li>
<li>Select your province – Pike only accepts players from provinces where online gambling is regulated.</li>
<li>Provide a phone number for two‑factor authentication (2FA). You’ll receive a code via SMS.</li>
<li>Agree to the terms, confirm you’re 19+ (or the legal age in your province), and submit.</li>
</ul>
<p>Within minutes you’ll get a confirmation email. Click the link, verify your phone code, and you’re ready for the first <strong>pike login</strong>. Remember, the account stays dormant until you make a deposit, so plan your payment method before you log in for the first time.</p>
<h2>Pike Login Process – What to Expect</h2>
<p>The actual login page is clean: a field for your email/username, a password box, and an optional “Remember me” tick box. Canadian players often enable the remember feature on personal devices for convenience, but on shared computers it’s safer to leave it unchecked.</p>
<p>After you hit “Log In”, Pike may prompt you for a one‑time security code sent to your phone. This 2FA step is mandatory for the first login from a new device and helps keep your bankroll secure. Once you’re in, the dashboard shows your balance, active bonuses, and quick links to the casino, sportsbook, and mobile app download.</p>
<h2>Common Login Issues & Troubleshooting</h2>
<p>Even with a straightforward process, things can go sideways. Below are the most frequent hiccups Canadian users report, plus quick fixes.</p>
<ol>
<li><strong>Forgotten password:</strong> Click “Forgot password” on the login page, enter your email, and follow the reset link. The email may land in your spam folder, so check there.</li>
<li><strong>Blocked by province:</strong> If you’re from a jurisdiction where online gambling isn’t licensed, Pike will block the login. The only remedy is to use a province‑approved alternative.</li>
<li><strong>Two‑factor code not received:</strong> Verify your phone number is correct, and ensure you have good mobile coverage. You can also request a voice call instead of SMS.</li>
</ol>
<p>If none of these solve the problem, contact support (see the section below) with a screenshot of the error message. They usually respond within an hour during business hours.</p>
<h2>Security, Verification, and Canadian Regulations</h2>
<p>Pike takes KYC (Know Your Customer) seriously. After your first <strong>pike login</strong>, you’ll be asked to upload a government‑issued ID (driver’s licence or passport) and a proof‑of‑address document such as a utility bill. This step unlocks higher withdrawal limits and faster payouts.</p>
<p>The platform is licensed by the Malta Gaming Authority and also holds a Canadian remote‑gaming licence where applicable. Encryption is 128‑bit SSL, the same standard banks use, so your personal data and payment info stay encrypted end‑to‑end.</p>
<h2>Payments, Bonuses, and Withdrawal After Login</h2>
<p>Once you’ve logged in, the next big decision is how to fund your account. Canadian players have a solid selection of deposit methods, each with its own speed and fee structure.</p>
<table border="1" cellpadding="5" cellspacing="0">
<thead>
<tr>
<th>Deposit Method</th>
<th>Processing Time</th>
<th>Typical Fees</th>
<th>Bonus Eligibility</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interac e‑Transfer</td>
<td>Instant</td>
<td>None</td>
<td>Yes – 100% match up to $500</td>
</tr>
<tr>
<td>Visa / MasterCard</td>
<td>Instant</td>
<td>1.5% (may be waived)</td>
<td>Yes – 150% match up to $300</td>
</tr>
<tr>
<td>PayPal</td>
<td>Instant</td>
<td>2% (first deposit free)</td>
<td>Yes – 200% match up to $200</td>
</tr>
<tr>
<td>Bank Transfer (EFT)</td>
<td>1‑2 business days</td>
<td>None</td>
<td>Yes – 100% match up to $400</td>
</tr>
</tbody>
</table>
<p>All welcome bonuses come with wagering requirements of 30x the bonus amount. Keep an eye on the “Terms & Conditions” tab after you claim a bonus – it spells out which games count toward wagering and the time limit (usually 30 days).</p>
<h2>Mobile Experience & Pike App Login</h2>
<p>Canada’s gaming audience is increasingly mobile, and Pike offers a dedicated iOS/Android app. The app uses the same <strong>pike login</strong> credentials as the desktop site, but it adds fingerprint or Face ID authentication for quicker access.</p>
<p>If you prefer not to download the app, the responsive web version works just fine on smartphones. The layout auto‑adjusts, and you’ll still see the live casino lobby, sports betting odds, and your personal balance without any loss of functionality.</p>
<h2>Customer Support and Responsible Gambling</h2>
<p>Good support can turn a frustrating login problem into a quick resolution. Pike offers 24/7 live chat, an email ticket system, and a toll‑free Canadian number (1‑800‑555‑PIKE). When you reach out, have your account email and the exact error message ready – it speeds up the process.</p>
<p>Responsible gambling tools are built into the account dashboard. You can set deposit limits, self‑exclude for a chosen period, or request a permanent ban. These controls are available immediately after you log in, and the support team will verify your identity before any limit changes are applied.</p>
<h2>Final Thoughts – Getting Started with Your Pike Login</h2>
<p>The biggest barrier to enjoying Pike’s casino and sportsbook is simply getting past the login screen. Follow the steps outlined above, keep your verification documents handy, and choose a deposit method that matches your speed preferences. Once you’re inside, the platform’s welcome bonus, live dealer tables and Canadian‑focused sports markets become instantly available.</p>
<p>Ready to try it yourself? Head over to the official site, create your account and experience the smooth <strong>pike login</strong> process first‑hand: <a href="https://pike-casino-ca.net/">https://pike-casino-ca.net/</a>.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/uncategorized/pike-login-review-overview-canadian-guide-to-quick-access/">Pike login review overview – Canadian guide to quick access</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Casoola app – betaalmethoden, iDEAL en snelle opnames voor Nederlandse spelers</title>
<link>https://edusehat.com/en/casoola-app-betaalmethoden-ideal-en-snelle-opnames-voor-nederlandse-spelers</link>
<guid>https://edusehat.com/en/casoola-app-betaalmethoden-ideal-en-snelle-opnames-voor-nederlandse-spelers</guid>
<description><![CDATA[ Casoola app: Praktische gids voor Nederlandse spelers Wat is de Casoola app en hoe werkt hij? De Casoola app is de mobiele versie van het online casino‑platform, speciaal 
The post Casoola app – betaalmethoden, iDEAL en snelle opnames voor Nederlandse spelers appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/v6UPYL2axq4/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 12 Nov 2026 14:55:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Casoola, app, –, betaalmethoden, iDEAL, snelle, opnames, voor, Nederlandse, spelers</media:keywords>
<content:encoded><![CDATA[<figure data-affgun-media="hero"><img decoding="async" src="https://i.ytimg.com/vi/v6UPYL2axq4/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<article>
<h1>Casoola app: Praktische gids voor Nederlandse spelers</h1>
<h2>Wat is de Casoola app en hoe werkt hij?</h2>
<div data-affgun-media="video"></div>
<p>De <strong>Casoola app</strong> is de mobiele versie van het online casino‑platform, speciaal ontwikkeld voor iOS‑ en Android‑apparaten. Je downloadt de app rechtstreeks vanuit de App Store of Google Play en logt vervolgens in met je bestaande account, of je maakt een nieuw profiel aan binnen een paar minuten. Dankzij een gestroomlijnde interface vind je meteen de populairste gokkasten, live casino‑tafels en sportweddenschappen, zonder dat je een apart webbrowser‑venster hoeft te openen. De app maakt gebruik van HTML5‑technologie, waardoor de graphics scherp blijven en de laadtijden kort zijn, zelfs op een gemiddelde 4G‑verbinding.</p>
<p>Voor Nederlandse spelers is de <em>casoola app</em> bovendien volledig vertaald naar het Nederlands, met lokale valuta en betalingsopties die je gewend bent. De navigatie is intuïtief: een tabblad onderaan geeft je snel toegang tot “Spelen”, “Bonussen”, “Wallet” en “Support”. Deze structuur voorkomt dat je verdwaalt in eindeloze menu’s en zorgt ervoor dat je in een paar klikken kunt beginnen met inzetten. Veel gebruikers geven aan dat de app zich net zo betrouwbaar voelt als de desktopversie, maar dan met het extra gemak van mobiel spelen.</p>
<h2>Aanmelden en registratie via de app</h2>
<p>Een vlotte registratie is cruciaal, zeker als je direct wilt profiteren van de welkomstbonus. De app vraagt alleen de basisgegevens: naam, e‑mail, geboortedatum en een sterk wachtwoord. Na het invoeren van deze informatie krijg je een bevestigingscode per sms of e‑mail, waarmee je je account activeert. Het hele proces duurt doorgaans minder dan drie minuten, en je kunt meteen je eerste storting doen.</p>
<h3>Stapsgewijze registratie</h3>
<ul>
<li>Open de Casoola app en tik op “Registreren”.</li>
<li>Vul je persoonlijke gegevens in en bevestig je leeftijd (je moet 18 jaar of ouder zijn).</li>
<li>Kies een betaalmethode en voer een eerste storting van minimaal €10 in.</li>
<li>Ontvang de verificatiecode, voer deze in en voltooi je account.</li>
<li>Claim de welkomstbonus via het bonus‑overzicht in de app.</li>
</ul>
<h2>Bonussen en promoties – wat kun je verwachten?</h2>
<p>De <strong>casoola app</strong> biedt een reeks aantrekkelijke bonussen, waarvan de welkomstbonus het meest opvallend is. Nieuwe spelers ontvangen een matchbonus op hun eerste storting plus een aantal gratis spins, waardoor de eerste speelsessie extra spannend wordt. Naast de welkomstbonus zijn er regelmatig reload‑bonussen, cash‑back‑acties en speciale promoties rond feestdagen. Houd altijd de “Promoties”‑pagina in de app in de gaten; hier staan de actuele voorwaarden en de exacte wagering requirements.</p>
<p>Om de verschillende aanbiedingen duidelijk te vergelijken, vind je hieronder een overzichtstabel. Let vooral op het aantal keren dat je de bonus moet inzetten (wagering requirements) en de maximale uitbetaling, zodat je niet voor verrassingen komt te staan.</p>
<table border="1" cellpadding="5" cellspacing="0">
<thead>
<tr>
<th>Bonus</th>
<th>Matchpercentage</th>
<th>Gratis spins</th>
<th>Wagering requirements</th>
<th>Max. uitbetaling</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welkomstbonus</td>
<td>100 %</td>
<td>50</td>
<td>30 x bonus</td>
<td>€500</td>
</tr>
<tr>
<td>Reload bonus (week 2)</td>
<td>50 %</td>
<td>20</td>
<td>25 x bonus</td>
<td>€200</td>
</tr>
<tr>
<td>Cashback vrijdag</td>
<td>10 % van verlies</td>
<td>–</td>
<td>0 x (direct)</td>
<td>€150</td>
</tr>
</tbody>
</table>
<p>Vergeet niet dat elke bonus onderhevig is aan de algemene voorwaarden, inclusief een minimale storting en een tijdslimiet voor het inzetten van de bonus. Door de voorwaarden goed te lezen, kun je de maximale waarde uit je spel halen zonder onnodige teleurstelling.</p>
<h2>Betaalmethoden & opnames in de app</h2>
<p>Een van de sterke punten van de <strong>casoola app</strong> is de ruime keuze aan betaalmethoden die specifiek voor Nederlandse spelers zijn geoptimaliseerd. Je kunt eenvoudig een storting doen met iDEAL, creditcards, en diverse e‑wallets zoals Skrill en Neteller. De meeste stortingen worden direct verwerkt, waardoor je binnen enkele seconden kunt beginnen met spelen. Bij het kiezen van een betaalmethode is het verstandig om rekening te houden met eventuele transactiekosten; iDEAL is meestal gratis, terwijl sommige e‑wallets een kleine vergoeding vragen.</p>
<h3>Beschikbare betaalopties</h3>
<ul>
<li><strong>iDEAL</strong> – directe verwerking, geen kosten.</li>
<li><strong>Visa / MasterCard</strong> – snelle creditcardbetalingen, kleine vergoeding mogelijk.</li>
<li><strong>Skrill</strong> – veilig, geschikt voor spelers die anonimiteit waarderen.</li>
<li><strong>Neteller</strong> – vergelijkbaar met Skrill, vaak gebruikt voor snelle opnames.</li>
<li><strong>Bankoverschrijving</strong> – hogere limieten, verwerking tot 24 uur.</li>
</ul>
<p>Opnames worden net zo veilig behandeld. Na het indienen van een opnameaanvraag via de “Wallet”‑sectie, wordt je verzoek meestal binnen 24 uur verwerkt, afhankelijk van de gekozen methode. iDEAL‑opnames zijn in de praktijk de snelste, vaak binnen enkele uren, terwijl e‑wallets meestal binnen één werkdag klaar zijn. Houd er rekening mee dat je eerst een KYC‑verificatie moet afronden voordat je grote bedragen kunt opnemen.</p>
<h2>Veiligheid, licentie en verantwoorde speelopties</h2>
<p>Casoola opereert onder een licentie van de Malta Gaming Authority (MGA) en voldoet aan de strenge Nederlandse Wet op Kansspelen dankzij een Nederlandse vergunning. Deze licentie garandeert dat de spellen eerlijk zijn, dat je persoonsgegevens beschermd worden en dat er een duidelijk klachtenproces bestaat. De <strong>casoola app</strong> maakt gebruik van SSL‑encryptie, zodat al je bankgegevens en persoonlijke informatie versleuteld worden verzonden.</p>
<p>Verantwoord gokken staat centraal. In de app vind je een “Responsible Gaming”‑sectie waar je limieten kunt instellen voor stortingen, verliezen en speeltijd. Daarnaast kun je een zelfuitsluiting aanvragen, wat je tijdelijk of permanent uitschakelt van deelname aan alle casinospellen. Deze tools zijn vooral nuttig voor beginners die hun speelgedrag in de gaten willen houden en voorkomen dat het uit de hand loopt.</p>
<h2>Live casino en sportweddenschappen op mobiel</h2>
<p>Naast de klassieke slots biedt de <strong>casoola app</strong> een uitgebreid live casino‑aanbod met echte dealers, blackjack, roulette en baccarat. De videostreams zijn van hoge kwaliteit en passen zich automatisch aan de schermgrootte van je telefoon aan. Veel live spellen hebben een redelijk hoge RTP (Return to Player) en een gematigde volatiliteit, waardoor ze geschikt zijn voor zowel casual als serieuze spelers.</p>
<p>Voor sportliefhebbers is er een geïntegreerde sportsbook‑module waar je kunt inzetten op voetbal, tennis, e‑sports en meer. De odds worden in real‑time geüpdatet en je kunt zelfs live weddenschappen plaatsen terwijl de wedstrijd nog gaande is. Dankzij de snelle verwerking van inzetten en de mogelijkheid om direct uit te betalen, biedt de app een naadloze ervaring voor zowel casino‑ als sportweddenschappen.</p>
<h2>Veelgestelde vragen over de Casoola app</h2>
<ul>
<li><strong>Is de Casoola app beschikbaar voor iPhone en Android?</strong> Ja, je vindt de app gratis in de Apple App Store en Google Play Store.</li>
<li><strong>Kan ik met iDEAL storten en opnemen?</strong> Storten met iDEAL is direct; opnames via iDEAL duren meestal enkele uren.</li>
<li><strong>Hoe snel wordt mijn bonus uitbetaald?</strong> Na het voldoen aan de wagering requirements en een succesvolle verificatie wordt de bonus binnen 24 uur uitbetaald.</li>
<li><strong>Is er klantenservice beschikbaar?</strong> De app biedt 24/7 live chat en een e‑mailsupport, beide in het Nederlands.</li>
<li><strong>Waar vind ik de licentie‑informatie?</strong> In het menu onder “Over ons” staat de MGA‑licentie en de Nederlandse vergunning vermeld.</li>
</ul>
<p>Wil je zelf de Casoola app uitproberen of meer details lezen over de huidige promoties, bezoek dan de officiële</p>
</article>
<p>Download de Casoola app nu via <a href="https://casolacasino.com/nl/">https://casolacasino.com/nl/</a> en profiteer van de beste bonussen!</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/uncategorized/casoola-app-betaalmethoden-ideal-en-snelle-opnames-voor-nederlandse-spelers/">Casoola app – betaalmethoden, iDEAL en snelle opnames voor Nederlandse spelers</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>SainiRS6 suomi login: yleiskatsaus ja vaihtoehdot</title>
<link>https://edusehat.com/en/sainirs6-suomi-login-yleiskatsaus-ja-vaihtoehdot</link>
<guid>https://edusehat.com/en/sainirs6-suomi-login-yleiskatsaus-ja-vaihtoehdot</guid>
<description><![CDATA[ SainiRS6 Suomi – Käytännön opas sainirs6 suomi login Mikä on SainiRS6 ja miten sainirs6 suomi login toimii? SainiRS6 on suomalaisille suunnattu nettikasino- ja vedonlyöntialusta, joka on saanut nopeasti 
The post SainiRS6 suomi login: yleiskatsaus ja vaihtoehdot appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/mt7YoauyR84/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 12 Nov 2026 14:55:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>SainiRS6, suomi, login:, yleiskatsaus, vaihtoehdot</media:keywords>
<content:encoded><![CDATA[<figure data-affgun-media="hero"><img decoding="async" src="https://i.ytimg.com/vi/mt7YoauyR84/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<h1>SainiRS6 Suomi – Käytännön opas sainirs6 suomi login</h1>
<h2>Mikä on SainiRS6 ja miten sainirs6 suomi login toimii?</h2>
<div data-affgun-media="video"></div>
<p>SainiRS6 on suomalaisille suunnattu nettikasino- ja vedonlyöntialusta, joka on saanut nopeasti jalansijaa paikallisessa pelimarkkinassa. Palvelu tarjoaa sekä kasinopelejä että live-vedonlyöntiä, ja sen takana on lisensoitu toimija, jonka toimilupa on annettu Maltan peliviranomaiselta. Kun suomalainen käyttäjä avaa sivuston, ensimmäinen askel on suorittaa <strong>sainirs6 suomi login</strong> -kirjautuminen, jonka jälkeen kaikki ominaisuudet avautuvat.</p>
<p>Kirjautuminen on suunniteltu mahdollisimman helpoksi: käyttäjän tarvitsee vain syöttää rekisteröintivaiheessa antamansa sähköpostiosoite ja valitsema salasana. Jos olet jo rekisteröitynyt, voit käyttää samaa tietoa kirjautuaksesi sisään mobiililaitteella tai tietokoneella. Sivuston käyttöliittymä on täysin suomenkielinen, ja kaikki bonustarjoukset näytetään selkeästi kirjautumisen jälkeen.</p>
<h2>Rekisteröityminen ja ensimmäinen kirjautuminen (sainirs6 suomi login)</h2>
<p>Ensimmäinen askel on avata SainiRS6:n kotisivu ja klikata “Rekisteröidy” –painiketta. Tässä vaiheessa kysytään perusasiat: nimi, syntymäaika, osoite, sähköpostiosoite ja puhelinnumero. Tietojen tarkkuus on tärkeä, koska myöhemmin KYC‑tarkastus (Know Your Customer) tarkistaa henkilöllisyytesi ennen ensimmäistä nostoa.</p>
<p>Kun tiedot on syötetty, saat vahvistuslinkin sähköpostiisi. Klikkaa linkkiä, aseta vahva salasana ja olet valmis suorittamaan <strong>sainirs6 suomi login</strong>-toiminnon. Jos unohdat salasanan, “Unohditko salasanan?” –linkki palauttaa sen helposti sähköpostilla. Kirjautumisen jälkeen näet henkilökohtaisen dashboardin, jossa voit tarkastella saldoa, bonuksia ja viimeisimpiä vedonlyönti­tuloksia.</p>
<h2>Bonukset ja tervetulotarjoukset – mitä odottaa kirjautumisen jälkeen</h2>
<p>Kirjautumisen yhteydessä SainiRS6 palkitsee uudet pelaajat yleensä tervetulobonuksella, joka voi olla 100 % talletusbonus tai jopa ilmainen kierrospaketti. Usein bonukseen liitetään <em>wagering requirements</em> eli kierrätysvaatimus, esimerkiksi 30x bonussummasta. Tämä tarkoittaa, että ennen kuin voit nostaa bonuksen, sinun täytyy panostaa 30‑kertaisesti bonuksen arvo.</p>
<p>Bonuksia voi myös saada säännöllisesti, kuten “viikonloppu‑tapahtumabonus” tai “live‑kasino‑bonus”. Kannattaa pitää silmällä kampanjasivua, jossa kaikki tarjoukset on listattu aikajärjestyksessä. Muista aina lukea bonusehdot huolellisesti: kierrätysvaatimukset, maksiminostoraja ja mahdolliset pelirajoitukset voivat vaikuttaa lopulliseen voittoon.</p>
<h2>Maksutavat ja nostot – nopeus ja turvallisuus</h2>
<p>SainiRS6 tarjoaa laajan valikoiman talletus- ja nostomenetelmiä, jotka on optimoitu suomalaisille käyttäjille. Suosituimpia maksutapoja ovat verkkopankit, luottokortit ja mobiilimaksut, ja ne kaikki tukevat nopeaa käsittelyä. Kun teet talletuksen, se näkyy tililläsi välittömästi, kun taas nostot käsitellään yleensä 24–48 tunnin sisällä, riippuen valitsemastasi maksutavasta.</p>
<table border="1" cellpadding="5" cellspacing="0">
<caption>Suositellut talletusmenetelmät SainiRS6:ssä</caption>
<thead>
<tr>
<th>Menetelmä</th>
<th>Maksuaika</th>
<th>Kustannus</th>
<th>Hyväksytyt</th>
</tr>
</thead>
<tbody>
<tr>
<td>Verkkopankki (Nordea, OP, etc.)</td>
<td>Välittömästi</td>
<td>0 €</td>
<td>Kyllä</td>
</tr>
<tr>
<td>Visa / Mastercard</td>
<td>Välittömästi</td>
<td>0 €</td>
<td>Kyllä</td>
</tr>
<tr>
<td>MobilePay</td>
<td>Välittömästi</td>
<td>0 €</td>
<td>Kyllä</td>
</tr>
<tr>
<td>Skrill</td>
<td>1–2 tuntia</td>
<td>0 €</td>
<td>Kyllä</td>
</tr>
</tbody>
</table>
<p>Kun nostat voitot, SainiRS6 suosittelee käyttämään samaa maksutapaa, jota käytit talletukseen, koska se nopeuttaa prosessia. Jos valitset pankkisiirron, nostojen käsittelyaika voi venyä 1–3 arkipäivään, mutta useimmat suomalaiset pankit hyväksyvät sen nopeasti. Muista tarkistaa, että tilisi on täysin vahvistettu, jotta nostot eivät jää jumiin KYC‑tarkastuksen takia.</p>
<h2>Mobiili‑ ja sovelluskokemus – pelaaminen puhelimella</h2>
<p>SainiRS6 on täysin responsiivinen, joten sen verkkosivut skaalautuvat automaattisesti älypuhelimelle tai tabletille. Jos haluat vieläkin sujuvamman pelikokemuksen, voit ladata <strong>SainiRS6‑sovelluksen</strong> sekä iOS‑ että Android‑laitteille. Sovelluksessa on kaikki tärkeimmät ominaisuudet: kirjautuminen, talletus, bonusten hallinta ja live‑kasino‑virta.</p>
<p>Mobiilikäyttäjille on erityisesti suunniteltu “yksi‑klikkaus‑talletus”, joka hyödyntää Google Pay‑ tai Apple Pay‑integraatioita. Tämä tekee talletuksista nopeita ja turvallisia, eikä sinun tarvitse erikseen syöttää korttitietoja. Lisäksi push‑ilmoitukset pitävät sinut ajan tasalla uusimmista bonuksista ja live‑vedonlyöntikierroksista.</p>
<h2>Tuki ja turvallisuus – miten varmistetaan turvallinen kirjautuminen</h2>
<p>Turvallisuus on SainiRS6:n ydin, ja kirjautumisprosessiin on sisällytetty kaksivaiheinen tunnistautuminen (2FA). Voit aktivoida 2FA‑sähköpostilla tai autentikaattorisovelluksella, jolloin jokainen kirjautumisyritys vaatii lisäkoodin. Tämä suojaa tiliäsi mahdollisilta hakkerointiyrityksiltä.</p>
<p>Jos kohtaat ongelmia kirjautumisessa, asiakaspalvelu on saatavilla 24/7 live‑chat‑ ja sähköpostipalvelun kautta. He auttavat muun muassa salasana‑ongelmissa, maksujen tarkistamisessa ja KYC‑tarkistusten läpikäymisessä. Voit myös tutustua laajaan tukikeskukseen, jossa on artikkeleita aiheesta “sainirs6 suomi login” sekä “tilin vahvistus”.</p>
<h2>Vastuullinen pelaaminen ja lisäpalvelut</h2>
<p>SainiRS6 on sitoutunut vastuulliseen pelaamiseen ja tarjoaa useita työkaluja, joilla voit hallita pelitottumuksiasi. Rekisteröityessäsi voit asettaa talletusrajan, pelikerran pituuden tai jopa itse asettaa peliaikakatkaisuja. Jos koet, että pelikäyttäytymisesi on hallitsematonta, voit myös sulkea tilisi tilapäisesti tai pysyvästi.</p>
<p>Lisäksi sivustolla on oma “Vastuullinen pelaaminen” -osio, jossa on linkkejä Suomen pelirahoitus‑yhteistyökumppaneihin ja mahdollisuus ottaa yhteyttä riippumattomaan tukipalveluun. Kun pelaat SainiRS6:ssä, voit siis olla varma, että sekä rahasi että hyvinvointisi ovat turvassa.</p>
<p>Jos haluat tutustua tarkemmin kaikkiin ominaisuuksiin ja aloittaa pelaamisen, käy suoraan <a href="https://sainirs6.com/">SainiRS6</a> -sivustolla ja kirjaudu sisään omilla tiedoillasi.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/uncategorized/sainirs6-suomi-login-yleiskatsaus-ja-vaihtoehdot/">SainiRS6 suomi login: yleiskatsaus ja vaihtoehdot</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>NaoBet : avis complet – inscription, bonus, paiements et jeux en ligne</title>
<link>https://edusehat.com/en/naobet-avis-complet-inscription-bonus-paiements-et-jeux-en-ligne</link>
<guid>https://edusehat.com/en/naobet-avis-complet-inscription-bonus-paiements-et-jeux-en-ligne</guid>
<description><![CDATA[ Tout savoir sur NaoBet : guide pratique pour les joueurs français Qu’est‑ce que NaoBet ? Présentation du casino et du bookmaker NaoBet se positionne comme une plateforme hybride qui 
The post NaoBet : avis complet – inscription, bonus, paiements et jeux en ligne appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/u564lza4m-U/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 12 Nov 2026 14:55:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>NaoBet, avis, complet, –, inscription, bonus, paiements, jeux, ligne</media:keywords>
<content:encoded><![CDATA[<figure data-affgun-media="hero"><img decoding="async" src="https://i.ytimg.com/vi/u564lza4m-U/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<h1>Tout savoir sur NaoBet : guide pratique pour les joueurs français</h1>
<h2>Qu’est‑ce que NaoBet ? Présentation du casino et du bookmaker</h2>
<div data-affgun-media="video"></div>
<p>NaoBet se positionne comme une plateforme hybride qui propose à la fois un casino en ligne complet et un service de paris sportifs. Le site a été lancé en 2021 et cible principalement les marchés européens, avec une offre française bien adaptée aux habitudes de jeu locales.</p>
<p>La licence principale provient de Malte (MGA) et a été complétée par une autorisation de la Commission de jeu française, ce qui garantit une conformité aux exigences de sécurité et de protection des joueurs français. En pratique, cela signifie que les joueurs bénéficient d’un cadre juridique solide tout en profitant d’une large sélection de jeux.</p>
<h2>Inscription et vérification sur NaoBet</h2>
<p>Le processus d’inscription est volontairement simple : il suffit de cliquer sur le bouton « S’inscrire », de renseigner votre adresse e‑mail, un mot de passe et de choisir votre devise (EUR). En moins de deux minutes, le compte est créé et vous avez immédiatement accès à la version de démonstration du casino.</p>
<p>La vérification d’identité (KYC) intervient uniquement lors de la première demande de retrait. Vous devrez fournir une pièce d’identité officielle, un justificatif de domicile et, parfois, une preuve de paiement. Ce processus, bien que court, est indispensable pour prévenir la fraude et garantir la sécurité de vos fonds.</p>
<h2>Bonus de bienvenue et promotions sur NaoBet</h2>
<p>Le premier avantage à ne pas manquer est le bonus de bienvenue « 100 % jusqu’à 200 € + 30 tours gratuits ». Les 30 tours sont généralement applicables aux machines à sous les plus populaires comme <em>Starburst</em> ou <em>Book of Dead</em>. Le bonus est soumis à un <strong>wagering requirement</strong> de 30x, ce qui est moyen comparé aux standards du secteur.</p>
<p>En plus du premier dépôt, NaoBet propose un programme de fidélité à plusieurs niveaux, des cashbacks hebdomadaires et des promotions ponctuelles sur le sportsbook (par exemple, “pariez 10 € et recevez un pari gratuit de 5 €”). Ces offres sont accessibles depuis le tableau de bord du joueur et sont régulièrement mises à jour.</p>
<h2>Méthodes de paiement et rapidité des retraits</h2>
<p>Le portefeuille de NaoBet comprend les options classiques : cartes bancaires (Visa, Mastercard), portefeuilles électroniques (Skrill, Neteller), virements bancaires et cartes prépayées (Paysafecard). Les dépôts sont instantanés, alors que les retraits sont traités selon la méthode choisie : les e‑wallets offrent généralement un délai de 24 h, les cartes bancaires de 2 à 3 jours ouvrés, et les virements de 3 à 5 jours.</p>
<table border="1" cellpadding="5" cellspacing="0">
<thead>
<tr>
<th>Moyen de paiement</th>
<th>Dépôt (temps)</th>
<th>Retrait (temps)</th>
<th>Frais éventuels</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visa / Mastercard</td>
<td>Instantané</td>
<td>2‑3 jours ouvrés</td>
<td>0 €</td>
</tr>
<tr>
<td>Skrill / Neteller</td>
<td>Instantané</td>
<td>24 h</td>
<td>0‑2 €</td>
</tr>
<tr>
<td>Virement bancaire</td>
<td>1‑2 jours ouvrés</td>
<td>3‑5 jours ouvrés</td>
<td>Gratuit</td>
</tr>
<tr>
<td>Paysafecard</td>
<td>Instantané</td>
<td>Non disponible</td>
<td>0 €</td>
</tr>
</tbody>
</table>
<p>Notez que NaoBet applique un contrôle supplémentaire sur les retraits supérieurs à 2 000 €, afin de respecter les normes de lutte contre le blanchiment d’argent.</p>
<h2>Jeux disponibles : casino, live et paris sportifs</h2>
<p>Le catalogue de NaoBet comprend plus de 2 000 titres, fournis par des fournisseurs reconnus tels que NetEnt, Microgaming et Evolution Gaming. Vous trouverez des machines à sous classiques, des jackpots progressifs, des jeux de table (blackjack, roulette) ainsi qu’un véritable <strong>live casino</strong> animé par des croupiers en temps réel.</p>
<p>Le sportsbook couvre les principaux championnats européens de football, le tennis, le basket‑ball et même des sports moins traditionnels comme le e‑sport. Les cotes sont généralement compétitives, avec une marge moyenne légèrement inférieure à la moyenne du marché, ce qui rend les paris plus attractifs.</p>
<h2>Expérience mobile et application NaoBet</h2>
<p>Le site s’adapte parfaitement aux navigateurs mobiles grâce à un design responsive. De plus, NaoBet propose une application native disponible sur Android et iOS, que vous pouvez télécharger directement depuis le site après inscription. L’app offre toutes les fonctionnalités du bureau, y compris les dépôts instantanés, les jeux en live et les paris en temps réel.</p>
<p>Un point fort de l’application est la fonction « push notification » qui vous alerte sur les nouveaux bonus, les matchs en cours et les promotions limitées. Cela permet de ne jamais rater une opportunité, même quand vous êtes en déplacement.</p>
<h2>Sécurité, licence et jeu responsable</h2>
<p>La plateforme utilise le chiffrement SSL 128‑bits, identique à celui des banques, pour protéger toutes les transmissions de données. Les serveurs sont hébergés dans des data‑centers certifiés ISO 27001, ce qui assure une disponibilité et une intégrité maximales.</p>
<p>En matière de jeu responsable, NaoBet propose des outils d’auto‑exclusion, des limites de dépôt et de mise, ainsi qu’une page d’aide détaillée sur la prévention de l’addiction. Vous pouvez aussi contacter le service d’assistance dédié au jeu responsable 24 h/24.</p>
<h2>Service client et assistance</h2>
<p>Le support de NaoBet est disponible via chat en direct, e‑mail et téléphone. Le chat fonctionne 24 h/24 et les réponses sont généralement fournies en moins de deux minutes. L’équipe parle français, anglais et plusieurs autres langues européennes.</p>
<p>En cas de problème avec un retrait ou une vérification, vous pouvez ouvrir un ticket directement depuis votre tableau de bord. La plupart des demandes sont résolues en moins de 24 h, ce qui est un bon indicateur de la qualité du service.</p>
<h2>Conclusion pratique pour les joueurs français</h2>
<p>Si vous recherchez un site qui combine casino, live casino et paris sportifs avec une interface claire, NaoBet répond à la plupart des exigences des joueurs français. Le bonus de bienvenue est intéressant, les méthodes de paiement sont variées et la licence européenne offre une protection fiable.</p>
<p>Pour commencer, il suffit de créer votre compte, de profiter du bonus de 100 % et de tester les jeux qui vous plaisent. N’oubliez pas de vérifier les <em>wagering requirements</em> et de jouer de manière responsable. Vous pouvez accéder directement à la plateforme en suivant ce lien : <a href="https://casino-naobets.com/fr/">https://casino-naobets.com/fr/</a>.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/uncategorized/naobet-avis-complet-inscription-bonus-paiements-et-jeux-en-ligne/">NaoBet : avis complet – inscription, bonus, paiements et jeux en ligne</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Goa’s bid for a bigger role in global pharma </title>
<link>https://edusehat.com/en/goas-bid-for-a-bigger-role-in-global-pharma</link>
<guid>https://edusehat.com/en/goas-bid-for-a-bigger-role-in-global-pharma</guid>
<description><![CDATA[ 
From CDMO expansion to digital quality systems, the Goa Pharma Summit, hosted by Express Pharma, explored the capabilities Goa needs to move into higher-value pharma activities, reports Neha Aathavale 
The post Goa’s bid for a bigger role in global pharma  appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/12131847/EP_Goa-Pharma-Summit.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 12 Nov 2026 14:55:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Goa’s, bid, for, bigger, role, global, pharma </media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/12131847/EP_Goa-Pharma-Summit.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/12131847/EP_Goa-Pharma-Summit.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/12131847/EP_Goa-Pharma-Summit-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>India has built its pharma strength on two formidable foundations: the ability to manufacture at scale and the capacity to reach markets across the world. In recent years, however, it has become increasingly clear that scale alone cannot determine how far the industry can go. The challenge is to keep pace with the shifts while moving beyond volume to create greater value. </span></p>
<p><span>For Goa, this challenge presents an opportunity to build on what it already does well. The state has an established pharma manufacturing base and a strong export orientation. The next step is to build capabilities in research and development (R&D), contract development and manufacturing organisations (CDMOs), advanced manufacturing and innovation. These priorities formed the backdrop of the Goa Pharma Summit, which brought together pharma industry leaders, policymakers, manufacturers, researchers and academic representatives to examine what it will take for Goa to move up the value chain and strengthen its position in the global pharma industry.</span></p>
<p><strong>Goa’s CDMO opportunity </strong></p>
<p><span>One area of opportunity lies in identifying where Goa can offer greater value to global pharma companies beyond manufacturing scale. Dr Praveen Khullar, Executive Director, VerGo Pharma Research Laboratories, emphasised the importance of building on the state’s export base while developing capabilities that would enable it to participate in more specialised development and manufacturing programmes. </span></p>
<p><span>This would mean moving from manufacturing as a standalone capability to building long-term partnerships with global companies. A focused approach to the CDMO market, particularly in complex formulations, specialty products and high-value, smaller-batch programmes, could help Goa address more specialised industry requirements and expand its role across the pharma value chain. </span></p>
<p><span>Reliability would be another part of this proposition. Continuity of supply, speed of formulations, advances in formulation development, processing technologies and analytical methods will play an important role in translating these ambitions into manufacturing capabilities. </span></p>
<p><strong>Advancing formulation technologies </strong></p>
<p><span>Against this backdrop, Manoj Bansal, Head of Business Development, Thermo Fisher Scientific India, discussed advancements in hot melt extrusion technology, focusing on instrumentation considerations and methodologies. The technology can improve the solubility and bioavailability of drugs, supporting formulation development from R&D through to manufacturing. </span></p>
<p><span>Bansal also highlighted the role of molecular spectroscopy in pharma workflows. Thermo Fisher Scientific’s portfolio includes Raman, near-infrared (NIR) spectroscopy and X-ray fluorescence (XRF), which enable rapid, non-destructive testing. These techniques support the analysis of materials and processes, while the integration of formulation technologies, spectroscopy, process analytical technology (PAT) and quality control systems can facilitate faster decision-making, regulatory compliance and manufacturing efficiency. </span></p>
<p><span>Beyond developing formulations and monitoring processes, controlling drug release is another consideration in product development. The choice of polymers and their proportions can influence release characteristics, allowing formulators to adjust drug-release profiles to specific requirements. </span></p>
<p><span>Krutik Prajapati, Manager (Techno Commercial), Vikram Thermo (India), discussed drugrelease modulation through DRUGCOAT RSPO/RLPO. Vikram Thermo’s DRUGCOAT RL/RS polymers enable controlled and extended drug release by adjusting polymer permeability and concentration. They can also be used in wet granulation to modulate release, offering a simpler processing approach with scope for improved scalability. Optimising the ratio of DRUGCOAT RSPO and RLPO further allows formulators to tailor release profiles to specific formulation needs. </span></p>
<p><span>Together, these approaches highlight the role of formulation technologies in translating research into manufacturing capabilities. However, moving towards higher-value products also involves considerations beyond the technical aspects of development. Pricing frameworks, investment decisions and the availability of specialised talent will influence how effectively Goa can capitalise on opportunities in complex generics and biologics. These questions came into focus during the first panel discussion at the summit. </span></p>
<p><strong>PPILT, patent cliffs and the biologics opportunity </strong></p>
<p><span>The first panel discussion, moderated by Dr Subrata Chakraborty, Founder, INOPHAR Consulting & Training, brought together Nilesh Hegu, Site Head – Goa II, Cipla; Dr Pankaj Kumar, VP/Head R&D & Director, Wallace Pharmaceuticals; Uttam Kadam, Sterile Head, Zydus Lifesciences, Goa; Dr Prabhat Dessai, Associate Professor & Assistant Director, Placement & Corporate Relations Cell, Parul University, Goa; and Prof (Dr) G Shaber Ali, Professor of Law and former Principal, V M Salgaocar College of Law, to examine whether Goa’s pricing model could support the next phase of pharma growth. </span></p>
<p><span>The key point of discussion was the role of PPILT, which combines procurement with negotiated pricing rather than operating as a standalone pricing policy. Its potential to influence investment decisions and attract new manufacturing opportunities must be considered alongside the interests of the pharma industry and the need for public transparency. Confidential pricing remains a challenge in this context, requiring a balance between commercial considerations and accountability.</span></p>
<p><span>The discussion also considered whether PPILT could help attract biologics manufacturing and technology transfer to Goa. As the industry responds to patent expiries and explores opportunities in more complex products, the state could benefit from investments that bring specialised manufacturing processes and technical capabilities. However, translating this potential into industrial growth would require more than a pricing mechanism. Complex generics, for instance, demand a different research and development approach, higher investment and advanced analytical capabilities. Developing these capabilities would be important for companies seeking to expand beyond conventional formulations. </span></p>
<p><span>Talent availability emerged as another consideration. As pharma manufacturing incorporates more specialised processes and technologies, the demand for skills is changing. Academia continues to face challenges in matching industry requirements, making closer collaboration between educational institutions and pharma companies important. Industry 4.0 and artificial intelligence are also reshaping manufacturing, increasing the need for talent equipped to work with evolving technologies and production systems. </span></p>
<p><span>The discussion highlighted the interdependence of pricing, investment, technical capabilities and talent development in shaping Goa’s pharma ambitions. For the state to capitalise on emerging opportunities in biologics and complex generics, its pricing framework will need to work alongside investments in R&D, manufacturing technology and specialised skills. But developing these capabilities is only part of the equation. </span></p>
<p><span>Their long-term value will also depend on how effectively companies translate them into products that meet international market needs and build a sustained presence beyond established export destinations. </span></p>
<p><strong>Diversifying India’s pharma exports </strong></p>
<p><span>This shift from building capabilities to converting them into market opportunities formed the basis of the next discussion. </span></p>
<p><span>Moderated by Mahesh Gurnasinghani, Executive Member, Goa Pharmaceutical Manufacturers’ Association (GPMA) and Visiting Faculty, Goa College of Pharmacy, the panel brought together Maneesh Madhukar Narkar, VP – Formulations, Centaur Pharmaceuticals; Pramod Poojari, Site Head – Warehouse – Manufacturing, Cipla; Hruday Jadhav, Associate VP – Analytical R&D, Micro Labs; Sandeep Kulkarni, Associate Director APAC Sourcing Global Procurement Category, Teva Pharmaceuticals; Niket Talauliker, Head of Site Quality, Sanofi India; and Himank Narvekar, DGM – BD & Strategy, VerGo Pharma Research Laboratories, to examine how India could identify its next export growth engines. </span></p>
<p><span>A key consideration was how India could translate its established manufacturing scale into greater value. While the country has developed the capacity to manufacture and supply medicines across international markets, the next phase of export growth may depend on its ability to develop products that require more specialised capabilities. Complex products and formulations could offer opportunities to move beyond competing primarily on volume, provided companies can build the technical expertise and manufacturing capabilities required to develop them. </span></p>
<p><span>This also changes how export diversification needs to be approached. Identifying new markets is only one part of the process; companies must also understand the requirements of those markets and develop products that address them. Market strategy and R&D, therefore, need to inform each other. Insights into demand, regulatory requirements and market-specific needs can help guide product development, while R&D capabilities can determine which opportunities a company is equipped to pursue. </span></p>
<p><span>Regulatory approval is an important step in entering an international market, but it does not, by itself, ensure sustained commercial presence. The ability to maintain supply, establish distribution and secure market acceptance also matters. Quality, in this context, needs to be built into product development from the outset rather than addressed only after a target market has been identified. Aligning quality requirements with product development and manufacturing can help companies prepare for the demands of their intended markets. </span></p>
<p><span>For Goa, these considerations point towards an opportunity to connect its manufacturing base with CDMOs, academic institutions and investment. Such collaboration could support the development of products and capabilities that respond to specific market requirements, while creating stronger links between research, manufacturing and commercial strategy. </span></p>
<p><span>The broader question, therefore, is no longer simply whether Goa can manufacture for international markets, but how it can participate in higher-value activities across the pharma value chain. Moving in this direction would require an export strategy that brings together product development, market intelligence, quality, supplychain reliability and ecosystem partnerships. Translating these priorities into practice will depend on how well companies embed them into their manufacturing operations, quality systems and workforce capabilities. </span></p>
<p><strong>From Panjim to the World: Goa’s export playbook</strong></p>
<p><span>This formed the focus of the summit’s final panel discussion, moderated by Dr Manoj Kumar Kashyap, Professor and Director, Research & Development, Parul University, Goa. The panel brought together Dr Pradeep Kumar Vishwakarma, Associate Director – COE Manufacturing Science and Technology Respiratory, Cipla; Dr Bhaskar Chauhan, Head R&D and Quality Management, Puniska Injectables; Sartaj Hanfi, Sr GM – Plant Head, Indoco Remedies; Vishwas J Desai, GM – Quality Assurance, Blue Cross Laboratories; Abhinay Ajgaonkar, DGM – Head of QA, Centaur Pharmaceuticals; and Urmila Deepak Naik, AGM, FDC Limited Goa (Unit III), to discuss the capabilities required to strengthen Goa’s position in international pharma markets. </span></p>
<p><span>A key consideration was the need to move beyond a compliance-led approach to quality. Passing audits is an important requirement, but sustained global competitiveness calls for organisations to remain prepared for scrutiny as part of their everyday operations. This means embedding quality into processes, systems and decision-making rather than treating inspections as isolated events. Such an approach can help companies strengthen operational consistency while responding to the expectations of international regulators and customers. </span></p>
<p><span>Technology is also changing how quality is managed. As pharma manufacturing becomes increasingly digital, quality systems can do more than maintain records. Digital tools can help organisations analyse data, identify deviations and translate findings into action. The shift towards data-led quality management, however, also brings a requirement for people who can interpret information and apply it to manufacturing decisions. With technology advancing faster than workforce skills, talent development could become a constraint on the industry’s ability to realise the full benefits of these systems. </span></p>
<p><span>Addressing this gap will require a stronger emphasis on practical exposure. The manufacturing shop floor can serve as an important learning environment, giving future professionals the opportunity to work with equipment, understand production processes and engage with real operational challenges. Hands-on experience can help bridge the gap between academic learning and the requirements of pharma manufacturing, particularly as plants adopt new technologies and processes. </span></p>
<p><span>The discussion also pointed to the need for Goa to build capabilities across a larger part of the pharma value chain, from R&D and technology transfer to commercial manufacturing. Expanding these capabilities would require companies to assess established practices critically and remain open to changing them when data and evidence support a better approach. Moving beyond legacy processes is particularly relevant in an environment where digitalisation, analytical capabilities and manufacturing technologies continue to evolve. </span></p>
<p><span>ld, collaboration between academia and industry must extend beyond formal agreements. Partnerships need to create practical opportunities for research, technical problem-solving and exposure to industrial requirements. By connecting academic expertise with manufacturing challenges, such collaborations could help develop the skills and capabilities needed to support innovation. </span></p>
<p><span>For Goa, strengthening its export position will therefore depend not only on meeting international quality requirements, but also on building organisations, technologies and talent capable of sustaining them. </span></p>
<p><span>A closer connection between quality management, digital systems, workforce development and industry-academia collaboration could help the state move towards a more integrated pharma ecosystem, with greater participation in R&D, technology transfer and higher value manufacturing. </span></p>
<p><strong>From scale to value </strong></p>
<p><span>For Goa’s pharma industry, the next phase of growth will depend on how effectively it connects manufacturing strength with innovation, technical expertise and global market requirements. This will require sustained investment in R&D, technology, talent and industry-academia collaboration, alongside a focus on quality and supply reliability. </span></p>
<p><span>The Goa Pharma Summit underscored that moving up the value chain is not a single step, but a coordinated effort to build capabilities that can support the state’s long-term role in the global pharma industry. </span></p>
<p> </p>
<p><strong><em>neha.aathavale@expressindia.com<br>
nehaaathavale75@gmail.com </em></strong></p>
<p>The post <a href="https://www.expresspharma.in/goas-bid-for-a-bigger-role-in-global-pharma/">Goa’s bid for a bigger role in global pharma </a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>How consumers’ demand for transparency will raise the scientific standard of dermocosmetics</title>
<link>https://edusehat.com/en/how-consumers-demand-for-transparency-will-raise-the-scientific-standard-of-dermocosmetics</link>
<guid>https://edusehat.com/en/how-consumers-demand-for-transparency-will-raise-the-scientific-standard-of-dermocosmetics</guid>
<description><![CDATA[ 
Professor Dr. Gabriel Serrano, Founder, Sesderma shares insights on how global formulations may not always address the needs of Indian skin types, and why precision dermatology and delivery can address these gaps, in an email interaction with Viveka Roychowdhury
The post How consumers’ demand for transparency will raise the scientific standard of dermocosmetics appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/11154138/Dr-Gabriel.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 11 Nov 2026 20:25:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>How, consumers’, demand, for, transparency, will, raise, the, scientific, standard, dermocosmetics</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/11154138/Dr-Gabriel.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/11154138/Dr-Gabriel.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/11154138/Dr-Gabriel-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><strong>How do Indian skin types and physiology differ and where do global dermacosmetic formulations, even though some may be innovative, fall short?</strong></p>
<p>India is not one skin type. There is enormous diversity in phototypes, pigmentation, climate, humidity and individual skin behaviour. However, in Indian and other Asian skin, pigmentation disorders such as melasma and post-inflammatory hyperpigmentation are particularly important, and inflammation or procedures can sometimes leave pigmentation behind.</p>
<p>This is where a global formulation can fall short: it may be scientifically excellent, but not necessarily designed around the specific biology and daily environment of Indian skin. We must formulate according to the skin need, not simply according to geography or marketing trends. In India, I would pay particular attention to pigmentation, photoprotection, barrier integrity, sensitivity and tolerance. The same active, at the same concentration and delivered in the same way, does not necessarily produce the same result in every population.</p>
<p>For me, the future is precision dermatology: understanding the individual skin and adapting the formulation, delivery system and regimen accordingly.</p>
<p><strong>Why does formulation science matter when it comes to dermocosmetics?</strong></p>
<p>Because an ingredient on an INCI list is not the same thing as an effective treatment. This is one of the most important lessons I have learned during my career. You can have an excellent active ingredient, but if it is unstable, poorly delivered, released too quickly, or present in a formulation that irritates the skin, the final result may be disappointing.</p>
<p>Formulation science connects the active ingredient with the biological target. We have to understand the molecule, its concentration, stability, compatibility, penetration, release and interaction with the skin. This is why I have always considered delivery technology fundamental. At Sesderma, we use nanotechnology and liposomes to encapsulate active ingredients, with the aim of improving their penetration, stability, efficacy and tolerance.</p>
<p>Dermocosmetics should not be “magic in a jar”. They should be the result of dermatology, chemistry, biology, technology and clinical experience working together. That is what transforms an interesting ingredient into an effective formulation.</p>
<p><strong>India’s consumers are now educating themselves and moving from blindly following trends and fads to asking for evidence-based solutions to support label claims. How has this changed the dermacosmetics business model for researchers, developers and manufacturers?</strong></p>
<p>This is a very positive evolution. An educated consumer is demanding something that dermatologists have always demanded: evidence. We cannot build the future of dermocosmetics on fashionable ingredients or attractive packaging. We must demonstrate that the active ingredient is stable, that it reaches the skin where it is needed, that the formulation is well tolerated and, most importantly, that it produces a measurable benefit.</p>
<p>For researchers and manufacturers, this changes the entire development model. Research must begin with a real dermatological problem and continue through formulation, delivery technology, safety and clinical evaluation. At Sesderma, this philosophy has always been important because we came from dermatology and from the needs of patients. Our collaborations with universities, hospitals and research centres reflect this approach.</p>
<p>Consumers today are asking the industry to be more transparent. I see this not as a challenge, but as an opportunity to raise the scientific standard of dermocosmetics.</p>
<p><strong>Most consumers, at a minimum, want ‘Clean Beauty’ products. What are the other asks: personalisation, etc.? What are the latest consumer trends in skin care formulation science?</strong></p>
<p>Clean beauty is important, but consumers increasingly want something beyond a clean ingredient list: they want results, tolerance, transparency and personalisation. They want products that understand their skin rather than simply products that follow a trend.</p>
<p>I see several important developments. First is personalised skincare, with formulations and routines organised around individual concerns such as pigmentation, ageing, sensitivity, dehydration or acne. Second is skin-barrier science: consumers increasingly understand that an effective product must also respect the skin. Third is biotechnology, including exosomes and other advanced biological systems. Fourth is intelligent delivery, because the active ingredient alone is not enough; we must control how it reaches the skin.</p>
<p>There is also growing interest in multifunctional formulations that combine several complementary benefits without unnecessarily increasing irritation. At Sesderma, we increasingly think in terms of the skin’s needs rather than simply the product category. That is where personalisation becomes meaningful.</p>
<p><strong>What are the next-generation drug delivery modes in skincare products and dermocosmetics?</strong></p>
<p>The future will be about precision delivery, and not simply putting more active ingredients into a cream. We need to transport the right molecule, in the right concentration, to the right biological location and release it at the right time.</p>
<p>We have already seen the importance of liposomes and nanotechnology. At Sesderma, we began applying NANOTECH technology in 2008, using liposomes to encapsulate active ingredients and improve their delivery into the skin while maintaining good tolerance.</p>
<p>The next evolution is biotechnology. Exosome-based systems are particularly interesting because these small vesicles are involved in communication between cells and can transport biological molecules. Sesderma has developed EXOSES using Lactobacillus-derived exosomes.</p>
<p>I also see significant potential in functionalised carriers, targeted delivery, biomimetic systems, microneedling-assisted delivery and regenerative approaches. The objective is always the same: more precision, greater efficacy and better tolerance.</p>
<p><em>viveka.r@expressindia.com</em></p>
<p><em>viveka.roy3@gmail.com</em></p>
<p>The post <a href="https://www.expresspharma.in/how-consumers-demand-for-transparency-will-raise-the-scientific-standard-of-dermocosmetics/">How consumers’ demand for transparency will raise the scientific standard of dermocosmetics</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Policy shifts test pharma’s resilience</title>
<link>https://edusehat.com/en/policy-shifts-test-pharmas-resilience</link>
<guid>https://edusehat.com/en/policy-shifts-test-pharmas-resilience</guid>
<description><![CDATA[ 
Will policy changes on affordability, ethical marketing and incentives translate into meaningful outcomes for patients while allowing the industry to remain sustainable?
The post Policy shifts test pharma’s resilience appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/11115127/EP_EditorsNote_Nov_2026_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 11 Nov 2026 16:50:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Policy, shifts, test, pharma’s, resilience</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/11115127/EP_EditorsNote_Nov_2026_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/11115127/EP_EditorsNote_Nov_2026_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/11115127/EP_EditorsNote_Nov_2026_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p>Important proposed policy changes reflect the government’s commitment to make medicines more affordable for patients, weed out unethical marketing practices across the pharma supply chain and over time, hopefully rebuild trust. However, while the sluggish pace of policy change remains a concern, how will these moves impact pharma companies in the long run?</p>
<p>Let’s consider the latest salvo on medicine prices. On October 17, the National Pharmaceutical Pricing Authority (NPPA) capped trade margins at 30 per cent for 137 nonscheduled anti-cancer medicines. This comes nearly eight years after a 2019 pilot exercise, which capped trade margins at 30 per cent for 42 non-scheduled anti-cancer medicines. According to government data, as part of the pilot, MRPs of 526 brands were reduced by up to 90 per cent <i>(https://www.expresspharma.in/nppa-capstrade-margins-at-30-per-cent-for-137-anti-cancer-medicines/</i>). While industry associations like IPA and OPPI have welcomed the move, both call for an assessment of the actual impact of this change on patient access and availability.</p>
<p>Other experts like Mayur Sirdesai, Co-Founding Partner, Somerset Indus Capital Partners, stress that affordability must be viewed across the entire cancer-care pathway, from screening and diagnosis to treatment.</p>
<p>In some cases, the delay in policy change has given industry time to clean up its act. On October 8, the Supreme Court directed the constitution of a threemember Committee to examine existing regulations on pharma marketing and their adequacy for curbing unethical practices. The Uniform Code for Pharmaceutical Marketing Practices (UCPMP), 2015, which was strengthened in 2024, could move from the current selfregulatory framework to a statutory regime. A final decision is still some time away, with the committee expected to submit its recommendations before the next hearing scheduled for January 2027.</p>
<p>Analysing the impact of this policy shift, Nandan Kulkarni and Shirsh Sawarna of Bernstein (India) point out that over the past 12-18 months, large Indian pharma companies have already been gearing up for implementation, by actively strengthening controls, documentation standards, training programmes and healthcare-professional engagement processes. If the regulatory framework ultimately moves toward a more formal statutory construct, they believe larger companies with established governance processes, stronger compliance infrastructure and ethical commercial practices are likely to be better positioned than smaller peers to navigate the transition.</p>
<p>While UCPMP governs manufacturers, the government is also plugging the loopholes across the pharma supply chain, by proposing to expand restrictions in advertisements of Schedule H, Schedule H1 and Schedule X drugs to retailers, wholesalers and distributors.</p>
<p>Again, like the trade margin caps on cancer medicines, this is good news for patients. The proposal is along the lines of the March 2026 advisory from CDSCO prohibiting direct and surrogate advertisements and promotional activities for Glucagon-like Peptide-1 (GLP-1) receptor agonists.</p>
<p>But as a recent analysis by Anushree Kataria, Tanya Kukade and Dr. Milind Antani of Nishith Desai Associates (NDA) points out, these proposed steps could increase the compliance burden for retailers, and could overlap with prior Central Government permissions already taken by manufacturers for the same prescription products.</p>
<p>The fact that non-compliance with the proposed advertising restriction may expose retailers, wholesalers and distributors to regulatory action, including suspension or cancellation of their sale and distribution licences, indicates the serious nature of the proposed draft amendment.</p>
<p>The NDA analysis also points out that the proposed amendment may cover promotional communications concerning Schedule H, Schedule H1 and Schedule X drugs disseminated through digital platforms like online pharmacies.</p>
<p>The November edition of <i>Express Pharma</i> does a status check on another evolving policy initiative, the Pharmaceutical Production Linked Incentive (PLI) scheme, and touches on an important issue: can the next phase incentivise pharma MSMEs to invest more to become globally competitive?</p>
<p>The grouse of pharma MSMEs has been that since its launch in February 2021, the bulk of PLI funds were bagged by big Indian pharma companies while pharma MSMEs, who actually need the funds to upgrade and move to the next level, continued to languish on the sidelines. In response to this feedback, PLI 2.0 was launched in 2024, with some tweaks to make it more accessible for pharma MSMEs. But as the story reveals, MSME leaders are pushing for different, broader metrics to evaluate the scheme’s success/impact.</p>
<p>As regulators seek to clean up the pharma sector focused on patient safety and affordability, industry will have to find new ways to be as sustainable as possible. The saga continues….</p>
<p>The post <a href="https://www.expresspharma.in/policy-shifts-test-pharmas-resilience/">Policy shifts test pharma’s resilience</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>BDR Pharma to acquire controlling stake in Acme’s oral solid formulations business from PAG</title>
<link>https://edusehat.com/en/bdr-pharma-to-acquire-controlling-stake-in-acmes-oral-solid-formulations-business-from-pag</link>
<guid>https://edusehat.com/en/bdr-pharma-to-acquire-controlling-stake-in-acmes-oral-solid-formulations-business-from-pag</guid>
<description><![CDATA[ 
PAG, together with Acme’s founder Viral Shah, to retain and scale the sterile injectables business, Immacule Lifesciences
The post BDR Pharma to acquire controlling stake in Acme’s oral solid formulations business from PAG appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/11122924/MA.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 11 Nov 2026 16:50:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>BDR, Pharma, acquire, controlling, stake, Acme’s, oral, solid, formulations, business, from, PAG</media:keywords>
<content:encoded><![CDATA[<div><img width="740" height="493" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/11122924/MA.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/11122924/MA.jpg 740w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/11122924/MA-300x200.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/11122924/MA-450x300.jpg 450w" sizes="auto, (max-width: 740px) 100vw, 740px"></div><p align="CENTER"><span>BDR Pharma and PAG announced that BDR Pharma will acquire a controlling stake in the oral solid formulations business of Acme Formulation and its subsidiaries from its existing shareholders, led by PAG. The acquisition aligns with BDR’s growth priorities across oncology, critical care and women’s healthcare, while creating opportunities to expand its product offerings in international markets. A key strategic rationale for the acquisition is the addition of complementary capabilities across thyroid products, female sex hormone products and general pharmaceutical products. o3 Capital acted as the exclusive financial advisor to BDR Pharma on the transaction.</span></p>
<p><span>“<span><span>We have been on a strong growth trajectory driven by strategic investments, innovation and an expanding global ambition. Acme will further strengthen our CDMO platform and add differentiated capabilities. We see this as part of a larger growth roadmap, with more strategic initiatives expected as we continue to build and expand our global presence”, said Dharmesh Shah, Chairman and Managing Director of BDR Pharma.</span></span></span></p>
<p><span><span><span>Having sold a controlling stake in the oral solid business, PAG and Viral Shah will retain full ownership of Immacule, one of India’s leading sterile injectable focused contract manufacturing businesses. Immacule has recently commissioned a new facility with a capacity of 200M+ units p.a. and provides a broad set of capabilities across dosage forms such as liquid / lyophilized vials, pre-filled syringes, cartridges and therapeutic areas such as oncology, ophthalmology and general injectables.</span></span></span></p>
<p><span>“<span><span>We are proud of what Acme has become during our partnership. This transaction reflects the strength of the platform we have built with Viral and the Acme team and we believe that BDR Pharma is the ideal owner to take it to the next level. We will now sharpen our focus on building Immacule into a leading global sterile injectables platform,” said Nikhil Srivastava, Partner and Co-Head of Private Equity at PAG.</span></span></span></p>
<p><span>“<span><span>Acme has been built on long-standing customer relationships and a committed team. BDR Pharma’s strength in new and complex medicines will bring more innovative products to Acme’s CMO and CDMO clients, existing and new, across geographies. I will work closely with BDR Pharma for a smooth transition, while I focus on growing Immacule,” said Viral Shah, Founder of Acme and MD of Immacule.</span></span></span></p>
<p><span><span><span>The acquisition deepens BDR Pharma’s CDMO platform without overlapping with its existing areas of focus, giving it a more specialised manufacturing base in women’s healthcare and thyroid therapies that complements its broader therapeutic footprint, informed a company statement </span></span></span></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/bdr-pharma-to-acquire-controlling-stake-in-acmes-oral-solid-formulations-business-from-pag/">BDR Pharma to acquire controlling stake in Acme’s oral solid formulations business from PAG</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>FDA mandates rare vision&#45;loss warning across all GLP&#45;1 drugs</title>
<link>https://edusehat.com/en/fda-mandates-rare-vision-loss-warning-across-all-glp-1-drugs</link>
<guid>https://edusehat.com/en/fda-mandates-rare-vision-loss-warning-across-all-glp-1-drugs</guid>
<description><![CDATA[ 
The labelling change follows a review indicating a potential increased risk of NAION, a rare eye condition that can cause permanent vision loss
The post FDA mandates rare vision-loss warning across all GLP-1 drugs appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/11141741/GLP1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 11 Nov 2026 16:50:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>FDA, mandates, rare, vision-loss, warning, across, all, GLP-1, drugs</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="418" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/11141741/GLP1.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/11141741/GLP1.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/11141741/GLP1-300x167.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p data-pm-slice="1 1 []">The US Food and Drug Administration (FDA) has directed manufacturers of all approved glucagon-like peptide-1 (GLP-1) receptor agonists to add a warning about the potential risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition that can cause sudden vision loss.</p>
<p>The directive, issued on November 9, 2026, requires the warning to be included in the Warnings and Precautions section of product labels. It covers medicines including Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Victoza, Saxenda, Trulicity, Xultophy, Soliqua and Foundayo.</p>
<p>The FDA reviewed data from 126 clinical trials involving 134,253 patients. The analysis identified 15 probable NAION cases: 10 among GLP-1 users and five among comparator groups. The incidence was 6.4 cases per 100,000 person-years among GLP-1 users, compared with 3.8 among comparator groups.</p>
<p>A separate FDA real-world study found a higher risk among GLP-1 users compared with patients taking DPP-4 inhibitors (hazard ratio 1.43). However, the increase was not statistically significant when compared with SGLT-2 inhibitors.</p>
<p>Based on its assessment of clinical trials, real-world evidence and published studies, the FDA concluded that there is a potential increased risk of NAION associated with GLP-1 medicines. However, it has not established a causal relationship.</p>
<p>NAION occurs when blood flow to the front part of the optic nerve is reduced. Symptoms include sudden, painless vision loss in one eye, blind spots, tunnel vision and blurred central vision. The condition can cause permanent damage.</p>
<p>The FDA has advised patients experiencing sudden vision changes to contact their healthcare professional immediately. Clinicians should promptly refer suspected cases to an ophthalmologist and consider discontinuing GLP-1 treatment in patients diagnosed with NAION, unless the benefits outweigh the risks.</p>
<p>The agency has clarified that the risk remains rare and has not advised patients to stop their medication as a precaution. Patients should discuss any treatment-related concerns with their healthcare professionals.</p>
<p>The post <a href="https://www.expresspharma.in/fda-mandates-rare-vision-loss-warning-across-all-glp-1-drugs/">FDA mandates rare vision-loss warning across all GLP-1 drugs</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>CBC India partners with Indmark Paperform for square fibre drum packaging solutions</title>
<link>https://edusehat.com/en/cbc-india-partners-with-indmark-paperform-for-square-fibre-drum-packaging-solutions</link>
<guid>https://edusehat.com/en/cbc-india-partners-with-indmark-paperform-for-square-fibre-drum-packaging-solutions</guid>
<description><![CDATA[ 
The partnership aims to introduce fibre drum packaging solutions to India&#039;s pharmaceutical and allied industries, with a focus on space utilisation, supply chain efficiency and sustainability
The post CBC India partners with Indmark Paperform for square fibre drum packaging solutions appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/05/04131504/handshake.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 09 Nov 2026 18:15:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>CBC, India, partners, with, Indmark, Paperform, for, square, fibre, drum, packaging, solutions</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/05/04131504/handshake.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/05/04131504/handshake.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/05/04131504/handshake-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>CBC India’s Ingredients & Packaging Solutions (CBC-IPS) Division has announced a strategic partnership with Indmark Paperform, a manufacturer of fibre-based packaging solutions for the pharmaceutical and healthcare industries.</span></p>
<p><span>The partnership aims to introduce square fibre drum solutions to customers across India by combining CBC India’s market reach and industry expertise with Indmark Paperform’s packaging capabilities.</span></p>
<p><span>Indmark Paperform’s square fibre drums are designed for space utilisation and offer an alternative to conventional packaging formats. Their square structure enables higher loading efficiency, allowing more units per shipment while reducing transportation and warehousing costs. Unlike round fibre drums and cardboard containers, these drums minimise unused space without compromising strength, stability or product protection.</span></p>
<p><span>The company stated that the drums are lightweight and durable and provide performance across industries, including pharmaceuticals, chemicals and specialty materials.</span></p>
<p><span>The partnership will support customers in adopting environmentally responsible packaging solutions while optimising supply chain efficiency and reducing logistics costs.</span></p>
<p><span>Swapnil Meher, CEO, Indmark Paperform, said, “We are pleased to partner with CBC India to further strengthen our presence in the Indian pharmaceutical packaging market. CBC India’s strong industry relationships, market understanding, and customerfocused approach make them an ideal strategic partner. Together, we look forward to delivering innovative and sustainable packaging solutions that support the evolving needs of the pharmaceutical industry.”</span></p>
<p><span>Durgesh Sharma, Managing Director, CBC India, said, “At CBC India, we are committed to building strong partnerships that deliver lasting value to our customers and the industries we serve. We are delighted to collaborate with Indmark Paperform to bring innovative square fiber drum packaging solutions to the Indian market. By combining our market expertise with Indmark Paperform’s packaging excellence, we aim to help customers improve operational efficiency, optimize logistics and advance their sustainability goals through environmentally responsible packaging solutions.”</span></p>
<p>The post <a href="https://www.expresspharma.in/cbc-india-partners-with-indmark-paperform-for-square-fibre-drum-packaging-solutions/">CBC India partners with Indmark Paperform for square fibre drum packaging solutions</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>NPPA anti&#45;cancer medicine price cuts to take effect from November 9</title>
<link>https://edusehat.com/en/nppa-anti-cancer-medicine-price-cuts-to-take-effect-from-november-9</link>
<guid>https://edusehat.com/en/nppa-anti-cancer-medicine-price-cuts-to-take-effect-from-november-9</guid>
<description><![CDATA[ 
Revised MRPs reported for 1,225 formulations across 121 drugs, with estimated annual consumer savings of ₹3,502.31 crore
The post NPPA anti-cancer medicine price cuts to take effect from November 9 appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/09110850/EP_price_cuts_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 09 Nov 2026 14:35:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>NPPA, anti-cancer, medicine, price, cuts, take, effect, from, November</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/09110850/EP_price_cuts_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/09110850/EP_price_cuts_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/09110850/EP_price_cuts_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, has capped trade margins on the MRP of 137 anti-cancer drugs, based on the recommendations of an Expert Committee constituted by the Directorate General of Health Services (DGHS) under the Ministry of Health and Family Welfare on October 17, 2026. The revised prices of these drugs will come into effect from November 9, 2026.</span></p>
<p><span>As of November 7, 2026, 76 pharma companies have reported revised MRPs for 1,225 anti-cancer formulations, covering 121 drugs. Reductions in MRP have been reported in 1,031 formulations of anti-cancer medicines, with 600 brands reporting reductions of above 50 per cent. The highest reduction reported is 96.45 per cent.</span></p>
<p><span>Further, of the 137 identified anti-cancer drugs, 10-15 drugs are yet to be launched in India. However, Trade Margin Rationalisation (TMR) will also apply to these drugs when they are launched.</span></p>
<p><span>Following the price reductions coming into effect from November 9, 2026, the estimated annual savings to consumers are expected to be ₹3,502.31 crore.</span></p>
<p>The post <a href="https://www.expresspharma.in/nppa-anti-cancer-medicine-price-cuts-to-take-effect-from-november-9/">NPPA anti-cancer medicine price cuts to take effect from November 9</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Pharma industry reports 97 deals worth $25.45 billion in October 2026</title>
<link>https://edusehat.com/en/pharma-industry-reports-97-deals-worth-2545-billion-in-october-2026</link>
<guid>https://edusehat.com/en/pharma-industry-reports-97-deals-worth-2545-billion-in-october-2026</guid>
<description><![CDATA[ 
M&amp;A deal value declined by 55.8 per cent, while venture capital funding decreased by 34.3 per cent compared with October 2025
The post Pharma industry reports 97 deals worth $25.45 billion in October 2026 appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/08/06144031/Acquisition.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 09 Nov 2026 14:35:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Pharma, industry, reports, deals, worth, 25.45, billion, October, 2026</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/08/06144031/Acquisition.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/08/06144031/Acquisition.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/08/06144031/Acquisition-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p data-pm-slice="1 1 []">According to GlobalData, industry reported 97 deals worth $25.45 billion in October 2026, compared with the average of 92 deals worth $29.7 billion over the last 12 months (October 2025 to September 2026).</p>
<p>Deal value decreased by 55.8 per cent in October 2026, compared with October 2025.</p>
<p>Among the major transactions reported during the month, Crown NL Bidco B.V. announced its acquisition of Qiagen NV, a life-science and diagnostics company that helps laboratories turn biological samples into clear test results and research insights, through an all-cash voluntary public takeover offer worth $12.1 billion. Shionogi & Co., Ltd. announced the acquisition of IntraBio Inc., a biopharmaceutical company developing and commercialising therapies for neurodegenerative diseases, for a total transaction value of $2 billion. Viatris Inc, a global healthcare company, announced the acquisition of Pacira BioSciences Inc, a pharmaceutical company that offers non-opioid pain management and regenerative health solutions, for an equity value of $1.65 billion. These were the three major deals reported in October 2026.</p>
<p>Venture capital funding decreased by 34.3 per cent in October 2026, compared with October 2025.</p>
<p>The healthcare industry reported 93 venture capital (VC) deals worth $3.41 billion in October 2026, compared with the average of 115 deals worth $3.5 billion over the last 12 months (October 2025 to September 2026).</p>
<p>Among the major VC transactions reported during the month, Dren Bio Inc., a clinical-stage biotechnology company developing first-in-class antibody therapeutics, raised $350 million in a financing round to support continued late-stage clinical development, regulatory submission and planned commercial launch of dibotatug (DR-01). OMass Therapeutics Limited, a biotechnology company developing small molecule therapeutics, raised $310 million in a Series C financing round to support the advancement of the Company’s lead programme, OMS1620. Matchpoint Therapeutics Inc, a biotechnology company, raised $150 million in Series B financing to advance its pipeline of first-in-class oral small molecules for autoimmune and inflammatory diseases. These were the three major VC deals reported in October 2026.</p>
<p>The post <a href="https://www.expresspharma.in/pharma-industry-reports-97-deals-worth-25-45-billion-in-october-2026/">Pharma industry reports 97 deals worth $25.45 billion in October 2026</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>FOPE seeks reconsideration of proposed automatic suspension of drug manufacturing licences on NSQ reports</title>
<link>https://edusehat.com/en/fope-seeks-reconsideration-of-proposed-automatic-suspension-of-drug-manufacturing-licences-on-nsq-reports</link>
<guid>https://edusehat.com/en/fope-seeks-reconsideration-of-proposed-automatic-suspension-of-drug-manufacturing-licences-on-nsq-reports</guid>
<description><![CDATA[ 
Federation of Pharma Entrepreneurs supports patient safety measures but calls for procedural safeguards, proportionality and an opportunity for manufacturers to present their case
The post FOPE seeks reconsideration of proposed automatic suspension of drug manufacturing licences on NSQ reports appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 09 Nov 2026 14:35:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>FOPE, seeks, reconsideration, proposed, automatic, suspension, drug, manufacturing, licences, NSQ, reports</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>The Federation of Pharma Entrepreneurs (FOPE) has taken note of the Ministry of Health and Family Welfare’s draft notification G.S.R. 956(E), proposing amendments to the Drugs Rules, 1945, to provide for immediate suspension of manufacturing licences when drugs are declared Not of Standard Quality (NSQ).</span></p>
<p><span>FOPE has stated its support for the Government’s commitment to patient safety and ensuring the availability of safe, effective and quality medicines. The organisation said the pharmaceutical industry recognises that quality compliance and patient safety are paramount and that regulatory authorities must have the powers to take action against manufacturers wherever quality failures or violations are established.</span></p>
<p><span>However, FOPE believes that the existing provisions of the Drugs and Cosmetics Act, 1940 and the Drugs Rules, 1945 already provide a regulatory framework that empowers authorities to investigate quality failures, take enforcement action and suspend or cancel manufacturing licences wherever warranted.</span></p>
<p><span>In this context, FOPE has called for reconsideration of the need for an additional provision mandating automatic suspension of manufacturing licences upon receipt of an NSQ report, without addressing procedural safeguards.</span></p>
<p><span>FOPE’s principal concern is that regulatory enforcement must be consistent with the principles of natural justice, fairness and proportionality. The organisation stated that an NSQ test report should trigger regulatory examination and investigation. However, the consequences of such a report should be determined after considering the nature and severity of the failure, its potential impact on patient safety, the circumstances leading to the deviation, and the manufacturer’s explanation and supporting evidence.</span></p>
<p><span>FOPE has identified five concerns regarding the proposed automatic suspension mechanism. These include the absence of an express provision allowing manufacturers to present their explanation before suspension, the lack of specific provisions for appellate confirmatory testing where analytical results are disputed, and the absence of a distinction between critical quality failures and other technical or analytical deviations.</span></p>
<p><span>The organisation has also raised concerns about the operational and financial consequences of suspension and the absence of prescribed timelines for regulatory assessment of corrective and preventive action (CAPA), verification and restoration of manufacturing permissions.</span></p>
<p><span>FOPE has emphasised that the principles of natural justice, including the opportunity to be heard, should form part of regulatory decision-making. It stated that where an urgent situation involving an immediate threat to patient safety requires interim action, post-decisional hearings and time-bound review mechanisms should be provided.</span></p>
<p><span>The proposed amendments should also distinguish between suspension of permission for the affected product and suspension of the entire manufacturing licence, according to FOPE. Regulatory action should be proportionate and product-specific unless wider systemic GMP failures are established.</span></p>
<p><span>In its statement, FOPE said:</span></p>
<p><span>“Patient safety is non-negotiable, and the pharmaceutical industry fully supports strong and effective regulatory oversight. However, strong regulation must also be fair, scientifically justified and consistent with established legal principles.</span></p>
<p><span>We believe that the existing legal framework already empowers regulatory authorities to take appropriate action against quality failures and protect public health. Introducing an additional automatic suspension mechanism without adequate safeguards may create unintended consequences without necessarily improving the effectiveness of quality enforcement.</span></p>
<p><span>An NSQ observation must lead to prompt investigation, identification of root causes and effective corrective and preventive action. At the same time, manufacturers must have a reasonable opportunity to present their case, seek appellate confirmatory testing wherever warranted and receive a reasoned regulatory decision in accordance with the principles of natural justice.</span></p>
<p><span>Our concern is particularly significant for manufacturers, where suspension of a product or manufacturing permission can have substantial operational and financial implications. Regulatory action must be proportionate to the nature of the failure and the actual risk to patients.</span></p>
<p><span>FOPE will submit a detailed representation to the Ministry of Health and Family Welfare and engage constructively with CDSCO and other regulatory authorities. We will seek reconsideration of the proposed automatic suspension provisions and advocate a balanced approach that strengthens patient safety while preserving fairness, transparency and due process.</span></p>
<p><span>We believe that patient safety, regulatory effectiveness and the sustainability of responsible pharmaceutical manufacturing are complementary objectives and must move forward together.”</span></p>
<p><span>FOPE stated that it will submit a representation to the Ministry of Health and Family Welfare and engage with CDSCO and other regulatory authorities to seek reconsideration of the proposed automatic suspension provisions.</span></p>
<p><span>The Federation of Pharma Entrepreneurs reiterated its commitment to working with the Government and regulatory authorities to strengthen India’s pharmaceutical quality ecosystem and sustain the country’s position as a global pharmaceutical manufacturing destination.</span></p>
<p>The post <a href="https://www.expresspharma.in/fope-seeks-reconsideration-of-proposed-automatic-suspension-of-drug-manufacturing-licences-on-nsq-reports/">FOPE seeks reconsideration of proposed automatic suspension of drug manufacturing licences on NSQ reports</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Dr. Reddy’s receives marketing authorisation for generic semaglutide injection in Brazil</title>
<link>https://edusehat.com/en/dr-reddys-receives-marketing-authorisation-for-generic-semaglutide-injection-in-brazil</link>
<guid>https://edusehat.com/en/dr-reddys-receives-marketing-authorisation-for-generic-semaglutide-injection-in-brazil</guid>
<description><![CDATA[ 
 The approval expands Dr. Reddy’s semaglutide presence to Brazil, one of the key markets in Latin America
The post Dr. Reddy’s receives marketing authorisation for generic semaglutide injection in Brazil appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/15105219/Dr.-Reddys-building.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 17:20:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Dr., Reddy’s, receives, marketing, authorisation, for, generic, semaglutide, injection, Brazil</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="431" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/15105219/Dr.-Reddys-building.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/15105219/Dr.-Reddys-building.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/15105219/Dr.-Reddys-building-300x172.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p>Dr. Reddy’s Laboratories announced that Brazil’s National Health Surveillance Agency (ANVISA) has granted marketing authorisation for generic semaglutide injection for the treatment of adults with insufficiently controlled type 2 diabetes mellitus, as an adjunct to diet and exercise, either as monotherapy when metformin is considered inappropriate due to intolerance or contraindications, or in addition to other medicinal products for the treatment of diabetes.</p>
<p>The product will be available as a pre-filled, multi-dose injectable pen in two presentations, 2 mg/1.5 mL and 4 mg/3 mL, for once-weekly dosing.</p>
<p>Brazil has 16.6 million adults aged 20–79 living with diabetes and ranks sixth globally in terms of the number of adults living with diabetes. Reflecting the significant treatment need in the country, the semaglutide market for diabetes is estimated at approximately USD 244.6 million.</p>
<p>Commenting on the approval, MV Ramana, Chief Executive Officer, Global Generics, Dr. Reddy’s Laboratories, said, “Our focus with semaglutide is to expand access to this treatment option across markets where the patient need is significant. Brazil, with its substantial burden of diabetes, is an important part of that journey. This approval builds on our broader semaglutide strategy and brings us another step closer to making semaglutide available to more patients. We plan to launch semaglutide in Brazil with Aché.”</p>
<p>The post <a href="https://www.expresspharma.in/dr-reddys-receives-marketing-authorisation-for-generic-semaglutide-injection-in-brazil/">Dr. Reddy’s receives marketing authorisation for generic semaglutide injection in Brazil</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>HRV Pharma acquires Phatebo GmbH; enters European finished formulations market</title>
<link>https://edusehat.com/en/hrv-pharma-acquires-phatebo-gmbh-enters-european-finished-formulations-market</link>
<guid>https://edusehat.com/en/hrv-pharma-acquires-phatebo-gmbh-enters-european-finished-formulations-market</guid>
<description><![CDATA[ 
Phatebo sources the comparator, investigational and ancillary medicines that pharmaceutical sponsors and clinical research organisations need to run their trials, and becomes HRV’s first finished formulations business in Europe
The post HRV Pharma acquires Phatebo GmbH; enters European finished formulations market appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/08/06144031/Acquisition.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 17:20:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>HRV, Pharma, acquires, Phatebo, GmbH, enters, European, finished, formulations, market</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/08/06144031/Acquisition.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/08/06144031/Acquisition.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/08/06144031/Acquisition-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p>HRV Pharma, a global virtual pharmaceutical company, announced that it has entered into definitive agreements to acquire 100 per cent of the equity of Phatebo GmbH from ZeroStack Corp.<br>
Phatebo is a licensed pharmaceutical company based in Hilzingen, Germany, specialising in clinical trial supply, with revenues of approximately ₹350 crore in 2025. The acquisition takes HRV beyond active pharmaceutical ingredients into finished formulations, and gives HRV a licensed operating business in Germany.</p>
<p>Clinical trial supply at the core</p>
<p>Every clinical trial depends on more than the new therapy being tested. Sponsors also need a reliable supply of comparator medicines, usually approved branded products against which the new treatment is measured, and of ancillary medicines used alongside it in the study. These have to be sourced through licensed channels, in the right quantities, with complete records of origin, batch and expiry, and they have to reach the study on schedule. When they do not, the trial waits.<br>
Founded in 2015, Phatebo holds a German pharmaceutical wholesale authorisation and has built its business around this work. It sources investigational, comparator and ancillary medicines, including innovative branded therapies, for global pharmaceutical companies and clinical research organisations. It operates quality systems built for good distribution practice, and it also trades in pharmaceuticals and medical devices across Europe and international markets.</p>
<p>How the two businesses fit</p>
<p>With Phatebo, HRV now operates across both layers of the pharmaceutical value chain: active pharmaceutical ingredients through its partner network, and finished medicines through a licensed European business that already supplies sponsors worldwide. The acquisition fits HRV’s IP-led, asset-light model, in which HRV works with certified manufacturing partners rather than owning plants. Phatebo brings a licensed European entity, established good distribution practice systems and long-standing relationships with sponsors and clinical research organisations. HRV brings relationships with more than 50 FDA and EU-GMP certified manufacturing partners and customers in 55 countries, across the US, Europe, the Middle East, Latin America and Asia-Pacific.</p>
<p>Phatebo continues to operate under its own name from Hilzingen, led by Managing Director Martin Lisker, with its existing team and customer agreements in place.</p>
<p>“ Clinical trials today run across many countries at once, and each one depends on the right medicine reaching the right patient at the right time. Very few companies do that work well, and Phatebo is one of them. Sponsors around the world trust this team with studies where there is no room for error. Bringing them into the HRV family gives us our first finished formulations business, alongside the API portfolio we have built since 2015. I could not have asked for a better team to take that step with.” Hari Kiran Chereddi, Founder, Managing Director and CEO, HRV Pharma</p>
<p>“Our customers rely on us to source the right medicines, at the right time, for trials that cannot wait. That responsibility shapes how we qualify every supply channel and how we document every shipment. In HRV we have an owner that understands quality and speed the way we do, and that matters to our team and to the sponsors we serve.” Martin Lisker, Managing Director, Phatebo GmbH</p>
<p> </p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/hrv-pharma-acquires-phatebo-gmbh-enters-european-finished-formulations-market/">HRV Pharma acquires Phatebo GmbH; enters European finished formulations market</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Formation Bio launches $600m drug development fund</title>
<link>https://edusehat.com/en/formation-bio-launches-600m-drug-development-fund</link>
<guid>https://edusehat.com/en/formation-bio-launches-600m-drug-development-fund</guid>
<description><![CDATA[ The initiative will support the acquisition and clinical advancement of ten to 15 drug programmes over the next three to five years. The company plans to source Phase 
The post Formation Bio launches $600m drug development fund appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/10/PT-29-10-2026-shutterstock_1884612922.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 13:45:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Formation, Bio, launches, 600m, drug, development, fund</media:keywords>
<content:encoded><![CDATA[<p>The initiative will support the acquisition and clinical advancement of ten to 15 drug programmes over the next three to five years.</p>
<p>The company plans to source Phase I and Phase II assets from biotechnology and pharmaceutical entities through acquisitions or in-licensing agreements.</p>
<p>Selection prioritises therapies addressing conditions with substantial unmet need and limited industry development, focusing on programmes with clear pathways to clinical proof of concept.</p>
<p>Formation Bio aims to reach major clinical milestones within two to four years of acquiring each asset, before pursuing commercialisation or co-commercialisation agreements with pharmaceutical partners.</p>
<p>Capital from the vehicle will be deployed through a hub-and-spoke operational model, with each funded programme housed within an independent corporate entity.</p>
<p>Formation Bio serves as the fund’s general partner via a wholly owned subsidiary and has invested its own capital alongside external limited partners.</p>
<p>These backers include hospitals, institutional endowments, philanthropic organisations, and research foundations.</p>
<p>Formation Bio co-founder and CEO Benjamine Liu said: “This fund gives our LPs access to an important and emerging investment category—individual drug assets—through a capital-efficient structure.</p>
<p>“For Formation Bio, it expands the number of promising drugs we can pursue, gives us strategic and financing flexibility, creates paths to liquidity without selling the parent company, and positions us to lower our cost of capital over time.</p>
<p>“Together, these advantages address structural challenges in our industry, allow us to develop more drugs for patients, and support our ambition to build this generation’s enduring pharma company.”</p>
<p>Formation Bio has its headquarters in New York City and a second office in Boston. It combines computational platforms with clinical trial operations to progress drug candidates.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/news/formation-bio-600m-drug-development-fund/">Formation Bio launches $600m drug development fund</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Dren Bio raises $350m for dibotatug clinical development</title>
<link>https://edusehat.com/en/dren-bio-raises-350m-for-dibotatug-clinical-development</link>
<guid>https://edusehat.com/en/dren-bio-raises-350m-for-dibotatug-clinical-development</guid>
<description><![CDATA[ The privately held clinical-stage biotechnology company will also use the capital to progress its broader research pipeline in autoimmune disorders, immunology, neurology, and oncology. Juvia Group and Lightspeed 
The post Dren Bio raises $350m for dibotatug clinical development appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/10/PT-30-10-2026-shutterstock_2311370891.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 13:45:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Dren, Bio, raises, 350m, for, dibotatug, clinical, development</media:keywords>
<content:encoded><![CDATA[<p>The privately held clinical-stage biotechnology company will also use the capital to progress its broader research pipeline in autoimmune disorders, immunology, neurology, and oncology.</p>
<p>Juvia Group and Lightspeed Venture Partners co-led the investment round.</p>
<p>Following the transaction, Juvia Group co-founder and managing director Sujal Shah and Lightspeed partner Shelley Chu have joined the Dren Bio Board of Directors.</p>
<p>Additional new participants included Cormorant Asset Management, General Catalyst, Mirae Asset Capital Life Science, and OrbiMed.</p>
<p>Existing investors 8VC, Aisling Capital, ArrowMark Partners, BVF Partners, HBM Healthcare Investments, Mission BioCapital, SR One, and Taiho Ventures also contributed capital.</p>
<p>Dibotatug is a fully human monoclonal antibody engineered to bind cluster of differentiation 94 (CD94). The therapy selectively removes disease-causing cytotoxic cells whilst sparing the wider immune system.</p>
<p>The company’s furthest advanced clinical programmes focus on cytotoxic T-cell lymphoma, an aggressive haematologic malignancy, and large granular lymphocytic leukaemia, a chronic condition associated with severe neutropenia, anaemia, and transfusion requirements.</p>
<p>Neither disease currently has approved therapeutic options.</p>
<p>More than 300 individuals have received treatment in an ongoing Phase I/II trial evaluating dibotatug for relapsed or refractory forms of both conditions.</p>
<p>Dren Bio plans to expand clinical testing of dibotatug into aplastic anaemia, other bone marrow failure syndromes, and autoimmune indications.</p>
<p>Dren Bio CEO and founder Nenad Tomasevic said: “We founded Dren Bio with a simple vision: pursue novel science to develop medicines that meaningfully improve the lives of patients with devastating diseases and few treatment options.</p>
<p>“Seeing dibotatug advance to this late stage of development, alongside a clinically validated platform that continues to generate promising new therapies, is deeply gratifying and reflects the vision that inspired us from day one.”</p>
<p>In July 2024, Dren Bio partnered with Novartis subsidiary Novartis Pharma to discover and develop therapeutic bispecific antibodies to treat cancer.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/news/dren-bio-350m-dibotatug-clinical-development/">Dren Bio raises $350m for dibotatug clinical development</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Enthorin and Rumi sign agreement for FXS therapy</title>
<link>https://edusehat.com/en/enthorin-and-rumi-sign-agreement-for-fxs-therapy</link>
<guid>https://edusehat.com/en/enthorin-and-rumi-sign-agreement-for-fxs-therapy</guid>
<description><![CDATA[ Under the deal, Rumi Therapeutics will develop the therapy, renaming it RTX-7340. Enthorin Therapeutics will receive an upfront sum, an option exercise fee, and milestone payments. The company 
The post Enthorin and Rumi sign agreement for FXS therapy appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/10/PT-2-29-10-2026-shutterstock_2378150581.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 13:45:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Enthorin, and, Rumi, sign, agreement, for, FXS, therapy</media:keywords>
<content:encoded><![CDATA[<p>Under the deal, Rumi Therapeutics will develop the therapy, renaming it RTX-7340.</p>
<p>Enthorin Therapeutics will receive an upfront sum, an option exercise fee, and milestone payments.</p>
<p>The company is also eligible for further payments linked to development, regulatory, and commercial targets, alongside royalties on future net product sales.</p>
<p>It will also contribute scientific and technical expertise to assist during the initial stages of the work.</p>
<p>ENT-7340 is an investigational new drug (IND) enabled small molecule that selectively inhibits phosphodiesterase 2A (PDE2A).</p>
<p>It controls cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate signalling pathways (cGMP), which influence neuronal function and synaptic plasticity.</p>
<p>FXS is an inherited neurodevelopmental disorder stemming from Fragile X messenger ribonucleoprotein 1 (FMR1) gene alterations that reduce or prevent the generation of functional FMRP, a protein essential for brain development.</p>
<p>The condition causes varying degrees of cognitive, behavioural, linguistic, and sensory difficulties in both males and females.</p>
<p>Enthorin Therapeutics co-founder and chief scientific officer Marco Peters said: “ENT-7340 represents years of discovery and development work aimed at translating the biology of PDE2 inhibition into effective therapeutics for the treatment of neurodevelopmental disorders such as Fragile X.</p>
<p>“Rumi brings distinctive capabilities for evaluating therapeutics in human cellular and organoid models, providing an opportunity to further validate the biology of RTX-7340 in human systems and explore its mechanism of action in FXS and additional indications.</p>
<p>“We are excited about this agreement and look forward to supporting Rumi during the initial development phase as they advance the programme toward clinical development.”</p>
<p>Rumi Therapeutics, an operating company under parent firm Rumi Holdings alongside Rumi Scientific, plans to advance the therapy into clinical testing by drawing on human organoid disease models.</p>
<p>Enthorin Therapeutics developed the programme with research support from the FRAXA Research Foundation.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/news/enthorin-rumi-agreement-fxs-therapy/">Enthorin and Rumi sign agreement for FXS therapy</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Bavarian Nordic secures four&#45;year UK vaccine supply deal</title>
<link>https://edusehat.com/en/bavarian-nordic-secures-four-year-uk-vaccine-supply-deal</link>
<guid>https://edusehat.com/en/bavarian-nordic-secures-four-year-uk-vaccine-supply-deal</guid>
<description><![CDATA[ The deal for the vaccine was awarded through the UK Health Security Agency. Under the contract, the company will deliver scheduled shipments of MVA-BN across the term. The 
The post Bavarian Nordic secures four-year UK vaccine supply deal appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/11/Vaccines-manufacturing.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 13:45:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Bavarian, Nordic, secures, four-year, vaccine, supply, deal</media:keywords>
<content:encoded><![CDATA[<p>The deal for the vaccine was awarded through the UK Health Security Agency.</p>
<p>Under the contract, the company will deliver scheduled shipments of MVA-BN across the term. The agreement also includes optional flexibility provisions, though further details were not disclosed.</p>
<p>MVA-BN is said to be the only non-replicating mpox vaccine that secured approval in the US, Singapore, Switzerland, Mexico, the EU/EEA, Canada and the UK. It is marketed under different brand names depending on the jurisdiction: Jynneos in the US and Mexico, Imvamune in Canada, and Imvanex in the EU/EEA and UK.</p>
<p>The vaccine was originally developed in collaboration with the US Government as a smallpox vaccine intended for the entire population, including those who are immunocompromised and not recommended for traditional replicating smallpox vaccines.</p>
<p>It is indicated for use in the general population from the age of two years in those considered at risk of smallpox or mpox infection.</p>
<p>Bavarian Nordic public preparedness senior vice-president Hitesh Sahni said: “Maintaining sustainable vaccine stockpiles and rapid response capabilities are essential to protecting public health and saving lives, and we are proud that our vaccine remains an important component of the UK’s resilience strategy.”</p>
<p>The latest contract builds on previous vaccine procurements by the UK Government and extends an existing relationship between Bavarian Nordic and UK authorities.</p>
<p>Earlier purchases were aimed at strengthening national preparedness while ensuring vaccine availability for eligible people and outbreak response.</p>
<p>Bavarian Nordic said the deal supports the long-term readiness of the UK against emerging threats of infectious diseases. Governments and public health bodies have continued to prioritise access to vaccines that can be rapidly deployed to address changing epidemiological conditions.</p>
<p> </p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/news/bavarian-nordic-uk-vaccine-supply-deal/">Bavarian Nordic secures four-year UK vaccine supply deal</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Inovio’s Voceryq receives FDA accelerated approval for RRP</title>
<link>https://edusehat.com/en/inovios-voceryq-receives-fda-accelerated-approval-for-rrp</link>
<guid>https://edusehat.com/en/inovios-voceryq-receives-fda-accelerated-approval-for-rrp</guid>
<description><![CDATA[ Caused by HPV-6 and/or HPV-11 primarily, RRP is characterised by the development of wart-like growths in the respiratory tract. The DNA-based immunotherapy, generically known as doruxapapogene ralaplasmid and 
The post Inovio’s Voceryq receives FDA accelerated approval for RRP appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/11/RRP-shutterstock_2501941397.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 13:45:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Inovio’s, Voceryq, receives, FDA, accelerated, approval, for, RRP</media:keywords>
<content:encoded><![CDATA[<p>Caused by HPV-6 and/or HPV-11 primarily, RRP is characterised by the development of wart-like growths in the respiratory tract.</p>
<p>The DNA-based immunotherapy, generically known as doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd and previously designated INO-3107, was cleared under the FDA’s accelerated approval pathway.</p>
<p>The approval was based on demonstrated complete response, defined as patients requiring no surgical intervention in the 12 months following treatment.</p>
<p>Continued approval may depend on verification of clinical benefit through a confirmatory study.</p>
<p>Inovio president and CEO Dr Jacqueline Shea said: “With the approval of Voceryq, we believe our DNA medicine platform has the potential to transform the treatment paradigm for RRP by offering a patient-centric treatment option.</p>
<p>“Voceryq is designed to deliver what we understand matters most to patients, which is the reduction of the surgical burden caused by RRP.”</p>
<p>Data from Inovio’s RRP-001 trial of Voceryq underpinned the regulatory decision. The study enrolled 32 adult patients who had undergone at least two papilloma excision surgeries in the preceding year.</p>
<div></div>
<p>Of these, 26 patients who had required three or more surgeries during the prior 12 months formed the efficacy population, with a median of 4.5 prior surgical excisions.</p>
<p>Seven of the 26 efficacy patients, or 27%, achieved a complete response after 12 months of follow-up, requiring no further surgical excision. This outcome is not expected in the natural history of untreated disease. No additional surgical excisions were required during the dosing window under the study protocol.</p>
<p>The treatment was well tolerated across the trial. The most common adverse reactions, occurring in more than 5% of patients, included injection site reactions, fatigue, headache, hypertension, dizziness and nausea.</p>
<p>Most treatment-related adverse reactions were classified as grade 1 or 2 and were transient, with no grade 4 or 5 common adverse events reported. All patients completed the trial.</p>
<p>Voceryq was approved for use alongside Cellectra 5PSP, Inovio’s DNA medicine delivery device. The company expects the product to be available for ordering and shipment within approximately 60 days, with full commercial deployment anticipated during the first quarter of 2027.</p>
<p>Inovio has engaged Syneos Health to support its medical and commercial field teams.</p>
<p>Inovio is required to submit a draft protocol to the FDA for a confirmatory study by the end of 2026, with the aim of finalising the protocol by mid-2027.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/news/inovios-voceryq-fda-approval/">Inovio’s Voceryq receives FDA accelerated approval for RRP</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Pelthos and Castle Creek plan merger to target skin diseases</title>
<link>https://edusehat.com/en/pelthos-and-castle-creek-plan-merger-to-target-skin-diseases</link>
<guid>https://edusehat.com/en/pelthos-and-castle-creek-plan-merger-to-target-skin-diseases</guid>
<description><![CDATA[ This transaction would add Castle Creek’s gene-modified cell therapy candidate D-Fi to Pelthos’s dermatology portfolio. The combined company would operate as Pelthos Therapeutics and continue trading on the 
The post Pelthos and Castle Creek plan merger to target skin diseases appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/11/Skin-shutterstock_2454056037.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 13:45:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Pelthos, and, Castle, Creek, plan, merger, target, skin, diseases</media:keywords>
<content:encoded><![CDATA[<p>This transaction would add Castle Creek’s gene-modified cell therapy candidate D-Fi to Pelthos’s dermatology portfolio.</p>
<p>The combined company would operate as Pelthos Therapeutics and continue trading on the NYSE American under the ticker ‘PTHS’.</p>
<p>Approved by both companies’ boards, the deal is expected to close by the end of the first quarter of 2027, subject to customary conditions, including approval from Castle Creek shareholders.</p>
<p>Castle Creek shareholders would receive 5.2 million shares of Pelthos common stock when the transaction closes. The shares would represent 32.5% of Pelthos’ fully diluted shares.</p>
<p>They could also receive up to a further 5.8 million Pelthos shares if D-Fi receives US Food and Drug Administration (FDA) approval.</p>
<p>The agreement also provides for up to $300m in milestone payments, including $50m tied to specified Phase III clinical endpoints and up to $250m linked to D-Fi’s first commercial sale and certain net sales targets.</p>
<p>The milestone payments would be made in cash, or in cash and Pelthos shares where necessary to maintain the intended tax treatment of the deal.</p>
<div></div>
<p>Castle Creek shareholders would also be entitled to 80% of net proceeds from the sale of any priority review voucher awarded following D-Fi’s FDA approval.</p>
<p>Also known as dabocemagene autoficel or FCX-007, D-Fi is Castle Creek’s lead development candidate. The company plans to continue a Phase III study of the injectable treatment for dystrophic epidermolysis bullosa, a rare inherited condition associated with mutations in the COL7A1 gene.</p>
<p>The treatment is designed as a redosable, gene-modified cell therapy delivered through intradermal injections every other month.</p>
<p>Castle Creek chairman and CEO Matt Gantz said: “Joining with Pelthos will provide the commercial infrastructure to help realise the D-Fi opportunity and accelerate the pipeline of new indications from our platform.”</p>
<p>Castle Creek is also developing a topical formulation of D-Fi using its fibroblast technology. It is pursuing other potential applications for the technology in skin diseases, including malignancies and inflammatory conditions.</p>
<p>The transaction would add Castle Creek’s fibroblast-based platform to Pelthos’s existing Nitricil platform.</p>
<p>Scott Plesha would remain CEO of the combined company while Peter Greenleaf would become executive chair. The board would have ten directors, including two appointed by Castle Creek.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/news/pelthos-castle-creek-merger/">Pelthos and Castle Creek plan merger to target skin diseases</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Glenmark opens Allentown distribution hub in US</title>
<link>https://edusehat.com/en/glenmark-opens-allentown-distribution-hub-in-us</link>
<guid>https://edusehat.com/en/glenmark-opens-allentown-distribution-hub-in-us</guid>
<description><![CDATA[ Set across a 6.5-acre site, the facility functions as the company’s sole distribution centre in the US. A workforce of 45 members handles administration, quality control, and general 
The post Glenmark opens Allentown distribution hub in US appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/10/PT-2-30-10-2026-Image-17.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 13:45:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Glenmark, opens, Allentown, distribution, hub</media:keywords>
<content:encoded><![CDATA[<p>Set across a 6.5-acre site, the facility functions as the company’s sole distribution centre in the US.</p>
<p>A workforce of 45 members handles administration, quality control, and general operations at the premises. These employees dispatch both over-the-counter and prescription pharmaceuticals to 321 destinations situated across 43 states.</p>
<p>Since it began operating, the facility has distributed in excess of 61 million units nationwide.</p>
<p>Glenmark Pharmaceuticals president and North America business head Marc Kikuchi said: “Glenmark has served US patients for more than two decades, and we continue to invest in the people and capabilities that enable us to serve patients, customers and partners across the country.</p>
<p>“Our growing US platform spans innovation, manufacturing and distribution, and the Allentown distribution centre is an important part of that commitment. We chose the Lehigh Valley for its exceptional workforce, strong community, and proximity to our customers and US headquarters.</p>
<p>“We are proud to operate a central distribution hub that helps keep Glenmark’s medicines moving to patients nationwide from right here in the Lehigh Valley.”</p>
<p>The facility conforms to regulatory standards set by the US Food and Drug Administration (FDA) and the Drug Enforcement Administration (DEA).</p>
<p>Its technical specifications feature cold-chain refrigerated areas, controlled-room-temperature sections, and DEA-compliant vaults and cages.</p>
<p>Operational practices at the property incorporate adjusted packaging, energy-efficiency initiatives, recycling, reduced waste, refined delivery routes, and specific protocols for shelter-in-place events, evacuations, and medical emergencies.</p>
<p>Across the US, Glenmark employs nearly 400 individuals and manages a portfolio of 229 FDA-authorised products that account for 90 million domestic prescriptions each year.</p>
<p>The company has directed close to $1bn into domestic manufacturing and research infrastructure, which includes almost $400m allocated to an FDA-cleared manufacturing site in Monroe, North Carolina.</p>
<p>The Allentown facility complements Glenmark’s other American properties, comprising its Elmwood Park corporate headquarters in New Jersey and Ichnos Glenmark Innovation, a wholly owned biotechnology subsidiary based in New York.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/news/glenmark-opens-allentown-distribution-hub-us/">Glenmark opens Allentown distribution hub in US</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>GEBRO and Spektus sign collaboration for ActraFlex</title>
<link>https://edusehat.com/en/gebro-and-spektus-sign-collaboration-for-actraflex</link>
<guid>https://edusehat.com/en/gebro-and-spektus-sign-collaboration-for-actraflex</guid>
<description><![CDATA[ The pharmaceutical companies did not disclose the financial terms of the deal. Under the agreement, the companies will manage regulatory approval processes and commercial operations within their allocated 
The post GEBRO and Spektus sign collaboration for ActraFlex appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/11/PT-2-04-11-2026-shutterstock_2426123175.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 13:45:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>GEBRO, and, Spektus, sign, collaboration, for, ActraFlex</media:keywords>
<content:encoded><![CDATA[<p>The pharmaceutical companies did not disclose the financial terms of the deal.</p>
<p>Under the agreement, the companies will manage regulatory approval processes and commercial operations within their allocated territories.</p>
<p>GEBRO will direct product supply and commercialisation across Europe and selected global markets, anchored by Spain.</p>
<p>Spektus will oversee supply and commercialisation across Africa, the Americas, and Asia, relying on an established network of regional pharmaceutical partners.</p>
<p>ActraFlex combines paracetamol and tramadol into a formulation engineered to provide sustained release using a twice-daily dosing regimen.</p>
<p>The therapy integrates Spektus’ AmyloFlex drug-delivery technology with GEBRO’s Diliban product that already maintains an established commercial presence in Spain.</p>
<p>GEBRO Holding managing director Christian Kollenz said: “GEBRO brings deep expertise in pain management and a strong foundation with Diliban in Europe.</p>
<p>“Together with Spektus’ established commercialisation partner network, we believe ActraFlex has the potential to become an important global product in pain management.”</p>
<p>Spektus Pharma CEO Zarvaan Merchant said: “Our partnership with GEBRO highlights the potential of Spektus’ proprietary AmyloFlex technology to create differentiated speciality medicines from established products and brands.</p>
<p>“Building on GEBRO’s successful commercialisation of Diliban in Europe, we see strong commercial potential for ActraFlex across the Americas, Africa and Asia.”</p>
<p>GEBRO has developmental and commercialisation experience in specialised medicines.</p>
<p>The organisation places a particular therapeutic focus on rheumatoid arthritis and pain management, conducting business across multiple European and global markets via its own corporate affiliates and external partner networks.</p>
<p>Spektus Pharma creates differentiated medicines by applying drug-delivery formulation platforms to established active pharmaceutical ingredients and products.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/news/gebro-spektus-agreement-actraflex/">GEBRO and Spektus sign collaboration for ActraFlex</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>FDA to review uniQure’s BLA for Huntington’s gene therapy</title>
<link>https://edusehat.com/en/fda-to-review-uniqures-bla-for-huntingtons-gene-therapy</link>
<guid>https://edusehat.com/en/fda-to-review-uniqures-bla-for-huntingtons-gene-therapy</guid>
<description><![CDATA[ The submission has been granted Priority Review, setting a target action date of 1 May 2027 under the Prescription Drug User Fee Act (PDUFA). The regulator also indicated 
The post FDA to review uniQure’s BLA for Huntington’s gene therapy appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/11/PT-04-11-2026-shutterstock_2574505743.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 13:45:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>FDA, review, uniQure’s, BLA, for, Huntington’s, gene, therapy</media:keywords>
<content:encoded><![CDATA[<p>The submission has been granted Priority Review, setting a target action date of 1 May 2027 under the Prescription Drug User Fee Act (PDUFA).</p>
<p>The regulator also indicated provisional plans to convene an Advisory Committee meeting regarding the application, with timing to be finalised later.</p>
<p>uniQure CEO Matt Kapusta said: “The FDA’s acceptance of our BLA for review marks an important milestone for the Huntington’s disease community, which has waited generations for a treatment that changes the course of this devastating disease.</p>
<p>“Backed by compelling data from our Phase I/II studies, we believe ifezuntirgene inilparvovec has the potential to become the first disease-modifying treatment for Huntington’s disease. With the FDA’s priority review underway, we will work in conjunction with the agency, clinicians, and the Huntington’s community to support the review process.</p>
<p>“The confirmatory trial remains a key priority, with screening anticipated to begin by year-end and the study is expected to be well underway by the time of potential approval.”</p>
<p>The filing relies on 36-month findings from Phase I/II study compared with an external cohort from the Enroll-HD natural history registry, reported on 24 September 2025.</p>
<p>In addition, uniQure has aligned with the FDA on key parameters for a confirmatory clinical study.</p>
<p>This randomised standard-of-care trial will enrol around 200 patients in a 2:1 ratio favouring ifezuntirgene inilparvovec, assessing Total Functional Capacity at 36 months as its primary endpoint.</p>
<p>Patient screening is scheduled to begin in the US before the end of this year.</p>
<p>Also known as AMT-130, ifezuntirgene inilparvovec received breakthrough therapy and regenerative medicine advanced therapy designations from the FDA, alongside fast track status.</p>
<p>Delivered via a single, MRI-guided neurosurgical administration directly into the striatum, the therapy uses microRNA to silence the huntingtin gene and its exon 1 protein fragment.</p>
<p>Huntington’s disease is an inherited disorder that causes motor symptoms, including chorea, behavioural changes, and progressive cognitive decline.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/news/fda-uniqures-bla-huntingtons-therapy/">FDA to review uniQure’s BLA for Huntington’s gene therapy</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Lonza to acquire five US manufacturing sites from Merck KGaA</title>
<link>https://edusehat.com/en/lonza-to-acquire-five-us-manufacturing-sites-from-merck-kgaa</link>
<guid>https://edusehat.com/en/lonza-to-acquire-five-us-manufacturing-sites-from-merck-kgaa</guid>
<description><![CDATA[ The acquisition involves a total enterprise valuation in the low- to mid-triple-digit millions of Swiss francs. It would expand Lonza’s US manufacturing presence from four to nine sites 
The post Lonza to acquire five US manufacturing sites from Merck KGaA appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/11/Lonza-shutterstock_1675420258.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 13:45:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Lonza, acquire, five, manufacturing, sites, from, Merck, KGaA</media:keywords>
<content:encoded><![CDATA[<p>The acquisition involves a total enterprise valuation in the low- to mid-triple-digit millions of Swiss francs.</p>
<p>It would expand Lonza’s US manufacturing presence from four to nine sites and bring 1,100 employees into its global workforce, raising its headcount to more than 6,000.</p>
<p>Closing is expected around mid-2027, subject to customary conditions.</p>
<p>The five facilities cover a range of pharmaceutical technologies. The St Louis-based site focuses on bioconjugates, while two locations in Madison and Verona, Wisconsin, produce high-potency payload-linkers.</p>
<p>A facility in Carlsbad, California, provides end-to-end viral vector solutions, comprising aseptic fill-finish capabilities. The site at Indianapolis, Indiana, handles lipid nanoparticle, liposome, and PEGylated protein solutions, also with aseptic fill-finish capacity.</p>
<p>Lonza CEO Wolfgang Wienand said: “This acquisition is a strong fit with our One Lonza Strategy and reflects our disciplined approach to capital allocation, investing in opportunities that will drive long-term, profitable growth and deliver attractive returns.</p>
<p>“With high demand for bioconjugates and viral vectors, the acquired sites will strengthen our ability to support customers from innovation to launch and commercial supply.”</p>
<p>Lonza said the acquired network supports customers from clinical-stage through to commercial manufacturing in areas including antibody-drug conjugates, other bioconjugates, viral vectors for cell and gene therapies, and latest drug-delivery technologies.</p>
<p>For full-year 2028, the sites are expected to contribute around SFr250m ($304m) in sales at a core earnings before interest, taxes, depreciation and amortisation (EBITDA) margin below Lonza’s group level.</p>
<p>Lonza will pay the consideration in cash, funded through cash at hand and existing credit facilities.</p>
<p>The acquisition follows other recent US investments by Lonza, including ongoing work to prepare its Vacaville site for CDMO operations and a recently announced commercial spray-drying facility in Bend, Oregon.</p>
<p>Until the deal concludes, the businesses will continue to run independently. Both parties said they would work together to support a smooth transition.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/news/lonza-us-manufacturing-sites/">Lonza to acquire five US manufacturing sites from Merck KGaA</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>India’s life sciences and healthcare sectors raise $173m in October 2026</title>
<link>https://edusehat.com/en/indias-life-sciences-and-healthcare-sectors-raise-173m-in-october-2026</link>
<guid>https://edusehat.com/en/indias-life-sciences-and-healthcare-sectors-raise-173m-in-october-2026</guid>
<description><![CDATA[ 
The sectors recorded 19 funding rounds during the month, with funding rising 6.91 per cent year on year and falling 7.35 per cent from September 2026
The post India’s life sciences and healthcare sectors raise $173m in October 2026 appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/04111758/EP_Tranxcn_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 04 Nov 2026 16:10:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>India’s, life, sciences, and, healthcare, sectors, raise, 173m, October, 2026</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/04111758/EP_Tranxcn_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/11/04111758/EP_Tranxcn_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/11/04111758/EP_Tranxcn_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>India’s HealthTech, Life Sciences and Healthcare sectors recorded funding of $172.96 million across 19 rounds in October 2026, according to data from Tracxn. Funding rose 6.91 per cent compared with $161.78 million in October 2025. However, it declined 7.35 per cent from $186.68 million recorded across 20 rounds in September 2026.</span></p>
<p><span>The sectors recorded 26 funding rounds in October 2025, compared with 19 in October 2026.</span></p>
<p><span>Early-stage funding accounted for $157.81 million, or 91.2 per cent of the total funding raised during October. Seed-stage funding stood at $5.15 million, accounting for 3 per cent, while late-stage funding amounted to $10 million, or 5.8 per cent. No private equity funding was recorded during the month.</span></p>
<p><span>Among the companies that raised funds during October, Even secured $50 million, followed by Baba with $40 million and Cent with $15 million. Clinics On Cloud raised $14.26 million, while Regency Healthcare secured $11.4 million.</span></p>
<p><span>MakeO raised $10 million, Ace Blend secured $9.91 million, CureBay raised $7.30 million and Sunfox secured $7 million. Jagruti Rehabilitation Center raised $2.94 million.</span></p>
<p><span>In terms of venture capital activity, 3one4 Capital led with investments in two companies, Ace Blend and Sunfox. Khosla Ventures invested in Even, while FirstMark invested in Baba, with each recording one round during the month.</span></p>
<p><span>The funding trend for the 12 months from November 2025 to October 2026 shows that the sectors recorded $30.34 million in November 2025, followed by $355.49 million in December 2025 and $227.12 million in January 2026. Funding stood at $93.85 million in February and $238.68 million in March.</span></p>
<p><span>In April 2026, the sectors recorded $309.89 million, followed by $185.49 million in May, $106.84 million in June and $105.84 million in July. Funding reached $371.39 million in August before recording $186.68 million in September and $172.96 million in October.</span></p>
<p><span>The data covers the HealthTech, Life Sciences and Healthcare sectors in India. The funding figures are sourced from Tracxn.</span></p>
<p>The post <a href="https://www.expresspharma.in/indias-life-sciences-and-healthcare-sectors-raise-173m-in-october-2026/">India’s life sciences and healthcare sectors raise $173m in October 2026</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Lupin appoints Akhil Gupta as Independent Director to its Board</title>
<link>https://edusehat.com/en/lupin-appoints-akhil-gupta-as-independent-director-to-its-board</link>
<guid>https://edusehat.com/en/lupin-appoints-akhil-gupta-as-independent-director-to-its-board</guid>
<description><![CDATA[ 
The appointment brings over four decades of experience in business development, corporate strategy, finance, governance and mergers and acquisitions to the Board
The post Lupin appoints Akhil Gupta as Independent Director to its Board appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123851/Acquisition.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 04 Nov 2026 16:10:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Lupin, appoints, Akhil, Gupta, Independent, Director, its, Board</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123851/Acquisition.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123851/Acquisition.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123851/Acquisition-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Lupin has announced the appointment of Akhil Gupta as an Independent Director to its Board.</span></p>
<p><span>Gupta brings more than four decades of experience in building and scaling businesses, corporate strategy, finance, governance, and mergers and acquisitions. As Vice Chairman of Bharti Enterprises Limited, he played a pivotal role in the group’s growth from inception, both organically and through acquisitions. A qualified Chartered Accountant, he has also completed the Advanced Management Programme at Harvard Business School.</span></p>
<p><span>He currently serves as Non-Executive Independent Chairman of 360 ONE WAM, Coforge and Valuedrive Technologies Ltd (Spinny); Independent Director of Lodha Developers and Zepto; and Nominee Director of Acevector Limited. He is also President of the Telecom Sector Skill Council, a Member of the CII National Committee on Telecom & Broadband and the CII Task Force on Insolvency and Bankruptcy, and Chairman of Inversion Advisory Services. In addition, he advises companies across infrastructure, renewable energy, automobiles, tourism, consulate services and footwear.</span></p>
<p><span>His recognitions include the EY Entrepreneur of the Year Award (Entrepreneur CEO), CA Global Achiever, CA Business Achiever, CEO of the Year Award, and CNBC TV18 Best CFO Awards.</span></p>
<p><span>Manju D Gupta, Chairperson, Lupin, said, “We are delighted to welcome Akhil to the Lupin Board. He brings a rare combination of strategic perspective, financial acumen, governance experience, and a proven track record of building businesses at scale. His counsel will be valuable as Lupin continues to strengthen its global position and pursue its next phase of growth.”</span></p>
<p>The post <a href="https://www.expresspharma.in/lupin-appoints-akhil-gupta-as-independent-director-to-its-board/">Lupin appoints Akhil Gupta as Independent Director to its Board</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Lupin launches Raltegravir Tablets USP, 600 mg in the US</title>
<link>https://edusehat.com/en/lupin-launches-raltegravir-tablets-usp-600-mg-in-the-us</link>
<guid>https://edusehat.com/en/lupin-launches-raltegravir-tablets-usp-600-mg-in-the-us</guid>
<description><![CDATA[ 
The product has received US FDA approval and is eligible for 180-day generic drug exclusivity
The post Lupin launches Raltegravir Tablets USP, 600 mg in the US appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 04 Nov 2026 16:10:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Lupin, launches, Raltegravir, Tablets, USP, 600, the</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>Lupin has announced the launch of Raltegravir Tablets USP, 600 mg in the United States, following approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA).</span></p>
<p><span>Raltegravir Tablets, 600 mg are bioequivalent to the reference listed drug (RLD), Isentress® HD Tablets, 600 mg, of Merck Sharp & Dohme, LLC. The product is indicated in combination with other antiretroviral agents for the treatment of Human Immunodeficiency Virus (HIV-1) infection in adult patients and paediatric patients weighing at least 40 kg.</span></p>
<p><span>Lupin is the exclusive first-to-file for this product and is eligible for 180-day generic drug exclusivity.</span></p>
<p><span>Raltegravir Tablets USP, 600 mg (RLD Isentress HD) had estimated annual sales of USD 26 million in the US, according to IQVIA MAT September 2026</span></p>
<p>The post <a href="https://www.expresspharma.in/lupin-launches-raltegravir-tablets-usp-600-mg-in-the-us/">Lupin launches Raltegravir Tablets USP, 600 mg in the US</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Shilpa CDMO invests $50 million to expand peptide manufacturing capacity</title>
<link>https://edusehat.com/en/shilpa-cdmo-invests-50-million-to-expand-peptide-manufacturing-capacity</link>
<guid>https://edusehat.com/en/shilpa-cdmo-invests-50-million-to-expand-peptide-manufacturing-capacity</guid>
<description><![CDATA[ 
The expansion will add 10 KL of SPPS reactor capacity and establish six parallel cGMP manufacturing lines to support peptide development and commercial supply
The post Shilpa CDMO invests $50 million to expand peptide manufacturing capacity appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/11/12182826/Growth-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 04 Nov 2026 12:35:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Shilpa, CDMO, invests, 50, million, expand, peptide, manufacturing, capacity</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/11/12182826/Growth-1.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/11/12182826/Growth-1.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/11/12182826/Growth-1-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>Shilpa CDMO is investing $50 million to expand its peptide manufacturing capabilities as demand for GLP-1s and peptide therapeutics increases.</span></p>
<p><span>The phased investments will span the next few years and add 10 KL of solid-phase peptide synthesis (SPPS) reactor capacity to the three existing clinical-phase manufacturing lines. A fourth line for commercial manufacturing at Shilpa’s Raichur Unit-I campus is scheduled to open in December 2026, with commercial supply expected to ramp up through 2027.</span></p>
<p><span>The CDMO plans to add further 2 KL, 3 KL and 5 KL SPPS reactors, establishing one of the largest multi-tonne peptide capacities in India.</span></p>
<p><span>The new commercial line features 500 L and 1,000 L reactors in a single block, supporting annual production of up to one metric tonne. Its purification infrastructure includes two 2-metre DAC columns with a 10,000 LPH preparative HPLC system. The line will also include 1,000 L/hr nanofiltration and a lyophiliser with a capacity of 1,000 L.</span></p>
<p><span>The expansion builds on Shilpa’s existing cytotoxic and peptide conjugate product development capabilities, with one line dedicated to cytotoxic peptide manufacturing using SPPS.</span></p>
<p><span>Keshav Bhutada, Chief Executive Officer, Shilpa CDMO, said, “Peptides are becoming one of the most important areas of pharmaceutical development, but the opportunity goes well beyond current GLP-1 demand. Innovator pipelines in oncology and rare diseases are producing increasingly sophisticated molecules and conjugates that require much greater expertise in route design, synthesis, purification and scale-up.</span></p>
<p><span>We are investing for where the peptide market is going next. Our aim is to give biotech and pharmaceutical partners a platform that can take challenging peptide programmes from early development through to reliable commercial supply.”</span></p>
<p><span>Shilpa CDMO’s expanded peptide operations will comprise six parallel cGMP manufacturing lines, allowing multiple programmes to run independently. The platform supports solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS) and hybrid synthesis (SPPS + LPPS), allowing manufacturing routes to be selected according to the molecule, its development stage and intended commercial scale.</span></p>
<p><span>Its capabilities cover linear, cyclic and branched peptides, including molecules incorporating unnatural and D-amino acids, lipidation, conjugation and radioligand peptides.</span></p>
<p><span>More than 100 scientists and manufacturing specialists work within Shilpa’s peptide business. This includes an R&D team of more than 50 members dedicated to peptide chemistries and 45 chemists working across production and purification. The team is also supported by the wider Shilpa Group’s more than 350 PhDs.</span></p>
<p><span>Dipak Kalita, Senior Vice President – CDMO Services, Shilpa CDMO, said, “As peptides become longer and more complex, the manufacturing route can determine whether a programme can scale successfully. We start with the molecule and its potential commercial requirements, then determine whether solid-phase, liquid-phase or a hybrid approach offers the most robust route. For longer peptides, that can mean moving from solid-phase synthesis to a hybrid fragment-based route as volumes grow. Considering commercial scale from the outset helps customers avoid reaching late-stage development with a process that is no longer technically or economically viable”.</span></p>
<p><span>Shilpa CDMO’s peptide operations are based at its 34-acre Unit-I campus in Raichur, Karnataka. The peptide unit operates within the wider site, which has dedicated R&D and cGMP manufacturing infrastructure for APIs, commercial linkers, HPAPIs spanning OEB 1-6 and peptide drug conjugates.</span></p>
<p><span>The new peptide facility also has a centralised Distributed Control System (DCS), with integrated Process Analytical Technology (PAT) and UV monitoring. Design of Experiments (DoE) and process simulation will be used to establish operating parameters ahead of scale-up and technology transfer, while automated data capture will support data integrity and regulatory compliance.</span></p>
<p><span>The investment follows the launch of Shilpa CDMO as a dedicated complex-molecule CDMO brand in October 2026.</span></p>
<p><em><span>Shilpa CDMO is the customer-facing brand of Shilpa Pharma Lifesciences </span></em></p>
<p>The post <a href="https://www.expresspharma.in/shilpa-cdmo-invests-50-million-to-expand-peptide-manufacturing-capacity/">Shilpa CDMO invests $50 million to expand peptide manufacturing capacity</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>US FDA grants tentative approval for Dr. Reddy’s twice&#45;yearly injectable lenacapavir </title>
<link>https://edusehat.com/en/us-fda-grants-tentative-approval-for-dr-reddys-twice-yearly-injectable-lenacapavir</link>
<guid>https://edusehat.com/en/us-fda-grants-tentative-approval-for-dr-reddys-twice-yearly-injectable-lenacapavir</guid>
<description><![CDATA[ 
Under the existing agreement, injectable lenacapavir will be available at US$40 per person per year across 120 countries covered by Gilead’s voluntary licence.
The post US FDA grants tentative approval for Dr. Reddy’s twice-yearly injectable lenacapavir  appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/15105219/Dr.-Reddys-building.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 03 Nov 2026 14:55:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>FDA, grants, tentative, approval, for, Dr., Reddy’s, twice-yearly, injectable, lenacapavir </media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="431" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/15105219/Dr.-Reddys-building.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/15105219/Dr.-Reddys-building.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/15105219/Dr.-Reddys-building-300x172.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p>Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced that the U.S. Food and Drug Administration (FDA) has granted tentative approval to its long-acting injectable lenacapavir for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 77 pounds (35 kg). The approval was granted under the U.S. FDA’s President’s Emergency Plan for AIDS Relief (PEPFAR) program.</p>
<p>The approval builds on the voluntary licence granted by Gilead Sciences to Dr. Reddy’s in October 2024, followed by an agreement with Unitaid, the Wits Reproductive Health and HIV Institute (Wits RHI) and the Clinton Health Access Initiative (CHAI) in September 2025 to support product development, accelerate the regulatory pathway and enable access to injectable lenacapavir at US$40 per person per year across 120 countries in Gilead’s voluntary licence.</p>
<p>The FDA approval represents an important milestone for Dr. Reddy’s Public Health Access portfolio and reflects the company’s capabilities in developing and manufacturing complex medicines. The first supplies are expected to reach people by the end of 2026, with broader rollout across eligible countries expected in 2027.</p>
<p>HIV continues to pose a significant global public health challenge, with gaps remaining in access to and uptake of effective prevention options. Long-acting lenacapavir, administered twice a year, provides an additional prevention option for people who may face challenges with more frequently administered pre-exposure prophylaxis (PrEP).</p>
<p>Deepak Sapra, Chief Executive Officer, API and Services, Dr. Reddy’s Laboratories said, “This is a moment of immense pride for all of us at Dr. Reddy’s. Developing and manufacturing a complex long-acting injectable like lenacapavir at an affordable price required strong scientific capabilities and manufacturing expertise to address an urgent access need. The U.S. FDA approval validates that work and brings us a significant step closer to making this twice-yearly HIV prevention option available to people across low- and middle-income countries. We are grateful to Gilead for the voluntary licence and to Unitaid, Wits RHI and CHAI for their support in accelerating this journey.”</p>
<p>Dr. Philppe Duneton, Executive Director at Unitaid said, “Unitaid’s early risk-taking is helping shorten the time between a scientific breakthrough and real access in countries. With best-in-class HIV treatment, we delivered in four years what used to take ten. Now, with lenacapavir, we have helped shorten that timeline to just over a year. For young women in Africa, this translates into faster access to a groundbreaking HIV prevention option, with the potential to avert countless infections and drive meaningful change in the HIV response.”</p>
<p>Dr. Neil Buddy Shah, CEO of CHAI said, “For someone at risk of HIV, taking a pill every day to prevent a disease they don’t have is a hard thing to ask. Two injections a year, of a product that is almost 100% effective at preventing HIV, changes that entirely. More than 125,000 people in Africa have already started on lenacapavir, and today’s approval brings us closer to making it available to millions more for just $40 a year. Getting a generic approved just 16 months after the originator, rather than a decade later, shows what’s possible when we prioritize access from the start. This should be the new standard for global health.”</p>
<p>Professor Saiqa Mullick, Director of Implementation Science at Wits RHI, University of the Witwatersrand said, “Generic lenacapavir has the potential to transform HIV prevention, and this is a significant milestone, but an affordable drug alone is not enough. Countries need health systems that are ready to deliver new prevention options, providers who are confident in offering them, and communities that are engaged as partners in their introduction and scale-up. Bringing these elements together will be critical to ensuring equitable access and impact.”</p>
<p>FDA approval provides an important regulatory basis for the remaining steps towards wider availability, including WHO prequalification and national regulatory approvals. Unitaid and partners are supporting countries and communities with product introduction and scale-up, including community engagement and real-world evidence generation to inform how lenacapavir can effectively reach diverse and underserved populations.</p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/us-fda-grants-tentative-approval-for-dr-reddys-twice-yearly-injectable-lenacapavir/">US FDA grants tentative approval for Dr. Reddy’s twice-yearly injectable lenacapavir </a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>OneSource receives USFDA EIR with VAI Classification for its SPD facility in Bengaluru</title>
<link>https://edusehat.com/en/onesource-receives-usfda-eir-with-vai-classification-for-its-spd-facility-in-bengaluru</link>
<guid>https://edusehat.com/en/onesource-receives-usfda-eir-with-vai-classification-for-its-spd-facility-in-bengaluru</guid>
<description><![CDATA[ 
The development adds to OneSource’s regulatory track record as it continues to build a differentiated globally competitive CDMO platform
The post OneSource receives USFDA EIR with VAI Classification for its SPD facility in Bengaluru appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/07/22100048/usfda-approved-black.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 02 Nov 2026 17:25:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>OneSource, receives, USFDA, EIR, with, VAI, Classification, for, its, SPD, facility, Bengaluru</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/07/22100048/usfda-approved-black.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/07/22100048/usfda-approved-black.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/07/22100048/usfda-approved-black-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>OneSource Specialty Pharma announced that it has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its Sterile Product Division (SPD) facility in Bengaluru, with a ‘Voluntary Action Indicated’ (VAI) classification. The report follows an inspection of the facility conducted from June 22 to June 30, 2026.</span></p>
<p><span>Commenting on the development, Neeraj Sharma, Managing Director & CEO, OneSource Specialty Pharma said, </span><span>“We are pleased to receive the EIR with VAI classification from the USFDA for our SPD facility. This inspection outcome reflects our continued commitment to maintaining high standards of quality, regulatory compliance and operational excellence across our operations. Our SPD facility plays an integral role in our sterile manufacturing capabilities, enabling us to support the evolving needs of our global partners.”</span></p>
<p><span>The development adds to OneSource’s regulatory track record as it continues to build a differentiated, globally competitive CDMO platform spanning four key modalities — drug-device combination, biologics, sterile injectables and soft gelatin capsules.</span></p>
<p>The post <a href="https://www.expresspharma.in/onesource-receives-usfda-eir-with-vai-classification-for-its-spd-facility-in-bengaluru/">OneSource receives USFDA EIR with VAI Classification for its SPD facility in Bengaluru</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Hikal signs multi&#45;year global CDMO contract with leading agrochemical company </title>
<link>https://edusehat.com/en/hikal-signs-multi-year-global-cdmo-contract-withleading-agrochemical-company</link>
<guid>https://edusehat.com/en/hikal-signs-multi-year-global-cdmo-contract-withleading-agrochemical-company</guid>
<description><![CDATA[ 
Contract follows successful Process Development and scale-up of a new product, marking a key  commercial milestone for Hikal’s Crop Protection business 
The post Hikal signs multi-year global CDMO contract with leading agrochemical company  appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2019/09/11121123/agreement-e1724903886928.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 02 Nov 2026 17:25:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Hikal, signs, multi-year, global, CDMO, contract, with leading, agrochemical, company </media:keywords>
<content:encoded><![CDATA[<div><img width="749" height="397" src="https://cdn.expresspharma.in/wp-content/uploads/2019/09/11121123/agreement-e1724903886928.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2019/09/11121123/agreement-e1724903886928.jpg 749w, https://cdn.expresspharma.in/wp-content/uploads/2019/09/11121123/agreement-e1724903886928-300x159.jpg 300w" sizes="(max-width: 749px) 100vw, 749px"></div><p><span>Hikal has signed a multi-year contract  </span><span>with a Europe-based global agrochemical company to supply a specialised agrochemical product to  markets worldwide. The contract, signed by Hikal’s Crop Protection division, covers contract  development and manufacturing (CDMO) of the product for which Hikal undertook process  development and scale-up. Commercial launch is expected towards the end of FY 2026–27, with  volumes anticipated to grow progressively as regulatory approvals are secured across global markets. </span></p>
<p><span>The partnership underscores Hikal’s capabilities in process development and commercialisation,  demonstrating its ability to translate customer requirements into long-term manufacturing  opportunities. It also strengthens Hikal’s Crop Protection business by expanding its portfolio of  specialised offerings for global customers. </span></p>
<p><span>Commenting on the development, </span>Sameer Hiremath, Chairman & Managing Director, Hikal said, <span>“This contract marks an important milestone for our Crop Protection business,  converting nearly three years of collaborative development and scale-up into a long-term commercial  partnership. It demonstrates Hikal’s ability to combine deep technical expertise with reliable  </span><span>manufacturing capabilities to take complex products from development to commercial supply. We are  </span><span>well positioned to support the planned launch and progressive expansion of supplies across global  markets. </span></p>
<p><span>Hikal partners with global companies across pharmaceuticals, crop protection, animal health and  specialty chemicals, leveraging its research and development, process chemistry and manufacturing  capabilities to support customers from development through commercial production. </span></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/hikal-signs-multi-year-global-cdmo-contract-with-leading-agrochemical-company/">Hikal signs multi-year global CDMO contract with leading agrochemical company </a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Express Pharma November 2026</title>
<link>https://edusehat.com/en/express-pharma-november-2026</link>
<guid>https://edusehat.com/en/express-pharma-november-2026</guid>
<description><![CDATA[ 
India&#039;s Foremost Pharma &amp; Biotech Magazine ~ PLI 2.0: Can MSMEs Catch Up?
The post Express Pharma November 2026 appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/11/01110939/EP-NOV-2026-MAG-COVER.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sun, 01 Nov 2026 12:45:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Express, Pharma, November, 2026</media:keywords>
<content:encoded><![CDATA[<div><img width="200" height="264" src="https://cdn.expresspharma.in/wp-content/uploads/2026/11/01110939/EP-NOV-2026-MAG-COVER.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async"></div><p><em>PLI 2.0: Can MSMEs Catch Up?</em><br>
</p><div class="_df_book df-lite" _slug="express-pharma-november-2026" data-title="express-pharma-november-2026" wpoptions="true" thumbtype=""></div>
<hr>
<p><strong>Click to download:</strong> <a href="https://cdn.expresspharma.in/wp-content/uploads/2026/11/01103313/EP_NOVEMBER_2026.pdf" target="_blank" rel="noopener noreferrer">November 2026 Digital Magazine</a></p>
<p>The post <a href="https://www.expresspharma.in/express-pharma-november-2026/">Express Pharma November 2026</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Our ambition is to be a trusted partner at each stage of that journey</title>
<link>https://edusehat.com/en/our-ambition-is-to-be-a-trusted-partner-at-each-stage-of-that-journey</link>
<guid>https://edusehat.com/en/our-ambition-is-to-be-a-trusted-partner-at-each-stage-of-that-journey</guid>
<description><![CDATA[ 
Payal Agrawal, MD - India &amp; South Asia, PerkinElmer India &amp; South Asia, discusses the evolving analytical needs of India’s pharmaceutical industry, PerkinElmer’s LC-MS/MS offering and the role of advanced technologies, application expertise and laboratory services in supporting pharma R&amp;D and quality testing, in an exclusive interview with Express Pharma
The post Our ambition is to be a trusted partner at each stage of that journey appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/30102633/EP_Payal_PerkinElmer_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 14:10:14 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Our, ambition, trusted, partner, each, stage, that, journey</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="430" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/30102633/EP_Payal_PerkinElmer_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/30102633/EP_Payal_PerkinElmer_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/30102633/EP_Payal_PerkinElmer_750-300x172.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><b>What pharma and life sciences trends do you see shaping India over the next three to five years, and where does PerkinElmer see the biggest opportunities in this changing landscape?</b></p>
<p><span>India’s pharmaceutical industry is moving into a new phase of growth, driven by complex generics, specialty formulations, API manufacturing and research-led drug development, underpinned by an increasing focus on quality and innovation. As Indian companies strengthen their presence in regulated global markets, the ability to consistently demonstrate product quality and meet evolving regulatory expectations will become an even greater competitive differentiator.</span></p>
<p><span>We see three core trends shaping the industry. First, India’s ambition to move up the pharma value chain is creating greater demand for advanced analytical technologies and scientific expertise. Second, the growing focus on impurity profiling, trace-level contaminants and analytical rigour is raising the bar for pharma testing. Third, manufacturers are looking to improve laboratory productivity through more efficient method development efficiency and reliable analytical data.</span></p>
<p><span>For PerkinElmer, these trends present opportunities across chromatography, mass spectrometry, spectroscopy and other analytical technologies that support pharma R&D and quality testing. Our focus is on helping customers address their specific analytical challenges with the right combination of technology, application expertise and service support.</span></p>
<p><span>More broadly, beyond its status as a major pharma manufacturing hub, India is increasingly becoming a centre for scientific development and global pharma supply. We see considerable potential through our OneSource Laboratory Services team to deepen partnerships with Indian pharma companies as they invest in more sophisticated analytical capabilities. As research and quality operations become more global, ensuring instruments perform consistently and compliantly becomes just as important as the technology itself. </span></p>
<p><b>PerkinElmer is entering the pharma space with its LC-MS/MS offering and new software. What is driving this move, and what gap in pharma analytical testing are you looking to address?</b></p>
<p><span>The QSight LC-MS/MS platform making inroads into the pharma segment marks an important step in expanding PerkinElmer’s presence in India’s pharma market. We see a clear opportunity to address the growing need for sensitive, selective and reliable quantitative analytical solutions as pharma companies work with increasingly demanding testing requirements.</span></p>
<p><span>For pharma R&D and analytical laboratories, challenges such as trace-level impurity quantification, nitrosamine analysis where suitable methods are established, and complex sample investigations can require analytical capabilities beyond conventional approaches. Triple-quadrupole LC-MS/MS is particularly valuable for targeted quantitative applications that demand high selectivity and sensitivity.</span></p>
<p><span>QSight brings together triple-quadrupole mass spectrometry, StayClean<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> ion-source technology and a dual ESI/APCI source configuration designed to offer flexibility across suitable applications. Complementing the platform is Simplicity 3Q software, which supports workflows spanning method development, data acquisition, processing and reporting.</span></p>
<p><span>Our approach goes beyond the launch of a new instrument. We are building pharma application readiness and helping laboratories evaluate technology against their specific analytical needs through relevant rigorous application development and expert technical support. We also recognise the importance of appropriate software configuration, validation and documentation for regulated laboratory use.</span></p>
<p><span>Ultimately, our objective is to give pharma laboratories another strong analytical option for addressing challenging quantitative applications while supporting dependable performance and greater laboratory productivity.</span></p>
<p><b>As Indian pharma moves towards complex molecules, biologics and higher-value R&D, what gaps do you see in the industry’s analytical capabilities, and how is PerkinElmer addressing them?</b></p>
<p><span>One of the key challenges for Indian pharma is ensuring analytical capabilities keep pace with increasingly complex products, more demanding impurity requirements and the expectations of global regulatory markets.</span></p>
<p><span>For small-molecule drugs, APIs and finished formulations, laboratories must address a series of critical challenges, including impurities, degradation products, method selectivity, reproducibility and data quality – while at the same time managing sample volumes, turnaround times and resource constraints.</span></p>
<p><span>We see opportunities in three areas: access to fit-for-purpose analytical technologies, greater efficiency in method development and routine testing and stronger application expertise within laboratories. Advanced instruments can deliver considerable value, but only when the method, workflow and supporting expertise are aligned with the analytical question.</span></p>
<p><span>PerkinElmer addresses these needs through a broad portfolio of analytical technologies, supported by application knowledge, as well as software and service capabilities delivered through OneSource. Depending on the application, this can include chromatography for routine assays and related-substances testing, mass spectrometry for demanding targeted quantitative analysis, and complementary techniques for other pharma testing requirements.</span></p>
<p><span>We also believe that customer support and knowledge transfer are critical. Our role is to help laboratories identify the right analytical approach, develop robust workflows and make effective use of their technology. The objective is not simply to provide more sophisticated instruments, but to help pharma companies build stronger analytical capabilities that support product quality, operational efficiency and scientific progress.</span></p>
<p><b>You have led business turnarounds and commercial transformations across multiple markets. What are you bringing from those experiences to your mandate at PerkinElmer India and South Asia?</b></p>
<p><span>My experience operating across international markets has reinforced a fundamental principle: sustainable growth comes from understanding customers deeply, making clear strategic choices and executing consistently.</span></p>
<p><span>India and South Asia are diverse markets, with pharma companies operating at varying scales and serving different segments. A successful strategy needs to recognise these differences, identify where we can create the greatest value and align our portfolio, people and capabilities with those opportunities.</span></p>
<p><span>My focus is always on bridging the gap between customers insights and our business approach. In practice, that means spending time in customers’ labs to understand their most important challenges – whether that is throughput, regulatory compliance or access to skilled analysts – and make sure our commercial, application and service teams respond as one team rather than three.</span></p>
<p><span>For PerkinElmer in India and South Asia, the opportunity is to combine our scientific strengths with the customised and execution-oriented service that customers expect.</span></p>
<p><b>With India emerging as a larger R&D and manufacturing hub, how do you see PerkinElmer’s role evolving in supporting the next phase of pharma growth in the region?</b></p>
<p><span>As India strengthens its position in global pharma R&D and manufacturing, analytical science will play an increasingly important role in enabling quality, innovation and competitiveness. Pharma companies will need to combine robust testing capabilities with efficient laboratory operations and the ability to meet the expectations of international markets.</span></p>
<p><span>We see PerkinElmer’s role evolving through closer collaboration with pharma manufacturers, API producers, contract research organisations and contract development and manufacturing organisations. Our objective is to help customers identify the technologies and workflows best suited to their requirements, based on their specific needs.</span></p>
<p><span>This involves much more than supplying instruments. Application expertise, reliable service, training and ongoing technical support are essential to helping laboratories realise the full value of their analytical investments. We also see opportunities to deepen engagement with customers as their needs evolve – whether in expanding analytical development capabilities, strengthening quality-control operations or investigating more challenging impurities.</span></p>
<p><span>Our broader analytical portfolio across chromatography, mass spectrometry and spectroscopy positions us to support a range of pharma applications, from routine laboratory testing to more advanced analytical investigations. We will continue to focus on making our technologies relevant to local customer needs while drawing on our wider scientific and technological capabilities.</span></p>
<p><span>India in particular represents a significant long-term opportunity for PerkinElmer. The industry is moving up the value chain, from generics and APIs towards complex generics, biosimilars and novel drug discovery, and the scientific and regulatory demands grow at every step. Our ambition is to be a trusted partner at each stage of that journey, helping pharma companies strengthen their analytical capabilities, improve laboratory performance and compete with confidence in global markets.</span></p>
<p>The post <a href="https://www.expresspharma.in/our-ambition-is-to-be-a-trusted-partner-at-each-stage-of-that-journey/">Our ambition is to be a trusted partner at each stage of that journey</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>AIIA launches national AI challenge for Ayurveda on incubation centre’s sixth Foundation Day</title>
<link>https://edusehat.com/en/aiia-launches-national-ai-challenge-for-ayurveda-on-incubation-centres-sixth-foundation-day</link>
<guid>https://edusehat.com/en/aiia-launches-national-ai-challenge-for-ayurveda-on-incubation-centres-sixth-foundation-day</guid>
<description><![CDATA[ 
AIIA-iCAINE launches an IPR facility, signs two MoUs with the World Ayurveda Foundation and Reliance Retail, and conducts a workshop on entrepreneurship and design thinking.
The post AIIA launches national AI challenge for Ayurveda on incubation centre’s sixth Foundation Day appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2022/08/29115645/event.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 14:10:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>AIIA, launches, national, challenge, for, Ayurveda, incubation, centre’s, sixth, Foundation, Day</media:keywords>
<content:encoded><![CDATA[<div><img width="888" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2022/08/29115645/event.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2022/08/29115645/event.jpg 888w, https://cdn.expresspharma.in/wp-content/uploads/2022/08/29115645/event-300x135.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2022/08/29115645/event-768x346.jpg 768w" sizes="auto, (max-width: 888px) 100vw, 888px"></div><p><span>The All India Institute of Ayurveda (AIIA), New Delhi, celebrated the sixth Foundation Day of its incubation centre, AIIA-iCAINE, with the launch of a national innovation challenge in Artificial Intelligence (AI) for Ayurveda, the signing of two strategic Memoranda of Understanding (MoUs), the launch of an Intellectual Property Rights (IPR) Facility for Ayurveda and a capacity-building workshop on entrepreneurship and design thinking.</span></p>
<p><span>On the occasion, Prof. Vd. P. K. Prajapati, Director, AIIA, highlighted the incubator’s efforts to promote innovation, strengthen industry–academia collaboration and translate Ayurvedic knowledge and research into practical solutions, products and enterprises.</span></p>
<p><span>“Over the past six years, AIIA-iCAINE has undertaken several initiatives to promote innovation and entrepreneurship in Ayurveda. The incubator has supported 52 problem statements and mentored more than 100 startup ideas. Furthermore, nine startups have received seed support of ₹3 lakh each, helping them advance their entrepreneurial journeys,” he said.</span></p>
<p><span>The celebration featured the launch of AyushTech Innovate: National Open Ayurveda AI Challenge, organised by Techfest, IIT Bombay, in collaboration with the Ministry of Ayush and AIIA.</span></p>
<p><span>Leveraging AyurParam, IIT Bombay’s open-source Ayurveda Large Language Model, the challenge aims to encourage the development of trustworthy, transparent, safe and practical AI solutions for Ayurveda. It will address challenges in Ayurvedic clinical practice, classical text retrieval, research, treatment planning and public health awareness. The national grand finale is scheduled to take place at IIT Bombay from December 15 to 18, 2026.</span></p>
<p><span>AIIA-iCAINE also signed two MoUs to strengthen research, innovation and commercialisation in Ayurveda.</span></p>
<p><span>The MoU with the World Ayurveda Foundation (WAF) will facilitate the establishment of “AI in Ay – Secretariat for Artificial Intelligence in Ayurveda”, a collaborative platform to advance AI-driven research, innovation and entrepreneurship. The collaboration will support joint research, funding and CSR proposals, capacity-building programmes, hackathons and startup incubation. It will also leverage WAF’s national and international networks to promote responsible AI applications in Ayurveda.</span></p>
<p><span>The MoU with Reliance Retail Limited (Pahadi Local) will facilitate the translation of classical Ayurvedic knowledge into commercially viable skincare products through formulation advisory. Reliance Retail will undertake product development, testing, manufacturing and marketing, creating a pathway for the commercialisation of Ayurveda-based innovations and strengthening industry–academia collaboration.</span></p>
<p><span>Another development was the launch of the Intellectual Property Rights (IPR) Facility for Ayurveda. The facility aims to promote awareness of intellectual property protection and help Ayurveda innovators and entrepreneurs understand the importance of safeguarding their innovations as they progress towards product development and commercialisation.</span></p>
<p><span>The Foundation Day activities also included a capacity-building workshop on branding, pricing strategies and design thinking for Ayurveda ventures. Jessica of Reliance Retail Limited conducted the masterclass on branding, while Sujith Eranezhath, CEO, AIIA-iCAINE, led the session on pricing strategies and the design-thinking masterclass. The sessions covered user needs assessment, problem identification, ideation, prototyping, testing and the development of practical, user-centred solutions for the Ayurveda sector.</span></p>
<p><span>Other activities included a briefing on the Smart India Hackathon (SIH), the launch of the Techfest Hackathon, the release of </span><i><span>Ayupreneur: A Beginner’s Glossary</span></i><span> and the release of grants to the SIH 2025 winners.</span></p>
<p><span>The official programme began with a welcome address by Dr Arun Kumar Mahaptra, Head of Incubation. It also featured an address by Prof. (Dr.) Sreenivasa Prasad Buduru, Chief Guest, and the presidential address by Prof. Vd. P. K. Prajapati, Director, AIIA.</span></p>
<p><span>The celebration concluded with a vote of thanks by Sujith Eranezhath, CEO, AIIA-iCAINE, followed by networking.</span></p>
<p>The post <a href="https://www.expresspharma.in/aiia-launches-national-ai-challenge-for-ayurveda-on-incubation-centres-sixth-foundation-day/">AIIA launches national AI challenge for Ayurveda on incubation centre’s sixth Foundation Day</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Hikal’s Bengaluru API facility receives Swissmedic GMP certification</title>
<link>https://edusehat.com/en/hikals-bengaluru-api-facility-receives-swissmedic-gmp-certification</link>
<guid>https://edusehat.com/en/hikals-bengaluru-api-facility-receives-swissmedic-gmp-certification</guid>
<description><![CDATA[ 
The certification follows inspections by Brazil’s ANVISA and Japan’s PMDA, supporting Hikal’s expansion across regulated pharma markets
The post Hikal’s Bengaluru API facility receives Swissmedic GMP certification appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 14:10:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Hikal’s, Bengaluru, API, facility, receives, Swissmedic, GMP, certification</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>Hikal has received a Certificate of GMP Compliance of a Manufacturer from Swissmedic, the Swiss Agency for Therapeutic Products, for its active pharmaceutical ingredient (API) facility in Bengaluru.</span></p>
<p><span>The certificate confirms that the facility meets the Good Manufacturing Practice (GMP) requirements of the Mutual Recognition Agreement between the European Union and Switzerland.</span></p>
<p><span>The Swissmedic certification follows inspections of the Bengaluru facility by Brazil’s ANVISA and Japan’s PMDA. These recognitions reinforce the facility’s standing with global regulators and position Hikal to serve a wider customer base across regulated markets.</span></p>
<p><span>The certifications also support the company’s strategy to diversify the geographic footprint of its pharmaceutical business and build resilience against geopolitical and trade uncertainties.</span></p>
<p><span>Commenting on the development, Sameer Hiremath, Chairman & Managing Director, Hikal, said, “The Swissmedic certification is a strong endorsement of the quality systems at our Bengaluru facility. It is an important step in expanding the global reach of our pharma business and opens new opportunities with customers in Europe and other regulated markets. Quality, compliance and manufacturing excellence remain the foundation of our long-term customer partnerships.”</span></p>
<p>The post <a href="https://www.expresspharma.in/hikals-bengaluru-api-facility-receives-swissmedic-gmp-certification/">Hikal’s Bengaluru API facility receives Swissmedic GMP certification</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Martin Casino App &amp;amp; Mobile Guide: So spielst du unterwegs</title>
<link>https://edusehat.com/en/martin-casino-app-mobile-guide-so-spielst-du-unterwegs</link>
<guid>https://edusehat.com/en/martin-casino-app-mobile-guide-so-spielst-du-unterwegs</guid>
<description><![CDATA[ Martin Casino – Praktischer Leitfaden für deutsche Spieler 1. Registrierung und erster Schritt beim Martin Casino Bevor du die ersten Spins drehst, musst du dich beim Martin Casino 
The post Martin Casino App &amp; Mobile Guide: So spielst du unterwegs appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/uBrtM1HesX0/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 07:00:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Martin, Casino, App, Mobile, Guide:, spielst, unterwegs</media:keywords>
<content:encoded><![CDATA[<figure data-affgun-media="hero"><img decoding="async" src="https://i.ytimg.com/vi/uBrtM1HesX0/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<h1>Martin Casino – Praktischer Leitfaden für deutsche Spieler</h1>
<section>
<h2>1. Registrierung und erster Schritt beim Martin Casino</h2>
<div data-affgun-media="video"></div>
<p>Bevor du die ersten Spins drehst, musst du dich beim Martin Casino anmelden. Der Anmeldeprozess ist bewusst simpel gehalten: Du gibst deine E‑Mail‑Adresse, ein Passwort und dein Geburtsdatum ein, bestätigst deine Identität per Klick und schon hast du ein Konto.</p>
<p>Nach dem Absenden erhältst du eine Bestätigungs‑E‑Mail. Klicke den Link darin, um dein Konto zu aktivieren – das ist nötig, um später Auszahlungen zu tätigen. Während der Registrierung wird nach dem Wohnsitz gefragt; hier gibst du „Deutschland“ an, damit alle länderspezifischen Angebote korrekt angezeigt werden.</p>
</section>
<section>
<h2>2. Willkommen‑Bonus und weitere Aktionen</h2>
<p>Der Willkommensbonus von Martin Casino ist das erste, was neue Spieler anzieht. Er besteht aus einem Einzahlungs‑Match‑Bonus und einer festgelegten Anzahl kostenloser Spins. Wichtig ist, die <strong>wagering requirements</strong> zu kennen, damit du die Bonusgewinne später auszahlen lassen kannst.</p>
<p>Im Folgenden siehst du die wichtigsten Bonusdetails übersichtlich in einer Tabelle:</p>
<table border="1" cellpadding="5" cellspacing="0">
<thead>
<tr>
<th>Bonusart</th>
<th>Prozentsatz</th>
<th>Max. Bonusbetrag</th>
<th>Wagering</th>
</tr>
</thead>
<tbody>
<tr>
<td>Willkommens‑Match</td>
<td>100 %</td>
<td>200 €</td>
<td>35×</td>
</tr>
<tr>
<td>Free Spins</td>
<td>–</td>
<td>50 Spins</td>
<td>30×</td>
</tr>
<tr>
<td>Wöchentliche Reload‑Bonus</td>
<td>50 %</td>
<td>100 €</td>
<td>25×</td>
</tr>
</tbody>
</table>
<p>Beachte, dass der Bonus nur bei der ersten Einzahlung aktiviert wird. Weitere Aktionen wie Cashback oder Turnier‑Preise findest du im Bonus‑Bereich des Casinos, wo du dich jederzeit über aktuelle Angebote informieren kannst.</p>
</section>
<section>
<h2>3. Einzahlungsmethoden – sicher und schnell</h2>
<p>Martin Casino bietet eine Auswahl bewährter Zahlungsmöglichkeiten, die sowohl Sicherheit als auch Geschwindigkeit garantieren. Alle gängigen Kredit‑ und Debitkarten werden akzeptiert, zudem stehen E‑Wallets und Direktüberweisungen zur Verfügung.</p>
<p>Typische Einzahlungs‑Optionen:</p>
<ul>
<li>Visa / Mastercard</li>
<li>PayPal</li>
<li>Sofortüberweisung</li>
<li>Giropay</li>
<li>Banküberweisung (SEPA)</li>
</ul>
<p>Die meisten Einzahlungen werden sofort gutgeschrieben, sodass du ohne Wartezeit mit dem Spielen beginnen kannst. Achte bei der Auswahl auf mögliche Mindestbeträge und eventuelle Gebühren, die je nach Methode variieren können.</p>
</section>
<section>
<h2>4. Auszahlungen – Geschwindigkeit und Gebühren</h2>
<p>Der Auszahlungsprozess im Martin Casino ist darauf ausgerichtet, Geld schnell auf dein Konto zu bringen. Nach der Anforderung wird die Auszahlung in der Regel innerhalb von 24 Stunden bearbeitet, vorausgesetzt, deine Identität wurde bereits verifiziert.</p>
<p>Folgende Auszahlungsmethoden stehen zur Verfügung:</p>
<ul>
<li>Banküberweisung (SEPA) – 1–3 Werktage</li>
<li>PayPal – sofort bis zu 30 Minuten</li>
<li>Sofortüberweisung – bis zu 1 Stunde</li>
</ul>
<p>Es fallen keine Gebühren für Auszahlungen an, solange du die gewählte Methode unterstützt. Bei höheren Beträgen kann das Casino zusätzliche Sicherheitsprüfungen durchführen – das ist Teil der KYC‑Richtlinien und schützt dich vor Betrug.</p>
</section>
<section>
<h2>5. Spielangebot – Slots, Live Casino und Sportwetten</h2>
<p>Das Portfolio von Martin Casino ist breit gefächert. Über 2 000 Slot‑Titel, darunter Klassiker wie <em>Starburst</em> und neue Video‑Slots mit hoher Volatilität, sorgen für Abwechslung. Jeder Slot zeigt die RTP‑Rate (Return to Player) direkt im Spiel, damit du die Gewinnchancen einschätzen kannst.</p>
<p>Im Live‑Casino kannst du gegen echte Dealer antreten – Blackjack, Roulette und Baccarat stehen rund um die Uhr bereit. Zusätzlich bietet das Casino eine kompakte Sportwetten‑Sektion, in der du auf Fußball, Tennis und E‑Sports setzen kannst. Die Integration von Sportwetten macht Martin Casino zu einer echten All‑In‑One‑Plattform.</p>
</section>
<section>
<h2>6. Mobile Nutzung und App‑Experience</h2>
<p>Für Spieler, die unterwegs sind, stellt Martin Casino sowohl eine responsive Web‑Version als auch eine native App für Android und iOS bereit. Die App ist leichtgewichtig, öffnet sich in wenigen Sekunden und unterstützt alle Kernfunktionen: Einzahlung, Bonusverwaltung, Live‑Casino und Sportwetten.</p>
<p>Die mobile Oberfläche wurde für schnelle Navigation optimiert. Das Menü ist in drei Hauptbereiche unterteilt – „Spiele“, „Casino“ und „Sport“. So findest du deine Lieblingsslots oder das aktuelle Fußballspiel, ohne lange suchen zu müssen.</p>
</section>
<section>
<h2>7. Sicherheit, Lizenzierung und verantwortungsvolles Spielen</h2>
<p>Martin Casino operiert unter einer Lizenz der Malta Gaming Authority (MGA) und ist zusätzlich bei der deutschen Glücksspielbehörde registriert. Diese Doppel‑Lizenz sorgt für strenge Kontrollen hinsichtlich Fairness und Datenschutz.</p>
<p>Zur Gewährleistung sicherer Transaktionen nutzt das Casino SSL‑Verschlüsselung. Spieler können zudem Tools zum verantwortungsvollen Spielen nutzen, etwa Einzahlungslimits, Selbstausschluss und ein 24‑Stunden‑Support für Fragen zum Thema Spielsucht.</p>
</section>
<section>
<h2>8. Kundenservice – Erreichbarkeit und Qualität</h2>
<p>Der Kundensupport von Martin Casino ist rund um die Uhr per Live‑Chat und E‑Mail verfügbar. Die durchschnittliche Antwortzeit im Chat liegt bei weniger als einer Minute, wodurch Probleme schnell gelöst werden können.</p>
<p>Ein umfassendes FAQ‑Archiv deckt häufige Themen ab: Konto‑Verifizierung, Bonusbedingungen, Einzahlungsmethoden und mehr. Wenn du lieber telefonisch Kontakt aufnehmen möchtest, steht dir eine kostenfreie Hotline für deutsche Nummern zur Verfügung.</p>
</section>
<section>
<h2>9. Fazit – Ist das Martin Casino das Richtige für dich?</h2>
<p>Martin Casino kombiniert ein breites Spielangebot, attraktive Boni und schnelle Auszahlungen – alles unterstützt durch eine zuverlässige Lizenz und robuste Sicherheitsmaßnahmen. Für deutsche Spieler, die sowohl Slots als auch Live‑Casino und Sportwetten in einer Plattform suchen, ist das Angebot besonders attraktiv.</p>
<p>Wenn du nach einem <a href="https://martin-casinos-germany.com/">martin online casino</a> suchst, das sowohl Anfänger als auch erfahrene Spieler anspricht, bietet Martin Casino genau das nötige Maß an Benutzerfreundlichkeit, Bonusvielfalt und vertrauenswürdiger Infrastruktur.</p>
</section>
<p>The post <a href="https://www.pharmaceutical-business-review.com/uncategorized/martin-casino-app-mobile-guide-so-spielst-du-unterwegs/">Martin Casino App & Mobile Guide: So spielst du unterwegs</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Martin Casino App – Was du wissen musst</title>
<link>https://edusehat.com/en/martin-casino-app-was-du-wissen-musst</link>
<guid>https://edusehat.com/en/martin-casino-app-was-du-wissen-musst</guid>
<description><![CDATA[ Martin Casino App – Praktischer Leitfaden für deutsche Spieler 1. Registrierung: Der erste Schritt zum Spielspaß Bevor du die martin casino app nutzen kannst, musst du ein Konto 
The post Martin Casino App – Was du wissen musst appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/uTSm4P1s1N4/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 07:00:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Martin, Casino, App, –, Was, wissen, musst</media:keywords>
<content:encoded><![CDATA[<figure data-affgun-media="hero"><img decoding="async" src="https://i.ytimg.com/vi/uTSm4P1s1N4/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<h1>Martin Casino App – Praktischer Leitfaden für deutsche Spieler</h1>
<h2>1. Registrierung: Der erste Schritt zum Spielspaß</h2>
<div data-affgun-media="video"></div>
<p>Bevor du die <strong>martin casino app</strong> nutzen kannst, musst du ein Konto anlegen. Der Prozess ist bewusst simpel gehalten: Auf der Startseite klickst du auf „Registrieren“, gibst deine E‑Mail‑Adresse, ein sicheres Passwort und dein Geburtsdatum an. Danach folgt eine kurze Verifizierung per E‑Mail‑Link.</p>
<p>Wichtig ist, dass du bei der Angabe deiner Daten keine Tippfehler machst – ein falscher Name oder ein falsches Geburtsdatum kann spätere Auszahlungen verzögern. Sobald dein Konto aktiv ist, kannst du dich sofort in die App einloggen und loslegen.</p>
<h2>2. Bonusübersicht & Wettanforderungen</h2>
<p>Martin Casino lockt neue Spieler mit einem großzügigen Willkommenspaket, das sich aus einem 100 % Einzahlungsbonus bis zu 200 €, plus 50 Freispielen im Slot‑Bereich, zusammensetzt. Der Bonus unterliegt regulären <em>wagering requirements</em> von 30 × des Bonusbetrags.</p>
<p>Damit du den Bonus optimal nutzen kannst, empfiehlt es sich, zuerst Spiele mit hoher <strong>RTP</strong> (Return to Player) zu wählen. Slots wie „Starburst“ oder „Book of Dead“ haben typischerweise eine RTP von 96 % oder mehr, was die Erfüllung der Wettanforderungen erleichtert.</p>
<h2>3. Einzahlung: Verfügbare Zahlungsmethoden</h2>
<p>Die <strong>martin casino app</strong> unterstützt zahlreiche gängige Zahlungsoptionen. Für deutsche Spieler sind vor allem Kreditkarte (Visa, Mastercard), Sofortüberweisung, Giropay und PayPal beliebt. Alle Methoden sind sofort einsatzbereit, sodass du nach dem Klick auf „Einzahlen“ sofort mit dem Spielen beginnen kannst.</p>
<ul>
<li>Kreditkarte – bis zu 5 000 € pro Transaktion.</li>
<li>Sofortüberweisung – 100 % sofortige Gutschrift.</li>
<li>Giropay – sichere Direktüberweisung vom Girokonto.</li>
<li>PayPal – schnelle und vertraute Abwicklung.</li>
</ul>
<h2>4. Auszahlungen & Geschwindigkeit</h2>
<p>Nach einem Gewinn ist das Wichtigste, das Geld schnell auf dein Bankkonto zu bekommen. Martin Casino bietet Auszahlungen per Banküberweisung, PayPal und Skrill an. Die durchschnittliche Bearbeitungszeit liegt bei 24‑48 Stunden für elektronische Methoden, während Banküberweisungen bis zu drei Werktage dauern können.</p>
<p>Um deine Auszahlung zu beschleunigen, stelle sicher, dass dein Konto bereits verifiziert ist (siehe Abschnitt 5). Unverifizierte Konten können bis zu sieben Tage in der Prüfung bleiben.</p>
<h2>5. Mobile Nutzung & App‑Funktionen</h2>
<p>Die <strong>martin casino app</strong> ist sowohl für Android als auch für iOS verfügbar und wurde für ein reibungsloses mobiles Erlebnis optimiert. Alle Casinospiele, Live-Dealer‑Tische und das Wettangebot stehen in der App zur Verfügung, ohne dass du die Seite im Browser öffnen musst.</p>
<p>Die App bietet Push‑Benachrichtigungen für exklusive Aktionen, persönliche Bonuscodes und schnelle Einzahlungs‑Links. Die offizielle Martin Casino App kann hier heruntergeladen werden: <a href="https://martins-cassinos.com/app">https://martins-cassinos.com/app</a>.</p>
<h2>6. Sicherheit, Lizenz & verantwortungsvolles Spielen</h2>
<p>Martin Casino operiert mit einer Lizenz der Malta Gaming Authority (MGA) und erfüllt strengste EU‑Sicherheitsstandards. Alle Daten werden mit SSL‑Verschlüsselung geschützt, sodass deine persönlichen Informationen sicher bleiben.</p>
<p>Verantwortungsvolles Spielen wird großgeschrieben. Du kannst Limits für Einzahlungen, Einsätze und Verlustbeträge festlegen. Außerdem gibt es eine Selbstsperrfunktion, die dich für bis zu sechs Monate vom Spiel ausschließt.</p>
<h2>7. Kundensupport – Hilfe, wenn du sie brauchst</h2>
<p>Der Kundenservice von Martin Casino ist rund um die Uhr per Live‑Chat und E‑Mail erreichbar. Das Team spricht Deutsch, Englisch und weitere europäische Sprachen, sodass du dich immer in deiner Muttersprache verständigen kannst.</p>
<p>Ein umfangreiches FAQ‑Portal deckt häufige Fragen zu Registrierung, Boni, Ein- und Auszahlungen sowie technische Probleme ab. Für komplexe Anliegen wird dir im Live‑Chat ein Spezialist zugewiesen, der innerhalb von 15 Minuten reagieren sollte.</p>
<h2>8. Funktionsvergleich: Martin Casino App vs. Konkurrenz</h2>
<table border="1" cellpadding="5" cellspacing="0">
<thead>
<tr>
<th>Kriterium</th>
<th>Martin Casino App</th>
<th>Durchschnittlicher Mitbewerber</th>
</tr>
</thead>
<tbody>
<tr>
<td>Willkommensbonus</td>
<td>100 % bis 200 € + 50 FS</td>
<td>100 % bis 150 €</td>
</tr>
<tr>
<td>Max. Einzahlung pro Tag</td>
<td>5 000 €</td>
<td>2 500 €</td>
</tr>
<tr>
<td>Auszahlungszeit (E‑Money)</td>
<td>24‑48 Std.</td>
<td>48‑72 Std.</td>
</tr>
<tr>
<td>Lizenz</td>
<td>MGA</td>
<td>UKGC / Curacao</td>
</tr>
<tr>
<td>Live‑Casino</td>
<td>Ja, 30+ Tische</td>
<td>Ja, 20‑25 Tische</td>
</tr>
</tbody>
</table>
<h2>9. Fazit: Ist die martin casino app das Richtige für dich?</h2>
<p>Wenn du nach einer benutzerfreundlichen App suchst, die sowohl ein attraktives Bonuspaket als auch schnelle Auszahlungen bietet, ist die Martin Casino App eine solide Wahl. Die Kombination aus breiter Zahlungsmethoden‑Palette, deutscher Lizenz und gutem Kundenservice macht das Angebot besonders attraktiv für Spieler in Deutschland.</p>
<p>Denke daran, deine Spiele verantwortungsbewusst zu gestalten, die Wettanforderungen zu prüfen und stets deine Kontodaten aktuell zu halten. Mit diesen Tipps steht einem sicheren und unterhaltsamen Casinobesuch nichts mehr im Wege.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/uncategorized/martin-casino-app-was-du-wissen-musst/">Martin Casino App – Was du wissen musst</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Casino Verde login – betalingsmetoder, innskudd og uttak for norske spillere</title>
<link>https://edusehat.com/en/casino-verde-login-betalingsmetoder-innskudd-og-uttak-for-norske-spillere</link>
<guid>https://edusehat.com/en/casino-verde-login-betalingsmetoder-innskudd-og-uttak-for-norske-spillere</guid>
<description><![CDATA[ Casino Verde Login – Praktisk guide for norske spillere 1. Registrering og første innlogging Før du kan bruke casino verde login, må du opprette en konto hos Verde 
The post Casino Verde login – betalingsmetoder, innskudd og uttak for norske spillere appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/OHTf5p6nbIU/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 07:00:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Casino, Verde, login, –, betalingsmetoder, innskudd, uttak, for, norske, spillere</media:keywords>
<content:encoded><![CDATA[<figure data-affgun-media="hero"><img decoding="async" src="https://i.ytimg.com/vi/OHTf5p6nbIU/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<article>
<h1>Casino Verde Login – Praktisk guide for norske spillere</h1>
<section>
<h2>1. Registrering og første innlogging</h2>
<div data-affgun-media="video"></div>
<p>Før du kan bruke <strong>casino verde login</strong>, må du opprette en konto hos Verde Casino. Registreringsprosessen er kort: du fyller inn navn, e‑post og velger et passord som er lett å huske, men vanskelig for andre å gjette. Når du har bekreftet e‑postadressen, er kontoen klar til å brukes, men mange spillere velger å gjennomføre KYC‑prosessen før første innskudd.</p>
<p>Et viktig steg er å sette opp sikkerhetsinnstillinger som to‑faktor‑autentisering dersom casinoet tilbyr dette. På den måten reduserer du risikoen for at uvedkommende får tilgang til kontoen din. Når registreringen er fullført, kan du gå videre til innlogging og utforske spillutvalget.</p>
</section>
<section>
<h2>2. Slik logger du inn på Verde Casino</h2>
<h3>Trinn‑for‑trinn‑veiledning</h3>
<ul>
<li>Åpne nettleseren og gå til casinoets hovedside.</li>
<li>Klikk på «Logg inn»‑knappen som vanligvis finnes øverst til høyre.</li>
<li>Skriv inn brukernavnet eller e‑posten du registrerte, samt passordet.</li>
<li>Bekreft med eventuelt to‑faktor‑kodesystem.</li>
<li>Trykk på «Logg inn» og du blir tatt inn i kontoen din.</li>
</ul>
<p>Hvis du har glemt passordet, finnes det en «Glemt passord?»-lenke som sender en tilbakestillings‑e‑post. Sørg for å sjekke spam‑mappen hvis du ikke ser e‑posten med en gang. Når du er innlogget, kan du gå rett til innskudd eller bonusutnyttelse.</p>
<p>For en rask pålogging fra mobilen, kan du lagre brukernavn og passord i en pålitelig passordbehandler. Dette sparer tid og gjør at du kan hoppe rett inn i spillene når du er på farten.</p>
</section>
<section>
<h2>3. Bonus og velkomsttilbud ved innlogging</h2>
<p>Etter vellykket <strong>casino verde login</strong> vil du ofte bli møtt av et velkomsttilbud som kan inkludere en match‑bonus på første innskudd og gratis spinn. Les alltid betingelsene nøye – spesielt wagering requirements, som ofte ligger på 30‑40 ganger bonusbeløpet.</p>
<p>For norske spillere er det vanlig med en bonus som gir 100 % match opp til 2 000 kr, pluss 50 gratis spinn på utvalgte slot‑spill. Husk at gratis spinn ofte har en egen omsetningskrav på 20x gevinsten fra spinnene.</p>
<p>Et tips er å bruke bonusen på spill med høy RTP (return to player) og moderat volatilitet, slik at du får flere vinnende kombinasjoner og dermed lettere kan oppfylle omsetningskravene.</p>
</section>
<section>
<h2>4. Betalingsmetoder og innskudd</h2>
<p>Verde Casino støtter flere betalingsmetoder som er populære blant norske spillere: bankkort (Visa, Mastercard), e‑wallets som Skrill og Neteller, samt direkte bankoverføring. De fleste innskudd er umiddelbare, noe som betyr at du kan begynne å spille så snart du har trykket «Innskudd».</p>
<p>Her er en oversikt over de mest brukte innskuddsalternativene og deres typiske behandlingstid:</p>
<table border="1" cellpadding="5" cellspacing="0">
<thead>
<tr>
<th>Betalingsmetode</th>
<th>Behandlingstid</th>
<th>Avgift</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visa / Mastercard</td>
<td>Øyeblikkelig</td>
<td>Ingen</td>
</tr>
<tr>
<td>Skrill</td>
<td>Øyeblikkelig</td>
<td>Ingen</td>
</tr>
<tr>
<td>Neteller</td>
<td>Øyeblikkelig</td>
<td>Ingen</td>
</tr>
<tr>
<td>Bankoverføring</td>
<td>1‑2 arbeidsdager</td>
<td>0‑30 kr</td>
</tr>
</tbody>
</table>
<p>Velg den betalingsmetoden som passer best for deg, og husk at enkelte metoder kan ha lavere grenser for innskudd enn andre.</p>
</section>
<section>
<h2>5. Uttaksprosessen – hva du bør vite</h2>
<p>Uttak blir ofte sett på som den mest kritiske delen av casinoopplevelsen. Når du har oppfylt eventuelle omsetningskrav, kan du be om uttak via «Kasse»‑menyen. De fleste norske spillere foretrekker e‑wallets fordi uttaket da er nesten umiddelbart.</p>
<p>Hvis du bruker bankkort eller bankoverføring, kan uttaket ta 2‑5 arbeidsdager. Det er lurt å ha KYC‑dokumentene klare (ID, adressebevis) for å unngå forsinkelser. Verge også at casinoet kan sette en minimumsgrense på 100 kr per uttak.</p>
<p>Et tips: be om uttak i samme betalingsmetode som du brukte ved innskudd, da dette ofte gir raskest behandlingstid.</p>
</section>
<section>
<h2>6. Mobilapp og responsivt spill</h2>
<p>Verde Casino har en moderne mobilversjon som fungerer i både iOS‑ og Android‑nettlesere. Du trenger ikke å laste ned en separat app, men du kan også finne en dedikert app i App Store og Google Play hvis du foretrekker det.</p>
<p>Spillutvalget på mobil er optimalisert for små skjermer, men du får fortsatt tilgang til live casino, bordspill og slots med høy grafikk. Hastigheten på innlogging på mobilen er identisk med desktop‑versjonen, så <strong>casino verde login</strong> fungerer sømløst uansett enhet.</p>
<p>For best mulig opplevelse, sørg for at du har en stabil internettforbindelse og at du har oppdatert nettleseren til siste versjon.</p>
</section>
<section>
<h2>7. Sikkerhet, KYC og ansvarlig spill</h2>
<p>Verde Casino er lisensiert av Malta Gaming Authority, noe som gir et solid rammeverk for rettferdig spill og spillerbeskyttelse. Alle personopplysninger lagres kryptert med SSL‑teknologi, og casinoet utfører rutinert KYC‑kontroll for å bekrefte identiteten din.</p>
<p>Ansvarlig spill er integrert i plattformen – du kan sette innskuddsgrenser, tap‑grenser og ta pause fra spillene når du føler behov for det. Hvis du opplever spillrelaterte problemer, finnes det en «Responsible Gaming»-side med lenker til støttetjenester.</p>
</section>
<section>
<h2>8. Kundeservice og support</h2>
<p>Support er tilgjengelig 24/7 via live‑chat og e‑post. Når du har logget inn, klikker du på «Kontakt oss» for å åpne en chat‑sesjon med en norsk‑snakkende rådgiver. Responsen er vanligvis under ett minutt.</p>
<p>Det finnes også en FAQ‑seksjon med svar på vanlige spørsmål om innskudd, uttak og bonusbetingelser. For mer komplekse saker kan du sende inn dokumentasjon gjennom sikker opplastning i support‑portalen.</p>
</section>
<section>
<h2>9. Vanlige spørsmål (FAQ)</h2>
<h3>Hvor raskt kan jeg logge inn etter registrering?</h3>
<p>Etter at du har bekreftet e‑posten, er kontoen klar til å brukes umiddelbart. Du kan logge inn med en gang du har satt et passord.</p>
<h3>Hva gjør jeg hvis jeg har glemt passordet?</h3>
<p>Klikk på «Glemt passord?», skriv inn e‑posten din, og følg instruksjonene i e‑posten for å lage et nytt passord.</p>
<h3>Hvor finner jeg bonusinformasjonen etter innlogging?</h3>
<p>Bonusene vises i en banner på dashbordet ditt så snart du er logget inn, og du kan også finne detaljer i «Kampanjer»-menyen.</p>
<h3>Er det noen spesiell nettside for innlogging?</h3>
<p>Ja, gå direkte til <a href="https://verdecasinos-no.com/login">https://verdecasinos-no.com/login</a> for å logge inn på kontoen din.</p>
</section>
</article>
<p>The post <a href="https://www.pharmaceutical-business-review.com/uncategorized/casino-verde-login-betalingsmetoder-innskudd-og-uttak-for-norske-spillere/">Casino Verde login – betalingsmetoder, innskudd og uttak for norske spillere</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Glorion Casino Login – Überblick und Optionen</title>
<link>https://edusehat.com/en/glorion-casino-login-uberblick-und-optionen</link>
<guid>https://edusehat.com/en/glorion-casino-login-uberblick-und-optionen</guid>
<description><![CDATA[ Glorion Casino Login – Ihre praktische Schritt‑für‑Schritt Anleitung 1. Schnell Überblick: Was ist Glorion Casino? Glorion Casino ist ein relativ neues Lizenz‑Casino, das 2022 gestartet wurde und seitdem 
The post Glorion Casino Login – Überblick und Optionen appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/lHERdxnL9Ts/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 07:00:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Glorion, Casino, Login, –, Überblick, und, Optionen</media:keywords>
<content:encoded><![CDATA[<figure data-affgun-media="hero"><img decoding="async" src="https://i.ytimg.com/vi/lHERdxnL9Ts/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<h1>Glorion Casino Login – Ihre praktische Schritt‑für‑Schritt Anleitung</h1>
<h2>1. Schnell Überblick: Was ist Glorion Casino?</h2>
<div data-affgun-media="video"></div>
<p>Glorion Casino ist ein relativ neues Lizenz‑Casino, das 2022 gestartet wurde und seitdem eine wachsende Community in Deutschland aufgebaut hat. Das Angebot reicht von klassischen Slots über Live‑Dealer‑Tische bis hin zu einer kleinen Sportwetten‑Sektion. Alle Spiele stammen von namhaften Providern wie NetEnt, Play’n GO und Evolution Gaming, sodass ein hoher RTP‑Durchschnitt und diverse Volatilitätsstufen garantiert sind. Das Casino wird von der Curaçao‑Gaming‑Authority lizenziert, was für die meisten deutschen Spieler ein akzeptabler Sicherheitsstandard ist.</p>
<p>Der Name „Glorion“ soll an Glorie und Triumph erinnern – ein Versprechen, das sich nicht nur im Design, sondern auch in Promotionen widerspiegelt. Für Einsteiger ist das Layout übersichtlich, die Navigation klar strukturiert und die wichtigsten Buttons (Registrieren, Einzahlen, Login) sofort sichtbar. Wer also nach einem neuen Portal für Slots und Live‑Casino sucht, findet hier ein komplettes Starter‑Pakete‑Programm.</p>
<h2>2. Registrierung: Der erste Schritt zum Login</h2>
<p>Bevor Sie den <strong>glorion casino login</strong> nutzen können, müssen Sie ein Konto anlegen. Der Registrierungsprozess dauert etwa drei Minuten und erfordert nur wenige Angaben: E‑Mail-Adresse, gewünschter Benutzername und ein sicheres Passwort. Zusätzlich wird nach Ihrem Geburtsdatum gefragt, um sicherzustellen, dass Sie das gesetzliche Mindestalter von 18 Jahren erfüllen.</p>
<p>Nach dem Absenden erhalten Sie eine Bestätigungs‑E‑Mail. Klicken Sie auf den enthaltenen Link, um die Registrierung abzuschließen. Erst dann wird Ihr Account aktiv und Sie können sich einloggen. Tipp: Verwenden Sie nach Möglichkeit eine E‑Mail, die Sie regelmäßig prüfen, um wichtige Mitteilungen zu Bonus­bedingungen oder Sicherheitshinweisen nicht zu verpassen.</p>
<h2>3. Login‑Prozess: So melden Sie sich an</h2>
<p>Der <em>glorion casino login</em> ist bewusst simpel gehalten. Auf der Startseite finden Sie das Login‑Feld oben rechts. Geben Sie Ihren Benutzernamen (oder Ihre E‑Mail) und das Passwort ein, setzen Sie optional den „Angemeldet bleiben“-Haken, und klicken Sie auf „Einloggen“. Sollte die Eingabe nicht funktionieren, prüft das System automatisiert, ob das Passwort falsch geschrieben wurde oder das Konto gesperrt ist.</p>
<p>Falls Sie Ihr Passwort vergessen haben, gibt es einen „Passwort vergessen?“-Link, der Ihnen einen Wiederherstellungs‑Code an die registrierte E‑Mail schickt. Der Vorgang ist in der Regel innerhalb von fünf Minuten abgeschlossen, vorausgesetzt, Sie haben Zugriff auf das Postfach. Für zusätzliche Sicherheit bietet Glorion optional die Zwei‑Faktor‑Authentifizierung (2FA) per SMS oder Authenticator‑App an.</p>
<h2>4. Bonus & Willkommensangebot beim ersten Login</h2>
<p>Gleich nach dem ersten <strong>glorion casino login</strong> wartet ein großzügiges Willkommenspaket auf Sie. Aktuell erhalten neue Spieler 100 % bis zu 200 €, plus 50 Freispiele für den Slot „Starburst“. Der Bonus unterliegt einer 30‑fachen Wettanforderung (Wagering) auf das Bonusguthaben, bevor eine Auszahlung möglich ist.</p>
<p>Wichtig zu beachten: Die Freispiele gelten nur für ausgewählte Slots und haben eine maximale Auszahlung von 50 € pro Spin. Die Bonusbedingungen gelten für 30 Kalendertage – verfallen also, wenn Sie das Konto innerhalb dieses Zeitraums nicht aktiv nutzen. Nutzen Sie das Angebot rasch, weil es nur für neue Spieler im ersten Monat nach Registrierung gilt.</p>
<h2>5. Zahlung & Auszahlung – Was Sie wissen müssen</h2>
<p>Glorion unterstützt in Deutschland gängige Einzahlungs‑ und Auszahlungsmethoden. Die beliebtesten Optionen sind Kredit‑/Debitkarten (Visa, Mastercard), Sofort‑Überweisung, Trustly und PayPal. Jeder Einzahlungsweg wird sofort gutgeschrieben, während Auszahlungen je nach Methode unterschiedlich lange dauern.</p>
<p>Im Folgenden finden Sie eine kompakte Übersicht:</p>
<table border="1" cellpadding="5" cellspacing="0">
<thead>
<tr>
<th>Zahlungsmethode</th>
<th>Einzahlungszeit</th>
<th>Auszahlungszeit</th>
<th>Max. Auszahlung pro Transaktion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visa / Mastercard</td>
<td>sofort</td>
<td>1‑3 Werktage</td>
<td>5.000 €</td>
</tr>
<tr>
<td>Sofort‑Überweisung</td>
<td>sofort</td>
<td>bis zu 24 Std.</td>
<td>3.000 €</td>
</tr>
<tr>
<td>Trustly</td>
<td>sofort</td>
<td>innerhalb von 2 Std.</td>
<td>2.500 €</td>
</tr>
<tr>
<td>PayPal</td>
<td>sofort</td>
<td>innerhalb von 24 Std.</td>
<td>4.000 €</td>
</tr>
</tbody>
</table>
<p>Bevor Sie eine Auszahlung anfordern, wird eine KYC‑Verifizierung (Know‑Your‑Customer) durchgeführt. Das bedeutet, Sie müssen einen Lichtbildausweis und ggf. einen Wohnsitznachweis hochladen. Sobald die Dokumente geprüft sind, erfolgen Auszahlungen in der Regel innerhalb der angegebenen Zeitrahmen.</p>
<h2>6. Mobile Nutzung & App – Spielen unterwegs</h2>
<p>Das Design von Glorion ist vollständig responsive, sodass Sie auf Smartphones und Tablets ohne Qualitätsverlust spielen können. Es gibt zudem eine offizielle Android‑App, die im Google Play Store (nach vorheriger Freigabe) verfügbar ist. Die iOS‑Nutzer können über den Safari‑Browser auf die mobile Seite zugreifen, weil eine native App aktuell noch in Entwicklung ist.</p>
<p>Die mobile Plattform bietet dieselben Bonus‑ und Zahlungsoptionen wie die Desktop‑Variante. Wichtig: Für den <strong>glorion casino login</strong> auf dem Handy müssen Sie die gleiche Zwei‑Faktor‑Authentifizierung aktivieren, wenn Sie das Sicherheitslevel hochhalten wollen. Die App speichert Ihre Lieblingsspiele im Schnellzugriff, damit Sie sofort dort weitermachen können, wo Sie aufgehört haben.</p>
<h2>7. Sicherheit, Verifikation und verantwortungsvolles Spielen</h2>
<p>Glorion nutzt SSL‑Verschlüsselung (256‑Bit) für alle Datenübertragungen, sodass Ihre persönlichen Informationen und finanziellen Transaktionen sicher bleiben. Die Lizenz aus Curaçao verpflichtet das Casino, regelmäßige Audits durchzuführen – unabhängige Prüfinstanzen testen die Zufallszahlengeneratoren (RNG) und garantieren faire Spielbedingungen.</p>
<p>Verantwortungsvolles Spielen wird aktiv gefördert: Es gibt Selbst‑Ausschluss‑Optionen, tägliche Einzahlungslimits und eine Übersicht über das eigene Spielverhalten. Sollten Sie das Gefühl haben, dass das Spielen überhandnimmt, können Sie über das Kunden‑Support‑Portal sofort eine Sperre anfordern.</p>
<h2>8. Kundenservice und Support</h2>
<p>Der Kundenservice ist rund um die Uhr per Live‑Chat und E‑Mail erreichbar. In der Regel erhalten Sie innerhalb von wenigen Minuten eine Antwort im Chat, während E‑Mails innerhalb von 24 Stunden bearbeitet werden. Für deutsche Spieler gibt es zudem eine telefonische Hotline, die werktags von 09:00 bis 18:00 Uhr besetzt ist.</p>
<p>Der Support kann Ihnen bei allen Themen helfen: <em>glorion casino login</em> Probleme, Bonus‑Fragen, Verifikations‑Dokumente oder technische Schwierigkeiten mit der mobilen App. Nutzen Sie das integrierte Ticket‑System, wenn Sie ein Problem schriftlich dokumentieren möchten – das System speichert den Verlauf für zukünftige Rückfragen.</p>
<h2>9. Häufige Fragen zum Glorion Casino Login</h2>
<ul>
<li>Wie lange dauert die Konto‑Verifikation? – Meistens 24‑48 Stunden nach Hochladen der Unterlagen.</li>
<li>Kann ich mich mit meiner E‑Mail statt dem Benutzernamen anmelden? – Ja, beides ist möglich.</li>
<li>Gibt es ein Limit für das tägliche Login? – Nein, das ist unbegrenzt, aber bei ungewöhnlichen Aktivitäten kann ein Sicherheits‑Check ausgelöst werden.</li>
<li>Wie kann ich meine Zugangsdaten zurücksetzen? – Nutzen Sie den „Passwort vergessen?“-Link und folgen Sie den Anweisungen.</li>
</ul>
<p>Wenn Sie nach einer zuverlässigen Anlaufstelle für Online‑Casino‑Spiele in Deutschland suchen, ist das <a href="https://glorion-casinos-de.com/">glorion casino</a> einen genauen Blick wert. Mit klaren Anmelde‑Schritten, attraktiven Boni und einer breiten Palette an Zahlungsoptionen bietet das Portal alles, was Spieler für ein sicheres und spaßiges Spielerlebnis erwarten.</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/uncategorized/glorion-casino-login-uberblick-und-optionen/">Glorion Casino Login – Überblick und Optionen</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Martin Casino Review – Konto‑Verifizierung einfach erklärt</title>
<link>https://edusehat.com/en/martin-casino-review-kontoverifizierung-einfach-erklaert</link>
<guid>https://edusehat.com/en/martin-casino-review-kontoverifizierung-einfach-erklaert</guid>
<description><![CDATA[ Martin Casino Review – Der umfassende Guide für deutsche Spieler 1. Überblick &amp; Lizenz – Ist das Martin Casino vertrauenswürdig? Ein guter erster Eindruck entsteht, wenn ein Casino 
The post Martin Casino Review – Konto‑Verifizierung einfach erklärt appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/T_UkDY_gkkI/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 07:00:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Martin, Casino, Review, –, Konto‑Verifizierung, einfach, erklärt</media:keywords>
<content:encoded><![CDATA[<figure data-affgun-media="hero"><img decoding="async" src="https://i.ytimg.com/vi/T_UkDY_gkkI/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<h1>Martin Casino Review – Der umfassende Guide für deutsche Spieler</h1>
<section>
<h2>1. Überblick & Lizenz – Ist das Martin Casino vertrauenswürdig?</h2>
<div data-affgun-media="video"></div>
<p>Ein guter erster Eindruck entsteht, wenn ein Casino transparent über seine Lizenzierung informiert. Das Martin Casino wird von der Malta Gaming Authority (MGA) lizenziert, einer der renommiertesten Aufsichtsbehörden in der EU. Diese Lizenz garantiert, dass das Casino strenge Sicherheits- und Fairness‑Standards einhält, was für deutsche Spieler besonders wichtig ist.</p>
<p>Zusätzlich wird das Spielangebot regelmäßig von unabhängigen Prüflabors wie eCOGRA auditiert. So können Sie sicher sein, dass die angezeigten RTP‑Werte (Return to Player) den tatsächlichen Gewinnchancen entsprechen. Für Spieler, die auf rechtliche Sicherheit achten, ist das ein starkes Argument, das die Entscheidung für das Martin Casino erleichtert.</p>
</section>
<section>
<h2>2. Registrierung und KYC – Schnell starten, aber sicher bleiben</h2>
<p>Die Anmeldung beim Martin Casino dauert nur wenige Minuten. Nach Klick auf „Registrieren“ geben Sie Name, Adresse, Geburtsdatum und eine gültige E‑Mail‑Adresse ein. Das System prüft sofort, ob das Mindestalter von 18 Jahren erreicht ist – ein unverzichtbarer Schritt im deutschen Glücksspielrecht.</p>
<p>Nach dem ersten Login folgt die KYC‑Verifizierung (Know Your Customer). Dafür müssen Sie einen Lichtbildausweis und einen Adressnachweis hochladen. Dieser Prozess dient nicht nur der Betrugsprävention, sondern beschleunigt zukünftige Auszahlungen erheblich, weil das Casino dann bereits alle Dokumente vorliegen hat.</p>
</section>
<section>
<h2>3. Bonusangebote & Willkommensbonus – Was steckt wirklich dahinter?</h2>
<p>Der Willkommensbonus ist das Aushängeschild jedes Online‑Casinos. Martin Casino lockt neue Spieler mit einem 100 % Bonus bis zu 200 €, plus 100 Freispiele auf ausgewählte Slots. Der Bonus wird automatisch nach der ersten Einzahlung gutgeschrieben, solange die Mindesteinzahlung von 20 € erreicht wird.</p>
<p>Wichtig zu beachten sind die <em>wagering requirements</em> – die Umsatzbedingungen. Bei Martin Casino beträgt die Umsatzbindung 35 × Bonusbetrag, was im deutschen Markt eher moderat ist. Die nachfolgende Tabelle gibt Ihnen einen schnellen Überblick:</p>
<table border="1" cellpadding="5" cellspacing="0">
<thead>
<tr>
<th>Bonustyp</th>
<th>Höhe</th>
<th>Umsatzbindung</th>
<th>Max. Auszahlung</th>
</tr>
</thead>
<tbody>
<tr>
<td>Willkommensbonus</td>
<td>100 % bis 200 € + 100 Freispiele</td>
<td>35 × Bonus</td>
<td>1 000 €</td>
</tr>
<tr>
<td>Einzahlungsbonus</td>
<td>50 % bis 100 €</td>
<td>30 × Bonus</td>
<td>500 €</td>
</tr>
<tr>
<td>Cashback</td>
<td>10 % Verlust‑Rückerstattung</td>
<td>–</td>
<td>200 € pro Monat</td>
</tr>
</tbody>
</table>
<p>Beachten Sie außerdem, dass Freispiele nur auf bestimmten Slot‑Titeln nutzbar sind und dass Gewinne aus Freispielen einer 30‑fachen Umsatzbindung unterliegen. Diese Details finden Sie in den Bonusbedingungen, die Sie unbedingt vor dem Annehmen lesen sollten.</p>
</section>
<section>
<h2>4. Spielangebot: Slots, Live Casino & Sportwetten</h2>
<p>Martin Casino bietet mehr als 2.000 Spiele, die von führenden Software‑Providern wie NetEnt, Microgaming und Evolution Gaming stammen. Das Portfolio umfasst klassische Video‑Slots, progressive Jackpot‑Titel und eine umfangreiche Auswahl an Tischspielen wie Blackjack, Roulette und Baccarat.</p>
<p>Für Fans von Live‑Glücksspiel gibt es ein eigenständiges Live‑Casino mit echten Dealern, das rund um die Uhr verfügbar ist. Hier können Sie per Video‑Stream an Blackjack‑Tischen mit mehreren Teilnehmern teilnehmen – ein echtes Casino‑Erlebnis, das von hoher Bildqualität und niedriger Latenz profitiert.</p>
<p>Ein weiteres Highlight ist die integrierte Sportwetten‑Plattform. Sie deckt beliebte Events aus Fußball, Tennis, Basketball und Esports ab. Wetten lassen sich direkt aus dem Casino‑Dashboard heraus platzieren, was für Spieler, die beides kombinieren möchten, besonders praktisch ist.</p>
</section>
<section>
<h2>5. Zahlungsarten & Auszahlungsdauer – Schnell und sicher Geld bewegen</h2>
<p>Ein breites Angebot an Ein- und Auszahlungsmethoden ist für deutsche Spieler entscheidend. Martin Casino unterstützt folgende Deposit‑Optionen:</p>
<ul>
<li>Kredit‑ und Debitkarten (Visa, Mastercard)</li>
<li>E‑Wallets (Skrill, Neteller, ecoPayz)</li>
<li>Banküberweisungen (SEPA)</li>
<li>Prepaid‑Karten (Paysafecard)</li>
</ul>
<p>Auszahlungen erfolgen in der Regel innerhalb von 24 Stunden, wenn die KYC‑Dokumente bereits geprüft wurden. E‑Wallet‑Abhebungen sind meist die schnellsten und werden innerhalb von 1‑2 Stunden bearbeitet. Banküberweisungen können bis zu 3 Werktage benötigen, was aber im deutschen Markt üblich ist.</p>
</section>
<section>
<h2>6. Mobile App & Benutzerfreundlichkeit – Spielen unterwegs</h2>
<p>Die mobile Erfahrung ist bei Martin Casino kein nachträglicher Gedanke, sondern von Anfang an integriert. Für Android und iOS gibt es eine native App, die im Google Play Store bzw. im Apple App Store verfügbar ist. Die App spiegelt das Desktop‑Layout wider, bietet schnelle Ladezeiten und unterstützt Touch‑Optimierung für Slots und Live‑Dealer‑Spiele.</p>
<p>Falls Sie lieber im Browser bleiben, funktioniert die komplette Plattform responsiv auf jedem Smartphone oder Tablet. Die Navigation ist intuitiv: Ein klar strukturiertes Menü führt Sie zu Bonusangeboten, Ihrem Konto und dem Live‑Casino – alles mit nur wenigen Klicks erreichbar.</p>
</section>
<section>
<h2>7. Kundenservice & Support – Hilfe, wenn Sie sie brauchen</h2>
<p>Der Kundensupport von Martin Casino ist rund um die Uhr per Live‑Chat, E‑Mail und telefonisch erreichbar. Der Live‑Chat ist in der Regel die schnellste Option und liefert innerhalb von wenigen Minuten Antworten auf gängige Fragen zu Einzahlungen, Bonusbedingungen oder technischen Problemen.</p>
<p>Ein FAQ‑Bereich auf der Website deckt häufig gestellte Fragen ab und spart oft Zeit, bevor Sie den Support kontaktieren. Für deutschsprachige Spieler gibt es sowohl deutschsprachige Chat‑Agenten als auch eine deutschsprachige E‑Mail‑Adresse, was den Service besonders benutzerfreundlich macht.</p>
</section>
<section>
<h2>8. Sicherheit & verantwortungsvolles Spielen – Ihr Schutz steht im Vordergrund</h2>
<p>Martin Casino verwendet modernste SSL‑Verschlüsselung, um alle Datenübertragungen zu schützen. Zusätzlich werden regelmäßige Pen‑Tests durchgeführt, um Schwachstellen frühzeitig zu erkennen. Die Einhaltung der EU‑Datenschutz‑Verordnung (DSGVO) sorgt dafür, dass Ihre persönlichen Daten sicher gespeichert werden.</p>
<p>Verantwortungsvolles Spielen wird aktiv gefördert. Das Casino bietet Selbstsperr‑Tools, Einzahlungslimits und eine 24‑Stunden‑Selbstausschluss‑Option. Sollten Sie das Gefühl haben, dass das Spielen aus dem Ruder läuft, können Sie über das Kundenkonto sofort eine Pause einlegen.</p>
</section>
<section>
<h2>9. Fazit & Entscheidungshilfe – Sollten Sie das Martin Casino wählen?</h2>
<p>Zusammenfassend lässt sich sagen, dass das Martin Casino mit einer soliden Lizenz, einem breiten Spielportfolio, attraktiven Boni und schnellen Auszahlungen punktet. Die deutschen Zahlungsoptionen, die mobile App und der mehrsprachige Kundenservice runden das Angebot ab und machen das Casino besonders für Einsteiger und erfahrene Spieler attraktiv.</p>
<p>Wenn Sie nach einem zuverlässigen, regulierten Anbieter suchen, der sowohl Casino‑ als auch Sportwetten unter einem Dach vereint, ist das Martin Casino einen genaueren Blick wert. Besuchen Sie den <a href="https://martin-casinos-online.com/">martin online casino</a>, um sich selbst ein Bild zu machen und das Willkommensangebot zu nutzen.</p>
</section>
<p>The post <a href="https://www.pharmaceutical-business-review.com/uncategorized/martin-casino-review-konto-verifizierung-einfach-erklart/">Martin Casino Review – Konto‑Verifizierung einfach erklärt</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Martin Casino App – Sicherheitsguide für deutsche Spieler 2026</title>
<link>https://edusehat.com/en/martin-casino-app-sicherheitsguide-fur-deutsche-spieler-2026</link>
<guid>https://edusehat.com/en/martin-casino-app-sicherheitsguide-fur-deutsche-spieler-2026</guid>
<description><![CDATA[ Martin Casino App – Dein praktischer Leitfaden für 2026 Warum die martin casino app? Die martin casino app ist nicht nur ein weiteres mobiles Casino, sie kombiniert schnelle 
The post Martin Casino App – Sicherheitsguide für deutsche Spieler 2026 appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/Gl3hy83SulM/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 07:00:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Martin, Casino, App, –, Sicherheitsguide, für, deutsche, Spieler, 2026</media:keywords>
<content:encoded><![CDATA[<figure data-affgun-media="hero"><img decoding="async" src="https://i.ytimg.com/vi/Gl3hy83SulM/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<article>
<h1>Martin Casino App – Dein praktischer Leitfaden für 2026</h1>
<section>
<h2>Warum die martin casino app?</h2>
<div data-affgun-media="video"></div>
<p>Die <strong>martin casino app</strong> ist nicht nur ein weiteres mobiles Casino, sie kombiniert schnelle Ladezeiten, ein übersichtliches Design und ein breites Spielangebot auf einem einzigen Gerät. Für deutsche Spieler bedeutet das sofortiger Zugriff auf Slots, Live‑Dealer‑Tische und sogar Sportwetten – alles ohne umständliche Desktop‑Navigation.</p>
<p>Ein weiterer Pluspunkt ist die nahtlose Integration von Bonusaktionen. Sobald du die App installierst, werden aktuelle Willkommensboni automatisch im Hintergrund aktualisiert, sodass du nie ein gutes Angebot verpasst. Das spart Zeit und erhöht deine Gewinnchancen bereits beim ersten Spiel.</p>
</section>
<section>
<h2>Registrierung und Verifizierung – Schritt für Schritt</h2>
<p>Der Anmeldeprozess in der <em>martin casino app</em> ist bewusst simpel gehalten. Nach dem Download öffnest du die App, klickst auf „Registrieren“ und gibst deine E‑Mail-Adresse, ein sicheres Passwort und dein Geburtsdatum ein. Die Eingabe wird sofort geprüft, und du erhältst einen Bestätigungscode per E‑Mail.</p>
<p>Die Verifizierung erfolgt danach in zwei Schritten: erstens das Hochladen eines gültigen Ausweisdokuments (Personalausweis oder Reisepass) und zweitens ein kurzer Selfie‑Check. Dieser KYC‑Prozess ist innerhalb von 24 Stunden abgeschlossen, danach kannst du Einzahlungen tätigen und das komplette Spielangebot nutzen.</p>
</section>
<section>
<h2>Bonusangebote und Wettanforderungen im Überblick</h2>
<p>Die <strong>martin casino app</strong> lockt neue Spieler mit einem 100 % Willkommensbonus bis zu 200 €, plus 50 Freispielen auf ausgewählte Slots. Die Bonusbedingungen sind transparent: 30‑fache Wettanforderungen (30x) auf den Bonusbetrag, nicht auf die Einzahlung.</p>
<p>Für Bestandskunden gibt es wöchentliche Reload‑Bonusse, Cash‑Back‑Aktionen und exklusive Mobile‑Only‑Promos. Wichtig ist, die jeweiligen Umsatzbedingungen zu prüfen – bei manchen Aktionen gelten niedrigere Multiplikatoren, wenn du mit Slots mit hoher Volatilität spielst.</p>
<ul>
<li>Willkommensbonus: 100 % bis 200 € + 50 FS</li>
<li>Wettanforderungen: 30x Bonus</li>
<li>Regelmäßige Reload‑Bonusse: 25 % bis 100 €</li>
<li>Cash‑Back: 5 % wöchentlich auf Nettoverlust</li>
</ul>
</section>
<section>
<h2>Zahlungsmethoden & Auszahlungsgeschwindigkeit</h2>
<p>Die App unterstützt alle gängigen deutschen Zahlungskanäle: Kredit‑ und Debitkarten (Visa, Mastercard), Sofortüberweisung, Giropay und gängige E‑Wallets wie Skrill oder Neteller. Einzahlungen werden in Echtzeit gutgeschrieben, sodass du sofort mit dem Spielen beginnen kannst.</p>
<p>Auszahlungen sind ebenfalls unkompliziert. Die meisten Methoden werden innerhalb von 24 Stunden bearbeitet, wobei E‑Wallets in der Regel die schnellsten Auszahlungszeiten von bis zu 2 Stunden bieten. Banküberweisungen können 3‑5 Werktage benötigen, was aber bei deutschen Banken üblich ist.</p>
<ul>
<li>Kreditkarte: Sofort, bis zu 5 % Bonus</li>
<li>Sofortüberweisung: 0 % Gebühren, 10‑15 Minuten</li>
<li>Skrill/Neteller: 0 % Gebühren, bis zu 2 Stunden</li>
<li>Banküberweisung: 1‑5 Werktage</li>
</ul>
</section>
<section>
<h2>Live Casino und Sportwetten auf dem Handy</h2>
<p>Dank der optimierten Streaming‑Technik bietet die <em>martin casino app</em> ein flüssiges Live‑Casino-Erlebnis. Du kannst an Echtzeit‑Tischspielen wie Blackjack, Roulette und Baccarat teilnehmen – alle mit professionellen Dealern aus europäischen Studios.</p>
<p>Zusätzlich integriert die App ein vollwertiges Sportwetten‑Modul. Ob Fußball, Handball oder E‑Sports – du findest aktuelle Quoten, Live‑Wetten und Pre‑Match‑Optionen. Die Kombination aus Casino‑ und Sportwetten macht die App zu einem All‑in‑One‑Portal für deutsche Spieler.</p>
</section>
<section>
<h2>Sicherheit, Lizenz und verantwortungsvolles Spielen</h2>
<p>Martin Casino ist von der Malta Gaming Authority (MGA) lizenziert und unterliegt strengen EU‑Regelungen. Die Datenverschlüsselung erfolgt nach dem aktuellen SSL‑Standard, sodass deine persönlichen Informationen und Transaktionen stets geschützt sind.</p>
<p>Verantwortungsvolles Spielen wird großgeschrieben. In der App findest du Tools für Einzahlungslimits, Verlustlimits und Selbstsperren. Solltest du das Gefühl haben, die Kontrolle zu verlieren, kannst du dich jederzeit an die 24/7‑Support‑Hotline wenden.</p>
</section>
<section>
<h2>Kundenservice und Support – was du erwarten kannst</h2>
<p>Der Kundensupport ist per Live‑Chat, E‑Mail und Telefon erreichbar. Anfragen werden in der Regel innerhalb von 5 Minuten beantwortet, wobei das Live‑Chat‑Team rund um die Uhr verfügbar ist. Für komplexe Fragen wie Auszahlungslimits gibt es eine ausführliche FAQ‑Sektion innerhalb der App.</p>
<p>Wenn du ein Problem hast, das du nicht sofort lösen kannst, steht dir ein dediziertes Beschwerdemanagement zur Verfügung. Der Service ist mehrsprachig, wobei Deutsch als primäre Sprache angeboten wird – ein echter Vorteil für lokale Spieler.</p>
</section>
<section>
<h2>Vergleichstabelle: martin casino app vs. Konkurrenz</h2>
<p>Um dir die Entscheidung zu erleichtern, haben wir die wichtigsten Kriterien der <strong>martin casino app</strong> mit zwei der beliebtesten deutschen Mobile‑Casinos verglichen:</p>
<table border="1" cellpadding="5" cellspacing="0">
<thead>
<tr>
<th>Kriterium</th>
<th>Martin Casino App</th>
<th>Casino A</th>
<th>Casino B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Willkommensbonus</td>
<td>100 % bis 200 € + 50 FS</td>
<td>150 % bis 300 €</td>
<td>100 % bis 250 € + 25 FS</td>
</tr>
<tr>
<td>Wettanforderungen</td>
<td>30x Bonus</td>
<td>40x Bonus</td>
<td>35x Bonus</td>
</tr>
<tr>
<td>Auszahlungsgeschwindigkeit</td>
<td>E‑Wallet 2 h, Bank 3‑5 Tage</td>
<td>E‑Wallet 4 h, Bank 5‑7 Tage</td>
<td>E‑Wallet 1 h, Bank 4‑6 Tage</td>
</tr>
<tr>
<td>Mobile‑Erlebnis</td>
<td>Native App iOS/Android</td>
<td>Responsive Web</td>
<td>Hybrid App</td>
</tr>
<tr>
<td>Lizenz</td>
<td>MGA</td>
<td>UKGC</td>
<td>Curacao</td>
</tr>
</tbody>
</table>
</section>
<section>
<h2>Fazit und Empfehlung</h2>
<p>Die <strong>martin casino app</strong> bietet ein ausgewogenes Paket aus attraktiven Boni, schnellen Auszahlungen und einem breiten Spielportfolio – alles verpackt in einer benutzerfreundlichen mobilen Oberfläche. Für deutsche Spieler, die sowohl Casino‑ als auch Sportwetten genießen wollen, stellt sie eine der besten Optionen im Jahr 2026 dar.</p>
<p>Wenn du bereit bist, das Angebot selbst zu testen, besuche einfach die offizielle Seite von <a href="https://martin-casino-deutschland.com/">martin casino</a> und lade die App herunter. Mit dem hier vorgestellten Leitfaden bist du bestens gerüstet, um sicher, schnell und gewinnbringend zu spielen.</p>
</section>
</article>
<p>The post <a href="https://www.pharmaceutical-business-review.com/uncategorized/martin-casino-app-sicherheitsguide-fur-deutsche-spieler-2026/">Martin Casino App – Sicherheitsguide für deutsche Spieler 2026</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Big Lucky Casino no deposit bonus – guide til app og mobil</title>
<link>https://edusehat.com/en/big-lucky-casino-no-deposit-bonus-guide-til-app-og-mobil</link>
<guid>https://edusehat.com/en/big-lucky-casino-no-deposit-bonus-guide-til-app-og-mobil</guid>
<description><![CDATA[ Big Lucky Casino – Din guide til big lucky casino no deposit bonus Hva er en big lucky casino no deposit bonus? En no‑deposit bonus er en liten 
The post Big Lucky Casino no deposit bonus – guide til app og mobil appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/rgvDGC2e5LI/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 07:00:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Big, Lucky, Casino, deposit, bonus, –, guide, til, app, mobil</media:keywords>
<content:encoded><![CDATA[<figure data-affgun-media="hero"><img decoding="async" src="https://i.ytimg.com/vi/rgvDGC2e5LI/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<h1>Big Lucky Casino – Din guide til big lucky casino no deposit bonus</h1>
<h2>Hva er en big lucky casino no deposit bonus?</h2>
<div data-affgun-media="video"></div>
<p>En no‑deposit bonus er en liten sum gratis penger eller gratisspinn som du kan få uten å sette inn egne penger. Hos Big Lucky Casino betyr dette at du kan starte spillopplevelsen med en gratis bankroll, vanligvis mellom 10 kr og 30 kr, bare ved å opprette en konto. Bonusen er ment som en velkomstgave og en mulighet til å teste kasinoets spillutvalg uten økonomisk risiko. Det er viktig å merke seg at selv om bonusen er gratis, er det ofte knyttet omsetningskrav og andre restriksjoner som du må godta før du kan ta ut eventuelle gevinster.</p>
<p>For norske spillere er dette spesielt attraktivt fordi mange andre kasinoer krever minimumsinnskudd som kan være høyere enn ønsket. Med en no‑deposit bonus kan du oppleve både slots og live casino‑bordspill før du bestemmer deg for om du vil satse ekte penger. Husk at bonustilbudet kan variere fra tid til annen, så det lønner seg å sjekke siden jevnlig for oppdaterte kampanjer.</p>
<h2>Hvordan registrere deg og kreve big lucky casino no deposit bonus</h2>
<p>Registreringsprosessen hos Big Lucky Casino er relativt enkel og krever kun noen få grunnleggende opplysninger. Du må oppgi navn, e‑postadresse, fødselsdato og velge et passord. Når kontoen er opprettet, vil du automatisk motta no‑deposit bonusten som er tilgjengelig for nye spillere i Norge.</p>
<h3>Steg‑for‑steg registrering</h3>
<ul>
<li>Gå til registreringssiden og fyll inn de nødvendige feltene.</li>
<li>Bekreft e‑postadressen ved å klikke på lenken du får i innboksen.</li>
<li>Logg inn på kontoen og sjekk «Bonuser»-fanen for å aktivere din gratis bonus.</li>
<li>Fullfør eventuell KYC‑verifisering før du kan ta ut eventuelle gevinster.</li>
</ul>
<p>Etter at du har aktivert bonusen, vil pengene eller gratisspinnene være tilgjengelige i spillkontoen din med en gang. Du kan umiddelbart begynne å spille på utvalgte slots eller live casino‑bord som er merket som «bonusgodkjente». </p>
<h2>Bonusvilkår: omsetningskrav og spillbegrensninger</h2>
<p>Selv om no‑deposit bonusen er gratis, kommer den med noen betingelser som du må oppfylle før du kan ta ut gevinster. Det viktigste er omsetningskravet, som vanligvis er mellom 20x og 30x bonusbeløpet. Dette betyr at du må satse bonusbeløpet et visst antall ganger i kvalifiserte spill før uttak er mulig.</p>
<h3>Forstå omsetningskrav</h3>
<p>Omsetningskrav beregnes kun på bonusbeløpet, ikke på innskuddet ditt. Dersom du får 20 kr i no‑deposit bonus med et 25x omsetningskrav, må du satse for totalt 500 kr i kvalifiserte spill før du kan be om en uttak. Spill med høy RTP og lav volatilitet er ofte best egnet for å møte kravene uten å tape for mye.</p>
<p>Det er også vanlig at maksimalt uttak fra en no‑deposit bonus er begrenset, ofte til 100 kr. Dette gjør at du kan teste kasinoet, men store gevinster krever et eget innskudd.</p>
<h2>Betalingsmetoder og uttakshastighet i Norge</h2>
<p>Big Lucky Casino støtter flere betalingsalternativer som er populære blant norske spillere. Du kan bruke bankkort, e‑wallet‑tjenester og direkte bankoverføring. For innskudd er behandlingstiden som regel umiddelbar, mens uttak kan ta fra noen timer til én virkedag avhengig av metode.</p>
<h3>Innskudd og uttak uten bonus</h3>
<p>Hvis du velger å fortsette å spille etter no‑deposit bonussen, vil du kunne sette inn penger med de samme metodene. De mest brukte betalingsløsningene i Norge er:</p>
<ul>
<li>Visa og MasterCard</li>
<li>Trustly – direkte fra nettbank</li>
<li>Skrill og Neteller</li>
<li>Vipps (kun for innskudd)</li>
</ul>
<p>Uttak behandles først etter at KYC‑verifiseringen er fullført. Når alt er i orden, kan du forvente at penger på din foretrukne e‑wallet er tilgjengelige innen 24 timer.</p>
<h2>Spillutvalg: live casino, slots og mer du kan prøve med bonusen</h2>
<p>Big Lucky Casino har et bredt spekter av spill som er tilgjengelige for no‑deposit bonusen. Slots med høy RTP og moderate volatilitet er ofte best egnet for å oppfylle omsetningskravene. Eksempler på populære titler er “Starburst”, “Gonzo’s Quest” og “Book of Dead”.</p>
<p>Live casino‑delen tilbyr bordspill som blackjack, roulette og baccarat med ekte dealere. Disse spillene er også bonusgodkjente, men husk at noen bordspill har lavere bidrag til omsetningskravene enn slots. Det er lurt å sjekke bonustabellen for å se hvilke spill som teller mest.</p>
<h2>Mobilapp og nettspill: spiller du på telefonen?</h2>
<p>For spillere som foretrekker å spille på farten, tilbyr Big Lucky Casino en mobiloptimalisert nettside og en dedikert app for både iOS og Android. Appen gir rask tilgang til slots, live casino og sportsbetting, samt muligheten til å sjekke bonusstatus og foreta innskudd med et par trykk.</p>
<p>Last ned appen her: <a href="https://biglucky-casinos.com/app">https://biglucky-casinos.com/app</a>. Appen er designet med norsk språkstøtte og har samme sikkerhetsnivå som desktop‑versjonen, så du kan spille trygt uansett hvor du er.</p>
<h2>Kundeservice, sikkerhet og lisensiering</h2>
<p>Big Lucky Casino er lisensiert av Malta Gaming Authority, som stiller strenge krav til spillersikkerhet og rettferdig spill. Kasinoet bruker SSL‑kryptering for å beskytte all personlig og økonomisk informasjon. Dette betyr at dataene dine er trygge både ved innskudd og ved uttak.</p>
<p>Kundeservice er tilgjengelig 24/7 via live chat og e‑post. Supportteamet kan svare på spørsmål om bonusvilkår, KYC‑prosessen og tekniske problemer. For norske spillere er det også mulig å kontakte support på norsk, noe som gjør kommunikasjonen enklere.</p>
<h2>Ansvarlig spill: hvordan holde kontrollen</h2>
<p>Ingen‑deposit bonuser er ment for underholdning, men det er viktig å spille ansvarlig. Big Lucky Casino tilbyr verktøy som innskuddsgrenser, tapsgrenser og mulighet for selv‑udelukkelse. Du kan sette daglige, ukentlige eller månedlige grenser direkte i kontoinnstillingene.</p>
<p>Hvis du føler at spillingen begynner å påvirke økonomien eller hverdagen din, bør du ta en pause og eventuelt kontakte Norsk Hjelpelinje for spillere med problemer. Å ha en klar plan før du begynner å spille med bonusen gjør opplevelsen både tryggere og mer fornøyelig.</p>
<h2>Oppsummering og siste tips</h2>
<p>Big Lucky Casino sin no‑deposit bonus gir norske spillere en enkel måte å prøve ut kasinoet uten å risikere egne penger. Ved å følge registreringsstegene, forstå omsetningskravene og bruke egnede betalingsmetoder, kan du maksimere sjansene for å konvertere gratispenger til ekte gevinster. Husk å spille ansvarlig og utnytte tilgjengelige verktøy for å holde kontrollen.</p>
<p>Et siste praktisk råd: før du gjør ditt første innskudd, test spillene med bonusen for å finne ut hvilke som passer din spillstil best. Når du har funnet favorittene, kan du vurdere å sette inn et beløp som gir deg mest mulig verdi i forhold til omsetningskrav og uttakshastighet.</p>
<h2>Bonusvilkår i en tabell</h2>
<p>                <</p>
<table border="1" cellpadding="5" cellspacing="0">
<thead>
<tr>
<th>Bonus</th>
<th>Omsetningskrav</th>
<th>Maks uttak</th>
<th>Gyldige spill</th>
<th>Gyldighet</th>
</tr>
</thead>
<tbody>
<tr>
<td>20 kr no‑deposit</td>
<td>25x (500 kr)</td>
<td>100 kr</td>
<td>Slots, live casino</td>
<td>7 dager</td>
</tr>
<tr>
<td>30 kr no‑deposit</td>
</tr>
</tbody>
</table>
<p>The post <a href="https://www.pharmaceutical-business-review.com/uncategorized/big-lucky-casino-no-deposit-bonus-guide-til-app-og-mobil/">Big Lucky Casino no deposit bonus – guide til app og mobil</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Big Lucky Casino app – registreringstrinn for norske spillere</title>
<link>https://edusehat.com/en/big-lucky-casino-app-registreringstrinn-for-norske-spillere</link>
<guid>https://edusehat.com/en/big-lucky-casino-app-registreringstrinn-for-norske-spillere</guid>
<description><![CDATA[ Big Lucky Casino app – den komplette veiledningen for norske spillere Registrering og komme i gang med Big Lucky Casino app Den første steget mot en trygg og 
The post Big Lucky Casino app – registreringstrinn for norske spillere appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/Z14fR2vd9tQ/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 07:00:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Big, Lucky, Casino, app, –, registreringstrinn, for, norske, spillere</media:keywords>
<content:encoded><![CDATA[<figure data-affgun-media="hero"><img decoding="async" src="https://i.ytimg.com/vi/Z14fR2vd9tQ/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<article>
<h1>Big Lucky Casino app – den komplette veiledningen for norske spillere</h1>
<section>
<h2>Registrering og komme i gang med Big Lucky Casino app</h2>
<div data-affgun-media="video"></div>
<p>Den første steget mot en trygg og underholdende spillopplevelse er å laste ned og installere Big Lucky Casino app på din smarttelefon eller nettbrett. Registreringsprosessen er designet for å være rask – du fyller inn e‑post, velger et passord og bekrefter kontoen med en kode sendt til innboksen. Når du har logget inn, blir du bedt om å oppgi grunnleggende informasjon som navn, fødselsdato og adresse for å oppfylle KYC‑kravene i Norge. Husk at du kan bruke både norske kort og lokale bankoverføringer som betalingsalternativer, noe som gjør innskudd enkelt og raskt. Etter at kontoen er verifisert, er du klar til å utforske appens spillbibliotek og benytte deg av velkomstbonusen.</p>
<p>For de som ønsker å hoppe rett inn i handlingen, kan du laste ned appen via denne lenken: <a href="https://bigluckycasino-norway.com/app">https://bigluckycasino-norway.com/app</a>. Når du har installert, åpner du appen og følger de tydelige instruksjonene på skjermen – det er lite som kan gå galt. Skulle du støte på problemer under registreringen, finnes det en detaljert FAQ i appen og et chat‑vindu som er åpent døgnet rundt. Det viktigste er at du setter deg inn i vilkårene for bonus og innskudd før du begynner å spille, slik at du unngår overraskelser senere. Så ta deg tid til å fullføre prosessen nøye, og du vil snart være klar for både slots og live casino.</p>
</section>
<section>
<h2>Bonus og velkomsttilbud – hva du får og hvordan du bruker dem</h2>
<p>Big Lucky Casino app kaster deg rett i en verden av generøse bonuser. Som ny spiller får du en velkomstpakke som ofte består av en 100 % innskuddsbonus opp til 2 000 kr, pluss noen gratis spinn på utvalgte spilleautomater. For å aktivere bonusen må du først foreta et første innskudd på minimum 200 kr og deretter oppgi bonuskoden som vises i appen. Når bonussaldoen er kreditert, vil du se både bonusbeløpet og antall gratis spinn i kontomenyen.</p>
<p>Viktig å merke seg er <strong>wagering requirements</strong> – vanligvis 30x bonusbeløpet før du kan ta ut gevinstene. Dette betyr at du må satse 60 000 kr i spill før uttak er mulig, men mange av spillene i appen har høy RTP som gjør dette oppnåelig. Bonusvilkårene kan også inneholde restriksjoner på hvilke spill som teller mot omsetningskravet; slots er som regel 100 % med, mens bordspill ofte teller kun 10 %. Sørg for å lese bonusvilkårene nøye i appens vilkår‑ og betingelser‑seksjon før du spiller videre.</p>
</section>
<section>
<h2>Betalingsmetoder og uttaksprosessen i appen</h2>
<p>Big Lucky Casino app støtter en rekke populære norske betalingsalternativer. Du kan sette inn penger med Visa, MasterCard, BankAxept, Trustly eller e‑wallets som Skrill og Neteller. Minsteinnskuddet er vanligvis 100 kr, og de fleste innskudd blir behandlet umiddelbart, slik at du kan begynne å spille med ett trykk.</p>
<p>Uttak er like enkelt, men krever at du har fullført KYC‑verifiseringen med dokumentasjon som legitimasjon og adressebevis. Når du har valgt ønsket uttaksmetode, blir de fleste forespørsler behandlet innen 24 timer – kredittkort og e‑wallets er spesielt raske. Nedbetalinger til bankkonto kan ta 2–3 virkedager, avhengig av din bank. Se tabellen nedenfor for en oversikt over de vanligste betalingsmetodene og behandlingstidene.</p>
<table border="1" cellpadding="5" cellspacing="0">
<thead>
<tr>
<th>Metode</th>
<th>Minsteinnskudd</th>
<th>Behandlingstid (innskudd)</th>
<th>Behandlingstid (uttak)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visa / MasterCard</td>
<td>100 kr</td>
<td>Øyeblikkelig</td>
<td>1‑2 dager</td>
</tr>
<tr>
<td>BankAxept</td>
<td>200 kr</td>
<td>Øyeblikkelig</td>
<td>2‑3 dager</td>
</tr>
<tr>
<td>Skrill</td>
<td>100 kr</td>
<td>30 sekunder</td>
<td>1 dag</td>
</tr>
<tr>
<td>Neteller</td>
<td>100 kr</td>
<td>30 sekunder</td>
<td>1 dag</td>
</tr>
<tr>
<td>Trustly</td>
<td>200 kr</td>
<td>Øyeblikkelig</td>
<td>1‑2 dager</td>
</tr>
</tbody>
</table>
</section>
<section>
<h2>Spillutvalg: spilleautomater, live casino og sportsbetting i appen</h2>
<p>Appens spillbibliotek er omfattende og dekker både klassiske og moderne spilleautomater. Her finner du høy‑RTP‑spill som <em>Starburst</em> og <em>Gonzo’s Quest</em>, samt høy‑volatilitet slots som <em>Book of Dead</em> for de som liker adrenalinfylte runder. Hver slot har tydelige informasjon om RTP, volatilitet og maksimal gevinst, noe som gjør det lett å velge riktig spill.</p>
<p>I tillegg til slots, tilbyr Big Lucky Casino app et levende live casino med ekte dealer‑bord som blackjack, roulette og baccarat. Streaming er i HD‑kvalitet og du kan bytte mellom bordene med et enkelt trykk. For sportsfans finnes det også en integrert sportsbook‑modul hvor du kan satse på fotball, håndball og vinteridrett – alt fra norsk Eliteserien til internasjonale turneringer.</p>
</section>
<section>
<h2>Sikkerhet, lisens og ansvarlig spill på Big Lucky Casino</h2>
<p>Big Lucky Casino app opererer under en gyldig Malta Gaming Authority‑lisens, som gir en høy standard for rettferdighet og spillerbeskyttelse. All kommunikasjon mellom din enhet og serverne er kryptert med 128‑bits SSL‑teknologi, slik at personlige data og finansielle transaksjoner er sikre.</p>
<p>Ansvarlig spill er integrert i appen med verktøy som innskuddsgrenser, tap‑grense og muligheten til å sette seg selv på selvutelukkelse. Du kan også finne lenker til nasjonale spillemyndigheter og rådgivningstjenester direkte i innstillingsmenyen. Disse tiltakene gir deg kontroll over spillvanene dine, uten at det går på bekostning av underholdningen.</p>
</section>
<section>
<h2>Kundeservice og support – hvordan få hjelp når du spiller</h2>
<p>Supportteamet i Big Lucky Casino app er tilgjengelig via live‑chat, e‑post og telefon døgnet rundt. Når du åpner chat‑vinduet, vil du umiddelbart bli matchet med en norsk‑snakkende rådgiver som kan veilede deg gjennom alt fra innskuddsspørsmål til bonusvilkår. E‑post‑support svarer vanligvis innen 24 timer, og du kan forvente en høflig og grundig tilbakemelding.</p>
<p>Det finnes også en omfattende kunnskapsbase med artikler om registrering, verifisering, spillregler og tekniske problemer. Hvis du har spørsmål om sikkerhet eller ansvarlig spill, er supportpersonalets kompetanse nøye trent for å gi klare svar. Å ha flere kontaktalternativer gjør at du raskt kan løse eventuelle utfordringer uten å avbryte spillopplevelsen.</p>
</section>
<section>
<h2>Mobilopplevelse: Appens funksjoner og ytelse på norske enheter</h2>
<p>Big Lucky Casino app er optimalisert for både iOS‑ og Android‑plattformer, med en responsiv design som tilpasser seg skjermstørrelsen på din telefon eller nettbrett. Lastetiden er kort, og du kan navigere mellom spillkategorier med kun ett trykk. Appen støtter push‑varsler, slik at du får umiddelbare oppdateringer om kampanjer, innskuddsbonuser og turneringer.</p>
<p>Ytelsen i spill er jevn, med minimal latency selv på slot‑spill med avanserte animasjoner. Live casino‑streamene lastes raskt og justerer automatisk kvaliteten etter din nettverkshastighet. Du kan også sette opp favorittspill i en personlig spilleliste for rask tilgang, noe som gjør appen både brukervennlig og effektiv for spillere på farten.</p>
</section>
<section>
<h2>Vanlige spørsmål og feilsøking</h2>
<h3>Jeg får ikke til å verifisere kontoen min – hva gjør jeg?</h3>
<p>Kontroller at dokumentene du laster opp er tydelige og i støttet format (PDF, JPG eller PNG). Pass på at alle fire kantene av ID‑kortet er synlige, og at navnet på dokumentet matcher nøyaktig det du har oppgitt i profilen. Hvis du fortsatt opplever problemer, kan du kontakte support via live‑chat for rask assistanse.</p>
<h3>Hvor raskt kan jeg trekke ut gevinster fra bonusen?</h3>
<p>Etter at du har oppfylt wagering‑kravene på 30x bonusbeløpet, kan du sende inn en uttaksforespørsel. Innen 24 timer vil supportteamet verifisere uttaket, og pengene vil vanligvis være på kontoen din innen 1‑2 virkedager, avhengig av hvilken betalingsmetode du har valgt.</p>
<h3>Er det noen ekstra kostnader ved innskudd eller uttak?</h3>
<p>Big Lucky Casino app tar ingen gebyrer for innskudd med de fleste betalingsmetodene. Noen e‑wallet-tjenester kan ha egne transaksjonskostnader, men dette blir tydelig oppgitt før du bekrefter innskuddet. Uttak er også gratis for de fleste metoder, med unntak av noen bankoverføringer der din egen bank eventuelt kan belaste et mindre gebyr.</p>
</section>
</article>
<p>The post <a href="https://www.pharmaceutical-business-review.com/uncategorized/big-lucky-casino-app-registreringstrinn-for-norske-spillere/">Big Lucky Casino app – registreringstrinn for norske spillere</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Verde Casino download – komplett bonusguide og nedlastingsguide for norske spillere</title>
<link>https://edusehat.com/en/verde-casino-download-komplett-bonusguide-og-nedlastingsguide-for-norske-spillere</link>
<guid>https://edusehat.com/en/verde-casino-download-komplett-bonusguide-og-nedlastingsguide-for-norske-spillere</guid>
<description><![CDATA[ Verde Casino – Praktisk guide til Verde Casino download Hvorfor velge Verde Casino? Verde Casino har raskt blitt et av de mest populære nettcasinoene blant norske spillere. Med 
The post Verde Casino download – komplett bonusguide og nedlastingsguide for norske spillere appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/V3hZ93cVdCc/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 07:00:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Verde, Casino, download, –, komplett, bonusguide, nedlastingsguide, for, norske, spillere</media:keywords>
<content:encoded><![CDATA[<figure data-affgun-media="hero"><img decoding="async" src="https://i.ytimg.com/vi/V3hZ93cVdCc/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<header>
<h1>Verde Casino – Praktisk guide til Verde Casino download</h1>
</header>
<section>
<h2>Hvorfor velge Verde Casino?</h2>
<div data-affgun-media="video"></div>
<p>Verde Casino har raskt blitt et av de mest populære nettcasinoene blant norske spillere. Med en lisens fra Malta Gaming Authority kan du stole på rettferdig spill og høy sikkerhet. Utvalget spenner fra klassiske spilleautomater til et omfattende live casino og sports betting‑seksjon, så det finnes noe for både nybegynnere og erfarne high rollers. Plattformen er også optimalisert for mobilbruk, noe som gjør at du kan spille både på PC og på smarttelefonen uten forsinkelse.</p>
<p>Et annet stort trekkplaster er de generøse velkomstbonusene, men også løpende kampanjer som gir ekstra kreditter eller gratis spinn. Når du først har gjort en innsats, vil du oppdage at uttakshastigheten er imponerende – ofte innen 24 timer for vanlige betalingsmetoder. Alt i alt gir Verde Casino en komplett spillopplevelse som er både brukervennlig og pålitelig.</p>
</section>
<section>
<h2>Slik laster du ned Verde Casino-appen – steg for steg</h2>
<p>Først og fremst må du besøke den offisielle nedlastingssiden for Verde Casino. På siden finner du en tydelig knapp merket “Last ned appen”. Når du klikker på den, starter nedlastingen automatisk for Android‑ eller iOS‑enheter, avhengig av hvilken plattform du bruker.</p>
<p>Etter at filen er lastet ned, åpner du installasjonsfilen og følger instruksjonene på skjermen. På Android må du kanskje tillate installasjon fra “ukjente kilder”, mens iOS‑brukere vil bli omdirigert til App Store for en sikker installasjon. Når appen er installert, åpner du den, godtar vilkårene og logger inn med din konto. For første gang kan du også dra nytte av et eksklusivt mobilbonus‑tilbud.</p>
<p>Hvis du foretrekker å spille i nettleseren i stedet for appen, er det også mulig å bruke Verde Casino direkte på www.verdecassino-no.com – men for den beste ytelsen anbefaler vi nedlastingen. Last ned appen her: <a href="https://verdecassino-no.com/app">https://verdecassino-no.com/app</a>.</p>
</section>
<section>
<h2>Registrering og verifisering – steg for steg</h2>
<p>Registreringsprosessen hos Verde Casino er enkel og tar kun noen minutter. Klikk på “Registrer” øverst på siden, fyll inn e‑postadresse, ønsket brukernavn og et sterkt passord. Du vil deretter bli bedt om å velge valuta – NOK er tilgjengelig, noe som gjør innskudd og uttak enklere for norske spillere.</p>
<p>Etter at kontoen er opprettet, må du gjennomføre KYC‑verifisering. Dette innebærer at du laster opp en kopi av gyldig ID (for eksempel pass eller førerkort) samt et bevis på adresse, som en strømregning eller kontoutskrift. Verifiseringen er vanligvis fullført innen én virkedag, og du kan da begynne å sette inn penger og benytte deg av bonuser.</p>
<p>Det kan også være lurt å sette opp to‑faktor‑autentisering (2FA) i kontoinnstillingene for ekstra sikkerhet. Verde Casino tilbyr dette som en gratis funksjon, og det gjør at du får et ekstra lag av beskyttelse mot uautorisert tilgang.</p>
</section>
<section>
<h2>Bonuser og vilkår – hva du får ved første innskudd</h2>
<p>Nyankomne spillere blir møtt med en velkomstpakke som vanligvis består av 100% matchbonus på første innskudd, opptil 2 000 NOK, pluss 100 gratis spinn på utvalgte spilleautomater. Bonusen er underlagt en rimelig omsetningskrav på 30x bonusbeløpet, noe som er standard i bransjen.</p>
<p>Etter den første innskuddsbonusen kan du også benytte deg av ukentlige kampanjer, som “Cashback Tuesday” eller “Free Spin Friday”. Disse kampanjene gir ekstra penger eller spinn uten ekstra innskudd, men husk alltid å lese de små skriftene – noen bonuser gjelder kun på bestemte spill eller har tidsbegrensninger.</p>
<p>For å aktivere en bonus, går du inn i kampanje‑menyen etter innskuddet og klikker på “Claim”. Bonusen vil da bli kreditert umiddelbart, og du kan begynne å spille med en gang.</p>
</section>
<section>
<h2>Betalingsmetoder og uttakshastighet</h2>
<p>Verde Casino støtter en rekke populære innskuddsmetoder for norske spillere. Du kan bruke Visa, Mastercard, Skrill, Neteller, og direkte bankoverføring via Trustly. Minimum innskudd er 100 NOK, og de fleste metoder behandler transaksjoner i løpet av noen sekunder.</p>
<p>Uttak er like enkelt: gå til kassen, velg “Uttak”, og angi beløpet du ønsker å ta ut. Minimum uttak er 200 NOK. De vanligste uttaksmetodene (Skrill, Neteller, Trustly) har en typisk behandlingstid på 1–2 virkedager, mens bankoverføring kan ta opptil 3 dager. Alle uttak blir grundig sjekket for å sikre at kontoen er verifisert før midlene blir overført.</p>
<table>
<thead>
<tr>
<th>Metode</th>
<th>Minimum innskudd</th>
<th>Uttakstid</th>
<th>Avgift</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visa / Mastercard</td>
<td>100 NOK</td>
<td>1–2 dager</td>
<td>Ingen</td>
</tr>
<tr>
<td>Skrill</td>
<td>100 NOK</td>
<td>1 dag</td>
<td>Ingen</td>
</tr>
<tr>
<td>Neteller</td>
<td>100 NOK</td>
<td>1 dag</td>
<td>Ingen</td>
</tr>
<tr>
<td>Trustly (bank)</td>
<td>100 NOK</td>
<td>1–2 dager</td>
<td>Ingen</td>
</tr>
</tbody>
</table>
</section>
<section>
<h2>Live casino og sports betting – spillopplevelsen</h2>
<p>Live casino‑delen i Verde Casino tilbyr ekte dealere som strømmer spill i HD‑kvalitet. Du kan velge mellom klassikere som Blackjack, Roulette og Baccarat, samt spesialspill som Dream Catcher. All interaksjon skjer i sanntid, og du kan chatte med dealeren for en mer personlig opplevelse.</p>
<p>Sports betting‑plattformen dekker alt fra fotball og håndball til tennis og e‑sports. Oddsene oppdateres i sanntid, og du kan plassere både enkeltspill og kombinasjonsspill. For nybegynnere finnes det også en “Bet Builder” som hjelper deg å sette sammen spill basert på lagstatistikk og formkurver.</p>
<p>Begge seksjonene er tilgjengelige via mobilappen, så du kan satse eller spille mens du er på farten. Live‑streaming er optimalisert for både Wi‑Fi og mobildata, slik at du unngår buffering og kan fokusere på spillet.</p>
</section>
<section>
<h2>Sikkerhet, lisens og ansvarlig spill</h2>
<p>Verde Casino er lisensiert av Malta Gaming Authority, en av de mest anerkjente reguleringsmyndighetene i EU. Dette betyr at casinoet må følge strenge retningslinjer for spillersikkerhet, rettferdighet og beskyttelse av personopplysninger. Alle transaksjoner krypteres med 128‑bit SSL‑teknologi, som er samme standard som brukes av store banker.</p>
<p>Ansvarlig spill er en viktig del av Verde Casinos politikk. På siden finner du verktøy for å sette innskuddsgrenser, tapsgrenser og tidsbegrensninger. Dersom du føler at spillingen blir et problem, kan du kontakte kundeservice for å sette en selvutelukkelsesperiode, eller du kan benytte deg av nasjonale hjelpelinjer som Hjelpelinjen for spillavhengige.</p>
<p>Kundeservice er tilgjengelig 24/7 via live‑chat, e‑post og telefon. Support‑teamet snakker både norsk og engelsk, og de er trente i å håndtere både tekniske og ansvarlig‑spill‑spørsmål.</p>
</section>
<section>
<h2>Ofte stilte spørsmål om Verde Casino download</h2>
<ul>
<li><strong>Kan jeg bruke Verde Casino uten å laste ned appen?</strong> Ja, du kan spille direkte i nettleseren, men appen gir raskere lasting og push‑varsler om kampanjer.</li>
<li><strong>Er Verde Casino tilgjengelig på både Android og iOS?</strong> Ja, begge operativsystemene støttes fullt ut, og oppdateringer skjer automatisk.</li>
<li><strong>Hvor lang tid tar det å verifisere kontoen?</strong> Vanligvis innen én virkedag, men kan ta lengre tid ved høyt volum av dokumenter.</li>
<li><strong>Finnes det norske kundeservicemedarbeidere?</strong> Ja, både chat og e‑post betjenes av norsktalende agenter.</li>
<li><strong>Hva er minimumsinnsatsen i live casino?</strong> De fleste bordspill starter fra 10 NOK per hånd.</li>
</ul>
</section>
<footer></footer>
<p>The post <a href="https://www.pharmaceutical-business-review.com/uncategorized/verde-casino-download-komplett-bonusguide-og-nedlastingsguide-for-norske-spillere/">Verde Casino download – komplett bonusguide og nedlastingsguide for norske spillere</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>biglucky casino review – komplett guide for norske spillere</title>
<link>https://edusehat.com/en/biglucky-casino-review-komplett-guide-for-norske-spillere</link>
<guid>https://edusehat.com/en/biglucky-casino-review-komplett-guide-for-norske-spillere</guid>
<description><![CDATA[ Big Lucky Casino – en grundig biglucky casino review Her får du en praktisk veiledning om alt du trenger å vite før du setter deg ved Big Lucky 
The post biglucky casino review – komplett guide for norske spillere appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/BvhxGf05pg4/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 07:00:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>biglucky, casino, review, –, komplett, guide, for, norske, spillere</media:keywords>
<content:encoded><![CDATA[<figure data-affgun-media="hero"><img decoding="async" src="https://i.ytimg.com/vi/BvhxGf05pg4/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<h1>Big Lucky Casino – en grundig biglucky casino review</h1>
<p>Her får du en praktisk veiledning om alt du trenger å vite før du setter deg ved Big Lucky Casino. Artiklen er laget for norske spillere som vil vurdere om dette casinoet er rett for dem, med fokus på bonuser, betalingsmetoder, spillutvalg, mobilopplevelse og sikkerhet.</p>
<h2>Registrering og første steg</h2>
<div data-affgun-media="video"></div>
<p>For å komme i gang med Big Lucky Casino, starter du med en rask registreringsprosedyre. Du fyller inn e‑post, løsenord og noen personlige opplysninger. Systemet validerer e‑posten umiddelbart, så du kan logge inn på minutter.</p>
<p>Etter innlogging blir du bedt om å gjennomføre KYC‑verifisering. Dette innebærer opplasting av legitimasjon og bevis på adresse – standard prosedyre for lisensierte nettcasinoer. Verifiseringen tar vanligvis 24–48 timer, men du kan ofte spille med begrensede innskudd før den er fullført.</p>
<h2>Bonus og kampanjer</h2>
<p>Big Lucky Casino lokker nye spillere med en solid velkomstbonus. Første innskudd gir 100 % bonus opptil 1 000 kr, pluss 200 gratis spinn på utvalgte spilleautomater. Bonussjansen er attraktiv, men husk alltid å sjekke omsetningskravene.</p>
<p>Omsetningskravene er på 35× bonusbeløpet, noe som er i snitt for norske nettkasinoer. Bonusen er tilgjengelig kun på spill med RTP over 96 % og medium til høy volatilitet. Merk også at gratis spinn har en egen omsetningskrav på 30× gevinst.</p>
<ul>
<li>Velkomstbonus: 100 % opptil 1 000 kr + 200 spinn</li>
<li>Omsetningskrav: 35× bonus, 30× spinn</li>
<li>Gyldig for spill med RTP ≥ 96 %</li>
<li>Bonusperiode: 7 dager fra innskudd</li>
</ul>
<h2>Spillutvalg – automater, live casino og sportsbetting</h2>
<p>Casinoet har et bredt spekter av spill fra ledende leverandører som NetEnt, Microgaming og Evolution Gaming. Du finner alt fra klassiske enarmede banditter til moderne Video‑Slots med progressive jackpot.</p>
<p>Live casino‑delen inkluderer ekte dealere for blackjack, roulette og baccarat, noe som gir en autentisk casinofølelse. Sportsbetting‑modulen er også integrert, med odds på fotball, håndball og andre populære sportsgrener i Norge.</p>
<table border="1" cellpadding="5" cellspacing="0">
<caption>Et utvalg av spill og nøkkeltall</caption>
<tbody>
<tr>
<th>Spilltype</th>
<th>Leverandør</th>
<th>RTP</th>
<th>Volatilitet</th>
</tr>
<tr>
<td>Starburst</td>
<td>NetEnt</td>
<td>96,1 %</td>
<td>Lav</td>
</tr>
<tr>
<td>Immortal Romance</td>
<td>Microgaming</td>
<td>96,6 %</td>
<td>Medium</td>
</tr>
<tr>
<td>Live Blackjack</td>
<td>Evolution Gaming</td>
<td>99,5 %</td>
<td>Lav</td>
</tr>
<tr>
<td>Football Betting</td>
<td>BetConstruct</td>
<td>Varierer</td>
<td>Varierer</td>
</tr>
</tbody>
</table>
<h2>Betalingsmetoder og uttak</h2>
<p>Big Lucky Casino støtter flere populære betalingsalternativer for norske spillere. Du kan bruke vanlige bankkort som Visa og Mastercard, samt e‑betalingsløsninger som Neteller, Skrill og Trustly.</p>
<p>Uttak behandles vanligvis innen 24 timer for e‑wallets, mens bankkort kan ta 3–5 arbeidsdager. Alle transaksjoner er kryptert med 128‑bit SSL, så du kan føle deg trygg på at pengene dine er sikre.</p>
<table border="1" cellpadding="5" cellspacing="0">
<caption>Betalingsmetoder og behandlingstid</caption>
<tbody>
<tr>
<th>Metode</th>
<th>Innskudd</th>
<th>Uttak</th>
<th>Behandlingstid</th>
</tr>
<tr>
<td>Visa / Mastercard</td>
<td>Umiddelbart</td>
<td>Ja</td>
<td>3–5 dager</td>
</tr>
<tr>
<td>Trustly</td>
<td>Umiddelbart</td>
<td>Ja</td>
<td>Innen 24 timer</td>
</tr>
<tr>
<td>Neteller</td>
<td>Umiddelbart</td>
<td>Ja</td>
<td>Innen 24 timer</td>
</tr>
<tr>
<td>Skrill</td>
<td>Umiddelbart</td>
<td>Ja</td>
<td>Innen 24 timer</td>
</tr>
</tbody>
</table>
<ul>
<li>Minste innskudd: 100 kr</li>
<li>Maks uttak per transaksjon: 20 000 kr</li>
<li>Gebyrer: Ingen på de fleste metoder</li>
</ul>
<h2>Mobilopplevelse og app</h2>
<p>Casinoet er optimalisert for både Android og iOS, og du kan spille direkte i nettleseren uten nedlasting. For de som foretrekker en dedikert app, har Big Lucky en mobilapp med samme funksjonalitet som desktop‑versjonen.</p>
<p>Appen gir rask tilgang til bonuser, live casino og sportsbetting, samt push‑varsler om nye kampanjer. Last ned mobilappen her: <a href="https://big-lucky-casinos.com/app">https://big-lucky-casinos.com/app</a>. Appen er bygget med samme sikkerhetsstandarder som nettsiden.</p>
<h2>Kundeservice og sikkerhet</h2>
<p>Kundeservice er tilgjengelig 24/7 via live‑chat og e‑post. Supportteamet svarer vanligvis innen noen minutter på chat, og innen én time på e‑post. De kan hjelpe med alt fra konto‑spørsmål til betalingsproblemer.</p>
<p>Sikkerheten er ivaretatt gjennom en lisens fra Malta Gaming Authority (MGA), som garanterer rettferdig spill og beskyttelse av personopplysninger. Casinoet bruker også regelmessige tredjepartsrevisjoner for å verifisere spillintegriteten.</p>
<ul>
<li>Live‑chat: 24/7</li>
<li>E‑post: support@bigluckycasino.com</li>
<li>Lisens: MGA (Malta Gaming Authority)</li>
<li>Sikkerhet: SSL‑kryptering, regelmessige revisjoner</li>
</ul>
<h2>Ansvarlig spilling og lisens</h2>
<p>Big</p>
<p>The post <a href="https://www.pharmaceutical-business-review.com/uncategorized/biglucky-casino-review-komplett-guide-for-norske-spillere/">biglucky casino review – komplett guide for norske spillere</a> appeared first on <a href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>NPPA revises MRPs of 543 brands of anti&#45;cancer medicines</title>
<link>https://edusehat.com/en/nppa-revises-mrps-of-543-brands-of-anti-cancer-medicines</link>
<guid>https://edusehat.com/en/nppa-revises-mrps-of-543-brands-of-anti-cancer-medicines</guid>
<description><![CDATA[ 
Revised prices will come into effect from November 9, 2026, following trade margin rationalisation of 137 non-scheduled anti-cancer drugs
The post NPPA revises MRPs of 543 brands of anti-cancer medicines appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2018/11/20154710/cancer-ThinkstockPhotos-490575333-e1545048577610.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 16:15:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>NPPA, revises, MRPs, 543, brands, anti-cancer, medicines</media:keywords>
<content:encoded><![CDATA[<div><img width="600" height="354" src="https://cdn.expresspharma.in/wp-content/uploads/2018/11/20154710/cancer-ThinkstockPhotos-490575333-e1545048577610.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2018/11/20154710/cancer-ThinkstockPhotos-490575333-e1545048577610.jpg 600w, https://cdn.expresspharma.in/wp-content/uploads/2018/11/20154710/cancer-ThinkstockPhotos-490575333-e1545048577610-300x177.jpg 300w" sizes="auto, (max-width: 600px) 100vw, 600px"></div><p><span>The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, has released a list of 543 brands of anti-cancer medicines with revised Maximum Retail Prices (MRPs). The revised MRPs will come into effect from November 9, 2026.</span></p>
<p><span>The revised price list reflects information submitted by companies up to October 27, 2026. It will be updated as and when manufacturers submit revised prices for non-scheduled anti-cancer drugs.</span></p>
<p><span>The complete list of 543 brands of anti-cancer medicines with revised MRPs is available on the</span><a href="https://nppa.gov.in/en"> <span>NPPA website</span></a><span>. The portal is updated on a continual basis.</span></p>
<p><span>On October 17, 2026, the NPPA announced Trade Margin Rationalisation (TMR) of 137 non-scheduled anti-cancer drugs in public interest to address excessive trade margins, make cancer treatment more affordable and improve access to anti-cancer medicines. Manufacturers were instructed to submit their revised price lists to the NPPA.</span></p>
<p><span>The 137 non-scheduled anti-cancer drugs include immunotherapy medicines used in the treatment of over 20 types of cancer, Denosumab used by breast and prostate cancer patients, Pegfilgrastim used to prevent neutropenia in cancer patients, and Bevacizumab, which is approved for the treatment of colon, ovarian and cervical cancers.</span></p>
<p>The post <a href="https://www.expresspharma.in/nppa-revises-mrps-of-543-brands-of-anti-cancer-medicines/">NPPA revises MRPs of 543 brands of anti-cancer medicines</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>DoP conducts 14,700 cleanliness drives under SCDPM 6.0</title>
<link>https://edusehat.com/en/dop-conducts-14700-cleanliness-drives-under-scdpm-60</link>
<guid>https://edusehat.com/en/dop-conducts-14700-cleanliness-drives-under-scdpm-60</guid>
<description><![CDATA[ 
The Department of Pharmaceuticals has reviewed 4,283 physical files and 20 e-files, weeded out 489 files and freed 2,200 square feet of office space during the campaign
The post DoP conducts 14,700 cleanliness drives under SCDPM 6.0 appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 16:15:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>DoP, conducts, 14, 700, cleanliness, drives, under, SCDPM, 6.0</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>The Department of Pharmaceuticals (DoP), Ministry of Chemicals and Fertilizers, is participating in the Special Campaign for Disposal of Pending Matters (SCDPM) 6.0, along with its attached office, the National Pharmaceutical Pricing Authority (NPPA), and its organisations. These include the seven National Institutes of Pharmaceutical Education and Research (NIPERs), the Pharmaceuticals & Medical Devices Bureau of India (PMBI), and three public sector undertakings (PSUs), namely Bengal Chemicals & Pharmaceuticals Limited (BCPL), Hindustan Antibiotics Limited (HAL) and Karnataka Antibiotics & Pharmaceuticals Limited (KAPL).</span></p>
<p><span>The campaign, being conducted from October 2 to October 31, 2026, focuses on cleanliness, scientific management and disposal of e-waste, record management, grievance redressal and utilisation of office space. It aims to enhance administrative efficiency and promote a clean, organised and productive work environment.</span></p>
<p><span>As part of field office outreach and sustainable workplace practices, 14,700 cleanliness drives have been conducted across field and outstation offices against a baseline target of 12,208. The campaign also aims to improve workplace hygiene and sanitation, strengthen environmental awareness and promote sustainable workplace practices.</span></p>
<p><span>Under record management and office space utilisation, the Department has reviewed 4,283 physical files and 20 e-files against baseline targets of 2,716 physical files and 20 e-files. A total of 489 files have been weeded out and closed. These efforts have also freed up 2,200 square feet of office space.</span></p>
<p><span>The campaign is also addressing pending matters, including Members of Parliament (MP) references, parliamentary assurances, Cabinet proposals, State references and Prime Minister’s Office (PMO) references. The Department has addressed three MP references against a target of four, one parliamentary assurance against a target of two, two Cabinet proposals, 57 State references against a target of 58, and two PMO cases.</span></p>
<p><span>Against targets of 72 public grievances and 28 appeals registered on the Centralised Public Grievance Redress and Monitoring System (CPGRAMS), 132 public grievance cases and 39 appeals have been settled. Of the 20 items identified for easing rules and processes, work has been completed on 17 items.</span></p>
<p><span>Scientific e-waste management is another focus area of SCDPM 6.0. The Department has targeted 1,011 obsolete electronic and electrical items, comprising IT equipment, consumer electronics, appliances and laboratory tools, for safe disposal through empanelled recyclers under the E-Waste (Management) Rules, 2022. The disposal process is underway.</span></p>
<p><span>The Department has also earned revenue of ₹2,30,187 from the disposal of office scrap. It remains committed to the objectives of SCDPM 6.0, monitoring targets and documenting achievements through the National Special Campaign Portal.</span></p>
<p>The post <a href="https://www.expresspharma.in/dop-conducts-14700-cleanliness-drives-under-scdpm-6-0/">DoP conducts 14,700 cleanliness drives under SCDPM 6.0</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Spektus Pharma, GEBRO partner to commercialise ActraFlex globally</title>
<link>https://edusehat.com/en/spektus-pharma-gebro-partner-to-commercialise-actraflex-globally</link>
<guid>https://edusehat.com/en/spektus-pharma-gebro-partner-to-commercialise-actraflex-globally</guid>
<description><![CDATA[ 
The partnership covers Europe, the Americas and selected Rest of World markets for the twice-daily extended-release tramadol and paracetamol formulation
The post Spektus Pharma, GEBRO partner to commercialise ActraFlex globally appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123851/Acquisition.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 16:15:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Spektus, Pharma, GEBRO, partner, commercialise, ActraFlex, globally</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123851/Acquisition.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123851/Acquisition.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123851/Acquisition-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Spektus Pharma and GEBRO Holding GmbH (GEBRO) have announced a global commercialisation partnership for ActraFlex, a twice-daily extended-release formulation of tramadol and paracetamol for pain management.</span></p>
<p><span>ActraFlex combines Spektus’ patented AmyloFlex drug-delivery platform technology with GEBRO’s Diliban tramadol/paracetamol product. The formulation is designed to provide sustained drug release with twice-daily dosing.</span></p>
<p><span>Under the partnership, GEBRO will lead commercialisation and supply across Europe and selected Rest of World (RoW) markets, with Spain serving as a key market, where Diliban has an established regulatory and commercial foundation. Spektus will lead commercialisation and supply across North America, South America and selected RoW markets through its network of regional commercialisation partners.</span></p>
<p><span>The partnership brings together GEBRO’s expertise and commercial presence in pain management with Spektus’ proprietary drug-delivery technology and global partnership network. The companies intend to use their capabilities and geographic reach to introduce ActraFlex across international markets.</span></p>
<p><span>“Our partnership with GEBRO highlights the potential of Spektus’ proprietary AmyloFlex technology to create differentiated specialty medicines from established products and brands. Building on GEBRO’s successful commercialization of Diliban in Europe, we see strong commercial potential for ActraFlex across the Americas and selected markets in Africa and Asia.” said Zarvaan Merchant, CEO of Spektus Pharma.</span></p>
<p><span>“GEBRO brings deep expertise in pain management and a strong foundation with Diliban in Europe. Together with Spektus’ established commercialisation partner network across the Americas and other international markets, we believe ActraFlex has the potential to become an important global product in pain management,” said Christian Kollenz, managing director of GEBRO Holding.</span></p>
<p><span>The agreement establishes a global commercialisation framework under which both companies will lead the regulatory and commercial introduction of ActraFlex in their respective territories, supported by a common product platform and shared global strategy.</span></p>
<p><span>Financial terms of the agreement were not disclosed.</span></p>
<p>The post <a href="https://www.expresspharma.in/spektus-pharma-gebro-partner-to-commercialise-actraflex-globally/">Spektus Pharma, GEBRO partner to commercialise ActraFlex globally</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Lilly’s retatrutide shows greater A1C reduction and weight loss than Ozempic in Phase 3 trial</title>
<link>https://edusehat.com/en/lillys-retatrutide-shows-greater-a1c-reduction-and-weight-loss-than-ozempic-in-phase-3-trial</link>
<guid>https://edusehat.com/en/lillys-retatrutide-shows-greater-a1c-reduction-and-weight-loss-than-ozempic-in-phase-3-trial</guid>
<description><![CDATA[ 
The TRANSCEND-T2D-2 trial found greater reductions in A1C, body weight and certain cardiovascular risk factors with retatrutide at 80 weeks
The post Lilly’s retatrutide shows greater A1C reduction and weight loss than Ozempic in Phase 3 trial appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2024/05/09110331/Weight-loss.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 16:15:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Lilly’s, retatrutide, shows, greater, A1C, reduction, and, weight, loss, than, Ozempic, Phase, trial</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2024/05/09110331/Weight-loss.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2024/05/09110331/Weight-loss.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2024/05/09110331/Weight-loss-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>Eli Lilly and Company has announced positive topline results from TRANSCEND-T2D-2, a head-to-head Phase 3 trial comparing retatrutide with injectable Ozempic 2 mg in adults with type 2 diabetes. At 80 weeks, retatrutide met the primary and all key secondary endpoints, delivering greater A1C reduction and weight loss than Ozempic.1,2</span></p>
<p><span>Kenneth Custer, Ph.D., Executive Vice President and President of Lilly Cardiometabolic Health, said, “Head-to-head trials show patients and physicians how a potential new medicine compares with treatments that are available and reimbursed today. In TRANSCEND-T2D-2, the first Phase 3 trial comparing retatrutide with another incretin medicine, retatrutide delivered greater A1C reduction and more than double the weight loss of the highest dose of Ozempic approved in the U.S. for type 2 diabetes. Based on these results and those from across our Phase 3 program, we believe retatrutide, if approved, could shift the treatment paradigm for people living with type 2 diabetes, obesity and related cardiometabolic conditions.”</span></p>
<p><span>In the TRANSCEND-T2D-2 trial, both doses of retatrutide reduced A1C by an average of 2.2 per cent, compared with 1.8 per cent with Ozempic at 80 weeks.</span></p>
<p><span>Participants taking retatrutide lost an average of 20.1 kg (19.5 per cent) with the 9 mg dose and 21.5 kg (20.9 per cent) with the 12 mg dose, compared with 9.5 kg (9.4 per cent) with Ozempic.</span></p>
<p><span>Retatrutide also delivered greater improvements than Ozempic in certain cardiovascular risk factors, including non-HDL cholesterol, triglycerides and systolic blood pressure.</span></p>
<p><span>The most common adverse events reported in the trial with retatrutide at 9 mg and 12 mg, respectively, compared with Ozempic, were diarrhoea (28.3 per cent and 32.7 per cent versus 26.4 per cent), nausea (21.2 per cent and 23.8 per cent versus 21.3 per cent), constipation (14.2 per cent and 13.1 per cent versus 19.8 per cent), vomiting (10.2 per cent and 15.0 per cent versus 13.2 per cent), and dyspepsia (10.4 per cent and 8.5 per cent versus 11.6 per cent).</span></p>
<p><span>The incidence of dysesthesia was 4.8 per cent with retatrutide 9 mg, 6.5 per cent with retatrutide 12 mg and 2.7 per cent with Ozempic. The incidence of urinary tract infections was 5.8 per cent, 4.2 per cent and 5.8 per cent, respectively.</span></p>
<p><span>The majority of these events were mild to moderate and typically resolved during treatment. Treatment discontinuation rates due to adverse events were 4.8 per cent with retatrutide 9 mg, 7.9 per cent with retatrutide 12 mg and 2.7 per cent with Ozempic.</span></p>
<p>The post <a href="https://www.expresspharma.in/lillys-retatrutide-shows-greater-a1c-reduction-and-weight-loss-than-ozempic-in-phase-3-trial/">Lilly’s retatrutide shows greater A1C reduction and weight loss than Ozempic in Phase 3 trial</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>From Ojas to evidence: Measuring resilience in immune care</title>
<link>https://edusehat.com/en/from-ojas-to-evidence-measuring-resilience-in-immune-care</link>
<guid>https://edusehat.com/en/from-ojas-to-evidence-measuring-resilience-in-immune-care</guid>
<description><![CDATA[ 
 Dr Ravi K V, Assistant Professor, Department of Kriya Sharira, SDM College of Ayurveda Hospital and Research Centre, Udupi, explains how the Ayurvedic concept of Ojas can be assessed in relation to immunity and resilience, drawing on an observational study examining its association with healthy days and illness
The post From Ojas to evidence: Measuring resilience in immune care appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/28134014/EP_Dr_Ravi-K-V_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 28 Oct 2026 18:25:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>From, Ojas, evidence:, Measuring, resilience, immune, care</media:keywords>
<content:encoded><![CDATA[<div><img width="1280" height="720" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/28134014/EP_Dr_Ravi-K-V_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/28134014/EP_Dr_Ravi-K-V_750.jpg 1280w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/28134014/EP_Dr_Ravi-K-V_750-300x169.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/28134014/EP_Dr_Ravi-K-V_750-1024x576.jpg 1024w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/28134014/EP_Dr_Ravi-K-V_750-768x432.jpg 768w" sizes="auto, (max-width: 1280px) 100vw, 1280px"></div><p><span>Ayurveda is one of the oldest systems of medicine practiced in India. The word Ayurveda means “science of life.” Its foundations lie in classical texts such as the Charaka Samhita, Sushruta Samhita and several others. It views health as a dynamic balance among the doshas (Vata, Pitta and Kapha), the dhatus (tissues), the malas (waste products) and agni, the digestive and metabolic fire.</span></p>
<p><b>Swastha: The Ayurvedic idea of health</b></p>
<p><span>Ayurveda’s definition of health goes beyond the absence of disease. The Sushruta Samhita describes the healthy person, or Swastha, in a single verse:</span></p>
<p><b>समदोषः</b> <b>समाग्निश्च</b> <b>समधातुमलक्रियः।</b></p>
<p><b>प्रसन्नात्मेन्द्रियमनाः</b> <b>स्वस्थ</b> <b>इत्यभिधीयते॥</b></p>
<p><span>Sama dosha samagnischa sama dhatu mala kriyah,</span></p>
<p><span>Prasanna atma indriya manah swastha iti abhidhiyate.</span></p>
<p><span>A person is Swastha when the doshas, agni, dhatus and malas are in equilibrium, and when the atma (self), indriyas (senses) and manas (mind) are serene. Health here is physical, metabolic, sensory and psychological at once.</span></p>
<p><b>Ojas: the essence of vitality</b></p>
<p><span>The concept of Ojas is central to this idea of health. The classical texts describe it as the finest essence of all the dhatus, the substance that sustains vitality, strength and vyadhikshamatva, the body’s capacity to resist and withstand disease. When Ojas is abundant, the person is robust and resilient. When it is depleted or disturbed (Ojakshaya or Ojovisramsa), vulnerability to illness rises. Ojas is often compared to the modern concept of immunity, though the two are not identical. Ojas is broader, covering physical resilience, metabolic integrity and mental stability together.</span></p>
<p><b>Ojas, immunity and autoimmunity</b></p>
<p><span>In modern terms, Ojas may be interpreted as the integrative expression of immune competence, endocrine stability, and metabolic balance, mirroring the body’s innate defense mechanisms. The nourishing, stabilising, and life-sustaining attributes of Ojas, parallel the role of the immune system and homeostatic regulation in modern physiology. Thus, a person rich in Ojas embodies the Ayurvedic ideal of health, a balanced state of Doṣa, Dhātu, Agni, and Manas, which ensures resilience against disease and promotes longevity.</span></p>
<p><span>In practical terms, the classical position is simple: good Ojas means good immunity, and diminished Ojas means diminished immunity. A person with abundant Ojas resists disease and recovers well, while a person whose Ojas is depleted is more susceptible to illness and slower to recover.</span></p>
<p><span>The classical texts, however, describe more than depletion. They speak of Ojas being displaced (Ojovisramsa), vitiated (Ojovyapat) and diminished (Ojakshaya). This matters because immunity is not only a question of strength. Immune protection can fail in two ways: it can be too weak to resist infection, or it can be misdirected against the body’s own tissues. Depleted Ojas fits the first picture. Ojas that is displaced or vitiated, present but unstable and poorly regulated, offers a way to think about the second. Autoimmunity can thus be read as an expression of Ojas that is disturbed rather than merely reduced. This is a hypothesis, not a conclusion, and only measurement can test it.</span></p>
<p><span>This framework offers a distinctive lens on autoimmune disease. Classical descriptions of conditions such as Amavata point to impaired agni producing ama, a metabolic by-product that obstructs the body’s channels and disturbs its balance. The immune system’s loss of self-regulation can thus be read through Ojas, agni and ama. The challenge, and the opportunity, is to move from interpretation to measurement: translating these concepts into outcomes that can be studied, validated and compared.</span></p>
<p><b>Our research: quantifying Ojas</b></p>
<p><span>At SDM College of Ayurveda Hospital and Research Centre Udupi, we undertook an observational, cross-sectional study to ask a simple question: can Ojas, the classical determinant of resilience, be measured, and does it relate to health outcomes?</span></p>
<p><b>Design and participants. </b><span>Thirty apparently healthy participants were assessed, with no intervention. Participants with major acute or chronic illness, or on regular medication, were excluded.</span></p>
<p><b>Assessment. </b><span>Ojas was scored (0 to 53) using a multi-dimensional tool developed by our team. Participants also reported their number of ill days over the past one year, from which the percentage of healthy days was derived.</span></p>
<p><b>Findings. </b><span>Ojas scores ranged from 26 to 47, and healthy days from 50.7 per cent to 98.6 per cent. Participants with higher Ojas scores reported fewer ill days, while those with lower scores reported more. In other words, good Ojas was associated with less illness and diminished Ojas with more, as the classical concept would predict.</span></p>
<p><b>Preserving Ojas: the role of daily conduct</b></p>
<p><span>If Ojas sustains resilience, the next question is how it is preserved and built. The classical answer is daily conduct, summarised in a well-known verse:</span></p>
<p><b>नित्यं</b> <b>हिताहारविहारसेवी</b> <b>समीक्ष्यकारी</b> <b>विषयेष्वसक्तः।</b></p>
<p><b>दाता</b> <b>समः</b> <b>सत्यपरः</b> <b>क्षमावान्</b> <b>आप्तोपसेवी</b> <b>च</b> <b>भवत्यरोगः॥</b></p>
<p><span>Nityam hita-ahara-vihara-sevi samikshya-kari vishayeshvasaktah,</span></p>
<p><span>Data samah satyaparah kshamavan apta-upasevi cha bhavatyarogah.</span></p>
<p><span>The person who consistently follows wholesome diet (hita ahara) and lifestyle (vihara), acts with due consideration, remains unattached to sensory excess, and is generous, balanced, truthful and forgiving, while keeping the company of the wise, remains free from disease. The verse joins physical habits to mental and social conduct: food, sleep and routine on one side, restraint, equanimity and good relationships on the other. This is the Ayurvedic route to strong Ojas and, in practical terms, to better immunity.</span></p>
<p><b>Conclusion</b></p>
<p><span>Autoimmune disease is, at its core, a failure of immune self-regulation. Ayurveda’s concept of Ojas, the essence of resilience and vyadhikshamatva, offers a lens for understanding that failure. When Ojas is disturbed or depleted and agni is impaired, the resulting ama may be read as the soil in which chronic, relapsing disease takes root. Preserving Ojas through hita ahara and vihara, and restoring agni, thus become not only classical principles but testable hypotheses.</span></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/from-ojas-to-evidence-measuring-resilience-in-immune-care/">From Ojas to evidence: Measuring resilience in immune care</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>CPHI India &amp;amp; PMEC India 2026 to connect India’s pharma value chain across ingredients, manufacturing and technology</title>
<link>https://edusehat.com/en/cphi-india-pmec-india-2026-to-connect-indias-pharma-value-chain-across-ingredients-manufacturing-and-technology</link>
<guid>https://edusehat.com/en/cphi-india-pmec-india-2026-to-connect-indias-pharma-value-chain-across-ingredients-manufacturing-and-technology</guid>
<description><![CDATA[ 
Dual-venue events will bring together pharmaceutical manufacturers, ingredient suppliers, CDMOs and technology providers, with participation expected from 120+ countries
The post CPHI India &amp; PMEC India 2026 to connect India’s pharma value chain across ingredients, manufacturing and technology appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/28141429/EP_CPHI-2026.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 28 Oct 2026 18:25:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>CPHI, India, PMEC, India, 2026, connect, India’s, pharma, value, chain, across, ingredients, manufacturing, and, technology</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/28141429/EP_CPHI-2026.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/28141429/EP_CPHI-2026.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/28141429/EP_CPHI-2026-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><b>CPHI India and PMEC India 2026,</b><span> organised by Informa Markets in India, will bring together stakeholders from across the pharmaceutical value chain from </span><b>November 23–26, 2026,</b><span> across two specialised venues in Delhi-NCR. </span><b>CPHI India will take place from November 23–25 at IICC, Yashobhoomi, Dwarka, while PMEC India will run from November 24–26 at IEML, Greater Noida.</b><span> The expanded format is designed to connect the pharmaceutical ingredients, contract manufacturing, machinery and technology sectors, facilitating business engagement, knowledge exchange and industry partnerships.</span></p>
<p><b>Visitor Registration:</b><span> Industry professionals can register to visit CPHI India and PMEC India 2026 and explore solutions, connect with industry leaders and discover opportunities across the pharmaceutical value chain.</span></p>
<p><b>Register here:</b><span> Visitor registration <a href="https://cphi-india-register.cphi.com/?form=short&ref=google&utm_source=google&utm_medium=perf_mrktg_cmpgn&utm_campaign=VM_CPHI_Search_Brand_17June26&gad_source=1&gad_campaignid=23950138469&gbraid=0AAAABD6CFthJTmpJLZ4AkMLnJwm77FL4g&gclid=CjwKCAjwuobXBhBXEiwAYUaIlUYPZOFLfPX7FkJJ0y7FMryt8FobRqMB_-E9_m3OeOP2frVNvo0tSBoCENsQAvD_BwE">link </a></span></p>
<p><b>Early-bird registration deadline:  </b></p>
<p><b>Article-specific UTM link:</b></p>
<p><span>The 2026 edition is expected to feature</span><b> 2,000+ exhibitors,</b><span> welcome </span><b>50,000+ </b><span>pharmaceutical professionals and visitors, and attract participation from</span><b> 120+ countries</b><span>. CPHI India will focus on active pharmaceutical ingredients (APIs), finished dosage, excipients, natural extracts, fine chemicals, intermediates and contract development and manufacturing organisations (CDMOs). PMEC India will showcase pharmaceutical machinery, equipment, packaging, laboratory and analytical systems, cleanroom technology and related manufacturing solutions.</span></p>
<p><span>The two events will offer complementary platforms for manufacturers, suppliers, research and development professionals, procurement teams and technology providers to assess solutions, explore sourcing opportunities and build partnerships across domestic and international markets. The Connections Programme will offer eligible buyers curated, pre-arranged meetings with exhibitors, while the Startup Market package will enable eligible businesses to showcase their solutions and connect with potential customers and partners.</span></p>
<p><b>A connected experience across two specialised venues</b></p>
<p><span>With CPHI India and PMEC India taking place at separate venues for the first time, the visitor experience has been designed to facilitate access to both exhibitions. A single visitor badge will provide entry to both events, while complimentary shuttle services will connect IICC, Yashobhoomi, Dwarka, and IEML, Greater Noida. The arrangement will allow visitors to explore pharmaceutical ingredients, contract manufacturing, production machinery and related technologies through one integrated visit.</span></p>
<p><b>India’s pharmaceutical industry: Scale, exports and manufacturing priorities</b></p>
<p><span>India’s pharmaceutical industry recorded an annual turnover of</span><b> ₹4.72 lakh crore in FY2024–25</b><span> and ranks third globally by production volume. The sector comprises more than </span><b>3,000 companies and 10,500 manufacturing units,</b><span> supported by a broad ecosystem spanning APIs, formulations, contract manufacturing, research, packaging and pharmaceutical production technologies.</span></p>
<p><span>Pharmaceutical exports reached approximately </span><b>USD 30.5 billion in FY2024–25, </b><span>registering year-on-year growth of 9.4%, with shipments reaching 191 countries. Around half of these exports were directed to highly regulated markets, including the United States and Europe. India’s domestic pharmaceutical market, estimated at around USD 60 billion, is projected to reach approximately USD 130 billion by 2030.</span></p>
<p><span>As the industry responds to evolving global requirements, investments in manufacturing efficiency, advanced formulations, API capabilities, automation, packaging, laboratory systems and quality assurance will remain important to strengthening competitiveness and meeting international standards.</span></p>
<p><span>Against this backdrop, CPHI India and PMEC India will provide a platform for industry stakeholders to assess emerging technologies, exchange insights on manufacturing priorities and identify business opportunities across the pharmaceutical value chain.</span></p>
<p><b>Conference, leadership and industry engagement</b></p>
<p><span>The events will address key industry themes spanning market trends, regulation, pharmaceutical manufacturing, outsourcing, emerging technologies, supply chains, sustainability and biopharma, including cell and gene therapies.</span></p>
<p><b>Pharma Connect,</b><span> a two-day conference scheduled for November 23–24, 2026, will feature industry leaders including Dr. Declan Byrne of the European Directorate for the Quality of Medicines & HealthCare (EDQM), Devender Kumar Singh of Pfizer Inc., and Vaibhavi Shah and Dr. Ankur Shah of Invengene. Sessions will explore India’s ambition to strengthen its position in API manufacturing, the growth of the CDMO sector, and developments in cell and gene therapy.</span></p>
<p><span>CPHI India will also host the</span><b> India Pharma Awards 2026, the Pharma Leadership Exchange </b><span>and </span><b>Women in Pharma.</b><span> PMEC India will feature a </span><b>CXO Roundtable</b><span> and a </span><b>Regulators Panel Discussion.</b><span> Together, these initiatives will support knowledge exchange, industry dialogue and connections between business leaders, manufacturers, suppliers and technology providers.</span></p>
<p><span>Key exhibitors at CPHI India include </span><b>IMCD India Pvt Ltd (Signet), Dr. Reddy’s Laboratories Ltd, Akums Drugs and Pharmaceuticals Ltd, Morepen Laboratories Limited </b><span>and</span><b> Hetero Labs Limited, </b><span>among others</span><b>.</b><span> Leading exhibitors at PMEC India include </span><b>Fette Compacting Machinery India Private Limited, ACG Pam Pharma Technologies Pvt. Ltd., Parle Global Technologies Pvt. Ltd., IMA-PG India Pvt. Ltd. </b><span>and</span><b> Ace Technologies & Packaging Systems Pvt. Ltd.</b></p>
<p><span>The events have also garnered considerable support from association partners including </span><b>OPPI, IPEC India, BDMAI, GPMA and KDPMA, </b><span>representing stakeholders across the pharmaceutical value chain.</span></p>
<p><span>Yogesh Mudras, Managing Director, Informa Markets in India, said: “India’s pharmaceutical industry is strengthening its manufacturing capabilities and global competitiveness. Government data shows that the pharmaceutical drugs PLI scheme generated approximately 1.15 lakh jobs by March 2026, reflecting the sector’s manufacturing potential. With investment in APIs, formulations, automation and quality systems becoming increasingly important, CPHI India and PMEC India 2026 will connect manufacturers, ingredient suppliers, CDMOs and technology providers through specialised platforms and targeted business interactions. </span></p>
<p><span>This year, the dual-venue expanded structure of the expos is designed to further help industry stakeholders explore partnerships, identify solutions and pursue new business opportunities across the pharmaceutical value chain in a focused manner.”</span></p>
<p><b>Event details</b></p>
<table>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td><b>CPHI India 2026</b></td>
</tr>
<tr>
<td>
<ul>
<li aria-level="1"><span>Dates: November 23–25, 2026</span></li>
</ul>
</td>
</tr>
<tr>
<td>
<ul>
<li aria-level="1"><span>Venue: IICC, Yashobhoomi, Dwarka, New Delhi</span></li>
</ul>
</td>
</tr>
<tr>
<td>
<ul>
<li aria-level="1"><span>Website: </span><a href="https://www.cphi.com/india/"><span>https://www.cphi.com/india/</span></a></li>
</ul>
</td>
</tr>
<tr>
<td><b>PMEC India 2026</b></td>
</tr>
<tr>
<td>
<ul>
<li aria-level="1"><span>Dates: November 24–26, 2026</span></li>
</ul>
</td>
</tr>
<tr>
<td>
<ul>
<li aria-level="1"><span>Venue: IEML, Greater Noida, Uttar Pradesh</span></li>
</ul>
</td>
</tr>
<tr>
<td>
<ul>
<li aria-level="1"><span>Website: </span><a href="https://www.cphi.com/india/"><span>https://www.cphi.com/india/</span></a></li>
</ul>
</td>
</tr>
<tr>
<td><b>Visitor access:</b><span> A single visitor badge provides access to both events. Complimentary shuttle services will connect the two venues.</span></td>
</tr>
<tr>
<td><b>Register to visit: </b></td>
</tr>
<tr>
<td><b>Social media and visuals</b></td>
</tr>
<tr>
<td>
<ul>
<li aria-level="1"><span>Hashtags:</span></li>
</ul>
</td>
</tr>
<tr>
<td>
<ul>
<li aria-level="1"><span>Social media handles: </span></li>
</ul>
</td>
</tr>
<tr>
<td>
<ul>
<li aria-level="1"><span>Event image/video: </span></li>
</ul>
</td>
</tr>
</tbody>
</table>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/cphi-india-pmec-india-2026-to-connect-indias-pharma-value-chain-across-ingredients-manufacturing-and-technology/">CPHI India & PMEC India 2026 to connect India’s pharma value chain across ingredients, manufacturing and technology</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Nucelion, Pandorum partner on two PRIP&#45;backed ophthalmology projects</title>
<link>https://edusehat.com/en/nucelion-pandorum-partner-on-two-prip-backed-ophthalmology-projects</link>
<guid>https://edusehat.com/en/nucelion-pandorum-partner-on-two-prip-backed-ophthalmology-projects</guid>
<description><![CDATA[ 
The projects will focus on investigational therapies for advanced keratopathy and wet age-related macular degeneration, with a combined planned outlay of ₹16.97 crore
The post Nucelion, Pandorum partner on two PRIP-backed ophthalmology projects appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/05/04131504/handshake.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 28 Oct 2026 18:25:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Nucelion, Pandorum, partner, two, PRIP-backed, ophthalmology, projects</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/05/04131504/handshake.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/05/04131504/handshake.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/05/04131504/handshake-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p dir="ltr"><span>Hyderabad-based Nucelion Therapeutics, a cell and gene therapy contract development and manufacturing organisation (CDMO) and wholly owned subsidiary of Bharat Biotech, and Bengaluru-headquartered Pandorum Technologies, a tissue engineering and regenerative medicine company, have announced a manufacturing partnership to advance two PRIP-backed ophthalmology projects focused on developing investigational therapies for advanced keratopathy and wet age-related macular degeneration (wet AMD).</span></p>
<p dir="ltr"><span>Pandorum is developing cell-free regenerative medicines based on designer exosomes that carry biological signals involved in communication between cells. The biological activity of these exosomes is tuned to address inflammation, fibrosis and vascular pathology while supporting tissue repair. The platform connects the manufacturing process, the product, its biological activities and the corresponding tissue response in an integrated learning loop.</span></p>
<p dir="ltr"><span>Through its collaboration with Nucelion, Pandorum is connecting programmable regenerative medicine design with reproducible manufacturing and indication-specific development, while building this capability in India with national research support.</span></p>
<p dir="ltr"><span>Nucelion’s role in the two investigational ophthalmology projects will centre on process development and manufacturing support for Pandorum’s designer exosomes, aligned with the requirements and development stage of each programme. The partnership reflects the role specialised manufacturing capabilities can play in the development of emerging regenerative medicines.</span></p>
<p dir="ltr"><span>The broader Pandorum–Nucelion collaboration is intended to provide material manufactured under Good Manufacturing Practice (GMP) for clinical studies in India and abroad, subject to applicable regulatory approvals.</span></p>
<p dir="ltr"><span>Pandorum’s advanced-keratopathy programme is directed towards clinical evaluation of investigational therapies for severe corneal disease. The wet-AMD programme extends the platform into retinal disease, with the current project focused on preclinical development and preparation for subsequent clinical translation. Each programme will advance according to its own evidence, milestones and regulatory requirements.</span></p>
<p dir="ltr"><span>The two projects reflect the potential of India’s research and manufacturing ecosystem to advance approaches to treating eye diseases.</span></p>
<p dir="ltr"><span>The projects have a combined planned outlay of ₹16.97 crore, comprising up to ₹8 crore in funding under the PRIP scheme.</span></p>
<p dir="ltr"><span>“Advanced therapies require process development, analytical methods and manufacturing discipline to progress together. Our role is to help translate Pandorum’s product requirements into reproducible processes and development-stage manufacturing, with quality built into the work from the outset. This collaboration brings complementary capabilities together to advance complex biologics within India’s growing advanced-therapies ecosystem,” said Dr Raghu Malapaka, Chief Business Officer, Nucelion Therapeutics.</span></p>
<div><span> </span></div>
<p>The post <a href="https://www.expresspharma.in/nucelion-pandorum-partner-on-two-prip-backed-ophthalmology-projects/">Nucelion, Pandorum partner on two PRIP-backed ophthalmology projects</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>SCHOTT Poonawalla renamed SCHOTT Pharma India Private Limited</title>
<link>https://edusehat.com/en/schott-poonawalla-renamed-schott-pharma-india-private-limited</link>
<guid>https://edusehat.com/en/schott-poonawalla-renamed-schott-pharma-india-private-limited</guid>
<description><![CDATA[ 
The name change takes effect on October 28, 2026, with no changes to ownership, management, operations, products or services
The post SCHOTT Poonawalla renamed SCHOTT Pharma India Private Limited appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 28 Oct 2026 14:50:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>SCHOTT, Poonawalla, renamed, SCHOTT, Pharma, India, Private, Limited</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>SCHOTT Poonawalla Private Limited will become SCHOTT Pharma India Private Limited with effect from October 28, 2026, marking a new chapter in the company’s journey and strengthening its connection with the global SCHOTT Pharma organisation.</span></p>
<p><span>The new identity reflects the India business’s place within SCHOTT Pharma’s global network and its role in advancing drug containment and delivery solutions for the pharmaceutical and biotechnology industries. It brings together the company’s manufacturing footprint, customer relationships and market expertise in India with SCHOTT Pharma’s global capabilities, innovation and scientific expertise.</span></p>
<p><span>The company stated that the change is limited to its name and does not affect its ownership, management, employees, business strategy, operations, products, services or existing customer commitments.</span></p>
<p><span>The transition reinforces SCHOTT Pharma India’s commitment to customers in India and international markets, while establishing a consistent connection with the global SCHOTT Pharma brand.</span></p>
<p><span>Building on a heritage of more than 140 years, the new identity brings the company’s heritage and future ambitions under one global name, reflecting SCHOTT Pharma’s values of innovation, quality, scientific expertise and trust.</span></p>
<p><span>Commenting on the development, Roy Joseph, CEO and Managing Director, SCHOTT Pharma India Private Limited, said, “SCHOTT Pharma India represents the next chapter of our journey, combining our strength in India with SCHOTT Pharma’s global innovation and expertise. We see significant opportunity to build on our capabilities, deepen collaboration with pharmaceutical and biotechnology partners, and advance drug containment and delivery solutions. As we move forward, our focus remains on growing with our customers and contributing to the safe and reliable delivery of critical therapies to patients worldwide.”</span></p>
<p><span>Dr Christian Mias, CEO of SCHOTT Pharma AG & Co. KGaA, SCHOTT Pharma India’s major shareholder, said, “SCHOTT Pharma India plays a critical role in patient care. With more than 3 billion containers produced annually, this company enables around 7,000 injections to reach patients every minute. The name change from SCHOTT Poonawalla to SCHOTT Pharma India reinforces our strategic partnership and confirms our long-term commitment to India as a key pharma hub.”</span></p>
<p><span>The new identity builds on the company’s operations in India. During the COVID-19 pandemic, its pharmaceutical vials supported more than 4.3 billion vaccine doses worldwide, including 3 billion doses in India.</span></p>
<p><span>As India’s only manufacturer of glass pre-fillable syringes and sterile formats, the company also contributes to local supply capabilities. It continues to invest in manufacturing capacity expansions for pre-fillable syringes and cartridges to support the requirements of biologics, biosimilars, GLP-1-based treatments and other injectable therapies.</span></p>
<p><span>Going forward, SCHOTT Pharma India will focus on expanding its capabilities in pharmaceutical drug containment and delivery solutions, driving innovation through customer collaboration, and strengthening operational excellence and sustainability. These priorities will support the company in responding to the needs of pharmaceutical and biotechnology companies and contribute to India’s role in the global pharmaceutical value chain.</span></p>
<p>The post <a href="https://www.expresspharma.in/schott-poonawalla-renamed-schott-pharma-india-private-limited/">SCHOTT Poonawalla renamed SCHOTT Pharma India Private Limited</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Indoco Remedies’ AnaCipher gets ANVISA approval for clinical and bioanalytical facilities</title>
<link>https://edusehat.com/en/indoco-remedies-anacipher-gets-anvisa-approval-for-clinical-and-bioanalytical-facilities</link>
<guid>https://edusehat.com/en/indoco-remedies-anacipher-gets-anvisa-approval-for-clinical-and-bioanalytical-facilities</guid>
<description><![CDATA[ 
The approval authorises the CRO to conduct bioavailability and bioequivalence studies for submission to Brazil, with associated bioanalytical support
The post Indoco Remedies’ AnaCipher gets ANVISA approval for clinical and bioanalytical facilities appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 28 Oct 2026 14:50:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Indoco, Remedies’, AnaCipher, gets, ANVISA, approval, for, clinical, and, bioanalytical, facilities</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Indoco Remedies has announced that its Clinical Research Organisation (CRO), AnaCipher, has received approval from Brazil’s National Health Surveillance Agency (Agência Nacional de Vigilância Sanitária, ANVISA) for its clinical and bioanalytical facilities. The inspection was conducted from March 30 to April 7, 2026.</span></p>
<p><span>With this approval, AnaCipher is authorised to conduct bioavailability and bioequivalence studies for submission to Brazil, along with associated bioanalytical support in accordance with ANVISA’s regulatory requirements.</span></p>
<p><span>Commenting on the development, Aditi Panandikar, Managing Director, Indoco Remedies, said, “The approval reflects our CRO’s robust quality management systems, qualified scientific and clinical teams, validated analytical capabilities, and adherence to international regulatory and Good Clinical Practice standards. It reinforces our commitment to global quality standards and enhances our ability to support pharmaceutical companies in conducting studies for Brazil and expanding across Latin America.”</span></p>
<p><span>The approval further strengthens AnaCipher’s international regulatory footprint and reinforces its position as a trusted partner for global clinical research programmes.</span></p>
<p><span>Headquartered in Hyderabad, India, AnaCipher provides bioequivalence and bioavailability studies, bioanalysis, clinical operations, regulatory affairs, data management and biostatistics services to pharmaceutical companies worldwide.</span></p>
<p><span>The CRO has been accredited by the Central Drugs Standard Control Organisation (CDSCO), the US Food and Drug Administration (USFDA), the World Health Organization (WHO), the European Medicines Agency (EMA), the UK Medicines and Healthcare products Regulatory Agency (MHRA), and the Ministry of Health of Oman. It has also received project-based approvals from Health Canada’s Therapeutic Products Directorate (TPD), China’s National Medical Products Administration (NMPA), South Africa’s Medicines Control Council (MCC) and the Ministry of Health of Iraq.</span></p>
<p>The post <a href="https://www.expresspharma.in/indoco-remedies-anacipher-gets-anvisa-approval-for-clinical-and-bioanalytical-facilities/">Indoco Remedies’ AnaCipher gets ANVISA approval for clinical and bioanalytical facilities</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>MCADDI 2026 brings together drug discovery experts at University of Hyderabad</title>
<link>https://edusehat.com/en/mcaddi-2026-brings-together-drug-discovery-experts-at-university-of-hyderabad</link>
<guid>https://edusehat.com/en/mcaddi-2026-brings-together-drug-discovery-experts-at-university-of-hyderabad</guid>
<description><![CDATA[ 
The six-day programme, organised by FABA with academic and industry partners, covers medicinal chemistry, AI-based drug design, biologics and emerging therapeutic modalities
The post MCADDI 2026 brings together drug discovery experts at University of Hyderabad appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/28114102/EP_MCADDI_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 28 Oct 2026 14:50:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>MCADDI, 2026, brings, together, drug, discovery, experts, University, Hyderabad</media:keywords>
<content:encoded><![CDATA[<div><img width="1280" height="720" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/28114102/EP_MCADDI_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/28114102/EP_MCADDI_750.jpg 1280w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/28114102/EP_MCADDI_750-300x169.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/28114102/EP_MCADDI_750-1024x576.jpg 1024w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/28114102/EP_MCADDI_750-768x432.jpg 768w" sizes="(max-width: 1280px) 100vw, 1280px"></div><p><span>The Medicinal Chemistry, Drug Discovery & Development India 2026 (MCADDI 2026) is bringing together more than 200 professionals, researchers and industry experts for a six-day programme at the University of Hyderabad from October 25 to 30, 2026.</span></p>
<p><span>Organised by the Federation of Asian Biotech Associations (FABA) in collaboration with the University of Hyderabad, Biocon Academy, Aragen Academy and Science Gurus, the programme brings together international faculty and industry practitioners to examine developments in pharmaceutical research and development (R&D).</span></p>
<p><span>With 31 lectures, case studies and interactive sessions, MCADDI 2026 covers the drug discovery process, from medicinal chemistry and target identification to computational drug design, biologics, antibody-drug conjugates (ADCs), oncology, immunotherapy and emerging therapeutic modalities.</span></p>
<p><span>Experts from organisations including Novartis, AbbVie, Pfizer, Merck, Aragen, Sun Pharma, Aurobindo and biotechnology companies are contributing perspectives from different stages of drug discovery and development.</span></p>
<p><span>The programme opened with sessions on medicinal chemistry and drug discovery. Prof. Thomas Prisinzano of the University of Kentucky, USA, is addressing the principles of medicinal chemistry, while Manjunath Ramarao, EVP and Chief Scientific Officer, Aragen, is covering target identification and validation, as well as high-throughput, virtual and phenotypic screening approaches.</span></p>
<p><span>Ralf Glatthaar, Executive Director, Global Discovery Chemistry, Novartis, Basel, is contributing sessions on hit-to-lead and lead optimisation. These discussions address approaches to improving early-stage discovery and increasing the probability of advancing molecules into development.</span></p>
<p><span>Computational science and artificial intelligence (AI) also feature in the programme. Sessions on molecular interactions, in-silico tools for medicinal chemists, applications of in-silico approaches in drug discovery and AI-based drug design examine the integration of computational capabilities into drug discovery workflows.</span></p>
<p><span>Vincent Stoll, Senior Research Fellow, AbbVie, USA, is contributing to discussions on molecular interactions and structure-based drug design, while Rachel Lagkallos, US Head of Digital Medicinal Chemistry, Novartis, is addressing in-silico tools and their application in drug discovery.</span></p>
<p><span>The programme examines the use of digital and computational approaches to identify, design, evaluate and progress molecules through the discovery process.</span></p>
<p><span>MCADDI 2026 also covers biologics and therapeutic modalities. Sessions on biologics, developability, biopharmaceutics and formulation are complemented by discussions on ADCs, including their principles, next-generation approaches and case studies.</span></p>
<p><span>Rustam Mody, Consultant – Biologics, Sun Pharmaceutical Industries Ltd., and Jagath Reddy Junutula, Co-founder, President and CEO, Aavrık Therapeutics, USA, are among the experts contributing to this part of the programme.</span></p>
<p><span>The sessions on ADCs examine the convergence of targeted biology, antibody engineering and drug delivery in oncology drug development.</span></p>
<p><span>Oncology is another theme, with sessions and case studies covering pancreatic cancer, breast cancer therapy and drug discovery. Perry Carter, CEO of BlueSphere Bio, USA, is delivering the CEO Conclave keynote on advances in breast cancer therapy, while other sessions examine approaches in cancer therapeutics.</span></p>
<p><span>The programme also covers targeted protein degraders, molecular glues, immunotherapy and direct-acting antivirals, focusing on mechanisms and therapeutic modalities beyond conventional small-molecule approaches.</span></p>
<p><span>MCADDI 2026 combines scientific discussions, industry experience and case-based learning to examine how scientific advances translate into drug discovery and development programmes.</span></p>
<p><span>The programme also features a CEO Conclave and FABA Innovation Awards. The CEO Conclave brings together industry leaders to discuss drug discovery and development and the innovation ecosystem.</span></p>
<p><span>For India, the programme comes as the country seeks to expand its role in the pharmaceutical value chain beyond manufacturing and generic medicines. The next phase of growth will require capabilities in original research, discovery chemistry, computational drug design, novel modalities, translational science and product innovation.</span></p>
<p><span>Developing these capabilities requires interaction between academia and industry, exposure to global scientific practices, access to emerging technologies and a pipeline of researchers and drug discovery professionals.</span></p>
<p><span>MCADDI 2026 addresses these requirements by bringing international expertise and Indian scientific and industrial capabilities into one forum.</span></p>
<p><span>The vision, leadership and efforts of Prof. P. Reddanna, Executive Director and President, FABA, have been central to bringing MCADDI 2026 together as a platform for scientific exchange and collaboration. The efforts of Dr. P. Ratnakar, Secretary General, FABA, and the wider FABA team, together with the University of Hyderabad, Biocon Academy, Aragen Academy, Science Gurus, the organising committee, faculty, sponsors and institutional partners, have contributed to the programme.</span></p>
<p><span>As the six-day programme progresses, MCADDI 2026 highlights the convergence of chemistry, biology, computation, artificial intelligence, data science and clinical understanding in drug discovery.</span></p>
<p><span>For India, developing these capabilities could support the next phase of pharmaceutical growth, expanding its contribution from the global supply of medicines to the discovery and development of medicines.</span></p>
<p>The post <a href="https://www.expresspharma.in/mcaddi-2026-brings-together-drug-discovery-experts-at-university-of-hyderabad/">MCADDI 2026 brings together drug discovery experts at University of Hyderabad</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Can technology and clinical evidence make skincare more personalised?</title>
<link>https://edusehat.com/en/can-technology-and-clinical-evidence-make-skincare-more-personalised</link>
<guid>https://edusehat.com/en/can-technology-and-clinical-evidence-make-skincare-more-personalised</guid>
<description><![CDATA[ 
What gaps in India’s dermatology and skincare market led to the creation of Puresta, and how does the company plan to build a business at the intersection of healthcare, technology […]
The post Can technology and clinical evidence make skincare more personalised? appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/27155941/Hitaysh-Dhingraa-Co-Founder-CEO-Puresta.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 27 Oct 2026 20:50:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Can, technology, and, clinical, evidence, make, skincare, more, personalised</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/27155941/Hitaysh-Dhingraa-Co-Founder-CEO-Puresta.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/27155941/Hitaysh-Dhingraa-Co-Founder-CEO-Puresta.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/27155941/Hitaysh-Dhingraa-Co-Founder-CEO-Puresta-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span><span><span><b>What gaps in India’s dermatology and skincare market led to the creation of Puresta, and how does the company plan to build a business at the intersection of healthcare, technology and skincare?</b></span></span></span></p>
<p><span><span><span>Before building anything, we spoke to around 1,400 women aged 21–30 over several months. One insight came through very clearly: India does not have a shortage of skincare products; it has a shortage of personalised skin-health guidance.</span></span></span></p>
<p><span><span><span>Consumers today are surrounded by ingredients, routines, influencers and product choices, but often have very little clarity on what their skin actually needs. Dermatologists remain the most trusted experts, yet access, continuity and follow-up can be inconsistent. The journey is also fragmented — assessment happens in one place, consultation in another, products are bought somewhere else, and progress is rarely tracked.</span></span></span></p>
<p><span><span><span>That insight shaped Puresta. Rather than starting with another product brand, we acquired a majority stake in HealthQ Life Sciences, the company behind SKINQ and SKINQ-Rx, founded by dermatologist Dr Chytra V Anand. That gave us a strong clinical and formulation foundation. Around it, we are building EVERQ — our technology and care platform that helps consumers understand their skin, access a dermatologist when required, follow the recommended treatment and track progress over time.</span></span></span></p>
<p><span><span><span>Our ambition is to move skincare from a largely transactional, product-led category towards a more outcome-led skin-health ecosystem — bringing together clinical expertise, technology and evidence-led products.</span></span></span></p>
<p><span><span><span><b>AI-led skin assessment is emerging as a tool for personalised skincare. How reliable are these systems in identifying skin concerns, and how do you ensure that technology complements rather than substitutes clinical judgement?</b></span></span></span></p>
<p><span><span><span>We are very clear about one principle: AI should not replace a dermatologist. It should make dermatological care more accessible, personalised and continuous.</span></span></span></p>
<p><span><span><span>Our skin-assessment technology has been tested on more than 10,000 Indian users/patient images and reviewed with expert inputs. This focus on Indian skin matters because skin tone, pigmentation patterns and the way certain concerns present can differ significantly across populations.</span></span></span></p>
<p><span><span><span>Within EVERQ, AI is designed to play three roles. First, assessment — helping a consumer structure and understand a concern through images and relevant questions. Second, care navigation — helping identify when professional medical consultation may be appropriate. Third, longitudinal monitoring — helping track visible changes over time so that follow-ups can be more informed.</span></span></span></p>
<p><span><span><span>Clinical diagnosis and prescription decisions remain with qualified dermatologists. We see AI as the layer that can make the journey more intelligent and efficient, while the dermatologist remains central wherever medical judgement is required.</span></span></span></p>
<p><span><span><span><b>What role do clinical evidence, formulation science and testing play in developing dermatology-focused skincare products, particularly for concerns such as pigmentation, acne and sensitivity in Indian skin types?</b></span></span></span></p>
<p><span><span><span>The skincare industry has spent years selling ingredients. We believe the next phase will increasingly be about scientifically supported outcomes.</span></span></span></p>
<p><span><span><span>Concerns such as acne, pigmentation and sensitivity can behave differently across skin tones and environmental conditions. India adds its own realities — heat, humidity, pollution, sun exposure and a wide range of skin tones. Formulations therefore need to be developed and evaluated with the intended consumer in mind.</span></span></span></p>
<p><span><span><span>SKINQ was developed specifically with Indian skin and climate in mind, drawing on Dr Chytra Anand’s more than two decades of clinical experience. Our philosophy is simple: proof should come before promise. We have in-vivo testing on our product portfolio so that claims are supported by evidence generated on real users, rather than relying only on ingredient-level claims.</span></span></span></p>
<p><span><span><span>We also believe skincare needs to become simpler and more purposeful. Consumers should first understand the concern, then use the right intervention for the right duration, and finally measure whether it is working. That is a fundamentally different approach from adding more and more steps to a routine.</span></span></span></p>
<p><span><span><span><b>With the launch of EVERQ, Puresta is connecting skin assessment, dermatologist consultations, treatment and maintenance skincare. What are the key operational and clinical challenges in integrating these stages into a single care pathway?</b></span></span></span></p>
<p><span><span><span>The biggest opportunity — and challenge is that the skin-health journey today is highly fragmented. A consumer may discover a concern on social media, self-select a product, consult a dermatologist later, buy a prescription elsewhere and then have no structured follow-up. Each interaction can sit in a different silo.</span></span></span></p>
<p><span><span><span>EVERQ is designed to bring that journey together, but doing that responsibly requires solving three things.</span></span></span></p>
<p><span><span><span>First is clinical independence. Dermatologists must remain free to make the treatment decision they believe is appropriate; the technology should support their judgement, not influence it.</span></span></span></p>
<p><span><span><span>Second is continuity. Many skin concerns require patience and adherence. Consumers need to follow the right treatment for the right duration and know when to come back for a review. Progress tracking, follow-ups and care support can help close that gap.</span></span></span></p>
<p><span><span><span>Third is technology integration — connecting assessment, consultation, treatment recommendations, fulfilment and progress monitoring without making the experience complicated for the consumer.</span></span></span></p>
<p><span><span><span>We are still early in this journey, so our focus is on getting the care pathway right before scaling it aggressively. The goal is not simply to facilitate a consultation; it is to create a continuous relationship around better skin-health outcomes.</span></span></span></p>
<p><span><span><span><b>How do you see the relationship between dermatologists, pharmaceutical companies and skincare brands evolving as prescription-led treatments, clinically validated formulations and digital health platforms increasingly overlap?</b></span></span></span></p>
<p><span><span><span>Historically, these have operated in separate lanes. Dermatologists focus on diagnosis and treatment, pharmaceutical companies build prescription products, and consumer skincare brands focus on daily care and maintenance. The consumer is often left to connect these experiences independently.</span></span></span></p>
<p><span><span><span>I believe the next generation of dermatology platforms will bring these ecosystems closer together around the consumer’s journey. Dermatologists will remain at the centre of clinical decision-making. Technology can improve access, continuity and monitoring, while evidence-led OTC and prescription products can support treatment as well as long-term maintenance.</span></span></span></p>
<p><span><span><span>That is the ecosystem we are building at Puresta: EVERQ as the technology and care layer, SKINQ as the consumer skincare portfolio, and SKINQ Rx as the dermatologist-focused prescription portfolio.</span></span></span></p>
<p><span><span><span>The future of dermatology, in my view, is not pharma versus beauty. It is the convergence of healthcare, technology and consumer products — with clinical credibility and patient outcomes at the centre.</span></span></span></p>
<p><span><span><span><b>What are Puresta’s priorities for scaling its business over the next three to five years, particularly in terms of research and development, technology capabilities, access to dermatology care and building a sustainable business model?</b></span></span></span></p>
<p><span><span><span>Our priorities over the next three to five years are built around four areas.</span></span></span></p>
<p><span><span><span>First, building an integrated skin-health platform that can support a consumer from the first assessment through consultation, treatment, follow-up and long-term maintenance.</span></span></span></p>
<p><span><span><span>Second, investing deeply in evidence and R&D. We want to build a portfolio of clinically relevant OTC and prescription products where claims are supported by meaningful testing and real-world outcomes.</span></span></span></p>
<p><span><span><span>Third, strengthening our technology and AI capabilities — not just for initial assessment, but increasingly for personalisation, care navigation, progress monitoring and making expert dermatology knowledge easier to access.</span></span></span></p>
<p><span><span><span>Fourth, expanding access to high-quality dermatology care. Digital consultations can reduce geographic friction and make expert guidance available to consumers beyond the largest metros, including tier 1, 2 and 3 India.</span></span></span></p>
<p><span><span><span>From a business perspective, the opportunity is to move from one-time product transactions towards longer-term consumer relationships built around treatment, follow-ups, maintenance and prevention.</span></span></span></p>
<p><span><span><span>Our ambition is not simply to build another large skincare brand. It is to build a trusted skin-health platform that can stay with consumers through different concerns and stages of their lives.</span></span></span></p>
<p>The post <a href="https://www.expresspharma.in/can-technology-and-clinical-evidence-make-skincare-more-personalised/">Can technology and clinical evidence make skincare more personalised?</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Messe Muenchen India acquires PharmaTech Expo from PharmaTechnologyindex.com</title>
<link>https://edusehat.com/en/messe-muenchen-india-acquires-pharmatech-expo-from-pharmatechnologyindexcom</link>
<guid>https://edusehat.com/en/messe-muenchen-india-acquires-pharmatech-expo-from-pharmatechnologyindexcom</guid>
<description><![CDATA[ 
Acquisition adds a 30,000 sqm pharmaceutical platform to Messe Muenchen India’s portfolio,  connecting research, manufacturing, production technologies and regional markets. 
The post Messe Muenchen India acquires PharmaTech Expo from PharmaTechnologyindex.com appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/27140957/EP_Messe.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 27 Oct 2026 17:15:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Messe, Muenchen, India, acquires, PharmaTech, Expo, from, PharmaTechnologyindex.com</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/27140957/EP_Messe.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/27140957/EP_Messe.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/27140957/EP_Messe-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p>Messe Muenchen India, a subsidiary of Messe München GmbH and a leading  organiser of B2B trade fairs in India, has acquired PharmaTech Expo from PharmaTechnologyindex.com (A Division of KNS Group), Ahmedabad. The acquisition strengthens Messe Muenchen India’s position in India’s  pharmaceutical and laboratory technology sectors by adding a 30,000 sqm, well-established platform focused on  pharmaceutical manufacturing, production systems and plant infrastructure.</p>
<p>Over the years, PharmaTech Expo has emerged as an important meeting point for pharmaceutical  manufacturers, technology providers and industry professionals across western and northern India. With more  than 750 exhibitors and over 30,000 visitors, the event brings together solutions across pharmaceutical  machinery, processing and production equipment, cleanroom technologies, utilities, packaging systems,  laboratory solutions and allied services.</p>
<p>Following the acquisition, PharmaTech Expo will continue to build on its regional strengths, industry relationships  and market relevance while gaining access to Messe Muenchen India’s broader industry networks, international  expertise and organisational capabilities.</p>
<p>Dr Reinhard Pfeiffer and Stefan Rummel, CEOs of Messe München Group, said, “The acquisition of  PharmaTech Expo fits perfectly into the analytica cluster and further underlines our long-term commitment to the  Indian market and to the development of specialised industry platforms. India has established itself as an  important pillar of the global pharmaceutical industry, supported by its strong manufacturing capabilities, growing  research landscape, high-quality standards and resilient supply chains. By combining the exhibition’s regional  expertise with Messe München’s international network and experience in organizing world-leading life science  and biochemistry exhibitions, we aim to create sustainable value for exhibitors, visitors and the wider  pharmaceutical community.”</p>
<p>PharmaTech Expo will take place as scheduled in Chandigarh from April 8–10, 2027 and from August 5–7,  2027 at the Helipad Exhibition Centre, Gandhinagar.</p>
<p>With PharmaTech Expo joining the portfolio, Messe Muenchen India will offer a broader suite of pharmaceutical  and laboratory industry platforms through analytica Lab India, PharmaCore India and PharmaTech Expo.</p>
<p>Together, these exhibitions address critical stages of the pharmaceutical value chain — from laboratory  research, analytical testing and diagnostics to APIs, formulations, contract manufacturing, production  technologies, plant engineering, cleanrooms, utilities and packaging solutions.</p>
<p>Bhupinder Singh, President IMEA, Messe München, and CEO, Messe Muenchen India, said, “This  acquisition marks a significant step in strengthening our position as a strategic partner to India’s pharmaceutical  and laboratory industries. By bringing together specialised platforms under one integrated portfolio, we are  creating a powerful ecosystem that connects technology leaders, manufacturers and decision-makers, enabling  collaboration, innovation and business growth across the sector. Our vision is to build industry platforms that not  only reflect the evolving needs of businesses but also accelerate opportunities for knowledge exchange,  technology adoption and strategic partnerships across India’s pharmaceutical and laboratory communities.”</p>
<p>Aarjav Shah and Ramesh Shah, Directors of PharmaTechnologyindex.com (A Division of KNS  Group), expressed that, “Over the years, PharmaTech Expo has advanced into an important interaction place  and interface zone at each of the centres for pharmaceutical manufacturers, technology providers and industry  professionals across crucial regional markets with their distinct strengths. Joining the Messe Muenchen India  portfolio marks a significant step forward, bringing together our strong industry connections with its global  capabilities and market reach. We look forward to building on this robust foundation and enhancing prospects for  exhibitors, partners and the pharmaceutical manufacturing ecosystem.”</p>
<p>The expanded portfolio will cater to pharmaceutical manufacturers, laboratory professionals, production and  plant managers, procurement teams, quality specialists, researchers, technology providers and other  stakeholders seeking solutions across the pharmaceutical value chain.</p>
<p>Each exhibition will retain its distinct identity and market focus while contributing to a connected portfolio  designed to serve the evolving needs of India’s pharmaceutical and laboratory industries.</p>
<p>The post <a href="https://www.expresspharma.in/messe-muenchen-india-acquires-pharmatech-expo-from-pharmatechnologyindex-com/">Messe Muenchen India acquires PharmaTech Expo from PharmaTechnologyindex.com</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Biocon secures Yesintek biosimilar rights in nine markets</title>
<link>https://edusehat.com/en/biocon-secures-yesintek-biosimilar-rights-in-nine-markets</link>
<guid>https://edusehat.com/en/biocon-secures-yesintek-biosimilar-rights-in-nine-markets</guid>
<description><![CDATA[ 
The agreement with Janssen Sciences Ireland enables commercialisation of the proposed Stelara biosimilar in Australia, Brazil, China, Hong Kong, Israel, Mexico, New Zealand, South Korea and Kazakhstan
The post Biocon secures Yesintek biosimilar rights in nine markets appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 26 Oct 2026 15:40:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Biocon, secures, Yesintek, biosimilar, rights, nine, markets</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Biocon has signed a licence agreement with Janssen Sciences Ireland to enable the commercialisation of Yesintek, its proposed biosimilar to Stelara (ustekinumab), in Australia, Brazil, China, Hong Kong, Israel, Mexico, New Zealand, South Korea and Kazakhstan, with immediate effect.</span></p>
<p><span>The agreement builds on the company’s previously announced agreements with Janssen, which secured market entry dates for Yesintek in the US, Europe, the UK, Canada and Japan.</span></p>
<p><span>According to Biocon, the additional market entry rights for biosimilar ustekinumab will allow it to offer an affordable and effective treatment option for patients affected by autoimmune diseases in these markets.</span></p>
<p><span>Yesintek is a human interleukin-12 and -23 antagonist that disrupts IL-12 and IL-23-mediated signalling in immune-mediated diseases. It has been approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis.</span></p>
<p><span>The reference brand, Stelara, recorded worldwide sales of $6.08 billion in 2025, according to Johnson & Johnson’s reported 2025 sales.</span></p>
<p>The post <a href="https://www.expresspharma.in/biocon-secures-yesintek-biosimilar-rights-in-nine-markets/">Biocon secures Yesintek biosimilar rights in nine markets</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Entering pharma drug discovery presents an opportunity to apply scientific capabilities to a new set of health challenges</title>
<link>https://edusehat.com/en/entering-pharma-drug-discovery-presents-an-opportunity-to-apply-scientific-capabilities-to-a-new-set-of-health-challenges</link>
<guid>https://edusehat.com/en/entering-pharma-drug-discovery-presents-an-opportunity-to-apply-scientific-capabilities-to-a-new-set-of-health-challenges</guid>
<description><![CDATA[ 
Godavari Biorefineries is advancing research into novel cancer therapies, securing US patent protection and expanding the geographical reach of its intellectual property following earlier grants in India, China and Japan. Dr Sangeeta Srivastava, Executive Director, Godavari Biorefineries, discusses the research outcomes, therapeutic potential and significance of this milestone.
The post Entering pharma drug discovery presents an opportunity to apply scientific capabilities to a new set of health challenges appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/26111455/EP_Dr-Sangeeta-Srivastava_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 26 Oct 2026 15:40:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Entering, pharma, drug, discovery, presents, opportunity, apply, scientific, capabilities, new, set, health, challenges</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/26111455/EP_Dr-Sangeeta-Srivastava_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/26111455/EP_Dr-Sangeeta-Srivastava_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/26111455/EP_Dr-Sangeeta-Srivastava_750-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><b>What do the Mexican patent for “Use of Compounds for Treating Viral Infections” and the </b><b>US patent for a cancer-treatment molecule signify for Godavari Biorefineries’ life sciences </b><b>research programme and long-term business strategy?</b></p>
<p><span>The grant of the US patent for our oncology molecule and the Mexican patent for our antiviral </span><span>compounds marks a strategic shift for Godavari Biorefineries. These patents reflect how our </span><span>R&D capabilities have evolved from bio-based chemical innovation to high-value, IP-driven drug </span><span>discovery. By focusing on cancer stem cell inhibition and host-targeting antivirals, our research </span><span>directly addresses two of medicine’s greatest challenges: disease recurrence and drug </span><span>resistance.</span></p>
<p><span>Securing protection across key markets such as the US, Mexico, Japan, and China </span><span>strengthens our ability to pursue international collaborations, co-development opportunities, </span><span>and future commercialisation pathways.</span></p>
<p><span>Most importantly, it reinforces our belief that science-driven innovation from India can </span><span>contribute meaningfully to global healthcare challenges.</span></p>
<p><b>How is Godavari Biorefineries leveraging its legacy in sugar manufacturing and bio-based </b><b>chemicals to expand into drug discovery, antiviral research, and cancer therapeutics?</b></p>
<p><span>Godavari Biorefineries’ expansion into life sciences reflects the company’s continued </span><span>focus on research and development, with work extending into drug discovery and the </span><span>development of potential therapies for cancer and viral infections.</span></p>
<p><span>The company’s life sciences research encompasses a lead candidate being developed for triple- </span><span>negative breast cancer (TNBC), an aggressive form of breast cancer. The candidate has </span><span>completed Phase I studies, with safety, tolerability, and pharmacokinetics among the </span><span>parameters evaluated. Preclinical research has also reported anti-cancer activity in breast and </span><span>prostate cancer models, alongside potential antiviral activity against SARS-CoV-2 and influenza </span><span>virus.</span></p>
<p><span>Beyond this programme, research is exploring potential treatments for other difficult-to-treat </span><span>cancers, including prostate cancer and glioblastoma, as well as potential antiviral therapies. </span><span>These programmes reflect the breadth of the company’s efforts to address areas of significant </span><span>unmet medical need. </span><span>Through its growing capabilities in life sciences research, Godavari Biorefineries is extending its </span><span>research-led approach into the development of potential therapeutic applications. The focus </span><span>remains on advancing promising molecules through the drug-development process, supported </span><span>by scientific research, intellectual property development, and opportunities for collaboration.</span></p>
<p><span>What are the next steps for these patented molecules?</span></p>
<p><span>Having secured intellectual property protection in key international markets, our focus is now </span><span>on advancing these molecules through rigorous scientific evaluation and translational research. </span><span>Our immediate priority is to build on the encouraging safety data from our completed Phase 1a </span><span>oncology study as we prepare for the next stage of clinical development, focusing on triple- </span><span>negative breast cancer (TNBC) and other solid tumours. This progress provides a foundation for </span><span>discussions with prospective partners who can support further clinical development. </span></p>
<p><span>In parallel, we are advancing our newer oncology and antiviral compounds through their </span><span>respective development programmes. Through our presence in Princeton, New Jersey, we are </span><span>engaging partners on clinical co-development, joint research, licensing by asset or territory, and </span><span>strategic investment. We believe flexible partnership models can help bring together </span><span>complementary expertise to advance these programmes.</span></p>
<p><b>Which types of cancer are you currently targeting through your research? Which viral </b><b>infections are you prioritising in your antiviral research?</b></p>
<p><span>In oncology, our primary areas of interest include Triple Negative Breast Cancer (TNBC) and </span><span>advanced prostate cancer. We are also exploring potential applications in oral, glioblastoma, </span><span>liver, cervical, colon, and lung cancers.</span></p>
<p><span>A key aspect of our research is targeting cancer stem cells, which are believed to contribute to </span><span>tumour recurrence, metastasis, and resistance to conventional therapies. Investigating these </span><span>cells is an important area of research in understanding these challenges. </span><span>In antiviral research, we are focusing on SARS-CoV-2 and influenza. Rather than targeting the </span><span>virus directly, our approach aims to study and interfere with the cellular pathways that viruses </span><span>rely on to infect human cells. This host-targeting approach focuses on cellular mechanisms </span><span>involved in viral infection, rather than on the virus itself.</span></p>
<p><b>What are the key scientific, regulatory and financial challenges a company rooted in the </b><b>sugar and bio-based chemicals industry faces when entering the pharmaceutical drug- </b><b>discovery space?</b></p>
<p><span>For a company with its foundations in sugar and bio-based chemicals, entering pharmaceutical </span><span>drug discovery presents an opportunity to apply its scientific capabilities to a new set of </span><span>healthcare challenges. Our experience in cosmetics, flavours and fragrances, and personal care </span><span>has helped build a foundation in scientific research, product development and regulatory </span><span>discipline, which can be extended as we develop our capabilities in cancer research and </span><span>antiviral drug discovery.</span></p>
<p><span>In cancer research, one of the key priorities is identifying promising molecules and </span><span>understanding their activity across different cancer types, including difficult-to-treat cancers. </span><span>This requires a multidisciplinary approach combining chemistry, molecular biology, </span><span>pharmacology, and toxicity evaluation. Similarly, antiviral research involves studying how </span><span>viruses interact with host cells and identifying potential therapeutic approaches that can be </span><span>evaluated for their activity and safety. In both areas, rigorous preclinical evaluation and a </span><span>systematic progression through the stages of drug development are essential to building a </span><span>strong scientific foundation.</span></p>
<p><span>From a regulatory perspective, each candidate must be supported by appropriate safety, </span><span>efficacy, and quality data as it progresses through the relevant stages of development. This calls </span><span>for robust research practices, careful documentation, and alignment with applicable regulatory </span><span>requirements. Developing specialised scientific capabilities and infrastructure, while fostering </span><span>collaboration across disciplines, helps strengthen this process. </span><span>Drug discovery also requires a long-term approach to investment, given the time involved in </span><span>evaluating molecules and advancing them through development. Prioritising research </span><span>programmes, allocating resources carefully and assessing scientific progress at each stage are </span><span>important to maintaining a balanced and sustainable pipeline. These considerations encourage </span><span>a disciplined approach to decision-making while allowing promising research to progress. </span><span>Our focus is on building scientific capabilities that can translate research into potential </span><span>therapeutic applications. By combining rigorous research, responsible development, and </span><span>collaboration, we aim to advance our work in cancer and antiviral research while contributing </span><span>to progress in areas where new treatment options are needed.</span></p>
<p><b>What is the potential commercial value of these discoveries? Do you see intellectual </b><b>property licensing and partnerships with established pharmaceutical companies as a viable </b><b>route to market?</b></p>
<p><span>We see potential in building a portfolio of therapeutic candidates rather than relying on a single </span><span>molecule. Our lead oncology programme has completed Phase 1a, while other molecules in our </span><span>pipeline are at different stages of research and evaluation, including studies assessing their </span><span>efficacy. Our patented compounds have shown inhibitory effects against cancer cells and </span><span>cancer stem cells in in vitro studies, with activity observed across multiple cancer cell types, </span><span>including breast and prostate cancer.</span></p>
<p><span>Our research focuses on developing original molecules and exploring new approaches to </span><span>addressing cancer and other healthcare challenges. Partnerships can play an important role in </span><span>advancing these research programmes. Drug development requires clinical expertise, </span><span>regulatory capabilities, funding, and market access, which can complement our strengths in </span><span>research and intellectual property. Depending on the molecule and its stage of development, </span><span>we can explore asset-specific arrangements or broader research collaborations with partners </span><span>whose capabilities align with our programmes.</span></p>
<p><b>Beyond these two patented discoveries, what other life sciences research programmes or </b><b>therapeutic areas are in your pipeline?</b></p>
<p><span>Beyond the two recently patented discoveries, we are building a growing portfolio of </span><span>proprietary molecules, with oncology as a central focus. Our lead clinical-stage programme </span><span>provides an important foundation, while emerging candidates are being investigated through </span><span>different mechanisms of action and for potential applications across several solid tumours. </span><span>Having multiple molecules at different stages of development allows us to explore a wider </span><span>range of research opportunities and work with partners based on their areas of interest. </span><span>We continue to develop our intellectual property portfolio and evaluate opportunities to </span><span>advance these candidates. Our long-term objective is to combine scientific innovation, </span><span>responsible development and strategic collaboration to build a sustainable life sciences </span><span>business. This reflects our broader purpose of creating value through research and contributing </span><span>to a healthier future.</span></p>
<p> </p>
<p><em><strong>sanjiv.das@expressindia.com</strong></em></p>
<p><em><strong>sanjivdas1@gmail.com</strong></em></p>
<p>The post <a href="https://www.expresspharma.in/entering-pharma-drug-discovery-presents-an-opportunity-to-apply-scientific-capabilities-to-a-new-set-of-health-challenges/">Entering pharma drug discovery presents an opportunity to apply scientific capabilities to a new set of health challenges</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Government sets up panel to review pharma marketing rules</title>
<link>https://edusehat.com/en/government-sets-up-panel-to-review-pharma-marketing-rules</link>
<guid>https://edusehat.com/en/government-sets-up-panel-to-review-pharma-marketing-rules</guid>
<description><![CDATA[ 
Three-member committee to assess whether existing safeguards against unethical marketing are effective and recommend changes to improve monitoring and enforcement.
The post Government sets up panel to review pharma marketing rules appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2020/08/13102945/Boardroom.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 24 Oct 2026 20:00:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Government, sets, panel, review, pharma, marketing, rules</media:keywords>
<content:encoded><![CDATA[<div><img width="888" height="500" src="https://cdn.expresspharma.in/wp-content/uploads/2020/08/13102945/Boardroom.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2020/08/13102945/Boardroom.jpg 888w, https://cdn.expresspharma.in/wp-content/uploads/2020/08/13102945/Boardroom-300x169.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2020/08/13102945/Boardroom-768x432.jpg 768w" sizes="(max-width: 888px) 100vw, 888px"></div><p><span><span>The Department of Pharmaceuticals has set up a three-member committee to review the rules governing pharmaceutical marketing practices and recommend measures to curb unethical practices.</span></span></p>
<p><span><span>According to a recent order, the committee will examine whether the existing system for monitoring and enforcing ethical marketing practices is working effectively. It will identify gaps and recommend measures to improve transparency, accountability and compliance.</span></span></p>
<p><span><span>The committee will be chaired by Dr M Srinivas, Member, NITI Aayog. The other members are Preeti Sudan, former Union Health Secretary, and Dr Naresh Trehan, Chairman and Managing Director, Medanta.</span></span></p>
<p><span><span>The committee will review the Uniform Code for Pharmaceutical Marketing Practices (UCPMP), introduced in 2015 as a voluntary, industry-led mechanism to promote ethical marketing by pharma companies. The UCPMP 2024 replaced the original code and strengthened its implementation framework.</span></span></p>
<p><span><span>Its terms of reference include examining issues related to unethical pharmaceutical marketing and assessing the effectiveness of existing monitoring, oversight and enforcement mechanisms.</span></span></p>
<p><span><span>The committee has been asked to recommend improvements to the existing framework. The government order does not specify any immediate changes to the UCPMP or announce new restrictions or penalties.</span></span><span><span> Any changes will depend on the recommendations and subsequent government decisions.</span></span></p>
<p><span><span>The UCPMP aims to ensure that pharma promotion is accurate and evidence-based, and that doctors’ prescribing decisions are not improperly influenced by gifts, financial inducements or other benefits from pharma companies.</span></span></p>
<p>The post <a href="https://www.expresspharma.in/government-sets-up-panel-to-review-pharma-marketing-rules/">Government sets up panel to review pharma marketing rules</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Amneal Pharmaceuticals inaugurates Rs 135 crore office in Ahmedabad</title>
<link>https://edusehat.com/en/amneal-pharmaceuticals-inaugurates-rs-135-crore-office-in-ahmedabad</link>
<guid>https://edusehat.com/en/amneal-pharmaceuticals-inaugurates-rs-135-crore-office-in-ahmedabad</guid>
<description><![CDATA[ 
The 3.35 lakh sq ft facility will accommodate around 1,200 employees and support the company’s operations in India
The post Amneal Pharmaceuticals inaugurates Rs 135 crore office in Ahmedabad appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 23 Oct 2026 18:55:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Amneal, Pharmaceuticals, inaugurates, 135, crore, office, Ahmedabad</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>Amneal Pharmaceuticals has inaugurated its new administrative office in Ahmedabad, with an investment of approximately Rs 135 crore ($15 million), to support its teams in India and strengthen collaboration across its global business.</span></p>
<p><span>Located on Cliantha Road, Ahmedabad, the office spans approximately 3.35 lakh square feet and will accommodate around 1,200 employees. The facility is designed to support Amneal’s workforce, bring key teams together, strengthen collaboration and provide infrastructure for the company’s operations in India.</span></p>
<p><span>Amneal has expanded its capabilities in India across manufacturing, research and development, quality and commercial operations, including its commercial office in Mumbai. These operations form part of the company’s global network, which spans the US, India and Ireland. In August, the company acquired Kashiv BioSciences, expanding its global biosimilar development and manufacturing capabilities.</span></p>
<p><span>“This new Ahmedabad office reflects Amneal’s continued investment in the people and capabilities that support its global business. India is an important part of our network, complementing our significant and growing U.S. manufacturing footprint,” said Chirag Patel, co-founder and co-chief executive officer of Amneal. “Across our operations, we are investing in scientific expertise, manufacturing and infrastructure to support sustainable growth and expand access to high-quality, affordable medicines.”</span></p>
<p><span>“Our colleagues in India play an important role in advancing Amneal’s research, development, manufacturing and business operations,” said Chintu Patel, co-founder and co-chief executive officer of Amneal. “This new office brings key teams together in a space designed to support collaboration and their continued development. By connecting our people and expertise across our global network, we can strengthen execution, advance increasingly complex medicines and better serve patients.”</span></p>
<p><span>Amneal is also advancing plans for two greenfield manufacturing facilities in Gujarat, focused on peptide synthesis and sterile fill-finish manufacturing. These projects form part of the company’s investment in capabilities to support its future portfolio.</span></p>
<p><span>The new office supports Amneal’s strategy to strengthen its global capabilities and expand access to high-quality, affordable medicines.</span></p>
<p>The post <a href="https://www.expresspharma.in/amneal-pharmaceuticals-inaugurates-rs-135-crore-office-in-ahmedabad/">Amneal Pharmaceuticals inaugurates Rs 135 crore office in Ahmedabad</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Lupin appoints Brian Savage as President and Chief Legal Officer</title>
<link>https://edusehat.com/en/lupin-appoints-brian-savage-as-president-and-chief-legal-officer</link>
<guid>https://edusehat.com/en/lupin-appoints-brian-savage-as-president-and-chief-legal-officer</guid>
<description><![CDATA[ 
Savage will lead Lupin’s global Legal, Compliance and Intellectual Property Management Group functions and will be based in New Jersey
The post Lupin appoints Brian Savage as President and Chief Legal Officer appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/23111055/EP_Brian_Savage_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 23 Oct 2026 15:20:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Lupin, appoints, Brian, Savage, President, and, Chief, Legal, Officer</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/23111055/EP_Brian_Savage_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/23111055/EP_Brian_Savage_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/23111055/EP_Brian_Savage_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Lupin has announced the appointment of Brian Savage as President and Chief Legal Officer. Savage will lead the company’s global Legal, Compliance and Intellectual Property Management Group (IPMG) functions and will be based in New Jersey.</span></p>
<p><span>Savage joins Lupin from Teva Pharmaceuticals, where he held several senior leadership roles since 2015. Most recently, he served as Teva’s Executive Vice President and Interim Global Chief Legal Officer. During his tenure, he also led Teva’s global litigation strategy and served as General Counsel for its US Generics business. Before joining Teva, Savage practised law at Dechert LLP.</span></p>
<p><span>Savage holds a Juris Doctor (J.D.) from Yale Law School and a B.A., summa cum laude, from the University of Pennsylvania.</span></p>
<p><span>Commenting on the appointment, Lupin CEO Vinita Gupta and Managing Director Nilesh Gupta said, “We are delighted to welcome Brian to our executive leadership team. His deep understanding of the pharmaceutical industry landscape, extensive legal expertise, and proven leadership will be valuable as we continue to strengthen our governance framework, navigate an evolving regulatory environment, and advance our long term growth ambitions.”</span></p>
<p>The post <a href="https://www.expresspharma.in/lupin-appoints-brian-savage-as-president-and-chief-legal-officer/">Lupin appoints Brian Savage as President and Chief Legal Officer</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Bharat Biotech cuts malaria vaccine price by 40 % under Gavi&#45;UNICEF agreement</title>
<link>https://edusehat.com/en/bharat-biotech-cuts-malaria-vaccine-price-by-40-under-gavi-unicef-agreement</link>
<guid>https://edusehat.com/en/bharat-biotech-cuts-malaria-vaccine-price-by-40-under-gavi-unicef-agreement</guid>
<description><![CDATA[ 
The agreement is expected to generate US$50 million in savings and help protect one million more children with the RTS,S/AS01 vaccine between 2027 and 2029
The post Bharat Biotech cuts malaria vaccine price by 40 % under Gavi-UNICEF agreement appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2019/10/11180711/stocks-down-e1722252808109.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 23 Oct 2026 15:20:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Bharat, Biotech, cuts, malaria, vaccine, price, under, Gavi-UNICEF, agreement</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="399" src="https://cdn.expresspharma.in/wp-content/uploads/2019/10/11180711/stocks-down-e1722252808109.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2019/10/11180711/stocks-down-e1722252808109.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2019/10/11180711/stocks-down-e1722252808109-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>Bharat Biotech International Limited (BBIL) has announced an equitable pricing agreement with Gavi, the Vaccine Alliance, and UNICEF for the RTS,S/AS01 malaria vaccine, developed by GSK and manufactured by BBIL under the brand name Mosqivac.</span></p>
<p><span>The agreement, executed by UNICEF and financially backed by Gavi, will reduce the vaccine’s price by approximately 40 per cent. It is expected to generate around US$50 million in savings for child immunisation programmes between 2027 and 2029 and enable up to one million more children to receive the full four-dose course.</span></p>
<p><span>Enabled through an advance payment by the International Finance Facility for Immunisation (IFFIm), the agreement will bring the vaccine’s price to EUR 5.50 per dose, a reduction of approximately 40 per cent from the price paid today. The lower price is expected to take effect by early 2027 and reflects efforts to establish a sustainable and competitive malaria vaccine market.</span></p>
<p><span>RTS,S/AS01, developed by GSK, PATH and partners, was the first malaria vaccine to be recommended by the World Health Organization (WHO), in 2021. Since then, GSK and Bharat Biotech have invested US$200 million in manufacturing facilities with higher output, product development and technology transfer to expand and strengthen supply at a lower cost. These investments are supporting access to the vaccine and its potential public health impact.</span></p>
<p><span>“The Gavi–UNICEF deal is a far-reaching commitment to expand malaria vaccination and according to Gavi/UNICEF estimates, can help ensure one million more children are protected from malaria. As partners in global public health, we have invested significantly to expand supply, strengthen manufacturing and support sustainable, affordable access to malaria vaccines,” Dr. Krishna Ella, Executive Chairman of Bharat Biotech International said.</span></p>
<p><span>“The opportunity is to turn this progress into public health. Countries and global organizations now have an important role to play in accelerating vaccine introductions so that more children and communities at risk can benefit. We remain committed to working with partners to help make that happen and reduce the burden of malaria,” Dr. Ella added.</span></p>
<p><span>Dr. Harmony P. Garges, GSK’s Chief Global Health Officer, said “This new agreement follows major investment by both GSK and BBIL to help secure long-term equitable access to RTS,S/AS01 for many more children. At a time when global health resources are under increasing pressure – both for international organisations and for countries – partnership matters more than ever and this deal with Gavi–UNICEF further demonstrates how close collaboration across the global health landscape can help deliver real impact for children most at risk of malaria.”</span></p>
<p><span>Demand for malaria vaccines has exceeded initial forecasts since rollout began in 2024. To date, UNICEF has procured and delivered more than 74 million doses. The Gavi-funded malaria programme is now part of routine immunisation in 25 African countries, which account for more than 70 per cent of the global malaria burden.</span></p>
<p><span>At a time of decline in funding for international aid, efforts to establish affordable and sustainable supply are critical to meeting the Alliance’s target of vaccinating 50 million more children against malaria by 2030.</span></p>
<p><span>One child dies from malaria every minute, accounting for nearly half a million deaths each year. In 2024, an estimated 282 million malaria cases and 610,000 deaths were reported globally. Up to 95 per cent of cases and deaths occurred in Africa, where around 74 per cent of deaths were among children under five.</span></p>
<p><span>A full four-dose course of RTS,S/AS01 reduces malaria cases by about 75 per cent when administered seasonally in areas with high seasonal transmission. New and improved malaria vaccines will be increasingly important as rising temperatures alter transmission patterns and extend malaria into new areas, while flooding and other extreme events displace communities, damage infrastructure and disrupt health systems.</span></p>
<p><span>Vaccines are one of several malaria interventions, alongside insecticide-treated nets, spatial emanators, repellents and other vector control interventions, chemoprevention, and prompt diagnosis and treatment.</span></p>
<p>The post <a href="https://www.expresspharma.in/bharat-biotech-cuts-malaria-vaccine-price-by-40-under-gavi-unicef-agreement/">Bharat Biotech cuts malaria vaccine price by 40 % under Gavi-UNICEF agreement</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>1win Global App Mobile Guide – Registration, Play &amp;amp; Cash Out</title>
<link>https://edusehat.com/en/1win-global-app-mobile-guide-registration-play-cash-out</link>
<guid>https://edusehat.com/en/1win-global-app-mobile-guide-registration-play-cash-out</guid>
<description><![CDATA[ Practical Guide to the 1win Global App – How to Register, Play, and Cash Out Getting Started: Registration and First Steps When you open the 1win global app 
The post 1win Global App Mobile Guide – Registration, Play &amp; Cash Out appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/Bvya_4hXzkc/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 21:20:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>1win, Global, App, Mobile, Guide, –, Registration, Play, Cash, Out</media:keywords>
<content:encoded><![CDATA[<figure data-affgun-media="hero"><img src="https://i.ytimg.com/vi/Bvya_4hXzkc/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<h1>Practical Guide to the 1win Global App – How to Register, Play, and Cash Out</h1>
<h2>Getting Started: Registration and First Steps</h2>
<div data-affgun-media="video"></div>
<p>When you open the 1win global app for the first time, the onboarding screen asks for a simple email address or phone number. The form is deliberately short – you type your contact, create a password, and confirm you are over 18. After you hit “Sign Up”, an activation code lands in your inbox, and you type it back into the app to finish the registration. This quick process is designed for beginners who do not want to fill out long questionnaires before they can start playing.</p>
<nav aria-label="Table of contents">
<ol>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1win-global-app-mobile-guide-registration-play-cash-out/#getting-started-registration-and-first-steps">Getting Started: Registration and First Steps</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1win-global-app-mobile-guide-registration-play-cash-out/#navigating-the-1win-global-app-interface">Navigating the 1win Global App Interface</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1win-global-app-mobile-guide-registration-play-cash-out/#bonuses-and-promotions-what-to-expect">Bonuses and Promotions: What to Expect</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1win-global-app-mobile-guide-registration-play-cash-out/#payment-methods-deposits-and-withdrawals">Payment Methods, Deposits and Withdrawals</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1win-global-app-mobile-guide-registration-play-cash-out/#security-verification-and-responsible-gambling">Security, Verification and Responsible Gambling</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1win-global-app-mobile-guide-registration-play-cash-out/#mobile-experience-vs-desktop-performance-and-features">Mobile Experience vs Desktop: Performance and Features</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1win-global-app-mobile-guide-registration-play-cash-out/#live-casino-and-sportsbook-highlights">Live Casino and Sportsbook Highlights</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1win-global-app-mobile-guide-registration-play-cash-out/#customer-support-and-licensing-details">Customer Support and Licensing Details</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1win-global-app-mobile-guide-registration-play-cash-out/#frequently-asked-questions">Frequently Asked Questions</a></li>
</ol>
</nav>
<p>Once your account is active, the app immediately offers a welcome bonus that usually matches your first deposit. Keep an eye on the bonus terms, because the wagering requirements can vary between 20x and 40x depending on the promotion. If you plan to use the bonus, it is wise to read the fine print early, otherwise you might be surprised when you try to withdraw winnings later.</p>
<h2>Navigating the 1win Global App Interface</h2>
<p>The home screen of the 1win global app is split into three main tabs: Casino, Sportsbook, and Live. Each tab is represented by a clear icon, making it easy for users to jump straight to the section they want. The casino tab lists slots, table games, and a live dealer area, while the sportsbook shows current matches with live odds. A small notification bell in the top right corner alerts you to new promotions or pending verification steps.</p>
<p>If you prefer a more classic layout, you can swipe left to reveal a “Classic View” that mimics a desktop browser. This view shows a full menu on the left side, where you can access payment methods, settings, and responsible gambling tools. The app also remembers your last played game, so you can continue a slot round where you left it – a handy feature for players who like short, frequent sessions.</p>
<h2>Bonuses and Promotions: What to Expect</h2>
<p>The 1win global app rolls out a rotating set of bonuses, from a 100% welcome match to weekly free spin offers. Most promotions are tied to specific games, for example “50 free spins on Starburst every Friday”. The key term you will see is <strong>wagering requirements</strong>; a typical 30x requirement means you need to bet thirty times the bonus amount before you can cash out.</p>
<p>Below is a quick snapshot of the current main offers:</p>
<ul>
<li>Welcome Bonus: 100% up to $200 + 50 free spins</li>
<li>Reload Bonus: 50% up to $100 every Monday</li>
<li>Live Casino Cashback: 10% of losses returned weekly</li>
<li>Sportsbook Accumulator Boost: 20% extra winnings on 3+ leg bets</li>
</ul>
<h2>Payment Methods, Deposits and Withdrawals</h2>
<p>The app supports a range of popular deposit methods, including credit cards, e‑wallets, and bank transfers. Each method has its own minimum amount and typical processing time. When you request a withdrawal, the speed largely depends on the method you choose; e‑wallets are usually instant, while bank transfers can take up to three business days.</p>
<table border="1" cellpadding="5" cellspacing="0">
<thead>
<tr>
<th>Method</th>
<th>Minimum Deposit</th>
<th>Withdrawal Speed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visa / MasterCard</td>
<td>$10</td>
<td>1‑2 business days</td>
</tr>
<tr>
<td>PayPal</td>
<td>$20</td>
<td>Instant</td>
</tr>
<tr>
<td>Bank Transfer</td>
<td>$50</td>
<td>1‑3 business days</td>
</tr>
<tr>
<td>Trustly</td>
<td>$15</td>
<td>Instant</td>
</tr>
</tbody>
</table>
<p>Remember to check the <a href="https://nickodemus.com/">1win rwanda withdrawal online</a> guide if you are based in East Africa, as local banking partners may affect the final payout time.</p>
<h2>Security, Verification and Responsible Gambling</h2>
<p>Security is taken seriously on the 1win global app. All data transmission is encrypted with SSL, and the platform holds a licence from a reputable gambling authority. Before you can withdraw large sums, the app will ask you to complete a KYC (Know Your Customer) verification. This typically involves uploading a photo ID and a utility bill, a process that takes a few minutes if the documents are clear.</p>
<p>For responsible gambling, the app includes self‑exclusion tools, deposit limits, and a “time out” button that temporarily blocks access. These features are hidden in the Settings → Responsible Gaming menu, making them easy to find without cluttering the main gaming area.</p>
<h2>Mobile Experience vs Desktop: Performance and Features</h2>
<p>While the 1win global app is built for smartphones, the desktop version offers a slightly larger screen for live dealer tables. On mobile, the app automatically reduces graphic load to keep the slots running smoothly, which can be a plus for users on slower connections. Both platforms share the same account balance, bonus status, and game library, so you can start a session on your phone and finish it on a laptop without any loss of progress.</p>
<p>One practical tip: enable push notifications on the mobile app. You will receive real‑time alerts when your favourite sport goes live, when a new casino bonus drops, or when a withdrawal has been processed. This keeps you in the loop without constantly checking the website.</p>
<h2>Live Casino and Sportsbook Highlights</h2>
<p>The live casino section of the 1win global app streams real dealers in high definition. Popular tables include Blackjack, Roulette, and Baccarat, each with a chat function so you can talk to the dealer or other players. The RTP (Return to Player) on most live games matches the standard casino average, usually around 96% for Blackjack and 97% for Roulette.</p>
<p>On the sportsbook side, the app covers major leagues worldwide, from the English Premier League to the NBA. You can place pre‑match bets, in‑play wagers, and even virtual sports. The app displays live odds updates every few seconds, and you can cash out early on many selections, which is handy if a match turns against you.</p>
<h2>Customer Support and Licensing Details</h2>
<p>Support is available 24/7 through live chat, email, and a toll‑free phone line. The chat window often includes quick‑reply buttons for common issues such as “Deposit not received” or “How to verify my account”. Response times are usually under two minutes for chat, and within a few hours for email.</p>
<p>The 1win global app operates under a licence issued by the Curacao eGaming Authority. While this licence is respected in many jurisdictions, the app does not accept players from some restricted countries. Before you sign up, check the “Country Availability” list in the FAQ to ensure your location is permitted.</p>
<h2>Frequently Asked Questions</h2>
<ul>
<li><strong>Is the 1win global app available on iOS and Android?</strong> Yes, you can download it from the Apple App Store or Google Play Store.</li>
<li><strong>How long does a withdrawal take?</strong> E‑wallets are instant, while bank transfers may need up to three business days.</li>
<li><strong>Can I set a deposit limit?</strong> Absolutely – the app lets you set daily, weekly, or monthly limits in the Responsible Gaming menu.</li>
<li><strong>What is the minimum age to play?</strong> You must be at least 18 years old, and verification will confirm your age.</li>
</ul>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/uncategorized/1win-global-app-mobile-guide-registration-play-cash-out/">1win Global App Mobile Guide – Registration, Play & Cash Out</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>1win App Registration Download Bonus Guide</title>
<link>https://edusehat.com/en/1win-app-registration-download-bonus-guide</link>
<guid>https://edusehat.com/en/1win-app-registration-download-bonus-guide</guid>
<description><![CDATA[ Why Choose the 1win Mobile App? How to Perform the 1win App Registration Download Safely 1win App Registration Download: Step‑by‑Step Account Creation Verification (KYC) – Making Your 1win 
The post 1win App Registration Download Bonus Guide appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/uyv6WRV_RB8/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 21:20:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>1win, App, Registration, Download, Bonus, Guide</media:keywords>
<content:encoded><![CDATA[<nav aria-label="Table of contents">
<ol>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1win-app-registration-download-bonus-guide/#why-choose-the-1win-mobile-app">Why Choose the 1win Mobile App?</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1win-app-registration-download-bonus-guide/#how-to-perform-the-1win-app-registration-download-safely">How to Perform the 1win App Registration Download Safely</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1win-app-registration-download-bonus-guide/#1win-app-registration-download-stepbystep-account-creation">1win App Registration Download: Step‑by‑Step Account Creation</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1win-app-registration-download-bonus-guide/#verification-kyc-making-your-1win-account-fully-functional">Verification (KYC) – Making Your 1win Account Fully Functional</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1win-app-registration-download-bonus-guide/#first-deposit-welcome-bonus-what-to-expect">First Deposit & Welcome Bonus – What to Expect</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1win-app-registration-download-bonus-guide/#payment-methods-withdrawals-and-speed">Payment Methods, Withdrawals and Speed</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1win-app-registration-download-bonus-guide/#mobile-casino-and-sportsbook-how-to-navigate-the-app">Mobile Casino and Sportsbook – How to Navigate the App</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1win-app-registration-download-bonus-guide/#support-security-and-responsible-gambling">Support, Security, and Responsible Gambling</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1win-app-registration-download-bonus-guide/#common-issues-troubleshooting-tips">Common Issues & Troubleshooting Tips</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1win-app-registration-download-bonus-guide/#final-thoughts">Final Thoughts</a></li>
</ol>
</nav>
<figure data-affgun-media="hero"><img src="https://i.ytimg.com/vi/uyv6WRV_RB8/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<h1>1win App Registration Download: A Practical Guide for Beginners</h1>
<section>
<h2>Why Choose the 1win Mobile App?</h2>
<div data-affgun-media="video"></div>
<p>The 1win app brings the full casino and sportsbook experience straight to your pocket. Unlike a desktop browser, the mobile version is optimised for touch‑screen navigation, fast loading times and push notifications about live odds and exclusive promotions. Players also benefit from a streamlined interface that groups favourite games, live casino tables and betting markets in one easy‑to‑reach dashboard.</p>
<p>From a security perspective the app uses the same SSL encryption as the web platform, so all personal data and financial transactions stay protected. If you travel often or simply prefer betting on the go, the 1win app registration download is the fastest way to stay connected to your account wherever you are.</p>
</section>
<section>
<h2>How to Perform the 1win App Registration Download Safely</h2>
<p>The first step is to obtain the official installer. The safest source is the 1win website – look for the “Download App” button that redirects to a direct APK file for Android or an App Store link for iOS. Avoid third‑party sites that promise “modified” versions; these can contain malware or be blocked by your device’s security settings.</p>
<p>After you tap the download link, you may need to enable “Install from unknown sources” on Android. This setting is found under Settings → Security. Once enabled, open the APK and follow the on‑screen prompts. iOS users will simply tap “Get” and the app will install automatically.</p>
<ul>
<li>Check the file size – the official APK is around 80 MB.</li>
<li>Verify the digital signature – the installer should be signed by “1win Ltd”.</li>
<li>Keep the app updated; new versions bring faster performance and fresh game selections.</li>
</ul>
</section>
<section>
<h2>1win App Registration Download: Step‑by‑Step Account Creation</h2>
<p>When you launch the freshly installed app, you’ll see a welcoming splash screen followed by a “Sign Up” button. Click it and you’ll be guided through a short registration form. Here’s the typical flow:</p>
<ol>
<li>Enter your email address and create a strong password.</li>
<li>Choose a unique username – this is how you’ll be identified in the chat and leaderboards.</li>
<li>Select your preferred currency (USD, EUR, etc.) and indicate your country of residence.</li>
<li>Accept the terms and conditions, then tap “Create Account”.</li>
</ol>
<p>After submission, the system sends a verification email. Click the link inside the email to activate your account. If the email doesn’t appear, check your spam folder or request a new one from the app’s “Resend verification” option.</p>
</section>
<section>
<h2>Verification (KYC) – Making Your 1win Account Fully Functional</h2>
<p>Most players can start betting right after email verification, but to withdraw funds you’ll need to complete the KYC (Know Your Customer) process. This involves uploading a government‑issued ID, proof of address, and sometimes a selfie for facial verification.</p>
<p>The app makes this simple: navigate to “Profile” → “Verification”, then use your device’s camera to capture each document. Files should be clear and under 5 MB. Once submitted, the compliance team usually reviews within 24‑48 hours. In the meantime, you can still place bets and enjoy bonus offers, but withdrawals will be held until verification is approved.</p>
</section>
<section>
<h2>First Deposit & Welcome Bonus – What to Expect</h2>
<p>After you’ve completed registration and verification, it’s time to fund your account. The 1win welcome bonus typically matches your first deposit up to a certain amount (e.g., 100 % up to $200). To claim it, use the promo code “RAZOR” during the deposit process – the same code featured in the video promo.</p>
<p>Be aware of the wagering requirements: the bonus amount must be wagered 30 times before any winnings can be withdrawn. Some games contribute at different rates; slots usually count 100 %, while table games might count only 10 % toward the requirement.</p>
<ul>
<li>Deposit methods include credit cards, e‑wallets (Skrill, Neteller) and bank transfers.</li>
<li>Minimum deposit is typically $10.</li>
<li>Bonus funds are credited instantly after a successful payment.</li>
</ul>
</section>
<section>
<h2>Payment Methods, Withdrawals and Speed</h2>
<p>Choosing the right payment method can affect how quickly you can start playing and how fast you can cash out. Below is a quick comparison of the most common options available on the 1win app.</p>
<table border="1" cellpadding="5" cellspacing="0">
<thead>
<tr>
<th>Method</th>
<th>Deposit Speed</th>
<th>Withdrawal Speed</th>
<th>Typical Fees</th>
</tr>
</thead>
<tbody>
<tr>
<td>Credit/Debit Card</td>
<td>Instant</td>
<td>3‑5 business days</td>
<td>No fee for deposits, small fee for withdrawals</td>
</tr>
<tr>
<td>E‑wallet (Skrill, Neteller)</td>
<td>Instant</td>
<td>24‑48 hours</td>
<td>No fee</td>
</tr>
<tr>
<td>Bank Transfer</td>
<td>1‑2 business days</td>
<td>3‑7 business days</td>
<td>Variable fee depending on bank</td>
</tr>
</tbody>
</table>
<p>For most players, e‑wallets provide the best balance between speed and convenience. If you’re concerned about privacy, card transactions are still fully encrypted and safe.</p>
</section>
<section>
<h2>Mobile Casino and Sportsbook – How to Navigate the App</h2>
<p>Once logged in, the bottom navigation bar splits the experience into three main tabs: Casino, Sportsbook, and Account. The Casino section houses slots, live dealer tables, and jackpot games. You can filter by “Live” to see real‑time dealers and chat with other players – a great way to feel the buzz of a brick‑and‑mortar casino from your couch.</p>
<p>The Sportsbook tab covers a wide range of events, from football and basketball to e‑sports. Live betting is highlighted with a flashing icon, allowing you to place wagers as the action unfolds. The app also offers a “Quick Bet” button for favorite selections, saving you a few taps during high‑intensity moments.</p>
<ul>
<li>Use the search bar to find specific games or matches.</li>
<li>Set your preferred language and currency in the settings.</li>
<li>Enable push notifications for bonus alerts and game results.</li>
</ul>
</section>
<section>
<h2>Support, Security, and Responsible Gambling</h2>
<p>If you run into any trouble, the 1win app provides 24/7 live chat support. The chat window pops up from the “Help” icon in the Account section, and agents typically respond within a minute. There’s also an extensive FAQ covering topics from deposit limits to account closure.</p>
<p>Security measures include two‑factor authentication (2FA) and regular security audits by a reputable licensing body (the Curacao eGaming Authority). For responsible gambling, you can set daily deposit limits, self‑exclude for a chosen period, or contact the support team for personalised assistance.</p>
<p>As an example, a player from Kenya once reported difficulty withdrawing winnings due to a missing document; after uploading a clear passport scan, the verification team processed the request within 12 hours and the funds arrived via e‑wallet the next day.</p>
</section>
<section>
<h2>Common Issues & Troubleshooting Tips</h2>
<p>Even with a smooth 1win app registration download, occasional hiccups may arise. Below are the most frequent problems and quick fixes:</p>
<ul>
<li><strong>App won’t install:</strong> Ensure “Install from unknown sources” is enabled (Android) or that your iOS version meets the minimum requirement.</li>
<li><strong>Verification stuck:</strong> Clear the app cache, re‑upload the documents, and double‑check that the images are not blurred.</li>
<li><strong>Bonus not credited:</strong> Verify that you entered the promo code “RAZOR” correctly and that the deposit meets the minimum amount.</li>
</ul>
<p>If none of these steps solve the issue, open a chat with the support team and provide your user ID – they can look up the account history and resolve the matter promptly.</p>
</section>
<section>
<h2>Final Thoughts</h2>
<p>Downloading and registering on the 1win app is a straightforward process that opens the door to a world of casino games and sports betting opportunities. By following the steps outlined above, you’ll have a verified, funded account ready to claim bonuses, place wagers, and enjoy secure, fast payouts. Remember to gamble responsibly and make use of the built‑in tools for limits and self‑exclusion.</p>
<p>Ready to start? The journey begins with a single tap – and if you’re in Tanzania, you might find the localized version of the site useful: <a href="https://minecraftapk12.com/">1win tanzania</a>.</p>
</section>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/uncategorized/1win-app-registration-download-bonus-guide/">1win App Registration Download Bonus Guide</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>MSD’s Keytruda and Padcev combination receives EC approval</title>
<link>https://edusehat.com/en/msds-keytruda-and-padcev-combination-receives-ec-approval</link>
<guid>https://edusehat.com/en/msds-keytruda-and-padcev-combination-receives-ec-approval</guid>
<description><![CDATA[ The clearance permits the therapies to be administered before radical cystectomy as neoadjuvant therapy and continued following surgery as adjuvant treatment. Applicable to patients irrespective of cisplatin eligibility, 
The post MSD’s Keytruda and Padcev combination receives EC approval appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/10/PT-22-10-2026-shutterstock_2518831137.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 21:20:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>MSD’s, Keytruda, and, Padcev, combination, receives, approval</media:keywords>
<content:encoded><![CDATA[<p>The clearance permits the therapies to be administered before radical cystectomy as neoadjuvant therapy and continued following surgery as adjuvant treatment.</p>
<p>Applicable to patients irrespective of cisplatin eligibility, the authorisation covers Iceland, Liechtenstein, Norway, and all 27 EU member states.</p>
<p>The regulatory decision also encompasses Keytruda SC, marketed in the US as Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph).</p>
<p>MSD research laboratories senior vice-president and oncology, global clinical development head Dr Marjorie Green said: “Building on the previous approval of Keytruda plus Padcev in the European Union less than six months ago, we’re pleased to bring this important treatment option to a broader patient population as the first PD-1 inhibitor plus antibody-drug conjugate regimen approved for people with muscle-invasive bladder cancer regardless of cisplatin eligibility.</p>
<p>“This approval represents encouraging progress in bladder cancer care and underscores our commitment to addressing the needs of people who are living with this disease.”</p>
<p>The decision follows a positive opinion granted last month by the European Medicines Agency’s Committee for Medicinal Products for Human Use.</p>
<p>The assessment was based on the open-label, randomised Phase III KEYNOTE-B15 study, also designated EV-304, conducted alongside Astellas and Pfizer.</p>
<p>In 808 patients, perioperative treatment lowered the risk of disease recurrence, progression, or death by 47% compared to neoadjuvant cisplatin and gemcitabine chemotherapy alongside surgical resection.</p>
<p>MSD stated that local availability across Europe will depend on country-level reimbursement processes.</p>
<p>The decision follows regulatory clearance from the US Food and Drug Administration in July 2026.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/msds-keytruda-padcev-combination-ec/">MSD’s Keytruda and Padcev combination receives EC approval</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>تحميل وان اكس بت: دليل الأمان الكامل للعب آمن في الإمارات</title>
<link>https://edusehat.com/en/%D8%AA%D8%AD%D9%85%D9%8A%D9%84-%D9%88%D8%A7%D9%86-%D8%A7%D9%83%D8%B3-%D8%A8%D8%AA-%D8%AF%D9%84%D9%8A%D9%84-%D8%A7%D9%84%D8%A3%D9%85%D8%A7%D9%86-%D8%A7%D9%84%D9%83%D8%A7%D9%85%D9%84-%D9%84%D9%84%D8%B9%D8%A8-%D8%A2%D9%85%D9%86-%D9%81%D9%8A-%D8%A7%D9%84%D8%A5%D9%85%D8%A7%D8%B1%D8%A7%D8%AA</link>
<guid>https://edusehat.com/en/%D8%AA%D8%AD%D9%85%D9%8A%D9%84-%D9%88%D8%A7%D9%86-%D8%A7%D9%83%D8%B3-%D8%A8%D8%AA-%D8%AF%D9%84%D9%8A%D9%84-%D8%A7%D9%84%D8%A3%D9%85%D8%A7%D9%86-%D8%A7%D9%84%D9%83%D8%A7%D9%85%D9%84-%D9%84%D9%84%D8%B9%D8%A8-%D8%A2%D9%85%D9%86-%D9%81%D9%8A-%D8%A7%D9%84%D8%A5%D9%85%D8%A7%D8%B1%D8%A7%D8%AA</guid>
<description><![CDATA[ ما هو تطبيق وان اكس بت وكيف يعمل؟ خطوات تحميل وان اكس بت على الهواتف الذكية المتطلبات التقنية قبل التحميل طريقة التحميل عبر المتصفح أو المتجر التسجيل وإنشاء 
The post تحميل وان اكس بت: دليل الأمان الكامل للعب آمن في الإمارات appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/qgw4nd_QWIE/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 21:20:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>تحميل, وان, اكس, بت:, دليل, الأمان, الكامل, للعب, آمن, في, الإمارات</media:keywords>
<content:encoded><![CDATA[<nav aria-label="Table of contents">
<ol>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/thmyl-wn-ks-bt-dlyl-l-mn-lkml-llaab-amn-fy-lmrt/#section">ما هو تطبيق وان اكس بت وكيف يعمل؟</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/thmyl-wn-ks-bt-dlyl-l-mn-lkml-llaab-amn-fy-lmrt/#section-2">خطوات تحميل وان اكس بت على الهواتف الذكية</a>
<ol>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/thmyl-wn-ks-bt-dlyl-l-mn-lkml-llaab-amn-fy-lmrt/#section-3">المتطلبات التقنية قبل التحميل</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/thmyl-wn-ks-bt-dlyl-l-mn-lkml-llaab-amn-fy-lmrt/#section-4">طريقة التحميل عبر المتصفح أو المتجر</a></li>
</ol>
</li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/thmyl-wn-ks-bt-dlyl-l-mn-lkml-llaab-amn-fy-lmrt/#section-5">التسجيل وإنشاء حساب جديد في وان اكس بت</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/thmyl-wn-ks-bt-dlyl-l-mn-lkml-llaab-amn-fy-lmrt/#section-6">العروض والترحيب: كيفية الاستفادة من البونص عند تحميل وان اكس بت</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/thmyl-wn-ks-bt-dlyl-l-mn-lkml-llaab-amn-fy-lmrt/#section-7">طرق الدفع والسحب في وان اكس بت</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/thmyl-wn-ks-bt-dlyl-l-mn-lkml-llaab-amn-fy-lmrt/#kyc">الأمان والتحقق (KYC) في وان اكس بت</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/thmyl-wn-ks-bt-dlyl-l-mn-lkml-llaab-amn-fy-lmrt/#section-8">تجربة اللعب على الموبايل: التطبيقات، الألعاب الحية، والرياضة</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/thmyl-wn-ks-bt-dlyl-l-mn-lkml-llaab-amn-fy-lmrt/#section-9">دعم العملاء والمسؤولية الاجتماعية</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/thmyl-wn-ks-bt-dlyl-l-mn-lkml-llaab-amn-fy-lmrt/#section-10">نصائح نهائية لتجربة آمنة ومربحة مع تحميل وان اكس بت</a></li>
</ol>
</nav>
<figure data-affgun-media="hero"><img src="https://i.ytimg.com/vi/qgw4nd_QWIE/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<h1>دليل شامل لتحميل وان اكس بت: كل ما تحتاج معرفته لتجربة كازينو مميزة</h1>
<section>
<h2>ما هو تطبيق وان اكس بت وكيف يعمل؟</h2>
<div data-affgun-media="video"></div>
<p>وان اكس بت هو منصة كازينو إلكترونية تتخصص في الألعاب التقليدية والحديثة، وتقدم تجربة مدمجة بين الموقع الإلكتروني وتطبيق الهواتف الذكية. التطبيق يتيح للاعبين الوصول إلى مئات الألعاب من ألعاب السلوتس إلى الطاولة الحية، بالإضافة إلى قسم المراهنات الرياضية المتكامل.</p>
<p>من الناحية التقنية، يعتمد التطبيق على تقنيات HTML5 وWebGL لتوفير رسومات عالية الدقة وسرعة استجابة ممتازة حتى على الشبكات المتوسطة. لذلك عند <strong>تحميل وان اكس بت</strong> ستجد بيئة لعب مستقرة لا تحتاج إلى تنزيل ملفات ضخمة أو إعدادات معقدة.</p>
</section>
<section>
<h2>خطوات تحميل وان اكس بت على الهواتف الذكية</h2>
<h3>المتطلبات التقنية قبل التحميل</h3>
<p>قبل البدء في تحميل التطبيق، تأكد من أن هاتفك يعمل بنظام iOS 12 أو أعلى، أو Android 8.0 وما فوق. كما يفضل أن تكون سعة الذاكرة المتوفرة لا تقل عن 150 ميجابايت لضمان تثبيت سليم.</p>
<p>تحقق أيضاً من اتصال إنترنت ثابت؛ تحميل الملف قد يستغرق بضع دقائق إذا كان الاتصال بطيئاً، لكن بعد التثبيت سيتجاوز التطبيق أي تأخير في اللعب.</p>
<h3>طريقة التحميل عبر المتصفح أو المتجر</h3>
<p>لتجنب الحجب المفاجئ، يفضل زيارة الموقع الرسمي لوان اكس بت من خلال متصفحك المفضل ثم الضغط على زر “تحميل التطبيق”. سيتوجهك الرابط إلى صفحة مباشرة تسمح بتنزيل ملف APK لأجهزة Android أو فتح متجر App Store لأجهزة iOS.</p>
<p>بعد إكمال التحميل، افتح ملف APK ووافق على تثبيت التطبيقات من مصادر غير معروفة (يمكنك إلغاء هذا الخيار بعد انتهاء العملية). على iOS سيتطلب فقط الضغط على زر “Get” ثم إدخال Apple ID للمتابعة.</p>
</section>
<section>
<h2>التسجيل وإنشاء حساب جديد في وان اكس بت</h2>
<p>بعد <strong>تحميل وان اكس بت</strong> وتثبيته، افتح التطبيق وستظهر لك شاشة الترحيب مع زر “ابدأ التسجيل”. العملية بسيطة: أدخل بريدك الإلكتروني، اختر كلمة مرور قوية، ثم حدد اسم المستخدم الذي يفضله.</p>
<p>إضافةً إلى ذلك، يطلب منك التطبيق بعض المعلومات الشخصية الأساسية مثل تاريخ الميلاد والجنسية لتلبية متطلبات الترخيص المحلي. لا تقلق، جميع البيانات مشفرة باستخدام تقنية SSL لضمان سرية المعلومات.</p>
</section>
<section>
<h2>العروض والترحيب: كيفية الاستفادة من البونص عند تحميل وان اكس بت</h2>
<p>من أهم ما يجذب اللاعبين إلى وان اكس بت هو برنامج الترحيب الضخم. عند إكمال عملية الإيداع الأولى، ستحصل على بونص ترحيبي يصل إلى 200% من قيمة الإيداع، مع حد أقصى يصل إلى ١٠٠٠ درهم إماراتي.</p>
<p>لكن هناك شرط أساسي: <em>متطلبات المراهنة</em> (wagering requirements) تكون عادة 30 مرة من قيمة البونص + الإيداع. يمكنك قراءة تفاصيل الشرط في قسم “الشروط والأحكام” داخل التطبيق لتجنب أي مفاجآت.</p>
<ul>
<li>استخدم كود الدعوة “UAXB2024” للحصول على بونص إضافي 50 درهم.</li>
<li>الاشتراك في “نادي VIP” يتيح لك بونصات أسبوعية دون الحاجة لتحقيق متطلبات المراهنة.</li>
</ul>
</section>
<section>
<h2>طرق الدفع والسحب في وان اكس بت</h2>
<p>ينوع تطبيق وان اكس بت بين مجموعة واسعة من طرق الإيداع والسحب لتناسب اللاعبين في الإمارات. جميع عمليات الدفع تدعم العملة المحلية (درهم إماراتي) وتتم معالجتها عبر بوابات دفع معتمدة.</p>
<p>إليك جدول يوضح أهم طرق الدفع وسرعة التنفيذ:</p>
<table border="1" cellpadding="5" cellspacing="0">
<thead>
<tr>
<th>طريقة الدفع</th>
<th>الحد الأدنى (د.إ)</th>
<th>وقت المعالجة</th>
<th>ملحوظة</th>
</tr>
<tr>
<th colspan="4">إيداع</th>
</tr>
</thead>
<tbody>
<tr>
<td>بطاقة الائتمان/الخصم</td>
<td>50</td>
<td>فوري</td>
<td>آمن ومشفر</td>
</tr>
<tr>
<td>محفظة إلكترونية (PayPal, Skrill)</td>
<td>30</td>
<td>فوري</td>
<td>دعم متعدد العملات</td>
</tr>
<tr>
<td>تحويل بنكي</td>
<td>100</td>
<td>1‑2 يوم عمل</td>
<td>يتطلب توثيق إضافي</td>
</tr>
<tr>
<th colspan="4">سحب</th>
</tr>
<tr>
<td>بطاقة الائتمان/الخصم</td>
<td>100</td>
<td>1‑2 يوم عمل</td>
<td>حد أقصى لسحب يومي 5000 د.إ</td>
</tr>
<tr>
<td>محفظة إلكترونية</td>
<td>50</td>
<td>فوري</td>
<td>مناسب للمرونة</td>
</tr>
<tr>
<td>تحويل بنكي</td>
<td>200</td>
<td>2‑3 أيام عمل</td>
<td>يتطلب موافقة KYC</td>
</tr>
</tbody>
</table>
<p>تأكد من إكمال عملية التحقق (KYC) قبل طلب السحب لتسريع العملية وتجنب أي تأخير.</p>
</section>
<section>
<h2>الأمان والتحقق (KYC) في وان اكس بت</h2>
<p>يولي وان اكس بت أولوية قصوى لأمان اللاعبين من خلال بروتوكولات تشفير SSL وتقييم مستمر للتهديدات. عملية التحقق من الهوية (KYC) لا تتجاوز ثلاث خطوات: رفع صورة الهوية، إثبات العنوان (فاتورة خدمات)، وإثبات وسيلة الدفع.</p>
<p>تستغرق عملية المراجعة عادة من 15 دقيقة إلى ساعة واحدة، وتُجرى بواسطة فريق متخصص يتأكد من صحة المستندات. بمجرد إتمام KYC، ستحصل على وصول غير محدود إلى جميع الألعاب والخدمات.</p>
<p>لمزيد من الدعم أو الاستفسارات، يمكنك التواصل مع <a href="https://criticalpath.net/">جروبات تليجرام وان اكس بت</a> حيث يجيب فريق الدعم على أسئلتك في الوقت الفعلي.</p>
</section>
<section>
<h2>تجربة اللعب على الموبايل: التطبيقات، الألعاب الحية، والرياضة</h2>
<p>بعد <strong>تحميل وان اكس بت</strong>، تتوفر لك واجهة مريحة تدعم وضعية portrait وlandscape لتناسب جميع الأجهزة. تحتوي المكتبة على أكثر من 1500 لعبة، من بينها:</p>
<ul>
<li>سلوتس ذات RTP عالي (من 96.5% إلى 98.2%).</li>
<li>كازينو مباشر (Live Casino) مع موزعين حقيقيين من أوروبا.</li>
<li>قسم المراهنات الرياضية يغطي أكثر من 30 رياضة، مع خيارات للرهان المباشر.</li>
</ul>
<p>التطبيق يضمن أن جميع الألعاب متوافقة مع أحدث معايير المسؤولية الاجتماعية، حيث يمكنك تفعيل حد الخسارة اليومي أو الإيقاف المؤقت لحسابك.</p>
</section>
<section>
<h2>دعم العملاء والمسؤولية الاجتماعية</h2>
<p>يتوفر دعم العملاء على مدار 24/7 عبر قنوات متعددة: الدردشة الحية، البريد الإلكتروني، والواتساب. يهدف فريق الدعم إلى حل المشكلات خلال 5 دقائق في أغلب الحالات.</p>
<p>بالإضافة إلى ذلك، يلتزم وان اكس بت بسياسات اللعب المسؤول، بما في ذلك أدوات لتحديد الحدود الذاتية، وتقديم روابط لمواقع الإرشاد في حالة الإدمان.</p>
</section>
<section>
<h2>نصائح نهائية لتجربة آمنة ومربحة مع تحميل وان اكس بت</h2>
<p>1- ابدأ بميزانية محددة ولا تتجاوزها مهما كان إغراء البونص. 2- اقرأ تفاصيل متطلبات المراهنة قبل قبول أي بونص لتفادي التقييد غير المرغوب فيه.</p>
<p>3- استغل ألعاب ذات RTP مرتفع إذا كنت تسعى إلى عوائد مستدامة، وتجنب الألعاب ذات الفولاتيليتي العالية إذا كنت مبتدئًا.</p>
<p>4- تأكد من استخدام شبكة إنترنت مستقرة لتقليل انقطاع اللعب، ولا تنسَ تفعيل خاصية “تأكيد السحب” عبر البريد الإلكتروني لتقوية الأمان.</p>
<p>باتباع هذه الخطوات، ستحصل على تجربة تحميل وان اكس بت سلسة، وستتمكن من الاستمتاع بأفضل عروض الكازينو في الإمارات مع ضمان أمان حسابك وسرعة عمليات السحب.</p>
</section>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/uncategorized/thmyl-wn-ks-bt-dlyl-l-mn-lkml-llaab-amn-fy-lmrt/">تحميل وان اكس بت: دليل الأمان الكامل للعب آمن في الإمارات</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Astellas and AI Proteins sign miniprotein therapeutics deal</title>
<link>https://edusehat.com/en/astellas-and-ai-proteins-sign-miniprotein-therapeutics-deal</link>
<guid>https://edusehat.com/en/astellas-and-ai-proteins-sign-miniprotein-therapeutics-deal</guid>
<description><![CDATA[ Under the deal, AI Proteins is set to receive an upfront cash sum of more than $400m to design and optimise de novo miniproteins directed at targets selected 
The post Astellas and AI Proteins sign miniprotein therapeutics deal appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/10/PT-2-22-10-2026-shutterstock_1924512515.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 21:20:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Astellas, and, Proteins, sign, miniprotein, therapeutics, deal</media:keywords>
<content:encoded><![CDATA[<p>Under the deal, AI Proteins is set to receive an upfront cash sum of more than $400m to design and optimise de novo miniproteins directed at targets selected by Astellas.</p>
<p>AI Proteins also qualifies for milestone payments and royalties on net sales generated by resulting therapies.</p>
<p>AI Proteins president, CEO and founder Chris Bahl said: “Every biologic medicine on the market today is based on a molecule borrowed from nature that evolved to do something else.</p>
<p>“Designing miniproteins de novo lets us work from the other direction, meaning we specify what a medicine needs to do, then build a molecule from scratch to do precisely that.</p>
<p>“It’s a shift from repurposing to design, and it puts problems within reach that traditional biologics can’t solve. Astellas has deep expertise in translating innovative science into medicines, and they’re the right partner to carry this forward to patients.”</p>
<p>Astellas holds an exclusive global licence to therapeutic candidates produced through the partnership. The company will oversee all subsequent development, regulatory processes, and commercialisation.</p>
<p>AI Proteins will deploy its computational discovery platform to design proteins targeting multiple pathways to generate the candidates.</p>
<p>Astellas Innovation Lab senior vice-president Morten Sogaard said: “Our collaboration with AI Proteins reflects our strategic focus on strengthening our early-stage research pipeline through partnerships that provide access to novel biology, differentiated technologies and new therapeutic possibilities.</p>
<p>“By combining AI Proteins’ advanced de novo protein design capabilities with Astellas’ expertise in translating scientific breakthroughs into innovative medicines, we aim to accelerate the discovery of high-quality therapeutic candidates that can help fuel long-term innovation and support our pipeline-led growth strategy.”</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/ai-proteins-astellas-miniprotein-therapeutics/">Astellas and AI Proteins sign miniprotein therapeutics deal</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>1xbet app – what you need to know</title>
<link>https://edusehat.com/en/1xbet-app-what-you-need-to-know</link>
<guid>https://edusehat.com/en/1xbet-app-what-you-need-to-know</guid>
<description><![CDATA[ Getting Started – Registration and First Steps Verifying Your Identity (KYC) Navigating the 1xbet App – Interface and Core Features Sportsbook vs Live Casino Mobile Experience Tips Bonuses 
The post 1xbet app – what you need to know appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/svqHnx9LYvg/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 21:20:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>1xbet, app, –, what, you, need, know</media:keywords>
<content:encoded><![CDATA[<nav aria-label="Table of contents">
<ol>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1xbet-app-what-you-need-to-know/#getting-started-registration-and-first-steps">Getting Started – Registration and First Steps</a>
<ol>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1xbet-app-what-you-need-to-know/#verifying-your-identity-kyc">Verifying Your Identity (KYC)</a></li>
</ol>
</li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1xbet-app-what-you-need-to-know/#navigating-the-1xbet-app-interface-and-core-features">Navigating the 1xbet App – Interface and Core Features</a>
<ol>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1xbet-app-what-you-need-to-know/#sportsbook-vs-live-casino">Sportsbook vs Live Casino</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1xbet-app-what-you-need-to-know/#mobile-experience-tips">Mobile Experience Tips</a></li>
</ol>
</li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1xbet-app-what-you-need-to-know/#bonuses-and-promotions-on-the-1xbet-app">Bonuses and Promotions on the 1xbet App</a>
<ol>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1xbet-app-what-you-need-to-know/#understanding-wagering-requirements">Understanding Wagering Requirements</a></li>
</ol>
</li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1xbet-app-what-you-need-to-know/#payment-methods-deposits-and-withdrawals">Payment Methods – Deposits and Withdrawals</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1xbet-app-what-you-need-to-know/#security-licensing-and-responsible-gambling">Security, Licensing, and Responsible Gambling</a>
<ol>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1xbet-app-what-you-need-to-know/#responsible-play-tools">Responsible Play Tools</a></li>
</ol>
</li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1xbet-app-what-you-need-to-know/#customer-support-and-troubleshooting">Customer Support and Troubleshooting</a>
<ol>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1xbet-app-what-you-need-to-know/#common-issues-and-quick-fixes">Common Issues and Quick Fixes</a></li>
</ol>
</li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/1xbet-app-what-you-need-to-know/#common-pitfalls-and-how-to-avoid-them">Common Pitfalls and How to Avoid Them</a></li>
</ol>
</nav>
<figure data-affgun-media="hero"><img src="https://i.ytimg.com/vi/svqHnx9LYvg/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<h1>Practical Guide to Using the 1xbet App</h1>
<section>
<h2>Getting Started – Registration and First Steps</h2>
<div data-affgun-media="video"></div>
<p>Before you can spin the roulette or place a football bet, you need an account on the 1xbet app. The registration process is deliberately short: you enter a valid e‑mail address, pick a password, and confirm your country. Most users finish this step in under two minutes, but it helps to have a phone number handy for the optional two‑factor verification.</p>
<p>After the basic data, the system will ask for your preferred currency and whether you want promotional emails. Choose wisely – the welcome bonus is tied to the currency you pick, and changing it later can be a hassle. When you click “Register”, you’ll receive a confirmation link; once you click that, the account becomes active and you can log in straight away.</p>
<h3>Verifying Your Identity (KYC)</h3>
<p>Many jurisdictions require 1xbet to verify who you are, especially before any large withdrawal. The app will prompt you to upload a photo of a government ID and a selfie. The upload is simple: take a clear picture, make sure the file size is under 5 MB, and submit. Usually the verification is approved within a few hours, though sometimes it can stretch to a day.</p>
<p>If the verification is delayed, double‑check that the document is not expired and that all details are legible. In most cases, a quick chat with support clears the issue, and you can start betting without further interruptions.</p>
</section>
<section>
<h2>Navigating the 1xbet App – Interface and Core Features</h2>
<p>The 1xbet app is split into three main tabs: Sportsbook, Live Casino, and My Account. The navigation bar stays at the bottom of the screen, making it easy to switch between live betting and casino games without leaving the app. Colors are bold, icons are big, and the search function works both for teams and for specific slot titles.</p>
<p>For beginners, the “Featured” carousel on the home screen shows the most popular events and newest slot releases. Tap any item to see odds, RTP (return to player) percentages, and quick bet buttons. The app also supports “Quick Bet” – a one‑tap wager on pre‑selected odds, great for those who like instant action.</p>
<h3>Sportsbook vs Live Casino</h3>
<p>Sportsbook is where you find pre‑match odds for football, basketball, tennis and many other sports. Live betting appears once a match starts, with odds updating every few seconds. Live Casino, on the other hand, offers streamed tables with real dealers, plus classic slots that run on the same server as the desktop version.</p>
<p>If you enjoy the social vibe of a real dealer, the live casino section works best on a stable Wi‑Fi connection. For fast, on‑the‑go action, the sportsbook’s “Bet Slip” lets you add multiple selections and place a parlay in seconds.</p>
<h3>Mobile Experience Tips</h3>
<p>To keep the app running smooth, clear the cache once a week and close background apps that consume memory. The 1xbet app supports both Android and iOS, but the iOS version has a slightly tighter security sandbox, meaning you may need to enable “Trust” for the enterprise profile after installation.</p>
<p>Enable push notifications only for the sports you follow – otherwise you’ll be flooded with promotional alerts. A well‑tuned notification setting lets you hear about live odds changes without being distracted by unrelated offers.</p>
</section>
<section>
<h2>Bonuses and Promotions on the 1xbet App</h2>
<p>One of the biggest draws of the 1xbet app is the range of bonuses that greet new players and keep regulars coming back. The welcome package typically includes a 100 % match bonus on the first deposit, plus a few free spins for selected slot games. Always read the fine print: wagering requirements are usually set at 30x the bonus amount.</p>
<p>Beyond the welcome offer, the app rolls out weekly reload bonuses, cash‑back on sports losses, and special tournament prizes. These promotions are listed under the “Bonus” tab, where you can claim them with a single tap. Remember, most bonuses are limited to certain payment methods, so check the eligibility before you deposit.</p>
<h3>Understanding Wagering Requirements</h3>
<p>Wagering requirements dictate how many times you must bet the bonus before you can withdraw any winnings. For example, a 20 % deposit bonus of €50 with a 30x requirement means you need to place bets totalling €1 500 before cashing out. Some games contribute at different rates – slots usually count 100 %, while table games may only count 10 %.</p>
<p>Plan your play accordingly: if you prefer low‑variance slots, you’ll meet the requirement faster. If you enjoy sports betting, look for “Sport‑only” bonuses that exclude casino games from the wagering calculation.</p>
</section>
<section>
<h2>Payment Methods – Deposits and Withdrawals</h2>
<p>The 1xbet app supports a wide variety of payment options, from credit cards to e‑wallets. Deposit is almost always instant, while withdrawal speed depends on the method you choose. Below is a quick comparison of the most common options.</p>
<table border="1" cellpadding="5" cellspacing="0">
<thead>
<tr>
<th>Method</th>
<th>Deposit Speed</th>
<th>Withdrawal Speed</th>
<th>Typical Fees</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visa / MasterCard</td>
<td>Instant</td>
<td>2‑3 business days</td>
<td>No fee for deposit, 1‑2% on withdrawal</td>
</tr>
<tr>
<td>Skrill</td>
<td>Instant</td>
<td>Same day</td>
<td>Free deposit, $2 withdrawal fee</td>
</tr>
<tr>
<td>Bank Transfer</td>
<td>1‑2 business days</td>
<td>3‑5 business days</td>
<td>Variable, often $5‑$10</td>
</tr>
<tr>
<td>PayPal (via partner)</td>
<td>Instant</td>
<td>Within 24 hours</td>
<td>No deposit fee, 1% withdrawal fee</td>
</tr>
</tbody>
</table>
<p>When you choose a method, also consider the currency conversion rate. The app automatically shows the amount you’ll receive after conversion, but hidden spreads can affect the final figure. For the fastest cash‑out, e‑wallets like Skrill or PayPal tend to be the best choice.</p>
<p>If you encounter a delayed withdrawal, the first step is to check the “Withdrawal History” section – it shows the exact processing stage. Often the delay is due to pending KYC verification, which you can resolve by uploading the missing documents.</p>
</section>
<section>
<h2>Security, Licensing, and Responsible Gambling</h2>
<p>Security is a top priority for the 1xbet app. It uses SSL encryption to protect every data packet between your device and the server. The platform is licensed by the Curacao Gaming Authority, which means it follows internationally recognized standards for fair play and player protection.</p>
<p>To keep your account safe, enable two‑factor authentication (2FA) in the “Security” settings. This adds a code sent to your phone every time you log in from a new device. The app also monitors unusual betting patterns and may temporarily freeze an account if it suspects fraud.</p>
<h3>Responsible Play Tools</h3>
<p>Every user can set deposit limits, loss limits, or even a self‑exclusion period directly in the app. These tools are hidden under “Responsible Gambling”. Once set, the limits are enforced automatically – you cannot place a bet that exceeds your daily deposit cap.</p>
<p>Should you feel the need for a break, the self‑exclusion option blocks access for 6 months, 1 year, or permanently. The app also provides links to professional help lines for problem gambling, ensuring that help is just a tap away.</p>
</section>
<section>
<h2>Customer Support and Troubleshooting</h2>
<p>When you run into an issue, the 1xbet app offers several support channels. The live chat button is available 24/7 and usually replies within a minute. For more detailed queries, you can submit a ticket through the “Help Center” and expect a response within 24 hours.</p>
<p>Phone support is also listed for certain regions, but the numbers are often toll‑free only for local callers. If you prefer written communication, the FAQ section covers the most common questions about bonuses, payment methods, and account verification.</p>
<h3>Common Issues and Quick Fixes</h3>
<ul>
<li><strong>Login problems:</strong> Clear the app cache, ensure you are using the latest version, and verify that your password isn’t expired.</li>
<li><strong>Bonus not credited:</strong> Check the “Bonus History” – some promotions require a minimum deposit or a specific game to be played before they appear.</li>
<li><strong>Withdrawal delayed:</strong> Review the “Verification” status; incomplete KYC is the most frequent cause.</li>
</ul>
<p>For a hands‑on experience without risking money, you can try the <a href="https://unclebillysaustin.com/">1xbet demo game free</a> and see how the interface feels before you commit to a real deposit.</p>
</section>
<section>
<h2>Common Pitfalls and How to Avoid Them</h2>
<p>New users often jump straight into high‑risk bets, forgetting to read the terms of the welcome bonus. This leads to frustration when the wagering requirement seems impossible. Take a moment to calculate the required turnover using a simple spreadsheet – it clarifies whether the bonus is worth the effort.</p>
<p>Another frequent mistake is ignoring the currency conversion fees. If your bank account is in USD but the app defaults to EUR, you may lose several percent on each transaction. Switch the app’s default currency to match your</p>
</section>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/uncategorized/1xbet-app-what-you-need-to-know/">1xbet app – what you need to know</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>تنزيل وان اكس بت مصر: خطوات التسجيل وتحميل التطبيق خطوة بخطوة</title>
<link>https://edusehat.com/en/%D8%AA%D9%86%D8%B2%D9%8A%D9%84-%D9%88%D8%A7%D9%86-%D8%A7%D9%83%D8%B3-%D8%A8%D8%AA-%D9%85%D8%B5%D8%B1-%D8%AE%D8%B7%D9%88%D8%A7%D8%AA-%D8%A7%D9%84%D8%AA%D8%B3%D8%AC%D9%8A%D9%84-%D9%88%D8%AA%D8%AD%D9%85%D9%8A%D9%84-%D8%A7%D9%84%D8%AA%D8%B7%D8%A8%D9%8A%D9%82-%D8%AE%D8%B7%D9%88%D8%A9-%D8%A8%D8%AE%D8%B7%D9%88%D8%A9</link>
<guid>https://edusehat.com/en/%D8%AA%D9%86%D8%B2%D9%8A%D9%84-%D9%88%D8%A7%D9%86-%D8%A7%D9%83%D8%B3-%D8%A8%D8%AA-%D9%85%D8%B5%D8%B1-%D8%AE%D8%B7%D9%88%D8%A7%D8%AA-%D8%A7%D9%84%D8%AA%D8%B3%D8%AC%D9%8A%D9%84-%D9%88%D8%AA%D8%AD%D9%85%D9%8A%D9%84-%D8%A7%D9%84%D8%AA%D8%B7%D8%A8%D9%8A%D9%82-%D8%AE%D8%B7%D9%88%D8%A9-%D8%A8%D8%AE%D8%B7%D9%88%D8%A9</guid>
<description><![CDATA[ دليل شامل لتنزيل وان اكس بت مصر: كل ما تحتاج معرفته مقدمة حول تنزيل وان اكس بت مصر يبحث الكثير من عشاق القمار على الإنترنت عن طريقة سريعة 
The post تنزيل وان اكس بت مصر: خطوات التسجيل وتحميل التطبيق خطوة بخطوة appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://i.ytimg.com/vi/U3cvbkWEVEk/hqdefault.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 21:20:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>تنزيل, وان, اكس, بت, مصر:, خطوات, التسجيل, وتحميل, التطبيق, خطوة, بخطوة</media:keywords>
<content:encoded><![CDATA[<figure data-affgun-media="hero"><img src="https://i.ytimg.com/vi/U3cvbkWEVEk/hqdefault.jpg" alt="" loading="lazy" referrerpolicy="no-referrer"></figure>
<h1>دليل شامل لتنزيل وان اكس بت مصر: كل ما تحتاج معرفته</h1>
<h2>مقدمة حول تنزيل وان اكس بت مصر</h2>
<div data-affgun-media="video"></div>
<p>يبحث الكثير من عشاق القمار على الإنترنت عن طريقة سريعة وآمنة لتحميل تطبيق 1XBET في مصر والإمارات.  <strong>تنزيل وان اكس بت مصر</strong> ليس مجرد ملف تثبيت؛ فهو بوابة للوصول إلى كازينوهات مرخصة، بونصات ترحيبية، ومجموعة واسعة من ألعاب الروليت والبلاك جاك والسبورتس بايت.</p>
<nav aria-label="Table of contents">
<ol>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/tnzyl-wn-ks-bt-msr-khtwt-ltsjyl-wthmyl-lttbyq-khtw-bkhtw/#section">مقدمة حول تنزيل وان اكس بت مصر</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/tnzyl-wn-ks-bt-msr-khtwt-ltsjyl-wthmyl-lttbyq-khtw-bkhtw/#section-2">خطوات التسجيل وتحميل التطبيق</a>
<ol>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/tnzyl-wn-ks-bt-msr-khtwt-ltsjyl-wthmyl-lttbyq-khtw-bkhtw/#section-3">إنشاء حساب جديد</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/tnzyl-wn-ks-bt-msr-khtwt-ltsjyl-wthmyl-lttbyq-khtw-bkhtw/#1xbet">تحميل تطبيق 1XBET للهواتف</a></li>
</ol>
</li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/tnzyl-wn-ks-bt-msr-khtwt-ltsjyl-wthmyl-lttbyq-khtw-bkhtw/#section-4">طرق الدفع المسموحة في الإمارات ومصر</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/tnzyl-wn-ks-bt-msr-khtwt-ltsjyl-wthmyl-lttbyq-khtw-bkhtw/#section-5">كيفية الاستفادة من البونص والترحيب</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/tnzyl-wn-ks-bt-msr-khtwt-ltsjyl-wthmyl-lttbyq-khtw-bkhtw/#section-6">اللعب الآمن والمسؤول</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/tnzyl-wn-ks-bt-msr-khtwt-ltsjyl-wthmyl-lttbyq-khtw-bkhtw/#section-7">الدعم الفني وتقييمات العملاء</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/tnzyl-wn-ks-bt-msr-khtwt-ltsjyl-wthmyl-lttbyq-khtw-bkhtw/#section-8">الأسئلة الشائعة حول تنزيل وان اكس بت مصر</a></li>
<li><a href="https://www.pharmaceutical-business-review.com/uncategorized/tnzyl-wn-ks-bt-msr-khtwt-ltsjyl-wthmyl-lttbyq-khtw-bkhtw/#section-9">خاتمة عملية للبدء في اللعب</a></li>
</ol>
</nav>
<p>الموقع يقدّم تجربة متميزة للمبتدئين والمحترفين على حد سواء، مع دعم للغات متعددة واتصال سريع لتقليل وقت الانتظار أثناء اللعب. في هذا الدليل سنغطي كل خطوة، من التسجيل إلى السحب، لتضمن لك أقصى استفادة من حسابك.</p>
<h2>خطوات التسجيل وتحميل التطبيق</h2>
<h3>إنشاء حساب جديد</h3>
<p>ابدأ بزيارة الصفحة الرسمية للمنصة واختر “تسجيل”. سيُطلب منك إدخال بريد إلكتروني صالح، كلمة مرور قوية، ورقم هاتف يُستخدم للتحقق. تأكد من اختيار كلمة مرور لا تقل عن 8 أحرف وتحتوي على أرقام وحروف.</p>
<p>بعد إكمال النموذج، سيُرسل لك رمز تحقق عبر الرسائل القصيرة. أدخل الرمز لتفعيل حسابك، ثم انتقل إلى مرحلة <em>التحقق (KYC)</em> لإثبات هويتك عبر إرفاق جواز السفر أو البطاقة الوطنية.</p>
<h3>تحميل تطبيق 1XBET للهواتف</h3>
<p>التطبيق متاح للهواتف الذكية بنظامي Android وiOS. للتحميل، اضغط على زر “تنزيل وان اكس بت مصر” الموجود في صفحة الدعم داخل الموقع، وسيتم توجيهك إلى المتجر المناسب. إذا كنت في الإمارات، قد تحتاج إلى تفعيل خيار السماح بالمصادر غير المعروفة لتثبيت ملف الـAPK.</p>
<p>بعد التثبيت، سجّل الدخول باستخدام بياناتك، وستظهر لك واجهة مستخدم عربية بالكامل مع خيارات الألعاب، الكازينو المباشر، والرياضات.</p>
<h2>طرق الدفع المسموحة في الإمارات ومصر</h2>
<p>من أهم العوامل التي يبحث عنها اللاعبين هي طريقة الإيداع والسحب السريعة. يقدم 1XBET مجموعة واسعة من طرق الدفع التي تتوافق مع القوانين المحلية في كل من الإمارات ومصر.</p>
<p>اختر الطريقة التي تناسبك بناءً على الحد الأدنى للإيداع، وسرعة التحويل، وأمان العملية.</p>
<table border="1" cellpadding="5" cellspacing="0">
<caption>أبرز طرق الدفع في 1XBET</caption>
<thead>
<tr>
<th>طريقة الدفع</th>
<th>الحد الأدنى للإيداع (دولار)</th>
<th>سرعة الإيداع</th>
<th>سرعة السحب</th>
</tr>
</thead>
<tbody>
<tr>
<td>بطاقة الائتمان (Visa/MasterCard)</td>
<td>10</td>
<td>فورية</td>
<td>1-3 أيام عمل</td>
</tr>
<tr>
<td>محفظة إلكترونية (PayPal, Skrill)</td>
<td>5</td>
<td>فورية</td>
<td>ساعات معدودة</td>
</tr>
<tr>
<td>تحويل بنكي</td>
<td>50</td>
<td>2-4 أيام</td>
<td>5-7 أيام</td>
</tr>
<tr>
<td>نقدًا عبر نقاط البيع</td>
<td>20</td>
<td>فورية</td>
<td>يوم عمل واحد</td>
</tr>
</tbody>
</table>
<h2>كيفية الاستفادة من البونص والترحيب</h2>
<p>عند إكمال أول إيداع، ستحصل على <strong>بونص الترحيب</strong> الذي قد يصل إلى 100% من مبلغ الإيداع مع حد أقصى 200 دولار. هذا البونص يأتي مع <em>متطلبات مراهنة</em> (wagering requirements) تبلغ 30x، ما يعني أنك تحتاج إلى لعب بما يعادل 30 ضعف قيمة البونص قبل سحب الأرباح.</p>
<p>يُفضَّل قراءة الشروط الدقيقة للعرض، فبعض الألعاب مثل البوكر لا تُحتسب ضمن المتطلبات، بينما تُحتسب ألعاب السلوتس بنسبة 100%، وهذا يؤثر على سرعة تحقيق السحب.</p>
<h2>اللعب الآمن والمسؤول</h2>
<p>يُعتبر <em>الأمان</em> أحد أهم عوامل اختيار الكازينو. 1XBET مرخص من سلطة جبل طارق (Gibraltar) ومراقب من قبل هيئة الألعاب البريطانية، ما يعني أن جميع المعاملات تتم وفق تشفير SSL 256‑bit.</p>
<p>بالإضافة إلى ذلك، يُوفر الموقع أدوات للعب المسؤول مثل حدود الإيداع اليومية، وقت اللعب المسموح، وإمكانية طلب وقف حساب مؤقت. هذه الخيارات تساعد اللاعبين على تجنب الإدمان والحفاظ على ميزانية اللعب.</p>
<h2>الدعم الفني وتقييمات العملاء</h2>
<p>خدمة العملاء متاحة على مدار 24 ساعة عبر الدردشة الحية، البريد الإلكتروني، والهاتف. فريق الدعم يتحدث العربية والإنجليزية ويستجيب بسرعة لتسوية المشكلات المتعلقة بالتحقق، السحب، أو أي استفسار عن الألعاب.</p>
<p>تقييمات المستخدمين تشير إلى رضا عام عن <a href="https://drinksoundspirits.com/">1xbet تغيير كلمة المرور</a>، حيث يثنون على سرعة الاستجابة وكفاءة عملية السحب الفوري.</p>
<h2>الأسئلة الشائعة حول تنزيل وان اكس بت مصر</h2>
<ul>
<li><strong>هل يمكنني اللعب من هاتف iPhone؟</strong> نعم، التطبيق متوفر على App Store مع دعم كامل للغة العربية.</li>
<li><strong>ما هو الحد الأدنى للانسحاب؟</strong> يختلف بحسب طريقة السحب، لكنه عادةً لا يقل عن 20 دولار.</li>
<li><strong>هل أحتاج إلى VPN للدخول من الإمارات؟</strong> لا، الموقع متاح مباشرةً في الإمارات ولا يتطلب أي تقنيات مخفية.</li>
<li><strong>كيف أتحقق من أرصدة البونص؟</strong> من خلال قسم “المكافآت” داخل التطبيق، حيث يُظهر لك تفاصيل المتطلبات المتبقية.</li>
</ul>
<h2>خاتمة عملية للبدء في اللعب</h2>
<p>بعد إتمام جميع الخطوات السابقة – تحميل التطبيق، إكمال عملية التسجيل والتحقق، اختيار طريقة الدفع، والاستفادة من البونص – يمكنك الآن الانغماس في تجربة كازينو شاملة تشمل ألعاب الكازينو الحية، الروليت، والرياضات.</p>
<p>تذكر دائمًا أن تتبع حدودك المالية، وتستغل أدوات اللعب المسؤول لتبقى مستمتعًا دون مخاطر. نتمنى لك تجربة مليئة بالمتعة وربحٍ مستدام.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/uncategorized/tnzyl-wn-ks-bt-msr-khtwt-ltsjyl-wthmyl-lttbyq-khtw-bkhtw/">تنزيل وان اكس بت مصر: خطوات التسجيل وتحميل التطبيق خطوة بخطوة</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Building the pharma talent India needs for the digital era</title>
<link>https://edusehat.com/en/building-the-pharma-talent-india-needs-for-the-digital-era</link>
<guid>https://edusehat.com/en/building-the-pharma-talent-india-needs-for-the-digital-era</guid>
<description><![CDATA[ 
Dr Supriya Shidaye, Principal, Vivekanand Education Society’s College of Pharmacy, discusses how AI, automation and digital technologies are reshaping pharmacy education, while closer industry-academia collaboration can help prepare students for the changing pharma workplace, in an exclusive interview with Neha Aathavale
The post Building the pharma talent India needs for the digital era appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/22143745/EP_Dr-Supriya-Shidaye_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 21:20:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Building, the, pharma, talent, India, needs, for, the, digital, era</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/22143745/EP_Dr-Supriya-Shidaye_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/22143745/EP_Dr-Supriya-Shidaye_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/22143745/EP_Dr-Supriya-Shidaye_750-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><b>As Indian pharma companies now move towards AI and automation and even connected manufacturing, what talent gaps are you seeing emerging at the plant level and are companies struggling more to find digital skills or professionals who can combine the pharmaceutical knowledge with technology?</b></p>
<p><span>With this emerging AI, automation, industrial internet of things, the entire pharma industry landscape is changing very rapidly. This change is happening not just at manufacturing level, but it is taking place at every stage of the entire product life cycle that is at the research and development, drug discovery, manufacturing, quality control, in process quality control, supply chain and further regulatory guidelines or regulatory compliances. Obviously the things are being done in much shorter time with more precision and more accuracy.</span></p>
<p><span>When we talk about industry, it is all data driven. Earlier also conventionally a lot of data was getting generated, because equipment is running, they are being monitored for various parameters. So data is getting generated, then there is a quality control happening, in process quality control happening, then supply chain the product is being delivered.</span></p>
<p><span>Everywhere there are logs, maintenance logs, batch manufacturing records, master files, data has been always getting generated. But in the past the approach was about using that data to understand whether the product complies with the required standard and what went wrong, but that was a kind of reactive type of approach. But now the industry has been changing rapidly and now industry is making the right use of AI, machine learning, internet of thing for more kind of predictive approach, responsive approach.</span></p>
<p><span>It is not only about AI or digital knowledge which will sustain or only the technical knowledge which will sustain, because AI has a lot of role to enhance your decision making, to expedite the efficiency of your work. So it is going to complement your skill, it is not going to substitute your skill. So every person has to have a very strong scientific knowledge, there cannot be a substitute for scientific knowledge, but AI is going to help you in a number of ways like the data is being studied by AI and it is helping you in decision making, informed decision making.</span></p>
<p><span>People should have digital literacy, AI literacy. Once the data is being analysed by the system and it is showing you some kind of results, you should have an ability to interpret those results and arrive at some decision. So if you are not able to observe it carefully, critically analyse it further and arrive at some informed decision, then somewhere there will be a gap in your efficiency as well as your delivery of the output.</span></p>
<p><span>The industry now requires a person who not only has a very good in depth knowledge when it comes to science, but also he has a very good smart way to work by adopting the technology and arriving at a right decision by using the technology and these decisions because they are based on data, there will be more accuracy, there would not be just the assumptions, but there is an evidence based decision that is possible.</span></p>
<p><span>Industry is moving in that way, in that direction and this person has the requirement of a person who has both science based knowledge as well as digital literacy to convert that knowledge into informed decisions.</span></p>
<p><b>Pharma 4.0 as I see it is bringing production, engineering, quality, IT and data functions together. How far should a pharma manufacturing professional be expected to work beyond their traditional domain and which capabilities will increasingly be required to nurture that specialised talent?</b></p>
<p><span>When we are talking about 4.0, it is all about automation, it is about digitalisation, it is about continuous manufacturing, it is about smart ways of handling the product and delivering the results. The industry when it is moving ahead with these skills, the personnel also should align themselves with all these requisites.</span></p>
<p><span>When you said that it is a blend of technology, engineering, this engineering is also very much important because these equipments that are being designed, they are not an equipment which have all controls and these controls are also generating lot of data, there are sensors, we call it as industrial internet of things.</span></p>
<p><span>These sensors are giving you red flags, they are predicting that there is something going wrong and you are able to understand that there is a beginning of something going wrong and you need to stop the operation at that stage and take some corrective action. So, all these red flags you are able to get because of that 4.0 and 4.2 talks about continuous manufacturing. Now, in India and abroad also more commonly it is seen in manufacturing of oral solid dosage forms like tablets.</span></p>
<p><span>This is the entire pipeline operation, it starts from raw material and then the mixing, then milling, then granulation, then again milling, then blending with lubrication and then compression and then further levelling, packaging, levelling everything is happening on a single line.</span></p>
<p><span>There is something called process analytical technology which is developing very fast. So, we have NIR near infrared Raman where those probes are able to at entire pipeline everywhere they are able to understand, they are able to monitor the micro changes in the pipeline, what is going to be the bottleneck, where these micro changes are happening, what is the trade of changes taking place and bridge pad will be able to tell you whether everything is going on well and there is a go status or no go status, there is some micro change happening, there is some kind of missing of some kind of required specification.</span></p>
<p><span>This is how development happens where a lot of core engineering knowledge is required. So, for designing these equipment and installing those sensors, the displays, the PLC boards. This is what is the integration of engineering with the science and pharmaceutical technology and that is only giving us a lot of data.</span></p>
<p><span>Data logs are getting generated and so when it comes to regulations, regulation is becoming very easy because earlier may be conventionally, traditionally whenever there is an inspection people used to run around and generate the data, but there is no such need every minute you are ready for any kind of regulatory compliances or audits because you have a data logs and there is a very high degree of data integrity because everything is available digitally.</span></p>
<p><span>You cannot manually say there is no intervention except that you have to read it and interpret it and take the decisions that are the intervention, but otherwise data integrity is going on very well, the trained analysis is possible, audit trails are available. That is how industries benefited a lot due to this 4.0 developments and automations.</span></p>
<p><b>As AI and digital systems enter regulated manufacturing environments, how should the industry balance digital capabilities with fundamentals like GMP and data integrity, validation and mostly cyber security? Is the current talent pool equipped to manage this convergence?</b></p>
<p><span>I am an educationist. I would like to share with you that the Pharmacy Council of India is an apex body for pharma programs in all India and now in this year 26-27 academic year they have come up with a revised syllabus and that revised syllabus is introducing AI and ML at almost every semester.</span></p>
<p><span>Students are going to start from basics of Python and its application and then they are going to also study data analysis, further they are going to study AI and ML and then application of AI in clinical research, pharma for vigilance, regulatory and healthcare. So, students will be definitely getting equipped with all these skills required with the new syllabus that has emerged. That does not mean the previous students who have stepped into the corporate are not equipped with that.</span></p>
<p><span>We always had a platform called Swayam. That is the government of India created MOOCs platform, Massive Online Open Courses. So, through that platform our students were studying all these AI and ML related subjects through self-study and completing some certificate courses.</span></p>
<p><span>Also there are number of online educational edtech companies like Coursera, UpGrad which has given many such programs our students and when I talked about VES College of Pharmacy and my role as a chairman of board of studies of Pharmacy of University of Mumbai, four years back I had designed one course on AI in healthcare which was a value added course for University of Mumbai affiliated pharmacy colleges.</span></p>
<p><span>Almost every college offers a value added course. In our college every year we offer it and we integrate it or we collaborate with our engineering college, VES Institute of Technology and their faculty members come and deliver that course.</span></p>
<p><span>That is how we are trying to train our students to get adapted to these new trends because that is important.</span></p>
<p><span>When you talk about cyber security, the government of Maharashtra also takes lot of initiatives and they always insist that our institutions should also conduct the programs on cyber security because students are now more available online because online resources are huge in number.</span></p>
<p><span>There are chances that while using digital transactions and on accessing online data somewhere their mails can get hacked, their data can get hacked or if they are working for their organisation there also such threat is always there of hacking of the data.</span></p>
<p><span>It is very important that students are aware about how to protect your data, what should be revealed, what should not be revealed, how you can have security measures and what are those measures, how you have to encrypt your files, password protected.</span></p>
<p><span>That kind of education is also equally important because we know that when we are travelling somewhere the Google comes to know where we are and Google starts giving us the information about the shopping malls, theatres and everything in that area. That means whatever we are doing on WhatsApp or online through any kind of online platform it is getting recorded and AI is able to understand your whereabouts.</span></p>
<p><span>Students should know. We also keep telling students when you are generating a research paper or you are using chat GPT for example, for redrafting or paraphrasing your research publication it is you should be careful you cannot directly put your entire abstract there or a lot of very big length of article there because once you put it in the AI chat GPT has also captured it as a data.</span></p>
<p><span>Sometimes your own data will be shown as plagiarised because chat GPT has captured it.</span></p>
<p><span>These are the threats also when the technology is moving on and everything is available through smart means that data somewhere is getting generated. So, protection of data becomes very important and we know that there is an act about privacy of data.</span></p>
<p><span>Even industry and employers are worried about what data of your employee or your organisation should be revealed and what should not be revealed, what comes under the umbrella of disclosure allowed, what should not be allowed for instance Aadhaar number you are not supposed to disclose.</span></p>
<p><span>Cyber security when it comes to this is a challenge to everybody, the employer, the employee, the student, the educational institutions, the management and we need to be careful about it and digital literacy that is indispensable and we need to train students and our syllabus is now framed. So, their students will be completely updated by the time they graduate.</span></p>
<p><b>India is no longer looking only to strengthen its manufacturing base, but also trying to enhance its capabilities in innovation and product development. What kind of talent will this shift require and is the current industry academia ecosystem equipped to prepare professionals who can contribute both to manufacturing and innovation?</b></p>
<p><span>Innovation since last 4, 5 years I can say that innovation has become a very important component in the educational systems.</span></p>
<p><span>Especially so, when our government of India and Honorable Prime Minister promoted Make in India, start up India policies and the Ministry of Education also incorporated Institution Innovation Council, Ministry of Education’s Innovation Council.</span></p>
<p><span>Through that Innovation Council every institution was required to set up their own institutional innovation cell and not just that to promote that kind of activity. The Ministry of Education earlier it was MHID, now it is the Ministry of Education. So, they also encouraged colleges to take part in the ranking framework based on your Institutional Innovation Council activity that is called IIC short form.</span></p>
<p><span>Every institution including our institution we are taking part every year in the IIC activities ranking framework. So, through that framework every institution conducts a lot of programs to encourage students to think differently.</span></p>
<p><span>Entrepreneurship related programs, design thinking then we invite people having their own start ups and how. So, how commercial adaptability is important, how do you convert the prototype into a commercially viable product, that kind of training is being given the entire business canvas is being taught to students while they are graduating and that is how innovation is innovative.</span></p>
<p><span>For entrepreneurship the skills and the kind of knowledge that you need that institutions are providing.</span></p>
<p><span>Now, when it comes to innovation as an attitude, we know that it is not taught in the classroom, but it is all about the kind of spark that you have about creativity, critical thinking, and problem solving. You are always very creative when it comes to thinking out of the box.</span></p>
<p><span>Students are deliberately made to think about the community based problems, what is going around and based on that do you find out some unmet need that society is facing and for which solution is right now not available and it need not be very hi-fi thing because at first year and second year level what advanced research you can think about.</span></p>
<p><span>It need not be about genomics, proteomics or bioinformatics. It can be about small small things like some kind of smart watch which has an alarm which takes up your vital and gives you some kind of indication like there is something wrong with tachycardia.</span></p>
<p><span>So, you need to consult a doctor or in my college I developed one film which was just a plain film of a polymer, but it was water insoluble and it was a peelable and biodegradable polymer.</span></p>
<p><span>Our idea was just to apply the film and then go into and do the work where you have to deal with some detergents or some for the agricultural community, some fertilizers, manure, soil. So, your hands will be protected and it is not a glove, but it is just a film which is mixing with your skin.</span></p>
<p><span>It is almost invisible. You do not have a feeling here you are wearing something, but your hands are completely protected and after work is over and you do not have to now deal with the hasardous material just peel it off and it is biodisposable.</span></p>
<p><span>Such types of innovations have a lot of concepts that are strong, but the work can be very simple: just dissolve, mix and make a solution. So, these kinds of innovations we are asking students to think about.</span></p>
<p><span>That is what is called design thinking. We are trying to create them about finding out some problem statement for which solution is available and what can be that solution, that solution oriented approach that is being taught to students by giving various examples, the contemporary examples in day to day life like food products, nutraceuticals, formulations, drugs, medicines, devices.</span></p>
<p><span>Innovation, We know that when there is necessity there is an invention, but we are going beyond that like we are trying to tell them that you have to whatever is your idea you just try to experiment it do not just neglect it.</span></p>
<p><span>That is what a tinkerer’s lab is. We are giving them the platform, we give you chemicals, we give you equipment, you just do it and see whether you are able to convert it into a product or you are able to convert it into some prototype which can be seen as this is how it will work.</span></p>
<p><span>We have heard about digital twins right, what is a digital twin? It is a mock or prototype of the simulated model which before physically we make it that digital twin tells you that this is how the process will appear, this is how the product will appear and this is how it will work.</span></p>
<p><span>We are also trying to tell them you make a twin which is in the form of a prototype and then later on maybe in the phases we have our own incubation centre Hashu Advani Business Technology Incubation Centre where you can incubate and we can convert it into a viable solution.</span></p>
<p><span>That is how institutions are encouraging innovation, VES College of Pharmacy has our own institution innovation council, we conduct many sessions, we invite speakers who have their own startups, we also conduct workshops on design thinking and we nurture that innovation thought.</span></p>
<p><span>Our second year student recently when we had a design thinking workshop she came up with the idea of a digital watch and she is saying in that digital watch we will have a strips blister pack of the anti asthma drug like salbutamol and it will also have a kind of sensor.</span></p>
<p><span>So when a person is having bronchospasm because of an allergen to which he or she has been exposed to, the sensor will be able to capture that anatomical change and it will show a red brick.</span></p>
<p><span>The person who is allergic to certain things will come to know, okay I am going to land up in an asthma attack.</span></p>
<p><span>So I will just dial the next dose and I will inhale it through the asthma digital valve. So the idea was so good that we took her to the Tinkerer lab and also we introduced her to some other engineering college students of VES and we found a team and we would now tell them, now go ahead and try to design a certain type of watch.</span></p>
<p><span>That is how we are encouraging students.</span></p>
<p><b>As India seeks to strengthen its position as a global pharma manufacturing hub, could talent become a constraint to the adoption of smart manufacturing and what should industry and academia start doing to ensure that the talent pipeline keeps pace with its transition?</b></p>
<p><span>Very good question. The Pharmacy Council of India is telling us, it is making it mandatory that every institution should have 10 MOUs with the industry and hospitals.</span></p>
<p><span>Out of that 10, at least 5 should be with the industry. Now these MOUs should not be just the on paper record, but it should be an active MOU.</span></p>
<p><span>My suggestion is that industry should adopt at least 3 to 4 colleges, may be based on geographical location or may be because of the, based on the research interest that these institutions are having and their research forte and then industry should hand hold these academia.</span></p>
<p><span>Each industry if it adopts 2 or 3 institutions and they hand hold them, it is like a sharing of the expertise, sharing of the facilities, sharing of the knowledge and that can become a very good collaborative model.</span></p>
<p><span>Because we know abroad in the US, so many products, so many vaccines, even for example Covishield vaccine that was, that has emerged from one institutional research. Institutions have got a lot of creativity.</span></p>
<p><span>Institutional faculty members have got a lot of new ideas, but they lack its commercial translation into commercial products, whereas industry has expertise in commercialising it.</span></p>
<p><span>What I feel is that industry should set up the industry training center in the colleges and they can identify one such college in the cluster of 10 colleges and then this training center should give training to all the students available in that cluster.</span></p>
<p><span>The host institute may be considered based on its location and its overall expertise and the trainers available with their experience in research and in that institution the industry can invest through their CSR funding or any other source and install all industry compliant CSR compliant equipment, having all digital monitors, sensors, then PLC controls.</span></p>
<p><span>So that it is not the primitive machine or equipment that academic institutions can afford to have, but it is actually GMP CSR compliant equipment that industry uses.</span></p>
<p><span>But this training should be provided while the student is studying here. So that is what hands on training.</span></p>
<p><span>Merely going for an industry visit will not help in fulfilling that requirement. But if you have such type of center and it is catering to 10 nearby institutions, students can be visiting to this host institute for some 2 days workshops, additional their work for which this center can cater to their need for scaling up, for giving them better product with proper log and proper data which is printed and available as a digital copy.</span></p>
<p><span>While they are studying they come to know what are the industry practices and industry also should talk about QMS.</span></p>
<p><span>Academic institutions should set up the quality management system through their instrument rooms, pilot plant. So in our college we have already consulted Mr. Sunil Putkar who is a regulatory auditor and under his guidance we are setting up QMS systems, quality management systems in our instrumentation and pilot plant and record keeping.</span></p>
<p><span>Then we are going to ask students to maintain it.</span></p>
<p><span>These are industrial practices. So in the college level itself they should come to know how the records are maintained, documents are made, done, then common technical data, CDDs, files are made. So everything should be trained.</span></p>
<p><span>How SOPs are made, standard operating procedures. So that training is required plus hands on training to handle the equipment because the industry has set up that kind of training.</span></p>
<p><span>My vision is that in our college there should be a translational research and development center.</span></p>
<p><span>This center will cater to translating your research into commercially viable products. That is one thing for which we are working on.</span></p>
<p><span>And second thing is that industry training center where we can tie up with the company and we can provide this facility for the nearby colleges.</span></p>
<p><span>We can volunteer to train them. That is what my vision is.</span></p>
<p><em><strong>neha.aathavale@expressindia.com</strong></em></p>
<p><em><strong>nehaaathavale75@gmail.com</strong></em></p>
<p>The post <a href="https://www.expresspharma.in/building-the-pharma-talent-india-needs-for-the-digital-era/">Building the pharma talent India needs for the digital era</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>FDA approves Cosette’s Evoxac oral solution for Sjögren’s disease</title>
<link>https://edusehat.com/en/fda-approves-cosettes-evoxac-oral-solution-for-sjoegrens-disease</link>
<guid>https://edusehat.com/en/fda-approves-cosettes-evoxac-oral-solution-for-sjoegrens-disease</guid>
<description><![CDATA[ The regulatory decision represents the first new drug application (NDA) approval secured by the speciality pharmaceutical manufacturer. Cosette expects the therapy to be commercially accessible in the US 
The post FDA approves Cosette’s Evoxac oral solution for Sjögren’s disease appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/10/PT-2-21-10-2026-shutterstock_2310421981.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 21 Oct 2026 20:20:14 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>FDA, approves, Cosette’s, Evoxac, oral, solution, for, Sjögren’s, disease</media:keywords>
<content:encoded><![CDATA[<p>The regulatory decision represents the first new drug application (NDA) approval secured by the speciality pharmaceutical manufacturer.</p>
<p>Cosette expects the therapy to be commercially accessible in the US by late 2026, with further distribution details scheduled for release nearer to the commercial launch.</p>
<p>It conceived and formulated the therapy internally to provide an option for adult Sjögren’s disease patients who face difficulties when swallowing traditional solid capsules.</p>
<p>The chronic autoimmune condition damages the body’s moisture-producing glands, primarily causing dry mouth and eyes, which can impede a patient’s capacity to ingest capsule-based treatments.</p>
<p>The active ingredient in the newly approved formulation is cevimeline hydrochloride, identical to the compound used in existing Evoxac capsules authorised for adult dry mouth in Sjögren’s disease.</p>
<p>Cosette utilised a streamlined regulatory pathway that allowed it to reference historical safety and efficacy findings from Evoxac capsules, avoiding a full-scale clinical development programme.</p>
<p>Cosette Pharmaceuticals president and CEO Apurva Saraf said: “Evoxac oral solution marks an important milestone for Cosette—our first NDA approval, achieved through the dedication and ingenuity of our own teams.</p>
<p>“Today, we are demonstrating that we can also create value through our own product development capabilities. I am incredibly proud of our teams and excited about what this achievement makes possible for the patients and our future.”</p>
<p>Evoxac is a prescription medicine whose paediatric safety and effectiveness remain unconfirmed.</p>
<p>The therapy is associated with potential adverse effects, including heart rhythm and heart rate issues, lung complications such as restricted airflow and increased mucus, vision alterations particularly in darkness, and nervous system disorders linked to cholinergic reactions.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/fda-cosettes-evoxac-sjogrens-disease/">FDA approves Cosette’s Evoxac oral solution for Sjögren’s disease</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Sanofi and ScionxBio partner on mRNA therapies</title>
<link>https://edusehat.com/en/sanofi-and-scionxbio-partner-on-mrna-therapies</link>
<guid>https://edusehat.com/en/sanofi-and-scionxbio-partner-on-mrna-therapies</guid>
<description><![CDATA[ Under the arrangement, the companies will create extended-exposure formulations of selected mRNA candidates from Sanofi by applying ScionxBio’s TERA technology. The partnership divides research and clinical duties between 
The post Sanofi and ScionxBio partner on mRNA therapies appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/10/PT-21-10-2026-shutterstock_1989605270.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 21 Oct 2026 20:20:14 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Sanofi, and, ScionxBio, partner, mRNA, therapies</media:keywords>
<content:encoded><![CDATA[<p>Under the arrangement, the companies will create extended-exposure formulations of selected mRNA candidates from Sanofi by applying ScionxBio’s TERA technology.</p>
<p>The partnership divides research and clinical duties between both organisations. ScionxBio will direct optimisation programmes through to in vivo validation.</p>
<p>Following this phase, Sanofi will assume responsibility for all subsequent preclinical research, investigational new drug (IND)-enabling evaluations, clinical trials, manufacturing, and global commercialisation.</p>
<p>ScionxBio CEO Dr Adi Gilboa-Geffen said: “This collaboration with Sanofi is a defining milestone for our company. It validates the revolutionary potential of our AI-driven TERA platform to overcome the historical limitations of mRNA durability.</p>
<p>“Partnering with a global powerhouse like Sanofi ensures that our innovations in therapeutic RNA reach patients with life-altering protein deficiencies and chronic conditions more rapidly than ever before.</p>
<p>“I am also deeply grateful to the entire team, whose contributions were instrumental in bringing this collaboration to fruition.”</p>
<p>The agreement combines the work of Sanofi’s mRNA Center of Excellence with the TERA platform. The discovery system uses deep learning models to assess structure-activity relationships from high-throughput combinatorial screens.</p>
<div></div>
<p>By incorporating chemically synthesised regulatory components, the engineered molecules are designed to resist enzymatic breakdown more effectively than conventional mRNA, supporting sustained protein expression in vivo.</p>
<p>While specific disease targets were not disclosed, the research focuses on conditions that require sustained protein expression, spanning both inherited and acquired protein deficiencies.</p>
<p>The platform is also intended to generate sustained exposure to cardiometabolic or immune corrective modulators for potential preventive or disease-modifying applications.</p>
<p>ScionxBio is a privately held, preclinical-stage biotechnology company operating as a brand identity of Eleven Therapeutics following a horizontal corporate split.</p>
<p>In June 2026, Sanofi entered a multi-year agreement with France-based agentic AI company Owkin to co-develop next-generation AI-driven biopharma agents.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/sanofi-scionxbio-long-acting-mrna-therapies/">Sanofi and ScionxBio partner on mRNA therapies</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Exclusive Interview with Dr. Villoo Morawala Patell, Founder &amp;amp; Chairperson of Avesthagen Limited and The Avestagenome Project® International</title>
<link>https://edusehat.com/en/exclusive-interview-with-dr-villoo-morawala-patell-founder-chairperson-of-avesthagen-limited-and-the-avestagenome-project-international</link>
<guid>https://edusehat.com/en/exclusive-interview-with-dr-villoo-morawala-patell-founder-chairperson-of-avesthagen-limited-and-the-avestagenome-project-international</guid>
<description><![CDATA[ 
On the sidelines of the Bengaluru Pharma Summit, Dr. Villoo Morawala Patell, Founder &amp; Chairperson of Avesthagen Limited and The Avestagenome Project® International, speaks with Neha Aathavale, Correspondent, Express Pharma […]
The post Exclusive Interview with Dr. Villoo Morawala Patell, Founder &amp; Chairperson of Avesthagen Limited and The Avestagenome Project® International appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/21154900/EP_Excl_Intv_Dr_Villoo_Morawala_Patell_Founder_Avesthagen__Avestagenome_Project_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 21 Oct 2026 20:20:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Exclusive, Interview, with, Dr., Villoo, Morawala, Patell, Founder, Chairperson, Avesthagen, Limited, and, The, Avestagenome, Project®, International</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="422" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/21154900/EP_Excl_Intv_Dr_Villoo_Morawala_Patell_Founder_Avesthagen__Avestagenome_Project_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/21154900/EP_Excl_Intv_Dr_Villoo_Morawala_Patell_Founder_Avesthagen__Avestagenome_Project_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/21154900/EP_Excl_Intv_Dr_Villoo_Morawala_Patell_Founder_Avesthagen__Avestagenome_Project_750-300x169.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p></p>
<hr>
<p>On the sidelines of the Bengaluru Pharma Summit,  Dr. Villoo Morawala Patell, Founder & Chairperson of Avesthagen Limited and The Avestagenome Project® International, speaks with Neha Aathavale, Correspondent, Express Pharma in an exclusive video interview on India’s biodiversity, genomics research and the journey from scientific discovery to commercial biotech innovation.</p>
<p>Watch the full interview.</p>
<p>The post <a href="https://www.expresspharma.in/exclusive-interview-with-dr-villoo-morawala-patell-founder-chairperson-of-avesthagen-limited-and-the-avestagenome-project-international/">Exclusive Interview with Dr. Villoo Morawala Patell, Founder & Chairperson of Avesthagen Limited and The Avestagenome Project® International</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Nucelion Therapeutics, VeGen Bio collaborate on CAR&#45;T cell therapy manufacturing</title>
<link>https://edusehat.com/en/nucelion-therapeutics-vegen-bio-collaborate-on-car-t-cell-therapy-manufacturing</link>
<guid>https://edusehat.com/en/nucelion-therapeutics-vegen-bio-collaborate-on-car-t-cell-therapy-manufacturing</guid>
<description><![CDATA[ 
The partnership will cover technology transfer, clinical manufacturing and commercial production of VeGen Bio’s VL-2511 in India
The post Nucelion Therapeutics, VeGen Bio collaborate on CAR-T cell therapy manufacturing appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/05/04131504/handshake.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 21 Oct 2026 20:20:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Nucelion, Therapeutics, VeGen, Bio, collaborate, CAR-T, cell, therapy, manufacturing</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/05/04131504/handshake.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/05/04131504/handshake.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/05/04131504/handshake-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Nucelion Therapeutics, a cell and gene therapy contract research, development and manufacturing organisation (CRDMO), and VeGen Bio Pvt. Ltd. (VeGen Bio / VeGen Labs), a Hyderabad-based precision oncology company, have announced a strategic collaboration for the technology transfer, clinical manufacturing and commercial production of cell therapies in India.</span></p>
<p><span>Under the agreement, Nucelion, a wholly owned subsidiary of Bharat Biotech, will serve as the technology transfer and clinical- and commercial-stage manufacturing partner for VeGen Bio’s lead candidate, VL-2511, a dual BCMA/CD19 autologous CAR-T therapy for multiple myeloma. The programme will be transferred to Nucelion’s single-site GMP manufacturing facility, designed to meet CDSCO, US FDA and EMA regulatory standards.</span></p>
<p><span>The collaboration will focus on therapeutic translation, process development and manufacturing scale-up, rather than marketing or distribution. The partnership combines Nucelion’s manufacturing infrastructure, technical expertise and production capabilities with VeGen Bio’s scientific expertise and therapeutic pipeline. The framework is intended to support additional cell therapy candidates across VeGen Bio’s pipeline.</span></p>
<p><span>The companies will also focus on process optimisation, manufacturing yields and operational efficiency, with the aim of reducing manufacturing costs and improving access to cell therapies in India.</span></p>
<p><span>“Many CAR-T programs stall between a promising construct and a product that can be made reliably at scale. As one of India’s first dedicated cell and gene therapy CRDMOs, Nucelion closes that gap, taking partners like VeGen from process development through clinical and commercial manufacturing. Our work on VeGen’s dual-target CAR-T program shows that model in action and builds the capacity India needs to bring these therapies to more patients. As our facility is designed to meet US FDA and EMA standards, companies can also commercially launch their products worldwide,” said Raghu Malapaka, PhD, CBO, Nucelion Therapeutics Pvt. Ltd.</span></p>
<p><span>“CAR-T cell therapy holds significant promise for patients with serious cancers, but realizing its full potential requires a coordinated approach to technology transfer, manufacturing, scalability, and commercialization. VL-2511 is a key program in VeGen Bio’s mission to advance innovative therapies for unmet medical needs. This partnership combines complementary strengths, providing VeGen Bio with a pathway to technology transfer, manufacturing, and pipeline expansion, while enabling our CDMO partner to establish and grow its cell therapy manufacturing capabilities. Together, we aim to build an end-to-end ecosystem for Indian cell therapy innovation that creates sustainable value while making next-generation treatments more accessible and affordable for Indian patients,” said Prashant Bhavar, Director, VeGen Bio Pvt. Ltd.</span></p>
<p><span>VL-2511 is a Phase II clinical-stage, dual-target autologous CAR-T cell therapy with an established recommended Phase II dose (RP2D), designed to target BCMA and CD19 simultaneously. Multiple myeloma remains a haematological malignancy associated with unmet medical needs and treatment-access challenges in India.</span></p>
<p><span>By targeting two antigens, VL-2511 is designed to address antigen escape, a mechanism through which malignant cells evade immune recognition by losing or downregulating a targeted antigen.</span></p>
<p><span>With clinical experience in China and ongoing clinical development in the United States, VL-2511 has demonstrated clinical activity, including activity in patients with extramedullary disease (EMD), alongside a safety profile described by the company as favourable. Its manufacturing process is designed to offer opportunities to improve treatment affordability and accessibility, particularly in India.</span></p>
<p><span>VL-2511 is also being clinically investigated in POEMS syndrome and selected autoimmune disorders, including systemic lupus erythematosus (SLE). These programmes reflect the potential applications of dual-target CAR-T technology across haematological malignancies and immune-mediated diseases, while creating opportunities for further clinical development and commercial value creation.</span></p>
<p><span>Through technology transfer and process development, VeGen Bio and Nucelion aim to establish the technical and operational foundations required to address manufacturing complexity, process consistency, quality systems and supply economics during the development process.</span></p>
<p><span>Nucelion’s facility features segregated cell processing suites, continuous environmental monitoring, and chain-of-identity and chain-of-custody tracking systems for patient-linked cellular materials. Its technical scope for the VL-2511 programme includes process development and analytical testing to establish assays and quality controls; GMP cell processing and vector-enabled transduction under aseptic conditions; aseptic fill-finish and clinical-grade cryopreservation to ensure product stability; and quality control and release testing in line with global advanced therapy standards.</span></p>
<p><span>The collaboration is structured to align scientific development, manufacturing and commercial viability. For VeGen Bio, access to technology-transfer and manufacturing infrastructure is intended to support the development of VL-2511 and allow the company to allocate scientific resources to pipeline expansion without independently replicating capital-intensive manufacturing facilities.</span></p>
<p><span>For Nucelion, applying its infrastructure and expertise to the dual-target CAR-T candidate will support the development of a cell therapy manufacturing product line spanning plasmid DNA, viral vectors and advanced cellular processing.</span></p>
<p>The post <a href="https://www.expresspharma.in/nucelion-therapeutics-vegen-bio-collaborate-on-car-t-cell-therapy-manufacturing/">Nucelion Therapeutics, VeGen Bio collaborate on CAR-T cell therapy manufacturing</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>CDSCO approves Sanofi’s Qfitlia for haemophilia A and B in India</title>
<link>https://edusehat.com/en/cdsco-approves-sanofis-qfitlia-for-haemophilia-a-and-b-in-india</link>
<guid>https://edusehat.com/en/cdsco-approves-sanofis-qfitlia-for-haemophilia-a-and-b-in-india</guid>
<description><![CDATA[ 
Fitusiran is indicated for routine prophylaxis to prevent or reduce bleeding episodes in adults and adolescents aged 12 years and older, with or without factor VIII or IX inhibitors
The post CDSCO approves Sanofi’s Qfitlia for haemophilia A and B in India appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 21 Oct 2026 20:20:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>CDSCO, approves, Sanofi’s, Qfitlia, for, haemophilia, and, India</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>The Central Drugs Standard Control Organization (CDSCO), under the Drug Controller General of India (DCGI), has granted marketing authorisation to Qfitlia (fitusiran), an antithrombin-lowering (AT) therapy for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and adolescents aged 12 years or older living with haemophilia A or B, with or without factor VIII or IX inhibitors.</span></p>
<p><span>The approval is based on data from the ATLAS Phase III clinical development programme, which demonstrated clinically meaningful bleed protection, as measured by annualised bleeding rates (ABR), among people living with haemophilia, with and without inhibitors.</span></p>
<p><span>Parwas Mahajan, Business Head, Rare Diseases, Sanofi India, said, “India carries a heavy Hemophilia burden – an estimated ~28.9k# registered people living with Hemophilia. Of those receiving treatment, a significant percent is still on on-demand therapy, meaning they treat bleeds only after they occur, living in constant anticipation of the next joint bleed, the next hospital visit, the next disruption to their lives and livelihoods. The approval expands prophylactic treatment options for people living with Hemophilia in India and (Prophylaxis) is increasingly recognized as an important treatment approach in the management of hemophilia, and today’s approval of Qfitlia® is a significant step toward making that a reality. Our vision is a ‘Hemophilia-free mind’ and a life where people are not defined by their condition, where they are not held hostage by the fear of the next bleed. Qfitlia®, with its unique ability to protect both those living with Hemophilia A and Hemophilia B (with or without inhibitors) with as few as six injections a year, has the potential to significantly expand access to prophylaxis in India. Sanofi is deeply committed to India’s Hemophilia community, and this approval marks the beginning of a long-term partnership with the objective of supporting improved awareness and access to appropriate hemophilia care in India.”</span></p>
<p><span>Dr Milan Choksey, Medical Lead, Rare Diseases Business, Sanofi India, said, “The approval of Qfitlia introduces a concept that is still largely new to India: the role of antithrombin in hemostasis, and the power of lowering it to rebalance the coagulation system. For decades, our approach to Hemophilia has been to replace what is missing (factor VIII or Factor IX). Fitusiran asks a fundamentally different question: what if, instead of replacing the missing piece, we removed a brake on the system?</span></p>
<p><span>“Antithrombin is a natural inhibitor of thrombin generation. By reducing AT levels, Fitusiran allows the body’s remaining coagulation machinery to work more effectively, regardless of whether the person has Hemophilia A or B, with or without inhibitors. This is the science of rebalancing and introduces a novel treatment approach that may be of interest to treating physicians. Equally important is the role of proactive AT monitoring.</span></p>
<p><span>“The dosing of Qfitlia is guided by AT levels – a measurable, reliable biomarker that allows physicians to personalize treatment and optimise the risk-benefit profile for each person living with Hemophilia. This is a new discipline for India, and Sanofi is committed to supporting education and appropriate implementation of AT monitoring, because the science of Fitusiran is only as powerful as the ecosystem that supports it.”</span></p>
<p>The post <a href="https://www.expresspharma.in/cdsco-approves-sanofis-qfitlia-for-haemophilia-a-and-b-in-india/">CDSCO approves Sanofi’s Qfitlia for haemophilia A and B in India</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Sun Pharma’s UNLOXCYT receives NCCN Category 2A recommendation for laCSCC</title>
<link>https://edusehat.com/en/sun-pharmas-unloxcyt-receives-nccn-category-2a-recommendation-for-lacscc</link>
<guid>https://edusehat.com/en/sun-pharmas-unloxcyt-receives-nccn-category-2a-recommendation-for-lacscc</guid>
<description><![CDATA[ 
The recommendation adds to UNLOXCYT’s Category 2A designation for metastatic cutaneous squamous cell carcinoma, assigned in 2025
The post Sun Pharma’s UNLOXCYT receives NCCN Category 2A recommendation for laCSCC appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 21 Oct 2026 16:45:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Sun, Pharma’s, UNLOXCYT, receives, NCCN, Category, recommendation, for, laCSCC</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Sun Pharmaceutical Industries, together with its subsidiaries and/or affiliated companies, announced that UNLOXCYT (cosibelimab-ipdl) has been elevated to a National Comprehensive Cancer Network (NCCN) Category 2A recommended option for patients with locally advanced cutaneous squamous cell carcinoma (laCSCC) who are not candidates for curative surgery or curative radiation.</span></p>
<p><span>This adds to the Category 2A designation for UNLOXCYT in metastatic cutaneous squamous cell carcinoma (mCSCC), which was assigned in 2025.</span></p>
<p><span>UNLOXCYT was approved by the US Food and Drug Administration (FDA) in 2024 and is indicated for the treatment of adults with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation. The recommended dosage is 1,200 mg as an intravenous infusion over 60 minutes every three weeks. UNLOXCYT is the first and only FDA-approved PD-L1-blocking antibody for advanced CSCC (aCSCC).</span></p>
<p><span>The evidence submitted to NCCN in support of the change was based on the pivotal registration study, in which 55 per cent of patients achieved an objective response, including 26 per cent who achieved a complete response. Responses were durable: at a median follow-up of 24.1 months, the median duration of response had not been reached (range: 8.3 to 31.3+ months). In addition, fewer than 1 per cent of patients experienced a high-grade (Grade 3-5) immune-mediated adverse reaction (imARs). There were no Grade 4 or 5 imARs.</span></p>
<p><span>“The NCCN Guidelines play an important role in helping physicians evaluate appropriate treatment options for patients across different disease settings,” said Ahmad Naim, MD, Senior Vice President, North American Chief Medical Officer, Sun Pharma. “The elevation of UNLOXCYT to a Category 2A recommendation for patients with laCSCC marks an important milestone, validating the growing body of clinical evidence supporting UNLOXCYT and reflecting increasing confidence among oncology experts in its role as a treatment option for patients with this challenging disease.”</span></p>
<p><span>NCCN is an alliance of 34 leading cancer centres in the US. Its Clinical Practice Guidelines in Oncology, referred to as the NCCN Guidelines, provide recommendations for the prevention, diagnosis, evaluation and treatment of different types of cancer. The NCCN Guidelines are among the most influential clinical guidelines in cancer care, offering evidence-based, expert-developed recommendations intended to help clinicians make treatment decisions for patients with cancer.</span></p>
<p><span>One such expert clinician is Dr Francis Worden, Clinical Professor of Internal Medicine at the University of Michigan Rogel Cancer Center, whose institution is one of the 34 NCCN member cancer centres in the alliance.</span></p>
<p><span>Dr Worden said, “This guideline update reflects the strength of the published evidence supporting the use of UNLOXCYT as first line treatment for laCSCC. In the pivotal study, patients experienced durable and clinically meaningful responses. UNLOXCYT also demonstrated a low incidence of high-grade imARs—an important consideration when selecting immune checkpoint inhibitor therapy for a patient population that is mainly elderly and is often afflicted with other health issues. These clinical outcomes may be explained by the mechanism of action that restores adaptive immunity, engages innate immunity through antibody-dependent cellular cytotoxicity (ADCC), and preserves PD-L2 signaling that may be linked to the presence of some immune tolerance in non-tumor tissues.”</span></p>
<p><span>The NCCN Guidelines also have an impact on patient access because they inform payer coverage policies, prior-authorization criteria, institutional formularies and clinical pathways.</span></p>
<p><span>“For patients with laCSCC—many of whom are older, medically complex, and vulnerable to treatment-related complications—access to a therapy that offers durable responses together with a low rate of high-grade imARs is especially important. NCCN recognition helps ensure that appropriate patients can receive this treatment up front without unnecessary access barriers,” said Mark Gimbert, Senior Vice President, Head of Market and Patient Access, North America, Sun Pharma.</span></p>
<p>The post <a href="https://www.expresspharma.in/sun-pharmas-unloxcyt-receives-nccn-category-2a-recommendation-for-lacscc/">Sun Pharma’s UNLOXCYT receives NCCN Category 2A recommendation for laCSCC</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Dr. Reddy’s gets CDSCO approval for Zytorvi in advanced esophageal cancer</title>
<link>https://edusehat.com/en/dr-reddys-gets-cdsco-approval-for-zytorvi-in-advanced-esophageal-cancer</link>
<guid>https://edusehat.com/en/dr-reddys-gets-cdsco-approval-for-zytorvi-in-advanced-esophageal-cancer</guid>
<description><![CDATA[ 
Toripalimab in combination with cisplatin and paclitaxel is approved for first-line treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma
The post Dr. Reddy’s gets CDSCO approval for Zytorvi in advanced esophageal cancer appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/07/21134006/approved-logo.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 21 Oct 2026 16:45:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Dr., Reddy’s, gets, CDSCO, approval, for, Zytorvi, advanced, esophageal, cancer</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/07/21134006/approved-logo.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/07/21134006/approved-logo.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/07/21134006/approved-logo-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Dr. Reddy’s Laboratories announced that the Central Drugs Standard Control Organisation (CDSCO), under the Drugs Controller General of India (DCGI), has approved Zytorvi (toripalimab) in combination with cisplatin and paclitaxel for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).</span></p>
<p><span>Dr. Reddy’s entered into a licensing and commercialisation agreement with Junshi Biosciences in 2023 for toripalimab across 21 countries. Globally, toripalimab is approved by regulatory authorities including the US Food and Drug Administration (USFDA), the European Medicines Agency (EMA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). The EMA approval is for the first-line treatment of ESCC irrespective of PD-L1 expression. The approved indication in India similarly does not require patient selection based on PD-L1 expression, enabling appropriate patients to be considered for treatment regardless of their biomarker status.</span></p>
<p><span>In 2024, esophageal cancer was the fourth leading cause of cancer-related death in India, accounting for approximately 8.1 per cent of all cancer deaths. ESCC, the predominant subtype, accounts for approximately 80 per cent of all esophageal cancer cases in India. Through Zytorvi, Dr. Reddy’s Laboratories aims to expand access to first-line immunotherapy for appropriate patients with advanced ESCC in India.</span></p>
<p><span>The approval is supported by results from the Phase 3 JUPITER-06 trial. In the study, toripalimab in combination with paclitaxel and cisplatin reduced the risk of disease or death by 42 per cent compared with chemotherapy alone. At the final overall survival analysis, median overall survival was 17.7 months with toripalimab plus chemotherapy, compared with 12.9 months with chemotherapy alone. Clinical benefit was observed across PD-L1 expression subgroups.</span></p>
<p><span>M.V. Ramana, Chief Executive Officer, Global Generics, Dr. Reddy’s Laboratories, said, “Following the approval of Zytorvi in nasopharyngeal carcinoma, this second indication marks an important step in extending the reach of immunotherapy to patients with advanced esophageal squamous cell carcinoma. It gives physicians an additional first-line treatment option for appropriate patients. As we continue to build our oncology portfolio, our focus remains on bringing meaningful advances and expanding access to innovative treatment options.”</span></p>
<p><span>Esophageal cancer begins in the tissues of the esophagus, the muscular tube that carries food and liquids from the throat to the stomach. ESCC develops from the squamous cells lining the esophagus.</span></p>
<p><span>Risk factors associated with ESCC include smoked and smokeless tobacco, alcohol consumption, areca-nut use, consumption of very hot beverages, poor diet, and certain environmental and socioeconomic factors. Risk varies between individuals, and the presence of one or more risk factors does not mean that a person will necessarily develop cancer.</span></p>
<p><span>Progressive difficulty in swallowing, pain or discomfort when swallowing, unexplained weight loss, persistent chest discomfort and regurgitation may be associated with esophageal cancer. These symptoms may also be caused by other conditions and require evaluation by a qualified healthcare professional.</span></p>
<p>The post <a href="https://www.expresspharma.in/dr-reddys-gets-cdsco-approval-for-zytorvi-in-advanced-esophageal-cancer/">Dr. Reddy’s gets CDSCO approval for Zytorvi in advanced esophageal cancer</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Student’s NanoClear project explores magnetic separation of microplastics from blood</title>
<link>https://edusehat.com/en/students-nanoclear-project-explores-magnetic-separation-of-microplastics-from-blood</link>
<guid>https://edusehat.com/en/students-nanoclear-project-explores-magnetic-separation-of-microplastics-from-blood</guid>
<description><![CDATA[ 
Suramrit Singh Kohli’s research has received recognition at IRIS National Fair and the Regeneron International Science and Engineering Fair 2026
The post Student’s NanoClear project explores magnetic separation of microplastics from blood appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/10/13112310/Award.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 21 Oct 2026 16:45:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Student’s, NanoClear, project, explores, magnetic, separation, microplastics, from, blood</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/10/13112310/Award.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/10/13112310/Award.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/10/13112310/Award-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>What happens to microplastics once they enter the human bloodstream? This question has led Suramrit Singh Kohli, a Grade 12 student at Jayshree Periwal International School, to develop NanoClear, a research project exploring whether magnetic nanoparticles could capture microplastics from blood. The project has received recognition at two science competitions.</span></p>
<p><span>Kohli’s interest in the project stems from his engagement with robotics, which began in 2018, and his interest in applying engineering to real-world challenges. With NanoClear, he has explored whether magnetic nanoparticles can bind to plastic particles, allowing them to be separated using an external magnetic field.</span></p>
<p><span>The project began to take shape during Brown University’s Summer@Brown programme under Dr Thomas Webster. In August 2025, Kohli continued his research at ReeLABs Research Centre in Mumbai under Dr Abhijit Bhopadikar, working with human blood samples for approximately 20 hours a week.</span></p>
<p><span>“Microplastics are a problem that we are still learning to understand, and I wanted to explore whether engineering could offer a way to address what happens once these particles enter the bloodstream. NanoClear is still at the research stage, but working on it has shown me that building a possible solution also means understanding its limitations and working out what to solve next,” said Kohli.</span></p>
<p><span>The research involved nanoparticles measuring approximately 91 nanometres, with a positively charged inner coating designed to attract negatively charged plastic particles. Building on this principle, Kohli developed an external magnetic separation system in which blood is intended to mix with the nanoparticles and pass through a magnet-lined coil. The system is designed to capture the resulting clusters before the blood returns to the circuit.</span></p>
<p><span>Early laboratory investigations provided preliminary evidence of particle binding. Electron microscope images captured at Brown University by Dr Webster showed nanoparticles surrounding a fragment of polyvinyl chloride (PVC). In a separate experiment using human blood spiked with microplastics, a turbidity sensor recorded a reduction in the sample’s cloudiness reading from 249.3 to zero after one pass through the system.</span></p>
<p><span>At the IRIS National Fair in January 2026, NanoClear won Gold and the Yale Science and Engineering Association’s Award for Most Outstanding Exhibit in STEM, one of three such awards among approximately 120 finalists. The Gold award secured the project a place among roughly 20 projects representing India at the Regeneron International Science and Engineering Fair (ISEF) 2026 in Phoenix, Arizona. At ISEF, NanoClear received a Special Award from Zydus carrying a prize of US$1,250.</span></p>
<p><span>The research has also progressed into academic publication and intellectual property development. In August 2026, Springer Nature published Kohli’s paper, presented at TIBS 2026, in its Lecture Notes in Networks and Systems (LNNS) series. The project also has an Indian design patent, a provisional patent filing and an ongoing United States patent filing.</span></p>
<p><span>Kohli is also the founder of 7 STEM Labs, an initiative focused on expanding access to practical STEM learning, mentorship and robotics education for students in underserved communities. He plans to continue developing his research interests at university.</span></p>
<p><span>NanoClear remains at the research stage. The prototype has not been tested on patients or approved for medical use, and further work is needed to assess toxicity, blood compatibility and performance at a larger scale. Proposed next steps include toxicity studies, scaling the system to process five litres of blood and animal trials, subject to the necessary ethical approvals. Kohli’s next phase of research at university will focus on addressing the remaining questions and developing the approach from a laboratory-based concept into a practical, real-world solution.</span></p>
<p>The post <a href="https://www.expresspharma.in/students-nanoclear-project-explores-magnetic-separation-of-microplastics-from-blood/">Student’s NanoClear project explores magnetic separation of microplastics from blood</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Zydus gets USFDA approval for estradiol and levonorgestrel transdermal system</title>
<link>https://edusehat.com/en/zydus-gets-usfda-approval-for-estradiol-and-levonorgestrel-transdermal-system</link>
<guid>https://edusehat.com/en/zydus-gets-usfda-approval-for-estradiol-and-levonorgestrel-transdermal-system</guid>
<description><![CDATA[ 
The product has been designated as a Competitive Generic Therapy and is eligible for a 180-day exclusivity period, subject to applicable provisions
The post Zydus gets USFDA approval for estradiol and levonorgestrel transdermal system appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/06/25113229/us-fda-approval-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 21 Oct 2026 16:45:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Zydus, gets, USFDA, approval, for, estradiol, and, levonorgestrel, transdermal, system</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/06/25113229/us-fda-approval-1.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/06/25113229/us-fda-approval-1.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/06/25113229/us-fda-approval-1-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>Zydus Lifesciences has announced that the United States Food and Drug Administration (USFDA) has granted final approval for its Abbreviated New Drug Application (ANDA) for Estradiol and Levonorgestrel Transdermal System, 0.045 mg/0.015 mg per day (URLD: Climara Pro Transdermal System 0.045 mg/0.015 mg per day).</span></p>
<p><span>The USFDA has designated the ANDA as a Competitive Generic Therapy (CGT). The product is eligible for the 180-day exclusivity period available to certain first approved applicants under the CGT pathway, subject to the provisions of the US Federal Food, Drug, and Cosmetic Act. Any exclusivity period, where applicable, would commence upon the first commercial marketing of the product.</span></p>
<p><span>Estradiol and Levonorgestrel Transdermal System is primarily used to treat moderate to severe symptoms of menopause. It is also used in postmenopausal women for the prevention of osteoporosis. The product will be manufactured at the group’s manufacturing plant in Moraiya, near Ahmedabad, Gujarat.</span></p>
<p><span>According to IQVIA MAT August 2026 data, Estradiol and Levonorgestrel Transdermal System had annual sales of approximately USD 45.7 million in the United States.</span></p>
<p><span>As of 30 September 2026, the group has 458 approvals and has filed 516 ANDAs with the USFDA.</span></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/zydus-gets-usfda-approval-for-estradiol-and-levonorgestrel-transdermal-system/">Zydus gets USFDA approval for estradiol and levonorgestrel transdermal system</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>From hair loss to hair health: Why diagnosis must come before treatment</title>
<link>https://edusehat.com/en/from-hair-loss-to-hair-health-why-diagnosis-must-come-before-treatment</link>
<guid>https://edusehat.com/en/from-hair-loss-to-hair-health-why-diagnosis-must-come-before-treatment</guid>
<description><![CDATA[ 
How is the shift to medical treatment changing how hair loss is assessed and managed, and what gaps remain? For decades, Indian men treated hair loss as a grooming problem. […]
The post From hair loss to hair health: Why diagnosis must come before treatment appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/21102142/Geet-Rathi-Co-founder-Man-Matters-and-Founding-Member-Mosaic-Wellness.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 21 Oct 2026 13:10:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>From, hair, loss, hair, health:, Why, diagnosis, must, come, before, treatment</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/21102142/Geet-Rathi-Co-founder-Man-Matters-and-Founding-Member-Mosaic-Wellness.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/21102142/Geet-Rathi-Co-founder-Man-Matters-and-Founding-Member-Mosaic-Wellness.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/21102142/Geet-Rathi-Co-founder-Man-Matters-and-Founding-Member-Mosaic-Wellness-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p align="LEFT"><span><span><span><b>How is the shift to medical treatment changing how hair loss is assessed and managed, and what gaps remain?</b></span></span></span></p>
<p align="LEFT"><span><span><span>For decades, Indian men treated hair loss as a grooming problem. By the time most of them seek real help, they’ve already tried an oil, an anti-hairfall shampoo and at least one thing their mother swore by.</span></span></span></p>
<p align="LEFT"><span><span><span>That’s changing, and it’s the biggest shift in the category. Hair loss is increasingly understood as a medical condition with a cause. Most often that’s androgenetic alopecia, but nutrition, stress, thyroid and scalp health all show up too. Once you accept there’s a cause, assessment has to come before treatment. So the category is layering diagnosis: doctor consultations first, then scalp assessments, and now blood work to catch deficiencies or hormonal triggers that a questionnaire can’t.</span></span></span></p>
<p align="LEFT"><span><span><span>Man Matters has championed this shift, which is visible in our own numbers. We’ve facilitated over 32 lakh doctor consultations, and the number of men consulting our doctors each month has roughly doubled in the past year. This quarter, Man Matters became the first platform in India to launch a blood test for hair loss, because if a man’s hair fall is linked to a deficiency or a thyroid issue, he deserves to know before starting treatment so that it can be addressed.</span></span></span></p>
<p align="LEFT"><span><span><span>The gaps are time and access. Men wait until it’s visible, often years in, and acting earlier usually leaves more options open. Good specialists are concentrated in big cities, yet six in ten men who start with Man Matters today live outside India’s top eight metros. For a guy in a smaller town, a digital consult is often the most practical way to reach a qualified doctor at all.</span></span></span></p>
<p align="LEFT"><span><span><span><b>What clinical evidence guides the selection and combination of approaches, and how do you assess effectiveness in real-world use?</b></span></span></span></p>
<p align="LEFT"><span><span><span>At Man Matters, we start from the cause, not the cart. A doctor assesses the likely type and stage of hair loss, and the plan follows from that.</span></span></span></p>
<p align="LEFT"><span><span><span>For pattern hair loss, the foundation is treatments with the strongest published evidence, like topical minoxidil, plus prescription options where a doctor thinks they’re right for that person. Nutrition plays a supporting role where there’s a deficiency or a lifestyle gap. It complements treatment; it doesn’t replace it. And sleep, diet, stress and a routine a man can actually stick to all affect his hair, so Man Matters plans give him the whole picture, not just what goes on his scalp.</span></span></span></p>
<p align="LEFT"><span><span><span>Real-world effectiveness is the honest-to-god hard part. Trials happen under close supervision. Real life is a 28-year-old with a demanding job who forgets his routine on the third night, and hair changes too slowly for him to notice in the mirror.</span></span></span></p>
<p align="LEFT"><span><span><span>So we’ve made tracking part of the treatment. On the Man Matters app, men can track their hair loss, regrowth and overall journey over months. That helps him see progress he’d otherwise miss, which keeps him going, and it helps our doctors adjust his plan based on how he’s actually responding. Six in ten Man Matters orders come from men who’ve bought from us before, which tells us many are staying the course.</span></span></span></p>
<p align="LEFT"><span><span><span>That said, the industry as a whole needs to get much better at measuring outcomes, not just sales.</span></span></span></p>
<p align="LEFT"><span><span><span><b>What are the key R&D and formulation challenges for the Indian market, and how are companies working to improve delivery, tolerability, adherence and consistency?</b></span></span></span></p>
<p align="LEFT"><span><span><span>India is a tough place to make hair treatments work. Heat, humidity, sweat, hard water. A formulation that feels fine in a lab can feel greasy or itchy on a Mumbai commute in June. And when something is unpleasant to use every day, men don’t complain. They just quietly stop.</span></span></span></p>
<p align="LEFT"><span><span><span>That’s why tolerability has been one of the biggest R&D priorities for Man Matters. Traditional minoxidil formulations were alcohol-based, and for many men that meant irritation and a burning sensation on the scalp. They had a bad experience and gave up on a treatment that could have helped them. The industry has been steadily moving away from alcohol-based formulations, and Man Matters was one of the first brands to popularise alcohol-free minoxidil in India. Our own next step was cetosomal minoxidil, designed for higher absorption and a lighter, better feel after application, so using it every day doesn’t feel like a chore.</span></span></span></p>
<p align="LEFT"><span><span><span>Adherence is the bigger fight across the category. Hair treatment takes months, and many men drop off in the early weeks, before they’ve seen any change.</span></span></span></p>
<p align="LEFT"><span><span><span>Most men don’t quit because they’re lazy. They miss a few days, feel they’ve ruined it, and never restart. So the better players are building for the habit, not just the product: simple routines, honest expectation-setting, follow-ups and reminders that make coming back easy, not guilt-ridden.</span></span></span></p>
<p align="LEFT"><span><span><span>Consistency of outcomes comes back to diagnosis. Two men with thinning hair can need completely different plans.</span></span></span></p>
<p align="LEFT"><span><span><span><b>How can the industry strengthen evidence-based claims, pharmacovigilance and consumer safety? Where is greater regulatory clarity needed?</b></span></span></span></p>
<p align="LEFT"><span><span><span>Right now, a prescription treatment, an over-the-counter product and a supplement can sit next to each other on the same screen, with similar-sounding promises. No wonder consumers are confused.</span></span></span></p>
<p align="LEFT"><span><span><span>Three things would help. First, claims should match the evidence for that specific ingredient and dose, with cosmetic benefits kept clearly separate from therapeutic ones. Second, consumers should get to speak to a doctor or expert so they’re on the right treatment for their cause, not just the most-advertised one. Third, there need to be proper protocols for follow-up and escalation: someone checks in, side effects are recorded and acted on, and a man is referred onward when his case needs more than an online plan.</span></span></span></p>
<p align="LEFT"><span><span><span>Where we’d welcome more regulatory clarity is claims. Too many products in this category make big promises based on weak studies or internal reports. That bar needs to get much tighter. Evidence-backed claims should be the norm in hair loss, not a differentiator. Clear rules reward the companies doing it properly, and that’s good for everyone, especially the consumer.</span></span></span></p>
<p align="LEFT"><span><span><span><b>What will determine the long-term credibility and growth of India’s digital hair health market, and how can technology, medical oversight and longitudinal data contribute?</b></span></span></span></p>
<p align="LEFT"><span><span><span>Outcomes, not reach. Hair loss is a category built on doubt. Almost every man who comes to a digital platform has tried something that didn’t work. In that world, trust isn’t a marketing line. It’s the product.</span></span></span></p>
<p align="LEFT"><span><span><span>Three things will separate the players who last. First, real doctors making actual clinical calls. Not coaches sitting at the end of a sales funnel. Second, deeper diagnosis that pinpoints each man’s specific cause, so his plan actually fits him. Third, longitudinal data. Following a man over months, not just at checkout, tells you what works for which profile and makes the next decision better.</span></span></span></p>
<p align="LEFT"><span><span><span>That’s exactly what Man Matters is building towards. Our blood test for hair loss is the first step in going deeper on diagnosis. The next is helping men complete the journey: building the right habits, seeing treatment as a whole rather than a single product, and staying on their plan long enough to give it a real chance.</span></span></span></p>
<p align="LEFT"><span><span><span>Hair loss isn’t a product problem. It’s a system problem, and Man Matters is built to solve it as one: diagnose, treat, handhold. We don’t just want to be where men start. We want to be where they finish.</span></span></span></p>
<p align="LEFT">
</p><p>The post <a href="https://www.expresspharma.in/from-hair-loss-to-hair-health-why-diagnosis-must-come-before-treatment/">From hair loss to hair health: Why diagnosis must come before treatment</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>FDA approves Viatris’ Ryzumvi for adult presbyopia</title>
<link>https://edusehat.com/en/fda-approves-viatris-ryzumvi-for-adult-presbyopia</link>
<guid>https://edusehat.com/en/fda-approves-viatris-ryzumvi-for-adult-presbyopia</guid>
<description><![CDATA[ In the US, Ryzumvi is already marketed as the sole authorised treatment for pharmacologically-induced mydriasis. Under a global licensing agreement with Opus Genetics, Viatris holds exclusive rights to 
The post FDA approves Viatris’ Ryzumvi for adult presbyopia appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/10/PT-2-19-10-2026-shutterstock_254316538.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 19 Oct 2026 18:00:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>FDA, approves, Viatris’, Ryzumvi, for, adult, presbyopia</media:keywords>
<content:encoded><![CDATA[<p>In the US, Ryzumvi is already marketed as the sole authorised treatment for pharmacologically-induced mydriasis.</p>
<p>Under a global licensing agreement with Opus Genetics, Viatris holds exclusive rights to commercialise phentolamine ophthalmic solution 0.75% across the US.</p>
<p>Following the expanded clearance, the company is exploring opportunities to secure a commercial partner to distribute the solution for presbyopia nationwide.</p>
<p>Presbyopia involves the progressive loss of near-focusing capacity brought on by ageing. The condition typically emerges when individuals reach their early to mid-40s and affects nearly the entire adult population.</p>
<p>When left uncorrected, it contributes significantly to vision-related disability, causing symptoms such as blurred near vision and eye strain that impair everyday activities and productivity.</p>
<p>Safety guidance for the medication instructs contact lens wearers to take out their lenses prior to administering Ryzumvi and wait 10 minutes following the dose before reinserting them.</p>
<p>In clinical studies for presbyopia, the most frequent adverse ocular reactions reported in more than 5% of participants were conjunctival hyperaemia (21%) and instillation site irritation (16%).</p>
<p>Ryzumvi is also indicated to treat pharmacologically-induced mydriasis caused by adrenergic agonists such as phenylephrine or parasympatholytic agents like tropicamide in adults and paediatric patients aged three years and older.</p>
<p>In that indication, the most common reactions exceeding 5% were instillation site discomfort with burning, pain, and stinging (16%), conjunctival hyperaemia (12%), and dysgeusia (6%), with most events remaining self-resolving, mild, and transient.</p>
<p>Viatris maintains its corporate headquarters in the US, alongside global centres situated in Hyderabad, India; Pittsburgh, the US; and Shanghai.</p>
<p>In July 2024, Viatris announced the finalisation of a transaction to divest its over-the-counter (OTC) business, completing the last step in its previously declared $3.37bn divestitures.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/fda-viatris-ryzumvi-adult-presbyopia/">FDA approves Viatris’ Ryzumvi for adult presbyopia</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Estuary secures $103m to advance kidney disease gene therapies</title>
<link>https://edusehat.com/en/estuary-secures-103m-to-advance-kidney-disease-gene-therapies</link>
<guid>https://edusehat.com/en/estuary-secures-103m-to-advance-kidney-disease-gene-therapies</guid>
<description><![CDATA[ The capital will fund clinical proof-of-concept testing for the biotechnology company’s lead gene therapy candidates, EST-101 and EST-201, whilst advancing its platform for direct kidney delivery. The total 
The post Estuary secures $103m to advance kidney disease gene therapies appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/10/PT-19-10-2026-shutterstock_2468583845.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 19 Oct 2026 18:00:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Estuary, secures, 103m, advance, kidney, disease, gene, therapies</media:keywords>
<content:encoded><![CDATA[<p>The capital will fund clinical proof-of-concept testing for the biotechnology company’s lead gene therapy candidates, EST-101 and EST-201, whilst advancing its platform for direct kidney delivery.</p>
<p>The total comprises a $93m Series A round led by RA Capital Management, alongside Biogen New Ventures, Deep Track Capital, the National Kidney Foundation Innovation Fund, Pivotal bioVenture Partners, UPMC Enterprises, and a family office linked to an autosomal dominant polycystic kidney disease (ADPKD) patient.</p>
<p>Estuary previously completed a $10m seed financing co-led by 4BIO Capital and GV, both of which also took part in the Series A financing.</p>
<p>ADPKD is an inherited, progressive disorder where fluid-filled cysts expand in both kidneys, displacing healthy tissue over time and causing organ failure that requires dialysis or transplantation.</p>
<p>Rather than targeting downstream biological pathways, Estuary seeks to treat the underlying genetic defect.</p>
<p>The company uses a locally administered adeno-associated virus (AAV) to transduce epithelial cells and restore polycystin levels across the nephron, aiming to avoid safety and delivery issues linked to systemic AAV administration.</p>
<p>Estuary co-founder and CEO Wayne Sackett said: “ADPKD is one of the world’s most common genetic diseases, yet patients are still awaiting a therapy that can transform the course of their disease.</p>
<p>“We paired our scientific co-founders’ landmark breakthroughs in disease biology with a dedicated and passionate team focused on solving the most crucial remaining barrier to kidney gene therapy: delivery.</p>
<p>“By pioneering fit-for-purpose local administration and an efficient global development strategy, our team is moving with urgency to bring these important medicines into the clinic.”</p>
<p>EST-101, an AAV-delivered therapy targeting the PC1 functional region in ADPKD patients with PKD1 mutations, is projected to enter clinical testing in 2028.</p>
<p>EST-201, a full-length PKD2 gene therapy delivered via AAV for individuals with PKD2 mutations, is scheduled to enter the clinic in 2027.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/estuary-103m-advance-kidney-gene-therapies/">Estuary secures $103m to advance kidney disease gene therapies</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Dr Praveen Khullar, Executive Director, VerGo Pharma Research Laboratories</title>
<link>https://edusehat.com/en/dr-praveen-khullar-executive-director-vergo-pharma-research-laboratories</link>
<guid>https://edusehat.com/en/dr-praveen-khullar-executive-director-vergo-pharma-research-laboratories</guid>
<description><![CDATA[ 
Goa Pharma Summit | 30th September 2026 | Panjim
The post Dr Praveen Khullar, Executive Director, VerGo Pharma Research Laboratories appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/19125634/EP_Goa_Pharma_Summit_Sept_2026_01_Dr_Praveen_Khullar_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 19 Oct 2026 18:00:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Praveen, Khullar, Executive, Director, VerGo, Pharma, Research, Laboratories</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="422" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/19125634/EP_Goa_Pharma_Summit_Sept_2026_01_Dr_Praveen_Khullar_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/19125634/EP_Goa_Pharma_Summit_Sept_2026_01_Dr_Praveen_Khullar_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/19125634/EP_Goa_Pharma_Summit_Sept_2026_01_Dr_Praveen_Khullar_750-300x169.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p></p>
<hr>
<p><strong>Speaker in this video:</strong><br>
Dr Praveen Khullar, Executive Director, VerGo Pharma Research Laboratories</p>
<p><strong>Topic:</strong> Positioning Goa in the global CDMO map</p>
<p><strong>Key Highlights:</strong><br>
[1] Build on what Goa already does well. Its strong export base gives it a head start in moving up the pharma value chain.</p>
<p>[2] Shift from manufacturing to partnerships. The opportunity is to become a trusted destination for global development and manufacturing programmes.</p>
<p>[3] Own a clear space in the CDMO market. Focus on complex formulations, specialty products and high-value, smaller-batch programmes.</p>
<p>[4] Turn reliability into a competitive advantage. Supply continuity, speed and resilience can become part of Goa’s value proposition.</p>
<p>[5] Build an ecosystem, not just individual capabilities. Industry, government and academia need to work together on talent, regulation, technology and global partnerships. </p>
<p>The post <a href="https://www.expresspharma.in/dr-praveen-khullar-executive-director-vergo-pharma-research-laboratories-30-sep-2026-goa/">Dr Praveen Khullar, Executive Director, VerGo Pharma Research Laboratories</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Panel Discussion: PPILT meets the patent cliff — Can Goa’s pricing model handle a biologics wave?</title>
<link>https://edusehat.com/en/panel-discussion-ppilt-meets-the-patent-cliff-can-goas-pricing-model-handle-a-biologics-wave</link>
<guid>https://edusehat.com/en/panel-discussion-ppilt-meets-the-patent-cliff-can-goas-pricing-model-handle-a-biologics-wave</guid>
<description><![CDATA[ 
Goa Pharma Summit | 30th September 2026 | Panjim
The post Panel Discussion: PPILT meets the patent cliff — Can Goa’s pricing model handle a biologics wave? appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/19131016/EP_Goa_Pharma_Summit_Sept_2026_04_PD1_PPILT_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 19 Oct 2026 18:00:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Panel, Discussion:, PPILT, meets, the, patent, cliff, —, Can, Goa’s, pricing, model, handle, biologics, wave</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="422" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/19131016/EP_Goa_Pharma_Summit_Sept_2026_04_PD1_PPILT_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/19131016/EP_Goa_Pharma_Summit_Sept_2026_04_PD1_PPILT_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/19131016/EP_Goa_Pharma_Summit_Sept_2026_04_PD1_PPILT_750-300x169.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p></p>
<hr>
<p><strong>Panelists in this video:</strong><br>
• Dr Subrata Chakraborty, Founder, INOPHAR Consulting & Training (MODERATOR)<br>
• Mr Nilesh Hegu, Site Head – Goa II, Cipla<br>
• Dr Pankaj Kumar, VP/Head R&D & Director, Wallace Pharmaceuticals<br>
• Mr Uttam Kadam, Sterile Head, Zydus Lifesciences, Goa<br>
• Dr Prabhat Dessai, Associate Professor & Assistant Director, Placement & Corporate Relations Cell, Parul University, Goa<br>
• Prof (Dr) G Shaber Ali, Professor Of Law, Former Principal, V M Salgaocar College of Law</p>
<p><strong>Key Highlights:</strong><br>
[1] PPILT combines procurement and negotiated pricing, rather than functioning as a standalone pricing policy.</p>
<p>[2] Confidential pricing remains a key challenge, requiring a balance between industry interests and public transparency.</p>
<p>[3] PPILT could attract biologics manufacturing and technology transfer to Goa.</p>
<p>[4] Goa’s next growth phase will require specialised talent, with academia currently struggling to match industry demand.</p>
<p>[5] Complex generics require a fundamentally different R&D approach, with higher investment and advanced analytical capabilities.</p>
<p>[6] Industry 4.0 and AI are reshaping pharma manufacturing, but stronger academia-industry collaboration will be essential.</p>
<p>The post <a href="https://www.expresspharma.in/panel-discussion-ppilt-meets-the-patent-cliff-can-goas-pricing-model-handle-a-biologics-wave-30-sep-2026-goa/">Panel Discussion: PPILT meets the patent cliff — Can Goa’s pricing model handle a biologics wave?</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Mr Manoj Bansal, Head – Business Development, Thermo Fisher Scientific India</title>
<link>https://edusehat.com/en/mr-manoj-bansal-head-business-development-thermo-fisher-scientific-india</link>
<guid>https://edusehat.com/en/mr-manoj-bansal-head-business-development-thermo-fisher-scientific-india</guid>
<description><![CDATA[ 
Goa Pharma Summit | 30th September 2026 | Panjim
The post Mr Manoj Bansal, Head – Business Development, Thermo Fisher Scientific India appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/19125637/EP_Goa_Pharma_Summit_Sept_2026_02_Manoj_Bansal_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 19 Oct 2026 18:00:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Manoj, Bansal, Head, –, Business, Development, Thermo, Fisher, Scientific, India</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="422" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/19125637/EP_Goa_Pharma_Summit_Sept_2026_02_Manoj_Bansal_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/19125637/EP_Goa_Pharma_Summit_Sept_2026_02_Manoj_Bansal_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/19125637/EP_Goa_Pharma_Summit_Sept_2026_02_Manoj_Bansal_750-300x169.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p></p>
<hr>
<p><strong>Speaker in this video:</strong><br>
Mr Manoj Bansal, Head – Business Development, Thermo Fisher Scientific India</p>
<p><strong>Topic:</strong> Advancements in hot melt extrusion technology – Instrumentation considerations and methodologies</p>
<p><strong>Key Highlights:</strong><br>
[1] Thermo Fisher’s hot melt extrusion technology helps improve solubility and bioavailability. It supports the journey from R&D to manufacturing.</p>
<p>[2] Its molecular spectroscopy portfolio uses Raman, NIR and XRF for rapid, non-destructive testing across pharma workflows.</p>
<p>[3] Thermo Fisher combines formulation, spectroscopy, PAT and quality-control technologies to support faster decisions, compliance and efficient manufacturing.</p>
<p>The post <a href="https://www.expresspharma.in/mr-manoj-bansal-head-business-development-thermo-fisher-scientific-india-30-sep-2026-goa/">Mr Manoj Bansal, Head – Business Development, Thermo Fisher Scientific India</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Panel Discussion: Beyond America — Finding India’s next export growth engines</title>
<link>https://edusehat.com/en/panel-discussion-beyond-america-finding-indias-next-export-growth-engines</link>
<guid>https://edusehat.com/en/panel-discussion-beyond-america-finding-indias-next-export-growth-engines</guid>
<description><![CDATA[ 
Goa Pharma Summit | 30th September 2026 | Panjim
The post Panel Discussion: Beyond America — Finding India’s next export growth engines appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/19131019/EP_Goa_Pharma_Summit_Sept_2026_05_PD2_Beyond_America_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 19 Oct 2026 18:00:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Panel, Discussion:, Beyond, America, —, Finding, India’s, next, export, growth, engines</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="422" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/19131019/EP_Goa_Pharma_Summit_Sept_2026_05_PD2_Beyond_America_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/19131019/EP_Goa_Pharma_Summit_Sept_2026_05_PD2_Beyond_America_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/19131019/EP_Goa_Pharma_Summit_Sept_2026_05_PD2_Beyond_America_750-300x169.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p></p>
<hr>
<p><strong>Panelists in this video:</strong><br>
• Mr Mahesh Gurnasinghani, Executive Member GPMA and Visiting Faculty – Goa College of Pharmacy (MODERATOR)<br>
• Mr Maneesh Madhukar Narkar, VP – Formulations, Centaur Pharmaceuticals<br>
• Mr Pramod Poojari, Site Head – Warehouse – Manufacturing, Cipla<br>
• Mr Hruday Jadhav, Associate VP – Analytical R&D, Micro Labs<br>
• Mr Sandeep Kulkarni, Associate Director APAC Sourcing Global Procurement Category, Teva Pharmaceuticals<br>
• Mr Niket Talauliker, Head of Site Quality, Sanofi India<br>
• Mr Himank Narvekar, DGM – BD & Strategy, VerGo Pharma Research Laboratories</p>
<p><strong>Key Highlights:</strong><br>
[1] India has mastered scale. The next challenge is turning that scale into value. </p>
<p>[2] The next export opportunity may lie in what is harder to make, not simply what is easier to sell. </p>
<p>[3] Diversification is not just about finding new markets. It is about building products those markets actually need. </p>
<p>[4] The market strategy and the R&D strategy can no longer be separate conversations. </p>
<p>[5] Regulatory approval opens the door. Supply, distribution and acceptance determine whether you can stay in the room. </p>
<p>[6] Quality has to be designed into the product from Day One, not added when the market is identified. </p>
<p>[7] For Goa, the bigger opportunity may be to connect manufacturing, CDMOs, academia and investment into one innovation ecosystem. </p>
<p>[8] The real question for Goa is no longer whether it can manufacture. It is whether it can move up the value chain.</p>
<p>The post <a href="https://www.expresspharma.in/panel-discussion-beyond-america-finding-indias-next-export-growth-engines-30-sep-2026-goa/">Panel Discussion: Beyond America — Finding India’s next export growth engines</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Panel Discussion: From Panjim to the World — Goa’s export playbook</title>
<link>https://edusehat.com/en/panel-discussion-from-panjim-to-the-world-goas-export-playbook</link>
<guid>https://edusehat.com/en/panel-discussion-from-panjim-to-the-world-goas-export-playbook</guid>
<description><![CDATA[ 
Goa Pharma Summit | 30th September 2026 | Panjim
The post Panel Discussion: From Panjim to the World — Goa’s export playbook appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/19131023/EP_Goa_Pharma_Summit_Sept_2026_06_PD3_From_Panjim_to_World_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 19 Oct 2026 18:00:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Panel, Discussion:, From, Panjim, the, World, —, Goa’s, export, playbook</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="422" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/19131023/EP_Goa_Pharma_Summit_Sept_2026_06_PD3_From_Panjim_to_World_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/19131023/EP_Goa_Pharma_Summit_Sept_2026_06_PD3_From_Panjim_to_World_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/19131023/EP_Goa_Pharma_Summit_Sept_2026_06_PD3_From_Panjim_to_World_750-300x169.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p></p>
<hr>
<p><strong>Panelists in this video:</strong><br>
• Dr Manoj Kumar Kashyap, Professor and Director, Research & Development, Parul University, Goa (MODERATOR)<br>
• Dr Pradeep Kumar Vishwakarma, Associate Director – COE Manufacturing Science and Technology Respiratory, Cipla<br>
• Dr Bhaskar Chauhan, Head R&D and Quality Management, Puniska Injectables<br>
• Mr Sartaj Hanfi, Sr GM – Plant Head, Indoco Remedies<br>
• Mr Vishwas J Desai, GM – Quality Assurance, Blue Cross Laboratories<br>
• Mr Abhinay Ajgaonkar, DGM – Head of QA, Centaur Pharmaceuticals<br>
• Ms Urmila Deepak Naik, AGM, FDC Limited Goa (Unit III)</p>
<p><strong>Key Highlights:</strong><br>
[1] The real shift is from “passing audits” to building organisations that are always ready for scrutiny. </p>
<p>[2] Talent could become the next bottleneck for pharma quality. Technology is advancing faster than skills. </p>
<p>[3] The future of quality is increasingly data-led. Digital systems can turn quality data into action, not just documentation. </p>
<p>[4] To compete globally, Goa needs to own more of the pharma value chain—from R&D to technology transfer to manufacturing.</p>
<p>[5] Question the legacy. If the data supports a better way, pharma needs the confidence to challenge “how it has always been done.” </p>
<p>[6] The shop floor is the new classroom. Future-ready talent needs hands-on exposure to machines, technology and real manufacturing problems. </p>
<p>[7] Innovation needs a bridge between campus and industry. Collaboration should go beyond MOUs to creating real opportunities for research and problem-solving.</p>
<p>The post <a href="https://www.expresspharma.in/panel-discussion-from-panjim-to-the-world-goas-export-playbook-30-sep-2026-goa/">Panel Discussion: From Panjim to the World — Goa’s export playbook</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Alembic Pharma gets USFDA nod for Ciprofloxacin and Dexamethasone Otic Suspension USP, 0.3% / 0.1%</title>
<link>https://edusehat.com/en/alembic-pharma-gets-usfda-nod-for-ciprofloxacin-and-dexamethasone-otic-suspension-usp-03-01</link>
<guid>https://edusehat.com/en/alembic-pharma-gets-usfda-nod-for-ciprofloxacin-and-dexamethasone-otic-suspension-usp-03-01</guid>
<description><![CDATA[ 
According to IQVIA, the estimated market size for Ciprofloxacin and Dexamethasone Otic Suspension USP, 0.3% / 0.1%, was $110 million for twelve months ending June 2026
The post Alembic Pharma gets USFDA nod for Ciprofloxacin and Dexamethasone Otic Suspension USP, 0.3% / 0.1% appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2020/08/07111742/US-FDA-stamp-e1722586514279.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 19 Oct 2026 18:00:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Alembic, Pharma, gets, USFDA, nod, for, Ciprofloxacin, and, Dexamethasone, Otic, Suspension, USP, 0.3, 0.1</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="399" src="https://cdn.expresspharma.in/wp-content/uploads/2020/08/07111742/US-FDA-stamp-e1722586514279.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2020/08/07111742/US-FDA-stamp-e1722586514279.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2020/08/07111742/US-FDA-stamp-e1722586514279-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p align="JUSTIFY"><span><span><span><span><span lang="en-US">Alembic Pharmaceuticals announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Ciprofloxacin and Dexamethasone Otic Suspension USP, 0.3% / 0.1%.</span></span></span></span></span></p>
<p lang="en-US" align="JUSTIFY"><span><span><span>The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Ciprodex Otic Suspension, 0.3%/0.1%, of Sandoz Inc. Ciprofloxacin and Dexamethasone Otic suspension is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions: </span></span></span></p>
<ul>
<li>
<p lang="en-US" align="JUSTIFY"><span><span><span>Acute Otitis Media (AOM) in pediatric patients (age 6 months and older) with tympanostomy tubes, and</span></span></span></p>
</li>
<li>
<p lang="en-US" align="JUSTIFY"><span><span><span>Acute Otitis Externa (AOE) in pediatric (age 6 months and older), adult, and elderly patients. Refer label for a detailed indication.</span></span></span></p>
</li>
</ul>
<p lang="en-US" align="JUSTIFY"><span><span><span>According to IQVIA, the estimated market size for Ciprofloxacin and Dexamethasone Otic Suspension USP, 0.3% / 0.1%, was $110 million for twelve months ending June 2026.</span></span></span></p>
<p lang="en-US" align="JUSTIFY"><span><span><span>Alembic has a cumulative total of 246 ANDA approvals (226 final approvals and 20 tentative approvals) from USFDA.</span></span></span></p>
<p>The post <a href="https://www.expresspharma.in/alembic-pharma-gets-usfda-nod-for-ciprofloxacin-and-dexamethasone-otic-suspension-usp-0-3-0-1/">Alembic Pharma gets USFDA nod for Ciprofloxacin and Dexamethasone Otic Suspension USP, 0.3% / 0.1%</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>NPPA caps trade margins at 30 per cent for 137 anti&#45;cancer medicines</title>
<link>https://edusehat.com/en/nppa-caps-trade-margins-at-30-per-cent-for-137-anti-cancer-medicines</link>
<guid>https://edusehat.com/en/nppa-caps-trade-margins-at-30-per-cent-for-137-anti-cancer-medicines</guid>
<description><![CDATA[ 
Industry associations like IPA and OPPI welcomes the move; but highlight the need to ensure affordability and uninterrupted availability
The post NPPA caps trade margins at 30 per cent for 137 anti-cancer medicines appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2024/09/02120205/Colourful-medicines.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 19 Oct 2026 18:00:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>NPPA, caps, trade, margins, per, cent, for, 137, anti-cancer, medicines</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2024/09/02120205/Colourful-medicines.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2024/09/02120205/Colourful-medicines.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2024/09/02120205/Colourful-medicines-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p>The National Pharmaceutical Pricing Authority (NPPA) has capped trade margins at 30 per cent for 137 non-scheduled anti-cancer medicines. The revised prices will take effect from November 9, 2026, under an order issued on October 17.</p>
<p>The move aims to reduce excessive trade margins on cancer medicines and make treatment more affordable. The government expects the maximum retail prices (MRPs) of the identified medicines to fall by up to 70 per cent, depending on their existing price structures.</p>
<p>Under the order, manufacturers must calculate revised MRPs using the prescribed formula based on the price to stockists or distributors in March 2026. They must submit the revised price details to the NPPA and the relevant State Drug Controller within seven days of the notification. Manufacturers must also maintain current production levels to help ensure continued availability of the medicines.</p>
<p>The decision builds on the NPPA’s 2019 pilot exercise, which capped trade margins at 30 per cent for 42 non-scheduled anti-cancer medicines. According to the government’s account of that exercise, MRPs of 526 brands were reduced by up to 90 per cent. The latest order extends the approach to 137 medicines recommended by an expert committee.</p>
<p>Sudarshan Jain, Secretary General, IPA welcomed the notification and highlighted the need to balance affordability with the interests of stakeholders across oncology care.</p>
<p>“We welcome the notification on Trade Margin Rationalisation (TMR) for oncology products. With the increasing incidence of cancer in the country, access to affordable, quality-assured medicines is critical.</p>
<p>TMR will help to optimise the pricing for oncology products while allowing adequate margin to channel partners. It is important to maintain balance between affordability for patients and the interests of all stakeholders involved in oncology care, while ensuring the uninterrupted availability of medicines.</p>
<p>The impact of TMR on affordability and patient access will need to be evaluated. Companies will continue to take appropriate steps to ensure the availability of medicines and to passing on the intended benefits to patients. Creating awareness among patients and other stakeholders will be equally important to ensure that patients derive the intended benefits without compromising continuity of care.”</p>
<p>Anil Matai, Director General, Organisation of Pharmaceutical Producers of India (OPPI), also said, “OPPI welcomes the Government’s notification extending Trade Margin Rationalisation to 137 non-scheduled anti-cancer medicines. With the revised prices set to take effect from November 9, the focus now is on smooth implementation across the supply chain so that the intended benefits reach patients while ensuring continued availability of these critical medicines.”</p>
<p>“The industry remains committed to working constructively with the Government and other stakeholders to support effective implementation. It will be important to monitor the impact of the measure on patient access, availability and the broader cancer-care ecosystem as the revised pricing takes effect,” he added.</p>
<p>As the revised prices take effect, their impact on patient affordability and access, as well as the availability of medicines, will need to be assessed.</p>
<p>The post <a href="https://www.expresspharma.in/nppa-caps-trade-margins-at-30-per-cent-for-137-anti-cancer-medicines/">NPPA caps trade margins at 30 per cent for 137 anti-cancer medicines</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The growing role of OTC medicines in preventive healthcare and self&#45;care</title>
<link>https://edusehat.com/en/the-growing-role-of-otc-medicines-in-preventive-healthcare-and-self-care</link>
<guid>https://edusehat.com/en/the-growing-role-of-otc-medicines-in-preventive-healthcare-and-self-care</guid>
<description><![CDATA[ 
Sushmita Kuswa, Head – Medical and Regulatory Affairs, Piramal Consumer Healthcare, looks at how responsible self-medication can empower consumers and bring about a paradigm shift toward health ownership, while supporting India’s healthcare system
The post The growing role of OTC medicines in preventive healthcare and self-care appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/19115454/Sushmita-Kuswa.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 19 Oct 2026 14:25:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, growing, role, OTC, medicines, preventive, healthcare, and, self-care</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/19115454/Sushmita-Kuswa.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/19115454/Sushmita-Kuswa.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/19115454/Sushmita-Kuswa-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span><span><span>The global healthcare landscape is undergoing a fundamental shift from reactive disease management to proactive health ownership. In India, this transition is particularly pronounced. Driven by rising disposable incomes, expanding digital literacy, and an acute post-pandemic focus on wellness, consumers are increasingly seeking immediate, accessible tools to manage minor health conditions independently. At the heart of this movement lie Over-the-Counter (OTC) medicines—pharmaceutical and wellness products sold directly to consumers without requiring a prescription from a healthcare professional.</span></span></span></p>
<p><span><span><span>Once viewed merely as episodic fixes for minor symptoms, OTC solutions are now recognised as essential components of preventive healthcare and routine self-care. By enabling early intervention for self-limiting conditions, OTC medications empower individuals while preserving critical capacity within India’s primary and secondary healthcare infrastructure.</span></span></span></p>
<p><span><span><span><b>Empowering the Indian consumer through self-care</b></span></span></span></p>
<p><span><span><span>Self-care is defined by the World Health Organisation (WHO) as the ability of individuals, families, and communities to promote health, prevent disease, maintain wellness, and cope with illness with or without the support of a healthcare provider. In a country like India, where doctor-to-patient ratios in semi-urban and rural regions often remain below global benchmarks, self-care is both a practical benefit and a public health necessity.</span></span></span></p>
<p><span><span><span>OTC products serve as the frontline defense across a spectrum of daily wellness needs:</span></span></span></p>
<ul>
<li><span><span><span><b>Targeted pain management</b>: providing localised relief from joint inflammation, muscle strain, and stiffness to maintain daily mobility and productivity.</span></span></span></li>
<li><span><span><span><b>Digestive & gastrointestinal care</b>: neutralising excess acidity and supporting proper ensymatic digestion to prevent minor gastric distress from escalating.</span></span></span></li>
<li><span><span><span><b>Medicated dermatological solutions</b>: addressing everyday skin barrier issues, fungal irritation, and persistent itching to prevent secondary bacterial infections.</span></span></span></li>
<li><span><span><span><b>Routine wellness & diagnostics</b>: supporting personal health tracking and reproductive health awareness directly at home.</span></span></span></li>
</ul>
<p><span><span><span>By offering swift access to quality-assured formulations, OTC products eliminate unnecessary non-emergency clinical visits, saving both time and financial resources for households.</span></span></span></p>
<p><span><span><span><b>Piramal Consumer Healthcare: Pioneering trusted self-care solutions</b></span></span></span></p>
<p><span><span><span>Piramal Consumer Healthcare (PCH) has played a pivotal role in shaping India’s self-care ecosystem by delivering science-backed, heritage OTC brands that consumers trust for routine health disruptions.</span></span></span></p>
<p><span><span><span>Piramal has a wide portfolio of modern OTC solutions fit seamlessly into daily preventive care and symptom management:</span></span></span></p>
<table border="1" width="601" cellspacing="0" cellpadding="2">
<tbody>
<tr valign="TOP">
<td width="122">
<p align="CENTER"><span><b>BRAND</b></span></p>
</td>
<td width="195">
<p align="CENTER"><span><b>CATEGORY</b></span></p>
</td>
<td width="271">
<p align="CENTER"><span><b>SELF-CARE FUNCTION</b></span></p>
</td>
</tr>
<tr valign="TOP">
<td width="122"><span>Polycrol range</span></td>
<td width="195"><span>Gastrointestinal</span></td>
<td width="271"><span>Ensyme-aided digestion</span></td>
</tr>
<tr valign="TOP">
<td width="122"><span>Digeplex range</span></td>
<td width="195"><span>Digestive Health</span></td>
<td width="271"><span>Fast acidity & gas relief</span></td>
</tr>
<tr valign="TOP">
<td width="122"><span>Tetmosol range</span></td>
<td width="195"><span>Medicated Skincare</span></td>
<td width="271"><span>Antifungal & itch prevention</span></td>
</tr>
<tr valign="TOP">
<td width="122"><span>Sloan’s range</span></td>
<td width="195"><span>Pain Management</span></td>
<td width="271"><span>Deep heat joint/muscle relief</span></td>
</tr>
<tr valign="TOP">
<td width="122"><span>QuickKool</span></td>
<td width="195"><span>Oral Care</span></td>
<td width="271"><span>Fast relief from mouth ulcers</span></td>
</tr>
<tr valign="TOP">
<td width="122"><span>i-pill</span></td>
<td width="195"><span>Emergency Contraception</span></td>
<td width="271"><span>Single-dose emergency relief</span></td>
</tr>
<tr valign="TOP">
<td width="122"><span>i-pill Daily</span></td>
<td width="195"><span>Daily Birth Control</span></td>
<td width="271"><span>21-day regular family planning</span></td>
</tr>
<tr valign="TOP">
<td width="122"><span>i-choose</span></td>
<td width="195"><span>Women’s Diagnostics</span></td>
<td width="271"><span>Home reproductive tracking (ovulation, early pregnancy and menopause) and rapid UTI testing kit</span></td>
</tr>
</tbody>
</table>
<p><span> </span></p>
<p><span><span><span><b>The macroeconomic value of responsible self-care</b></span></span></span></p>
<p><span><span><span>Beyond individual convenience, the growing role of OTC healthcare delivers substantial economic value to the broader nation. Out-of-pocket health expenditure remains a key financial consideration for Indian households. Early self-treatment using accessible OTC remedies prevents routine symptoms from advancing into severe conditions that require expensive diagnostic tests or clinical consultations.</span></span></span></p>
<p><span><span><span>Furthermore, when individuals manage non-serious ailments at home, primary healthcare clinics and hospital OPDs can focus vital resources toward managing chronic lifestyle diseases, acute infections, and emergency surgical cases.</span></span></span></p>
<p><span><span><span><b>Conclusion</b></span></span></span></p>
<p><span><span><span>The evolution of OTC medicines from basic remedies to integral self-care tools reflects a modern healthcare paradigm centered on patient empowerment, informed decision-making, and scientific credibility. As Indian consumers become increasingly health-conscious and proactive about managing their well-being, the demand for safe, transparent, effective, and easily accessible OTC solutions will continue to grow. OTC medicines from Piramal Consumer Healthcare exemplify how evidence-based innovation, trusted quality, and consumer-centric accessibility can bridge the gap between healthcare and everyday wellness. By combining clinical credibility with convenience, OTC medicines are not only addressing unmet consumer needs but also fostering a healthier, more informed, and self-reliant society.</span></span></span></p>
<p>The post <a href="https://www.expresspharma.in/the-growing-role-of-otc-medicines-in-preventive-healthcare-and-self-care/">The growing role of OTC medicines in preventive healthcare and self-care</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Cotecna Group acquires Energon Labs, strengthens global pharma testing capabilities</title>
<link>https://edusehat.com/en/cotecna-group-acquires-energon-labs-strengthens-global-pharma-testing-capabilities</link>
<guid>https://edusehat.com/en/cotecna-group-acquires-energon-labs-strengthens-global-pharma-testing-capabilities</guid>
<description><![CDATA[ 
The acquisition enhances Cotecna&#039;s ability to support both Indian and international  customers with high-quality and regulatory-compliant testing services 
The post Cotecna Group acquires Energon Labs, strengthens global pharma testing capabilities appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/16162521/EH_Cotecna.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 16 Oct 2026 21:25:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Cotecna, Group, acquires, Energon, Labs, strengthens, global, pharma, testing, capabilities</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/16162521/EH_Cotecna.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/16162521/EH_Cotecna.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/16162521/EH_Cotecna-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>Cotecna, a leading provider of Testing, Inspection and Certification (TIC) services, today announced the acquisition of Energon Labs, a cGMP-compliant, USFDA-inspected, ISO 9001:2015 and ISO 17025:2017 certified analytical testing laboratory based in Hyderabad, India.</span></p>
<p><span>The acquisition strengthens Cotecna’s global Life Sciences platform and expands its pharmaceutical testing capabilities across the Pharmaceutical, Biopharmaceutical, Medical Device and Packaging sectors. Serving customers across India, the United States, Asia-Pacific, and the Middle East, Energon is recognized for its scientific excellence, regulatory expertise and commitment to quality. </span></p>
<p><span>Strategically located in Hyderabad, one of the world’s leading pharmaceutical and biotechnology hubs, Energon provides Cotecna with access to highly specialized scientific talent, advanced laboratory infrastructure and a well-established pharmaceutical ecosystem. India is also one of the world’s fastest-growing pharmaceutical markets and a critical manufacturing hub for global healthcare supply chains.</span></p>
<p><span>The acquisition enhances the Cotecna’s ability to support both Indian and international  customers with high-quality, regulatory-compliant testing services while delivering greater responsiveness, scalability and operational efficiency across key markets.</span></p>
<p><span>The addition of Energon further complements Cotecna’s growing pharmaceutical testing network which includes Cotecna Life Sciences, Shiva Analyticals and Neotron Pharma. Together, this capabilities strengthen the Group’s ability to support customers throughout the product lifecycle and address evolving global quality, compliance and regulatory requirements.</span></p>
<p><span>Energon offers a comprehensive portfolio of analytical testing and quality assurance services, including analytical method development and validation, stability studies, impurity profiling, extractables and leachables, glass delamination studies, peptides and oligonucleotide characterisation, raw material and finished product testing, in-vitro binding studies, packaging compatibility studies, and regulatory support services. These capabilities will further strengthen Cotecna’s position as a trusted partner to pharmaceutical manufacturers serving regulated markets worldwide.</span></p>
<p><span>Sébastien Dannaud, Chief Executive Officer of Cotecna Group, commented: “We are pleased to welcome Energon Labs to the Cotecna Group. This acquisition represents another important step to support our ambition to become one of the largest providers of Life Sciences testing services in India,and strengthens our position in one of the world’s most important pharmaceutical markets.”</span></p>
<p><span>Amit Chopra, CEO South Asia and Middle East, Cotecna Group, added: “I am delighted to welcome Manikanth Reddy and the talented team of Energon Labs to the Cotecna group. This acquisition aligns perfectly with our strategy of building a comprehensive pharmaceutical testing ecosystem across key growth markets. Energon’s strong technical capabilities, experienced team and established customer relationships will enhance our ability to serve pharmaceutical, biopharmaceutical and medical device companies across India and globally. Together, we are creating a stronger platform to support the evolving needs of the pharmaceutical and healthcare sectors. “</span></p>
<p><span>Manikanth Reddy, Founder, Energon, said: “Joining the Cotecna Group opens an exciting new chapter for Energon Labs. Over the years, we have focused on building a laboratory recognized for quality, scientific expertise and reliability. Becoming part of a global organization like Cotecna provides new opportunities to expand our capabilities, strengthen our service offerings and deliver even greater value to our customers. Our team remains committed to maintaining the highest standards of analytical excellence while supporting the continued growth of the life sciences industry.”</span></p>
<p>The post <a href="https://www.expresspharma.in/cotecna-group-acquires-energon-labs-strengthens-global-pharma-testing-capabilities/">Cotecna Group acquires Energon Labs, strengthens global pharma testing capabilities</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Acta Pharmaceuticals raises $24m for Alzheimer’s therapies</title>
<link>https://edusehat.com/en/acta-pharmaceuticals-raises-24m-for-alzheimers-therapies</link>
<guid>https://edusehat.com/en/acta-pharmaceuticals-raises-24m-for-alzheimers-therapies</guid>
<description><![CDATA[ It is a gamma-secretase modulator being developed as a potent once-daily oral therapy for the treatment and potential prevention of AD. According to the company, existing therapies approved 
The post Acta Pharmaceuticals raises $24m for Alzheimer’s therapies appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/10/PT-2-16-10-2026-shutterstock_1924512707.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 16 Oct 2026 17:50:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Acta, Pharmaceuticals, raises, 24m, for, Alzheimer’s, therapies</media:keywords>
<content:encoded><![CDATA[<p>It is a gamma-secretase modulator being developed as a potent once-daily oral therapy for the treatment and potential prevention of AD.</p>
<p>According to the company, existing therapies approved by the US Food and Drug Administration (FDA) either treat symptoms or clear amyloid beta (Aβ) after senile plaques accumulate.</p>
<p>In contrast, gamma-secretase modulators alter protein production before plaques form.</p>
<p>GSM-779690T lowers plaque-forming Aβ42 while boosting shorter peptides, Aβ37 and Aβ38, which impede plaque build-up.</p>
<p>Earlier gamma-secretase inhibitors interrupted overall enzyme activity, whereas modulators preserve normal biological functions.</p>
<p>Acta Pharmaceuticals expects to begin a Phase I clinical trial in October 2026 for its lead asset, GSM-779690T.</p>
<p>The placebo-controlled, randomised, double-blind study will assess single and multiple ascending doses in healthy adult participants.</p>
<p>Researchers will examine the oral small-molecule candidate’s tolerability, pharmacokinetics, and safety.</p>
<p>GSM-779690T remains an investigational therapy that lacks regulatory approval, with its safety and efficacy not yet established.</p>
<p>Acta Pharmaceuticals co-founder and CEO George Alex said: “We founded Acta Pharmaceuticals to translate more than four decades of Dr Rudolph Tanzi’s discoveries into new Alzheimer’s disease treatments to enable early intervention and prevention.</p>
<p>“GSM-779690T is the culmination of 25 years of research at Massachusetts General Hospital and the University of California, San Diego and approximately $70m in preclinical development funding.</p>
<p>“We’re privileged to build on Drs Tanzi and Wagner’s pioneering GSM research and decades of discoveries to give the broadest group of people the opportunity for early prevention and treatment of one of the world’s most devastating and costly diseases.”</p>
<p>Acta Pharmaceuticals is also progressing a combination therapies programme using intellectual property licensed from Massachusetts General Hospital.</p>
<p>The approach applies human brain cell models known as Alzheimer’s-in-a-Dish, which simulate disease features to screen hundreds of compounds simultaneously within six weeks.</p>
<p>Backers in the funding round include Gamma Bio Investors, Dolby Family Ventures, Alzheimer’s Disease Research Foundation, and multiple family offices and investors.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/acta-24m-alzheimers-therapies/">Acta Pharmaceuticals raises $24m for Alzheimer’s therapies</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Transcripta Bio, Mayo Clinic join force on ALS therapies</title>
<link>https://edusehat.com/en/transcripta-bio-mayo-clinic-join-force-on-als-therapies</link>
<guid>https://edusehat.com/en/transcripta-bio-mayo-clinic-join-force-on-als-therapies</guid>
<description><![CDATA[ The initiative centres on creating a high-resolution, patient-derived molecular map of the fatal neurodegenerative disorder, which currently has few effective therapies. Under the terms of the agreement, Mayo 
The post Transcripta Bio, Mayo Clinic join force on ALS therapies appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/10/PT-16-10-2026-shutterstock_2708859873.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 16 Oct 2026 17:50:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Transcripta, Bio, Mayo, Clinic, join, force, ALS, therapies</media:keywords>
<content:encoded><![CDATA[<p>The initiative centres on creating a high-resolution, patient-derived molecular map of the fatal neurodegenerative disorder, which currently has few effective therapies.</p>
<p>Under the terms of the agreement, Mayo Clinic is prospectively recruiting living ALS patients through an Institutional Review Board-approved protocol.</p>
<p>The study group includes individuals with sporadic ALS as well as familial forms of the disease, spanning genetic profiles such as chromosome 9 open reading frame 72 (C9orf72), fused in sarcoma (FUS), superoxide dismutase 1 (SOD1), and TAR DNA-binding protein (TARDBP).</p>
<p>Donated patient tissue will undergo single-cell RNA sequencing and be evaluated alongside anonymised clinical information, including age at onset, disease duration, progression rates, genetic status, and prescribed medications.</p>
<p>Transcripta Bio plans to apply its transcriptomic drug-discovery platform to the tissue samples to generate patient-derived disease profiles.</p>
<p>By comparing these signatures against its existing drug-response data, the company seeks to nominate new intervention targets and prospective drug candidates.</p>
<p>The work aims to elucidate how ALS biology varies across individual patients and throughout disease progression, while generating findings that could inform patient care and accelerate the development of targeted therapies.</p>
<p>Transcripta Bio founder and CEO Chris Moxham said: “Mayo Clinic is one of the country’s leading centres for ALS care and research, with exceptional clinical expertise and a deep understanding of how the disease progresses in patients.</p>
<p>“We now have the opportunity to connect that clinical depth with molecular data derived directly from patient tissue, giving us a new way to understand the biology of ALS and identify therapeutic targets and potential treatments grounded in patients themselves.”</p>
<p>Headquartered in Palo Alto, California, US, Transcripta Bio is an AI-driven biotechnology company focused on treatments for neurological and neuromuscular illnesses.</p>
<p>Its discovery platform matches disease profiles with opposing compound signatures to identify prospective drugs.</p>
<p>In addition to its ALS research, the company maintains discovery programmes in Autism Spectrum Disorder (ASD), Facioscapulohumeral Muscular Dystrophy (FSHD), Huntington’s Disease (HD), and Myotonic Dystrophy.</p>
<p>Earlier this year, Merck & Co (MSD) and Mayo Clinic entered a research and development collaboration to utilise AI, advanced analytics, and multimodal clinical data in support of drug discovery and precision medicine.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/transcripta-bio-mayo-clinic-als-therapies/">Transcripta Bio, Mayo Clinic join force on ALS therapies</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Pharmacovigilance systems for India: What companies need to have in place</title>
<link>https://edusehat.com/en/pharmacovigilance-systems-for-india-what-companies-need-to-have-in-place</link>
<guid>https://edusehat.com/en/pharmacovigilance-systems-for-india-what-companies-need-to-have-in-place</guid>
<description><![CDATA[ 
Dr J Vijay Venkatraman, Managing Director &amp; CEO, Oviya MedSafe examines the evolving pharmacovigilance expectations in India and highlights the systems, processes and accountability companies need to demonstrate regulatory readiness
The post Pharmacovigilance systems for India: What companies need to have in place appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2018/07/20152937/ep-drvijayvenkatraman-Pharmacovigilance.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 16 Oct 2026 17:50:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Pharmacovigilance, systems, for, India:, What, companies, need, have, place</media:keywords>
<content:encoded><![CDATA[<div><img width="600" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2018/07/20152937/ep-drvijayvenkatraman-Pharmacovigilance.jpeg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2018/07/20152937/ep-drvijayvenkatraman-Pharmacovigilance.jpeg 600w, https://cdn.expresspharma.in/wp-content/uploads/2018/07/20152937/ep-drvijayvenkatraman-Pharmacovigilance-300x200.jpeg 300w" sizes="auto, (max-width: 600px) 100vw, 600px"></div><p><span>The 3 June 2026 CDSCO circular reiterating the requirement for an effective pharmacovigilance system under Paragraph 6.11 of Schedule M of the Drugs and Cosmetics Rules has brought a fundamental question into sharper focus for pharmaceutical and biotechnology companies in India: what must an organisation actually have in place to demonstrate a functioning pharmacovigilance system? </span></p>
<p><span>The answer extends well beyond adverse event reporting, timelines and regulatory submissions. A company must be able to show how safety information is identified across the organisation, transferred to pharmacovigilance personnel, scientifically evaluated, reported within applicable timelines, documented, quality-controlled and kept under effective oversight throughout the product lifecycle.</span></p>
<p><span>This question is especially relevant for companies that manufacture, import or market medicinal products in India. They are expected to ensure that safety information arising from product use can be collected, processed, evaluated and forwarded appropriately. For organisations in which pharmacovigilance has not yet developed into a mature independent function, meeting this expectation requires a deliberate review of responsibilities, procedures, interfaces and regulatory preparedness. </span></p>
<p><span>For many companies, the immediate task is therefore to determine whether their present arrangements can reliably capture safety information, support timely regulatory reporting and withstand regulatory scrutiny. </span></p>
<p><span>A pharmacovigilance system is not merely a database, a reporting mailbox or a set of SOPs kept ready for inspection. It is an organisational arrangement through which a company identifies where safety information may arise, ensures that such information reaches the right people, evaluates it scientifically, reports it when required and continuously reviews whether the system is working as intended. </span></p>
<p><span>In simple terms, if a company places a medicinal product in the market, it must also have a mechanism to listen to what happens to patients after that product is used. The question then becomes how that information reaches the organisation and what happens to it once it arrives. </span></p>
<p><b>Pharmacovigilance begins long before the first case is processed </b></p>
<p><span>In many companies, the first instinct is to think of pharmacovigilance as something that begins when an adverse event report reaches the PV team. In practice, the system has to begin much earlier. It begins by asking a simple question: from where can safety information reach the company? </span></p>
<p><span>A doctor may mention a suspected adverse reaction to a medical representative. A patient may call the company helpline. A product quality complaint may contain a medical outcome. A market research or patient support programme may reveal lack of efficacy, misuse, overdose, pregnancy exposure, or another medically relevant situation. A literature article may report an adverse event involving a marketed product. Even a company’s own social media channel may become a source of safety information. </span></p>
<p><span>The challenge is that safety information does not always arrive in technical language. Reporters may use words such as side effect, problem, complaint, not working, reaction, intolerance, or many other expressions. Therefore, a company must train its people to recognise potential safety information and forward it appropriately, even when the information is incomplete or indirect. </span></p>
<p><span>This is why sources of safety information must be identified, owned, monitored and periodically assessed for effectiveness. Telephone calls, email inboxes, medical information channels, quality complaints, websites, social media, commercial teams and contractual partners all need clear ownership. Recording every phone call may not be mandatory, but relevant information received during a call must be captured accurately, documented promptly and made retrievable. The organisation should also be able to demonstrate that these channels are actually working as intended and that safety information is reaching pharmacovigilance personnel appropriately. </span></p>
<p><span>One of the most common mistakes organisations make is assuming that pharmacovigilance is owned exclusively by the PV department. Because potential safety information can enter through many channels, the pharmacovigilance system must extend across the organisation. Commercial teams, medical information personnel, quality teams, customer service functions, distributors and business partners may receive relevant information before the pharmacovigilance team does. Each function must therefore know what to recognise, how quickly to forward it and who is responsible for ensuring that it reaches the appropriate pharmacovigilance personnel. </span></p>
<p><b>Defining ownership and accountability </b></p>
<p><span>Once the routes through which safety information may enter the company are understood, the next requirement is clear accountability for ensuring that the information is acted upon. Every organisation should clearly define: </span></p>
<ul>
<li><span> Who is responsible for oversight of pharmacovigilance activities? </span></li>
<li><span> How are safety decisions made? </span></li>
<li><span> How are responsibilities delegated? </span></li>
<li><span> How are pharmacovigilance obligations communicated internally? </span></li>
</ul>
<p><span>In the Indian context, particular attention should be paid to the responsibilities of the Marketing Authorisation Holder (MAH) and the Pharmacovigilance Officer in Charge (PVOIC). </span></p>
<p><span>While specific activities may be outsourced, accountability cannot. </span></p>
<p><span>This is an important principle that companies should remember when developing their pharmacovigilance framework. </span></p>
<p><span>In India, accountability should be assigned based on the relevant licence and regulatory responsibility for the product, rather than assumed to rest simply with the company that manufactures or markets it. Depending on the business model, this may involve a manufacturer, importer, loan licensee, contract manufacturer, marketer or another entity with defined regulatory responsibility. Where different companies manufacture and market the product, their respective pharmacovigilance obligations must be clearly understood and documented so that safety information is not lost between commercial and regulatory arrangements. </span></p>
<p><span>This determination should be made explicitly when the pharmacovigilance system is designed, because uncertainty over which entity owns regulatory reporting, oversight and safety-data exchange can create gaps precisely when a case requires prompt action. </span></p>
<p><span>The PVOIC also requires careful attention. The role should not be treated as a nominal appointment. According to the Pharmacovigilance Guidance Document for MAHs of Pharmaceutical Products, the PVOIC should be a medical or pharmacy professional trained in the collection and analysis of adverse event reports. Where the PVOIC is a pharmacy professional, there should be appropriate access to a medically qualified person for causality assessment when required. </span></p>
<p><span>Beyond regulatory compliance, the PVOIC frequently serves as the focal point for coordination between safety information sources, management, quality systems and regulatory reporting activities. As organisations grow, the effectiveness of this role often influences the effectiveness of the broader pharmacovigilance system. </span></p>
<p><b>Why SOPs alone do not constitute a pharmacovigilance system </b></p>
<p><span>Clear accountability must then be translated into documented procedures that explain how pharmacovigilance activities will be performed in practice. </span></p>
<p><span>SOPs are written to be followed, not to be filed. They should specify responsibilities, escalation pathways, reporting timelines, decision-making processes, communication requirements and quality activities clearly enough for personnel to follow them consistently. </span></p>
<p><span>For companies operating across multiple countries or as affiliates of global organisations, company-wide procedures may need to be supplemented by local work instructions. This helps ensure that corporate requirements and India-specific regulatory obligations are both addressed without creating avoidable conflicts or procedural gaps. </span></p>
<p><b>A safety database is not a pharmacovigilance system </b></p>
<p><span>With responsibilities and procedures defined, the organisation needs an appropriate means of recording, managing, tracking and reporting adverse event information. This is where a safety database becomes important. </span></p>
<p><span>A safety database serves as the system of record for adverse event information and supports case management, reporting, tracking and oversight. </span></p>
<p><span>A safety database is necessary, but purchasing one does not by itself create a functioning pharmacovigilance system. Its effectiveness depends on sound governance, defined processes, trained personnel, data quality and management oversight. </span></p>
<p><span>The effectiveness of a database ultimately depends upon: </span></p>
<ul>
<li><span> Data quality </span></li>
<li><span> Defined processes </span></li>
<li><span> Trained personnel </span></li>
<li><span> Quality oversight </span></li>
<li><span> Management commitment </span></li>
</ul>
<p><span>Technology is an enabler, not a substitute for governance. </span></p>
<p><b>Documentation and inspection readiness </b></p>
<p><span>As these arrangements become operational, the company must be able to document how the pharmacovigilance system is organised, how responsibilities are fulfilled and how performance is monitored. </span></p>
<p><span>The Pharmacovigilance System Master File (PSMF) serves as a comprehensive description of the pharmacovigilance system and provides regulators with an overview of how pharmacovigilance activities are organised and managed. It brings together key elements of the system, including the organisation and responsibilities, sources of safety information, relevant computerised systems and databases, pharmacovigilance processes, system performance and the quality system. </span></p>
<p><span>Alongside the PSMF, organisations should ensure that training records, quality records, reconciliation activities, vendor oversight documentation, and procedural controls remain current and consistently maintained. </span></p>
<p><span>Inspection readiness is not a separate exercise undertaken in the weeks before an inspection; it is the natural outcome of a well-designed pharmacovigilance system that has been documented, monitored and maintained consistently over time. </span></p>
<p><b>Outsourcing activities is not the same as outsourcing accountability </b></p>
<p><span>The same principles of defined responsibility, documented processes and oversight apply when pharmacovigilance activities are outsourced. External support can provide specialised expertise and scalable capacity, but it does not transfer the organisation’s regulatory accountability for the product. </span></p>
<p><span>Case processing, literature monitoring, aggregate reporting, medical review and other pharmacovigilance activities may be delegated to qualified service providers, but accountability remains with the organisation responsible for the product. </span></p>
<p><span>Effective vendor oversight, performance monitoring, quality agreements and governance structures are essential elements of any outsourced pharmacovigilance model. Outsourcing should therefore be viewed as a management responsibility rather than merely a procurement exercise, with ongoing oversight remaining just as important as vendor selection. </span></p>
<p><span>Where multiple parties are involved in manufacturing, marketing, distribution or licensing arrangements, pharmacovigilance agreements or safety data exchange agreements become especially important. These documents should specify how safety information will move between parties, timelines for exchange, points of contact, escalation pathways, and responsibility for regulatory reporting. </span></p>
<p><b>Sustaining the pharmacovigilance system </b></p>
<p><span>Establishing the system is only the first step; the company must also ensure that it continues to operate effectively as products, partnerships and business volumes change. </span></p>
<p><span>This also requires appropriately trained and competent personnel; competence should be demonstrated rather than assumed. </span></p>
<p><span>A robust quality framework supports continuous improvement through: </span></p>
<ul>
<li><span> Internal audits </span></li>
<li><span> Deviation management </span></li>
<li><span> CAPA processes </span></li>
<li><span> Training programmes </span></li>
<li><span> Vendor oversight </span></li>
<li><span> Periodic review of system performance </span></li>
</ul>
<p><span>Without these elements, even well-designed systems may gradually deteriorate over time. Quality management helps the company maintain regulatory compliance by identifying weaknesses, correcting deviations and ensuring that the pharmacovigilance system continues to perform as intended. </span></p>
<p><b>Building before it becomes urgent </b></p>
<p><span>Perhaps the most important lesson for organisations is that pharmacovigilance systems should be developed before they become an immediate regulatory necessity.</span></p>
<p><span>Many organisations begin investing in pharmacovigilance only after inspections, partner requirements or regulatory expectations create immediate pressure. Systems established reactively can often address short-term compliance needs, but systems built proactively are typically more sustainable and effective over the long term. </span></p>
<p><span>As product portfolios expand, distribution networks grow, partnerships evolve and market exposure increases, pharmacovigilance requirements become more complex. </span></p>
<p><span>Smaller organisations do not necessarily require large pharmacovigilance departments or complex infrastructures. However, even a small system should contain all of the essential elements required for effective operation. It is often better to build a complete system at a modest scale than an incomplete system at a larger scale. </span></p>
<p><span>Technology should support this system rather than define it. Organisations could use technology where it genuinely improves efficiency, quality or control, including newer tools such as artificial intelligence. However, such tools should be adopted to solve clearly identified business or compliance challenges, not merely because they are available. </span></p>
<p><span>Pharmacovigilance should therefore be viewed not merely as a compliance obligation, but as an essential component of patient safety, product stewardship and responsible business practice. </span></p>
<p><span>Taken together, the minimum practical expectation is that a company can answer seven questions clearly: </span></p>
<ol>
<li><span> Who is accountable for pharmacovigilance? </span></li>
<li><span> Where can safety information enter the organisation? </span></li>
<li><span> How is it transferred and assessed? </span></li>
<li><span> Which procedures and tools govern the work? </span></li>
<li><span> How are partners and vendors controlled? </span></li>
<li><span> What records demonstrate that the system is operating? </span></li>
<li><span> How are deficiencies identified and corrected? </span></li>
</ol>
<p><span>If any answer is unclear, the pharmacovigilance system is not yet fully established. </span></p>
<p><b>Conclusion </b></p>
<p><span>For pharmaceutical and biotechnology companies in India, the immediate priority is to establish a complete and workable pharmacovigilance system that meets regulatory expectations throughout the product lifecycle.</span></p>
<p><span>The regulatory requirement is clear, but its purpose is equally important: every company that places a medicinal product on the market must be able to understand, monitor and continuously evaluate its benefit-risk profile. Behind every adverse event report, product complaint, signal or safety concern is a patient, and a functioning pharmacovigilance system is how the company fulfils that responsibility.</span></p>
<p>The post <a href="https://www.expresspharma.in/pharmacovigilance-systems-for-india-what-companies-need-to-have-in-place/">Pharmacovigilance systems for India: What companies need to have in place</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Godavari Biorefineries secures US patent for cancer treatment molecule</title>
<link>https://edusehat.com/en/godavari-biorefineries-secures-us-patent-for-cancer-treatment-molecule</link>
<guid>https://edusehat.com/en/godavari-biorefineries-secures-us-patent-for-cancer-treatment-molecule</guid>
<description><![CDATA[ 
The patent extends the company’s intellectual property protection in life sciences following grants in India, China and Japan
The post Godavari Biorefineries secures US patent for cancer treatment molecule appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 16 Oct 2026 17:50:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Godavari, Biorefineries, secures, patent, for, cancer, treatment, molecule</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>Godavari Biorefineries has secured a United States patent for its invention titled “5-Hydroxy-1,4-Naphthalenedione for use in the treatment of cancer”, extending its intellectual property protection in life sciences.</span></p>
<p><span>The molecule represents a class of compounds that inhibit cancer and cancer stem cells, with potential applications across cancer types, including breast and prostate cancer.</span></p>
<p><span>The US patent expands Godavari Biorefineries’ international intellectual property footprint in life sciences and supports the company’s research into compounds with potential applications in cancer treatment.</span></p>
<p><span>“Our approach to innovation is guided by a larger purpose: advancing human health and wellbeing. The Sanskrit mantra ‘सर्वे सन्तु निरामयाः’, meaning ‘Health for All’, reflects this commitment. The grant of this US patent marks an important milestone in our life sciences research, strengthening our intellectual property and advancing our work on compounds with potential applications in cancer treatment. It reinforces our belief that scientific progress should strive to make better health and wellbeing accessible to all, contributing to a healthier future for everyone,” said Samir Somaiya, Chairman and Managing Director, Godavari Biorefineries Ltd.</span></p>
<p><span>Dr Sangeeta Srivastava, Executive Director, Godavari Biorefineries Ltd, said, “The development of novel molecules for potential applications in cancer treatment requires sustained scientific research and a deeper understanding of the mechanisms involved in cancer cell growth. This patent represents an important step in our research journey, particularly in exploring compounds that target cancer and cancer stem cells. Our focus remains on advancing scientific understanding and building on our research capabilities to explore potential approaches to complex human health challenges.”</span></p>
<p><span>Dr Srivastava is one of the four inventors of the patent, alongside Dr Sandip Gavade, Dr Prashant Kharkar and Dr Maithili Athavale.</span></p>
<p><span>The patent adds to Godavari Biorefineries Ltd’s intellectual property in life sciences and its research portfolio in cancer-related applications.</span></p>
<p>The post <a href="https://www.expresspharma.in/godavari-biorefineries-secures-us-patent-for-cancer-treatment-molecule/">Godavari Biorefineries secures US patent for cancer treatment molecule</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Mankind Pharma to acquire 70% stake in Armed Cell Therapeutics for EUR 48 million</title>
<link>https://edusehat.com/en/mankind-pharma-to-acquire-70-stake-in-armed-cell-therapeutics-for-eur-48-million</link>
<guid>https://edusehat.com/en/mankind-pharma-to-acquire-70-stake-in-armed-cell-therapeutics-for-eur-48-million</guid>
<description><![CDATA[ 
The deal will give Mankind Pharma access to a pipeline of CAR-T therapies for cancer, including programmes targeting non-Hodgkin lymphoma and small cell lung cancer
The post Mankind Pharma to acquire 70% stake in Armed Cell Therapeutics for EUR 48 million appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123851/Acquisition.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 16 Oct 2026 14:15:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Mankind, Pharma, acquire, 70, stake, Armed, Cell, Therapeutics, for, EUR, million</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123851/Acquisition.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123851/Acquisition.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123851/Acquisition-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>Mankind Pharma, through its subsidiary Mankind Pharma (Netherlands) B.V., has entered into a definitive agreement to acquire a majority stake in Armed Cell Therapeutics B.V. (ACTx), a Belgium-incorporated biotechnology company developing CAR-T (chimeric antigen receptor T-cell) therapies for cancer.</span></p>
<p><span>Under the agreement, Mankind Pharma will invest EUR 48 million for a 70 per cent stake in ACTx. The company has a pipeline of next-generation CAR-T assets, with lead programmes in non-Hodgkin lymphoma and small cell lung cancer. ACTx will pursue approaches to CAR-T cell therapy, including in vivo CAR-T cell generation. Its R&D activities are led by teams based in the US and Europe.</span></p>
<p><span>Armed Cell Therapeutics was founded by a team with experience in drug development, cell therapy and company building. Its founders include Paul Stoffels, MD, Chair of the Board, former Chief Executive Officer of Galapagos and former Chief Scientific Officer of Johnson & Johnson; John Mellors, MD, Chief Scientific Officer, Distinguished Professor of Medicine at the University of Pittsburgh and former SVP Discovery and Early Development at Galapagos; and Peter Verhaeghe, former Chair of argenx.</span></p>
<p><span>CAR-T therapies have transformed the treatment of some blood cancers. However, many patients relapse because of a lack of CAR-T cell persistence, CAR-T exhaustion or the emergence of resistant cancer cells. Solid cancers pose challenges for CAR-T cells in penetrating tumours and functioning in hostile tumour microenvironments.</span></p>
<p><span>Armed CAR-T cells are engineered with additional payloads to strengthen and sustain their anti-tumour activity, with the goal of achieving deeper and more durable responses. Targeting more than one cancer antigen is designed to make it harder for cancer cells to escape.</span></p>
<p><span>The partnership is part of Mankind Pharma’s vision of becoming an innovative, research-focused healthcare company. It is intended to strengthen the company’s ability to deliver innovation-led therapies globally while maintaining its commitment to quality, affordability and accessibility.</span></p>
<p><span>Arjun Juneja, Chief Operating Officer, Mankind Pharma, said, “Innovation will be one of the defining growth engines for Mankind over the coming decades. This investment is the first step in building a global pipeline of breakthrough therapies. As the company scales its presence across complex and chronic therapy areas, Mankind, with this venture, is getting access to cutting-edge & differentiated scientific platforms, experienced leadership team and potential to generate multiple next-generation CAR-T candidates. Our long-term ambition is not only to participate in scientific innovation globally, but ultimately to make these transformative therapies more accessible to patients in India and around the world.”</span></p>
<p><span>Dr Paul Stoffels, Chair of the Board, Armed Cell Therapeutics, said, “Next-generation CAR-T therapies can reach many more patients if we make them more powerful and durable. Armed Cell Therapeutics has the assets, the team and now the backing of Mankind to do exactly that. I am pleased to chair the Board and support the team.”</span></p>
<p>The post <a href="https://www.expresspharma.in/mankind-pharma-to-acquire-70-stake-in-armed-cell-therapeutics-for-eur-48-million/">Mankind Pharma to acquire 70% stake in Armed Cell Therapeutics for EUR 48 million</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Alentis and PinotBio partner to develop claudin&#45;1 oncology ADCs</title>
<link>https://edusehat.com/en/alentis-and-pinotbio-partner-to-develop-claudin-1-oncology-adcs</link>
<guid>https://edusehat.com/en/alentis-and-pinotbio-partner-to-develop-claudin-1-oncology-adcs</guid>
<description><![CDATA[ Under the agreement, Alentis has secured an exclusive option to in-license linkers and payloads from PinotBio for use in its pipeline candidates. Financially, PinotBio will receive an upfront 
The post Alentis and PinotBio partner to develop claudin-1 oncology ADCs appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/10/PT-15-10-2026-shutterstock_2466743483.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 15 Oct 2026 19:20:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Alentis, and, PinotBio, partner, develop, claudin-1, oncology, ADCs</media:keywords>
<content:encoded><![CDATA[<p>Under the agreement, Alentis has secured an exclusive option to in-license linkers and payloads from PinotBio for use in its pipeline candidates.</p>
<p>Financially, PinotBio will receive an upfront payment alongside eligibility for development, regulatory, and commercial milestone payments.</p>
<p>Alentis will also pay royalties on net sales for any therapy candidate it chooses to commercialise.</p>
<p>The partnership aims to apply PinotBio’s platform technologies to Alentis’ antibody assets to address claudin-1, a target expressed across more than ten tumour types.</p>
<p>Alentis Therapeutics CEO Dr Mark Pruzanski said: “Claudin-1 continues to gain recognition as a highly promising target and, together with our partner PinotBio, we aim to further expand its therapeutic potential and maximise patient benefit across a range of high-unmet need cancers.</p>
<p>“This expanded relationship builds on our successful research collaboration, during which we explored dozens of ADC constructs and saw firsthand the strength of PinotBio’s science and execution.”</p>
<p>Alentis is currently assessing two clinical-stage oncology conjugates in Phase I/II trials across solid tumours expressing claudin-1: ALE.P02, which carries a tubulin inhibitor payload, and ALE.P03, which uses a topoisomerase I inhibitor payload.</p>
<p>The US Food and Drug Administration (FDA) granted fast track designation to ALE.P02 for advanced or metastatic claudin-1-positive squamous tumours.</p>
<p>Additionally, Alentis is evaluating lixudebart in a Phase Ib trial for advanced liver fibrosis and a Phase II study in anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis with renal involvement.</p>
<p>The company has partnered with Commonwealth Serum Laboratories (CSL) to co-develop and co-promote the antibody for conditions including associated vasculitis with rapidly progressive glomerulonephritis (AAV-RPGN), focal segmental glomerulosclerosis (FSGS), and primary sclerosing cholangitis (PSC).</p>
<p>Alentis was founded on research conducted in France at the University of Strasbourg and Inserm.</p>
<p>Headquartered in South Korea and founded in 2017, PinotBio focuses on therapies for recurrent and resistant disease. Four programmes currently use its PINOT-ADC platform: CT-P70, CT-P71, CT-P73, and PBX-004.</p>
<p>The three partnered candidates being developed with Celltrion have received US FDA Fast Track designation, whilst PBX-004 remains wholly owned. PinotBio’s institutional backers include IMM Investment and KB Investment.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/alentis-pinotbio-claudin-1-oncology-adcs/">Alentis and PinotBio partner to develop claudin-1 oncology ADCs</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>QCi and INmune Bio partner to study XPro in Alzheimer’s</title>
<link>https://edusehat.com/en/qci-and-inmune-bio-partner-to-study-xpro-in-alzheimers</link>
<guid>https://edusehat.com/en/qci-and-inmune-bio-partner-to-study-xpro-in-alzheimers</guid>
<description><![CDATA[ The initial agreement marks the first commercial contract in the pharmaceutical and biotechnology sector for QCi. Under the first stage of the project, the companies will analyse clinical 
The post QCi and INmune Bio partner to study XPro in Alzheimer’s appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/10/PT-2-15-10-2026-shutterstock_1884612580.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 15 Oct 2026 19:20:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>QCi, and, INmune, Bio, partner, study, XPro, Alzheimer’s</media:keywords>
<content:encoded><![CDATA[<p>The initial agreement marks the first commercial contract in the pharmaceutical and biotechnology sector for QCi.</p>
<p>Under the first stage of the project, the companies will analyse clinical and publicly accessible biomedical datasets to identify conditions sharing the biological mechanisms targeted by XPro.</p>
<p>The agreement also includes options for additional work as clinical programmes progress.</p>
<p>Researchers will combine INmune Bio’s findings from pre-clinical studies and four clinical trials with QCi’s Dirac-3S entropy quantum optimisation machine.</p>
<p>The hardware runs at room temperature and low power, avoiding the specialised cooling systems used by alternative quantum platforms.</p>
<p>The teams will benchmark the quantum machine against standard statistical and machine-learning tools to assess which computational method is best suited for each stage of analysis, while working to build a repeatable discovery model.</p>
<p>INmune Bio CEO David Moss said: “We’ve built a large clinical dataset on Alzheimer’s and other diseases, backed by years of work with XPro. This collaboration allows us to examine patient populations and biomarkers most likely to predict responses by analysing large data sets.</p>
<p>“We’ll look for the diseases with the greatest potential for success, those whose human biology matches what we’ve already seen XPro do, starting with rare diseases where trials can be smaller, faster and more capital-efficient, and where qualifying paediatric approvals may earn a Priority Review Voucher.”</p>
<p>XPro is engineered to neutralise soluble tumour necrosis factor, reducing neuroinflammation whilst preserving protective immune defences.</p>
<p>The therapy holds fast track designation from the US Food and Drug Administration (FDA) and has completed an End-of-Phase II regulatory meeting, positioning it for an integrated Phase IIb/III trial in early Alzheimer’s disease.</p>
<p>Additionally, INmune Bio is developing CORDStrom, a mesenchymal stromal cell platform for recessive dystrophic epidermolysis bullosa.</p>
<p>Regulatory filings for CORDStrom are scheduled with the UK Medicines and Healthcare products Regulatory Agency in 2026, the European Medicines Agency in 2027, and the US FDA.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/qci-inmune-bio-study-xpro-alzheimers/">QCi and INmune Bio partner to study XPro in Alzheimer’s</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Zydus launches Season 3 of ‘Easiest Exam’ campaign to promote breast cancer awareness</title>
<link>https://edusehat.com/en/zydus-launches-season-3-of-easiest-exam-campaign-to-promote-breast-cancer-awareness</link>
<guid>https://edusehat.com/en/zydus-launches-season-3-of-easiest-exam-campaign-to-promote-breast-cancer-awareness</guid>
<description><![CDATA[ 
The campaign will also feature oncologists sharing insights on early detection, timely screening and treatment, while highlighting the important role of caregiver
The post Zydus launches Season 3 of ‘Easiest Exam’ campaign to promote breast cancer awareness appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/15154522/Breast-cancer-awareness.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 15 Oct 2026 19:20:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Zydus, launches, Season, ‘Easiest, Exam’, campaign, promote, breast, cancer, awareness</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="423" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/15154522/Breast-cancer-awareness.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/15154522/Breast-cancer-awareness.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/15154522/Breast-cancer-awareness-300x169.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p>Marking Breast Cancer Awareness Month, Zydus has launched Season 3 of its nationwide ‘Easiest Exam’ campaign, encouraging women to spend just three minutes every month checking their breasts for unusual changes.</p>
<p>Breast cancer continues to be a growing health concern in India. A recent study found that the country’s breast cancer incidence rate increased from 13 per 100,000 women in 1990 to 29.4 in 2023. During the same period, the mortality rate rose by 74 per cent, from 8.9 to 15.5 per 100,000 women.  Late diagnosis remains another concern, with studies suggesting that nearly 60 per cent of patients are diagnosed at advanced stages (III or IV).</p>
<p>This year’s campaign carries the message <em>‘Do Haath, Teen Minute Aur Ek Aasaan Sa Exam’</em>, encouraging women to become more aware of their breast health. The campaign video features people from different walks of life across India, with a song sung by playback singer Bhoomi Trivedi.</p>
<p>The campaign will also feature oncologists sharing insights on early detection, timely screening and treatment, while highlighting the important role of caregivers.</p>
<p>Through this initiative, Zydus aims to encourage conversations around breast health and the importance of recognising changes early and seeking timely medical advice.</p>
<p><strong>Watch the campaign:</strong> <a href="https://youtu.be/gvQQMinGkrM" data-saferedirecturl="https://www.google.com/url?q=https://youtu.be/gvQQMinGkrM&source=gmail&ust=1792144443041000&usg=AOvVaw2jS5SBNbwC3zqpUezvsdBi">https://youtu.be/gvQQMinGkrM</a></p>
<p>The post <a href="https://www.expresspharma.in/zydus-launches-season-3-of-easiest-exam-campaign-to-promote-breast-cancer-awareness/">Zydus launches Season 3 of ‘Easiest Exam’ campaign to promote breast cancer awareness</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>VP inaugurates KAUMARACON&#45;2026, launches digital initiatives at AIIA</title>
<link>https://edusehat.com/en/vp-inaugurates-kaumaracon-2026-launches-digital-initiatives-at-aiia</link>
<guid>https://edusehat.com/en/vp-inaugurates-kaumaracon-2026-launches-digital-initiatives-at-aiia</guid>
<description><![CDATA[ 
Calls for scientific validation of Ayurveda, highlights child health as a national priority
The post VP inaugurates KAUMARACON-2026, launches digital initiatives at AIIA appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/15163123/AYUSH.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 15 Oct 2026 19:20:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>inaugurates, KAUMARACON-2026, launches, digital, initiatives, AIIA</media:keywords>
<content:encoded><![CDATA[<div><img width="700" height="401" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/15163123/AYUSH.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/15163123/AYUSH.jpg 700w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/15163123/AYUSH-300x172.jpg 300w" sizes="auto, (max-width: 700px) 100vw, 700px"></div><p>CP Radhakrishnan, Vice President of India inaugurated the third edition of the international conference on Kaumarabhritya, KAUMARACON-2026, organised by the All India Institute of Ayurveda (AIIA), New Delhi, and called for greater scientific research to establish the efficacy of traditional healthcare practices and strengthen their global acceptance.</p>
<p>Addressing the conference, he emphasised the need to integrate traditional knowledge with scientific research to improve healthcare outcomes and build patient confidence. Referring to Prime Minister Narendra Modi’s vision of developing AIIA on a par with AIIMS, he said the Institute was moving towards realising this vision. He also congratulated AIIA on its 10th Foundation Day and stressed the importance of research, innovation and academic excellence.</p>
<p>The Vice President highlighted the role of the Ministry of AYUSH, established in 2014, in strengthening education, expanding healthcare services and promoting scientific research. He also noted collaborations between the Ministry and institutions such as ICMR, CSIR, DBT, DST and AIIMS to advance interdisciplinary research and dialogue between traditional medicine and modern healthcare.</p>
<p>He cited the international recognition of Yoga and the establishment of the WHO Global Centre for Traditional Medicine in Jamnagar as milestones in promoting India’s traditional knowledge globally.</p>
<p>Emphasising the importance of paediatric healthcare, Radhakrishnan said the conference theme, “Shaping the Future of Child Health: Global Perspectives, Research Innovations, and Clinical Frontiers in Kaumarabhritya”, reflected the shared responsibility of ensuring children’s healthy growth and development.</p>
<p>He called for greater attention to nutrition, physical growth, disease prevention and emotional well-being, adding that child health and the quality of human capital would be crucial to India’s vision of becoming a developed nation by 2047.</p>
<p>During the event, the Vice President inaugurated the AYUSH Start-up Portal, the AIIA–iCAINE website and the Ayurveda Digital Innovation and Venture Acceleration Facility (AyuDIVA). He also launched the Vamana App and the Panchakarma Assessment App.</p>
<p>An international memorandum of understanding between Maharishi International University (MIU), USA, and AIIA, New Delhi, was exchanged in his presence.</p>
<p>Earlier, the Vice-President visited AIIA’s hospital facilities and Dhanwantari Vatika, where he was briefed on the Institute’s contributions to public health and the Ayurvedic significance of medicinal plants, herbs and rocks displayed at the Vatika.</p>
<p>The event was attended by Prataprao Jadhav, Minister of State for AYUSH and Health and Family Welfare; Vaidya Rajesh Kotecha, Secretary, Ministry of AYUSH; Dr Maneesha Upendra, Chairperson, National Commission for Indian System of Medicine; Professor P. K. Prajapati, Director, AIIA, New Delhi; and other dignitaries, researchers, faculty members and students.</p>
<p><em>Source: PIB</em></p>
<p>The post <a href="https://www.expresspharma.in/vp-inaugurates-kaumaracon-2026-launches-digital-initiatives-at-aiia/">VP inaugurates KAUMARACON-2026, launches digital initiatives at AIIA</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Our next phase of growth focuses on deepening technology adoption</title>
<link>https://edusehat.com/en/our-next-phase-of-growth-focuses-on-deepening-technology-adoption</link>
<guid>https://edusehat.com/en/our-next-phase-of-growth-focuses-on-deepening-technology-adoption</guid>
<description><![CDATA[ 
MOVIN Express, through its specialised MOVIN Healthcare vertical is addressing needs with time-critical delivery solutions, validated temperature-controlled packaging and real-time shipment monitoring. Dr Dilip Sharma, Chief Operating Officer (COO), MOVIN Express, discusses how the company is transforming healthcare logistics and addressing the evolving needs of India’s pharma industry
The post Our next phase of growth focuses on deepening technology adoption appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/15165625/EP_Dr_Dilip_Sharma_COO_MOVIN_Express_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 15 Oct 2026 19:20:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Our, next, phase, growth, focuses, deepening, technology, adoption</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/15165625/EP_Dr_Dilip_Sharma_COO_MOVIN_Express_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/15165625/EP_Dr_Dilip_Sharma_COO_MOVIN_Express_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/15165625/EP_Dr_Dilip_Sharma_COO_MOVIN_Express_750-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p lang="en-IN" align="JUSTIFY"><span><span><b>How is MOVIN adapting its network and operating model to handle expanding volumes across India’s B2B express corridors?</b></span></span></p>
<p lang="en-IN" align="JUSTIFY"><span><span>At MOVIN, we have engineered a precision-first express logistics model that moves beyond traditional infrastructure constraints. By synthesising UPS’s global logistics standards with InterGlobe’s deep domestic insight, we have established an extensive footprint PAN India. Our operations are built on day-definite and time-definite predictability across critical commercial corridors spread across all major Industries. We do not view physical footprint in isolation; our infrastructure is tightly integrated with its central data lake dynamic capacity planning. This allows us to deliver uninterrupted flow of goods across the country spanning from clients across diverse sectors—including IT peripherals, automotive, apparel, FMCG, pharmaceuticals and more.</span></span></p>
<p lang="en-IN" align="JUSTIFY"><span><span><b>Which technologies are delivering the most tangible impact in managing complex express operations and contingency planning?</b></span></span></p>
<p lang="en-IN" align="JUSTIFY"><span><span>Technology has fundamentally transformed how we manage express logistics, shifting operations from reactive surge handling into a digitally orchestrated, predictive ecosystem. MOVIN’s central Data Lake allow us to maintain always-on scalability and complete network visibility. Centralised 24/7 control towers and tracking platforms, Data analytics, empower our operational teams to actively monitor shipments, anticipate bottlenecks, and execute dynamic route optimisation whenever required. Furthermore, our AI-powered mobile application with Azure OCR integration accelerates first-mile accuracy by speeding up shipment creation at customer locations, while IoT-enabled tracking strengthens end-to-end traceability across both surface and air networks.</span></span></p>
<p lang="en-IN" align="JUSTIFY"><span><span><b>What is the strategic objective behind launching MOVIN Healthcare, and how does it address sector-specific requirements?</b></span></span></p>
<p lang="en-IN" align="JUSTIFY"><span><span>In healthcare and pharma logistics, our core philosophy is that we are not just moving a package; we are serving a patient. To address the critical needs of India’s $5.5–7.5 billion healthcare express market, we launched MOVIN Healthcare as a dedicated vertical catering to the pharmaceutical, medtech, diagnostics, and laboratory sectors across an initial rollout of 50 strategic markets. The offering features our flagship Next Flight Out (NFO) service for time-critical medical shipments, along with specialised end-to-end temperature-controlled packaging capable of sustaining Refrigerated (2°C to 8°C), Controlled Ambient (15°C to 25°C), and Dry Ice Frozen (-80°C to -20°C) conditions. Operations are securely monitored in real time by a dedicated 24/7 control tower, supported by priority handling, comprehensive carrier insurance, and a strict Quality Assurance framework incorporating proactive Corrective and Preventive Actions (CAPA).</span></span></p>
<p lang="en-IN" align="JUSTIFY"><span><span><b>How does MOVIN ensure service quality and operational standards keep pace with rapid expansion?</b></span></span></p>
<p lang="en-IN" align="JUSTIFY"><span><span>Our core operating strategy rests on four foundational pillars: People, Partners, Technology, and Excellence. Advanced infrastructure and technology are only as effective as the workforce behind them, which is why we place immense focus on continuous talent development and tech enablement. Through specialised Learning Management System (LMS) platforms, On-the-Job Training (OJTs), apprenticeships, and soft skill enhancement programs, we ensure our frontline teams, customer service representatives, and logistics partners possess practical experience and up-to-date industry capabilities. This people-first, performance-driven culture ensures that our teams take ownership on the ground, maintain strict operational compliance, and deliver superior customer satisfaction as we scale.</span></span></p>
<p lang="en-IN" align="JUSTIFY"><span><span><b>Looking forward, how is MOVIN positioning itself to support India’s $5 trillion economic vision and MSME growth?</b></span></span></p>
<p lang="en-IN" align="JUSTIFY"><span><span>India’s journey toward becoming a $5 trillion economy depends heavily on a resilient, technology-led supply chain ecosystem aligned with national initiatives like the National Logistics Policy. </span></span></p>
<p lang="en-IN" align="JUSTIFY"><span><span>MOVIN’s focus is on building a stronger, more connected and more responsive B2B logistics network that enables businesses to move goods with greater speed, visibility and predictability. We are continuing to strengthen our presence across key business markets, expand connectivity and enhance our technology capabilities so that customers can serve their markets more efficiently.</span></span></p>
<p><span><span><span lang="en-IN">At MOVIN, our next phase of growth focuses on deepening technology adoption, expanding into strategic sectors like healthcare, and empowering MSMEs by giving them access to reliable, nationwide express logistics to scale beyond regional boundaries. Through our partnership with UPS, we are also facilitating seamless cross-border trade opportunities for domestic businesses. By advancing API-driven digital connectivity, upgrading connectivity across Tier 2 and Tier 3 gateways, and expanding sustainability commitments like EV deployments in major metros, MOVIN is establishing the structural resilience needed to power India’s accelerating economy.</span></span></span><span><span><span lang="en-IN"><b></b></span></span></span></p>
<p>What are the biggest challenges you face when delivering sensitive medicines and healthcare products safely across India?</p>
<p lang="en-IN"><span><span>At MOVIN, we believe the biggest challenge in healthcare logistics is not simply moving a sensitive shipment from one point to another but protecting its integrity throughout the entire journey.</span></span></p>
<p lang="en-IN"><span><span>India’s diverse geography, varying climatic conditions and time-sensitive healthcare requirements make temperature control, speed and consistency critical. For products such as vaccines, diagnostics, and MedTech equipment, even a small delay or temperature excursion can have significant consequences. Ensuring end-to-end visibility, maintaining the right handling conditions, and preserving an unbroken chain of custody across the network are therefore key priorities.</span></span></p>
<p lang="en-IN"><span><span>Through MOVIN Healthcare, we address these challenges with specialised healthcare logistics capabilities, including temperature-controlled packaging, defined handling processes, real-time shipment visibility, and quality assurance protocols. Our Next Flight Out (NFO) service is designed for highly time-critical healthcare shipments, supported by a 99.5% service-level guarantee. Ultimately, our focus is to give healthcare customers the confidence that their critical products will reach the destination safely, securely and on time.</span></span></p>
<p lang="en-IN"><span><span><b>What specific solutions and technologies, such as temperature tracking and IoT sensors, are you using to protect and monitor pharma shipments?</b></span></span></p>
<p><span><span><span lang="en-IN">At MOVIN Healthcare, we have built our approach around visibility, control, and quality at every stage of the shipment journey. For sensitive healthcare products, including vaccines, diagnostics, and MedTech products, we use temperature-controlled packaging solutions designed to maintain the required temperature conditions during transit.</span></span></span></p>
<p><span><span><span lang="en-IN">Our healthcare logistics framework combines shipment tracking, temperature monitoring, defined handling protocols, and chain-of-custody controls to provide greater visibility and accountability. This is particularly important for time- and temperature-sensitive shipments, where knowing the location of a shipment is only one part of the equation, we also need confidence that it is being handled under the right conditions throughout its journey.</span></span></span></p>
<p lang="en-IN"><span><span>For highly time-critical shipments, our Next Flight Out (NFO) service provides priority movement with real-time tracking and a 99.5 per cent service-level guarantee. We also have quality assurance processes, including CAPA (Corrective and Preventive Action), to identify issues, address root causes and continuously strengthen our processes.</span></span></p>
<p lang="en-IN"><span><span>At MOVIN, our objective is to bring together technology, specialised packaging, process controls, and operational expertise so that our customers have greater confidence that critical healthcare shipments are protected from origin to destination.</span></span></p>
<p lang="en-IN">
</p><p><em><span><span><span lang="en-IN">sanjiv.</span></span></span><span><span lang="zxx"><span><span><span lang="en-IN">das@expressindia.com</span></span></span></span></span><span><span><span lang="en-IN"><br>
sanjivdas1@gmail.com</span></span></span></em></p>
<p>The post <a href="https://www.expresspharma.in/our-next-phase-of-growth-focuses-on-deepening-technology-adoption/">Our next phase of growth focuses on deepening technology adoption</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Indian pharmaceutical market records 17.1% growth in September: Equirus Securities</title>
<link>https://edusehat.com/en/indian-pharmaceutical-market-records-171-growth-in-september-equirus-securities</link>
<guid>https://edusehat.com/en/indian-pharmaceutical-market-records-171-growth-in-september-equirus-securities</guid>
<description><![CDATA[ 
Strongest monthly growth in three years; 2QFY27 growth reaches 14.7 per cent
The post Indian pharmaceutical market records 17.1% growth in September: Equirus Securities appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2019/08/13111109/expansion-growth.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 15 Oct 2026 15:45:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Indian, pharmaceutical, market, records, 17.1, growth, September:, Equirus, Securities</media:keywords>
<content:encoded><![CDATA[<div><img width="887" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2019/08/13111109/expansion-growth.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2019/08/13111109/expansion-growth.jpg 887w, https://cdn.expresspharma.in/wp-content/uploads/2019/08/13111109/expansion-growth-300x135.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2019/08/13111109/expansion-growth-768x346.jpg 768w" sizes="auto, (max-width: 887px) 100vw, 887px"></div><p><span><span><span>India’s pharmaceutical market (IPM) recorded year-on-year growth of 17.1 per cent in September 2026, its strongest monthly performance in three years, accelerating from 13.1 per cent in August 2026 and significantly ahead of the 6.6 per cent recorded in September 2025. Market sales stood at approximately ₹253 billion during the month, while unit growth rose to 5.4 per cent, the strongest monthly reading since October 2023, according to a sector report by Equirus Securities.</span></span></span></p>
<p><span><span><span>For the second quarter of FY2027, IPM sales stood at ₹746.1 billion, registering growth of 14.7 per cent year-on-year, compared with 7.7 per cent in 2QFY26 and 13.9 per cent in 1QFY27. The quarter marked the strongest growth in the series. On a moving annual total (MAT) basis, market growth improved to 13.2 per cent in September, from 12.3 per cent in August 2026 and 7.9 per cent in September 2025.</span></span></span></p>
<p><span><span><span>The composition of market growth also continued to improve, with volume emerging as the largest contributor. On a MAT basis, volume, price and new introductions contributed 4.9 per cent, 4.8 per cent and 3.4 per cent, respectively, compared with 0.9 per cent, 4.6 per cent and 2.4 per cent a year earlier. The improvement reflects a broader recovery in demand, with market growth becoming less dependent on price increases alone.</span></span></span></p>
<p><span><span><span>Chronic therapies grew 16.8 per cent on a MAT basis, compared with 10.9 per cent for acute therapies. While chronic therapies remained the principal structural growth driver, the improvement in acute therapies indicated that market momentum was broadening across segments.</span></span></span></p>
<p><strong><span><span><span><b>Broad-based therapy growth; respiratory remains an exception</b></span></span></span></strong></p>
<p><span><span><span>Eight of the ten key therapy segments recorded growth above the mid-teens in September. Vitamins, Minerals and Nutritionals (VMN) led with 22.2 per cent growth, followed by Anti-Diabetic at 21.2 per cent and Cardiac at 20.4 per cent. Pain grew 20.0 per cent, Dermatology 19.6 per cent, Neuro/CNS 17.9 per cent, Gastroenterology 17.6 per cent and Gynaecology 16.6 per cent.</span></span></span></p>
<p><span><span><span>The quarterly trend was similarly strong, with Anti-Diabetic growing 19.3 per cent, VMN 18.5 per cent and Cardiac 17.5 per cent in 2QFY27. Pain recorded growth of 16.5 per cent, while Neuro/CNS grew 15.2 per cent.</span></span></span></p>
<p><span><span><span>Respiratory remained the principal exception, growing 3.1 per cent in September against a high base of 15.1 per cent in September 2025. The segment recorded growth of 5.3 per cent during the quarter. Anti-Infectives, meanwhile, recovered to 9.3 per cent growth in September from 3.6 per cent in August.</span></span></span></p>
<p><span><span><span>Outside the ten key therapy segments, Oncology grew 29.4 per cent in September and 27.5 per cent during the quarter. Vaccines and Urology recorded quarterly growth of 20.0 per cent and 19.3 per cent, respectively.</span></span></span></p>
<p><strong><span><span><span><b>All ten tracked pharma companies record double-digit growth</b></span></span></span></strong></p>
<p><span><span><span>All ten tracked pharma companies recorded double-digit growth in September for the sixth consecutive month. However, only five outperformed the IPM’s 17.1 per cent growth, compared with seven companies in August.</span></span></span></p>
<p><span><span><span>Zydus led the September rankings with 19.7 per cent growth, followed by Torrent at 18.9 per cent, Sun Pharma at 17.6 per cent, Mankind Pharma at 17.3 per cent and Dr. Reddy’s at 17.2 per cent. IPCA Laboratories and Lupin recorded growth of 16.2 per cent and 16.1 per cent, respectively, while Cipla grew 15.2 per cent, Alkem 14.8 per cent and Abbott India 14.6 per cent.</span></span></span></p>
<p><span><span><span>For 2QFY27, Dr. Reddy’s led the tracked companies with growth of 21.0 per cent, around 630 basis points ahead of the IPM. Torrent recorded growth of 16.9 per cent, followed by Zydus at 16.3 per cent, Lupin at 15.8 per cent, Mankind Pharma at 15.7 per cent and Sun Pharma at 15.3 per cent. These six companies outperformed the market’s quarterly growth of 14.7 per cent.</span></span></span></p>
<p><span><span><span>IPCA Laboratories recorded quarterly growth of 14.4 per cent, followed by Alkem at 13.9 per cent, Cipla at 13.8 per cent and Abbott India at 12.3 per cent.</span></span></span></p>
<p><span><span><span>According to the report, the stronger performers benefited from their exposure to faster-growing therapy segments and established brands. Dr Reddy’s performance was supported by Oncology and Vaccines, while Cardiac, Anti-Diabetic, VMN, Gastroenterology and Oncology contributed to growth across other leading companies.</span></span></span></p>
<p><span><span><span>Mankind Pharma recorded a sharp improvement from the previous quarter, supported by momentum in VMN, Gastroenterology and Neurology. Cipla and Alkem continued to face pressure from seasonal weakness in Respiratory and Anti-Infectives, while Abbott India’s performance was affected by a decline in its Anti-Diabetic franchise.</span></span></span></p>
<p><strong><span><span><span><b>Volume recovery supports a broad-based growth outlook</b></span></span></span></strong></p>
<p><span><span><span>The September performance capped a steadily strengthening quarter, with IPM growth reaching 14.7 per cent in 2QFY27 following 13.9 per cent growth in 1QFY27. Quarterly unit growth stood at 3.0 per cent, while September’s 5.4 per cent unit growth marked the strongest monthly reading since October 2023.</span></span></span></p>
<p><span><span><span>The report attributes the improvement in volume growth to factors including better diagnosis, greater emphasis on preventive healthcare, tighter regulatory compliance and lifestyle-related growth in chronic diseases. The strengthening contribution of volumes, alongside price and new product introductions, has made the market’s growth more broad-based.</span></span></span></p>
<p><span><span><span>Equirus Securities expects volume expansion to continue steadily, albeit at a slightly lower intensity. The improvement across chronic and acute therapies indicates that market momentum extends beyond a limited number of segments, although Respiratory and seasonal pressures in Anti-Infectives remain areas to watch.</span></span></span></p>
<p><span><span><span><b>Table 1: Indian pharma market performance</b></span></span></span></p>
<table border="1" width="365" cellspacing="3" cellpadding="2">
<tbody>
<tr>
<td width="238">
<p align="JUSTIFY"><span><span><span><b>Key indicator</b></span></span></span></p>
</td>
<td width="108">
<p align="JUSTIFY"><span><span><span><b>Performance</b></span></span></span></p>
</td>
</tr>
<tr>
<td width="238">
<p align="JUSTIFY"><span><span><span>September 2026 market growth (YoY)</span></span></span></p>
</td>
<td width="108">
<p align="JUSTIFY"><span><span><span>17.1 per cent</span></span></span></p>
</td>
</tr>
<tr>
<td width="238">
<p align="JUSTIFY"><span><span><span>September 2025 market growth (YoY)</span></span></span></p>
</td>
<td width="108">
<p align="JUSTIFY"><span><span><span>6.6 per cent</span></span></span></p>
</td>
</tr>
<tr>
<td width="238">
<p align="JUSTIFY"><span><span><span>August 2026 market growth (YoY)</span></span></span></p>
</td>
<td width="108">
<p align="JUSTIFY"><span><span><span>13.1 per cent</span></span></span></p>
</td>
</tr>
<tr>
<td width="238">
<p align="JUSTIFY"><span><span><span>2QFY27 market growth (YoY)</span></span></span></p>
</td>
<td width="108">
<p align="JUSTIFY"><span><span><span>14.7 per cent</span></span></span></p>
</td>
</tr>
<tr>
<td width="238">
<p align="JUSTIFY"><span><span><span>1QFY27 market growth (YoY)</span></span></span></p>
</td>
<td width="108">
<p align="JUSTIFY"><span><span><span>13.9 per cent</span></span></span></p>
</td>
</tr>
<tr>
<td width="238">
<p align="JUSTIFY"><span><span><span>2QFY27 market sales</span></span></span></p>
</td>
<td width="108">
<p align="JUSTIFY"><span>₹<span><span>746.1 billion</span></span></span></p>
</td>
</tr>
<tr>
<td width="238">
<p align="JUSTIFY"><span><span><span>September 2026 unit growth</span></span></span></p>
</td>
<td width="108">
<p align="JUSTIFY"><span><span><span>5.4 per cent</span></span></span></p>
</td>
</tr>
<tr>
<td width="238">
<p align="JUSTIFY"><span><span><span>MAT September 2026 growth</span></span></span></p>
</td>
<td width="108">
<p align="JUSTIFY"><span><span><span>13.2 per cent</span></span></span></p>
</td>
</tr>
</tbody>
</table>
<p><span><span><span>Source: Equirus Securities, Healthcare & Pharmaceuticals Sector Report, 14 October 2026.</span></span></span></p>
<p><span><span><span><b>Table 2: September 2026 growth across key therapy segments</b></span></span></span></p>
<table border="1" width="279" cellspacing="3" cellpadding="2">
<tbody>
<tr>
<td width="134">
<p align="JUSTIFY"><span><span><span><b>Therapy segment</b></span></span></span></p>
</td>
<td width="126">
<p align="JUSTIFY"><span><span><span><b>Growth (YoY)</b></span></span></span></p>
</td>
</tr>
<tr>
<td width="134">
<p align="JUSTIFY"><span><span><span>VMN</span></span></span></p>
</td>
<td width="126">
<p align="JUSTIFY"><span><span><span>22.2 per cent</span></span></span></p>
</td>
</tr>
<tr>
<td width="134">
<p align="JUSTIFY"><span><span><span>Anti-Diabetic</span></span></span></p>
</td>
<td width="126">
<p align="JUSTIFY"><span><span><span>21.2 per cent</span></span></span></p>
</td>
</tr>
<tr>
<td width="134">
<p align="JUSTIFY"><span><span><span>Cardiac</span></span></span></p>
</td>
<td width="126">
<p align="JUSTIFY"><span><span><span>20.4 per cent</span></span></span></p>
</td>
</tr>
<tr>
<td width="134">
<p align="JUSTIFY"><span><span><span>Pain</span></span></span></p>
</td>
<td width="126">
<p align="JUSTIFY"><span><span><span>20.0 per cent</span></span></span></p>
</td>
</tr>
<tr>
<td width="134">
<p align="JUSTIFY"><span><span><span>Dermatology</span></span></span></p>
</td>
<td width="126">
<p align="JUSTIFY"><span><span><span>19.6 per cent</span></span></span></p>
</td>
</tr>
<tr>
<td width="134">
<p align="JUSTIFY"><span><span><span>Neuro/CNS</span></span></span></p>
</td>
<td width="126">
<p align="JUSTIFY"><span><span><span>17.9 per cent</span></span></span></p>
</td>
</tr>
<tr>
<td width="134">
<p align="JUSTIFY"><span><span><span>Gastroenterology</span></span></span></p>
</td>
<td width="126">
<p align="JUSTIFY"><span><span><span>17.6 per cent</span></span></span></p>
</td>
</tr>
<tr>
<td width="134">
<p align="JUSTIFY"><span><span><span>Gynaecology</span></span></span></p>
</td>
<td width="126">
<p align="JUSTIFY"><span><span><span>16.6 per cent</span></span></span></p>
</td>
</tr>
<tr>
<td width="134">
<p align="JUSTIFY"><span><span><span>Anti-Infectives</span></span></span></p>
</td>
<td width="126">
<p align="JUSTIFY"><span><span><span>9.3 per cent</span></span></span></p>
</td>
</tr>
<tr>
<td width="134">
<p align="JUSTIFY"><span><span><span>Respiratory</span></span></span></p>
</td>
<td width="126">
<p align="JUSTIFY"><span><span><span>3.1 per cent</span></span></span></p>
</td>
</tr>
<tr>
<td width="134">
<p align="JUSTIFY"><span><span><span>Oncology*</span></span></span></p>
</td>
<td width="126">
<p align="JUSTIFY"><span><span><span>29.4 per cent</span></span></span></p>
</td>
</tr>
</tbody>
</table>
<p><span><span><span>*Oncology is outside the ten key therapy segments. Source: Equirus Securities.</span></span></span></p>
<p><span><span><span><b>Table 3: Pharmaceutical company growth comparison</b></span></span></span></p>
<table border="1" width="451" cellspacing="3" cellpadding="2">
<tbody>
<tr>
<td width="173">
<p align="JUSTIFY"><span><span><span><b>Company</b></span></span></span></p>
</td>
<td width="103">
<p align="JUSTIFY"><span><span><span><b>September 2026</b></span></span></span></p>
</td>
<td width="93">
<p align="JUSTIFY"><span><span><span><b>2QFY27</b></span></span></span></p>
</td>
</tr>
<tr>
<td width="173">
<p align="JUSTIFY"><span><span><span>Dr. Reddy’s</span></span></span></p>
</td>
<td width="103">
<p align="JUSTIFY"><span><span><span>17.2 per cent</span></span></span></p>
</td>
<td width="93">
<p align="JUSTIFY"><span><span><span>21.0 per cent</span></span></span></p>
</td>
</tr>
<tr>
<td width="173">
<p align="JUSTIFY"><span><span><span>Torrent</span></span></span></p>
</td>
<td width="103">
<p align="JUSTIFY"><span><span><span>18.9 per cent</span></span></span></p>
</td>
<td width="93">
<p align="JUSTIFY"><span><span><span>16.9 per cent</span></span></span></p>
</td>
</tr>
<tr>
<td width="173">
<p align="JUSTIFY"><span><span><span>Zydus</span></span></span></p>
</td>
<td width="103">
<p align="JUSTIFY"><span><span><span>19.7 per cent</span></span></span></p>
</td>
<td width="93">
<p align="JUSTIFY"><span><span><span>16.3 per cent</span></span></span></p>
</td>
</tr>
<tr>
<td width="173">
<p align="JUSTIFY"><span><span><span>Lupin</span></span></span></p>
</td>
<td width="103">
<p align="JUSTIFY"><span><span><span>16.1 per cent</span></span></span></p>
</td>
<td width="93">
<p align="JUSTIFY"><span><span><span>15.8 per cent</span></span></span></p>
</td>
</tr>
<tr>
<td width="173">
<p align="JUSTIFY"><span><span><span>Mankind Pharma</span></span></span></p>
</td>
<td width="103">
<p align="JUSTIFY"><span><span><span>17.3 per cent</span></span></span></p>
</td>
<td width="93">
<p align="JUSTIFY"><span><span><span>15.7 per cent</span></span></span></p>
</td>
</tr>
<tr>
<td width="173">
<p align="JUSTIFY"><span><span><span>Sun Pharma</span></span></span></p>
</td>
<td width="103">
<p align="JUSTIFY"><span><span><span>17.6 per cent</span></span></span></p>
</td>
<td width="93">
<p align="JUSTIFY"><span><span><span>15.3 per cent</span></span></span></p>
</td>
</tr>
<tr>
<td width="173">
<p align="JUSTIFY"><span><span><span>IPCA Laboratories</span></span></span></p>
</td>
<td width="103">
<p align="JUSTIFY"><span><span><span>16.2 per cent</span></span></span></p>
</td>
<td width="93">
<p align="JUSTIFY"><span><span><span>14.4 per cent</span></span></span></p>
</td>
</tr>
<tr>
<td width="173">
<p align="JUSTIFY"><span><span><span>Alkem</span></span></span></p>
</td>
<td width="103">
<p align="JUSTIFY"><span><span><span>14.8 per cent</span></span></span></p>
</td>
<td width="93">
<p align="JUSTIFY"><span><span><span>13.9 per cent</span></span></span></p>
</td>
</tr>
<tr>
<td width="173">
<p align="JUSTIFY"><span><span><span>Cipla</span></span></span></p>
</td>
<td width="103">
<p align="JUSTIFY"><span><span><span>15.2 per cent</span></span></span></p>
</td>
<td width="93">
<p align="JUSTIFY"><span><span><span>13.8 per cent</span></span></span></p>
</td>
</tr>
<tr>
<td width="173">
<p align="JUSTIFY"><span><span><span>Abbott India</span></span></span></p>
</td>
<td width="103">
<p align="JUSTIFY"><span><span><span>14.6 per cent</span></span></span></p>
</td>
<td width="93">
<p align="JUSTIFY"><span><span><span>12.3 per cent</span></span></span></p>
</td>
</tr>
<tr>
<td width="173">
<p align="JUSTIFY"><span><span><span>Indian Pharma Market (IPM)</span></span></span></p>
</td>
<td width="103">
<p align="JUSTIFY"><span><span><span>17.1 per cent</span></span></span></p>
</td>
<td width="93">
<p align="JUSTIFY"><span><span><span>14.7 per cent</span></span></span></p>
</td>
</tr>
</tbody>
</table>
<p><span><span><span>Source: Equirus Securities, pages 1 and 7. Company growth figures are year-on-year.</span></span></span></p>
<p>The post <a href="https://www.expresspharma.in/indian-pharmaceutical-market-records-17-1-growth-in-september-equirus-securities/">Indian pharmaceutical market records 17.1% growth in September: Equirus Securities</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Zydus Sunshine Lifesciences signs agreement to set up pharma facility in Sri Lanka</title>
<link>https://edusehat.com/en/zydus-sunshine-lifesciences-signs-agreement-to-set-up-pharma-facility-in-sri-lanka</link>
<guid>https://edusehat.com/en/zydus-sunshine-lifesciences-signs-agreement-to-set-up-pharma-facility-in-sri-lanka</guid>
<description><![CDATA[ 
The proposed facility in Horana involves a phased investment of over $20 million, with commercial operations expected to begin in 2028
The post Zydus Sunshine Lifesciences signs agreement to set up pharma facility in Sri Lanka appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/07/22171615/signing-agreement.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 15 Oct 2026 15:45:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Zydus, Sunshine, Lifesciences, signs, agreement, set, pharma, facility, Sri, Lanka</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/07/22171615/signing-agreement.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/07/22171615/signing-agreement.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/07/22171615/signing-agreement-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p>Zydus Sunshine Lifesciences, the proposed joint venture between Zydus Lifesciences and Sunshine Healthcare, part of Sunshine Holdings PLC, have signed an agreement with the Board of Investment of Sri Lanka to establish a pharma manufacturing facility in the BOI zone in Horana, Sri Lanka.</p>
<p>Both companies had announced the formation of the joint venture on June 26, 2026.</p>
<p>The facility will be developed on a site of nearly four acres, with a phased investment of over $20 million. Commercial operations are expected to commence in 2028, subject to project timelines and relevant regulatory approvals. In its first phase, the facility will manufacture oral solid dosage forms for the Sri Lankan market.</p>
<p>The investment supports Zydus’ international presence and commitment to expanding access to quality medicines. Local manufacturing is expected to strengthen medicine supply chain resilience and support the availability of essential medicines in Sri Lanka.</p>
<p>The post <a href="https://www.expresspharma.in/zydus-sunshine-lifesciences-signs-agreement-to-set-up-pharma-facility-in-sri-lanka/">Zydus Sunshine Lifesciences signs agreement to set up pharma facility in Sri Lanka</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Charles River partners with Magellan Stem Cells on cell therapy</title>
<link>https://edusehat.com/en/charles-river-partners-with-magellan-stem-cells-on-cell-therapy</link>
<guid>https://edusehat.com/en/charles-river-partners-with-magellan-stem-cells-on-cell-therapy</guid>
<description><![CDATA[ The partnership focuses on biologics quality control as well as viral and release testing under current good manufacturing practice (cGMP) standards. Magellan recently completed Phase I/II clinical studies 
The post Charles River partners with Magellan Stem Cells on cell therapy appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/10/PT-2-14-10-2026-shutterstock_2556717801.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 14 Oct 2026 20:25:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Charles, River, partners, with, Magellan, Stem, Cells, cell, therapy</media:keywords>
<content:encoded><![CDATA[<p>The partnership focuses on biologics quality control as well as viral and release testing under current good manufacturing practice (cGMP) standards.</p>
<p>Magellan recently completed Phase I/II clinical studies evaluating Zelestrocel, an off-the-shelf, allogeneic stem cell therapy designed to treat osteoarthritis.</p>
<p>The company is now preparing to initiate a pivotal Phase III clinical programme.</p>
<p>Charles River global manufacturing corporate senior vice president Kerstin Dolph said: “Working with organisations at the forefront of innovation allows us to expand our GMP testing capabilities and help accelerate the delivery of safe, compliant therapies to patients.</p>
<p>“We are excited to support Magellan as they work towards advancing Zelestrocel from the clinic to potential commercialisation.”</p>
<p>To support the therapy’s progress towards international regulatory standards, Charles River will provide viral safety assessments using next-generation sequencing (NGS) for cell and gene therapy (CGT).</p>
<p>The testing protocols comply with regulatory benchmarks from the European Medicines Agency (EMA), the Food and Drug Administration (FDA), GMP standards, and International Council for Harmonisation (ICH) Q5A and Q5B guidelines.</p>
<p>Charles River expanded its sequencing capabilities through the acquisition of Pathoquest, a company specialising in biopharmaceutical quality control and characterisation.</p>
<p>Magellan COO Nick Bliesner said: “Charles River’s GMP NGS capabilities provide an innovative approach to viral safety testing that supports both product quality and regulatory readiness. This collaboration strengthens our ability to advance Zelestrocel toward commercialisation with confidence.”</p>
<p>Magellan manufactures the cell therapy internally at its Melbourne facility, which holds GMP certification from the Therapeutic Goods Administration (TGA).</p>
<p>It is one of only four cell therapy manufacturing centres in Australia to hold GMP certification.</p>
<p>The sequencing work also aligns with Charles River’s Alternative Methods Advancement Project (AMAP), an initiative guided by a scientific advisory board chaired by Dr Namandjé Bumpus to reduce animal testing by implementing new approach methodologies (NAMs).</p>
<p>In addition, Charles River operates nine CGMP-compliant International Organization for Standardization-6 (ISO-6) cleanroom suites, offers cell bank release within eight to ten weeks, and has produced more than 2,000 cell and viral banks.</p>
<p>In August this year, CRL and Medigen Vaccine Biologics (MVC) entered into a collaboration to support the characterisation and validation of the virus seed bank for MVC’s next-generation multivalent enterovirus vaccine.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/charles-river-magellan-stem-cell-therapy/">Charles River partners with Magellan Stem Cells on cell therapy</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Pfizer partners with Enodia Therapeutics in $500m drug deal</title>
<link>https://edusehat.com/en/pfizer-partners-with-enodia-therapeutics-in-500m-drug-deal</link>
<guid>https://edusehat.com/en/pfizer-partners-with-enodia-therapeutics-in-500m-drug-deal</guid>
<description><![CDATA[ Under the partnership, Enodia Therapeutics will handle initial discovery work to identify, refine, and advance small-molecule candidates directed at multiple targets. Pfizer will take full responsibility for subsequent 
The post Pfizer partners with Enodia Therapeutics in $500m drug deal appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/10/PT-14-10-2026-shutterstock_2323283999.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 14 Oct 2026 20:25:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Pfizer, partners, with, Enodia, Therapeutics, 500m, drug, deal</media:keywords>
<content:encoded><![CDATA[<p>Under the partnership, Enodia Therapeutics will handle initial discovery work to identify, refine, and advance small-molecule candidates directed at multiple targets.</p>
<p>Pfizer will take full responsibility for subsequent clinical trials, manufacturing, regulatory submissions, and commercial operations once the collaboration phase concludes.</p>
<p>Financially, Enodia Therapeutics will receive an upfront fee, plus potential payments tied to research, development, and sales milestones. The biotechnology company is also eligible to receive tiered royalties based on future net sales.</p>
<p>Founding partner Alexandra Carrel and MCE Carrel Avocats member Thomas Rocco provided legal counsel for Enodia Therapeutics during the transaction.</p>
<p>The programme centres on Enodia Therapeutics’ drug discovery platform, which modulates the Sec61 Translocon to halt harmful proteins during synthesis prior to the onset of disease pathology, whilst maintaining normal cellular functions.</p>
<p>The company utilises machine learning alongside structural biology data, such as cryo-EM, in combination with proteomics and tailored cell-line libraries to guide the design of small molecules across several Sec61 inhibitor families.</p>
<p>Enodia Therapeutics CEO Yves Ribeill said: “Enodia has built a broad platform that enables selective Sec61 Translocon modulation, a novel approach to inhibit disease-driving proteins while preserving essential physiological functions.</p>
<p>“We look forward to collaborating with Pfizer, combining their deep expertise and clinical resources with our approach for precisely targeting pathological proteins to bring forth potential new medicines.”</p>
<p>Established through Argobio Studio and based on foundational research conducted at the Institut Pasteur, Enodia Therapeutics concentrates on targeted protein degradation at synthesis.</p>
<p>The company is directing its internal Sec61 research pipeline primarily towards immunology, oncology and inflammation, with further prospects in virology.</p>
<p>In June this year, Pfizer and Chai Discovery agreed on a licensing deal enabling the former to incorporate Chai’s AI platform into its drug discovery operations.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/pfizer-enodia-therapeutics-500m-drug-deal/">Pfizer partners with Enodia Therapeutics in $500m drug deal</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>From botox to algorithms: How AI is redefining cosmetic medicine</title>
<link>https://edusehat.com/en/from-botox-to-algorithms-how-ai-is-redefining-cosmetic-medicine</link>
<guid>https://edusehat.com/en/from-botox-to-algorithms-how-ai-is-redefining-cosmetic-medicine</guid>
<description><![CDATA[ 
Dr Ashok Patel, Aesthetic Surgeon, Founder and Chief Medical Officer, Brilliance Cosmocare, explains how AI is shaping skin analysis, cosmetic treatment planning, hair restoration and patient consultations, while highlighting the role of clinical judgement in aesthetic medicine
The post From botox to algorithms: How AI is redefining cosmetic medicine appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/14165737/EP_Dr_Ashok_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 14 Oct 2026 20:25:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>From, botox, algorithms:, How, redefining, cosmetic, medicine</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/14165737/EP_Dr_Ashok_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/14165737/EP_Dr_Ashok_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/14165737/EP_Dr_Ashok_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>In a clinic in Bandra, a patient holds up her phone under a ring light while an app maps her pores, the depth of a nasolabial fold, the faint brown patch near her left cheekbone. The doctor has not touched her face yet. The screen has already produced a skin score, a projected ageing curve and three treatment options ranked by expected impact. Ten years ago this conversation started with a mirror and a guess. Today it starts with a dataset.</span></p>
<p><span>This is the exciting part of the AI story in aesthetic medicine. The headlines go to botox and fillers, but underneath them sits a growing layer of software: imaging tools that read skin the way a radiologist reads a scan and algorithms that suggest a neurotoxin dose. Then there are robots that extract hair follicles one at a time, and simulators that show a patient her own face five years forward before she signs a consent form.</span></p>
<p><b>Reading the skin before touching it</b></p>
<p><span>AI-based skin analysis is the most mature layer of this shift. Devices such as VISIA complexion analysis and apps built by big companies now generate detailed maps of wrinkles, pigmentation, pore size and sebum activity in seconds. Earlier, this work relied on a dermatologist’s trained eye and a good light source. The scale of this shift shows up in the numbers. Future Market Insights projects that the Indian AI skin market will grow at a compound annual rate of 20 per cent through 2035, placing India alongside China as one of the two fastest-growing markets globally.</span></p>
<p><b>From diagnosis to dosage</b></p>
<p><span>The more contested frontier is treatment planning itself. Software used in some botox and filler training programmes now offers simulation-based facial assessment, mapping dynamic muscle movement and suggesting a starting dose. Smart filler mapping tools overlay a patient’s scan with known arterial risk zones, flagging areas where an injection could be dangerous before the needle comes anywhere near the skin.</span></p>
<p><span>None of this removes the injector from the room. Every account of these tools, from clinical training literature to industry commentary, repeats the same line: AI supports judgement, it does not replace it. A hairline, a smile, the particular way one eyebrow sits higher than the other, these are still read by a trained clinician, not a model.</span></p>
<p><span>There is also a healthy dose of scientific caution built into this story. A study published in Plastic and Reconstructive Surgery Global Open, using facial-analysis tools to estimate age before and after filler injections, found that AI-estimated age did not shift over the 90 days following treatment, even though patients reported feeling and looking younger. It is a useful reminder that an algorithm and a mirror do not always agree, and that patient-reported outcomes remain a measure AI has not yet learned to fully capture.</span></p>
<p><b>Robots in the hair transplant chair</b></p>
<p><span>Nowhere is automation more visible than in hair restoration. Robotic systems such as ARTAS now scan the scalp in real time, select the healthiest follicles and extract them with a precision no human hand can consistently match, a shift already available at clinics in cities including Ahmedabad. Robotic-assisted extraction reduces the physical fatigue of a procedure that can otherwise run six to eight hours with a surgeon bent over a single patient, freeing that time for planning the hairline and pattern instead of the repetitive mechanics of extraction.</span></p>
<p><b>Seeing the future face first</b></p>
<p><span>Perhaps the most patient-facing use of AI is the preview. Simulators now take a single selfie and generate a realistic projection of how a face might look after filler, a neurotoxin treatment or resurfacing, built on a database of tens of thousands of real treatment cases. For a patient nervous about looking overdone or unnatural, seeing an approximation before committing changes the entire consultation conversation.</span></p>
<p><span>Every clinic offering these simulators adds the same caveat. A projection cannot account for a patient’s bone structure, muscle movement or how their particular skin will respond to a needle, so the final say still belongs to the person holding it.</span></p>
<p><b>What 2035 might actually look like</b></p>
<p><span>A review published in the Journal of Cosmetic Dermatology describes cosmetic dermatology moving away from short-term aesthetic fixes and toward long-term, AI-guided strategies for preserving skin health over a lifetime, folding in microbiome data, immune modulation and generative AI-designed formulations. </span></p>
<p><span>That framing matters, particularly in India, where the same review notes that culturally adapted AI systems, trained on Indian skin tones and ageing patterns rather than datasets built largely on lighter skin, remain a research priority rather than a solved problem. A tool trained mostly on Korean or American faces will not automatically read a face in Lucknow or Coimbatore with the same accuracy.</span></p>
<p><span>By 2035, the realistic picture looks like this. Skin analysis will be near-instant and standard at the first consultation, not a premium add-on. Predictive software will assist dosing for neurotoxins and fillers, with a trained doctor checking and overriding it when a face doesn’t match the model. Robotic-assisted hair restoration will be common, not a novelty reserved for flagship clinics in Mumbai or Bangalore. And previews generated from a single photograph will be a normal part of the first conversation, not a gimmick.</span></p>
<p><b>The miracle, and its fine print</b></p>
<p><span>It is tempting to describe all this as a miracle for ageing, a phrase that shows up often in clinic marketing and rarely in peer-reviewed journals. The more accurate description sits somewhere quieter. AI is proving useful at what machines do best: measuring, mapping, predicting, and repeating a precise motion thousands of times without fatigue. What it has not replaced, and what none of the research reviewed here suggests it will replace by 2035, is the judgement of a trained doctor who knows when a template does not fit the person sitting in the chair.</span></p>
<p><span>For patients, the practical advice has not changed much even as the tools have. Ask what the AI tool actually measured, ask what data trained it, and ask what the doctor would do differently from what the screen recommends. The algorithm can suggest. For the foreseeable future, the decision still needs a human signature.</span></p>
<p>The post <a href="https://www.expresspharma.in/from-botox-to-algorithms-how-ai-is-redefining-cosmetic-medicine/">From botox to algorithms: How AI is redefining cosmetic medicine</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>NIPER Raebareli, AstraZeneca India partner to expand clinical trial sites across India</title>
<link>https://edusehat.com/en/niper-raebareli-astrazeneca-india-partner-to-expand-clinical-trial-sites-across-india</link>
<guid>https://edusehat.com/en/niper-raebareli-astrazeneca-india-partner-to-expand-clinical-trial-sites-across-india</guid>
<description><![CDATA[ 
The collaboration will assess and support 25 clinical trial sites across emerging research geographies, with training, mentoring and site-readiness measures
The post NIPER Raebareli, AstraZeneca India partner to expand clinical trial sites across India appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/05/04131504/handshake.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 14 Oct 2026 20:25:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>NIPER, Raebareli, AstraZeneca, India, partner, expand, clinical, trial, sites, across, India</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/05/04131504/handshake.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/05/04131504/handshake.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/05/04131504/handshake-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>The National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, and AstraZeneca India have partnered to extend clinical trial capabilities beyond metropolitan centres, build a trained workforce and prepare sites for inspections across 25 emerging research geographies in India.</span></p>
<p><span>The memorandum of understanding (MoU) was signed in New Delhi in the presence of Manoj Joshi, Secretary, Department of Pharmaceuticals, Ministry of Chemicals and Fertilisers. The collaboration supports the vision of Biopharma SHAKTI, the Government of India’s initiative to build the biopharma ecosystem, including the establishment of 1,000 clinical trial sites across the country.</span></p>
<p><span>The collaboration will begin with the adoption of 25 clinical trial sites, assessment of their capabilities, targeted training and mentoring, and measures to strengthen documentation and support processes related to ethics, safety and trial feasibility.</span></p>
<p><span>The Department of Pharmaceuticals will provide direction and endorsement, aligning the initiative with national clinical research priorities. AstraZeneca India will contribute clinical development expertise to design and deliver the programme, engage Indian and global faculty, and support participating sites through training, workshops, governance and site-readiness measures.</span></p>
<p><span>Manoj Joshi, Secretary, Department of Pharmaceuticals, said, “Our country has the talent and expertise to play a larger role in global clinical trials. Strengthening clinical trials capabilities beyond major metropolitan centres will help expand the pool of skilled professionals and research-ready sites across the country. This collaboration brings together government, academia and industry to strengthen clinical research capabilities in a structured manner and directly advances key objectives of Biopharma SHAKTI.”</span></p>
<p><span>Dr Shubhini Saraf, Director, NIPER Raebareli, said, “The Centre of Excellence will provide a dedicated platform for structured training and certification in clinical research. By combining academic and industry expertise, NIPER Raebareli will help develop a skilled workforce and create a model that can be expanded to other geographies and therapeutic areas.”</span></p>
<p><span>Praveen Rao Akkinepally, Country President and Managing Director of AstraZeneca Pharma India Limited, said, “Clinical research is central to bringing innovative medicines to patients. Our collaboration with NIPER Raebareli, with Government support, aims to strengthen India’s clinical research capabilities, expand trial participation and build a sustainable, high-quality research ecosystem.”</span></p>
<p><span>The initiative is designed as a national model that could expand to additional geographies and therapeutic areas beyond oncology following the proof-of-concept phase.</span></p>
<p>The post <a href="https://www.expresspharma.in/niper-raebareli-astrazeneca-india-partner-to-expand-clinical-trial-sites-across-india/">NIPER Raebareli, AstraZeneca India partner to expand clinical trial sites across India</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>ISCR, CHAKRA sign MoU to strengthen clinical research capacity in Maharashtra</title>
<link>https://edusehat.com/en/iscr-chakra-sign-mou-to-strengthen-clinical-research-capacity-in-maharashtra</link>
<guid>https://edusehat.com/en/iscr-chakra-sign-mou-to-strengthen-clinical-research-capacity-in-maharashtra</guid>
<description><![CDATA[ 
The partnership will focus on GCP and ethics training, research governance, quality frameworks and site readiness across CHAKRA’s hub-and-spoke network
The post ISCR, CHAKRA sign MoU to strengthen clinical research capacity in Maharashtra appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/07/22171615/signing-agreement.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 14 Oct 2026 20:25:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>ISCR, CHAKRA, sign, MoU, strengthen, clinical, research, capacity, Maharashtra</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/07/22171615/signing-agreement.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/07/22171615/signing-agreement.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/07/22171615/signing-agreement-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>The Indian Society for Clinical Research (ISCR) and the Centre for Health Applied Knowledge & Research Autonomy (CHAKRA) have signed a memorandum of understanding (MoU) to strengthen responsible, ethical and high-quality clinical research capacity across Maharashtra.</span></p>
<p><span>According to Built on Scale, Turning to Science, a July 2026 report by BCG and HealthKois, India’s life sciences innovation ecosystem is gaining momentum, with more than 10 novel drug assets originating from India over the past decade and the innovation pipeline expanding by around 1.5 times.</span></p>
<p><span>However, India’s participation in clinical research remains low compared with its population and disease burden. The BCG–HealthKois report notes that India carries about 15 per cent of the global disease burden but conducts around 4 per cent of global clinical trials. Separately, ICMR INTENT reports that India accounts for 18 per cent of the world’s population but 1.4 per cent of global clinical research.</span></p>
<p><span>Through the MoU, ISCR and CHAKRA will work together to strengthen clinical research capabilities at site and institutional levels. The collaboration will focus on Good Clinical Practice (GCP) and ethics training, research governance, standard operating procedures, quality frameworks, and site readiness and capability mapping across CHAKRA’s hub-and-spoke network.</span></p>
<p><span>The partnership will also support academic and professional development and facilitate knowledge exchange to promote globally benchmarked clinical research practices across Maharashtra.</span></p>
<p><span>Commenting on the partnership, Dr Seema Pai, President, ISCR, said, “Only one in 5,000 to 10,000 molecules tested in the laboratory progresses to human studies, underscoring the importance of ensuring that the sites carrying this science forward are built on equally rigorous foundations. Our collaboration with CHAKRA brings together ISCR’s expertise in training, ethics and quality with CHAKRA’s network to strengthen the readiness of research sites across Maharashtra to conduct high-quality, globally benchmarked studies. We look forward to building this capacity together.”</span></p>
<p><span>Dr Ranjana Kumar, CEO, CHAKRA, said, “Strengthening research capacity at the grassroots is central to CHAKRA’s mission. Partnering with ISCR will help our hub-and-spoke network build the skills, governance frameworks and site readiness needed to participate in ethical, high-quality clinical research. Ultimately, stronger research capabilities can benefit researchers, institutions, patients and the communities we serve.”</span></p>
<p><span>The partnership reflects a shared commitment by ISCR and CHAKRA to build institutional capacity and promote standards of quality and ethics in clinical research across Maharashtra.</span></p>
<p>The post <a href="https://www.expresspharma.in/iscr-chakra-sign-mou-to-strengthen-clinical-research-capacity-in-maharashtra/">ISCR, CHAKRA sign MoU to strengthen clinical research capacity in Maharashtra</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Biocon secures global settlement with Genentech for Pebrilzo launch</title>
<link>https://edusehat.com/en/biocon-secures-global-settlement-with-genentech-for-pebrilzo-launch</link>
<guid>https://edusehat.com/en/biocon-secures-global-settlement-with-genentech-for-pebrilzo-launch</guid>
<description><![CDATA[ 
The agreement sets licensed launch dates for Biocon’s pertuzumab biosimilar in the EU, UK, US and other markets
The post Biocon secures global settlement with Genentech for Pebrilzo launch appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 14 Oct 2026 16:45:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Biocon, secures, global, settlement, with, Genentech, for, Pebrilzo, launch</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>Biocon has entered into a global settlement and licence agreement with Genentech, securing the earliest licensed launch dates for Pebrilzo, its biosimilar to the reference product Perjeta® (pertuzumab).</span></p>
<p><span>Biocon and Genentech executed the patent settlement agreement to resolve all pending disputes between the companies, including in the US, Canada and other jurisdictions.</span></p>
<p><span>The global patent settlement and licence agreement enables Biocon to launch Pebrilzo in the European Union and the UK in Q1 of calendar year (CY) 2027, in the US in Q3 of CY 2028, and in other Rest of the World (RoW) countries during CY 2026-2028, or earlier in certain circumstances.</span></p>
<p><span>The other terms of the agreement are confidential.</span></p>
<p><span>Pebrilzo is a biosimilar medicinal product containing pertuzumab as its active substance. Pertuzumab is a monoclonal antibody that binds with high affinity and specificity to the human epidermal growth factor receptor 2 (HER2), inhibiting the proliferation of tumour cells that overexpress HER2.</span></p>
<p><span>Pebrilzo is used for the treatment of HER2-positive breast cancer across multiple disease stages.</span></p>
<p>The post <a href="https://www.expresspharma.in/biocon-secures-global-settlement-with-genentech-for-pebrilzo-launch/">Biocon secures global settlement with Genentech for Pebrilzo launch</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Godavari Biorefineries secures Mexican patent for antiviral research</title>
<link>https://edusehat.com/en/godavari-biorefineries-secures-mexican-patent-for-antiviral-research</link>
<guid>https://edusehat.com/en/godavari-biorefineries-secures-mexican-patent-for-antiviral-research</guid>
<description><![CDATA[ 
The patent covers compounds that inhibit V-ATPase and their use in the manufacture of medicaments for treating viral infections
The post Godavari Biorefineries secures Mexican patent for antiviral research appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 14 Oct 2026 13:10:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Godavari, Biorefineries, secures, Mexican, patent, for, antiviral, research</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>Godavari Biorefineries has secured a patent from the Mexican Patent Office for its invention titled “Use of Compounds for Treating Viral Infections”. The patent follows earlier grants in Japan and China for the same invention, expanding the geographical protection of the compound class.</span></p>
<p><span>The patent covers compounds that inhibit Vacuolar ATPase (V-ATPase), a cellular mechanism involved in the infection process of some viruses, and their use in the manufacture of medicaments for treating viral infections. The research focuses on understanding the role of V-ATPase in viral infection and its potential as a target in antiviral research.</span></p>
<p><span>“We need to think of a new India, one that is confident in its ability to innovate and compete globally. Expanding our patent protection into Mexico, after Japan and China, marks another milestone in our promise to serve a larger global community. It reflects both the international reach of our research and our commitment to building high-impact life science solutions. That road asks for patience and hard work, but every new market we enter brings us closer to addressing critical human health needs on a truly global scale,” said Samir Somaiya, Chairman and Managing Director, Godavari Biorefineries.</span></p>
<p><span>Dr Sangeeta Srivastava, Executive Director, Godavari Biorefineries, said, “The research has allowed us to examine how compounds that inhibit V-ATPase activity could be applied in antiviral research. This patent recognises a specific application of these compounds and represents an important outcome of our work in this area.”</span></p>
<p><span>Dr Srivastava is one of four inventors named on the patent, alongside Dr Sandip Gavade, Dr Maithili Athavale and Dr Prashant Kharkar.</span></p>
<p><span>The patent adds to Godavari Biorefineries’s intellectual property in the antiviral compound class and its life sciences portfolio.</span></p>
<p>The post <a href="https://www.expresspharma.in/godavari-biorefineries-secures-mexican-patent-for-antiviral-research/">Godavari Biorefineries secures Mexican patent for antiviral research</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>China’s NMPA clears Foresee’s Camcevi 42 mg for prostate cancer</title>
<link>https://edusehat.com/en/chinas-nmpa-clears-foresees-camcevi-42-mg-for-prostate-cancer</link>
<guid>https://edusehat.com/en/chinas-nmpa-clears-foresees-camcevi-42-mg-for-prostate-cancer</guid>
<description><![CDATA[ The company was informed of the decision by its domestic licensing partner, Changchun GeneScience Pharmaceutical (GenSci). GenSci holds exclusive Chinese commercial rights to Camcevi across all existing and 
The post China’s NMPA clears Foresee’s Camcevi 42 mg for prostate cancer appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/10/PT-2-13-10-2026-shutterstock_2427658425.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 13 Oct 2026 19:10:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>China’s, NMPA, clears, Foresee’s, Camcevi, for, prostate, cancer</media:keywords>
<content:encoded><![CDATA[<p>The company was informed of the decision by its domestic licensing partner, Changchun GeneScience Pharmaceutical (GenSci).</p>
<p>GenSci holds exclusive Chinese commercial rights to Camcevi across all existing and developmental indications, covering central precocious puberty, premenopausal breast cancer, and advanced prostate cancer.</p>
<p>The therapy is a ready-to-use, six-month subcutaneous depot formulation of leuprolide mesylate, a gonadotropin-releasing hormone agonist developed as an alternative to existing treatments.</p>
<p>Foresee Pharmaceuticals chairman and CEO Dr Ben Chien said: “We are pleased that our partner GenSci will be launching Camcevi 42 mg in China. These efforts will significantly contribute to the growth of our global Camcevi franchise.”</p>
<p>The 42 mg formulation is approved for adult advanced prostate cancer across Canada, China, the European Union (EU), Israel, Taiwan, the UK, and the US, where commercial sales started in April 2022.</p>
<p>Outside China, licensing partners Accord Biopharma/Intas and Accord Healthcare support the franchise, which includes the EU approval from May 2022 and the US Food and Drug Administration’s (FDA) approval of Camcevi ETM in August 2025.</p>
<p>In China, regulators are reviewing a supplemental application filed in May 2026 for leuprolide injectable emulsion in premenopausal breast cancer after a completed Phase III trial.</p>
<p>Foresee Pharmaceuticals based in Taiwan and the US, is preparing commercial operations in Taiwan and the US for FP-001 in central precocious puberty following Phase III Casppian trial results in December 2025.</p>
<p>The company plans to file a US application in the second half of 2026. Its formulation technology is also expanding into the multi-billion-dollar central nervous system sector, with candidates FP-016 and FP-018 scheduled for clinical trials in late 2027.</p>
<p>Pipeline assets also include aderamastat (FP-025), which completed a Phase II study; linvemastat (FP-020), which completed Phase I evaluation; and mirivadelgat (FP-045), which entered the Phase II WINDWARD trial in the second quarter of 2025.</p>
<p>Rights to aderamastat and linvemastat were licensed to Primevera Therapeutics in January 2026.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/chinas-nmpa-foresees-camcevi-42-mg/">China’s NMPA clears Foresee’s Camcevi 42 mg for prostate cancer</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Southern Research secures NIH funding for drug testing hub</title>
<link>https://edusehat.com/en/southern-research-secures-nih-funding-for-drug-testing-hub</link>
<guid>https://edusehat.com/en/southern-research-secures-nih-funding-for-drug-testing-hub</guid>
<description><![CDATA[ The planned facility will focus on the development, validation, and adoption of new approach methodologies (NAMs). These laboratory, computational, and data-oriented methods are designed to mirror human biology 
The post Southern Research secures NIH funding for drug testing hub appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/10/PT-13-10-2026-SR_lab.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 13 Oct 2026 19:10:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Southern, Research, secures, NIH, funding, for, drug, testing, hub</media:keywords>
<content:encoded><![CDATA[<p>The planned facility will focus on the development, validation, and adoption of new approach methodologies (NAMs).</p>
<p>These laboratory, computational, and data-oriented methods are designed to mirror human biology more closely while decreasing dependence on animal testing within drug discovery and development.</p>
<p>As a shared national resource, THRIVE will collaborate directly with external partners to implement NAMs for targeted research needs, assessing them alongside existing human and animal datasets.</p>
<p>The facility will grant access to its models, data, and scientific expertise to NIH investigators, US government researchers, and commercial biotechnology and pharmaceutical companies.</p>
<p>Southern Research chief operating officer Harry Ledebur said: “This NIH award gives us the opportunity to build something much more than a new laboratory. THRIVE is designed to close the gap between innovation and application by bringing human-relevant models, advanced analytics, reference data, and scientific and regulatory expertise together in one environment.</p>
<p>“This integration will allow us to rigorously evaluate NAMs, benchmark their performance, and generate the evidence needed for their use across drug discovery, development, and regulatory decision-making.”</p>
<p>According to the organisation, establishing dependable tools for researchers, drug developers, and regulators remains a central objective. The methodologies aim to help scientists determine how experimental medicines function in humans prior to clinical trials.</p>
<p>By applying human-relevant models alongside computational tools, investigators can refine treatment strategies, transition promising therapies into clinical testing earlier, and identify which candidate treatments are most likely to succeed in patients.</p>
<p>The facility will be based in Birmingham adjacent to Station 41, the commercialisation hub of Southern Research that includes an incubator, an accelerator, and a therapeutics fund.</p>
<p>This co-location is designed to provide startup biotechnology companies with direct access to testing models, data, and scientific expertise alongside the organisation’s existing preclinical and translational operations.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/southern-research-nih-drug-testing-hub/">Southern Research secures NIH funding for drug testing hub</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>India’s biotech innovation may be hidden in its biodiversity</title>
<link>https://edusehat.com/en/indias-biotech-innovation-may-be-hidden-in-its-biodiversity</link>
<guid>https://edusehat.com/en/indias-biotech-innovation-may-be-hidden-in-its-biodiversity</guid>
<description><![CDATA[ 
Dr Villoo Morawala Patell, founder of Avesthagen and Avestagenome Project International, discusses how India can turn its biodiversity into an innovation story, while taking ownership of the science and moving discoveries from the lab to the market, in an exclusive interview with Neha Aathavale 
The post India’s biotech innovation may be hidden in its biodiversity appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/13144325/EP_Dr_Villoo_Morawala_Patell_Founder_Avesthagen_and_Avestagenome_Project_International_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 13 Oct 2026 19:10:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>India’s, biotech, innovation, may, hidden, its, biodiversity</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/13144325/EP_Dr_Villoo_Morawala_Patell_Founder_Avesthagen_and_Avestagenome_Project_International_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/13144325/EP_Dr_Villoo_Morawala_Patell_Founder_Avesthagen_and_Avestagenome_Project_International_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/13144325/EP_Dr_Villoo_Morawala_Patell_Founder_Avesthagen_and_Avestagenome_Project_International_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><b>You have studied the Parsi population for quite a few years. What has the data taught you that surprised you? </b></p>
<p><span>Actually, being a Parsi myself, and being a biologist and a geneticist, I knew what lay within these genomes due to endogamy, because I have worked on diversity. So I know that a gene in humans or a gene in bacteria will have common features. So those common features can be elucidated. So when you have endogamy, where the population is completely, you know, almost similar because they’ve married internally for so many years. I mean, when did we arrive in India? It was the 8th century. So it was a big opportunity there, because also the community was rapidly vanishing. It was endangered. So I thought that was the moment and we just started on the collection. </span></p>
<p><span>It took planning and it was done fully bioethically and was the topmost quality multi omic collection. So we collected nine tubes per person, seven millilitres each. We took 60 pages of the data. It was a methodical collection, a biobank creation. And we reached around 4,700 across nine cities in India. So that itself took a while. </span></p>
<p><span>And then it was after that we went into the sequencing of 100 mitochondrial genomes and created a very deep, reference standard of the genome, both male and female. So all that has revealed something extraordinary, that what we And then it was after that we went into the sequencing of 100 mitochondrial genomes and created a very deep, reference standard of the genome, both male and female. So all that has revealed something extraordinary, that what we suspected was validated to some level by the early biomarkers that surfaced, that all of, because they live long, so they do have longevity markers in the mitochondrial data that we did. And they also have autoimmune conditions, which was also well known, but biomarkers were found in this population, and colon cancer. And IBS. So all those markers showed up. And so now we have to validate that. </span></p>
<p><span>We have embarked on an AI-enabled drug discovery, which could result in anything. It could result in antibodies, monoclonal, or it could be cell therapies, it could be stem cell therapies, CAR T therapies, but we are embarking on that. With the original data, which we have, so the biobank was created. </span></p>
<p><span>What I was trying to stress on today, you have to own where you begin. The idea has to be yours for innovation to succeed. Of course, the innovation cycle is 20 years. I mean, now with AI, we can shorten it to say 7 to 8 years, maybe. But again, very focused. It has to be very focused. </span></p>
<p><span>If you’re doing Alzheimer’s, you have a set of team there. But through partnerships, you cannot do this on your own. The ownership of the data remains with you. The ownership of the pipelines remains with you. But you have to partner for various things to drive an effective molecule, unique innovation into the market in the 8th year or 10th year. </span></p>
<p><b>Parsi dataset is unique. Can this model work with other Indian populations as well? </b></p>
<p><span>Absolutely, it will work. So for example, there are these tribal populations that are haemophilic. </span></p>
<p><span>You can go into those populations, do a proper collection. The thing is to do it properly, not half-heartedly. And you do a full scientific collection with background data, you know, create the biobank, create the database, put it all together. </span></p>
<p><span>So that becomes the unique treasure. And on that, you apply science to elucidate information out of it, to create novel drugs. That’s where I started. </span></p>
<p><span>India is a biodiversity story. It is one of its biggest trends. But how we do it, where we do it, and how we use the data, capitalise and analyse the data, it’s in the analytics. It’s in the analytics. And the ability to see across, you know, which AI is enabling now. Earlier we used to do it ourselves by writing the code.</span></p>
<p><span>But today you can do it. You can see, like, if supposing the haemophilic tribal population could have a gene in common with the Parsis in their rare disease. So you could make a connect. So that is possible also.</span></p>
<p><b>You have taken genomics into diagnostics, food and agriculture as well. How do you turn a genomic discovery into something people can actually use? </b></p>
<p><span>See, the first outcome is the diagnostics. So the biomarkers, say, for example, for colon cancer that we have, we should pick them out and validate them. Now that goes as part of the panel. So there are already panels existing, say, for colon cancer. It adds to the panel. Also, people are different. </span></p>
<p><span>So if you were to do a colon cancer test and I were to do it, different genes would light up because different biochemical pathways result in different outcomes. So then the doctor would know which pathway is where your, I mean, a person’s colon cancer biomarkers lie, and they can give the proper precision drug therapy. That’s how it will apply. </span></p>
<p><span>Because all are not the same. There are 20 types of diabetes. Similarly, from that panel where the diagnostic biomarkers come on, you can predict which pathway you fall under. </span></p>
<p><span>You know, we may all fall under groups of people who fall under this pathway. Your family may be on this path and our family may be on another path, and then the drug appropriately has to be done. Now doctors, of course, also have to increase their range of knowledge in all of this. That is another story. </span></p>
<p><b>What’s your advice for Indian biotech founders trying to raise global PE and strategic capital? </b></p>
<p><span>See, I do it all the time. It’s my job. For every idea, for every say, as I was mentioning, the colon cancer, for that I’ve written a project.</span></p>
<p><span>So where do I go with that? I mean, I’ve raised global capital, but at the stage where I am today, it’s different, I’ve got too many things as an outcome. So my 50 products, they need different types of capital. So there maybe it’s strategic. </span></p>
<p><span>What do I need that capital for? Scale, manufacturing, and marketing. That is a different beast altogether, different set of investors. There, international capital won’t be interested. </span></p>
<p><span>It will have to be your local capital, unless you’re going overseas. That brand is an overseas brand, and then you can go for Indian. But you will have to rely on local or strategic investors internationally who may be wanting to enter India, and who may say, okay, we want to position ourselves in this area, and they may pick up that technology from you, or they will invest. </span></p>
<p><span>There are multiple models that will emerge there. It’s not one thing. It’s not, I want capital one way. There are multiple ways. There’s the grant, sustain the foundation, keep writing grants. Don’t lose your science. </span></p>
<p><span>In your journey, you may fail. I mean, your molecule may, but if you have that grant chugging underneath, the grants must chug on underneath. That’s sort of the basic bread, not even butter.</span></p>
<p><span>Then you go into these licensing partnerships, where you licence and pick up some money, co-develop, that kind. Third money is venture capital money. Fourth money is private equity, and the fifth is strategic partnerships. Private equity, strategic go together. They play together, and it depends on what stage you’re at and which product and where. So there’s no one general prescription. </span></p>
<p><span>And of course, today, as I was saying, there are the MSME markets. Go for them. At some point, just jump. And the government should facilitate MSMEs, not ask for ‘what’s your revenue here?’ This is not about revenue. This is about a product that’s been created. You want to go to the market. The public will decide whether they want to invest in you or not. It’s not the government law that can stop.</span></p>
<p><span>So the government should facilitate startups to go to the markets as soon as possible through the MSME exchange or through the GIFT City exchange or whatever new exchange. They have to create new exchanges to facilitate product-led companies to move. Because how can they scale? How can they manufacture? If not, you want them to waste another 10 years of their life? No. </span></p>
<p><b>Where does India still fall short in converting scientific research into commercial biotech success? </b></p>
<p><span>I think it’s happening. The science from the labs is coming out in certain institutions. But there is still a lot of work to do. Also, the people doing that science in the labs, they have to be sufficiently motivated. They are not people who execute, the do-or-die type. </span></p>
<p><span>They are scientists from certain types of families where the families don’t encourage you to take risks. They don’t have the wherewithal. So, that’s where it stalls. </span></p>
<p><span>So now, you should create, perhaps, within that institutional system, a leader who can pick up and who is like a networker also. Every institute should have a business development and/or IP licensor head. And that guy should move around and pick up whatever looks interesting. And he should be a networker. He should move to companies. He should travel, putting these out into the market. </span></p>
<p><span>That’s the only way we can move forward fast. A proper business, corporate-type business development. Not your from academia, one guy picking up, trying to flop. That won’t work. A corporate deliverer. </span></p>
<p> </p>
<p><b><i>neha.aathavale@expressindia.com </i></b></p>
<p><b><i>nehaaathavale75@gmail.com </i></b></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/indias-biotech-innovation-may-be-hidden-in-its-biodiversity/">India’s biotech innovation may be hidden in its biodiversity</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>India’s biotech growth story is now a manufacturing story: G Balaji</title>
<link>https://edusehat.com/en/indias-biotech-growth-story-is-now-a-manufacturing-story-g-balaji</link>
<guid>https://edusehat.com/en/indias-biotech-growth-story-is-now-a-manufacturing-story-g-balaji</guid>
<description><![CDATA[ 
As production becomes more complex and highly regulated, digitalisation and automation are emerging as critical enablers. G Balaji, SVP, Energy Industries, ABB India in an exclusive interview with Swati Rana discusses how Pharma 4.0, connected manufacturing and integrated plant infrastructure can help India’s biotech sector translate scientific innovation into commercially viable production
The post India’s biotech growth story is now a manufacturing story: G Balaji appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/13160226/EC_G_Balaji_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 13 Oct 2026 19:10:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>India’s, biotech, growth, story, now, manufacturing, story:, Balaji</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/13160226/EC_G_Balaji_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/13160226/EC_G_Balaji_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/13160226/EC_G_Balaji_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><b>How do you see India’s biotechnology sector evolving as it moves from scientific breakthroughs towards large-scale commercial manufacturing? </b></p>
<p><span>We have witnessed a remarkable transformation in India’s biotech industry over the past decade, driven by the expansion of the start-up ecosystem and the emergence of high-value opportunities across the life sciences. Biosimilars, in particular, have become an important part of India’s growing biomanufacturing capabilities. The opportunity now extends well beyond healthcare, with increasing demand across food and nutrition, sustainable materials, bio-based chemicals, and precision fermentation. </span></p>
<p><span>As these sectors mature, manufacturers will need to expand production capacity while maintaining quality, consistency, and cost competitiveness. That requires industrial-scale execution. Companies that can scale reliably, meet global quality standards, and bring products to market faster will have a significant advantage in international markets. India is well placed to combine its strong scientific talent base with advanced digital manufacturing and automation capabilities to realise the broader potential of its life sciences sector. </span></p>
<p><span>Manufacturing excellence is becoming just as important as scientific innovation in determining long-term success. </span></p>
<p><b>What are the biggest operational challenges biotech manufacturers face when scaling production, particularly in maintaining consistency, quality and regulatory compliance? </b></p>
<p><span>One of the biggest operational challenges in biomanufacturing is maintaining consistency as production scales. Even small deviations in critical process parameters can impact yield, product quality, and batch-tobatch reproducibility, leading to costly investigations, rework, or production delays. </span></p>
<p><span>The challenge is compounded by stringent regulatory requirements, where every recipe modification, process adjustment, or equipment change must be fully documented and traceable. Manufacturers need a clear audit trail showing what changed, who approved it, and how it affected production. At the same time, they must manage vast amounts of process and quality data while maintaining data integrity and end-to-end traceability.</span></p>
<p><span>Successfully scaling production therefore requires more than adding capacity; it demands robust process control, real-time visibility, and rigorous change management to ensure quality, compliance, and operational efficiency at every stage. </span></p>
<p><b>What role do you see Pharma 4.0 and digital manufacturing playing in shaping the next generation of biotech production facilities in India? </b></p>
<p><span>Biomanufacturers often manage multiple processes simultaneously. The challenge is maintaining consistent quality, ensuring compliance, and having complete visibility into what’s happening across the plant without creating additional operational overhead. That’s where I believe Pharma 4.0 delivers its greatest value. A connected manufacturing environment enables information to flow seamlessly across the facilities, leading to faster decisions, stronger compliance, and more reliable production outcomes. </span></p>
<p><span>We’ve seen this firsthand at a life sciences facility, where ABB integrated nine manufacturing blocks onto a common automation platform. Rather than operating as separate islands of information, production, utilities, environmental monitoring, and quality related data were integrated into a unified control system. This gave operators and plant managers a real-time view of site-wide operations, making it easier to identify deviations, understand the impact of process changes, and maintain traceability throughout the manufacturing lifecycle. </span></p>
<p><b>Why are data visibility, traceability and data integrity becoming increasingly critical for biotech manufacturers, and how can digital technologies address these requirements? </b></p>
<p><span>Data is no longer just a record of what happened; it is the foundation for better decisions, faster scale-up, and more consistent outcomes. Reliable, traceable, and accessible data is critical to maintaining product quality and compliance. When a process deviation occurs, for example, manufacturers need immediate visibility into every material, process step, and operating condition associated with a batch. </span></p>
<p><span>A unified automation platform enables this by connecting operations, capturing information in real time, reducing manual errors, and creating a trusted data foundation across the manufacturing lifecycle. In highly regulated environments, compliance with standards such as FDA 21 CFR Part 11 requires secure electronic records, electronic signatures, and time-stamped audit trails. By bringing production data, workflows, and quality processes together, manufacturers can strengthen data integrity and end-to-end traceability while remaining audit-ready. Built in cybersecurity, secure data management, reporting, and automated compliance capabilities further help create a more connected, transparent, and resilient manufacturing environment.</span></p>
<p><b>What opportunities does automation create for biotech companies looking to transition towards larger scale or continuous production models? </b></p>
<p><span>Think of automation as the brain of a manufacturing operation, continuously coordinating thousands of interconnected activities across the plant. Just as the brain enables different parts of the body to work together seamlessly, automation connects processes, equipment, and data to keep production running smoothly and consistently. It helps maintain tight control over critical conditions, reducing variability and enabling faster, more reliable decisionmaking. This is especially important in continuous production, where operations must run 24×7 seamlessly without interruption. More broadly, automation allows manufacturers to scale with confidence, transfer processes more effectively, strengthen compliance, and respond more quickly to changing market demands. It is not simply a tool for operating a larger facility but the foundation for turning scientific innovation into repeatable, commercially viable production. </span></p>
<p><b>Why is it important for biotech manufacturers to take an integrated approach to plant infrastructure, connecting production, utilities and other critical systems? </b></p>
<p><span>A biomanufacturing facility functions as a connected ecosystem, where production is only one part of the equation. Supporting systems such as utilities, power infrastructure, building management, and process controls must operate seamlessly together to create the stable, controlled environment required for efficient and reliable manufacturing. </span></p>
<p><span>A “one plant, one system” approach brings these elements together through a common automation platform, providing a unified view of the entire ecosystem. The result is a single source of truth across the facility, improving visibility, strengthening data integrity, and creating a scalable foundation for growth. An integrated architecture also lowers maintenance costs, simplifies upgrades, and eliminates the need to train personnel on multiple automation platforms. </span></p>
<p><span>By standardising operations on a common platform, manufacturers can accelerate onboarding, enhance workforce flexibility, and maintain consistency across sites. Ultimately, an integrated plant is not only easier to operate but also more resilient, efficient, and better equipped to support the rapid scale-up and agility that modern biotech manufacturing demands. </span></p>
<p><b><i>swati.rana@expressindia.com </i></b></p>
<p><b><i>Swatirana.express@gmail.com </i></b></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/indias-biotech-growth-story-is-now-a-manufacturing-story-g-balaji/">India’s biotech growth story is now a manufacturing story: G Balaji</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Dermatology meets aesthetics: Why the boundary between skin health and cosmetic care is changing</title>
<link>https://edusehat.com/en/dermatology-meets-aesthetics-why-the-boundary-between-skin-health-and-cosmetic-care-is-changing</link>
<guid>https://edusehat.com/en/dermatology-meets-aesthetics-why-the-boundary-between-skin-health-and-cosmetic-care-is-changing</guid>
<description><![CDATA[ 
The relationship between dermatology and aesthetic medicine is one of the most compelling issues in recent years. Dermatology has always concerned itself with the diagnosis and treatment of skin diseases, […]
The post Dermatology meets aesthetics: Why the boundary between skin health and cosmetic care is changing appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/13162627/Dr-Ajay-Rana-Founder-and-Director-ILAMED-and-President-of-the-Indian-Society-of-Aesthetic-Medicine-ISAM.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 13 Oct 2026 19:10:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Dermatology, meets, aesthetics:, Why, the, boundary, between, skin, health, and, cosmetic, care, changing</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/13162627/Dr-Ajay-Rana-Founder-and-Director-ILAMED-and-President-of-the-Indian-Society-of-Aesthetic-Medicine-ISAM.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/13162627/Dr-Ajay-Rana-Founder-and-Director-ILAMED-and-President-of-the-Indian-Society-of-Aesthetic-Medicine-ISAM.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/13162627/Dr-Ajay-Rana-Founder-and-Director-ILAMED-and-President-of-the-Indian-Society-of-Aesthetic-Medicine-ISAM-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p align="LEFT"><span><span><span>The relationship between dermatology and aesthetic medicine is one of the most compelling issues in recent years. Dermatology has always concerned itself with the diagnosis and treatment of skin diseases, and aesthetic medicine has focused on the aspects of beauty. Now, these two areas are joining together in an attempt to consider the skin health and beauty in a holistic manner. This convergence is significant, as it reflects a broader effort to provide more comprehensive care for skin health and appearance.</span></span></span></p>
<p align="LEFT"><span><span><span><b>The issue of beauty is not black and white</b></span></span></span></p>
<p align="LEFT"><span><span><span>Dermatology deals with the diagnosis and treatment of the skin conditions such as, acne, psoriasis, eczema, hair loss. Aesthetic medicine usually focuses on wrinkles, scars, uneven skin tone and other issues. At the same time, these problems often occur together, example a person might have acne scars that require a special treatment. There are also skin conditions that manifest themselves in the changes in skin tone, like melasma. If they are not diagnosed and treated, any cosmetic procedures may yield unsatisfactory results. A correct dermatological diagnosis is crucial for successful aesthetic treatment. The ultimate goal is to achieve beautiful skin while promoting and maintaining its health.</span></span></span></p>
<p align="LEFT"><span><span><span><b>From vanity to wellness: The new aesthetic ideals</b></span></span></span></p>
<p align="LEFT"><span><span><span>The new wave of aesthetic medicine is about improving the skin quality and promoting collagen production for a younger-looking skin. The main concerns are the same as in dermatology – acne, scars, wrinkles, uneven tone, melasma, stretch marks and others. Depending on the case, a healthcare professional may suggest a mild course of treatments with chemical exfoliation or more invasive laser-resurfacing procedures.</span></span></span></p>
<p align="LEFT"><span><span><span>It is important to note that any intervention has its own risks and benefits, and there is no universally valid approach that would suit everyone’s expectations and budget. A person’s age, skin type, the course of treatment and even the physician’s experience may affect the outcome. It is also crucial to manage patients’ expectations, as a realistic approach is more likely to lead to satisfaction with the results.</span></span></span></p>
<p align="LEFT"><span><span><span>Aesthetic medicine should supplement dermatological and cosmetic skin care, rather than replace it.</span></span></span></p>
<p align="LEFT"><span><span><span><b>Advanced technologies are still limited by physicians’ expertise</b></span></span></span></p>
<p align="LEFT"><span><span><span>Modern laser and other technologies allow physicians to resolve many aesthetic concerns through minimally invasive procedures.. The latest minimally invasive procedures effectively remove scars, spots and wrinkles, tighten the skin, remove unwanted body hair and pores, and get rid of spider veins. However, any technology is only as good as the physician operating it. Correct diagnosis, years of experience, thorough preparation and the ability to choose the right intervention are crucial for achieving satisfying results.</span></span></span></p>
<p align="LEFT"><span><span><span>In my professional opinion, the physician should take the patient’s skin type into consideration when planning aesthetic interventions, particularly when lasers are involved. People with dark skin tones are more likely to have post-intervention complications, like post-inflammatory hyperpigmentation. A wrong approach or inadequate preparation of the skin before a procedure may aggravate this condition. A physician needs to understand that the success of an intervention depends on their skills and the patient’s skin type and prepare accordingly.</span></span></span></p>
<p align="LEFT"><span><span><span><b>Modern aesthetic medicine: Towards personalised treatments</b></span></span></span></p>
<p align="LEFT"><span><span><span>The goal of modern aesthetic medicine is to provide each patient with individual care. The physician should thoroughly assess the patient’s skin, take their concerns and budget into account and choose the interventions that would yield the most satisfying results. An individual approach also means that the patient is well-informed about the planned interventions and has realistic expectations.</span></span></span></p>
<p align="LEFT"><span><span><span>Clinical experience has shown that the best treatment is one that addresses what a patient actually needs, rather than simply what they may want. Physicians should offer the interventions that have proven benefits and be ready to explain the risks and the expected outcome. The personalisation of treatment is a hallmark of the contemporary approaches to aesthetic medicine.</span></span></span></p>
<p align="LEFT"><span><span><span><b>Ethics are the new beauty standards</b></span></span></span></p>
<p align="LEFT"><span><span><span>As the popularity of aesthetic medicine grows, so do the demand for its services and the variety of providers. Patients often turn to social media to research their options, but not all information found there is reliable. Moreover, many beauty gurus exaggerate the benefits of various procedures while downplaying the risks. However, an ethical physician should educate the patient and help them to make an informed choice. In my view, an aesthetic physician should always put the patient first and recommend the interventions that are indicated and would yield satisfying results.</span></span></span></p>
<p align="LEFT"><span><span><span>To conclude, the convergence of dermatology and aesthetic medicine allows for a more comprehensive approach to skin care. The future of aesthetic medicine lies in new technologies and minimally invasive procedures. At the same time, physicians should always follow ethical guidelines and prescribe individual treatment to each patient.</span></span></span></p>
<p align="LEFT"><span><span><span>Dermatology and aesthetic medicine should unite their efforts to promote the health and beauty of the skin. Dermatologists will continue to be at the forefront of combating skin disease, and their collaboration with aesthetic physicians will enhance the results of non-surgical interventions. The ultimate aim of aesthetic medicine should be the improvement of the skin quality; as beautiful skin is healthy skin.</span></span></span></p>
<p>The post <a href="https://www.expresspharma.in/dermatology-meets-aesthetics-why-the-boundary-between-skin-health-and-cosmetic-care-is-changing/">Dermatology meets aesthetics: Why the boundary between skin health and cosmetic care is changing</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>NuSynth to build chemical process innovation platform with new capital</title>
<link>https://edusehat.com/en/nusynth-to-build-chemical-process-innovation-platform-with-new-capital</link>
<guid>https://edusehat.com/en/nusynth-to-build-chemical-process-innovation-platform-with-new-capital</guid>
<description><![CDATA[ 
The company will use the capital to develop its R&amp;D and technology capabilities, proprietary processes, scale-up capabilities and team
The post NuSynth to build chemical process innovation platform with new capital appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/08/11173227/growth.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 13 Oct 2026 19:10:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>NuSynth, build, chemical, process, innovation, platform, with, new, capital</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/08/11173227/growth.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/08/11173227/growth.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/08/11173227/growth-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>NuSynth Technologies is developing a platform to redesign chemical processes, with a focus on cost efficiency, yield, cycle time, safety, sustainability and scalability.</span></p>
<p><span>Over the last two decades, India has built capacity in chemical manufacturing. However, many molecules continue to rely on multi-step synthesis routes that involve higher material and energy costs, import-dependent intermediates and hazardous reagents, while posing challenges during commercial scale-up. This creates an opportunity to strengthen domestic R&D and develop chemical process innovation capabilities.</span></p>
<p><span>NuSynth addresses this through process redesign based on first principles rather than incremental changes. By re-evaluating starting materials, reaction pathways and process economics, the company develops synthetic routes designed to improve cost efficiency, yield, cycle time, safety, sustainability and scalability.</span></p>
<p><span>Each R&D cycle combines first-principles process redesign with predictive synthesis models, incorporating manufacturability, raw-material economics, safety and quality from the outset. The cycles also feed the company’s AI engine, which converts experimental data into a proprietary knowledge base. This enables future molecule selection, experimentation and commercial scale-up to draw on accumulated data, with the aim of shortening traditional R&D gestation cycles.</span></p>
<p><span>NuSynth’s platform approach is based on the premise that commercially important molecules can be produced through redesigned processes. The company is beginning with pharmaceuticals and electronics chemicals and aims to extend its process innovation capabilities across chemistry-led sectors over time.</span></p>
<p><span>By combining its R&D engine with in-house scientific expertise and collaboration with a network of scientists and entrepreneurs, NuSynth is developing a repeatable approach to originating chemistry and translating it into commercially scalable processes.</span></p>
<p><span>“Over the last two decades, India has built significant strength at manufacturing established chemistry. We believe the next chapter will be defined by our ability to innovate on the underlying chemistry itself. At NuSynth, we are going back to first principles – questioning established routes, redesigning processes and engineering them for commercial scale from day one. Our ambition is to build proprietary processes from India that can deliver superior economics and sustainability, and serve customers across global markets,” said Poorvank Purohit, Co-Founder & CEO, NuSynth Technologies.</span></p>
<p><span>The company’s founding team brings together expertise in scientific R&D, commercialisation and business building. Poorvank Purohit, former MD & CEO of Solara Active Pharma Sciences, brings industry experience and global customer relationships. Dr Ramesha A R, a postdoctoral researcher from NIH, Washington, and PhD graduate from IISc, brings scientific and R&D expertise.</span></p>
<p><span>Abhishek Deo and Dipak Bajaj bring commercial and operating experience across Zetwerk, Mstack, Ola, JPMorgan, BlackBuck and SUN Mobility. Together, the team has led multiple zero-to-scale journeys, including companies that have reached unicorn scale and public-market milestones.</span></p>
<p><span>The new capital will support the development of NuSynth’s R&D and technology capabilities, its initial portfolio of proprietary processes, scale-up capabilities and team.</span></p>
<p><span>Shruti Srivastava, Partner, Avaana Capital, said, “The next phase of India’s growth in high-performance industrial chemistry will increasingly be shaped by the ability to originate proprietary synthesis pathways that are fundamentally more efficient and commercially scalable over time. NuSynth brings together deep expertise across R&D, innovation and commercial scale-up, combining first-principles approach with AI, to build differentiated process IP from India. We believe this approach will improve the economics, resource efficiency and resilience of chemical manufacturing across critical sectors, while creating globally competitive technology platforms from India.”</span></p>
<p><span>Avijeet Alagathi, Managing Partner, Shastra VC, said, “What excites us about NuSynth is how they are using AI to make chemical R&D faster and more efficient. By learning from each experiment, they reduce trial and error and shorten timelines for developing and scaling new chemistries. The founding team brings together a rare combination of scientific depth, industry experience, and execution capability, and we believe this combination, along with its data and an AI engine, strongly positions NuSynth to build a differentiated process innovation platform from India for global markets.”</span></p>
<p>The post <a href="https://www.expresspharma.in/nusynth-to-build-chemical-process-innovation-platform-with-new-capital/">NuSynth to build chemical process innovation platform with new capital</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Zydus, Formycon’s Keytruda biosimilar FYB206 accepted for USFDA review</title>
<link>https://edusehat.com/en/zydus-formycons-keytruda-biosimilar-fyb206-accepted-for-usfda-review</link>
<guid>https://edusehat.com/en/zydus-formycons-keytruda-biosimilar-fyb206-accepted-for-usfda-review</guid>
<description><![CDATA[ 
The BLA was submitted in Q3 2026, with a regulatory decision potentially expected in Q3 2027
The post Zydus, Formycon’s Keytruda biosimilar FYB206 accepted for USFDA review appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 13 Oct 2026 12:00:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Zydus, Formycon’s, Keytruda, biosimilar, FYB206, accepted, for, USFDA, review</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>Zydus Lifesciences (Zydus) and Formycon AG (Formycon) have announced that the US Food and Drug Administration (USFDA) has accepted for review the Biologics License Application (BLA) for FYB206, a proposed biosimilar to Keytruda (pembrolizumab).</span></p>
<p><span>According to the companies, this is the first publicly announced acceptance by the USFDA of an application for a Keytruda biosimilar, to the best of their knowledge.</span></p>
<p><span>The BLA was submitted in the third quarter of 2026. Under the Biosimilar User Fee Amendments (BsUFA), the USFDA aims to complete its review within 12 months of submission, comprising up to 60 days for the filing review and 10 months for the substantive review. Based on this timeline, a decision could be expected in the third quarter of 2027.</span></p>
<p><span>The regulatory dossier for FYB206 has also been submitted to Health Canada.</span></p>
<p><span>Dr Sharvil P Patel, Managing Director of Zydus Lifesciences, said, “Acceptance of the application marks a significant step toward expanding access to affordable pembrolizumab therapy in the U.S. and Canada. As demand for high-quality, accessible oncology treatments continues to rise, FYB206 has the potential to improve patient access and outcomes while strengthening our oncology biosimilars portfolio. Leveraging the biologics expertise of Formycon and our established oncology platform in North America, we remain focused on delivering meaningful value to patients.”</span></p>
<p><span>Dr Stefan Glombitza, CEO of Formycon AG, said, “With the FDA’s acceptance of the FYB206 application for review, we are among the very first companies to advance a biosimilar to the world’s bestselling biologic medicine to this stage. We developed FYB206 on a path agreed with the FDA, without conducting a comparative Phase III efficacy trial. This enabled us to accelerate the program and substantially reduce development investment while maintaining the rigorous scientific standards required for biosimilar approval. With Zydus, we have a partner with strong commercial capabilities and a clear oncology strategy in the US and Canada. Together, we aim to make this important cancer therapy accessible to more patients.”</span></p>
<p><span>Pembrolizumab is an immune checkpoint inhibitor that binds to and blocks the PD-1 receptor and is used to treat numerous types of cancer.</span></p>
<p><span>In 2025, worldwide sales of Keytruda, including the subcutaneous formulation Keytruda Qlex, reached USD 31.7 billion. In the first half of 2026, combined sales of Keytruda and Keytruda Qlex totalled USD 16.40 billion. Keytruda therefore remains the world’s bestselling biologic medicine.</span></p>
<p><span>In February 2025, Formycon agreed with the USFDA that FYB206 does not require a comparative Phase III efficacy trial. In December 2025, Formycon and Zydus entered into an exclusive licensing and supply agreement for FYB206 in the United States and Canada.</span></p>
<p><span>Under the agreement, Formycon is responsible for completing development, preparing and filing the regulatory dossiers, and supplying the product. With the USFDA’s acceptance of the BLA for review, Formycon has reached a regulatory milestone under the agreement that entitles it to a milestone payment from Zydus.</span></p>
<p><span>Zydus will commercialise FYB206 in both markets, subject to regulatory approval and the resolution of any intellectual property issues. Formycon holds the global rights to FYB206 and will participate in the gross profits of its commercialisation partners.</span></p>
<p>The post <a href="https://www.expresspharma.in/zydus-formycons-keytruda-biosimilar-fyb206-accepted-for-usfda-review/">Zydus, Formycon’s Keytruda biosimilar FYB206 accepted for USFDA review</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>FDA approves Asahi Kasei’s Hovilpri for refractory HSV</title>
<link>https://edusehat.com/en/fda-approves-asahi-kaseis-hovilpri-for-refractory-hsv</link>
<guid>https://edusehat.com/en/fda-approves-asahi-kaseis-hovilpri-for-refractory-hsv</guid>
<description><![CDATA[ This oral medication is indicated for patients whose infections do not respond, with or without documented resistance, to standard antiviral therapies including acyclovir, famciclovir, or valacyclovir. The company 
The post FDA approves Asahi Kasei’s Hovilpri for refractory HSV appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/10/PT-2-12-10-2026-entrance.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 12 Oct 2026 18:05:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>FDA, approves, Asahi, Kasei’s, Hovilpri, for, refractory, HSV</media:keywords>
<content:encoded><![CDATA[<p>This oral medication is indicated for patients whose infections do not respond, with or without documented resistance, to standard antiviral therapies including acyclovir, famciclovir, or valacyclovir.</p>
<p>The company anticipates that the medicine will become available in the US before this year end.</p>
<p>The regulatory decision followed findings from PRIOH-1 Part C, an open-label, comparator-controlled Phase III superiority trial involving 101 immunocompromised adults.</p>
<p>Patients received either pritelivir or Investigator’s Choice therapy consisting of cidofovir, foscarnet, or imiquimod.</p>
<p>By day 28, complete lesion healing occurred in 63% of patients receiving Hovilpri compared with 34% on Investigator’s Choice, representing an adjusted treatment difference of 28.4%.</p>
<p>By Day 42, response rates reached 82% and 42%, respectively, an adjusted difference of 40.0%.</p>
<p>Safety findings from the trial showed adverse reactions in 22% of pritelivir recipients against 54% in the comparator arm. Discontinuations due to adverse drug reactions occurred in 2% of the Hovilpri cohort versus 20% receiving Investigator’s Choice.</p>
<p>Headache was the most frequent adverse reaction, reported in 6% of HOVILPRI patients and 4% of those receiving Investigator’s Choice.</p>
<p>Asahi Kasei Therapeutics US and Europe CEO Stacy Wheeler said: “Today’s approval delivers the first FDA-approved treatment for refractory mucocutaneous HSV lesions with a novel mechanism of action in nearly 30 years and marks an important advancement for immunocompromised adults.</p>
<p>“Hovilpri offers a new oral treatment option for adult patients with a persistent, difficult-to-treat disease.”</p>
<p>Unlike nucleoside analogues that require viral thymidine kinase enzyme activation, Hovilpri operates as a helicase-primase inhibitor active against both HSV-1 and HSV-2 strains, including those resistant to nucleoside analogues and foscarnet.</p>
<p>The therapy was originated by AiCuris Anti-infective Cures, now part of Asahi Kasei Therapeutics, the global specialty pharmaceutical unit of Tokyo-headquartered Asahi Kasei.</p>
<p>HSV is an incurable, lifelong infection that can cause severe, prolonged complications in immunocompromised people, including transplant recipients, cancer patients, and those living with HIV.</p>
<p>Earlier this month, Asahi Kasei signed a definitive agreement to acquire all issued shares of German-based Aicuris Anti-infective Cures for approximately $920.7m.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/fda-asahi-kaseis-hovilpri-hsv/">FDA approves Asahi Kasei’s Hovilpri for refractory HSV</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Perceptive, Nucleus partner to support radiopharmaceutical development</title>
<link>https://edusehat.com/en/perceptive-nucleus-partner-to-support-radiopharmaceutical-development</link>
<guid>https://edusehat.com/en/perceptive-nucleus-partner-to-support-radiopharmaceutical-development</guid>
<description><![CDATA[ Under the terms of the agreement, the two companies will direct qualified customer opportunities to the other across the development pipeline. A joint governance structure will oversee the 
The post Perceptive, Nucleus partner to support radiopharmaceutical development appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/10/PT-12-10-2026-shutterstock_1268263645.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 12 Oct 2026 18:05:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Perceptive, Nucleus, partner, support, radiopharmaceutical, development</media:keywords>
<content:encoded><![CDATA[<p>Under the terms of the agreement, the two companies will direct qualified customer opportunities to the other across the development pipeline.</p>
<p>A joint governance structure will oversee the collaboration.</p>
<p>Both entities will maintain independent operations, ensuring customer choice is retained. Over time, the companies plan to evaluate operational performance and broaden the remit of the partnership according to customer demand.</p>
<p>The collaboration aims to address common development obstacles, focusing on minimising the time, cost, and operational friction that programmes face when transitioning between preclinical imaging and good manufacturing practice (GMP) processes.</p>
<p>For Perceptive Discovery, the collaboration establishes an aligned route toward clinical-scale radiopharmaceutical manufacturing.</p>
<p>Imaging-derived dosimetry and biodistribution metrics support radioligand candidate selection as well as first-in-human trial planning, and structured coordination ensures scientific continuity as programmes progress.</p>
<p>Nucleus RadioPharma CEO Stephen Hahn said: “Discovery to Dose is more than a handoff between companies. It is an integrated pathway designed to move promising radiopharmaceuticals from early science to patients faster, with manufacturability and scale considered from the beginning.</p>
<p>“By connecting Perceptive Discovery’s preclinical imaging leadership with our clinical and commercial manufacturing capabilities, we are giving our shared customers a clearer, faster route from target to clinic – and ultimately helping important new therapies reach patients sooner.”</p>
<p>Nucleus RadioPharma operates as a contract development and manufacturing organisation specialising in targeted radiotherapies.</p>
<p>Its technical capabilities include GMP radiolabelling, process development, formulation and analytical development, regulatory and quality documentation, and clinical and commercial drug product supply, alongside a specialised isotope supply chain.</p>
<p>Perceptive Discovery functions as a preclinical and translational research organisation backing work in oncology, central nervous system therapies, and radiopharmaceuticals.</p>
<p>The company conducts preclinical modelling, radiochemistry, biodistribution, molecular imaging, quantitative analysis, dosimetry, and in vitro and in vivo studies to help sponsors resolve development difficulties and select clinical candidates.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/perceptive-nucleus-support-radiopharmaceutical-development/">Perceptive, Nucleus partner to support radiopharmaceutical development</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Cohance Lifesciences appoints Abhimanyu Ojha as CFO</title>
<link>https://edusehat.com/en/cohance-lifesciences-appoints-abhimanyu-ojha-as-cfo</link>
<guid>https://edusehat.com/en/cohance-lifesciences-appoints-abhimanyu-ojha-as-cfo</guid>
<description><![CDATA[ 
Ojha joins as Chief Financial Officer and Key Managerial Personnel, effective October 12, 2026
The post Cohance Lifesciences appoints Abhimanyu Ojha as CFO appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/12140724/EP_Abhimanyu_Ojha_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 12 Oct 2026 18:05:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Cohance, Lifesciences, appoints, Abhimanyu, Ojha, CFO</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/12140724/EP_Abhimanyu_Ojha_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/12140724/EP_Abhimanyu_Ojha_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/12140724/EP_Abhimanyu_Ojha_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Cohance Lifesciences, a technology-driven, integrated contract development and manufacturing organisation (CDMO), has announced the appointment of Abhimanyu Ojha as Chief Financial Officer (CFO) and Key Managerial Personnel, effective October 12, 2026.</span></p>
<p><span>Ojha brings over two decades of experience in finance leadership across multinational healthcare and pharmaceutical companies. Most recently, he served as Global CFO and President Finance at Intas Pharmaceuticals, where he led global finance teams spanning business operations, manufacturing, research and development, accounting, treasury, audit, taxation, corporate finance and financial planning and analysis (FP&A).</span></p>
<p><span>Earlier in his career, Ojha held leadership positions at Viatris, Mylan, Sun Pharmaceuticals and Ranbaxy Laboratories, working with business and functional leaders across geographies.</span></p>
<p><span>His experience spans financial strategy, business partnering, corporate governance, mergers and acquisitions, treasury, taxation, risk management and operational excellence. He has also built and led global finance teams, partnering with executive leadership, boards, investors and business leaders on strategic decision-making and business performance.</span></p>
<p>The post <a href="https://www.expresspharma.in/cohance-lifesciences-appoints-abhimanyu-ojha-as-cfo/">Cohance Lifesciences appoints Abhimanyu Ojha as CFO</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>TDB approves ₹86 crore RDI support for Peptris’ AI&#45;driven drug development</title>
<link>https://edusehat.com/en/tdb-approves-86-crore-rdi-support-for-peptris-ai-driven-drug-development</link>
<guid>https://edusehat.com/en/tdb-approves-86-crore-rdi-support-for-peptris-ai-driven-drug-development</guid>
<description><![CDATA[ 
The VIGOR programme will advance four drug candidates from TRL-4 to TRL-6 over three years, covering preclinical development and preparation for clinical trials
The post TDB approves ₹86 crore RDI support for Peptris’ AI-driven drug development appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 12 Oct 2026 18:05:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>TDB, approves, ₹86, crore, RDI, support, for, Peptris’, AI-driven, drug, development</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>The Technology Development Board (TDB), Department of Science & Technology (DST), Government of India, has signed an agreement with Peptris Technologies, Bengaluru, Karnataka, for financial support of ₹86 crore under the Research Development and Innovation (RDI) Fund.</span></p>
<p><span>The project, titled VIGOR: Advancing AI-Discovered Molecules from Bench to Clinic, has a total project cost of ₹172 crore. It aims to advance four drug candidates from Technology Readiness Level (TRL)-4 to TRL-6 through preclinical development, validation and preparation for clinical trials. The financial support will be provided through Optionally Convertible Debt (OCD).</span></p>
<p><span>Artificial intelligence is being used in drug discovery to identify molecules, investigate disease mechanisms and support the search for potential therapies. Translating computational discoveries into drug candidates requires experimental validation, preclinical studies and clinical development.</span></p>
<p><span>Peptris’ VIGOR programme aims to advance a portfolio of molecules towards clinical development using its proprietary AI-driven drug discovery platform. The programme focuses on therapeutic areas with unmet medical needs and combines computational capabilities, scientific validation and drug-development processes to identify and develop therapies.</span></p>
<p><span>The programme covers four drug candidates: PEPR111, targeting neuromuscular disorders and oncology; PEPRX101, focused on alopecia; PEPR202, targeting neuropathy; and PEPR112, focused on DMD. Each candidate is currently at TRL-4, with the project targeting advancement to TRL-6.</span></p>
<p><span>The development programme envisages a three-year progression covering advanced preclinical and investigational new drug (IND)-enabling studies, formulation development, clinical trial preparation and initiation activities, subject to the relevant scientific and regulatory requirements.</span></p>
<p><span>The VIGOR programme will build on Peptris’ AI-based drug discovery capabilities and existing platform experience to advance drug candidates. The approach combines AI-enabled discovery with drug-development expertise, including the use of global contract research organisation (CRO) networks to support development and validation.</span></p>
<p><span>By supporting the advancement of multiple candidates within a coordinated programme, the project aims to strengthen the translation of AI-led research into potential therapeutic products. Its focus on selected disease areas also reflects the opportunity to direct innovation towards conditions where treatment options remain limited.</span></p>
<p><span>Rajesh Kumar Pathak, Secretary, TDB, said, “The application of artificial intelligence in pharmaceutical research has the potential to transform how new drug candidates are identified and developed. However, translating promising discoveries into validated therapeutic candidates requires sustained investment, rigorous scientific evaluation and a structured development pathway. Through the RDI Fund, TDB is supporting such technology-intensive programmes to help bridge the gap between innovation and clinical development, while strengthening India’s capabilities in biotechnology, pharmaceuticals and AI-led healthcare innovation.”</span></p>
<p><span>A representative of Peptris Technologies said, “The support from TDB under the RDI Fund will help us advance our VIGOR programme and progress our AI-discovered molecules through critical preclinical development milestones. Our approach combines AI-driven discovery with experimental validation and established drug-development processes to address unmet medical needs. This partnership will support our efforts to translate promising computational discoveries into therapeutic candidates with the potential to progress towards clinical development.”</span></p>
<p>The post <a href="https://www.expresspharma.in/tdb-approves-%E2%82%B986-crore-rdi-support-for-peptris-ai-driven-drug-development/">TDB approves ₹86 crore RDI support for Peptris’ AI-driven drug development</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Akums develops moisturisation formulations for evolving skincare needs</title>
<link>https://edusehat.com/en/akums-develops-moisturisation-formulations-for-evolving-skincare-needs</link>
<guid>https://edusehat.com/en/akums-develops-moisturisation-formulations-for-evolving-skincare-needs</guid>
<description><![CDATA[ 
Akums Drugs &amp; Pharmaceuticals Ltd., a contract development and manufacturing organisation (CDMO), has introduced a portfolio of moisturisation formulations ahead of the winter skincare season. The formulations incorporate different ingredients […]
The post Akums develops moisturisation formulations for evolving skincare needs appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/12162444/New-Project.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 12 Oct 2026 18:05:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Akums, develops, moisturisation, formulations, for, evolving, skincare, needs</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/12162444/New-Project.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/12162444/New-Project.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/12162444/New-Project-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span><span><span>Akums Drugs & Pharmaceuticals Ltd., a contract development and manufacturing organisation (CDMO), has introduced a portfolio of moisturisation formulations ahead of the winter skincare season. The formulations incorporate different ingredients and approaches to hydration, skin-barrier care and targeted skincare.</span></span></span></p>
<p><span><span><span>Akums’ portfolio includes formulations incorporating ceramides, peptides, butters, minerals and other active ingredients. The range covers everyday hydration, intensive moisturisation, nourishment and barrier-focused care, as well as formulations developed for specific requirements such as acne-prone skin and uneven-looking skin tone.</span></span></span></p>
<p><span>“<span><span>Winter naturally brings moisturization into sharper focus, but the opportunity goes beyond a seasonal product cycle. Consumers are becoming more aware of ingredients and increasingly looking for products that serve a specific purpose. Our focus has therefore been on developing different formulation directions within an established category, while keeping the requirements of commercial manufacturing in view,” said Sanjeev Jain, Managing Director, AKUMS Drugs & Pharmaceuticals Ltd.</span></span></span></p>
<p><span><span><span>The development is part of Akums’ work across cosmetic, dermatology and topical manufacturing, alongside its pharmaceutical CDMO business. Its capabilities include product development across topical formulations, with scope to work on different ingredients, textures and formats for domestic and international markets.</span></span></span></p>
<p><span><span><span>Arushi Jain, Director, Akums Drugs & Pharmaceuticals Ltd., said, “Moisturisation is an established category, but there is still considerable scope to innovate through formulation, texture and ingredient selection. Consumers are increasingly looking for products that fit specific skincare routines rather than a single solution for everyone. This portfolio has been developed with that shift in mind, while keeping formulation feasibility and commercial scalability important to the development process.”</span></span></span></p>
<p><span><span><span>The formulations can be developed across different formats and textures depending on product requirements, intended use and market positioning. Their development also reflects the role of formulation choices and manufacturing feasibility in translating skincare concepts into commercial products.</span></span></span></p>
<p> </p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/akums-develops-moisturisation-formulations-for-evolving-skincare-needs/">Akums develops moisturisation formulations for evolving skincare needs</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Beyond US: New shores, new bets</title>
<link>https://edusehat.com/en/beyond-us-new-shores-new-bets</link>
<guid>https://edusehat.com/en/beyond-us-new-shores-new-bets</guid>
<description><![CDATA[ 
The US remains a key market for Indian pharma. But changing conditions are pushing India to diversify its global footprint. The core question is what should that footprint look like five years from now? 
The post Beyond US: New shores, new bets appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/12105627/EP_DigiMag_CS_Oct_2026_Ft_Image_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 12 Oct 2026 14:30:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Beyond, US:, New, shores, new, bets</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/12105627/EP_DigiMag_CS_Oct_2026_Ft_Image_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/12105627/EP_DigiMag_CS_Oct_2026_Ft_Image_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/12105627/EP_DigiMag_CS_Oct_2026_Ft_Image_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>For years, the story of Indian pharma and the US has been told through the lens of opportunity. However, as the terms of that relationship begin to shift, so too does the certainty around a market Indian pharma has long known. </span></p>
<p><span>The </span><i><span>American Dream</span></i><span>, once imported almost as freely as the products and ideas that helped build it, now sits rather awkwardly beside “</span><i><span>Make America Great Again</span></i><span>”. The change is not confined to rhetoric, with the much awaited India-US trade deal still being worked out and its fine print yet to be settled </span></p>
<p><span>So perhaps the question facing Indian pharma is not simply whether to look beyond the US, but which shores to reach next, how to make landfall, and how to build a business once there. </span></p>
<p><b>How exposed is Indian pharma to the US? </b></p>
<p><span>Before asking where Indian pharma can go next, it is worth establishing how much of its global business has been shaped by the US. </span></p>
<p><span>For decades, serving the US market has meant building capabilities around its regulatory requirements, manufacturing standards and commercial systems. Those capabilities have, in turn, travelled with Indian companies as they entered other markets. </span></p>
<p><span>Harish Jain, President, FOPE, points out that India’s pharma exports now span around 191 countries and are estimated at $32-33 billion in 2025-26. The US, however, accounts for around 45-55 per cent of the business of some leading Indian companies.</span></p>
<p><span>“The thing is, the market that made Indian pharma globally competitive may also be the market that exposes its geopolitical pricing and regulatory risk.” </span></p>
<p><span>That exposure is being tested by tariffs, localisation requirements and generic price erosion. However, the US relationship has also given Indian pharma an important advantage: experience and credibility in a closely regulated market. </span></p>
<p><span>And that is why, for Jain, exposure to the US is not a strategic risk in itself, but a position from which Indian pharma can diversify without withdrawing from the market. </span></p>
<p><span>Namit Joshi, Chairman, Pharmexcil, offers another reason why the US will remain central to this equation, by highlighting the scale of the ecosystem built around generic medicines. </span></p>
<p><span>“See, if you believe in the theory of assumptions, then it looks a very remote possibility that we will lose the total market share in US because to rebuild a sort of ecosystem for generic medicine manufacturing, I think a lot of investments goes into that particular segment.” </span></p>
<p><span>Uday Harle, CEO of Shilpa Biologicals, brings the same question to the level of products and future value pools. For him, diversification does not mean finding another market of the same scale as the US. </span></p>
<p><span>“I don’t think there is a single market that replaces the US. The bigger opportunity is a diversified global portfolio, particularly as the pharmaceutical value pool increasingly shifts towards biologics and other advanced therapies.” </span></p>
<p><span>The focus, therefore, shifts from replacing the US to understanding what other markets can offer, and what it takes for Indian pharma to build a sustainable presence in them. </span></p>
<p><img decoding="async" class="wp-image-459858 alignleft" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/12105622/EP_DigiMag_CS_Oct_2026_Inside_Image_01_1000.jpg" alt="" width="585" height="1095" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/12105622/EP_DigiMag_CS_Oct_2026_Inside_Image_01_1000.jpg 1000w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/12105622/EP_DigiMag_CS_Oct_2026_Inside_Image_01_1000-160x300.jpg 160w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/12105622/EP_DigiMag_CS_Oct_2026_Inside_Image_01_1000-547x1024.jpg 547w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/12105622/EP_DigiMag_CS_Oct_2026_Inside_Image_01_1000-768x1437.jpg 768w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/12105622/EP_DigiMag_CS_Oct_2026_Inside_Image_01_1000-821x1536.jpg 821w" sizes="(max-width: 585px) 100vw, 585px"></p>
<p><b>What makes a market worth entering? </b></p>
<p><span>If diversification is the direction, market size alone cannot determine where Indian pharma goes next. </span></p>
<p><span>For Archana Jatkar, Associate Secretary General, IPA, the starting point is the combination of patient need, commercial viability and regulatory predictability. A large market may offer scale, but that does not necessarily translate into a sustainable opportunity for an Indian company, particularly when pharma investments are made over long time horizons. </span></p>
<p><span>“Market size is one important consideration, but the focus is on how effectively Indian pharma company can address that opportunity and build a sustainable long-term presence.” </span></p>
<p><span>Regulatory access, pricing, reimbursement and competition therefore, become an important part of the assessment. So does the company’s own portfolio. Jatkar argues that companies need to examine where they have a genuine competitive advantage. </span></p>
<p><span>“We also need to assess where the Indian pharma has a genuine competitive advantage, right? Whether it is in generics, complex generics, are we good in APIs, biosimilars or what areas?” </span></p>
<p> </p>
<p><span>The difference between market size and actual export opportunity can be seen across geographies. Jatkar points to Europe and Africa as an example. </span></p>
<p><span>“If you look at Europe, it has a larger gross market in say this year of financial year 2026, while Africa generated higher net export earnings for India. It shows why market selection must go beyond the headline of market size.” </span></p>
<p><span>The criteria therefore extend beyond demand. A company has to assess whether its products fit the market, whether it can navigate its regulatory system and whether it has the commercial infrastructure to build a sustainable presence. </span></p>
<p><b>Beyond the familiar coast </b></p>
<p><span>That makes it difficult to identify one country as a replacement to the US. Europe offers scale but is fragmented across markets and pricing systems. Africa brings population and healthcare needs. ASEAN offers proximity and growing healthcare demand, while Latin America provides further diversification. The Middle East is linked to healthcare investment and localisation, while Japan presents a longer-term opportunity for companies prepared to meet its regulatory requirements. </span></p>
<p><span>“So, the point I’m trying to make is, these are different opportunities for the Indian industry, and I do not see choosing one upon the other,” concludes Jatkar.</span></p>
<p><span>The decision also depends on the company’s starting point. Dharmesh Kharwar, Joint Secretary, FPME; distinguishes between entering a new market and expanding an existing presence. Approvals, dossiers, infrastructure and reference country requirements can shape the regulatory pathway, while the commercial model depends on whether a company works through a distributor, importer, local partner or its own sales force. </span></p>
<p><span>For Jain, the focus should be on the Global South, particularly ASEAN, Africa and Latin America, with Brazil as a key market within the latter. </span></p>
<p><span>The opportunity, however, is not simply about competing on price. Jain argues that India’s experience in regulated markets has created credibility that can support a broader role. </span></p>
<p><span>“But they (other countries) are not looking for cheaper medicines. They are looking for reliable supply, regulatory credibility, as I said earlier, India has such an enormous amount of regulatory credibility due to US business, technology partnerships, and increasingly local manufacturing.” </span></p>
<p><span>Therefore as Jain highlights, “our next export strategy cannot be sell more generics to more countries, it has to be build deeper healthcare partnership with more countries.” </span></p>
<p><span>For Shilpa Biologicals, that portfolio already extends across Europe, Japan, Latin America, the GCC and Middle East, ASEAN, Australia, Canada and Africa. Harle points to healthcare modernisation in the GCC, increasing biologics adoption in Latin America and demand for advanced therapies across Asia, with partnerships already developing across these regions. </span></p>
<p><span>“So the opportunity beyond America is not theoretical — it is already developing,” he confirms. </span></p>
<p><img decoding="async" class="wp-image-459857 alignleft" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/12105616/EP_DigiMag_CS_Oct_2026_Inside_Image_02_1000.jpg" alt="" width="530" height="532" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/12105616/EP_DigiMag_CS_Oct_2026_Inside_Image_02_1000.jpg 1000w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/12105616/EP_DigiMag_CS_Oct_2026_Inside_Image_02_1000-300x300.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/12105616/EP_DigiMag_CS_Oct_2026_Inside_Image_02_1000-150x150.jpg 150w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/12105616/EP_DigiMag_CS_Oct_2026_Inside_Image_02_1000-768x771.jpg 768w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/12105616/EP_DigiMag_CS_Oct_2026_Inside_Image_02_1000-100x100.jpg 100w" sizes="(max-width: 530px) 100vw, 530px"></p>
<p><b>Diversification is already taking shape </b></p>
<p><span>The idea of a diversified portfolio is also visible in the experience of companies that have had to rebalance their export portfolios. Joshi points to the loss of US revenue alongside growth in other regions. </span></p>
<p><span>“Last year, we diversified basically because we lost approximately 1 billion of revenue from the US. There was a big growth of 9 per cent.” Latin America, particularly Brazil, was among the markets that recorded growth. </span></p>
<p><span>“But then parallelly, we have a double digit growth in certain Latin American market, in particular Brazil, I would say. We have grown by 17 to 21 per cent in all of Latin America. And particularly Brazil, if you talk, about 21 per cent growth, was registered.” </span></p>
<p><span>Europe remains another significant part of the export portfolio. </span></p>
<p><span>“And in parallel to Brazil, then Europe still stands tall as a partner. Approximately more than $6 billion of pharmaceuticals to Europe, and which is growing again with a rate of 14 per cent to 15 per cent.” Joshi adds.</span></p>
<p><span>He also points to the recovery of some African markets that had lost momentum. “Plus, certain African markets, which we lost to this issue of cough syrup, the trust was lost. I think we have regained all those markets and we see now a double digit growth in same continent where we were losing earlier.” </span></p>
<p><span>For Amit Patni, Co-founder and Chairman of Nirvana Venture Advisors and Founder of Raay Investments, whose company is building its international business, the approach is centred on markets where the route to entry and portfolio fit make sense rather than simply pursuing the largest markets. “In the international business as strategy, We aren’t chasing the biggest markets rather focusing on the emerging markets or some of them call it as ROW markets. Here we chase the ones where the registration pathway is fastest and where our therapeutic categories fill a real gap.” </span></p>
<p><span>His approach takes into account regulatory predictability, the quality of distribution partners, therapeutic gaps, currency and payment stability, and the structure of institutional purchasing. The broader strategy is to avoid replacing one concentration with another. </span></p>
<p><span>“As our growth strategy, We build a portfolio of markets the same way we build a therapeutic portfolio — so no single regulatory regime or currency bloc or trade barrier can take out our revenue base.” </span></p>
<p><span>But a portfolio of markets alone does not create a viable international business. Companies still need to convert that geographical spread into businesses that can sustain themselves. </span></p>
<p><b>From approval to business </b></p>
<p><span>For companies entering new markets, securing regulatory approval is only the beginning. Kharwar points to instances where companies have spent years registering products without achieving the sales they had expected. </span></p>
<p><span>“There are some examples where companies have spent, 24 to 36 months and even more on registrations, spend a lot of money trying to get their long list of portfolio products thinking these are niche therapies or mass therapies. But then there is absolutely actually no sales happening to the quantum of which there was expectation of.” </span></p>
<p><span>The issue, he argues, is treating market entry primarily as a regulatory exercise. Once approvals are secured, companies still need to decide who will lead the operation, how products will be priced, how much working capital is required and how the business will manage local credit cycles and tender dependence. </span></p>
<p><span>“The real solution lies in the capital allocation and the entire business planning post the registration and the approval of these products.” Kharwar estimates that the regulatory and quality component represents a smaller share of the overall commercial planning. </span></p>
<p><span>“So my thumb rule is that the regulatory part and the quality part is just about 20 per cent of your cost of that business planning. But 80 per cent would be actually sales, marketing, distribution and a credit cycle capital allocation.” </span></p>
<p><span>For younger companies, there is an additional hurdle: establishing trust before there is a track record. Patni highlights that, “For a young company, the barriers are less about product and business offerings but more about trust and infrastructure. Everyone wants to avoid to be a first customer.” </span></p>
<p><span>Patni’s approach is to build credibility through experienced international business development leadership and face-to-face engagement at trade shows, while positioning the company as ‘R&D-led, partner-executed’ rather than overstating the infrastructure it owns. </span></p>
<p><span>The financial equation also affects the pace of expansion. Registration fees, dossier licensing, samples and other market-entry costs begin accumulating before revenue starts flowing, while distributor payment cycles can extend for months. For a young company, that makes the choice of market and partner as important as the choice of product. </span></p>
<p><span>This also changes the role of partnerships. Joshi argues that geopolitical uncertainty makes operating in isolation less practical. “It’s the time of collaboration. And we need to know our capabilities, our differentiators and our benefits for the customer or a consumer.” </span></p>
<p><span>For Kharwar, that collaboration can extend beyond conventional distribution into local manufacturing, business set-ups and government-togovernment projects. </span></p>
<p><span>“The key should be that we should be the first preferred choice partner for any local manufacturing, any business setup, any innovation, as compared to anyone else.” </span></p>
<p><span>Jain predicts this shift in the Global South. Rather than reproducing the traditional model of manufacturing in India and selling through distributors, he argues that companies will increasingly need to work with local partners across functions. </span></p>
<p><span>“I think that we should be looking at this next business model is how we can partner on the technology side, how we can partner on the formulation development, regulatory capability, manufacturing, local partnership and overall, what we should be looking at is a long-term healthcare platform.” </span></p>
<p><span>The emerging model is therefore more complex than simply registering products in more countries. It involves choosing where to invest directly, where to work with partners and where Indian manufacturing and capabilities can be combined with local infrastructure. </span></p>
<p><b>The road to $120 billion </b></p>
<p><span>Five years from now, the measure of India’s global pharma footprint may not be how many markets it serves, but what it contributes to each of them. </span></p>
<p><span>The IPA has set a target of a $120 billion industry by 2030. Reaching it will require both continued generic volumes and greater participation in highervalue products and capabilities. Joshi sees both elements as necessary, with the next phase requiring a combination of volume and value. </span></p>
<p><span>While generic exports will continue to drive volumes, higher-value segments could provide the next source of growth. Kharwar sees particular potential in large molecules. “The number is not aspirational. It’s doable. And I would like to put it a little bit more granularly that I would say that the opportunity lies in the large molecules.” He states it confidently. </span></p>
<p><span>For Jatkar, the change is also about the role India plays in global healthcare. “Our aim is also to move from being a major supplier to being a trusted global partner, delivering quality and affordable medicines, someone who is driving innovation and keeping patient welfare at the centre.” </span></p>
<p><span>Overall, she distils the ambition into a simple operating principle: “These companies will have to understand locally and they will have to execute consistently. So think globally, understand locally and execute consistently.” </span></p>
<p> </p>
<p><strong>For an in-depth discussion on the future of Indian pharma exports and the strategic priorities shaping global market diversification, the full episode of the <em>Pharma Frontiers</em> podcast will be released shortly.</strong></p>
<p> </p>
<p> </p>
<p><b><i>neha.aathavale@expressindia.com</i></b></p>
<p><b><i>nehaaathavale75@gmail.com</i></b></p>
<p>The post <a href="https://www.expresspharma.in/beyond-us-new-shores-new-bets/">Beyond US: New shores, new bets</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Bio&#45;Techne opens GMP small molecule facility in Bristol, UK</title>
<link>https://edusehat.com/en/bio-techne-opens-gmp-small-molecule-facility-in-bristol-uk</link>
<guid>https://edusehat.com/en/bio-techne-opens-gmp-small-molecule-facility-in-bristol-uk</guid>
<description><![CDATA[ The purpose-built 10,000ft² site is fully operational and produces materials to support developers working on cell therapies globally. The facility features two International Organization for Standardization-7 (ISO-7) cleanrooms 
The post Bio-Techne opens GMP small molecule facility in Bristol, UK appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/10/PT-2-09-10-2026-shutterstock_2214557877.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 09 Oct 2026 20:35:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Bio-Techne, opens, GMP, small, molecule, facility, Bristol</media:keywords>
<content:encoded><![CDATA[<p>The purpose-built 10,000ft² site is fully operational and produces materials to support developers working on cell therapies globally.</p>
<p>The facility features two International Organization for Standardization-7 (ISO-7) cleanrooms alongside five ISO-8 multifunctional cleanrooms for GMP small molecule production and material handling.</p>
<p>It was established to help developers address industry-wide production challenges, including the need to standardise workflows, reduce batch variability, and scale output from initial research through to commercialisation while complying with evolving regulatory expectations.</p>
<p>Industry discussions have increasingly pointed to manufacturing scalability as a central requirement for broadening patient access to advanced cell therapies.</p>
<p>Bio-Techne president and CEO Kim Kelderman said: “As the cell therapy field continues to mature, success increasingly depends on the ability to manufacture therapies consistently and at scale.</p>
<p>“Our investment in Bristol demonstrates Bio-Techne’s commitment to providing customers with the GMP materials, manufacturing expertise, and supply chain reliability needed to accelerate development and ultimately bring transformative therapies to patients worldwide.”</p>
<p>The Bristol site expands the company’s manufacturing operations across the UK and the US. Bio-Techne also operates recombinant protein production in Minneapolis, Minnesota, alongside GMP facilities in St Paul.</p>
<p>In conjunction with cell culture device maker Wilson Wolf Corporation, developer of the G-Rex platform, Bio-Techne supplies analytical solutions, custom manufacturing services, GMP cell media, proteins, small molecules, and process development support across the cell therapy workflow.</p>
<p>Headquartered in Minnesota, Bio-Techne operates across 34 locations worldwide and employs over 3,000 people.</p>
<p>During fiscal year 2025, the company generated net sales exceeding $1.2bn.</p>
<p>It supplies biopharmaceutical companies, academic researchers, clinical diagnostic laboratories, and biotechnology firms with over 500,000 products across three commercial divisions: Bio-Techne Diagnostics, Bio-Techne Spatial, and R&D Systems.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/bio-techne-gmp-small-molecule-facility-uk/">Bio-Techne opens GMP small molecule facility in Bristol, UK</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Biohaven partners with Ono in $100m IgG degrader deal</title>
<link>https://edusehat.com/en/biohaven-partners-with-ono-in-100m-igg-degrader-deal</link>
<guid>https://edusehat.com/en/biohaven-partners-with-ono-in-100m-igg-degrader-deal</guid>
<description><![CDATA[ The transaction grants Ono exclusive development and commercialisation rights for drug candidates BHV-1300, BHV-1310, and BHV-1320 across the Association of Southeast Asian Nations (ASEAN) countries, Taiwan, South Korea, 
The post Biohaven partners with Ono in $100m IgG degrader deal appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/10/PT-09-10-2026-shutterstock_1894467382.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 09 Oct 2026 17:00:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Biohaven, partners, with, Ono, 100m, IgG, degrader, deal</media:keywords>
<content:encoded><![CDATA[<p>The transaction grants Ono exclusive development and commercialisation rights for drug candidates BHV-1300, BHV-1310, and BHV-1320 across the Association of Southeast Asian Nations (ASEAN) countries, Taiwan, South Korea, and Japan.</p>
<p>The financial consideration includes an initial payment of $80m at closing alongside a $20m milestone payment anticipated within 12 months.</p>
<p>Biohaven is also eligible to receive royalties of around 20% on net product sales generated within the licensed territory.</p>
<p>The company retains all rights to the MoDE IgG degrader assets across all other international markets, including China, Europe, and the US.</p>
<p>The partnered assets target IgG-mediated autoimmune disorders. The principal candidate, BHV-1300, is an investigational small-molecule degrader currently under evaluation in a pivotal Phase III clinical study for Graves’ disease.</p>
<p>In ongoing Phase I testing administered subcutaneously, the compound achieved reductions in total IgG of up to 87% while sparing IgG3. The agreement also incorporates next-generation follow-on degraders BHV-1310 and BHV-1320.</p>
<p>Biohaven chairman and CEO Vlad Coric said: “Ono will be the ideal partner to bring this innovative immune-modulating technology to patients across Japan and key Asian markets.</p>
<p>“This is the first regional collaboration for an extracellular protein degrader, and it validates a platform that began with pioneering chemistry from the Spiegel Lab at Yale University and now spans a broad and diverse portfolio of MoDE and TRAP degraders.</p>
<p>“Few companies in the world can match Ono’s innovation in drug development or its demonstrated ability to translate breakthrough science into transformative therapies, as it did in helping to define modern cancer immunotherapy. We are excited for an outstanding collaboration to accelerate new therapeutics to patients.”</p>
<p>The underlying MoDE degrader platform originated from scientific research at Yale University. For this transaction, J.P. Morgan Securities acted as exclusive financial advisor to Biohaven, and Sullivan & Cromwell served as legal advisor.</p>
<p>In April 2025, Biohaven secured a funding deal worth up to $600m from Oberland Capital Management, providing the biotech with non-dilutive capital as it prepares for a potential US launch of troriluzole for spinocerebellar ataxia (SCA).</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/biohaven-ono-100m-igg-degrader-deal/">Biohaven partners with Ono in $100m IgG degrader deal</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Lupin receives USFDA approval for Phytonadione Injectable Emulsion</title>
<link>https://edusehat.com/en/lupin-receives-usfda-approval-for-phytonadione-injectable-emulsion</link>
<guid>https://edusehat.com/en/lupin-receives-usfda-approval-for-phytonadione-injectable-emulsion</guid>
<description><![CDATA[ 
The product is indicated for the treatment and prophylaxis of hypoprothrombinemia and vitamin K deficiency
The post Lupin receives USFDA approval for Phytonadione Injectable Emulsion appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 09 Oct 2026 17:00:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Lupin, receives, USFDA, approval, for, Phytonadione, Injectable, Emulsion</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Lupin has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Phytonadione Injectable Emulsion USP, 1 mg/0.5 mL Single-dose Prefilled Syringe.</span></p>
<p><span>The USFDA has approved Lupin’s Phytonadione Injectable Emulsion USP, 1 mg/0.5 mL Single-dose Prefilled Syringe as bioequivalent to the reference listed drug (RLD), Phytonadione Injectable Emulsion, 1 mg/0.5 mL, of International Medication Systems, Limited.</span></p>
<p><span>The product is indicated for the treatment and prophylaxis of hypoprothrombinemia (low blood clotting) and vitamin K deficiency.</span></p>
<p><span>According to IQVIA MAT August 2026 data, Phytonadione Injectable Emulsion had estimated annual sales of USD 52.3 million in the US.</span></p>
<p>The post <a href="https://www.expresspharma.in/lupin-receives-usfda-approval-for-phytonadione-injectable-emulsion/">Lupin receives USFDA approval for Phytonadione Injectable Emulsion</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Government caps margins on cancer medicines at 30%, targets ₹2,500 Cr annual savings</title>
<link>https://edusehat.com/en/government-caps-margins-on-cancer-medicines-at-30-targets-2500-cr-annual-savings</link>
<guid>https://edusehat.com/en/government-caps-margins-on-cancer-medicines-at-30-targets-2500-cr-annual-savings</guid>
<description><![CDATA[ 
The price control measure covers non-scheduled anti-cancer drugs and aims to reduce medicine prices by up to 70%
The post Government caps margins on cancer medicines at 30%, targets ₹2,500 Cr annual savings appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 09 Oct 2026 17:00:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Government, caps, margins, cancer, medicines, 30, targets, ₹2, 500, annual, savings</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>The Government has approved a cap on trade margins charged in the supply and sale of non-scheduled anti-cancer drugs at 30 per cent of the Maximum Retail Price (MRP). The measure is expected to reduce medicine prices by up to 70 per cent and help cancer patients save ₹2,500 crore annually.</span></p>
<p><span>Essential cancer medicines included in the scheduled list are already subject to government-set ceiling prices. The new decision extends price protection to non-scheduled cancer medicines, which fall outside the list, by limiting the margins added before the medicines reach patients.</span></p>
<p><span>An expert committee under the Directorate General of Health Services (DGHS) will finalise the list of medicines to be covered. The National Pharmaceutical Pricing Authority (NPPA) will then take a decision and issue the notification.</span></p>
<p><span>Cancer incidence in India is rising, with approximately 60 people per one lakh population affected by the disease. Treatment places a financial burden on patients and their families, who often have to pay substantial amounts from their own pockets.</span></p>
<p><span>NPPA’s analysis of market data found that non-scheduled anti-cancer medicines carry an average price mark-up of approximately 170 per cent, reaching 700 per cent or more in some cases. The price increases as medicines move through the supply chain before reaching patients.</span></p>
<p><span>Prices also vary depending on whether medicines are purchased from a retail pharmacy, a hospital pharmacy or an online pharmacy.</span></p>
<p><span>State authorities, including those in Maharashtra, Rajasthan and Karnataka, along with patients and civil society, have raised concerns about medicine prices. These concerns have also been voiced on public platforms, particularly regarding the gap between the price at which medicines are purchased for sale and the MRP charged to consumers.</span></p>
<p><span>The Government said the margin cap will curb excessive profiteering, address unfair pricing practices in the market and help ensure fairer prices for patients.</span></p>
<p><span>In February 2019, on the Government’s direction, NPPA capped trade margins on 42 selected non-scheduled anti-cancer drugs under Paragraph 19 of the Drugs (Prices Control) Order, 2013.</span></p>
<p><span>The decision reduced MRPs by up to 91 per cent, with reported annual savings of ₹984 crore across 526 brands. It reduced the financial burden on cancer patients and improved their ease of living.</span></p>
<p><span>Building on that experience and addressing pricing issues identified in the supply chain, the Government has now approved the wider cap. The expected annual savings of ₹2,500 crore are intended to provide further relief to patients undergoing cancer treatment.</span></p>
<p><span>To ensure the continued availability of these medicines, manufacturers of non-scheduled anti-cancer drugs will be required to maintain their current production levels.</span></p>
<p><span>The intervention will cover non-scheduled anti-cancer medicines across categories, including branded and generic, domestically produced and imported, and patented and non-patented medicines. The measure aims to enable patients to benefit from lower prices while ensuring the continued availability of the medicines they need.</span></p>
<p><span>Commenting on the Government’s Trade Margin Rationalisation (TMR) announcement, Mr Anil Matai, Director General, OPPI, said:</span></p>
<blockquote><p><i><span>“OPPI welcomes the Government’s Trade Margin Rationalisation (TMR) initiative aimed at improving the affordability and accessibility of cancer medicines for patients across India. We support measures that help reduce the treatment burden on patients while ensuring continued access to quality therapies. We believe that improving patient outcomes requires sustained collaboration among government, industry and other stakeholders. As the implementation progresses, it will be important to maintain a balanced and predictable environment that supports patient access, healthcare system sustainability and the continued introduction of innovative treatments. OPPI remains committed to working with all stakeholders towards the shared goal of advancing patient-centric healthcare in India.”</span></i></p></blockquote>
<p>The post <a href="https://www.expresspharma.in/government-caps-margins-on-cancer-medicines-at-30-targets-%E2%82%B92500-cr-annual-savings/">Government caps margins on cancer medicines at 30%, targets ₹2,500 Cr annual savings</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Beyond cost what will shape India’s pharma competitiveness?</title>
<link>https://edusehat.com/en/beyond-cost-what-will-shape-indias-pharma-competitiveness</link>
<guid>https://edusehat.com/en/beyond-cost-what-will-shape-indias-pharma-competitiveness</guid>
<description><![CDATA[ 
Christoph Funke, Chief Technical Operations Officer, Lupin, explains why India’s pharma industry needs to look beyond its cost advantage. He outlines how manufacturing intelligence, supply-chain resilience and stronger capabilities can help the industry compete in complex products and higher-value segments. In an exclusive interview with Lakshmipriya Nair 
The post Beyond cost what will shape India’s pharma competitiveness? appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/09110727/EP_Christoph_Funke_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 09 Oct 2026 13:25:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Beyond, cost, what, will, shape, India’s, pharma, competitiveness</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/09110727/EP_Christoph_Funke_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/09110727/EP_Christoph_Funke_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/09110727/EP_Christoph_Funke_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><b>Lupin is moving towards a fully integrated, technology enabled operations ecosystem. How is the integration of manufacturing, supply chain and procurement helping the company build greater agility and resilience in an increasingly volatile global environment? </b></p>
<p><span>The biggest change is that we no longer treat manufacturing, supply chain and procurement as separate functions. Under Global Technical Operations, we have brought Manufacturing, Supply Chain, Procurement, Engineering, Operational Excellence and EHS into one integrated operating model. This matters because some of the greatest opportunities to improve performance and efficiency lie at the interfaces between functions. By managing these interdependencies more effectively, we are able to improve throughput and resilience while making decisions across the value chain with a balanced focus on quality, service, compliance, cost and sustainability. This has helped us build a truly global operating model, allowing us to leverage capabilities, scale, best practices and insights across our network more effectively. </span></p>
<p><span>In today’s environment, supply chain resilience starts with de-risking. This includes reducing dependency on single sources, strengthening supplier diversification, enhancing strategic sourcing and investing in backward integration where it creates long-term value. We view our suppliers of products and services as long-term partners in value creation, and we invest in partnerships that enhance reliability, innovation and continuity across the supply chain. </span></p>
<p><span>Technology is the connective tissue that brings this model to life. Through digitalisation, automation and AI-enabled insights, we are improving visibility, accelerating decision-making and strengthening our ability to anticipate and respond to change. But technology creates value only when it improves outcomes for customers, patients and the business. Our focus is therefore not on technology for its own sake, but on applying it in ways that strengthen quality, service, resilience and performance. </span></p>
<p><span>Ultimately, resilience is engineered through the seamless integration of quality, technology, supply planning and people. This is how we strengthen throughput and ensure a dependable and uninterrupted flow of medicines to patients worldwide. </span></p>
<p><b>India has long competed on cost. From your experience across markets, is that advantage still enough? What will drive competitiveness over the next five years? </b></p>
<p><span>Affordability is fundamental to ensuring broad and equitable access to quality medicines. However, cost advantage alone is no longer sufficient to create sustainable differentiation. </span></p>
<p><span>Across global markets, success is increasingly being defined not just by scale and cost efficiency, but by quality, reliability, scientific excellence, innovation, technology adoption and speed of execution. </span></p>
<p><span>In my opinion, four factors will shape the next phase of growth for the industry. First is patient centricity. Every decision across the value chain, from procurement and manufacturing to supply chain and quality, must ultimately be guided by patient needs. Organisations that can consistently ensure quality, reliability and uninterrupted access to medicines will be best positioned to build trust and create long-term value.</span></p>
<p><span>Second is quality. As we often say, compliance is the license to operate, but quality is what differentiates an organisation over time. Regulators, customers and patients expect consistent, world-class standards. Organisations that anticipate regulatory and industry trends, rather than simply follow them, will be better positioned to participate in more complex and highervalue segments. </span></p>
<p><span>Third is innovation. As the industry evolves, long-term competitive advantage will depend on our ability to develop innovative solutions for complex healthcare challenges. Simply replicating what already exists is unlikely to create lasting value. The future will belong to organisations that can combine scientific expertise, technology and deep customer understanding to deliver differentiated products, processes and solutions.</span></p>
<p><span>Fourth is capability. As digitalisation, automation and AI redefine manufacturing and supply chains, lasting advantage will depend not on technology alone, but on how effectively it is combined with scientific expertise, process excellence and skilled talent. Technology is a means to an end; the real measure is the impact created for customers and patients. </span></p>
<p><span>For years, India’s cost competitiveness laid the foundation for its success as a global pharmaceutical manufacturing hub. The next phase of growth will be driven by our ability to deliver quality, innovation, reliability and advanced manufacturing at scale, particularly in complex generics, biologics, specialty medicines and emerging modalities. </span></p>
<p><b>The global pharma supply chain is being reshaped by geopolitics, China dependence and the push for local manufacturing. Where does this leave India? </b></p>
<p><span>Over the last two decades, India has built a strong reputation as a trusted supplier of high-quality medicines to patients around the world. At the same time, recent geopolitical developments have highlighted the importance of building greater resilience across supply networks, particularly for APIs and key starting materials. Today, there is a greater focus on reducing concentration risk and creating more diversified, reliable supply chains. </span></p>
<p><span>In this evolving landscape, India is well positioned to play a larger role. The country is already the world’s third largest pharmaceutical producer by volume, supplies nearly 50 per cent of all generic prescriptions dispensed in the United States, and is home to more than 750 US FDA-approved manufacturing facilities, the largest outside the United States. These strengths, combined with deep scientific talent, manufacturing scale and regulatory expertise, make India a natural partner for companies looking to build more diversified and resilient supply networks. </span></p>
<p><span>As a trusted supplier to patients worldwide, the industry must continue to raise the bar on quality, reliability, compliance and supply continuity while investing in the capabilities needed to support future healthcare needs. If India continues to strengthen these foundations, it can elevate its position as a global manufacturing hub to a strategic partner in innovation, manufacturing and supply reliability for the global pharmaceutical industry. </span></p>
<p><b>Resilience comes at a cost. How should pharma companies decide how much resilience they really need without losing their cost advantage? </b></p>
<p><span>Resilience should be a calibrated capability, not a blanket strategy. The right approach is to understand where risks truly exist, assess their potential impact on patients and business continuity, and invest accordingly. </span></p>
<p><span>At Lupin, we use a risk-segmented lens. For high volume, low-margin generics, cost efficiency remains the primary driver because patients depend on affordability. However, for critical therapies or products where we serve a large patient population and hold significant market share, the calculus changes. The higher the market share and the greater the potential impact on patients, the more deliberately we must focus on resilience. In such cases, the cost of a stockout or regulatory failure can far outweigh the cost of redundancy. </span></p>
<p><span>Data and technology allow us to build resilient supply networks in a targeted and efficient way. We use AI-driven risk modeling to map our supply chain end-to-end, identify genuine vulnerabilities and quantify actual exposure — investing in dual sourcing, safety stock or nearshoring only where risk justifies it, while optimising aggressively elsewhere. </span></p>
<p><span>The other lever is efficiency itself — automation, better yield management and leaner processes fund the resilience investments we need. The ultimate goal is to allocate resources where they can create the greatest impact, balancing affordability, supply reliability and patient needs in a disciplined and sustainable way. </span></p>
<p><b>Lupin and other Indian companies are moving into more complex products. What changes when you move from high-volume manufacturing to more complex, high-value manufacturing? </b></p>
<p><span>The model changes fundamentally. In traditional high-volume manufacturing, scale, standardisation and cost efficiency are the primary differentiators. In more complex products, success increasingly depends on scientific capability, deep process understanding, advanced technologies, manufacturing expertise and the ability to consistently meet stringent quality and regulatory standards. </span></p>
<p><span>Complex products also carry higher execution risk — longer development cycles, more demanding technology transfer, higher regulatory expectations, and manufacturing processes that require greater precision and control. This is why we’re investing deliberately across complex generics, injectables, inhalation therapies, biosimilars, peptides and specialty products. </span></p>
<p><span>The shift to complex, highvalue products is a shift from competing on efficiency alone to competing on capability. The organisations that succeed will be those that can consistently translate scientific innovation into highquality, differentiated therapies for patients at scale. </span></p>
<p><span>Success therefore depends on the ability to connect science, quality, digital capability, manufacturing expertise and talent within one integrated operating system. </span></p>
<p><b>Technology, AI and automation are changing manufacturing. Where do you see the biggest opportunity to create real business value, rather than simply improve efficiency? </b></p>
<p><span>Technology, AI, and automation have traditionally been viewed from the lens of efficiency, but their greatest value lies in enabling better decisions, agility, and resilience across manufacturing operations. </span></p>
<p><span>One of the most significant opportunities is in creating more predictive and proactive operations. By combining AI, advanced analytics and realtime manufacturing data, organisations can anticipate potential issues before they occur, whether that is equipment reliability, process variability or supply risks. The value extends beyond cost savings to improving quality, reliability and speed of execution. </span></p>
<p><span>Another important area is end-to-end visibility across the value chain. Manufacturing does not operate in isolation, and the ability to connect demand signals, production planning, inventory, procurement and logistics enables faster, more informed decision-making. </span></p>
<p><span>Technology also has the potential to accelerate innovation. Digital tools can improve process understanding, support smoother technology transfers and help bring new products to patients more efficiently. At the same time, particularly in a highly regulated industry like pharmaceuticals, technology adoption must be accompanied by strong governance, data integrity, transparency, clear accountability and appropriate human oversight. Ultimately, we do not get paid for technology itself; we get paid for the positive impact it helps us create for customers and patients. </span></p>
<p><b>You have managed large, multi-country operations. What is the biggest shift you see coming in pharma manufacturing in the way companies invest, operate or compete? </b></p>
<p><span>The biggest shift is that pharmaceutical manufacturing is moving from a scale-driven model to a capability-driven one. As products become more complex, supply chains more interconnected, and regulatory expectations more demanding, competitive advantage will increasingly depend on an organisation’s ability to combine scientific expertise, operational excellence, innovation and quality at scale. </span></p>
<p><span>Technology, automation and AI will undoubtedly reshape how companies operate, but technology alone does not create value. The real differentiator will be an organisation’s ability to translate these tools into better quality, greater agility, stronger resilience and improved outcomes for patients. In that sense, the industry is moving from an era of manufacturing efficiency to one of manufacturing intelligence. </span></p>
<p><span>India is uniquely positioned in this regard, with a deep pool of young, highly talented scientific, technical and engineering professionals. At Lupin, we believe strategy and capability building must go hand in hand. As we expand our focus on complex products, advanced manufacturing and digital technologies, we are equally committed to investing heavily in our talent pipeline, developing future-ready skills and building the leadership capabilities required for long-term growth. This requires one connected operating model in which strategy, capability building and execution reinforce one another. Sustainable performance is created when teams take shared ownership across functions and geographies, rather than optimising individual parts of the organisation in isolation. </span></p>
<p><span>In line with that vision, Lupin’s FY26 investments included capacity enhancement and debottlenecking, infrastructure modernisation, technology upgrades, automation and process efficiency. These investments are not simply about adding capacity; they are about strengthening capability, improving utilisation, enhancing supply reliability and supporting sustainable long-term performance. </span></p>
<p><b>Looking at India from both a local and global perspective, what is the one capability the industry must build now if it wants to remain a leading pharma manufacturing hub? </b></p>
<p><span>The one capability India must continue to build is the ability to combine manufacturing excellence with innovation. India’s opportunity lies not just in manufacturing medicines efficiently, but in becoming a partner of choice for complex products. </span></p>
<p><span>Innovation does not always mean inventing entirely new technologies. It is also about finding smarter ways to apply technology, science and data to solve complex challenges more effectively. As products, processes and supply chains become more sophisticated, the companies and countries that succeed will be those that can manage an important paradox: delivering greater complexity, quality and resilience while remaining competitive and affordable. </span></p>
<p><span>That requires an ecosystem, not a single intervention: investment in technology, process science, digital systems, regulatory capability, infrastructure and people, alongside stronger collaboration between industry, technology providers, academia, regulators and specialised talent. </span></p>
<p> </p>
<p><b><i>References: </i></b></p>
<p><span>https://static.pib.gov.in/WriteReadData/specificdocs/documents/2026/mar/doc2026321831401.pdf https://www.ibef.org/exports/ph armaceutical-exports-fromindia </span></p>
<p> </p>
<p><em><strong>lakshmipriya.nair@expressindia.com<br>
</strong></em></p>
<p><strong><em>laxmipriyanair@gmail.com</em></strong></p>
<p>The post <a href="https://www.expresspharma.in/beyond-cost-what-will-shape-indias-pharma-competitiveness/">Beyond cost what will shape India’s pharma competitiveness?</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Why industry&#45;academia collaboration will shape India’s next R&amp;amp;D chapter</title>
<link>https://edusehat.com/en/why-industry-academia-collaboration-will-shape-indias-next-rd-chapter</link>
<guid>https://edusehat.com/en/why-industry-academia-collaboration-will-shape-indias-next-rd-chapter</guid>
<description><![CDATA[ 
Suneela Thatte, VP &amp; Head, Merck Healthcare R&amp;D India in an exclusive conversation with Swati Rana, speaks about the skills the next generation of R&amp;D professionals will need, the role of universities and industry partnerships, and what India must do to strengthen its position in global healthcare innovation
The post Why industry-academia collaboration will shape India’s next R&amp;D chapter appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/01/14174257/EP_Suneela.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 09 Oct 2026 13:25:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Why, industry-academia, collaboration, will, shape, India’s, next, R&amp;D, chapter</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/01/14174257/EP_Suneela.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/01/14174257/EP_Suneela.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/01/14174257/EP_Suneela-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><b>India has traditionally been seen as a strong talent pool for the global pharmaceutical industry. What needs to change for India to become a stronger global hub for healthcare R&D and innovation? </b></p>
<p><span>Today, India is well established as a major global talent and capability hub. The number of global pharma and healthcare GCCs operating here, and the growing complexity of the work they bring, reflect that well. We are no longer contributing scale alone. We are increasingly contributing to the science, the thinking and the decisions that shape global healthcare R&D. </span></p>
<p><span>What needs attention now is depth. Two things can make a real difference. First, institutions such as the NIPERs must be strengthened as true centres of excellence, so that more advanced work in biologics, translational science and data-driven research finds a stronger home here within our ecosystem. Second, initiatives such as the Biopharma SHAKTI mission need sustained followthrough, because capability in specialised emerging science is built over years, not through one cycle of investment. </span></p>
<p><span>Alongside this, addressing supply chain dependencies, particularly around critical APIs, will be important for India to hold a more central role in global R&D. The foundation is in place. What matters now is consistent follow-through. </span></p>
<p><b>As pharmaceutical R&D becomes more complex and technology-driven, what new skills will the next generation of R&D professionals need? </b></p>
<p><span>Science is changing faster than any curriculum can keep up. Deep scientific grounding in biologics, genomics and translational research remains nonnegotiable, but it must now be complemented by fluency in computational biology, AIenabled analytics and digital tools that can compress timelines and improve probability of success. </span></p>
<p><span>This is not an either-or shift. Tomorrow’s breakthroughs will come from scientists who are comfortable with interpreting data and algorithms, and equally strong in understanding the science. They also need to collaborate across borders as the normal way of working. R&D today is continuous, not sequential. For example – Our teams here work on the same datasets and participate in the same decision-making forums as global counterparts. That requires confidence beyond execution: the ability to shape thinking, challenge assumptions and own outcomes.</span></p>
<p><b>What role should universities play in preparing students for areas such as clinical research, pharmacovigilance, regulatory affairs, data science and other emerging R&D functions? </b></p>
<p><span>Universities no doubt play a foundational role, but they need to move beyond teaching concepts alone and also teach context. A student can understand pharmacovigilance in theory, but real exposure shows how a safety signal is evaluated, documented and acted upon. That kind of applied understanding is difficult to build entirely within a classroom, which is why closer industry engagement is so important. </span></p>
<p><span>What universities can do well is build the foundation: strong scientific fundamentals, analytical thinking, and curiosity that stays sharp even as functions evolve. Where they truly add value is by inviting industry in early, through curricula that reflect real R&D functions, faculty who stay connected to practice, and structured collaborations that let students engage with live problems, not simulated ones. </span></p>
<p><span>The strongest outcomes happen when academia and industry design that exposure together. </span></p>
<p><b>How can stronger industry–academia partnerships help bridge this gap and make students more industry-ready? </b></p>
<p><span>Industry academia collaboration provides the students an opportunity to interact with and learn from seasoned professionals solving real R&D problems, in various R&D functions such as pharmacovigilance, medical writing, regulatory affairs, scientific communication etc. That shift changes how a student thinks, not just what they know. </span></p>
<p><span>This is why we have built Catalyst with a growing network of academic partners, including prestigious institutions such JSS Academy of Higher Education & Research (AHER), Dayananda Sagar University, Manipal Academy of Higher Education (MAHE), NITTE and NMIMS Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management (SPPSPTM). </span></p>
<p><span>The idea is simple: keep academic rigor intact but give students a chance to apply what they are learning against real industry expectations early enough that the gap between classroom and career starts to reduce.</span></p>
<p><span>Done well, these partnerships do not just prepare students for interviews. They prepare them to contribute from day one. Through Catalyst, we have already seen this play out: some of the students trained through the programme have gone on to join us and are doing exceptionally well. </span></p>
<p><b>Merck has partnered with eight academic institutions and launched the Catalyst programme in few of them. What are the learnings from these collaborations about the skills and expectations of today’s students? </b></p>
<p><span>Working with academic institutions through Catalyst has taught us a few important things about today’s students. What stands out first is scientific curiosity, and a genuine eagerness to work on problems that carry real world impact, not just theoretical ones. </span></p>
<p><span>What’s equally clear is that students are looking beyond technical knowledge. They want to build skills like problem-solving, collaboration, adaptability, and communication capabilities that matter as much as domain expertise in today’s innovation environment. </span></p>
<p><span>We have also seen that students respond best to experiences that are interactive and industry connected. Direct engagement with practitioners helps them understand not only possible career pathways, but also what the workplace actually expects from them in terms of problem-solving, collaboration, accountability and communication. </span></p>
<p><span>If there’s one thing these collaborations have reinforced, it’s this: academia-industry partnerships don’t just build skills, they build readiness and confidence for the professional roles ahead. </span></p>
<p><b>Beyond employability, can academia–industry collaboration help strengthen India’s overall innovation capacity? If so, what would a successful model look like? </b></p>
<p><span>Yes, and this is where the real potential lies. Employability is often the visible outcome, but the deeper value of these partnerships is in building research culture, curiosity, and problem solving ability that extends beyond any single job outcome. </span></p>
<p><span>A successful model is one where industry does not just guest lecture but co-designs the learning experience around real R&D problems. </span></p>
<p><span>When this becomes consistent, not episodic, universities start producing not just job-ready graduates, but young professionals who can think originally. That, over time, is what strengthens a country’s innovation capacity.</span></p>
<p><b>Looking ahead, what should industry, academia and policymakers do together to ensure that India has the talent needed for the next phase of pharmaceutical and healthcare R&D? </b></p>
<p><span>We are no longer dealing with talent availability alone; the bigger issue now is coordination. The pieces already exist: policy frameworks like Biopharma SHAKTI, institutions like the NIPERs, and industry programmes building earlycareer pipelines. What is missing is better alignment between them. In my experience, real progress happens when good ideas are connected into one system, instead of being left to work in separate lanes. </span></p>
<p><span>Policymakers need to treat talent infrastructure with the same urgency as R&D infrastructure. Academia needs to treat curriculum renewal as a continuous process, tied directly to where science and technology are moving. Industry needs to move from occasional engagement to sustained ownership of talent pipelines, not only at the point of recruitment, but much earlier in the learning journey. </span></p>
<p><span>The real shift happens when these three stakeholders stop working in parallel and start working to a shared timeline. We already have strong initiatives in place. What we need now is that they move together, with discipline, coordination and urgency.</span></p>
<p><span>If we get this right, the impact will not be limited to any one organisation or institution. It will show up in the quality of science we produce, in the confidence with which young researchers step into complex roles, and in how the world begins to see our ecosystem: not just as a place where healthcare R&D happens, but as a place where it is shaped. </span></p>
<p><b><i>swati.rana@expressindia.com </i></b></p>
<p><b><i>Swatirana.express@gmail.com </i></b></p>
<p>The post <a href="https://www.expresspharma.in/why-industry-academia-collaboration-will-shape-indias-next-rd-chapter/">Why industry-academia collaboration will shape India’s next R&D chapter</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>FDA approves Pfizer’s Tukysa regimen for metastatic breast cancer</title>
<link>https://edusehat.com/en/fda-approves-pfizers-tukysa-regimen-for-metastatic-breast-cancer</link>
<guid>https://edusehat.com/en/fda-approves-pfizers-tukysa-regimen-for-metastatic-breast-cancer</guid>
<description><![CDATA[ This regimen is indicated for adults with unresectable locally advanced or metastatic human epidermal growth factor 2-positive (HER2+) disease following induction treatment. The regulatory decision introduces an oral 
The post FDA approves Pfizer’s Tukysa regimen for metastatic breast cancer appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/10/PT-2-08-10-2026-shutterstock_2558537859.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 08 Oct 2026 19:25:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>FDA, approves, Pfizer’s, Tukysa, regimen, for, metastatic, breast, cancer</media:keywords>
<content:encoded><![CDATA[<p>This regimen is indicated for adults with unresectable locally advanced or metastatic human epidermal growth factor 2-positive (HER2+) disease following induction treatment.</p>
<p>The regulatory decision introduces an oral tyrosine kinase inhibitor to the frontline maintenance setting, providing a chemotherapy-free option intended to delay disease progression.</p>
<p>Regulatory clearance was based on findings from the double-blind, placebo-controlled Phase III HER2CLIMB-05 trial.</p>
<p>Investigators evaluated the three-drug combination against a regimen of pertuzumab, placebo, and trastuzumab in patients who showed no disease progression following taxane-based induction therapy.</p>
<p>In the trial, adding Tukysa lowered the risk of disease progression or death by 35.9% compared to the control arm.</p>
<p>Patients receiving the Tukysa regimen achieved a median investigator-assessed progression-free survival of 24.9 months, compared to 16.3 months for those receiving placebo, marking an 8.6-month extension.</p>
<p>Overall survival remains a key secondary endpoint.</p>
<p>Pfizer executive vice-president and US chief commercial officer Aamir Malik said: “Since its first approval in 2020, Tukysa has become an important treatment for patients with second-line HER2+ metastatic breast cancer.</p>
<p>“Today’s FDA approval marks the next chapter for Tukysa, bringing it into the front-line maintenance setting and offering patients a chemotherapy-free option that can help delay disease progression after initial treatment.</p>
<p>“This approval reflects Pfizer’s commitment to advancing therapies across the breast cancer treatment journey and delivering meaningful new options for people living with metastatic breast cancer.”</p>
<p>Adverse events reported in at least 20% of participants included, fatigue, diarrhoea musculoskeletal pain, hepatotoxicity, rash, vomiting, and nausea.</p>
<p>Hepatotoxicity occurred at higher severity than previously observed, though cases were largely asymptomatic and reversible via dose adjustments or treatment halts.</p>
<p>Serious adverse reactions involving hepatotoxicity occurred in 3.9% of patients, including one fatal case of drug-induced liver injury.</p>
<p>Tukysa previously gained US approval alongside capecitabine and trastuzumab for patients with pretreated HER2-positive metastatic disease, including those with brain metastases.</p>
<p>In August 2026, the European Medicines Agency (EMA) validated the marketing authorisation application (MAA) from Pfizer and Valneva for their Lyme disease vaccine candidate, PF-07307405.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/fda-pfizers-tukysa-metastatic-breast-cancer/">FDA approves Pfizer’s Tukysa regimen for metastatic breast cancer</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>10x Genomics and Fred Hutch partner on cancer technologies</title>
<link>https://edusehat.com/en/10x-genomics-and-fred-hutch-partner-on-cancer-technologies</link>
<guid>https://edusehat.com/en/10x-genomics-and-fred-hutch-partner-on-cancer-technologies</guid>
<description><![CDATA[ The initiative represents the first time 10x Genomics has widened its clinical research scope past solid tumours to include haematologic malignancies. Under the partnership, the organisations will carry 
The post 10x Genomics and Fred Hutch partner on cancer technologies appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/10/PT-08-10-2026-shutterstock_1924516355.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 08 Oct 2026 19:25:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>10x, Genomics, and, Fred, Hutch, partner, cancer, technologies</media:keywords>
<content:encoded><![CDATA[<p>The initiative represents the first time 10x Genomics has widened its clinical research scope past solid tumours to include haematologic malignancies.</p>
<p>Under the partnership, the organisations will carry out two studies to generate clinical evidence for oncology diagnostics.</p>
<p>One study centres on acute myeloid leukaemia to assess whether single cell analysis can enhance existing gold-standard methods for tracking residual disease.</p>
<p>Care teams currently depend on multiple separate tools to monitor remaining leukemic cells after treatment. For this investigation, researchers will employ the Flex Apex platform.</p>
<p>A second project focuses on advanced bladder cancer, analysing tissue from patients who received antibody-drug conjugates, immune checkpoint inhibitors, and other therapies.</p>
<p>It intends to link clinical outcomes and therapy responses with tumour microenvironment characteristics and drug target expression, with the aim of identifying biomarkers that assist oncologists in therapy selection.</p>
<p>The team will deploy the Flex Apex and Xenium platforms, with future plans to incorporate the Atera platform.</p>
<p>Fred Hutchinson Cancer Center Integrated Immunotherapy Research Center scientific director Lawrence Fong leads the collaboration and treats patients with bladder, kidney, and prostate cancers.</p>
<p>Fong said: “This project will help us better characterise the cellular and molecular responses to cancer treatments. We look forward to seeing how the results of this research could help guide treatment decisions for people with cancer.”</p>
<p>10x Genomics co-founder and CEO Serge Saxonov said: “Across cancer care, we have more effective therapies than ever, and too little insight into which patient will actually benefit from which one.</p>
<p>“Single cell and spatial biology let us look directly at the biology that drives treatment response, whether it’s in a tumour or in the blood, and we believe that’s the missing foundation for precision oncology. We’re excited to work with Fred Hutch on this research.”</p>
<p>Alongside a planned Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory, the programme supports future diagnostic uses in autoimmune disease and oncology.</p>
<p>Both groups also intend to establish guidelines for clinical reporting to define how spatial and single cell data can inform patient treatment plans.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/10x-genomics-fred-hutch-cancer-technologies/">10x Genomics and Fred Hutch partner on cancer technologies</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>ACG launches RecycloPod PP Ultra polypropylene blister packaging system</title>
<link>https://edusehat.com/en/acg-launches-recyclopod-pp-ultra-polypropylene-blister-packaging-system</link>
<guid>https://edusehat.com/en/acg-launches-recyclopod-pp-ultra-polypropylene-blister-packaging-system</guid>
<description><![CDATA[ 
The packaging system combines moisture and oxygen barrier protection with design for recyclability for pharmaceutical applications
The post ACG launches RecycloPod PP Ultra polypropylene blister packaging system appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 08 Oct 2026 15:50:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>ACG, launches, RecycloPod, Ultra, polypropylene, blister, packaging, system</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>ACG has launched RecycloPod PP Ultra, a polypropylene-based blister packaging system that combines moisture and oxygen barrier protection with design for recyclability.</span></p>
<p><span>The company identified a gap in the market where existing polypropylene blister solutions can meet moisture barrier requirements, while oxygen protection can remain a challenge. RecycloPod PP Ultra has been developed to address both requirements and provide a barrier solution for sensitive pharmaceutical formulations.</span></p>
<p><span>The launch also introduces ACG’s ‘Pod’ family of sustainable packaging solutions. Inspired by the way a pea pod protects what is inside, the range is designed with sustainability, future packaging needs and evolving regulatory requirements in mind.</span></p>
<p><span>Developed in collaboration with customers, RecycloPod PP Ultra uses a PP/EVOH/PP forming structure with a water vapour transmission rate of less than 0.60 g/m² per day and an oxygen transmission rate of less than 0.20 cm³/m² per day.</span></p>
<p><span>Used with a PP lidding film, the system creates a predominantly polypropylene blister structure designed for thermoforming and sealing on pharmaceutical packaging lines.</span></p>
<p><span>The development comes as manufacturers prepare for evolving requirements, including the EU Packaging and Packaging Waste Regulation (PPWR), and an increased focus on packaging recyclability.</span></p>
<p><span>Dr Akbar Ali, Head – Development & Technology at ACG Packaging Materials, said: “Pharmaceutical companies should not have to choose between protecting their product and progressing their packaging sustainability objectives.”</span></p>
<p><span>“With RecycloPod PP Ultra, our objective was to provide both high moisture and oxygen barrier protection while meeting the practical requirements of pharmaceutical manufacturing and supporting design for recyclability.”</span></p>
<p><span>SR Shivshankar CEO, ACG Packaging Materials, adds: “RecycloPod PP Ultra forms part of our wider sustainability strategy. We are participating in the Science Based Targets initiative (SBTi) as part of its net-zero ambitions and using digitalisation to support more efficient and sustainable manufacturing, with facilities recognised by the World Economic Forum’s Global Lighthouse Network.</span></p>
<p><span>At ACG, we also monitor more than 125 sustainability parameters through the framework underpinning our Sustainability Report.</span></p>
<p><span>Together with continued investment in packaging innovation, these initiatives reflect ACG’s focus on future readiness – helping both our own operations and pharmaceutical customers prepare for a lower-impact, increasingly circular manufacturing environment.”</span></p>
<p>The post <a href="https://www.expresspharma.in/acg-launches-recyclopod-pp-ultra-polypropylene-blister-packaging-system/">ACG launches RecycloPod PP Ultra polypropylene blister packaging system</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Pharma deal value falls 78.8% in September 2026: GlobalData</title>
<link>https://edusehat.com/en/pharma-deal-value-falls-788-in-september-2026-globaldata</link>
<guid>https://edusehat.com/en/pharma-deal-value-falls-788-in-september-2026-globaldata</guid>
<description><![CDATA[ 
Healthcare industry reported 85 deals worth $6.2 billion in September 2026, while VC funding increased by 21.6% to $4.2 billion
The post Pharma deal value falls 78.8% in September 2026: GlobalData appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2019/04/20161830/Swiss.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 08 Oct 2026 15:50:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Pharma, deal, value, falls, 78.8, September, 2026:, GlobalData</media:keywords>
<content:encoded><![CDATA[<div><img width="600" height="401" src="https://cdn.expresspharma.in/wp-content/uploads/2019/04/20161830/Swiss.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2019/04/20161830/Swiss.jpg 600w, https://cdn.expresspharma.in/wp-content/uploads/2019/04/20161830/Swiss-300x201.jpg 300w" sizes="(max-width: 600px) 100vw, 600px"></div><p class="isSelectedEnd">Deal value in the pharmaceuticals industry decreased by 78.8 per cent in September 2026 compared to September 2025, according to GlobalData.</p>
<p class="isSelectedEnd">In September 2026, the healthcare industry reported 85 deals worth $6.2 billion, compared to the last 12 months’ average of 90 deals worth $31.8 billion for the period from September 2025 to August 2026.</p>
<p class="isSelectedEnd">The three major deals reported in September 2026 were Telix Pharmaceuticals Limited’s acquisition of ITM Isotope Technologies Munich SE, a biotechnology company that develops and produces therapeutic and diagnostic radiopharmaceuticals and radioisotopes to treat cancer, for up to $2.3 billion; Puig’s acquisition of a 50 per cent stake in ISDIN SA, a pharmaceutical company that produces and distributes skin care products, for $1.39 billion; and GSK plc’s acquisition of a potential best-in-class trispecific T cell-engager (TCE) from Chimagen Biosciences Ltd, a clinical-stage biotechnology company focused on discovering and developing innovative multi-specific antibody therapeutics, for a total transaction value of up to $750 million.</p>
<p><strong>VC funding increases 21.6 per cent</strong></p>
<p class="isSelectedEnd">Venture capital funding increased by 21.6 per cent in September 2026 compared to September 2025.</p>
<p class="isSelectedEnd">The healthcare industry reported 124 venture capital (VC) deals worth $4.2 billion in September 2026, compared to the last 12 months’ average of 114 deals worth $3.4 billion for the period from September 2025 to August 2026.</p>
<p>The three major VC deals reported in September 2026 were Enveda Therapeutics Inc.’s $311 million Series E financing to advance ENV-294, ENV-308, and ENV-6946 into later-stage trials and additional indications; Anew Labs, a China based full-chain artificial intelligence drug discovery and development platform, raising $290 million in a financing round to establish a suitable organisational incentive system around its AI-driven pharmaceutical business; and Encoded Therapeutics Inc., a clinical-stage biotechnology company developing precision genetic medicines for severe neurological disorders, raising $275 million in a Series F financing round to support the pivotal study of ETX101.</p>
<p>The post <a href="https://www.expresspharma.in/pharma-deal-value-falls-78-8-in-september-2026-globaldata/">Pharma deal value falls 78.8% in September 2026: GlobalData</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>CCTV at pharmacies: Is surveillance enough to curb unauthorised drug sales?</title>
<link>https://edusehat.com/en/cctv-at-pharmacies-is-surveillance-enough-to-curb-unauthorised-drug-sales</link>
<guid>https://edusehat.com/en/cctv-at-pharmacies-is-surveillance-enough-to-curb-unauthorised-drug-sales</guid>
<description><![CDATA[ 
Ashwin Sapra, Partner Life Sciences and Healthcare, Trilegal shares a critical examination of the proposed amendment to the Drugs Rules, 1945
The post CCTV at pharmacies: Is surveillance enough to curb unauthorised drug sales? appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/08101159/EP_Ashwin.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 08 Oct 2026 12:15:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>CCTV, pharmacies:, surveillance, enough, curb, unauthorised, drug, sales</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/08101159/EP_Ashwin.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/08101159/EP_Ashwin.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/08101159/EP_Ashwin-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>The Ministry of Health has proposed, through draft G.S.R. 791(E)</span><span> dated 8 September 2026, mandatory CCTV surveillance at pharmacies for the retail supply of prescription medicines, with recordings retained for at least three months. The proposal aims to strengthen oversight of Schedule H, H1 and X drugs and curb unauthorised sales. It remains a draft, pending stakeholder comments and final notification.</span></p>
<p><span>The objective is legitimate. The question is whether the regulatory design is proportionate to the problem. The Drugs Rules, 1945 already prescribe significant controls, and stronger enforcement is a legitimate regulatory objective. But CCTV may strengthen evidentiary oversight; it cannot, by itself, substitute for an effective prescription-control regime.</span></p>
<p><span>The draft refers to “any drug”, while the Government’s stated objective is to strengthen oversight of Schedule H, H1 and X drugs. As drafted, Rule 65(2A) could therefore require CCTV surveillance for the retail supply of any prescription drug, not merely drugs falling within those schedules. If the intended scope is limited to higher-risk medicines, the rule should say so expressly. An obligation of this breadth should not be left to interpretation, as ambiguity could result in inconsistent enforcement, compliance exposure and avoidable litigation.</span></p>
<p><span>A pharmacist can still sell a prescription drug without a valid prescription in front of a camera. CCTV does not authenticate the prescription, establish that the prescriber actually issued it, determine whether the quantity is appropriate, or verify that the medicine supplied corresponds to the prescription. At best, it creates retrospective evidence of the transaction. If CCTV is to have genuine regulatory value, it should form part of an auditable evidentiary chain linking the prescription to the dispensing record, transaction receipt and CCTV timestamp. The draft does not establish this linkage. CCTV should therefore operate as corroborative evidence, not as a substitute for prescription verification and transaction records.</span></p>
<p><span>The draft also leaves fundamental compliance questions unanswered. How many cameras are required? Which areas must they cover? Must the dispensing counter be visible? What resolution is required? Is continuous recording necessary? Must the system have time-stamping, backup and tamper protection? Can cloud storage be used? Does the prescription itself need to be captured? An obligation without objective standards can invite subjective enforcement. If the Government mandates technology, it should also define minimum technical standards for compliance.</span></p>
<p><span>The proposed three-month retention period is understandable from an enforcement perspective, but it is not matched by an equivalent framework for access, security and use. Who may access the footage? Can a Drugs Inspector demand the entire archive? What happens after three months? These questions matter because pharmacy CCTV can reveal information about an individual’s treatment and health, including when a person sought a particular medicine.</span></p>
<p><span>Privacy should therefore be addressed through design. The final rules should establish purpose limitation, controlled access, security, disclosure protocols and deletion requirements. If the State requires the private sector to create and retain a sensitive surveillance record, it should also prescribe the conditions under which that record may be accessed and used. The interaction with the DPDP Act, the constitutional right to privacy and patient confidentiality merits careful consideration.</span></p>
<p><span>Operational failures also require attention. A patient may present a valid prescription while CCTV is temporarily unavailable because of a power interruption or hardware failure. The final framework needs a clear downtime protocol and should distinguish deliberate evasion from bona fide technical failure despite reasonable maintenance.</span></p>
<p><span>The compliance burden will not be uniform. Large pharmacy chains may already have sophisticated CCTV systems, while a small independent pharmacy may face significant costs of installation, storage, maintenance and data security. If the regulatory concern is concentrated in particular categories of medicines, a risk-based approach should be considered. Regulation should target risk rather than impose identical technological obligations regardless of the nature, scale or risk profile of the dispensing activity.</span></p>
<p><span>Hospitals, institutional pharmacies and e-pharmacies also require express treatment. Dispensing may occur pursuant to inpatient orders or emergency protocols, while online transactions may involve digital prescription verification, warehouses and fulfilment centres. Where does “supply” occur for purposes of the CCTV requirement? The framework should be technologically neutral and clarify how these models are covered.</span></p>
<p><span>The more fundamental question is whether CCTV is the right regulatory intervention. Other tools could strengthen compliance: electronic prescription verification, transaction-level digital records, prescription identifiers, stronger Schedule H1 record systems, targeted inspections, risk-based surveillance and supply-chain traceability. CCTV may complement these mechanisms, but it should not become a substitute for them.</span></p>
<p><span>A workable framework should therefore define the drugs and premises covered; connect prescription, dispensing, transaction and CCTV records; prescribe minimum technical and data-governance standards; provide a safe harbour or alternative process for bona fide technical failures; and address hospitals, institutional pharmacies, e-pharmacies and fulfilment centres.</span></p>
<p><span>The Government’s objective is legitimate, but the instrument must be proportionate, precise and workable. As drafted, the proposal is potentially overbroad, under-specified and insufficiently attentive to the sensitivity of the data captured. A more workable pathway would be to define the drugs and premises covered, prescribe clear technical and data-governance standards, phase in compliance, and begin with risk-based inspections and audits before considering a broader CCTV mandate. The issue is not whether pharmacies need stronger oversight; it is whether a blanket CCTV mandate is the right regulatory tool. A camera can record a transaction; it cannot make the transaction lawful. Regulation must do that</span></p>
<p><span>(<em>Disclaimer: The above views are based on a review of the quoted draft rules and are views of the author based on his experience in the sector. The views are not to be considered as legal advice.)</em></span></p>
<p>The post <a href="https://www.expresspharma.in/cctv-at-pharmacies-is-surveillance-enough-to-curb-unauthorised-drug-sales/">CCTV at pharmacies: Is surveillance enough to curb unauthorised drug sales?</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Anton Paar India hosts NEXUS 2026 to discuss analytical technologies for pharma and food sectors</title>
<link>https://edusehat.com/en/anton-paar-india-hosts-nexus-2026-to-discuss-analytical-technologies-for-pharma-and-food-sectors</link>
<guid>https://edusehat.com/en/anton-paar-india-hosts-nexus-2026-to-discuss-analytical-technologies-for-pharma-and-food-sectors</guid>
<description><![CDATA[ 
Industry forum brings experts together to discuss product development, quality, regulatory compliance and manufacturing
The post Anton Paar India hosts NEXUS 2026 to discuss analytical technologies for pharma and food sectors appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/07170730/EP_Nexus_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 07 Oct 2026 21:50:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Anton, Paar, India, hosts, NEXUS, 2026, discuss, analytical, technologies, for, pharma, and, food, sectors</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/07170730/EP_Nexus_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/07170730/EP_Nexus_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/07170730/EP_Nexus_750-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p dir="ltr"><span>Anton Paar India hosted the first day of NEXUS 2026 at Ramada by Wyndham, Navi Mumbai, bringing together experts, scientists, researchers and industry professionals from the pharmaceutical and food sectors for discussions on how analytical technologies can address challenges in product development, quality, regulatory compliance and manufacturing.</span></p>
<p dir="ltr"><span>The two-day industry forum is being held under the theme “Industry Insights. Technology. Experience.” and combines expert-led sessions with live demonstrations of analytical and measurement technologies.</span></p>
<p dir="ltr"><span>Nitin Prabhakar, Managing Director, Anton Paar India, said “NEXUS is designed to take analytical science beyond theoretical discussions and connect it directly with the challenges faced by industry. The first day demonstrated the value of bringing pharmaceutical and food experts together with application specialists and live technologies on one platform. From understanding the structure of pharmaceutical materials and improving regulatory preparedness to analysing food texture, flow and processing behaviour, the discussions highlighted how the right measurements can support better decisions across the product lifecycle.”</span></p>
<p dir="ltr"><span>The pharmaceutical sessions brought together perspectives from drug development, formulation, analytical research and regulated laboratory environments. Dr. Benedikt Schrode, Global Product Manager – X-ray Diffraction, Anton Paar GmbH, discussed how X-ray diffraction can provide insights into APIs and pharmaceutical materials.</span></p>
<p dir="ltr"><span>Dr. Vaibhav Dubey, Senior General Manager, Sun Pharma, highlighted the importance of understanding particles, interfaces and stability in next-generation drug delivery systems. Dr. Amit Gosar, Vice President – Analytical Research, Indoco Remedies, addressed the changing regulatory landscape, including trace-level impurities, nitrosamines, NDSRIs, elemental impurities and advanced solid-state characterisation.</span></p>
<p dir="ltr"><span>The programme also explored how laboratories can move beyond compliance towards greater confidence in analytical processes. Jörg Bämpfer, Global Product Manager, Anton Paar GmbH, shared insights into data integrity, traceability, qualification, digital data management and integrated laboratory workflows.</span></p>
<p dir="ltr"><span>The food-focused sessions examined the relationship between raw materials, processing behaviour, structure and finished-product quality. Prof. Dr. Narpinder Singh, Vice Chancellor, Graphic Era (Deemed to be University), discussed rheological characterisation and extrusion technology, while Dr. Suresh Sakhare, Scientist G, CSIR-CFTRI, Mysuru, examined flour, dough and starch behaviour for improved food products.</span></p>
<p dir="ltr"><span>Dr Nitin further added “Food science is increasingly moving towards a deeper understanding of what happens between raw material and consumer experience. The sessions by Prof. Dr. Narpinder Singh and Dr. Suresh Sakhare showed how rheology, starch behaviour, dough characteristics and processing conditions can influence consistency and product quality. Dr. Banu Sezer’s session further connected particle size, viscosity, rheology, texture, crystallisation and other measurements with practical considerations such as processing, stability and consumer acceptance.”</span></p>
<p dir="ltr"><span>A key highlight of Day One was the NEXUS Technology Expo, where participants experienced live demonstrations of Anton Paar’s analytical and measurement technologies and interacted with application specialists. The showcase covered rheology and viscometry, density and concentration, particle characterisation, surface and material characterisation, FTIR and Raman spectroscopy, X-ray analysis, microwave sample preparation, true density, flash point and petroleum testing, process measurement and laboratory automation.</span></p>
<p dir="ltr"><span>The day concluded with participants gaining practical insights into how complementary analytical techniques can be integrated into measurement workflows.</span></p>
<p> </p>
<p dir="ltr"><span>The second day of NEXUS 2026 will continue on October 8, bringing industry perspectives and analytical technologies together. The platform will further focus on enabling industries to understand materials, optimise processes and make informed technology-driven decisions.</span></p>
<p>The post <a href="https://www.expresspharma.in/anton-paar-india-hosts-nexus-2026-to-discuss-analytical-technologies-for-pharma-and-food-sectors/">Anton Paar India hosts NEXUS 2026 to discuss analytical technologies for pharma and food sectors</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Gilead Sciences signs five&#45;year DevOps agreement with Cognizant</title>
<link>https://edusehat.com/en/gilead-sciences-signs-five-year-devops-agreement-with-cognizant</link>
<guid>https://edusehat.com/en/gilead-sciences-signs-five-year-devops-agreement-with-cognizant</guid>
<description><![CDATA[ The renewed arrangement will see Cognizant combine its life sciences sector knowledge with technical services to aid Gilead’s ongoing development and operational processes. The joint work is intended 
The post Gilead Sciences signs five-year DevOps agreement with Cognizant appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/10/PT-07-10-2026-shutterstock_1658318347.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 07 Oct 2026 18:15:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Gilead, Sciences, signs, five-year, DevOps, agreement, with, Cognizant</media:keywords>
<content:encoded><![CDATA[<p>The renewed arrangement will see Cognizant combine its life sciences sector knowledge with technical services to aid Gilead’s ongoing development and operational processes.</p>
<p>The joint work is intended to focus on targeted, practical use cases designed to simplify operational procedures, streamline technical delivery, and enable Gilead’s project teams to implement priority technology programmes more efficiently.</p>
<p>Gilead Global CIO Anna Berg Asberg said: “Our focus is on giving our teams reliable, efficient technology that helps them move important work forward.</p>
<p>“This agreement provides additional support as we strengthen our DevOps capabilities and evaluate practical, responsible uses of AI across our technology environment—all in service of our broader mission to deliver for patients.”</p>
<p>Cognizant Americas president Surya Gummadi said: “We value the opportunity to continue supporting Gilead’s technology priorities. Our work will bring together life sciences experience, DevOps capabilities and AI tools to help Gilead improve delivery across selected programmes.”</p>
<p>This agreement builds on over a decade of collaboration between the two companies.</p>
<p>Over that timeframe, Cognizant has provided ongoing technical support for elements of Gilead’s worldwide information technology infrastructure, software platforms, enterprise applications, and advanced analytics capabilities.</p>
<p>The expanded remit provides additional resources for selected DevOps and AI-driven capabilities, supporting the core technical foundations that underpin Gilead’s business and research priorities.</p>
<p>Last month, Gilead Sciences and the Pan American Health Organization (PAHO) signed an agreement to expedite access to the company’s twice-yearly lenacapavir injection for human immunodeficiency virus (HIV) prevention as pre-exposure prophylaxis (PrEP) across Latin America and the Caribbean.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/gilead-sciences-cognizant-devops/">Gilead Sciences signs five-year DevOps agreement with Cognizant</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Rocket receives $150m credit facility to advance cardiovascular portfolio</title>
<link>https://edusehat.com/en/rocket-receives-150m-credit-facility-to-advance-cardiovascular-portfolio</link>
<guid>https://edusehat.com/en/rocket-receives-150m-credit-facility-to-advance-cardiovascular-portfolio</guid>
<description><![CDATA[ The financing arrangement extends the biotechnology company’s projected operational cash runway into the third quarter of 2028 when combined with existing reserves, with further drawdowns potentially extending funding 
The post Rocket receives $150m credit facility to advance cardiovascular portfolio appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/10/PT-2-07-10-2026-shutterstock_2627023655.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 07 Oct 2026 18:15:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Rocket, receives, 150m, credit, facility, advance, cardiovascular, portfolio</media:keywords>
<content:encoded><![CDATA[<p>The financing arrangement extends the biotechnology company’s projected operational cash runway into the third quarter of 2028 when combined with existing reserves, with further drawdowns potentially extending funding into 2029.</p>
<p>Rocket plans to use the proceeds to advance its clinical pipeline, primarily focusing on its pivotal Phase II trial of RP-A501 for Danon disease.</p>
<p>As of 30 June 2026, the company held $283.7m in cash, cash equivalents and investments. Under the terms of the agreement, Rocket drew an initial $35m upon closing.</p>
<p>An additional $35m remains accessible at Rocket’s option during designated periods, subject to contractual terms.</p>
<p>A further $30m tranche may become available upon reaching a specified clinical milestone in the Danon programme, whilst the final $50m tranche remains subject to approval by the investment committee at Hercules Capital.</p>
<p>Rocket Pharmaceuticals CEO Gaurav Shah said: “Building on the sale of our priority review voucher, this financing diversifies our sources of capital and strengthens our ability to execute and deliver on our cardiovascular strategy.</p>
<p>“The staged structure provides flexibility to align additional funding with progress across our programmes. We remain focused on allocating capital thoughtfully, executing the pivotal Danon study and advancing genetic medicines for patients with serious inherited heart diseases.”</p>
<p>Hercules Capital senior managing director and life sciences group head R. Bryan Jadot said: “Rocket is advancing toward important milestones across its cardiovascular pipeline, led by the pivotal Danon programme.</p>
<p>“We are pleased to provide a flexible financing solution that supports the Company’s development priorities. We look forward to working alongside Rocket as it builds on its expertise in cardiovascular genetic medicines.”</p>
<p>The facility carries an initial 30-month interest-only period alongside a 48-month maturity, with extensions accessible upon achieving designated milestones.</p>
<p>The transaction also includes warrants to purchase shares of common stock in Rocket Pharmaceuticals.</p>
<p>LifeSci Capital acted as financial adviser to Rocket on the term loan, while PJT acted as capital markets adviser. Additional details regarding the credit agreement will be submitted in regulatory filings with the Securities and Exchange Commission.</p>
<p>Rocket Pharmaceuticals develops genetic medicines for rare as well as life-threatening diseases, with a focus on cardiovascular disorders that are inherited.</p>
<p>In April this year, Rocket Pharmaceuticals signed an agreement to sell its rare paediatric disease priority review voucher (PRV) for $180m to advance its gene therapy pipeline.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/rocket-150m-advance-cardiovascular-portfolio/">Rocket receives $150m credit facility to advance cardiovascular portfolio</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Eris Lifesciences appoints Chirag Mehta as Executive Director</title>
<link>https://edusehat.com/en/eris-lifesciences-appoints-chirag-mehta-as-executive-director</link>
<guid>https://edusehat.com/en/eris-lifesciences-appoints-chirag-mehta-as-executive-director</guid>
<description><![CDATA[ 
Mehta will oversee Finance, Investor Relations and International Business in his non-statutory executive role
The post Eris Lifesciences appoints Chirag Mehta as Executive Director appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123851/Acquisition.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 07 Oct 2026 18:15:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Eris, Lifesciences, appoints, Chirag, Mehta, Executive, Director</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123851/Acquisition.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123851/Acquisition.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123851/Acquisition-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Eris Lifesciences has announced the appointment of Chirag Mehta as Executive Director. He will be based at the company’s Mumbai office and will report to the CMD.</span></p>
<p><span>In his non-statutory executive role, Mehta will oversee Finance, Investor Relations and the International Business.</span></p>
<p><span>Mehta brings over two decades of senior leadership experience in finance, strategy and M&A across the Indian and international pharmaceutical industry. He was most recently CFO at Bharat Serums and Vaccines Ltd., a Mankind Group company. Earlier, he served as SVP & CFO at Biological E. Ltd., Hyderabad, and CFO – International at Cipla.</span></p>
<p><span>He holds an MBA from Grand Valley State University, Michigan, USA.</span></p>
<p><span>Commenting on the appointment, Amit Bakshi, CMD, Eris Lifesciences, said, “We are happy to have Chirag with us. He brings a strong base in finance, international business and biotech, which is a good fit for the phase we are entering.”</span></p>
<p>The post <a href="https://www.expresspharma.in/eris-lifesciences-appoints-chirag-mehta-as-executive-director/">Eris Lifesciences appoints Chirag Mehta as Executive Director</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Granules India files Paragraph IV certification for Ruxolitinib Extended&#45;Release Tablets</title>
<link>https://edusehat.com/en/granules-india-files-paragraph-iv-certification-for-ruxolitinib-extended-release-tablets</link>
<guid>https://edusehat.com/en/granules-india-files-paragraph-iv-certification-for-ruxolitinib-extended-release-tablets</guid>
<description><![CDATA[ 
Company says it believes it is eligible for first-to-file status, subject to FDA review and determination
The post Granules India files Paragraph IV certification for Ruxolitinib Extended-Release Tablets appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2022/01/06111112/Report.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 07 Oct 2026 18:15:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Granules, India, files, Paragraph, certification, for, Ruxolitinib, Extended-Release, Tablets</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2022/01/06111112/Report.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2022/01/06111112/Report.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2022/01/06111112/Report-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>Granules India Limited (GIL) announced that it has submitted a Paragraph IV certification in connection with its ANDA for Ruxolitinib Extended-Release Tablets with respect to applicable patents listed in the US Food and Drug Administration’s (FDA) Orange Book. The company has also provided the required notice to the relevant parties in accordance with applicable US regulatory requirements.</span></p>
<p><span>Based on the timing and status of its ANDA and Paragraph IV certification, and subject to FDA review and determination, GIL believes that it is eligible for first-to-file status for Ruxolitinib Extended-Release Tablets. If confirmed by the FDA and all applicable statutory and regulatory requirements are satisfied, first-to-file status may provide eligibility for 180 days of generic drug exclusivity under US law.</span></p>
<p><span>The ANDA remains subject to FDA review. The announcement should not be construed as FDA approval of the product or confirmation by the FDA of first-to-file status or exclusivity.</span></p>
<p><span>Commenting on the development, Dr. Krishna Prasad Chigurupati, Chairman & Managing Director, Granules India, said, “First-to-file opportunities are an important part of our strategy to build a more differentiated and higher-value product portfolio in the U.S. This filing reflects our focus on identifying technically and commercially attractive opportunities where our development and manufacturing capabilities can create sustainable value. We look forward to progressing the product through the regulatory process.”</span></p>
<p><span>The company will provide further updates, as appropriate, in accordance with applicable disclosure requirements.</span></p>
<p>The post <a href="https://www.expresspharma.in/granules-india-files-paragraph-iv-certification-for-ruxolitinib-extended-release-tablets/">Granules India files Paragraph IV certification for Ruxolitinib Extended-Release Tablets</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Aragen Life Sciences begins operations at high&#45;potency platform in Hyderabad</title>
<link>https://edusehat.com/en/aragen-life-sciences-begins-operations-at-high-potency-platform-in-hyderabad</link>
<guid>https://edusehat.com/en/aragen-life-sciences-begins-operations-at-high-potency-platform-in-hyderabad</guid>
<description><![CDATA[ 
Aragen OneHP provides development and cGMP manufacturing capabilities for highly potent molecules, including cytotoxic compounds used in oncology
The post Aragen Life Sciences begins operations at high-potency platform in Hyderabad appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/05/04175401/Profits.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 07 Oct 2026 14:40:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Aragen, Life, Sciences, begins, operations, high-potency, platform, Hyderabad</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/05/04175401/Profits.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/05/04175401/Profits.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/05/04175401/Profits-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Aragen Life Sciences has begun operations at Aragen OneHP, a high-potency development and manufacturing platform at its Nacharam campus in Hyderabad.</span></p>
<p><span>The platform adds capabilities for highly potent molecules, including cytotoxic payloads used in oncology, and provides customers with an integrated pathway from milligram-scale discovery through process development and multi-kilogram cGMP manufacturing.</span></p>
<p><span>Aragen OneHP spans approximately 15,000 sq ft and operates one manufacturing line with a designed capacity of 500 to 600 kg of active pharmaceutical ingredient a year. The platform supports highly potent compounds, including cytotoxic molecules and targeted oncology therapies, and will lay the foundation for future expansion into advanced modalities.</span></p>
<p><span>OneHP provides an integrated pathway from development through clinical and commercial supply worldwide. Manufacturing covers small-scale chemistry synthesis of up to 10 g, non-GMP process development and scale-up of up to 500 g, and cGMP manufacturing from 500 g to 5 kg per batch.</span></p>
<p><span>Advanced containment systems are designed to handle compounds at occupational exposure limits of up to 10 ng/m³, subject to ongoing validation.</span></p>
<p><span>The platform is the latest addition to Aragen’s expansion programme, which is adding new capabilities. Aragen spent more than ₹1,000 crore on capital expenditure over the three years to March 2026, building capabilities across small molecules and biologics.</span></p>
<p><span>Its contract development and manufacturing business grew at a 19% compound annual rate over the period, while its contract research arm grew at 12%. Installed small-molecule capacity stood at 364 KL across Hyderabad and Visakhapatnam as of March 31, 2026.</span></p>
<p><span>The company drew nearly 95% of its revenue from global customers in the year ending March 2026 and served 591 customers globally during the year, including 16 of the world’s Top 20 Big pharmaceutical companies.</span></p>
<p><span>Mr. Aniel Khubchandani, Chief Executive Officer – Small Molecules-CDMO, Aragen Life Sciences, said, “With OneHP, we are bringing discovery, development and cGMP manufacturing for highly potent molecules onto a more integrated platform. This can reduce handoffs between providers, while keeping process knowledge and programme context connected as a molecule moves from early development towards commercial supply.”</span></p>
<p><span>Highly potent molecules, including cytotoxic compounds, require specialised handling, containment and manufacturing infrastructure. OneHP brings together capabilities across small-scale chemistry synthesis, process development, scale-up and cGMP manufacturing, enabling customers to progress programmes through an integrated platform.</span></p>
<p><span>The platform also lays the foundation for Aragen’s future expansion into advanced modalities such as antibody-drug conjugates and peptide-drug conjugates.</span></p>
<p><span>Aragen’s Hyderabad manufacturing and analytical operations are accredited by the USFDA, EDQM, PMDA, MFDS, ANVISA, WHO Geneva and CDSCO.</span></p>
<p>The post <a href="https://www.expresspharma.in/aragen-life-sciences-begins-operations-at-high-potency-platform-in-hyderabad/">Aragen Life Sciences begins operations at high-potency platform in Hyderabad</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>India pharma and healthcare funding falls to $256.7M in September 2026</title>
<link>https://edusehat.com/en/india-pharma-and-healthcare-funding-falls-to-2567m-in-september-2026</link>
<guid>https://edusehat.com/en/india-pharma-and-healthcare-funding-falls-to-2567m-in-september-2026</guid>
<description><![CDATA[ 
Funding across HealthTech, Life Sciences and Healthcare sectors stood at $256.7M across 22 rounds
The post India pharma and healthcare funding falls to $256.7M in September 2026 appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/07100035/EP_Tracxn_Sep_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 07 Oct 2026 14:40:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>India, pharma, and, healthcare, funding, falls, 256.7M, September, 2026</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/07100035/EP_Tracxn_Sep_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/07100035/EP_Tracxn_Sep_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/07100035/EP_Tracxn_Sep_750-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>According to a Tracxn report, funding in the HealthTech, Life Sciences and Healthcare sectors in India stood at $256.7M across 22 rounds in September 2026. The funding was 30.87 per cent lower than the previous month and 99.85 per cent higher than the same month last year.</span></p>
<p><span>The data covers September 1 to September 30, 2026. The previous month refers to August 1 to August 31, 2026, while the same month last year refers to September 1 to September 30, 2025.</span></p>
<p><span>Funding in September 2026 stood at $256.7M, compared with $371.3M in August 2026. Funding in October 2025 stood at $161.8M, followed by $25.3M in November, $162.1M in December, $177.1M in January 2026, $51.5M in February, $235.7M in March, $305.8M in April, $119.0M in May, $106.4M in June, $80.6M in July and $371.3M in August.</span></p>
<p><span>The stagewise funding split in September 2026 comprised 63.1 per cent late-stage funding, 31.6 per cent early-stage funding and 5.3 per cent seed funding.</span></p>
<p><span>The top deals in September 2026 included Linux Laboratories and Ultrahuman, with $70.0M each, followed by Nua with $50.0M, Marengo Asia Healthcare with $41.9M, Disha Health with $4.6M, Rio Health with $4.5M and Fundly with $4.0M.</span></p>
<p><span>Among the most active venture capital investors, Peak XV Partners participated in two rounds involving Nua and August AI. Equentis Wealth Advisory Services participated in two rounds involving MeduLance and DocPharma, while Qualcomm Ventures participated in one round involving Ultrahuman.</span></p>
<p><span>The data is for the HealthTech, Life Sciences and Healthcare sectors in India, with Tracxn cited as the source.</span></p>
<p>The post <a href="https://www.expresspharma.in/india-pharma-and-healthcare-funding-falls-to-256-7m-in-september-2026/">India pharma and healthcare funding falls to $256.7M in September 2026</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Pacira partners with Molteni for Exparel commercialisation</title>
<link>https://edusehat.com/en/pacira-partners-with-molteni-for-exparel-commercialisation</link>
<guid>https://edusehat.com/en/pacira-partners-with-molteni-for-exparel-commercialisation</guid>
<description><![CDATA[ Exparel (bupivacaine liposome injectable suspension), is a long-acting local analgesic used for postsurgical pain management. Under the agreement, Pacira will obtain an undisclosed upfront payment, alongside a supply 
The post Pacira partners with Molteni for Exparel commercialisation appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/10/MDN-2-07-10-2026-shutterstock_2297089595.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 06 Oct 2026 20:40:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Pacira, partners, with, Molteni, for, Exparel, commercialisation</media:keywords>
<content:encoded><![CDATA[<p>Exparel (bupivacaine liposome injectable suspension), is a long-acting local analgesic used for postsurgical pain management.</p>
<p>Under the agreement, Pacira will obtain an undisclosed upfront payment, alongside a supply price and royalties generated from future commercial sales across the licensed territories.</p>
<p>Pacira will be responsible for manufacturing the therapy. Molteni Farmaceutici will manage regulatory procedures, market access, and commercialisation efforts in the designated markets.</p>
<p>Molteni Farmaceutici plans a phased commercial rollout of the analgesic, starting in Austria, Germany, Italy, and Poland, while also seeking regulatory approval in Switzerland.</p>
<p>The companies expect the first commercial sale under the partnership to occur in 2027. Locust Walk served as the exclusive financial advisor to Pacira for the transaction.</p>
<p>Pacira BioSciences CEO Frank Lee said: “We are excited to announce another strategic partnership that advances our 5×30 growth strategy and reinforces our commitment to expanding patient access to best-practice opioid-sparing postsurgical pain management.</p>
<p>“With Molteni Farmaceutici’s longstanding leadership in pain management and extensive distribution network across Europe, they are ideally positioned to unlock EXPAREL’s full potential in key European markets.”</p>
<p>Molteni Farmaceutici focuses on specialty healthcare, operating in the fields of hospital-based treatments, oncology supportive care, and pain management.</p>
<p>Alongside Exparel, Pacira’s commercial portfolio includes Zilretta (triamcinolone acetonide extended-release injectable suspension), an intra-articular extended-release injection indicated for managing osteoarthritis knee pain.</p>
<p>The company is also developing a pipeline of clinical-stage candidates for musculoskeletal pain and related conditions.</p>
<p>Its investigational product, PCRX-201 (enekinragene inzadenovec), is a locally administered gene therapy currently undergoing Phase II clinical development for knee osteoarthritis.</p>
<p>In November 2025, AmacaThera entered into an exclusive worldwide licensing agreement with Pacira BioSciences for up to $230m for AMT-143, an investigational long-acting non-opioid anaesthetic.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/pacira-molteni-exparel-commercialisation/">Pacira partners with Molteni for Exparel commercialisation</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>AstraZeneca opens new R&amp;amp;D centre in Cambridge, US</title>
<link>https://edusehat.com/en/astrazeneca-opens-new-rd-centre-in-cambridge-us</link>
<guid>https://edusehat.com/en/astrazeneca-opens-new-rd-centre-in-cambridge-us</guid>
<description><![CDATA[ The 18-storey, 570,000ft² facility at 290 Binney Street features ten floors of interconnecting laboratories equipped with continuous automation, robotics, and agentic AI. Combined with the company’s genomic medicine 
The post AstraZeneca opens new R&amp;D centre in Cambridge, US appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/10/PT-07-10-2026-original.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 06 Oct 2026 17:05:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>AstraZeneca, opens, new, R&amp;D, centre, Cambridge</media:keywords>
<content:encoded><![CDATA[<p>The 18-storey, 570,000ft² facility at 290 Binney Street features ten floors of interconnecting laboratories equipped with continuous automation, robotics, and agentic AI.</p>
<p>Combined with the company’s genomic medicine facility at 100 Binney Street, the site located in Kendall Square, Cambridge will accommodate around 2,000 researchers and scientists.</p>
<p>The expansion will increase AstraZeneca’s Massachusetts workforce by more than 50% in the coming years.</p>
<p>Research teams at the Kendall Square centre will focus on developing therapies across several disease areas, including breast cancer, chronic obstructive pulmonary disease (COPD), metabolic disease, obesity, oncology, and rare conditions, alongside work in biologics and cell therapy.</p>
<p>AstraZeneca CEO Pascal Soriot said: “Kendall Square is a leading innovation ecosystem, and it is one of the key locations where AstraZeneca will discover the next generation of scientific breakthroughs.</p>
<p>“Our new R&D centre not only reflects AstraZeneca’s long-term commitment to Massachusetts but also our belief in delivering US-led innovation to patients around the world.”</p>
<p>The Massachusetts project forms part of a wider $50bn investment programme by AstraZeneca in the US, where the business has operated in the state for more than 75 years.</p>
<p>AstraZeneca currently employs over 25,000 staff across 24 corporate, commercial, manufacturing, and research sites nationwide, supporting nearly 100,000 jobs.</p>
<p>The Kendall Square opening expands AstraZeneca’s global research network across over 40 countries, including its other primary US strategic R&D centre located in Gaithersburg, Maryland.</p>
<p>Prior to this, AstraZeneca and Daiichi Sankyo partnered with Summit Therapeutics to explore the potential of their co-developed antibody-drug conjugate (ADC), Datroway (datopotamab deruxtecan), alongside Summit’s in-licensed candidate, ivonescimab.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/astrazeneca-new-rd-centre-us/">AstraZeneca opens new R&D centre in Cambridge, US</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Pharma accounts for 88.8% of healthcare M&amp;amp;A value in September 2026: Equirus</title>
<link>https://edusehat.com/en/pharma-accounts-for-888-of-healthcare-ma-value-in-september-2026-equirus</link>
<guid>https://edusehat.com/en/pharma-accounts-for-888-of-healthcare-ma-value-in-september-2026-equirus</guid>
<description><![CDATA[ 
Healthcare M&amp;A activity stood at INR 19 billion during the month, while hospitals and healthcare technology led private equity investment
The post Pharma accounts for 88.8% of healthcare M&amp;A value in September 2026: Equirus appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2022/01/06111112/Report.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 06 Oct 2026 17:05:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Pharma, accounts, for, 88.8, healthcare, M&amp;A, value, September, 2026:, Equirus</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2022/01/06111112/Report.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2022/01/06111112/Report.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2022/01/06111112/Report-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>Pharmaceuticals accounted for 88.8 per cent of healthcare M&A activity by value in September 2026, while investment activity in the private equity space was led by hospitals and healthcare technology, according to an Equirus analysis of the healthcare sector.</span></p>
<p><span>The healthcare sector saw three major M&A deals in September, with the pharmaceutical sector accounting for the bulk of transaction value during the month.</span></p>
<p><span>Pharmaceuticals and biotech accounted for 88.8 per cent of M&A transactions by value in September, followed by healthcare technology at 10 per cent and other segments at 1.2 per cent. For comparison, pharmaceuticals accounted for 71 per cent of M&A transaction value in CY25 and 91.4 per cent in YTD 2026.</span></p>
<p><span>Healthcare M&A activity stood at INR 19 billion in September 2026, compared with INR 354 billion in CY25 and INR 1,386 billion in YTD 2026.</span></p>
<p><span>The private equity market also remained active, with hospitals and healthcare technology emerging as the key areas of investment during September. The average deal size during the month stood at around INR 2,220 million, while the healthcare sector saw one major PE deal and one VC deal during the period.</span></p>
<p><span>“In terms of deal value in the September’26 period, investment in the hospital sector is the highest followed by healthcare technology sector,” the analysis said.</span></p>
<p><span>The pharmaceutical segment also witnessed consolidation activity during the month. Anupam Rasayan India acquired a 50.1 per cent controlling stake in Bliss GVS Pharma for about INR 1,750 crore, marking its entry into pharmaceutical formulations.</span></p>
<p><span>Separately, RPG Life Sciences acquired the API and intermediates business of Raghava Life Sciences for INR 135 crore through its wholly owned subsidiary RPG Active Pharma. The transaction is expected to expand RPG Life Sciences’ API manufacturing operations product portfolio and scale in pharmaceutical APIs and intermediates.</span></p>
<p><span>The healthcare capital markets also remained active. The healthcare and pharma ECM data showed that Symbiotec Pharmaceuticals’ IPO, which opened on September 1, 2026, raised INR 17,570 million and was subscribed 71.3 times, with the stock listing at an initial gain of 0 per cent.</span></p>
<p><span>The September healthcare data also comes against a broader backdrop of sustained capital deployment across the sector, with healthcare M&A activity in YTD 2026 standing at INR 1,386 billion and private equity activity at INR 79 billion.</span></p>
<p>The post <a href="https://www.expresspharma.in/pharma-accounts-for-88-8-of-healthcare-ma-value-in-september-2026-equirus/">Pharma accounts for 88.8% of healthcare M&A value in September 2026: Equirus</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Glenmark launches Adapalene Gel USP 0.1% in new pump packs in US</title>
<link>https://edusehat.com/en/glenmark-launches-adapalene-gel-usp-01-in-new-pump-packs-in-us</link>
<guid>https://edusehat.com/en/glenmark-launches-adapalene-gel-usp-01-in-new-pump-packs-in-us</guid>
<description><![CDATA[ 
Glenmark’s Adapalene Gel USP, 0.1% can be compared to the active ingredient of Differin Gel, 0.1%
The post Glenmark launches Adapalene Gel USP 0.1% in new pump packs in US appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/06/10153151/healthtech.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 06 Oct 2026 13:30:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Glenmark, launches, Adapalene, Gel, USP, 0.1, new, pump, packs</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/06/10153151/healthtech.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/06/10153151/healthtech.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/06/10153151/healthtech-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Glenmark Therapeutics Inc., USA (Glenmark) has announced the launch of Adapalene Gel USP, 0.1 per cent (OTC) in new pump packs in the US.</span></p>
<p><span>Glenmark’s Adapalene Gel USP, 0.1 per cent can be compared to the active ingredient of Differin Gel, 0.1 per cent.</span></p>
<p><span>According to Nielsen syndicated data for the latest 52-week period ending September 5, 2026, the Differin Gel, 0.1 per cent (OTC) market achieved annual sales of approximately $45.8 million*.</span></p>
<p><span>Commenting on the launch, Marc Kikuchi, President & Business Head, North America, said, “The introduction of Adapalene Gel USP, 0.1 per cent (OTC) in a new pump pack enhances consumer experience by offering a convenient and easy to use dispensing option while further strengthening our growing U.S. dermatology portfolio. This launch reflects our commitment to delivering high-quality and affordable healthcare solutions that meet evolving consumer needs.”</span></p>
<p><span>*Nielsen® NIQ Discover; Syndicated Data for Period Ending September 5, 2026</span></p>
<p>The post <a href="https://www.expresspharma.in/glenmark-launches-adapalene-gel-usp-0-1-in-new-pump-packs-in-us/">Glenmark launches Adapalene Gel USP 0.1% in new pump packs in US</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Zydus, MSN launch generic riociguat in US</title>
<link>https://edusehat.com/en/zydus-msn-launch-generic-riociguat-in-us</link>
<guid>https://edusehat.com/en/zydus-msn-launch-generic-riociguat-in-us</guid>
<description><![CDATA[ 
Riociguat Tablets are approved by the USFDA as a generic equivalent of Adempas Tablets in five strengths
The post Zydus, MSN launch generic riociguat in US appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/05/04131504/handshake.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 06 Oct 2026 13:30:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Zydus, MSN, launch, generic, riociguat</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/05/04131504/handshake.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/05/04131504/handshake.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/05/04131504/handshake-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Zydus Lifesciences (Zydus), in partnership with MSN Laboratories (MSN), has announced the launch of Riociguat Tablets, 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg, in the United States. Zydus and MSN are the first companies to launch a generic version of Adempas (riociguat) in the US market. The product was developed and is manufactured by MSN.</span></p>
<p><span>Riociguat Tablets are approved by the United States Food and Drug Administration (USFDA) as a generic equivalent of Adempas Tablets in all five strengths. Riociguat is a soluble guanylate cyclase (sGC) stimulator indicated for the treatment of adults with persistent or recurrent chronic thromboembolic pulmonary hypertension (CTEPH, WHO Group 4) after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class; and for adults with pulmonary arterial hypertension (PAH, WHO Group 1), to improve exercise capacity, improve WHO functional class and to delay clinical worsening.</span></p>
<p><span>Commenting on the development, Dr Sharvil Patel, Managing Director, Zydus Lifesciences, said, “Being first to market with generic riociguat is a milestone for our U.S. business and for patients with pulmonary hypertension. It reflects the strength of our complex-generics pipeline, our ability to execute day-one launches in specialty categories, and the strength of our partnerships that complement our commercial reach in the United States. We are pleased to enable access to the drug across all five strengths, allowing physicians and pharmacies to transition patients with confidence.”</span></p>
<p><span>Dr MSN Reddy, Founder & CMD, MSN Laboratories, said, “Riociguat is a technically demanding molecule, and bringing the first generic to the U.S. demonstrates the depth of MSN’s integrated API and formulation R&D and the scale of our manufacturing. Together with Zydus’ established U.S. commercial platform, we are confident of delivering consistent, high-quality supply of this important therapy.”</span></p>
<p><span>PAH and CTEPH are rare, progressive and life-threatening conditions in which patients typically remain on therapy for life. So far, riociguat was available in the United States only as the branded product.</span></p>
<p><span>Sales of riociguat are not reported by IQVIA. According to Bayer’s Annual Report 2025, the global sales of Adempas were approximately EUR 745 million (approximately USD 850 million) in 2025.</span></p>
<p>The post <a href="https://www.expresspharma.in/zydus-msn-launch-generic-riociguat-in-us/">Zydus, MSN launch generic riociguat in US</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Lupin launches triple&#45;combination MDI for COPD in India</title>
<link>https://edusehat.com/en/lupin-launches-triple-combination-mdi-for-copd-in-india</link>
<guid>https://edusehat.com/en/lupin-launches-triple-combination-mdi-for-copd-in-india</guid>
<description><![CDATA[ 
Formoflo-G MDI combines Glycopyrronium Bromide, Formoterol Fumarate and Fluticasone Propionate for the management and treatment of moderate to severe COPD
The post Lupin launches triple-combination MDI for COPD in India appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 06 Oct 2026 13:30:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Lupin, launches, triple-combination, MDI, for, COPD, India</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>Lupin has launched Formoflo-G MDI, the world’s first fixed-dose triple combination metered-dose inhaler (MDI) for chronic obstructive pulmonary disease (COPD) in India, following approval from the Drug Controller General of India (DCGI).</span></p>
<p><span>Lupin Formoflo-G is a first-of-its-kind MDI that combines Glycopyrronium Bromide, Formoterol Fumarate and Fluticasone Propionate for the long-term management and treatment of moderate to severe COPD. The product is available as a twice-daily, single-strength fixed dose, bringing hope to more than 55 million people living with COPD in India, a condition that remains a leading cause of death and disability.</span></p>
<p><span>Commenting on the launch, Nilesh Gupta, Managing Director, Lupin, said, “As respiratory diseases continue to impact millions across India, access to effective therapies remains critical. Formoflo-G MDI reflects our commitment to addressing unmet patient needs through differentiated, high-quality therapies. By combining innovation with accessibility, we aim to improve outcomes for patients living with respiratory diseases.”</span></p>
<p><span>Rajeev Sibal, President – India Region Formulations, Lupin, said, “Formoflo-G MDI marks an important addition to our respiratory portfolio, bringing together three established therapies in a single inhaler. It strengthens Lupin’s respiratory portfolio and provides healthcare professionals with an important treatment option for appropriate COPD patients. It reflects our commitment to delivering innovative, high-quality therapies that help improve patient outcomes.”</span></p>
<p><span>Ranked #2 in the respiratory therapy segment in India (IQVIA, MAT Mar 2026), Lupin continues to strengthen its leadership in respiratory care with the launch of Formoflo-G MDI, reinforcing its focus on addressing unmet patient needs through innovation-driven therapies.</span></p>
<p>The post <a href="https://www.expresspharma.in/lupin-launches-triple-combination-mdi-for-copd-in-india/">Lupin launches triple-combination MDI for COPD in India</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Bayer plans $2.2bn pharmaceutical manufacturing facility in Ohio, US</title>
<link>https://edusehat.com/en/bayer-plans-22bn-pharmaceutical-manufacturing-facility-in-ohio-us</link>
<guid>https://edusehat.com/en/bayer-plans-22bn-pharmaceutical-manufacturing-facility-in-ohio-us</guid>
<description><![CDATA[ The facility will be constructed in the New Albany International Business Park. This investment adds to more than $7bn spent by the company on pharmaceutical research, development, and 
The post Bayer plans $2.2bn pharmaceutical manufacturing facility in Ohio, US appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/10/PT-05-10-2026-1920_2026-0168.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 05 Oct 2026 19:20:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Bayer, plans, 2.2bn, pharmaceutical, manufacturing, facility, Ohio</media:keywords>
<content:encoded><![CDATA[<p>The facility will be constructed in the New Albany International Business Park.</p>
<p>This investment adds to more than $7bn spent by the company on pharmaceutical research, development, and manufacturing in the US over the past five years.</p>
<p>The planned site will operate as a modular facility merging drug substance and drug product manufacturing, incorporating automated and digital systems.</p>
<p>It will support treatments across cardiovascular, oncology, and renal care. Production will roll out in stages, with the initial drug substance module scheduled to open in 2031, followed by a drug product manufacturing unit in 2034.</p>
<p>Construction of the site is expected to generate nearly 1,500 jobs, whilst ongoing operations are projected to create approximately 600 roles.</p>
<p>Bayer also intends to integrate the facility into a US-based collaboration network linking commercial manufacturing with academic research.</p>
<p>Bayer CEO Bill Anderson said: “Bayer has long seen the US as a key manufacturing base and innovation hub. This landmark investment underscores our commitment.</p>
<p>“The new site will be home to manufacturing expertise and a skilled workforce that will strengthen our ability to deliver innovative, high-quality medicines to patients both in the US and abroad.”</p>
<p>The Ohio project will complement Bayer’s US pharmaceutical headquarters in Whippany, New Jersey, as well as facilities in Berkeley, California; Cambridge, Massachusetts; Pittsburgh, Pennsylvania; Research Triangle Park, North Carolina; and San Diego, California.</p>
<p>In fiscal 2025, Bayer employed nearly 88,000 staff worldwide, reporting total sales of €45.6bn ($51.3bn) and research and development expenditure of €5.8bn.</p>
<p>In June 2026, the European Medicines Agency (EMA) validated Bayer’s marketing authorisation application for asundexian, an oral Factor XIa inhibitor, to prevent ischaemic stroke.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/bayer-2bn-pharmaceutical-manufacturing-facility-us/">Bayer plans $2.2bn pharmaceutical manufacturing facility in Ohio, US</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>FDA approves expanded indication for Lilly’s Jaypirca</title>
<link>https://edusehat.com/en/fda-approves-expanded-indication-for-lillys-jaypirca</link>
<guid>https://edusehat.com/en/fda-approves-expanded-indication-for-lillys-jaypirca</guid>
<description><![CDATA[ Jaypirca is a non-covalent Bruton tyrosine kinase (BTK) inhibitor and is administered orally as 50mg or 100mg tablets to achieve a daily 200mg dose. The regulatory decision is 
The post FDA approves expanded indication for Lilly’s Jaypirca appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/10/PT-2-05-10-2026-shutterstock_2269531787.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 05 Oct 2026 19:20:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>FDA, approves, expanded, indication, for, Lilly’s, Jaypirca</media:keywords>
<content:encoded><![CDATA[<p>Jaypirca is a non-covalent Bruton tyrosine kinase (BTK) inhibitor and is administered orally as 50mg or 100mg tablets to achieve a daily 200mg dose.</p>
<p>The regulatory decision is supported by data from the primary analysis of the global, open-label Phase III BRUIN CLL-313 clinical study.</p>
<p>The trial randomised 282 treatment-naive patients to receive either single-agent pirtobrutinib or a chemoimmunotherapy regimen of bendamustine and rituximab.</p>
<p>Over a median follow-up period of 28 months, pirtobrutinib demonstrated a statistically significant improvement in progression-free survival assessed by an independent review committee, recording a hazard ratio of 0.20.</p>
<p>Median progression-free survival was not reached in the pirtobrutinib cohort compared to 33.5 months in the comparator arm. The overall response rate reached 94% for pirtobrutinib and 81% for the control group.</p>
<p>Lilly Oncology executive vice-president and president Jacob Van Naarden said: “This additional approval for Jaypirca, based on BRUIN CLL-313, marks a significant step forward, expanding its potential to reach more patients who may benefit – this time as an initial treatment for certain previously untreated patients with CLL or SLL.</p>
<p>“This milestone underscores Jaypirca’s versatility in the CLL continuum of care, from the first-line setting for appropriate patients to its valuable role in the relapsed or refractory post-covalent BTK inhibitor setting, reinforcing Jaypirca’s broad applicability as a meaningful treatment option for people with CLL or SLL.”</p>
<p>During the Phase III trial, serious adverse reactions occurred in 28% of patients treated with Jaypirca, with pneumonia observed in 5%. Adverse events resulted in dose reductions for 3.6% of patients and treatment discontinuation for 4.3%.</p>
<p>The National Comprehensive Cancer Network guidelines include Jaypirca as a Category 2A recommendation for untreated CLL/SLL patients without 17p deletions who are older with cardiac comorbidities.</p>
<p>It is also listed as a Category 1 preferred option for patients with relapsed or refractory disease following prior covalent BTK inhibitor therapy.</p>
<p>Both CLL and SLL are slow-growing non-Hodgkin lymphomas that originate in lymphocytes.</p>
<p>Last month, the US FDA approved Lilly’s Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin injection for adults with type 2 diabetes (T2D).</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/fda-expanded-indication-lillys-jaypirca/">FDA approves expanded indication for Lilly’s Jaypirca</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Making AI work on the shop floor: What pharma manufacturers need to get right</title>
<link>https://edusehat.com/en/making-ai-work-on-the-shop-floor-what-pharma-manufacturers-need-to-get-right</link>
<guid>https://edusehat.com/en/making-ai-work-on-the-shop-floor-what-pharma-manufacturers-need-to-get-right</guid>
<description><![CDATA[ 
Dr Rajiv Desai, Senior Technical Advisor – Quality and Regulatory, IPA, highlights what pharma manufacturers need to get right when deploying AI at scale, from data and validation to quality, workforce readiness and human judgement
The post Making AI work on the shop floor: What pharma manufacturers need to get right appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/05143954/EP_GB_Dr_Rajiv_Desai_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 05 Oct 2026 19:20:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Making, work, the, shop, floor:, What, pharma, manufacturers, need, get, right</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/05143954/EP_GB_Dr_Rajiv_Desai_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/05143954/EP_GB_Dr_Rajiv_Desai_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/05143954/EP_GB_Dr_Rajiv_Desai_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>India’s pharmaceutical industry has built its global reputation on scale, quality, scientific capability and affordability. As the industry enters its next phase of growth, technology will play an increasingly important role in strengthening these foundations. Artificial intelligence (AI), in particular, has the potential to make pharmaceutical manufacturing more predictive, efficient and responsive. Most important “First Time Right”.</span></p>
<p><span>But the opportunity is not simply about introducing AI into Pharma manufacturing sites</span><span>.</span><span> The real question is how manufacturers can deploy it responsibly, at scale and in a way that strengthens quality and consistency and safe for patients.</span><span>     </span></p>
<p><span>The first step is to focus on the problem, not the technology. Manufacturers should identify where AI can create measurable value addition, whether in predictive maintenance, process optimisation, early warnings on potential failures</span><span>,</span><span> visual inspection, Quality monitoring, deviation analysis, failure investigations and root cause analysis</span><span>. </span><span>AI should solve a clearly defined manufacturing challenge rather than become another technology pilot.</span></p>
<p><span>The second requirement is a strong data foundation. Modern pharmaceutical plants generate vast amounts of information through manufacturing equipment</span><span>, </span><span>laboratory instruments</span><span>, </span><span>equipment sensors and quality processes. Yet data which</span> <span>is fragmented, inconsistent or difficult to access limits the implementation and value of AI. Manufacturers therefore need reliable, connected and well-governed data, with appropriate controls for integrity, traceability and access.</span></p>
<p><span>This becomes particularly important in pharmaceuticals because AI should operate</span> <span>within a highly regulated environment. Quality cannot be an afterthought. AI-enabled systems must be developed with a clear understanding of their intended use, validation requirements, risk management and ongoing performance. </span><span>As India strengthens its manufacturing quality framework, digital technologies must support, rather than complicate, the industry’s commitment to GMP and regulatory excellence.</span></p>
<p><span>There is also a need to keep people at the centre of this transformation. AI should augment human expertise, not replace it. Experienced manufacturing, engineering and quality professionals bring contextual knowledge that cannot always be captured in datasets. AI can help them identify patterns, anticipate risks and analyse information faster, enabling better and more timely decisions.</span></p>
<p><span>This makes talent development as important as technology investment. India’s pharmaceutical ecosystem already benefits from strong scientific, engineering and technical capabilities. The next step is to build digital fluency across the manufacturing workforce so that employees understand both the potential and limitations of AI-enabled systems.</span></p>
<p><span>The bigger challenge will be moving from isolated pilots to scalable implementation. A successful AI application should be capable of being governed, monitored and responsibly extended across value chain of the pharma manufacturing setup.</span> <span>Recognising that different plants and processes may require different models and controls. This calls for collaboration between manufacturers, technology providers, scientists, engineers and regulators.</span></p>
<p><span>This is also where India’s existing manufacturing strengths can become a competitive advantage. The country has spent decades building capabilities in process engineering, quality systems, regulatory compliance and large-scale production. AI can build on this foundation rather than replace it, helping manufacturers turn accumulated operational data into actionable intelligence.</span></p>
<p><span>For India, the opportunity is significant. The country has already demonstrated that it can combine scientific capability, manufacturing scale and cost competitiveness to serve the ever increasing needs of the patients globally. AI can help add another dimension to that advantage: manufacturing intelligence.</span></p>
<p><span>The future factory should therefore not be defined by how much AI it uses, but by how effectively it combines technology with science, quality and human judgement. If implemented on these foundations, AI can help Indian pharmaceutical manufacturers detect problems earlier, improve consistency, strengthen quality and build more resilient operations.</span></p>
<p><span>India’s pharmaceutical journey has always been about capability building. The next chapter can be about using intelligence at scale, while keeping quality, trust and the patient at the centre</span><b>.</b></p>
<p><strong>References: </strong></p>
<p><em>1. <span> U.S. Food and Drug Administration (FDA), Artificial Intelligence in Drug Manufacturing / Advanced Manufacturing Framework</span></em></p>
<p><em>2. <span>European Medicines Agency (EMA), Reflection paper on the use of Artificial Intelligence (AI) in the medicinal product lifecycle, 2024</span></em></p>
<p><em>3. <span>International Council for Harmonisation (ICH), ICH Q9(R1): Quality Risk Management.</span></em></p>
<p><em>4. <span>Central Drugs Standard Control Organisation (CDSCO), Revised Schedule M, Government of India.</span></em></p>
<p><em>5. <span>EMA & U.S. FDA, Guiding Principles of Good AI Practice in Drug Development, 2026</span></em></p>
<p><em>6. <span>Government of India, Press Information Bureau, Steps taken to ensure drug quality and curb counterfeit medicines, 2026</span></em></p>
<p>The post <a href="https://www.expresspharma.in/making-ai-work-on-the-shop-floor-what-pharma-manufacturers-need-to-get-right/">Making AI work on the shop floor: What pharma manufacturers need to get right</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Sun Pharma presents LEQSELVI long&#45;term data at EADV Congress 2026</title>
<link>https://edusehat.com/en/sun-pharma-presents-leqselvi-long-term-data-at-eadv-congress-2026</link>
<guid>https://edusehat.com/en/sun-pharma-presents-leqselvi-long-term-data-at-eadv-congress-2026</guid>
<description><![CDATA[ 
Sun Pharma will present seven LEQSELVI presentations at the EADV Congress 2026, including long-term safety and efficacy data in adults with severe alopecia areata
The post Sun Pharma presents LEQSELVI long-term data at EADV Congress 2026 appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 05 Oct 2026 19:20:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Sun, Pharma, presents, LEQSELVI, long-term, data, EADV, Congress, 2026</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Sun Pharmaceutical Industries announced that LEQSELVI (deuruxolitinib) will be featured in seven presentations at the 2026 European Academy of Dermatology and Venereology (EADV) Congress, including a featured oral presentation reporting long-term safety results from a European open-label extension (OLE) study evaluating up to two years of treatment in adults with severe alopecia areata (AA).</span></p>
<p><span>Results from the featured oral presentation found that the safety profile of LEQSELVI remained generally consistent with previous clinical experience through up to two years of open-label treatment in adults with severe AA. Most treatment-emergent adverse events were mild or moderate in severity, treatment discontinuations due to adverse events were uncommon, and no deaths, thrombosis or major adverse cardiovascular events were reported among patients receiving the FDA-approved dose of 8 mg twice-daily.</span></p>
<p><span>Long-term efficacy analyses presented in a poster also showed scalp hair regrowth through Week 108 in patients receiving LEQSELVI in the European OLE. Of OLE baseline treatment responders (SALT score ≤20) maintaining response at Week 52 and continuing in the study, 93.9 per cent maintained response at Week 108. Nonresponders completed the study at Week 52.</span></p>
<p><span>Among patients who were baseline nonresponders (SALT score >20), 76.6 per cent achieved response by Week 52. At Week 52, only responders continued in the study, and of these, 96.8 per cent maintained that response at Week 108. A Severity of Alopecia Tool (SALT) score of 100 represents total scalp hair loss, whereas a score of 0 represents no scalp hair loss.</span></p>
<p><span>“Severe alopecia areata is a chronic autoimmune disease, making long-term treatment considerations particularly important for both patients and their clinicians,” said Arash Mostaghimi, MD, MPA, MPH, FAAD, Vice Chair of Clinical Trials and Innovation and Associate Professor of Dermatology at Brigham and Women’s Hospital. “Collectively, these data show durable efficacy and maintenance of response for deuruxolitinib over time and reinforce the growing body of evidence supporting its use as a long-term treatment option for eligible adults.”</span></p>
<p><span>Data presented at the EADV Congress 2026 provide additional insights into the long-term treatment experience with LEQSELVI in a chronic autoimmune disease that often requires ongoing management. Additional presentations of pooled post hoc analyses of THRIVE-AA1 and THRIVE-AA2 showed consistent efficacy across clinically relevant patient subgroups, including patients with baseline eyebrow, eyelash or nail involvement, and those with both shorter- and longer-duration disease episodes.</span></p>
<p><span>“Our data at EADV 2026 expands our understanding of LEQSELVI beyond initial treatment response and provides important evidence for dermatologists and advance practice providers into long-term tolerability, durability of response, and maintenance of clinical benefit in adults with severe alopecia areata,” said Ahmad Naim, MD, Senior Vice President, North America Chief Medical Officer, Sun Pharma. “We remain committed to advancing research that addresses the significant unmet needs of people living with this autoimmune disease impacting their daily lives.”</span></p>
<p><b>Summary of Safety for the Patient</b></p>
<p><span>LEQSELVI can lower the ability to fight infections. LEQSELVI is not for CYP2C9 poor metabolizers or anyone taking a CYP2C9 inhibitor. Before and during treatment, test for TB and do bloodwork. Serious infections, blood clots, cancers including lymphoma, stomach or intestinal tears have occurred. People 50+ taking a JAK inhibitor with risk for heart disease may have a greater chance of heart attack, stroke, or death. Doctors should be informed about an infection, hepatitis B or C, or when patients are pregnant or planning or have any problems with low blood sugar. Please full Prescribing Information, including Boxed Warning and Medication Guide, and see below for Important Safety Information.</span></p>
<p><span>The LEQSELVI data presentation is one of 22 presentations from Sun Pharma across its dermatology and immunology portfolio.</span></p>
<p>The post <a href="https://www.expresspharma.in/sun-pharma-presents-leqselvi-long-term-data-at-eadv-congress-2026/">Sun Pharma presents LEQSELVI long-term data at EADV Congress 2026</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Kusum Healthcare facility in Ukraine hit by drone attack</title>
<link>https://edusehat.com/en/kusum-healthcare-facility-in-ukraine-hit-by-drone-attack</link>
<guid>https://edusehat.com/en/kusum-healthcare-facility-in-ukraine-hit-by-drone-attack</guid>
<description><![CDATA[ 
Kusum Healthcare says its manufacturing facility in Sumy, Ukraine, was hit by a Russian drone attack, with one employee confirmed dead and several others injured.
The post Kusum Healthcare facility in Ukraine hit by drone attack appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2022/09/13104819/indian-flag-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 05 Oct 2026 19:20:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Kusum, Healthcare, facility, Ukraine, hit, drone, attack</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2022/09/13104819/indian-flag-1.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2022/09/13104819/indian-flag-1.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2022/09/13104819/indian-flag-1-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Kusum Healthcare said its manufacturing facility in Sumy, Ukraine, was hit by a Russian drone attack, resulting in the death of one employee and injuries to several others. The company said the total damage is projected to exceed USD 50 million.</span></p>
<p><span>Kusum Healthcare, which exports to 22 nations worldwide, including through KUSUM IN UKRAINE, condemned the attack on its manufacturing facility in Sumy, Ukraine.</span></p>
<p><span>The company said the facility is dedicated to manufacturing life-saving drugs. It also said the incident follows an attack on its Ukrainian warehouse on April 14, 2025, when a Russian drone destroyed the facility.</span></p>
<p><span>Kusum Healthcare said it has manufacturing facilities in India, including two units in Bhiwadi, Rajasthan, and one unit in SEZ-Pithampur, Indore, Madhya Pradesh.</span></p>
<p><span>According to the company, losses from the previous attack exceeded UAH 1 billion, while the total current damage is projected to exceed USD 50 million. Kusum Healthcare said it had made repeated pleas through Indian pharma forums for intervention at the international diplomatic level to protect private healthcare businesses from the conflict.</span></p>
<p><span>The company said one employee was confirmed dead at the site and several others were injured. The India business and management authorities at Kusum Healthcare are reviewing the situation.</span></p>
<p><span>The Federation of Pharma Entrepreneurs (FOPE) also expressed concern over the reported attack. In a statement posted on LinkedIn by Harish Jain, President, FOPE, the organisation offered condolences to the family of the employee who died and wished those injured a speedy recovery.</span></p>
<p><span>FOPE said pharma manufacturing facilities form part of healthcare infrastructure and that their safety and continued operation are important during a conflict. The organisation said it stands with Kusum Group, the affected employees and their families, and hopes the company can assess the damage, protect its workforce and restore operations when conditions permit.</span></p>
<p><span>FOPE also reiterated its support for India’s position on the Russia-Ukraine conflict, stating that a lasting resolution should be pursued through dialogue and diplomacy, with respect for sovereignty and territorial integrity. It also said that medicines, healthcare and humanitarian needs should be insulated from the consequences of conflict as far as possible.</span></p>
<p><span>“FOPE stands in solidarity with Kusum Group and hopes for the safety of all its employees and for peace and stability to return to the region at the earliest,” said the organisation.</span></p>
<p>The post <a href="https://www.expresspharma.in/kusum-healthcare-facility-in-ukraine-hit-by-drone-attack/">Kusum Healthcare facility in Ukraine hit by drone attack</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Does India Pharma Inc need a new blueprint?</title>
<link>https://edusehat.com/en/does-india-pharma-inc-need-a-new-blueprint</link>
<guid>https://edusehat.com/en/does-india-pharma-inc-need-a-new-blueprint</guid>
<description><![CDATA[ 
The open letter from nine EU pharma leaders and China’s new five year pharma plan are the latest and clearest signals that the stakes are only getting higher
The post Does India Pharma Inc need a new blueprint? appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/05171542/EP_EditorsNote_Oct_2026_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 05 Oct 2026 19:20:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Does, India, Pharma, Inc, need, new, blueprint</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/05171542/EP_EditorsNote_Oct_2026_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/05171542/EP_EditorsNote_Oct_2026_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/05171542/EP_EditorsNote_Oct_2026_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>China’s new five-year plan for its pharmaceutical sector, released on September 18, places innovation and globalisation at the centre of a major repositioning from scale to innovation driven growth. </span></p>
<p><span>If this sounds similar to India Pharma Inc’s stated volume to value transition, it is only to be expected, as both move from their generics moorings. </span></p>
<p><span>A few days later, on September 22, an open letter from nine European pharma companies, cautioned that “Europe (is) losing ground to global competition” as “over $600 billion in pharmaceutical investment has been announced in the US and China in the last two years alone.” It makes the case that “European governments must create conditions that attract investment in next-generation medicines before it’s too late.” </span></p>
<p><span>Industry observers in India point out that what worries EU pharma leaders is a worry for India too. The question is, how will we respond? And will we respond fast enough? </span></p>
<p><span>China’s move away from its traditional APIs and intermediates towards innovative medicines could in fact be a short term opportunity for India. </span></p>
<p><span>Commenting on this aspect of China’s 15th five year plan Bharat Shah, MD, S Kant Healthcare and National President, IDMA pointed out that IDMA’s members are MSMEs with strong technical skills, so moving into and competing in this API space is not difficult, but what they need is more regulatory support, low interest rates and faster approvals. </span></p>
<p><span>But Namit Joshi, Chairman, Pharmexcil went to the heart of the issue when he pointed out that China has state owned companies so when Indian pharma companies go up against their Chinese counterparts, they are actually competing with a country, not a company. Both Shah and Joshi were part of a panel discussion at the Peptides & Complex Generics Symposium 2026 (PCG 2026). </span></p>
<p><span>China is already on this path and the new plan is designed to accelerate this transition. Dr Mahesh Bhalgat, CEO and founder, AAPM Therapeutics and an independent consultant, terms it “a bold plan where China displays ambition to further significantly step up its innovation game.” He also points out that the journey from being a leader in quantity (of pharma manufacturing) to a leader in quality (of pharma innovative assets) is already demonstrated by China having increased deal value considerably from single digit to $130+billion in 2025. </span></p>
<p><span>As per media reports quoting a Nomura research analysis, the plan lays out targets in 10 areas, including raising the average R&D expenditure-to-sales ratio, increasing the global market share of first-in-class and having more than five drugs with global annual sales exceeding $1 billion. These are framed as goals, without legal binding. The plan does not give details of how the companies are to achieve this nor an implementation path. </span></p>
<p><span>India Pharma Inc and policy makers must closely analyse the plan and modify India Pharma Inc’s strategic blueprint because it would have crucial implications for India.</span></p>
<p><span>But China’s government and regulators have traditionally supported the pharma industry with industry-friendly policies, geared towards growth. The plan does mention 20 pharma parks, which would no doubt help Chinese pharma companies meet these goals.</span></p>
<p><span>And where does India stand? The average R&D expenditure-to-sales ratio for most listed pharma companies in India is estimated to be below 10 per cent. The good news is that India is on the same path, with a clear push to move from volume to value. </span></p>
<p><span>In the near term, India’s pharma sector seems to be weathering the current turbulence reasonably well. The latest Crisil Ratings report predicts that the pharma sector will see stronger dose of revenue growth at 11-13 per cent this fiscal, up from 8 per cent last fiscal, driven by accelerating exports and firmer domestic demand. The analysis is based on nearly 190 Crisil-rated pharma companies, accounting for about half of the sector’s revenue last fiscal. </span></p>
<p><span>The caveat is that this growth spurt is unlikely to flow through fully to earnings, as inflation in raw material, energy and freight costs is expected to compress operating margins by 150-200 basis points (bps). </span></p>
<p><span>In tune with the experts in our cover story in this edition (Read story, Beyond US: New shores, new bets), India’s exports now show a balance between regulated and semiregulated markets, with approximately 57 per cent to the former, as per Crisil. </span></p>
<p><span>Also of significance is the fact that the sector’s domestic and export revenues are almost equal. The strong domestic buffer will be crucial, as potential US tariffs on pharma exports still hang over the sector. </span></p>
<p><span>Zooming back to the open letter from nine EU pharma leaders and China’s new five year pharma plan, these are the latest and clearest signals that the stakes are only getting higher. </span></p>
<p><span>Each country’s healthcare leadership is lobbying their governments and regulators for more supportive policies, to double down on securing the sovereignty and sustainable future of its pharma and biopharma sector, so that they are positioned to best serve the medical needs of their patient populations. </span></p>
<p><span>India Pharma Inc too will need much more policy and regulatory support, with quality and pricing guardrails, to map a future path that is sustainable, plays to its strengths, and safeguards patients’ lives in India and beyond. </span></p>
<p> </p>
<p><em><strong>VIVEKA ROYCHOWDHURY, Editor </strong></em></p>
<p><em><strong>viveka.r@expressindia.com </strong></em></p>
<p><em><strong>viveka.roy3@gmail.com </strong></em></p>
<p>The post <a href="https://www.expresspharma.in/does-india-pharma-inc-need-a-new-blueprint/">Does India Pharma Inc need a new blueprint?</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Getting glutathione into the blood is not the same as getting glutathione into the cell</title>
<link>https://edusehat.com/en/getting-glutathione-into-the-blood-is-not-the-same-as-getting-glutathione-into-the-cell</link>
<guid>https://edusehat.com/en/getting-glutathione-into-the-blood-is-not-the-same-as-getting-glutathione-into-the-cell</guid>
<description><![CDATA[ 
Skin Beyond Borders announced its audited skincare marketplace in August. What industry gap are you trying to address? My experience in the industry spans around 20 years. I formally started working in dermatology in 2009, although before that I was in formulation development and clinical research. In 2009 I started Adroit Digital Ideas, a medical […]
The post Getting glutathione into the blood is not the same as getting glutathione into the cell appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/15174116/Ajit-Marathe-Founder-Chief-Innovation-Officer-Skin-Beyond-Borders.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 05 Oct 2026 19:20:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Getting, glutathione, into, the, blood, not, the, same, getting, glutathione, into, the, cell</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/15174116/Ajit-Marathe-Founder-Chief-Innovation-Officer-Skin-Beyond-Borders.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/15174116/Ajit-Marathe-Founder-Chief-Innovation-Officer-Skin-Beyond-Borders.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/15174116/Ajit-Marathe-Founder-Chief-Innovation-Officer-Skin-Beyond-Borders-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p align="LEFT"><span><span><span><b>Skin Beyond Borders announced its audited skincare marketplace in August. What industry gap are you trying to address?</b></span></span></span></p>
<p align="LEFT"><span><span><span>My experience in the industry spans around 20 years. I formally started working in dermatology in 2009, although before that I was in formulation development and clinical research. In 2009 I started Adroit Digital Ideas, a medical marketing company, doing product-launch support, technical brochures, training decks and product-information material for doctors, for clients including GSK, Abbott, Ranbaxy and Clariant. </span></span></span></p>
<p align="LEFT"><span><span><span>Over time we realised that model could not be scaled. We also had an opportunity around a drug for skin cancer, which moved us into dermatology marketing. In 2011, Adroit Digital Ideas became Adroit Biomed. My background has always been on the science side — formulation development and clinical research but dermatology is also a dynamic and creative industry. Every day something new emerges.</span></span></span></p>
<p align="LEFT"><span> <span><span>should say where that ended, because it is relevant to why I am doing this now. We sold Adroit Biomed to Alkem Laboratories in April last year</span></span></span></p>
<p align="LEFT"><span><span><span>We were involved in introducing concepts such as 20 per cent vitamin C topical gel and 1 gram vitamin C effervescent in India in 2012. One of those, Enerc 1000, went on to become the third largest vitamin C brand in India on ORG data in 2015. We were also among the early companies working with glutathione in the dermatology space. At that time many doctors were not familiar with glutathione, because it was not extensively covered in their academic training.</span></span></span></p>
<p align="LEFT"><span><span><span>That experience showed us how much happens after a person starts using a product. We had both doctor and direct channels, so we heard from very different users. Some reported significant changes. Others said they had seen nothing after months. That made us look more closely at the science behind efficacy and individual response.</span></span></span></p>
<p align="LEFT"><span><span><span><b>You have worked extensively with glutathione. What does the science say about absorption and efficacy?</b></span></span></span></p>
<p align="LEFT"><span><span><span>One of the fundamental challenges with glutathione is absorption. It has been known for some time that oral glutathione is poorly absorbed, which is one reason different delivery systems, including liposomal formulations, have been explored. Intravenous administration is considered different because it delivers the ingredient directly into the bloodstream.</span></span></span></p>
<p align="LEFT"><span><span><span>However, getting glutathione into the blood is not the same as getting glutathione into the cell. Glutathione does not enter the cell intact, and the reason is not its size — it is a small molecule. It stays out because it is electrically charged and highly water-soluble, so it does not readily cross a lipid membrane, and because no import route for intact glutathione operates at a meaningful rate in most mammalian cells. The dominant route is breakdown at the cell surface. The fragments are taken in separately and used to build glutathione again inside.</span></span></span></p>
<p align="LEFT"><span><span><span>There is a second factor: the enzyme glutamate-cysteine ligase, or GCL. It runs the first step of glutathione synthesis and is the rate-limiting one. Its activity and expression decline with age and can be affected by chronic conditions and higher levels of inflammation. </span></span></span></p>
<p align="LEFT"><span><span><span>There is also a control mechanism I think the category has paid too little attention to. GCL is inhibited by glutathione itself — as glutathione accumulates, the enzyme slows down.</span></span></span></p>
<p align="LEFT"><span><span><span>So if the cell has sufficient GCL but lacks raw materials, supplying those building blocks may help. But if GCL activity itself is low, simply supplying more glutathione or its precursors may not produce the increase people expect.</span></span></span></p>
<p align="LEFT"><span><span><span><b>Does that mean higher doses are more effective, particularly as a person ages?</b></span></span></span></p>
<p align="LEFT"><span><span><span>Not necessarily. If only a proportion of oral glutathione is absorbed, increasing the dose may increase what reaches the bloodstream. But that does not automatically mean more glutathione enters the cell.</span></span></span></p>
<p align="LEFT"><span><span><span>The bigger question is what is happening inside the cell. Someone may have adequate GCL activity but insufficient amino-acid availability, and in that situation providing the raw materials could support production. If GCL activity is inadequate, increasing the supply of raw materials may not have the same effect. That can partly explain why people respond differently to glutathione supplementation.</span></span></span></p>
<p align="LEFT"><span><span><span><b>Where does gamma-glutamylcysteine fit, and what is your interest in it?</b>Let me put the commercial position first. We retail Continual-G, a gamma-glutamylcysteine supplement, on our platform. So I have an interest here, and it is better that I say so than that somebody else points it out.</span></span></span></p>
<p align="LEFT"><span><span><span>Gamma-glutamylcysteine, or GGC, is one step before glutathione in the cellular biosynthesis pathway — the same pathway, one piece short of finished. The proposition is that GGC is absorbed, enters the cell, and joins the pathway after the first step, so the rate-limiting enzyme is not the constraint.</span></span></span></p>
<p align="LEFT"><span><span><span>Two qualifications belong with that. The uptake mechanism has not been established — the published work says so directly. And GGC is also cleaved at the cell surface by the same enzyme that cleaves glutathione; a 2022 study found it handles GGC comparably. So what can reasonably be claimed is that uptake outruns breakdown, not that GGC avoids breakdown. </span></span></span></p>
<p align="LEFT"><span><span><span><b>And the human evidence?</b></span></span></span></p>
<p align="LEFT"><span><span><span>There is one published pharmacokinetic trial, and I would rather describe it accurately than favourably, because anybody can read it.</span></span></span></p>
<p align="LEFT"><span><span><span>Zarka and Bridge, <i>Redox Biology</i>, 2017. A single 2 gram oral dose raised glutathione inside lymphocytes by 53 per cent within 90 minutes, peaking at around three hours and returning close to baseline by five.</span></span></span></p>
<p align="LEFT"><span><span><span>The caveats matter. Fourteen trials in thirteen participants. Doses of 2 grams and 4 grams. Individual responses ranged from 10 to 161 per cent, so 53 is an average across a very wide spread. There was no placebo control — placebo capsules were used only to match capsule count between the two doses. The pharmacokinetic arm had six people; one withdrew during the study and one 4 gram dataset was excluded, so five carry the 2 gram data and four the 4 gram. And the authors hold the manufacturing patents.</span></span></span></p>
<p align="LEFT"><span><span><span>It is a pilot study and should be called one. I would add two things. There is no head-to-head trial of oral glutathione against GGC — the comparison is drawn across separate studies with different designs, and it should be labelled that way. And the dose studied is not the dose sold: the trial used 2 and 4 grams, and the product is 400 milligrams. A 400 milligram study is registered in India, sponsored by the manufacturer, and has not yet begun recruiting.</span></span></span></p>
<p align="LEFT"><span><span><span>That is where the evidence currently stands.</span></span></span></p>
<p align="LEFT"><span><span><span><b>Glutathione injections have attracted attention for skin brightening. What are the safety considerations?</b></span></span></span></p>
<p align="LEFT"><span><span><span>There is an important distinction between glutathione’s use for established medical indications and its off-label use for skin brightening. Glutathione is naturally present in the body and is an important antioxidant. It is also used in medical settings for certain conditions.</span></span></span></p>
<p align="LEFT"><span><span><span>When physiologically unusual amounts are administered, there can be effects on the body’s redox balance. Some patients report symptoms such as tingling. There is also the possibility of hypersensitivity or other adverse reactions.</span></span></span></p>
<p align="LEFT"><span><span><span>For skin lightening specifically, the regulatory position is clearer than the market appears to assume. The Philippines FDA attributes to injectable glutathione used this way toxic effects on the liver, kidneys and nervous system, the possibility of Stevens-Johnson syndrome, and — where it is given by a non-medical practitioner in a non-sterile facility — transmission of infectious agents including HIV and hepatitis B and C. Its advisory also states there are no published clinical trials evaluating injectable glutathione for skin lightening, and no published guidelines for dosing or duration.</span></span></span></p>
<p align="LEFT"><span> <span><span>In India, CDSCO issued a public notice on 18 May this year clarifying that injectable preparations do not fall within the definition of a cosmetic, and that no cosmetic may be administered by injection — by consumers, professionals or aesthetic clinics. Trade coverage has read glutathione drips as falling within its scope. Enforcement is uneven, though, and a range of other intravenous products continue with very little oversight.</span></span></span></p>
<p align="LEFT"><span><span><span>The larger issue, in my view, is not the molecule. It is who is administering it, and in what setting.</span></span></span></p>
<p align="LEFT"><span><span><span>A qualified medical professional takes an appropriate history, understands the protocol, is trained to manage an adverse event, and has the infrastructure to respond if something goes wrong. There are instances where procedures are offered in inappropriate settings without adequate medical support — people may book hotel rooms, bring clients in, and conduct procedures without the necessary emergency infrastructure. That is a serious concern. </span></span></span></p>
<p align="LEFT"><span><span><span>Glutathione is not an alien substance to the human body, but that does not mean its administration is risk-free.</span></span></span></p>
<p align="LEFT"><span><span><span><b>You have spoken about the need for indigenous innovation in skincare. What prompted that?</b></span></span></span></p>
<p align="LEFT"><span><span><span>In 2017 I was at a cosmetics exhibition in Paris. We were using a cinnamon extract supplied from France, for acne and oily skin. At the supplier’s stall, the product manager told me they were buying the raw material from India, processing it into an extract in France, and selling that extract back to India.</span></span></span></p>
<p align="LEFT"><span><span><span>I knew this at some level already. Hearing it said out loud made me look at the larger pattern.</span></span></span></p>
<p align="LEFT"><span><span><span>India has a strong pharmaceutical industry, a large scientific talent pool and significant IT capability. Yet in cosmetics and skincare we have historically been more dependent on imported active ingredients and technologies. At Adroit, most of our active ingredients were imported. We would talk about an active coming from Japan, Korea or the US, because that was how the market operated.</span></span></span></p>
<p align="LEFT"><span><span><span>Alongside that there was a perception that products associated with international brands were inherently better. That mindset persists, even though there are several good products being developed in India now.</span></span></span></p>
<p align="LEFT"><span><span><span>The same issue now extends to technology. Many of the facial-scanning technologies being integrated into skincare platforms originate outside India. Indian brands pay licence fees to use them, while the systems may also learn from data generated by Indian users, depending on the terms of the licence.</span></span></span></p>
<p align="LEFT"><span><span><span>That is a strange equation. We are paying for the technology and, in the process, providing the data that helps improve it.</span></span></span></p>
<p align="LEFT"><span><span><span>I should be straightforward that we are building a facial scanner ourselves and we collect user data, so I am not standing outside this. The question I care about is who collects more. It is where the data sits and who it ultimately benefits. </span></span></span></p>
<p align="LEFT"><span><span><span>India has the IT capability. We have one of the world’s largest pools of dermatologists. We have the scientific and clinical ecosystem. Data and technical capabilities are not necessarily scarce. What has been missing is the initiative to bring these capabilities together and build the technology here.</span></span></span></p>
<p align="LEFT"><span><span><span>That is the gap I wanted to address.</span></span></span></p>
<p align="LEFT"><span><span><span><b>Is the larger objective to make India a centre for skincare innovation?</b></span></span></span></p>
<p align="LEFT"><span><span><span>Yes. My objective is to see India become a centre of innovation for the world in skincare by 2035. Skin Beyond Borders is the first step in that direction.</span></span></span></p>
<p align="LEFT"><span><span><span>I don’t see it simply as a skincare brand. It is a platform, which means it can work with brands, ingredient suppliers, manufacturers, researchers and other stakeholders in India and internationally.</span></span></span></p>
<p align="LEFT"><span><span><span>One of the components we have developed is the Skin Friendliness Index, or SFI, which is a composite score developed by us. I would not call it clinically validated at this stage, because we do not yet have sufficient data to substantiate it. That is precisely why data generation matters.</span></span></span></p>
<p align="LEFT"><span><span><span>We are also working with a research group in Brazil that studies similar areas and has published in this field. We see scope for exchanging data and developing a more robust scoring mechanism over the next two to three years.</span></span></span></p>
<p align="LEFT"><span><span><span><b>How is Skin Beyond Borders different from a conventional beauty marketplace?</b></span></span></span></p>
<p align="LEFT"><span><span><span>I would start by saying we do not see a platform like Nykaa as a competitor. It is a different category of business. A marketplace of that kind is built to help someone reach a purchasing decision, and it does that job well. Our role begins after the purchase, when the person actually starts using the product.</span></span></span></p>
<p align="LEFT"><span><span><span>SkinBB is a collaborative platform and an audited marketplace, and what we intend to build on top of that is a predictive intelligence layer for the industry. </span></span></span></p>
<p align="LEFT"><span><span><span>The starting point is understanding what happens over time. Does the user continue with the product or switch? What changes are taking place in the skin? How consistently is the routine actually followed?</span></span></span></p>
<p align="LEFT"><span><span><span>We are developing a facial-scanning capability, and alongside it a daily-log feature through which users can take selfies and track changes over time. After 14 days, the system should be able to show how the skin looked on day one against day 14, with quantitative comparisons across different parameters.</span></span></span></p>
<p align="LEFT"><span><span><span>The idea is to link those changes with the user’s routine — which products, adherence to them, environmental conditions, outdoor activity, food, and other parameters they choose to log.</span></span></span></p>
<p align="LEFT"><span><span><span>Collected consistently and at scale, that record is what makes prediction possible — for the individual, and for an industry that has had very little visibility into how its products behave in real use. That is the objective, rather than simply recommending a product. </span></span></span></p>
<p align="LEFT"><span><span><span><b>For a data-driven platform, getting users to engage consistently is difficult. How are you approaching it?</b></span></span></span></p>
<p align="LEFT"><span><span><span>That is probably one of the biggest challenges. Getting users to log in every day and consistently provide data is difficult.</span></span></span></p>
<p align="LEFT"><span><span><span>At present the platform is free. We are not funded currently, and every aspect of operating it has a cost, so we will eventually have to determine a sustainable model. We are considering a subscription, but we first want to understand how users actually use the platform, what their behaviour looks like, and what the average cost of serving a user is.</span></span></span></p>
<p align="LEFT"><span><span><span>For the first few months our focus is therefore usage and data generation rather than monetisation. I don’t want to ask users to pay significant amounts and, at the same time, expect them to continuously provide data.</span></span></span></p>
<p align="LEFT"><span><span><span><b>Selfies and daily skin logs put you squarely inside India’s data protection regime. How are you approaching that?</b></span></span></span></p>
<p align="LEFT"><span><span><span>We treat it as a design constraint rather than a compliance exercise bolted on afterwards. With this kind of data you cannot retrofit it.</span></span></span></p>
<p align="LEFT"><span><span><span>The DPDP Act makes a platform like ours a data fiduciary. The Rules were notified in November 2025 and set an eighteen-month transition running to May 2027, so although enforcement is still in its early phase, the obligations are already known. For us the binding ones are the ordinary ones — notice, purpose limitation, consent that is specific and can be withdrawn, retention limits, deletion on request, breach reporting. All of those are far easier to build in now than to add at scale later.</span></span></span></p>
<p align="LEFT"><span><span><span>The provision that deserves more attention than it gets is Section 9. Under the Act anyone below eighteen is a child. Processing their data requires verifiable consent from a parent or guardian, and tracking, behavioural monitoring and targeted advertising directed at children are prohibited outright. A longitudinal skin diary is behavioural monitoring on any reasonable reading. So for a platform like ours this is not a consent checkbox — it decides whether you can serve that age group at all. </span></span></span></p>
<p align="LEFT"><span><span><span>There is also a point that matters to me beyond the legal minimum. We ask people to contribute data over months, which only works if they understand what they are contributing and why. If consent is buried, we have not really obtained it — whatever the law allows. </span></span></span></p>
<p align="LEFT"><span><span><span>We want to encourage users to contribute data because, ultimately, that data can help them understand their own skin better.</span></span></span></p>
<p align="LEFT"><span><span><span>This becomes particularly relevant for chronic skin conditions, where the skin may remain stable for a period and then suddenly flare. With a longitudinal record you can begin to identify patterns around those changes, instead of only asking why something happened suddenly.</span></span></span></p>
<p align="LEFT"><span><span><span>That is the direction in which we want to take the platform.</span></span></span></p>
<p>The post <a href="https://www.expresspharma.in/getting-glutathione-into-the-blood-is-not-the-same-as-getting-glutathione-into-the-cell/">Getting glutathione into the blood is not the same as getting glutathione into the cell</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The changing face of dermaceutical skincare</title>
<link>https://edusehat.com/en/the-changing-face-of-dermaceutical-skincare</link>
<guid>https://edusehat.com/en/the-changing-face-of-dermaceutical-skincare</guid>
<description><![CDATA[ 
Fixderma has grown from its 2010 launch into a company exporting to over 35 countries with a 130-plus product portfolio. Looking back, which single decision or pivot do you think had the biggest impact on that trajectory? I don’t think there is one single decision in business that brings a larger impact on the overall […]
The post The changing face of dermaceutical skincare appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/05115250/Shaily-Mehrotra-co-Founder-and-CEO-Fixderma-FCL-Skincare.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 05 Oct 2026 15:45:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, changing, face, dermaceutical, skincare</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/05115250/Shaily-Mehrotra-co-Founder-and-CEO-Fixderma-FCL-Skincare.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/05115250/Shaily-Mehrotra-co-Founder-and-CEO-Fixderma-FCL-Skincare.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/05115250/Shaily-Mehrotra-co-Founder-and-CEO-Fixderma-FCL-Skincare-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><strong><span><span>Fixderma has grown from its 2010 launch into a company exporting to over 35 countries with a 130-plus product portfolio. Looking back, which single decision or pivot do you think had the biggest impact on that trajectory?</span></span></strong></p>
<p><span><span>I don’t think there is one single decision in business that brings a larger impact on the overall performance of a company. It is a cumulative effect of many decisions, including wrong decisions, decisions taken at the right time and some decisions that you did not take at the right time.</span></span></p>
<p><span><span>If I look back, I think it was the persistence and resilience to keep going. That is why we are here today. For a company like ours, particularly in such a competitive category, continuing to move forward is not easy.</span></span></p>
<p><span><span>When we started, we were not an online or D2C company. We were a pure-play business selling through dermatologists. That was one of the more difficult routes to take, but we stayed with it. So, putting it in one line, it is difficult to point to one decision. It has been a collective and cumulative effect of several decisions over the years.</span></span></p>
<p><strong><span><span>You’ve positioned FCL as a premium range alongside the core Fixderma brand. What was the strategic thinking behind running two brand identities rather than just expanding one?</span></span></strong></p>
<p><span><span>I saw a need for a premium skincare range that was completely dedicated to specific skin problems. We are taking baby steps towards that.</span></span></p>
<p><span><span>FCL Skincare was launched about 10 years ago by Dr Raj to give dermatologists and aware users products with a strong focus on ingredients. Even the names of the products reflect this approach. Eye Refining Matrix is our under-eye cream, Intensive Eye Serum contains peptides, and we have a Skin Brightening Complex. We have also recently launched a Exosomes range that penetrates 20X deeper into the skin & Neck Firming Cream.</span></span></p>
<p><span><span>The formulations are quite complex, with multiple ingredients being used for specific purposes. So, the idea was to create a range that is focused on the problem, the formulation and the quality of ingredients.</span></span></p>
<p><strong><span><span>The line between cosmetic and pharmaceutical skincare has been getting blurrier, with the rise of what’s now called the dermaceutical or cosmeceutical category. How do you see this segment evolving over the next five years, and what’s driving that shift?</span></span></strong></p>
<p><span><span>We have seen a significant shift in the last two to three years. Users have become much more aware of ingredients and what they are putting on their skin.</span></span></p>
<p><span><span>Earlier, people were following different spokespeople and recommendations about what they should use. Now there is greater awareness about what ingredients are actually doing and whether using too many actives could affect the skin barrier.</span></span></p>
<p><span><span>I think this has created an opportunity for brands that are ingredient-focused and have the right documentation to support the claims they make. Consumers are becoming more informed, and they are looking for products where there is a clear connection between the ingredients, the formulation and the claims.</span></span></p>
<p><strong><span><span>India’s cosmeceutical exports have grown steadily, but so has competition from established global skincare majors. What do Indian dermaceutical companies need to get right to compete internationally rather than just domestically?</span></span></strong></p>
<p><span><span>I think the key is to understand the market and develop products accordingly. Indian skin, climate and lifestyle have their own characteristics, and these factors need to be considered while developing formulations.</span></span></p>
<p><span><span>We are a very diverse population, and skin characteristics can vary across populations. Climate and daily routines also influence how products perform. So formulations cannot simply be developed by looking at what works in another country and assuming the same approach will work in India or other markets.</span></span></p>
<p><span><span>At the same time, Indian companies need to have strong R&D capabilities and be able to build formulations around a clear understanding of the consumer and the market.</span></span></p>
<p><strong><span><span>Skincare innovation has increasingly leaned on newer actives and delivery technologies, from peptides to encapsulation methods. In your view, is the Indian dermaceutical industry keeping pace with that R&D curve, or is it still largely dependent on formulations developed elsewhere?</span></span></strong></p>
<p><span><span>There has to be a strong R&D curve, particularly when you are developing products for Indian skin and Indian conditions.</span></span></p>
<p><span><span>For us, the focus has been on formulations and ingredients rather than simply creating products around marketing claims. Some of our formulations are quite complex and use multiple ingredients for specific purposes.</span></span></p>
<p><span><span>I think understanding the ingredient, the formulation and how it works for the intended skin concern is important. The industry needs to keep building that capability rather than simply replicating what is being developed elsewhere.</span></span></p>
<p><strong><span><span>Regulatory frameworks for cosmeceuticals in India sit somewhere between cosmetics and drugs, and enforcement can be inconsistent. What changes, if any, would you like to see in how this category is regulated?</span></span></strong></p>
<p><span><span>I would simply say: be honest with your combinations and your claims.</span></span></p>
<p><span><span>There are products in the market where brands make claims around specific concentrations of ingredients. For example, they may claim three per cent Redensyl or two per cent Capixyl. </span></span></p>
<p><span><span>These are meaningful ingredients, but when such products are being sold at a very low price while making claims that suggest a particular level of active ingredients, consumers have a right to question whether those claims are realistic.</span></span></p>
<p><span><span>We cannot expect to get everything at an extremely low price and still assume that the formulation contains the claimed ingredients and concentrations. Something is wrong somewhere.</span></span></p>
<p><span><span>I think the industry needs greater honesty and transparency in how products are formulated, what they contain and what claims are made about them.</span></span></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/the-changing-face-of-dermaceutical-skincare/">The changing face of dermaceutical skincare</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Regenerative aesthetics: The new frontier of skin and hair health</title>
<link>https://edusehat.com/en/regenerative-aesthetics-the-new-frontier-of-skin-and-hair-health</link>
<guid>https://edusehat.com/en/regenerative-aesthetics-the-new-frontier-of-skin-and-hair-health</guid>
<description><![CDATA[ 
Aesthetic treatments were generally used for correction purposes until recently. The usual practice was to smooth out wrinkles, lessen pigmentation, resurface scars, and treat hair loss. All these things have changed as a new approach in this field has developed. This innovative method moves further than just improving the appearance of skin and hair. It […]
The post Regenerative aesthetics: The new frontier of skin and hair health appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/05120947/Dr-Madhu-Goyal-Founder-Director-DIOSA-Healthcare.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 05 Oct 2026 15:45:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Regenerative, aesthetics:, The, new, frontier, skin, and, hair, health</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/05120947/Dr-Madhu-Goyal-Founder-Director-DIOSA-Healthcare.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/05120947/Dr-Madhu-Goyal-Founder-Director-DIOSA-Healthcare.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/05120947/Dr-Madhu-Goyal-Founder-Director-DIOSA-Healthcare-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p align="LEFT"><span><span><span>Aesthetic treatments were generally used for correction purposes until recently. The usual practice was to smooth out wrinkles, lessen pigmentation, resurface scars, and treat hair loss. All these things have changed as a new approach in this field has developed.</span></span></span></p>
<p align="LEFT"><a name="Bookmark1"></a><span><span><span>This innovative method moves further than just improving the appearance of skin and hair. It deals with supporting the body’s self-regeneration process. The new approach is called regenerative aesthetics, which combines different fields such as dermatology, the hair restoration industry, modern technology, and regenerative medicine.</span></span></span></p>
<p align="LEFT"><span><span><span>The main objective is more than just changing somebody’s looks. The point lies in assisting the skin in becoming healthier, the scalp in functioning better, and the process of hair restoration being as natural as possible.</span></span></span></p>
<p align="LEFT"><strong><a name="Bookmark2"></a><span><span><span>What is regenerative aesthetics?</span></span></span></strong></p>
<p align="LEFT"><span><span><span>Regenerative aesthetics refers to methods that stimulate the body’s own natural systems responsible for healing, forming collagen and carrying out their activity at the cellular level. Unlike conventional aesthetic treatments that deal with outer correction only, regenerative aesthetics focuses more on the body’s biological processes occurring in the skin, hair follicles and the surrounding tissues.</span></span></span></p>
<p align="LEFT"><span><span><span>This trend is especially pertinent to individuals suffering from hair loss, the first signs of ageing, acne scars, skin unevenness, pigmentation and loss of skin elasticity.</span></span></span></p>
<p align="LEFT"><span><span><span>The principle is pretty simple: healthy-looking skin and hair cannot be only a result of surface preservation; a lot depends on what happens beneath the skin surface. Therefore, not only does the modern cosmetic industry intend to focus on one specific aspect while treating patients, but it is constantly combining various procedures, which allows certain positive outcomes.</span></span></span></p>
<p align="LEFT"><strong><a name="Bookmark3"></a><span><span><span>From surface correction to skin renewal</span></span></span></strong></p>
<p align="LEFT"><span><span><span>Take skin that’s ageing. It may have fine wrinkles on the surface, but what really occurs is a drop in collagen and elastin levels, skin structure modification and lagging regeneration.</span></span></span></p>
<p align="LEFT"><span><span><span>Treatments that aim for regeneration are different in focus from the preceding techniques. Microneedling, RF microneedling, skin boosters and particular injectable or energy forms can help with a tailored regeneration programme.</span></span></span></p>
<p align="LEFT"><span><span><span>Microneedling, for instance, produces small injuries that cause the skin to heal itself. RF microneedling enhances the procedure by using the energy of radio frequencies to solve the problems of skin firmness due to thermal stimulation.</span></span></span></p>
<p align="LEFT"><span><span><span>The aim is not to change the person’s face. Rather, the requirement that is expected from the process is a gentler result: good texture, enhanced firmness and a younger appearance.</span></span></span></p>
<p align="LEFT"><strong><a name="Bookmark4"></a><span><span><span>Regenerative approaches in hair restoration</span></span></span></strong></p>
<p align="LEFT"><span><span><span>In terms of hair loss, regenerative aesthetics is making its way into the limelight. Hair thinning can be caused by several factors. Genetic factors, hormonal changes, lack of nutrition, stress and some medical reasons can all be involved in hair loss. This tells us that treatment should start by addressing the cause of hair loss rather than choosing treatment based on its popularity.</span></span></span></p>
<p align="LEFT"><span><span><span>Modern hair restoration has many advanced techniques, including GFC hair therapy, exosome therapy, autologous micrograft treatment, and other procedures that can support hair growth. However, effectiveness will depend on the reason or severity of hair loss.</span></span></span></p>
<p align="LEFT"><span><span><span>In the most severe hair loss cases, regenerative types of methods will be examined together with surgical methods of hair restoration. For instance, FUE hair transplant is aimed at transferring healthy follicles to the bald area and creating a natural hairline. The trend nowadays is that combinations of therapies are used. That is, a person may use an approach for the scalp and another approach for the hairline, and later on, the strategy may be altered over time.</span></span></span></p>
<p align="LEFT"><a name="Bookmark5"></a> <span><span><span><b>Why personalisation matters</b></span></span></span></p>
<p align="LEFT"><span><span><span>There is no one-size-fits-all remedy for aged skin or hair thinning. Two people who visit the same clinic may have similar problems but will require two completely different treatment plans. While one patient may suffer from pigmentation and texture issues, the other may need help with collagen loss. Likewise, while one hair thinning case could be attributed to hereditary reasons, another one may be due to a temporary shedding cycle or a disease. This is why it is so important to have a consultation. An aesthetic-regenerative treatment plan must take into consideration one’s age, skin type, medical history, and lifestyle, as well as the condition to be treated and the person’s expectations. That is why it is the problem that should determine the treatment options rather than the other way around. This is how aesthetic medicine remains a part of healthcare.</span></span></span></p>
<p align="LEFT"><strong><a name="Bookmark6"></a><span><span><span>Combining technology with medical expertise</span></span></span></strong></p>
<p align="LEFT"><span><span><span>Regenerative aesthetics does not refer to a single revolutionary treatment. Rather, it refers to the practice of combining different practices and technologies smartly. For skin treatments, different methods might include peels, laser procedures, RF microneedling, skin boosters, resurfacing treatments, and other rejuvenation therapies. For hair treatments, regenerative options might include non-surgical methods of hair growth and hair transplant techniques. The actual needs of the skin or hair will determine which treatments will be applied. This is why modern aesthetic clinics employ a wider range of practitioners. Dermatologists, aesthetic physicians, plastic surgeons and other specialists are involved in the treatment process if the problem requires both medical and cosmetic approaches.</span></span></span></p>
<p align="LEFT"><strong><a name="Bookmark7"></a><span><span><span>Natural results are becoming the new definition of beauty</span></span></span></strong></p>
<p align="LEFT"><span><span><span>The ongoing shift in aesthetics brings about the idea of simplicity in beauty techniques. More and more people prefer looking natural and not twisted or artificially done. For those who face problems of hair loss, they expect their hairline to suit their face and not make them look transplanted. </span></span></span></p>
<p align="LEFT"><span><span><span>The practice of regenerative aesthetics totally embodies the above-mentioned trends. It suggests that instead of just altering tissue structures, work on improving tissue quality is undertaken.</span></span></span></p>
<p align="LEFT"><span><span><span>In sum, aesthetics goes from the question “What can we change?” to the question “How can we help skin and hair to look and function better?”</span></span></span></p>
<p align="LEFT"><strong><a name="Bookmark8"></a><span><span><span>The future of skin and hair care</span></span></span></strong></p>
<p align="LEFT"><span><span><span>Regenerative aesthetics is still an evolving field. Not every treatment marketed as regenerative has the same level of scientific evidence, and outcomes can differ considerably between individuals. Claims surrounding newer therapies should therefore be considered carefully, with attention to clinical evidence, regulatory status, practitioner qualifications and realistic expectations.</span></span></span></p>
<p align="LEFT"><span><span><span>For patients, this means asking questions matters. What exactly is being used? What evidence supports the treatment? Is it appropriate for the specific condition? How many sessions may be required? What are the risks and alternatives?</span></span></span></p>
<p align="LEFT"><span><span><span>The future of aesthetics is unlikely to be about choosing between beauty and medicine. It is increasingly about bringing the two together.</span></span></span></p>
<p align="LEFT"><span><span><span>Skin health, hair health and appearance are deeply connected. As regenerative approaches continue to develop, aesthetic care is moving toward a more personalised model, where prevention, restoration and appearance can be considered as parts of the same conversation.</span></span></span></p>
<p align="LEFT"><span><span><span>The new frontier is therefore not simply about looking younger or growing more hair. It is about healthier-looking skin, stronger approaches to hair restoration and results that respect the person underneath.</span></span></span></p>
<p align="LEFT"><span><span><span>That may ultimately be the most meaningful promise of regenerative aesthetics: not changing who you are, but helping your skin and hair look closer to their healthiest potential.</span></span></span></p>
<p>The post <a href="https://www.expresspharma.in/regenerative-aesthetics-the-new-frontier-of-skin-and-hair-health/">Regenerative aesthetics: The new frontier of skin and hair health</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>We aim to be a truly integrated partner across modalities</title>
<link>https://edusehat.com/en/we-aim-to-be-a-truly-integrated-partner-across-modalities</link>
<guid>https://edusehat.com/en/we-aim-to-be-a-truly-integrated-partner-across-modalities</guid>
<description><![CDATA[ 
India’s CRDMO sector is gaining importance as global pharma seeks resilient, cost-efficient supply chains. Akhil Ravi, CEO, Aurigene Pharmaceutical Services, discusses the company’s capabilities across small molecules, peptides, biologics and sterile injectables, its global manufacturing partnerships, and the challenges of scaling, quality, regulation and talent. In an exclusive interview with Sanjiv Das. 
The post We aim to be a truly integrated partner across modalities appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/05123132/EP_Akhil_Ravi_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 05 Oct 2026 15:45:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>aim, truly, integrated, partner, across, modalities</media:keywords>
<content:encoded><![CDATA[<div><img width="1280" height="720" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/05123132/EP_Akhil_Ravi_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/05123132/EP_Akhil_Ravi_750.jpg 1280w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/05123132/EP_Akhil_Ravi_750-300x169.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/05123132/EP_Akhil_Ravi_750-1024x576.jpg 1024w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/05123132/EP_Akhil_Ravi_750-768x432.jpg 768w" sizes="auto, (max-width: 1280px) 100vw, 1280px"></div><p><b>Aurigene has announced plans to invest around $100 million. What are the key areas where this investment will be deployed, and where do you expect it to have the greatest impact on the company’s growth and capabilities?</b></p>
<p><span>The investment is aimed at the areas where we see the most customer demand and where the industry has the least capacity: </span></p>
<ul>
<li aria-level="1"><span>Peptide research and manufacturing</span></li>
<li aria-level="1"><span>Capacity expansion for our core platforms</span></li>
<li aria-level="1"><span>Digital and AI platforms</span></li>
<li aria-level="1"><span>Biologics infrastructure</span></li>
</ul>
<p><span>The impact will be greatest where these areas connect, for example peptides and biologics that move from our discovery labs into development and manufacturing without a tech-transfer gap. The aim is to take on larger, more complex programmes and support them through to commercial supply.</span></p>
<p><b>Aurigene, together with its parent company Dr Reddy’s, recently signed a long-term agreement with a leading global pharmaceutical company for technology transfer and commercial drug-product manufacturing and supply of a diversified portfolio. How significant is this agreement for Aurigene, and are you seeing similar interest from other pharmaceutical and biotech companies?</b></p>
<p><span>This is one of the most important agreements in Aurigene’s journey. It is a 10-year master agreement covering technology transfer and commercial manufacturing of products across sterile injectables, biologics and topicals. The products will be made across five Aurigene / Dr Reddy’s sites in India, with revenue expected from calendar year 2028 . It gives us long-term visibility, and it shows that a global innovator trusts our drug-product capabilities, particularly in sterile injectables and biologics.</span></p>
<p><span>We are seeing growing interest of the same kind. Large pharma companies are cutting down their external manufacturing networks and moving from product-by-product outsourcing to fewer, strategic partners. That trend suits an integrated player like us. We already have multi-year commercial contracts with three of the top five innovator pharma companies. We are in active discussions with several global pharma and biotech companies. We will share more when those agreements are signed.</span></p>
<p><b>How is Aurigene leveraging AI and other emerging technologies across the drug discovery process—from target identification and validation to molecule design, optimisation and candidate selection?</b></p>
<p><span>AI is built into how we run discovery. Aurigene.AI combines generative design, predictive modelling and computational chemistry, and it is directly integrated with our wet chemistry and biology labs. The models suggest molecules; our chemists make and test them quickly.</span></p>
<p><span> This lets us run our integrated drug discovery (IDD) programmes more efficiently: we need fewer cycles, make better choices about which compounds to synthesise, and reach candidates faster. All programme data is used only for that programme and that customer.  A good example is our collaboration with Alveus Therapeutics, a biotech company developing next-generation therapies for obesity and metabolic disease. We combined Aurigene.AI with our medicinal chemistry and integrated biology platforms to support their discovery programmes. Together, we nominated ALV-200, a highly selective AMYR3 peptide candidate, as the first development candidate. Other discovery programmes under the collaboration are still ongoing. Across our integrated discovery work, we have delivered</span></p>
<p><span>around 75 projects, and six are now in the clinic.</span></p>
<p><b>What are the biggest challenges currently facing the drug discovery and development ecosystem, from target identification and validation to clinical development, and how is Aurigene addressing these challenges?</b></p>
<p><span>First, capital efficiency. Biotech funding has become more selective, and innovators have to show more data with less money and in less time. Every experiment and every month has to count. This is where India has a real advantage. We have a large pool of experienced chemists and biologists, and the cost of running discovery and development here is competitive. At Aurigene, we combine that talent with Aurigene.AI and our integrated wet</span></p>
<p><span>labs. Partners get more work done for every dollar they spend, and they reach decision points sooner.</span></p>
<p><span>Second, supply-chain risk. Recent years have shown the danger of relying too much on a few countries or single suppliers. Innovators are now reviewing where their molecules are developed and made, and they want partners they can trust over the long term. India is increasingly the natural choice. We add to that with R&D in India and the UK and manufacturing in India, the UK and Mexico, so we can offer customers geographic flexibility</span></p>
<p><span>and supply security.</span></p>
<p><span>Third, quality and trust at scale. Indian CDMOs have often had to prove that they can deliver innovator-grade quality, not only cost advantage. Our track record answers that. We have 16 USFDA-inspected facilities and have taken 20 NCEs to commercialisation.</span></p>
<p><span>Across all three, our answer is integration. Discovery, development and manufacturing sit under one roof, so innovators avoid the delays and risks of moving a programme between vendors. For our partners, that means lower cost, less risk and faster timelines, delivered from Aurigene to global standards.</span></p>
<p><b>Which therapeutic areas have the strongest demand?</b></p>
<p><span>CNS, oncology, immunology and metabolic disorders remain our strongest areas. Metabolic disease, especially obesity, has grown sharply, and it is pushing demand for both peptides and small molecules. Our discovery collaboration with Alveus Therapeutics is a good example. Working together, we nominated ALV-200, a selective AMYR3 peptide candidate for metabolic disorders. We also see strong growth in targeted therapies and in modalities</span></p>
<p><span>such as bispecifics, peptide conjugates and complex injectables. In these areas, customers need a partner that can handle both the science and the scale-up Q3. Use of AI and emerging technologies AI is built into how we run discovery. Aurigene.AI combines generative design, predictive modelling and computational chemistry, and it is directly integrated with our wet chemistry and biology labs. The models suggest molecules; our chemists make and test them quickly.</span></p>
<p><span>This lets us run our integrated drug discovery (IDD) programmes more efficiently: we need fewer cycles, make better choices about which compounds to synthesise, and reach candidates faster. All programme data is used only for that programme and that customer.  </span></p>
<p><span>A good example is our collaboration with Alveus Therapeutics, a biotech company developing next-generation therapies for obesity and metabolic disease. We combined Aurigene.AI with our medicinal chemistry and integrated biology platforms to support their discovery programmes. Together, we nominated ALV-200, a highly selective AMYR3 peptide candidate, as the first development candidate. Other discovery programmes under the collaboration are still ongoing. Across our integrated discovery work, we have delivered around 75 projects, and six are now in the clinic.</span></p>
<p><b>What will be your key priorities over the next three to five years?</b></p>
<p><span>We aim to be a truly integrated partner across modalities, taking a programme from discovery through development to commercial supply. We have taken 20 NCEs through to commercialisation and have 4 R&D centres with 16 USFDA-inspected facilities. We work across small molecules, peptides and biologics, and our next priority is to scale this integration. Our global presence is a big part of this, especially in today’s complex and fast-</span></p>
<p><span>changing geopolitical environment. We have R&D centres in India and the UK, and manufacturing in India, the UK and Mexico. This gives our partners geographic flexibility and supply security.</span></p>
<p><span>Over the next three to five years, we will focus on:</span></p>
<ul>
<li><span>Converting our relationships with large pharma into long-term, multi-product/platforms partnerships</span></li>
<li><span>Building a full stack peptide CRDMO</span></li>
<li><span>Scaling AI-led integrated drug discovery</span></li>
<li><span>Expanding into newer modalities such as ADC, biologics and complex drug products</span></li>
</ul>
<p><em><strong>Sanjiv.das@expressindia.com</strong></em></p>
<p><em><strong>sanjivdas1@gmail.com</strong></em></p>
<p>The post <a href="https://www.expresspharma.in/we-aim-to-be-a-truly-integrated-partner-across-modalities/">We aim to be a truly integrated partner across modalities</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>CERVAVAC receives WHO prequalification</title>
<link>https://edusehat.com/en/cervavac-receives-who-prequalification</link>
<guid>https://edusehat.com/en/cervavac-receives-who-prequalification</guid>
<description><![CDATA[ 
Serum Institute of India’s CERVAVAC, the country’s first indigenously developed gender-neutral quadrivalent human papillomavirus vaccine, has received prequalification from the World Health Organization (WHO)
The post CERVAVAC receives WHO prequalification appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 05 Oct 2026 15:45:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>CERVAVAC, receives, WHO, prequalification</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>CERVAVAC, India’s first indigenously developed gender-neutral Quadrivalent Human Papillomavirus vaccine (qHPV) developed by Serum Institute of India, has received prequalification by the World Health Organization (WHO).</span></p>
<p><span>This is the 32nd WHO prequalification for products/biologicals received by Serum Institute of India. Inclusion on the WHO List of Prequalified Vaccines allows CERVAVAC to be procured by United Nations agencies.</span></p>
<p><span>The recombinant quadrivalent HPV vaccine targets HPV types 6, 11, 16 and 18. It is indicated for girls and boys aged 9 through 26 years.</span></p>
<p><span>Adar Poonawalla, Chief Executive Officer, Serum Institute of India, said, “WHO prequalification of CERVAVAC is an important step in strengthening the global response to HPV. This milestone reflects the effectiveness of the vaccine and creates the opportunity for countries to prevent HPV-related risks. We are pleased to see this indigenously developed vaccine reach this achievement, and look forward to contributing to immunisation coverage, advancing global healthcare”</span></p>
<p><span>CERVAVAC was previously approved for use in India by the Drugs Controller General of India (DCGI). It is administered for the prevention of diseases caused by the four HPV types.</span></p>
<p><span>This includes the prevention of anal cancer in boys and young men, and cervical, vulvar, vaginal, and anal cancers in girls and young women. It is also indicated for preventing genital warts, as applicable to the indicated population.</span></p>
<p>The post <a href="https://www.expresspharma.in/cervavac-receives-who-prequalification/">CERVAVAC receives WHO prequalification</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Bristol Myers Squibb secures expanded US approval for Camzyos</title>
<link>https://edusehat.com/en/bristol-myers-squibb-secures-expanded-us-approval-for-camzyos</link>
<guid>https://edusehat.com/en/bristol-myers-squibb-secures-expanded-us-approval-for-camzyos</guid>
<description><![CDATA[ The therapy is indicated to improve functional capacity and symptoms. The regulatory decision was supported by findings from the double-blind, randomised Phase III SCOUT-HCM trial, which assessed the 
The post Bristol Myers Squibb secures expanded US approval for Camzyos appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/10/PT-2-01-10-2026-shutterstock_2526930649.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 01 Oct 2026 17:35:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Bristol, Myers, Squibb, secures, expanded, approval, for, Camzyos</media:keywords>
<content:encoded><![CDATA[<p>The therapy is indicated to improve functional capacity and symptoms.</p>
<p>The regulatory decision was supported by findings from the double-blind, randomised Phase III SCOUT-HCM trial, which assessed the cardiac myosin inhibitor (CMI) against a placebo in 44 adolescent patients aged 12 to under 18 years.</p>
<p>Camzyos achieved the primary endpoint by producing a statistically significant reduction in the Valsalva left ventricular outflow tract (LVOT) gradient at week 28 compared with placebo.</p>
<p>During the study, no patients recorded a left ventricular ejection fraction (LVEF) below 50%, and no adverse events led to treatment discontinuation.</p>
<p>Serious adverse events occurred in two patients in the Camzyos cohort (9%) and two in the placebo group (10%), with no new safety concerns identified beyond the known adult profile.</p>
<p>BMS immunology and cardiovascular commercialisation senior vice-president Al Reba said: “Today’s approval of Camzyos for paediatric patients with symptomatic obstructive hypertrophic cardiomyopathy marks an important milestone for young patients and families who are facing a serious cardiovascular disease with significant unmet medical need.</p>
<p>“For young patients living with this disease, the burden on daily life can be substantial during a critical stage of development, and we are proud to help bring an innovative new treatment option to this community.</p>
<p>“This approval also strengthens the growing body of clinical evidence supporting Camzyos, which is the most extensively studied cardiac myosin inhibitor with up to five years of follow-up in adults, and its role in the treatment of oHCM.”</p>
<p>Camzyos was initially approved by the FDA in 2022 for adult patients with symptomatic NYHA class II-III oHCM, with more than 5,000 healthcare providers prescribing it to over 25,000 US patients to date.</p>
<p>The therapy has gained regulatory clearances across more than 60 countries, supported by Phase III trials conducted in China, Japan, and other international regions, including EXPLORER-CN, HORIZON-HCM, and SCOUT-HCM.</p>
<p>The company is in discussions with other international regulatory authorities regarding potential paediatric approvals.</p>
<p>In August 2026, the FDA granted accelerated approval to BMS’ Zenbexus (iberdomide), along with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd), to treat adult multiple myeloma patients.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/bms-expanded-us-approval-camzyos/">Bristol Myers Squibb secures expanded US approval for Camzyos</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>BioMarin and Profluent partner on AI&#45;designed enzyme therapies</title>
<link>https://edusehat.com/en/biomarin-and-profluent-partner-on-ai-designed-enzyme-therapies</link>
<guid>https://edusehat.com/en/biomarin-and-profluent-partner-on-ai-designed-enzyme-therapies</guid>
<description><![CDATA[ Under the agreement, Profluent will deploy its proprietary suite of protein language models to generate new potential drug candidates. BioMarin will screen and evaluate the computational outputs to 
The post BioMarin and Profluent partner on AI-designed enzyme therapies appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/10/PT-01-10-2026-shutterstock_2817249549.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 01 Oct 2026 17:35:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>BioMarin, and, Profluent, partner, AI-designed, enzyme, therapies</media:keywords>
<content:encoded><![CDATA[<p>Under the agreement, Profluent will deploy its proprietary suite of protein language models to generate new potential drug candidates.</p>
<p>BioMarin will screen and evaluate the computational outputs to identify molecules with the desired target activity and stability profiles, advancing selected candidates into preclinical testing.</p>
<p>The creation and optimisation of therapeutic enzymes is typically a complex undertaking that requires extensive protein engineering and screening.</p>
<p>Profluent will conduct the computational design work using the Profluent Protein Atlas, a dataset of more than 115 billion unique protein sequences and reportedly the world’s largest protein sequence repository.</p>
<p>BioMarin intends to use these foundation models to rapidly assess alternative protein structures before selecting candidates for further laboratory evaluation.</p>
<p>BioMarin vice-president and metabolic conditions research head Pooja Agarwal said: “Profluent’s AI models represent the kind of external innovation that can complement our own capabilities and help us move promising science forward faster.</p>
<p>“By combining Profluent’s approach to de novo protein design and optimisation with BioMarin’s decades of expertise in enzyme therapies, we have an opportunity to identify promising candidates more efficiently for people with significant unmet need.”</p>
<p>Profluent CEO Ali Madani said: “BioMarin has one of the most credible track records in enzyme therapies, spending decades successfully advancing drugs through the clinic to improve the lives of patients.</p>
<p>“We’re excited to accelerate BioMarin’s drug discovery pipeline and unlock new medicines by combining the strengths of our latest foundation models for protein design with their deep track record of getting therapies to patients.”</p>
<p>Founded in 2022 and based in Emeryville, California, Profluent develops biological foundation models intended for applications across medicine, agriculture, and other fields.</p>
<p>The company’s financial backers include AIX Ventures, Air Street Capital, Bezos Expeditions, Altimeter Capital, Insight Partners, Convergent Ventures, and Spark Capital.</p>
<p>In April, BioMarin Pharmaceutical completed its acquisition of Amicus Therapeutics in an all-cash deal for a total equity value of nearly $4.8bn.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/biomarin-profluent-ai-enzyme-therapies/">BioMarin and Profluent partner on AI-designed enzyme therapies</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Express Pharma October 2026</title>
<link>https://edusehat.com/en/express-pharma-october-2026</link>
<guid>https://edusehat.com/en/express-pharma-october-2026</guid>
<description><![CDATA[ 
India&#039;s Foremost Pharma &amp; Biotech Magazine ~ Beyond US: New Shores, New Bets
The post Express Pharma October 2026 appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/01132041/EP-OCT-2026-MAG-COVER.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 01 Oct 2026 17:35:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Express, Pharma, October, 2026</media:keywords>
<content:encoded><![CDATA[<div><img width="200" height="264" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/01132041/EP-OCT-2026-MAG-COVER.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy"></div><p><em>Beyond US: New Shores, New Bets</em><br>
</p><div class="_df_book df-lite" _slug="express-pharma-october-2026" data-title="express-pharma-october-2026" wpoptions="true" thumbtype=""></div>
<hr>
<p><strong>Click to download:</strong> <a href="https://cdn.expresspharma.in/wp-content/uploads/2026/10/01130427/EP_OCTOBER_2026.pdf" target="_blank" rel="noopener noreferrer">October 2026 Digital Magazine</a></p>
<p>The post <a href="https://www.expresspharma.in/express-pharma-october-2026/">Express Pharma October 2026</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Acrotech Biopharma launches ADQUEY in US to establish dermatology business</title>
<link>https://edusehat.com/en/acrotech-biopharma-launches-adquey-in-us-to-establish-dermatology-business</link>
<guid>https://edusehat.com/en/acrotech-biopharma-launches-adquey-in-us-to-establish-dermatology-business</guid>
<description><![CDATA[ 
Dedicated Acrotech dermatology division established to support healthcare professionals and facilitate patient access
The post Acrotech Biopharma launches ADQUEY in US to establish dermatology business appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2020/04/30183622/GettyImages-1179214915-e1763466693590.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 01 Oct 2026 17:35:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Acrotech, Biopharma, launches, ADQUEY, establish, dermatology, business</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="338" src="https://cdn.expresspharma.in/wp-content/uploads/2020/04/30183622/GettyImages-1179214915-e1763466693590.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy"></div><p><span>Acrotech Biopharma, a biopharmaceutical company focused on developing and commercializing innovative proprietary medicines, announced the US launch of ADQUEY(difamilast 1%) ointment, a non-steroidal topical treatment for mild-to-moderate atopic dermatitis in adults and pediatric patients 2 years of age and older. Difamilast was originally discovered by Otsuka Pharmaceutical and licensed to Acrotech Biopharma for U.S. commercialization.</span></p>
<p><span>The launch marks Acrotech’s entry into the US dermatology market and expands the company’s commercial presence into a new strategic therapeutic area. To support the launch of ADQUEY and its long-term ambitions in dermatology, Acrotech has established a dedicated dermatology business unit with specialized commercial capabilities across marketing, sales and field-based engagement.</span></p>
<p><span>The product will compete in a market estimated to be around US$ 1.3 billion for the twelve months ending July 2026, according to IQVIA MAT.</span></p>
<p><span>“The launch of ADQUEY is an important milestone for Acrotech and marks our entry into the US dermatology market with a differentiated treatment option for patients living with atopic dermatitis,” said Ashish Anvekar, President of Acrotech Biopharma. “We are building more than a commercial organization around a single product. We are establishing a dedicated dermatology platform designed to support ADQUEY today while creating the capabilities to pursue additional opportunities that can address important unmet needs in dermatologic care.”</span></p>
<p><span>The dedicated dermatology business will focus on building awareness of ADQUEY, engaging with dermatology healthcare professionals and supporting patients throughout their treatment journey, while developing the infrastructure and expertise required to expand Acrotech’s presence in the specialty dermatology market.</span></p>
<p><span> </span><span>The launch of ADQUEY builds on Acrotech’s strategy to expand its portfolio of innovative medicines and establish focused commercial platforms in areas of significant patient need.</span></p>
<p>The post <a href="https://www.expresspharma.in/acrotech-biopharma-launches-adquey-in-us-to-establish-dermatology-business/">Acrotech Biopharma launches ADQUEY in US to establish dermatology business</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>9th Edition PURIFY26 – Chromatography Purification Conclave for thought provoking leadership</title>
<link>https://edusehat.com/en/9th-edition-purify26-chromatography-purification-conclave-for-thought-provoking-leadership</link>
<guid>https://edusehat.com/en/9th-edition-purify26-chromatography-purification-conclave-for-thought-provoking-leadership</guid>
<description><![CDATA[ 
In addition to deep technical sessions, the conclave serves as a primary networking hub in India for Heads of analytical and research, scale-up, production, kilo labs, supply chain, policy makers, and academic leaders.
The post 9th Edition PURIFY26 – Chromatography Purification Conclave for thought provoking leadership appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/10/01151645/EP_9th_Edition_PURIFY26_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 01 Oct 2026 17:35:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>9th, Edition, PURIFY26, –, Chromatography, Purification, Conclave, for, thought, provoking, leadership</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/10/01151645/EP_9th_Edition_PURIFY26_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/10/01151645/EP_9th_Edition_PURIFY26_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/10/01151645/EP_9th_Edition_PURIFY26_750-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p>PURIFY, India’s premier Chromatography Purification Conclave is dedicated towards pushing the boundaries of discovery, process development, and large-scale manufacturing in the pharmaceutical and life sciences sectors. As the global pharmaceutical industry delves deeper into advanced separation techniques, PURIFY continues its mission as a pioneer platform for scientists, research leaders, and industry decision-makers looking to overcome everyday purification challenges. The annual conference brings together high-purity separation experts across diverse industries—including active pharmaceutical ingredients (APIs), peptides, proteins, oligonucleotides, chiral molecules, biopharmaceuticals, fine chemicals, biotechnology, and natural products.</p>
<p>The conclave will bring together an expected 325+ participants, 30+ expert speakers, and 35+ exhibit zones, the event offers an unparalleled platform to connect with key decision-makers, explore cutting-edge solutions, and gain insights from top thought leaders.<br>
In today’s competitive landscape, time, yield, and purity are critical. Our goal with PURIFY is to provide attendees with actionable insights, niche techniques, and practical approaches that allow them to extract that critical additional gram of higher-purity substance in less time and with minimal resource expenditure. The comprehensive technical program will cover key advancements in preparative and process chromatography, novel analytical separation platforms, and emerging application areas.</p>
<p>Designed as an immersive knowledge-sharing platform, PURIFY features presentations, panels, and masterclasses led by globally recognized authorities and domain specialists. Attendees will gain direct exposure to next-generation technologies that streamline scale-up procedures, improve yield consistency, and solve complex purity bottlenecks encountered in daily laboratory and manufacturing workflows.<br>
In addition to deep technical sessions, the conclave serves as a primary networking hub in India for Heads of analytical and research, scale-up, production, kilo labs, supply chain, policy makers, and academic leaders. The hands-on teams for the related laboratories would benefit immensely by using this opportunity to have their daily purification challenges discussed. Overall, participants will have the opportunity to engage directly with solution providers, benchmark their operational strategies, and evaluate the latest instruments transforming separation science.<br>
<strong>Event Details:</strong><br>
Date: Tuesday, 3rd November, 2026<br>
Venue: ITC Kohenur, Hyderabad, India<br>
Timing: 9:00 am – 7:15 pm (Followed by Cocktails & Networking Dinner)</p>
<p>Registration for the PURIFY26 – Chromatography Purification Conclave is now open. To register for yourself and your team, please visit https://www.purifyconclaves.com/register/purify26–9th-edition<br>
<strong>Media Contact:</strong><br>
Fiona Fernandes | Custage Marketing Solutions LLP<br>
Fiona@custage.com<br>
+91 9930723498<br>
Mumbai, India</p>
<p>The post <a href="https://www.expresspharma.in/9th-edition-purify26-chromatography-purification-conclave-for-thought-provoking-leadership/">9th Edition PURIFY26 – Chromatography Purification Conclave for thought provoking leadership</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Zenex Animal Health complete acquisition of Sava Healthcare</title>
<link>https://edusehat.com/en/zenex-animal-health-complete-acquisition-of-sava-healthcare</link>
<guid>https://edusehat.com/en/zenex-animal-health-complete-acquisition-of-sava-healthcare</guid>
<description><![CDATA[ 
The acquisition marks Zenex&#039;s third strategic acquisition since partnering with Multiples and represents another significant milestone in its journey 
The post Zenex Animal Health complete acquisition of Sava Healthcare appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/08/06144031/Acquisition.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 01 Oct 2026 14:00:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Zenex, Animal, Health, complete, acquisition, Sava, Healthcare</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/08/06144031/Acquisition.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/08/06144031/Acquisition.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/08/06144031/Acquisition-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p>Zenex Animal Health India , one of India’s leading animal health companies backed by Multiples Alternate Asset Management, announced the acquisition of the companion animal business operating under the SAVAVET brand from SAVA Healthcare Limited (“SAVA Healthcare”).</p>
<p>The acquisition marks Zenex’s third strategic acquisition since partnering with Multiples and represents another significant milestone in its journey to build one of India’s most comprehensive animal healthcare platforms. Following the acquisitions of Ayurvet and VievePharm, the addition of SAVAVET further expands Zenex’s presence across companion animal healthcare and strengthens its diversified portfolio spanning livestock, poultry, companion animals, herbal healthcare and international markets.</p>
<p>Bringing SAVAVET into the Zenex family reinforces the platform across three key strategic fronts:</p>
<p>Scaling India’s companion animal franchise: SAVAVET is among India’s leading companion animal healthcare businesses, with a portfolio of approximately 70 brands spanning parasiticides, antibiotics, cardiac care, pain management, dermatology and wellness, distributed through a network of approximately 165 stockists and relationships with over 6,000 veterinarians nationwide.</p>
<p>Complementary brands and distribution: The acquisition combines SAVAVET’s established brands, veterinary relationships and specialist commercial capabilities with Zenex’s product development, distribution and integration expertise, creating a scaled platform positioned to address the evolving healthcare needs of companion animals in India.</p>
<p>Capturing a high-growth market: Companion animal healthcare is one of the fastest-growing segments of India’s animal health market, driven by rising pet ownership, growing awareness of preventive care and increased spending on animal wellness.</p>
<p>Dr. Arun Atrey, Managing Director, Zenex Animal Health, said, “Companion animal healthcare is one of the fastest-growing segments of animal health in India, and SAVAVET brings Zenex immediate scale through its strong portfolio, established market presence and network of over 6,000 veterinarians. Following the acquisitions of Ayurvet and VievePharm, this transaction is another important step in Zenex’s strategy of building one of India’s most comprehensive animal healthcare platforms.”</p>
<p>Manish Gaur, Managing Director, Multiples Alternate Asset Management, said: Multiples partnered with Zenex with a clear vision of building a scaled, diversified and innovation-led animal healthcare company. With its expanding portfolio, strong brands and presence across livestock, poultry and companion animal healthcare, Zenex is building one of India’s most comprehensive animal healthcare platforms. The addition of SAVAVET further strengthens that foundation and reinforces Zenex’s ability to serve the evolving needs of veterinarians, farmers, and pet parents across the country.”</p>
<p>Vinod R. Jadhav, Founder and Non-Executive Chairman, SAVA Healthcare Limited, said: “Over the past decade, our companion animal business has been built through the dedication of our people and the trust of veterinarians, pet parents and channel partners. We are proud of the business and the brands we have created. We believe Zenex, with its animal health expertise and commercial reach, is well placed to lead the business into its next phase of growth.”</p>
<p>Karthik Rajan, Chief Executive Officer, SAVA Healthcare Limited, said: “Completing this divestment allows SAVA Healthcare to focus management attention on human health formulations, pharmaceutical research and development, contract manufacturing and international business. We retain our farm animal business and will continue manufacturing agreed products for Zenex & other veterinary companies in India and Abroad under contract manufacturing arrangements. We thank the teams on both sides for bringing the transaction to completion.”</p>
<p>Ernst & Young LLP acted as financial advisor to Zenex on the transaction. Cyril Amarchand Mangaldas acted as legal counsel to Zenex. PwC acted as the exclusive transaction advisor to SAVA Healthcare. Legalogic acted as legal counsel to SAVA Healthcare</p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/zenex-animal-health-complete-acquisition-of-sava-healthcare/">Zenex Animal Health complete acquisition of Sava Healthcare</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>When the lab talks to the plant </title>
<link>https://edusehat.com/en/when-the-lab-talks-to-the-plant</link>
<guid>https://edusehat.com/en/when-the-lab-talks-to-the-plant</guid>
<description><![CDATA[ 
Lab informatics is changing how pharma companies transfer knowledge, control quality and move from development to commercial manufacturing, writes Swati Rana 
The post When the lab talks to the plant  appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/24113331/EP_Lab-informatic.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 01 Oct 2026 14:00:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>When, the, lab, talks, the, plant </media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/24113331/EP_Lab-informatic.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/24113331/EP_Lab-informatic.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/24113331/EP_Lab-informatic-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>As pharma companies accelerate digital transformation, lab informatics is emerging as a strategic enabler of faster R&D, stronger data integrity, regulatory compliance, technology transfer and operational efficiency. Solutions such as Laboratory Information Management Systems (LIMS), Electronic Laboratory Notebooks (ELNs), Chromatography Data Systems (CDS), Scientific Data Management Systems (SDMS) and AI-powered analytics are helping labs move from fragmented, paper-based processes towards connected, data-driven operations. </span></p>
<p><b>The business case for connected laboratories </b></p>
<p><span>The growing focus on lab automation, data integrity, regulatory compliance and AI-driven analytics is translating into strong market momentum. According to Grand View Research1, the global lab informatics market was valued at approximately $5.9 billion by 2033, representing a CAGR of 4.9 per cent between 2026 and 2033. LIMS accounted for the largest product segment, while cloud-based solutions represented the largest delivery mode. The life sciences sector was the largest end-use segment in 2025. </span></p>
<p><span>India is also emerging as an important growth market. Grand View Research estimates that the Indian lab informatics market will generate $397.3 million by 2033, growing at a CAGR of 7.8 per cent. </span></p>
<p><span>These figures reflect a broader shift in how pharma companies view lab informatics. It is no longer simply an IT system for managing lab records; it is increasingly becoming part of the digital infrastructure supporting R&D, quality, technology transfer and manufacturing.</span></p>
<p><b>Linking the lab to the pharma value chain </b></p>
<p><span>One of the most significant benefits of lab informatics is the creation of a single, reliable digital environment for lab data. Analytical development laboratories generate vast amounts of information from HPLC, GC, spectroscopy, dissolution, stability and microbiological testing. Historically, this information was often distributed across instruments, spreadsheets, paper records and standalone applications. </span></p>
<p><span>Integrated informatics platforms can capture, manage and connect this information, reducing manual transcription, improving traceability and enabling faster retrieval and review. Automated workflows, electronic records, audit trails, electronic signatures and controlled access further strengthen data integrity and support regulatory expectations, including ALCOA+ principles. </span></p>
<p><span>The benefits extend well beyond the lab. Technology transfer and scale-up are emerging as important areas where connected informatics can deliver significant value. Transferring a product or process from R&D to manufacturing involves far more than exchanging documents. It requires the transfer of process understanding, analytical knowledge, historical data and often tacit expertise.</span></p>
<p><span>Data silos, inconsistent documentation, equipment differences and communication gaps can create delays, deviations and costly rework. Integrated LIMS, ELN, MES and document-management environments can provide a common data ecosystem, ensuring that development, QC, QA, technology-transfer and manufacturing teams work from approved and consistent information. </span></p>
<p><b>The interoperability challenge </b></p>
<p><span>Despite the benefits, digital transformation is not without challenges. Integration with analytical instruments and legacy systems remains one of the biggest barriers. pharma laboratories often operate instruments from multiple vendors with different data formats, communication protocols and software versions. Legacy equipment and applications can be particularly difficult to connect to modern platforms. </span></p>
<p><span>At the same time, regulatory expectations around data integrity, cybersecurity, electronic records and auditability continue to evolve. Organisations therefore need to balance modernisation with the need to preserve valuable historical data and maintain validated systems. </span></p>
<p><span>Industry experts point towards a phased approach to digitalisation, rather than largescale replacement programmes. Standardising data sources, using open interfaces, establishing robust governance and involving lab, quality, IT and compliance teams from the beginning can help organisations manage integration and validation challenges more effectively. </span></p>
<p><b>The rise of the intelligent laboratory </b></p>
<p><span>The next phase of lab informatics will increasingly be shaped by AI, automation and advanced analytics. AI can help identify trends in stability data, detect anomalies in analytical results, support method optimisation and potentially predict instrument or process failures before they affect operations. </span></p>
<p><span>Automation can reduce routine activities such as sample tracking, data compilation, result verification and report generation, allowing scientists to focus more on scientific interpretation, problem-solving and innovation. Real-time analytics can also enable laboratories and manufacturing teams to move from reactive investigation.</span></p>
<p><b>Towards predictive decisionmaking </b></p>
<p><span>Concepts such as digital twins, AI-powered lab assistants and real-time data review are likely to become increasingly relevant as informatics platforms mature. </span></p>
<p><span>However, successful digital transformation will depend on more than technology. Legacy infrastructure, investment constraints, cybersecurity, regulatory requirements, workforce skills and resistance to change can all slow adoption. Organisations that demonstrate value through targeted pilots, secure executive sponsorship, engage end users, invest in training and adopt scalable and interoperable platforms will be better positioned to realise the benefits. </span></p>
<p><span>Ultimately, the future-ready pharma lab will be connected, intelligent, standardised and increasingly autonomous. The convergence of lab informatics, AI, automation and advanced analytics can create a continuous flow of trusted data from discovery and development through quality control, technology transfer and manufacturing. </span></p>
<p><span>For pharma companies seeking faster development timelines, stronger compliance, improved quality and greater operational agility, lab informatics is increasingly becoming not just a technology investment, but a foundation for digital transformation and the lab of the future. </span></p>
<p><b>What the industry is seeing on the ground </b></p>
<p><span>The market trends and technology shifts point to a lab environment that is becoming increasingly connected, automated and data-driven. </span></p>
<ul>
<li><span> But how are these changes playing out on the ground? </span></li>
<li><span> What are pharma companies prioritising, where are they encountering challenges </span></li>
<li><span> How do industry leaders see the next phase of lab digitalisation? </span></li>
</ul>
<p><span>To explore these questions,<strong><em> Express Pharma</em> </strong>spoke with industry experts and technology leaders on how lab informatics is evolving, its growing impact on analytical development and technology transfer, and the challenges of integrating legacy systems. They also share their perspectives on how AI and automation can help build more connected, agile and future-ready laboratories. The <strong>interviews</strong> that follow bring together their views and insights on this evolving landscape. </span></p>
<p><b>What lies ahead </b></p>
<p><span>Their perspectives highlight a common theme – while technology is an important enabler, successful digital transformation also depends on data governance, interoperability, regulatory readiness, process understanding, workforce capabilities and change management. </span></p>
<p><span>The opportunity for pharma companies lies in moving beyond isolated technology deployments towards an integrated digital ecosystem in which instruments, laboratory systems, manufacturing platforms and enterprise applications can exchange trusted data seamlessly. As AI and automation mature, the value of informatics will increasingly be measured not only by how effectively laboratories store and manage data, but by how quickly they can convert that data into actionable scientific and operational insight. </span></p>
<p> </p>
<hr>
<h3><strong>Taking the guesswork out of technology transfer </strong></h3>
<p><span><strong>Narotam Kumar Juneja</strong>, Technical Advisor, Uniserum Lifesciences discusses how lab informatics is helping organisations create a connected data environment, strengthen technology transfer and improve consistency across manufacturing sites </span></p>
<p><img decoding="async" class="wp-image-459702 alignleft" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/23155648/Narotam-Kumar-Juneja-225x300.jpg" alt="" width="297" height="396" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/23155648/Narotam-Kumar-Juneja-225x300.jpg 225w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/23155648/Narotam-Kumar-Juneja.jpg 345w" sizes="(max-width: 297px) 100vw, 297px"></p>
<p><b>How is lab informatics improving the efficiency and reliability of technology transfer across development and manufacturing sites? </b></p>
<p><span>Data management systems play a crucial role in the pharma industry where the stakes are high and the need for accurate and efficient data management systems is paramount. In an industry that deals with sensitive patient information, complex clinical trial data, and stringent regulatory requirements, having a robust data management system is essential for ensuring compliance, efficiency, and ultimately the success of drug development and patient care. </span></p>
<p><span>Lab informatics systems improve data reliability, streamline workflows, and ensure compliance across R&D and manufacturing by centralising information and eliminating manual errors. These digital tools connect instruments, tracking systems, and secure data from early discovery through manufacturing. Their positive impact extends well beyond the lab bench. </span></p>
<p><span>Shorter development life cycles mean drug candidates progress more efficiently. Consistent and accurate data management strengthens regulatory submissions and reduces the risk of delays or rework. Enhanced collaboration between R&D and manufacturing accelerates technology transfer, which is critical during scale-up and commercialisation. </span></p>
<p><span>By capturing all data from connected labs in a centralised system, lab informatics significantly improve reliability and efficiency during technology transfer. There are no typing errors, and verified results can be shared instantly among cross-functional teams across all sites, simplifying reviews and preventing lastminute issues. </span></p>
<p><span>Lab informatics also eliminate traceability and data integrity concerns through digital audit trails that record every change made during an experiment. No information is captured in paper notebooks; all data resides securely in one unified platform. </span></p>
<p><span>These benefits extend to manufacturing as well. Realtime process monitoring, automated alerts, and centralised data control improve reliability, efficiency, and process robustness. Early detection of test failures prevents batch-release issues and strengthens overall regulatory compliance. Data analytics further enhances this framework by predicting and preventing potential issues before they occur, resulting in a more reliable and consistent manufacturing process.</span></p>
<p><span>Standardising data formats and terminology across systems ensures data quality, consistency, and interoperability. Decentralised and connected data environments also facilitate seamless data sharing and collaboration among researchers, clinicians, regulators, and patients—an essential requirement for advancing scientific research and improving patient care. </span></p>
<p><span>Overall, data analytics has had a transformative impact on pharma manufacturing, driving greater efficiency, quality, and safety in the production of pharma products. </span></p>
<p><b>What are the biggest challenges in ensuring seamless knowledge and data transfer between R&D and manufacturing, and how can digital technologies help? </b></p>
<p><span>Tech transfer represents a critical bridge between development and commercial manufacturing. The complex process of transferring product and process knowledge between development teams and manufacturing sites requires precision at every stage. It is far more than a handover of documents or equipment; it is the migration of institutional knowledge, process understanding, expertise, and tacit know-how needed to reliably replicate and scale manufacturing. </span></p>
<p><span>However, data silos, fragmented documentation, and variability across sites often turn this essential step into a bottleneck that strains both timelines and budgets. Typical hurdles include incomplete documentation, unrecorded tacit knowledge, raw-material variability, regulatory complexities, and communication gaps between R&D and plant teams. </span></p>
<p><span>Traditionally, R&D teams handed over a static package of documents to manufacturing. These packages often lacked essential context—historical insights, minor operational nuances, and the rationale behind key decisions. Many steps were based on unwritten habits rather than accurately documented procedures. As a result, manufacturing teams faced missing batch records, incomplete method validations, unclear cleaning procedures, and difficulties in analytical method transfer. This frequently forced receiving sites to reverse-engineer processes, leading to deviations, investigations, product delays, and financial losses from rejected batches. </span></p>
<p><span>To move beyond these limitations, organisations must migrate from static documentation to an integrated, data-driven approach. A unified digital data environment transforms scattered information into complete, traceable, and auditready records. However, even with digital systems, the biggest challenge in tech transfer remains ensuring process robustness and predictability.</span></p>
<p><span>Applying Quality by Design (QbD) principles is key. QbD establishes the design space— the relationship between raw materials, process parameters, and critical quality attributes. Without this deep understanding, a new manufacturing site may struggle to remain in a state of control, replicate consistent process parameters, and build a sustainable quality culture. </span></p>
<p><span>Historically, process control has relied on reactive quality management—waiting for deviations and then investigating them. Today, AIdriven predictive analytics and real-time data integration allow teams to anticipate deviations before they occur. This gives receiving sites a continuous monitoring system that ensures operations remain within the validated design space. </span></p>
<p><span>The result is a more reliable, predictable, and scientifically robust technology-transfer process that reduces quality risks and builds confidence in long-term manufacturing performance. </span></p>
<p><b>What role do connected lab informatics systems play in enabling successful technology transfer across multiple manufacturing locations? </b></p>
<p><span>Multi-locational technology transfer in the pharma industry involves transferring manufacturing processes and analytical methods across different facilities. These transfers often face challenges such as equipment and facility variations, undocumented critical know-how that remains with R&D staff, fragmented data systems, incomplete batch histories, and communication or cultural barriers. Re-establishing cleaning procedures, analytical methods, and process controls at each site demands significant time and resources. </span></p>
<p><span>Multi-country and multistate facilities also encounter differing regulatory interpretations, pharmacopoeia standards, and audit expectations. These complexities can be effectively addressed through connected laboratory informatics. </span></p>
<p><span>Connected lab informatics link laboratory instruments, software systems like LIMS, ELN, CDS, and databases across all locations to create a unified digital ecosystem. This enables seamless data flow from instruments and workflows through analysis and reporting. Instead of functioning as disconnected tools, informatics components operate as an integrated system that reduces cross functional communication gaps, supports compliance, and enhances reliability. </span></p>
<p><span>During technology transfer to any location, a connected informatics platform replaces paper-based systems and outdated, siloed electronic tools with a single, unified application environment. Centralised data capture minimises transcription errors and inconsistencies, while unified platforms ensure complete data lineage, improving reproducibility and audit readiness. Automated workflows reduce manual effort and increase reliability, efficiency, precision, and accuracy during tech transfer.</span></p>
<p><span>As a result, scientists no longer need to spend extended durations at manufacturing sites. Harmonised and streamlined tech-transfer processes significantly improve productivity, shorten cycle times, and eliminate data-integrity issues and regulatory-compliance risks. </span></p>
<p><span>For any organisation aiming to remain competitive globally, implementing connected laboratory informatics is not optional—it is essential. While the initial implementation may seem costly and timeconsuming, the return on investment is rapid and substantial. </span></p>
<p> </p>
<hr>
<h3><b>Turning lab data into the next decision </b></h3>
<p><span><strong>Anurag Chauhan</strong>, Assistant GM, Digitalisation, Automation & Analytics (India & Ireland), Amneal Pharmaceuticals discusses how LIMS, ELN, CDS, AI and automation are transforming analytical workflows, while also highlighting the challenges of integrating diverse instruments and legacy systems </span></p>
<p><img decoding="async" class="wp-image-459703 alignleft" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/23155936/Anurag-Chauhan-225x300.jpeg" alt="" width="268" height="358" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/23155936/Anurag-Chauhan-225x300.jpeg 225w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/23155936/Anurag-Chauhan.jpeg 433w" sizes="(max-width: 268px) 100vw, 268px"></p>
<p><b>Analytical laboratories generate vast amounts of complex scientific data. How has lab informatics changed the way analytical development teams manage data, improve productivity, and ensure data integrity? </b></p>
<p><span>Analytical laboratories today generate data from multiple sources including HPLC, GC, dissolution systems, spectrometers, stability studies, and microbial testing platforms. Historically, much of this data was managed through standalone systems and paperbased records, making retrieval, review, and compliance management challenging. </span></p>
<p><span>Lab informatics has transformed this landscape by creating a connected digital ecosystem where instrument data, test results, methods, and workflows are managed seamlessly. Systems such as LIMS, ELN, and CDS enable automatic data capture, electronic review workflows, and centralised storage, reducing manual intervention and the risk of transcription errors.</span></p>
<p><span>For example, instead of analysts spending hours compiling chromatographic results from multiple instruments and manually preparing reports, data can now be collected, reviewed, and approved digitally within a controlled workflow. This significantly improves laboratory productivity and shortens turnaround times. </span></p>
<p><span>The recent trend is more towards compliance related solutions. New AI solutions focused on audit trail review, controlled user access, and real time alert support regulatory expectations around ALCOA+ principles. Beyond compliance, these systems enable laboratories to shift from simply generating data to extracting meaningful insights that support faster and better decision-making. </span></p>
<p><strong>What are the key challenges in integrating laboratory informatics platforms with analytical instruments, legacy systems, and evolving regulatory requirements, and how can organisations overcome them? </strong></p>
<p><span>While most pharma companies recognize the value of laboratory digitalisation, integration remains one of the biggest challenges. </span></p>
<p><span>Laboratories often contain instruments from multiple vendors, each with different communication protocols, data formats, and software versions. In addition to this Legacy equipment that has been in service for more than a decade is very common in the Pharma landscape. Connecting these diverse systems into a unified digital environment can be complex. </span></p>
<p><span>Another challenge is regulatory evolution. Expectations around data integrity, cybersecurity, electronic records, and auditability continue to increase, requiring organisations to continuously review and validate their digital infrastructure. </span></p>
<p><span>The most successful organisations address these challenges through a phased digitalisation strategy rather than attempting large-scale replacements. Standardizing data sources, leveraging open interfaces, establishing robust governance, and involving laboratory, quality, IT, and compliance teams right from the beginning of any project are key factors to mitigate integration challenges. </span></p>
<p><b>Looking ahead, what capabilities do you believe will define the analytical laboratory of the future, and what role will AI, automation, and digital workflows play in achieving that vision? </b></p>
<p><span>The analytical laboratory of the future will be connected, intelligent, and increasingly autonomous. Data from laboratory instruments, manufacturing systems, quality platforms, and enterprise applications will flow seamlessly across a digital ecosystem, creating a single source of truth.</span></p>
<p><span>Artificial Intelligence will help laboratories move from reactive analysis to predictive decision-making. For instance, AI can identify trends in stability data, detect anomalies in chromatographic results, recommend method optimisations, or predict potential instrument failures before they impact operations. The process of review will be completely removed from systems as all systems will be having inbuilt Realtime review mechanism. </span></p>
<p><span>Automation will continue to reduce routine manual activities such as sample preparation, data compilation, result verification, and report generation. This will allow scientists to focus more on problem-solving and scientific innovation rather than administrative work. </span></p>
<p><span>Looking ahead, concepts such as digital twins, advanced analytics, and AI-powered laboratory assistants will become increasingly relevant. The laboratories that embrace AI, automation, and integrated digital workflows will be better positioned to accelerate development timelines, strengthen compliance, improve quality, and ultimately enhance accessibility. </span></p>
<hr>
<h3><b>Connecting the dots across the laboratory </b></h3>
<p><span><strong>Dhananjay Dwivedi</strong>, Vice President -ARD, Amneal Pharmaceutical examines how connected informatics platforms can improve data management, productivity, collaboration and data integrity, while addressing the integration, regulatory and change-management challenges involved in digital transformation </span></p>
<p><img loading="lazy" decoding="async" class="wp-image-459700 alignleft" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/23155503/Mr-Dhananjay-Dwivedi-VP-Analytical-Research-and-Development-Amneal-Pharmaceuticals-239x300.jpg" alt="" width="278" height="349" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/23155503/Mr-Dhananjay-Dwivedi-VP-Analytical-Research-and-Development-Amneal-Pharmaceuticals-239x300.jpg 239w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/23155503/Mr-Dhananjay-Dwivedi-VP-Analytical-Research-and-Development-Amneal-Pharmaceuticals.jpg 679w" sizes="auto, (max-width: 278px) 100vw, 278px"></p>
<p><b>How does lab informatics transform analytical development laboratories in terms of data management, productivity, data integrity, decision-making, and collaboration? </b></p>
<p><span>Analytical development laboratories generate large volumes of complex data from instruments such as HPLC, GC, spectroscopy, dissolution, and stability studies. Lab informatics solutions, including LIMS, ELN, and Scientific Data Management Systems (SDMS), have transformed how this data is managed and utilised. </span></p>
<ul>
<li><b>Improved data management:</b><span> Lab informatics centralises data from multiple instruments and experiments into a single digital platform, making data storage, retrieval, and sharing more efficient. This eliminates data silos and enables researchers to access historical information quickly for method development and investigations. </span></li>
<li><b>Enhanced productivity:</b><span> Automation of sample tracking, data capture, calculations, and report generation reduces manual effort and turnaround times. By minimizing administrative tasks, scientists can focus more on data interpretation, problem-solving, and innovation. </span></li>
<li><b>Strengthened data integrity:</b><span> Electronic records, audit trails, electronic signatures, and controlled user access ensure that data remain accurate, traceable, and secure. Automated data acquisition also reduces transcription errors and supports compliance with regulatory requirements.</span></li>
<li><b>Better decision-making:</b><span> Advanced analytics and realtime monitoring tools help identify trends, deviations, and potential issues early. Interactive dashboards and data visualisation support faster, evidence-based decision-making and continuous process improvement.</span></li>
<li><b>Improved collaboration:</b><span> Cloud-based and integrated informatics systems facilitate seamless data sharing among analytical, quality, formulation, and regulatory teams, enhancing collaboration and knowledge management across sites. </span></li>
</ul>
<p><b>What are the major challenges organisations face when integrating lab informatics with analytical instruments, legacy systems, data integrity requirements, evolving regulations, growing data volumes, and laboratory workflows—and what strategies can help overcome them? </b></p>
<p><span>Laboratory informatics platforms such as LIMS, ELNs, and LES are essential for managing laboratory operations, ensuring data integrity, and supporting regulatory compliance. However, organisations often face significant challenges when integrating these platforms with analytical instruments, legacy systems, and evolving regulatory requirements. </span></p>
<ul>
<li><b>Integration with analytical instruments:</b><span> Modern laboratories use instruments from multiple vendors, each generating data in different formats and using proprietary software. This often results in manual data transfer, increasing the risk of transcription errors, data loss, and inconsistencies. Integrating instruments with LIMS or ELN systems can also be technically challenging due to compatibility and validation requirements. Organisations should implement standardised interfaces, middleware, and automated data capture solutions that enable direct transfer of data from instruments to informatics platforms. This reduces human intervention, improves data accuracy, and enhances traceability. </span></li>
<li><b>Legacy system integration: </b><span>Many pharma and life sciences companies continue to rely on older systems that contain valuable historical data but lack modern integration capabilities. These systems often create data silos, limiting visibility across the organisation and complicating data sharing and reporting. A phased modernisation approach should be adopted, using integration middleware and carefully planned data migration strategies. This allows organisations to preserve historical data while gradually transitioning to modern, scalable platforms. </span></li>
<li><b>Maintaining data integrity: </b><span>Data integrity is a critical requirement in regulated environments. Laboratory data must remain accurate, complete, consistent, and traceable throughout its lifecycle. Manual data entry and disconnected systems increase the likelihood of errors and regulatory findings during inspections. </span></li>
</ul>
<p><span>Automated workflows, electronic records, audit trails, and strong data governance practices help ensure compliance with ALCOA+ principles and improve confidence in laboratory results.</span></p>
<ul>
<li><b>Meeting evolving regulatory requirements:</b><span> Regulations such as FDA 21 CFR Part 11, EU Annex 11, and GxP guidelines continuously evolve, placing additional demands on laboratory systems. Every integration, system upgrade, or process change may require validation and compliance assessments. Organisations should implement risk-based validation, establish strong change-control processes, conduct regular audits, and continuously monitor regulatory updates to ensure ongoing compliance. </span></li>
<li><b>Handling large and complex data volumes:</b><span> Advances in analytical technologies, genomics, automation, and high throughput screening have resulted in enormous data generation. Traditional systems often struggle to manage and analyze these growing datasets effectively. Cloud-based informatics platforms, advanced analytics, artificial intelligence, and machine learning tools provide the scalability needed to store, process, and derive insights from large datasets while improving decisionmaking and research productivity. </span></li>
<li><b> User adoption and change management: </b><span>Even technically successful implementations can fail if scientists and laboratory personnel resist adopting new systems. Common barriers include workflow disruption, lack of training, system complexity, and concerns about usability. Successful organisations involve end users early in system selection and design, provide comprehensive training programs, and ensure that new systems align with existing laboratory workflows. Effective change management significantly improves adoption and long-term success. </span></li>
</ul>
<hr>
<h3><b>Connecting development, transfer and manufacturing </b></h3>
<p><span>Technology transfer is increasingly becoming a data-driven process, with laboratory informatics helping bridge the gap between R&D, quality and manufacturing. <strong>Deepak Shinde</strong>, Sr Executive – R&D (Formulations-TT), FDC explores how connected systems can improve knowledge transfer, standardise processes, strengthen data integrity and accelerate technology transfer across development and manufacturing sites </span></p>
<p><img loading="lazy" decoding="async" class=" wp-image-459701 alignleft" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/23155507/Deepak-shinde-295x300.jpg" alt="" width="307" height="312" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/23155507/Deepak-shinde-295x300.jpg 295w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/23155507/Deepak-shinde-1009x1024.jpg 1009w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/23155507/Deepak-shinde-768x780.jpg 768w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/23155507/Deepak-shinde.jpg 1045w" sizes="auto, (max-width: 307px) 100vw, 307px"></p>
<p><b>How does lab informatics enable better control, consistency, and knowledge management throughout the technology-transfer process from development to manufacturing? </b></p>
<p><span>Technology transfer is a critical stage in the pharma development lifecycle, where scientific knowledge, analytical methods, process understanding, and quality requirements must be transferred accurately from development to manufacturing. Lab informatics plays an increasingly important role in making this process more structured, transparent, and reliable. By connecting laboratory data, analytical workflows, documentation, and knowledge across sites, informatics solutions help reduce manual effort, improve data integrity, maintain process consistency, and provide greater visibility throughout the transfer lifecycle. </span></p>
<p><span>Key contributions include: </span></p>
<ul>
<li><b>Centralised and standardised data</b><span> – Laboratory data, analytical methods, specifications, test results, and stability data can be maintained in integrated systems such as LIMS/ELN, reducing dependence on spreadsheets and manual records. </span></li>
<li><b> Improved data integrity</b><span> – Automated workflows, audit trails, electronic signatures, controlled access, and version control help ensure ALCOA+ principles are maintained throughout the technology transfer lifecycle. </span></li>
<li><b>Better method transfer</b><span> – Analytical methods, method parameters, system suitability requirements, and validation/verification data can be transferred in a controlled manner, reducing transcription errors and interpretation differences between sites. </span></li>
<li><b>Real-time visibility</b><span> – Development, QC, QA, manufacturing, and technology-transfer teams can access the same approved information, making it easier to identify gaps and resolve issues before commercial manufacturing.</span></li>
<li><b>Process consistency</b><span> – Standardised electronic workflows and templates help ensure that the same procedures, specifications, sampling plans, and acceptance criteria are followed at both sending and receiving sites. </span></li>
<li><b>Trend and comparative analysis</b><span> – Historical batch, analytical, and stability data can be rapidly compared between sites. This is particularly useful for identifying differences in assay, dissolution, impurities, process parameters, or other critical quality attributes during site transfer. </span></li>
<li><b>Reduced transfer timelines </b><span>– Automated data capture, approval workflows, document management, and electronic review reduce manual effort and accelerate activities such as batch document review, analytical transfer, deviation assessment, and change control. </span></li>
<li><b>Stronger knowledge retention</b><span> – ELNs and electronic document repositories preserve development knowledge, experimental data, process understanding, and previous investigation outcomes, making this information readily available during future site transfers or process improvements. </span></li>
</ul>
<p><b>What are the main barriers to transferring scientific knowledge and data from R&D to manufacturing, and how can digital solutions help overcome them? </b></p>
<p><span>The biggest challenges in transferring knowledge and data from R&D to manufacturing are data fragmentation, inconsistent documentation, loss of process knowledge, differences in equipment and processes, manual data entry, and lack of real-time visibility between sites. Digital technologies can address these challenges in several ways: </span></p>
<ul>
<li><b>Data silos and fragmented information</b><span> – R&D, QC, QA, and manufacturing may use different systems. Integrated platforms such as LIMS, ELN, MES, and document management systems can create a common data environment. </span></li>
<li><b>Inconsistent documentation and version control</b><span> – Multiple versions of MFRs, specifications, analytical methods, and development reports can create confusion. Electronic document management with controlled workflows ensures that teams work with the latest approved information. </span></li>
<li><b>Loss of tacit process knowledge </b><span>– Important development knowledge may remain with individual scientists. ELNs and structured knowledge management systems can capture process rationale, development history, experimental results, and lessons learned. </span></li>
<li><b>Manual data transfer and transcription errors</b><span> – Reentering laboratory or process data into different systems increases the risk of errors. System-to-system integration and automated data transfer improve accuracy and reduce manual intervention. </span></li>
<li><b>Differences between development and manufacturing equipment</b><span> – Scale-up may introduce differences in equipment capability and process parameters. Digital tools can support process mapping, historical batch-data analysis, equipment comparison, and data-driven scale-up decisions. </span></li>
<li><b>Limited visibility during technology transfer</b><span> – Teams may not have immediate visibility of transfer activities, deviations, analytical results, or pending actions. Digital dashboards and workflow systems provide real-time status and accountability. </span></li>
<li><b>Data integrity and traceability</b><span> – Maintaining reliable and attributable data throughout the transfer is critical. Audit trails, electronic signatures, role based access, and automated controls strengthen data integrity and regulatory compliance. </span></li>
<li><b>Difficulty comparing R&D and manufacturing data </b><span>– Analytics and visualisation tools can rapidly compare CPPs, CQAs, assay, dissolution, impurities, yield, and stability trends between development and commercial batches. </span></li>
</ul>
<p><strong>How can connected laboratory informatics systems support standardised and efficient technology transfer across global manufacturing sites? </strong></p>
<p><span>As pharma companies expand globally, connected laboratory informatics systems play a critical role in ensuring that the same scientific knowledge, data, methods, and quality standards are consistently applied across multiple manufacturing locations. Key roles include: </span></p>
<ul>
<li><b>Global data standardisation</b><span> – Connected LIMS, ELN, and other laboratory systems provide standardised formats for analytical methods, specifications, test results, and stability data, making information easier to transfer between sites. </span></li>
<li><b>Single source of truth</b><span> – Centralised or integrated systems ensure that R&D, QC, QA, and manufacturing sites access the same approved and current information, reducing discrepancies caused by multiple local versions of documents or data. </span></li>
<li><b>Faster technology transfer</b><span> – Analytical methods, specifications, historical results, validation data, and process knowledge can be accessed electronically by receiving sites, reducing reliance on manual document exchange and accelerating transfer activities. </span></li>
<li><b>Consistent analytical practices </b><span>– Controlled methods, workflows, calculations, system suitability requirements, and specifications help ensure that laboratories at different locations perform testing consistently.</span></li>
<li><b>Real-time visibility across sites</b><span> – Global teams can monitor transfer activities, analytical results, deviations, investigations, and stability trends remotely. This enables faster identification and resolution of issues. </span></li>
<li><b>Improved data integrity and compliance</b><span> – Electronic audit trails, access controls, electronic signatures, and controlled workflows support ALCOA+ principles and help maintain regulatory compliance across different regions. </span></li>
<li><b>Cross-site comparison and trending </b><span>– Connected systems allow companies to compare analytical and manufacturing data across locations, helping identify differences in assay, dissolution, impurities, process parameters, yield, and stability performance.</span></li>
<li><b>Knowledge retention and continuity</b><span> – Development history, process understanding, analytical knowledge, and previous investigations remain digitally available even when personnel or manufacturing locations change. </span></li>
<li><b>Better collaboration and decision-making</b><span> – R&D, technology transfer, QC, QA, and manufacturing teams can work from a common data environment, reducing communication gaps and enabling faster, evidence based decisions. </span></li>
</ul>
<hr>
<h3><b>Investing in the lab of the future </b></h3>
<p><span>Drawing on his extensive industry experience, <strong>Shirish G Belapure</strong>, Sr Technical Advisor, IPA looks at the milestones that have shaped this evolution, the factors slowing adoption, and the strategic investments pharma companies should prioritise to build future-ready laboratories </span></p>
<p><img loading="lazy" decoding="async" class="wp-image-410478 alignleft" src="https://cdn.expresspharma.in/wp-content/uploads/2019/04/20162041/Shirish-G-Belapure.jpg" alt="" width="277" height="416"></p>
<p><b>Based on your industry experience, what have been the biggest milestones in the evolution of laboratory informatics, and what trends are likely to define its next phase of growth?</b></p>
<p><span>The field has transformed dramatically over the decades—from manual, paper-based processes to robust digital platforms like LIMS and ELN. Integration across instruments and seamless data exchange have been game-changers, further enhanced by cloud adoption for scalability and collaboration. The rise of AI and advanced analytics has taken laboratory operations to a new level. Going forward, I expect intelligent automation, data standardisation following FAIR principles, support for precision medicine, and heightened cybersecurity will be key trends. </span></p>
<p><b>Despite significant advancements in digital laboratory technologies, adoption remains uneven across the industry. What factors are slowing adoption, and how can organisations accelerate their digital transformation journey? </b></p>
<p><span>Despite these advances, digital adoption is uneven across the industry. Legacy infrastructure, budgetary limits, regulatory challenges, and resistance to change are common hurdles. </span></p>
<p><span>Organisations can accelerate digital transformation by securing executive buy-in, demonstrating ROI through well-designed pilot projects, engaging users with thorough training, and phasing implementation to build confidence and momentum. </span></p>
<p><b>If you were advising pharma companies on building future-ready laboratories, what strategic investments and capabilities would you recommend they prioritize over the next five years? </b></p>
<p><span>My recommendation for pharma companies is to invest in scalable cloud platforms, robust AI and analytics capabilities, interoperable systems, advanced cybersecurity, workforce upskilling, and sustainable lab practices. These priorities will help labs stay agile, innovative, and competitive in the fast-evolving landscape. </span></p>
<p><span>Drawing on nearly five decades of experience, I’m confident that organisations focusing on these areas will drive operational excellence and industry leadership.</span></p>
<p><em><span>swati.rana@expressindia.com<br>
</span><span>swatirana.express@gmail.com </span></em></p>
<p>The post <a href="https://www.expresspharma.in/when-the-lab-talks-to-the-plant/">When the lab talks to the plant </a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>OBIO marks $704m funding milestone for Canadian health tech ventures</title>
<link>https://edusehat.com/en/obio-marks-704m-funding-milestone-for-canadian-health-tech-ventures</link>
<guid>https://edusehat.com/en/obio-marks-704m-funding-milestone-for-canadian-health-tech-ventures</guid>
<description><![CDATA[ The initiative is supported by the Government of Canada through the Federal Economic Development Agency for Southern Ontario. It is designed to help post-seed health science enterprises secure 
The post OBIO marks $704m funding milestone for Canadian health tech ventures appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/09/PT-2-30-09-2026-shutterstock_1924516388.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 30 Sep 2026 20:00:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>OBIO, marks, 704m, funding, milestone, for, Canadian, health, tech, ventures</media:keywords>
<content:encoded><![CDATA[<p>The initiative is supported by the Government of Canada through the Federal Economic Development Agency for Southern Ontario.</p>
<p>It is designed to help post-seed health science enterprises secure venture investment, form corporate partnerships, and commercialise technologies.</p>
<p>Alongside reaching the financial milestone, OBIO confirmed the six enterprises selected for its 2026 intake.</p>
<p>The new cohort includes Toronto-based AI. Vali, which specialises in AI-guided diagnostic imaging analysis, and Hamilton-based Block Biosciences that is developing therapies to prevent cancer spreading to the brain.</p>
<p>Ottawa-based Hylid Diagnostics also joins the group with its optical sensor technology for at-home blood testing in kidney disease and heart failure patients.</p>
<p>The remaining participants are all based in Toronto: Orb Therapeutics, a ribonucleic acid (RNA) therapy developer; Synakis, a pre-clinical start-up targeting ocular diseases such as glaucoma; and Thornhill Medical, creator of the RespirAct brain stress test system.</p>
<p>All six companies will receive strategic commercial planning and introductions to potential investors and industry partners.</p>
<p>They will also present at the OBIO Investment Summit in Toronto from 2 to 4 February 2027, an event where presenting enterprises have raised more than C$3.1bn since 2018.</p>
<p>OBIO president and CEO Dr Maura Campbell said: “Reaching this C$1bn milestone is a testament to the world-class innovation emerging from Canada’s health science sector and to the effectiveness of OBIO’s targeted approach.</p>
<p>“Through CAAP, we not only equip founders with intensive coaching, but also provide actionable commercial strategies and direct access to global capital networks via our annual OBIO Investment Summit.</p>
<p>“Every dollar raised by our programme alumni contributes to the creation of new jobs, concrete clinical advancements, and the scaling of Canadian health technologies on the global stage.”</p>
<p>Till date, 127 health science businesses have graduated from the advisory scheme, with 65% securing capital or strategic partnerships within 18 months of completing the programme.</p>
<p>Established in 2009, OBIO is a not-for-profit, membership-led entity providing strategy, programming, and commercialisation support for diagnostics, medical technology, therapeutics, and digital health businesses across Canada.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/obio-1bn-canadian-health-tech-ventures/">OBIO marks $704m funding milestone for Canadian health tech ventures</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Kyowa Kirin, Knight agree Latin American distribution deal for mogamulizumab</title>
<link>https://edusehat.com/en/kyowa-kirin-knight-agree-latin-american-distribution-deal-for-mogamulizumab</link>
<guid>https://edusehat.com/en/kyowa-kirin-knight-agree-latin-american-distribution-deal-for-mogamulizumab</guid>
<description><![CDATA[ Under the terms of the transaction, Knight Therapeutics will oversee regulatory submissions and commercial distribution of the therapy across Brazil, Argentina, Mexico, and Colombia. The agreement grants Knight 
The post Kyowa Kirin, Knight agree Latin American distribution deal for mogamulizumab appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/09/PT-30-09-2026-shutterstock_2817249601.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 30 Sep 2026 20:00:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Kyowa, Kirin, Knight, agree, Latin, American, distribution, deal, for, mogamulizumab</media:keywords>
<content:encoded><![CDATA[<p>Under the terms of the transaction, Knight Therapeutics will oversee regulatory submissions and commercial distribution of the therapy across Brazil, Argentina, Mexico, and Colombia.</p>
<p>The agreement grants Knight Therapeutics exclusive rights to market the medicine for mycosis fungoides (MF) and Sézary syndrome (SS), two subtypes of cutaneous T-cell lymphoma (CTCL), which is a rare form of non-Hodgkin’s lymphoma.</p>
<p>The arrangement marks Kyowa Kirin’s first commercial partnership for mogamulizumab in Latin America.</p>
<p>Kyowa Kirin Emerging Growth Markets Cluster general manager Céline Rhême said: “CTCL is more common in this region than many realise, and further work is needed to identify unmet needs and therefore drive improvements in patient outcomes. We have an opportunity, and a responsibility to change that.</p>
<p>“Through our proud partnership with Knight Therapeutics, we can help to increase patient access in Latin America, as part of our ongoing and relentless commitment to bring life-changing value and make people smile.”</p>
<p>Mogamulizumab is described as a first-in-class humanised monoclonal antibody engineered to target CC-chemokine receptor 4 (CCR4), a protein expressed on cancerous T lymphocytes in both MF and SS.</p>
<p>When the antibody attaches to CCR4, it stimulates immune cells to destroy the malignant cells.</p>
<p>In both conditions, these cancerous white blood cells travel from the bloodstream to the skin, causing visible early symptoms such as red patches or plaques that can resemble eczema or psoriasis.</p>
<p>In some patients, the disease may subsequently progress to tumours or widespread reddening of the skin surface, known as erythroderma.</p>
<p>In July 2026, Kyowa Kirin subsidiary Kyowa Kirin EMEA received approval from the European Commission (EC) to expand the use of Crysvita (burosumab) for treating X-linked hypophosphataemia (XLH) in infants aged one month to one year across the EU and European Economic Area.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/kyowa-kirin-knight-latin-american-distribution-mogamulizumab/">Kyowa Kirin, Knight agree Latin American distribution deal for mogamulizumab</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Beyond three validation batches: Building a lifecycle approach for Indian OSD manufacturing</title>
<link>https://edusehat.com/en/beyond-three-validation-batches-building-a-lifecycle-approach-for-indian-osd-manufacturing</link>
<guid>https://edusehat.com/en/beyond-three-validation-batches-building-a-lifecycle-approach-for-indian-osd-manufacturing</guid>
<description><![CDATA[ 
Sri Harsha Chakrapani, Pharmaceutical Process Engineer and Independent Researcher highlights the need for pharma manufacturers to move from batch-based validation to a lifecycle approach, with continued process verification, risk-based monitoring and ongoing process control throughout commercial manufacturing. 
The post Beyond three validation batches: Building a lifecycle approach for Indian OSD manufacturing appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/30172140/EP_GB_Sri_Harsha_Chakrapani_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 30 Sep 2026 20:00:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Beyond, three, validation, batches:, Building, lifecycle, approach, for, Indian, OSD, manufacturing</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/30172140/EP_GB_Sri_Harsha_Chakrapani_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/30172140/EP_GB_Sri_Harsha_Chakrapani_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/30172140/EP_GB_Sri_Harsha_Chakrapani_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>For oral solid dosage manufacturers, validation should not be treated as a milestone that ends after a small set of successful qualification batches. A lifecycle approach connects process understanding, process performance qualification, continued process verification, change management and periodic review so that evidence of control is maintained throughout commercial manufacturing.</span></p>
<p><span>Validation should answer a continuing question: does the process remain capable of reproducibly delivering the intended product quality under routine commercial conditions? Yet in many organizations, validation is still experienced as a project with a closing date. Development is completed, equipment is qualified, a defined number of process performance qualification (PPQ) batches are executed, the report is approved and the validation team moves to the next product.</span></p>
<p><span>That sequence may complete an important qualification milestone, but it does not by itself establish that the process will remain in control as raw-material lots change, equipment ages, operators rotate, suppliers change, demand increases, maintenance interventions occur and process knowledge accumulates. For an oral solid dosage (OSD) process, those effects can appear gradually through shifts in blend uniformity, granulation end points, compression performance, coating behavior, dissolution, assay or other critical quality attributes.</span></p>
<p><span>The more useful question is therefore not, “Did three batches pass?” It is, “What evidence shows that the process is understood, appropriately controlled and continuing to perform as intended?”</span></p>
<p><b>From batch-count thinking to lifecycle thinking</b></p>
<p><span>The U.S. FDA’s 2011 process validation guidance sets out a lifecycle model with three stages: process design, process qualification and continued process verification. FDA’s current CGMP questions and answers also state that neither the regulations nor FDA policy specifies a minimum number of validation batches. Manufacturers should have a sound rationale for the number of PPQ runs and use a science-based approach; batch count should reflect process knowledge and the evidence needed to demonstrate reproducibility, not substitute for them. [2,3]</span></p>
<p><span>For Indian manufacturers supplying multiple markets, a lifecycle approach creates common operating logic across development, technology transfer, commercial manufacturing and post-change verification. It also aligns with ICH Q9 quality risk management and ICH Q10 pharmaceutical quality system principles on risk-based decisions, state of control and continual improvement. [4,5]</span></p>
<p><b>Revised Schedule M strengthens the same direction</b></p>
<p><span>India’s revised Schedule M makes the ongoing nature of validation especially relevant. It requires a pharmaceutical quality system incorporating GMP and quality risk management, regular product quality reviews, a formal change control system, and effective systems for monitoring process performance and product quality. It also states that qualification and validation shall not be considered one-off exercises; an ongoing programme shall follow initial implementation, based on periodic review, with a commitment to maintain continued validation status. [1]</span></p>
<p><span>That language changes the management implication of validation. The validation master plan cannot be only a calendar of qualification protocols. It should describe how the organization will maintain assurance after initial qualification: what will be monitored, who reviews it, how signals are escalated, how changes are assessed, and when additional verification or revalidation is warranted.</span></p>
<p><b>Start with the control strategy, not the report template</b></p>
<p><span>For an OSD product, lifecycle validation begins with a clear chain of reasoning from product quality to process control. Critical quality attributes (CQAs) should be linked to the material attributes and process parameters capable of influencing them. The control strategy should then define the controls that keep those sources of variability within an acceptable range. [6]</span></p>
<p><span>For example, a tablet process may require knowledge of how incoming active pharmaceutical ingredient particle-size distribution, granulation conditions, lubrication, compression force and coating parameters can influence manufacturability and finished-product performance. The purpose is not to label every variable “critical.” It is to identify the variables that genuinely matter, understand the mechanisms where possible, and create controls proportionate to risk.</span></p>
<p><span>PPQ then becomes a focused confirmation that the commercial process, people, equipment, materials, methods and controls work together reproducibly. A strong PPQ protocol should therefore be traceable to prior process knowledge and risk assessment. Sampling intensity, acceptance criteria and the number of runs should have a rationale that can be explained scientifically. [2,6]</span></p>
<p><b>Make continued process verification operational</b></p>
<p><span>Continued process verification (CPV) is where lifecycle validation becomes a routine manufacturing discipline rather than a periodic validation activity. The objective is to identify meaningful changes in process behavior and increasing variability in time to support investigation and action, rather than waiting for recurring deviations or out-of-specification results to become the first signal. [2,5]</span></p>
<p><span>A practical CPV programme does not require collecting every available data point. It requires selecting the right data. For each product or product family, manufacturers can identify a focused set of process parameters, in-process controls, CQAs and supporting indicators that provide meaningful evidence of process performance. Statistical process control charts, trend analysis, capability measures and other statistical methods can be used where appropriate, but the tool should fit the data and the decision. [2,5]</span></p>
<p><span>The review frequency should also be risk based. A recently transferred product, a process with narrow operating margins or a parameter associated with historical variability may require closer monitoring than a mature, highly capable process. The monitoring strategy can evolve as knowledge increases. [2,4,5]</span></p>
<p><b>Connect CPV with deviations, change control and product quality review</b></p>
<p><span>A practical weakness arises when useful information remains separated across systems. CPV trends may sit in one report, deviations in another, change controls in another and annual product quality reviews in yet another. Lifecycle validation works better when these records inform one another.</span></p>
<table>
<tbody>
<tr>
<td><b>Evidence stream</b></td>
<td><b>Management question</b></td>
</tr>
<tr>
<td><span>Continued process verification</span></td>
<td><span>Is process behavior shifting or variability increasing?</span></td>
</tr>
<tr>
<td><span>Deviations and CAPA</span></td>
<td><span>Are recurring failure modes or weak signals emerging?</span></td>
</tr>
<tr>
<td><span>Change control</span></td>
<td><span>What new uncertainty is introduced, and what evidence is needed after implementation?</span></td>
</tr>
<tr>
<td><span>Product quality review</span></td>
<td><span>Does the combined evidence support a continuing state of control and identify improvement or revalidation needs?</span></td>
</tr>
</tbody>
</table>
<p> </p>
<p><span>A small but persistent shift in compression force, for example, may not trigger a batch failure. If the same period includes a raw-material supplier change, higher tablet-weight variability and an increase in minor compression interventions, the combined evidence may justify investigation even though every batch meets specification.</span></p>
<p><span>Similarly, change control should ask more than whether a change requires a validation protocol. It should assess what process knowledge is affected, what risks change, what evidence is needed before implementation and what enhanced monitoring is required afterward. Post-implementation verification can then confirm whether the change achieved its objective without introducing unintended effects. [1,5]</span></p>
<p><span>Product quality review provides a periodic synthesis. Revised Schedule M expects review of critical in-process controls and finished-product results; deviations or non-conformances and CAPA; process or analytical-method changes; stability trends; returns, complaints and recalls; and qualification status of relevant equipment and utilities. The output should support decisions—not simply completion of an annual report. [1]</span></p>
<p><b>Revalidation should be triggered by evidence and risk</b></p>
<p><span>Lifecycle validation does not mean repeating full validation at arbitrary intervals. Nor does it mean that any process change automatically requires three new batches. The appropriate response should depend on the potential impact of the change, the strength of existing process knowledge, historical performance, the ability of existing controls to detect emerging failure modes and the evidence available after implementation. [1,2,4]</span></p>
<p><span>Risk-based triggers for additional verification or requalification can include significant formulation or process changes, major equipment or site changes, new sources of critical materials, adverse trends, repeated deviations, loss of process capability or signals from product quality review. The scope may range from enhanced CPV to targeted qualification or full revalidation, depending on impact and uncertainty. [1,2,4]</span></p>
<p><span>This is where quality risk management is most useful: effort, formality and documentation should be commensurate with the level of risk and the uncertainty of the decision. [4]</span></p>
<p><b>Avoid turning lifecycle validation into documentation inflation</b></p>
<p><span>A lifecycle approach should not create a second bureaucracy layered on top of existing GMP systems. Much of the required evidence already exists in batch records, laboratory systems, deviation management, change control, maintenance, stability programmes and product quality reviews. The opportunity is to connect these data sources around a defined set of process questions.</span></p>
<p><span>For senior management, this means funding the capability to convert manufacturing data into decisions: reliable data capture, appropriate statistical skills, clear ownership, cross-functional review and escalation rules. The objective is not more charts. It is earlier detection of drift, better change decisions, stronger process knowledge and fewer surprises.</span></p>
<p><b>A practical path for Indian OSD manufacturers</b></p>
<p><span>Indian manufacturers can begin without redesigning the entire quality system. First, select a small number of products representing different risk profiles. Reconstruct the relationship between CQAs, material attributes, process parameters and the existing control strategy. Review whether PPQ rationale is supported by process knowledge. Define a concise CPV plan with meaningful metrics, alert criteria, review frequency and escalation responsibilities. Finally, connect CPV conclusions to deviation management, change control and product quality review.</span></p>
<p><span>The maturity test is simple: if a process begins to drift, can the organization recognize the signal, understand its potential impact and act before product quality or supply is affected?</span></p>
<p><span>The most important shift is cultural. Validation is not evidence generated once and archived. It is a lifecycle of knowledge and control. Successful PPQ batches remain important, but they are the beginning of commercial process assurance—not the end.</span></p>
<p><b>References:</b></p>
<ol>
<li>
<h5><span> Government of India, Ministry of Health and Family Welfare, Department of Health and Family Welfare. G.S.R. 922(E), dated 28 December 2023, amending the Drugs Rules, 1945 and substituting Schedule M: Good Manufacturing Practices and Requirements of Premises, Plant and Equipment for Pharmaceutical Products. Gazette of India, Extraordinary, Part II, Section 3, Sub-section (i).</span></h5>
</li>
<li>
<h5><span> U.S. Food and Drug Administration. Process Validation: General Principles and Practices. Guidance for Industry. January 2011.</span></h5>
</li>
<li>
<h5><span> U.S. Food and Drug Administration. Questions and Answers on Current Good Manufacturing Practice Regulations: Production and Process Controls, Question 5: Does CGMP require three successful process validation batches before a new API or finished drug product is released for distribution?</span></h5>
</li>
<li>
<h5><span> International Council for Harmonisation (ICH). Q9(R1): Quality Risk Management. Final version adopted 18 January 2023.</span></h5>
</li>
<li>
<h5><span> International Council for Harmonisation (ICH). Q10: Pharmaceutical Quality System. Step 4 adopted 4 June 2008.</span></h5>
</li>
<li>
<h5><span> International Council for Harmonisation (ICH). Q8(R2): Pharmaceutical Development. Current Step 4 version dated August 2009.</span></h5>
</li>
</ol>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/beyond-three-validation-batches-building-a-lifecycle-approach-for-indian-osd-manufacturing/">Beyond three validation batches: Building a lifecycle approach for Indian OSD manufacturing</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Biodeal Pharmaceuticals acquires Biological E facility, expands into sterile injectables</title>
<link>https://edusehat.com/en/biodeal-pharmaceuticals-acquires-biological-e-facility-expands-into-sterile-injectables</link>
<guid>https://edusehat.com/en/biodeal-pharmaceuticals-acquires-biological-e-facility-expands-into-sterile-injectables</guid>
<description><![CDATA[ 
The manufacturing facility adds 135 million-unit annual capacity, with Carbapenem line now operational and validated under Biodeal’s ownership
The post Biodeal Pharmaceuticals acquires Biological E facility, expands into sterile injectables appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/30173153/EP_Biodeal.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 30 Sep 2026 20:00:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Biodeal, Pharmaceuticals, acquires, Biological, facility, expands, into, sterile, injectables</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/30173153/EP_Biodeal.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/30173153/EP_Biodeal.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/30173153/EP_Biodeal-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p>Biodeal Pharmaceuticals, a leading Contract Development and Manufacturing Organisation (CDMO), has acquired a sterile injectable manufacturing facility in Paonta Sahib, Himachal Pradesh – one of the largest manufacturing facilities in the state – from Biological E. The acquisition marks a strategic expansion of Biodeal’s manufacturing platform into sterile injectables for global markets, adding established regulatory credentials, specialised capabilities and significant manufacturing capacity to its portfolio.</p>
<p>The facility is equipped for general injectables and Carbapenem manufacturing in vial formats, supported by German-made Groninger processing lines, with current annual capacity of around 135 million units. There is scope to expand to the facility’s full capacity of 17 production lines and to add pre-filled syringe (PFS) and lyophilised formats. Biodeal is pursuing PIC/S and EU accreditation for the facility as part of its plans to expand into additional regulated markets.</p>
<p>Spread across a 14-acre campus, the Paonta Sahib facility comprises approximately 39,000 square metres of built-up manufacturing space and has the potential to add a further capacity of 30 million units through near-term expansion. Located approximately 50 kilometres from Biodeal’s existing Nalagarh facility, the acquisition also strengthens the company’s manufacturing footprint within Himachal Pradesh’s established pharmaceutical corridor.</p>
<p>“This acquisition is a deliberate step, not an opportunistic one. RMB Capitalworks backed our growth path with conviction, and Paonta Sahib gives us a regulated-market manufacturing base with credentials and capabilities that normally take years to build. It changes the category of company Biodeal competes in and puts us in a strong position to continue building a durable, high-value regulated-market business,” said Anurag Kumar, Chairman & Managing Director, Biodeal Pharmaceuticals.</p>
<p>The facility was acquired from Biological E., a Hyderabad-headquartered vaccine and pharmaceutical manufacturer with nearly seven decades of operations, as part of Biological E’s ongoing investment in its new vaccine R&D and CDMO campus in Telangana. With this acquisition, Biodeal adds established manufacturing capacity and credentials to its platform, broadening the range of complex injectable manufacturing it can offer pharmaceutical customers globally – spanning Carbapenems for serious bacterial and drug-resistant infections, and in process of expanding into ready-to-use pre-filled syringe formats, and lyophilised products with extended stability and shelf life.</p>
<p>“As Biological E continues to focus our investment on our new vaccine R&D and CDMO campus in Telangana, divesting our Paonta Sahib facility to a capable, growth-oriented partner was a natural next step. We are confident Biodeal Pharmaceuticals is well positioned to build on the strong foundation established at this facility, and we wish them continued success as they take it forward,” said Mahima Datla, Managing Director, Biological E.</p>
<p>The post <a href="https://www.expresspharma.in/biodeal-pharmaceuticals-acquires-biological-e-facility-expands-into-sterile-injectables/">Biodeal Pharmaceuticals acquires Biological E facility, expands into sterile injectables</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Linux secures USD 70mn strategic investment from ChrysCapital and Tata Capital Healthcare Fund</title>
<link>https://edusehat.com/en/linux-secures-usd-70mn-strategic-investment-from-chryscapital-and-tata-capital-healthcare-fund</link>
<guid>https://edusehat.com/en/linux-secures-usd-70mn-strategic-investment-from-chryscapital-and-tata-capital-healthcare-fund</guid>
<description><![CDATA[ 
Linux is a specialty-focused domestic formulations platform with a portfolio of over 125 brands spanning ~400 SKUs.
The post Linux secures USD 70mn strategic investment from ChrysCapital and Tata Capital Healthcare Fund appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/05/04123258/investment.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 30 Sep 2026 16:25:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Linux, secures, USD, 70mn, strategic, investment, from, ChrysCapital, and, Tata, Capital, Healthcare, Fund</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/05/04123258/investment.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/05/04123258/investment.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/05/04123258/investment-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>Linux Laboratories, one of India’s fastest-growing domestic formulations companies, has secured USD 70 million in equity capital from ChrysCapital and Tata Capital Healthcare Fund III (“TCHF III”). ChrysCapital has acquired a significant minority stake in Linux. </span></p>
<p><span>The transaction comprises a combination of primary capital and secondary purchase and includes the full exit of Tata Capital Healthcare Fund II (“TCHF II”) at approximately 4x returns. Avendus Capital acted as the exclusive financial advisor to Linux on the transaction.</span></p>
<p><span>Founded in 2007 and headquartered in Chennai, Linux is a specialty-focused domestic formulations platform with a portfolio of over 125 brands spanning ~400 SKUs. Linux has established a leadership position in central nervous system (CNS) therapies, covering epilepsy, neuropathic pain, depression and autism, and has extended into dermatology, cardio-diabetics and nutraceuticals. Linux reaches over 60,000 doctors through a field force of more than 1,000 medical representatives across seven divisions, with a pan-India presence and a deliberate focus on specialists.</span></p>
<p><span>Linux has combined organic brand-building with a disciplined acquisition track record, having integrated and scaled the Biomedica and Indiabulls Pharmaceuticals portfolios alongside brands acquired from Cipla and Dr. Reddy’s Laboratories. The Company also operates its own WHO-GMP certified manufacturing facility, which supports backward integration for the branded business while anchoring a growing contract development and manufacturing (CDMO) operation and an export presence across countries.</span></p>
<p><span>The proceeds will support Linux’s next phase of growth, including deepening its presence in core specialties, entry into adjacent therapeutic areas, continued brand acquisitions, and further investment in manufacturing and R&D capabilities. India’s branded formulations market continues to attract strong investor interest, driven by the rising burden of chronic and sub-chronic conditions and the growing share of specialty-led, prescriber-facing portfolios.</span></p>
<p>S Ananda Kumar, Co-Founder and Executive Director, Linux <span>said, “Linux was built on the conviction that a focused, science-led portfolio with affordability and access to quality healthcare can compete with the largest players in Indian pharma. ChrysCapital and Tata Capital Healthcare Fund III bring the sector experience and capital to take that conviction into a much larger business, and we thank TCHF II for five years of partnership on the journey so far”.</span></p>
<p>P Hariharan, Co-Founder and Executive Director, Linux <span>said, “Our growth has come from earning the trust of specialists, one therapy at a time. With over 125 brands and a field force of more than 1,400, we now have the reach to scale proven brands, enter new therapies and new geographies considerably faster than before”.</span></p>
<p>K Keerthivasan, Co-Founder and Executive Director, Linux <span>said, “Alongside our growth, we remain committed to strengthening our manufacturing, quality systems, R&D, technology and people. This capital marks an important milestone, enabling us to expand our capacity and scale our business. We see strong opportunities in international markets and are focussed on building new partnerships and expanding our global presence. This journey would not have been possible without the dedication and contribution of our Linuxians, customers, partners, investors, family and everyone who have supported us along the way. I sincerely thank each and every one of them. We look forward to continuing this journey together and creating new opportunities for growth”.</span></p>
<p>Kshitij Sheth, Managing Director, ChrysCapital Advisors,<span> said, “ChrysCapital is excited to partner with Linux during the next phase of its growth and is deeply impressed by its specialty-focused franchise, rigorous execution, and M&A track record. This investment aligns with ChrysCapital’s strategy of backing fast-growing domestic formulations companies focused on chronic therapies and led by dynamic entrepreneurs. ChrysCapital looks forward to leveraging its rich experience in the sector to help Linux become a leading player in the Indian pharmaceutical market”.</span></p>
<p>Dr Jagriti Gupta, Senior Vice President, ChrysCapital Advisors,<span> added, “Linux has built a rare combination of depth in CNS, a specialist-focused field force reaching over 60,000 doctors, and its own WHO-GMP manufacturing base. This gives the Company a strong platform to scale its existing brands and extend into adjacent therapies. ChrysCapital looks forward to working closely with the founders and the Linux team to build an enduring specialty pharma franchise”.</span></p>
<p>Visalakshi Chandramouli, Managing Partner, Tata Capital Healthcare Fund<span> said, “Linux has been an exemplary partnership for TCHF. The founders, Dr. P Hariharan, K Keerthivasan and S Ananda Kumar, have combined deep industry expertise with entrepreneurial ambition and a strong execution culture to build Linux into a fast-growing pan-India, multi-therapy platform. Our successful exit from TCHF II is a testament to the substantial value created during this period. At the same time, our decision to reinvest through TCHF III reflects our continued conviction in the founders, the management team, and Linux’s long-term growth potential. We are delighted to continue our partnership with Linux as it embarks on its next phase of expansion and value creation.”</span></p>
<p>The post <a href="https://www.expresspharma.in/linux-secures-usd-70mn-strategic-investment-from-chryscapital-and-tata-capital-healthcare-fund/">Linux secures USD 70mn strategic investment from ChrysCapital and Tata Capital Healthcare Fund</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Morepen strengthens integrated CDMO capabilities with first US ANDA submission</title>
<link>https://edusehat.com/en/morepen-strengthens-integrated-cdmo-capabilities-with-first-us-anda-submission</link>
<guid>https://edusehat.com/en/morepen-strengthens-integrated-cdmo-capabilities-with-first-us-anda-submission</guid>
<description><![CDATA[ 
Morepen Laboratories has submitted its first Abbreviated New Drug Application (ANDA) to the US Food and Drug Administration for Sitagliptin Tablets USP in 25 mg, 50 mg and 100 mg strengths. The submission extends the company’s established API and CDMO expertise into integrated finished dosage development and regulatory filing. The Sitagliptin program brings together formulation […]
The post Morepen strengthens integrated CDMO capabilities with first US ANDA submission appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2022/01/05131511/Tablets-white.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 30 Sep 2026 12:50:19 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Morepen, strengthens, integrated, CDMO, capabilities, with, first, ANDA, submission</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2022/01/05131511/Tablets-white.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2022/01/05131511/Tablets-white.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2022/01/05131511/Tablets-white-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p>Morepen Laboratories has submitted its first Abbreviated New Drug Application (ANDA) to the US Food and Drug Administration for Sitagliptin Tablets USP in 25 mg, 50 mg and 100 mg strengths. The submission extends the company’s established API and CDMO expertise into integrated finished dosage development and regulatory filing.</p>
<p>The Sitagliptin program brings together formulation development and scale-up, analytical method development and validation, impurity control, stability studies and manufacture of regulatory batches under GMP systems. It also incorporates bioequivalence strategy, coordination with contract research organizations and integration of development and study data into the regulatory dossier.</p>
<p>These capabilities strengthen Morepen’s ability to support specialized CDMO assignments spanning API development, finished dosage formulation and regulatory submission, broadening the scope and complexity of customer programs it can undertake.</p>
<p>Sanjay Suri, Managing Director, Morepen Laboratories Limited said “Capability building is central to Morepen’s next phase of growth. Our first ANDA submission brings together the scientific, manufacturing and regulatory skills needed to take an API through finished dosage development to a US filing,”</p>
<p>Suri Further added, “Alongside our planned Innovation Hub and investments in advanced chemistry and technology, this milestone strengthens our ability to undertake specialized CDMO assignments and build long-term development partnerships.”</p>
<p>Morepen intends to build on this foundation through customer development programs, technology transfer, co-development and licensing opportunities. These capabilities can also support product and dossier development for regulated markets across Europe and Asia, tailored to each jurisdiction’s requirements.</p>
<p>Over time, the Company aims to explore differentiated formulations, including potential US 505(b)(2) development programs, subject to product-specific studies and regulatory requirements.</p>
<p>Sitagliptin is an established oral treatment for adults with Type 2 diabetes, belonging to the DPP 4 inhibitor class, commonly known as gliptins. Its innovator product, Januvia, recorded worldwide sales of approximately US$1.604 billion in 2025. The relevant US phosphate salt patent is scheduled to expire in November 2026, with associated paediatric exclusivity extending to May 2027; certain manufacturers have separate arrangements permitting earlier entry.</p>
<p>Morepen currently estimates 24–36 months from submission to progress towards approval and commercial supply, subject to FDA review, satisfactory completion of applicable formulation facility inspection requirements and applicable patent and exclusivity requirements.</p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/morepen-strengthens-integrated-cdmo-capabilities-with-first-us-anda-submission/">Morepen strengthens integrated CDMO capabilities with first US ANDA submission</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Anupam Rasayan concludes acquisition of Bliss GVS Pharma</title>
<link>https://edusehat.com/en/anupam-rasayan-concludes-acquisition-of-bliss-gvs-pharma</link>
<guid>https://edusehat.com/en/anupam-rasayan-concludes-acquisition-of-bliss-gvs-pharma</guid>
<description><![CDATA[ 
The acquisition of Bliss GVS Pharma marks the latest step in Anupam Rasayan’s broader inorganic growth strategy
The post Anupam Rasayan concludes acquisition of Bliss GVS Pharma appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123851/Acquisition.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 30 Sep 2026 12:50:15 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Anupam, Rasayan, concludes, acquisition, Bliss, GVS, Pharma</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123851/Acquisition.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123851/Acquisition.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123851/Acquisition-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><div>Anupam Rasayan India, one of India’s leading custom synthesis and specialty chemical companies, has paid the consideration towards the transaction of a 48.2 per cent controlling stake in Bliss GVS Pharma Limited at ₹299 per share, marking its third strategic inorganic transaction and expanding its presence into finished dosage formulations.</div>
<div></div>
<div>The acquisition, undertaken through Mates Visa Consultancy, a wholly owned subsidiary of Anupam Rasayan, follows the definitive agreement signed on May 23, 2026, and the subsequent completion of the mandatory open offer process. With the acquisition now completed, Bliss GVS Pharma becomes an integral part of Anupam Rasayan’s expanding portfolio of businesses across specialty chemicals and pharmaceuticals.</div>
<div></div>
<div>The transaction has been funded through a combination of a ₹300 crore term loan and approximately ₹1,450 crore raised through non-controlling, non-voting instruments from a group of financial investors led by Bain Capital and including Trust Group and Investec. The financing structure enables Anupam Rasayan to fund the acquisition while preserving balance-sheet capacity for future growth and expansion.</div>
<div></div>
<div>Founded in 1984, Bliss GVS Pharma is a branded formulations company with more than 150 brands across therapeutic segments, including anti-malarial, anti-fungal, anti-bacterial, anti-inflammatory, anti-diabetic and cardiovascular therapies. The company operates six manufacturing facilities across Maharashtra, with its manufacturing facilities certified to international quality and regulatory standards including US FDA, EU-GMP and WHO-GMP. Bliss GVS is also recognised as India’s first EU-GMP certified suppositories manufacturer, reinforcing its strong manufacturing and quality credentials. With its manufacturing infrastructure currently operating at approximately 30% capacity utilisation, the business provides significant headroom for future growth.</div>
<div></div>
<div>On the acquisition, Anand Desai, Managing Director of Anupam Rasayan India said, “We are pleased to announce the successful completion of the acquisition of Bliss GVS Pharma. This transaction marks an important milestone in our long-term strategy to build a diversified, integrated and innovation-led global pharmaceutical platform.</div>
<div></div>
<div>The acquisition strengthens our presence in finished pharmaceutical formulations and complements Anupam Rasayan’s expertise in key starting materials, intermediates and specialty chemicals. Combining our manufacturing and process chemistry capabilities with Bliss GVS Pharma’s formulation expertise, customer relationships, and market presence, we are well positioned to pursue forward integration, new product development, and geographic expansion.</div>
<div></div>
<div>We believe this integration will strengthen our capabilities, unlock meaningful operational and commercial synergies, and support sustainable, long-term value creation for all our stakeholders.”</div>
<div></div>
<div>Building a ₹4,000+ crore integrated platform</div>
<div></div>
<div>The acquisition of Bliss GVS Pharma marks the latest step in Anupam Rasayan’s broader inorganic growth strategy, with each transaction adding a distinct capability to the group’s evolving business platform.</div>
<div></div>
<div>Following the consolidation of Anupam Rasayan, Tanfac Industries, Jayhawk Fine Chemicals and Bliss GVS Pharma, the combined platform is expected to have pro-forma revenue of more than ₹4,000 crore and EBITDA of approximately ₹834 crore. The pro-forma revenue comprises approximately ₹1,676 crore from Anupam Rasayan standalone, ₹711 crore from Tanfac Industries, ₹722 crore from Jayhawk Fine Chemicals and ₹927 crore from Bliss GVS Pharma.</div>
<div></div>
<div>The three strategic acquisitions have each been undertaken with a distinct objective: strengthening access to critical raw materials, establishing a global manufacturing footprint and, now, extending the value chain into finished dosage formulations.</div>
<div></div>
<div>From raw materials to finished formulations Tanfac Industries – Backward Integration:</div>
<div></div>
<div>Anupam Rasayan’s first major strategic acquisition was its investment in Tanfac Industries in 2022. The company acquired a 24.96% stake and management control in Tanfac, a leading manufacturer of specialty fluorides, and subsequently participated in an open offer for an additional stake.</div>
<div></div>
<div>Tanfac provides critical fluorine-based raw materials, including hydrofluoric acid and potassium fluoride, strengthening Anupam Rasayan’s access to key inputs and reducing dependence on imports. The acquisition also created opportunities to develop additional fluorine derivatives for applications across crop protection, pharmaceuticals, solar cells, polymers and semiconductors.</div>
<div></div>
<div>Jayhawk Fine Chemicals – Global Manufacturing & Nearshoring:</div>
<div></div>
<div>In February 2026, Anupam Rasayan completed the acquisition of 100% of Jayhawk Fine Chemicals Corporation, a specialty chemicals manufacturer based in Galena, Kansas, for an enterprise value of approximately US$134 million.</div>
<div></div>
<div>The acquisition established Anupam Rasayan’s manufacturing presence in the US and brought the company closer to customers in developed markets. Jayhawk also expands Anupam Rasayan’s exposure to performance materials used in electronics, energy, aerospace and polymers, with approximately 65% of its revenue coming from these applications. In Q1 FY27, Jayhawk contributed approximately 20–22% of Anupam Rasayan’s consolidated revenue, with EBITDA margins of around 19–20%.</div>
<div></div>
<div>Bliss GVS Pharma – Forward Integration:</div>
<div></div>
<div>With Bliss GVS Pharma, Anupam Rasayan is extending its value chain into finished dosage formulations, moving beyond its established capabilities in custom synthesis, specialty chemicals and pharmaceutical intermediates.</div>
<div></div>
<div>The acquisition provides access to Bliss GVS Pharma’s established portfolio of branded formulations, manufacturing infrastructure and presence across multiple therapeutic segments. It also creates opportunities for greater integration across Anupam Rasayan’s pharmaceutical value chain and strengthens its ability to participate across the journey from key starting materials and intermediates to finished formulations.</div>
<div></div>
<div>Together, the three transactions represent a progression in Anupam Rasayan’s inorganic growth strategy backward integration through Tanfac, global manufacturing and nearshoring through Jayhawk, and forward integration into finished dosages through Bliss GVS Pharma.</div>
<div></div>
<div>The acquisition of Bliss GVS Pharma has been made at approximately 24x LTM earnings, providing Anupam Rasayan with an earnings-accretive opportunity at a valuation lower than the multiple at which the parent company trades. With Bliss GVS Pharma’s existing manufacturing footprint, established product portfolio and available capacity, the transaction provides Anupam Rasayan with an additional platform for growth in the pharmaceutical formulations segment.</div>
<div></div>
<div>The transaction therefore brings together four complementary businesses across geographies and stages of the value chain, creating a larger integrated platform spanning specialty chemicals, pharmaceutical intermediates, advanced materials and finished dosage formulations.</div>
<div></div>
<p>The post <a href="https://www.expresspharma.in/anupam-rasayan-concludes-acquisition-of-bliss-gvs-pharma/">Anupam Rasayan concludes acquisition of Bliss GVS Pharma</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>OPPI collaborates with NIPER Hajipur to advance research excellence</title>
<link>https://edusehat.com/en/oppi-collaborates-with-niper-hajipur-to-advance-research-excellence</link>
<guid>https://edusehat.com/en/oppi-collaborates-with-niper-hajipur-to-advance-research-excellence</guid>
<description><![CDATA[ 
The collaboration aims to strengthen industry-academia collaboration to drive translational research and innovation
The post OPPI collaborates with NIPER Hajipur to advance research excellence appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/29115115/EP_NIPER.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 30 Sep 2026 12:50:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>OPPI, collaborates, with, NIPER, Hajipur, advance, research, excellence</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/29115115/EP_NIPER.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/29115115/EP_NIPER.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/29115115/EP_NIPER-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p>The Organisation of Pharmaceutical Producers of India (OPPI) has announced a strategic collaboration with the National Institute of Pharmaceutical Education and Research, Hajipur to support and promote outcome-oriented pharmaceutical research in India.</p>
<p>As part of this initiative, OPPI will award gold and silver scholarships to two meritorious research scholars currently in their third or fourth year at NIPER Hajipur. The scholarships will be extended as research grants to support ongoing projects that demonstrate strong potential to address real-world healthcare challenges and contribute to meaningful advances in patient care. OPPI will also actively support the development of a ‘Professor of Practice’ framework, enabling experienced industry professionals from OPPI member companies to engage directly with students and researchers at NIPER Hajipur.</p>
<p>The collaboration also builds on NIPER Hajipur’s focus on strengthening evidence-led healthcare research through its dedicated Centre of Excellence (CoE) for Health Technology Assessment (HTA). The Centre provides an important platform for advancing research and capacity building in HTA and supporting a deeper understanding of how health technologies can be evaluated to inform healthcare decision-making.</p>
<p>As part of its engagement with NIPER Hajipur, OPPI is also conducting guest lectures covering Health Technology Assessment (HTA), Health Economics and Outcomes Research (HEOR), and evidence-based healthcare decision-making. Through this initiative, subject-matter experts from OPPI member companies will deliver curated knowledge sessions, workshops and mentorship engagements for students. These interactions will provide valuable real-world insights, bridge the gap between academic research and evolving industry needs, and equip students with the practical understanding required to translate scientific discoveries into impactful healthcare solutions.</p>
<p>Anil Matai, Director General, OPPI said, “India’s aspiration to emerge as a global pharmaceutical innovation hub will depend not only on the strength of our research ecosystem, but also on our ability to connect scientific talent, industry expertise and real-world healthcare needs. Our collaboration with NIPER Hajipur is an effort to strengthen this critical bridge. By supporting promising researchers, facilitating exposure to industry perspectives and building capabilities in areas such as HTA and HEOR, we hope to encourage research that is both scientifically rigorous and relevant to the needs of patients and healthcare systems. This initiative is also aligned with the Government’s continued focus on strengthening pharmaceutical education and research, including the recent push to establish three new NIPERs and upgrade seven existing institutions, as highlighted by the Department of Pharmaceuticals. This collaboration further builds on OPPI’s longstanding commitment to advancing research and development in India, with several member companies already partnering with NIPER institutions across the country to foster innovation and talent development.”</p>
<p>Prof. Ruckmani Kandasamy, Director, NIPER Hajipur said, “NIPER Hajipur is delighted to collaborate with OPPI to strengthen industry–academia engagement and advance outcome-oriented pharmaceutical research. This partnership will provide our students and research scholars with valuable opportunities for research support, industry mentorship and meaningful exposure to real-world challenges and evolving industry practices. The curated knowledge sessions and engagements in areas such as Health Technology Assessment (HTA) and Health Economics and Outcomes Research (HEOR) will further strengthen their understanding of evidence-based healthcare decision-making and the translation of research into practical solutions. The partnership will also complement and strengthen NIPER Hajipur’s HTAIn–DHR activities by bringing industry perspectives, expertise and real-world insights into HTA and HEOR. We look forward to building a sustained and mutually beneficial partnership that nurtures future-ready scientific talent, encourages innovation and contributes to research that can make a meaningful difference to patients and healthcare systems.”</p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/oppi-collaborates-with-niper-hajipur-to-advance-research-excellence/">OPPI collaborates with NIPER Hajipur to advance research excellence</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Akums receives DCGI approval for Colchicine 0.5 mg tablets</title>
<link>https://edusehat.com/en/akums-receives-dcgi-approval-for-colchicine-05-mg-tablets</link>
<guid>https://edusehat.com/en/akums-receives-dcgi-approval-for-colchicine-05-mg-tablets</guid>
<description><![CDATA[ 
First-time-in-India approval strengthens Akums’ presence in the growing cardiovascular therapeutics segment
The post Akums receives DCGI approval for Colchicine 0.5 mg tablets appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/11/23115124/approval.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 30 Sep 2026 12:50:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Akums, receives, DCGI, approval, for, Colchicine, 0.5, tablets</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/11/23115124/approval.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/11/23115124/approval.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/11/23115124/approval-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p>Akums Drugs & Pharmaceuticals, India’s largest Contract Development and Manufacturing Organization (CDMO), has received DCGI approval for Colchicine 0.5 mg Tablets, marking a significant addition to its cardiovascular and preventive cardiology portfolio. The approval represents a first-time-in-India regulatory milestone for this application and reinforces Akums’ focus on differentiated therapies addressing evolving healthcare needs.</p>
<p>The approval comes at a time when India’s pharmaceutical market continues to witness strong growth, particularly across chronic therapies. According to Pharmarack, the Indian Pharmaceutical Market (IPM) grew 10.7% year-on-year in August 2026 to ₹23,272 crore. Chronic therapies continued to be an important growth driver, reflecting the increasing demand associated with long-term disease management. The cardiac segment has emerged as one of the key contributors to this growth. In July 2026, the cardiac therapy market recorded 14.7% year-on-year growth and sales of approximately ₹3,299 crore, according to Pharmarack.</p>
<p>The underlying disease burden further highlights the opportunity for cardiovascular prevention and long-term management. Government data released in March 2026 reported that more than 40.87 crore people had been screened for hypertension in India, of whom over 7 crore had been diagnosed and 5.57 crore were receiving treatment as of February 2026. Against this backdrop, cardiovascular treatment is increasingly moving beyond the management of conventional risk factors towards a more comprehensive approach to cardiovascular risk reduction.</p>
<p>Colchicine is a well-established anti-inflammatory agent that works through mechanisms including inhibition of microtubule polymerisation and modulation of inflammatory signalling pathways. Akums’ approved 0.5 mg formulation is indicated to reduce the risk of myocardial infarction, stroke, coronary revascularisation and cardiovascular death in adult patients with established atherosclerotic disease or multiple cardiovascular risk factors.</p>
<p>The product information identifies mechanisms including inhibition of NLRP3 inflammasome activation, reduction of neutrophil activation and migration, and suppression of endothelial inflammation—pathways associated with vascular inflammation and atherosclerotic plaque vulnerability.</p>
<p>Sanjeev Jain, Managing Director, Akums Drugs & Pharmaceuticals said: “Cardiovascular disease represents one of the most important healthcare challenges facing India, and the focus of treatment is increasingly moving towards comprehensive and long-term risk management. The DCGI approval of Colchicine 0.5 mg reflects Akums’ commitment to enabling differentiated therapies that address evolving areas of medical need. We are leveraging our scientific, regulatory and manufacturing capabilities to support the availability of relevant therapeutic options for physicians and patients.”</p>
<p>Sandeep Jain, Managing Director, Akums Drugs & Pharmaceuticals said: “The continued growth of the cardiac therapy segment reflects growing emphasis on chronic disease management. Colchicine 0.5 mg strengthens our cardiovascular portfolio by addressing the inflammatory component of cardiovascular risk.. This approval is aligned with our broader strategy of developing and enabling high-quality pharmaceutical solutions in therapeutic areas where there is significant unmet or evolving healthcare need.”</p>
<p>The market opportunity is supported not only by India’s growing cardiovascular disease burden but also by the country’s expanding focus on early screening, diagnosis and chronic disease management. The Government of India has increasingly strengthened its NCD infrastructure and preventive-health programmes, creating a broader ecosystem for long-term management of cardiovascular and metabolic diseases.</p>
<p>For Akums, the approval represents another step in expanding its differentiated pharmaceutical portfolio across complex and emerging therapeutic areas. The company’s Colchicine 0.5 mg formulation is positioned as an additional therapeutic option for appropriate adult patients, alongside established cardiovascular management approaches, as determined by physicians.</p>
<p>The company will continue to focus on leveraging its R&D, formulation development, manufacturing and regulatory capabilities to address evolving healthcare requirements and enable access to differentiated pharmaceutical solutions.</p>
<p>The post <a href="https://www.expresspharma.in/akums-receives-dcgi-approval-for-colchicine-0-5-mg-tablets/">Akums receives DCGI approval for Colchicine 0.5 mg tablets</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>India is the hub of our R&amp;amp;D strength, process innovation and regulatory excellence </title>
<link>https://edusehat.com/en/india-is-the-hub-of-our-rd-strength-process-innovation-and-regulatory-excellence</link>
<guid>https://edusehat.com/en/india-is-the-hub-of-our-rd-strength-process-innovation-and-regulatory-excellence</guid>
<description><![CDATA[ 
Jeevan Kasara, Chairman of the Board, STERIS Healthcare, believes India’s next pharma growth story will be built on trust, innovation and value, not cost alone. He discusses the China+1 opportunity, the shift towards complex therapies and CDMOs, and how India can grow to become a global hub for pharma innovation, in an exclusive interaction with Lakshmipriya Nair
The post India is the hub of our R&amp;D strength, process innovation and regulatory excellence  appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/29171631/EP_Jeevan_Kasara_Chairman_of_the_Board_STERIS_Healthcare_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 30 Sep 2026 12:50:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>India, the, hub, our, R&amp;D, strength, process, innovation, and, regulatory, excellence </media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/29171631/EP_Jeevan_Kasara_Chairman_of_the_Board_STERIS_Healthcare_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/29171631/EP_Jeevan_Kasara_Chairman_of_the_Board_STERIS_Healthcare_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/29171631/EP_Jeevan_Kasara_Chairman_of_the_Board_STERIS_Healthcare_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p dir="ltr"><span>What will fuel the next round of growth, and how can companies stay ahead in this race? </span></p>
<p dir="ltr"><span>The combination of cost competitiveness and scale has brought India into the fold of the global pharma industry, but what keeps us here now is our ability to be consistent in maintaining the quality of our drugs and our maturity in handling regulations and developing products further up the value chain. It is not the companies that are trying to compete through cost alone that will succeed, but those who invest in their research capability and sophisticated manufacturing processes. </span></p>
<p dir="ltr"><span>Reshaping the approach to growth in light of diversifying supply chains and heightened regulatory expectations? </span></p>
<p dir="ltr"><span>The ‘China +1’ discussion is essentially a discussion about trust. Buyers around the world don’t just want another supply source, they want a reliable one. It’s time for Indian pharma to view compliance as an investment and not an obligation. Companies that take the proactive approach to incorporate quality by design, upgrade facilities at an early stage, and stay ahead of changing international regulatory requirements will turn their diversification into sustained relationships rather than sporadic purchases. It’s also time for the sector to increase backward integration, given its reliance on external sourcing of critical raw materials. </span></p>
<p dir="ltr"><span>Which of the opportunities – complex generics, specialty, biologics, peptides or CDMO – has the greatest potential for value creation? </span></p>
<p dir="ltr"><span>All of them have their own importance, but complex generics and CDMO offer the best opportunity for value creation for the Indian pharmaceutical industry because in both cases our strengths can be used. We are familiar with the regulatory requirements and large scale production, so we can use that for complex generics. CDMO is equally important as Indian companies can collaborate at an advanced stage in the pipeline without taking full responsibility of development. Biologics and specialty products will take more time because of the investment and scientific expertise required. </span></p>
<p dir="ltr"><span>What has to happen for India to become more than the ‘pharmacy of the world’? </span></p>
<p dir="ltr"><span>The key shift is not just a function of infrastructure but also a mind-set one. The Indian pharma sector has shown its ability to manufacture consistently on a large scale. But now it must show its ability to innovate. This will require sustained investment in research and development, as well as a policy environment that recognises the risks associated with innovation over the more easily recognised manufacturing efficiencies. Intellectual property security, expedited regulatory approval of new molecules, and availability of research funding are the ingredients needed. But it will also require that Indian firms get used to slower development processes and less certainty in their early stages. </span></p>
<p dir="ltr"><span>Looking at STERIS Healthcare, where do you see the biggest opportunities for growth? </span></p>
<p dir="ltr"><span>Our most promising growth vectors are super specialty therapies in oncology, cardiology and nephrology, paired up with our recently expanded production capacity . We’re going full steam on digitising the supply chain so patient access gets better across tier 2 and tier 3 cities, not just the usual metros. Also, the planned IPO plus greenfield expansion in South India puts us in a strong spot to grab both domestic demand and some export upside. STERIS is, honestly, uniquely poised to lead in complex, high margin formulations that hit critical healthcare gaps. </span></p>
<p dir="ltr"><span>As global pharma companies look for partners that can offer quality, reliability and supply-chain resilience, how is STERIS positioning itself to become a more strategic partner to them? </span></p>
<p dir="ltr"><span>Because quality is part of everything we do – right from where the raw material begins right up to where the finished product stops. With zero-defect at our ISO-certified & WHOGMP manufacturing sites, and nimble logistics that neither falter, nor stall. With regulatory intelligence that aligns seamlessly.</span></p>
<p dir="ltr"><span>The clear communication and bespoke development support we offer for sensitive and complex molecules are just part of the equation. </span></p>
<p dir="ltr"><span>It is this dependable end-to-end ownership that makes STERIS feel like the vital partner of choice for world leaders seeking enduring global partnerships.</span></p>
<p dir="ltr"><span>How important is India to STERIS’ global growth plans? Could India become more than a manufacturing base and emerge as a larger global capability hub for the company? </span></p>
<p dir="ltr"><span>India is not just the hub of our global ambition but rather the hub of our R&D strength, process innovation and regulatory excellence. With an investment of Rs 50 crore in our expansion and the world class talent that supports us, we will be creating biosimilars and novel drug delivery systems for our regulated markets. The increase in our IP portfolio and robust, audit ready facilities is already transforming India into a strategic capability hub that will drive innovation globally for STERIS. </span></p>
<p dir="ltr"><span>From a boardroom perspective, what is the one big strategic decision Indian pharma leaders need to make today to build sustainable growth over the next five to ten years? </span></p>
<p dir="ltr"><span>To India’s pharma leaders, my honest advice is: be prepared to do a paradigm shift from volume competition to innovation led value creation. By focusing on differentiated R&D, complex therapies and a strong regulatory science, Indian companies will stand on the threshold of infinite possibilities globally. Rather than dilution in resources everywhere, deploy capital on patent-protected high value driven and needs-filling portfolio. With such a transition, India will command leadership globally. </span></p>
<p><b> </b></p>
<p dir="ltr"><span><b><i>lakshmipriya.nair@expressindia.com laxmipriyanair@gmail.com </i></b></span></p>
<p dir="ltr">
</p><p> </p>
<p>The post <a href="https://www.expresspharma.in/india-is-the-hub-of-our-rd-strength-process-innovation-and-regulatory-excellence/">India is the hub of our R&D strength, process innovation and regulatory excellence </a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Chhattisgarh CM announces 141&#45;acre Pharma Park in Naya Raipur</title>
<link>https://edusehat.com/en/chhattisgarh-cm-announces-141-acre-pharma-park-in-naya-raipur</link>
<guid>https://edusehat.com/en/chhattisgarh-cm-announces-141-acre-pharma-park-in-naya-raipur</guid>
<description><![CDATA[ 
The Pharma Park spread across 141 acres, is being built with plug-and-play facilities for pharmaceutical manufacturing, common utilities and logistics support.
The post Chhattisgarh CM announces 141-acre Pharma Park in Naya Raipur appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/30103242/EP_Vishnu-Deo-Sai-Chief-Minister-Chhattisgarh-2.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 30 Sep 2026 12:50:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Chhattisgarh, announces, 141-acre, Pharma, Park, Naya, Raipur</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/30103242/EP_Vishnu-Deo-Sai-Chief-Minister-Chhattisgarh-2.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/30103242/EP_Vishnu-Deo-Sai-Chief-Minister-Chhattisgarh-2.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/30103242/EP_Vishnu-Deo-Sai-Chief-Minister-Chhattisgarh-2-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p>A 141-acre Pharma Park and a 200-acre Medicity are set to give Chhattisgarh a new impetus to healthcare services, investment and employment as it seeks to build a healthcare ecosystem.</p>
<p>The two projects are designed to merge pharmaceutical manufacturing, medical education, research and healthcare services into an integrated ecosystem. The move will strengthen healthcare delivery while also creating new avenues for investment and employment in the state.</p>
<p>In December 2024, the state government proposed a project across 200 acres in Sector 37 of Naya Raipur, comprising multi-speciality hospitals, medical colleges, diagnostic centres, hostels, dharamshalas, hotels and other facilities. The Medicity also intends to strengthen super-speciality treatment, medical education and research, creating potential for medical tourism.  CM Sai recently announced the development of a 5,000-bed Medicity across nearly 100 acres in Naya Raipur.</p>
<p>The Pharma Park spread across 141 acres, is being built with plug-and-play facilities for pharmaceutical manufacturing, common utilities and logistics support. Infrastructure development is underway and is expected to be completed by December, with an expenditure estimated at around Rs 100 crore in Sector 22, Gram Tuta, Naya Raipur. Ten companies have shown interest in setting up units at the Pharma Park for medicines, ventilators and other devices. 24 developed plots will be allotted in the first phase and production is expected to begin in the next 2 years.</p>
<p>Under the Industrial Development Policy 2024-30, Chhattisgarh has received pharma investment proposals worth Rs 992.53 crore over the last 18 months. Seven plots in the park have been allotted and four projects valued at about Rs 216 crore are in various stages of implementation.</p>
<p>Vishnu Deo Sai, Chief Minister, Chhattisgarh has said Chhattisgarh is developing new sectors like pharmaceuticals, alongside its traditional industrial strengths, as pillars of development. The government’s focus, he said, is on promoting high-quality healthcare services, employment and new technologies alongside investment.</p>
<p>Pharmaceuticals and medical devices have been included as priority sectors in Chhattisgarh’s Industrial Policy 2024-30, with incentives for attracting investment as well as for research and development, clinical trials and technological innovation. The policy gives investment subsidy, interest subsidy, net SGST reimbursement, 100% stamp duty exemption, employment assistance along with EPF reimbursement, and incentives for patents, technology purchase and quality certification.</p>
<p>According to the official investment portal, Chhattisgarh has over 1,500 varieties of medicinal plants and herbs. This creates opportunities for AYUSH, herbal pharmaceuticals and natural products.</p>
<p>Chhattisgarh’s pharma policy contains provisions for job creation, training and technological innovation. The Medicity and Pharma Park are expected to deliver economic impact well beyond healthcare itself. New opportunities will emerge in nursing, paramedical services, diagnostics, medical technology, hospital management and healthcare IT, alongside technical services.</p>
<p>Medical education in the state has also expanded, with 15 government and private colleges presently operating and five new institutions now under development. Institutions like AIIMS Raipur and other hospitals can further strengthen the base for medical research and education.</p>
<p>In Bilaspur, a new medical college and hospital encompassing 800 beds is being developed at Koni. The estimated cost for the same is around Rs 1,400 crore. The project includes 250 MBBS seats, along with plans for PG (postgraduate) and super-speciality courses. Alongside this, it will comprise hostel facilities for nearly 1,700 students, residential facilities for doctors and staff, an auditorium, a sports complex and facilities for attendants of the patients.</p>
<p>Together, the Medicity and Pharma Park signal a shift from viewing healthcare primarily as a public-service sector to developing it as part of a broader investment, employment and industrial ecosystem in Chhattisgarh.</p>
<p>The post <a href="https://www.expresspharma.in/chhattisgarh-cm-announces-141-acre-pharma-park-in-naya-raipur/">Chhattisgarh CM announces 141-acre Pharma Park in Naya Raipur</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>AstraZeneca to invest $2bn in Summit for ADC combination therapies</title>
<link>https://edusehat.com/en/astrazeneca-to-invest-2bn-in-summit-for-adc-combination-therapies</link>
<guid>https://edusehat.com/en/astrazeneca-to-invest-2bn-in-summit-for-adc-combination-therapies</guid>
<description><![CDATA[ Under the transaction, AstraZeneca will acquire around 109,000 preferred shares convertible into Summit common stock at a 1:1,000 ratio. This will provide an estimated 12% stake in the 
The post AstraZeneca to invest $2bn in Summit for ADC combination therapies appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/09/PT-2-29-09-2026-shutterstock_1946937748.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 29 Sep 2026 18:25:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>AstraZeneca, invest, 2bn, Summit, for, ADC, combination, therapies</media:keywords>
<content:encoded><![CDATA[<p>Under the transaction, AstraZeneca will acquire around 109,000 preferred shares convertible into Summit common stock at a 1:1,000 ratio.</p>
<p>This will provide an estimated 12% stake in the outstanding common stock, or 10.6% on a fully diluted basis.</p>
<p>Alongside the equity investment, the two companies agreed to a clinical collaboration to assess ivonescimab in combination with sonesitatug vedotin (Sone-Ve), an ADC targeting CLDN18.2 with a monomethyl auristatin E payload.</p>
<p>The partners plan to begin clinical trials in gastrointestinal cancers imminently, with each party supplying its respective candidate, sharing clinical trial expenditures, and retaining independent commercial and development rights.</p>
<p>Concurrently, a non-binding memorandum of understanding (MoU) was executed to pursue a wider global programme evaluating ivonescimab with additional AstraZeneca oncology therapies.</p>
<p>Ivonescimab is a bispecific antibody engineered by Akeso and blocks both programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF).</p>
<p>Summit holds exclusive development and commercialisation rights for Ivonescimab outside China, while Akeso retains rights in China and other regions.</p>
<p>The therapy is approved in China for certain non-small cell lung cancer (NSCLC) patients, and a biologics license application (BLA) for EGFR-mutated NSCLC is being reviewed by the US Food and Drug Administration (FDA).</p>
<p>AstraZeneca oncology haematology R&D executive vice-president Susan Galbraith said: “A core pillar of our oncology strategy is to broaden the reach of our ADC portfolio as the backbone of treatment across tumour types with combinations alongside next-generation immunotherapies.</p>
<p>“Bispecifics targeting PD-1 and VEGF are rapidly advancing in development and have the potential to improve on current immunotherapies, particularly in lung, breast and gastrointestinal cancers.</p>
<p>“This opportunity to combine ivonescimab with AstraZeneca’s ADC portfolio, including with Sone-Ve, could enable new regimens that raise the bar for patients with cancer across the treatment landscape.”</p>
<p>AstraZeneca licensed Sone-Ve globally from KYM Biosciences in March 2023.</p>
<p>Earlier this month, the FDA granted accelerated approval to AstraZeneca’s Etcamah (camizestrant), used with a cyclin-dependent kinase (CDK) 4/6 inhibitor (abemaciclib, palbociclib or ribociclib), for breast cancer.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/astrazeneca-to-invest-2bn-summit-adc-therapies/">AstraZeneca to invest $2bn in Summit for ADC combination therapies</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Tolerance Bio signs $560m worldwide TLB&#45;33 deal with Tanabe Pharma</title>
<link>https://edusehat.com/en/tolerance-bio-signs-560m-worldwide-tlb-33-deal-with-tanabe-pharma</link>
<guid>https://edusehat.com/en/tolerance-bio-signs-560m-worldwide-tlb-33-deal-with-tanabe-pharma</guid>
<description><![CDATA[ The agreement grants Tolerance Bio exclusive commercialisation rights outside Japan, whilst Tanabe Pharma retains marketing rights within Japan. The terms also include equity consideration and tiered royalties on 
The post Tolerance Bio signs $560m worldwide TLB-33 deal with Tanabe Pharma appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/09/PT-29-09-2026-shutterstock_2643126935.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 29 Sep 2026 18:25:02 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Tolerance, Bio, signs, 560m, worldwide, TLB-33, deal, with, Tanabe, Pharma</media:keywords>
<content:encoded><![CDATA[<p>The agreement grants Tolerance Bio exclusive commercialisation rights outside Japan, whilst Tanabe Pharma retains marketing rights within Japan.</p>
<p>The terms also include equity consideration and tiered royalties on net sales.</p>
<p>Through this contract, Tolerance Bio will seek to expand its portfolio focused on medicines that preserve and modulate thymic biology to address various immune diseases.</p>
<p>The company plans to initiate Phase II clinical development of TLB-33 to assess its use for thymic preservation and broader immune resilience and is also considering its application in additional immune indications.</p>
<p>The latest licence follows Tolerance Bio’s recent acquisition of NeoImmuneTech’s long-acting interleukin 7 (efineptakin alfa).</p>
<p>Tolerance Bio has also announced intentions to complete a financing round to support clinical trials for both assets.</p>
<p>TLB-33 has been tested in more than 150 participants across five separate clinical studies, yielding safety and pharmacological data.</p>
<p>According to Tolerance Bio, results provide proof-of-biological principle supporting ongoing clinical development, particularly in new indications such as thymic preservation.</p>
<p>Tolerance Bio CEO Francisco Leon said: “This agreement represents another important milestone for Tolerance Bio as we continue to build a clinical-stage pipeline around complementary approaches to thymic biology.”</p>
<p>“TLB-33 is a well-characterised clinical-stage antibody with substantial human safety and pharmacologic data, and its development builds on our team’s experience repositioning clinical-stage assets in high-value new indications.</p>
<p>“IL-33 signalling has been implicated in thymic involution in inflammatory settings, and we believe that blocking IL-33 offers an opportunity to preserve thymic function and improve immune resilience.”</p>
<p>TLB-33 is a human immunoglobulin G1 monoclonal antibody that targets and neutralises IL-33, an immune system mediator linked to thymic dysfunction and age-related immune decline.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/tolerance-bio-560m-worldwide-deal-tanabe-pharma/">Tolerance Bio signs $560m worldwide TLB-33 deal with Tanabe Pharma</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Daiichi Sankyo, MSD withdraw cancer drug application</title>
<link>https://edusehat.com/en/daiichi-sankyo-msd-withdraw-cancer-drug-application</link>
<guid>https://edusehat.com/en/daiichi-sankyo-msd-withdraw-cancer-drug-application</guid>
<description><![CDATA[ The companies submitted the application seeking accelerated approval in the US. Their decision to withdraw follows discussions with the US Food and Drug Administration (FDA), which indicated that 
The post Daiichi Sankyo, MSD withdraw cancer drug application appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/09/Daiichi-Sankyo-shutterstock_1349461175.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 28 Sep 2026 17:10:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Daiichi, Sankyo, MSD, withdraw, cancer, drug, application</media:keywords>
<content:encoded><![CDATA[<p>The companies submitted the application seeking accelerated approval in the US.</p>
<p>Their decision to withdraw follows discussions with the US Food and Drug Administration (FDA), which indicated that the data, including those from the IDeate-Lung01 Phase II trial, did not meet the criteria necessary for approval.</p>
<p>The accelerated approval pathway, designed for earlier access to medicines for serious conditions with unmet medical needs, allows approval based on surrogate endpoints.</p>
<p>Despite the withdrawal, enrolment continues in the IDeate-Lung02 Phase III trial, which is assessing the safety and efficacy of ifinatamab deruxtecan compared to chemotherapy options like amrubicin, lurbinectedin, or topotecan for patients who have experienced disease progression after one line of platinum-based chemotherapy.</p>
<p>Ifinatamab deruxtecan, a potential first-in-class B7-H3 directed antibody drug conjugate (ADC), was discovered by Daiichi Sankyo and is being developed in partnership with MSD.</p>
<p>Daiichi Sankyo Therapeutic Area Oncology Development head Abderrahmane Laadem said: “Extensive-stage small cell lung cancer is a challenging disease to treat, leaving patients in need of new options.</p>
<p>“Enrolment into the IDeate-Lung02 Phase III trial is near completion and we look forward to assessing the potential for a future filing of ifinatamab deruxtecan with the FDA and other global regulatory authorities based on those results.”</p>
<p>Its development continues in other Phase III trials, namely IDeate-Prostate01, which targets castration-resistant prostate cancer, and IDeate-Esophageal01, focusing on oesophageal squamous cell carcinoma.</p>
<p>Designed with Daiichi Sankyo’s DXd ADC technology, ifinatamab deruxtecan comprises a humanised anti-B7-H3 IgG1 monoclonal antibody linked to DXd, a topoisomerase I inhibitor payload, using cleavable tetrapeptide-based linkers.</p>
<p>In April 2026, MSD and Daiichi Sankyo <a href="https://www.pharmaceutical-technology.com/news/msd-daiichi-sankyos-ifinatamab-fda-priority/" target="_blank" rel="noopener">received priority review</a> from the FDA for ifinatamab deruxtecan’s BLA to treat ES-SCLC.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/daiichi-sankyo-msd-cancer-application/">Daiichi Sankyo, MSD withdraw cancer drug application</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Mirum and Incyte’s Atebrioz approved for FOP in US</title>
<link>https://edusehat.com/en/mirum-and-incytes-atebrioz-approved-for-fop-in-us</link>
<guid>https://edusehat.com/en/mirum-and-incytes-atebrioz-approved-for-fop-in-us</guid>
<description><![CDATA[ The medication aims to reduce the volume of heterotopic ossification (HO) in these individuals and is administered orally at a recommended dose of 100mg once daily. Developed by 
The post Mirum and Incyte’s Atebrioz approved for FOP in US appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/09/Lab-shutterstock_2289579433.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 28 Sep 2026 17:10:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Mirum, and, Incyte’s, Atebrioz, approved, for, FOP</media:keywords>
<content:encoded><![CDATA[<p>The medication aims to reduce the volume of heterotopic ossification (HO) in these individuals and is administered orally at a recommended dose of 100mg once daily.</p>
<p>Developed by Incyte and licensed to Mirum for global commercialisation, Atebrioz acts as an activin receptor-like kinase 2 (ALK2) inhibitor, targeting the key pathway involved in FOP. This rare genetic disorder causes abnormal bone formation in soft tissues due to variants in the ACVR1 gene, leading to potential significant disability.</p>
<p>Mirum Pharmaceuticals CEO Chris Peetz said: “Today marks an important milestone for people living with FOP, bringing a new treatment option to adult and paediatric patients living with this devastating disease.</p>
<p>“At Mirum, we are driven to serve rare disease communities where the unmet need is significant and the opportunity to make a difference is profound. The approval of Atebrioz reflects what can be achieved when industry, researchers and patient communities work together, and we remain committed to fostering that spirit of collaboration in FOP.”</p>
<p>The FDA’s approval was supported by data from the PROGRESS study’s cohort 1. In this trial, patients treated with zilurgisertib showed a mean reduction in HO lesion volume of 3.2cm³, in contrast to a 24.6cm³ increase in the placebo group after 24 weeks. The effects persisted through a 48-week open-label extension.</p>
<p>During the 24-week controlled study period, common side effects of zilurgisertib included headache, upper respiratory tract infections, arthralgia, epistaxis and nausea. These were generally mild to moderate, with no participants needing to discontinue or reduce their dose.</p>
<p>The PROGRESS study is ongoing, with enrolment concluded for children aged six to under 12 in cohort 2 and underway for those aged two to under six in cohort 3.</p>
<div></div>
<p>Atebrioz will be accessible through Mirum Access Plus (MAP), a support programme providing insurance and financial assistance, along with educational resources.</p>
<p>It is expected to be available in the US starting October, with costs potentially as low as $0 per month for eligible patients.</p>
<p>Additionally, the FDA has awarded Incyte a rare paediatric disease priority review voucher, which can be used for a future drug application.</p>
<p>Atebrioz’s marketing authorisation application is currently under evaluation by the European Medicines Agency (EMA).</p>
<p>In February 2025, Mirum’s Ctexli (chenodiol) has <a href="https://www.pharmaceutical-technology.com/news/mirum-ctexli-fda-ctx/" target="_blank" rel="noopener">gained the FDA approval</a> for treating adults with cerebrotendinous xanthomatosis (CTX), a rare lipid storage disease.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/mirum-incytes-atebrioz-fop/">Mirum and Incyte’s Atebrioz approved for FOP in US</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>India’s pharma industry is entering AI execution phase: What comes after the pilot? </title>
<link>https://edusehat.com/en/indias-pharma-industry-is-entering-ai-execution-phase-what-comes-after-the-pilot</link>
<guid>https://edusehat.com/en/indias-pharma-industry-is-entering-ai-execution-phase-what-comes-after-the-pilot</guid>
<description><![CDATA[ 
Shammi Thakur, Research Director, Vyansa Intelligence highlights that the next phase of AI adoption in Indian pharma will depend not on successful pilots alone, but on building reliable, validated and accountable systems that can deliver measurable value in real-world, regulated environments.
The post India’s pharma industry is entering AI execution phase: What comes after the pilot?  appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/24174258/EP_GB_Shammi_Thakur_Research_Director_Vyansa_Intelligence_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 28 Sep 2026 17:10:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>India’s, pharma, industry, entering, execution, phase:, What, comes, after, the, pilot </media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/24174258/EP_GB_Shammi_Thakur_Research_Director_Vyansa_Intelligence_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/24174258/EP_GB_Shammi_Thakur_Research_Director_Vyansa_Intelligence_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/24174258/EP_GB_Shammi_Thakur_Research_Director_Vyansa_Intelligence_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>For pharma companies, proving that an AI system can produce a useful result is becoming a smaller part of the challenge. Far harder questions emerge when that system has to operate inside research environments, manufacturing processes, quality functions or regulated decision-making. </span></p>
<p><span>Who owns an output when operating conditions change? How much evidence is enough before people can rely on it? What happens when relevant information sits across systems that were never designed to work together? </span></p>
<p><span>Those questions signal a different stage of adoption. Experimentation can establish possibility; execution has to establish reliability, accountability and value. India’s pharmaceutical sector is beginning to encounter that transition, making the next phase less about finding another promising use case and more about deciding which applications can withstand operational reality. </span></p>
<p><b>From pilot success to operating reality </b></p>
<p><span>Pilot environments offer something production systems rarely can: control. Teams can work with selected datasets, limited users, fixed objectives, and close technical supervision. </span></p>
<p><span>Operational pharma environments are different. </span></p>
<ul>
<li aria-level="1"><b>Pilot conditions:</b><span> controlled inputs, narrow scope, frequent intervention and a clearly defined test environment. </span></li>
<li aria-level="1"><b>Production conditions:</b><span> changing datasets, multiple users, system interfaces, exceptions, compliance requirements and decisions that carry consequences. </span></li>
</ul>
<p><span>Consider a predictive model used to flag a potential manufacturing deviation. During a pilot, performance can be assessed against a clean historical dataset. Inside production, missing sensor readings, changes in equipment behaviour or a new batch characteristic may alter the quality of its output. </span></p>
<p><span>Operational success therefore depends on more than model accuracy. It requires a dependable path from data input to model inference, human review and final action. </span></p>
<p><span>That is where many pilots meet their first serious test. </span></p>
<p><b>Data quality becomes an execution question </b></p>
<p><span>Useful AI depends on information that can be found, understood, connected and trusted. Pharmaceutical organisations may hold substantial volumes of laboratory, manufacturing and quality data while still dealing with fragmented systems, inconsistent definitions and gaps in lineage. </span></p>
<p><span>Vyansa Intelligence estimates India’s laboratory information management systems market at USD 110 million in 2025, with the market projected to reach USD 197 million by 2032, representing an 8.68% CAGR during 2026–2032. Regulated pharmaceutical laboratories form part of the market scope, alongside other scientific and testing environments. </span></p>
<p><span>Significance goes beyond the market’s size. LIMS can support sample tracking, instrument connectivity, result management, quality-controlled workflows, and interoperability—functions that become increasingly important when analytical data are later used in automated or model-assisted decision processes. </span></p>
<p><span>For an AI application to work reliably, its underlying information needs to be: </span></p>
<ul>
<li aria-level="1"><span>Traceable to its source and handling history;</span></li>
<li aria-level="1"><span>Structured consistently enough for meaningful comparison;</span></li>
<li aria-level="1"><span>Available within the workflow where decisions are made;</span></li>
<li aria-level="1"><span>Protected through suitable access and change controls;</span></li>
<li aria-level="1"><span>Connected to a clear owner when something goes wrong.</span></li>
</ul>
<p><span>Data lineage matters particularly when an AI-generated recommendation needs to be investigated. A scientist or quality professional should be able to determine which records fed the model, what version of the model produced the output and whether any relevant input changed. </span></p>
<p><span>AI readiness, therefore, is partly an information-architecture problem. Model sophistication cannot compensate indefinitely for unreliable inputs. </span></p>
<p><b>Validation has to move with the model </b></p>
<p><span>Technical performance provides only one part of the evidence required for regulated deployment. Pharmaceutical teams also need to establish whether a model performs appropriately for its intended use, under its intended conditions and at an acceptable level of risk. </span></p>
<p><span>FDA and EMA’s January 2026 guidance on good AI practice in drug development places particular emphasis on human-centric design, risk-based approaches, clear context of use, multidisciplinary expertise, data governance, performance assessment and lifecycle management. </span></p>
<p><span>Three questions become particularly important before moving beyond experimentation: </span></p>
<ol>
<li aria-level="1"><span>Where will the model be used? </span></li>
<li aria-level="1"><span>What decision will its output influence? </span></li>
<li aria-level="1"><span>What happens when its performance changes? </span></li>
</ol>
<p><span>Context matters because the consequences of an incorrect output differ sharply across applications. A document-classification system and a model influencing a formulation decision cannot be assessed against identical risk thresholds. </span></p>
<p><span>Model behaviour can also change when the underlying data change. New products, different raw-material characteristics, altered process conditions or shifts in patient populations can introduce forms of data drift that were absent during the original pilot. </span></p>
<p><span>Consequently, validation cannot end on deployment day. Performance monitoring, change control, version tracking, documented review and defined escalation routes need to become part of the operating model. </span></p>
<p><b>Scale needs a business case </b></p>
<p><span>Technical teams naturally measure what the pilot can observe: prediction accuracy, processing time, automation rates and user activity. Senior management eventually looks further downstream. </span></p>
<ul>
<li aria-level="1"><span>Did investigation time actually fall? </span></li>
<li aria-level="1"><span>Did development cycles become shorter? </span></li>
<li aria-level="1"><span>Did production capacity improve? </span></li>
<li aria-level="1"><span>Did quality teams spend less time on repetitive review? </span></li>
</ul>
<p><span>Lupin provides one example of a move toward portfolio-level execution. Its FY2025–26 integrated report says more than 250 ideas had progressed toward 25+ high-impact use cases, built on reusable enterprise platforms and reaching more than 15,000 users. </span></p>
<p><span>The important lesson is not the number alone. Moving from hundreds of ideas to a smaller group of scaled use cases introduces an investment discipline that most organisations eventually need. </span></p>
<table>
<tbody>
<tr>
<td><b>Pilot metric </b></td>
<td><b>Bigger business question </b></td>
</tr>
<tr>
<td><span>Prediction accuracy </span></td>
<td><span>Did decision quality improve? </span></td>
</tr>
<tr>
<td><span>Time saved </span></td>
<td><span>Where did that capacity go? </span></td>
</tr>
<tr>
<td><span>Tasks automated </span></td>
<td><span>Did overall process performance improve? </span></td>
</tr>
<tr>
<td><span>Users onboarded </span></td>
<td><span>Is adoption translating into outcomes? </span></td>
</tr>
<tr>
<td><span>Model performance </span></td>
<td><span>Can value be sustained over time? </span></td>
</tr>
</tbody>
</table>
<p> </p>
<p><span>A useful business case therefore follows a chain: </span></p>
<p><span>Model output → workflow change → operational outcome → business result </span></p>
<p><span>Without that connection, an AI programme can accumulate technically successful pilots without establishing why they deserve wider investment. </span></p>
<p><b>India’s AI ecosystem is moving beyond experimentation </b></p>
<p><span>Enterprise deployment also depends on what surrounds individual companies. Evaluation mechanisms, data governance practices and public policy can influence how responsibly emerging applications move into real-world use. </span></p>
<p><span>India’s Ministry of Health and Family Welfare launched SAHI and BODH in February 2026. SAHI is intended to guide safe, ethical, evidence-based, and inclusive AI adoption, while BODH provides a platform for benchmarking health AI models against diverse real-world data. </span></p>
<p><span>Evaluation becomes more important as AI moves closer to consequential decisions. </span></p>
<p><span>For pharmaceutical organisations, that principle has practical relevance. Internal benchmarking can reveal where a model performs well, where it produces false positives or negatives, and whether its results remain stable across different datasets or operating conditions. </span></p>
<p><span>External frameworks will not remove the need for enterprise-level controls. They can, however, help shift AI adoption away from informal experimentation toward evidence-based deployment. </span></p>
<p><b>People still sit inside the system </b></p>
<p><span>Pharma AI will not operate in isolation from scientific judgement. Even when software generates predictions, recommendations or ranked options, someone still has to determine whether the output makes sense in the physical and regulatory environment where it will be used. </span></p>
<p><span>Express Pharma’s recent coverage of </span><a href="https://www.expresspharma.in/ai-driven-qbd-advancing-predictive-data-driven-pharma-formulation-development-using-artificial-neural-networks"><span>AI-driven Quality by Design </span></a><span>offers a useful illustration. Its workflow combines Design of Experiments data, artificial neural-network modelling and targeted experimental validation, rather than treating model output as a substitute for laboratory evidence. </span></p>
<p><span>That relationship can be viewed as a simple decision chain: </span></p>
<p><span>Historical/experimental data → model prediction → scientific review → targeted testing → decision </span></p>
<p><span>Human involvement becomes particularly important when model output conflicts with observed behaviour. A formulation may perform differently during scale-up because of raw-material variability, process conditions, or interactions that were not adequately represented in historical training data. In such cases, scientific experience becomes part of the control mechanism rather than an obstacle to automation. </span></p>
<p><span>Execution will therefore require more than AI specialists. Scientists, QA teams, regulatory professionals, data specialists and business owners all need clarity around where AI supports judgement and where human judgement remains decisive. </span></p>
<p><b>What comes after the pilot? </b></p>
<p><span>Five questions can help determine whether an initiative deserves to move into production. </span></p>
<p><b>Is the use case important enough to scale? </b></p>
<p><span>Technical novelty should not outweigh operational relevance. Problems with clear business or scientific consequences deserve priority over applications that generate impressive demonstrations but change little. </span></p>
<p><b>Is the data fit for purpose? </b></p>
<p><span>Historical data may be plentiful yet inconsistent. Missing values, shifting definitions, unstructured records, and weak traceability can become much more expensive problems once a model depends on them at scale. </span></p>
<p><b>What evidence is required? </b></p>
<p><span>Validation needs to reflect intended use and associated risk. Evidence requirements should be established before deployment rather than added after an operational problem exposes a gap. </span></p>
<p><b>Who owns the decision? </b></p>
<p><span>Human-in-the-loop does not mean placing a person somewhere near a screen. Responsibility needs to be explicit: who reviews the output, who can override it, who records the rationale and who investigates an unexpected result? </span></p>
<p><b>What happens after launch? </b></p>
<p><span>Production deployment should trigger monitoring rather than end it. Changes in data, workflows, model versions and performance can all alter risk over time. </span></p>
<p><b>Execution becomes the real test </b></p>
<p><span>India’s pharmaceutical industry no longer needs to debate whether AI can generate useful predictions or automate selected tasks. Evidence from research, regulation and industry practice increasingly points toward real adoption across parts of the pharmaceutical value chain. </span></p>
<p><span>The harder question concerns endurance. </span></p>
<p><span>Can an application remain useful when data become messy, workflows change, scientists challenge its output, regulators ask how it was validated, and management wants evidence of business value? </span></p>
<p><span>The next important AI milestone for Indian pharma may therefore be far less visible than a new pilot. It may be the point at which a useful system becomes dependable enough to live inside a real pharmaceutical workflow—and remains trustworthy as that workflow evolves. </span></p>
<p>The post <a href="https://www.expresspharma.in/indias-pharma-industry-is-entering-ai-execution-phase-what-comes-after-the-pilot/">India’s pharma industry is entering AI execution phase: What comes after the pilot? </a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>LIB Therapeutics and Sun Pharma announce manufacturing agreement for Lerodalcibep, a PCSK9 Inhibitor</title>
<link>https://edusehat.com/en/lib-therapeutics-and-sun-pharma-announce-manufacturing-agreement-for-lerodalcibep-a-pcsk9-inhibitor</link>
<guid>https://edusehat.com/en/lib-therapeutics-and-sun-pharma-announce-manufacturing-agreement-for-lerodalcibep-a-pcsk9-inhibitor</guid>
<description><![CDATA[ 
Lerodalcibep is approved in the EU under the brand name Lyrokaul for the treatment of adult patients with hypercholesterolaemia and mixed dyslipidaemia
The post LIB Therapeutics and Sun Pharma announce manufacturing agreement for Lerodalcibep, a PCSK9 Inhibitor appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/07/22171615/signing-agreement.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 28 Sep 2026 17:10:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>LIB, Therapeutics, and, Sun, Pharma, announce, manufacturing, agreement, for, Lerodalcibep, PCSK9, Inhibitor</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/07/22171615/signing-agreement.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/07/22171615/signing-agreement.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/07/22171615/signing-agreement-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Sun Pharmaceutical Industries announced an exclusive licensing agreement granting Sun Pharma rights to commercialise and manufacture lerodalcibep worldwide, excluding the United States and China.</span></p>
<p><span>Lyrokaul (lerodalcibep), a once-monthly PCSK9 inhibitor for LDL-C lowering, comes with 6-month EU ambient storage; received EU approval on September 21, 2026.  The agreement strengthens Sun Pharma’s Innovative Medicines portfolio through access to a US$3.7 billion PCSK9 market Ex-US and China, growing at 38% CAGR; global PCSK9 market approaching US$7 billion in 2026. LIB will receive an upfront and future milestone payments, together with royalties based on net sales in the licensed territories.</span></p>
<p><span>Lerodalcibep is approved in the EU under the brand name Lyrokaul for the treatment of adult patients with hypercholesterolaemia and mixed dyslipidaemia. In the United States, it is US FDA-approved under the brand name Lerochol as an adjunct to diet and exercise: to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH).</span></p>
<p><span>The partnership helps address a significant global unmet need in cardiovascular care. Many patients at high or very high cardiovascular risk remain above recently updated and more globally harmonized 2026 guideline-recommended LDL-cholesterol (LDL-C) goals despite treatment. In the DA VINCI observational study across 18 European countries, only 33% of patients assessed on stable oral lipid-lowering therapy achieved their risk-based 2019 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) LDL-C goals.</span><span><br>
</span></p>
<p><span>Treatment guidelines now emphasise both additional LDL-C reductions and lower targets for patients at high and very high cardiovascular risk, with additional therapies when statins alone are insufficient. PCSK9 inhibitors provide the efficacy and safety to achieve these goals.</span><span>4 </span><span>This gap between treatment goals and real-world control reinforces the opportunity for Sun Pharma and LIB to broaden access to innovative lipid-lowering care across Europe and Sun’s world-wide licensed markets.</span></p>
<p><span>“Once-monthly lerodalcibep dosing, with robust LDL-C reduction and the added benefits of a small-volume injection and six-month ambient storage, simplifies treatment for patients and offers greater convenience”, said Kirti W Ganorkar, Managing Director of Sun Pharma. “This agreement marks a significant step in strengthening our global Innovative Medicines portfolio, particularly in cardiovascular care. With exclusive rights outside the United States and China, we look forward to expanding access to this important treatment option for patients globally.”</span></p>
<p>The post <a href="https://www.expresspharma.in/lib-therapeutics-and-sun-pharma-announce-manufacturing-agreement-for-lerodalcibep-a-pcsk9-inhibitor/">LIB Therapeutics and Sun Pharma announce manufacturing agreement for Lerodalcibep, a PCSK9 Inhibitor</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Lupin receives tentative approval from US FDA for novel Apixaban Oral Suspension</title>
<link>https://edusehat.com/en/lupin-receives-tentative-approval-from-us-fda-for-novel-apixaban-oral-suspension</link>
<guid>https://edusehat.com/en/lupin-receives-tentative-approval-from-us-fda-for-novel-apixaban-oral-suspension</guid>
<description><![CDATA[ 
Global pharma major, Lupin announced that it has received tentative approval from the United States Food and Drug Administration (US FDA) for its New Drug Application for Apixaban Oral Suspension […]
The post Lupin receives tentative approval from US FDA for novel Apixaban Oral Suspension appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/07/22100048/usfda-approved-black.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 28 Sep 2026 17:10:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Lupin, receives, tentative, approval, from, FDA, for, novel, Apixaban, Oral, Suspension</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/07/22100048/usfda-approved-black.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/07/22100048/usfda-approved-black.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/07/22100048/usfda-approved-black-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>Global pharma major, Lupin announced that it has received tentative approval from the United States Food and Drug Administration (US FDA) for its New Drug Application for Apixaban Oral Suspension 1.25mg/mL via the 505(b)(2) pathway.</span></p>
<p><span>Lupin’s Apixaban Oral Suspension 1.25 mg/mL is an oral liquid formulation of apixaban, the active ingredient in Eliquis (apixaban) of Bristol Myers Squibb, and provides an alternative administration option for adult patients requiring anticoagulation therapy Including those who may have difficulty swallowing tablets.</span></p>
<p><span>“This tentative approval reflects our continued focus on developing differentiated medicines that address meaningful patient needs. Apixaban oral suspension expands the ways in which this important therapy could be administered, while reinforcing our commitment to building a differentiated portfolio,” said Vinita Gupta, CEO, Lupin.</span></p>
<p><span>Upon final approval, the product will be manufactured at Lupin’s Somerset, New Jersey facility, leveraging the company’s US-based manufacturing expertise to support high-quality standards, and supply reliability.</span></p>
<p>The post <a href="https://www.expresspharma.in/lupin-receives-tentative-approval-from-us-fda-for-novel-apixaban-oral-suspension/">Lupin receives tentative approval from US FDA for novel Apixaban Oral Suspension</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Amberstone and Henlius agree to develop solid&#45;tumour T&#45;cell engagers</title>
<link>https://edusehat.com/en/amberstone-and-henlius-agree-to-develop-solid-tumour-t-cell-engagers</link>
<guid>https://edusehat.com/en/amberstone-and-henlius-agree-to-develop-solid-tumour-t-cell-engagers</guid>
<description><![CDATA[ The preclinical T-cell engagers will be developed using Amberstone’s Tumor Microenvironment Activated ThErapeutics (T-MATE) platform. Henlius will select up to two targets under the agreement. The company will 
The post Amberstone and Henlius agree to develop solid-tumour T-cell engagers appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/09/PT-2-25-09-2026-shutterstock_1924516355.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 25 Sep 2026 17:10:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Amberstone, and, Henlius, agree, develop, solid-tumour, T-cell, engagers</media:keywords>
<content:encoded><![CDATA[<p>The preclinical T-cell engagers will be developed using Amberstone’s Tumor Microenvironment Activated ThErapeutics (T-MATE) platform.</p>
<p>Henlius will select up to two targets under the agreement. The company will oversee their global research, development, manufacturing and commercialisation.</p>
<p>The agreement provides Amberstone with an upfront payment and research funding. The company is also eligible for up to $440m in development, regulatory and sales milestones for each target, along with tiered royalties on net sales.</p>
<p>T-cell engagers redirect the T cells of a patient to destroy cancer cells. Their development in solid tumours has been limited by cytokine release syndrome and on-target, off-tumour toxicity.</p>
<p>Amberstone’s platform uses reversible potential of hydrogen (pH) gating and addresses these limitations.</p>
<p>The approach is intended to reduce T-cell activation in the bloodstream and healthy tissue while maintaining activity across the pH range found in solid tumours.</p>
<p>Amberstone said preclinical studies showed potent tumour-cell killing under tumour-like pH conditions while activity was markedly lower at physiological pH.</p>
<p>Its lead T-MATE T-cell engager is expected to enter clinical development in the first half of 2027.</p>
<p>The asset is currently in investigational new drug (IND)-enabling development, with other internal programmes at the discovery stage.</p>
<p>Amberstone is developing pH-gated, tumour-activated T-cell engagers and other antibody therapeutics through internal programmes and partnerships.</p>
<p>Henlius has operations spanning clinical operations, research and development, manufacturing, commercialisation and regulatory affairs.</p>
<p>Ten of its products have secured regulatory approvals in more than 60 countries and regions. Four have been approved by the US Food and Drug Administration and five by the European Commission.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/amberstone-henlius-solid-tumour-t-cell-engagers/">Amberstone and Henlius agree to develop solid-tumour T-cell engagers</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>FDA approves Lilly’s Onswik for type 2 diabetes in adults</title>
<link>https://edusehat.com/en/fda-approves-lillys-onswik-for-type-2-diabetes-in-adults</link>
<guid>https://edusehat.com/en/fda-approves-lillys-onswik-for-type-2-diabetes-in-adults</guid>
<description><![CDATA[ This treatment is approved for use alongside diet and exercise to improve blood sugar control. Onswik is intended to provide steady basal insulin levels for seven days. The 
The post FDA approves Lilly’s Onswik for type 2 diabetes in adults appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/09/PT-25-09-2026-shutterstock_2498260713.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 25 Sep 2026 17:10:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>FDA, approves, Lilly’s, Onswik, for, type, diabetes, adults</media:keywords>
<content:encoded><![CDATA[<p>This treatment is approved for use alongside diet and exercise to improve blood sugar control. Onswik is intended to provide steady basal insulin levels for seven days.</p>
<p>The FDA decision was supported by Lilly’s QWINT Phase III clinical programme, which enrolled more than 3,400 adults with T2D across four registration trials.</p>
<p>In each trial, once-weekly Onswik met its primary endpoint for non-inferior reductions in A1C from baseline, compared with daily insulin glargine U-100 or insulin degludec U-100.</p>
<p>The programme included patients new to insulin treatment and those already using basal insulin.</p>
<p>QWINT-1 enrolled 795 participants in Argentina, Mexico and the US, while QWINT-2 enrolled 928 people in Brazil, Canada, China, Czechia, Germany, Greece, Korea, Japan, Mexico, Puerto Rico and the US.</p>
<p>QWINT-3 involved 986 participants in Argentina, Hungary, Japan, Korea, Poland, Puerto Rico, Slovakia, Spain, Taiwan and the US. QWINT-4 enrolled 730 participants in Argentina, Germany, India, Italy, Mexico, Puerto Rico, Spain and the US.</p>
<p>The studies compared efsitora with insulin degludec or insulin glargine, with QWINT-4 also using insulin lispro.</p>
<p>Lilly said the trials showed an overall safety profile for Onswik similar to that of the daily basal insulins assessed.</p>
<p>Reported common side effects include allergic reactions, injection-site reactions, itching, lipodystrophy, low blood sugar, rash, swelling of the hands and feet, and weight gain.</p>
<p>Lilly executive vice-president and cardiometabolic health president Kenneth Custer said: “For over a century, Lilly has been developing insulins that transformed diabetes care for millions of people worldwide, but delays in initiating treatment and the burden of daily injections can have a real impact on patients’ day-to-day experience managing T2D.</p>
<p>“Onswik offers a new once-weekly basal insulin option for patients and reflects our continued commitment to deliver innovative treatment options that expand choice and provide greater flexibility in how people manage type 2 diabetes.”</p>
<p>Lilly plans to make the Onswik KwikPen available in the US in the coming months. It will be supplied in 500 units/mL pens containing 1,500 units and 1,000 units/mL pens containing 3,000 units.</p>
<p>The FDA approval is the fourth global approval for Onswik in adults with type 2 diabetes, following regulatory actions by the European Medicines Agency, Mexico’s Federal Commission for the Protection against Sanitary Risks and Japan’s Pharmaceuticals and Medical Devices Agency.</p>
<p>Earlier this week, Eli Lilly partnered with China-based InnoCare Pharma in a five-drug research and licensing agreement.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/fda-lillys-onswik-type-2-diabetes/">FDA approves Lilly’s Onswik for type 2 diabetes in adults</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Basecamp Research secures $140m for AI&#45;driven therapies</title>
<link>https://edusehat.com/en/basecamp-research-secures-140m-for-ai-driven-therapies</link>
<guid>https://edusehat.com/en/basecamp-research-secures-140m-for-ai-driven-therapies</guid>
<description><![CDATA[ S32 led the oversubscribed financing round. Investors included Catalio Capital Management, European Tech Collective, and Firebrand River Capital. Other backers were Nvidia, PostScriptum, Redalpine, The Rockefeller Foundation, Singular, 
The post Basecamp Research secures $140m for AI-driven therapies appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/09/PT-24-09-2026-6ab2a14735f15aa3c8901042_16-3.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 24 Sep 2026 19:40:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Basecamp, Research, secures, 140m, for, AI-driven, therapies</media:keywords>
<content:encoded><![CDATA[<p>S32 led the oversubscribed financing round. Investors included Catalio Capital Management, European Tech Collective, and Firebrand River Capital.</p>
<p>Other backers were Nvidia, PostScriptum, Redalpine, The Rockefeller Foundation, Singular, Sovereign AI and True Ventures.</p>
<p>The company said the latest funding would also support an expansion of its pharmaceutical partnerships.</p>
<p>Basecamp’s initial therapeutic focus is in vivo cell therapy, which involves reprogramming the cells of a patient inside the body.</p>
<p>Its technology combines AI models trained on biological data with methods for writing deoxyribonucleic acid (DNA) sequences into cells.</p>
<p>Basecamp Research co-founder and CEO Glen Gowers said: “We believe the future of medicine lies in reprogramming the body to repair itself. We design the models and the medicines to teach it how.</p>
<p>“AI-based approaches promise to change what’s possible for patients who currently have few alternatives. This funding brings this technology closer to those who need it most.”</p>
<p>The company said current cell therapies are constrained by the complexity of treatments and manufacturing costs that can reach hundreds of thousands of dollars per patient.</p>
<p>It is pairing EDEN’s ability to design long DNA sequences with large serine recombinases, which can integrate sequences into the genome.</p>
<p>To develop pharmaceutical relationships, the company has named former Biogen executive Richard Pearce as chief business officer. S32 general partner and former Google Verily CEO Andy Conrad will join Basecamp’s board of directors.</p>
<p>EDEN is trained on Basecamp’s Trillion Gene Atlas, a genomic dataset built through partnerships in more than 30 countries.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/basecamp-research-140m-ai-driven-therapies/">Basecamp Research secures $140m for AI-driven therapies</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Genialis and Inventia to enhance pancreatic cancer treatment testing</title>
<link>https://edusehat.com/en/genialis-and-inventia-to-enhance-pancreatic-cancer-treatment-testing</link>
<guid>https://edusehat.com/en/genialis-and-inventia-to-enhance-pancreatic-cancer-treatment-testing</guid>
<description><![CDATA[ The companies will integrate the Genialis Supermodel with Inventia’s RASTRUM 3D cell model platform to study pancreatic ductal adenocarcinoma (PDAC) and test therapeutic hypotheses. Initial findings from the 
The post Genialis and Inventia to enhance pancreatic cancer treatment testing appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/09/PT-2-24-09-2026-shutterstock_2619784163.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 24 Sep 2026 19:40:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Genialis, and, Inventia, enhance, pancreatic, cancer, treatment, testing</media:keywords>
<content:encoded><![CDATA[<p>The companies will integrate the Genialis Supermodel with Inventia’s RASTRUM 3D cell model platform to study pancreatic ductal adenocarcinoma (PDAC) and test therapeutic hypotheses.</p>
<p>Initial findings from the collaboration are due to be presented on 25 September at the Pancreatic Cancer Action Network (PanCAN)’s 2026 Scientific Summit in San Diego.</p>
<p>The study examined 644 pancreatic cancer tumours from PanCAN SPARK’s “Know Your Tumor” cohort.</p>
<p>Genialis identified PDAC patients with poor prognosis using the composition and activity of the tumour microenvironment.</p>
<p>Researchers then mapped the resulting patient profiles to tumour-fibroblast co-culture models produced using RASTRUM.</p>
<p>The approach is intended to allow investigation of biological features associated with poorer outcomes and the testing of potential therapeutic strategies in laboratory models corresponding to those patient profiles.</p>
<p>RASTRUM creates 3D pancreatic cancer models in which tumour and stromal components can be controlled and altered independently.</p>
<p>Genialis will characterise the models through Supermodel, its molecular model trained on a harmonised and curated transcriptomics dataset, and compare them with molecular states seen in clinical settings.</p>
<p>The work also uses data generated through Genialis’ existing collaboration with PanCAN.</p>
<p>Inventia Life Science CEO and co-founder Cameron Ferris said: “This collaboration closes an important gap in drug discovery by connecting what we learn from patients with what we can test in the lab.</p>
<p>“Genialis can identify clinically meaningful biological states in real tumours, while RASTRUM allows us to model and perturb those states at scale.</p>
<p>“Together, that creates a powerful way to generate and test therapeutic hypotheses that are grounded in the biology of the patients we ultimately want to treat.”</p>
<p>The collaboration follows interest in targeted treatments for pancreatic cancer and the challenge of determining which patient groups may benefit from particular approaches.</p>
<p>The companies said their process links patient-derived hypotheses with experimental testing in human-relevant systems before relating findings to clinical populations.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/genialis-inventia-pancreatic-cancer-treatments-testing/">Genialis and Inventia to enhance pancreatic cancer treatment testing</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Generic Remedy crosses 700+ franchise outlets across 9 States</title>
<link>https://edusehat.com/en/generic-remedy-crosses-700-franchise-outlets-across-9-states</link>
<guid>https://edusehat.com/en/generic-remedy-crosses-700-franchise-outlets-across-9-states</guid>
<description><![CDATA[ 
India’s emerging True MRP generic pharmacy network expands rapidly since its November 2024 launch, targeting 10,000 outlets by 2031
The post Generic Remedy crosses 700+ franchise outlets across 9 States appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2022/11/01114501/expansion-growth.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 24 Sep 2026 16:00:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Generic, Remedy, crosses, 700, franchise, outlets, across, States</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2022/11/01114501/expansion-growth.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2022/11/01114501/expansion-growth.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2022/11/01114501/expansion-growth-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p>Generic Remedy, the fast-growing generic medicines brand operated by First Remedy Pharmacies Private Limited has crossed 700+ retail franchise outlets across 9 states. The milestone advances its mission to make high-quality, affordable medicines accessible to more Indian households.</p>
<p>Launched in November 2024, the brand now operates in Uttar Pradesh, Bihar, Jharkhand, Odisha, West Bengal, North East, Uttarakhand, Delhi NCR and Punjab. It grows mainly through Retail Pharmacy outlets (Shop-In-Shop). The portfolio exceeds 1,000 products. It covers chronic care medicines for diabetes, cardiac conditions and other long-term therapies, plus premium OTC products, supplements and cosmetics. All medicines come from WHO-GMP certified plants, so affordability never compromises quality or safety.</p>
<p>“Generic Remedy was founded on a simple principle: high-quality healthcare must be a right, not a privilege,” said Rajesh Kumar, Chief Executive Officer. “Crossing 700 franchise outlets in under two years shows strong partner confidence and clear demand for transparent, value-driven pharmacy retail. We remain focused on expanding access while upholding quality standards.”</p>
<p>The company aims to build an exclusive network across 100 major cities and reach 10,000 outlets by 2031. Franchise partners receive centrally managed stocks, free billing software, low expiry risk, promotional materials, staff training, digital marketing support and an integrated business dashboard.</p>
<p>A FOFO (Franchise Owned Franchise Operated) outlet requires an investment of about ₹8-9 lakh. This covers franchise fees, infrastructure, initial stock, IT equipment, licensing and marketing. Break-even is expected in 6-8 months, with additional company support of ₹10,000 per month for five years under applicable terms. Going forward, Generic Remedy will deepen its presence in existing states, enter southern and western markets, and expand its product range while maintaining WHO-GMP standards.</p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/generic-remedy-crosses-700-franchise-outlets-across-9-states/">Generic Remedy crosses 700+ franchise outlets across 9 States</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Boehringer and Envisagenics to develop precision cancer therapies</title>
<link>https://edusehat.com/en/boehringer-and-envisagenics-to-develop-precision-cancer-therapies</link>
<guid>https://edusehat.com/en/boehringer-and-envisagenics-to-develop-precision-cancer-therapies</guid>
<description><![CDATA[ Under the agreement, Envisagenics is set to receive more than $1bn through potential payments. These include an upfront sum, research funding, option fees, and milestones related to commercialisation, 
The post Boehringer and Envisagenics to develop precision cancer therapies appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/09/PT-23-09-2026-shutterstock_1843369093.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 23 Sep 2026 18:00:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Boehringer, and, Envisagenics, develop, precision, cancer, therapies</media:keywords>
<content:encoded><![CDATA[<p>Under the agreement, Envisagenics is set to receive more than $1bn through potential payments. These include an upfront sum, research funding, option fees, and milestones related to commercialisation, development, regulatory approval, and royalties on future sales.</p>
<p>The multi-year partnership will focus on targets identified through Envisagenics’ SpliceCore AI platform.</p>
<p>This technology analyses alternative ribonucleic acid (RNA) splicing events with the goal of improving therapy options for people with difficult-to-treat cancers.</p>
<p>The new partnership intends to validate selected tumour-specific targets which may be used to develop therapies that could be more selective in recognising and attacking cancer cells, while aiming to reduce impact on normal cells.</p>
<p>Boehringer Ingelheim oncology research global head Mark Petronczki said: “Growing innovation together with partners is central to how we build our oncology pipeline.</p>
<p>“Alternative RNA splicing offers access to a largely unexplored target space, and Envisagenics has built a distinctive capability to investigate it.</p>
<p>“Through this collaboration, we hope to identify highly tumour-selective targets for the development of new cancer therapies to address the needs of patients who are still waiting for better treatment options.”</p>
<p>The agreement allows Boehringer to license selected targets exclusively to further develop and commercialise upon successful completion of the research phase.</p>
<p>Areas under review include antibody-drug conjugates (ADCs), multi-specific antibodies, and T-cell engagers (TcEs).</p>
<p>Envisagenics’ SpliceCore platform is reported to screen over 14 million alternative splicing events to predict target suitability.</p>
<p>The company’s pipeline also covers neurodegeneration and other oncology programmes.</p>
<p>In June 2026, Boehringer signed a research collaboration agreement with Combotope Therapeutics to advance tumour-selective antibody therapies targeting cancer.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/boehringer-envisagenics-develop-precision-cancer-therapies/">Boehringer and Envisagenics to develop precision cancer therapies</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>BoomRay and Novartis Pharma sign $900m deal for radioligand therapy</title>
<link>https://edusehat.com/en/boomray-and-novartis-pharma-sign-900m-deal-for-radioligand-therapy</link>
<guid>https://edusehat.com/en/boomray-and-novartis-pharma-sign-900m-deal-for-radioligand-therapy</guid>
<description><![CDATA[ The agreement includes an upfront payment, as well as potential development, regulatory, and sales milestone payments for BoomRay, along with possible royalties on future global net sales. The 
The post BoomRay and Novartis Pharma sign $900m deal for radioligand therapy appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/09/PT-2-23-09-2026-shutterstock_2214180715.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 23 Sep 2026 18:00:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>BoomRay, and, Novartis, Pharma, sign, 900m, deal, for, radioligand, therapy</media:keywords>
<content:encoded><![CDATA[<p>The agreement includes an upfront payment, as well as potential development, regulatory, and sales milestone payments for BoomRay, along with possible royalties on future global net sales.</p>
<p>The partnership combines BoomRay’s development experience in RLTs and Novartis’s global presence in the field.</p>
<p>BoomRay focuses on advancing radioligand therapies for precision oncology diagnostics and therapeutics, with activities across candidate discovery, radiochemistry, and clinical translation.</p>
<p>BoomRay CEO Bo Shan said: “This agreement marks a significant milestone for BoomRay and is a strong validation of our discovery and development capabilities. We believe this agreement with Novartis will unlock the full potential of this asset and accelerate its path to patients worldwide.”</p>
<p>Novartis oncology, biomedical research global head Shiva Malek said: “Radioligand therapies represent an important frontier in oncology, and at Novartis, we remain focused on driving breakthrough science that can expand their potential for patients.</p>
<p>“Our agreement with BoomRay complements our growing radioligand therapy portfolio and reflects our strategy of combining external innovation with our cutting-edge research and development capabilities.</p>
<p>“We look forward to advancing this promising programme and helping to bring new treatment options to patients around the world.”</p>
<p>BFC Group served as the financial adviser to BoomRay in this transaction.</p>
<p>BoomRay is advancing a pipeline of radiopharmaceutical candidates and operates a fully integrated research and development platform with a focus on addressing unmet medical needs in oncology.</p>
<p>In May 2024, Novartis strengthened its position in the radiopharmaceutical sector by acquiring Mariana Oncology for an upfront payment of $1bn, and up to an additional $750m tied to milestone achievements.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/boomray-novartis-900m-deal-radioligand-therapy/">BoomRay and Novartis Pharma sign $900m deal for radioligand therapy</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Treating hair loss as a health issue, not just a haircare concern</title>
<link>https://edusehat.com/en/treating-hair-loss-as-a-health-issue-not-just-a-haircare-concern</link>
<guid>https://edusehat.com/en/treating-hair-loss-as-a-health-issue-not-just-a-haircare-concern</guid>
<description><![CDATA[ 
Traya has treated hair loss as a health issue rather than simply a cosmetic concern. How has this approach shaped the way you have built the business and developed your offerings? We operate very differently from a conventional haircare brand. In most cases, consumers either buy a product off the shelf, such as an oil […]
The post Treating hair loss as a health issue, not just a haircare concern appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/23142222/Saloni-Anand-Co-founder-Traya-Health.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 23 Sep 2026 18:00:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Treating, hair, loss, health, issue, not, just, haircare, concern</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/23142222/Saloni-Anand-Co-founder-Traya-Health.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/23142222/Saloni-Anand-Co-founder-Traya-Health.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/23142222/Saloni-Anand-Co-founder-Traya-Health-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><strong><span><span><span>Traya has treated hair loss as a health issue rather than simply a cosmetic concern. How has this approach shaped the way you have built the business and developed your offerings?</span></span></span></strong></p>
<p><span><span><span>We operate very differently from a conventional haircare brand. In most cases, consumers either buy a product off the shelf, such as an oil or shampoo, or visit a website and select products. In a clinical setting, a dermatologist may prescribe a particular set of products, with the approach largely focused on the hair follicle.</span></span></span></p>
<p><span><span><span>We felt that hair loss also needed to be addressed internally because many of its contributing factors are internal. Stress, hormones, nutrition, gut health and sleep can all have an impact. Ayurveda has a wealth of knowledge around lifestyle, gut health, sleep, stress management and nourishing the body, while dermatology works at the follicle level. We saw the two approaches as complementary.</span></span></span></p>
<p><span><span><span>Food science is the third pillar. What we eat can play an important role in supporting health and nutrition. Six years ago, we started looking at how dermatology, Ayurveda and food science could come together to manage hair loss not only externally, but as a health issue.</span></span></span></p>
<p><span><span><span>We also realised that there cannot be one product that works for everyone. That is why diagnosis became an important part of our model. A person can take a hair assessment through our app and upload photographs of their scalp. We look at factors such as sleep, stress and digestion to understand the possible underlying causes.</span></span></span></p>
<p><span><span><span>Based on that assessment, the treatment can address the scalp externally through products such as oils and shampoos, while also providing supplements for internal nourishment. The formulations are different, but so is the process. A person cannot simply visit the website and choose a product. The recommendation is based on the diagnosis.</span></span></span></p>
<p><strong><span><span><span>What led you to start Traya and build this integrated model?</span></span></span></strong></p>
<p><span><span><span>It came out of a personal health journey. My co-founder Altaf and I are also husband and wife. He had severe hypothyroidism when he was around 30-31 and had always experienced hair loss. At one point, he had gained around 25 kg and was struggling to control his condition.</span></span></span></p>
<p><span><span><span>While continuing with allopathic treatment, we also explored Ayurveda and food science. Over six to eight months of focusing on his overall health, his thyroid came under much better control. His medication dosage reduced from 125 to 25, and during the same period his hair also started coming back.</span></span></span></p>
<p><span><span><span>At the time, we did not think this could become a company. Two years later, we started discussing the idea of creating a chronic healthcare model where different disciplines could work together rather than operate in silos.</span></span></span></p>
<p><span><span><span>When you think about chronic conditions, you typically think of diabetes, cholesterol or thyroid. We felt hair loss also belonged in that conversation, particularly because male pattern hair loss can have a chronic and genetic component.</span></span></span></p>
<p><span><span><span>We started speaking to people and realised how much interest there was in hair loss. Everyone around us seemed to be experiencing it. That is how the idea evolved organically.</span></span></span></p>
<p><span><span><span>We then spent around a year and a half on R&D to develop the formulations. The Ayurveda doctor who had helped my husband with his thyroid continues to head Ayurveda at Traya. He was the first person we brought on board when we decided to build the company.</span></span></span></p>
<p><strong><span><span><span>The haircare and hair loss market has long been crowded with products making broad or difficult-to-verify claims. What needs to change across the industry to bring greater scientific rigour and credibility to the category?</span></span></span></strong></p>
<p><span><span><span>The market is extremely cluttered, and I believe there are several areas where regulation needs to become stronger.</span></span></span></p>
<p><span><span><span>One of the biggest issues is the use of terms such as “hair fall control” on shampoos and oils. In many cases, the underlying study may actually be looking at hair breakage rather than hair fall. A shampoo may reduce breakage because of its formulation, but that is not the same as addressing hair loss.</span></span></span></p>
<p><span><span><span>There should be greater clarity around what products such as shampoos and oils can legitimately claim. Terms such as hair fall, hair growth and hair regrowth need to be used responsibly and backed by appropriate evidence.</span></span></span></p>
<p><span><span><span>The second issue is transparency around studies. In the cosmetic industry, when a brand makes a claim and references a study, there is not always a requirement to make that study publicly available. If a consumer wants to understand whether the study involved 10 people or 100 people, whether it lasted 10 days or six months, or whether it was independently conducted or blinded, that information may not be accessible.</span></span></span></p>
<p><span><span><span>In pharma, when a study is used to substantiate a claim, there are established mechanisms through which the evidence can be published and scrutinised. We need greater transparency in the broader haircare category as well.</span></span></span></p>
<p><span><span><span>The third issue is that some brands may use ingredient-level claims rather than conducting studies on the finished product. When I first entered a manufacturing R&D setup and wanted to develop a shampoo, I was shown a list of ingredients and the claims associated with them. It made me realise that there can be a tendency to select ingredients based on the claims that can subsequently be made.</span></span></span></p>
<p><span><span><span>An ingredient may have been studied in a particular context, but that does not necessarily mean the finished product containing that ingredient has been clinically studied.</span></span></span></p>
<p><span><span><span>There are also significant challenges in the digital environment. Hundreds of brands can enter the market and make claims through digital advertising, while creators can post before-and-after testimonials without sufficient clarity around how those results were achieved or whether they are representative.</span></span></span></p>
<p><span><span><span>There needs to be greater accountability and some form of regulatory framework for digital and creator-led advertising, similar to the oversight that exists for television advertising.</span></span></span></p>
<p><strong><span><span><span>Traya brings together Ayurveda, dermatology and nutrition in its approach. What have you learnt from bringing these disciplines together, and what are the challenges of taking such a model to scale?</span></span></span></strong></p>
<p><span><span><span>The biggest challenge is that this is a much more difficult model to sell. It is far easier to sell a ₹600 shampoo or oil. People can buy it without giving it much thought.</span></span></span></p>
<p><span><span><span>Our approach requires the person to follow a complete routine. We may provide a kit containing four or five products, ask them not to use other products, look at their diet and have them use the app and follow the recommended regime.</span></span></span></p>
<p><span><span><span>It is a much more involved process, and it is also more expensive to sell. The first two or three years were particularly difficult because nobody knew us and we were a new brand.</span></span></span></p>
<p><span><span><span>What kept us going was seeing the results among customers. Word-of-mouth and organic purchases helped us survive. Even today, around ₹2 crore of our monthly revenue comes from people who purchase through referrals, without any marketing spend associated with those purchases. Existing customers recommend us to friends and family.</span></span></span></p>
<p><span><span><span>From a marketing perspective, it is a difficult model. That is also what makes it difficult for copycat brands to replicate and scale.</span></span></span></p>
<p><strong><span><span><span>How is technology helping make personalised hair loss assessment and treatment more practical, and where does the role of doctors remain critical?</span></span></span></strong></p>
<p><span><span><span>Technology is an enabler rather than a replacement for doctors.</span></span></span></p>
<p><span><span><span>From the initial hair assessment onwards, we use algorithms to analyse a person’s condition and understand what they may be experiencing. We now have around 30 lakh data points that the algorithm uses. This allows us to provide a more individualised assessment, including an indication of whether a person may respond to treatment and over what timeframe.</span></span></span></p>
<p><span><span><span>We also do not allow every person to purchase treatment. In some cases, the algorithm identifies that we may not be able to help, and the person is not allowed to proceed.</span></span></span></p>
<p><span><span><span>Once an order is placed, every case goes to a doctor. The doctor reviews the algorithm’s assessment, dosage and recommendations, and can modify the prescription, change a product or reject the case altogether.</span></span></span></p>
<p><span><span><span>This doctor review remains critical. In a conventional clinic, a doctor may see around 30 patients a day. At Traya, technology allows a doctor to review around 120 cases a day because much of the information is already structured. The case details and photographs are available, and the algorithm has prepared a preliminary prescription for the doctor to review.</span></span></span></p>
<p><span><span><span>Our algorithm has now reached what we estimate to be 99.99 per cent accuracy, although doctors continue to review every case. This has improved significantly over time.</span></span></span></p>
<p><span><span><span>We currently work with around 300 doctors, including MD dermatologists, MBBS doctors and Ayurveda doctors, along with a smaller number of nutritionists. Nutrition is increasingly supported by AI.</span></span></span></p>
<p><strong><span><span><span>Can you give an example of how the technology helps determine whether someone is likely to respond to treatment?</span></span></span></strong></p>
<p><span><span><span>Our treatment fundamentally operates around the health of the hair follicles. Hair fall, hair damage and hair length are relatively different problems from hair regrowth.</span></span></span></p>
<p><span><span><span>For example, if someone says they experienced significant hair loss 15 or 25 years ago, perhaps after having a child, and they are now 52 and menopausal, the follicles may have eventually ceased functioning. Once the follicles are no longer viable, no treatment can bring the hair back.</span></span></span></p>
<p><span><span><span>The same principle applies to people undergoing chemotherapy. The follicles remain active, but the treatment causes the shedding. Once chemotherapy stops, the hair can grow back. Such patients do not necessarily need a hair loss treatment; they should focus on nutrition, exercise and overall health.</span></span></span></p>
<p><span><span><span>On the other hand, if someone is younger, generally below 45-50, and the hair loss is relatively recent, there may still be viable follicles that can potentially be regenerated.</span></span></span></p>
<p><span><span><span>This is important because one of our core values is to be an honest brand. Technology helps us identify cases where we may not be able to deliver the outcome expected and prevents those customers from starting a treatment that may not benefit them.</span></span></span></p>
<p><strong><span><span><span>Where do you see the biggest opportunities for science-led hair loss care in India?</span></span></span></strong></p>
<p><span><span><span>The opportunity is enormous because hair loss is so widespread. Even after six years, despite our efforts to educate people, many continue to buy hair fall shampoos. Honestly, we would be happy if people simply went to a doctor, even if they did not choose Traya.</span></span></span></p>
<p><span><span><span>We are trying to bring scientific, pharma-grade molecules to people, but access to specialist care remains a challenge. Our survey indicates that only two in 100 people experiencing hair fall actually consult a doctor.</span></span></span></p>
<p><span><span><span>India has around 15,000 registered dermatologists, which is a very small number relative to the population. In major cities, we may feel that dermatologists are easily accessible, but the situation is very different across the country.</span></span></span></p>
<p><span><span><span>That creates a significant opportunity for the broader haircare industry to distinguish between hair care and hair treatment. Shampoos, oils, serums, spas and salons are part of hair care, but hair loss can be a treatment issue.</span></span></span></p>
<p><span><span><span>The same distinction applies to skincare. People may use multiple skincare products without consulting a doctor to understand the underlying reason for acne or another condition.</span></span></span></p>
<p><span><span><span>Another issue is that some of the most efficacious molecules used in treatment are not available through OTC products because of regulatory restrictions. In hair, for example, minoxidil is available through pharma products prescribed by doctors. Similarly, certain molecules used for acne treatment are available through prescription products.</span></span></span></p>
<p><span><span><span>The opportunity, therefore, is also about education and improving access to evidence-based treatment.</span></span></span></p>
<p><strong><span><span><span>Traya reported a topline of Rs 343 crore in FY2025 and is targeting Rs 500-600 crore in FY2026. At this stage of growth, what are the key levers for taking the business to the next level?</span></span></span></strong></p>
<p><span><span><span>One important area for us has been our ability to penetrate the interiors of the country.</span></span></span></p>
<p><span><span><span>Although the first purchase can be relatively expensive, at around ₹2,500 for the box, we have seen adoption beyond the major cities. Last month, we delivered across around 19,000 pincodes, out of approximately 25,000 pincodes in the country.</span></span></span></p>
<p><span><span><span>Around 80 per cent of our revenue last year came from outside Tier 1 and Tier 2 cities. This has changed our view of the market. Earlier, we were largely a Tier 1 and Tier 2 brand. Over the last one and a half years, we have focused significantly on making the model work across Bharat.</span></span></span></p>
<p><span><span><span>The opportunity is no longer limited to Tier 1, Tier 2 or Tier 3 cities. There are states where we already have strong penetration and others where we need to build awareness.</span></span></span></p>
<p><span><span><span>Uttar Pradesh is currently one of our top states in terms of revenue and brand awareness. Over the next two to three years, our focus will be on bringing some of the other states closer to that level.</span></span></span></p>
<p><strong><span><span><span>How are you building the operational infrastructure to support this expansion?</span></span></span></strong></p>
<p><span><span><span>Our largest office is in Mumbai, where the leadership team is based. We also have another office nearby where our medical team operates. Around 120 people, including doctors and the escalation and coaching teams, work there.</span></span></span></p>
<p><span><span><span>We have an office in Bengaluru with around 60 people, primarily supporting engineering and technology.</span></span></span></p>
<p><span><span><span>Beyond our own offices, we have outsourced coach centres across India. Every Traya customer gets access to a hair coach, and we currently handle around 2,500 coach conversations a day. Customers can book an appointment through the app to speak to their coach, discuss their progress, provide feedback and plan their next month’s kit.</span></span></span></p>
<p><span><span><span>As we scaled, we realised we could not continue hiring everyone in Mumbai. We therefore built centres across India, which also helped us address regional-language requirements.</span></span></span></p>
<p><span><span><span>We have centres in locations including Siliguri, Amritsar and Indore, along with support for languages such as Kannada, Malayalam and Tamil. These centres allow us to access qualified people at a more sustainable cost than Mumbai.</span></span></span></p>
<p><span><span><span>We also have an academy where people undergo a three-month training programme to become hair coaches. They have to complete the training, take examinations and receive certification before becoming a coach.</span></span></span></p>
<p>The post <a href="https://www.expresspharma.in/treating-hair-loss-as-a-health-issue-not-just-a-haircare-concern/">Treating hair loss as a health issue, not just a haircare concern</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>A missed opportunity for GS1 to explain why India’s barcoding programme is not a danger to society</title>
<link>https://edusehat.com/en/a-missed-opportunity-for-gs1-to-explain-why-indias-barcoding-programme-is-not-a-danger-to-society</link>
<guid>https://edusehat.com/en/a-missed-opportunity-for-gs1-to-explain-why-indias-barcoding-programme-is-not-a-danger-to-society</guid>
<description><![CDATA[ 
A recent essay in Express Pharma by Mr. S. Swaminathan, CEO of GS1 India, extolled the benefits of the QR barcoding programme and its importance for protecting Indian citizens against the terrible menace of counterfeit medicines [1]. Launched by India’s Ministry of Health and Family Welfare in 2023, the QR programme soon began to suffer […]
The post A missed opportunity for GS1 to explain why India’s barcoding programme is not a danger to society appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2025/04/28101212/EP_GB_Dr_Avi_Chaudhuri_750-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 23 Sep 2026 14:20:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>missed, opportunity, for, GS1, explain, why, India’s, barcoding, programme, not, danger, society</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2025/04/28101212/EP_GB_Dr_Avi_Chaudhuri_750-1.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2025/04/28101212/EP_GB_Dr_Avi_Chaudhuri_750-1.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2025/04/28101212/EP_GB_Dr_Avi_Chaudhuri_750-1-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>A recent essay in Express Pharma by Mr. S. Swaminathan, CEO of GS1 India, extolled the benefits of the QR barcoding programme and its importance for protecting Indian citizens against the terrible menace of counterfeit medicines [1]. Launched by India’s Ministry of Health and Family Welfare in 2023, the QR programme soon began to suffer failures that have now been well documented [2]. It turns out that criminal cartels can easily hijack the programme, place fake QR codes on fake medicines and then, in a paradoxically cruel twist, lead consumers to believe those fake drugs are actually genuine [3].</span></p>
<p><span>India’s failed experiment on use of QR codes as an anti-counterfeiting tool, which had been widely criticized by global security experts, can be attributed to two causes — a poorly designed solution that adopted the well-known vulnerability of QR codes [4,5] combined with a regulatory mandate filled with serious loopholes. The resulting lack of clarity allowed many Indian drug makers to cut corners and roll out a programme that further exposed their products and bring serious harm to their patients. </span></p>
<p><span>And now in a truly stunning development the very programme that earlier failed on both structural and operational grounds is being expanded to cover life-saving medicines that include antibiotics, vaccines and cancer drugs. The looming harm to India will be incalculable, a prediction that is not mere hyperbole but based on the very failures to which the same programme had earlier succumbed.</span></p>
<p><span>Those who proclaim India’s QR programme to be beneficial have not explained why a solution that aleady experienced serious failures should now be expanded to life-saving medicines that protect among the most vulnerable people in our society. And that is why the essay from GS1 was so disappointing because it was a missed opportunity to address the earlier fiasco head on. Instead, GS1 offered a pablum of false and dangerous claims that deserve a forceful response.</span></p>
<p><span>Here, I take up two of those claims and conclude by reexamining the principal motive for why GS1 continues to deceive the global public and India’s pharmaceutical industry in particular.</span><b></b></p>
<p><b>India does not have a drug traceability programme … and never will</b></p>
<p><span>The central argument offered by GS1 in support of expanding India’s QR coding directive is that it will allow drug packages to be tracked from plant to pharmacy. This claim is both false and dangerous. </span></p>
<p><span>The Indian barcoding mandate, both in its original articulation [6] and recent expansion [7], contains no mention that medicine packages must be endowed with a unique serial number. Consequently, only about one-half of the drug companies that fell under the original mandate chose to print serial numbers, and the majority of them did not even do so on the primary package sold to consumers [8].</span></p>
<p><span>It is simply not possible to have a traceability (Track & Trace) programme without the foundational requirement for every drug package to have its own digital identity, a fact that GS1 knows very well. And in the absence of that mandatory requirement from the Health Ministry, India will simply be unable to implement a traceability programme. GS1’s claim that the government’s barcode mandate will usher in a new era of drug traceability is therefore demonstrably false.</span></p>
<p><span>It may be the case that GS1 has come to recognize the serious flaws in India’s mandate and therefore has used the theoretical possibility of future drug traceability as a means of rescue. This would be in keeping with its core mission to advance the standards it has developed in support of traceability across healthcare supply chains. However, any effort to persuade India into making yet another attempt at implementing drug traceability is not only disingenuous, because of the absence of mandatory serialization, it is actually dangerous.</span></p>
<p><span>India has seen the drug traceability movie before. Starting around 2011, the Ministry of Commerce collaborated with GS1 to issue a compulsory requirement for all drug exporters to install a </span><i><span>Track and Trace </span></i><span>system. That effort suffered one setback after another. The Indian government quietly pulled the program last year after more than a decade of effort [9]. The factors that led to this collapse were known (or should have been known) to GS1 at the very outset, given its leadership in the field of drug traceability.</span></p>
<p><span>GS1 now continues to promote the same dishonest claim, as it did back in 2011, that a drug traceability programme can be implemented in India and other emerging markets. I have recently offered evidence-based arguments that a traceability programme will in fact never work in the Indian domestic context due to the size, complexity and operational facets of its drug supply chain [10]. There has been no effort by GS1 or its enablement partners to rebut those arguments and explain why such a renewed effort, now at much larger scale across the entirety of India’s drug manufacturing landscape, would overcome the inherent structural and operational challenges of its supply chain.</span></p>
<p><span>GS1’s inability to explain exactly how an Indian traceability programme can succeed, rather than just offering superficial sermons on its benefits, actually creates substantial peril for India, as I explain next. </span></p>
<p><b>India’s expanded QR programme will bring immense harm to its people and the drug industry</b></p>
<p><span>GS1 is a prominent organization that enjoys access to and influence on policy makers. Consequently, its claim that QR coding will lead to drug traceability becoming an imminent reality carries considerable adoption resonance across both government and industry. The certainty of great harm to India in that event will come in two forms.</span></p>
<p><span>The first is economic harm, which will be manifested through the substantial capital investments and ongoing costs that will be necessary on the part of Indian drug makers [11]. GS1 makes the case that many plants have already invested in machinery to print and scan barcodes on drug packages, which is the necessary first step in a traceability regime. That is certainly true. However, what is not mentioned is that India’s barcoding expansion will now affect nearly every single drug manufacturer, including the many hundreds (possibly thousands) involved only in domestic sales and which had no prior requirement to make any investments in online barcode printing and vision inspection equipment.</span></p>
<p><span>Those companies will now have to install print-and-inspect machinery that can easily exceed twenty thousand dollars per line along with significant operating costs to maintain an IT programme that must also include perpetual payments to GS1 for use of its proprietary coding formats. GS1’s continuing campaign for India to yet again embark on a massive effort to resurrect its traceability dream will come at steep cost to the industry. And as before, it will be the pharmaceutical industry, including now the legions of SMEs that are the backbone of India’s drug supply, who will be coerced into making those massive investments toward a failed cause.</span></p>
<p><span>The economic harm from the programme will however be overshadowed by the personal harm to consumers who will continue to suffer under ineffective protection from those very barcodes. To make matters worse, it has now been established that consumers can be misled into believing a fake drug is actually genuine due to the cunning way that counterfeiters have been able to hijack Indian’s current system [12]. That false reassurance to patients is really the worst outcome in this scenario because it will lead to a maddening aftermath where ensuing medical failure from a fake drug is what will cause it to be detected rather than the government-mandated QR code.</span></p>
<p><span>Consider for a moment the impact of that outcome. The current QR coding programme was launched to protect the top 300 selling medicines as a way to test the system. Fake QR codes then quickly appeared on fake medicines for treatment of high blood pressure [13], diabetes [14], blood clotting [15], vertigo [16] and epilepsy [17]. Four of these products belonged to drug makers that opted to follow a QR coding format designed by GS1, whose lobbying efforts now argue for the same programme to encompass highly sensitive life-saving medicines. These medicines — antibiotics, cancer drugs and vaccines — are among the most counterfeited because they are specifically so lucrative to the criminals [18-20]. And yet, all formulations that fall under those very broad categories, all of them, will soon become even more vulnerable due to the same weakness that plagued earlier barcoded products.</span></p>
<p><span>And that is why expanding India’s barcoding programme is such a danger to public safety.</span></p>
<p><b>A betrayal of trust</b></p>
<p><span>We are thus left with two troubling facts — QR coding is unarguably a dangerous anti-counterfeiting solution and that any claim for its use in drug traceability is highly specious because such a programme can never be successfully implemented in India. As it turns out, the major beneficiary in both arms of that equation is GS1 itself. How? </span></p>
<p><span>The answer comes from the business side of traceability. GS1 doesn’t just publish a set of standards and leave it at that but additionally has created a business structure that requires companies to pay into it to use their protocols, starting with an initial requirement to enroll into its ecosystem followed by perpetual subscription and other fees [21,22]. GS1’s business operations even extend to the very way that QR code content is structured. A new web-based protocol has been defined by GS1, known as </span><i><span>Digital Link</span></i><span>, in which product information can be retrieved by way of a QR code that is structured around its proprietary syntax [23]. In fact, the Indian affiliate of GS1 claims that it is the only authorized source for barcodes in the country [24].</span></p>
<p><span>So, the revenue to GS1 is accrued first by way of its proprietary QR coding structure, which it argues would then set the stage for a nationwide traceability programme. Both the problematic nature of QR codes and the unfeasibility of drug traceability in India make this a nakedly deceptive proposition, and one that is made worse by a troubling conflict of interest. An organization cannot simultaneously be responsible for issuing traceability standards or creating QR code designs whose adoption is then assured through its relationship with policy makers to in turn earn it vast sums of money. That is unarguably the very definition of conflict of interest because the financial benefit that GS1 accrues is a direct outcome of its government access [25].</span></p>
<p><span>GS1’s business agenda can therefore be in stark contradiction to a nation’s goal to protect its citizens, as evidenced by a dreadful outcome that can be directly attributed to its earlier actions. GS1’s advocacy that a drug traceability programme would solve the counterfeiting problem in Africa led the Indian government to adopt that approach and abandon more effective solutions that were readily available back in 2011. As a result, African nations continued to suffer from the epidemic of counterfeit drugs, which only continued to grow over the past decade to become a public health crisis that according to the United Nations now kills more than half a million people annually [26-28].</span></p>
<p><span>During that period, Africa remained helpless in the face of continued penetration of fake drugs. And given its role as the largest supplier of medicines to sub-Saharan Africa [29], India was uniquely positioned to greatly reduce suffering and save lives there over the past decade. And that is the tragedy of it all — the devastating consequence on African humanity from India’s decision to adopt GS1’s arguments and roll out a drug traceability programme that never had any chance of success.</span></p>
<p><b>Summary</b></p>
<p><span>India is dealing with a serious and growing drug counterfeiting problem that deserves thoughtful analysis and discourse. However, neither GS1 nor its business enablement partners have yet provided an intellectually rigorous argument for why India’s expanded barcode programme will now suddenly be immune to its past problems.</span></p>
<p><span>To the contrary, there is now considerable evidence of the economic harm to Indian industry and personal harm to its citizens. In fact, each and every stakeholder across the full pharmaceutical ecosystem — drug makers (both small and large), wholesalers, pharmacists, clinics, healthcare personnel and most notably patients — will face undeniable harm at some point from the effects of expanding the barcoding mandate.</span></p>
<p><span>GS1 can, and should, play a role in this debate and yet has curiously avoided answering some key questions previously directed at it [30], as follows:</span></p>
<p><i><span>How does GS1 justify use of a system that can be so easily compromised such that fake QR codes on fake medicines have become widespread and actually provide false reassurance to patients?</span></i></p>
<p><i><span>Why does GS1 continue to promote traceability (Track & Trace) to combat drug counterfeiting in light of the past failure in India and the severe operational constraints in that market?</span></i></p>
<p><i><span>How does GS1 reconcile the conflict of interest between developing traceability standards and then pursuing government advocacy for its adoption in light of the business benefits it can later derive?</span></i></p>
<p><span>A broad-based evidence-driven public discussion is now necessary to do what is right by India and bring forth an enduring era of patient safety — something that will not be met through the absence of honest leadership from organizations such as GS1.</span></p>
<p> </p>
<h5><b>References</b></h5>
<h5><span>[1]</span><a href="https://www.expresspharma.in/traceability-pays-back-in-many-ways/"><span>https://www.expresspharma.in/traceability-pays-back-in-many-ways/</span></a></h5>
<h5><span>[2]</span><a href="https://www.expresspharma.in/a-troubling-new-development-in-indias-qr-code-saga/"><span>https://www.expresspharma.in/a-troubling-new-development-in-indias-qr-code-saga/</span></a></h5>
<h5><span>[3]</span><a href="https://app.box.com/s/4njfkz8ued1u7wcokv5z9ge1xq4ltw6x"><span>https://app.box.com/s/4njfkz8ued1u7wcokv5z9ge1xq4ltw6x</span></a></h5>
<h5><span>[4]</span><a href="https://threatpost.com/fbi-malicious-qr-codes/177902/"><span>https://threatpost.com/fbi-malicious-qr-codes/177902/</span></a></h5>
<h5><span>[5]</span><a href="https://consumer.ftc.gov/consumer-alerts/2023/12/scammers-hide-harmful-links-qr-codes-steal-your-information"><span>https://consumer.ftc.gov/consumer-alerts/2023/12/scammers-hide-harmful-links-qr-codes-steal-your-information</span></a></h5>
<h5><span>[6]</span><a href="https://app.box.com/s/zwzp60rat9p9rdrl5duof8v28lzkgi0j"><span>https://app.box.com/s/zwzp60rat9p9rdrl5duof8v28lzkgi0j</span></a></h5>
<h5><span>[7]</span><a href="https://app.box.com/s/q4yiceku0z0b7t2axhzsobdaq096jnr5"><span>https://app.box.com/s/q4yiceku0z0b7t2axhzsobdaq096jnr5</span></a></h5>
<h5><span>[8]</span><a href="https://app.box.com/s/tgy8xc223rxtxzfminufo2pr31q8f522"><span>https://app.box.com/s/tgy8xc223rxtxzfminufo2pr31q8f522</span></a></h5>
<h5><span>[9]</span><a href="https://pib.gov.in/PressReleseDetailm.aspx?PRID=2098042&reg=3&lang=1"><span>https://pib.gov.in/PressReleseDetailm.aspx?PRID=2098042&reg=3&lang=1</span></a></h5>
<h5><span>[10]</span><a href="https://www.expresspharma.in/the-myth-of-drug-traceability-in-india/"><span>https://www.expresspharma.in/the-myth-of-drug-traceability-in-india/</span></a></h5>
<h5><span>[11]</span><a href="https://medwinpublishers.com/OAJPR/current-status-and-challenges-of-serialization-in-pharma-industry.pdf"><span>https://medwinpublishers.com/OAJPR/current-status-and-challenges-of-serialization-in-pharma-industry.pdf</span></a></h5>
<h5><span>[12]</span><a href="https://www.expresspharma.in/sun-pharma-must-immediately-declare-a-voluntary-recall-of-levipil-500/"><span>https://www.expresspharma.in/sun-pharma-must-immediately-declare-a-voluntary-recall-of-levipil-500/</span></a></h5>
<h5><span>[13]https://indianexpress.com/article/cities/ahmedabad/fake-nicardia-retard-10-racket-gujarat-police-10852207/</span></h5>
<h5><span>[14]https://www.medindia.net/news/bitter-pill-who-warns-of-fake-diabetes-drugs-216140-1.htm</span></h5>
<h5><span>[15]</span><a href="https://indianexpress.com/article/cities/delhi/counterfeit-medicines-worth-over-rs-2-5-lakh-seized-from-delhi-wholesaler-9944475/"><span>https://indianexpress.com/article/cities/delhi/counterfeit-medicines-worth-over-rs-2-5-lakh-seized-from-delhi-wholesaler-9944475/</span></a></h5>
<h5><span>[16]</span><a href="https://drugscontrol.org/news-detail.php?newsid=42246"><span>https://drugscontrol.org/news-detail.php?newsid=42246</span></a></h5>
<h5><span>[17]</span><a href="https://medicaldialogues.in/news/industry/pharma/fake-levipil-500-tablets-posing-as-sun-pharma-product-seized-in-telangana-162709"><span>https://medicaldialogues.in/news/industry/pharma/fake-levipil-500-tablets-posing-as-sun-pharma-product-seized-in-telangana-162709</span></a></h5>
<h5><span>[18]https://www.cdc.gov.au/newsroom/news-and-articles/fake-rabies-vaccines-india</span></h5>
<h5><span>[19]</span><a href="https://www.independent.co.uk/asia/india/fake-drugs-racket-delhi-johnson-johnson-gsk-b2803425.html"><span>https://www.independent.co.uk/asia/india/fake-drugs-racket-delhi-johnson-johnson-gsk-b2803425.html</span></a></h5>
<h5><span>[20]</span><a href="https://gh.bmj.com/content/10/6/e017078"><span>https://gh.bmj.com/content/10/6/e017078</span></a></h5>
<h5><span>[21]</span><a href="https://www.gs1india.org/wp-content/uploads/2022/07/GST-Certificate-37.pdf"><span>https://www.gs1india.org/wp-content/uploads/2022/07/GST-Certificate-37.pdf</span></a></h5>
<h5><span>[22]</span><a href="https://www.gs1india.org/content/register-for-barcodes/"><span>https://www.gs1india.org/content/register-for-barcodes/</span></a></h5>
<h5><span>[23]</span><a href="https://ref.gs1.org/docs/2023/QR-Code_powered-by-GS1-best-practices"><span>https://ref.gs1.org/docs/2023/QR-Code_powered-by-GS1-best-practices</span></a></h5>
<h5><span>[24]</span><a href="https://www.gs1india.org/blog/know-all-about-barcode-authentication/"><span>https://www.gs1india.org/blog/know-all-about-barcode-authentication/</span></a></h5>
<h5><span>[25]</span><a href="https://app.box.com/s/kj916h3mmr3n1vxgr5y0vl26bpko97ze"><span>https://app.box.com/s/kj916h3mmr3n1vxgr5y0vl26bpko97ze</span></a></h5>
<h5><span>[26]</span><a href="https://news.un.org/en/story/2023/02/1133062"><span>https://news.un.org/en/story/2023/02/1133062</span></a></h5>
<h5><span>[27]</span><a href="https://www.bbc.com/news/world-africa-53387216"><span>https://www.bbc.com/news/world-africa-53387216</span></a></h5>
<h5><span>[28]</span><a href="https://www.theguardian.com/world/article/2024/aug/04/fifth-of-medicines-africa-substandard-fake-research"><span>https://www.theguardian.com/world/article/2024/aug/04/fifth-of-medicines-africa-substandard-fake-research</span></a></h5>
<h5><span>29]</span><a href="https://www.thebureauinvestigates.com/stories/2025-04-16/indias-drugs-industry-global-medicine-market"><span>https://www.thebureauinvestigates.com/stories/2025-04-16/indias-drugs-industry-global-medicine-market</span></a></h5>
<h5><span>[30]</span><a href="https://www.expresspharma.in/a-defining-opportunity-for-clarity-from-gs1/"><span>https://www.expresspharma.in/a-defining-opportunity-for-clarity-from-gs1/</span></a></h5>
<p>The post <a href="https://www.expresspharma.in/a-missed-opportunity-for-gs1-to-explain-why-indias-barcoding-programme-is-not-a-danger-to-society/">A missed opportunity for GS1 to explain why India’s barcoding programme is not a danger to society</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>ERS Genomics and Sai Life Sciences sign CRISPR/Cas9 license agreement </title>
<link>https://edusehat.com/en/ers-genomics-and-sai-life-sciences-sign-crisprcas9-license-agreement</link>
<guid>https://edusehat.com/en/ers-genomics-and-sai-life-sciences-sign-crisprcas9-license-agreement</guid>
<description><![CDATA[ 
ERS Genomics Limited (‘ERS’), the CRISPR licensing company, announced that it has signed a non-exclusive license agreement with Sai Life Sciences , an integrated contract research, development, and manufacturing organization (CRDMO). The agreement grants Sai Life Sciences access to ERS Genomics’ foundational CRISPR/Cas9 patent portfolio for use in research and product development. Through this license, […]
The post ERS Genomics and Sai Life Sciences sign CRISPR/Cas9 license agreement  appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/07/22171615/signing-agreement.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 23 Sep 2026 14:20:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>ERS, Genomics, and, Sai, Life, Sciences, sign, CRISPRCas9, license, agreement </media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/07/22171615/signing-agreement.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/07/22171615/signing-agreement.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/07/22171615/signing-agreement-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>ERS Genomics Limited (‘ERS’), the CRISPR licensing company, announced that it has signed a non-exclusive license agreement with Sai Life Sciences , an integrated contract research, development, and manufacturing organization (CRDMO).</span></p>
<p><span>The agreement grants Sai Life Sciences access to ERS Genomics’ foundational CRISPR/Cas9 patent portfolio for use in research and product development. Through this license, Sai Life Sciences can integrate precision genome editing capabilities into its discovery and development platforms, strengthening its ability to support global pharmaceutical and biotechnology partners across small molecule programs.</span></p>
<p><span>Building on this access, Sai Life Sciences can deploy CRISPR/Cas9-enabled models and workflows to help clients validate targets, screen compounds and generate decision-relevant biological insights earlier in discovery, complementing its biology, DMPK and pharmacology platforms.</span></p>
<p><span>Maneesh Pingle, President, Discovery, Sai Life Sciences, said:</span><i><span> “</span></i><span>As the industry moves towards more complex biological questions and novel therapeutic approaches, we are continually expanding our scientific capabilities to stay ahead. The addition of CRISPR-Cas9 to our discovery platform is another step in that journey, strengthening our ability to support clients as they pursue the next generation of medicines. Our agreement with ERS Genomics gives us access to foundational CRISPR-Cas9 technology that will further strengthen these capabilities and expand the ways in which we can support our clients across discovery and development.”</span></p>
<p><span>John E. Milad, Chief Executive Officer, ERS Genomics, said: “We are delighted to welcome Sai Life Sciences as a licensee. Sai Life Sciences’ integrated discovery, development and manufacturing capabilities and its global base of innovator partners make it a strong addition to our growing network of CRISPR licensees. By securing access to our foundational CRISPR/Cas9 portfolio, Sai Life Sciences is well positioned to advance innovative research and development programmes with clarity and confidence.”</span></p>
<p><span>ERS Genomics provides access to the pioneering CRISPR/Cas9 intellectual property developed by Dr. Emmanuelle Charpentier and her collaborators. Through its streamlined licensing program, enables companies and institutions worldwide to access foundational patents covering the use of CRISPR/Cas9 technology across research and commercial applications.</span></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/ers-genomics-and-sai-life-sciences-sign-crispr-cas9-license-agreement/">ERS Genomics and Sai Life Sciences sign CRISPR/Cas9 license agreement </a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>SIRO Clintech reloaded </title>
<link>https://edusehat.com/en/siro-clintech-reloaded</link>
<guid>https://edusehat.com/en/siro-clintech-reloaded</guid>
<description><![CDATA[ 
Corporate history is replete with examples of the ‘third generation curse’, but the Daftary family seem to be bucking that trend. Sure, they sold Bharat Serums &amp; Vaccines (BSV), founded in 1971 by family patriarch Vinod G Daftary, to Advent International in 2020.  But the family has ambitious plans for SIRO Clintech, a company founded […]
The post SIRO Clintech reloaded  appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/21155158/EP_Dr_Gautam_Daftary_Akshay_and_Karan_Daftary_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 23 Sep 2026 10:45:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>SIRO, Clintech, reloaded </media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/21155158/EP_Dr_Gautam_Daftary_Akshay_and_Karan_Daftary_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/21155158/EP_Dr_Gautam_Daftary_Akshay_and_Karan_Daftary_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/21155158/EP_Dr_Gautam_Daftary_Akshay_and_Karan_Daftary_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Corporate history is replete with examples of the ‘third generation curse’, but the Daftary family seem to be bucking that trend. Sure, they sold Bharat Serums & Vaccines (BSV), founded in 1971 by family patriarch Vinod G Daftary, to Advent International in 2020. </span></p>
<p><span>But the family has ambitious plans for SIRO Clintech, a company founded in 1996, by the second generation, Dr Gautam V Daftary. The third generation, Dr Daftary’s sons Akshay and Karan, are firmly in the saddle.</span></p>
<p><span>“Divestment of SIRO is not part of the strategic plan”, says Founder and Chairman of SIRO Clintech Dr Daftary. Karan Daftary, MD, SIRO Clintech, emphasises that “the focus is much more on growth than on an exit plan. SIRO Clintech is today focused on becoming the largest and most advanced technology-enabled CRO in India. ” </span></p>
<p><b>Divestment increased focus </b></p>
<p><span>BSV’s divestment to private equity Advent International in 2019 “was an inflection point for the family”, reflects Dr Daftary, as it allowed the family “to focus our leadership attention on SIRO in a way that wasn’t possible before, and the past decade has been the most focused period of growth in SIRO’s history.” </span></p>
<p><span>He explains that SIRO’s independence is deliberate as it allows them to invest with a long-term perspective, something that is difficult in a private equity-owned model. “We are among the very few Indian CROs to make sustained investments in R&D, and SIROai is the result of more than five years of foundational work. That kind of commitment is only possible when you have a long-term vision beyond the next business cycle.” </span></p>
<p><span>Daftary concurs, saying “We remain open to divestment or strategic options over the longer term, but right now the priority is to grow each business, organically or inorganically, rather than pursue an exit plan. Across all businesses, the immediate focus is on infusing safe technology to reduce manual effort, expand the revenue base and grow the client base and service portfolio.” </span></p>
<p><span>Agreeing with his father, Daftary points out that the demerger two years ago was an important structural change because it gave each business greater focus across its respective markets, clients and positioning. “We are now at a point where we believe the longevity of companies is highly dependent on the technology built into them, as well as on how safely that technology is implemented. That has influenced how we have repositioned the group and how we approach the business.” </span></p>
<p><span>On the other revenue streams, Daftary says the medical writing business has moved its focus to the UK and other larger European and US markets because of the opportunities for standardised service offerings. SIRO’s staffing business is India-centric in terms of operations, while hiring globally. The demerger therefore created focused businesses that can grow in their own manner. </span></p>
<p><b>Making the generational divide work </b></p>
<p><span>As much as the two generations are in sync on this aspect, Dr Daftary admits that “the generational difference is real.” But the family has made this difference work, as “differences resolve through the discipline of asking each other the harder version of the question, and through mutual respect for what each generation genuinely brings.” </span></p>
<figure aria-describedby="caption-attachment-459661" class="wp-caption alignright"><img decoding="async" class=" wp-image-459661" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/21160547/Karan-Daftary-Image-300x296.jpg" alt="" width="369" height="364" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/21160547/Karan-Daftary-Image-300x296.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/21160547/Karan-Daftary-Image-100x100.jpg 100w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/21160547/Karan-Daftary-Image.jpg 488w" sizes="(max-width: 369px) 100vw, 369px"><figcaption class="wp-caption-text">Karan Daftary</figcaption></figure>
<p><span>As Dr Daftary explains, “I carry the memory of every cycle SIRO has been through over three decades. Karan carries the read on where the industry is heading next, and the operational tempo the current market demands. Neither view is complete on its own. The way it works in practice is not that one voice wins. It is that we test each other. When Karan pushes for something aggressive on AI or capability build, the question I ask in return is whether we have thought through the downside. When I am cautious on a market move, the question Karan asks is whether the caution reflects the current market or a market that has already changed. Both questions are useful, and neither is decorative.” </span></p>
<p><span>As Daftary puts it, “I would describe the difference less as “safe versus aggressive” and more as “experience versus youth.” Experienced leaders understand not only the opportunities but also the downstream consequences of decisions. The younger generation tends to have a stronger pulse on how quickly technology and market adoption are changing. The combination works well: we can move quickly while still operating in a realistic and safe manner.” </span></p>
<p><span>He emphasises that they are not trying to build the business around quick profits, but “to build a brand and a legacy over decades. We have seen that model work within the family and want to replicate it. In that sense, the combination of access to AI and technology, together with experienced oversight and guidance around the requirements of drug development and patient care, is a major advantage.” </span></p>
<p><b>The past three decades </b></p>
<p><span>SIRO has ridden both the crests and troughs of global and India’s clinical research sector. </span></p>
<p><span>Looking back over the past three decades, Dr Daftary agrees, “The last three decades of Indian CRO business has not been a straight line story. Every five to seven years, the industry has had to reset, and each of those resets pushed SIRO to strengthen a different capability. That is the discipline of an evidence business.” </span></p>
<p><span>At each reset, SIRO seems to have redefined itself, moving to where the market is. </span></p>
<p><span>For instance, as Dr Daftary points out, “When competition grew, SIRO moved up the value chain into strategic services. Medical writing, biometrics, and regulatory science were less commoditised than trial operations, and quality mattered more than headcount. The diversification from medical writing came through a deliberate build over the past decade of what is now the four-pillar architecture: Development clinical trials, Post-approval clinical programs, Real-world evidence, and Evidence platforms and intelligence. Medical writing sits inside the fourth pillar as one capability among several.” </span></p>
<p><span>Similarly, “when global pharma tightened R&D investment through the 2010s, we deepened the Indian sponsor base and the Post-Approval and RWE offerings, both of which grew as regulators moved to require more local evidence. And on US client over-dependence, geographic and sponsor diversification was a deliberate multi-year shift. US concentration was reduced by design, not by accident, and the Indian sponsor base has become a genuine growth engine over the past decade.” </span></p>
<p><span>Giving his perspective, Daftary narrates how as India’s first CRO in 1996, SIRO was involved in building parts of the Indian CRO ecosystem, including work around ethics committee and site guidelines. Over the early years, the company developed large partnerships with global companies, which made them one of the prominent players in the Indian clinical research market.</span></p>
<p><span>As the clinical trial market in India reached a peak, SIRO opened to private equity investment. 3i Group and Kotak Private Equity became part of the growth story, and a decision was subsequently made to acquire Omega, a large European CRO, in 2008. </span></p>
<p><span>In hindsight, Daftary feels that that “was the right decision at the wrong time” as the acquisition coincided with the recession, which led to reduced R&D spending and made the economics and local operations considerably more difficult. Ultimately, SIRO wound down those operations. </span></p>
<p><span>Around 2016–2017, the company retained the conviction that clinical research was a business they could scale. With the third generation ready to join the company, SIRO acquired the business back. </span></p>
<p><span>The group is now 100 per cent family-owned and completely debt-free, says Daftary, with operations funded through their own cash flows and investments, “which gives us a lean operating model across the group.” </span></p>
<p><span>He reveals that SIRO’s clinical research work today is focused primarily on Indian patients. The client roster comprises large Indian pharma companies and Indian affiliates of global companies, as well as FMCG, medical device and vaccine companies. Medical writing has a global footprint, particularly across Europe, the US, APAC and the Middle East, because it can be delivered as a standardised service within larger development programmes, reasons Daftary. The staffing arm is geography-agnostic and works across markets. Overall, the group remains under complete family control. </span></p>
<p><span>Revenue wise, across the group, growth was around 40 per cent last year and approximately 15–20 per cent the year before, following some ups and downs in the earlier period. “The momentum over the last two to three years has been strong, and we are looking to build on it further this year. We have also added around 10–12 new clients in the six months since January. The key lesson has been that systems, people and processes need to be built first; only then can the business scale. The last two years have provided that launchpad and enabled us to grow well above industry averages,” claims Daftary. </span></p>
<p><span>All this has positioned SIRO for the next reset. </span></p>
<p><b>From clinical trials to clinical evidence </b></p>
<p><span>As Dr Daftary puts it, “The shift from project-based clinical trials to lifecycle evidence partnerships is the single biggest change in the CRO business model in the last decade. It reflects a change in what sponsors actually need. They need evidence at every stage of the product lifecycle: before approval, immediately after approval, and years into commercialisation.” </span></p>
<p><span>While project-based CROs deliver a trial, Lifecycle Evidence Partners deliver a continuous evidence stream across the full commercial life of the product. According to Dr Daftary, “SIRO has architected the business around this shift. The four pillars are the operating structure, not a marketing frame. The tagline that captures this shift is clinical trials to clinical evidence, and it reflects both the direction the industry is moving in and the direction SIRO has already moved to.” </span></p>
<p><span>Looking ahead, Dr Daftary believes that the next chapter is scaling the model. “The shift is not just a business model change; it also reflects a maturing regulatory environment that asks for evidence long after approval, and a maturing scientific standard that asks for evidence from the population the drug will actually treat.” </span></p>
<p><b>So, how does a lifecycle evidence partnership look like in practice? </b></p>
<p><span>Dr Somesh Bolegave, Head Biometrics, Regulatory & Medical Services, SIRO Clintech explains with an example, citing an oral insulin product that had been approved in the US but faced challenges around integration and adoption in India. The product represented an important area of formulation science because moving insulin away from injectable delivery has long been an important goal in diabetes care. </span></p>
<figure aria-describedby="caption-attachment-459660" class="wp-caption alignleft"><img decoding="async" class=" wp-image-459660" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/21160228/Dr-Somesh-Bolegave-2-200x300.jpg" alt="" width="246" height="370" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/21160228/Dr-Somesh-Bolegave-2-200x300.jpg 200w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/21160228/Dr-Somesh-Bolegave-2-683x1024.jpg 683w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/21160228/Dr-Somesh-Bolegave-2-768x1152.jpg 768w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/21160228/Dr-Somesh-Bolegave-2.jpg 1024w" sizes="(max-width: 246px) 100vw, 246px"><figcaption class="wp-caption-text">Dr Somesh Bolegave, Head Biometrics, Regulatory & Medical Services, SIRO Clintech</figcaption></figure>
<p><span>The regulatory challenge in India was the absence of sufficient local evidence for the product. Rather than treating approval as the end of the process, the strategy was to develop an India-specific evidence pathway. SIRO Clintech partnered with Cipla to define a route that would satisfy regulatory requirements while also generating confidence in the evidence. SIRO Clintech conducted the Phase III trial, which received approval from the Indian regulator in 2025. The product is now available in the Indian market. </span></p>
<p><span>However, Dr Bolegave emphasises that regulatory approval is not the end of the evidence journey. Phase III trials are conducted in selected populations, so evidence from Phase IV and post-marketing studies is important for understanding performance in a broader, realworld population. </span></p>
<p><span>He points out that that is the shift from seeing regulatory approval as a milestone to building evidence throughout the product lifecycle. “As AI capabilities expand, patient voice and social media feedback can also be incorporated into the evidence generation process, so that decision-making is informed not only by developers and companies but also by patient experience and needs.” </span></p>
<p><span>He cautions that the challenge is to generate evidence quickly while ensuring that it remains scientifically robust and validated, and reasons that this is where an experienced CRO can combine its knowledge of trial conduct and evidence generation with technology to make the process more efficient. </span></p>
<p><strong>Policy support </strong></p>
<p><span>India’s policy framework and regulation seems to have finally caught up with the industry’s evolution, with long awaited policy changes closing gaps. </span></p>
<p><span>Both Daftary and Dr Bolegave believe that the New Drugs and Clinical Trial (NDCT) Rules 2019 fundamentally changed the pace and predictability of clinical trial approvals in India. </span></p>
<p><span>The measurable difference has been in timelines. Approval cycles that could earlier run six to nine months now sit within defined statutory timelines that regulators have largely honoured. NDCT 2019 delivered defined timelines, expanded scope of oversight, and a formalised SEC review structure, creating the foundation for subsequent reforms. </span></p>
<p><span>In their opinion, the 2026 prior intimation pathway is the clearest recent signal of the direction of travel. It compressed review timelines from 90 to 45 working days for eligible studies. They reason that that is a signal that the regulator is willing to move fast when the scientific case is well made and the CRO track record is established. </span></p>
<p><span>Going forward, they both believe that the industry would benefit from faster review timelines for standard applications, clearer guidance on Rule 101 country-waiver criteria for cell and gene therapies and rare diseases, stronger SEC composition for emerging modalities, and a risk-based inspection framework for CROs post-registration. </span></p>
<p><span>They also point out that infrastructure policy support matters equally: SHAKTI-scale site expansion beyond the first thousand, stronger biomarker testing capacity, patient registry consolidation across therapeutic areas, and continued investment in the digital health infrastructure that decentralised trials depend on. </span></p>
<p><span>SIRO has apparently had a good compliance record. Both Daftary and Dr Bolegave emphasise that the company has been inspected and audited by global and national regulatory agencies, including the US FDA, European regulators, the WHO, Indian regulators and Japanese regulators, with no critical observations. </span></p>
<p><span>But quality inspections are not limited to regulators. Daftary and Dr Bolegave point out that many global pharma companies operate quality systems that are more stringent than minimum regulatory requirements. They stress that SIRO has been audited more than 250 times by such global organisations, with no critical observations, which validates the company’s quality systems and data integrity.</span></p>
<p><span>Thanks to these regulations, they point out that the landscape has evolved on four important fronts. Firstly, mandatory CRO registration under the NDCT Amendment 2024 has raised quality standards. Secondly, CDASH-aligned workflows are now standard rather than optional. Thirdly, risk-based quality management is being formalised in the draft GCP revision. And lastly, AI governance frameworks are becoming part of CRO operating models. </span></p>
<p><b>Changing sponsor perceptions </b></p>
<p><span>But India’s clinical research sector has not made its global mark as expected. Though India’s CRO market is expected to reach $ 4,956.7 million by 2033 at a 9.5 per cent CAGR, India accounted for only 5.3 per cent of the global pharma CRO market in 2025. This clearly points to major issues that still need to be addressed. </span></p>
<p><span>As Dr Daftary puts it bluntly, “The 5.3 per cent number changes when we stop pitching cost and start pitching evidence quality.” </span></p>
<p><span>Taking this further, both Daftary and Dr Bolegave believe that the credibility of that proposition will ultimately depend on whether operational delivery can withstand global regulatory scrutiny and inspection.</span></p>
<p><span>They point out that global sponsors are increasingly seeking high-quality evidence: meaningful, publishable, decision-useful insights from every study run in India. India has structural advantages that remain underutilised in the current sponsor narrative, including diverse patient population, a disease burden across therapeutic areas, rapidly evolving digital health infrastructure, and English-language regulatory operations that make audit trails accessible to global reviewers. </span></p>
<p><span>They agree that the larger challenge lies in changing sponsor perception. India continues to be viewed as primarily a delivery venue when it should be recognised as a strategic hub for evidence generation. Changing this narrative will require leadership from Indian CROs supported by an enabling regulatory environment. </span></p>
<p><b>The road ahead </b></p>
<p><span>Daftary and Dr Bolegave caution that on the regulations front, while the direction is right and the pace has been steady, what the industry needs now is sustained momentum, not new frameworks every year, cautions the duo. </span></p>
<p><span>Similarly, the Biopharma SHAKTI programme to establish 1,000-plus clinical trial sites is a step in the right direction, as India has been site-constrained for several years, particularly in therapeutic areas beyond the top three or four, and expanding the site base is therefore a meaningful structural intervention. </span></p>
<p><span>But they once again sound a cautionary note, pointing out that this expansion should be matched by quality. Establishing a thousand new sites will be meaningful only if investigator training, ethics committee readiness, and site infrastructure are matched to that pace, and early signals suggest the government recognises this requirement and is investing in supporting this ecosystem. </span></p>
<p><span>Operationally, they believe that the impact is likely to show up first in post-approval clinical programmes and post marketing surveillance studies (PMS studies), as these are the categories where India needs greater site density. Development-stage clinical trials are likely to follow as investigator and sponsor confidence at the newer sites increases. </span></p>
<p><span>The duo point out that data quality was a legitimate concern in an earlier era, but it is no longer the barrier it once was. Today global sponsors audit the strength of the underlying quality management system, not just the data produced, and Indian CROs that have invested in that system are winning global trials on the strength of their capabilities . </span></p>
<p><span>At SIRO, we operate a globally aligned quality management system, supported by ISO-certified diagnostics AI capabilities at the parent group level, a formal AI governance framework, and immutable audit trails for AI-assisted workflows. These are operational capabilities, embedded in our processes , not simply claims made on paper. </span></p>
<p><span>On AI, the generational balance steps into the picture once again. </span></p>
<p><span>“AI has a role across the drug and evidence lifecycle, but it is important to separate real capability from industry hype. Our approach is to be clear about what AI can and cannot do,” states Dr Daftary. </span></p>
<p><span>He agrees that today AI is effective in drafting scientific documents under human review, extracting insights from completed clinical study reports, structuring safety and pharmacovigilance signal detection, and capturing patient voice from digital sources at scale. </span></p>
<p><span>But he also points out that AI is not credibly ready for autonomous clinical decisions, independent regulatory submissions, or unsupervised medical writing. </span></p>
<p><span>Therefore Dr Daftary believes that AI is a system enhancement, it is not a substitute for clinical governance. “Applied appropriately, AI can materially strengthen informed consent quality through multilanguage e-consent, data integrity through real-time query resolution, and evidence generation through capturing patient voice at scale. SIROai is built as an internal capability layer, not a SaaS product sold to sponsors, and that model matters. AI works when it is embedded within a robust quality system, not when it is bolted on top. Our governance principle is simple: AI is a drafting assistant, not a decision-maker. Every AI-assisted output goes through mandatory human scientific review before release, every AI interaction is logged, and audit trails are immutable.” </span></p>
<p><b>The case for India’s clinical research sector </b></p>
<p><span>Dr Bolegave is of the firm opinion that India’s clinical research industry has matured significantly and become increasingly science driven. The overall trend has been positive, including during COVID-19 when India played a significant role in the global development and testing of COVID-related products and vaccines, supported by increasingly robust mechanisms and a maturing policy environment. </span></p>
<p><span>He points out that another major area of focus is diversity and the need to understand why products may perform differently across populations. It is no longer sufficient to assume that a product developed and approved elsewhere will automatically provide all the evidence required for another population. Regulators increasingly recognise the importance of generating appropriate India-specific evidence while also avoiding unnecessary duplication where robust global evidence already exists. This represents a more mature regulatory approach. Regulators are better able to distinguish between situations where India-specific trials are essential and situations where existing global evidence can be leveraged, complemented by focused local evidence, analyses Dr Bolegave.</span></p>
<p><span>Both generations of the Daftary family agree on the strategy going forward. To attract more global trials, they believe that India must keep investing in quality across the CRO ecosystem, educate sponsors that Indian data quality has evolved, and increase participation of Indian organisations in global multi-country trials. </span></p>
<p><span>While the systems are largely in place, they reiterate that the bigger challenge now is changing global perception, and that requires India’s CRO industry to communicate its capabilities more effectively. </span></p>
<p><span>Can SIRO Clintech navigate scaling up with the same quality? Will regulatory oversight continue to keep pace with the deployment of new technologies like AI in clinical research and trials? And when will sponsor perception change to view India as more than a delivery venue but a strategic hub for evidence generation? India’s clinical research sector needs to convert potential into reality and the next few years will be crucial toward this goal. </span><span></span></p>
<p></p>
<p><em><span>viveka.r@expressindia.com </span><span><br>
</span><span>viveka.roy3@gmail.com </span></em></p>
<p>The post <a href="https://www.expresspharma.in/siro-clintech-reloaded/">SIRO Clintech reloaded </a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>EC approves Menarini and NewAmsterdam’s obicetrapib therapies</title>
<link>https://edusehat.com/en/ec-approves-menarini-and-newamsterdams-obicetrapib-therapies</link>
<guid>https://edusehat.com/en/ec-approves-menarini-and-newamsterdams-obicetrapib-therapies</guid>
<description><![CDATA[ The authorisation allows both treatments to be used for patients with primary hypercholesterolaemia, including those with heterozygous familial and non-familial forms or mixed dyslipidaemia. This is said to 
The post EC approves Menarini and NewAmsterdam’s obicetrapib therapies appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/09/PT-22-09-2026-shutterstock_2518831137.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 22 Sep 2026 20:25:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>approves, Menarini, and, NewAmsterdam’s, obicetrapib, therapies</media:keywords>
<content:encoded><![CDATA[<p>The authorisation allows both treatments to be used for patients with primary hypercholesterolaemia, including those with heterozygous familial and non-familial forms or mixed dyslipidaemia.</p>
<p>This is said to be the first regulatory approval anywhere in the world for obicetrapib.</p>
<p>The EC’s decision follows a recommendation from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use.</p>
<p>Backing for the approval comes from data in NewAmsterdam’s clinical development programme, including Phase III BROADWAY, BROOKLYN and TANDEM trials.</p>
<p>Results from these studies showed statistically significant reductions in Low-density lipoprotein (LDL) cholesterol, with obicetrapib monotherapy reducing LDL-C by up to 40% compared to placebo, and the combination with ezetimibe reducing it by about 50%.</p>
<p>The safety profile was reported as similar to placebo.</p>
<p>Under the collaboration, Menarini holds exclusive rights to market obicetrapib in Europe and is responsible for regulatory and commercial activities there.</p>
<p>NewAmsterdam will receive tiered double-digit royalties and could qualify for up to €833m in milestone-related payments.</p>
<p>Both firms continue to evaluate obicetrapib in ongoing Phase III trials, including PREVAIL, REMBRANDT, and RUBENS.</p>
<p>Obicetrapib is being developed as a low-dose, oral Cholesteryl ester transfer protein (CETP) inhibitor for lowering LDL cholesterol in patients who do not respond adequately to existing treatments.</p>
<p>NewAmsterdam Pharma CEO Michael Davidson said: “The EC approval of Ubeslo and Evlarco marks a major milestone for NewAmsterdam as the first regulatory approval of obicetrapib globally, a novel oral therapy, and validates years of work focused on delivering a potential new treatment option for patients who continue to struggle to achieve recommended LDL-C levels despite previously available therapies.</p>
<p>“This first-in-class approval reflects the strength of the clinical evidence supporting obicetrapib, the dedication of our team and partners, and our commitment to addressing one of the largest unmet needs in cardiovascular medicine.</p>
<p>“Together with Menarini, we look forward to bringing Ubeslo and Evlarco to patients across Europe and building on this important milestone as we advance our vision of making obicetrapib available to patients around the world.”</p>
<p>In March 2025, the Menarini Group and its subsidiary Stemline Therapeutics announced a partnership with VisualDx to enhance the detection of blastic plasmacytoid dendritic cell neoplasm (BPDCN).</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/ec-menarini-newamsterdams-obicetrapib-therapies/">EC approves Menarini and NewAmsterdam’s obicetrapib therapies</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Made Scientific acquires cell therapy facility in Pennsylvania, US</title>
<link>https://edusehat.com/en/made-scientific-acquires-cell-therapy-facility-in-pennsylvania-us</link>
<guid>https://edusehat.com/en/made-scientific-acquires-cell-therapy-facility-in-pennsylvania-us</guid>
<description><![CDATA[ The company said programmes could be onboarded at the facility immediately, rather than after a construction and qualification period, with the site intended to support clinical and commercial 
The post Made Scientific acquires cell therapy facility in Pennsylvania, US appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/09/PT-2-22-09-2026-shutterstock_1219433356.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 22 Sep 2026 20:25:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Made, Scientific, acquires, cell, therapy, facility, Pennsylvania</media:keywords>
<content:encoded><![CDATA[<p>The company said programmes could be onboarded at the facility immediately, rather than after a construction and qualification period, with the site intended to support clinical and commercial supply from 2027.</p>
<p>It has completed 145 good manufacturing practice (GMP) manufacturing batches across various autologous and allogeneic cell therapy programmes, including chimeric antigen receptor T-cell (CAR-T) and B-cell therapies.</p>
<p>The facility is designed for large-scale, end-to-end cell therapy production and includes eight Grade B/C cleanrooms, a Grade C ballroom, and a Grade B fill-finish suite.</p>
<p>It also features on-site quality control and analytical testing laboratories, high-bay warehousing, and 30,000ft² of expansion space. Plans allow for the construction of eight additional ballrooms to support future growth.</p>
<p>The facility can manufacture starting material, drug substance, and drug product using both customised processes and platform technology transfers.</p>
<p>Planned upgrades include scalable 3D bioreactor platforms of up to 200L, advanced cell harvest equipment, automated fill-finish, and lyophilisation capacity.</p>
<p>The site’s integration into Made Scientific’s network expands its overall footprint to 145,000ft² along the US East Coast, with 15 qualified GMP suites and development and quality control laboratories across both the new and existing Princeton facility.</p>
<p>The company expects the Princeton site to undergo a US Food and Drug Administration (FDA) pre-licensure inspection in early 2027, followed by the East Norriton facility.</p>
<p>Made Scientific chairman and CEO Syed Husain said: “The acquisition of an operational facility with an experienced manufacturing team represents a significant advance in our ability to support clients from clinical to commercial.</p>
<p>“Sponsors advancing therapies toward approval require manufacturing capacity that is available when their programmes reach it.</p>
<p>“It is also the next step in a manufacturing network we are building deliberately and for the long term, with a strategic shareholder that has backed Made Scientific since 2022.”</p>
<p>Made Scientific is a contract development and manufacturing organisation focused on autologous and allogeneic cell therapy products, operating facilities in New Jersey and Pennsylvania.</p>
<p>In November 2025, Made Scientific and Cellergy Therapeutics formed a manufacturing partnership to advance the latter’s CLG-001 mitochondrial therapy toward first-in-human studies.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/made-scientific-cell-therapy-facility-us/">Made Scientific acquires cell therapy facility in Pennsylvania, US</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>GCF organises three day conference on ‘Advancing green &amp;amp; sustainable chemistry in the pharma supply chain’</title>
<link>https://edusehat.com/en/gcf-organises-three-day-conference-on-advancing-green-sustainable-chemistry-in-the-pharma-supply-chain</link>
<guid>https://edusehat.com/en/gcf-organises-three-day-conference-on-advancing-green-sustainable-chemistry-in-the-pharma-supply-chain</guid>
<description><![CDATA[ 
The pharmaceutical industry is increasingly focusing on integrating Green and Sustainable Chemistry into manufacturing processes and supply chains. Moving from sustainability commitments to practical implementation requires collaboration, innovation, and industry-wide knowledge sharing. To advance this dialogue, Green ChemisTree Foundation (GCF) is organising the 5th Conference &amp; Exhibition on “Advancing Implementation of Green &amp; Sustainable Chemistry […]
The post GCF organises three day conference on ‘Advancing green &amp; sustainable chemistry in the pharma supply chain’ appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/22172249/EP_GCF.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 22 Sep 2026 20:20:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>GCF, organises, three, day, conference, ‘Advancing, green, sustainable, chemistry, the, pharma, supply, chain’</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/22172249/EP_GCF.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/22172249/EP_GCF.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/22172249/EP_GCF-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>The pharmaceutical industry is increasingly focusing on integrating Green and Sustainable Chemistry into manufacturing processes and supply chains. Moving from sustainability commitments to practical implementation requires collaboration, innovation, and industry-wide knowledge sharing.</span></p>
<p><span>To advance this dialogue, Green ChemisTree Foundation (GCF) is organising the 5th Conference & Exhibition on “Advancing Implementation of Green & Sustainable Chemistry in the Pharma Supply Chain”, from 27–29 October 2026 at Hotel Trident, Hyderabad.</span></p>
<p><b>Over a decade of pharma-specific engagement</b></p>
<p><span>GCF has been working to promote Green Chemistry and Green Engineering in the pharmaceutical and API sector since 2012, through industry seminars, conferences, leadership roundtables, and direct engagement with pharmaceutical companies.</span></p>
<p><span>Key milestones include a dedicated seminar for BDMA, Hyderabad, in 2012; a pharma industry awareness seminar in collaboration with the Department of Pharmaceuticals, Government of India, and Telangana State Pollution Control Board in 2015, which brought together 152 pharma delegates; and a 2017 conference on Green & Sustainable Pharma Supply Chains, followed by a Pharma CEO Roundtable and engagement between the ACS Green Chemistry Institute Pharma Roundtable and Indian pharmaceutical companies.</span></p>
<p><span>In 2022, GCF organised a virtual Conference & EXPO that engaged 200+ pharma delegates from across India. Building on this sustained journey, the 2026 conference aims to further advance implementation-focused discussions across the pharmaceutical supply chain.</span></p>
<p><b>Advancing collaboration and implementation</b></p>
<p><span>The upcoming conference will focus on four key themes:</span></p>
<ul>
<li aria-level="1"><span>Green Chemistry Tools for Process Research</span></li>
<li aria-level="1"><span>People, Process & Plant Safety</span></li>
<li aria-level="1"><span>Emerging Green & Sustainable Technologies</span></li>
<li aria-level="1"><span>Environmental Sustainability Management</span></li>
</ul>
<p><span>The event will feature a Leadership Summit on 27 October and 4 Technical Sessions on the above themes on 28</span><span>th</span><span> and 29</span><span>th</span><span> October, networking opportunities, and an exhibition showcasing innovative solutions relevant to the pharmaceutical sector.</span></p>
<p><span>GCF gratefully acknowledges the continued support and partnership of ACS-GCIPR (American Chemical Society – Green Chemistry Institute Pharmaceutical Roundtable) in advancing the green chemistry agenda within the pharmaceutical industry. This collaboration highlights the importance of connecting industry expertise, international knowledge, and practical innovation to promote sustainable pharmaceutical manufacturing.</span></p>
<p><span>The conference invites pharmaceutical industry leaders, API manufacturers, R&D professionals, technology providers, researchers, and sustainability practitioners to participate in this platform for knowledge exchange and collaboration.</span></p>
<p><b>Event details:</b></p>
<p><span><img src="https://s.w.org/images/core/emoji/17.0.2/72x72/1f4c5.png" alt="📅" class="wp-smiley"></span><span> 27–29 October 2026</span></p>
<p><span><img src="https://s.w.org/images/core/emoji/17.0.2/72x72/1f4cd.png" alt="📍" class="wp-smiley"></span><span> Hotel Trident, Hyderabad</span></p>
<p><span><img src="https://s.w.org/images/core/emoji/17.0.2/72x72/1f517.png" alt="🔗" class="wp-smiley"></span><span> Registration: </span><a href="https://greenchemistreefoundation.co.in/pharma-supply-chain-2026.php"><span>https://greenchemistreefoundation.co.in/pharma-supply-chain-2026.php </span></a></p>
<p><span>Register now and be part of the journey towards a more sustainable pharmaceutical industry.</span></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/gcf-organises-three-day-conference-on-advancing-green-sustainable-chemistry-in-the-pharma-supply-chain/">GCF organises three day conference on ‘Advancing green & sustainable chemistry in the pharma supply chain’</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>BDR Pharmaceuticals International appoints Niral Bhatt as CHRO</title>
<link>https://edusehat.com/en/bdr-pharmaceuticals-international-appoints-niral-bhatt-as-chro</link>
<guid>https://edusehat.com/en/bdr-pharmaceuticals-international-appoints-niral-bhatt-as-chro</guid>
<description><![CDATA[ 
BDR Pharmaceuticals International Pvt Ltd has announced the appointment of Niral Bhatt as Chief Human Resources Officer (CHRO), strengthening its leadership team and focus on people and organisational development. In his new role, Bhatt will spearhead initiatives aimed at fostering a proactive and progressive work culture through a range of organisational development (OD) and human […]
The post BDR Pharmaceuticals International appoints Niral Bhatt as CHRO appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/22172805/EP_Niral-Bhatt.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 22 Sep 2026 20:20:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>BDR, Pharmaceuticals, International, appoints, Niral, Bhatt, CHRO</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/22172805/EP_Niral-Bhatt.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/22172805/EP_Niral-Bhatt.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/22172805/EP_Niral-Bhatt-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p>BDR Pharmaceuticals International Pvt Ltd has announced the appointment of Niral Bhatt as Chief Human Resources Officer (CHRO), strengthening its leadership team and focus on people and organisational development.</p>
<p>In his new role, Bhatt will spearhead initiatives aimed at fostering a proactive and progressive work culture through a range of organisational development (OD) and human resources interventions. He will focus on strengthening people practices and aligning HR strategies with the organisation’s business objectives.</p>
<p>Bhatt brings nearly 20 years of experience across human resources and people management. Prior to joining BDR Pharmaceuticals International Pvt Ltd, he was associated with the Zydus Group for 13 years, where he served as General Manager, HR. During his tenure, he was responsible for key areas including talent management and development, employee well-being, learning and development, performance management, and evolving HR strategies aligned with business needs.</p>
<p>Over the course of his career, Bhatt has held HR roles across leading organisations, including the Aditya Birla Group, Larsen & Toubro, Café Coffee Day and Future Group India, among others.</p>
<p>With his extensive experience spanning talent management, organisational development and strategic HR, Bhatt is expected to play a key role in strengthening BDR Pharmaceuticals’ people-centric approach and building a progressive workplace culture.</p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/bdr-pharmaceuticals-international-appoints-niral-bhatt-as-chro/">BDR Pharmaceuticals International appoints Niral Bhatt as CHRO</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>India’s biotech self&#45;reliance moment </title>
<link>https://edusehat.com/en/indias-biotech-self-reliance-moment</link>
<guid>https://edusehat.com/en/indias-biotech-self-reliance-moment</guid>
<description><![CDATA[ 
For much of the past two decades, global biotech leadership has clustered around a handful of hubs, each anchored by patient capital, deep research infrastructure and institutions capable of turning early science into approved medicines. That map is being redrawn. Regulators are rethinking what counts as valid preclinical evidence, global supply chains for research services […]
The post India’s biotech self-reliance moment  appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/22111953/ARUN.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 22 Sep 2026 16:25:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>India’s, biotech, self-reliance, moment </media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/22111953/ARUN.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/22111953/ARUN.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/22111953/ARUN-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p dir="ltr"><span>For much of the past two decades, global biotech leadership has clustered around a handful of hubs, each anchored by patient capital, deep research infrastructure and institutions capable of turning early science into approved medicines. That map is being redrawn. Regulators are rethinking what counts as valid preclinical evidence, global supply chains for research services are shifting, and the definition of a valuable biotech asset is expanding to include the data and platforms behind a drug, not only the drug itself. </span></p>
<p dir="ltr"><span>India sits at the center of this redrawing, with a genuine chance to build real strength in oncology innovation rather than simply supply services to hubs built elsewhere. This opportunity comes at a time when India’s bio economy has grown from around US$10 billion in 2014 to US$195.3 billion in 2025, contributing nearly 4.8 per cent to the country’s GDP, with the government targeting a $300 billion bio economy by 2030. Oncology, given the scale of unmet need, is where that opportunity is sharpest. Realising it will mean learning deliberately from the hubs that came before while building an approach suited to India’s own strengths. </span></p>
<p dir="ltr"><span>What global biotech leaders have done right </span></p>
<p dir="ltr"><span>The world’s leading biotech ecosystems did not emerge overnight. They were built through sustained investment, supportive regulation, and close collaboration between research institutions, healthcare systems and industry. </span></p>
<p dir="ltr"><span>For example, the US built its biotech ecosystem through sustained public investment in basic research, supported by institutions such as the NIH, alongside venture capital willing to back science-led companies through long development cycles. Innovation clusters such as Boston-Cambridge illustrate the advantages of bringing universities, hospitals, startups and pharmaceutical companies together. Regulatory evolution has reinforced this ecosystem, with the FDA increasingly recognising New Approach Methodologies (NAMs) as valid evidence for investigational new drug (IND)-enabling studies. China followed a different but equally deliberate path. By treating biotechnology as a strategic national priority, it rapidly expanded manufacturing, contract research and translational capabilities while creating an environment that encouraged companies to move beyond service delivery and develop original therapies. Although India cannot replicate either model, both underline the importance of patient capital, regulatory support and sustained collaboration across the innovation ecosystem. Why this is India’s moment These lessons are becoming particularly relevant as several global developments converge in India’s favor. The FDA’s growing acceptance of NAMs is encouraging wider adoption of human-relevant preclinical models, while the newly enacted US BIOSECURE Act – signed into law in December 2025 – is prompting pharmaceutical companies to actively reassess portions of their research supply chains across Asia. Together, these shifts are creating demand for trusted research partners capable of delivering compliant, high-quality preclinical evidence. </span></p>
<p dir="ltr"><span>This evolving landscape presents India with a significant opportunity to strengthen its role in the global preclinical research ecosystem. The country already has many of the essential building blocks in place, including scientific talent, ICMR-compliant ethical frameworks, FDA-aligned quality standards, and an extensive network of hospitals and research institutions capable of generating high-quality, consented biological data at competitive costs. This foundation is further reinforced by a rapidly expanding biotechnology ecosystem, with 11,800 registered biotech startups in 2025. The continued growth of this ecosystem reflects stronger support from research institutions, incubators and industry partnerships, creating an environment that is increasingly conducive to scientific innovation and commercialisation. </span></p>
<p dir="ltr"><span>Building indigenous AI-driven oncology innovation </span></p>
<p dir="ltr"><span>Having the right scientific ecosystem, however, is only the starting point. The next challenge is converting these strengths into differentiated innovation, and artificial intelligence is becoming central to that effort. The quality of AI-driven oncology research depends increasingly on the biological data used to train it. While traditional models such as two-dimensional cell lines, animal studies and archived tumour samples have advanced cancer research significantly, they are increasingly being complemented by more human-relevant evidence that better reflects the complexity of disease. </span></p>
<p dir="ltr"><span>India has an opportunity to build a differentiated approach centered on fresh human tumour tissue that preserves native tumour architecture and immune interactions. Emerging platforms can generate fresh tissue, three dimensional tumour models and multi-modal molecular analysis from a single patient sample for around $950 to $1,500, compared with $20,000-30,000 for a comparable package in Western markets. Combined with India’s clinical diversity, scientific expertise and cost-efficient research ecosystem, this creates the potential to build high-quality biological datasets at scale, strengthening both AI-driven drug discovery and global research partnerships. </span></p>
<p dir="ltr"><span>Translational research and collaboration must go together </span></p>
<p dir="ltr"><span>Scientific discovery creates value only when it reaches patients. Translational research bridges this gap by connecting laboratory findings with clinical application. India already has important foundations through institutions such as the Centre for Cellular and Molecular Platforms, the National Centre for Biological Sciences and an expanding network of hospitals capable of supporting ethically governed fresh-tissue research. </span></p>
<p dir="ltr"><span>Scaling this ecosystem will require stronger collaboration across academia, healthcare, industry and government. Shared standards for tissue procurement, chain of custody and data governance, alongside initiatives such as BIRAC’s BioE3 Bio-AI Hub, the Government of India’s Research, Development and Innovation (RDI) Fund and international collaborations, can accelerate the movement of discoveries from research laboratories to clinical development while strengthening India’s long-term innovation capacity. Building these capabilities is not simply a scientific objective. Increasingly, it is also becoming a commercial advantage. </span></p>
<p dir="ltr"><span>Rewarding innovation platforms </span></p>
<p dir="ltr"><span>Recent transactions demonstrate that global pharmaceutical companies increasingly value the technologies behind drug discovery as much as the therapies themselves. Deals involving AI foundation models, proprietary datasets and computational discovery platforms, including transactions by GSK, Takeda and Eli Lilly, show that platform capabilities have become commercially valuable assets in their own right. GSK’s January 2026 partnership with Noetik, for example, committed $50 million upfront plus recurring annual licensing fees to access AI foundation models trained on large-scale human tumour data – a five-year agreement that treats the model itself, rather than any single molecule, as the licensed asset. </span></p>
<p dir="ltr"><span>For India, this represents an important strategic shift. The opportunity extends beyond discovering individual drug candidates to building proprietary datasets, AI-enabled platforms and translational capabilities that attract global partnerships while supporting home-grown innovation. Equally important, scientific credibility must continue to be built through rigorous validation, transparent reporting and evidence-based progress. </span></p>
<p dir="ltr"><span>Looking ahead </span></p>
<p dir="ltr"><span>India stands at an important inflection point. Regulatory change, geopolitical realignment and advances in AI are reshaping where oncology innovation can emerge. Combined with India’s scientific talent, clinical depth and growing research infrastructure, these developments create an opportunity to move beyond being a global research services provider towards becoming a center for original biomedical innovation. </span></p>
<p> </p>
<p dir="ltr"><span>The path is not without real obstacles. Chronic shortages of patient capital, and still-maturing standards for data governance and tissue chain-of-custody, remain genuine constraints on turning these building blocks into sustained innovation. Realising that ambition will require sustained investment in indigenous R&D, stronger translational research capabilities and deeper alignment between researchers, clinicians, industry and policymakers. If these elements come together, India will not simply participate in the next generation of oncology innovation but help define it. </span></p>
<p>The post <a href="https://www.expresspharma.in/indias-biotech-self-reliance-moment/">India’s biotech self-reliance moment </a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Lex Witness announces 12th Annual Pharmaceutical Legal &amp;amp; Compliance Summit 2026</title>
<link>https://edusehat.com/en/lex-witness-announces-12th-annual-pharmaceutical-legal-compliance-summit-2026</link>
<guid>https://edusehat.com/en/lex-witness-announces-12th-annual-pharmaceutical-legal-compliance-summit-2026</guid>
<description><![CDATA[ 
Like previous editions, the Summit will focus on practical perspectives, peer learning and candid dialogue rather than conventional conference-style discussions.
The post Lex Witness announces 12th Annual Pharmaceutical Legal &amp; Compliance Summit 2026 appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/22102408/Untitled-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 22 Sep 2026 12:50:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Lex, Witness, announces, 12th, Annual, Pharmaceutical, Legal, Compliance, Summit, 2026</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/22102408/Untitled-1.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="Lex Witness Pharma Legal & Compliance Summit 2026" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/22102408/Untitled-1.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/22102408/Untitled-1-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p>Lex Witness is set to host the 12th Annual Pharmaceutical Legal & Compliance Summit 2026 on Friday, October 9, 2026 at Taj Santacruz, Mumbai, bringing together some of the most prominent voices from India’s pharmaceutical, life sciences, legal and compliance ecosystem.</p>
<p>Now in its 12th year, the Summit has grown into a specialised industry platform for General Counsels, Chief Legal Officers, Heads of Legal, Compliance and Regulatory Affairs, senior corporate leaders, law firm partners and subject-matter experts to engage on the legal and regulatory issues directly impacting the pharmaceutical and life sciences sector. <em>Express Pharma</em> is a media partner for this year’s Summit.</p>
<p>The 2026 edition will feature practitioner-led conversations around the evolving regulatory and compliance environment, governance and enforcement, intellectual property, technology and data, contracting, investigations, disputes and emerging business risks. The emphasis will remain on practical perspectives, peer learning and candid dialogue rather than conventional conference-style discussions.</p>
<p>Commenting on the journey of the Summit, Bhupinder Kaur Minhas, Sr. Manager Brand Innovation, Lex Witness, said,“When we began building this platform 12 years ago, the idea was to create a dedicated space where the pharmaceutical sector’s legal, regulatory, IPR and compliance leadership could have conversations that were relevant to their businesses. Over the years, we have consciously built the summit around the community – listening to the issues that matter to them, bringing the right voices into the room and allowing the dialogue to evolve with the sector. It is extremely rewarding to see it emerge as one of the preferred legal dialogues for the pharmaceutical, healthcare, medtech and life sciences industry, and the 12th Annual Edition is about taking that engagement even further.”</p>
<p>With limited seats available for the invitation-led gathering, registrations are now open. Early Bird and Group Registration benefits of up to 25 per cent are currently available for eligible registrations.</p>
<p>Lex Witness is also inviting speaking interests from senior legal, compliance, regulatory, business and domain leaders who can contribute meaningfully to the Summit’s conversations. Organisations looking to engage with this focused community can also explore a limited number of sponsorship and partnership opportunities for the 12th Annual Edition.</p>
<p>The Summit will combine high-quality content with curated networking, enabling participants to exchange perspectives with peers and build meaningful connections across the pharmaceutical and life sciences legal ecosystem.</p>
<p>For participation opportunities, visit <a href="http://www.plcs.co.in/">www.plcs.co.in</a></p>
<p>The post <a href="https://www.expresspharma.in/lex-witness-announces-12th-annual-pharmaceutical-legal-compliance-summit-2026/">Lex Witness announces 12th Annual Pharmaceutical Legal & Compliance Summit 2026</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Andelyn Biosciences begins commercial manufacturing of FDA&#45;Approved Fayuvi Gene Therapy </title>
<link>https://edusehat.com/en/andelyn-biosciences-begins-commercial-manufacturing-of-fda-approved-fayuvi-gene-therapy</link>
<guid>https://edusehat.com/en/andelyn-biosciences-begins-commercial-manufacturing-of-fda-approved-fayuvi-gene-therapy</guid>
<description><![CDATA[ 
Andelyn Biosciences, a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (“CDMO”), announced that it is now manufacturing Fayuvi (rebisufligene etisparvovec-hopf), an FDA-approved gene therapy, for commercial supply at its Columbus, Ohio facility. The announcement follows the US Food and Drug Administration’s approval of Ultragenyx Pharmaceutical Inc.’s Fayuvi for the treatment […]
The post Andelyn Biosciences begins commercial manufacturing of FDA-Approved Fayuvi Gene Therapy  appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/06/25113229/us-fda-approval-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 22 Sep 2026 12:50:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Andelyn, Biosciences, begins, commercial, manufacturing, FDA-Approved, Fayuvi, Gene, Therapy </media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/06/25113229/us-fda-approval-1.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/06/25113229/us-fda-approval-1.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/06/25113229/us-fda-approval-1-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>Andelyn Biosciences, a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (“CDMO”), announced that it is now manufacturing Fayuvi (rebisufligene etisparvovec-hopf), an FDA-approved gene therapy, for commercial supply at its Columbus, Ohio facility. The announcement follows the US Food and Drug Administration’s approval of Ultragenyx Pharmaceutical Inc.’s Fayuvi for the treatment of Sanfilippo syndrome type A, also known as mucopolysaccharidosis type IIIA (MPS IIIA).</span></p>
<p><span>The approval is a significant milestone for the MPS IIIA community and for families affected by the disease, and it reflects the sustained commitment of the Ultragenyx team, clinical investigators, patient advocates, and others who helped advance the program.</span></p>
<p><span>Sanfilippo syndrome type A (MPS IIIA) is a rare, fatal lysosomal storage disease that primarily affects the central nervous system (CNS) and is marked by rapid neurodegeneration beginning in early childhood. MPS IIIA is estimated to affect 3,000 to 5,000 patients worldwide, with a median life expectancy of 15 years.</span></p>
<p><span>Fayuvi is the first FDA-approved gene therapy manufactured using the Andelyn AAV Curator Platform process. Its commercial manufacturing at Andelyn’s Columbus facility reflects the disciplined process development, scientific and quality systems rigor, and cross-functional execution required to bring a gene therapy program to market.</span></p>
<p><span>“We congratulate Ultragenyx on this significant achievement and recognize the MPS IIIA community, investigators, and everyone who contributed to advancing this program,” said Wade Macedone, Chief Executive Officer of Andelyn Biosciences. “We are proud to manufacture an FDA-approved gene therapy for commercial use using an AAV Curator Platform process. This milestone reflects the purpose behind Andelyn’s founding and underscores the importance of building commercial readiness through rigorous science, accountable execution, and quality at every stage. We look forward to supporting our other late-stage clients and the industry with our FDA-stamped commercial capabilities.”</span></p>
<p><span>Andelyn’s AAV Curator Platform uses a configurable, data-informed approach to AAV process development and manufacturing. It integrates process knowledge, modular manufacturing strategies, and fit-for-purpose analytics to support gene therapy programs from development through commercial launch.</span></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/andelyn-biosciences-begins-commercial-manufacturing-of-fda-approved-fayuvi-gene-therapy/">Andelyn Biosciences begins commercial manufacturing of FDA-Approved Fayuvi Gene Therapy </a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Telix to acquire ITM in deal worth up to $2.35bn</title>
<link>https://edusehat.com/en/telix-to-acquire-itm-in-deal-worth-up-to-235bn</link>
<guid>https://edusehat.com/en/telix-to-acquire-itm-in-deal-worth-up-to-235bn</guid>
<description><![CDATA[ The Australian company will pay $1.65bn upfront on a cash-free, debt-free basis. An additional $700m may be payable if ITM-11 meets specified regulatory approval and sales milestones. The 
The post Telix to acquire ITM in deal worth up to $2.35bn appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/09/PT-2-21-09-2026-shutterstock_2839676471.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 21 Sep 2026 20:35:13 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Telix, acquire, ITM, deal, worth, 2.35bn</media:keywords>
<content:encoded><![CDATA[<p>The Australian company will pay $1.65bn upfront on a cash-free, debt-free basis. An additional $700m may be payable if ITM-11 meets specified regulatory approval and sales milestones.</p>
<p>The upfront consideration includes $1.25bn to be paid through 105.8m Telix shares, priced at $11.841 each using the 30-day trailing volume-weighted average price at signing.</p>
<p>The shares will be released as Nasdaq-listed American depositary receipts (ADRs) after applicable escrow periods.</p>
<p>Telix will also assume $302m of ITM net debt at closing, alongside $96m of management equity rollover and transaction expenses payable by sellers, subject to closing adjustments.</p>
<p>ITM shareholders are expected to hold about 23.7% of Telix shares after completion, while existing Telix shareholders would own about 76.3%.</p>
<p>Telix’s board has approved the transaction, and shareholders holding more than 90% of ITM shares had approved it at signing.</p>
<p>ITM produced $273m in revenue in 2025 and reported a compound annual growth rate of 40% from 2021 to 2025.</p>
<p>The privately held company, founded in 2004, manufactures radioisotopes including actinium-225, lutetium-177 and terbium-161, and has a distribution network covering more than 65 countries.</p>
<p>Its pipeline includes ITM-11, also known as lutetium-177 edotreotide, which is being developed for gastro-enteropancreatic neuroendocrine tumours.</p>
<p>The candidate has completed its primary Phase III clinical development programme, including the COMPETE and COMPOSE trials.</p>
<p>Contingent payments include up to $250m for US Food and Drug Administration (FDA) approvals across three indications, subject to stated deadlines, and up to $450m based on ITM-11 global net sales exceeding $150m in the 2030 financial year.</p>
<p>Telix may pay the milestone consideration in cash or shares.</p>
<p>Telix managing director and group CEO Dr Christian Behrenbruch said: “This merger positions Telix at the forefront of the consolidation that is occurring as the industry matures.</p>
<p>“ITM is the leader in radioisotope production, with deep scientific expertise and a track record of value-adding innovation.</p>
<p>“We have enjoyed a close working relationship with ITM for many years, and there is strong management alignment for the rationale behind this transaction.”</p>
<p>The deal is expected to close by the end of the 2026 financial year, subject to Telix shareholder and regulatory approvals. Telix expects to hold an extraordinary general meeting in November 2026.</p>
<p>In July this year, Telix Pharmaceuticals officially opened a radiopharmaceutical research, manufacturing, and treatment facility in Melbourne, Australia, to expedite the delivery of new treatments for cancer.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/telix-to-acquire-itm/">Telix to acquire ITM in deal worth up to $2.35bn</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Sandoz and mAbxience agree on emicizumab biosimilar partnership</title>
<link>https://edusehat.com/en/sandoz-and-mabxience-agree-on-emicizumab-biosimilar-partnership</link>
<guid>https://edusehat.com/en/sandoz-and-mabxience-agree-on-emicizumab-biosimilar-partnership</guid>
<description><![CDATA[ The candidate is in early-stage development and references Hemlibra (emicizumab), a medicine used to treat patients with haemophilia A. The companies said the reference medicine has estimated global 
The post Sandoz and mAbxience agree on emicizumab biosimilar partnership appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/09/PT-21-09-2026-shutterstock_2141389237.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 21 Sep 2026 20:35:13 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Sandoz, and, mAbxience, agree, emicizumab, biosimilar, partnership</media:keywords>
<content:encoded><![CDATA[<p>The candidate is in early-stage development and references Hemlibra (emicizumab), a medicine used to treat patients with haemophilia A. The companies said the reference medicine has estimated global sales of $5.7bn.</p>
<p>Under the agreement, mAbxience will develop and manufacture the proposed biosimilar at its good manufacturing practice (GMP)-approved facilities in Argentina and Spain.</p>
<p>Sandoz will receive exclusive global commercialisation rights, excluding Argentina, Paraguay and Uruguay. The financial terms were not disclosed.</p>
<p>The agreement is said to be the first haemophilia medicine in Sandoz’s biosimilar pipeline. It also expands mAbxience’s rare-disease portfolio to include haemophilia A.</p>
<p>Haemophilia A is a genetic disorder caused by insufficient or defective factor VIII, a blood-clotting protein. It represents 80% of haemophilia cases worldwide, according to the companies.</p>
<p>mAbxience CEO Jurgen Van Broeck said: “This agreement with Sandoz represents a significant recognition of mAbxience’s development and manufacturing platform and the expertise of our teams.</p>
<p>“This agreement combines our capabilities with Sandoz’s global biosimilars reach and provides a clear pathway to broaden access to treatment for patients living with haemophilia A.</p>
<p>“It also reinforces our strategy of combining world-class development and manufacturing capabilities with selected commercial partnerships that can help accelerate patient access to high-quality biologic medicines worldwide.”</p>
<p>Based in Spain, mAbxience is majority-owned by Fresenius Kabi, with Insud Pharma holding a partial stake. The company develops, produces and commercialises biopharmaceuticals.</p>
<p>The company has three approved products and operates in more than 100 markets via a business-to-business model. It has over 40 partners and more than 1,300 employees.</p>
<p>Its biosimilar pipeline includes products across bone diseases, immunology, oncology and other speciality care areas. mAbxience also provides contract development and manufacturing services.</p>
<p>Last month, Sandoz entered a collaboration agreement with Shanghai Henlius Biotech to work on new biosimilars.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/sandoz-mabxience-emicizumab-biosimilar/">Sandoz and mAbxience agree on emicizumab biosimilar partnership</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>How pharma is charting a greener path to growth </title>
<link>https://edusehat.com/en/how-pharma-is-charting-a-greener-path-to-growth</link>
<guid>https://edusehat.com/en/how-pharma-is-charting-a-greener-path-to-growth</guid>
<description><![CDATA[ 
The conversation around environmental sustainability in the pharma industry is now expanding beyond the traditional boundaries of the compliance department. For years, the life sciences sector treated sustainability largely as a peripheral function, focusing primarily on meeting local waste management rules, running safety checklists, and fulfilling regulatory mandates. Today, industry leaders are viewing it as […]
The post How pharma is charting a greener path to growth  appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/21140559/EP_Pramuch-Goel.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 21 Sep 2026 20:35:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>How, pharma, charting, greener, path, growth </media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/21140559/EP_Pramuch-Goel.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/21140559/EP_Pramuch-Goel.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/21140559/EP_Pramuch-Goel-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>The conversation around environmental sustainability in the pharma industry is now expanding beyond the traditional boundaries of the compliance department. For years, the life sciences sector treated sustainability largely as a peripheral function, focusing primarily on meeting local waste management rules, running safety checklists, and fulfilling regulatory mandates. Today, industry leaders are viewing it as a core business strategy that is central to competitiveness, risk management, operational resilience, brand reputation, and long-term value creation </span></p>
<p><span>This changing industry outlook is becoming increasingly important as the sector begins to confront the scale of its environmental footprint. Making medicines is far more resourceintensive than most people realise. Data from a recent study published in The Lancet Planetary Health shows that the pharma sector’s direct emissions intensity is around 60 per cent higher than healthcare services, and nearly 80 per cent higher when total emissions are considered. At the same time, the industry’s greenhouse gas footprint is growing faster than both healthcare services and the global average. </span></p>
<p><span>The urgency around this challenge is only compounding as the industry continues to expand. The global pharma market is on track to cross $2.8 trillion by 2033, while India’s pharma sector alone is projected to surpass $130 billion by 2030. Therefore, the sector has the responsibility to scale commercial growth in a way that also reduces its environmental footprint and preserves the ecosystems that sustain both manufacturing operations and long-term public health. </span></p>
<p><span>Many leading pharma companies and contract research, development, and manufacturing organisations (CRDMOs) are responding proactively by accelerating the adoption of green technologies to align with changing client and regulatory expectations. Manufacturers are actively seeking greener alternatives for hazardous reagents, solvents, and chemicals. By overcoming traditional technical barriers and embedding the core principles of reducing, reusing, and recycling directly into waste management loops, labs and manufacturing facilities are establishing clear actions for carbon emission reduction. This includes department-level self-assessments of carbon dioxide output and the integration of rigorous environment, occupational health, safety, and sustainability (EHSS) management systems, which builds deeper trust with stakeholders, including governments, communities, partners, and employees. </span></p>
<p><span>Beyond materials and chemistry, energy utilisation has emerged as a critical area where sustainability directly dictates business performance. Because pharma manufacturing plants run on continuous, 24-hour operating cycles, they are acutely vulnerable to rising power tariffs and grid instability. However, by investing in captive power capabilities, particularly green energy assets, companies are securing both supply continuity and cost insulation. This establishes a clear, undeniable business case: sustainability is not merely an exercise in corporate altruism, but a powerful lever for profitability. Across the broader pharma value chain, locking in long-term renewable energy contracts allows manufacturers to mitigate emissions while simultaneously stabilising operating expenditures. This operational predictability is what ultimately protects production timelines, safeguards supply continuity and stabilises pricing. </span></p>
<p><span>A similar business impact is playing out in the realm of water management, where resource conservation has rapidly evolved into a high-stakes risk-management issue. Highpurity water is the absolute lifeblood of medicine formulation and sterile equipment cleaning; yet a significant portion of global manufacturing capacity is concentrated in regions already grappling with acute water scarcity. At Syngene, we recognise that resource depletion poses a risk to operational continuity. We are investing in zero-liquid discharge (ZLD) technologies and closed-loop water purification infrastructure to enhance water security and sustainability across our operations. By recycling and reusing industrial wastewater on-site, these systems significantly reduce dependence on municipal freshwater sources, helping ensure uninterrupted manufacturing operations even during periods of water scarcity. </span></p>
<p><span>As organisations globally realise that sustainability yields broader business resilience, they are looking beyond their own factory walls to audit their entire value chain. Global pharma innovators are leading this charge, committing to greenhouse gas reductions that explicitly include their supplier networks under Science Based Targets initiative (SBTi) Scope 3 mandates. Because indirect emissions from raw material sourcing, outsourced manufacturing, and logistics often represent the lion’s share of a pharma multinational’s total carbon footprint, environmental transparency is no longer an optional procurement metric. Instead, sustainability has become a decisive factor in vendor selection, weighted alongside traditional benchmarks like scientific capability, regulatory track records, delivery reliability, and cost. This paradigm shift creates a powerful cascading effect: suppliers must adopt rigorous, sustainable operating models simply to qualify as preferred partners for global drug innovators. </span></p>
<p><span>This rigorous corporate scrutiny is being mirrored closely in the capital markets, where institutional investors have stopped treating environmental reporting as an optional footnote in the annual report. Today, climate risks, resource dependencies, and carbon liabilities are analysed as leading indicators of a company’s longterm financial viability. To command premium valuations and optimise their cost of capital, pharma boards are bringing sustainability directly into corporate governance. This capital market pressure is accelerating the adoption of strict, auditable reporting frameworks, ensuring that environmental performance data is processed with the same accuracy, granularity, and trustworthiness as traditional financial accounting. </span></p>
<p><span>The Indian pharma sector has been at the forefront of the sustainability transition, adopting best practices to align its production capacity with global eco-standards. This green transition is creating competitive advantage for India’s contract manufacturing sector, which has developed a global reputation for scientific talent, scale, and cost efficiencies. By embedding sustainable engineering, transparent life-cycle tracking, and low-emission production into their core value proposition, Indian contract manufacturers are strengthening their positioning, transitioning from service providers to long-term strategic partners for global innovators. Over the coming decade, leadership in the life sciences world will be redefined by the ability to scale responsibly through resilient, circular operations. For India’s pharma ecosystem, this transformation offers an opportunity to move beyond its identity as a high-volume manufacturing hub and emerge as a global model for sustainable, highvalue pharma production. </span></p>
<p>The post <a href="https://www.expresspharma.in/how-pharma-is-charting-a-greener-path-to-growth/">How pharma is charting a greener path to growth </a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Akums announces DCGI&#45;approved triple therapy for H. pylori infection</title>
<link>https://edusehat.com/en/akums-announces-dcgi-approved-triple-therapy-for-h-pylori-infection</link>
<guid>https://edusehat.com/en/akums-announces-dcgi-approved-triple-therapy-for-h-pylori-infection</guid>
<description><![CDATA[ 
Akums Drugs &amp; Pharmaceuticals has announced the development of a DCGI-approved Clarithromycin + Vonoprazan + Amoxicillin Combikit for the treatment of Helicobacter pylori (H. pylori) infection in adults. The development is part of the company’s ongoing work in pharmaceutical formulation and reflects the growing focus within healthcare on treatment approaches that consider both therapeutic requirements […]
The post Akums announces DCGI-approved triple therapy for H. pylori infection appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/07/21134006/approved-logo.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 21 Sep 2026 20:35:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Akums, announces, DCGI-approved, triple, therapy, for, pylori, infection</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/07/21134006/approved-logo.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/07/21134006/approved-logo.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/07/21134006/approved-logo-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p>Akums Drugs & Pharmaceuticals has announced the development of a DCGI-approved Clarithromycin + Vonoprazan + Amoxicillin Combikit for the treatment of Helicobacter pylori (H. pylori) infection in adults.</p>
<p>The development is part of the company’s ongoing work in pharmaceutical formulation and reflects the growing focus within healthcare on treatment approaches that consider both therapeutic requirements and the practical aspects of completing a prescribed regimen.</p>
<p>H. pylori infection is associated with chronic gastritis and peptic ulcer disease and is recognised as an important risk factor for gastric cancer. Effective eradication of the infection is therefore an important therapeutic objective and can help reduce infection-related complications.</p>
<p>The combikit combines Vonoprazan, a potassium-competitive acid blocker (P-CAB), with Clarithromycin and Amoxicillin. Vonoprazan provides sustained suppression of gastric acid secretion, while the two antibiotics provide complementary antibacterial action against H. pylori. The prescribed regimen involves twice-daily dosing over a period of 14 days.</p>
<p>The formulation brings the three components together in an organised treatment pack containing Clarithromycin 500 mg, Vonoprazan 20 mg and Amoxicillin 1000 mg. The formulation also provides the full 1000 mg dose of Amoxicillin in one tablet.</p>
<p>Sanjeev Jain, Managing Director, Akums Drugs & Pharmaceuticals said, “Pharmaceutical innovation increasingly needs to consider the complete treatment journey. While scientific development and therapeutic effectiveness remain central, the practical experience of patients undergoing treatment is also an important consideration. Convenience, clarity and the ability to follow a prescribed regimen can influence how treatment is experienced in everyday life. Our work in formulation development is guided by the need to address evolving healthcare requirements through appropriate scientific and pharmaceutical solutions.</p>
<p>Sandeep Jain, Managing Director, Akums Drugs & Pharmaceuticals said, “Developments such as this are enabled by a strong and integrated pharmaceutical ecosystem, where research, formulation development, quality systems and advanced manufacturing capabilities work together. Our focus has been on building capabilities across the pharmaceutical value chain that can support the development and manufacturing of increasingly specialised formulations. A robust manufacturing ecosystem, supported by scientific expertise, is essential to translating pharmaceutical innovation from the development stage into scalable products for the market.”</p>
<p>The announcement comes at a time when the pharmaceutical industry is placing greater emphasis on patient-centred approaches to healthcare. In combination therapies, the organisation and administration of treatment can be an important consideration alongside the therapeutic properties of individual medicines.</p>
<p>For Akums, this development reflects its continued focus on advancing innovative pharmaceutical solutions through its integrated capabilities across research, formulation development, quality and manufacturing. As healthcare requirements continue to evolve, the company remains focused on developing differentiated and innovative formulations across therapeutic areas, leveraging scientific expertise and advanced pharmaceutical technologies to address the needs of pharmaceutical partners, healthcare providers and patients. Going forward, Akums will continue to strengthen its innovation-led approach, translating research and formulation expertise into scalable pharmaceutical solutions that can support evolving healthcare needs.</p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/akums-announces-dcgi-approved-triple-therapy-for-h-pylori-infection/">Akums announces DCGI-approved triple therapy for H. pylori infection</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Biocon receives EMA CHMP approval for Pertuzumab biosimilar</title>
<link>https://edusehat.com/en/biocon-receives-ema-chmp-approval-for-pertuzumab-biosimilar</link>
<guid>https://edusehat.com/en/biocon-receives-ema-chmp-approval-for-pertuzumab-biosimilar</guid>
<description><![CDATA[ 
Biocon Biologics announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the granting of a marketing authorisation to its Pertuzumab biosimilar as 420 mg concentrate solution for infusion, under the brand name Pebrilzo, for the treatment of HER2-positive breast cancer across […]
The post Biocon receives EMA CHMP approval for Pertuzumab biosimilar appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/06/24134132/approved-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 21 Sep 2026 20:35:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Biocon, receives, EMA, CHMP, approval, for, Pertuzumab, biosimilar</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/06/24134132/approved-1.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/06/24134132/approved-1.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/06/24134132/approved-1-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p>Biocon Biologics announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the granting of a marketing authorisation to its Pertuzumab biosimilar as 420 mg concentrate solution for infusion, under the brand name Pebrilzo, for the treatment of HER2-positive breast cancer across multiple disease stages.</p>
<p>The positive opinion follows the review of the marketing authorization application submitted by Biocon Biologics Ireland Limited (formerly Biosimilar Collaborations Ireland Limited), an indirect wholly-owned subsidiary of Biocon Biologics Limited.</p>
<p>Shreehas Tambe, CEO & Managing Director, Biocon, said: “The positive CHMP opinion for our Pertuzumab biosimilar marks an important step toward expanding access to biologic therapies for patients with HER2-positive breast cancer in Europe. As the first monoclonal antibody biosimilar to receive a positive CHMP opinion under EMA’s tailored clinical development approach, it reflects an important milestone in the evolution of biosimilar science and greater regulatory confidence on advanced analytical and clinical pharmacology evidence to establish biosimilarity.”</p>
<p>The European Commission will now proceed with the final review of the application and issue its decision. Following a positive decision, the Summary of Product Characteristics (SmPC) will be available in all official European Union languages, while the European Public Assessment Report (EPAR) will be published on the EMA website in the weeks following the decision. Until marketing authorisation is granted by the European Commission, the product is not authorised for use in the European Union.</p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/biocon-receives-ema-chmp-approval-for-pertuzumab-biosimilar/">Biocon receives EMA CHMP approval for Pertuzumab biosimilar</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Why pharma needs smarter decision&#45;making, not just more digital systems </title>
<link>https://edusehat.com/en/why-pharma-needs-smarter-decision-making-not-just-more-digital-systems</link>
<guid>https://edusehat.com/en/why-pharma-needs-smarter-decision-making-not-just-more-digital-systems</guid>
<description><![CDATA[ The pharmaceutical industry has invested heavily in digitisation over the past few years. What gaps in existing digital systems prompted the development of an operating system focused on decision-making rather than workflow automation?  Most people in this industry looked at the same landscape and saw a digitisation problem. I saw a different problem entirely. The […] ]]></description>
<enclosure url="https://www.expresspharma.in/wp-content/uploads/2026/09/EP_hari-kiran.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 21 Sep 2026 13:00:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Why, pharma, needs, smarter, decision-making, not, just, more, digital, systems </media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://www.expresspharma.in/wp-content/uploads/2026/09/EP_hari-kiran.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://www.expresspharma.in/wp-content/uploads/2026/09/EP_hari-kiran.jpg 750w, https://www.expresspharma.in/wp-content/uploads/2026/09/EP_hari-kiran-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><strong>The pharmaceutical industry has invested heavily in digitisation over the past few years. What gaps in existing digital systems prompted the development of an operating system focused on decision-making rather than workflow automation? </strong></p>
<p><span>Most people in this industry looked at the same landscape and saw a digitisation problem. I saw a different problem entirely. The industry did not lack systems. It lacked reasoning. </span></p>
<p><span>Every major digital investment in pharma over the past decade was built to answer one question: what happened? ERP, LIMS, CRM, extraordinary at recording. Built to tell you what occurred after it occurred. </span></p>
<p><span>Nobody built something that answers a different question: what should we do next and why? </span></p>
<p><span>That gap between recording and reasoning is what we saw. And that is what RIKO<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> was built to close. Not because we wanted to build technology. Because we needed it to run the business. </span></p>
<p><strong>RIKO is introduced as an AI-native pharmaceutical operating system built on operational intelligence. How do you validate the reliability and consistency of its recommendations in regulated environments where human accountability remains critical? </strong></p>
<p><span>We designed RIKO around one principle from day one, it recommends, humans decide. </span></p>
<p><span>Every output RIKO produces shows its work. Not just what it recommends but why, with the specific data points and their weights visible to the person making the decision. That person can agree, override, or challenge it. Every override is logged. Every reason is captured. </span></p>
<p><span>That audit trail is not a compliance afterthought. It is the point. Over time the pattern of where humans override RIKO tells us exactly where the model needs to improve. The human judgment does not just check RIKO, it trains RIKO. </span></p>
<p><span>On validation – we apply the same standard we apply to any analytical method in a GMP environment. You retrospectively test the system against historical outcomes. You document the accuracy. You set thresholds. You review it periodically. The industry has been doing this for computerised systems for decades under GAMP principles. An AI recommendation engine is not fundamentally different. It requires evidence that it does what it claims to do, consistently, within defined parameters. We treat that as a design requirement, not a burden. </span></p>
<p><strong>With regulators placing greater emphasis on data integrity, quality risk management and supply chain resilience, how do you see AI-driven decision support changing compliance practices across the pharmaceutical industry over the next five years? </strong></p>
<p><span>The shift that is coming is from reactive compliance to predictive compliance. And that is significant. </span></p>
<p><span>Today compliance in pharma is almost entirely retrospective. An inspection finds something that went wrong months ago. A warning letter documents a pattern that existed for years. A CAPA closes a deviation that already happened. The entire quality management architecture is built around responding to events after they occur. </span></p>
<p><span>What changes when you have continuous intelligence when a system is monitoring your supplier’s GMP certificate, inspection history, deviation patterns and regulatory alerts in real time is that you stop being surprised. You see the warning letter pattern before the warning letter arrives. You see the GMP risk before the audit. </span></p>
<p><span>Over five years I think three specific things happen. Regulators begin recognising continuous monitoring as a quality indicator in its own right. A company that can demonstrate real-time supply chain surveillance will be treated differently in an inspection than one relying on periodic audits. Second, data standards will emerge that allow intelligence to flow across company boundaries without compromising confidentiality. Third and this is what most people are not thinking about yet, the definition of a qualified supplier will start to include the supplier’s data connectivity. Can they give you what you need to monitor them continuously? If not, they are a higher-risk supplier by definition. </span></p>
<p><span>The companies investing in this infrastructure now will not just be better positioned. They will have set the standard everyone else has to catch up to. </span></p>
<p><strong>Many pharmaceutical companies struggle with fragmented data across manufacturing, quality, regulatory and commercial functions. What are the biggest barriers to creating an integrated decisionmaking framework, and how can companies overcome them? </strong></p>
<p><span>I will tell you what it is not. It is not the technology. The technology to integrate these systems has existed for years. The barriers are entirely human. </span></p>
<p><span>The first is data ownership politics. In most pharmaceutical organisations quality owns quality data, commercial owns commercial data, regulatory owns regulatory data. Each function treats its data as institutional territory. An integrated decision framework requires that data to cross those boundaries. That is a culture and governance problem, and it can only be solved from the top. If the CEO does not personally own the integration agenda it does not happen. </span></p>
<p><span>The second is what I call the single version of truth problem. When three different teams maintain three slightly different versions of the same product portfolio, different molecule names, different supplier codes, different filing statuses, no AI system can reason coherently across them. You have to fix the data before you can build the intelligence. That work is unglamorous and nobody wants to fund it, but it is the prerequisite for everything else. </span></p>
<p><span>The third is specific to regulated industries. People in pharma are conditioned to be conservative about change. An AI system influencing a compliance decision feels riskier than a spreadsheet doing the same thing, even when the AI is more accurate. You overcome that by starting with lowstakes, high-frequency decisions where people can build trust in the system before applying it to anything consequential. Trust is earned incrementally. You cannot shortcut it. </span></p>
<p><strong>The platform claims to predict quality and compliance risks, including nitrosamine-related concerns, at an early stage. How should the industry balance predictive technologies with established regulatory and quality assurance processes to ensure confidence in such systems? </strong></p>
<p><span>Predictive tools should trigger the regulatory process, not replace it. That distinction matters enormously and the industry needs to hold it firmly. </span></p>
<p><span>ICH M7 does not change because RIKO exists. What changes is when the risk is caught. Before the route is selected, not after the batch is manufactured. The regulatory process stays intact. It simply starts earlier. </span></p>
<p><span>The confidence question is straightforward. A model whose outputs are reviewed by a qualified person before any action is taken is a defensible tool in a regulated environment. What is not defensible is using predictive confidence to skip steps that exist for good reason. Low probability in a model is not the same as tested and confirmed. That line does not move. </span></p>
<p><strong>As AI becomes more deeply embedded in pharmaceutical operations, what governance frameworks including transparency, validation, cybersecurity and data ownership do you believe will be essential for wider industry adoption? </strong></p>
<p><span>Four things. And I will be direct about why each one matters. </span></p>
<p><span>Transparency first. Every AI output in a regulated context needs a visible reasoning trail: not a black box recommendation, but a documented chain from input to output with sources and weights visible. If someone asks why a decision was made, the answer cannot be the AI said so. It has to be the AI said so based on these specific inputs, reviewed and approved by this person, on this date. Design for that from day one. </span></p>
<p><span>Validation second. The GAMP principles the industry already uses for computerised system validation apply here. Validation rigor should match the risk of the decision being influenced. A screening tool that identifies molecules for commercial consideration needs different validation than a system influencing batch release. Proportionate, documented, periodically reviewed. </span></p>
<p><span>Cybersecurity third and this one is underestimated. Supply chain intelligence, regulatory filing data, commercial pricing: this data is valuable and it is increasingly targeted. The security architecture needs to match the commercial value of what the system knows. </span></p>
<p><span>Data ownership fourth and this will be the most contested question in the industry over the next five years. The industry needs to establish those principles now before the systems are sophisticated enough that the answer has large commercial consequences. Write the rules before anyone has broken them. </span></p>
<p><span>The principle underneath all four is simple. Governance is not there to restrict what AI can do. It is there to make what AI does trustworthy enough that the industry can rely on it. Restriction without trustworthiness is bureaucracy. Trustworthiness without governance is recklessness. You need both. </span><span><br>
</span><span><br>
</span></p>
<p><span></span></p>
<p><em><span>Kalyani.sharma@expressindia.com </span><span><br>
</span><span>journokalyani@gmail.com </span></em></p>]]> </content:encoded>
</item>

<item>
<title>Ona Therapeutics to develop ADC with WuXi’s payload&#45;linker platform</title>
<link>https://edusehat.com/en/ona-therapeutics-to-develop-adc-with-wuxis-payload-linker-platform</link>
<guid>https://edusehat.com/en/ona-therapeutics-to-develop-adc-with-wuxis-payload-linker-platform</guid>
<description><![CDATA[ The deal grants Ona Therapeutics rights to develop the ADC targeting a single undisclosed target. It includes an upfront payment from Ona Therapeutics to WuXi XDC, along with 
The post Ona Therapeutics to develop ADC with WuXi’s payload-linker platform appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/09/PT-2-18-09-2026-shutterstock_1912524379.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 18 Sep 2026 19:10:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Ona, Therapeutics, develop, ADC, with, WuXi’s, payload-linker, platform</media:keywords>
<content:encoded><![CDATA[<p>The deal grants Ona Therapeutics rights to develop the ADC targeting a single undisclosed target.</p>
<p>It includes an upfront payment from Ona Therapeutics to WuXi XDC, along with additional payments tied to development, regulatory, and sales milestones.</p>
<p>WuXi XDC will also be eligible for tiered royalties on net sales if the ADC product reaches commercialisation.</p>
<p>The company will also deliver chemistry, manufacturing and controls development.</p>
<p>It will also provide manufacturing support through its integrated ADC contract research, development, and manufacturing platform.</p>
<p>This collaboration marks the second time that Ona Therapeutics and WuXi XDC have worked together in the ADC sector.</p>
<p>The companies previously entered a partnership in 2024, in which Ona Therapeutics licensed additional technologies for its ADC pipeline.</p>
<p>WuXi XDC CEO Jimmy Li said: “We are truly honoured to join forces once again with Ona Therapeutics. As an innovative biotech company focused on first-in-class targets, Ona’s deep insights into novel targets are highly complementary to WuXi XDC’s leading ADC technology platforms.</p>
<p>“With its hydrophilic linker delivering significantly enhanced ADC stability, the WuXiTecan 2 platform has completed two out-licensing deals within just six months. This collaboration not only further validates the value of our WuXiTecan 2 platform but also reaffirms WuXi XDC’s commitment to empowering innovative biotech companies worldwide.</p>
<p>“Through our integrated, end-to-end CRDMO platform, we look forward to fully supporting Ona Therapeutics in accelerating this first-in-class ADC candidate into the clinic, bringing new treatment options to patients.”</p>
<p>Ona Therapeutics is engaged in developing ADCs for cancers that are resistant to treatment by utilising a discovery platform focused on new tumour-specific antigens and epitopes.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/ona-therapeutics-adc-wuxis-payload-linker-platform/">Ona Therapeutics to develop ADC with WuXi’s payload-linker platform</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Roche agrees $1bn deal with Dualitas for bispecific antibody research</title>
<link>https://edusehat.com/en/roche-agrees-1bn-deal-with-dualitas-for-bispecific-antibody-research</link>
<guid>https://edusehat.com/en/roche-agrees-1bn-deal-with-dualitas-for-bispecific-antibody-research</guid>
<description><![CDATA[ Under this arrangement, Dualitas will use its DualScreen Bispecific Discovery Engine to functionally screen more than 300,000 new bispecific combinations. The company is set to receive $36.5m in 
The post Roche agrees $1bn deal with Dualitas for bispecific antibody research appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/09/PT-18-09-2026-shutterstock_2466743473.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 18 Sep 2026 19:10:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Roche, agrees, 1bn, deal, with, Dualitas, for, bispecific, antibody, research</media:keywords>
<content:encoded><![CDATA[<p>Under this arrangement, Dualitas will use its DualScreen Bispecific Discovery Engine to functionally screen more than 300,000 new bispecific combinations.</p>
<p>The company is set to receive $36.5m in upfront payments and could become eligible for additional research, development and commercial milestone payments, alongside tiered royalties.</p>
<p>Once bispecific antibody candidates are identified, Roche will take over all subsequent stages of preclinical development, regulatory activities, manufacturing and commercialisation.</p>
<p>The collaboration is expected to leverage Dualitas’ capabilities in proximity biology to produce bispecific antibody therapeutics with synergistic activities, pursuing opportunities that conventional antibody therapies may not provide.</p>
<p>Dualitas co-founder, chief operating officer and chief business officer Forbes Huang said: “We are thrilled to partner with Roche on this first-of-its-kind collaboration to functionally screen and develop novel proximity BsAbs at a scale that was previously unachievable.</p>
<p>“Since founding Dualitas in 2023, we have established our DualScreen discovery engine as the premier technology for discovering next-generation proximity BsAbs, as exemplified by our robust therapeutic pipeline entering clinic next year for I&I diseases.”</p>
<p>Roche, which maintains a portfolio that includes bispecific antibodies, intends to advance its efforts in I&I through this and other external collaborations.</p>
<p>Roche corporate business development head Boris Zaïtra said: “Bispecific antibodies remain central to Roche’s portfolio strategy across many disease areas.</p>
<p>“We are committed to continue pushing the boundaries of scientific innovation in immunology and inflammation diseases that will ultimately benefit patients through external partnerships.”</p>
<p>Dualitas is developing several antibody candidates, including DTX-101, DTX-102 and DTX-103 for a range of autoimmune and allergic conditions.</p>
<p>Last month, Roche conducted its joint-largest deal of the year so far, licensing a clinical-stage UCN2 [urocortin-2] analogue being developed for weight loss by South Korea-based Hanmi Pharm.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/roche-dualitas-1bn-bispecific-antibody-research/">Roche agrees $1bn deal with Dualitas for bispecific antibody research</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Tenthpin launches Bengaluru Innovation Hub for life sciences digital solutions</title>
<link>https://edusehat.com/en/tenthpin-launches-bengaluru-innovation-hub-for-life-sciences-digital-solutions</link>
<guid>https://edusehat.com/en/tenthpin-launches-bengaluru-innovation-hub-for-life-sciences-digital-solutions</guid>
<description><![CDATA[ 
Centre will focus on AI, cloud technologies, advanced therapies, IoMT and intelligent clinical supply chain solutions
The post Tenthpin launches Bengaluru Innovation Hub for life sciences digital solutions appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/08/09122110/digital-healthcare.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 18 Sep 2026 19:10:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Tenthpin, launches, Bengaluru, Innovation, Hub, for, life, sciences, digital, solutions</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/08/09122110/digital-healthcare.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/08/09122110/digital-healthcare.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/08/09122110/digital-healthcare-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p dir="auto" data-start="238" data-end="573">Switzerland-based Tenthpin Management Consultants has announced the launch of an Innovation Hub in Bengaluru, establishing a Global Centre of Excellence dedicated to advanced therapies. The centre will deliver AI and cloud-driven solutions to help organisations accelerate and transform gene, cell and tissue treatments into medicines.</p>
<p dir="auto" data-start="575" data-end="948">The centre brings together scientific expertise and technology partnerships and will support biotech and pharmaceutical organisations across the transformation journey, from early-stage research and process optimisation to scale-up, manufacturing and regulatory readiness. According to Tenthpin, the centre will help reduce time-to-market while upholding quality standards.</p>
<p dir="auto" data-start="950" data-end="1166">Through AI-powered analytics, predictive modelling and cloud-based collaboration tools, the centre will enable faster decision-making, greater reproducibility and efficient use of resources, according to the company.</p>
<p dir="auto" data-start="1168" data-end="1461">The facility at Global Tech Park, Koramangala, was inaugurated by Juergen Bauer, Founder and Chairman of the Executive Board of Tenthpin, in the presence of Michael Schmidt, Founder and Member of the Executive Board of Tenthpin, and Sachin Bhure, Partner and Managing Director, Tenthpin India.</p>
<p dir="auto" data-start="1463" data-end="1796">As the Life Sciences industry continues to evolve through scientific and technological advances, companies require digital solutions to address emerging market needs, Tenthpin said. The Innovation Hub in Bengaluru will develop solutions and deliver services to help organisations navigate industrial needs and prepare for the future.</p>
<p dir="auto" data-start="1798" data-end="2185">Built on cloud technologies, the innovations will support pharmaceutical, biotechnology, healthcare, animal health and CDMOs in accelerating growth while maintaining regulatory compliance, according to Tenthpin. The Innovation Hub will focus on Artificial Intelligence, Internet of Medical Things (IoMT), Advanced Therapy Medicinal Products (ATMPs) and intelligent clinical supply chain.</p>
<p dir="auto" data-start="2187" data-end="2647">Speaking on the occasion of the launch, Juergen Bauer said, “Our new office in Bengaluru is more than an expansion — it’s an investment in the future of Life Sciences innovation. Scaling and expanding of our presence in Bengaluru underscores Tenthpin’s strong belief in the power of Indian talent and innovation. India has proven to be a cornerstone of our global delivery model — combining expertise, technical excellence, and a deep commitment to quality.”</p>
<p dir="auto" data-start="2649" data-end="3267">He added, “India’s exceptional talent and deep technology expertise align perfectly with Tenthpin’s mission to redefine how global Life Sciences organizations run their businesses. Together with our teams in Pune and Hyderabad, our Bengaluru team will be at the heart of co-creating intelligent, compliant, and transformative solutions. We are excited to expand an Innovation hub that not only delivers excellence but also fosters collaboration, creativity, and long-term value for our clients and partners by deliver high-value services and next-generation digital solutions to our life sciences clients worldwide.”</p>
<p dir="auto" data-start="3269" data-end="3693">The Innovation Hub in Bengaluru will serve as a global hub for developing and enhancing AI-based products and accelerators for Life Sciences companies. The centre will focus on solutions to simplify complexity, ensure regulatory compliance and support scale in a digital ecosystem. It will also collaborate with local research institutions, universities and industry partners to drive advancements of Life Sciences in India.</p>
<p dir="auto" data-start="3695" data-end="4334">Speaking on the occasion, Michael Schmidt said, “Opening of our new office in Bengaluru marks an important milestone in Tenthpin’s global growth journey. As delivery headquarters of India, Bengaluru plays a pivotal role in delivering innovative, high-quality solutions for our Life Sciences clients around the world. With deep expertise in SAP Batch Release Hub (BRH), SAP Intelligent Clinical Supply Management (ICSM), and SAP Advanced Therapy Orchestration (ATO), and our own AI-powered, GxP-ready Tenthpin software solutions, this centre will strengthen our ability to accelerate digital transformation in the Life Sciences industry.”</p>
<p dir="auto" data-start="4336" data-end="4560">He also stated, “Our team in India embodies our commitment to excellence, innovation, and partnership — ensuring that Tenthpin continues to set the global benchmark for SAP transformations and Life Sciences cloud solutions.”</p>
<p dir="auto" data-start="4562" data-end="4967">“We also aim to help Indian Life Sciences companies to become global leaders in innovation with the help of local talent,” said Sachin Bhure. “Bengaluru possesses world class talent pool and the augmentation of this talent and practitioners will help in the speed to market and innovation to great extent. We plan to expand our Bengaluru footprint and double the current team in next two years,” he added.</p>
<p dir="auto" data-start="4969" data-end="5124" data-is-last-node="" data-is-only-node="">
</p><p>The post <a href="https://www.expresspharma.in/tenthpin-launches-bengaluru-innovation-hub-for-life-sciences-digital-solutions/">Tenthpin launches Bengaluru Innovation Hub for life sciences digital solutions</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Merck expands Jigani facility to boost life science manufacturing in India</title>
<link>https://edusehat.com/en/merck-expands-jigani-facility-to-boost-life-science-manufacturing-in-india</link>
<guid>https://edusehat.com/en/merck-expands-jigani-facility-to-boost-life-science-manufacturing-in-india</guid>
<description><![CDATA[ 
€13 million investment will add biological buffer manufacturing and expand chemistry and biology capabilities for India and Asia-Pacific
The post Merck expands Jigani facility to boost life science manufacturing in India appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2022/11/01114501/expansion-growth.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 18 Sep 2026 19:10:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Merck, expands, Jigani, facility, boost, life, science, manufacturing, India</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2022/11/01114501/expansion-growth.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2022/11/01114501/expansion-growth.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2022/11/01114501/expansion-growth-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p>Merck has expanded its manufacturing facility in Jigani, Bengaluru, strengthening local production of chemistry and biology materials for India’s life science sector and customers across the Asia-Pacific region.</p>
<p>“India is emerging as an increasingly important hub for life science innovation and manufacturing,” said Dhananjay Singh, Managing Director, Life Science business of Merck, India. “Merck is investing about €13 million in its Jigani site to strengthen regional manufacturing and expand biology and chemistry capabilities across India and the Asia-Pacific region. This investment will reinforce our global supply chain and support the ‘Make in India’ initiative. We appreciate the continued collaboration from DPIIT, the Heavy Water Board, the Government of Karnataka, and Invest India as Merck expands Jigani.”</p>
<p>The expansion will add biological buffer manufacturing to the site’s established chemistry capabilities, providing customers in research, diagnostics, biotechnology and biopharmaceutical manufacturing with an integrated offering. By supporting customers from research and development through scale-up and commercial production, the expanded facility will support India’s role in global life science innovation.</p>
<p>The facility reserves 34 per cent of its site area for greenbelt, including trees and vegetation that support environmental protection and sustainable operations.</p>
<p>The Jigani site will manufacture biological buffers and raw materials for diagnostic applications used in DNA research, cell culture, diagnostics and drug manufacturing. These materials will be produced locally under temperature-controlled conditions. According to Merck, this will help improve supply reliability, reduce import dependence and enable faster responses to customers’ scientific and manufacturing needs. It will also support Merck’s in-region, for-region approach to strengthening supply and access across key markets.</p>
<p>“Merck’s Bengaluru manufacturing Hub shows what the India–Germany partnership can achieve when world-class German enterprise meets India’s manufacturing ambition. In the year we celebrate 75 years of diplomatic relations, Merck will make advanced materials in Bengaluru for pharmaceutical research and semiconductor manufacturing, for India and for the world, in the true spirit of Make in India,” said Shri Amardeep Singh Bhatia, IAS, Secretary to the Government of India, Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry.</p>
<p>“With its expansion plans of Jigani Bangalore site, Merck is taking its Life Science presence in India by scaling up its advanced materials production capabilities to enable and amplify pharmaceutical research and semiconductor manufacturing ecosystems. The initiative supports bilateral research and economic prosperity in pharma, biotech and advanced manufacturing, an exemplary development with regard to Indo German high-tech cooperation in a strategic sector,” said Alexandre Callegaro, Minister Counsellor, Head of the Department for Economic and Global Affairs, German Embassy, New Delhi.</p>
<p>Operational since 2003, the 10-acre Jigani site has capabilities in specialty and fine chemicals, custom synthesis and catalog product manufacturing. The site also includes a Microbiology Application and Training Lab, a Stable Isotopes Manufacturing Plant established through collaboration with the Heavy Water Board under the Department of Atomic Energy, Government of India, and a 7,200 square metre distribution centre with temperature-controlled infrastructure.</p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/merck-expands-jigani-facility-to-boost-life-science-manufacturing-in-india/">Merck expands Jigani facility to boost life science manufacturing in India</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Gujarat Themis Biosyn completes JPY 21.5 billion acquisition of MicroBiopharm Japan</title>
<link>https://edusehat.com/en/gujarat-themis-biosyn-completes-jpy-215-billion-acquisition-of-microbiopharm-japan</link>
<guid>https://edusehat.com/en/gujarat-themis-biosyn-completes-jpy-215-billion-acquisition-of-microbiopharm-japan</guid>
<description><![CDATA[ 
The acquisition gives GTBL access to MBJ’s fermentation, biotechnology and CDMO capabilities across three GMP-compliant manufacturing plants
The post Gujarat Themis Biosyn completes JPY 21.5 billion acquisition of MicroBiopharm Japan appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/07/23095347/Handshake-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 18 Sep 2026 19:10:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Gujarat, Themis, Biosyn, completes, JPY, 21.5, billion, acquisition, MicroBiopharm, Japan</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/07/23095347/Handshake-1.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/07/23095347/Handshake-1.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/07/23095347/Handshake-1-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p>Gujarat Themis Biosyn  has completed the acquisition of 100 per cent equity shareholding in MicroBiopharm Japan Co., Ltd. (MBJ), Japan, through Themis Biosyn Japan, a wholly owned subsidiary incorporated in Japan. The transaction, first announced on May 22, 2026, was closed following receipt of regulatory approvals and satisfaction of closing conditions.</p>
<p>The acquisition was made from funds managed or advised by T Capital Partners, a Japan-based private equity fund, for a total consideration of JPY 21.5 billion, funded through a mix of debt and equity. The transaction is expected to be EPS accretive for GTBL. The existing MBJ management team will continue to lead operations.</p>
<p>MBJ has over 60 years of experience and operates three GMP-compliant manufacturing plants with an FDA and PMDA inspection track record. For FY26, MBJ registered revenue of JPY 9.5 billion, with a business mix spanning Proprietary APIs/Intermediates, CDMO, CDMO Bio and Developed Pharmaceuticals (bio)/Non-Pharma. The company has serviced its top six customers for over two decades, with approximately 40 per cent of its revenue generated from outside Japan.</p>
<p>The acquisition accelerates GTBL’s transition towards becoming a fermentation-based, globally integrated CDMO. Through the acquisition, GTBL will enter precision fermentation through MBJ’s proprietary P450 enzyme library for hydroxylation, complementing GTBL’s existing fermentation strengths and reducing reliance on traditional chemical routes.</p>
<p>MBJ will also supply APIs and intermediates for oncology, immunosuppressants, peptides and antibiotics to global pharmaceutical companies, including Big Pharma, broadening GTBL’s product portfolio and revenue base.</p>
<p>The acquisition provides GTBL access to plasmid DNA, ADC conjugation and recombinant protein technologies. It also adds three GMP-compliant manufacturing sites with FDA and PMDA inspection track records, enabling access to regulated global markets and a CDMO platform spanning discovery, development and commercial manufacturing.</p>
<p>Approximately 40 per cent of MBJ’s revenues are generated from outside Japan, with relationships with pharmaceutical customers across Asia, Europe and North America. GTBL said this will enable cross-selling and market penetration.</p>
<p>The acquisition also provides an opportunity to leverage GTBL’s India manufacturing scale to improve cost competitiveness and drive margin expansion on high-value products.</p>
<p>Commenting on the completion of the acquisition, Dr. Sachin Patel, Managing Director, Gujarat Themis Biosyn Limited, said, “The successful completion of this acquisition marks a defining milestone in GTBL’s journey towards becoming a fermentation-based, globally integrated CDMO. MBJ brings to us over six decades of fermentation expertise, a proprietary P450 enzyme platform, and deep, long-standing relationships with leading global pharmaceutical companies. Together, we are well placed to expand our presence across various avenues including oncology, immunosuppressants, peptides and advanced biologics, while leveraging GTBL’s India manufacturing scale to drive growth. We warmly welcome the MBJ team, who will continue to lead operations, and look forward to building this platform together for a mutually rewarding journey ahead.”</p>
<p>Commenting on the completion of the acquisition, Shiota, CEO, MicroBiopharm Japan Co., Ltd, said, “This acquisition paves the way for a mutually rewarding journey, combining MBJ’s precision fermentation capabilities, biotechnology platforms, and strong relationships with leading pharmaceutical companies, with GTBL’s long-standing expertise in fermentation technology, large- scale manufacturing capabilities, and broad portfolio. Together, these complementary strengths will enable us to create greater value and, as part of the Themis Group, grow into a leading CDMO witha strong global footprint.”</p>
<p>Deloitte India acted as an exclusive financial advisor to GTBL, Tokyo International Law Office (TKI) Japan served as legal counsel and Avendus Capital acted as the exclusive financing arranger to GTBL on the transaction.</p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/gujarat-themis-biosyn-completes-jpy-21-5-billion-acquisition-of-microbiopharm-japan/">Gujarat Themis Biosyn completes JPY 21.5 billion acquisition of MicroBiopharm Japan</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Dr Sundaram Palaniswamy, Senior Global Product Manager – Analytical Chemistry, Merck Lifescience</title>
<link>https://edusehat.com/en/dr-sundaram-palaniswamy-senior-global-product-manager-analytical-chemistry-merck-lifescience</link>
<guid>https://edusehat.com/en/dr-sundaram-palaniswamy-senior-global-product-manager-analytical-chemistry-merck-lifescience</guid>
<description><![CDATA[ 
Bengaluru Pharma Summit 2026 | 25th August 2026
The post Dr Sundaram Palaniswamy, Senior Global Product Manager – Analytical Chemistry, Merck Lifescience appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/18121446/EP_BPS_25th_Aug_2026_03_Dr_Sundaram_Palaniswamy_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 18 Sep 2026 15:35:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Sundaram, Palaniswamy, Senior, Global, Product, Manager, –, Analytical, Chemistry, Merck, Lifescience</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="422" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/18121446/EP_BPS_25th_Aug_2026_03_Dr_Sundaram_Palaniswamy_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/18121446/EP_BPS_25th_Aug_2026_03_Dr_Sundaram_Palaniswamy_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/18121446/EP_BPS_25th_Aug_2026_03_Dr_Sundaram_Palaniswamy_750-300x169.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p></p>
<hr>
<p><strong>Speaker in this video:</strong><br>
Dr Sundaram Palaniswamy, Senior Global Product Manager – Analytical Chemistry, Merck Lifescience</p>
<p><strong>Topic:</strong> Analytical Characterization of Critical Quality Attributes (CQAs) in Biologics</p>
<p><strong>Key Highlights:</strong><br>
[1] Merck and Supelco cover the entire large molecule QC pipeline, sample prep to reference standards, under one roof.</p>
<p>[2] Biosimilar approval pathways differ by region, both the US and EU require quality, non-clinical, and clinical comparability data against the originator.</p>
<p>[3] For India’s biosimilar push, Merck offers on-site support, trial samples, and regulatory documentation for CDSCO, FDA, and EMA submissions</p>
<p>The post <a href="https://www.expresspharma.in/dr-sundaram-palaniswamy-senior-global-product-manager-analytical-chemistry-merck-lifescience-25-aug-2026-blr/">Dr Sundaram Palaniswamy, Senior Global Product Manager – Analytical Chemistry, Merck Lifescience</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Dr Parthasarathy Sampathkumar, Head Group – COE, Biocon</title>
<link>https://edusehat.com/en/dr-parthasarathy-sampathkumar-head-group-coe-biocon</link>
<guid>https://edusehat.com/en/dr-parthasarathy-sampathkumar-head-group-coe-biocon</guid>
<description><![CDATA[ 
Bengaluru Pharma Summit 2026 | 25th August 2026
The post Dr Parthasarathy Sampathkumar, Head Group – COE, Biocon appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/18122039/EP_BPS_25th_Aug_2026_05_Dr_Parthasarathy_Sampathkumar_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 18 Sep 2026 15:35:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Parthasarathy, Sampathkumar, Head, Group, –, COE, Biocon</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="422" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/18122039/EP_BPS_25th_Aug_2026_05_Dr_Parthasarathy_Sampathkumar_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/18122039/EP_BPS_25th_Aug_2026_05_Dr_Parthasarathy_Sampathkumar_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/18122039/EP_BPS_25th_Aug_2026_05_Dr_Parthasarathy_Sampathkumar_750-300x169.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p></p>
<hr>
<p><strong>Speaker in this video:</strong><br>
Dr Parthasarathy Sampathkumar, Head Group – COE, Biocon</p>
<p><strong>Topic:</strong> Beyond the Pharmacy of the World: How India Can Become the World’s Most Trusted Innovation Partner</p>
<p><strong>Key Highlights:</strong><br>
[1] India can become the world’s most trusted innovation partner through quality, excellence & collaboration</p>
<p>[2] Trust in pharma isn’t built on occasional excellence, it comes from consistent choices across quality, culture, ecosystem, and patient focus</p>
<p>[3] Innovation runs on four pillars, frontier science exploring novel targets, translational R&D that scales discovery into development, platform science across biologics and biosimilars, and frugal science delivering world-class rigor at lower cost</p>
<p>The post <a href="https://www.expresspharma.in/dr-parthasarathy-sampathkumar-head-group-coe-biocon-25-aug-2026-blr/">Dr Parthasarathy Sampathkumar, Head Group – COE, Biocon</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Mr Prashanth Bajaj, Business Unit Director, Lindstrom Services India</title>
<link>https://edusehat.com/en/mr-prashanth-bajaj-business-unit-director-lindstrom-services-india</link>
<guid>https://edusehat.com/en/mr-prashanth-bajaj-business-unit-director-lindstrom-services-india</guid>
<description><![CDATA[ 
Bengaluru Pharma Summit 2026 | 25th August 2026
The post Mr Prashanth Bajaj, Business Unit Director, Lindstrom Services India appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/18123537/EP_BPS_25th_Aug_2026_07_Prashanth_Bajaj_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 18 Sep 2026 15:35:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Prashanth, Bajaj, Business, Unit, Director, Lindstrom, Services, India</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="422" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/18123537/EP_BPS_25th_Aug_2026_07_Prashanth_Bajaj_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/18123537/EP_BPS_25th_Aug_2026_07_Prashanth_Bajaj_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/18123537/EP_BPS_25th_Aug_2026_07_Prashanth_Bajaj_750-300x169.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p></p>
<hr>
<p><strong>Speaker in this video:</strong><br>
Mr Prashanth Bajaj, Business Unit Director, Lindstrom Services India</p>
<p><strong>Topic:</strong> Rethinking Cleanroom Garment Management</p>
<p><strong>Key Highlights:</strong><br>
[1] Innovation is not only technology. Innovation is accountability</p>
<p>[2] Cleanroom garment management is becoming a strategic part of human contamination control</p>
<p>[3] The next level of innovation is to manage the human barrier scientifically, digitally and end-to-end throughout its lifecycle</p>
<p>The post <a href="https://www.expresspharma.in/mr-prashanth-bajaj-business-unit-director-lindstrom-services-india-25-aug-2026-blr/">Mr Prashanth Bajaj, Business Unit Director, Lindstrom Services India</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Mr Vasudevan (Vasu) Ramanujam, Global Business Head, Innovation Acceleration Services, UST</title>
<link>https://edusehat.com/en/mr-vasudevan-vasu-ramanujam-global-business-head-innovation-acceleration-services-ust</link>
<guid>https://edusehat.com/en/mr-vasudevan-vasu-ramanujam-global-business-head-innovation-acceleration-services-ust</guid>
<description><![CDATA[ 
Bengaluru Pharma Summit 2026 | 25th August 2026
The post Mr Vasudevan (Vasu) Ramanujam, Global Business Head, Innovation Acceleration Services, UST appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/18122041/EP_BPS_25th_Aug_2026_06_Vasudevan_Ramanujam_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 18 Sep 2026 15:35:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Vasudevan, Vasu, Ramanujam, Global, Business, Head, Innovation, Acceleration, Services, UST</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="422" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/18122041/EP_BPS_25th_Aug_2026_06_Vasudevan_Ramanujam_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/18122041/EP_BPS_25th_Aug_2026_06_Vasudevan_Ramanujam_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/18122041/EP_BPS_25th_Aug_2026_06_Vasudevan_Ramanujam_750-300x169.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p></p>
<hr>
<p><strong>Speaker in this video:</strong><br>
Mr Vasudevan (Vasu) Ramanujam, Global Business Head, Innovation Acceleration Services, UST</p>
<p><strong>Topic:</strong> Tale of Two CDMOs – Building Boundless Visibility  </p>
<p><strong>Key Highlights:</strong><br>
[1] Compliance creates trust, but understanding creates value, moving beyond visibility to real operational insight.</p>
<p>[2] A capacity framework explains and recovers productive time by tracking changeover, sequence gaps, and batch execution patterns.</p>
<p>[3] Prevention identifies emerging risk early through vial density, flow monitoring, and choke-point congestion signals, already proven in live RABS and isolator deployments.</p>
<p>The post <a href="https://www.expresspharma.in/mr-vasudevan-vasu-ramanujam-global-business-head-innovation-acceleration-services-ust-25-aug-2026-blr/">Mr Vasudevan (Vasu) Ramanujam, Global Business Head, Innovation Acceleration Services, UST</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Dr Pravin Mhapankar, Director, Thermolab Scientific Equipments</title>
<link>https://edusehat.com/en/dr-pravin-mhapankar-director-thermolab-scientific-equipments</link>
<guid>https://edusehat.com/en/dr-pravin-mhapankar-director-thermolab-scientific-equipments</guid>
<description><![CDATA[ 
Bengaluru Pharma Summit 2026 | 25th August 2026
The post Dr Pravin Mhapankar, Director, Thermolab Scientific Equipments appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/18123540/EP_BPS_25th_Aug_2026_08_Dr_Pravin_Mhapankar_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 18 Sep 2026 15:35:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Pravin, Mhapankar, Director, Thermolab, Scientific, Equipments</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="422" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/18123540/EP_BPS_25th_Aug_2026_08_Dr_Pravin_Mhapankar_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/18123540/EP_BPS_25th_Aug_2026_08_Dr_Pravin_Mhapankar_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/18123540/EP_BPS_25th_Aug_2026_08_Dr_Pravin_Mhapankar_750-300x169.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p></p>
<hr>
<p><strong>Speaker in this video:</strong><br>
Dr Pravin Mhapankar, Director, Thermolab Scientific Equipments </p>
<p><strong>Topic:</strong> Empowering Excellence Through Innovation in the Pharmaceutical Industry</p>
<p><strong>Key Highlights:</strong><br>
[1] Stability testing helps establish a drug’s shelf life and recommended storage conditions by tracking how quality changes with temperature and humidity over time.</p>
<p>[2] ICH stability zones classify regions from temperate to hot/humid, each requiring specific test conditions for accurate, region-relevant results.</p>
<p>[3] Thermolab has strong presence across major climatic zones in Asia and globally.</p>
<p>The post <a href="https://www.expresspharma.in/dr-pravin-mhapankar-director-thermolab-scientific-equipments-25-aug-2026-blr/">Dr Pravin Mhapankar, Director, Thermolab Scientific Equipments</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Panel Discussion: The new innovation economy: Building the ecosystem behind the molecule</title>
<link>https://edusehat.com/en/panel-discussion-the-new-innovation-economy-building-the-ecosystem-behind-the-molecule</link>
<guid>https://edusehat.com/en/panel-discussion-the-new-innovation-economy-building-the-ecosystem-behind-the-molecule</guid>
<description><![CDATA[ 
Bengaluru Pharma Summit 2026 | 25th August 2026
The post Panel Discussion: The new innovation economy: Building the ecosystem behind the molecule appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/18123547/EP_BPS_25th_Aug_2026_09_PD_The_new_innovation_economy_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 18 Sep 2026 15:35:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Panel, Discussion:, The, new, innovation, economy:, Building, the, ecosystem, behind, the, molecule</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="422" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/18123547/EP_BPS_25th_Aug_2026_09_PD_The_new_innovation_economy_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/18123547/EP_BPS_25th_Aug_2026_09_PD_The_new_innovation_economy_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/18123547/EP_BPS_25th_Aug_2026_09_PD_The_new_innovation_economy_750-300x169.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p></p>
<hr>
<p><strong>Panellists in this video:</strong><br>
• Dr Maneesh Paul. S.; M.Sc., Ph.D., FIDSA; CEO, Microvioma (MODERATOR)<br>
• Ms Kavitha Iyer Rodrigues, Founder & CEO, Zumutor Biologics<br>
• Dr Anandkrishna Kulkarni, VP & Head-Global Program Office and Operational Excellence, Syngene International<br>
• Dr M.S. Vijaykanth, M.Pharm, Ph.D., Sr VP and Head R&D Formulations, OneSource Specialty Pharma<br>
• Dr Mohamed Adil, MD, Bangalore Bioinnovation Centre<br>
• Dr Rakesh Kumar Bhasin, Head GF R&D, Biocon Pharma<br>
• Dr Huzaifa S Choonia, AVP and Head, Drug Substance MSAT, OneSource Specialty Pharma<br>
• Dr Shailendra Gaur, Director, Process Science, Aspergen Inc (Cipla and Kemwell’s JV)</p>
<p><strong>Key Highlights:</strong><br>
[1] Strong programme governance is critical to accelerate innovation, enabling clear accountability, structured risk assessment and faster go/no-go decisions at different stages of drug development.</p>
<p>[2] Startups need to be treated as innovation engines rather than small pharma companies, with CROs and CDMOs providing the expertise, platforms and regulatory support needed to move molecules forward</p>
<p>[3] The biggest gaps in transferring a molecule to a medicine lie in development ability, scalability, regulatory strategy and IP protection, all of which need to be addressed early and in parallel</p>
<p>[4] Technology transfer must go beyond product performance to ensure commercial reproducibility, with robust process controls, critical process parameters and analytical requirements built into the development process</p>
<p>[5] A common technology-transfer framework can improve handoffs across the pharma ecosystem, but it must combine a standard core information set with modality-specific requirements for small molecules, biologics, biosimilars and cell therapies</p>
<p>[6] The future competitive advantage will increasingly depend on how efficiently knowledge and data are preserved and transferred, rather than simply on who discovers a molecule first</p>
<p>[7] Standardisation should focus on the architecture and format, not the science, as each molecule, formulation and process is distinct and requires flexibility based on its development stage and modality</p>
<p>[8] India needs a more integrated and dynamic innovation ecosystem, bringing together academia, startups, CROs, CDMOs and pharma companies to establish consistent processes while creating room for emerging technologies and new modalities.</p>
<p>The post <a href="https://www.expresspharma.in/panel-discussion-the-new-innovation-economy-building-the-ecosystem-behind-the-molecule-25-aug-2026-blr/">Panel Discussion: The new innovation economy: Building the ecosystem behind the molecule</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Mr Loganathan S, AVP, Onesource Biopharma</title>
<link>https://edusehat.com/en/mr-loganathan-s-avp-onesource-biopharma</link>
<guid>https://edusehat.com/en/mr-loganathan-s-avp-onesource-biopharma</guid>
<description><![CDATA[ 
Bengaluru Pharma Summit 2026 | 25th August 2026
The post Mr Loganathan S, AVP, Onesource Biopharma appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/18124418/EP_BPS_25th_Aug_2026_10_Loganathan_S_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 18 Sep 2026 15:35:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Loganathan, AVP, Onesource, Biopharma</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="422" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/18124418/EP_BPS_25th_Aug_2026_10_Loganathan_S_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/18124418/EP_BPS_25th_Aug_2026_10_Loganathan_S_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/18124418/EP_BPS_25th_Aug_2026_10_Loganathan_S_750-300x169.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p></p>
<hr>
<p><strong>Speaker in this video:</strong><br>
Mr Loganathan S, AVP, Onesource Biopharma</p>
<p><strong>Topic:</strong> The strategic shift: Why CDMOs are becoming central to pharma growth</p>
<p><strong>Key Highlights:</strong><br>
[1] Drug delivery combinations are the fastest-growing CDMO segment, with US DDC sales rising 16% annually, driven mainly by GLP-1s and biologics.</p>
<p>[2] OneSource offers end-to-end capability, from cell line development through to drug device assembly and commercial manufacturing.</p>
<p>[3] OneSource combines strong technical acumen with worldwide quality and regulatory expertise across its manufacturing operations.</p>
<p>The post <a href="https://www.expresspharma.in/mr-loganathan-s-avp-onesource-biopharma-25-aug-2026-blr/">Mr Loganathan S, AVP, Onesource Biopharma</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Panel Discussion: The biopharma pivot: Can India move from manufacturing medicines to inventing them?</title>
<link>https://edusehat.com/en/panel-discussion-the-biopharma-pivot-can-india-move-from-manufacturing-medicines-to-inventing-them</link>
<guid>https://edusehat.com/en/panel-discussion-the-biopharma-pivot-can-india-move-from-manufacturing-medicines-to-inventing-them</guid>
<description><![CDATA[ 
Bengaluru Pharma Summit 2026 | 25th August 2026
The post Panel Discussion: The biopharma pivot: Can India move from manufacturing medicines to inventing them? appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/18124420/EP_BPS_25th_Aug_2026_11_PD_The_biopharma_pivot_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 18 Sep 2026 15:35:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Panel, Discussion:, The, biopharma, pivot:, Can, India, move, from, manufacturing, medicines, inventing, them</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="422" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/18124420/EP_BPS_25th_Aug_2026_11_PD_The_biopharma_pivot_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/18124420/EP_BPS_25th_Aug_2026_11_PD_The_biopharma_pivot_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/18124420/EP_BPS_25th_Aug_2026_11_PD_The_biopharma_pivot_750-300x169.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p></p>
<hr>
<p><strong>Panellists in this video:</strong><br>
• Dr Sanjib Banerjee, COO (Biopharma Services), Veeda Lifesciences (MODERATOR)<br>
• Dr Jayashree Aiyar, CSO, Syngene International<br>
• Dr Maloy Ghosh, CSO, Zumutor Biologics<br>
• Dr Rajkumar Aland, Assistant VP, Bioplus Life Science<br>
• Mr Aditya Viswanath Garimella, Associate Director, Corporate Quality Control, OneSource Specialty Pharma<br>
• Dr Amarnath Chatterjee, Head analytical sciences Cipla Biosimilars, Cipla<br>
• Dr Subhra Prakash Chakrabarty, Director and Head, Antibody Engineering, Aurigene Oncology</p>
<p><strong>Key Highlights:</strong><br>
[1] India has the potential to emerge as a global leader in biosimilars and biopharma over the next 10–15 years, building on its strong pharmaceutical manufacturing base</p>
<p>[2] India needs to move beyond its traditional generics-led model and build stronger capabilities in novel drug discovery, development and innovative biologics</p>
<p>[3] Start-ups can accelerate innovation by using CROs/CDMOs through co-development and risk-sharing models instead of spending heavily on their own laboratories and infrastructure</p>
<p>[4] Regulatory reforms, stronger IP policies, greater industry–academia collaboration and better access to advanced technologies are critical to creating an innovation-driven biopharma ecosystem</p>
<p>[5] India needs to develop and retain a highly skilled scientific talent pool, including creating policies that can attract Indian scientists with global drug discovery and development experience back to the country</p>
<p>[6] Rather than betting on a single emerging modality, India should invest across technologies such as ADCs, cell and gene therapies, mRNA and multispecifics, as the next major breakthrough cannot be predicted</p>
<p>[7] Indian pharma companies need a phased transition from generics to innovation, balancing existing revenues with higher-risk investments in novel drug discovery through a structured allocation of resources.</p>
<p>The post <a href="https://www.expresspharma.in/panel-discussion-the-biopharma-pivot-can-india-move-from-manufacturing-medicines-to-inventing-them-25-aug-2026-blr/">Panel Discussion: The biopharma pivot: Can India move from manufacturing medicines to inventing them?</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Panel Discussion: The Bengaluru Bet: How GCCs are redefining India Pharma Inc</title>
<link>https://edusehat.com/en/panel-discussion-the-bengaluru-bet-how-gccs-are-redefining-india-pharma-inc</link>
<guid>https://edusehat.com/en/panel-discussion-the-bengaluru-bet-how-gccs-are-redefining-india-pharma-inc</guid>
<description><![CDATA[ 
Bengaluru Pharma Summit 2026 | 25th August 2026
The post Panel Discussion: The Bengaluru Bet: How GCCs are redefining India Pharma Inc appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/18124423/EP_BPS_25th_Aug_2026_12_PD_The_Bengaluru_Bet_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 18 Sep 2026 15:35:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Panel, Discussion:, The, Bengaluru, Bet:, How, GCCs, are, redefining, India, Pharma, Inc</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="422" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/18124423/EP_BPS_25th_Aug_2026_12_PD_The_Bengaluru_Bet_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/18124423/EP_BPS_25th_Aug_2026_12_PD_The_Bengaluru_Bet_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/18124423/EP_BPS_25th_Aug_2026_12_PD_The_Bengaluru_Bet_750-300x169.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p></p>
<hr>
<p><strong>Panellists in this video:</strong><br>
• Dr Mahesh Bhalgat, CEO and Founder, AAPM Therapeutics (MODERATOR)<br>
• Dr Gursharan Singh, GM – Medical Sciences, Clinical Development, Biocon<br>
• Dr Raghavender Gunda, Head-R&D QA, VJ Biosciences<br>
• Mr Shrenik Kole, VP and Head Sterile Product Development, Micro Lab<br>
• Dr Goutam Pujari, VP, Clinical Research and R&D, Apotex Research<br>
• Dr Manoj Kumar Singh, Sr VP, Micro Labs<br>
• Mr Siddalingaswamy, VP Operations, Zuventus Healthcare Limited (Emcure Group)<br>
• Mr Kesavalu Purushothaman, GM – Formulation Development, Lyrus Life Sciences<br>
• Dr Nandakumar Sundaramoorthy, Associate VP, OneSource Specialty Pharma</p>
<p><strong>Key Highlights:</strong><br>
[1] Pharma GCCs in India need to move beyond execution and take ownership of portfolio strategy, clinical development and medical affairs</p>
<p>[2] India’s proven capabilities in global clinical trials, regulatory approvals and biosimilars create a strong case for shifting higher-value pharma work from the US and Europe to Indian GCCs</p>
<p>[3] GCCs can potentially deliver 50–60% savings in FTE costs while improving efficiency by leveraging India’s talent pool and emerging AI capabilities</p>
<p>[4] Complex R&D activities such as novel formulations, complex injectables and sameness/similarity studies should increasingly be brought into Indian GCCs to move them up the value chain</p>
<p>[5] AI, automation and digitisation are emerging as key enablers across clinical, quality, manufacturing and analytical functions, including automated review, investigations and faster batch release</p>
<p>[6] India’s GCC talent is increasingly taking on global leadership responsibilities, with areas such as clinical development, regulatory strategy and pharmacovigilance being significantly driven from India</p>
<p>[7] The next phase of GCC growth will depend on combining talent with advanced technology, including generative AI, data analytics, computational tools and AI applications in pharma operations</p>
<p>[8] Stronger collaboration between GCCs, pharma companies, startups, academia and institutions such as IITs and IISc can accelerate innovation and help build India into a global pharma centre of excellence.</p>
<p>The post <a href="https://www.expresspharma.in/panel-discussion-the-bengaluru-bet-how-gccs-are-redefining-india-pharma-inc-25-aug-2026-blr/">Panel Discussion: The Bengaluru Bet: How GCCs are redefining India Pharma Inc</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Geopolitics and pharma packaging: Building greater security across the supply chain </title>
<link>https://edusehat.com/en/geopolitics-and-pharma-packaging-building-greater-security-across-the-supply-chain</link>
<guid>https://edusehat.com/en/geopolitics-and-pharma-packaging-building-greater-security-across-the-supply-chain</guid>
<description><![CDATA[ 
India’s pharma strength and its new operating reality  The Indian pharmaceutical industry has evolved into one of the most globally significant healthcare sectors. As per the Economic Survey 2025-26, India ranks third globally by volume and eleventh by value in pharmaceuticals, meeting around 20 per cent of global generics demand, with exports to 191 countries […]
The post Geopolitics and pharma packaging: Building greater security across the supply chain  appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/17134346/EP_Bhupesh-Kumar-Mittal.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 18 Sep 2026 12:00:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Geopolitics, and, pharma, packaging:, Building, greater, security, across, the, supply, chain </media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/17134346/EP_Bhupesh-Kumar-Mittal.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/17134346/EP_Bhupesh-Kumar-Mittal.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/17134346/EP_Bhupesh-Kumar-Mittal-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><b>India’s pharma strength and its new operating reality </b></p>
<p><span>The Indian pharmaceutical industry has evolved into one of the most globally significant healthcare sectors. As per the Economic Survey 2025-26, India ranks third globally by volume and eleventh by value in pharmaceuticals, meeting around 20 per cent of global generics demand, with exports to 191 countries in FY25 and sector turnover reaching Rs 4.72 lakh crore. Over 50 per cent of these exports are directed to highly regulated markets such as the United States and Europe. India is also a leading global supplier of low-cost vaccines, including DPT, BCG and measles vaccines. </span></p>
<p><span>IBEF further notes that the domestic pharmaceutical market, valued at around $60 billion in 2026, is projected to grow to $130 billion by 2030, supported by more than 3,000 companies, 10,500 manufacturing units and government initiatives such as the PLI scheme, Biopharma SHAKTI and the API-push announced in December 2025. According to KPMG’s Q1 FY26 pharma sector snapshot, the Indian pharmaceutical packaging market itself is projected to reach around Rs. 259 billion by FY30. India’s scale, therefore, is not only industrial; it is deeply linked to global healthcare access. </span></p>
<p><span>However, the operating environment around this strength is changing. Geopolitical tensions, shipping disruptions, energy volatility, tariff uncertainties and import dependencies are increasingly influencing daily operations. Express Pharma’s June 2026 cover story on “Navigating a VUCA World” rightly noted that geopolitics is reshaping the pharma landscape, and that supply chain disruption has become a structural feature, not a passing crisis. </span></p>
<p><span>Recent events around the Red Sea, the Strait of Hormuz and the wider Gulf shipping corridors have made this more visible. Industry reports have highlighted rerouting risks, delays, doubled freight charges and shipment surcharges for Indian pharma exporters. UNCTAD’s June 2026 note observed that, even after the reopening process for the Strait of Hormuz, more than 100 days of disruption had already affected energy markets, transport costs and global trade flows, with an uneven recovery for value chains. </span></p>
<p><span>For patients, these events are ultimately about medicine availability. For packaging professionals, they translate into a very practical question: will the right material reach the right site, with the right quality documentation, at the right time, so that a medicine can safely reach the patient? </span></p>
<p><b>Key geopolitical risks currently affecting Indian pharma and their implications for packaging </b></p>
<p><span>The most visible risk is upstream dependency. The Government of India has reported that in FY2024-25 India imported around $4.35 billion worth of APIs, bulk drugs and intermediates across 200 categories, with China accounting for about 73.7 per cent of these imports. The government has identified single-source vulnerability, price volatility and predatory pricing as risks arising from such dependence. </span></p>
<p><span>Packaging carries its own dependency map. Even when conversion happens in India, many upstream inputs – aluminium foil, cold-form laminates, PVC, PVDC, high-barrier films, specialty polymers, glass tubing, elastomeric components, desiccants, closures, inks, adhesives, coatings and machine spares – are linked to global energy, chemical and logistics networks.</span></p>
<p><span>The Red Sea crisis showed how quickly this can turn operational. Industry reports noted that shipments earlier taking around 25 days began taking 34 days or more as vessels rerouted around the Cape of Good Hope, and that over 65 per cent of India’s pharma exports move by sea. Key routes such as the Red Sea, Strait of Hormuz and Gulf shipping corridors have faced risks of rerouting and delays, affecting delivery schedules and increasing logistics costs for Indian pharma exporters. </span></p>
<p><span>For packaging operations, such risks appear as delayed inbound materials, extended lead times, supplier allocation, higher freight cost, production rescheduling, artwork implementation delays and pressure to move to alternates that may not yet be fully qualified. </span></p>
<p><b>Impact on packaging material availability, sourcing dependencies and operational continuity </b></p>
<p><span>Packaging supply chains are often more complex than they appear. A local converter may still depend on imported foil stock, imported resin, imported coating chemistry or overseas machine spares. This creates hidden dependency, which becomes visible only during disruption. </span></p>
<p><span>In primary packaging, the impact is especially critical. Blister films, aluminium lidding foil, cold-form laminates, bottles, closures, glass vials, ampoules, cartridges, stoppers and plungers are not commodity items. They are product-contact and product-protection systems, and any change can affect stability, compatibility, machinability, regulatory documentation and patient safety. </span></p>
<p><span>Secondary and tertiary packaging can also become critical. Cartons, labels, leaflets, shippers and serialisation components are closely tied to market release. A missing leaflet, incorrect label stock, delayed artwork or unavailable shipper can hold a batch even when the formulation is ready. </span></p>
<p><span>Supplier reliability also becomes a bigger issue in disruption. Suppliers may prioritise larger customers, domestic markets or high-margin segments during global stress, leaving smaller-volume SKUs or niche pack formats more vulnerable. Packaging teams therefore need supplier relationships that go beyond transactional purchasing, with transparency on capacity, upstream inputs and business continuity plans. </span></p>
<p><span>Operational continuity depends equally on planning discipline. Standard lead times cannot be assumed during a crisis. Transit times extend, port operations become uncertain, freight capacity tightens and emergency air freight becomes expensive. Packaging, procurement, planning, quality, logistics and manufacturing must work together to identify materials that can stop production and markets that are most exposed. </span></p>
<p><b>Emerging challenges: timelines, costs, compliance, sustainability and product integrity </b></p>
<p><span>The first challenge is timeline uncertainty. Packaging touches multiple time-sensitive steps – component procurement, artwork approval, vendor release, machine trials, batch packing, quality release and dispatch. Even small delays in a critical component can affect packing campaigns, sequencing and market service. </span></p>
<p><span>The second is cost escalation. Industry bodies have flagged that freight charges for imports and exports have nearly doubled, with surcharges of $4,000 to $8,000 per shipment, while rising logistics costs, crude oil prices and shipping delays continue to affect inventory cycles. For packaging, cost pressure appears through higher raw material prices, increased inbound freight, emergency logistics, currency volatility, inventory carrying cost and additional qualification work – all difficult to pass on in generic markets.</span></p>
<p><span>generic markets. The third is compliance. Pharma cannot simply switch a packaging material because it is available or cheaper. Depending on the market, a change may require change control, stability data, comparability assessment, dossier update, notification or prior variation approval. </span></p>
<p><span>The fourth is sustainability. Pharma companies are moving toward lower material intensity, recyclable structures, responsible sourcing and reduced carbon impact. But a sustainable material with only one qualified supplier can become a vulnerability, and a lower-carbon option that cannot protect the product through longer, disrupted routes may create quality risk. The answer is not to slow sustainability, but to design it with resilience built in. </span></p>
<p><span>The fifth is product integrity during disturbed logistics. Longer routes, port congestion, temperature and humidity exposure and additional handling can affect moisture-sensitive tablets, cold-chain products, biologics and injectables. Packaging and distribution systems must be validated for real-world stress, not only for ideal lanes. </span></p>
<p><span>Behind each of these challenges is a human dimension. When a medicine is delayed, it is not only a supply chain metric. It can mean a chronic-therapy patient waiting for refills, a hospital managing shortages, or a public health programme facing uncertainty. Resilience must therefore be framed as patient access protection, not only as cost protection. </span></p>
<p><b>Strategies to strengthen resilience across packaging supply chains </b></p>
<p><span>The first strategy is meaningful dual sourcing. Alternate suppliers must be technically qualified, quality approved, commercially ready, operationally trialled and regulatory assessed. For critical materials, dual sourcing should be treated as business-continuity insurance, not only as a negotiation lever.</span></p>
<p><span>The second is multi-geography and multi-site thinking. If two suppliers depend on the same upstream raw material source or the same shipping corridor, the resilience benefit is limited. Companies should ensure critical materials can be produced from different sites, regions or logistics routes. </span></p>
<p><span>The third is Tier 2 and Tier 3 visibility. Packaging teams must know where key inputs originate – foil, resin, paper, glass tubing, elastomers, coatings, adhesives, specialty chemicals – so that hidden single points of failure can be identified. </span></p>
<p><span>The fourth is risk-based inventory. Strategic safety stock should be based on business impact, material criticality, leadtime volatility, storage conditions, shelf life, regulatory complexity and patient criticality. The objective is not excess everywhere, but protection where supply can stop.</span></p>
<p><span>The fifth is specification harmonisation. Multiple similar carton sizes, bottle families, foil structures and shipper formats increase inventory, reduce flexibility and slow supplier switching. Harmonisation improves buying power, simplifies qualification and enables faster response during disruption. </span></p>
<p><span>The sixth is design for supply continuity. Packaging development must balance product protection, patient convenience and sustainability with material availability, supplier base and alternate options. Highly specialised structures should be justified by product need, not by habit. </span></p>
<p><span>The seventh is regulatory preparedness. Packaging, quality and regulatory teams should work together before disruption occurs, so that critical alternates are documentation-ready and change categories are pre-assessed. </span></p>
<p><span>The eighth is digital visibility. Dashboards connecting supplier performance, inventory cover, lead-time movement, port disruptions, freight changes, artwork status and production priorities help teams act earlier. AI can further support scenario planning by identifying exposed SKUs, materials and markets. </span></p>
<p><span>The ninth is closer supplier partnership. Strategic supplier relationships should include capacity planning, business-continuity audits, joint risk reviews, sustainability roadmaps and transparent escalation mechanisms. </span></p>
<p><span>The tenth is cross-functional governance. Packaging risk requires procurement, quality, regulatory, manufacturing, planning, logistics, finance and commercial teams working together, with clear escalation pathways and defined decision rights for critical materials. </span></p>
<p><b>Long-term measures to future-proof pharma packaging functions </b></p>
<p><span>First, build stronger local and regional packaging ecosystems. India’s pharma growth is increasingly being shaped by clusters such as Hyderabad Pharma City, Genome Valley, Jawaharlal Nehru Pharma City and Gujarat’s bulk drug park at Jambusar. Packaging must be part of this cluster thinking, with domestic strength in high-barrier films, pharma-grade polymers, glass, elastomers, compliant printing, serialisation, cold-chain packaging and sustainable material platforms. </span></p>
<p><span>Second, introduce packaging resilience scorecards. Each critical component should be evaluated for supply risk, supplier concentration, geography exposure, upstream dependency, lead time, regulatory complexity, alternate readiness, cost volatility and business impact. </span></p>
<p><span>Third, embed packaging in enterprise risk management. A company may secure API and manufacturing capacity, but if packaging is not available, the product still cannot reach the market. Senior leadership should review packaging risks for critical brands, export markets, tender products and patient-critical therapies. </span></p>
<p><span>Fourth, invest in packaging talent. The future packaging leader must understand geopolitics, trade corridors, regulatory pathways, supplier economics, sustainability, digital tools, manufacturing constraints and enterprise risk – moving from execution excellence to strategic resilience thinking. </span></p>
<p><span>Fifth, build distribution resilience into packaging validation. Transport simulation, lane qualification, temperature and humidity monitoring and shipper robustness must be revisited for critical products, given how quickly logistics lanes can change. </span></p>
<p><span>Sixth, connect sustainability with security of supply. The best sustainable solution for pharma will be one that reduces environmental impact without increasing patient risk or supply fragility. </span></p>
<p><span>Seventh, institutionalise scenario planning. Companies should ask: What if a major corridor is disrupted for three months? What if freight doubles? What if a key supplier allocates capacity? What if an imported resin becomes unavailable? Scenario thinking converts uncertainty into preparedness. </span></p>
<p><b>The human dimension: why this matters beyond industry metrics </b></p>
<p><span>Behind every packaging decision is a patient. A parent seeking a child’s antibiotic, a diabetic patient depending on regular therapy, a cancer patient waiting for treatment, a hospital pharmacy planning inventory, or a public health programme managing vaccine supply – each depends on supply continuity. Packaging supports that continuity quietly, protecting the product from moisture, light, oxygen, contamination, tampering, breakage, temperature variation and handling stress, while carrying information that helps patients and healthcare professionals use the medicine correctly. </span></p>
<p><span>When packaging fails or is delayed, even the best-manufactured medicine may not reach the patient on time. In a volatile world, packaging resilience is not a back-office topic. It is a public health enabler, and packaging leaders have a responsibility to make this visible to boards, regulators, suppliers and partners. </span></p>
<p><b>Conclusion: Preparedness is the new competitive advantage </b></p>
<p><span>Indian pharma has earned global trust through scale, quality, affordability and reliability. The next phase will test whether the sector can protect that trust in a more unstable world. Geopolitical uncertainty is no longer an external event that occasionally interrupts business. It is becoming a design condition for supply chains. </span></p>
<p><span>For packaging functions, the message is clear. The future will not be secured only by better materials or lower costs. It will be secured by resilient design, diversified sourcing, regulatoryready alternates, intelligent inventory, specification harmonisation, digital risk visibility, supplier partnership and strong cross-functional governance. </span></p>
<p><span>The way forward is not panic. It is preparedness. Indian pharma packaging must evolve from a downstream operational function to a strategic resilience function – protecting not only the product, but the promise behind the product: that medicines will reach patients safely, reliably and on time, even when the world around the supply chain is uncertain. </span></p>
<p><span>In a geopolitical crossfire, packaging becomes more than a container, closure, label or carton. It becomes a strategic shield for the medicine, the business and the patient. The organisations that recognise this early will be better prepared for what comes next. </span></p>
<p>The post <a href="https://www.expresspharma.in/geopolitics-and-pharma-packaging-building-greater-security-across-the-supply-chain/">Geopolitics and pharma packaging: Building greater security across the supply chain </a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>GST on vaccines: Time for clarity, not litigation</title>
<link>https://edusehat.com/en/gst-on-vaccines-time-for-clarity-not-litigation</link>
<guid>https://edusehat.com/en/gst-on-vaccines-time-for-clarity-not-litigation</guid>
<description><![CDATA[ 
Santosh Dalvi and Saurabh Jain highlight the need for clarity on GST classification of vaccines to reduce interpretational uncertainty and litigation
The post GST on vaccines: Time for clarity, not litigation appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/18102526/EP_GB_KPMG_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 18 Sep 2026 12:00:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>GST, vaccines:, Time, for, clarity, not, litigation</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/18102526/EP_GB_KPMG_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/18102526/EP_GB_KPMG_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/18102526/EP_GB_KPMG_750-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>As India continues to prioritise preventive healthcare and universal immunisation, a seemingly technical GST classification issue concerning vaccines has assumed considerable significance. Under Customs law, Vaccines have always been classified as ‘vaccines for human medicine’ or ‘vaccines for veterinary medicine’ However, the issue lies in GST rate classification wherein Entry 174 of Schedule I to Notification No. 1/2017-Central Tax (Rate), prescribes GST at 5 per cent for “Animal or Human Blood Vaccines” falling under Heading 3002.</span></p>
<p><span>While the intention behind granting a concessional rate for vaccines appears clear, the language used in the notification has given rise to interpretational uncertainty.</span></p>
<p><span>The expression “Animal or Human Blood Vaccines” is not a recognised category in medical science or pharmaceutical trade parlance. Consequently, questions have arisen regarding the scope of the entry and the GST rate applicable to vaccines.</span></p>
<p><span>Importantly, this ambiguity is not a recent development. As early as March 2018, the CGST authorities formally brought the issue to the attention of the GST Fitment Committee. The communication acknowledged the possibility of multiple interpretations of the entry and specifically recommended issuance of a clarification to avoid confusion among taxpayers and tax authorities. The Commissionerate further observed that such a clarification would greatly assist both trade and field formations. Despite the issue having been highlighted more than eight years ago, no definitive clarification has been issued. The resulting uncertainty has compelled taxpayers to adopt varying positions, thereby creating the very inconsistency that the GST framework sought to eliminate. </span></p>
<p><span>The issue has also come under judicial consideration. In a recent writ petition before the Hon’ble Bombay High Court, it was contended that there is no identifiable product known as “Animal or Human Blood Vaccines” and that the wording of the notification has given rise to avoidable interpretational concerns. The Court found prima facie substance in the contention and has since referred the same to the Ministry of Finance for consideration.</span></p>
<p><span>The significance of this issue extends beyond tax classification. Vaccines are essential public health products that play a critical role in disease prevention. Uncertainty regarding their tax treatment can lead to can result in interpretational disputes, increased compliance costs and avoidable litigation. A clear policy position would benefit both industry and tax administration while supporting the Government’s broader healthcare objectives. Given the long standing nature of the issue, stakeholders had expected greater clarity through the GST Council’s deliberations. With the council’s meeting now scheduled for 7</span><span>th</span><span> October the industry must wait a little longer for clarity. While the postponement provides additional time for deliberation, it also presents an opportunity for the Council to comprehensively resolve a dispute that has remained pending since the inception of GST.</span></p>
<p><span>The solution itself need not be complicated. A simple clarification explaining the intended scope would bring much needed certainty, reduce litigation and ensure uniform tax treatment across the sector. Varying interpretations of the relevant entry by GST authorities have given rise to multiple ongoing investigations.</span></p>
<p><span>More importantly, it would reaffirm the GST Council’s commitment to fostering a predictable and taxpayer-friendly indirect tax regime. It would strengthen confidence in the GST framework and demonstrate that genuine interpretational concerns can be addressed through timely and responsive policymaking rather than prolonged litigation.</span></p>
<p>The post <a href="https://www.expresspharma.in/gst-on-vaccines-time-for-clarity-not-litigation/">GST on vaccines: Time for clarity, not litigation</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Viatris’ Wakix receives Japanese approval to treat OSAS and narcolepsy</title>
<link>https://edusehat.com/en/viatris-wakix-receives-japanese-approval-to-treat-osas-and-narcolepsy</link>
<guid>https://edusehat.com/en/viatris-wakix-receives-japanese-approval-to-treat-osas-and-narcolepsy</guid>
<description><![CDATA[ The approval covers patients with OSAS who continue to experience EDS while receiving treatment for airway obstruction. It also applies to narcolepsy with and without cataplexy, a condition 
The post Viatris’ Wakix receives Japanese approval to treat OSAS and narcolepsy appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/09/PT-17-09-2026-shutterstock_1688252596.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 17 Sep 2026 18:05:15 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Viatris’, Wakix, receives, Japanese, approval, treat, OSAS, and, narcolepsy</media:keywords>
<content:encoded><![CDATA[<p>The approval covers patients with OSAS who continue to experience EDS while receiving treatment for airway obstruction.</p>
<p>It also applies to narcolepsy with and without cataplexy, a condition involving sudden muscle weakness.</p>
<p>Wakix is said to be the first histamine H3 receptor antagonist/inverse agonist to be authorised in Japan for these indications.</p>
<p>Viatris chief research and development (R&D) officer Philippe Martin said: “As Japan’s first approved histamine H3 receptor antagonist/inverse agonist for these conditions, Wakix offers a much-needed novel treatment option for patients.</p>
<p>“This milestone marks an important advancement for sleep medicine in Japan and brings forward a treatment option that is not classified as a controlled substance.</p>
<p>“We continue to strengthen Viatris’ innovative medicines portfolio in this strategically important market by investing in differentiated therapies for patients.”</p>
<p>The approval in Japan is based on encouraging domestic Phase III studies and supporting evidence from international clinical research.</p>
<p>Wakix is an orally administered therapy that modulates the brain’s sleep–wake pathways and is not classified as a controlled substance.</p>
<p>In Japan, pitolisant is licensed exclusively to Viatris by Bioprojet (Paris, France), the company that discovered the drug.</p>
<p>Wakix has previously received regulatory authorisation for narcolepsy in over 38 countries, including the US and countries in Europe, as well as for OSAS-related EDS in more than 29 European countries.</p>
<p>In Japan, the therapy received orphan drug designation for narcolepsy.</p>
<p>In December 2025, Viatris signed definitive agreements for the sale of its equity stake in Biocon Biologics to Biocon for $815m.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/viatris-wakix-japanese-approval-osas-narcolepsy/">Viatris’ Wakix receives Japanese approval to treat OSAS and narcolepsy</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Cellares and GenomeFrontier to assess automated GF&#45;CART01 production</title>
<link>https://edusehat.com/en/cellares-and-genomefrontier-to-assess-automated-gf-cart01-production</link>
<guid>https://edusehat.com/en/cellares-and-genomefrontier-to-assess-automated-gf-cart01-production</guid>
<description><![CDATA[ The collaboration, which marks Cellares’ first development project in Asia, will explore adapting GenomeFrontier’s virus-free process to the Cell Shuttle system. It aims to assist GenomeFrontier’s clinical activities 
The post Cellares and GenomeFrontier to assess automated GF-CART01 production appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/09/PT-2-17-09-2026-shutterstock_2709646703.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 17 Sep 2026 18:05:15 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Cellares, and, GenomeFrontier, assess, automated, GF-CART01, production</media:keywords>
<content:encoded><![CDATA[<p>The collaboration, which marks Cellares’ first development project in Asia, will explore adapting GenomeFrontier’s virus-free process to the Cell Shuttle system.</p>
<p>It aims to assist GenomeFrontier’s clinical activities for GF-CART01 in the US.</p>
<p>GF-CART01 is being developed for a range of B-cell malignancies. Target indications include diffuse large B-cell lymphoma, follicular lymphoma, high-grade B-cell lymphoma and primary mediastinal large B-cell lymphoma.</p>
<p>It has shown positive clinical trial data in Taiwan, and patient recruitment is ongoing for a Phase I trial in the US.</p>
<p>GenomeFrontier founder, CEO and chief scientific officer Sareina Wu said: “As we advance GF-CART01, it is important that our manufacturing strategy can support both clinical development and future scale.”</p>
<p>The evaluation will concentrate on translating GenomeFrontier’s manufacturing technique to the Cell Shuttle platform, particularly focusing on transfection operations using Cellares’ integrated electroporator.</p>
<p>The companies aim to examine the feasibility of automating the process while maintaining the flexibility GenomeFrontier’s virus-free system requires.</p>
<p>Cellares co-founder and CEO Fabian Gerlinghaus said: “GenomeFrontier’s virus-free approach reflects the increasing complexity of next-generation cell therapy manufacturing.</p>
<p>“The Cell Shuttle is built to automate complex processes, including electroporation-based workflows, with the scalability and reliability needed as therapies advance through clinical development. This partnership brings that capability to GenomeFrontier as it expands its programme in the US.”</p>
<p>Autologous CAR-T production is typically labour-intensive, variable and challenging to scale, which affects manufacturing reliability, cost and patient access.</p>
<p>Cellares’ Cell Shuttle is intended to address these challenges by automating end-to-end cell therapy manufacturing.</p>
<p>GenomeFrontier and Cellares intend to establish whether the automated process can support the virus-free approach, with objectives to enhance reliability and reduce costs.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/cellares-genomefrontier-gf-cart01-production/">Cellares and GenomeFrontier to assess automated GF-CART01 production</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Oncodesign Services, Nexus BioQuest partners to give biotechs a clearer route</title>
<link>https://edusehat.com/en/oncodesign-services-nexus-bioquest-partners-to-give-biotechs-a-clearer-route</link>
<guid>https://edusehat.com/en/oncodesign-services-nexus-bioquest-partners-to-give-biotechs-a-clearer-route</guid>
<description><![CDATA[ 
Oncodesign Services and Nexus BioQuest have formed a partnership connecting their respective in vitro and in vivo expertise, giving biotech companies a clearer route to specialist support as preclinical programs progress. The collaboration links Nexus BioQuest’s human-relevant in vitro expertise with Oncodesign Services’ three decades of experience in in vivo pharmacology. With shared experience across […]
The post Oncodesign Services, Nexus BioQuest partners to give biotechs a clearer route appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/17123529/EP_Oncodesign-Services.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 17 Sep 2026 18:05:13 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Oncodesign, Services, Nexus, BioQuest, partners, give, biotechs, clearer, route</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/17123529/EP_Oncodesign-Services.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/17123529/EP_Oncodesign-Services.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/17123529/EP_Oncodesign-Services-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Oncodesign Services and Nexus BioQuest have formed a partnership connecting their respective </span><i><span>in vitro</span></i><span> and </span><i><span>in vivo</span></i><span> expertise, giving biotech companies a clearer route to specialist support as preclinical programs progress.</span></p>
<p><span>The collaboration links Nexus BioQuest’s human-relevant </span><i><span>in vitro </span></i><span>expertise with Oncodesign Services’ three decades of experience in </span><i><span>in vivo</span></i><span> pharmacology. With shared experience across oncology, inflammation and autoimmunity, the two companies will be able to contribute complementary scientific approaches within individual development programs. </span></p>
<p><span>The partnership is intended to give biotech companies, particularly those with compact internal teams, access to specialist capabilities from either organization as their scientific requirements evolve. Where appropriate, clients can involve both teams in discussions around preclinical study requirements, while retaining the flexibility to select the studies and providers relevant to their program. </span></p>
<p><span>Nexus BioQuest brings expertise in human primary cell-based immunology, combining translational 2D and 3D models that integrate immune cells and relevant tissue targets with validated and bespoke assay development across immuno-oncology, inflammation and autoimmunity. Oncodesign Services’ capabilities include syngeneic, patient-derived xenograft (PDX), cell-derived xenograft (CDX) and humanized immune system </span><i><span>in vivo</span></i><span> models, inflammatory disease models, radiopharmaceuticals, and preclinical imaging. These complementary capabilities give biotech teams access to different types of preclinical evidence to support informed decision-making as their scientific requirements evolve.</span></p>
<p><span>Endometriosis is a proof-of-concept for this joint approach and an emerging therapeutic area for immune targeting drugs within the broader women’s health and inflammation space. As endometriosis is a highly complex, multifactorial disease, this is an area where Nexus BioQuest’s </span><i><span>in vitro</span></i><span> primary cell inflammatory models can be used to complement Oncodesign Services’ validated </span><i><span>in vivo</span></i><span> endometriosis models that can assess pathophysiological endpoints including lesion development, fibrosis and inflammatory responses. </span></p>
<p><span>Aidan Synnott, CEO at Oncodesign Services, said: “For biotech teams, the challenge is often not finding another CRO, but finding the right expertise for the scientific question they need to answer next.</span></p>
<p><span>“We know the Nexus BioQuest team and the quality of its science, which means we can make an introduction with confidence when a program needs capabilities outside of our specialist scope. The same applies in the other direction. For researchers, it provides a route to another specialist team without having to start that search from scratch. Our goal is to help minimize the uncertainty and risk that go hand-in-hand with limited funds and timelines.”</span></p>
<p><span>Both organizations emphasize close scientific collaboration with clients and adapting study approaches as new questions emerge during a program.</span></p>
<p><span>Will Parish, CEO at Nexus BioQuest, said: “Early drug discovery rarely comes down to a single experiment or model. There are points where you need to understand what is happening in a human-relevant </span><i><span>in vitro</span></i><span> system and others where an </span><i><span>in vivo</span></i><span> model can provide a different level of insight.</span></p>
<p><span>“Having access to trusted specialist expertise in both areas gives biotech teams a clearer route to the support they need at different points in preclinical development, helping them make more informed decisions about where to place their work.”</span></p>
<p><span>Recommendations made through the partnership will be based on the scientific requirements of each program and where partner organizations can bring the most relevant expertise, providing clients with informed choices and full control over which provider they engage and how their program is staged.</span></p>
<p>The post <a href="https://www.expresspharma.in/oncodesign-services-nexus-bioquest-partners-to-give-biotechs-a-clearer-route/">Oncodesign Services, Nexus BioQuest partners to give biotechs a clearer route</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Dr. Reddy’s expands collaboration with Gilead Sciences for investigational once&#45;yearly lenacapavir for HIV prevention</title>
<link>https://edusehat.com/en/dr-reddys-expands-collaboration-with-gilead-sciences-for-investigational-once-yearly-lenacapavir-for-hiv-prevention</link>
<guid>https://edusehat.com/en/dr-reddys-expands-collaboration-with-gilead-sciences-for-investigational-once-yearly-lenacapavir-for-hiv-prevention</guid>
<description><![CDATA[ 
Dr. Reddy’s Laboratories announced a royalty-free non-exclusive voluntary licensing agreement with Gilead Sciences for investigational once-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP). The agreement builds on Dr. Reddy’s existing voluntary licensing arrangement with Gilead, signed in October 2024, for twice-yearly lenacapavir for HIV prevention and treatment and reflects the continued confidence between the […]
The post Dr. Reddy’s expands collaboration with Gilead Sciences for investigational once-yearly lenacapavir for HIV prevention appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/15105219/Dr.-Reddys-building.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 17 Sep 2026 18:05:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Dr., Reddy’s, expands, collaboration, with, Gilead, Sciences, for, investigational, once-yearly, lenacapavir, for, HIV, prevention</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="431" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/15105219/Dr.-Reddys-building.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/15105219/Dr.-Reddys-building.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/15105219/Dr.-Reddys-building-300x172.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Dr. Reddy’s Laboratories announced a royalty-free non-exclusive voluntary licensing agreement with Gilead Sciences for investigational once-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP).</span></p>
<p><span>The agreement builds on Dr. Reddy’s existing voluntary licensing arrangement with Gilead, signed in October 2024, for twice-yearly lenacapavir for HIV prevention and treatment and reflects the continued confidence between the two companies as they work towards broadening future access to long-acting HIV prevention options in licensed markets.</span></p>
<p><span>The agreement aims to facilitate manufacturing readiness, technology transfer and future supply planning for investigational once-yearly lenacapavir while clinical development efforts continue in the licensed territories, primarily low- and lower-middle-income countries.</span></p>
<p><span>The collaboration further strengthens Dr. Reddy’s Public Health Access portfolio, which focuses on improving access to medicines across communicable diseases, reproductive health, and maternal and child health. HIV continues to represent a significant global public health challenge, underscoring the need for innovative long-acting prevention options.</span></p>
<p><span>“At Dr. Reddy’s, we are committed to improving patient access to innovative medicines across the world,” said Deepak Sapra, Chief Executive Officer, API and Services, Dr. Reddy’s Laboratories Ltd. “This agreement builds on our existing collaboration with Gilead and reflects our continued commitment to supporting global HIV prevention efforts. If approved, investigational once-yearly lenacapavir may offer an additional long-acting HIV prevention option for people at risk of HIV acquisition, particularly in regions where access and adherence remain significant challenges.</span><span><br>
</span></p>
<p><span>Investigational once-yearly lenacapavir is currently being evaluated in Gilead’s ongoing Phase 3 PURPOSE 365 study. Once-yearly lenacapavir for HIV prevention is investigational and has not been approved by any regulatory authority. Its safety and efficacy have not been established.</span></p>
<p>The post <a href="https://www.expresspharma.in/dr-reddys-expands-collaboration-with-gilead-sciences-for-investigational-once-yearly-lenacapavir-for-hiv-prevention/">Dr. Reddy’s expands collaboration with Gilead Sciences for investigational once-yearly lenacapavir for HIV prevention</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Alkem launches NeuCeno for treatment of partial&#45;onset seizures in adult patients</title>
<link>https://edusehat.com/en/alkem-launches-neuceno-for-treatment-of-partial-onset-seizures-in-adult-patients</link>
<guid>https://edusehat.com/en/alkem-launches-neuceno-for-treatment-of-partial-onset-seizures-in-adult-patients</guid>
<description><![CDATA[ 
Alkem Laboratories announced the launch of NeuCeno (cenobamate), anti-seizure medication (ASM) for the treatment of partial-onset seizures in adult patients. Cenobamate, being launched for the first time in India, represents a significant advancement in the management of epilepsy.  NeuCeno is a once daily oral therapy, and is available in 12.5 mg, 25 mg, 50 mg, […]
The post Alkem launches NeuCeno for treatment of partial-onset seizures in adult patients appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2024/09/02120205/Colourful-medicines.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 17 Sep 2026 18:05:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Alkem, launches, NeuCeno, for, treatment, partial-onset, seizures, adult, patients</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2024/09/02120205/Colourful-medicines.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2024/09/02120205/Colourful-medicines.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2024/09/02120205/Colourful-medicines-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>Alkem Laboratories announced the launch of NeuCeno (cenobamate), anti-seizure medication (ASM) for the treatment of partial-onset seizures in adult patients. Cenobamate, being launched for the first time in India, represents a significant advancement in the management of epilepsy. </span></p>
<p><span>NeuCeno is a once daily oral therapy, and is available in 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg and 200 mg tablets. Epilepsy is a significant healthcare burden in India, with an estimated 9.4 million people living with the condition. </span></p>
<p><span>Despite the availability of multiple anti-seizure medications, a significant proportion of patients continue to experience uncontrolled seizures, substantially affecting their independence, daily functioning and overall quality of life. NeuCeno (cenobamate) acts through a unique dual mechanism of action, selectively inhibiting the persistent sodium current that drives repetitive neuronal firing, while enhancing the brain’s natural inhibitory signaling via positive modulation of GABA-A receptors. </span></p>
<p><span>In randomized clinical studies of adults with uncontrolled focal seizures on existing anti-seizure medications, adjunctive cenobamate produced up to 78% reduction in seizure frequency, with up to 30% patients achieving seizure freedom during the maintenance phase.   </span></p>
<p><span>Commenting on the launch, Sandeep Singh, Managing Director, Alkem Laboratories Limited, said, “People living with epilepsy and their caregivers face significant challenges in achieving effective seizure control. Cenobamate has the potential to transform treatment outcomes towards delivering better epilepsy management. At Alkem, we believe patients deserve access to advanced treatment options that can help address unmet medical needs. With the launch of NeuCeno (cenobamate), we reaffirm our commitment to improving patient care by enabling access to an important therapeutic option and supporting healthcare professionals in making informed treatment decisions for adults living with partial-onset seizures.” </span></p>
<p><span>Alkem remains committed to advancing high-quality, affordable medicines across key therapeutic areas and supporting better patient care in India.</span></p>
<p>The post <a href="https://www.expresspharma.in/alkem-launches-neuceno-for-treatment-of-partial-onset-seizures-in-adult-patients/">Alkem launches NeuCeno for treatment of partial-onset seizures in adult patients</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Unclogging India’s innovation pipeline </title>
<link>https://edusehat.com/en/unclogging-indias-innovation-pipeline</link>
<guid>https://edusehat.com/en/unclogging-indias-innovation-pipeline</guid>
<description><![CDATA[ 
Innovation is often measured through rankings, patents and startup success stories. While these are important indicators, they capture only a part of the picture. A truly innovation-led economy is built […]
The post Unclogging India’s innovation pipeline  appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/16133226/EP_Srinath.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 17 Sep 2026 00:05:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Unclogging, India’s, innovation, pipeline </media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/16133226/EP_Srinath.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/16133226/EP_Srinath.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/16133226/EP_Srinath-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p>Innovation is often measured through rankings, patents and startup success stories. While these are important indicators, they capture only a part of the picture. A truly innovation-led economy is built on a continuous pipeline that connects STEM education, scientific research and industry. When even one part of that pipeline weakens, the country’s ability to translate ideas into real-world impact is constrained.</p>
<p>Going by the numbers, India appears to be on the cusp of being considered as an innovation-driven economy. However, that deserves a closer look.</p>
<p>India produces around 2.6 million STEM graduates each year, including around 1.5 million engineers. Over the past decade, the country has risen from 66th 3 to 38th 4 rank in the Global Innovation Index, while its startups ecosystem has grown to more than 0.2 million DPIIT-recognised startups. These achievements reflect India’s growing ambition to become an innovation-led economy, but they also invite a deeper question: are we strengthening every part of the innovation pipeline that makes such progress sustainable?</p>
<p>These are encouraging signs that India’s innovation ambitions are gathering momentum. Yet, innovation cannot be measured solely by outputs such as rankings or startup numbers. The strength of any innovation ecosystem lies in its ability to consistently generate, nurture and translate scientific knowledge into meaningful economic and societal outcomes.</p>
<p>But statistics often hide a more important story.</p>
<p>The real question is not whether India is producing talent, but whether it is creating the conditions for that talent to become researchers, innovators and problem-solvers. This is where the country’s innovation pipeline begins to narrow. Of the 1.5 million people who graduate with a science degree each year, about half enrol in post-graduate degrees, and slightly less than half (365,000) graduate, according to AISHE. The funnel narrows further: 7,400 candidates are awarded a PhD in sciences each year.</p>
<p>What emerges is a ‘missing middle’- the crucial layer of scientific research that connects education with industrial innovation.</p>
<p>One number presents the culmination of all the data shared above: the number of full-time equivalent (FTE) researchers per million people. That figure is just 255 in India, against a global average of 1,1987. This gap is significant because research capacity ultimately determines how quickly ideas move from laboratories into products, technologies and scalable solutions. Countries that consistently lead in innovation invest not only in talent, but also in creating an environment where researchers can thrive.</p>
<p>India’s rise to 38th rank in the Global Innovation Index is encouraging. India has been climbing up the list by one rank over the last three years. Sustaining this trajectory will require translating scientific research into globally competitive products, technologies and companies, if the country is to join the world’s leading innovation economies. As experts have pointed out, cutting-edge research is happening so fast that the country cannot afford to fall too far behind.</p>
<p>The government’s ambitions on innovation are clearly laid out as part of Viksit Bharat and Atmanirbhar Bharat. In this year’s Union Budget, finance minister Nirmala Sitharaman announced a Research, Development and Innovation (RDI) fund of Rs 1 trillion (Rs 1 lakh crore), of which Rs 200 billion (or Rs 20,000 crore) will be allocated in this financial year itself. This includes a Deep Tech fund and financial resources targeted at advanced materials, robotics and artificial intelligence (AI).</p>
<p>These policy measures signal an important shift in how India views research and innovation, not as isolated scientific pursuits, but as strategic drivers of economic growth, technological self-reliance and global competitiveness. Funding is undoubtedly essential, but its real value lies in creating an ecosystem where researchers, startups, academia and industry can work together with shared purpose.</p>
<p>In 2023, the government established the Anusandhan National Research Foundation (ANRF) through an Act of Parliament. One of its main objectives was to promote industry academia collaboration in R&D.</p>
<p>While India’s investment in R&D (0.64% of GDP) remains below that of many innovationled economies, an equally important challenge is broadening participation beyond government funding. Innovation ecosystems are strongest when public investment is complemented by sustained commitment from industry. Industries are not simply end-users of research; they are partners in shaping research priorities, investing in translational research, accelerating commercialisation and building futureready capabilities.</p>
<p>India must find ways to address this ‘missing middle’, and that must start with STEM education. Building research capacity is not simply about increasing the number of PhD programmes or research institutions. It is about creating an environment where curiosity is encouraged, interdisciplinary collaboration is valued and young researchers see long term opportunities to pursue scientific discovery. A strong innovation ecosystem is built over decades, through consistent investment in people as much as infrastructure.</p>
<p>First, teaching and research must both be strengthened significantly on an accelerated basis, using financing provided for in the Union Budget and the ANRF Fund. Resources from other initiatives and missions sponsored by the government can also play a key role in developing world-class lab infrastructure, shared scientific facilities and faster access to advanced instrumentation. The will exists, and ways must be found.</p>
<p>Second, STEM education and pedagogy must be integrated into skills, built on foundational education, specialised education, opportunities, and innovation. Included in all of this must be ways of translating research outputs into applied science and solutions that meet industrial and technological needs.</p>
<p>Third, drawing from the two steps outlined above, industry-academia collaboration must increase significantly. In healthcare, climate science and energy, and advanced materials sciences, such collaboration can begin with institutions of national importance like the Indian Institute of Technology, the Indian Institute of Science, and specialised institutions. These are already primed to do this; what is needed is rapid expansion of such activity.</p>
<p>For private sector corporate strategy, the goal of R&D is to create new sources of competitive advantage. Nationwide, companies haven’t been doing enough; that can change now. R&D is a layered phenomenon; addressing the layers can help us understand how to go about maximising what companies and the country at large can get out of investing in it. India’s aspiration to become an innovation-led economy cannot be achieved by government or academia alone. It requires industry to move from being a consumer of innovation to becoming a co-creator of it.</p>
<h6 dir="ltr"><span>
<p>Sources </p></span></h6>
<h6 dir="ltr"><span>1https://educationforallinindia.co m/the-stem-pipeline-in-indiafrom-science-classrooms-to-stemdegrees/ </span></h6>
<h6 dir="ltr"><span>2 https://www.pib.gov.in/Pressreleaseshare.aspx?PRID=1702450 ®=48&lang=2 3https://www.wipo.int/edocs/pubdocs/en/economics/gii/gii_2013.pd f 4https://www.wipo.int/web-publications/global-innovation-index2025/en/gii-2025-results.html 5https://www.pib.gov.in/PressReleasePage.aspx?PRID=2214872 ®=3&lang=2 6https://www.education.gov.in/sit es/upload_files/mhrd/files/statistics-new/AISHE%20Book_2021- 22_4.pdf 7https://dst.gov.in/sites/default/fil es/S%26T%20Indicators%20Tables%2C%202019- 20.pdf?utm_source=chatgpt.com 8https://www.pib.gov.in/PressReleasePage.aspx?PRID=2150817 ®=48&lang=2 9https://www.pib.gov.in/PressReleasePage.aspx?PRID=2153547 ®=3&lang=2 </span></h6>
<h6><span> </span></h6>
<p>The post <a href="https://www.expresspharma.in/unclogging-indias-innovation-pipeline/">Unclogging India’s innovation pipeline </a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>DoP Secretary Manoj Joshi visits Amneal Pharmaceuticals in Ahmedabad</title>
<link>https://edusehat.com/en/dop-secretary-manoj-joshi-visits-amneal-pharmaceuticals-in-ahmedabad</link>
<guid>https://edusehat.com/en/dop-secretary-manoj-joshi-visits-amneal-pharmaceuticals-in-ahmedabad</guid>
<description><![CDATA[ 
Manoj Joshi, Secretary, Department of Pharmaceuticals, Government of India, visited Amneal Pharmaceuticals’ corporate office in Ahmedabad on Tuesday and met with company leaders to discuss Amneal’s growth, investments, pipeline and […]
The post DoP Secretary Manoj Joshi visits Amneal Pharmaceuticals in Ahmedabad appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/16140303/EP_DoP-Amneal.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 17 Sep 2026 00:05:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>DoP, Secretary, Manoj, Joshi, visits, Amneal, Pharmaceuticals, Ahmedabad</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/16140303/EP_DoP-Amneal.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/16140303/EP_DoP-Amneal.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/16140303/EP_DoP-Amneal-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p>Manoj Joshi, Secretary, Department of Pharmaceuticals, Government of India, visited Amneal Pharmaceuticals’ corporate office in Ahmedabad on Tuesday and met with company leaders to discuss Amneal’s growth, investments, pipeline and expanding capabilities. The discussions covered Amneal’s contribution to pharmaceutical manufacturing and innovation and its expanded biosimilars capabilities following the acquisition of Kashiv BioSciences.</p>
<p><span>The discussions highlighted Amneal’s growing contribution to India’s pharmaceutical ecosystem through its manufacturing footprint, investments in advanced manufacturing and R&D and capabilities across complex generics, injectables, peptides and APIs. Amneal also shared an overview of its diversified global manufacturing expertise, innovation capabilities, partnerships and its role in supporting global pharmaceutical supply chains.</span></p>
<p><span>Amneal’s recent acquisition of Kashiv BioSciences has further strengthened these capabilities, creating a fully integrated global biosimilars platform spanning research, development, manufacturing and commercialisation. The combination brings together Kashiv’s biologics capabilities with Amneal’s commercial and manufacturing scale, expanding the company’s biosimilars pipeline and positioning the business for long-term growth.</span></p>
<p><span>The visit also included a discussion of India’s opportunity to build on its pharmaceutical manufacturing capabilities and advance biopharmaceutical innovation, including through greater investment in R&D, innovation capital, advanced infrastructure, industry-academia collaboration and regulatory science. These priorities are reflected in the Government’s proposed Biopharma SHAKTI programme, with an outlay of ₹10,000 crore over five years to elevate India’s biopharmaceutical ecosystem.</span></p>
<p><span>Dr. Parva Purohit, Senior Vice President and Head R&D, Amneal Pharmaceuticals, said, “India has a strong foundation in pharmaceutical manufacturing and now has an opportunity to add greater depth in biopharmaceutical innovation. At Amneal, we remain committed to building capabilities across manufacturing, R&D, biosimilars and complex medicines.”</span></p>
<p><span>Rahul Maitra, Senior VP, Human Resources, Amneal, added, “We are encouraged by Manoj Joshi’s visit and the productive discussion towards skill development efforts that are underway within the existing government schemes. Pharmaceuticals industry in India is growing rapidly, both in terms of R&D as well as manufacturing.  Hence it is important that equal emphasis is laid on industry-academia- government collaborations to attain trained and industry-ready workforce.”</span></p>
<p><span>During the visit, Amneal leaders and Secretary Manoj Joshi discussed the company’s investments and growing capabilities across manufacturing, R&D, biosimilars and complex medicines. The discussion also covered the challenges and enablers for biopharmaceutical growth, including innovation capital, advanced research infrastructure, industry-academia-government collaboration and regulatory science.</span></p>
<p><span>The interaction reinforced the importance of continued government-industry collaboration to strengthen India’s biopharmaceutical capabilities, advance innovation and support investment in advanced manufacturing.</span></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/dop-secretary-manoj-joshi-visits-amneal-pharmaceuticals-in-ahmedabad/">DoP Secretary Manoj Joshi visits Amneal Pharmaceuticals in Ahmedabad</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Yokogawa wins orders from Kawasaki Heavy Industries for hydrogen vessels</title>
<link>https://edusehat.com/en/yokogawa-wins-orders-from-kawasaki-heavy-industries-for-hydrogen-vessels</link>
<guid>https://edusehat.com/en/yokogawa-wins-orders-from-kawasaki-heavy-industries-for-hydrogen-vessels</guid>
<description><![CDATA[ 
The orders cover integrated automation systems for a 40,000 m³ liquefied hydrogen carrier and two hydrogen-fuelled vessels
The post Yokogawa wins orders from Kawasaki Heavy Industries for hydrogen vessels appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/16162516/EP_Yokogawa_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 17 Sep 2026 00:05:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Yokogawa, wins, orders, from, Kawasaki, Heavy, Industries, for, hydrogen, vessels</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/16162516/EP_Yokogawa_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/16162516/EP_Yokogawa_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/16162516/EP_Yokogawa_750-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>Yokogawa Electric Corporation (TOKYO: 6841) announces that it has received orders from Kawasaki Heavy Industries, Ltd. to supply integrated automation systems for a 40,000 m³ liquefied hydrogen carrier that will be the world’s largest vessel of its type, and for two hydrogen-fueled vessels. The company will contribute to the realisation of a sustainable society by supporting the promotion of new energy utilisation through the provision of monitoring and control solutions for the hydrogen supply chain, including storage and transportation.</span></p>
<p><span>As the adoption of hydrogen accelerates, establishing a supply chain capable of safely transporting and storing large volumes of hydrogen is increasingly important. Liquefied hydrogen is expected to play a key role in such a supply chain, while efforts to use hydrogen as a maritime fuel are also progressing. In Japan, demonstration projects covering the entire hydrogen supply chain are underway for the commercialisation of liquefied hydrogen.</span></p>
<p><span>The system that Yokogawa will supply for the liquefied hydrogen carrier provides integrated monitoring and control of onboard equipment and incorporates emergency shutdown functions. It supports the safe and efficient handling of liquefied hydrogen that is transported at extremely low temperatures, helping to ensure safe and reliable vessel operations. In addition, its advanced integrated control capabilities will help to improve equipment performance and reduce crew workload throughout the vessel’s lifecycle.</span></p>
<p><span>Yokogawa has also received an order to supply integrated automation systems for marine hydrogen fuel systems (MHFS) that are to be installed on hydrogen-fueled vessels. An MHFS consists of liquefied hydrogen tanks and fuel supply equipment, and is a key technology for advancing maritime decarbonisation.</span></p>
<p><span>These vessels are being built as part of a Green Innovation Fund project led by Japan’s New Energy and Industrial Technology Development Organization (NEDO) and will support safe, large-scale maritime transportation, contributing to the development of the liquefied hydrogen supply chain and the transition to a sustainable society.</span></p>
<p><span>Koji Nakaoka, a Yokogawa Electric executive vice president & executive officer and head of the company’s Energy & Sustainability Business Headquarters, commented, “Yokogawa has extensive experience with liquefied natural gas carriers, and our technology is also being applied to liquefied hydrogen carriers. Leveraging the technologies and expertise we have developed in the field of control and safety instrumentation, we will continue to provide solutions that support safe and reliable operations for our customers in the energy sector, including hydrogen.”</span></p>
<p>The post <a href="https://www.expresspharma.in/yokogawa-wins-orders-from-kawasaki-heavy-industries-for-hydrogen-vessels/">Yokogawa wins orders from Kawasaki Heavy Industries for hydrogen vessels</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Eli Lilly and QurCan sign genetic medicine deal</title>
<link>https://edusehat.com/en/eli-lilly-and-qurcan-sign-genetic-medicine-deal</link>
<guid>https://edusehat.com/en/eli-lilly-and-qurcan-sign-genetic-medicine-deal</guid>
<description><![CDATA[ The companies intend to work together on several research programmes focused on QurCan’s Target-Engineered Responsive Polymer (TERP) polymer-lipid nanoparticle (PLNP) delivery platform development. QurCan uses its TERP platform 
The post Eli Lilly and QurCan sign genetic medicine deal appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/09/PT-16-09-2026-shutterstock_1385338208.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 16 Sep 2026 18:35:14 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Eli, Lilly, and, QurCan, sign, genetic, medicine, deal</media:keywords>
<content:encoded><![CDATA[<p>The companies intend to work together on several research programmes focused on QurCan’s Target-Engineered Responsive Polymer (TERP) polymer-lipid nanoparticle (PLNP) delivery platform development.</p>
<p>QurCan uses its TERP platform to facilitate non-viral delivery of genetic medicines.</p>
<p>The collaboration will see the Canada-based company optimise genetic therapeutics using this technology, with Lilly overseeing further research, clinical development, and commercialisation of selected projects.</p>
<p>QurCan will receive an upfront payment and a strategic investment from Lilly as part of the agreement.</p>
<p>In addition, QurCan is eligible for research support payments, and could receive research, development and commercial milestone payments of up to $237m per programme.</p>
<p>The agreement also includes potential for the company to earn tiered royalties on global net sales of any commercialised products.</p>
<p>QurCan Therapeutics CEO Mohammad Ali Amini said: “This collaboration with Lilly represents a validation of our PLNP technology platform and its potential to address some of the most challenging delivery problems in genetic medicine.</p>
<p>“The CNS and PNS remain among the most underserved areas in genetic medicine delivery, and we believe our non-viral approach offers a differentiated and versatile solution across various nucleotide cargos.</p>
<p>“We are thrilled to work with Lilly, a company with unparalleled expertise in neuroscience drug development and commercialisation, to bring these therapies to patients who urgently need them.”</p>
<p>QurCan’s TERP platform enables systemic, repeat-dosable and targeted delivery of messenger ribonucleic acid (mRNA), deoxyribonucleic acid (DNA), and oligonucleotide payloads to relevant cells.</p>
<p>Last month, the US Food and Drug Administration granted breakthrough therapy designation to Lilly’s olomorasib as a potential treatment for adults with advanced pancreatic cancer who have already received at least one prior systemic therapy.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/eli-lilly-qurcan-genetic-medicine-deal/">Eli Lilly and QurCan sign genetic medicine deal</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Gilead and PAHO agree to expedite lenacapavir access for HIV prevention</title>
<link>https://edusehat.com/en/gilead-and-paho-agree-to-expedite-lenacapavir-access-for-hiv-prevention</link>
<guid>https://edusehat.com/en/gilead-and-paho-agree-to-expedite-lenacapavir-access-for-hiv-prevention</guid>
<description><![CDATA[ The arrangement offers a new regional pathway for long-acting HIV prevention in all PAHO Member States through its Regional Revolving Funds. The collaboration enables 14 countries, including Argentina, 
The post Gilead and PAHO agree to expedite lenacapavir access for HIV prevention appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/09/PT-2-16-09-2026-shutterstock_2486304439.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 16 Sep 2026 18:35:13 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Gilead, and, PAHO, agree, expedite, lenacapavir, access, for, HIV, prevention</media:keywords>
<content:encoded><![CDATA[<p>The arrangement offers a new regional pathway for long-acting HIV prevention in all PAHO Member States through its Regional Revolving Funds.</p>
<p>The collaboration enables 14 countries, including Argentina, Brazil, Chile, Ecuador, Mexico, Peru, Uruguay, and Venezuela, to access lenacapavir for PrEP outside of Gilead’s current voluntary licensing agreements.</p>
<p>This complements existing generic access mechanisms and aims to address gaps in prevention, particularly after a reported 13% rise in new HIV infections between 2010 and 2024 in the region.</p>
<p>According to Gilead, the partnership is built upon ongoing efforts to improve HIV prevention in Latin America and the Caribbean.</p>
<p>This includes the PURPOSE 2 trial, which assessed the safety and efficacy of lenacapavir as PrEP and forms part of the company’s commitment to support broader prevention strategies.</p>
<p>Gilead Sciences chief commercial and corporate affairs officer Johanna Mercier said: “The agreement between Gilead and PAHO reflects our shared commitment to help countries move as quickly as possible from scientific innovation to real-world access to HIV prevention and public health impact.</p>
<p>“For decades, Gilead has worked alongside governments, public health organisations and communities to expand access to HIV innovation around the world. These strategic partnerships are essential to our ambition to help end the HIV epidemic.</p>
<p>“This agreement demonstrates how collaboration can help accelerate access, support country-led implementation and create the conditions for sustainable scale.”</p>
<p>Gilead will continue to explore further work with PAHO and other regional partners, including support for local production in Brazil, as part of its ongoing global access strategy for lenacapavir, which includes voluntary licensing, technology transfer, and non-profit supply.</p>
<p>Lenacapavir is currently approved in multiple countries for both HIV prevention and treatment of multi-drug-resistant HIV.</p>
<p>Prior to this, Gilead Sciences opened a new 182,000ft² research centre at its Foster City headquarters in California, US, for advancing medicines to treat challenging diseases.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/gilead-paho-lenacapavir-hiv-prevention/">Gilead and PAHO agree to expedite lenacapavir access for HIV prevention</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>From scale to science: Ahmedabad’s pharma ecosystem at crossroads </title>
<link>https://edusehat.com/en/from-scale-to-science-ahmedabads-pharma-ecosystem-at-crossroads</link>
<guid>https://edusehat.com/en/from-scale-to-science-ahmedabads-pharma-ecosystem-at-crossroads</guid>
<description><![CDATA[ 
The Formulation Development and Drug Delivery (FDD) Conclave has become a meeting ground for India’s formulation R&amp;D community. Scientists, innovators, and industry leaders gather to exchange ideas and tackle real […]
The post From scale to science: Ahmedabad’s pharma ecosystem at crossroads  appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/16124656/EP_Ahmedabad-FDD.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 16 Sep 2026 15:00:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>From, scale, science:, Ahmedabad’s, pharma, ecosystem, crossroads </media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/16124656/EP_Ahmedabad-FDD.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/16124656/EP_Ahmedabad-FDD.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/16124656/EP_Ahmedabad-FDD-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p dir="ltr"><span>The Formulation Development and Drug Delivery (FDD) Conclave has become a meeting ground for India’s formulation R&D community. Scientists, innovators, and industry leaders gather to exchange ideas and tackle real challenges in formulation science and drug delivery.</span></p>
<p></p>
<p dir="ltr"><span>However, FR&D is no longer just about getting a molecule to market. It is about how well that molecule scales and whether the formulation holds up under real manufacturing conditions. It is about whether patients actually benefit.</span></p>
<p></p>
<p dir="ltr"><span>So, Express Pharma decided to take the FDD Conclave beyond a single annual event, and into the country’s key pharma hubs.</span></p>
<p></p>
<p dir="ltr"><span>Ahmedabad was a natural stop. The city brings together formulation R&D, manufacturing excellence, and scientific talent in one ecosystem. It is home to leading pharma companies, research centres, CDMOs, and CROs. That combination has helped strengthen India’s position in global pharma markets.</span></p>
<p></p>
<p dir="ltr"><span>The FDD Conclave: Ahmedabad Connect built on that strength. Its theme, Innovation at scale: Advancing FR&D for global markets, set the frame for everything that followed. Ahmedabad already has scale, manufacturing capacity, cost efficiency, a deep base of generic drug production. But, can it also become a city built on innovation, without giving up what made it strong in the first place was the real focus of the event.</span></p>
<p></p>
<p dir="ltr"><span>Rethinking success</span></p>
<p></p>
<p dir="ltr"><span>The conference opened with a panel titled, ‘Are we measuring FR&D success the right way?’ Lakshmipriya Nair, Assistant Editor, Express Pharma, moderated this panel discussion which included other experts like Dr Parva Purohit, Sr VP – R&D, Amneal Pharmaceuticals. Dr Amarender Reddy Donthidi, VP and Head of R&D for Injectables and Ophthalmics, Amneal Pharmaceuticals and Ravikiran Bhabad, Deputy GM – OSD, FTF Pharma, a Shilpa Medicare subsidiary.</span></p>
<p></p>
<p dir="ltr"><span>The conversation moved through several layers of the same question. What actually defines FR&D success today? Is it enough to look at approvals and launches, or does real impact sit somewhere else? Do the KPIs teams actually drive the right behaviours, or do they just reward speed? The experts agreed that speed still matters, but it cannot come at the cost of quality. R&D teams need agility too. Markets shift, regulations change and teams have to keep up.</span></p>
<p></p>
<p dir="ltr"><span>The panel’s larger point was about scope. Success is not just a launch. It runs from early development through to manufacturing. A weak link anywhere in that chain puts patient safety at risk.</span></p>
<p></p>
<p dir="ltr"><span>That reframing had a practical implication. If FR&D outcomes are meant to link to business growth, the scorecard used to judge them has to change too. A metric built only around timelines will miss whether a product actually scales, or whether it holds up once it leaves the lab. The panel’s conclusion was clear. The FR&D scorecard of the future needs to weigh manufacturability, quality, and downstream performance alongside speed, not treat them as separate conversations.</span></p>
<p></p>
<p dir="ltr"><span>The formulation toolbox</span></p>
<p></p>
<p dir="ltr"><span>The discussion was followed by a few informative technical sessions.</span></p>
<p></p>
<p dir="ltr"><span>Jaynil Doshi, Director – Techno Commercial, Pioma Chemicals, gave a session titled Hydrocel: Multi-functional cellulose technologies for modern formulators. Hydrocel is a family of six functional cellulose excipients, sold under one brand.</span></p>
<p></p>
<p dir="ltr"><span>Doshi’s point was about control. Hydrocel is built for tighter parameters than standard pharmacopeial ranges allow. That control lowers development risk. It also makes manufacturing more predictable.</span></p>
<p></p>
<p dir="ltr"><span>Krutik Prajapati, Manager (Techno Commercial), Vikram Thermo, followed with a presentation on ‘Drug release modulation through DRUGCOAT RSPO/RLPO’. He introduced DRUGCOAT RL and RS polymers, used as binding agents to modulate release.</span></p>
<p></p>
<p dir="ltr"><span>Prajapati explained that drug release depends on polymer concentration. The right RL-to-RS ratio has to match the drug’s own solubility and permeability. Every product needs its own answer.</span></p>
<p></p>
<p dir="ltr"><span>Beyond generics</span></p>
<p></p>
<p dir="ltr"><span>Dr Ajay Jaysingh Khopade, Site Head R&D and VP, Head of Formulation and Analytical R&D, Sun Pharmaceutical Industries, took the discussion in a different direction with a session titled, ‘Beyond generics: Creating a competitive edge through innovation’.</span></p>
<p></p>
<p dir="ltr"><span>Volume is no longer enough, he said. India’s generics strength built the industry’s global position. But the next phase needs more. Complex formulations and specialty products carry stronger margins and a harder-to-copy edge. Khopade named three things that have to work together, i.e. product innovation, process excellence, and regulatory strategy. He added a caution too. Innovation only counts if it improves patient outcomes. Science for its own sake is not the goal.</span></p>
<p></p>
<p dir="ltr"><span>Moving beyond generics is a long-term bet and the returns take time.</span></p>
<p></p>
<p dir="ltr"><span>Proven technology, new roles</span></p>
<p></p>
<p dir="ltr"><span>Not every advance means replacing what already works.</span></p>
<p></p>
<p dir="ltr"><span>Dr Abhijit Gothoskar, Technical Expert, Sigachi Industries, made that case in Matrix formulation using Ultramod systems. Hydrophilic matrix systems, he said, remain a proven, commercially viable route to controlled drug release.</span></p>
<p></p>
<p dir="ltr"><span>The company’s UltraMod system, he said, improves their robustness and predictability. Gothoskar’s session also pointed to a shift in what formulators expect from suppliers. It is no longer just about buying an excipient. Companies want formulation support and application expertise alongside it. Sigachi is positioning itself as that kind of partner.</span></p>
<p></p>
<p dir="ltr"><span><strong>Delivery as differentiation </strong></span></p>
<p></p>
<p dir="ltr"><span>Ritu Laddha, Senior VP and Cluster Head, Zydus Lifesciences, closed the morning’s technical sessions with ‘Reimagining pain therapy: Oral-to-intranasal product innovation’, a case study on drug delivery. </span></p>
<p dir="ltr"><span>Zydus developed an intranasal version of cyclobenzaprine, a pain medicine usually taken orally. The goal was faster relief.</span></p>
<p></p>
<p dir="ltr"><span>Preclinical and human studies backed that up. They showed faster absorption and higher drug exposure through the nasal route.</span></p>
<p></p>
<p dir="ltr"><span>Laddha framed the result on three fronts i.e. efficacy, tolerability, and patent potential. Her presentation showcased how changing the route of administration can create a new proposition around an existing molecule.</span></p>
<p></p>
<p dir="ltr"><span>AI in the formulation lab</span></p>
<p></p>
<p dir="ltr"><span>After the unconference and lunch, the focus moved to artificial intelligence, with a panel titled, ‘AI, talent and technology: The new FR&D toolkit’. Dr Tushar N Mehta, VP – Respiratory and Advanced Analytical R&D, Amneal Pharmaceuticals, moderated this session.</span></p>
<p></p>
<p dir="ltr"><span>Nilesh Malaviya, Head of Formulation Development, Alembic Pharmaceuticals; Dr Sanju Dhawan, Sr Director GPRD and Site Leader, Baxter Pharmaceuticals India; Dr Dhaval Pethani, Co-Founder and CTO, Cutyx Research; Dr Prabhat Shrivastava, Associate Director and Vertical Head for Formulation and Packaging Development, Piramal Pharma Solutions, Ahmedabad; Dr Vinod Venkatpurwar, Senior GM, Formulation Development, Cadila Pharmaceuticals; Dr Ajay Vairale, Senior GM, Cadila Pharmaceuticals; and Dr Sunny P Desai, Senior Manager and Site Lead for Technology Transfer, Zydus Lifesciences joined him for this discussion.</span></p>
<p></p>
<p dir="ltr"><span>The panel’s central idea was that AI is shifting formulation from trial-and-error toward predict-and-design. It is helping teams shortlist promising formulations faster. It is flagging manufacturing risks earlier and compressing timelines that used to run for months.</span></p>
<p></p>
<p dir="ltr"><span>The panel pointed to high impact use cases such as formulation screening, stability prediction, and early risk-flagging as the areas where AI is already paying off.</span></p>
<p></p>
<p dir="ltr"><span>Digital twins, AI models and electronic lab notebooks came up as the practical tools behind that shift. They can cut scaleup failures, reduce repetitive work and speed up technology transfer.</span></p>
<p></p>
<p dir="ltr"><span>But there was a condition attached. AI is only as good as the data behind it. Without a strong digital foundation, none of it works. Fragmented systems and disconnected data can foil even a well-built model. The panel was candid about the barriers still in the way.</span></p>
<p></p>
<p dir="ltr"><span>They spoke of legacy systems, siloed data, and teams that have not yet been trained to work alongside these tools. Getting past that is as much an organisational challenge as a technical one, pointed out the panelists. </span></p>
<p dir="ltr"><span>The panel also opined that AI should augment scientists, not replace them. Human judgement and accountability stay central to every decision. Balancing that human expertise with machine intelligence, rather than choosing between them, was the panel’s recurring theme. The panel also emphasised on governance, particularly around ethical use and protecting confidential data.</span></p>
<p></p>
<p dir="ltr"><span>They opined that emerging model is the AI-enabled scientist. Someone who understands both what these tools can do and where their limits sit.</span></p>
<p></p>
<p dir="ltr"><span>Complexity moves closer to the patient</span></p>
<p></p>
<p dir="ltr"><span>Dr Richa Dayaramani, Scientist Grade F, NIPER Ahmedabad, spoke about injectables and specialty formulations later in the afternoon, in a session titled Injectables and specialty formulations: Driving the next wave of growth. </span></p>
<p dir="ltr"><span>Biologics and GLP-1 therapies are growing. That growth demands stronger capability in advanced drug delivery and injectable technology, she said.</span></p>
<p></p>
<p dir="ltr"><span>Formulation itself is becoming the differentiator. The more complex it gets, the more value there is to capture. </span></p>
<p dir="ltr"><span>Dayaramani also brought the discussion back to the patient. Future formulations need to support self-administration, through devices like pre-filled syringes and wearable injectors. That means formulation, device compatibility, and manufacturing all need to work together. None of it succeeds in isolation.</span></p>
<p></p>
<p dir="ltr"><span>Ahmedabad’s own opportunity</span></p>
<p></p>
<p dir="ltr"><span>The last panel of the day was a session titled Ahmedabad’s innovation edge: Where science meets scale. </span></p>
<p dir="ltr"><span>Naresh Kumar Gaur, Consultant, Pharma Manufacturing Operations, moderated this discussion. The panel included Dr Madhusudhan Bommagani, President – FR&D, Cadila Pharmaceuticals; Dr Mukesh Patel, MD, QualiHeal Pharmaceuticals; Anshu Rathore, AVP – Pharma and Regulatory, Molkem Labs; Gopal Thakur, Senior Manager, Immacule Life Sciences; Abhikumar Turakhiya, Senior GM and Head of Formulation R&D, Avance Research and Dr Kashyap Nagariya, Assistant Division Head, Otsuka Pharmaceutical India.</span></p>
<p></p>
<p dir="ltr"><span>The discussion opened with Ahmedabad’s role in India’s broader pharma growth story, then narrowed to specifics.</span></p>
<p></p>
<p dir="ltr"><span>The city’s advantages came up first. A large pool of skilled talent from pharmacy universities across Ahmedabad and Gujarat. Strong local technical and digital support. A growing base of CMOs and CDMOs, which brings opportunities for technology transfer and faster market access. Governmentbacked skill-development programmes reinforcing all of it.</span></p>
<p></p>
<p dir="ltr"><span>The panel treated manufacturing strength as a starting point, not an end point. The real question was how to leverage that strength to accelerate innovation. They also discussed how building development capabilities that can compete globally was the next test for the city’s pharma ecosystem.</span></p>
<p></p>
<p dir="ltr"><span>Complex products and specialty therapies came up as the clearest opening. Biologics, advanced delivery systems, and value-added formulations offer margins and differentiation that conventional generics cannot match. The city already has adjacent capability in manufacturing and talent. What it needs is to direct more of that capability toward development rather than production alone.</span></p>
<p></p>
<p dir="ltr"><span>The panelists were emphatic that Ahmedabad needs to move beyond conventional generics. Complex products, biologics, and value-added offerings are crucial to the next phase of growth. Manufacturing strength is not enough on its own. Quality has to keep pace. That combination, the panel said, will decide whether Ahmedabad becomes a genuine global pharma hub.</span></p>
<p></p>
<p dir="ltr"><span>The panel closed on an open question rather than a clear answer. What comes next for Ahmedabad as a pharma innovation hub depends on whether the ecosystem i.e. talent, manufacturers, CDMOs, and regulators, can pull in the same direction.</span></p>
<p></p>
<p dir="ltr"><span>What the day added up to</span></p>
<p></p>
<p dir="ltr"><span>A strong FR&D organisation today has to deliver products that are innovative, manufacturable, scalable and relevant to patients. That takes earlier attention to scale-up, wider use of data and AI, more sophisticated delivery approaches and tighter coordination between R&D, manufacturing and regulatory teams.</span></p>
<p></p>
<p dir="ltr"><span>For Ahmedabad, the pieces are largely in place. Talent, manufacturing scale, technical capability, a growing ecosystem.</span></p>
<p></p>
<p dir="ltr"><span>The task now is to connect them. </span></p>
<p><b> </b></p>
<p dir="ltr"><em><span>lakshmipriya.nair@expressindia.com </span><span><br>
</span><span>laxmipriyanair@gmail.com </span></em></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/from-scale-to-science-ahmedabads-pharma-ecosystem-at-crossroads/">From scale to science: Ahmedabad’s pharma ecosystem at crossroads </a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Shilpa Biologicals and SPIMACO Bio sign strategic license agreement for PD&#45;1 Biosimilar for MENA market</title>
<link>https://edusehat.com/en/shilpa-biologicals-and-spimaco-bio-sign-strategic-license-agreement-for-pd-1-biosimilar-for-mena-market</link>
<guid>https://edusehat.com/en/shilpa-biologicals-and-spimaco-bio-sign-strategic-license-agreement-for-pd-1-biosimilar-for-mena-market</guid>
<description><![CDATA[ 
Shilpa Biologicals, an integrated biologics development and manufacturing organisation, announces an exclusive Middle East and North Africa (MENA) strategic licensing and commercialization agreement with SPIMACO Bio of Saudi Arabia for  […]
The post Shilpa Biologicals and SPIMACO Bio sign strategic license agreement for PD-1 Biosimilar for MENA market appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/16130003/EP_Shilpa.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 16 Sep 2026 15:00:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Shilpa, Biologicals, and, SPIMACO, Bio, sign, strategic, license, agreement, for, PD-1, Biosimilar, for, MENA, market</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/16130003/EP_Shilpa.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/16130003/EP_Shilpa.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/16130003/EP_Shilpa-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p>Shilpa Biologicals, an integrated biologics development and manufacturing organisation, announces an exclusive Middle East and North Africa (MENA) strategic licensing and commercialization agreement with SPIMACO Bio of Saudi Arabia for  portfolio of PD-1 inhibitor biosimilars across the Middle East and North Africa (MENA).</p>
<p>Under the agreement, Shilpa Biologicals retains ownership of the intellectual property and serves as exclusive developer and manufacturer — earning upfront, development, and commercial milestone payments and product-supply revenue — while SPIMACO Bio leads commercialization, regulatory execution, and market access across the region. The partnership demonstrates Shilpa Biologicals’ integrated biologics development and manufacturing capabilities, reinforcing its position as a global partner for the development, technology transfer and commercial manufacture of complex biologic medicines.</p>
<p>PD-1 inhibitors are among the most important advances in modern oncology — a class of immunotherapy that helps the body’s own immune system recognize and attack cancer cells across a broad range of tumor types. By combining Shilpa Biologicals’ end-to-end development and manufacturing capabilities with SPIMACO Bio’s regional reach, the partnership aims to make these life-changing therapies more accessible and affordable for patients across MENA, where the cancer burden continues to rise.</p>
<p>The collaboration is structured around a phased technology transfer programme that will establish local manufacturing of the biosimilars in Saudi Arabia. This will strengthen regional supply security, build high-value biomanufacturing capability within the Kingdom, and support the localization objectives of Saudi Vision 2030 — reinforcing both companies’ commitment to a resilient and increasingly self-sufficient regional healthcare ecosystem.</p>
<p>“This partnership creates significant long-term value for Shilpa Biologicals while advancing our mission to make world-class biologic medicines accessible to patients wherever they live,” said Madhav Bhutada, Director, Shilpa Biologicals Private Limited. “This agreement demonstrates Shilpa Biologicals’ ability to develop, manufacture and transfer complex biologics to global partners while creating long-term value through milestone payments, and commercial supply – and through a future technology transfer we will also help build durable local manufacturing capability for the region.”</p>
<p>The global PD-1/PD-L1 inhibitor market is valued at approximately US$74 billion in 2026 and is projected to reach US$142 billion by 2031, a compound annual growth rate of about 13.9% (Mordor Intelligence, 2026). Within the Middle East oncology drugs market is estimated at US$3.4 billion and forecast to grow at roughly 7.7% annually through 2031 (Cognitive Market Research, 2025). This opportunity is expected to widen further as leading originator PD-1 therapies approach loss of market exclusivity, accelerating demand for high-quality, more affordable biosimilar alternatives.</p>
<p>“Expanding access to advanced cancer immunotherapies is a strategic priority for the health and resilience of our region,” said Prof. Ahmed Al-Jedai , Vice Chairman and Managing Director of  SPIMACO Bio. “Partnering with Shilpa Biologicals allows us to bring high-quality, affordable PD-1 biosimilars to patients across Saudi Arabia and the wider MENA market. Shilpa’s scientific depth and scalable GMP manufacturing capabilities make them an ideal partner.</p>
<p>The post <a href="https://www.expresspharma.in/shilpa-biologicals-and-spimaco-bio-sign-strategic-license-agreement-for-pd-1-biosimilar-for-mena-market/">Shilpa Biologicals and SPIMACO Bio sign strategic license agreement for PD-1 Biosimilar for MENA market</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>AstraZeneca’s AZD6793 holds potential to expand oral COPD treatment options, says GlobalData</title>
<link>https://edusehat.com/en/astrazenecas-azd6793-holds-potential-to-expand-oral-copd-treatment-options-says-globaldata</link>
<guid>https://edusehat.com/en/astrazenecas-azd6793-holds-potential-to-expand-oral-copd-treatment-options-says-globaldata</guid>
<description><![CDATA[ 
At the European Respiratory Society (ERS) Congress 2026, AstraZeneca presented the design of the Phase IIb PRESTO trial, a large study set to evaluate whether AZD6793, an oral IRAK4 inhibitor, […]
The post AstraZeneca’s AZD6793 holds potential to expand oral COPD treatment options, says GlobalData appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2019/06/24072344/GettyImages-940685570.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 16 Sep 2026 04:15:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>AstraZeneca’s, AZD6793, holds, potential, expand, oral, COPD, treatment, options, says, GlobalData</media:keywords>
<content:encoded><![CDATA[<div><img width="600" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2019/06/24072344/GettyImages-940685570.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2019/06/24072344/GettyImages-940685570.jpg 600w, https://cdn.expresspharma.in/wp-content/uploads/2019/06/24072344/GettyImages-940685570-300x200.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2019/06/24072344/GettyImages-940685570-450x300.jpg 450w" sizes="auto, (max-width: 600px) 100vw, 600px"></div><p><span>At the European Respiratory Society (ERS) Congress 2026, AstraZeneca presented the design of the Phase IIb PRESTO trial, a large study set to evaluate whether AZD6793, an oral IRAK4 inhibitor, can reduce disease exacerbations in adults with moderate to very severe chronic obstructive pulmonary disease (COPD). </span></p>
<p><span>By targeting a shared signalling protein downstream of several inflammatory pathways, AZD6793 could offer a broad and convenient anti-inflammatory approach for patients who remain at risk despite stable inhaled treatment, says</span><a href="https://email.cisionone.cision.com/c/eJxEkM2u2yAQhZ8G74hg-DFeeBE1itRdF1W7tAYYJ6gmdsG5bt--okp0WX6H82lm4gguaNHRKHs3aCuFVd191F4ZBDt7JGu0MAqChl4OIaL3blBdGi3iIEA5kuAnCTFq48A419uZaVFTpF_pN8-YFiqV97O3xvphdnyeq7GnFnTLeN_3rTJ1ZnBlcD2O43RbVo9LxB1PYc0N3ld-EMdCDK451ZrWB8dH5B-4PKm2prp-wbxhuj1-NMbUpRfyexLtffs5LOLr-cLAPvc81fVZQvsRUhO9aKaYnpmpy1aoVl5oIaz0CsPLzdTlFqewlm0tuNO0Ff45bNcU-G7yFMf_YHqr1FkZKYzoyrjgn5y2kv7iA1NhWtzaMdq2Xd0LUW5tINS2B8NRGsW1iZI7b4iDEM6TGmIg0X2M8C8AAP__1tqQJw"> <span>GlobalData</span></a><span>, a leading intelligence and productivity platform.</span></p>
<p><span>AZD6793 inhibits IRAK4 downstream of IL-33/ST2, IL-1 beta, IL-18, IL-36, and toll-like receptor signalling, with the aim of modulating neutrophilic and eosinophilic inflammation and mucus production.</span></p>
<p><span>Eligible participants in the study are aged 40 years or older; have a post-bronchodilator FEV1 of 25% to less than 80% predicted and an FEV1/forced vital capacity ratio below 0.7; and have a recent exacerbation history while receiving stable inhaled therapy. The investigators note that a recent protocol amendment has reduced the initial submitted design from four arms and approximately 1,160 participants to two active-dose arms and one placebo arm, with approximately 970 participants randomized 1:1:1.</span></p>
<p><span>The primary endpoint is the annualized rate of moderate or severe COPD exacerbations over 24 weeks. Secondary measures include time to first exacerbation, severe and healthcare-intensive exacerbations, COPDCompEx events, pre- and post-bronchodilator lung function, pharmacokinetics, patient-reported outcomes, adverse events, and tolerability.</span></p>
<p><span>Graysen Vigneux,</span><a href="https://email.cisionone.cision.com/c/eJxEUL2unDoQfhrTeWXG2JiCYnVXSLdLESUlGvDAWscGYpts9u0jH3GUqUbf34w-24OZG1FRX7ema3QttKyePSrAeUIj5llPiyGUzaIbIKlsJ7p6qlyvETsB0lAN01iDtY0yoIxp9cIakZylD_eLB3SeYuLtMmmlp24xfFmS0rdCVL5_5nwkJu8MBgbD6_W6rX6f0FvMeJv3wGBIeY_EYHCbPVOO77KGcG6739c3Dxg_KBe7HP7DcKBbtx_oT2Ly0Yr6uxNlvv3svPj__mCgzxzGtJ9xLorZJbdvFxrIujMw-TgipcQjecJEFzlf2Uw-Vjt-KhgoEJdqPJ4YA47_PrvYY485VSUavxK5s_0nMH6dkHepaqFEFXuPf4I7onvjhi6yRqylqVJFlXIkCsUNhI1uQXGsleSNsjU3kyIOQpiJZGdnEtXvHv4GAAD__80Gm2E"> <span>Immunology</span></a><span> Analyst at GlobalData, comments: “PRESTO is an important clinical test because it moves IRAK4 inhibition beyond target engagement and into a large trial focused on exacerbations, a clear, real-world clinical outcome. A meaningful reduction on top of stable inhaled therapy would provide strong support for this upstream anti-inflammatory strategy.”</span></p>
<p><span>Reported Phase I data showed acceptable safety, pharmacokinetics, and pharmacodynamic target engagement in healthy participants and participants with COPD. The Phase IIb dose-ranging design is intended to identify a dose that provides sufficient pathway inhibition while retaining a safety profile suitable for chronic treatment.</span></p>
<p><span>Vigneux adds: “AZD6793 is differentiated by combining broad pathway coverage with oral administration. The practical advantage of an oral option could be valuable in COPD, but convenience will only matter if the study demonstrates a clear and durable clinical benefit without introducing limiting adverse effects.”</span></p>
<p><span>Patients with COPD can continue to experience exacerbations despite maintenance treatment. PRESTO directly addresses this residual risk through a clinically relevant primary endpoint, while its severe and healthcare-use measures should show whether any benefit extends to the events with the greatest consequences for patients and health systems.</span></p>
<p><span>Vigneux concludes: “Currently, PRESTO is active recruiting, and no Phase II efficacy results are available. The 24-week observation period, amended dose structure, and safety implications of inhibiting several innate immune pathways will be important when interpreting the findings. The trial must also demonstrate that any numerical reduction is both statistically reliable and clinically meaningful.”</span></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/astrazenecas-azd6793-holds-potential-to-expand-oral-copd-treatment-options-says-globaldata/">AstraZeneca’s AZD6793 holds potential to expand oral COPD treatment options, says GlobalData</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Dr. Reddy’s Laboratories launches NIVORZ in India</title>
<link>https://edusehat.com/en/dr-reddys-laboratories-launches-nivorz-in-india</link>
<guid>https://edusehat.com/en/dr-reddys-laboratories-launches-nivorz-in-india</guid>
<description><![CDATA[ 
Dr. Reddy’s Laboratories announced the launch of NIVORZ (Nivolumab Biosimilar) in India. NIVORZ is a biosimilar to Opdivo(nivolumab). The launch represents a significant milestone for Dr. Reddy’s, with NIVORZ marking […]
The post Dr. Reddy’s Laboratories launches NIVORZ in India appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/15105219/Dr.-Reddys-building.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 16 Sep 2026 04:15:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Dr., Reddy’s, Laboratories, launches, NIVORZ, India</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="431" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/15105219/Dr.-Reddys-building.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/15105219/Dr.-Reddys-building.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/15105219/Dr.-Reddys-building-300x172.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Dr. Reddy’s Laboratories announced the launch of NIVORZ (Nivolumab Biosimilar) in India. NIVORZ is a biosimilar to Opdivo(nivolumab).</span></p>
<p><span>The launch represents a significant milestone for Dr. Reddy’s, with NIVORZ marking its entry into biosimilar immuno-oncology in India. Developed and manufactured entirely in-house at Dr. Reddy’s biologics facility in Bachupally, Hyderabad, it reflects the company’s end-to-end capabilities across the biosimilar value chain, from development through commercialization.</span></p>
<p><span>Oncology remains an important focus area for Dr. Reddy’s. The launch of NIVORZ further strengthens the company’s oncology portfolio and expands its presence in immuno-oncology. The Immuno-Oncology market in India is estimated at approximately ₹3,900 crore in 2025 and is predominantly driven by checkpoint inhibitors such as nivolumab, pembrolizumab and toripalimab.</span></p>
<p><span>Access to immuno-oncology therapies remains a challenge for many patients due to the cost and duration of treatment. Through NIVORZ, Dr. Reddy’s aims to broaden access to high-quality nivolumab therapy with an affordable biosimilar option for eligible patients.</span></p>
<p><span>NIVORZ was evaluated through a multi-country clinical development programme involving 288 patients, including 252 from India and 36 from Russia, and demonstrated comparable efficacy, safety, pharmacokinetics and immunogenicity to the reference nivolumab. Based on this clinical development programme, NIVORZ has been approved in India by the Drugs Controller General of India (DCGI).</span></p>
<p><span>Dr. Sridevi Khambhampaty, Global Head of Biologics, Dr. Reddy’s Laboratories, said: “The launch of NIVORZ marks an important milestone for our biologics business. It reinforces our commitment to expanding patient access to high-quality biologic therapies, strengthens our oncology portfolio and reflects our continued focus on developing complex biosimilars.”</span></p>
<p><span>M.V. Ramana, CEO Global Generics, Dr. Reddy’s Laboratories, said: “The launch of NIVORZ strengthens our oncology portfolio and expands our presence in immuno-oncology. As access to immunotherapy continues to be a challenge for many patients, we remain committed to improving access to high-quality treatment options through affordable biosimilars such as NIVORZ.”</span></p>
<p>The post <a href="https://www.expresspharma.in/dr-reddys-laboratories-launches-nivorz-in-india/">Dr. Reddy’s Laboratories launches NIVORZ in India</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The glutathione problem nobody in the category talks about</title>
<link>https://edusehat.com/en/the-glutathione-problem-nobody-in-the-category-talks-about</link>
<guid>https://edusehat.com/en/the-glutathione-problem-nobody-in-the-category-talks-about</guid>
<description><![CDATA[ 
Glutathione has become one of India’s fastest-moving supplement categories, and overwhelmingly it is bought for skin. Consumers have absorbed a broadly accurate idea of why: it is the body’s central […]
The post The glutathione problem nobody in the category talks about appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/15174116/Ajit-Marathe-Founder-Chief-Innovation-Officer-Skin-Beyond-Borders.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 16 Sep 2026 04:15:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, glutathione, problem, nobody, the, category, talks, about</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/15174116/Ajit-Marathe-Founder-Chief-Innovation-Officer-Skin-Beyond-Borders.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/15174116/Ajit-Marathe-Founder-Chief-Innovation-Officer-Skin-Beyond-Borders.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/15174116/Ajit-Marathe-Founder-Chief-Innovation-Officer-Skin-Beyond-Borders-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span><span>Glutathione has become one of India’s fastest-moving supplement categories, and overwhelmingly it is bought for skin. Consumers have absorbed a broadly accurate idea of why: it is the body’s central antioxidant defence. More recently they are meeting it a second time, in the longevity conversation. Demand is real, informed, and growing.</span></span></p>
<p><span><span>What almost nobody explains is that glutathione is one of the hardest molecules in the supplement aisle to actually deliver to the place it works.</span></span></p>
<p><strong><span><span>The absorption problem and the industry’s answer</span></span></strong></p>
<p><span><span>That oral glutathione is poorly absorbed is well documented and no longer controversial. The industry has responded intelligently: liposomal and micellar formats now dominate the premium shelf, and consumers actively ask for them. These formats do work on the problem they were designed for. Human data shows they get meaningfully more glutathione into circulation than a plain tablet does.</span></span></p>
<p><span><span>But absorption was never the end of the story. It was the first of two problems, and the category has treated it as the only one.</span></span></p>
<p><strong><span><span>Getting into the blood and getting into a cell are different problems</span></span></strong></p>
<p><span><span>Glutathione does its work inside cells. Circulation is only the corridor. Yet almost every bioavailability claim in this category measures glutathione in blood and lets the reader assume it arrived where it is needed.</span></span></p>
<p><span><span>It hasn’t and here is the part that deserves to be stated plainly. Glutathione does not enter cells. It is an electrically charged, highly water-soluble molecule that cannot pass through a fatty cell membrane on its own, and cells have no dedicated import route to let it in. What circulates is broken down at the cell surface, and the fragments are taken in separately.</span></span></p>
<p><span><span>No dose changes this. Not 500 mg, not a gram, not an intravenous drip. There is no door.</span></span></p>
<p><strong><span><span>So where does cellular glutathione come from?</span></span></strong></p>
<p><span><span>The cell makes its own, from amino acids, in two steps. And the enzyme that runs the first step is deliberately self-limiting — it slows as glutathione accumulates, exactly like a thermostat. Worse, its activity declines with age and in several chronic conditions, which is precisely when more glutathione would be useful.</span></span></p>
<p><span><span>Put those two facts together and the conclusion is uncomfortable but unavoidable: glutathione inside a cell cannot rise beyond a set ceiling, regardless of the dose you take or how long you take it and that ceiling falls as you get older.</span></span></p>
<p><span><span>This also catches the popular precursors. NAC and whey protein supply cysteine into the same pathway. They can help a depleted cell recover toward normal, which is genuinely useful. But they enter before the throttled step, so they meet the same limit. NAC additionally has poor oral bioavailability of its own, in the region of 10 per cent.</span></span></p>
<p><span><span>None of this is disputed science. It is standard biochemistry, decades old. And the category has grown regardless.</span></span></p>
<p><strong><span><span>Where the science has actually moved</span></span></strong></p>
<p><span><span>The molecule that changes this arithmetic is gamma-glutamylcysteine, or GGC — the dipeptide the cell produces one step before glutathione. Same pathway, one piece short of finished. It is a naturally occurring compound found across animals, plants and microbes, and a normal human metabolite. It carries antioxidant activity in its own right, and cell and animal studies point to anti-inflammatory effects, though that work has not yet been done in people.</span></span></p>
<p><span><span>A research group at the University of New South Wales in Australia has worked on it for roughly two decades. Their argument is simple: GGC crosses into the cell, and once inside it joins the pathway after the throttled step. The second step is not self-limiting, so the cell completes the molecule without the brake applying. In a single move it clears both bottlenecks — the door glutathione cannot pass, and the ceiling it cannot exceed.</span></span></p>
<p><span><span>The human evidence follows the mechanism. In a published pharmacokinetic trial, a single 2 g dose of GGC raised glutathione inside cells by 53 per cent within 90 minutes, peaking around three hours and returning close to normal by five.</span></span></p>
<p><span><span>I would rather characterise that study accurately than flatteringly. It is a pilot: thirteen participants, individual responses ranging from 10 per cent to 161 per cent, measured in white blood cells, and conducted by the researchers who hold the manufacturing patents. It is not a body of evidence. What makes it significant is that it is the first demonstration of cellular glutathione rising above its normal ceiling after a single oral dose. Everything before it was pushing against a locked door.</span></span></p>
<p><span><span>For an industry selling glutathione at scale, that distinction matters more than another format war. The question was never how much glutathione we can get into the bloodstream. It was whether any of it was ever getting in.</span></span></p>
<p>The post <a href="https://www.expresspharma.in/the-glutathione-problem-nobody-in-the-category-talks-about/">The glutathione problem nobody in the category talks about</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Cheplapharm to take over 20 medicines and three sites from Sanofi</title>
<link>https://edusehat.com/en/cheplapharm-to-take-over-20-medicines-and-three-sites-from-sanofi</link>
<guid>https://edusehat.com/en/cheplapharm-to-take-over-20-medicines-and-three-sites-from-sanofi</guid>
<description><![CDATA[ Under the proposed arrangement, Sanofi will receive a 26.4% equity stake in Cheplapharm. The partnership expands on a working relationship between the two companies, which began in 2014. 
The post Cheplapharm to take over 20 medicines and three sites from Sanofi appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/09/PT-2-15-09-2026-shutterstock_691546411.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 15 Sep 2026 17:50:18 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Cheplapharm, take, over, medicines, and, three, sites, from, Sanofi</media:keywords>
<content:encoded><![CDATA[<p>Under the proposed arrangement, Sanofi will receive a 26.4% equity stake in Cheplapharm. The partnership expands on a working relationship between the two companies, which began in 2014.</p>
<p>The selected medicines, including Lovenox/Clexane (enoxaparin), are intended to benefit from Cheplapharm’s operational approach.</p>
<p>The companies stated that different operating models may better address the manufacturing, regulatory and commercial characteristics of established treatments compared to new medicines.</p>
<p>Cheplapharm will acquire production sites located in Csanyikvölgy in Hungary, Jurong in Singapore, and Ploërmel in France. The facilities employ approximately 400, 100, and 65 employees, respectively.</p>
<p>Existing employment terms and collective agreements are expected to remain in place, and both entities plan to jointly manage the transition, aiming to maintain supply continuity and manufacturing standards.</p>
<p>Sanofi General Medicines executive vice-president Thomas Grenier said: “Our multi-year journey to simplify our mature portfolio has enabled us to focus on innovation while ensuring mature medicines continue to reach patients who need them.</p>
<p>“Cheplapharm has been a trusted partner for more than a decade, and this transaction significantly builds on its prior acquisitions from Sanofi’s mature medicines portfolio.</p>
<p>“This new partnership, together with our equity stake in Cheplapharm, underscores our commitment to ensuring patients continue to benefit from today’s essential medicines while also pursuing tomorrow’s breakthroughs.”</p>
<p>The planned commercial transition is targeted to begin in the first quarter of 2027, with full completion anticipated by the third quarter of 2027, subject to regulatory approvals and employee consultations.</p>
<p>The transaction is not expected to affect Sanofi’s financial guidance for 2026. Further financial details have not yet been disclosed.</p>
<p>In June, Sanofi received approval from Japan’s Ministry of Health, Labour and Welfare for its subcutaneous formulation of Sarclisa (isatuximab) in combination with standard therapies to treat multiple myeloma.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/cheplapharm-20-medicines-three-sites-sanofi/">Cheplapharm to take over 20 medicines and three sites from Sanofi</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>FDA reduces monitoring time for Amgen’s Imdelltra infusions</title>
<link>https://edusehat.com/en/fda-reduces-monitoring-time-for-amgens-imdelltra-infusions</link>
<guid>https://edusehat.com/en/fda-reduces-monitoring-time-for-amgens-imdelltra-infusions</guid>
<description><![CDATA[ The revised guidance is intended for adults whose ES-SCLC has progressed after treatment with platinum-based chemotherapy. It recommends a monitoring period ranging between six and eight hours in 
The post FDA reduces monitoring time for Amgen’s Imdelltra infusions appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/09/PT-15-09-2026-shutterstock_2709265637.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 15 Sep 2026 17:50:18 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>FDA, reduces, monitoring, time, for, Amgen’s, Imdelltra, infusions</media:keywords>
<content:encoded><![CDATA[<p>The revised guidance is intended for adults whose ES-SCLC has progressed after treatment with platinum-based chemotherapy.</p>
<p>It recommends a monitoring period ranging between six and eight hours in an appropriate healthcare setting following the initial two doses of Imdelltra. This replaces the previous requirement for 22 to 24 hours of observation.</p>
<p>Additionally, patients will receive a follow-up assessment, including vital signs, the day after each of these first two doses.</p>
<p>For subsequent doses, the monitoring requirements remain unchanged: six to eight hours for the third dose and throughout Cycle 2, three to four hours for Cycles 3 to 4, and two hours for Cycle 5 and beyond.</p>
<p>The updated label also continues to advise that patients remain within one hour of suitable medical facilities for 48 hours from the start of the first and eighth day infusions, accompanied by a caregiver.</p>
<p>Amgen highlighted that this regulatory decision could cut the need for patients to spend extended periods in healthcare settings during the early stages of treatment.</p>
<p>Amgen AI and data research and development executive vice-president Jay Bradner said: “This approval is an important step in simplifying care for people living with and treating ES-SCLC.</p>
<p>“Reducing monitoring to six to eight hours for the initial doses may help address practical barriers associated with administering Imdelltra and enable more patients to receive care closer to home.</p>
<p>“We continue to work closely with the healthcare community to ensure appropriate educational support for navigating Imdelltra treatment is available to providers, patients and care partners.”</p>
<p>Imdelltra is described as a targeted immunotherapy designed to bind to DLL3 proteins on tumour cells and CD3 on T cells, activating the immune system to target SCLC cells.</p>
<p>The update to monitoring procedures is limited to the first two doses of Imdelltra.</p>
<p>In January 2025, Amgen secured conditional approval from the UK Medicines and Healthcare products Regulatory Agency for Imdelltra as a treatment for ES-SCLC.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/fda-reduces-monitoring-time-amgens-imdelltra/">FDA reduces monitoring time for Amgen’s Imdelltra infusions</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Dr. Reddy’s launches initiative to train India’s obesity care workforce</title>
<link>https://edusehat.com/en/dr-reddys-launches-initiative-to-train-indias-obesity-care-workforce</link>
<guid>https://edusehat.com/en/dr-reddys-launches-initiative-to-train-indias-obesity-care-workforce</guid>
<description><![CDATA[ 
More than 5,000 healthcare support professionals to be trained to strengthen obesity prevention, education and long-term management across India
The post Dr. Reddy’s launches initiative to train India’s obesity care workforce appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/15105219/Dr.-Reddys-building.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 15 Sep 2026 17:50:16 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Dr., Reddy’s, launches, initiative, train, India’s, obesity, care, workforce</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="431" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/15105219/Dr.-Reddys-building.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/15105219/Dr.-Reddys-building.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/15105219/Dr.-Reddys-building-300x172.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p align="JUSTIFY"><span><span><span>Dr. Reddy’s Laboratories announced a nationwide educational initiative aimed at strengthening India’s obesity care workforce through the development of a network of Certified Obesity Educators. The initiative seeks to equip more than 5,000 healthcare support professionals with specialised training in obesity prevention, risk assessment, patient counselling and long-term management, helping bridge a critical gap in obesity care delivery across the country.</span></span></span></p>
<p align="JUSTIFY"><span><span><span>Dr. Reddy’s is investing in capability building across the healthcare ecosystem. Through a structured education and certification programme developed in collaboration with endocrinologists and clinicians, the initiative will train nurses, diabetes educators, dietitians and allied healthcare support professionals to become Certified Obesity Educators. Upon certification, these professionals will gain evidence-based knowledge and practical skills to support obesity risk assessment, lifestyle modification, behavioural change, treatment adherence and promote structured long-term obesity management.</span></span></span></p>
<p align="JUSTIFY"><span><span><span>Commenting on the initiative, M V Ramana, CEO, Global Generics, Dr. Reddy’s Laboratories said, ” India’s obesity challenge extends far beyond weight management. It is increasingly becoming a driver of diabetes, cardiovascular disease and several other chronic health conditions that impact millions of lives. While treatment options continue to evolve, sustainable outcomes require a broader support ecosystem built on informed patients, trained support professionals, sustained counselling and coordinated care. Through this initiative, we aim to strengthen a critical but often overlooked pillar of obesity management by building a workforce that can support physicians and patients alike, helping create a more capable, connected and patient-centred obesity care ecosystem in India.”</span></span></span></p>
<p align="JUSTIFY"><span><span><span>The programme aims to create a cadre of trained professionals who can work alongside physicians to support patients throughout their obesity management journey. By strengthening frontline capabilities and expanding access to structured counselling and education, the initiative aims to improve continuity of care, encourage earlier intervention and drive better long-term health outcomes.</span></span></span></p>
<p>The post <a href="https://www.expresspharma.in/dr-reddys-launches-initiative-to-train-indias-obesity-care-workforce/">Dr. Reddy’s launches initiative to train India’s obesity care workforce</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>CONNECTA Therapeutics announces new investment to advance clinical development of Fragile X Syndrome Program</title>
<link>https://edusehat.com/en/connecta-therapeutics-announces-new-investment-to-advance-clinical-developmentof-fragile-x-syndrome-program</link>
<guid>https://edusehat.com/en/connecta-therapeutics-announces-new-investment-to-advance-clinical-developmentof-fragile-x-syndrome-program</guid>
<description><![CDATA[ 
CONNECTA Therapeutics, a clinical-stage biotech company pioneering first-in-class neuroplasticity modulators to address unmet medical needs in central nervous system (CNS) disorders announced that it has closed a €3.1 million financing […]
The post CONNECTA Therapeutics announces new investment to advance clinical development of Fragile X Syndrome Program appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/05/04123258/investment.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 15 Sep 2026 17:50:15 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>CONNECTA, Therapeutics, announces, new, investment, advance, clinical, development of, Fragile, Syndrome, Program</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/05/04123258/investment.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/05/04123258/investment.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/05/04123258/investment-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p>CONNECTA Therapeutics, a clinical-stage biotech company pioneering first-in-class neuroplasticity modulators to address unmet medical needs in central nervous system (CNS) disorders announced that it has closed a €3.1 million financing led by new investor<a href="https://clave.capital/"> Clave Capital</a> through its Innvierte Science Tech Clave Innohealth, F.C.R. fund and supported by existing investors<a href="https://inveready.com/"> Inveready</a>,<a href="https://www.cdti.es/en/node/889"> CDTI Innvierte</a> and<a href="https://prousresearch.com/"> Prous Institute for Biomedical Research</a>.</p>
<p>The funds will support CONNECTA in accelerating the Phase IIa clinical trial of CTH120 in adult males with Fragile X syndrome (FXS) (<a href="https://clinicaltrials.gov/study/NCT07654114?cond=FXS&intr=CTH120&viewType=Card&rank=1">NCT07654114</a>).</p>
<p>Jordi Fàbrega, Co‑Founder and CEO of CONNECTA Therapeutics said, “This represents a significant milestone for CONNECTA and supports our efforts to advance CTH120 for FXS. We believe the Phase IIa data expected in mid-2027 will be an important step in demonstrating the potential of CTH120 to address the underlying biology of the disease and improve outcomes for patients living with FXS.”</p>
<p>Backed by strong preclinical and Phase I safety data<a href="https://clinicaltrials.gov/study/NCT06480968?id=NCT06480968&rank=1"> (NCT06480968)</a>, the study, initiated in<a href="https://prolinks.rediffmailpro.com/cgi-bin/prored.cgi?red=https%3A%2F%2Fconnectatherapeutics.com%2Fnews%2Fconnecta-therapeutics-initiates-phase-iia-clinical-trial-of-cth120-a-first-in-class-neuroplasticity-modulator-in-fragile-x-syndrome%2F&isImage=0&BlockImage=0&rediffng=0"> June 2026</a>,  is evaluating CTH120 in 30 randomized adult males with FXS. The trial is assessing safety, tolerability and effectiveness at the Hospital del Mar Research Institute (HMRIB) and the Parc Taulí Research and Innovation Institute Foundation (I3PT), alongside biomarker research with the Centre for Genomic Regulation (CRG). The trial is funded by the Spanish Ministry of Science, Innovation and Universities and the European Union’s NextGeneration EU program (Project reference: CPP2022‑009659). In parallel, CONNECTA is advancing preparations for the future pediatric development of CTH120 through the<a href="https://cordis.europa.eu/project/id/101217931"> FRAXCURE</a> project.</p>
<p>Ignacio Prieto Fernández, Investment Associate at Clave Capital commented, “CONNECTA has built a differentiated approach to targeting neuroplasticity in FXS, supported by a clear clinical development strategy and an experienced team. The Company has made important progress in advancing CTH120 into Phase IIa clinical development, and we look forward to supporting the team as it works toward its next key milestone.”</p>
<p>Sara Secall, General Partner at Inveready, added, “As seed investor, we have seen CONNECTA make significant progress in advancing CTH120 from a compelling scientific concept into clinical development. Our participation through our latest BIO Fund IV reflects our continued confidence in the team, its strategy and the potential significance of the upcoming clinical milestones.”</p>
<p>In connection with the financing, Ignacio Prieto Fernández will join CONNECTA’s Board of Directors as the representative of Clave Capital.</p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/connecta-therapeutics-announces-new-investment-to-advance-clinical-development-of-fragile-x-syndrome-program/">CONNECTA Therapeutics announces new investment to advance clinical development of Fragile X Syndrome Program</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>15 startups, 4 student teams win C&#45;CAMP National Bio Entrepreneurship Competition 2026</title>
<link>https://edusehat.com/en/15-startups-4-student-teams-win-c-camp-national-bio-entrepreneurship-competition-2026</link>
<guid>https://edusehat.com/en/15-startups-4-student-teams-win-c-camp-national-bio-entrepreneurship-competition-2026</guid>
<description><![CDATA[ 
Fifteen startups and four student teams were announced as the winners of the 9th edition of C-CAMP’s National Bio Entrepreneurship Competition (NBEC) 2026, held today in the presence of Dr […]
The post 15 startups, 4 student teams win C-CAMP National Bio Entrepreneurship Competition 2026 appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/15112558/EP_C-Camp-2.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 15 Sep 2026 17:50:14 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>startups, student, teams, win, C-CAMP, National, Bio, Entrepreneurship, Competition, 2026</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/15112558/EP_C-Camp-2.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/15112558/EP_C-Camp-2.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/15112558/EP_C-Camp-2-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p dir="ltr"><span>Fifteen startups and four student teams were announced as the winners of the 9</span><span><span>th</span></span><span> edition of C-CAMP’s National Bio Entrepreneurship Competition (NBEC) 2026, held today in the presence of Dr Kiran Mazumdar Shaw, Executive Chairperson, Biocon. The competition has been conducted with the support of the Department of IT, BT, S&T, Government of Karnataka as Home State Ecosystem Partner.</span></p>
<p></p>
<p dir="ltr"><span>The winning startups received a total of 35+ Crore INR in cash prizes and investment opportunities, while student-led teams secured 4 Lakhs INR in cash prizes across various awards presented at the Finale held at The Lalit Ashok, Bengaluru. All winners will also receive mentorship and handholding support through partnerships with key industry leaders.</span></p>
<p></p>
<p dir="ltr"><span>NBEC is C-CAMP’s flagship platform that identifies, nurtures and rewards India’s finest breakthrough solutions with strong impact potential to address critical challenges across Health, Agriculture and Environment. Over the past 8 years, it has positioned itself as India’s largest and most prestigious national biotech competition giving away more than 90Cr+ INR in cash prizes and investment opportunities to 130+ winners over 8 editions. The NBEC past winners’ cohort has together raised a total of 125 million+ USD VC funding from 120+ VCs, national and international, and has launched 300+ products making their mark in markets not just in India but worldwide.</span></p>
<p></p>
<p dir="ltr"><span>This year’s competition, attracted 3200+ registrations from across 34 States and UTs, including a significant number from Tier 2 and Tier 3 cities. Moreover, 40% of the applicants were female innovators. This highlights the remarkable gender diversity of the innovators, as well as the depth of biotech ideas unearthed by NBEC from smaller cities— adding tangible substance to India’s Women in Biotech vision.</span></p>
<p></p>
<p dir="ltr"><span>NBEC 2026 showcased groundbreaking innovations with a strong societal impact. The winning projects in 2026 are developing solutions ranging from </span></p>
<ul>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation"><span>next-gen cancer pathology, </span></p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation"><span>screening of kidney injury through quantum sensing, </span></p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation"><span>biopolymer based insitu bone regenerators, </span></p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation"><span>affordable insulin patch pumps, </span></p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation"><span>frugal surgery resources and training platforms for low resource surgery settings </span></p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation"><span>compact grey water treatment appliances for home use</span></p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation"><span>satellite imagery embedded smart spraying of agri inputs in farms,</span></p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation"><span>bioformulations to enhance soil health, and so on. </span></p>
</li>
</ul>
<p dir="ltr"><span>The winners were selected from 25 finalists who pitched to the Grand Jury at the Finale, chaired by Dr. Murali Ramachandra, CEO, Aurigene Oncology. The finalists had been shortlisted from a total of 74 pre-finalist startups based on their novelty, scalability and business potential parameters.  </span></p>
<p dir="ltr"><span>Dr Kiran Mazumdar-Shaw, Chairperson, Biocon Group</span><span>: </span><span>“The future of biology looks very promising as its convergence with digital technology and AI accelerates innovation at a never-before pace. With AI and deep tech unlocking biology’s complexity, we have a good understanding of the science. Now would be the time to leverage this deep science and combine with great business opportunities. As biotech entrepreneurs I urge you to address both science and the business of science. Once you have created value with your innovative science, think of how to scale a business. This will build a strong economy for an aspiring India and lift the country’s bioeconomy from 195 Bn USD to 2.6 trillion USD by 2047. I congratulate </span><span>C-CAMP on identifying and supporting such a wide diversity of innovative ideas at NBEC year on year.”</span></p>
<p></p>
<p><span>Dr Taslimarif Saiyed, CEO and Director, C-CAMP </span><span>expressed his thanks to Dr Kiran Shaw for being a pillar of support and mentor for NBEC from the first conceptualisation of the flagship platform in 2017 to its current 9</span><span><span>th</span></span><span> edition. He congratulated all the 74 pre-finalists of NBEC 2026, 25 of whom pitched today and highlighted the quality and impact potential of the cohort. He underlined the ambition to dream big with entrepreneurships and said, “We want India’s innovators to aim higher and trust ecosystems like C-CAMP to support with an ecosystem that enables your science and business growth.” </span></p>
<p>The post <a href="https://www.expresspharma.in/15-startups-4-student-teams-win-c-camp-national-bio-entrepreneurship-competition-2026/">15 startups, 4 student teams win C-CAMP National Bio Entrepreneurship Competition 2026</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Why Rashida Najmi believes in running quality on trust, not vigilance </title>
<link>https://edusehat.com/en/why-rashida-najmi-believes-in-running-quality-on-trust-not-vigilance</link>
<guid>https://edusehat.com/en/why-rashida-najmi-believes-in-running-quality-on-trust-not-vigilance</guid>
<description><![CDATA[ 
In your article for Express Pharma in April 2019, you mentioned that quality needs to be part of culture, beyond compliance. (https://www.expresspharm a.in/quality-from compliance-to-culture/) Can you give practical examples of […]
The post Why Rashida Najmi believes in running quality on trust, not vigilance  appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/15121845/Rashida-Najmi_EP_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 15 Sep 2026 17:50:13 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Why, Rashida, Najmi, believes, running, quality, trust, not, vigilance </media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/15121845/Rashida-Najmi_EP_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/15121845/Rashida-Najmi_EP_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/15121845/Rashida-Najmi_EP_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><strong>In your article for Express Pharma in April 2019, you mentioned that quality needs to be part of culture, beyond compliance. (https://www.expresspharm a.in/quality-from compliance-to-culture/) Can you give practical examples of how Piramal Pharma has implemented this? What’s been the stance of the pharma industry, given the growing importance of quality culture and compliance in global pharma manufacturing, backed by increasing regulatory rigour? </strong></p>
<p><span>I will take your second question first. Across the industry, quality is no longer a choice; it is a necessity. Quality cannot be confined to a department—it has to be embedded in the culture. Whether it is manufacturing, clinical research or any other life sciences function, we are dealing with people’s lives. So quality cannot be optional; it has to be integral to everything we do. </span></p>
<p><span>At Piramal Pharma, one of the most important steps we have taken is building futureready teams—not just within quality, but across all associated functions. We already had a strong quality foundation, but we have significantly strengthened our teams to make them high performing and future ready. We also launched our own internal Quality Academy to build what we call our quality DNA. It is a 20-month programme that takes employees through every aspect of quality at Piramal Pharma. Since we operate with harmonised quality standards across all our geographies and sites, the academy helps employees understand our quality philosophy, systems and expectations. More than 200 employees have graduated from the programme, and after completing Phases One and Two, we are preparing to launch the next phase. Continuous learning is critical because regulations evolve rapidly.</span></p>
<p><span>We also restructured our quality organisation at the global, regional and site levels to ensure the right balance between strategy and execution. The global team focuses primarily on strategy, regional teams balance strategy and execution, while site teams focus largely on execution with site-specific strategic responsibilities. Strategic direction flows from the global team, while regular quality town halls ensure alignment across the organisation. These sessions help everyone stay updated on evolving regulations, standards and expectations. </span></p>
<p><span>Another important initiative has been strengthening regulatory compliance across every business and site. As data integrity became increasingly important, we established a dedicated Data Integrity Coordinating Officer (DICO) structure. Every site has its own DICO, reporting to a central DICO, who in turn reports directly to me. Any data integrity event is escalated to me within 24 hours. We also have a defined white paper outlining how such events are handled. Our teams are empowered to make decisions within their responsibilities, supported by a robust escalation framework. This balances operational autonomy with strong governance, ensuring that critical issues receive timely attention at the global level. </span></p>
<p><span>Customer engagement has also become an important part of our quality culture. We conduct regular Quality Steering Committee meetings with customers, bringing together both quality teams to align expectations, review performance and strengthen collaboration. </span></p>
<p><span>We have also built a sustainable, scalable and quality-led global supply chain. Consistent quality depends on consistent availability of materials, supported by clearly defined assets and capable teams across our global network. Digitisation has been another major focus area. We have significantly expanded automation across our quality systems, and my goal is to make our shop floors completely paperless over time. Today, digitisation is no longer optional—it is as essential as quality culture itself. </span></p>
<p><span>In addition, we established a central governance and compliance cell that works closely with every business and site to continuously strengthen compliance. We have also moved high-volume, low complexity compliance activities from international sites to our central shared services team in India. This gives us economies of scale, enables 24×7 operations across time zones and allows site teams to focus on higher-value activities. Ultimately, the most important message remains the same: quality is everyone’s responsibility. My team may be the torchbearers and custodians of quality, but every employee owns it. This philosophy has enabled us to maintain perpetual audit readiness. You cannot become inspection-ready only when an audit is announced—you have to be ready every single day. Our quality track record reflects that commitment. </span></p>
<p><strong>When we talk about the company’s quality track record, what has been Piramal Pharma’s history with 483s, warning letters and other regulatory actions? </strong></p>
<p><span>Our track record speaks for itself. Over the past 15 years, across our 17 manufacturing sites, the majority of which are regulated by the US FDA, European, UK, Japanese and Australian authorities, we have not received a single Official Action Indicated (OAI). </span></p>
<p><span>During this period, we have successfully undergone more than 200 regulatory inspections, over 2,000 customer inspections and more than 50 US FDA inspections. We have not received a warning letter, consent decree, letter of noncompliance or any major regulatory non-compliance from the US, Europe, UK or any other regulatory agency. </span></p>
<p><span>That reflects both the strength of our quality systems and the consistency of our execution. Across the organisation, we undergo around 150-160 inspections every year when regulatory and customer audits are combined. In effect, almost every other day is an inspection somewhere within the company. That is why we maintain continuous inspection readiness. </span></p>
<p><span>For us, compliance is not about meeting regulations because we have to—it is about doing the right thing. I always tell my teams not to begin with the regulations during execution. Instead, ask what is right for the patient. If you do what is right for the patient, you will naturally meet regulatory requirements. </span></p>
<p><span>That is also why I say we run quality through trust, not vigilance. Regulations are important, but simply telling people to comply because of regulation is not enough. We want people to understand why quality matters and why doing the right thing is important. When people are guided by that mindset, regulatory compliance follows naturally.</span></p>
<p><strong>How are pharma companies adapting to evolving regulatory expectations, especially global CDMOs like Piramla Pharma operating across multiple geographies? Does biologics manufacturing add further complexity? </strong></p>
<p><span>A patient is a patient, whether the medicine is a small molecule or a biologic. </span></p>
<p><span>Every molecule has different characteristics, therapeutic effects and potential adverse effects. Naturally, biologics—including mRNA therapies, RNA vaccines, gene therapies, antibody-drug conjugates (ADCs) and injectable biologics—bring additional complexity. We manufacture biologic injectables and ADCs ourselves. The key is to develop quality systems that are appropriate for each molecule and ensure patient safety and efficacy. As complexity increases, your quality systems, processes, mindset and, most importantly, your teams must evolve accordingly. </span></p>
<p><span>Regarding changing regulations, I do not see regulators simply as regulators. I see them as an extension of my own quality organisation, helping us make the right decisions for patients. Their role is to ensure patient safety, and if they identify something we have missed, we welcome that feedback. To manage evolving global standards, we have a robust global quality risk management system. If an issue arises at one site, it is immediately communicated across our global network so that similar risks can be identified and addressed proactively elsewhere. </span></p>
<p><span>Within our central quality organisation, we also have a team that continuously monitors warning letters, emerging regulatory expectations and developments across global regulatory agencies. Relevant updates are shared across the organisation through our Quality Intelligence Platform, QUENCH. </span></p>
<p><span>QUENCH allows us to proactively monitor regulatory developments and prepare well before new requirements become mandatory. For example, we tracked the nitrosamine issue from the very beginning and achieved full compliance within the August 2025 regulatory timeline. </span></p>
<p><span>As a CDMO, staying ahead of regulatory changes is critical. While some companies struggle to be ready when new expectations emerge, our tracking systems, structured reviews and cross-learning sessions help us respond proactively. Regulatory expectations will continue to evolve, and the industry must evolve with them. Rather than resisting these changes, we should embrace them. I have personally participated in working groups that helped develop several global standards, including those relating to particulate matter in injectables, nonantibacterial beta-lactams and nitrosamines. </span></p>
<p><span>Ultimately, technology and systems are important, but future-ready teams remain equally critical. Strong quality culture, automation and capable people must all work together.</span></p>
<p><strong>What technologies are helping pharma companies meet the rising regulatory bar? How close are you to your goal of becoming paperless, and how much is Piramal Pharma investing in these technologies? </strong></p>
<p><span>We are very close to achieving a paperless environment at our regulated sites. </span></p>
<p><span>Automation has been part of our quality strategy for many years—it is not something we adopted recently. Our quality management systems and document management systems have long been digitised, significantly strengthening compliance. </span></p>
<p><span>We are now expanding several additional digital platforms. One of our biggest initiatives is migrating from SAP to SAP S/4HANA. The rollout has already been completed across our India sites and will be completed across the organisation next year. </span></p>
<p><span>SAP S/4HANA will become a major data lake for quality information, supporting every stage from vendor qualification through product delivery. There are around 15-16 quality intervention points across that lifecycle, all of which are integrated into the system. While these processes were already managed digitally, we are now scaling them through a much more robust platform. </span></p>
<p><span>Our digitalisation journey, however, will never really end because technology keeps evolving. We have also begun our AI journey within quality. AI is advancing rapidly, and we need to keep pace with new developments so that we can continue strengthening our quality systems. We are embarking on an AI journey in GxP processes keeping human in the loop and working with a partner who understands the life science space well. </span></p>
<p><span>We have made significant investments in automation, with a significant percentage of our infrastructure-related spend currently directed towards automation and digital technologies. This proportion is expected to increase as automation becomes central to our capital expenditure planning. Every new manufacturing facility is designed with automation built in from the outset, whether through SCADA, MES, LIMS or other digital systems. Alongside expanding our facilities, we are also upgrading existing plants with newer technologies. Automation is becoming central not only to our operations, but also to our long-term investment strategy. </span></p>
<p><strong>What would you estimate as the industry benchmark for technology investment? </strong></p>
<p><span>It varies significantly from company to company because it depends on each organisation’s priorities and mindset towards automation.For companies that are serious about quality, I would estimate that around 30 per cent of infrastructure related investment could be directed towards automation, although that is only my personal estimate. What is clear is that the industry is investing far more in automation today than it did in the past. One of the drivers has been the increased focus on data integrity. </span></p>
<p><span>Technology alone cannot guarantee data integrity—that ultimately depends on an organisation’s culture and values—but automation provides built-in controls that greatly strengthen compliance. </span></p>
<p><span>Beyond compliance, digitisation improves efficiency and gives leaders immediate access to data for faster decision-making. It therefore delivers both operational benefits and stronger regulatory compliance. Geopolitical disruptions have repeatedly tested global pharma supply chains. How is Piramal Pharma building resilience and maintaining customer trust? Recent geopolitical developments—including the Red Sea disruptions, tariffs and ongoing conflicts—have certainly created challenges. In such an environment, the strength of a company’s supply chain becomes extremely important. </span></p>
<p><span>Our vendor management network is quality driven, and our global footprint gives us significant flexibility. Because we operate across multiple geographies, we can source materials closer to individual manufacturing locations while also supporting sites in other regions whenever required. </span></p>
<p><span>Our global presence also allows us to leverage local expertise. For example, if a supplier in the UK needs to be qualified for one of our India sites, our UK quality team can conduct the vendor audit rather than sending a team from India. This improves efficiency and responsiveness. </span></p>
<p><span>Our supply chain, quality and manufacturing teams work very closely together, and we continuously monitor geopolitical developments so that we can take risk-based decisions early. That may include building inventory, securing alternate supplies or advancing shipments before disruptions occur. </span></p>
<p><span>So far, we have been able to maintain reliable supplies for our customers, and we have not faced situations where customer commitments could not be fulfilled because materials were unavailable. </span></p>
<p><strong>When you talk about futureproofing quality systems and building future-ready teams, what would be your key message for pharma quality professionals? </strong></p>
<p><span>My message remains the same: quality is not a department—it is a commitment. </span></p>
<p><span>You have to build quality on trust, not vigilance. Oversight will always be necessary, but vigilance alone cannot sustain quality. If people only do the right thing when someone is watching, the system will eventually fail. </span></p>
<p><span>Every tablet we manufacture, every grain of API we produce and every vial we fill must meet the highest quality standards—not only during an inspection, but every single day.</span></p>
<p><span>That is why culture remains the foundation of everything we do. Quality must become part of how people think and work, not simply a compliance requirement.</span></p>
<p> </p>
<p> </p>
<p>viveka.r@expressindia.com<br>
viveka.roy3@gmail.com</p>
<p>The post <a href="https://www.expresspharma.in/why-rashida-najmi-believes-in-running-quality-on-trust-not-vigilance/">Why Rashida Najmi believes in running quality on trust, not vigilance </a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>How does India Pharma Inc stay relevant in Global Pharma’s new world order?</title>
<link>https://edusehat.com/en/how-does-india-pharma-inc-stay-relevant-in-global-pharmas-new-world-order</link>
<guid>https://edusehat.com/en/how-does-india-pharma-inc-stay-relevant-in-global-pharmas-new-world-order</guid>
<description><![CDATA[ 
In Express Pharma&#039;s inaugural episode of Pharma Frontlines, Viveka Roychowdhury, Editor, Express Pharma, gets Sudarshan Jain IPA and Dr. TS Parmar IDMA to weigh in on the challenges ahead, emerging opportunities and strategic choices shaping India&#039;s destiny in the global pharma landscape.
The post How does India Pharma Inc stay relevant in Global Pharma’s new world order? appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/15123346/EP_Pharma-Frontlines_EP_01_SJ_TSP_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 15 Sep 2026 17:50:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>How, does, India, Pharma, Inc, stay, relevant, Global, Pharma’s, new, world, order</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="422" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/15123346/EP_Pharma-Frontlines_EP_01_SJ_TSP_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/15123346/EP_Pharma-Frontlines_EP_01_SJ_TSP_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/15123346/EP_Pharma-Frontlines_EP_01_SJ_TSP_750-300x169.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p></p>
<hr>
<p>In Express Pharma’s inaugural episode of Pharma Frontlines, Viveka Roychowdhury, Editor, Express Pharma, gets Sudarshan Jain IPA and Dr. TS Parmar IDMA to weigh in on the challenges ahead, emerging opportunities and strategic choices shaping India’s destiny in the global pharma landscape. </p>
<p>Pharma Frontlines is a virtual thought leadership series, where industry leaders have candid conversations on the trends and decisions shaping the future of the pharma sector.</p>
<p>For more details on future themes or to explore speaking opportunities, email viveka.r@expressindia.com and lakshmipriya.nair@expressindia.com</p>
<p>The post <a href="https://www.expresspharma.in/how-does-india-pharma-inc-stay-relevant-in-global-pharmas-new-world-order/">How does India Pharma Inc stay relevant in Global Pharma’s new world order?</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Scientists rethink how rare lysosomal disorders are classified</title>
<link>https://edusehat.com/en/scientists-rethink-how-rare-lysosomal-disorders-are-classified</link>
<guid>https://edusehat.com/en/scientists-rethink-how-rare-lysosomal-disorders-are-classified</guid>
<description><![CDATA[ 
A landmark collaborative study led by the University of Sheffield has proposed a new framework bringing 108 rare lysosomal disorders together, potentially enabling more precise diagnosis and helping researchers identify shared targets for future treatments
The post Scientists rethink how rare lysosomal disorders are classified appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2020/05/19145556/research.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 15 Sep 2026 17:50:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Scientists, rethink, how, rare, lysosomal, disorders, are, classified</media:keywords>
<content:encoded><![CDATA[<div><img width="880" height="586" src="https://cdn.expresspharma.in/wp-content/uploads/2020/05/19145556/research.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2020/05/19145556/research.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2020/05/19145556/research.jpg 768w, https://cdn.expresspharma.in/wp-content/uploads/2020/05/19145556/research.jpg 450w, https://cdn.expresspharma.in/wp-content/uploads/2020/05/19145556/research.jpg 880w" sizes="auto, (max-width: 880px) 100vw, 880px"></div><p><span><span><span>Scientists have brought together the most comprehensive picture yet of rare metabolic disorders, identifying 108 conditions, almost double those originally understood to exist, bringing new hope for early diagnosis and innovative treatments.</span></span></span></p>
<p><span><span><span>People living with lysosomal disorders can endure a range of symptoms, such as kidney problems, severe muscle weakness, progressive and fatal damage to the nervous system, depending on their diagnosis.</span></span></span></p>
<p><span><span><span>Lysosomes are specialised structures within cells that break down and recycle cellular material.</span></span></span></p>
<p><span><span><span>Traditionally, lysosomal disorders have largely been understood as conditions in which deficiencies of lysosomal enzymes or related proteins lead to the accumulation of “storage” material within cells.</span></span></span></p>
<p><span><span><span>However, advances in cell biology have revealed that lysosomes do much more than dispose of cellular waste.</span></span></span></p>
<p><span><span><span>They are involved in processes including cellular signalling, nutrient sensing, membrane trafficking, autophagy (the process by which cells recycle their own components) and communication between different structures within cells.</span></span></span></p>
<p><span><span><span>Established science only classed 70 conditions as lysosomal disorders.</span></span></span></p>
<p><span><span><span>But a pioneering study involving researchers at the University of Sheffield and across the country has now uncovered 108 disorders, including those not caused by enzyme deficiencies, for the first time.</span></span></span></p>
<p><span><span><span>Published in the </span></span></span><span><span><span><i>Journal of Inherited Metabolic Disease (JIMD)</i></span></span></span><span><span><span>, the study presents a new classification encompassing inherited disorders in which disruption of these wider lysosomal functions contribute significantly to disease. </span></span></span></p>
<p><span><span><span>After evaluating disorders against predefined criteria, the researchers classified 108 conditions caused by defects in 102 genes across 11 categories.The analysis also highlighted the complex and frequently multisystem nature of these disorders.</span></span></span></p>
<p><span><span><span>The findings show that the disease reaches far beyond a single area of the body. Roughly 80 per cent of patients experienced brain and nerve issues, and 68 per cent experienced eye complications. Digestive, bone, and blood-related issues were also common.</span></span></span></p>
<p><span><span><span>Dr Eamon McCarron, lead author of the study, Honorary Senior Lecturer at the University of Sheffield’s School of Medicine and Population Health and Consultant and Clinical Lead in Adult Inherited Metabolic Disorders at the Sheffield Adult Metabolic Service, said, “Lysosomal disorders are individually rare, but their effects can be debilitating and, in some cases, life-limiting.</span></span></span></p>
<p><span>“</span><span><span><span>Our understanding of the lysosome has changed enormously. We now know that it is not simply the cell’s waste-disposal system, and lysosomal disease cannot always be understood solely in terms of an enzyme deficiency and the accumulation of material within cells.</span></span></span></p>
<p><span>“</span><span><span><span>By bringing together 108 inherited disorders within a framework based on modern lysosomal biology, we hope to provide a clearer way of understanding how these diseases relate to one another.</span></span></span></p>
<p><span>“</span><span><span><span>This could support more precise diagnosis and genetic interpretation and, in the longer term, help researchers identify shared disease mechanisms that could become targets for new treatments. It may also help inform the future development of newborn screening strategies and clinical trials.”</span></span></span></p>
<p><span><span><span>The researchers say grouping diseases according to shared biological mechanisms could help identify groups of patients who may benefit from therapies targeting common disease pathways.</span></span></span></p>
<p><span><span><span>This could be particularly important for ultra-rare conditions, where conventional clinical trials evaluating treatments for individual disorders can be difficult.</span></span></span></p>
<p><span><span><span><span>The study was led by Dr Eamon McCarron at the University of Sheffield and Dr Karolina Stepien, Consultant in Adult Inherited Metabolic Diseases at Salford Royal Hospital and brought together expertise from institutions across the UK and internationally, including the University of Oxford, University College London and the University of Manchester, alongside international experts from University Children’s Hospital Zürich in Switzerland, Leiden University in the Netherlands, and the Eunice Kennedy Shriver National Institute of Child Health and Human Development at the US National Institutes of Health.</span></span></span></span></p>
<p>The post <a href="https://www.expresspharma.in/scientists-rethink-how-rare-lysosomal-disorders-are-classified/">Scientists rethink how rare lysosomal disorders are classified</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Ahmedabad&#45;based researcher develops novel formulation for tinnitus that targets brain pathways</title>
<link>https://edusehat.com/en/ahmedabad-based-researcher-develops-novel-formulation-for-tinnitus-that-targets-brain-pathways</link>
<guid>https://edusehat.com/en/ahmedabad-based-researcher-develops-novel-formulation-for-tinnitus-that-targets-brain-pathways</guid>
<description><![CDATA[ 
Dr Sanjay Agrawal has developed a novel formulation aimed at addressing changes in auditory processing as well as factors associated with the emotional and perceptual experience of tinnitus
The post Ahmedabad-based researcher develops novel formulation for tinnitus that targets brain pathways appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2020/08/21144641/research.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 15 Sep 2026 17:50:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Ahmedabad-based, researcher, develops, novel, formulation, for, tinnitus, that, targets, brain, pathways</media:keywords>
<content:encoded><![CDATA[<div><img width="888" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2020/08/21144641/research.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2020/08/21144641/research.jpg 888w, https://cdn.expresspharma.in/wp-content/uploads/2020/08/21144641/research-300x135.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2020/08/21144641/research-768x346.jpg 768w" sizes="(max-width: 888px) 100vw, 888px"></div><p><span><span><span>Scientific researcher and pharmaceutical consultant Dr Sanjay Agrawal, who reportedly holds 42 patents for drug formulations, has developed a new formulation for tinnitus.</span></span></span></p>
<p><span><span>He stated that the new formulation is designed to address the neuroplastic changes and emotional amplification mechanisms that underlie tinnitus. By targeting both peripheral damage and central compensation, it holds promise for reducing the phantom sound perception and associated distress.</span></span></p>
<p><span><span>Tinnitus often stems from cochlear damage and loss of sensory hair cells, leading to reduced auditory input. The brain compensates through neuroplastic changes, increasing spontaneous activity in the auditory cortex. Emotional and attentional centres like the limbic system and prefrontal cortex further amplify the distress.</span></span></p>
<p><span><span>Current pharmacological treatments focus on managing associated symptoms rather than eliminating tinnitus itself. Antidepressants like amitriptyline and nortriptyline, SSRIs, benzodiazepines (clonazepam, alprazolam), anticonvulsants (gabapentin, carbamazepine), melatonin, and zinc supplementation have all been explored, though most are used off-label and show variable efficacy.</span></span></p>
<p><span><span>Non-drug interventions are increasingly favored. Cognitive Behavioral Therapy (CBT), Tinnitus Retraining Therapy (TRT), sound therapy, hearing aids, mindfulness, relaxation techniques, and repetitive transcranial magnetic stimulation (rTMS) are among the most effective strategies for reducing perception and improving quality of life.</span></span></p>
<p><span><span>International health bodies advocate a multidisciplinary, patient-centred approach. CBT, sound therapy, and education are recommended as first-line treatments, while routine pharmacological intervention is discouraged. Guidelines from the American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS), the UK’s NICE, and European associations emphasize early diagnosis and psychological support. The World Health Organization (WHO) also underscores prevention through noise control and cautious use of ototoxic drugs.</span></span></p>
<p><span><span>Dr Agrawal’s formulation aligns with efforts to move beyond symptomatic relief by targeting the neurological mechanisms associated with tinnitus, including its auditory and emotional pathways.</span></span></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/ahmedabad-based-researcher-develops-novel-formulation-for-tinnitus-that-targets-brain-pathways/">Ahmedabad-based researcher develops novel formulation for tinnitus that targets brain pathways</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>ABEC to expand global manufacturing network with new Wilson facility</title>
<link>https://edusehat.com/en/abec-to-expand-global-manufacturing-network-with-new-wilson-facility</link>
<guid>https://edusehat.com/en/abec-to-expand-global-manufacturing-network-with-new-wilson-facility</guid>
<description><![CDATA[ A ribbon-cutting ceremony to mark the opening is scheduled for 24 September, with company leadership, employees, partners and community leaders expected to attend. According to ABEC, the site 
The post ABEC to expand global manufacturing network with new Wilson facility appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/09/PT-11-09-2026-shutterstock_2210207325.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 11 Sep 2026 19:15:13 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>ABEC, expand, global, manufacturing, network, with, new, Wilson, facility</media:keywords>
<content:encoded><![CDATA[<p>A ribbon-cutting ceremony to mark the opening is scheduled for 24 September, with company leadership, employees, partners and community leaders expected to attend.</p>
<p>According to ABEC, the site will produce bioprocess equipment and consumable products that are used in developing and manufacturing biologics, vaccines, and related advanced medicines.</p>
<p>The new plant complements ABEC’s existing operations in Bethlehem, Pennsylvania; Springfield, Missouri; US, and Fermoy and Kells in Ireland.</p>
<p>ABEC CEO Scott Pickering said: “Opening our Wilson facility represents another important milestone in ABEC’s commitment to supporting the global biopharmaceutical industry.</p>
<p>“This investment expands our manufacturing capabilities, brings us closer to customers in the southeastern US, and reinforces our ability to deliver the industry’s most comprehensive portfolio of bioprocess equipment, consumables, and engineering solutions.</p>
<p>“We are proud to become part of the Wilson community and look forward to building long-term partnerships throughout the region.”</p>
<p>The company indicated that the choice of Wilson was influenced by the area’s role as one of the country’s fastest-growing regions for life sciences. The new plant is expected to create additional manufacturing and technical jobs in eastern North Carolina.</p>
<p>The upcoming opening event will also include tours of the facility and recognise the collaboration between employees, contractors, community partners, and local authorities who supported the project.</p>
<p>ABEC provides engineered process solutions and services for biotechnology manufacturing. Its activities include process development, facility design, equipment manufacturing, installation and support services.</p>
<p>The company’s customers include pharmaceutical and biotechnology businesses using ABEC equipment and processes in therapy manufacturing.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/abec-global-manufacturing-network-wilson-facility/">ABEC to expand global manufacturing network with new Wilson facility</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Exegenesis Bio and Modalis sign research deal for Duchenne therapy</title>
<link>https://edusehat.com/en/exegenesis-bio-and-modalis-sign-research-deal-for-duchenne-therapy</link>
<guid>https://edusehat.com/en/exegenesis-bio-and-modalis-sign-research-deal-for-duchenne-therapy</guid>
<description><![CDATA[ The agreement involves the use of Modalis’ CRISPR-GNDM (Guide Nucleotide-Directed Modulation) technology in combination with Exegenesis Bio’s engineered muscle-tropic adeno-associated virus (AAV) capsid, EMC181. EMC181 is designed for 
The post Exegenesis Bio and Modalis sign research deal for Duchenne therapy appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/09/PT-2-11-09-2026-shutterstock_2511340521.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 11 Sep 2026 19:15:13 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Exegenesis, Bio, and, Modalis, sign, research, deal, for, Duchenne, therapy</media:keywords>
<content:encoded><![CDATA[<p>The agreement involves the use of Modalis’ CRISPR-GNDM (Guide Nucleotide-Directed Modulation) technology in combination with Exegenesis Bio’s engineered muscle-tropic adeno-associated virus (AAV) capsid, EMC181.</p>
<p>EMC181 is designed for enhanced delivery to muscle tissue.</p>
<p>The arrangement is set to become effective on 14 September 2026.</p>
<p>Under the agreement, Modalis will be granted rights to utilise EMC181 in the development of MDL-201.</p>
<p>The therapy aims to address DMD by selectively and sustainably activating utrophin expression in muscle using CRISPR-GNDM, potentially providing an approach independent of the specific genetic mutation in the dystrophin gene.</p>
<p>The companies intend for this combination to facilitate efficient targeting of muscle tissues and reduce exposure to off-target organs such as the liver.</p>
<p>Employing EMC181 as the delivery vector is expected to enhance the safety profile of MDL-201 due to its liver-detargeting properties.</p>
<p>In addition to DMD’s progressive muscle decline, the disease presents a challenge for long-term disease control in all patients, so alternative approaches are sought to support or complement existing therapies.</p>
<p>Exegenesis Bio CEO Zhenhua Wu said: “We are pleased to collaborate with Modalis to advance MDL-201. EMC181 was developed to enable efficient muscle targeting while reducing liver exposure, and we believe its combination with Modalis’ innovative CRISPR-GNDM payload represents a compelling approach for DMD.</p>
<p>“This collaboration reflects our strategy of applying our next-generation AAV capsid platform to differentiated gene therapies with the potential to address significant unmet medical needs.”</p>
<p>Modalis stated that the financial effects of this partnership are expected to be immaterial for the current fiscal year and no changes to the full-year earnings forecast have been made.</p>
<p>In September 2024, Modalis Therapeutics was awarded a rare paediatric disease designation by the US Food and Drug Administration for its congenital muscular dystrophy type 1a (LAMA2-CMD) gene therapy.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/exegenesis-bio-modalis-deal-duchenne-therapy/">Exegenesis Bio and Modalis sign research deal for Duchenne therapy</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Glenmark launches RYALTRIS nasal spray in Brazil for allergic rhinitis</title>
<link>https://edusehat.com/en/glenmark-launches-ryaltris-nasal-spray-in-brazil-for-allergic-rhinitis</link>
<guid>https://edusehat.com/en/glenmark-launches-ryaltris-nasal-spray-in-brazil-for-allergic-rhinitis</guid>
<description><![CDATA[ 
The launch follows ANVISA approval and introduces an olopatadine-containing intranasal combination therapy in Brazil
The post Glenmark launches RYALTRIS nasal spray in Brazil for allergic rhinitis appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 11 Sep 2026 15:40:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Glenmark, launches, RYALTRIS, nasal, spray, Brazil, for, allergic, rhinitis</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Glenmark Specialty S.A., a wholly-owned subsidiary of Glenmark Pharmaceuticals, (Glenmark), has announced the launch of RYALTRIS Nasal Spray in Brazil for the treatment of moderate to severe symptoms associated with allergic rhinitis (AR) in adults and adolescents aged 12 years and older. The launch follows regulatory approval granted by the Brazilian Health Regulatory Agency, Agência Nacional de Vigilância Sanitária (ANVISA), earlier this year.</span></p>
<p><span>The launch reflects Glenmark’s continued commitment to advancing its respiratory innovation journey and the Company’s continued progress in expanding access to differentiated therapies across global markets.</span></p>
<p><span>Allergic rhinitis is a chronic condition in Brazil, affecting an estimated 20–30 per cent of the population, equivalent to nearly 40–60 million people. This disease burden highlights the need for effective, convenient, and differentiated treatment options for patients across the country.</span></p>
<p><span>The launch of RYALTRIS introduces the first olopatadine-containing intranasal combination therapy in Brazil, combining an antihistamine, olopatadine hydrochloride, and a corticosteroid, mometasone furoate, in a single nasal spray. This offers a differentiated dual-action treatment option for symptoms associated with allergic rhinitis.</span></p>
<p><span>Commenting on the launch, Marco Cerato, Executive Vice President & Global Head – Innovative Business, Glenmark Pharmaceuticals said, “The launch of RYALTRIS in Brazil marks a significant milestone for our innovative respiratory portfolio and reflects our continued commitment to advancing respiratory care through science-led innovation and a patient-centric approach. As the largest healthcare market in Latin America, Brazil provides a strategic opportunity to bring this differentiated treatment option to patients and healthcare professionals.”</span></p>
<p><span>RYALTRIS is Glenmark’s first globally commercialized branded innovative product and has already been approved in 57 markets worldwide, including the United States, European Union, United Kingdom, Australia, South Korea, Russia, and China.</span></p>
<p>The post <a href="https://www.expresspharma.in/glenmark-launches-ryaltris-nasal-spray-in-brazil-for-allergic-rhinitis/">Glenmark launches RYALTRIS nasal spray in Brazil for allergic rhinitis</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The next injectable pharma race will be won on reliability </title>
<link>https://edusehat.com/en/the-next-injectable-pharma-race-will-be-won-on-reliability</link>
<guid>https://edusehat.com/en/the-next-injectable-pharma-race-will-be-won-on-reliability</guid>
<description><![CDATA[ 
The injectable pharma landscape is becoming increasingly interconnected, with pharma companies, CDMOs, device manufacturers and technology partners working more closely than ever before. What factors are driving this shift towards […]
The post The next injectable pharma race will be won on reliability  appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/10165139/Vaibhavi-Shah-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 11 Sep 2026 15:40:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, next, injectable, pharma, race, will, won, reliability </media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/10165139/Vaibhavi-Shah-1.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/10165139/Vaibhavi-Shah-1.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/10165139/Vaibhavi-Shah-1-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><strong>The injectable pharma landscape is becoming increasingly interconnected, with pharma companies, CDMOs, device manufacturers and technology partners working more closely than ever before. What factors are driving this shift towards ecosystem based collaboration, and how will it reshape competitive advantage over the next decade? </strong></p>
<p><span>A big shift has been taking place, and three forces are pushing in the same direction at once. The first is the nature of the work itself. Global companies are no longer handing partners discrete tasks to execute at low cost; they are setting up global capability centres and codevelopment relationships and asking teams to help solve hard development problems. When the work becomes collaborative rather than transactional, the boundaries between pharma company, CDMO, device maker and technology partner naturally dissolve. </span></p>
<p><span>The second force is scale that has matured into credibility. India’s contract research and development market has roughly doubled in recent years and is growing at almost twice the global rate, while the contract development and manufacturing sector is on a path from around USD 22 billion today toward USD 44 billion by the end of the decade. </span></p>
<p><span>The third is intent backed by capital: the patent cliff on biologics – over USD 40 billion of annual revenue losing exclusivity between now and 2029 – has opened a window in biosimilars and complex products, and public policy has moved to meet it. The injectable ecosystem is developing into a network of partners because of the growing alignment of science, demand and policy. </span></p>
<p><span>Over the next decade this reshapes competitive advantage in a fundamental way. Capacity is now widely available; what remains scarce is the assurance that a programme handed over will be returned on time, to specification, and able to withstand a regulator’s scrutiny. So, advantage will accrue to those who can be trusted inside an ecosystem – who bring regulatory predictability, the integrity of their quality and data systems, and depth of scientific talent. Price was always a borrowed advantage, because anyone can be undercut. The ability to be relied upon as a co-developer is an advantage no one can take away. </span></p>
<p><strong>As injectable therapies become more complex, particularly with the growth of biologics, GLP-1 therapies, long-acting injectables and drug-device combinations, what operational and organisational capabilities will companies need to prioritise to successfully scale their businesses while maintaining quality, operational efficiency and regulatory compliance? </strong></p>
<p><span>In complex injectables – the field in which I have spent most of my career and which Invengene works in – the test is sharper than anywhere else, because the margin for error is smaller. A partner is judged on sterile and aseptic capability, on its grasp of stability and the cold chain, and on whether it can carry a molecule through technology transfer and scaleup without the product quietly changing character. As therapies grow more complex, those capabilities move from being differentiators to being the price of entry.</span></p>
<p><span>But the capabilities that actually determine whether a company can scale are organisational, not just technical, and there are three. The first is data integrity as a culture rather than a checkbox – records that are complete, contemporaneous and traceable, and systems built so that the honest result is the only result that can be recorded. This is why the move to digital, paperless laboratories matters; at Invengene we treated it not as a technology upgrade but as a way to remove ambiguity from the data a partner is asked to rely on. </span></p>
<p><span>The second is institutional repeatability. Global partners are wary of organisations that depend on a handful of brilliant individuals, because that talent is mobile and the result is not reproducible. What earns long term programmes is a professionally governed, process-led organisation that can deliver the same outcome twice. The third is honest project management – realistic timelines, early disclosure of problems, and the discipline to take a molecule from concept to a regulatory-ready dossier. A partner who flags a deviation early is worth far more than one who reports only success. Companies that prioritise these three will scale complexity; those that rely on heroics will not. </span></p>
<p><strong>As manufacturing technologies continue to evolve and therapeutic pipelines become more diverse, how should organisations balance investments in capacity, flexibility and advanced technologies while managing commercial and regulatory risk? </strong></p>
<p><span>The instinct is to compete on capacity, but capacity is now the wrong thing to optimise for. What global companies are really buying is confidence, not capacity – and the factors that actually decide where they place their programmes are, in order: regulatory predictability, the integrity of a partner’s quality and data systems, the depth of its scientific talent, its speed to clinic and to filing, and only then, cost. Investment should follow that order of priorities rather than the order that is easiest to build. </span></p>
<p><span>Practically, that means the teams that win these mandates compete on the total cost of getting a compliant, reliable product to market – not on the lowest unit price. Flexibility matters because pipelines are diversifying toward biologics, long-acting injectables and drug-device combinations, so the ability to reconfigure a line or a technology-transfer process for a new modality protects an organisation against betting on a single therapeutic direction. Advanced technology – particularly digital, paperless quality systems – earns its place not as a showpiece but because it removes ambiguity from data and lowers regulatory risk directly. </span></p>
<p><span>On managing risk, the honest lesson is that programmes are usually lost at the compliance and consistency layer, not the scientific one. So the disciplined approach is to invest first in the systems that make quality reproducible and regulatory outcomes predictable, then in flexible capacity matched to real pipeline demand, and to resist the temptation to over-build capacity ahead of the credibility to fill it. Predictability – of quality, of timelines, of behaviour – is the product an organisation is actually selling, and investment should be weighted toward protecting it. </span></p>
<p><strong>The injectable pharma landscape is evolving beyond the product itself. How are innovations in drug delivery, digital health and supply chain resilience redefining patient value and competitive differentiation? </strong></p>
<p><span>In injectables, access is very often an engineering problem disguised as a pricing one, and this is where the real opportunity lies. A medicine that must be held between two and eight degrees is effectively unavailable across large parts of Africa, Asia and Latin America however cheaply it is priced, because the cold chain it depends on simply is not there. A vial that must be discarded a few hours after it is opened imposes a quiet, daily tax of waste on every intensive-care unit that uses it. The barrier in both cases is design – and design is precisely what science is built to solve. </span></p>
<p><span>Two examples from our own work at Invengene make the point. We re-engineered the formulation of a critical antifungal so that it is stable at room temperature rather than dependent on cold storage, which means it can now travel to, and survive in, places the cold chain never reached. And by changing the preservative system in a fast-acting cardiac injectable, we extended its in use stability after the vial is punctured from twelve hours to seventy-two, so a single vial serves longer and far less is thrown away. The active molecule is untouched in both cases; everything around it is rebuilt. Same efficacy, a fundamentally wider reach. </span></p>
<p><span>Framed properly, this is not a product story but a public health one. Reformulating for room-temperature stability and reducing in-use wastage speaks directly to UN Sustainable Development Goal 3 – good health and well-being, and universal access to safe, affordable, essential medicines – and it does so most powerfully for remote and under-served countries, the very places where a broken cold chain or a wasted vial decides whether a patient is treated at all. That is how delivery innovation, digital-quality systems and supply-chain resilience redefine both patient value and competitive differentiation: not the most expensive science, but the most consequential. </span></p>
<p><strong>As the injectable pharmaceutical market continues to evolve, what strategic choices made today will determine which companies emerge as industry leaders over the next decade? </strong></p>
<p><span>The strategic choice that matters most is deciding what you are actually selling. The world does not, in the end, need its medicines made a little cheaper. It needs partners who can make difficult medicines reach difficult places and keep working when they arrive. Companies that choose to compete on that higher standard – designing access into the molecule and being trusted while doing it – will lead. Those that stay in the generics playbook of lowest unit price will keep winning a race that anyone can undercut. </span></p>
<p><span>The second choice is to treat reliability as something built in the laboratory and the quality system, not asserted in a pitch. If programmes are lost, they are usually lost at the compliance and consistency layer. The biggest single source of hesitation remains quality and data-integrity findings, and the damage is never confined to the firm that is cited – a handful of weak actors colours how the whole ecosystem is perceived. The leaders will be those who fix this at the level of governance and culture, and who manage talent volatility so that continuity over a multi-year programme can be taken for granted, because continuity is precisely what co-development demands. </span></p>
<p><span>The third choice is continuity itself. Every ecosystem that has successfully attracted long-term R&D – Boston, Singapore, South Korea, Ireland – did the same unglamorous thing: it made long, consistent bets and stayed with them across political and economic cycles. The building blocks already exist. What determines leadership is execution velocity and consistency: protecting intellectual property visibly, keeping regulatory timelines predictable, and resisting the urge to change direction every few years. Affordability earned India the trust of the world as its pharmacy. Re-engineered science and unwavering reliability, sustained patiently over a decade, will earn something far rarer – a seat at the table where the world’s medicines are imagined, not merely manufactured. </span></p>
<p> </p>
<p><em><span>neha.aathavale@expressindia.com </span><span><br>
</span><span>nehaaathavale75@gmail.com </span></em></p>
<p>The post <a href="https://www.expresspharma.in/the-next-injectable-pharma-race-will-be-won-on-reliability/">The next injectable pharma race will be won on reliability </a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>HAB Pharma appoints Pankaj Agarwal as Chief Financial Officer</title>
<link>https://edusehat.com/en/hab-pharma-appoints-pankaj-agarwal-as-chief-financial-officer</link>
<guid>https://edusehat.com/en/hab-pharma-appoints-pankaj-agarwal-as-chief-financial-officer</guid>
<description><![CDATA[ 
The appointment comes as the company strengthens its financial and organisational capabilities to support growth across manufacturing, R&amp;D, domestic and international markets
The post HAB Pharma appoints Pankaj Agarwal as Chief Financial Officer appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/11131524/EP_Pankaj_Agarwal_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 11 Sep 2026 15:40:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>HAB, Pharma, appoints, Pankaj, Agarwal, Chief, Financial, Officer</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/11131524/EP_Pankaj_Agarwal_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/11131524/EP_Pankaj_Agarwal_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/11131524/EP_Pankaj_Agarwal_750-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>HAB Pharmaceuticals & Research Limited (HAB Pharma), an Indian pharmaceutical company with a legacy spanning over four decades, has appointed Pankaj Agarwal as Chief Financial Officer (CFO).</span></p>
<p><span>The appointment comes as HAB Pharma strengthens its financial and organisational capabilities to support its next phase of growth, driven by expanding manufacturing capacities, R&D initiatives, domestic presence and international market opportunities.</span></p>
<p><span>A Chartered Accountant with almost 18 years of experience across the healthcare and pharmaceutical sectors, Pankaj brings expertise in financial strategy, planning and forecasting, financial reporting and compliance, fundraising, treasury management, audit, risk assessment and operational efficiency.</span></p>
<p><span>Prior to joining HAB Pharma, he held senior finance roles at Innovcare Lifesciences, Max Healthcare and Vyome Biosciences. At Innovcare, he contributed to a US$5 million Series C fundraise and a further US$1 million through non-convertible debentures and led the implementation of SAP for the accounts function. He began his career in audit and compliance with PricewaterhouseCoopers (PwC) and later worked as a Partner at Lahoti Roy & Associates.</span></p>
<p><span>At HAB Pharma, Pankaj oversees financial planning, budgeting, reporting, compliance, risk management and corporate governance, while providing financial insights to support informed business decisions. He works closely with the leadership team to strengthen financial discipline, operational efficiency and sustainable value creation across the organisation.</span></p>
<p><span>He is a Chartered Accountant and holds a Post Graduate Executive Management Programme in Finance and Sales from SPJIMR, Mumbai.</span></p>
<p><span>Commenting on the appointment, </span>Saurabh Agarwal, CEO and Director, HAB Pharma<span>, said “Since joining HAB Pharma in February, Pankaj has brought a strong focus on financial discipline, structured planning and informed decision-making. His understanding of finance, compliance and business operations has been valuable as the company continues to strengthen its manufacturing capabilities, R&D initiatives and market presence. We are confident that his continued contribution will support HAB Pharma’s growth ambitions and help build a stronger financial and governance framework for the organisation.”</span></p>
<p>Pankaj Agarwal, Chief Financial Officer, HAB Pharma<span>, said, “Over the past six months at HAB Pharma, it has been an enriching experience to work closely with the leadership team and gain a deeper understanding of the company’s business, operations and growth priorities. The organisation is at an important stage of its evolution, with significant opportunities across manufacturing, R&D, exports and domestic markets. I look forward to continuing to strengthen financial processes, improve operational efficiency and support disciplined and sustainable growth.”</span></p>
<p><span>The appointment marks another step in HAB Pharma’s ongoing organisational strengthening as the company expands its manufacturing footprint, advances its product and R&D pipeline, and builds its presence across domestic and international markets.</span></p>
<p>The post <a href="https://www.expresspharma.in/hab-pharma-appoints-pankaj-agarwal-as-chief-financial-officer/">HAB Pharma appoints Pankaj Agarwal as Chief Financial Officer</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>OPPI appoints Amitabh Dube as its President</title>
<link>https://edusehat.com/en/oppi-appoints-amitabh-dube-as-its-president</link>
<guid>https://edusehat.com/en/oppi-appoints-amitabh-dube-as-its-president</guid>
<description><![CDATA[ 
The Organisation of Pharmaceutical Producers of India (OPPI), which represents the global research-based pharmaceutical companies in India, has appointed Amitabh Dube as its President for a term of two years […]
The post OPPI appoints Amitabh Dube as its President appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/10173228/EP_OPPI-Amitabh-Dube.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 10 Sep 2026 21:45:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>OPPI, appoints, Amitabh, Dube, its, President</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/10173228/EP_OPPI-Amitabh-Dube.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/10173228/EP_OPPI-Amitabh-Dube.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/10173228/EP_OPPI-Amitabh-Dube-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>The Organisation of Pharmaceutical Producers of India (OPPI), which represents the global research-based pharmaceutical companies in India, has appointed Amitabh Dube as its President for a term of two years effective 10</span><span>th</span><span> September 2026.</span></p>
<p><span>Amitabh Dube is the Country President and Managing Director of Novartis India. With nearly three decades of experience in the pharmaceutical industry, he has held leadership roles across India and international markets. Prior to his current position, Amitabh served as Country President of Novartis Vietnam, where he also chaired the country’s leading pharmaceutical industry association, contributing to the advancement of the healthcare ecosystem in the country.</span></p>
<p><span>Speaking on his appointment, Amitabh Dube, President OPPI, said, “It is a privilege to lead OPPI at a time when India’s healthcare landscape is undergoing rapid transformation. The innovative pharmaceutical industry has an important role to play in improving patient outcomes, advancing scientific innovation and supporting India’s emergence as a global life sciences powerhouse. By harnessing the collective expertise of our member companies and working collaboratively with stakeholders across the healthcare ecosystem, we can help shape an environment that promotes innovation, improves access and delivers lasting value for patients. I am excited about the opportunity to contribute to India’s journey towards a Viksit Bharat.”</span></p>
<p><span>Welcoming Amitabh as the President, Bhushan Akshikar said, “It has been a privilege to serve as the OPPI President and contribute to the organization’s journey of advancing innovation, access and collaboration in healthcare. Over the past two years, OPPI has continued to strengthen its engagement with stakeholders and reinforce its commitment to the nation’s healthcare priorities. I am delighted to pass the baton to Amitabh, whose deep industry experience, global perspective and strong understanding of India’s healthcare landscape will be invaluable to OPPI. I am confident that under his leadership, OPPI will continue to build on its momentum and further strengthen the industry’s contribution towards a healthier India.”</span></p>
<p><span>Anil Matai, Director General, OPPI, said, “We are deeply grateful to Bhushan for the energy, clarity and commitment he brought to OPPI during his tenure. Under his stewardship, the organisation strengthened its engagement with stakeholders and kept innovation, access and patient needs firmly at the centre of its agenda. We are excited to welcome Amitabh as the President. His breadth of experience, global outlook and strong conviction in the power of partnerships will bring fresh momentum to OPPI’s work. At a time when India is poised to play a larger role in shaping the future of healthcare, his leadership will help us sharpen our priorities, amplify our collective voice and translate dialogue into meaningful action for patients and the wider healthcare ecosystem.”</span></p>
<p>The post <a href="https://www.expresspharma.in/oppi-appoints-amitabh-dube-as-its-president/">OPPI appoints Amitabh Dube as its President</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>TwoStep Therapeutics secures $62.5m funding to advance TS&#45;104</title>
<link>https://edusehat.com/en/twostep-therapeutics-secures-625m-funding-to-advance-ts-104</link>
<guid>https://edusehat.com/en/twostep-therapeutics-secures-625m-funding-to-advance-ts-104</guid>
<description><![CDATA[ Insight Partners and Medical Excellence Capital led the round, with additional investment from Pfizer Ventures and M Ventures, the corporate venture capital arm of Merck KGaA, all joining 
The post TwoStep Therapeutics secures $62.5m funding to advance TS-104 appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/09/PT-10-09-2026-shutterstock_2156317271.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 10 Sep 2026 18:10:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>TwoStep, Therapeutics, secures, 62.5m, funding, advance, TS-104</media:keywords>
<content:encoded><![CDATA[<p>Insight Partners and Medical Excellence Capital led the round, with additional investment from Pfizer Ventures and M Ventures, the corporate venture capital arm of Merck KGaA, all joining as co-lead investors.</p>
<p>Previous backers NFX and 2048 Ventures also participated, alongside Stanford University, where the company’s core scientific platform originated before it launched in 2024.</p>
<p>TwoStep’s total capital raised now stands at $71.2m.</p>
<p>The company also received investigational new drug (IND) application clearance for TS-104 from the US Food and Drug Administration (FDA).</p>
<p>This approval enables a first-in-human Phase I study of TS-104, with patient enrolment expected to commence later this year.</p>
<p>TwoStep Therapeutics co-founder and CEO Caitlyn Miller said: “This financing, together with FDA clearance of the IND, marks an important inflection point for TwoStep and positions us to advance TS-104, our lead peptide-drug conjugate, through Phase I clinical development in oncology.</p>
<p>“This trial will provide the first clinical evaluation of the multi-specific targeting approach at the heart of TwoStep and begin to assess its potential to broaden the reach of targeted therapies.”</p>
<p>TwoStep said that most existing tumour-targeted therapies rely on the presence of a single cell-surface target, which may not be uniformly expressed across all patients or tumour cells.</p>
<p>Its approach uses a polyspecific integrin-binding peptide (PIP), designed to bind five tumour-associated integrins found across a variety of solid tumours.</p>
<p>The company’s TS-104 conjugates the PIP to Monomethyl auristatin E (MMAE), a cytotoxic payload.</p>
<p>In connection with the fundraising, TwoStep appointed Insight Partners vice-president Matias Porras Paniagua, Medical Excellence Capital CEO John Prufeta, M Ventures biotechnology investment associate Oliver Lyth, and Pfizer Ventures operations head Rana Al-Hallaq to the company’s board. Existing members include Miller and NFX general partner Omri Amirav-Drory.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/twostep-therapeutics-funding-advance-ts-104/">TwoStep Therapeutics secures $62.5m funding to advance TS-104</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Solstice Oncology secures $225m to drive porustobart’s development for cancer</title>
<link>https://edusehat.com/en/solstice-oncology-secures-225m-to-drive-porustobarts-development-for-cancer</link>
<guid>https://edusehat.com/en/solstice-oncology-secures-225m-to-drive-porustobarts-development-for-cancer</guid>
<description><![CDATA[ The financing was raised in a Series A round led by RA Capital Management, with participation from Forbion, Canaan Partners and other investors. Porustobart is a second-generation, Fc-enhanced 
The post Solstice Oncology secures $225m to drive porustobart’s development for cancer appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/09/PT-2-10-09-2026-shutterstock_2825883837.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 10 Sep 2026 18:10:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Solstice, Oncology, secures, 225m, drive, porustobart’s, development, for, cancer</media:keywords>
<content:encoded><![CDATA[<p>The financing was raised in a Series A round led by RA Capital Management, with participation from Forbion, Canaan Partners and other investors.</p>
<p>Porustobart is a second-generation, Fc-enhanced cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody developed by Harbour BioMed.</p>
<p>The therapy is being investigated for use in two indications, with initial focus on treating microsatellite-stable (MSS) clinical stage II–III colon cancer in the neoadjuvant setting.</p>
<p>Enrolment for a Phase II trial of porustobart in combination with pembrolizumab is scheduled to begin in the fourth quarter of 2026.</p>
<p>The study will evaluate the effect of the combination therapy before surgery in patients with MSS colon cancer, which represents the largest subgroup of colon cancer cases and does not currently benefit from approved immunotherapies.</p>
<p>Harbour BioMed entered a licence and equity partnership with Solstice Oncology in February 2026.</p>
<p>The agreement grants Solstice exclusive rights to develop and commercialise porustobart, also known in Harbour BioMed’s pipeline as HBM4003, outside Greater China.</p>
<p>A Phase II clinical trial previously conducted by Harbour BioMed tested porustobart with the PD-1 inhibitor tislelizumab in patients with MSS metastatic colorectal cancer without liver metastases.</p>
<p>The combination yielded a 30% objective response rate, with seven out of 23 patients responding to treatment.</p>
<p>The median duration of response was reported at 8.4 months, and the therapy exhibited a favourable safety profile.</p>
<p>These results will inform further studies of porustobart in combination with PD-(L)1 inhibitors for patients at earlier disease stages.</p>
<p>Harbour BioMed founder, chairman and CEO Dr Jingsong Wang said: “We are pleased to see Solstice Oncology launch with strong support from leading investors and advance porustobart into the neoadjuvant setting.</p>
<p>“As the originator of porustobart and a partner of Solstice, we look forward to supporting the continued development of this differentiated CTLA-4 antibody and exploring its potential to benefit patients worldwide.”</p>
<p>In November 2025, Harbour BioMed and Evinova China formed a collaboration to implement AI and digital technologies to improve biologics development.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/solstice-225m-porustobart-development/">Solstice Oncology secures $225m to drive porustobart’s development for cancer</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>High Commissioner highlights stronger pharma partnership for India &amp;amp; Sri Lanka</title>
<link>https://edusehat.com/en/high-commissioner-highlights-stronger-pharma-partnership-for-india-sri-lanka</link>
<guid>https://edusehat.com/en/high-commissioner-highlights-stronger-pharma-partnership-for-india-sri-lanka</guid>
<description><![CDATA[ 
Sri Lanka’s High Commissioner to India Mahishini Colonne highlighted opportunities for deeper India – Sri Lanka cooperation in pharmaceutical manufacturing, investment, healthcare technologies and resilient supply chains at the Ambassadors’ […]
The post High Commissioner highlights stronger pharma partnership for India &amp; Sri Lanka appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/10151313/EP_India-SriLanka.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 10 Sep 2026 18:10:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>High, Commissioner, highlights, stronger, pharma, partnership, for, India, Sri, Lanka</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/10151313/EP_India-SriLanka.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/10151313/EP_India-SriLanka.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/10151313/EP_India-SriLanka-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Sri Lanka’s High Commissioner to India Mahishini Colonne highlighted opportunities for deeper India – Sri Lanka cooperation in pharmaceutical manufacturing, investment, healthcare technologies and resilient supply chains at the Ambassadors’ Conference on Healthcare Technologies and Pharmaceutical Manufacturing, held on 08 September 2026 as part of the Pharma MachTech Expo & LabNext Expo 2026 in New Delhi.</span></p>
<p><span>Organised by the Engineering Export Promotion Council of India (EEPC India), the conference brought together diplomatic representatives from 15 countries, senior Indian government policymakers and industry representatives to exchange perspectives on investment and trade opportunities, emerging developments in pharmaceutical manufacturing and healthcare technologies, and the scope for international partnerships.</span></p>
<p><span>High Commissioner Colonne highlighted that India and Sri Lanka already share a strong pharmaceutical trading relationship, while emphasising the considerable scope to build on this foundation through manufacturing, investment and technology partnerships.</span></p>
<p><span>She outlined opportunities across the pharmaceutical value chain, including active pharmaceutical ingredients (APIs), medical devices, laboratory and diagnostic technologies, and quality-control systems. Sri Lanka currently imports the majority of its pharmaceutical requirements, with domestic manufacturers meeting a modest share of demand, creating significant opportunities for investment and manufacturing partnerships.</span></p>
<p><span>The High Commissioner highlighted Sri Lanka’s growing policy focus on pharmaceutical manufacturing, with pharmaceuticals designated as a priority investment sector. Qualifying manufacturing projects are eligible for extended tax incentives and fast-tracked regulatory approval through the National Medicines Regulatory Authority.</span></p>
<p><span>She also drew attention to the dedicated pharmaceutical manufacturing zone in Hambantota, established for companies seeking to develop production and technology capabilities in Sri Lanka.</span></p>
<p><span>Sri Lanka’s existing Free Trade Agreement with India provides an additional advantage, with more than 50 categories of pharmaceutical products and medical devices already receiving duty-free access to the Indian market.</span></p>
<p><span>She emphasised that, for both countries and the wider region, building manufacturing capacity closer to markets has increasingly become a matter of health security and supply-chain resilience, in addition to commercial considerations. In this context, she highlighted the potential for greater cooperation in technology transfer, skills development, research collaboration and regulatory cooperation.</span></p>
<p><span>Sri Lanka’s geographical proximity to India, established institutional relationship with India, and growing openness to investment across the pharmaceutical value chain were identified as important foundations for deeper collaboration.</span></p>
<p><span>The High Commissioner also invited Indian industry stakeholders to participate in Sri Lanka Expo 2027, Sri Lanka’s flagship trade and investment exhibition, to be held in Colombo from 14 – 17 January 2027. The Expo will provide an opportunity for Indian companies and other international stakeholders to explore trade, investment and partnership opportunities in Sri Lanka.</span></p>
<p><span>The Ambassadors’ Conference formed part of the second edition of Pharma MachTech Expo & LabNext Expo, held from 7 – 9 September 2026 in New Delhi.</span></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/high-commissioner-highlights-stronger-pharma-partnership-for-india-sri-lanka/">High Commissioner highlights stronger pharma partnership for India & Sri Lanka</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>FOPE seeks transition period, clarity on new FDC warning requirement</title>
<link>https://edusehat.com/en/fope-seeks-transition-period-clarity-on-new-fdc-warning-requirement</link>
<guid>https://edusehat.com/en/fope-seeks-transition-period-clarity-on-new-fdc-warning-requirement</guid>
<description><![CDATA[ 
The Federation of Pharma Entrepreneurs (FOPE) has sought clarification and a reasonable transition period for implementing the Ministry of Health &amp; Family Welfare’s Notification S.O. 4595(E), dated August 18, 2026, […]
The post FOPE seeks transition period, clarity on new FDC warning requirement appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2024/09/02120205/Colourful-medicines.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 10 Sep 2026 18:10:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>FOPE, seeks, transition, period, clarity, new, FDC, warning, requirement</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2024/09/02120205/Colourful-medicines.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2024/09/02120205/Colourful-medicines.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2024/09/02120205/Colourful-medicines-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p>The Federation of Pharma Entrepreneurs (FOPE) has sought clarification and a reasonable transition period for implementing the Ministry of Health & Family Welfare’s Notification S.O. 4595(E), dated August 18, 2026, concerning fixed-dose combinations (FDCs) containing Chlorpheniramine Maleate and Phenylephrine Hydrochloride.</p>
<p>In its representation to the government, FOPE said the industry supports the notification’s objective of ensuring patient safety and rational use of medicines, particularly among children below four years of age. However, it highlighted several practical and regulatory concerns that could affect manufacturers and stakeholders across the supply chain.</p>
<p>A key concern raised by FOPE is the implementation of the new warning requirement on existing stocks. The notification requires the warning, “Fixed dose combination shall not be used in children below four years of age,” to be included on labels, package inserts or promotional literature.</p>
<p>FOPE pointed out that products manufactured before the notification may already be held by carrying and forwarding agents, distributors, stockists, retail pharmacies, hospitals and institutions. It has therefore sought an adequate transition period to allow depletion or appropriate modification of existing stocks.</p>
<p>The federation has also urged the government to clarify that the new requirements will apply prospectively and that products manufactured, distributed and marketed in compliance with regulations applicable at the time should not face retrospective action solely because they do not carry the newly mandated warning.</p>
<p>FOPE has further sought clarity on the scope of Notification S.O. 4595(E) in relation to the earlier Notification S.O. 1717(E), dated April 15, 2025. It said the term FDC is broad and could encompass different dosage forms, including eye drops and injectables, which may not be relevant to the intended warning requirement.</p>
<p>The federation has also called for greater emphasis on rational prescribing and guidance to registered medical practitioners, noting that several such formulations are prescription medicines and that healthcare professionals are already subject to applicable obligations relating to rational prescribing and patient safety.</p>
<p>To facilitate implementation without disrupting existing inventory, FOPE has proposed a mechanism under Rule 104A of the Drugs and Cosmetics Rules, 1945, including permitting stakeholders to affix warning stickers or stamps on existing stocks and modify package inserts, wherever applicable.</p>
<p>FOPE has cited the precedent of regulatory permissions allowing stickers or stamps for compliance with ceiling prices under the DPCO and has sought a similar mechanism for the FDC warning.</p>
<p>The federation has urged the government to:</p>
<ul>
<li>clarify that Notification S.O. 4595(E) will operate prospectively;</li>
<li>provide a reasonable transition period for existing stocks;</li>
<li>ensure that compliant pre-notification stocks are not subjected to coercive action solely due to the absence of the new warning;</li>
<li>permit an appropriate compliance mechanism for existing inventory;</li>
<li>issue uniform implementation guidance to all stakeholders; and</li>
<li>clarify the precise formulations and dosage forms covered by the notification.</li>
</ul>
<p>FOPE reiterated its commitment to working with the government on regulatory compliance while ensuring patient safety and minimising avoidable disruption to the pharmaceutical supply chain.</p>
<p>The post <a href="https://www.expresspharma.in/fope-seeks-transition-period-clarity-on-new-fdc-warning-requirement/">FOPE seeks transition period, clarity on new FDC warning requirement</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Complex&#45;molecule specialist Shilpa CDMO launches at CPHI Milan</title>
<link>https://edusehat.com/en/complex-molecule-specialist-shilpa-cdmo-launches-at-cphi-milan</link>
<guid>https://edusehat.com/en/complex-molecule-specialist-shilpa-cdmo-launches-at-cphi-milan</guid>
<description><![CDATA[ 
Shilpa CDMO, a dedicated complex small-molecule contract development and manufacturing organisation will launch next month at CPHI Milan. The new brand, separate from parent company Shilpa Medicare, provides  a specialist […]
The post Complex-molecule specialist Shilpa CDMO launches at CPHI Milan appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/10153008/EP_Shilpa-CDMO.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 10 Sep 2026 18:10:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Complex-molecule, specialist, Shilpa, CDMO, launches, CPHI, Milan</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/10153008/EP_Shilpa-CDMO.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/10153008/EP_Shilpa-CDMO.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/10153008/EP_Shilpa-CDMO-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p>Shilpa CDMO, a dedicated complex small-molecule contract development and manufacturing organisation will launch next month at CPHI Milan. The new brand, separate from parent company Shilpa Medicare, provides  a specialist development and commercial manufacturing partner for biotech and pharma customers with complex small molecules, building on Shilpa’s more than 30 years of oncology expertise.</p>
<p>Keshav Bhutada, Chief Executive Officer of Shilpa CDMO, said: “We have long been known among our existing partners as incredibly capable, particularly for challenging molecules such as HPAPIs and peptides, and more recently ADC payloads and linkers, PROTACs and oligonucleotides.</p>
<p>However, with the growth and opportunity we are now seeing in the CDMO division, it became clear that we needed a much stronger and more distinct business that shows a broader range of innovators our extensive contract service capabilities for novel and complex molecules. Shilpa Pharma’s CDMO division will therefore now go to market as Shilpa CDMO and is dedicated to complex molecule development. Essentially, we love working on our partners’ most challenging projects.”</p>
<p>The launch comes as US and European biotechnology companies increasingly seek to diversify their development and manufacturing strategies beyond China. Yet while the global CDMO market contains hundreds of providers, the expertise and infrastructure required to advance genuinely complex molecules remain concentrated among a relatively small number of organisations – many of which have limited near-term availability, are China-centric or naturally prioritise their largest customers.</p>
<p>“Available capacity is not the same as capable capacity,” Yagnesh Solanki, Director – CDMO at Shilpa CDMO, said. “For a next-generation compound, the choice of CDMO can be the difference between a programme progressing successfully and encountering years of avoidable redevelopment, delay and additional cost.”</p>
<p>To meet this rising demand, Shilpa CDMO is continuing to invest in what is already one of India’s largest small-molecule development and manufacturing platforms. Its infrastructure includes 230 kL of reactor capacity, three R&D centres, more than 400 scientists and two dedicated API manufacturing sites.</p>
<p>In addition to significant commercial infrastructure, the new CDMO brings together dedicated R&D teams for HPAPIs and oncology, peptides, ADC payloads and linkers, oligonucleotides and PROTACs. Its integrated capabilities extend from discovery and route scouting through process and analytical development to commercial drug-substance and finished-dose manufacturing. This gives Shilpa CDMO one of the world’s most complete small-molecule platforms and will help US-based and European biotechnology partners advance more quickly through development.</p>
<p>To be unveiled at CPHI Milan 2026 (6–8 October, Fiera Milano) under the promise “Your complex molecules → medicines,” Shilpa CDMO brings together more than 30 years of chemistry, development and manufacturing experience to shape the future of medicines through scientific innovation, passion and purpose.</p>
<p>Uniquely among global CDMOs, Shilpa CDMO’s payload and linker chemistry sits within 200 miles of sister company Shilpa Biologicals, which provides antibody production, conjugation and fill-finish. For ADC and conjugate programmes, this removes intercontinental shipping of intermediates, shortens development timelines and materially simplifies the supply chain.</p>
<p>Commenting on the rising demand from new NCE partners, Dipak Kalita, Senior Vice President – CDMO Services at Shilpa CDMO, said: “What has often surprised new customers – and demonstrated why we need a clearer brand — is the breadth and depth of our capabilities beyond our established position in oncology. We are also investing heavily in PROTACs and peptides. When paired with our sister company, Shilpa Biologicals—a complex-biologics CDMO—we offer payload and linker chemistry, antibody production, conjugation and fill-finish, all from sites inside 200 miles of each other. This is near unique among global CDMOs and means development timelines are faster and supply chains much simpler.”</p>
<p>At CPHI Milan, Shilpa CDMO will also announce details of its new commercial-scale peptide manufacturing capabilities, further strengthening its ability to support complex peptide programmes from development through to commercial supply.</p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/complex-molecule-specialist-shilpa-cdmo-launches-at-cphi-milan/">Complex-molecule specialist Shilpa CDMO launches at CPHI Milan</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>UK&#45;MHRA inspects Indoco’s solid dosages facility in Goa</title>
<link>https://edusehat.com/en/uk-mhra-inspects-indocos-solid-dosages-facility-in-goa</link>
<guid>https://edusehat.com/en/uk-mhra-inspects-indocos-solid-dosages-facility-in-goa</guid>
<description><![CDATA[ 
Indoco Remedies announced that the UK Medicines and Healthcare Products Regulatory Agency (UKMHRA) inspected its solid dosages manufacturing facility in Goa (Plant I) from September 7 to September 9, 2026. […]
The post UK-MHRA inspects Indoco’s solid dosages facility in Goa appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2022/12/28115212/Drug-inspection.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 10 Sep 2026 18:10:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>UK-MHRA, inspects, Indoco’s, solid, dosages, facility, Goa</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2022/12/28115212/Drug-inspection.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2022/12/28115212/Drug-inspection.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2022/12/28115212/Drug-inspection-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>Indoco Remedies announced that the UK Medicines and Healthcare Products Regulatory Agency (UKMHRA) inspected its solid dosages manufacturing facility in Goa (Plant I) from September 7 to September 9, 2026.</span></p>
<p><span>The UK-MHRA current Good Manufacturing Practices (cGMP) inspection concluded with no critical or major observations. </span></p>
<p><span>Commenting on the development, Aditi Panandikar, Managing Director – Indoco Remedies said, “This plant has been consistently catering to the regulated markets of UK, Europe, South Africa, New Zealand, Australia and Canada for several years and is expected to contribute to approx. 30 per cent of total international business. The successful completion of the UKMHRA cGMP inspection with no critical or major observations is a strong validation of our robust quality systems. This further testifies our unwavering commitment to Good Manufacturing Practices and world class quality standards. The accolade not only reinforces the trust our global partners place in us, but strengthens our ability to serve patients worldwide.” </span></p>
<p><span>The facility which manufactures solid dosages and liquid dosages is approved by USFDA, (solid dosages, creams and capsules), TGA-Australia (solid dosages, liquid orals, creams and ointments) and by EU Malta, i.e., MMA – Malta Medicine Authority (solid dosages). The Plant also holds WHO-GMP approval and has successfully faced an audit by SAHPRA (for solid dosages).</span></p>
<p>The post <a href="https://www.expresspharma.in/uk-mhra-inspects-indocos-solid-dosages-facility-in-goa/">UK-MHRA inspects Indoco’s solid dosages facility in Goa</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Fredun Pharmaceuticals acquires Furlicks from pharma major USV</title>
<link>https://edusehat.com/en/fredun-pharmaceuticals-acquires-furlicks-from-pharma-major-usv</link>
<guid>https://edusehat.com/en/fredun-pharmaceuticals-acquires-furlicks-from-pharma-major-usv</guid>
<description><![CDATA[ 
Fredun Pharmaceuticals Limited (FPL), has acquired Furlicks, an innovative pet-wellness brand focused on convenient, easy-to-administer oral-strip solutions for pets. The acquisition of Furlicks from USV &amp; Wellbeing Nutrition brings the brand’s differentiated product innovation and consumer understanding into […]
The post Fredun Pharmaceuticals acquires Furlicks from pharma major USV appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2019/12/04112329/Acquisition.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 10 Sep 2026 14:35:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Fredun, Pharmaceuticals, acquires, Furlicks, from, pharma, major, USV</media:keywords>
<content:encoded><![CDATA[<div><img width="888" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2019/12/04112329/Acquisition.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2019/12/04112329/Acquisition.jpg 888w, https://cdn.expresspharma.in/wp-content/uploads/2019/12/04112329/Acquisition-300x135.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2019/12/04112329/Acquisition-768x346.jpg 768w" sizes="auto, (max-width: 888px) 100vw, 888px"></div><p>Fredun Pharmaceuticals Limited (FPL), has acquired Furlicks, an innovative pet-wellness brand focused on convenient, easy-to-administer oral-strip solutions for pets. The acquisition of Furlicks from USV & Wellbeing Nutrition brings the brand’s differentiated product innovation and consumer understanding into the FPL Group.</p>
<p>This move further creates an opportunity to leverage FPL’s established capabilities in manufacturing, product development, quality systems, R&D, supply chain and distribution in the pet-care industry.</p>
<p>With pet parenting evolving from a predominantly need-based approach towards a more proactive focus on preventive health, the acquisition comes at a time when pet parents are becoming more aware and increasingly willing to invest in nutrition and specialised products for their pets.</p>
<p>Furlicks addresses this consumer need through its oral-strip format, offering an alternative to conventional forms of pet supplements. Its existing portfolio spans key pet-wellness categories including skin and coat, gut health, joint care, calming, oral care and multivitamins, providing a strong foundation for further category expansion and product innovation.</p>
<p>Speaking on the acquisition, Fredun Medhora, MD & CFO, Fredun Pharmaceuticals Ltd. stated, “Furlicks marks a bold new chapter in FPL’s journey into pet wellness. We see Furlicks as more than an addition to our portfolio- it is a differentiated platform with the potential to build a significant</p>
<p>pet-wellness business. By combining Furlicks’ innovation and consumer-first approach with FPL’s manufacturing capabilities, scale and execution strength, we aim to make quality pet care more accessible to millions of pet parents across India. Our focus is to scale Furlicks while preserving what makes the brand special: its innovation, simplicity and deep understanding of pet parents. With FPL’s resources and capabilities behind it, we see a strong opportunity to take what Furlicks has built to the next level and create India’s first comprehensive pet-wellness platform.”</p>
<p>The immediate focus for FPL will be on scaling the existing business by introducing 12 new SKUs in the 1st phase, with 32 new SKUs aligned for launch in the second phase. Over time, the ambition is to evolve Furlicks from a differentiated oral-strip proposition into a broader everyday pet-wellness platform.</p>
<p>
</p><p>The post <a href="https://www.expresspharma.in/fredun-pharmaceuticals-acquires-furlicks-from-pharma-major-usv/">Fredun Pharmaceuticals acquires Furlicks from pharma major USV</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title> MSD inaugurates Technology Centre in Hyderabad</title>
<link>https://edusehat.com/en/msd-inaugurates-technology-centre-in-hyderabad</link>
<guid>https://edusehat.com/en/msd-inaugurates-technology-centre-in-hyderabad</guid>
<description><![CDATA[ 
MSD, a  global biopharmaceutical leader, inaugurated its new 2.5 lakh sq. ft Technology Centre in  Hyderabad, further strengthening the city’s position as a global hub for life sciences, technology and  […]
The post  MSD inaugurates Technology Centre in Hyderabad appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/10120918/EP_MSD.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 10 Sep 2026 14:35:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords> MSD, inaugurates, Technology, Centre, Hyderabad</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/10120918/EP_MSD.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/10120918/EP_MSD.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/10120918/EP_MSD-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>MSD, a  global biopharmaceutical leader, inaugurated its new 2.5 lakh sq. ft Technology Centre in  Hyderabad, further strengthening the city’s position as a global hub for life sciences, technology and  innovation. The new centre will bring together advanced capabilities across digital, data, analytics,  artificial intelligence, technology and engineering, supporting MSD’s global Human Health business and  contributing to its worldwide technology network. </span></p>
<p><span>The Centre located at Hitech City was inaugurated by  D. Sridhar Babu, Minister for Information Technology, Electronics & Communications,  Industries & Commerce and Legislative Affairs, Government of Telangana, in the presence of  Abhishek Narayan Singh, Senior Vice President, Digital Human Health, MSD; Ritesh Srivastava,  Executive Director, MSD; Sai Krishna, IT Advisor to the Government of Telangana; and Sarvesh Singh,  CEO, Telangana Life Sciences, and other senior members of the MSD leadership team. </span></p>
<p><span>Telangana’s life sciences ecosystem, with more than 2,000 companies, is increasingly evolving from a  manufacturing-led base into a hub for advanced R&D, innovation and global technology capabilities. Over  the last two years, the state has attracted major global players including Amgen, Eli Lilly, Bristol Myers  Squibb, Sanofi, Align Technology and Zoetis, with operations spanning advanced technology,  innovation and R&D. MSD’s new Technology Centre adds further depth to this ecosystem, bringing high </span></p>
<p><span>value digital and technology capabilities to Hyderabad and strengthening the city’s role in supporting  global healthcare operations.</span></p>
<p>D. <span>Sridhar Babu, Minister for Information Technology, Electronics &  Communications, Industries & Commerce, and Legislative Affairs, Government of Telangana said,  </span><i><span>“Telangana has built a truly end-to-end life sciences ecosystem, with more than 2,000 companies  spanning APIs, bulk drugs, generics, CDMO, vaccines, research and discovery. Hyderabad has emerged  as a global leader in vaccines and is home to one of the largest concentrations of USFDA-approved  facilities outside the United States. Over the last two years, we have been deliberate about taking this  ecosystem from manufacturing scale to the next generation of discovery, innovation, advanced R&D and  global capability creation. In this journey, Telangana has welcomed major global companies and  advanced technology and innovation operations. Today, we are proud to welcome MSD to Telangana  and to our growing life sciences ecosystem. Through our Next-Gen Life Sciences Policy 2026–30, we are  bringing the entire value chain together, from discovery and manufacturing to clinical research and  technology. This convergence gives Hyderabad a unique global advantage. We will soon reach 100  GCCs, building on the 75+ GCCs established in Telangana last year, creating 4 lakh direct and indirect high-value opportunities at scale and further strengthening Hyderabad’s position as a global life sciences  and technology hub.” </span></i></p>
<p><span>The Hyderabad Technology Centre will be an important part of MSD’s global technology network,  enabling teams in Hyderabad to contribute to enterprise technology solutions, collaborate with colleagues  across the world and advance digital capabilities that support MSD’s work to deliver innovative health  solutions for people and animals globally. Together with strategic partnerships supporting manufacturing  excellence and reliable access to medicines, the Centre reflects the breadth of capabilities across India  that contribute to MSD’s global operations and its mission to improve health outcomes worldwide. </span></p>
<p><span>Abhishek Narayan Singh, Senior Vice President, Digital Human Health, MSD said, “The inauguration  of our Hyderabad Technology Centre reflects MSD’s long-term commitment to building world-class digital  capabilities that drive business value at scale. Hyderabad’s vibrant technology ecosystem, deep digital  expertise and strong talent pool make it an ideal location for MSD, and we are grateful for the support and  engagement of the Telangana government. This Technology Centre strengthens our ability to bring together talent, technology and global collaboration to deliver scalable solutions that contribute to MSD’s  purpose.” </span></p>
<p><span>Hyderabad’s unique advantage lies in the convergence of its established life sciences ecosystem and  advanced technology infrastructure, with Genome Valley located alongside one of India’s largest  technology corridors. The Government is further strengthening this foundation through Bharat Future  City, including a 2,100-acre life sciences zone with a specialised 100-acre hub for advanced biologics,  alongside the 1Bio model, which provides plug-and-play access to advanced bio-foundry infrastructure to  accelerate innovation and scale. </span></p>
<p><span>Telangana’s strong talent base further strengthens this ecosystem, with leading institutions such as  CSIR-IICT, CCMB and NIPER producing highly skilled scientific talent. Through initiatives such as the  Telangana School of Life Sciences and Industry-Integrated PhD programmes, the state is bringing  academia and industry closer together, creating talent equipped to work at the intersection of life  sciences, technology and advanced R&D, added the minister.  </span></p>
<p><span>MSD’s presence adds another dimension to Hyderabad’s life sciences landscape, bringing together  global expertise, digital capabilities and technology-driven solutions. The new Technology Centre will enable teams in Hyderabad to work on enterprise solutions for MSD’s global operations, creating  opportunities for high-value technology work and strengthening the city’s role in supporting global  healthcare innovation. </span></p>
<p>The post <a href="https://www.expresspharma.in/msd-inaugurates-technology-centre-in-hyderabad/"> MSD inaugurates Technology Centre in Hyderabad</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Gilead launches research facility in US for new medicine development</title>
<link>https://edusehat.com/en/gilead-launches-research-facility-in-us-for-new-medicine-development</link>
<guid>https://edusehat.com/en/gilead-launches-research-facility-in-us-for-new-medicine-development</guid>
<description><![CDATA[ The new facility expands the company’s capabilities in inflammation, oncology and data science. Gilead currently employs 11,000 people in the US, with more than 7,400 based in California 
The post Gilead launches research facility in US for new medicine development appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/09/PT-2-09-09-2026-Gilead-building-1000.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 09 Sep 2026 20:30:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Gilead, launches, research, facility, for, new, medicine, development</media:keywords>
<content:encoded><![CDATA[<p>The new facility expands the company’s capabilities in inflammation, oncology and data science.</p>
<p>Gilead currently employs 11,000 people in the US, with more than 7,400 based in California and approximately 4,700 in the Bay Area.</p>
<p>The facility was officially opened with a ribbon-cutting ceremony attended by company leaders, employees and guests, including US Representative Kevin Mullin of California’s 15th Congressional District and California State Assembly member Diane Papan.</p>
<p>Gilead Sciences chairman and CEO Daniel O’Day said: “We are in a moment of unprecedented opportunity in science and technology.</p>
<p>“Our new research centre will help Gilead scientists make the most of that opportunity, delivering more breakthrough medicines faster.</p>
<p>“As part of our broader $32bn investment in the US, this new facility also reflects our long-term commitment to American innovation.”</p>
<p>The centre is part of a broader strategy by Gilead to advance research, development, and manufacturing assets in the US through to 2030.</p>
<p>Two other Foster City projects are also underway: the Technical Development Center, anticipated to open in 2027; and a biologics facility scheduled for completion in 2029.</p>
<p>Gilead Sciences research executive vice-president Flavius Martin said: “The future of biomedical innovation depends on bringing together exceptional science, advanced technologies and diverse expertise.</p>
<p>“This centre was designed to do exactly that. By co-locating key research disciplines and expanding our data science capabilities, we are strengthening the infrastructure needed to accelerate discovery and advance meaningful innovations.”</p>
<p>The five-storey building will accommodate around 325 employees, including 260 laboratory scientists. It features adaptable laboratory spaces, collaborative work areas, and shared technology platforms.</p>
<p>Sustainability features include all-electric systems, energy-efficient design, and landscaping with native California plants, aimed at achieving LEED Gold certification.</p>
<p>The centre is linked to an adjacent building for efficient transfer of equipment and provides a new central gathering space for collaboration.</p>
<p>In May 2026, Gilead Sciences concluded its acquisition of Tubulis, a Germany-based biotechnology company developing next-generation antibody-drug conjugates (ADCs), in a transaction valued at up to $5bn.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/gilead-research-facility-medicine-development/">Gilead launches research facility in US for new medicine development</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Fermenta Biotech signs exclusive licence agreement with VIT Vellore for vitamin B12 fortification technology</title>
<link>https://edusehat.com/en/fermenta-biotech-signs-exclusive-licence-agreement-with-vit-vellore-for-vitamin-b12-fortification-technology</link>
<guid>https://edusehat.com/en/fermenta-biotech-signs-exclusive-licence-agreement-with-vit-vellore-for-vitamin-b12-fortification-technology</guid>
<description><![CDATA[ 
Fermenta Biotech, India’s leading manufacturer of premium-grade APIs, intermediates, and nutritional premixes for the global markets, announced the signing of an Exclusive Licence Agreement with Vellore Institute of Technology (“VIT”), […]
The post Fermenta Biotech signs exclusive licence agreement with VIT Vellore for vitamin B12 fortification technology appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/09135223/EP_Fermenta.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 09 Sep 2026 20:30:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Fermenta, Biotech, signs, exclusive, licence, agreement, with, VIT, Vellore, for, vitamin, B12, fortification, technology</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/09135223/EP_Fermenta.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/09135223/EP_Fermenta.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/09135223/EP_Fermenta-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p>Fermenta Biotech, India’s leading manufacturer of premium-grade APIs, intermediates, and nutritional premixes for the global markets, announced the signing of an Exclusive Licence Agreement with Vellore Institute of Technology (“VIT”), Vellore, for the commercialisation of a technology for Natural In-Situ Vitamin B12 Fortification in Fermented Foods.</p>
<p>Vitamin B12 deficiency remains a significant nutritional challenge, particularly among vegetarian and vegan populations with limited natural dietary sources. Fortifying widely consumed foods offers a potentially more accessible approach to improving intake than relying solely on tablets or injectables. The demand for Vitamin B12 solutions is also being supported by trends such as vegetarianism, ageing populations and greater focus on fortified foods.</p>
<p>Against this backdrop, VIT’s technology, covered under Indian Patent Application No. 202441015300, has been developed by Dr Krishnan Venkataraman and his team at the Centre for BioSeparation Technology (“CBST”), VIT Vellore. It provides an approach to enhancing Vitamin B12 directly within fermented foods during the natural fermentation process, rather than through the conventional addition of Vitamin B12 to the finished food product.</p>
<p>The process uses selected nutrients and cofactors during fermentation to enhance the formation of Vitamin B12 within the food matrix. It is designed to integrate with existing food fermentation processes without requiring substantial alterations to conventional production methods. Laboratory studies demonstrated approximately 80 per cent retention of the enhanced Vitamin B12 levels following cooking, indicating the technology’s potential applicability across both fermented and subsequently cooked foods.</p>
<p>Commenting on the milestone, Prashant Nagre, Managing Director, Fermenta Biotech said, “Fermenta’s collaboration with VIT Vellore brings together scientific depth and industrial capability with a shared purpose: to make nutrition more meaningful, relevant and accessible. This technology opens a differentiated route to Vitamin B12 enrichment and extends Fermenta’s food fortification capabilities beyond customised vitamin and mineral premixes. It also reflects a larger ambition of translating emerging nutrition research into scalable solutions that can become part of everyday foods and, over time, contribute to better nutritional outcomes. Our focus will now be on advancing this technology towards practical, market-ready applications with the potential to support improved nutritional outcomes.”.</p>
<p>Commenting on the milestone during the signing and exchange of the exclusive licence  agreement,  G . Viswanathan, Chancellor   VITv said, “This MoU with Fermenta Biotech Ltd is a significant one and it reflects VIT’s long-standing commitment to transform academic learning into a solution provider for real world challenges especially in healthcare industry. I am confident that this MoU will contribute to India’s capabilities in nutritional science and also fight against micronutrient deficiency.”</p>
<p>The next phase will include application development, nutritional validation, assessment of final Vitamin B12 concentrations, regulatory evaluation and development of commercially viable solutions for relevant food applications. The commercial potential extends across FMCG, food and nutrition, nutraceutical and broader health-related applications. Fermenta will leverage its capabilities in this domain to enable scale-up into accessible pre-mixes and fortified food solutions, exemplifying a meaningful industry-academia synergy to combat widespread dietary deficiencies worldwide.</p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/fermenta-biotech-signs-exclusive-licence-agreement-with-vit-vellore-for-vitamin-b12-fortification-technology/">Fermenta Biotech signs exclusive licence agreement with VIT Vellore for vitamin B12 fortification technology</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>CDSCO move towards smarter, risk&#45;based regulation to ease doing business for Indian pharma: iPHEX 2026</title>
<link>https://edusehat.com/en/cdsco-move-towards-smarter-risk-based-regulation-to-ease-doing-business-for-indian-pharma-iphex-2026</link>
<guid>https://edusehat.com/en/cdsco-move-towards-smarter-risk-based-regulation-to-ease-doing-business-for-indian-pharma-iphex-2026</guid>
<description><![CDATA[ 
The Central Drugs Standard Control Organisation (CDSCO) is moving towards a smarter, risk-based regulatory approach that reduces and prioritises intervention, simplifies processes and applies greater proportionality to compliance, while continuing […]
The post CDSCO move towards smarter, risk-based regulation to ease doing business for Indian pharma: iPHEX 2026 appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/09150344/EP_Raja-Bhanu-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 09 Sep 2026 20:30:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>CDSCO, move, towards, smarter, risk-based, regulation, ease, doing, business, for, Indian, pharma:, iPHEX, 2026</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/09150344/EP_Raja-Bhanu-1.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/09150344/EP_Raja-Bhanu-1.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/09150344/EP_Raja-Bhanu-1-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>The Central Drugs Standard Control Organisation (CDSCO) is moving towards a smarter, risk-based regulatory approach that reduces and prioritises intervention, simplifies processes and applies greater proportionality to compliance, while continuing to safeguard the quality, safety and efficacy of medicines, Dr. Ranga Chandrashekhar, Joint Drug Controller, CDSCO, Ministry of Health & Family Welfare, Government of India, said during a panel discussion at iPHEX 2026 organised by Pharmexcil.</span></p>
<p><span>Speaking at a session focused on rationalising criminal provisions governing business and regulatory compliance, Dr. Chandrashekhar said CDSCO has examined the drug approval pathway to identify areas where regulatory intervention can be reduced without compromising quality. He pointed to measures where certain requirements have moved from prior approval to prior intimation, including manufacturing for test and analysis before approval, helping reduce processing time. He also said that for BA/BE studies clinical study designs are standardised and adequate guidance is provided enabling prior intimation for generation of data for export purpose.</span></p>
<p><span>He also highlighted CDSCO’s increasing use of digital systems, dashboards and supervisory mechanisms to reduce processing time and improve oversight. Referring to the Jan Vishwas</span> <span>framework, Dr. Chandrashekhar said certain procedural and record-keeping offences have been reviewed to ensure that the regulatory response is proportionate to the nature of the lapse, with compounding the offences with  monetary penalties available in appropriate cases while retaining deterrence.</span></p>
<p><span>Extending the principle of proportionality to controlled substances, Brijendra Chowdhary, IRS (Customs & Indirect Taxes), Deputy Narcotics Commissioner, Central Bureau of Narcotics, said regulation should facilitate legitimate pharmaceutical activity while maintaining strong safeguards against diversion.</span></p>
<p><span>Brijendra Chowdhary said, “The challenge is to enable legitimate economic expansion of the pharmaceutical industry while preventing illicit diversion. Regulation must serve as a protective guardrail, not as an operational hurdle. There should be proportionality, a clear distinction between a legitimate error and malfeasance, risk-based enforcement, and zero tolerance against drug trafficking and diversion.”</span></p>
<p><span>He added that the Central Bureau of Narcotics is working towards an ecosystem of self-regulation and voluntary compliance, supported by greater engagement and awareness among industry. He also noted that the NDPS Act is undergoing a process of amendment, with the principle of proportionality forming part of the deliberations.</span></p>
<p><span>The broader policy thinking was reinforced by Dr. Sonali Rawal, Senior Health Specialist, NITI Aayog, who said the government’s approach is not to do away with necessary regulation, but to simplify processes where delays can be avoided.</span></p>
<p><span>Dr. Sonali Rawal said, “The underlying basis of this process is trust, what we call Jan Vishwas. We work with the premise of trust in industry partners and regulators, and where processes can be undertaken in parallel or unnecessary requirements can be simplified to hasten approvals, we should look at doing so.”</span></p>
<p><span>From the industry side, Dr. Amit Talwar, Associate Secretary General, Indian Pharmaceutical Alliance, said regulatory reform should not be interpreted as a demand for weaker standards.</span></p>
<p><span>Dr. Amit Talwar said, “When we say deregulation, we are not asking for abolition of regulation. Medicines are different from other industries because public health, safety and efficacy are involved. What we are saying is that there has to be proportionality. An issue involving misconduct or intent should not be treated at par with a violation in a documentary process.”</span></p>
<p><span>Building on this, Meera Vanjari, Chief General Counsel, Cipla Ltd., stressed that greater proportionality also requires clearer and more consistently interpreted regulations.</span></p>
<p><span>Meera Vanjari said, “We do not want to dilute regulations. What we would definitely like to see is that regulations are more specific, objective, easy to interpret and not open to subjectivity. For minor offences such as documentation not being in order or missing certain deadlines, there should be other ways of dealing with them, including compounding, while ensuring that penalties remain a deterrent.”</span></p>
<p>K Raja Bhanu, Director General, Pharmexcil, said, “For Indian pharmaceutical companies, particularly exporters and MSMEs, regulatory clarity and predictability are critical to competitiveness. A smarter, risk-based approach can reduce avoidable compliance burden while maintaining the standards expected in global markets. This balance between strong regulation, ease & speed of doing business will be important as India strengthens its position as a trusted pharmaceutical partner worldwide.”</p>
<p><span>The discussion reflected a broad convergence that ease of doing business in pharmaceuticals does not mean weaker regulation, but a more risk-based and proportionate framework that simplifies compliance for legitimate businesses while retaining strong safeguards around quality, safety and serious violations.</span></p>
<p><span>The discussion formed part of iPHEX 2026, the 12th edition of India’s flagship pharmaceutical exhibition, organised by Pharmexcil with the support of the Department of Commerce, Ministry of Commerce and Industry, Government of India, under the Bharat Health Global Expo 2026 at Bharat Mandapam, New Delhi. With more than 800 stalls, 600 hosted international buyers and around 30,000 business visitors, and 10,000 business meetings.  Pharmexcil is targeting approximately USD 1.4 billion in export business opportunities through iPHEX 2026.</span></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/cdsco-move-towards-smarter-risk-based-regulation-to-ease-doing-business-for-indian-pharma-iphex-2026/">CDSCO move towards smarter, risk-based regulation to ease doing business for Indian pharma: iPHEX 2026</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>DIA India Annual Meeting 2026 to convene global and Indian healthcare leaders to shape the next era of innovation</title>
<link>https://edusehat.com/en/dia-india-annual-meeting-2026-to-convene-global-and-indian-healthcare-leaders-to-shape-the-next-era-of-innovation</link>
<guid>https://edusehat.com/en/dia-india-annual-meeting-2026-to-convene-global-and-indian-healthcare-leaders-to-shape-the-next-era-of-innovation</guid>
<description><![CDATA[ 
The Drug Information Association (DIA) will bring together leaders from across the life sciences and healthcare ecosystem at the DIA India Annual Meeting (IAM) 2026, to be held on 18–19 […]
The post DIA India Annual Meeting 2026 to convene global and Indian healthcare leaders to shape the next era of innovation appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2022/08/29115711/events.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 09 Sep 2026 20:30:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>DIA, India, Annual, Meeting, 2026, convene, global, and, Indian, healthcare, leaders, shape, the, next, era, innovation</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2022/08/29115711/events.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2022/08/29115711/events.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2022/08/29115711/events-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>The Drug Information Association (DIA) will bring together leaders from across the life sciences and healthcare ecosystem at the DIA India Annual Meeting (IAM) 2026, to be held on 18–19 November 2026 at the CIDCO Auditorium & Convention Centre, Navi Mumbai.</span></p>
<p><span>Centered on the theme, “Where India Meets the World in Healthcare Innovation. Global Impact, Locally Delivered,” the meeting will bring together perspectives from across pharma, biotech, regulatory authorities, academia, clinical research and technology to examine how India can help shape the next chapter of global healthcare innovation.</span><span><br>
</span><span><br>
</span><span>As science, technology and regulation converge at unprecedented speed, IAM 2026 marks an important platform for turning future-ready strategies into real-world impact. The meeting is designed to move beyond dialogue and enable decision-making, collaboration and execution across the healthcare product lifecycle.</span></p>
<p><span>A major highlight of the meeting will be the Opening Plenary Session, themed “India 2047 (Viksit Bharat) – From the Pharmacy of the World to the Innovation Engine of the World.”</span></p>
<p><span>The plenary programme is scheduled to include opening addresses from CDSCO and the US FDA, followed by keynote discussions examining India’s evolution from a global supplier towards becoming a healthcare and innovation powerhouse. The programme will also explore whether India can lead on access, affordability and innovation in the evolving GLP-1 landscape, and culminate in a plenary panel asking: “What Will It Take for India to Produce the Next Global Biopharma Giant?”</span></p>
<p><b>Six tracks. One converging healthcare future.</b></p>
<p><span>Over two days, IAM 2026 will feature </span>six focused tracks and two flagship plenary sessions<span>, bringing together experts and decision-makers across key areas shaping the future of life sciences and healthcare.</span></p>
<p><span>The programme will focus on:</span></p>
<ul>
<li aria-level="1"><b>Regulatory science & policy</b></li>
</ul>
<p><span>Discussions will explore future-ready regulatory frameworks, digital transformation and AI in regulatory science, global collaboration, operational excellence and strategies to accelerate access to life-changing therapies.</span></p>
<ul>
<li aria-level="1"><b>Advanced therapy medicinal products</b></li>
</ul>
<p><span>Sessions will examine the future of advanced therapies, including oncology applications, radiopharmaceuticals, cell and gene therapies, regulatory pathways, manufacturing and quality considerations, and the challenges of moving breakthrough science towards scalable patient access.</span></p>
<ul>
<li aria-level="1"><b>Clinical development</b></li>
</ul>
<p><span>The clinical development track will explore India’s potential as a global biopharma and clinical research hub, the country’s clinical trial advantage, risk-based quality management, real-world evidence, digital biomarkers and the role of AI in improving clinical development.</span></p>
<ul>
<li aria-level="1"><b>Pharmacovigilance</b></li>
</ul>
<p><span>The programme will examine what the next generation of drug safety could look like, including AI governance, patient voice, predictive safety intelligence, integrated safety systems and emerging risks in an increasingly complex therapeutic landscape.</span></p>
<ul>
<li aria-level="1"><b>Medical affairs</b></li>
</ul>
<p><span>Sessions will focus on the evolving strategic role of medical affairs, lifecycle evidence generation, real-world evidence, health economics and outcomes research, cross-functional collaboration and India’s role in driving healthcare impact beyond its borders.</span></p>
<ul>
<li aria-level="1"><b>Data science & AI</b></li>
</ul>
<p><span>As AI increasingly moves from experimentation into implementation, this track will explore the realities of deploying AI in healthcare, data interoperability, advanced analytics, AI-enabled clinical development and the balance between automation, autonomy and accountability.</span></p>
<p><span>The meeting will conclude with a Closing Plenary Session featuring a keynote on how AI is redefining the drug development continuum, followed by a panel discussion on “The Future of Medicines: Who Will Shape the Next Era of Healthcare?”</span></p>
<p><b>A platform for what comes next</b></p>
<p><span>With innovation moving faster than traditional systems and silos can accommodate, the conversations at DIA India Annual Meeting 2026 will focus on a central challenge: how can India translate scientific, technological and regulatory progress into meaningful, scalable healthcare impact?</span></p>
<p><span>By bringing global perspectives together with India’s rapidly evolving life sciences capabilities, IAM 2026 aims to create a platform for the conversations, collaborations and decisions that will help shape the future of healthcare.</span></p>
<p><a href="https://www.diaglobal.org/en/conference-listing/meetings/2026/09/dia-india-annual-meeting-2026/register">Registration</a> for the DIA- India Annual Meeting 2026 is now open.<span> For more information on the conference and participation details, visit the official conference website or reach out at </span><a href="mailto:Indai.meetings@diagobal.org"><span>Indai.meetings@diagobal.org</span></a><span> </span></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/dia-india-annual-meeting-2026-to-convene-global-and-indian-healthcare-leaders-to-shape-the-next-era-of-innovation/">DIA India Annual Meeting 2026 to convene global and Indian healthcare leaders to shape the next era of innovation</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Leucine Rich Bio launches enhanced BugSpeaks Skin Microbiome Test 2026 edition</title>
<link>https://edusehat.com/en/leucine-rich-bio-launches-enhanced-bugspeaks-skin-microbiome-test-2026-edition</link>
<guid>https://edusehat.com/en/leucine-rich-bio-launches-enhanced-bugspeaks-skin-microbiome-test-2026-edition</guid>
<description><![CDATA[ 
Leucine Rich Bio has announced the launch of the upgraded BugSpeaks Skin Microbiome Test 2026 Edition. The company is ISO 9001:2015 and ISO/IEC 17025:2017 certified. The new report builds on […]
The post Leucine Rich Bio launches enhanced BugSpeaks Skin Microbiome Test 2026 edition appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/09150056/DNA.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 09 Sep 2026 20:30:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Leucine, Rich, Bio, launches, enhanced, BugSpeaks, Skin, Microbiome, Test, 2026, edition</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/09150056/DNA.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/09150056/DNA.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/09150056/DNA-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span><span><span>Leucine Rich Bio has announced the launch of the upgraded BugSpeaks Skin Microbiome Test 2026 Edition. The company is ISO 9001:2015 and ISO/IEC 17025:2017 certified. The new report builds on the 2025 version. It enables greater understanding and action regarding skin wellness due to metagenomic analysis.</span></span></span></p>
<p><span><span><span>The 2026 version enhances metagenomic analysis from five primary factors to 11 skin traits. These include collagen production, ceramide production, elasticity maintenance, pH maintenance, moisture retention, epidermal integrity, antioxidant defense, photoprotection and resilience, sebum regulation, inflammation tendency, and reactivity and tolerance. The traits map into 5 holistic skin impacts. These are barrier strength, hydration status, sensitivity profile, repair and recovery, and ageing and preservation. Results appear on an integrated visual scorecard.</span></span></span></p>
<p><span>“<span><span>The 2026 upgrade reflects our commitment to translating complex microbiome science into practical tools for better skin health,” said Dr Debojyoti Dhar, Co-Founder and Director, Leucine Rich Bio. </span></span></span></p>
<p><span><span><span>“We incorporated deeper functional metagenomic potential across multiple microbial kingdoms. We also refined population benchmarking. This enables more precise recommendations for individuals and practitioners alike” opined Kumar Sankaran, CEO and Co-founder, Leucine Rich Bio</span></span></span></p>
<p><span><span><span>The test uses high-throughput microbial DNA sequencing of a simple skin swab. It evaluates bacterial, fungal, archaeal, viral, and eukaryotic kingdoms. It also provides detailed pathogen characterisation and risk profiles. Results use a new 3-bin and 7-bin population scale system. Bin 4 serves as the optimal “bullseye” benchmark against healthy reference populations.</span></span></span></p>
<p><span><span><span>The report offers a full personalisation engine. It includes tailored recommendations for primary topical ingredients, natural topical extracts, topical probiotic lysates, oral probiotics, and dietary guidance. This will benefit skin-conscious consumers interested in anti-aging and prevention. This will also be helpful for dermatologists and aesthetic centers that require objective information to offer treatments. Skincare formulations can also be developed that do not harm the microbiome.</span></span></span></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/leucine-rich-bio-launches-enhanced-bugspeaks-skin-microbiome-test-2026-edition/">Leucine Rich Bio launches enhanced BugSpeaks Skin Microbiome Test 2026 edition</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>FDA grants RMAT designation to RiboX’s RXRG001 for xerostomia</title>
<link>https://edusehat.com/en/fda-grants-rmat-designation-to-riboxs-rxrg001-for-xerostomia</link>
<guid>https://edusehat.com/en/fda-grants-rmat-designation-to-riboxs-rxrg001-for-xerostomia</guid>
<description><![CDATA[ RXRG001 is a circular ribonucleic acid (RNA) therapy encoding human aquaporin-1, a protein involved in fluid transport. The therapy is encapsulated within lipid nanoparticles and directly administered to 
The post FDA grants RMAT designation to RiboX’s RXRG001 for xerostomia appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/09/PT-09-09-2026-shutterstock_2543793295.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 09 Sep 2026 16:55:13 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>FDA, grants, RMAT, designation, RiboX’s, RXRG001, for, xerostomia</media:keywords>
<content:encoded><![CDATA[<p>RXRG001 is a circular ribonucleic acid (RNA) therapy encoding human aquaporin-1, a protein involved in fluid transport.</p>
<p>The therapy is encapsulated within lipid nanoparticles and directly administered to the salivary glands. It is designed with the aim of restoring saliva production in glands damaged by radiation.</p>
<p>RXRG001 had previously received FDA fast track designation.</p>
<p>The designation was based on preliminary clinical evidence from the SPRINX-1 Phase I/IIa study underway.</p>
<p>This multi-centre trial is assessing RXRG001 in adult patients experiencing decreased saliva production and dry mouth.</p>
<p>It is examining the tolerability, preliminary efficacy, and safety of RXRG001 delivered via intraductal injection into the parotid glands.</p>
<p>RMAT designation, a programme established by the FDA, is intended to facilitate the development and review of regenerative medicine therapies for serious or life-threatening diseases where there is an unmet medical need.</p>
<p>The designation offers opportunities for early and enhanced engagement with the FDA, as well as potential access to expedited pathways for development and review.</p>
<p>RiboX co-founder and CEO Weiyi Zhang said: “The FDA’s RMAT designation for RXRG001 represents an important milestone for RiboX and recognises the promising preliminary clinical evidence generated with our circular RNA platform.</p>
<p>“Radiation-induced xerostomia and hyposalivation can have a significant impact on patients following treatment for head and neck cancer, yet current treatment options are primarily focused on symptom management.</p>
<p>“We look forward to working closely with FDA as we advance RXRG001 and evaluate its potential to restore salivary gland function for these patients.”</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/fda-rmat-designation-riboxs-rxrg001/">FDA grants RMAT designation to RiboX’s RXRG001 for xerostomia</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>DBT launches BIO&#45;NIVESH, a strategic platform for biotech innovation &amp;amp; investment engagement</title>
<link>https://edusehat.com/en/dbt-launches-bio-nivesh-a-strategic-platform-for-biotech-innovation-investment-engagement</link>
<guid>https://edusehat.com/en/dbt-launches-bio-nivesh-a-strategic-platform-for-biotech-innovation-investment-engagement</guid>
<description><![CDATA[ 
The Department of Biotechnology (DBT) and the Biotechnology Industry Research Assistance Council (BIRAC) launched BIO-NIVESH as a strategic platform for sustained engagement between biotechnology startups/innovators, investors, industry and other relevant […]
The post DBT launches BIO-NIVESH, a strategic platform for biotech innovation &amp; investment engagement appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/10/04120811/biotechnology.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 09 Sep 2026 13:20:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>DBT, launches, BIO-NIVESH, strategic, platform, for, biotech, innovation, investment, engagement</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/10/04120811/biotechnology.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/10/04120811/biotechnology.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/10/04120811/biotechnology-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p>The Department of Biotechnology (DBT) and the Biotechnology Industry Research Assistance Council (BIRAC) launched BIO-NIVESH as a strategic platform for sustained engagement between biotechnology startups/innovators, investors, industry and other relevant ecosystem stakeholders. India’s bioeconomy, valued at over $195 billion, up from roughly $10 billion in 2014, is being positioned by the government as one of the country’s core growth engines, with a target of $300 billion by 2030.</p>
<p>The launch of BIO-NIVESH, with the aim of strengthening the interface between innovation and investment, marks an essential step towards realising the Prime Minister’s vision of a Viksit Bharat powered by science, technology & innovation.</p>
<p>The inaugural edition of BIO-NIVESH was held on 3 September 2026 in New Delhi, in the gracious presence of the Union Minister of State (Independent Charge) for Science and Technology, Dr. Jitendra Singh, bringing together 20 high-potential biotechnology and deep-tech startups and 50 curated investors.</p>
<p>Over the years, BIRAC has played a catalytic role in building India’s biotechnology innovation ecosystem, supporting innovators in their journey from early-stage ideas and proof-of-concept towards technology development and commercialisation. BIO-NIVESH, featuring 20 startups drawn from this ecosystem, builds on that momentum by addressing the next critical transition: connecting innovation with private investment and scale.</p>
<p>BIO-NIVESH brings the innovation and investment communities closer, enabling them to better understand each other’s perspectives and priorities, and facilitating the flow of private capital, strategic partnerships and market linkages towards promising biotechnology innovations. It provides a platform for a two-way dialogue, where innovators can understand the investment lens and investors can gain deeper insights into the scientific, regulatory and development pathways characteristic of biotechnology. Such engagement is expected to help identify gaps that may constrain investment and enable promising innovations to move towards investment readiness, scale-up and commercialisation.</p>
<p>The event featured a Startup–Investor Connect session that facilitated direct interaction between 20 high-potential biotechnology/deep-tech startups and investors and provided an opportunity to exchange perspectives on the opportunities, challenges and investment considerations shaping biotechnology in India. The event also featured an engagement of the Hon’ble Minister with stakeholders, during which the Minister engaged in an interactive dialogue with participating investors and startups. The discussion focused on opportunities and challenges in India’s deep-tech and biotechnology innovation and investment ecosystem, including access to capital, commercialisation, scale-up and enabling measures for innovation-led growth. The dialogue brought together diverse perspectives and identified key ecosystem-level gaps and opportunities. The engagement is intended to help shape appropriate policy and institutional mechanisms to address key concerns and build a more connected, investment-ready innovation ecosystem.</p>
<p>BIO-NIVESH is thus envisaged as a strategic and sustained engagement mechanism to strengthen the interface between innovation and investment, enabling investors and innovators to engage with greater clarity and confidence and facilitating promising biotechnology innovations towards investment, scale-up and commercialisation.</p>
<p>The initiative reinforces BIRAC’s commitment to building an ecosystem where science can attract capital, innovations can achieve scale, and Indian biotechnology companies can compete globally. It marks a step towards building the investment architecture required for India’s next phase of bioeconomy growth.</p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/dbt-launches-bio-nivesh-a-strategic-platform-for-biotech-innovation-investment-engagement/">DBT launches BIO-NIVESH, a strategic platform for biotech innovation & investment engagement</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Novartis India acquires Pfizer brands for $132m</title>
<link>https://edusehat.com/en/novartis-india-acquires-pfizer-brands-for-132m</link>
<guid>https://edusehat.com/en/novartis-india-acquires-pfizer-brands-for-132m</guid>
<description><![CDATA[ The purchase adds an established hypertension brand to Novartis’ cardiovascular range. Novartis India’s board cleared the deal, after which the company signed an asset purchase agreement and trademark 
The post Novartis India acquires Pfizer brands for $132m appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/09/PT-08-09-2026-shutterstock_2141875239.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 08 Sep 2026 19:25:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Novartis, India, acquires, Pfizer, brands, for, 132m</media:keywords>
<content:encoded><![CDATA[<p>The purchase adds an established hypertension brand to Novartis’ cardiovascular range.</p>
<p>Novartis India’s board cleared the deal, after which the company signed an asset purchase agreement and trademark assignment deeds with the two Pfizer entities.</p>
<p>The transaction covers trademarks registered in India. In a stock exchange filing, Novartis India said signing and closing would occur at the same time.</p>
<p>The company also stated that the deal is not a related-party transaction, and that Pfizer has no connection with its promoter, promoter group or group companies.</p>
<p>The agreement coincides with Pfizer’s withdrawal of Minipress XL in India.</p>
<p>In a separate filing, Pfizer said it would stop marketing, distributing and selling Minipress XL from 7 September, after Pfizer USA decided to end manufacture of the product.</p>
<p>Minipress XL contains prazosin. In India, it is used mainly to treat hypertension, or high blood pressure, and to manage urinary symptoms linked to benign prostatic hyperplasia (BPH), a condition in which the prostate becomes enlarged.</p>
<p>The acquisition therefore gives Novartis India a brand spanning both cardiovascular treatment and BPH management.</p>
<p>Citing IQVIA data, Novartis India said Minipress XL recorded revenue of Rs2.28bn in the 12 months to July 2026.</p>
<p>The brand grew at a compound annual growth rate of 6.3% over the past four years, below the 9% recorded by the wider category in the same period.</p>
<p>The size of the payment makes the purchase a substantial one for Novartis India. The company has been building its portfolio through selective brand purchases.</p>
<p>Private equity company ChrysCapital agreed in December 2025 to acquire a controlling stake in Novartis India.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/novartis-india-acquires-pfizer-brands/">Novartis India acquires Pfizer brands for $132m</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>LSTM opens $23m robotic AI lab for infection research</title>
<link>https://edusehat.com/en/lstm-opens-23m-robotic-ai-lab-for-infection-research</link>
<guid>https://edusehat.com/en/lstm-opens-23m-robotic-ai-lab-for-infection-research</guid>
<description><![CDATA[ The Liverpool Accelerate Laboratory was developed with the LSTM-led iiCON: Infection Innovation Consortium and received funding from the Liverpool City Region Combined Authority. It is due to open 
The post LSTM opens $23m robotic AI lab for infection research appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/09/PT-2-08-09-2026-Liverpool-Accelerator-Lab-launch.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 08 Sep 2026 19:25:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>LSTM, opens, 23m, robotic, lab, for, infection, research</media:keywords>
<content:encoded><![CDATA[<p>The Liverpool Accelerate Laboratory was developed with the LSTM-led iiCON: Infection Innovation Consortium and received funding from the Liverpool City Region Combined Authority.</p>
<p>It is due to open next year and is expected to generate £40m in investment during its first three years, alongside new jobs in the region.</p>
<p>Researchers and companies will use human organoids, tissue cultures grown in the laboratory, to assess how potential treatments may perform in people, reducing reliance on animal testing.</p>
<p>The work will take place in a Containment Level 3 (CL3) facility, allowing scientists to handle pathogens, including salmonella and TB, using automated equipment.</p>
<p>LSTM research and innovation pro vice-chancellor Professor Giancarlo Biagini said: “The Liverpool Accelerate Laboratory is an advanced facility that builds on years of pioneering organoid research at LSTM and partner organisations.</p>
<p>“It harnesses the potential held by this exciting technology to accelerate the development of advanced human infection models for emerging and high-consequence diseases.</p>
<p>“By incorporating machine learning, AI and robotics in a highly secure Category 3 facility, we are automating the development and commercialisation of these advanced organoid models, to expand the scale and speed of infectious disease research and development while delivering precision and reproducibility.”</p>
<p>The steel-clad facility has been designed to meet forthcoming changes to the Terrorism Act. The project also aligns with the UK Government’s £75m national roadmap to shift away from animal testing towards human-relevant alternatives.</p>
<p>iiCON founding director Professor Janet Hemingway said: “Research using human organoids is at the cutting edge of infection research and development (R&D)—moving drug discovery away from animal testing and offering new ways of shaping more targeted treatments to respond to some of our most challenging infections.”</p>
<p>The laboratory will be open to businesses of all sizes, offering initial pilot studies aimed particularly at small and medium-sized enterprises (SMEs) and start-ups developing new vaccines and drugs.</p>
<p>Postdoctoral research assistant Claire Caygill has been working on integrating the robotics and biology systems at the lab.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/lstm-opens-robotic-ai-lab-infection-research/">LSTM opens $23m robotic AI lab for infection research</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Pivot Path appoints Mukta Arora as Independent Director</title>
<link>https://edusehat.com/en/pivot-path-appoints-mukta-arora-as-independent-director</link>
<guid>https://edusehat.com/en/pivot-path-appoints-mukta-arora-as-independent-director</guid>
<description><![CDATA[ 
She has held senior leadership roles at Eli Lilly, Elanco and Astellas Pharma, where she has focused on building and scaling global capability centres, managing regulated operations and driving cross-border initiatives. She has also held industry-level board roles with organisations including OPPI, CII, NASSCOM and the Biotechnology Vision Group
The post Pivot Path appoints Mukta Arora as Independent Director appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/08144952/Mukta-Arora.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 08 Sep 2026 19:25:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Pivot, Path, appoints, Mukta, Arora, Independent, Director</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/08144952/Mukta-Arora.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/08144952/Mukta-Arora.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/08144952/Mukta-Arora-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p>Pivot Path has appointed pharma veteran Mukta Arora as an Independent Director.</p>
<p>Arora is a gold medallist from the Delhi Institute of Pharmaceutical Sciences and Research and holds an Executive MBA from IIM Bangalore. She has held senior leadership roles at Eli Lilly, Elanco and Astellas Pharma, where she has focused on building and scaling global capability centres, managing regulated operations and driving cross-border initiatives.</p>
<p>At Eli Lilly, Arora set up the Lilly Capability Centre India, while at Elanco she established the Innovation and Alliance Centre. She currently serves as Managing Director of Astellas Pharma’s Global Capability Centre. Her experience spans FDA audits, EMA requirements, major product launches, validated processes, global operations and strategic alliances.</p>
<p>She has also held industry-level board roles with organisations including OPPI, CII, NASSCOM and the Biotechnology Vision Group.</p>
<p>The appointment comes at an interesting stage in Pivot Path’s evolution. The company grew out of ArcoLab, an internal capability and operations engine created within Strides Pharma, before becoming an independent, technology-led life sciences business. Today, Pivot Path focuses on using technology, platforms and domain expertise to address operational and compliance challenges faced by global pharma companies.</p>
<p>Arora’s experience closely aligns with this evolution, bringing an operator’s perspective on how global pharma organisations build capabilities, manage regulatory complexity and implement solutions across markets.</p>
<p>The post <a href="https://www.expresspharma.in/pivot-path-appoints-mukta-arora-as-independent-director/">Pivot Path appoints Mukta Arora as Independent Director</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Alkem launches Renocia Exo, Ginsenoside Exosome&#45;based hair growth serum</title>
<link>https://edusehat.com/en/alkem-launches-renocia-exo-ginsenoside-exosome-based-hair-growth-serum</link>
<guid>https://edusehat.com/en/alkem-launches-renocia-exo-ginsenoside-exosome-based-hair-growth-serum</guid>
<description><![CDATA[ 
The formulation integrates Ginsenoside phyto-exosomes, biomimetic peptides, copper peptides and stem cell-supportive actives to support follicular vitality, scalp health and the natural hair growth cycle
The post Alkem launches Renocia Exo, Ginsenoside Exosome-based hair growth serum appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/08163642/22219565-hair-6361059_1920.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 08 Sep 2026 19:25:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Alkem, launches, Renocia, Exo, Ginsenoside, Exosome-based, hair, growth, serum</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/08163642/22219565-hair-6361059_1920.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/08163642/22219565-hair-6361059_1920.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/08163642/22219565-hair-6361059_1920-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p align="JUSTIFY"><span><span><span lang="en-US">Alkem Laboratories announced the launch of Renocia Exo, a next-generation hair regeneration therapy developed to support the health and vitality of the hair follicle through a comprehensive scientific approach.</span></span></span></p>
<p align="JUSTIFY"><span><span><span lang="en-US">Hair loss has emerged as one of India’s fastest-growing dermatological concerns, affecting not only ageing adults but also an increasing number of younger individuals due to genetics, lifestyle changes, environmental stressors and evolving health patterns. While treatment options have expanded over the years, many continue to focus on a limited aspect of the hair growth cycle, even though hair loss is now understood to be driven by a complex interplay of biological mechanisms.</span></span></span></p>
<p align="JUSTIFY"><span><span><span lang="en-US">Commenting on the launch, Sandeep Singh, MD, Alkem, said,</span> <span lang="en-US">“The science of hair restoration has evolved significantly over the last decade, and so has our understanding of what drives progressive hair thinning. It is influenced by multiple biological processes, including follicular miniaturization, altered cellular signalling, oxidative stress, inflammation, and changes within the follicular microenvironment. This evolving understanding calls for equally evolved therapeutic solutions. With Renocia Exo<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley">, we bring together multiple regenerative technologies to support the biology of the hair follicle in a single daily therapy.”</span></span></span></p>
<p align="JUSTIFY"><span><span><span lang="en-IN">A company statement informs, “</span><span lang="en-US">Unlike conventional topical approaches that primarily focus on stimulating visible hair growth, Renocia Exo has been developed to support several interconnected biological processes associated with healthy hair follicle function.”</span></span></span></p>
<p align="JUSTIFY"><span><span><span lang="en-IN">He adds, “</span><span lang="en-US">The formulation also focuses on supporting multiple signalling pathways involved in hair follicle activity while promoting a favourable environment for healthier, stronger hair over time. Its lightweight, cosmetically elegant composition is free from alcohol, sulphates, silicones parabens and mineral oil, making it suitable for regular use as part of dermatologist-guided hair loss management.”</span></span></span></p>
<p>The post <a href="https://www.expresspharma.in/alkem-launches-renocia-exo-ginsenoside-exosome-based-hair-growth-serum/">Alkem launches Renocia Exo, Ginsenoside Exosome-based hair growth serum</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>HRV Pharma invests Rs 150 crore to expand peptide, high&#45;potent API capabilities</title>
<link>https://edusehat.com/en/hrv-pharma-invests-rs-150-crore-to-expand-peptide-high-potent-api-capabilities</link>
<guid>https://edusehat.com/en/hrv-pharma-invests-rs-150-crore-to-expand-peptide-high-potent-api-capabilities</guid>
<description><![CDATA[ 
The investment strengthens HRV Pharma&#039;s presence in high-value pharma segments
The post HRV Pharma invests Rs 150 crore to expand peptide, high-potent API capabilities appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/05/04123258/investment.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 08 Sep 2026 19:25:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>HRV, Pharma, invests, 150, crore, expand, peptide, high-potent, API, capabilities</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/05/04123258/investment.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/05/04123258/investment.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/05/04123258/investment-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p lang="en-IN" align="JUSTIFY"><span><span>HRV Pharma announced it will invest Rs 150 crore to expand capabilities across two high-value and supply-constrained pharma segments, synthetic peptides and high-potency oncology APIs.</span></span></p>
<p lang="en-IN" align="JUSTIFY"><span><span>The investment strengthens HRV Pharma’s presence in high-value pharma segments while retaining its asset-light operating model, the company said in a release.</span></span></p>
<p>These initiatives will strengthen HRV’s portfolio of complex molecules, accelerate access to regulated markets, and create dedicated supply capabilities while continuing to operate through its asset-light business model, it said. </p>
<p lang="en-IN" align="JUSTIFY"><span><span>HRV Pharma will invest Rs 40-50 crore to establish a dedicated cGMP peptide manufacturing capacity through a strategic capacity underwriting arrangement and establish a strategic joint venture with a focus on high-potency oncology active pharmaceutical ingredient (APIs) and specialised molecules, with an investment commitment of approximately Rs 100 crore. </span></span></p>
<p lang="en-IN" align="JUSTIFY"><span><span>Hari Kiran Chereddi, Founder, MD & CEO, HRV Pharma, said, “These investments of approximately Rs 150 crore represent the next step in our journey, securing access to critical capacities in areas such as peptides and high-potent APIs, while continuing to maintain the flexibility and capital efficiency of our asset-light model.”</span></span></p>
<p>The post <a href="https://www.expresspharma.in/hrv-pharma-invests-rs-150-crore-to-expand-peptide-high-potent-api-capabilities/">HRV Pharma invests Rs 150 crore to expand peptide, high-potent API capabilities</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Sanofi signs letter of intent with Tricog Health</title>
<link>https://edusehat.com/en/sanofi-signs-letter-of-intent-with-tricog-health</link>
<guid>https://edusehat.com/en/sanofi-signs-letter-of-intent-with-tricog-health</guid>
<description><![CDATA[ 
Sanofi will provide mentorship, market access support, and potential financial investment to Tricog, a health-tech startup that supplies virtual cardiac diagnostic tools and services that are built by combining artificial intelligence and medical expertise
The post Sanofi signs letter of intent with Tricog Health appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/08172432/Prateek-Golecha-Chief-Growth-Officer-Tricog-Health-L-with-Deepak-Arora-Managing-Director-Sanofi-India-R.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 08 Sep 2026 19:25:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Sanofi, signs, letter, intent, with, Tricog, Health</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/08172432/Prateek-Golecha-Chief-Growth-Officer-Tricog-Health-L-with-Deepak-Arora-Managing-Director-Sanofi-India-R.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/08172432/Prateek-Golecha-Chief-Growth-Officer-Tricog-Health-L-with-Deepak-Arora-Managing-Director-Sanofi-India-R.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/08172432/Prateek-Golecha-Chief-Growth-Officer-Tricog-Health-L-with-Deepak-Arora-Managing-Director-Sanofi-India-R-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p align="JUSTIFY"><span>Sanofi Healthcare India has signed a Letter of Intent (LOI) with Tricog Health, a Bharat Innovates startup. Under this partnership, .Sanofi will provide mentorship, market access support, and potential financial investment to Tricog, a health-tech startup that supplies virtual cardiac diagnostic tools and services that are built by combining artificial intelligence and medical expertise</span></p>
<p align="JUSTIFY"><span>The LOI was signed in the presence of Sebastien Coisne, Finance Business Partner International Pharma – General Medicines, Sanofi and senior officials from IIT Kanpur.</span></p>
<p align="JUSTIFY"><span>Sanofi came in touch with Tricog Health at the Bharat Innovates 2026 summit where the Ministry of Education, Government of India showcased 120 of India’s best deep tech startups at a global stage in France.</span></p>
<p align="JUSTIFY"><span>This partnership comes against the backdrop of the India-France Year of Innovation 2026, a bilateral initiative placing innovation at the core of the India-France relationship. </span></p>
<p align="JUSTIFY"><span>Deepak Arora, MD, Sanofi (India), said, </span><span>“At Sanofi, we believe that the most transformative breakthroughs happen at the intersection of science, enterprise, and public purpose. This partnership with Tricog Health is a testament to our conviction in public-private collaboration as a driving force for change. We are proud to bring Sanofi’s global expertise to India’s brightest innovators and help them scale ideas that are pushing the boundaries of health-tech.</span></p>
<p align="JUSTIFY"><span>The Make in India story in healthcare is shifting from ambition to execution, with AI serving as the accelerator for innovation that can serve our own population and the world; and Sanofi is proud to be part of that journey; and Sanofi is proud to be part of that journey. As the nation continues to strengthen its position on the global innovation map, we are excited by the possibilities that lie ahead — because when science dvances, lives improve.” </span></p>
<p align="JUSTIFY"><span>Prateek Golecha, Chief Growth Officer, Tricog Health, said,</span> <span>“Partnering with Sanofi is an important milestone for Tricog and a strong validation of our shared belief that innovation must ultimately translate into better patient outcomes. Sanofi’s global healthcare experience, scientific ecosystem and market reach, combined with Tricog’s AI-powered cardiac diagnostic capabilities, can help us take life-saving cardiac care to many more patients, in India and beyond. In cardiovascular disease, timely detection can make the difference between life and death. Through this partnership, our ambition is simple: scale innovation faster, detect diseases earlier, and help save more lives.” </span></p>
<p align="JUSTIFY"><span>Sanofi also plans to engage with other healthcare innovators among the deep-tech ventures identified under the Bharat Innovates initiative, including those emerging from IITs and other higher education institutions, incubators, and innovation hubs across the country.</span></p>
<p align="JUSTIFY"><span>Sanofi will be extending its support to more start-ups like Tricog, such as </span><span>Ahammune Biosciences</span><span>, which focuses on innovation-led drug discovery targeting the skin immune system, and the </span><span>Translational Health Science and Technology Institute</span><span>, an institute of biotechnology research and innovation council. </span></p>
<p lang="en-IN" align="JUSTIFY">
</p><p>The post <a href="https://www.expresspharma.in/sanofi-signs-letter-of-intent-with-tricog-health/">Sanofi signs letter of intent with Tricog Health</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>From capacity to capability: Five proofs for India’s pharma future</title>
<link>https://edusehat.com/en/from-capacity-to-capability-five-proofs-for-indias-pharma-future</link>
<guid>https://edusehat.com/en/from-capacity-to-capability-five-proofs-for-indias-pharma-future</guid>
<description><![CDATA[ 
India’s ability to supply affordable medicines at scale is strategic infrastructure for patients, health systems and global supply chains—not a past chapter to leave behind. The 75th Indian Pharmaceutical Congress […]
The post From capacity to capability: Five proofs for India’s pharma future appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/07132141/EP_GB_Varun_Sharma_Founder_CEO_NEUVIOR_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 07 Sep 2026 21:55:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>From, capacity, capability:, Five, proofs, for, India’s, pharma, future</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/07132141/EP_GB_Varun_Sharma_Founder_CEO_NEUVIOR_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/07132141/EP_GB_Varun_Sharma_Founder_CEO_NEUVIOR_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/07132141/EP_GB_Varun_Sharma_Founder_CEO_NEUVIOR_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p dir="ltr"><span>India’s ability to supply affordable medicines at scale is strategic infrastructure for patients, health systems and global supply chains—not a past chapter to leave behind. The 75th Indian Pharmaceutical Congress has chosen a fitting Platinum Jubilee theme: “Transforming India from Pharmacy of the World to Pharma Powerhouse @2047”. The harder test is not simply whether India can make more. It is whether scientific knowledge remains intact as a medicine moves from development to a plant, from one site to another, and from an approved process into years of reliable supply.</span></p>
<p dir="ltr"><span>Capacity is what a plant can make. Capability is what an organisation can reproduce when the molecule, team, supplier, site or market changes.</span></p>
<h2 dir="ltr"><span>Capacity is not capability</span></h2>
<p dir="ltr"><span>The Economic Survey 2025-26 describes India as the world’s third-largest pharmaceutical industry by volume, while ranking it eleventh in pharmaceutical exports by value. Those measures have different denominators and should not be turned into a simplistic productivity ratio. They do, however, reveal the strategic brief: protect the scale that widened access while building more of the knowledge, evidence and specialised execution that can compound from one programme to the next.</span></p>
<p dir="ltr"><span>“Value” must also be handled carefully. It is not a polite synonym for higher prices, stronger patents or abandoning generics. A reliable generic that prevents a shortage can create enormous patient and health-system value. A costly product supported by weak evidence or fragile supply can destroy it. The stronger definition combines patient benefit, reliable access, embedded know-how, regulatory confidence and an economic return capable of funding the next cycle of development.</span></p>
<h2 dir="ltr"><span>The decisive test is the handoff</span></h2>
<p dir="ltr"><span>Industry naturally celebrates discovery, approval and commercial capacity. Patients, however, receive the result of a chain of handoffs: from a patient or delivery problem to a formulation; from formulation to analytical and clinical evidence; from development to manufacturing; from one supplier or site to another; and from market experience back into the product lifecycle.</span></p>
<p dir="ltr"><span>The first proof is therefore not the category label attached to a programme. It is whether formulation choices begin with a clear target product profile: the intended patient benefit, dose and delivery requirements, stability, usability, manufacturability and supply constraints. Scientific novelty matters, but it must remain workable under the conditions in which a medicine will actually be made, stored and used.</span></p>
<p dir="ltr"><span>The next handoff is technical transfer. A receiving team needs more than a recipe. It needs the scientific rationale, critical quality attributes, material and process knowledge, analytical methods, control strategy, development history, relevant process changes, deviations and investigations. Some of the most valuable knowledge is tacit: why one excipient grade was selected, which parameter first signalled drift, where an assay proved fragile, and what was tried and abandoned.</span></p>
<p dir="ltr"><span>WHO’s 2022 technology-transfer guidance describes a demanding but practical test of success: documented evidence that the receiving unit can routinely reproduce the transferred product, process or procedure against predefined specifications. ICH Q10 reinforces the same lifecycle logic by connecting pharmaceutical development, technology transfer and commercial manufacturing within one quality system. The real proof is reproducibility across shifts, sites, suppliers and teams—not continuing dependence on tacit knowledge held by a small number of people.</span></p>
<h2 dir="ltr"><span>Evidence and quality must travel together</span></h2>
<p dir="ltr"><span>Evidence should not be assembled at the end as a dossier detached from the decisions that shaped the product. It should travel with the medicine: formulation performance, stability, comparability, bioequivalence or clinical evidence where appropriate, process data, deviations, complaints and post-market learning. Each layer should make the next decision more informed and the remaining uncertainty more visible.</span></p>
<p dir="ltr"><span>The most useful evidence of capability is therefore receiving-side performance. Can a prepared team reproduce the product or process routinely against predefined criteria? How much avoidable rework was required? Which analytical methods failed to transfer, and did the lessons change development or the control strategy? Those questions turn “knowledge retained” into observable results. They also prevent a successful batch at the sending site from being mistaken for a transferable operating capability.</span></p>
<p dir="ltr"><span>Revised Schedule M is an important foundation because it encompasses pharmaceutical quality systems, quality-risk management, qualification and validation. A requirement being in force is not proof of universal compliance, however, and compliance alone is not differentiation. The higher-order question is whether the quality system preserves scientific intent as variability and organisational distance increase: whether changes remain controlled, signals are investigated, learning reaches development and the process continues to perform after transfer.</span></p>
<h2 dir="ltr"><span>Capital must follow proof</span></h2>
<p dir="ltr"><span>The easy prescription is to spend more on R&D. The harder question is what each rupee buys. Capital can create reusable capability or prolong attachment to a programme whose assumptions have weakened.</span></p>
<p dir="ltr"><span>Investment should therefore be released against pre-agreed evidence gates. Is the unmet need clear? Does the formulation offer a credible advantage? What evidence would change a regulatory, clinical or purchasing decision? Can the process and analytical methods transfer? Is the receiving site ready? At each gate, leadership should be prepared to continue, redesign, partner, license or stop.</span></p>
<p dir="ltr"><span>Pharmaceutical development requires long horizons, failed hypotheses and persistence. Long-duration capital must tolerate scientific time while remaining responsive to stage-appropriate evidence. Boards should favour platforms, analytical capability, experienced people and transfer readiness that remain useful beyond one asset. Announced schemes, laboratories, patents and project starts are enabling inputs; validated products, accepted evidence, reproducible transfer and dependable supply are outcomes.</span></p>
<p> </p>
<p dir="ltr"><span>By 2047, a meaningful powerhouse scorecard should ask how often receiving units meet predefined transfer criteria, whether analytical methods perform at the new site, how quickly dependence on the sending team can end and whether methods and learning are reused in the next programme. A difficult medicine made once is an achievement. A system that can reproduce it, transfer it and learn from it is a pharmaceutical powerhouse.</span></p>
<div><span> </span></div>
<p>The post <a href="https://www.expresspharma.in/from-capacity-to-capability-five-proofs-for-indias-pharma-future/">From capacity to capability: Five proofs for India’s pharma future</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Cipla partners with Qilu Pharmaceutical for licensing and supply of biosimilar to Keytruda in US</title>
<link>https://edusehat.com/en/cipla-partners-with-qilu-pharmaceutical-for-licensing-and-supply-of-biosimilar-to-keytruda-in-us</link>
<guid>https://edusehat.com/en/cipla-partners-with-qilu-pharmaceutical-for-licensing-and-supply-of-biosimilar-to-keytruda-in-us</guid>
<description><![CDATA[ 
Invagen Pharmaceuticals, a wholly owned subsidiary of Cipla announced that it has entered into a strategic partnership with Qilu Pharmaceutical, for the exclusive licensing and supply of QL2107, a biosimilar […]
The post Cipla partners with Qilu Pharmaceutical for licensing and supply of biosimilar to Keytruda in US appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123759/Partnership.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 07 Sep 2026 21:55:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Cipla, partners, with, Qilu, Pharmaceutical, for, licensing, and, supply, biosimilar, Keytruda</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123759/Partnership.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123759/Partnership.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123759/Partnership-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p>Invagen Pharmaceuticals, a wholly owned subsidiary of Cipla announced that it has entered into a strategic partnership with Qilu Pharmaceutical, for the exclusive licensing and supply of QL2107, a biosimilar to Keytruda® (pembrolizumab), for the United States.</p>
<p>As part of the agreement, Qilu will be responsible for development, regulatory registration, and supply of the product while Cipla USA will be responsible for the commercialization of the asset by leveraging its strong commercial presence in the defined territory.</p>
<p>The collaboration reflects both companies’ shared commitment to addressing the growing burden of cancer and improving access to advanced biologic therapies.</p>
<p>Commenting on the partnership, Achin Gupta, Managing Director & Global Chief Executive Officer, Cipla, said, “This partnership reflects Cipla’s confidence in the long-term potential of biosimilars and supports our strategy to build a strong oncology-focused portfolio. By combining Qilu’s development strengths with Cipla’s commercial presence and patient-centric legacy, we aim to expand access to high-quality biologics for patients across our focus markets.”</p>
<p>Marc Falkin, Chief Executive Officer, Cipla North America, said, “This collaboration is aligned with our strategy to expand our biosimilar portfolio in the coming fiscal years, and we are excited to add QL2107 with Qilu who have been great partners. With our established commercial capabilities, we are well-positioned to successfully launch QL2107, subject to regulatory approval, and help ensure it reaches patients in need while lowering the cost of treatment.”</p>
<p>Hanchang Zhang, General Manager of Qilu Pharmaceutical, said, “We are pleased to establish this partnership with Cipla for QL2107. Qilu boasts a robust and growing biosimilar product pipeline. By combining our R&D and manufacturing strengths with Cipla’s US commercial expertise, we aim to bring a high‑quality, affordable pembrolizumab biosimilar to US patients.”</p>
<p>The post <a href="https://www.expresspharma.in/cipla-partners-with-qilu-pharmaceutical-for-licensing-and-supply-of-biosimilar-to-keytruda-in-us/">Cipla partners with Qilu Pharmaceutical for licensing and supply of biosimilar to Keytruda in US</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Union Minister of Commerce and Industry inaugurates Bharat Health Global Expo 2026</title>
<link>https://edusehat.com/en/union-minister-of-commerce-and-industry-inaugurates-bharat-health-global-expo-2026</link>
<guid>https://edusehat.com/en/union-minister-of-commerce-and-industry-inaugurates-bharat-health-global-expo-2026</guid>
<description><![CDATA[ 
Piyush Goyal, Union Minister of Commerce and Industry, Government of India, today inaugurated the Bharat Health Global Expo 2026 at Bharat Mandapam, New Delhi. As the pharmaceutical industry enters its […]
The post Union Minister of Commerce and Industry inaugurates Bharat Health Global Expo 2026 appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/07140622/EP_Bharat-Health.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 07 Sep 2026 21:55:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Union, Minister, Commerce, and, Industry, inaugurates, Bharat, Health, Global, Expo, 2026</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/07140622/EP_Bharat-Health.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/07140622/EP_Bharat-Health.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/07140622/EP_Bharat-Health-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p>Piyush Goyal, Union Minister of Commerce and Industry, Government of India, today inaugurated the Bharat Health Global Expo 2026 at Bharat Mandapam, New Delhi. As the pharmaceutical industry enters its next phase of growth, he called for a sharper focus on innovation, quality systems and complex, higher-value products.</p>
<p>He said, “With the active and hard work of the pharma industry over the years on generics, India has become quite a success story. But we cannot rest our case with generics. We will have to promote more and more R&D, patent our own products, and put pharma at the forefront of research and innovation. Biosimilars and biotech should become our next frontier. We need a regulatory environment where R&D and innovation become attractive in India, with greater openness to investments in clinical trials, patenting, research and new product development.”</p>
<p>He further said India must match its existing scale with stronger R&D, better quality systems, greater resilience and deeper capabilities in complex products. He also called for closer regulatory convergence with developed markets, and for a policy approach that listens to investors and responds to what global markets require.</p>
<p>“The world is now looking for resilience,” he added. “Resilience does not mean being inward-looking. It means ensuring that supply chains are diversified across geographies and companies, while also identifying areas where India has the potential to build indigenous capabilities.”</p>
<p>Speaking at the event, Jitin Prasada, Union Minister of State for Commerce and Industry, said, “India’s next phase will be from affordable medicines towards pharmaceutical innovation. We have great research, talent and young people with the expertise to take this forward, but technology adoption will be critical. Artificial intelligence in particular will have to be adopted across the pharmaceutical value chain if Indian companies are to remain competitive and move to the next level.”</p>
<p>Rajesh Agrawal, IAS, Secretary, Department of Commerce, said, “India has already unlocked the volume opportunity across the world, and the next priority is to tap the value opportunity. We need to look towards more innovative drugs and solutions and build capabilities across the healthcare supply chain. Our trade agreements are also opening more markets, with pharmaceutical annexes focused not only on tariff concessions but on regulatory harmonisation and clearer pathways for Indian companies to enter and grow in global markets.”</p>
<p>Namit Joshi, Chairman, Pharmexcil, said, “India has predominantly been called the pharmacy of the world because of its strength in generics. The focus now must be on value-added products, including APIs, KSMs, complex generics and biosimilars. Indian companies and overseas delegates should explore these opportunities and build long-term partnerships, including in CDMO, to create value for both sides.”</p>
<p>Bhavin Mehta, Vice Chairman, Pharmexcil, said, “India’s strength in affordable medicines has established its position in global healthcare, but the next phase lies in complex formulations, biosimilars, biologics, vaccines and specialised products. Greater investment in research, product development, advanced manufacturing and quality systems will help Indian companies move up the value curve and build long-term global partnerships.”</p>
<p>The Bharat Health Global Expo 2026 brings India’s healthcare and life-sciences capabilities onto a single platform for international markets, with a focus on exports, innovation, global buyers and long-term partnerships. Pharmaceuticals form the principal pillar, alongside pharmaceutical machinery and laboratory solutions, nutraceuticals and healthcare services. The Expo is built around four events: iPHEX 2026, the 12th edition of India’s flagship pharmaceutical exhibition, organised by the Pharmaceuticals Export Promotion Council of India (Pharmexcil) with the support of the Department of Commerce; Pharma Mach and Lab Next Expo, organised by EEPC India, covering machinery, laboratory, automation and packaging technologies; Bharat Nutraverse, organised by the Shellac and Forest Products Export Promotion Council (SHEFEXIL), covering nutraceuticals, natural products and wellness; and SANJEEVANI, organised by the Services Export Promotion Council (SEPC), covering hospitals, diagnostics, digital health and medical value travel. iPHEX 2026 will run from 7 to 9 September.</p>
<p>Pharmexcil is targeting around USD 1.4 billion in export business opportunities through iPHEX 2026, which will feature more than 800 stalls, 600 hosted international buyers, around 30,000 business visitors and 10,000+ business meetings.</p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/union-minister-of-commerce-and-industry-inaugurated-bharat-health-global-expo-2026/">Union Minister of Commerce and Industry inaugurates Bharat Health Global Expo 2026</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Lupin receives US FDA approval for Modafinil Tablets, USP</title>
<link>https://edusehat.com/en/lupin-receives-us-fda-approval-for-modafinil-tablets-usp</link>
<guid>https://edusehat.com/en/lupin-receives-us-fda-approval-for-modafinil-tablets-usp</guid>
<description><![CDATA[ 
Global pharma major Lupin announced that it has received approval from the United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) for Modafinil Tablets […]
The post Lupin receives US FDA approval for Modafinil Tablets, USP appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/07/22100048/usfda-approved-black.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 07 Sep 2026 21:55:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Lupin, receives, FDA, approval, for, Modafinil, Tablets, USP</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/07/22100048/usfda-approved-black.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/07/22100048/usfda-approved-black.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/07/22100048/usfda-approved-black-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p>Global pharma major Lupin announced that it has received approval from the United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) for Modafinil Tablets USP, 100 mg and 200 mg.</p>
<p>The US FDA has approved Lupin’s Modafinil Tablets USP, 100 mg and 200 mg as bioequivalent to the reference listed drug (RLD), Provigil Tablets of Nuvo Pharmaceuticals (Ireland) DAC, and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA) or shift work disorder (SWD).</p>
<p>Modafinil Tablets (RLD Provigil) had estimated annual sales of USD 70.7 million in the US (IQVIA MAT Jul 2026).</p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/lupin-receives-us-fda-approval-for-modafinil-tablets-usp/">Lupin receives US FDA approval for Modafinil Tablets, USP</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Classys partners with Photonence to bring aesthetics technology to India</title>
<link>https://edusehat.com/en/classys-partners-with-photonence-to-bring-aesthetics-technology-to-india</link>
<guid>https://edusehat.com/en/classys-partners-with-photonence-to-bring-aesthetics-technology-to-india</guid>
<description><![CDATA[ 
The growing use of non-surgical procedures in aesthetic dermatology is expanding the range of treatment options available for concerns such as skin laxity, loss of firmness and changes in facial […]
The post Classys partners with Photonence to bring aesthetics technology to India appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/07165313/partnership.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 07 Sep 2026 21:55:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Classys, partners, with, Photonence, bring, aesthetics, technology, India</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/07165313/partnership.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/07165313/partnership.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/07165313/partnership-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span><span><span>The growing use of non-surgical procedures in aesthetic dermatology is expanding the range of treatment options available for concerns such as skin laxity, loss of firmness and changes in facial contours. Within this space, energy-based technologies are increasingly being used as alternatives or complements to surgical procedures.</span></span></span></p>
<p><span><span><span>Classys, a medical aesthetics technology company, has entered into a partnership with Photonence in India to introduce a treatment approach combining two of its technologies, Volnewmer and Ultraformer. The approach uses the technologies at different skin depths and is intended for applications related to skin lifting and tightening.</span></span></span></p>
<p><span><span><span>The move comes as aesthetic dermatology sees greater use of non-surgical technologies for concerns including facial sagging, reduced skin elasticity, jawline definition and body skin laxity. The adoption of such technologies also brings greater focus on patient selection, treatment protocols and practitioner expertise.</span></span></span></p>
<p><span><span><span><span>According to available estimates, India’s aesthetic dermatology market is expected to reach a USD 383.79 million by 2032 and is projected to grow at a CAGR of 16.34 per cent from 2025 to 2032. “India’s aesthetic medicine landscape is evolving rapidly, with patients becoming more informed and increasingly looking for non-surgical options. The focus now is not simply on cosmetic enhancement but on skin health, safety, appropriate patient selection and evidence-informed use of technology,” said </span></span></span></span><strong><span><span><span><span>Ashish Jha</span></span></span></span></strong><span><span><span><span>, </span></span></span></span><strong><span><span><span><span>Co-Founder and Director, </span></span></span></span></strong><strong><span><span><span><span>Photonence</span></span></span></span></strong><span><span><span><span>.</span></span></span></span></p>
<p><span>“<span><span><span>We are seeing in aesthetic medicine. Doctors are increasingly looking at how different technologies can work together rather than relying on a single approach. We are very happy to bring this concept to India and with practitioners who are willing to explore new possibilities in aesthetic treatment,” said </span></span></span></span><strong><span><span><span><span>Jin Park</span></span></span></span></strong><span><span><span><span>, </span></span></span></span><strong><span><span><span><span>Chief Sales Officer, Classys</span></span></span></span></strong><span><span><span><span>.</span></span></span></span></p>
<p><span><span><span>For dermatologists and plastic surgeons, the growing availability of energy-based technologies is widening the range of non-surgical treatment options. Their clinical application, however, continues to depend on factors such as patient suitability, treatment protocols and practitioner training.</span></span></span></p>
<p><strong><span><span><span><span>Dr Gurjot Marwah</span></span></span></span></strong><span><span><span><span>, a </span></span></span></span><strong><span><span><span><span>dermatologist (From Mumbai)</span></span></span></span></strong><span><span><span><span>, who has introduced the approach in India, said, “Patients today are looking for effective aesthetic procedures with no downtime. The ability to work across different skin layers gives dermatologists another option when managing concerns related to laxity and firmness. As with any aesthetic treatment, the approach needs to be tailored to the individual patient and their clinical requirements.”</span></span></span></span></p>
<p><span><span><span>Classys’ portfolio in India includes Ultraformer 3, Ultraformer MPT, Volnewmer, Curas Hybrid and Aquapure. The company said practitioner education and training will be an important part of introducing the new treatment approach, particularly as dermatologists and plastic surgeons evaluate its potential applications.</span></span></span></p>
<p><strong><span><span><span><span>Dr Marwah</span></span></span></span></strong><span><span><span><span> added, “The growth of non-surgical aesthetics is also reflecting a broader change in how patients approach cosmetic care, with greater emphasis on preventative treatments, skin health and maintaining natural-looking results rather than relying exclusively on surgical correction.”</span></span></span></span></p>
<p align="LEFT">
</p><p>The post <a href="https://www.expresspharma.in/classys-partners-with-photonence-to-bring-aesthetics-technology-to-india/">Classys partners with Photonence to bring aesthetics technology to India</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>AtomVie opens $160m radiopharmaceutical manufacturing facility in Ontario</title>
<link>https://edusehat.com/en/atomvie-opens-160m-radiopharmaceutical-manufacturing-facility-in-ontario</link>
<guid>https://edusehat.com/en/atomvie-opens-160m-radiopharmaceutical-manufacturing-facility-in-ontario</guid>
<description><![CDATA[ The 72,300ft² site is said to be the largest single-site contract development and manufacturing organisation (CDMO) facility in North America for radiopharmaceutical development to date. It supports low-to-high 
The post AtomVie opens $160m radiopharmaceutical manufacturing facility in Ontario appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/09/PT-2-07-09-2026-AtomVie-Global-Radiopharma-Inc-AtomVie-Global-Radiopharma-Celeb.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 07 Sep 2026 18:20:13 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>AtomVie, opens, 160m, radiopharmaceutical, manufacturing, facility, Ontario</media:keywords>
<content:encoded><![CDATA[<p>The 72,300ft² site is said to be the largest single-site contract development and manufacturing organisation (CDMO) facility in North America for radiopharmaceutical development to date.</p>
<p>It supports low-to-high throughput production and increases the company’s manufacturing capacity more than tenfold.</p>
<p>AtomVie said the building is designed to allow clients to move from early development through to commercial manufacturing, with customisable space set aside for future requirements.</p>
<p>Staffing is expected to grow as the site scales towards full operations. The company is targeting more than 200 employees by the end of this year.</p>
<p>AtomVie CEO Bruno Paquin said: “Our new purpose-built facility amplifies a proven track record of reliable global delivery and deep scientific expertise, enabling us to support the development and commercialisation of our partners’ pipelines.</p>
<p>“Above all, it advances our purpose of transforming patients’ lives by delivering high-quality radiopharmaceuticals to those who need them, all around the world.”</p>
<p>The company has worked on more than 70 clinical development and technology transfer programmes over more than a decade.</p>
<p>It has manufactured over 1,000 current good manufacturing practice (cGMP) batches and delivered more than 4,400 cGMP doses to patients in 28 countries across six continents.</p>
<p>AtomVie board of directors chairman Kevin McNeill said: “AtomVie’s new facility inauguration reflects the discipline and dedication of the AtomVie team and the confidence of the partners who have supported our growth.</p>
<p>“This facility continues AtomVie’s status as a leading radiopharmaceutical CDMO, now built at commercial scale to serve partners with the reliability the field requires.”</p>
<p>AtomVie was spun out of the Centre for Probe Development and Commercialization (CPDC), a McMaster University-based Centre of Excellence set up to build Canada’s capability in radiopharmaceutical innovation and manufacturing.</p>
<p>The opening event included facility tours for government representatives, clients, partners and members of the radiopharmaceutical community.</p>
<p>In October 2024, Radiopharm Theranostics and AtomVie entered a partnership for the development and manufacturing of 177Lu-BetaBart radioantibody to treat multiple solid tumours.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/atomvie-radiopharmaceutical-manufacturing-facility-ontario/">AtomVie opens $160m radiopharmaceutical manufacturing facility in Ontario</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer</title>
<link>https://edusehat.com/en/fda-approves-astrazenecas-etcamah-combo-for-advanced-breast-cancer</link>
<guid>https://edusehat.com/en/fda-approves-astrazenecas-etcamah-combo-for-advanced-breast-cancer</guid>
<description><![CDATA[ This combo is approved for adults with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer. The clearance applies when an estrogen receptor 1 (ESR1) mutation is 
The post FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/09/PT-07-09-2026-shutterstock_2509724073-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 07 Sep 2026 18:20:13 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>FDA, approves, AstraZeneca’s, Etcamah, combo, for, advanced, breast, cancer</media:keywords>
<content:encoded><![CDATA[<p>This combo is approved for adults with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer.</p>
<p>The clearance applies when an estrogen receptor 1 (ESR1) mutation is detected during treatment with an aromatase inhibitor and a CDK4/6 inhibitor, as identified by an FDA-authorised test.</p>
<p>It is based on findings from the SERENA-6 Phase III trial, presented at the 2025 American Society of Clinical Oncology Annual Meeting.</p>
<p>At a planned interim analysis, the Etcamah combination reduced the risk of disease progression or death by 56% compared with an aromatase inhibitor (anastrozole or letrozole) plus a CDK4/6 inhibitor.</p>
<p>Median progression-free survival was 16.0 months versus 9.2 months.</p>
<p>A later pre-planned analysis showed time to second disease progression of 25.7 months versus 19.1 months. Overall survival data remain immature and will continue to be assessed.</p>
<p>Safety findings matched the known profiles of each medicine, with no new concerns and low discontinuation rates in both arms.</p>
<p>SERENA-6 enrolled 315 patients and used circulating tumour deoxyribonucleic acid (ctDNA) blood testing at routine scans every two to three months.</p>
<p>The FDA simultaneously approved a companion diagnostic that detects emerging ESR1 resistance mutations in ctDNA.</p>
<p>AstraZeneca oncology haematology business unit executive vice-president Dave Fredrickson said: “Today’s approval is the tenth granted by the FDA this year across AstraZeneca’s portfolio and our fourth in breast cancer alone.</p>
<p>“The Etcamah combination reflects AstraZeneca’s leadership in redefining breast cancer care by pioneering a new approach using circulating tumour DNA and is the first and only medicine of its type in the first-line setting.”</p>
<p>Etcamah, an oral selective estrogen receptor degrader given once daily at 75mg alongside a CDK4/6 inhibitor, is cleared in more than 30 countries, including Canada, Japan, the UK and the EU.</p>
<p>In July 2026, AstraZeneca and Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ) signed an exclusive licence agreement for TQC3721.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/fda-approves-astrazeneca-etcamah-combo/">FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>How Pivot Path is in a sweet spot to address pharma’s pressure points </title>
<link>https://edusehat.com/en/how-pivot-path-is-in-a-sweet-spot-to-address-pharmas-pressure-points</link>
<guid>https://edusehat.com/en/how-pivot-path-is-in-a-sweet-spot-to-address-pharmas-pressure-points</guid>
<description><![CDATA[ 
Pivot Path emerged from Strides Pharma’s internal GCC. Are other pharma companies also following the same playbook? And if so, could you name some examples? Pivot Path, previously known as […]
The post How Pivot Path is in a sweet spot to address pharma’s pressure points  appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/04141636/Shashidhar-KL.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 07 Sep 2026 14:45:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>How, Pivot, Path, sweet, spot, address, pharma’s, pressure, points </media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/04141636/Shashidhar-KL.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/04141636/Shashidhar-KL.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/04141636/Shashidhar-KL-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p dir="ltr"><strong><span>Pivot Path emerged from Strides Pharma’s internal GCC. Are other pharma companies also following the same playbook? And if so, could you name some examples?</span></strong></p>
<p></p>
<p dir="ltr"><span>Pivot Path, previously known as Arcolab, started in 2019 as a shared services organisation within the Strides Group. At that time, Global Capability Centre (GCC) was not yet the commonly used nomenclature. </span></p>
<p dir="ltr"><span>The idea was to create a common platform for the group’s multiple pharmaceutical entities, which operated across APIs, injectables, oral dosage and biologics. They all had common requirements across IT, digital, clinical, pharmacovigilance, finance and HR, but were operating in silos.</span></p>
<p></p>
<p dir="ltr"><span>This created inefficiencies in resource allocation and limited knowledge sharing. For example, learnings from an FDA or regulatory audit at one unit were not necessarily reaching another unit. So, the objective was to allocate resources efficiently, build a scalable model and facilitate knowledge sharing.</span></p>
<p></p>
<p dir="ltr"><span>Many companies today have internal shared services or Centres of Excellence (COEs), but these are largely centralised functions operating within the organisation. We were ahead of the curve in 2019.</span></p>
<p></p>
<p dir="ltr"><span>A global example is Novo Nordisk. Its IT function eventually spun off as Novo Nordisk IT (NNIT), which now provides services to companies well beyond its former parent. We are taking a similar path, with a focus on large Indian and mid-sized pharma companies globally.</span></p>
<p></p>
<p dir="ltr"><strong><span>What are the differentiators?</span></strong></p>
<p></p>
<p dir="ltr"><span>Six years ago, we were a process- and operations centric organisation. We consolidated services, negotiated better rates with partners and vendors, and standardised processes. Our philosophy was COSA: consolidation, optimisation, standardisation and automation.</span></p>
<p></p>
<p dir="ltr"><span>Unlike many multinational GCCs, we did not have the benefit of labour arbitrage. We had the same people, infrastructure and location even as we transitioned into a standalone entity. So, from day one, we had to demonstrate value.</span></p>
<p></p>
<p dir="ltr"><span>In the third year, we realised that much of our process improvement was coming through technology and digital transformation. We already had deep pharma expertise, but we identified a technology gap. In 2022, we acquired a Bangalore based technology company and began building pharma-centric solutions.</span></p>
<p></p>
<p dir="ltr"><span>That is our key differentiator. We combine pharma domain expertise with technology. Technology companies may have solutions, but often need to first understand pharma’s nuances and workflows. We already understand the problem.</span></p>
<p></p>
<p dir="ltr"><span>Our approach is to use technology for business transformation, not the other way around. We combine domain knowledge and technology to offer integrated solutions.</span></p>
<p></p>
<p dir="ltr"><span>For mid-sized pharma companies, digital transformation does not have to be overwhelming or highly capital-intensive. We also understand the change management challenge. Those are the differentiators we bring to the table.</span></p>
<p></p>
<p dir="ltr"><strong><span>How would Pivot Path approach a mid-sized client? What is the value proposition, and what market trends are driving these companies to approach you?</span></strong></p>
<p></p>
<p dir="ltr"><span>Every company is experimenting with digital or IT transformation. But midsized pharma companies typically have significant legacy manufacturing processes and systems. Many initiatives therefore remain at the process or use-case level. Some POCs succeed, while others take too long and lose momentum.</span></p>
<p></p>
<p dir="ltr"><span>Legacy systems also need upgrading, whether in enterprise applications, infrastructure or processes. </span></p>
<p dir="ltr"><span>Our proposition is to look at digital transformation at the domain level rather than digitising individual processes. Take manufacturing, for example. Instead of digitising one process, we look at the entire manufacturing domain, including manual, offline, hybrid and already-digitised processes.</span></p>
<p></p>
<p dir="ltr"><span>We can help upgrade infrastructure and networks to the cloud, digitise manufacturing processes, use no-code or low-code platforms for workflows and build a nimble data lake to provide insights for decision-making.</span></p>
<p></p>
<p dir="ltr"><span>If a company can address all these requirements through one platform, that is the value proposition.</span></p>
<p></p>
<p dir="ltr"><span>We are now talking to more than 300 unique customers across India and parts of Europe on quality solutions, manufacturing digital transformation, pharmacovigilance and clinical operations. These are our three major solution buckets.</span></p>
<p></p>
<p dir="ltr"><span>The 70-plus pharmaceutical companies across five continents are our existing customer base, largely through single-line services, particularly PV services. The 300-plus companies represent the new opportunity we are pursuing.</span></p>
<p></p>
<p dir="ltr"><span><strong>The benchmark for regulatory compliance is increasing. Geopolitical tensions, tariffs, wars and other crises also affect supply chains. How is your solution relevant to these challenges?</strong></span></p>
<p></p>
<p dir="ltr"><span>The last 18 months have demonstrated how geopolitical developments can directly affect supply chains. Companies focused on the US market are also dealing with constant regulatory and tariff developments. </span></p>
<p dir="ltr"><span>At the same time, the generic market is shrinking and price erosion has been happening for several years. This creates margin pressure across both mid-sized and large pharma companies, driving consolidation.</span></p>
<p></p>
<p dir="ltr"><span>Regulatory expectations are also increasing globally, particularly around manufacturing operations, data management, data integrity and processes. Surprise audits are common, creating additional pressure. </span></p>
<p dir="ltr"><span>Companies therefore face price pressure while also needing to invest in compliance through technology and solutions.</span></p>
<p></p>
<p dir="ltr"><span>Our positioning is to address the compliance and regulatory requirements. We help clients assess processes, upgrade technology and undertake transformation. Our solutions can digitise processes, improve efficiency and reduce data-integrity issues. So, we are in a sweet spot to address both regulatory and competitive pressures through efficiency.</span></p>
<p></p>
<p dir="ltr"><strong><span>Currently, your company generates about INR 147 crore in revenue. What are the projected growth targets for the next few years? What are the growth drivers?</span></strong></p>
<p></p>
<p dir="ltr"><span>We are targeting around INR 450-500 crore in the next four to five years, with the majority coming from digital transformation and technology solutions.</span></p>
<p></p>
<p dir="ltr"><span>The opportunity is abundant, and we want to capture it.</span></p>
<p></p>
<p dir="ltr"><span>You’re looking at a global scale, not just India. India is a major market for us, particularly for our digital transformation solutions. Technology is no longer a differentiator or competitive advantage. Hundreds of startups use the same platforms.</span></p>
<p></p>
<p dir="ltr"><span>Our differentiator is domain-led solutions. We want to offer them to Indian companies at a competitive rate so they don’t have to depend on global platforms.</span></p>
<p></p>
<p dir="ltr"><span>We also want to approach Europe and the US with the same rigor. From a revenue perspective, we see India contributing around 40 per cent, Europe 20-25 per cent and the US around 40 per cent. </span></p>
<p dir="ltr"><span>We are working on our US go-to-market strategy. Having recently become independent and raised capital, our focus now is to build the business.</span></p>
<p></p>
<p dir="ltr"><strong><span>Are you a pharma company or an IT company?</span></strong></p>
<p></p>
<p dir="ltr"><span>We are purely a pharma company, but we are in a unique position. We acquired a Bangalore-based deep-tech firm in 2022, with 100-120 people. Our solutions are proprietary and IP-owned.</span></p>
<p></p>
<p dir="ltr"><span>We want to operate in the space between large platforms and the needs of mid-sized pharma. We have designed lighter solutions for them. For example, we have our own validation management systems (VMS) and document management systems (DMS) and can build lighter versions of the large enterprise quality platforms using available technology.</span></p>
<p> </p>
<p dir="ltr"><span>We also work with the platform that clients are already running. We help them integrate, customise and run their existing ERP, Quality & Manufacturing environments.</span></p>
<p></p>
<p dir="ltr"><span>The other challenge is that many startups and AI companies claim to be pharma centric, but they don’t necessarily understand the industry’s problems. We have worked with several startups and often ended up teaching them about pharma.</span></p>
<p></p>
<p dir="ltr"><span>That was one reason we established our own technology arm. Instead of spending time teaching third-party companies and then seeing them build solutions around that knowledge, we decided to build for pharma ourselves.</span></p>
<p></p>
<p dir="ltr"><span>The objective is to make digital transformation less difficult and less capital intensive for mid-sized pharma companies. Change management is equally important. Companies need the confidence that transformation does not mean people losing their jobs or power. It is a process.</span></p>
<p></p>
<p dir="ltr"><span>We speak the pharma language, and that’s where our conversation begins.</span></p>
<p></p>
<p dir="ltr"><strong><span>What does Ascent Capital’s investment in Pivot Path signal to pharma companies?</span></strong></p>
<p></p>
<p dir="ltr"><span>Ascent Capital has a strong track record of investing in the life sciences sector and understands the challenges pharma companies face. Their investment in Pivot Path reflects a continued belief in the sector and in the growing need for solutions that address industry-specific operational, regulatory, and transformation challenges.</span></p>
<p></p>
<p dir="ltr"><span>For pharma companies, it serves as a strong validation of our approach. Ascent’s familiarity with the industry gives them a clear perspective on both the challenges and the solutions required, and their investment reinforces confidence in the value we bring to the market. </span></p>
<p><b> </b></p>
<p dir="ltr"><em><span>viveka.r@expressindia.com </span><span><br>
</span><span>viveka.roy3@gmail.com  </span></em></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/how-pivot-path-is-in-a-sweet-spot-to-address-pharmas-pressure-points/">How Pivot Path is in a sweet spot to address pharma’s pressure points </a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>India’s race for the CDMO crown</title>
<link>https://edusehat.com/en/indias-race-for-the-cdmo-crown</link>
<guid>https://edusehat.com/en/indias-race-for-the-cdmo-crown</guid>
<description><![CDATA[ 
For years, China+1 has been the big story in India’s CDMO opportunity. Now, it is no longer enough. The shift away from China is well underway as global pharma seeks […]
The post India’s race for the CDMO crown appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/07120658/EP_DigiMag_CS_Sep_2026_Ft_Image_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 07 Sep 2026 14:45:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>India’s, race, for, the, CDMO, crown</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/07120658/EP_DigiMag_CS_Sep_2026_Ft_Image_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/07120658/EP_DigiMag_CS_Sep_2026_Ft_Image_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/07120658/EP_DigiMag_CS_Sep_2026_Ft_Image_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>For years, China+1 has been the big story in India’s CDMO opportunity. Now, it is no longer enough. The shift away from China is well underway as global pharma seeks to lessen their exposure to geopolitics, and this clearly benefitted India. </span></p>
<p><span>A BCG-IPSO’s report titled, Unleashing the Tiger: Indian CRDMO Sector 2025 estimates that “India’s CRDMO industry could grow from around $3–3.5 billion in 2024 to $22–25 billion by 2035.” </span></p>
<p><span>The same report also identifies $10-15 billion of potential value from global supply-chain realignment, along with opportunities in new modalities and India’s emerging innovation ecosystem. Its customer research, a survey of more than 200 CRDMO customers, estimates that around $5 billion of demand could move to India, while another $9-10 billion represents unmet demand that India could potentially capture.</span></p>
<p><span>The opportunity is significant. But some of the business coming to India today is still risk management, not conviction. Being the alternative is not the same as being the partner of choice. </span></p>
<p><span>The harder question is whether India can turn this initial advantage into something more durable such as long-term relationships with global pharma, a deeper position inside development pipelines and a place among the world’s preferred CDMO destinations. </span></p>
<p><span>As competition intensifies, India will have to earn that position on its own merits. </span></p>
<p><img decoding="async" class="wp-image-459366 alignleft" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/07115737/Chirag-Adatia-300x134.jpg" alt="" width="354" height="158" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/07115737/Chirag-Adatia-300x134.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/07115737/Chirag-Adatia-768x344.jpg 768w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/07115737/Chirag-Adatia.jpg 900w" sizes="(max-width: 354px) 100vw, 354px"></p>
<p><b><img decoding="async" class=" wp-image-459368 aligncenter" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/07115753/Peter-DeYoung-300x134.jpg" alt="" width="369" height="165" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/07115753/Peter-DeYoung-300x134.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/07115753/Peter-DeYoung-768x344.jpg 768w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/07115753/Peter-DeYoung.jpg 885w" sizes="(max-width: 369px) 100vw, 369px"></b></p>
<p> </p>
<p><b>Beyond China+1 </b></p>
<p><span>The industry is increasingly questioning whether China+1 can become the foundation of India’s long-term CDMO strategy. Dr Chirag Adatia, Partner Health & Life Sciences and Private Capital Practices, Oliver Wyman, thinks India should stop measuring its CDMO opportunity in terms of business that could move out of China. </span></p>
<p><span>“China+1 is a door-opener, not a moat,” Dr Adatia asserts. </span></p>
<p><span>Saurabh Agarwal, Director and CEO, HAB Pharmaceuticals and Research, is direct, “China’s CDMO market is roughly double India’s and built for volume; India’s opportunity, sharpened by BIOSECUREdriven derisking away from Chinese suppliers, is in complexity and trust — hard-to-formulate molecules, drug-device combinations, regulatory transparency — where scale matters less than judgment. India competing on China’s terms is a losing game; competing on a different axis is not.” </span></p>
<p><span>Hari Kiran Chereddi, Founder, MD & CEO, HRV Pharma, arrives at the same conclusion from a different route, “China achieved its position through vertically integrated, large-volume chemical manufacturing on a scale that India won’t be able to match in the short term, so if India wants to enter that arena it has to compete against China on her cost structure while also facing China’s advantage in infrastructure. India’s more sustainable approach is to compete along a different line: by building regulatory trust, through partnership models based on intellectual property, and by offering flexibility when it comes to complex, low-volume, high-value molecules, since global sponsors are looking for a partner who naturally understands FDA and EU-GMP requirements rather than one who is simply focused on volume. Global innovators do not intend to substitute one single-source dependency with another; instead, they are seeking a credible alternative source, either a second or third one with genuinely different risk profiles. That is the opportunity, and it is not about scale.” </span></p>
<p><span>Aniel Khubchandani, CEO – Development & Manufacturing Solutions, Aragen, frames the opportunity differently. He says, “India does not need to replicate China’s CDMO model; it needs to build a differentiated proposition of its own. China has developed significant scale, infrastructure and deep manufacturing ecosystems over many years. India’s opportunity lies in combining its established strengths in chemistry, scientific talent and cost competitiveness with stronger capabilities in integrated drug development, biologics, advanced modalities and high-quality manufacturing.” </span></p>
<p><span>Tuneer Ghosh, President – CMC at Sai Life Sciences, also shares similar views and looks at the same idea in operational terms. He says “China+1 is an important catalyst. Customers are looking to diversify their supply chains because of geopolitical uncertainty, intellectual property considerations, and the need for greater resilience. But this is not simply about moving work from China to another location. Customers are also looking for partners who can take on more complex programs.” </span></p>
<p><span>That shift is not just geographical. It is also about the kind of work India is expected to handle. </span></p>
<p><span>Chereddi puts the test more bluntly. He says, “The reason India has made it to the shortlist is scale, talent, and cost, but it won’t end up at the top of the list. Global innovators are not only moving away from China’s low costs but also from concentration risk that is, relying on a single geographical location for critical APIs and intermediates. India’s advantage is structural, not merely competitive. Yet having the capacity does not guarantee reliability, and it is reliability that determines a CDMO’s decision. The straightforward answer is that India has deserved a place at the table. Whether or not it wins the contract will depend on what happens in the future, specifically on the consistency of its quality systems, the speed of technology transfer, and the predictability of supply, not on cost advantages.” </span></p>
<p><img loading="lazy" decoding="async" class="alignnone  wp-image-459370" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/07115805/Suresh-Subramanian-300x134.jpg" alt="" width="358" height="160" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/07115805/Suresh-Subramanian-300x134.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/07115805/Suresh-Subramanian-768x343.jpg 768w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/07115805/Suresh-Subramanian.jpg 901w" sizes="auto, (max-width: 358px) 100vw, 358px"> <img loading="lazy" decoding="async" class="alignnone  wp-image-459371" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/07115808/Tushar-Ghosh-300x133.jpg" alt="" width="368" height="163" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/07115808/Tushar-Ghosh-300x133.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/07115808/Tushar-Ghosh-768x340.jpg 768w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/07115808/Tushar-Ghosh.jpg 901w" sizes="auto, (max-width: 368px) 100vw, 368px"></p>
<p><span>Khubchandani outlines how the role of a CDMO has evolved. “Indian CDMOs are already moving beyond a model defined primarily by cost and manufacturing scale. The next phase of the industry will be defined by how effectively CDMOs can contribute across the drug development journey, from early discovery and process development to scaleup, regulatory support and commercial manufacturing. Global innovators increasingly need partners who can understand the science behind a programme, anticipate challenges and help teams make better decisions earlier,” he points out. </span></p>
<p><span>However, he doesn’t present the transition as automatic and points out that it “requires deliberate capability investment, business model evolution, and willingness to own risk alongside clients – things most Indian CDMOs have historically avoided.” </span></p>
<p><span>That is where the definition of a CDMO partnership starts to change. </span></p>
<p><span>Peter DeYoung, CEO, Piramal Global Pharma, says development partnership requires a different level of engagement with the client. </span></p>
<p><span>He explains, “Generally speaking, acting as a development partner requires proactive regulatory (CMC) strategy, scientific and operational problemsolving expertise, and a commitment to project management. Taking a consultative approach to the clients’ programs helps innovators optimise molecules long before they hit clinical manufacturing.” </span></p>
<p><span>He adds, “Evolving from a transactional manufacturing model to a true development partnership requires owning the science from early-stage discovery and route scouting through to commercialisation. Piramal Pharma Solutions was built with this concept in mind; our cross-functional scientific expertise integrates discovery, development and manufacturing. To eliminate vendor handoffs, this model requires integrated process development, advanced analytical services, and multi-site tech transfer – all supported by a deep commitment to quality and patient centricity that spans every function.” </span></p>
<p><span>Ghosh sees that evolution already underway in the kind of work now coming to India. He outlines, “Historically, much of the work coming to India was discovery- and early-phase-oriented, while late-phase and manufacturing work was more tactical. Over the last few years, however, we have seen customers increasingly look to outsource late-phase development and manufacturing work to India. This is an area where we believe Sai Life Sciences is well prepared to take on that challenge.” </span></p>
<p><span>He predicts, “If we can do that, China+1 can help India evolve from an alternative supplier into a more strategic partner for global pharma.” </span></p>
<p><b>Where the money moves </b></p>
<p><span>The opportunity is also changing at the molecule level. </span></p>
<p><span>Dr Adatia breaks it down by segment, “Small molecules will continue to anchor the CDMO value pool — 75%+ of it. Beyond that, the highest-value ground is peptides, ADCs, oligonucleotides and HP-APIs, along with enabling platforms like flow chemistry, biocatalysis and continuous manufacturing. GLP-1 manufacturing alone could be a $20–25 billion opportunity by 2030, with roughly $5–6 billion genuinely addressable by CDMOs, that’s a category India cannot afford to sit out. Biologics is attractive but capital-hungry, and India is still sub-scale there. Peptides, oligonucleotides and ADCs are where India’s synthetic chemistry heritage transfers most directly, and that’s where I’d expect the fastest gains,” he predicts. </span></p>
<p><span>Suresh Subramanian, National Lifesciences Leader, EY Parthenon India, arrives at a similar shortlist but, in his opinion, “It won’t be one modality that defines the next phase – it’ll be whichever Indian players can move fastest from ‘can we make this’ to ‘can we make this at GMP scale, reliably, for a global regulator.’ That execution question matters as much as the science.” Ghosh also states, “Biologics will continue to be important, while peptides, ADCs, oligonucleotides, and other new modalities are creating new opportunities. And when we talk about peptides, it is important not to think only about GLP-1s. There are a lot of peptides outside of the realm of GLP-1s and hence a very interesting opportunity for us.” </span></p>
<p><span>He believes that what ties these modalities together isn’t the molecule but the capabilities required to develop and manufacture. Citing ADCs as an example, he says, “Supporting an ADC program requires capabilities around payloads, linkers, conjugation, and analytical characterisation, as well as the ability to manufacture the product. Similarly, peptides and oligonucleotides require specialised chemistry, analytics, and manufacturing infrastructure.” </span></p>
<p><span>He emphasises, “That is why I think the opportunity is increasingly about bringing capabilities together around the molecule, rather than building a business around one modality.” </span></p>
<p><span>Young also points to complex modalities and bioconjugates as important growth areas. </span></p>
<p><span>He states, “It’s fair to say that historically, India has been associated with cost as its primary benefit. But in an industry where patients are the end customers, cost does not supersede quality, safety, and functionality. As such, the real focus of partnering with an Indian CDMO should be on value. Value creation must be anchored in flawless compliance records, robust data integrity, sophisticated technical execution, and delivery.” </span></p>
<p><span>He adds, “The next wave of growth engines in pharma represents additional opportunities. For example, complex modalities and bioconjugates are a segment where Indian CDMOs are poised to move the needle. Piramal has made investments in capabilities and talent in Antibody-Drug Conjugates (ADCs), highly potent active pharmaceutical ingredients (HPAPIs), and complex peptides for exactly this purpose. Likewise, investing in specialized processing technologies and advanced delivery technologies such as advanced spray-drying suites for poorly soluble molecules and biotherapeutics aligns with where the market is heading.” </span></p>
<p><span>For an Indian CDMO, however, the opportunity is not only about what it can make. It is also about how reliably it can deliver. </span></p>
<p><span>Young says, “For an Indian CDMO, having resilient, global supply networks is a must. Building globally integrated asset platforms with localized hubs that offer the ‘best of both worlds’ in terms of Eastern and Western advantages can assure the compressed timelines that clients value most.” </span></p>
<p><span>Dr Adatia concurs, “On large, complex programmes: a handful of Indian players can already run them end to end. For most of the rest, the constraint isn’t chemistry — it’s scale: reactor capacity, sterile fill-finish and programme-management maturity. That’s a solvable problem, but it takes capital and discipline, not just ambition.” </span></p>
<p><img loading="lazy" decoding="async" class="alignnone  wp-image-459369" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/07115800/Saurabh-Agarwal-300x133.jpg" alt="" width="363" height="161" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/07115800/Saurabh-Agarwal-300x133.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/07115800/Saurabh-Agarwal-768x341.jpg 768w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/07115800/Saurabh-Agarwal.jpg 900w" sizes="auto, (max-width: 363px) 100vw, 363px"> <img loading="lazy" decoding="async" class="alignnone  wp-image-459367" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/07115746/Hari-Kiran-Chereddi-300x141.jpg" alt="" width="351" height="165" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/07115746/Hari-Kiran-Chereddi-300x141.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/07115746/Hari-Kiran-Chereddi-768x361.jpg 768w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/07115746/Hari-Kiran-Chereddi.jpg 849w" sizes="auto, (max-width: 351px) 100vw, 351px"></p>
<p><strong>The complexity test </strong></p>
<p><span>The answer from the industry is increasingly yes, but the differentiator is becoming the ability to execute those programmes consistently across development, manufacturing, technology transfer and supply. </span></p>
<p><span>Young says, “Leading Indian CDMOs have systematically dismantled the legacy perception that they are suited only for mature, generic APIs or simple packaging projects. Today’s Indian CDMOs feature state-ofthe-art facilities and the ability to handle complicated projects across both small and large molecules. Piramal has focused its most recent capex commitments with support of these complex programs in mind, including major investments in the areas of bioconjugates, high potency APIs, and commercial scale fill finish.” </span></p>
<p><span>This brings the discussion back to one of India’s most important advantages, the capabilities it already has. </span></p>
<p><b>What India already has </b></p>
<p><span>The case for India does not rest on geopolitics alone. It also has several structural strengths. </span></p>
<p><span>Subramanian points out that India already possesses several advantages. He lists them out, “The largest pool of pharma chemistry talent outside the West. One of the highest numbers of USFDA-approved manufacturing sites outside the United States. Deep expertise in process chemistry, scale-up and complex generic development. A growing biotech ecosystem and increasing biologics capabilities.” </span></p>
<p><span>Chereddi also says, “When it comes to quality, India is already in competition since the country possesses more US FDA-approved manufacturing sites than any other nation outside the US”.</span></p>
<p><span>Agarwal agrees, “On core quality systems and USFDAapproved facility counts, India already competes credibly.” </span></p>
<p><span>Khubchandani also concurs, but distinguishes between the industry’s top layer and its average. He says, “Tier 1 Indian CDMOs operate with genuinely embedded quality systems and have clean regulatory track records. Global pharma clients conducting audits are increasingly aware of this bifurcation.” </span></p>
<p><span>But that bifurcation may be one of the industry’s key challenges. </span></p>
<p><span>India does not have a capability problem, but it has a consistency problem across the ecosystem. </span></p>
<p><span>As Dr Adatia also highlights, “Capability depth also remains uneven in biologics, complex peptides, ADCs, high potency manufacturing, sterile drug product and advanced analytics. India has islands of excellence today. What it doesn’t yet have is ecosystem-wide depth, and that’s the gap to close.” </span></p>
<p><b>Cost is no longer the pitch </b></p>
<p><span>That also changes the way Indian CDMOs need to sell themselves. </span></p>
<p><span>Global pharma companies no longer just want a manufacturer that can execute a defined process. Increasingly, they want a partner that can help move a molecule through development, end to end. </span></p>
<p><span>Asked whether India can still win on price, Dr Adatia says, “Yes, but this requires a different business model. Global leaders earn 30%+ EBITDA through technology, reliability and speed, rather than labour arbitrage. Cost is table stakes; it gets you into the conversation, nothing more. In our conversations with pharma CXOs globally, technical capability, dependability, on-time delivery and problem-solving consistently rank above price. That’s because a molecule won at Phase I can convert into commercial supply a decade later, customers are choosing a long-term partner, not shopping for a quote,” he says.</span></p>
<p><span>He cautions, “India needs to retire the ’30–50 per cent cheaper’ pitch. If a delayed drug launch can destroy hundreds of millions of dollars of value, customers will pay a premium for speed and certainty every time.” </span></p>
<p><span>Ghosh shares similar views and reiterates, “Cost will remain an advantage for India, but it cannot be the only reason customers choose us. The more sustainable proposition is to combine cost competitiveness with scientific depth, quality, and reliable execution.” </span></p>
<p><span>He adds, “We are seeing work move beyond simply transferring an established process to India for manufacturing. Customers are increasingly bringing development activities and earlier-stage work, which suggests that they are placing greater confidence in the scientific capabilities available here.” </span></p>
<p><span>Khubchandani captures the mindset change in a single line and states, “The firms that survive and lead will be those that have moved from execution for-hire to genuine scientific partnership.” </span></p>
<p><img loading="lazy" decoding="async" class="alignnone  wp-image-459365" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/07115727/Aniel-Khubchandani-300x141.jpg" alt="" width="400" height="188" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/07115727/Aniel-Khubchandani-300x141.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/07115727/Aniel-Khubchandani-768x361.jpg 768w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/07115727/Aniel-Khubchandani.jpg 886w" sizes="auto, (max-width: 400px) 100vw, 400px"></p>
<p><b>The real gaps </b></p>
<p><span>The opportunity is clear. The gaps are becoming clearer too. </span></p>
<p><span>Dr Adatia’s diagnosis is direct. “India’s biggest constraint today is not manufacturing competence, it’s consistency of execution. Global customers expect faster RFQ turnaround, shorter technology-transfer timelines, stronger programme management and near-flawless delivery. That bar keeps rising, and India has to rise with it,” he says. </span></p>
<p><span>Ghosh makes the same point from a delivery standpoint and opines,”I also think we need to be clear about the difference between demonstrating a capability and being able to deliver it consistently at scale. Global innovators expect the same level of quality, reliability and execution whether the program is being run in India or anywhere else in the world.” </span></p>
<p><span>Chereddi locates the risk with precision. “Regarding speed and reliability, however, the situation is more uneven, and this unevenness is in fact the main limiting factor, not a lack of technical ability. One warning letter or one missed delivery deadline can nullify years of hard-earned reputation with a global client.” </span></p>
<p><span>His prescription is operational, not promotional. He advises, “The way to bridge that gap is not through a marketing effort but by adopting operational discipline: by making audit-ready documentation a permanent condition rather than something only done in anticipation of an inspection, by ensuring real-time visibility into a CMO’s performance rather than relying on reports at the end of each quarter, and by treating compliance as a design principle rather than as a mere checkpoint. The Indian companies that are securing repeat business from abroad have made this operational discipline a regular part of their operations rather than something they only do on an ad hoc basis.” </span></p>
<p><strong>The talent bottleneck </strong></p>
<p><span>Underneath the consistency problem sits a talent problem. </span></p>
<p><span>Agarwal names the exact functions India is short on and informs, “Talent depth in the functions that actually decide whether a global innovator signs a multi-year contract — EU-GMP-trained regulatory affairs, quality-by-design formulation science, project management for tech transfer — is where India is genuinely stretched. India adds capacity faster than it adds qualified regulatory and quality professionals, and that gap, not plant count, is what slows conversion from enquiry to contract.” </span></p>
<p><span>He returns to it in market terms and says, “‘Strategic partner’ status is earned deal by deal, through demonstrated regulatory judgment during a tech transfer or an FDA query, not through capacity announcements. The industry has the assets; it hasn’t yet built enough of that decisionmaking bench strength across mid-size players, which is where most of India’s real capacity actually sits.” </span></p>
<p><span>Technology remains part of the same equation. “The honest gap is technology adoption in mid-market plants — QMS, LIMS and MES are still inconsistently deployed outside the top-tier players — and that inconsistency is what innovators read as reliability risk. Speed follows the same pattern: the best Indian sites move as fast as anyone; the sector’s average doesn’t, because digital maturity and regulatory bench strength aren’t evenly spread.” </span></p>
<p><span>Khubchandani’s numbers point to progress and a persistent gap sitting side by side. He says, “AI-linked skill demand in Indian CDMO grew 180 per cent in last two years — the intent and the talent pipeline are real. Yet continuous manufacturing, where Lonza and Pfizer CentreOne are genuinely ahead, remains India’s clearest technology gap in small molecules. We are catching up fast.” </span></p>
<p><span>Chereddi adds, “Capacity utilisation in Indian API manufacturing is around 30 to 40 per cent, considerably lower than that in China, which shows that the industry has more untapped potential than it is currently bringing to market.” Subramanian identifies three structural gaps. </span></p>
<p><span>The first is regulatory agility, where “approval timelines, import clearances for research materials, and multiagency regulatory processes remain less predictable than competing jurisdictions”.</span></p>
<p><span>The second is innovation and risk capital, where “India remains underinvested in biotech innovation compared to the US, Europe and China”. </span></p>
<p><span>The third is talent in emerging technologies, where “the industry needs significantly larger pools of talent in biologics, bioprocess engineering, automation, data integrity, AIenabled quality systems, and regulatory science.” </span></p>
<p><b>From vendor to partner </b></p>
<p><span>The shift from manufacturing vendor to development partner is perhaps the clearest test of how far India’s CDMO industry has moved. </span></p>
<p><span>“Developed with India’ is a far more valuable proposition than ‘made in India’ and it’s within reach,” Dr Adatia says. “We’re already seeing several Indian players move upstream into discovery chemistry, DMPK, process development and clinical supply, with earlystage molecule counts up several-fold over the past two to three years,” he adds. </span></p>
<p><span>Chereddi is clear about what that transition requires. </span></p>
<p><span>In his opinion, “The move from being a vendor to being a partner is not about gaining new capabilities; it’s about altering the ownership model. When a vendor receives a specification, they carry out the specification. A strategic partner, on the other hand, shares in the regulatory and technical risks associated with getting a molecule to market, from the DMF filing all the way through to scale-up. This means that Indian companies must make investments upstream, in regulatory intellectual property, in process development, and in having the ability to enter a partnership conversation by owning the filings and the data, not just the factory floor space. The companies that close this gap by developing real development and filing capabilities rather than simply running someone else’s process are the ones who will be asked back for the next molecule, not just the current one.” </span></p>
<p><span>Young’s view reinforces that shift. The development partner has to be involved much earlier, own the science and remove handoffs across the development and manufacturing journey. </span></p>
<p><span>That is also where BCGIPSO reports recommendation runs parallel.Move from being a preferred outsourcing destination to a genuine innovation partner, by building differentiated capability rather than stacking commodity capacity, building end-to-end platforms across the value chain, locking in longer-term relationships instead of leaning on spot business, treating inspection readiness as a daily discipline, and building supply-chain resilience by localising critical starting materials. </span></p>
<p><span>The opportunity, then, is no longer simply about attracting work to India. It is about retaining that work through deeper relationships. </span></p>
<p><b>Execution, not potential </b></p>
<p><span>Dr Adatia gives that ambition a number and a deadline. He says, “My view is that the ambition should be explicit, not implicit: become a top-three global CRDMO geography, and move toward 10–12 per cent of global outsourced work within the next decade. That will take sustained investment in talent, specialist suppliers, worldclass quality systems and stronger customer-facing teams. The opportunity is real. Whether India captures it is now a question of execution, not potential.” </span></p>
<p><span>Ghosh frames the same ambition in terms of complexity. He states, “I think India should aspire to be one of the world’s leading CRDMO hubs, but I would measure that ambition by the complexity and value of the work we are able to undertake, rather than simply by the size of the industry.” </span></p>
<p><span>Capturing the larger opportunity, he explains, “The real ambition should be to build an industry that is globally competitive on science, technology, quality, and execution, while retaining the cost advantage that India has today. If we can make that transition, India can move from being an important outsourcing destination to becoming a strategic development and manufacturing partner for global pharma.” </span></p>
<p><span>Agarwal and Chereddi reach for almost the same conclusions. </span></p>
<p><span>Agarwal says “The CDMOs that get there first won’t be the ones with the most capacity; they’ll be the ones that closed the talent gap before their competitors noticed it existed.” </span></p>
<p><span>Chereddi asserts, “The Indian CDMOs who are selected first, rather than being chosen as a backup, will be the ones who stop merely selling capacity and begin selling certainty.” </span></p>
<p><span>China+1 gave India a strong push. It also delivered a quiet warning: diversification creates options for customers, not loyalty. </span></p>
<p><span>India is no longer just competing with China. It is competing with every geography trying to become the next trusted outsourcing destination. </span></p>
<p><span>The raw materials for success are already on the table.We have the scale, talent, cost competitiveness, manufacturing experience and a regulatory track record that is gradually maturing. </span></p>
<p><span>What’s left is unglamorous but unavoidable. Do what was promised, deliver when promised and get it right, consistently.</span></p>
<p><span>India’s CDMO opportunity was helped along by a geopolitical shift. Its future will be decided by something far more basic, whether global pharma can trust an Indian CDMO with its molecule for the next ten years. That’s the real test. And it is how India moves from being the alternative to becoming the choice. </span></p>
<p> </p>
<p><em><span>lakshmipriya.nair@expressindia.com<br>
</span><span>laxmipriyanair@gmail.com </span><span><br>
</span><span><br>
</span><span>(With inputs from Kalyani Sharma and Neha Aathavale) </span></em></p>
<p><span></span></p>
<p></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/indias-race-for-the-cdmo-crown/">India’s race for the CDMO crown</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>WPO marks September 6 as World Packaging Day</title>
<link>https://edusehat.com/en/wpo-marks-september-6-as-world-packaging-day</link>
<guid>https://edusehat.com/en/wpo-marks-september-6-as-world-packaging-day</guid>
<description><![CDATA[ 
With this move, WPO aims to spotlight packaging’s role in food security, economic growth, safety and sustainability.
The post WPO marks September 6 as World Packaging Day appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/06163051/WPO.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sun, 06 Sep 2026 20:50:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>WPO, marks, September, World, Packaging, Day</media:keywords>
<content:encoded><![CDATA[<div><img width="748" height="490" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/06163051/WPO.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/06163051/WPO.jpg 748w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/06163051/WPO-300x197.jpg 300w" sizes="(max-width: 748px) 100vw, 748px"></div><p class="isSelectedEnd">The packaging industry across the world is set to mark a significant milestone on September 6, 2026, with the first-ever World Packaging Day (WPD) being celebrated globally.</p>
<p class="isSelectedEnd">The World Packaging Organisation (WPO) has officially designated September 6 as World Packaging Day, coinciding with the anniversary of the organisation’s foundation. The annual observance seeks to create greater public understanding of the indispensable role packaging plays in modern society and to encourage a global dialogue on its future.</p>
<p class="isSelectedEnd">Disclosing these details, Chakravarthi AVPS, Global Ambassador of World Packaging Organisation said for decades, packaging has been an invisible yet essential backbone of global supply chains—protecting food and pharmaceuticals, reducing product losses, enabling safe transportation, supporting international trade and bringing products safely to consumers. World Packaging Day seeks to broaden the conversation beyond packaging waste and highlight its wider contribution to health, food security, economic development, innovation and quality of life.</p>
<p class="isSelectedEnd">WPO President Luciana Pellegrino has emphasised the everyday importance of packaging, noting that it is present in virtually every aspect of daily life, helping reduce losses and waste, enhance sustainability in consumption, and provide safe and convenient access to goods.</p>
<p class="isSelectedEnd">The inaugural World Packaging Day campaign is built around four key themes, added AVPS.</p>
<p class="isSelectedEnd"><strong>Packaging for Progress</strong> will highlight the contribution of packaging to healthcare, pharmaceutical safety, product security, accessibility and quality of life.</p>
<p class="isSelectedEnd"><strong>Packaging Against Food Waste</strong> will focus on the role of packaging technologies in protecting food, extending shelf life, maintaining quality and safety, and reducing losses across the supply chain.</p>
<p class="isSelectedEnd"><strong>Packaging and Economic Growth</strong> will showcase packaging as an important enabler of manufacturing, e-commerce, logistics, exports, international trade and employment.</p>
<p class="isSelectedEnd"><strong>Packaging and Sustainability</strong> will draw attention to circular economy principles, eco-design, recyclability, lightweighting, mono-material solutions and innovations in sustainable packaging.</p>
<p class="isSelectedEnd">A global movement with a lot of local participation, shared AVPS. World Packaging Day is envisaged as a decentralised, participatory global movement, with packaging associations, manufacturers, converters, machinery companies, material innovators, educational institutions, brands and other stakeholders encouraged to organise activities under the common World Packaging Day identity.</p>
<p class="isSelectedEnd">These may include technical seminars and conferences, factory open days, facility tours, packaging design competitions, student programmes, academic lectures, innovation showcases and digital campaigns.</p>
<p class="isSelectedEnd">The initiative also seeks to involve policymakers, retailers, supply-chain stakeholders, researchers, NGOs, media and consumers, creating a broader platform for dialogue on the future of packaging.</p>
<p class="isSelectedEnd">India’s packaging industry has an opportunity to lead. For India, World Packaging Day provides an important opportunity to showcase the country’s growing packaging ecosystem and its innovations in sustainable materials, printing, converting, machinery, logistics and product protection.</p>
<p class="isSelectedEnd">Indian packaging companies, industry associations, educational institutions and professionals can use the occasion to demonstrate how packaging is contributing not only to business and exports but also to food security, healthcare, employment, sustainability and consumer welfare.</p>
<p class="isSelectedEnd">The global campaign also encourages organisations to share their initiatives, innovations, events, photographs and videos through social media using #WorldPackagingDay, helping create a worldwide showcase of the industry’s contribution.</p>
<p class="isSelectedEnd">World Packaging Day comes at a time when packaging is often discussed primarily through the lens of waste and environmental impact. While responsible end-of-life management remains critical, the WPO initiative seeks to bring greater balance to the conversation by recognising the value packaging creates throughout the product lifecycle.</p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/wpo-marks-september-6-as-world-packaging-day/">WPO marks September 6 as World Packaging Day</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>FOPE opposes proposed exemption of retailers, hospitals from DPCO overcharging liability</title>
<link>https://edusehat.com/en/fope-opposes-proposed-exemption-of-retailers-hospitals-from-dpco-overcharging-liability</link>
<guid>https://edusehat.com/en/fope-opposes-proposed-exemption-of-retailers-hospitals-from-dpco-overcharging-liability</guid>
<description><![CDATA[ 
The Federation of Pharma Entrepreneurs (FOPE) has urged the National Pharmaceutical Pricing Authority (NPPA) to reconsider a reported proposal to exempt retailers, hospitals, nursing homes and other downstream sellers from […]
The post FOPE opposes proposed exemption of retailers, hospitals from DPCO overcharging liability appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/08/17130302/Drug-price.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 04 Sep 2026 22:05:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>FOPE, opposes, proposed, exemption, retailers, hospitals, from, DPCO, overcharging, liability</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/08/17130302/Drug-price.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/08/17130302/Drug-price.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/08/17130302/Drug-price-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>The Federation of Pharma Entrepreneurs (FOPE) has urged the National Pharmaceutical Pricing Authority (NPPA) to reconsider a reported proposal to exempt retailers, hospitals, nursing homes and other downstream sellers from liability for overcharging consumers under Para 26 of the Drugs (Prices Control) Order (DPCO), 2013.</span></p>
<p><span>In its representation to the NPPA, FOPE said it fully supports the government’s objective of preventing overcharging and protecting patients, but argued that regulatory responsibility should rest with the stakeholder who has control over the transaction in question.</span></p>
<p><span>FOPE pointed out that Para 26 of the DPCO states that “no person” shall sell a formulation to a consumer above the permissible price, and therefore, in its view, the provision is not intended to place responsibility exclusively on manufacturers.</span></p>
<p><span>The organisation argued that while manufacturers are responsible for correctly declaring the MRP, complying with NPPA price notifications and submitting prescribed price information through the Integrated Pharmaceutical Database Management System (IPDMS), the actual transaction with the consumer is controlled by the retailer, hospital, nursing home or other downstream seller.</span></p>
<p><span>“The party having control over the act should bear responsibility for that act. A manufacturer should not be made liable for an independent downstream transaction merely because it manufactured the product,” FOPE said in its representation.</span></p>
<p><b>FOPE seeks equal accountability across the supply chain</b></p>
<p><span>According to FOPE, the existing DPCO already distributes responsibilities across different stages of the pharmaceutical supply chain. Paras 14, 24 and 25 deal with manufacturers’ pricing and price communication obligations, while Para 26 addresses the actual sale of formulations to consumers.</span></p>
<p><span>The organisation has therefore opposed what it described as a potentially disproportionate transfer of liability to manufacturers, particularly where a manufacturer has fulfilled all statutory requirements but a downstream seller subsequently charges a consumer more than the permissible price.</span></p>
<p><span>FOPE also cautioned that making manufacturers solely liable could expose compliant companies to unnecessary complaints, disputes and potential misuse of the regulatory mechanism.</span></p>
<p><b>Calls for greater use of NPPA’s digital systems</b></p>
<p><span>Rather than amending the liability framework, FOPE has proposed greater use of the NPPA’s PHARMA SAHI DAAM (PSD) app to establish transparency on applicable medicine prices.</span></p>
<p><span>It has suggested that the PSD system should be updated as soon as manufacturers submit the relevant forms through IPDMS. Once the applicable price is reflected in the NPPA system, FOPE believes the manufacturer should not remain liable for subsequent transactions beyond its control.</span></p>
<p><span>The organisation has also proposed that revised prices should become applicable from the next production batch, which it says could provide greater clarity and support the government’s Ease of Doing Business objective.</span></p>
<p><span>FOPE has requested the NPPA to consider its representation and grant the organisation a personal hearing before finalising any amendment, notification, guideline or other regulatory measure concerning liability for overcharging.</span></p>
<p><span>The broader issue, according to FOPE, is how to balance patient protection with a fair allocation of regulatory responsibility across India’s pharmaceutical supply chain. The organisation maintains that all stakeholders—from manufacturers and distributors to retailers, hospitals and other sellers—should be accountable for complying with the prices fixed under the DPCO.</span></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/fope-opposes-proposed-exemption-of-retailers-hospitals-from-dpco-overcharging-liability/">FOPE opposes proposed exemption of retailers, hospitals from DPCO overcharging liability</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Médunik and Biocodex sign exclusive agreement for Diacomit in Canada</title>
<link>https://edusehat.com/en/medunik-and-biocodex-sign-exclusive-agreement-for-diacomit-in-canada</link>
<guid>https://edusehat.com/en/medunik-and-biocodex-sign-exclusive-agreement-for-diacomit-in-canada</guid>
<description><![CDATA[ The agreement gives Médunik Canada immediate responsibility for Diacomit’s sales, marketing, and medical affairs activities throughout the country. It aims to leverage Médunik Canada’s network and rare disease 
The post Médunik and Biocodex sign exclusive agreement for Diacomit in Canada appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/09/PT-04-09-2026-shutterstock_436372507.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 04 Sep 2026 18:30:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Médunik, and, Biocodex, sign, exclusive, agreement, for, Diacomit, Canada</media:keywords>
<content:encoded><![CDATA[<p>The agreement gives Médunik Canada immediate responsibility for Diacomit’s sales, marketing, and medical affairs activities throughout the country.</p>
<p>It aims to leverage Médunik Canada’s network and rare disease expertise to strengthen engagement with Canadian paediatric neurologists, epileptologists, and comprehensive epilepsy centres.</p>
<div>
<p>When used together with clobazam and valproate, Diacomit is indicated by Health Canada for managing seizures associated with Dravet syndrome, a severe and rare developmental and epileptic encephalopathy.</p>
<p>As part of the agreement, Médunik Canada will handle all commercial and medical engagement for the therapy while working to maintain consistency and reliability across the product’s supply chain and patient access.</p>
<p>The goal is to expand educational programmes and support for Canada’s epilepsy community while ensuring ongoing access to the medication for eligible patients.</p>
<p>Biocodex rare diseases international business head Hubert Chapellier said: “This alliance between our two companies marks a real turning point in our approach to Dravet syndrome in the Canadian market.</p>
<p>“We are confident that our efforts will help patients and families better understand this complex condition. I am extremely excited about the partnership between Biocodex and Médunik Canada.”</p>
<p>Dravet syndrome is described as a rare and lifelong neurological disorder, marked by frequent and often treatment-resistant seizures beginning in infancy.</p>
<p>The condition can have a considerable impact on patients and their caregivers and typically needs the attention of specialised epilepsy care teams.</p>
<p>Médunik Canada, part of Duchesnay Pharmaceutical Group (DPG), focuses on providing access to orphan drugs in Canada.</p>
<p>DPG is headquartered in Blainville, Quebec, and operates several companies in both Canada and the US, offering a range of speciality and generic medicines.</p>
</div>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/medunik-biocodex-diacomit-canada/">Médunik and Biocodex sign exclusive agreement for Diacomit in Canada</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Superluminal Medicines secures $60m to advance rare obesity therapy</title>
<link>https://edusehat.com/en/superluminal-medicines-secures-60m-to-advance-rare-obesity-therapy</link>
<guid>https://edusehat.com/en/superluminal-medicines-secures-60m-to-advance-rare-obesity-therapy</guid>
<description><![CDATA[ The funding was led by BVF Partners, with participation from new investors Deep Track Capital and Perceptive Advisors. Existing backers included Catalio Capital Management, Cooley, Eli Lilly and 
The post Superluminal Medicines secures $60m to advance rare obesity therapy appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/09/PT-2-04-09-2026-shutterstock_2257769993.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 04 Sep 2026 18:30:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Superluminal, Medicines, secures, 60m, advance, rare, obesity, therapy</media:keywords>
<content:encoded><![CDATA[<p>The funding was led by BVF Partners, with participation from new investors Deep Track Capital and Perceptive Advisors.</p>
<p>Existing backers included Catalio Capital Management, Cooley, Eli Lilly and Company, Gaingels, Insight Partners, Nvidia, and RA Capital Management.</p>
<p>The company plans to use the proceeds to progress its lead candidate, a selective, biased melanocortin-4 receptor (MC4R) agonist, towards a Phase I clinical trial by the end of this year.</p>
<p>The additional funds will support the expansion of other pipeline programmes and the development of small‑molecule, GPCR‑targeted therapies for endocrine and cardiometabolic diseases.</p>
<p>Superluminal’s MC4R agonist is being developed for rare genetic forms of obesity, including Bardet-Biedl syndrome (BBS) and hypothalamic obesity.</p>
<p>The MC4R pathway plays a key role in energy homeostasis and appetite regulation, which has been established in these rare diseases.</p>
<p>According to the company, activating only the signalling pathways responsible for the desired effect may maximise therapeutic activity and minimise unwanted side effects.</p>
<p>In preclinical models, the therapy demonstrated high selectivity and a favourable safety profile.</p>
<p>Superluminal has also suggested possible future applications in conditions such as Prader-Willi syndrome, and potential utility in broader populations in combination with GLP-1 therapies.</p>
<p>Superluminal Medicines CEO Cony D’Cruz said: “This financing represents an important milestone in Superluminal’s evolution as we transition from a discovery platform company to a clinical-stage biotechnology company.</p>
<p>“Rare genetic forms of obesity and hypothalamic obesity are devastating diseases with limited treatment options, and we believe our selective, biased MC4R agonist has the potential to make a meaningful difference for these patients.</p>
<p>“With the support of this exceptional investor syndicate, we are positioned to advance our first clinical programme while continuing to build a pipeline of GPCR-targeted medicines for patients with significant unmet needs in cardiometabolic diseases and obesity.”</p>
<p>The company’s research and development efforts focus on integrating advanced structural biology with proprietary machine learning tools.</p>
<p>Superluminal further maintains collaborations with pharmaceutical partners, including an existing partnership with Eli Lilly and Company, to develop small molecule therapeutics targeting undisclosed GPCRs for cardiometabolic diseases and obesity.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/superluminal-60m-advance-rare-obesity-therapy/">Superluminal Medicines secures $60m to advance rare obesity therapy</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Dadachanji Group launches Kaisha Pharma, renews 35&#45;year legacy in pharma glass packaging</title>
<link>https://edusehat.com/en/dadachanji-group-launches-kaisha-pharma-renews-35-year-legacy-in-pharma-glass-packaging</link>
<guid>https://edusehat.com/en/dadachanji-group-launches-kaisha-pharma-renews-35-year-legacy-in-pharma-glass-packaging</guid>
<description><![CDATA[ 
The visionary founders behind India’s largest manufacturing footprint for primary pharmaceutical glass packaging have launched Kaisha Pharma, a premier global platform engineered to serve the pharmaceutical and biotechnology sectors worldwide. […]
The post Dadachanji Group launches Kaisha Pharma, renews 35-year legacy in pharma glass packaging appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/04112246/EP_Kairus-Dadachanji-and-Rishad-Dadachanji.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 04 Sep 2026 14:55:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Dadachanji, Group, launches, Kaisha, Pharma, renews, 35-year, legacy, pharma, glass, packaging</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/04112246/EP_Kairus-Dadachanji-and-Rishad-Dadachanji.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/04112246/EP_Kairus-Dadachanji-and-Rishad-Dadachanji.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/04112246/EP_Kairus-Dadachanji-and-Rishad-Dadachanji-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>The visionary founders behind India’s largest manufacturing footprint for primary pharmaceutical glass packaging have launched Kaisha Pharma, a premier global platform engineered to serve the pharmaceutical and biotechnology sectors worldwide. As part of a substantial multi-million-euro commitment, the Group has already deployed an initial investment of €45 million to accelerate infrastructure, scale, and operational capabilities.</span></p>
<p><span>Kaisha Pharma represents something different — a proudly Made in India enterprise, built on decades of experience, indigenous innovation, and global ambition.</span></p>
<p><span>And while our earlier journey was primarily focused on India, this time our horizon is very different. We want to be a trusted global partner — delivering quality, consistency, innovation, scientific support, and long-term value to every customer we serve.</span></p>
<p><b>The world is our market.</b></p>
<p><span>Kaisha Pharma enters the market with a complete tubular glass portfolio — ampoules, vials, prefilled syringes, and cartridges — together with advanced Ready-to-Use (RTU) platforms for vials, prefilled syringes, and cartridges. These solutions are designed to enable safer, faster, and more efficient fill-finish operations while meeting the increasingly stringent expectations of global pharmaceutical manufacturers.</span></p>
<p><span>Founders’ vision, however, extends well beyond conventional packaging formats. We are developing a range of specialty containment solutions for high-value biologics, advanced therapeutics, and sensitive drug formulations, where product integrity, compatibility, and performance are critical. By bringing together innovative design, advanced materials science, and deep pharmaceutical expertise, we intend to create packaging solutions for the therapies of tomorrow.</span></p>
<p><span>“Our previous experience was a defining chapter in our professional journey,” said Kairus Dadachanji, Managing Director, Kaisha Pharma. “Our vision is to create a truly global company that combines entrepreneurial agility, technical excellence, and an unwavering commitment to customer success.”</span><span> </span></p>
<p><span>Kaisha Pharma is strengthened by the capabilities of the other arms of the Dadachanji Group, creating an integrated ecosystem that virtually makes us a one-stop solutions partner for pharmaceutical companies — spanning primary packaging, automation, machinery, fill-finish support systems, and allied pharmaceutical services.</span></p>
<p><span>The manufacturing complex will span over 300,000 square feet, with fully integrated state-of-the-art production lines, sophisticated high-end camera inspection systems, and fully equipped laboratories incorporating the latest analytical and testing equipment. These capabilities, combined with robust, time-tested processes and a highly skilled workforce, are designed to deliver consistent, high-quality products — every batch, every time.</span></p>
<p><b>Innovation has always been part of our DNA.</b></p>
<p><span>The company introduced syringe manufacturing in India at a time when many believed it could not be done successfully. It was also among the pioneers globally in bringing Ready-to-Use cartridge technology to the market. Those achievements were never endpoints; they were milestones in a continuing pursuit of innovation.</span></p>
<p><span>This time, we have gone further.</span></p>
<p><span>It has carefully studied, analysed, and re-engineered itself by substantially upgrading the technology, strengthening process controls, and applying deeper scientific understanding. The result is a new generation of products designed to deliver enhanced performance, reliability, and consistency — once again setting standards for others to follow.</span></p>
<p><span>“Over the years, we have earned the trust of customers, partners, and colleagues throughout the pharmaceutical industry,” added Rishad Dadachanji. “Kaisha Pharma builds upon that foundation while embracing the opportunities of a rapidly evolving global market. We are excited about the future and the value we can create for customers around the world.”</span><span> </span></p>
<p><span>Recognising that true partnership also requires proximity, the company is  establishing an International Business Development office in Europe to serve as a hub for customer engagement, technical collaboration, and market development across the region — bringing it closer to customers and enabling them to respond faster to their evolving requirements.</span></p>
<p><span>Behind all of this is the group’s significant multi-million-euro commitment — a clear reflection of long-term commitment to technology, capacity, quality, innovation, and the customers The company intends to serve for decades to come.</span></p>
<p><span>The company mentioned, “With the next generation of leadership actively involved, we are combining decades of experience with fresh thinking, agility, and a determination to build an organisation for the future. As we begin this new chapter, our commitment remains what it has always been: to challenge convention, raise standards, and create lasting value for our customers.”</span></p>
<p>The post <a href="https://www.expresspharma.in/dadachanji-group-launches-kaisha-pharma-renews-35-year-legacy-in-pharma-glass-packaging/">Dadachanji Group launches Kaisha Pharma, renews 35-year legacy in pharma glass packaging</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Cohance Lifesciences advances its ADC strategy</title>
<link>https://edusehat.com/en/cohance-lifesciences-advances-its-adc-strategy</link>
<guid>https://edusehat.com/en/cohance-lifesciences-advances-its-adc-strategy</guid>
<description><![CDATA[ 
Cohance Lifesciences announced two proposed transactions to strengthen its Antibody-drug Conjugate (ADC) strategy: an additional investment of USD 13 million in NJ Bio and a controlling investment of USD 5 […]
The post Cohance Lifesciences advances its ADC strategy appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/09/28173818/Partnership-for-digital.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 04 Sep 2026 14:55:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Cohance, Lifesciences, advances, its, ADC, strategy</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/09/28173818/Partnership-for-digital.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/09/28173818/Partnership-for-digital.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/09/28173818/Partnership-for-digital-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>Cohance Lifesciences announced two proposed transactions to strengthen its Antibody-drug Conjugate (ADC) strategy: an additional investment of USD 13 million in NJ Bio and a controlling investment of USD 5 million in Aruka Bio. Both the transactions will be funded through internal accruals. The re-organisation establishes distinct priorities: deeper integration of NJ Bio’s customer-facing services with Cohance, and focused development of Aruka’s proprietary pipeline through potential partnerships.</span></p>
<p><b>   NJ Bio: planned succession, continued founder engagement</b></p>
<p><span>Cohance will increase its common-equity ownership in NJ Bio from 56.0% to 67.3%, acquiring the entire holdings of Ms. Priyashri Nayak, and the Jain Family Irrevocable Trust. Dr. Jain will retain 32.7%.</span></p>
<p><span>Dr. Jain will continue to lead NJ Bio while also advancing Aruka’s pipeline and partnership initiatives.</span></p>
<p><span>NJ Bio will remain focused on customer-facing contract research, development and manufacturing services. Closer integration will combine its payload-linker and bioconjugation expertise with Cohance’s manufacturing capabilities to support customers end-to-end CRDMO development through commercial supply. This integration is expected to strengthen business performance across the combined platform over time.</span></p>
<p><span>  </span><b>Aruka Bio: control of the platform, development with partners</b></p>
<p><span>Aruka Bio, Inc. is a private biotechnology company based in Princeton, New Jersey, focused on developing next-generation antibody-drug conjugates. Its lead program is currently at the preclinical stage.</span></p>
<p><span>Cohance’s USD 5 million equity investment will fund the buyout of other existing shareholders and convertible noteholders along with working capital.</span></p>
<p><span>Following completion and Dr. Jain’s upfront equity grant, Aruka will be owned 65% directly by Cohance, 25% by NJ Bio and 10% by Dr. Jain. These percentages are before further dilution from Dr. Jain’s performance-linked equity award.</span></p>
<p><span>Aruka will become Cohance’s direct subsidiary. The investment consolidates control of Aruka’s proprietary ADC platform, positioning it to pursue co-development, licensing and other collaborations with pharmaceutical and biotechnology partners as its pipeline progresses.</span></p>
<p><span>This follows a review of NJ Bio’s performance and integration with Cohance since the original investment in December 2024, which identified an opportunity to strengthen commercial alignment between the two businesses as NJ Bio expands its GMP CDMO services and to give dedicated leadership focus to Aruka’s novel drug development pipeline.</span></p>
<p><span>Completion is expected by the end of September 2026, subject to definitive agreements, applicable approvals and customary closing conditions.</span></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/cohance-lifesciences-advances-its-adc-strategy/">Cohance Lifesciences advances its ADC strategy</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Novartis signs deal with Alteogen for drug delivery</title>
<link>https://edusehat.com/en/novartis-signs-deal-with-alteogen-for-drug-delivery</link>
<guid>https://edusehat.com/en/novartis-signs-deal-with-alteogen-for-drug-delivery</guid>
<description><![CDATA[ The deal allows Novartis to exercise multiple options for exclusive global rights to develop subcutaneous versions of several of its products employing the berahyaluronidase alfa enzyme, also known 
The post Novartis signs deal with Alteogen for drug delivery appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/09/PT-03-09-2026-shutterstock_2214180715.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 03 Sep 2026 17:20:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Novartis, signs, deal, with, Alteogen, for, drug, delivery</media:keywords>
<content:encoded><![CDATA[<p>The deal allows Novartis to exercise multiple options for exclusive global rights to develop subcutaneous versions of several of its products employing the berahyaluronidase alfa enzyme, also known as ALT-B4.</p>
<p>ALT-B4 is a proprietary recombinant human hyaluronidase developed via the Hybrozyme platform, designed to convert biologic drugs from intravenous to subcutaneous administration.</p>
<p>The enzyme works by temporarily breaking down hyaluronan in the extracellular matrix, enabling faster and more efficient absorption of co-administered therapies when administered subcutaneously.</p>
<p>Under the terms outlined by Alteogen, the agreement includes option exercise fees, development and commercial milestone payments, and royalties on net sales of any products commercialised with the ALT-B4 technology.</p>
<p>Alteogen indicated that the total potential value of the agreement, should all options be exercised and milestones met, would reach up to $3.22bn.</p>
<p>Alteogen CEO Tae-Yon Chun said: “Novartis is a world-leading pharmaceutical company at the forefront of the global healthcare industry and has evaluated the application of ALT-B4 across multiple modalities for subcutaneous formulation development.</p>
<p>“This agreement demonstrates the technological strength and commercial value of Alteogen’s Hybrozyme platform.”</p>
<p>The licence represents the fourth such agreement signed by Alteogen in 2024 related to its Hybrozyme platform, which supports the transition of intravenous drugs to subcutaneous formats.</p>
<p>Alteogen focuses on the development of new biologics, including antibody-drug conjugates and biosimilars, as well as proprietary enzymes developed using its platform technologies.</p>
<p>In July, Novartis entered a collaboration with Chai Discovery to advance the use of AI in the identification of therapeutic antibodies.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/novartis-3bn-agreement-alteogen-drug-delivery/">Novartis signs deal with Alteogen for drug delivery</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Biocytogen and Qilu Pharmaceutical sign agreement for VHH antibody molecule</title>
<link>https://edusehat.com/en/biocytogen-and-qilu-pharmaceutical-sign-agreement-for-vhh-antibody-molecule</link>
<guid>https://edusehat.com/en/biocytogen-and-qilu-pharmaceutical-sign-agreement-for-vhh-antibody-molecule</guid>
<description><![CDATA[ The contract allows Qilu Pharmaceutical to use the antibody, which was developed through Biocytogen’s RenNano platform, in its research and development (R&amp;D) activities focused on neuroscience therapeutics. It 
The post Biocytogen and Qilu Pharmaceutical sign agreement for VHH antibody molecule appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/09/PT-2-03-09-2026-shutterstock_2205585127.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 03 Sep 2026 17:20:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Biocytogen, and, Qilu, Pharmaceutical, sign, agreement, for, VHH, antibody, molecule</media:keywords>
<content:encoded><![CDATA[<p>The contract allows Qilu Pharmaceutical to use the antibody, which was developed through Biocytogen’s RenNano platform, in its research and development (R&D) activities focused on neuroscience therapeutics.</p>
<p>It includes an upfront payment to Biocytogen, as well as eligibility for milestone payments linked to certain development, regulatory, and commercial objectives. No further financial details were disclosed.</p>
<p>The licensed VHH antibody molecule originates from RenNano, Biocytogen’s technology designed to identify fully human VHH antibodies with specific binding characteristics and the capacity for subsequent drug development.</p>
<p>The platform can be used to develop VHH antibodies, bispecific or multispecific antibodies, antibody–drug conjugates, and other research modalities.</p>
<p>Qilu Pharmaceutical may progress research using the antibody in line with its development strategy, selecting the appropriate modality based on project requirements and therapeutic objectives.</p>
<p>Biocytogen president and CEO Dr Yuelei Shen said: “We are pleased to enter this collaboration with Qilu Pharmaceutical.</p>
<p>“Drug development in the neuroscience field involves high scientific and translational barriers and requires systematic consideration of target biology, molecular quality, and downstream development strategy.</p>
<p>“With their distinctive molecular features, VHH antibodies provide new possibilities for drug design in complex disease areas. Qilu Pharmaceutical has built strong capabilities in innovative drug R&D and industrialisation.</p>
<p>“We look forward to seeing this fully human VHH antibody molecule align with Qilu Pharmaceutical’s R&D system and support its exploration of innovative programmes with development potential, further expanding therapeutic opportunities in the neuroscience field.”</p>
<p>Qilu Pharmaceutical continues to invest in chemical drugs, biologics, and therapeutic innovation, with operations spanning early discovery, development, manufacturing, and commercialisation.</p>
<p>The collaboration with Biocytogen underscores RenNano’s potential in neuroscience drug research and could expand the use of Biocytogen’s VHH antibody assets in other therapeutic areas.</p>
<p>Biocytogen’s platforms focus on antibody discovery, preclinical research, and related services. The company currently has more than 455 agreements worldwide.</p>
<p>In April 2026, Biocytogen entered a strategic partnership with Sihuan Pharmaceutical to advance new therapeutics across several disease areas, including weight loss.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/biocytogen-qilu-pharmaceutical-vhh-antibody-molecule/">Biocytogen and Qilu Pharmaceutical sign agreement for VHH antibody molecule</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Redefining clinical research: how AI and digital innovation are putting patients at the center</title>
<link>https://edusehat.com/en/redefining-clinical-research-how-ai-and-digital-innovation-are-putting-patients-at-the-center</link>
<guid>https://edusehat.com/en/redefining-clinical-research-how-ai-and-digital-innovation-are-putting-patients-at-the-center</guid>
<description><![CDATA[ 
As per a recent research, around 80 percent of clinical trials fail to meet their original enrollment timelines. Such delays are not only significantly expensive, but they also often extend […]
The post Redefining clinical research: how AI and digital innovation are putting patients at the center appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/03121747/EP_Subhro-Malik.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 03 Sep 2026 17:20:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Redefining, clinical, research:, how, and, digital, innovation, are, putting, patients, the, center</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/03121747/EP_Subhro-Malik.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/03121747/EP_Subhro-Malik.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/03121747/EP_Subhro-Malik-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>As per a recent research, around 80 percent of clinical trials fail to meet their original enrollment timelines. Such delays are not only significantly expensive, but they also often extend the wait for patients in urgent need of life-changing treatments. Despite substantial funding and meticulous planning across the pharmaceutical sector, clinical trial delays are widespread.</span></p>
<p><span>In addition, clinical development already accounts for one of the largest components of the total cost involved in the development of a new drug. Bringing a single new molecular entity to approval now typically costs between $2 billion and $2.6 billion, once capital costs and the rate of clinical failures are factored in across a development lifecycle that can span 10 to 15 years. </span></p>
<p><span>The cost of clinical trial failures extends beyond just the balance sheet. Stalled trials mean delayed treatments, leaving vulnerable patients in limbo as health and quality of life hang in the balance. </span></p>
<p><b>Smarter trials by design</b></p>
<p><span>AI and advanced analytics are making a mark in improving trial design upstream, even before any patient is recruited into the trial, with a shift from intuition-led to data-led trial design. </span></p>
<p><span>McKinsey estimates suggest that in pharma, around 75 to 85 percent of workflows have at least some tasks that agents could handle, which could help free up 25 to 40 percent of capacity. </span></p>
<p><span>Identifying optimal patient populations is one of the toughest parts of planning a clinical trial. The process is simplified with predictive modeling by analyzing data from thousands of past trials and patient databases. Protocol optimization is used to cut through the complexity of trials, and clinical trial simulation tools often help anticipate points where trials could break or fail.</span></p>
<p><b>Reaching more patients, faster</b></p>
<p><span>Clinical trial models typically depended on patients who lived near major research centers and could make frequent visits to the hospital. This meant that trial populations were mainly from urban areas staying close to well-resourced hospitals, thus often excluding people who lived in rural areas and had mobility constraints. This resulted in an imbalance in the diversity of the population taking part in clinical trials. Decentralized trials are helping with correcting that imbalance by opening up trials even to those who live in remote areas.</span></p>
<p><span>Telemedicine, electronic consent, remote monitoring, and wearables increasingly make real-time data capture possible, closing much of the gap that once required on-site monitoring. This has led to trials that are more flexible, patient-centric, and diverse.</span></p>
<p><b>Monitoring and compliance in real time</b></p>
<p><span>Before clinical trials went digital, a monitor had to physically travel to each trial location to verify paper records, confirm data accuracy, and catch protocol violations, if any. Earlier, errors or deviations could compound for few weeks before they were noticed. AI-based monitoring has virtually almost eliminated this delay.</span></p>
<p><span>AI monitoring tools reduce dependence on periodic site visits and offer continuous, real-time insights. They enhance risk assessment in clinical trials. Such tools can help identify early warning signs of disease progression or adverse events, enabling proactive clinical management and reducing the probability of serious safety events. Traditional monitoring typically delivers 70 to 75 percent sensitivity for adverse event detection. On the other hand, AI-based digital biomarker systems deliver around 90 percent sensitivity with real-time alerts.</span></p>
<p><span>For regulators and sponsors, the usage of AI-based monitoring means faster and cleaner data, shorter review timelines, and a more transparent research process. Regulatory bodies are also increasingly receptive to these approaches, indicating that the regulatory environment is open to this shift.</span></p>
<p><span>As per a research by McKinsey, it is estimated that AI agents could give pharma companies incremental growth of 5-13 percentage points, with an EBITDA increase of 3.4 to 5.4 percentage points. The direction clinical trials are heading in, is fairly clear: shorter timelines, broader patient access, and data that regulators and sponsors can actually trust. Just buzzwords will not work anymore – this transformation will take real investment in better statistical methods and AI tools.</span></p>
<p>The post <a href="https://www.expresspharma.in/redefining-clinical-research-how-ai-and-digital-innovation-are-putting-patients-at-the-center/">Redefining clinical research: how AI and digital innovation are putting patients at the center</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Agilent launches new laboratory solutions to meet rising testing demands in Indian labs</title>
<link>https://edusehat.com/en/agilent-launches-new-laboratory-solutions-to-meet-rising-testing-demands-in-indian-labs</link>
<guid>https://edusehat.com/en/agilent-launches-new-laboratory-solutions-to-meet-rising-testing-demands-in-indian-labs</guid>
<description><![CDATA[ 
India’s pharmaceutical, food, environmental and industrial testing laboratories are under increasing pressure to process higher testing volumes while maintaining quality, compliance and operational efficiency. From safeguarding the quality of medicines […]
The post Agilent launches new laboratory solutions to meet rising testing demands in Indian labs appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/03133841/EP_Agilent-4.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 03 Sep 2026 17:20:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Agilent, launches, new, laboratory, solutions, meet, rising, testing, demands, Indian, labs</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/03133841/EP_Agilent-4.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/03133841/EP_Agilent-4.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/03133841/EP_Agilent-4-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p>India’s pharmaceutical, food, environmental and industrial testing laboratories are under increasing pressure to process higher testing volumes while maintaining quality, compliance and operational efficiency. From safeguarding the quality of medicines and food to supporting environmental monitoring and advanced manufacturing, laboratories are expected to deliver reliable results faster while meeting increasingly stringent quality and regulatory requirements.</p>
<p>To help laboratories meet these challenges, Agilent Technologies today announced the India launch of the Agilent 9500 Triple Quadrupole ICP-MS, the new 8890B and 8860B Gas Chromatography Systems with GC Assist, and OpenLab Sync, Agilent’s new Lab Execution System (LES) that brings guided digital workflows directly to the bench.</p>
<p>“India’s laboratories play a critical role in ensuring the quality of medicines, food, water and manufactured products that people rely on every day,” said Nandakumar Kalathil, Country General Manager, India, Agilent Technologies. “As testing requirements continue to grow across industries, laboratories are looking for ways to improve productivity without compromising quality. These new technologies are designed to make advanced capabilities easier to adopt while helping laboratories operate more efficiently and grow with confidence.”</p>
<p>Together, the solutions address three critical areas of laboratory operations: analytical performance, instrument productivity and workflow execution.</p>
<p>The Agilent 9500 Triple Quadrupole ICP-MS helps laboratories generate reliable results across complex sample matrices. Designed for applications ranging from pharmaceutical testing and food safety to environmental analysis and advanced materials research, the system simplifies elemental analysis through new technologies that reduce analytical interferences and streamline operation.</p>
<p>The new Agilent 8890B and 8860B Gas Chromatography Systems with GC Assist help laboratories keep instruments running efficiently through built-in monitoring, diagnostics and guided maintenance. By identifying potential issues earlier and simplifying routine upkeep, the systems help reduce downtime, improve productivity and support data quality.</p>
<p>OpenLab Sync digitizes laboratory procedures that are traditionally managed on paper, creating guided digital workflows that improve consistency, traceability and audit readiness. The solution helps laboratories standardize operations, reduce manual processes and address workforce and training challenges.</p>
<p>The products were unveiled today at a customer event in Mumbai that brought together scientists, laboratory leaders and quality professionals from the pharmaceutical, food, environmental, chemicals and research sectors. Mike Zhang, President, Applied Markets Group, Agilent Technologies, and Bharat Bhardwaj, Vice President and General Manager, Asia Pacific, Agilent Technologies, joined customers and industry stakeholders to discuss evolving laboratory needs, workforce trends, and opportunities to make advanced analytical capabilities more accessible to a broader range of users.</p>
<p>“Innovation has the greatest impact when it makes life simpler,” said Bharat Bhardwaj, Vice President and General Manager, Asia Pacific, Agilent Technologies. “The pace of science continues to accelerate, and customers want solutions that help them spend less time managing complexity and more time focusing on scientific discovery. Our goal is to help laboratories unlock the full value of their technology investments so they can focus on delivering meaningful scientific outcomes.”</p>
<p>The new products are now available across India. As part of its ongoing efforts to make support and expertise more accessible, Agilent has also introduced WhatsApp for Business in India, providing customers with an additional channel to connect with Agilent for information, service and support.</p>
<p>The post <a href="https://www.expresspharma.in/agilent-launches-new-laboratory-solutions-to-meet-rising-testing-demands-in-indian-labs/">Agilent launches new laboratory solutions to meet rising testing demands in Indian labs</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>ABB’s Machine Automation division (B&amp;amp;R) appoints Christian  Strahberger as Division President </title>
<link>https://edusehat.com/en/abbs-machine-automation-division-br-appoints-christian-strahberger-as-division-president</link>
<guid>https://edusehat.com/en/abbs-machine-automation-division-br-appoints-christian-strahberger-as-division-president</guid>
<description><![CDATA[ 
ABB’s Machine Automation Division (B&amp;R) today announced the appointment of Christian Strahberger  as its new Division President. Christian Strahberger succeeds Florian Schneeberger, who tragically  passed away in an accident in […]
The post ABB’s Machine Automation division (B&amp;R) appoints Christian  Strahberger as Division President  appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/03144955/EP_GB_Christian_Strahberger_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 03 Sep 2026 17:20:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>ABB’s, Machine, Automation, division, B&amp;R, appoints, Christian , Strahberger, Division, President </media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/03144955/EP_GB_Christian_Strahberger_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/03144955/EP_GB_Christian_Strahberger_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/03144955/EP_GB_Christian_Strahberger_750-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>ABB’s Machine Automation Division (B&R) today announced the appointment of Christian Strahberger  as its new Division President. Christian Strahberger succeeds Florian Schneeberger, who tragically  passed away in an accident in April. </span></p>
<p><span>Christian Strahberger brings 25 years of experience in senior leadership roles with full profit and loss  responsibility across the mechanical engineering, drive technology, motion control, and power electronics sectors. He joins the Austrian automation specialist from Danfoss, where he held a variety of  international leadership positions, most recently serving as Chief Technology Officer and Head of  Semiconductor Manufacturing at Semikron Danfoss. Prior to his time at Danfoss, Christian  Strahberger spent 14 years in senior technology and business leadership roles at Singulus Technologies, Schottel, and Voith. </span></p>
<p><span>“I am very excited about this new challenge at ABB and the opportunity to actively shape the next era  of the Machine Automation Division. My focus is on driving innovation with purpose and successfully  translating future technologies into market-relevant solutions. Together with our teams, I want to  help ensure that B&R continues to enable sustainable competitive advantages for our customers as a  trusted partner in a dynamic market environment,” says Christian Strahberger. </span></p>
<p><span>In his new role as Division President, Christian Strahberger will focus on driving innovation that helps  customers increase their productivity and competitiveness while enabling them to operate more sustainably. </span></p>
<p><span>Christian Strahberger holds a PhD in Semiconductor Physics from the Technical University of Munich.  His professional career combines scientific excellence with many years of international leadership experience in technology-driven industrial companies, underscoring his commitment to leveraging innovation as a key driver of sustainable growth.</span></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/abbs-machine-automation-division-br-appoints-christian-strahberger-as-division-president/">ABB’s Machine Automation division (B&R) appoints Christian  Strahberger as Division President </a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>RPG Active Pharma acquires API business of Raghava Life Sciences to strengthen its integrated API play</title>
<link>https://edusehat.com/en/rpg-active-pharma-acquires-api-business-of-raghava-life-sciences-to-strengthen-its-integrated-api-play</link>
<guid>https://edusehat.com/en/rpg-active-pharma-acquires-api-business-of-raghava-life-sciences-to-strengthen-its-integrated-api-play</guid>
<description><![CDATA[ 
RPG Life Sciences announced that its wholly owned subsidiary, RPG Active Pharma (RPGAP), has entered into a Business Transfer Agreement to acquire the Active Pharmaceutical Ingredients (API) and Intermediates business […]
The post RPG Active Pharma acquires API business of Raghava Life Sciences to strengthen its integrated API play appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/08/06144031/Acquisition.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 03 Sep 2026 13:45:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>RPG, Active, Pharma, acquires, API, business, Raghava, Life, Sciences, strengthen, its, integrated, API, play</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/08/06144031/Acquisition.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/08/06144031/Acquisition.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/08/06144031/Acquisition-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>RPG Life Sciences announced that its wholly owned subsidiary, RPG Active Pharma (RPGAP), has entered into a Business Transfer Agreement to acquire the Active Pharmaceutical Ingredients (API) and Intermediates business undertaking of Raghava Life Sciences on a going-concern basis through a slump sale. The transaction is subject to customary closing conditions and regulatory approvals. </span></p>
<p><span>The acquisition is the next step in RPGAP’s consolidation play based on a well-planned buy-and-build strategy to bolster organic growth and create an integrated, scaled API focused organisation. Following the recent acquisition of Actis Generics, this transaction broadens RPGAP’s manufacturing base, product portfolio, regulatory capabilities and customer access across geographies. The consolidated organisation is intended to strengthen RPGAP’s participation in the growing API market through greater scale, synergies, deeper integration and focused commercial execution. </span></p>
<p><strong>A high quality asset with significant value-unlock potential </strong></p>
<p><span>Raghava operates a modem API manufacturing facility near Hyderabad, spread across approximately 9 acres, with around 300 KL of installed capacity and a dedicated R&D set-up. The facility is WHO-GMP and EU-GMP approved with significant investment towards capacity expansion in recent years. Its established regulatory approvals, meaningful installed capacity and chemistry capabilities provide RPGAP with a high-quality manufacturing presence. </span></p>
<p><span>The business has developed a portfolio of high-growth APIs, comprising 22 commercialised products and 7 development-stage assets across diabetes, cardiovascular, CNS and other therapeutic segments. The portfolio includes commercially attractive molecules and is supported by multiple international regulatory credentials including CEP, EU Written Confirmation and KDMF approvals. This broad basket of commercialised and pipeline APls gives RPGAP access to therapy areas benefiting from strong market tailwinds. </span></p>
<p><span>RPGAP expects to unlock value through defined synergies across this acquisition, Actis and the wider RPGAP network, including backward integration, improved capacity utilisation, cost synergies and selected product transfers. Stronger business development, wider market access, deeper customer coverage and disciplined portfolio execution are poised to improve cost competitiveness, accelerate portfolio scale-up and enhance operating leverage over time. </span></p>
<p><span>The acquisition will be funded in line with the recent equity raise announced by RPGAP. </span></p>
<p><span>Commenting on the acquisition, Ashok Nair, Managing Director, RPG Life Sciences said, “This acquisWon marks an important addition to the RPG Active Pharma Limited consolidated organisation. It brings together a high-quality manufacturing asset, a broad portfolio of commercialised AP/s, established regulatory credentials and strong customer relationships. Following Actis, it further strengthens the scale and capabilities of RPGAP and advances our strategy of building an integrated and competitive scaled API business. </span></p>
<p><span>The real opportunity lies in unlocking the potential of the asset through stronger commercialisation, improved capacity utilisation and integration across the organisation. By combining these manufacturing and product capabilities with Actis’ intermediate strengths and RPGAP’s governance, talent and market access, we intend to build a larger presence and capture a greater share of the growing API market.” </span></p>
<p><span>Commenting on the acquisition, Lohith Ponguleti, Managing Director, Raghava Life Sciences said, “We are pleased to see Raghava Life Sciences embark on its next phase of growth as part of RPG. Over the years, we have built a differentiated business anchored by an EU-GMP approved manufacturing facility, strong technical capabilities and a portfolio with significant growth potential. We believe RPG is well positioned to build on this foundation, accelerate expansion across domestic and international markets, and unlock the next stage of value creation for the business.” </span></p>
<p><span>Quillan Partners acted as the legal advisors, o3 Capital acted as the financial advisors and Deloitte acted as the Financial Due Diligence partner to RPG Active Pharma. </span></p>
<p>The post <a href="https://www.expresspharma.in/rpg-active-pharma-acquires-api-business-of-raghava-life-sciences-to-strengthen-its-integrated-api-play/">RPG Active Pharma acquires API business of Raghava Life Sciences to strengthen its integrated API play</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Takeda and Weave Bio collaborate on AI&#45;driven automation in drug development</title>
<link>https://edusehat.com/en/takeda-and-weave-bio-collaborate-on-ai-driven-automation-in-drug-development</link>
<guid>https://edusehat.com/en/takeda-and-weave-bio-collaborate-on-ai-driven-automation-in-drug-development</guid>
<description><![CDATA[ The partnership aims to integrate Weave Bio’s AI tools with Takeda’s regulatory experience to streamline workflows within the regulatory process. The joint effort began with the use of 
The post Takeda and Weave Bio collaborate on AI-driven automation in drug development appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/09/PT-02-09-2026-shutterstock_1884612916.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 02 Sep 2026 19:45:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Takeda, and, Weave, Bio, collaborate, AI-driven, automation, drug, development</media:keywords>
<content:encoded><![CDATA[<p>The partnership aims to integrate Weave Bio’s AI tools with Takeda’s regulatory experience to streamline workflows within the regulatory process.</p>
<p>The joint effort began with the use of AI to assist investigational new drug (IND) submission preparation and has since expanded to cover health authority question (HAQ) and response to question (RTQ) processes.</p>
<p>A research paper co-authored by scientists from Takeda and Weave Bio that documented the IND phase data revealed a 97% reduction in the time required to draft an initial submission in the evaluated use case, from roughly 100 hours to three.</p>
<p>The deployment of HAQ and RTQ processes has recorded more than 100 questions without any extraction errors in the assessed dataset and achieved an average AI answer quality score of 68%, surpassing the goal of 50%-70%.</p>
<p>Takeda chief regulatory officer and global regulatory affairs head Nahid Latif said: “Takeda is working to become a leader in the responsible application of AI across every area of R&D, helping our teams work more effectively and accelerate the delivery of innovative medicines to patients.</p>
<p>“Our collaboration with Weave is an important example of this ambition in action, enabling us to implement AI-driven regulatory workflows while ensuring that regulatory professionals retain responsibility for content, verification and final decision-making.”</p>
<p>This collaboration comes as global regulatory agencies clarify their stances on the use of AI in drug development, focusing on areas such as safety, validation, and human oversight.</p>
<p>In January 2025, the US Food and Drug Administration (FDA) published draft guidance on using AI in regulatory decision-making, with joint guiding principles from the FDA and European Medicines Agency issued in January 2026.</p>
<p>Both Takeda and Weave Bio state that their approach supports these regulatory expectations.</p>
<p>Last month, Takeda received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for Orzeyful (oveporexton) to treat narcolepsy type 1 in adults.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/takeda-weave-bio-ai-driven-drug-development/">Takeda and Weave Bio collaborate on AI-driven automation in drug development</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Ono Pharmaceutical joins forces with Aitia for drug discovery in neurology</title>
<link>https://edusehat.com/en/ono-pharmaceutical-joins-forces-with-aitia-for-drug-discovery-in-neurology</link>
<guid>https://edusehat.com/en/ono-pharmaceutical-joins-forces-with-aitia-for-drug-discovery-in-neurology</guid>
<description><![CDATA[ The agreement will see Aitia apply its REFS technology to build Gemini Digital Twins (GDTs) of neurological conditions to identify potential new therapeutic targets and biomarkers. Ono Pharmaceutical 
The post Ono Pharmaceutical joins forces with Aitia for drug discovery in neurology appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/09/PT-2-02-09-2026-shutterstock_2459345331.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 02 Sep 2026 19:45:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Ono, Pharmaceutical, joins, forces, with, Aitia, for, drug, discovery, neurology</media:keywords>
<content:encoded><![CDATA[<p>The agreement will see Aitia apply its REFS technology to build Gemini Digital Twins (GDTs) of neurological conditions to identify potential new therapeutic targets and biomarkers.</p>
<p>Ono Pharmaceutical will secure exclusive global rights to research, develop, and commercialise drug candidates for targets identified through this approach.</p>
<p>Aitia’s REFS technology employs causal AI to create virtual patient models, known as GDTs.</p>
<p>These twins aim to mirror the disease characteristics of actual patients, enabling the identification of causal relationships that conventional correlation-based AI cannot achieve.</p>
<p>The technology could be particularly valuable in neurology, where disease mechanisms involve complex genetic, developmental, neural network, immune, and environmental factors.</p>
<p>Under the arrangement, Aitia will use its platform to analyse clinical and omics data and construct digital models to predict new therapeutic targets.</p>
<p>Ono discovery and research corporate officer and executive vice-president Seishi Katsumata said: “Ono has long been committed to creating innovative medicines for diseases with high unmet medical needs, including neurological diseases.</p>
<p>“Through this collaboration, we are delighted to leverage cutting-edge REFS technology to identify true therapeutic targets in neurological diseases, where disease mechanisms are complex and not yet fully understood.</p>
<p>“We believe this will accelerate the development of innovative medicines. We will continue to expand our R&D pipeline in the neurology field and strive to deliver new treatments to patients.”</p>
<p>Last month, Mediar Therapeutics announced a collaboration and option agreement with Ono Pharmaceutical to develop new treatments for fibro-inflammatory diseases.</p>
<p>Ono agreed to work with Mediar to utilise its fibrosis-focused discovery platform, expertise in myofibroblast development, and knowledge of fibrosis pathways.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/ono-pharmaceutical-aitia-drug-discovery-neurology/">Ono Pharmaceutical joins forces with Aitia for drug discovery in neurology</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Gland Pharma’s Visakhapatnam facilities clear USFDA inspection with zero observations</title>
<link>https://edusehat.com/en/gland-pharmas-visakhapatnam-facilities-clear-usfda-inspection-with-zero-observations</link>
<guid>https://edusehat.com/en/gland-pharmas-visakhapatnam-facilities-clear-usfda-inspection-with-zero-observations</guid>
<description><![CDATA[ 
The inspection was conducted from August 24 to September 1, 2026
The post Gland Pharma’s Visakhapatnam facilities clear USFDA inspection with zero observations appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2022/12/29111129/inspection-impurities.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 02 Sep 2026 19:45:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Gland, Pharma’s, Visakhapatnam, facilities, clear, USFDA, inspection, with, zero, observations</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2022/12/29111129/inspection-impurities.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2022/12/29111129/inspection-impurities.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2022/12/29111129/inspection-impurities-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p data-start="91" data-end="341"><span class="contents" data-content-reference-start="91" data-content-reference-end="158"><span class="hover:entity-accent entity-underline inline cursor-pointer align-baseline"><span class="whitespace-normal">Gland Pharma</span></span></span> has announced the conclusion of a routine US Food and Drug Administration (USFDA) Good Manufacturing Practice (GMP) inspection at its VSEZ sterile oncology formulations facility and API facility in Visakhapatnam.</p>
<p data-start="343" data-end="504">The inspection was conducted from August 24 to September 1, 2026, and concluded with zero Form 483 observations, the company said in a regulatory filing.</p>
<p data-start="506" data-end="838" data-is-last-node="" data-is-only-node="">Gland Pharma said the inspection covered its sterile oncology formulations and API facilities at the VSEZ site.</p>
<p data-start="506" data-end="838" data-is-last-node="" data-is-only-node="">
</p><p>The post <a href="https://www.expresspharma.in/gland-pharmas-visakhapatnam-facilities-clear-usfda-inspection-with-zero-observations/">Gland Pharma’s Visakhapatnam facilities clear USFDA inspection with zero observations</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The double burden of tighter enforcement, slower implementation</title>
<link>https://edusehat.com/en/the-double-burden-of-tighter-enforcement-slower-implementation</link>
<guid>https://edusehat.com/en/the-double-burden-of-tighter-enforcement-slower-implementation</guid>
<description><![CDATA[ 
India’s pharma MSMEs are facing a tough transition to revised GMP norms, hampered by slow implementation of the very schemes that were intended to help them upgrade. This highlights gaps between policy intent and implementation, and the subsequent drag on compliance levels
The post The double burden of tighter enforcement, slower implementation appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/02150353/EP_EditorsNote_Sept_2026_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 02 Sep 2026 19:45:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, double, burden, tighter, enforcement, slower, implementation</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/02150353/EP_EditorsNote_Sept_2026_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/02150353/EP_EditorsNote_Sept_2026_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/02150353/EP_EditorsNote_Sept_2026_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p align="JUSTIFY">While the Central Drugs Standard Control Organisation (CDSCO) is cracking down on erring industry actors, policy makers are pulling up government departments for slow implementation of schemes.</p>
<p align="JUSTIFY">Thus India’s pharma industry, at least the MSME sector, is facing a tough transition to revised GMP norms, hampered by slow implementation of the very schemes that were intended to help them upgrade. This highlights gaps between policy intent and implementation, and the subsequent drag on compliance levels.</p>
<p align="JUSTIFY">The Parliamentary Standing Committee on Chemicals and Fertilisers’ 34th Report presented in early August, pointed out that funds set aside under the Revamped Pharmaceutical Technology Upgradation Assistance Scheme (RPTUAS) for technological upgradation of eligible micro, small and medium pharma enterprises (MSMEs) was underutilised.</p>
<p align="JUSTIFY">The report noted that even though almost the full allocation of Rs. 300.10 crore was approved, implementation was lagging.</p>
<p align="JUSTIFY">In its reply, the DoP submitted that under the Scheme, 301 applications of pharma units for incentives aggregating to approximately Rs. 300.48 crore were approved, which is nearly equivalent to the total outlay of the sub-scheme, as on March 31, 2026.</p>
<p align="JUSTIFY">Of the 301 approved applicants, claims of 64 pharma units amounting to Rs. 45.80 crore were approved, which is just over 20 per cent of the approved applicants. Of this, Rs. 41.70 crore has already been disbursed for 55 pharma units during FY 2025–26.</p>
<p align="JUSTIFY">The DoP’s reply stated that the remaining 237 approved pharma units are at various stages, including claims under process, projects completed but yet to submit certificates and projects under implementation.</p>
<p align="JUSTIFY">Given this delay of units going from approval to implementation, the Parliamentary Committee has recommended that the DoP should put in place urgent facilitation mechanisms and hand holding measures.</p>
<p align="JUSTIFY">The RPTUAS was set up to help drug manufacturing units, specifically MSMEs, upgrade their facilities to meet Revised Schedule-M and WHO-GMP standards. Therefore delayed funds disbursement and implementation means that this segment of the sector will have patchy compliance until the upgradation.</p>
<p align="JUSTIFY">The DoP’s submission is that the upgradation process in MSME pharma units, especially smaller units, tended to take longer as it disrupted normal operations.</p>
<p align="JUSTIFY">It is but natural that smaller facilities tend to undertake upgrades in a phased manner over a period of time, while mid-sized firms can upgrade faster as they might have alternate facilities, so that production (and by that extension, revenue streams) are not completely disrupted or at a standstill.</p>
<p align="JUSTIFY">The same report has also asked the DoP for an update on the bulk drug park promotion scheme, under which three bulk drug parks, (in Gujarat, Himachal Pradesh and Andhra Pradesh), were approved, with a grant-in-aid of `1000 crore to each park. Here too implementation is lagging. The panel has directed the DoP to submit a detailed status report on the ongoing progress of the three approved bulk drug parks and stressed tracking concrete measures taken to resolve ground-level execution hurdles and deadline slippages.</p>
<p align="JUSTIFY">The Indian Pharmacopoeia Commission (IPC) is also reportedly setting up manufacturing guidelines for semaglutide, given the number of Indian pharma companies releasing generic copies of this complex molecule.</p>
<p align="JUSTIFY">The fact that Dr Reddy’s Laboratories, one of India’s well respected pharma companies, stumbled on the generic semaglutide front is probably what triggered this inclusion in the forthcoming Indian Pharmacopoeia (IP) Addendum 2028.</p>
<p align="JUSTIFY">DRL reportedly had to recall and pause commercial supplies of some batches of its generic semaglutide as an out-of-specification impurity was detected in the active pharmaceutical ingredient (API) during the production scale-up process.</p>
<p align="JUSTIFY">While the CDSCO has given approval to certain Indian pharma companies to manufacture generic semaglutide for treating type 2 diabetes and managing weight, it has also specified that its use has to be linked to lifestyle changes and strictly under prescription.</p>
<p align="JUSTIFY">CDSCO has also cracked down on illegal online sales, improper prescriptions, deceptive marketing and weight-loss claims, and influencer promotions. The agency has also conducted inspections of locations ranging from pharmacy warehouses, wholesalers, retailers, and slimming clinics, to curb misuse of weight-loss drugs. <em>(<a href="https://www.expresspharma.in/midst-global-headwinds-cdsco-cracks-down-on-glp-1-gold-rush/">https://www.expresspharma.in/midst-global-headwinds-cdsco-cracks-down-on-glp-1-gold-rush/</a>)</em></p>
<p align="JUSTIFY">Besides cracking down on manufacturing standards, the CDSCO has also turned its gaze on the clinical research segment. In late July, the CDSCO cancelled the registration certificates of seven ethics committees across India, flagging major compliance failures and serious regulatory deficiencies. This is a serious signal to India’s clinical research sector that enforcement of the New Drugs and Clinical Trial (NDCT) Rules 2019 and the amendments that followed will be strict.</p>
<p align="JUSTIFY">While this is a tough transition period, it’s been long overdue. No doubt, there will be some smaller manufacturing units which will decide to call it a day, unable to muster up the funds, or the bandwidth and patience, to upgrade.</p>
<p align="JUSTIFY">This is a necessary clean up of the sector, if we aim to compete to global norms. But these hard learnings will ensure better quality medicines for all. And that is the bottom line.</p>
<p>The post <a href="https://www.expresspharma.in/the-double-burden-of-tighter-enforcement-slower-implementation/">The double burden of tighter enforcement, slower implementation</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Cipla signs exclusive licensing deal with SBP Group for HER2&#45;targeted ADC</title>
<link>https://edusehat.com/en/cipla-signs-exclusive-licensing-deal-with-sbp-group-for-her2-targeted-adc</link>
<guid>https://edusehat.com/en/cipla-signs-exclusive-licensing-deal-with-sbp-group-for-her2-targeted-adc</guid>
<description><![CDATA[ 
SBP Group subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ) has granted Cipla exclusive rights to develop and commercialise TQB2102 in India, South Africa and five other emerging markets
The post Cipla signs exclusive licensing deal with SBP Group for HER2-targeted ADC appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2019/09/11121123/agreement-e1724903886928.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 02 Sep 2026 16:10:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Cipla, signs, exclusive, licensing, deal, with, SBP, Group, for, HER2-targeted, ADC</media:keywords>
<content:encoded><![CDATA[<div><img width="749" height="397" src="https://cdn.expresspharma.in/wp-content/uploads/2019/09/11121123/agreement-e1724903886928.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2019/09/11121123/agreement-e1724903886928.jpg 749w, https://cdn.expresspharma.in/wp-content/uploads/2019/09/11121123/agreement-e1724903886928-300x159.jpg 300w" sizes="auto, (max-width: 749px) 100vw, 749px"></div><h3 class="western" align="JUSTIFY"><strong><span><span><span>Cipla and Sino Biopharmaceutical (SBP Group) recently announced an exclusive license and supply agreement for Rolditamig Deuderuxtecan, also known as TQB2102, a potential best-in-class HER2 bispecific antibody-drug conjugate (ADC).</span></span></span></strong></h3>
<p align="JUSTIFY"><span><span>Under the agreement, SBP Group subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ) has granted Cipla exclusive rights to develop and commercialise TQB2102 in India, South Africa and five other emerging markets.</span></span></p>
<p align="JUSTIFY"><span><span>Cipla will be responsible for local clinical development, regulatory activities and commercialisation in the licensed territories, while CTTQ will continue to manufacture and supply TQB2102.</span></span></p>
<p align="JUSTIFY"><span><span>TQB2102 is being evaluated across HER2-expressing cancers and has demonstrated encouraging clinical potential in HER2-low advanced breast cancer.</span></span></p>
<p align="JUSTIFY"><span><span>The collaboration brings together SBP Group’s late-stage oncology asset and development and manufacturing capabilities with Cipla’s established regulatory, medical, market access and commercial presence across India, South Africa and other emerging markets.</span></span></p>
<p align="JUSTIFY"><span><span>The companies said the partnership is intended to accelerate local development and regulatory approvals and enable patient access across the licensed countries, subject to applicable approvals.</span></span></p>
<p>The post <a href="https://www.expresspharma.in/cipla-signs-exclusive-licensing-deal-with-sbp-group-for-her2-targeted-adc/">Cipla signs exclusive licensing deal with SBP Group for HER2-targeted ADC</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The discipline for next 2&#45;3 years will be to keep growing the base responsibly, not chasing volume</title>
<link>https://edusehat.com/en/the-discipline-for-next-2-3-years-will-be-to-keep-growing-the-base-responsibly-not-chasing-volume</link>
<guid>https://edusehat.com/en/the-discipline-for-next-2-3-years-will-be-to-keep-growing-the-base-responsibly-not-chasing-volume</guid>
<description><![CDATA[ 
India’s cold-chain logistics sector is witnessing rapid growth, led by rising demand for temperature-sensitive pharmaceuticals, biologics and injectables. ColdStar Logistics is capitalising on this opportunity through specialised pharma logistics, technology-led operations and network expansion, targeting significant growth in Tier-II and Tier-III cities. Sameer Varma, Executive Director, shares the company’s strategy with Express Pharma.
The post The discipline for next 2-3 years will be to keep growing the base responsibly, not chasing volume appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/02140829/Sameer-Verma.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 02 Sep 2026 16:10:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, discipline, for, next, 2-3, years, will, keep, growing, the, base, responsibly, not, chasing, volume</media:keywords>
<content:encoded><![CDATA[<div><img width="700" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/02140829/Sameer-Verma.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/09/02140829/Sameer-Verma.jpg 700w, https://cdn.expresspharma.in/wp-content/uploads/2026/09/02140829/Sameer-Verma-300x171.jpg 300w" sizes="(max-width: 700px) 100vw, 700px"></div><p><span><b>What are ColdStar’s biggest growth priorities over the next two to three years?</b></span></p>
<p><span>There are two things, and I would put them in this order.</span></p>
<p><span>First, specialised pharmaceutical logistics – it is a small part of our revenue, but it is the vertical that has the highest requirement for capabilities and the highest headroom, and we are investing in it, not as a side product of food. Second, technology. Our in-house platform helps us keep infrastructure growth from outpacing planning and visibility. We have been growing 50-60 per cent YoY for the past few years and the discipline for the next two to three years will be to keep growing the base responsibly and not chasing volume.</span></p>
<p><span><b>How is ColdStar differentiating itself from other cold-chain logistics providers in India?</b></span></p>
<p><span>We don’t sell assets. We are not selling pallet space or truck space; we are selling the product in the right place and in the right condition. This is the opposite of the typical ordering. We design the customer’s supply chain first based on their consumption pattern, inventory policy and demand forecast., and then build the infrastructure to serve their supply chain, not the other way around. That’s not a distinction that can be made for a pharma customer. The question is not how many square feet we have in a city, it’s whether the product’s stability profile, the batch size it flows in and the service level that the customer has agreed to their channel has been designed into the network. The second differentiator is that Never Stock-Out isn’t a service tier that we sell. It’s the design constraint that the whole business is based on, the warehouse layout, training, technology, daily operating rhythm.</span></p>
<p><span><b>How has the pharma cold-chain landscape evolved in recent years, and what will be ColdStar’s key priorities going forward?</b></span></p>
<p><span>Demand side has grown faster than the supply side. The distribution chain below the pharma industry has remained fragmented and largely unvalidated outside metros, whereas the pharma output has shifted towards injectables and biologics, which cannot afford a broken chain. Customers are also far more demanding when it comes to the evidence. Five years ago, they wanted to know that the product had arrived, today they want to know the temperature history, the excursion history and the audit trail behind it. We are currently working on the development of passive packaging solutions are available in our national network. Healthcare accounts for approximately 5-8 per cent of our total business, and is highly specialised, such as bulk consolidation, multimodal transport and delivery to research centres and hospitals. Moving forward, it’s about depth, not volume. The pharma cold chain failures cost the industry in India is estimated to be in the range of Rs 7,000-10,000 crore per year, which is a precision problem and not a capacity problem.</span></p>
<p><span><b>How is ColdStar’s Zero Stock-Out strategy evolving, and what role will technology and data play in scaling it?</b></span></p>
<p><span>The principle remains the same. If a customer orders 100, we must deliver 100. In food and retail, a shortfall is a lost sale. In pharma, it is a patient who doesn’t take a dose that week, and so it takes a different weight. The way we’ve gotten there has changed. We have shifted from experience-based judgement to technology, which is based on operational data and business intelligence, not just dashboards, forecasting, inventory planning and ongoing optimisation based on actual consumption. Our definition of visibility has expanded, too. The ability to locate a truck is a basic requirement. The key is to know the location, condition and timing of each unit’s arrival so we and the customer can be in the right place between overstocking working capital and running out of stock.</span></p>
<p><span><b>What are the biggest challenges facing ColdStar today, and how are you addressing them?</b></span></p>
<p><span>Our challenges are industry-level issues that we’ve decided to base the business on. India requires an estimated 60-70 MT of cold storage capacity while it has an estimated 37 MT, of which only about 90 per cent is available in three states and the capacity is skewed towards single commodities. That’s the problem for pharma – once you get outside the metros, the concentration of treatment volumes is rapidly decreasing, and that’s where purpose-built, temperature-assured capacity is needed. We are doing this by standardisation, creating one network to one specification as opposed to a bunch of different facilities, and Tier-II and Tier-III expansion to disperse it geographically. The other constraint is people. Quick commerce and D2C growth have reduced margins all along the line and increased attrition and cold chain execution is as good as the person on the dock. We have invested in training and made logistics work a skilled job and we have expanded our workforce from 427 in FY22 to more than 3100 in FY25 and improved retention.</span></p>
<p><span><b>What is ColdStar’s process for managing damaged, rejected, or temperature-compromised products across the cold chain?</b></span></p>
<p><span>Quality control is not a one-stop process, it is managed by a clearly defined SOP and our teams huddle each day on it. The answer to this question will depend on what it is we are dealing with. At inward, the temperature abused cargo is escalated to the customer and rejected. Rejected cargo is not inward at all – whatever the reason, it returns from the dock and not to our facilities. If the material is damaged it is flagged, quarantined and, after escalation and written customer sign-off, disposed of in accordance with the appropriate norms for the type of material. If a deviation is found on pharmaceutical consignment, the material is held and physically segregated and the logger data and deviation record are added to the customer’s quality function. The decision on disposition of a drug product is based on the stability data provided by the marketing authorisation holder, and we carry out their written instructions, with documentation held at each stage.</span></p>
<p><span><b>What will be your five-year growth outlook, and which segments or markets do you see offering the greatest opportunities?</b></span></p>
<p><span>Healthcare currently accounts for 5-8 per cent of our business and it is also the most underpenetrated and specialised segment in the pharma cold chain in India as the capability bar is quite high and the field is getting thinner. Today, food and retail are not only close to equally large, but both will continue to grow, but they are not where the capability frontier is at. Geography, especially Tier-II and Tier-III markets, are the best opportunity for us to take metro-standard services into cities that have not been served by anyone to a specification, only by whoever had a cold room. The nature of pharma demand is changing and favouring us, as we’re seeing an increasing trend of merchandise going into hospitals, research centres and directly to patients and it’s a different logistics problem than replenishment.</span></p>
<p><span><b>As you expand, which cities or regions in India do you see as potential locations for new bases, facilities, or distribution hubs?</b></span></p>
<p><span>We have recently added Patna, Guwahati and Lucknow, taking us to 45 distribution centres nationally and strengthening our position in India’s fastest-growing Tier-II markets. We have also opened our largest standalone facility to date in Bengaluru, a 1,75,000 sq ft site at Hoskote with daily processing capacity of 3,00,000 units, to serve rising urban demand in the South. The broader logic is that our next wave follows consumption growth into Tier-II and Tier-III cities across the East, North and South rather than deepening in metros that are already well served. For pharma specifically there is a second map layered on top of that one: manufacturing clusters and treatment centres do not sit in the same places as retail consumption, and a network that serves pharma properly has to answer to both.</span></p>
<p><span><span><span lang="zxx"><u>sanjivdas1@gmail.com</u></span></span></span><span><br>
</span><a href="mailto:sanjiv.das@expressindia.com" target="_blank" rel="noopener"><span><span>sanjiv.das@expressindia.com</span></span></a></p>
<p>The post <a href="https://www.expresspharma.in/the-discipline-for-next-2-3-years-will-be-to-keep-growing-the-base-responsibly-not-chasing-volume/">The discipline for next 2-3 years will be to keep growing the base responsibly, not chasing volume</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Andelyn Biosciences to scale manufacturing for Genprex’s Diabetes Gene Therapy Program</title>
<link>https://edusehat.com/en/andelyn-biosciences-to-scale-manufacturing-for-genprexs-diabetes-gene-therapy-program</link>
<guid>https://edusehat.com/en/andelyn-biosciences-to-scale-manufacturing-for-genprexs-diabetes-gene-therapy-program</guid>
<description><![CDATA[ 
The collaboration will support Genprex&#039;s AAV-based diabetes gene therapy candidate for IND-enabling preclinical studies and cGMP clinical manufacturing
The post Andelyn Biosciences to scale manufacturing for Genprex’s Diabetes Gene Therapy Program appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2019/08/14150934/Partnership-EH.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 02 Sep 2026 12:35:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Andelyn, Biosciences, scale, manufacturing, for, Genprex’s, Diabetes, Gene, Therapy, Program</media:keywords>
<content:encoded><![CDATA[<div><img width="888" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2019/08/14150934/Partnership-EH.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2019/08/14150934/Partnership-EH.jpg 888w, https://cdn.expresspharma.in/wp-content/uploads/2019/08/14150934/Partnership-EH-300x135.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2019/08/14150934/Partnership-EH-768x346.jpg 768w" sizes="(max-width: 888px) 100vw, 888px"></div><p><span><span><span>Andelyn Biosciences, a contract development and manufacturing organisation, announced that Genprex has selected Andelyn to support scale-up manufacturing for its diabetes gene therapy program.</span></span></span></p>
<p><span><span><span>Genprex’s diabetes gene therapy candidate is designed to deliver the Pdx1 and MafA genes directly to the pancreas via the pancreatic duct using an AAV vector. The program is being developed as a potential treatment for Type 1 and Type 2 diabetes.</span></span></span></p>
<p><span><span><span>Under the agreement, Andelyn will transition Genprex’s adeno-associated virus (AAV)-based diabetes gene therapy candidate with process optimisation, scale-up, and IND-enabling and clinical-stage manufacturing to support clinical trials.</span></span></span></p>
<p><span><span><span>The collaboration will draw on Andelyn’s Curator Cell and Gene Therapy Platform and experience in AAV process development, technology transfer, analytical development, and cGMP manufacturing. Manufacturing activities are expected to include process optimisation, scale-up, analytical qualification, potency assay development, and drug product manufacturing in a cGMP-compliant facility.</span></span></span></p>
<p><span><span><span>In Type 1 diabetes, Genprex’s candidate is designed to transform pancreatic alpha cells into functional beta-like cells capable of producing insulin. Genprex has reported preclinical findings in Type 1 diabetes mouse models showing restoration of normal blood glucose levels for an extended period, as well as findings in nonhuman primate models indicating reduced insulin requirements, increased C-peptide levels, and improved glucose tolerance.</span></span></span></p>
<p><span><span><span>For Type 2 diabetes, where autoimmunity is not a primary driver of disease, Genprex is evaluating whether its approach may help replenish and rejuvenate exhausted insulin-producing beta cells. The company has reported preclinical activity in both mouse and nonhuman primate models.</span></span></span></p>
<p><span><span><span>“Andelyn is pleased to support Genprex as it advances this important diabetes gene therapy program,” said Matt Niloff, CCO at Andelyn. “The transition from academic or research-grade manufacturing to a scalable cGMP process is a pivotal step in developing an advanced therapy. Our team will provide the technical, operational, and quality expertise needed to establish a robust manufacturing foundation for Genprex’s upcoming preclinical and clinical milestones.”</span></span></span></p>
<p><span><span><span>“Selecting Andelyn marks an important step in preparing our diabetes gene therapy program for IND-enabling studies and future clinical evaluation,” said Ryan Confer, President and Chief Executive Officer of Genprex. “Andelyn’s experience in AAV development and cGMP manufacturing will help us advance the manufacturing process as we work to move this program toward the clinic.”</span></span></span></p>
<p>The post <a href="https://www.expresspharma.in/andelyn-biosciences-to-scale-manufacturing-for-genprexs-diabetes-gene-therapy-program/">Andelyn Biosciences to scale manufacturing for Genprex’s Diabetes Gene Therapy Program</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Mankind Pharma sells Broadway Hospitality stake for Rs 49 crore</title>
<link>https://edusehat.com/en/mankind-pharma-sells-broadway-hospitality-stake-for-rs-49-crore</link>
<guid>https://edusehat.com/en/mankind-pharma-sells-broadway-hospitality-stake-for-rs-49-crore</guid>
<description><![CDATA[ 
In a regulatory filing, the company said the transaction was completed on August 31, 2026
The post Mankind Pharma sells Broadway Hospitality stake for Rs 49 crore appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2020/08/09133728/Deals-e1596960430891.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 01 Sep 2026 22:15:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Mankind, Pharma, sells, Broadway, Hospitality, stake, for, crore</media:keywords>
<content:encoded><![CDATA[<div><img width="889" height="483" src="https://cdn.expresspharma.in/wp-content/uploads/2020/08/09133728/Deals-e1596960430891.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async"></div><p class="isSelectedEnd">Mankind Pharma has completed the sale of its entire 100 per cent stake in Broadway Hospitality Services to AKRK Projects LLP and its partners for ₹49 crore.</p>
<p class="isSelectedEnd">In a regulatory filing, the company said the transaction was completed on August 31, 2026. Following the transfer, Broadway Hospitality Services has ceased to be a wholly owned subsidiary of Mankind Pharma with effect from the same date.</p>
<p class="isSelectedEnd">The company had first disclosed the proposed divestment in a filing dated July 11, 2026, stating that the total consideration for the transaction would be ₹49 crore, subject to closing adjustments.</p>
<p>The latest filing confirms the completion of the transaction and transfer of Mankind Pharma’s 100 per cent stake in Broadway Hospitality Services to AKRK Projects LLP and its partners.</p>
<p>The post <a href="https://www.expresspharma.in/mankind-pharma-sells-broadway-hospitality-stake-for-rs-49-crore/">Mankind Pharma sells Broadway Hospitality stake for Rs 49 crore</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>PharmaEssentia’s Besremi receives FDA approval for ET</title>
<link>https://edusehat.com/en/pharmaessentias-besremi-receives-fda-approval-for-et</link>
<guid>https://edusehat.com/en/pharmaessentias-besremi-receives-fda-approval-for-et</guid>
<description><![CDATA[ This marks the first FDA-approved treatment for ET in nearly 30 years. The approval is based on data from the global Phase III SURPASS ET trial, which demonstrated 
The post PharmaEssentia’s Besremi receives FDA approval for ET appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/09/PT-2-01-09-2026-shutterstock_1845586678.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 01 Sep 2026 18:35:25 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>PharmaEssentia’s, Besremi, receives, FDA, approval, for</media:keywords>
<content:encoded><![CDATA[<p>This marks the first FDA-approved treatment for ET in nearly 30 years.</p>
<p>The approval is based on data from the global Phase III SURPASS ET trial, which demonstrated durable modified European Leukaemia Net (ELN) responses and sustained haematologic control in this patient group.</p>
<p>Besremi may be prescribed for adults with ET regardless of genotype or disease status, including those newly diagnosed and those who have not previously received cytoreductive therapy.</p>
<p>The regulatory decision in the US expands Besremi’s existing indication, adding to its previous authorisation for adults with polycythaemia vera (PV).</p>
<p>ET is a rare, chronic blood cancer characterised by platelet overproduction, and patients face a risk of serious complications, including heart attacks, strokes, and pulmonary embolism.</p>
<p>Besremi is described as a long-acting, interferon-based therapy intended to provide sustained disease management, with a mechanism designed to target disease-driving cells in the bone marrow while reducing elevated platelet counts.</p>
<p>The Phase III SURPASS ET trial compared Besremi with anagrelide and found superior durable response rates and a drop in thromboembolic events over 12 months of treatment.</p>
<p>PharmaEssentia founder and CEO Ko-Chung Lin said: “Today’s FDA approval of Besremi for ET is a significant advancement for patients and reflects PharmaEssentia’s longstanding commitment to advancing innovative therapies for people living with myeloproliferative neoplasms.</p>
<p>“We have been working closely with the FDA, healthcare providers, advocacy organisations and payers to bring this important treatment option to the ET community.”</p>
<p>The US approval follows recent regulatory decisions in Japan and Taiwan for Besremi in ET.</p>
<p>Headquartered in Taiwan with operations in China, Japan, Korea, and the US, PharmaEssentia retains global intellectual property rights for Besremi, which holds orphan drug designation in the US for both PV and ET.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/pharmaessentias-besremi-fda-approval-et/">PharmaEssentia’s Besremi receives FDA approval for ET</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Kazia closes oversubscribed offering to fund paxalisib’s clinical development</title>
<link>https://edusehat.com/en/kazia-closes-oversubscribed-offering-to-fund-paxalisibs-clinical-development</link>
<guid>https://edusehat.com/en/kazia-closes-oversubscribed-offering-to-fund-paxalisibs-clinical-development</guid>
<description><![CDATA[ These proceeds will support the planned and ongoing studies of Kazia’s lead investigational therapy, paxalisib, in triple-negative breast cancer, hormone receptor positive/human epidermal growth factor receptor 2 negative 
The post Kazia closes oversubscribed offering to fund paxalisib’s clinical development appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/09/PT-01-09-2026-shutterstock_620440031.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 01 Sep 2026 18:35:25 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Kazia, closes, oversubscribed, offering, fund, paxalisib’s, clinical, development</media:keywords>
<content:encoded><![CDATA[<p>These proceeds will support the planned and ongoing studies of Kazia’s lead investigational therapy, paxalisib, in triple-negative breast cancer, hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) breast cancer, and proficient mismatch repair (pMMR) colorectal cancer.</p>
<p>Kazia also noted the funds may go toward working capital and general corporate purposes.</p>
<p>Paxalisib is being studied in various cancers and has received several regulatory designations from the US Food and Drug Administration (FDA), including orphan drug and fast track.</p>
<p>The offering generated $40m in upfront gross proceeds at closing. The oncology-focused company structured the offering in multiple tranches.</p>
<p>It comprised 2,580,000 American Depositary Shares (ADSs), each representing 500 ordinary shares, or pre-funded warrants in place of ADSs.</p>
<p>The package included Series A Warrants exercisable at $17.825 per ADS, a 15% premium to the $15.50 offering price, tied to the company’s Stage IV triple-negative breast cancer data readout expected in the second half of 2027.</p>
<p>With a $19.375 per ADS exercise price, a 25% premium, Series B Warrants are connected to HR+/HER2- breast cancer data expected in the first half of 2028.</p>
<p>If both series of milestone-linked warrants are exercised in full, Kazia would receive an estimated additional $80m, for total potential gross proceeds of approximately $120m.</p>
<p>All securities in the offering were sold by Kazia, with institutional investors such as ADAR1 Capital Management, Columbia Threadneedle Investments, Lynx1 Capital Management, Marshall Wace, and Pointillist Family Office participating.</p>
<p>The combined public offering price was $15.50 per ADS with accompanying Series A and B Warrants, or $15.4999 for each pre-funded warrant plus the warrants.</p>
<p>The $40m raised is stated as gross proceeds, before underwriting discounts, commissions, and offering expenses are deducted.</p>
<p>Other development programmes at Kazia include EVT801, NDL2, and MSETC, with research underway across several solid tumour types.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/kazia-oversubscribed-offering-paxalisibs-development/">Kazia closes oversubscribed offering to fund paxalisib’s clinical development</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Eli Lilly to acquire Merida Biosciences for up to $2.875 billion</title>
<link>https://edusehat.com/en/eli-lilly-to-acquire-merida-biosciences-for-up-to-2875-billion</link>
<guid>https://edusehat.com/en/eli-lilly-to-acquire-merida-biosciences-for-up-to-2875-billion</guid>
<description><![CDATA[ 
Deal gives Lilly access to Merida’s precision technology targeting disease-causing antibodies
The post Eli Lilly to acquire Merida Biosciences for up to $2.875 billion appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2020/08/17145457/MA-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 01 Sep 2026 18:35:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Eli, Lilly, acquire, Merida, Biosciences, for, 2.875, billion</media:keywords>
<content:encoded><![CDATA[<div><img width="888" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2020/08/17145457/MA-1.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2020/08/17145457/MA-1.jpg 888w, https://cdn.expresspharma.in/wp-content/uploads/2020/08/17145457/MA-1-300x135.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2020/08/17145457/MA-1-768x346.jpg 768w" sizes="(max-width: 888px) 100vw, 888px"></div><p>Eli Lilly and Company has entered into a definitive agreement to acquire Merida Biosciences for up to $2.875 billion in cash, including an upfront payment and contingent milestone payments.</p>
<p>Merida is developing biologics designed to selectively degrade disease-causing autoantibodies. Its approach aims to target the underlying cause of immune-mediated diseases rather than broadly suppressing the immune system.</p>
<p>Merida’s lead programme, MER511, is in Phase 1 development for Graves’ disease and thyroid eye disease (TED). The drug is designed to target thyroid-stimulating antibodies that drive these conditions.</p>
<p>Initial Phase 1 data showed that MER511 achieved robust reductions in pathogenic thyroid-stimulating antibodies, with an initial safety profile described by the company as favourable.</p>
<p>Merida also has MER769, a preclinical programme targeting diseases driven by IgE, including food allergy, asthma and chronic spontaneous urticaria. The company has additional early-stage programmes for kidney diseases, including membranous nephropathy, and other immune-mediated conditions.</p>
<p>Lilly said Merida’s technology could potentially be applied across a wider range of antibody-driven diseases.</p>
<p>The transaction is subject to customary closing conditions, including regulatory approvals, and is expected to close in the fourth quarter of 2026.</p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/eli-lilly-to-acquire-merida-biosciences-for-up-to-2-875-billion/">Eli Lilly to acquire Merida Biosciences for up to $2.875 billion</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Express Pharma September 2026</title>
<link>https://edusehat.com/en/express-pharma-september-2026</link>
<guid>https://edusehat.com/en/express-pharma-september-2026</guid>
<description><![CDATA[ 
India&#039;s Foremost Pharma &amp; Biotech Magazine ~ India&#039;s Race For The CDMO Crown
The post Express Pharma September 2026 appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/09/01115010/EP-SEP-2026-MAG-COVER.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 01 Sep 2026 14:55:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Express, Pharma, September, 2026</media:keywords>
<content:encoded><![CDATA[<div><img width="200" height="264" src="https://cdn.expresspharma.in/wp-content/uploads/2026/09/01115010/EP-SEP-2026-MAG-COVER.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy"></div><p><em>India’s Race For The CDMO Crown</em><br>
</p><div class="_df_book df-lite" _slug="express-pharma-september-2026" data-title="express-pharma-september-2026" wpoptions="true" thumbtype=""></div>
<hr>
<p><strong>Click to download:</strong> <a href="https://cdn.expresspharma.in/wp-content/uploads/2026/09/01100939/EP_SEPTEMBER_2026.pdf" target="_blank" rel="noopener noreferrer">September 2026 Digital Magazine</a></p>
<p>The post <a href="https://www.expresspharma.in/express-pharma-september-2026/">Express Pharma September 2026</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Sun Pharma joins US drug pricing deal, gets tariff relief</title>
<link>https://edusehat.com/en/sun-pharma-joins-us-drug-pricing-deal-gets-tariff-relief</link>
<guid>https://edusehat.com/en/sun-pharma-joins-us-drug-pricing-deal-gets-tariff-relief</guid>
<description><![CDATA[ 
The company will offer MFN pricing to state Medicaid programmes and for future innovative medicines under the agreement with the US government
The post Sun Pharma joins US drug pricing deal, gets tariff relief appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2020/09/03143717/letter.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 01 Sep 2026 14:55:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Sun, Pharma, joins, drug, pricing, deal, gets, tariff, relief</media:keywords>
<content:encoded><![CDATA[<div><img width="888" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2020/09/03143717/letter.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2020/09/03143717/letter.jpg 888w, https://cdn.expresspharma.in/wp-content/uploads/2020/09/03143717/letter-300x135.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2020/09/03143717/letter-768x346.jpg 768w" sizes="(max-width: 888px) 100vw, 888px"></div><p align="JUSTIFY">Sun Pharmaceutical Industries has joined several drugmakers in signing an agreement with the US government to improve access to affordable medicines for American patients.</p>
<p>Under the agreement, Sun Pharma will extend Most Favoured Nation (MFN) pricing to state Medicaid programmes. It will also offer MFN pricing for future innovative medicine launches in the US.</p>
<p>In return, the agreement delays Section 232 tariffs on innovative pharmaceutical products for more than two years, Sun Pharma said. Other terms of the agreement have not been disclosed.</p>
<p>Rick Ascroft, North America CEO, Sun Pharma, represented the company at the White House ceremony.</p>
<p>“The United States is a key area of investment and expansion for Sun Pharma across clinical development, sales and marketing, and both API and finished products manufacturing,” Ascroft said.</p>
<p>The US is Sun Pharma’s largest market for innovative medicines and accounts for about 27 per cent of its global revenue. The company has a strong presence in US dermatology, immunology, cutaneous oncology and ophthalmology, besides its generics and consumer health businesses.</p>
<p>Sun Pharma is also expanding its US presence through its proposed $11.75-billion acquisition of Organon.</p>
<p>The post <a href="https://www.expresspharma.in/ermatology-immunology-cutaneous-oncology-ophthalmology/">Sun Pharma joins US drug pricing deal, gets tariff relief</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Panel Discussion: Are we measuring FR&amp;amp;D success the right way?</title>
<link>https://edusehat.com/en/panel-discussion-are-we-measuring-frd-success-the-right-way</link>
<guid>https://edusehat.com/en/panel-discussion-are-we-measuring-frd-success-the-right-way</guid>
<description><![CDATA[ 
FDD Conclave 2026 | 6th August 2026 | Ahmedabad Connect
The post Panel Discussion: Are we measuring FR&amp;D success the right way? appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/08/31220437/EP_FDDC_Aug_2026_01_PD_Are_we_measuring_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 01 Sep 2026 00:35:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Panel, Discussion:, Are, measuring, FR&amp;D, success, the, right, way</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="422" src="https://cdn.expresspharma.in/wp-content/uploads/2026/08/31220437/EP_FDDC_Aug_2026_01_PD_Are_we_measuring_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/08/31220437/EP_FDDC_Aug_2026_01_PD_Are_we_measuring_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/31220437/EP_FDDC_Aug_2026_01_PD_Are_we_measuring_750-300x169.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p></p>
<hr>
<p><strong>Panellists in this video:</strong><br>
<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2666.png" alt="♦" class="wp-smiley"> Ms Lakshmipriya Nair, Assistant Editor, Express Pharma (MODERATOR)<br>
<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2666.png" alt="♦" class="wp-smiley"> Dr Parva Purohit, Sr VP – R&D, Amneal Pharmaceuticals<br>
<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2666.png" alt="♦" class="wp-smiley"> Dr Amarender Reddy Donthidi, VP & Head R&D (Injectables and Ophthalmics), Amneal Pharmaceuticals<br>
<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2666.png" alt="♦" class="wp-smiley"> Mr Ravikiran Bhabad, Deputy GM – OSD, FTF Pharma (Subsidiary of Shilpa Medicare)</p>
<p><strong>Key Highlights:</strong><br>
[1] Faster time-to-market must be balanced with stringent quality standards throughout product development.</p>
<p>[2] R&D teams need greater agility to adapt to changing market demand, priorities and regulatory requirements.</p>
<p>[3] Successful drug development extends beyond commercialisation, with every stage from R&D to scale-up playing a critical role.</p>
<p>[4] Robust scale-up and regulatory processes are essential to prevent quality issues and safeguard patient safety.</p>
<p>The post <a href="https://www.expresspharma.in/panel-discussion-are-we-measuring-frd-success-the-right-way-06-aug-2026-ahd/">Panel Discussion: Are we measuring FR&D success the right way?</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Dr Abhijit Gothoskar, Technical Expert, Sigachi Industries</title>
<link>https://edusehat.com/en/dr-abhijit-gothoskar-technical-expert-sigachi-industries</link>
<guid>https://edusehat.com/en/dr-abhijit-gothoskar-technical-expert-sigachi-industries</guid>
<description><![CDATA[ 
FDD Conclave 2026 | 6th August 2026 | Ahmedabad Connect
The post Dr Abhijit Gothoskar, Technical Expert, Sigachi Industries appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/08/31221238/EP_FDDC_Aug_2026_05_Dr_Abhijit_Gothoskar_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 01 Sep 2026 00:35:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Abhijit, Gothoskar, Technical, Expert, Sigachi, Industries</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="422" src="https://cdn.expresspharma.in/wp-content/uploads/2026/08/31221238/EP_FDDC_Aug_2026_05_Dr_Abhijit_Gothoskar_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/08/31221238/EP_FDDC_Aug_2026_05_Dr_Abhijit_Gothoskar_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/31221238/EP_FDDC_Aug_2026_05_Dr_Abhijit_Gothoskar_750-300x169.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p></p>
<hr>
<p><strong>Speaker in this video:</strong><br>
Dr Abhijit Gothoskar, Technical Expert, Sigachi Industries</p>
<p><strong>Topic:</strong> Matrix formulation using Ultramod systems</p>
<p><strong>Key Highlights:</strong><br>
[1] Hydrophilic matrix systems remain a proven and commercially viable technology for controlled drug release. </p>
<p>[2] UltraMod improves formulation robustness and delivers more predictable performance.</p>
<p>[3] Sigachi is an end-to-end formulation partner, offering solutions from excipients to formulation support.</p>
<p>The post <a href="https://www.expresspharma.in/dr-abhijit-gothoskar-technical-expert-sigachi-industries-06-aug-2026-ahd/">Dr Abhijit Gothoskar, Technical Expert, Sigachi Industries</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Dr Ajay Jaysingh Khopade, Site Head R&amp;amp;D, VP and Head&#45;Formulation and Analytical R&amp;amp;D, Sun Pharmaceutical Industries</title>
<link>https://edusehat.com/en/dr-ajay-jaysingh-khopade-site-head-rd-vp-and-head-formulation-and-analytical-rd-sun-pharmaceutical-industries</link>
<guid>https://edusehat.com/en/dr-ajay-jaysingh-khopade-site-head-rd-vp-and-head-formulation-and-analytical-rd-sun-pharmaceutical-industries</guid>
<description><![CDATA[ 
FDD Conclave 2026 | 6th August 2026 | Ahmedabad Connect
The post Dr Ajay Jaysingh Khopade, Site Head R&amp;D, VP and Head-Formulation and Analytical R&amp;D, Sun Pharmaceutical Industries appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/08/31221233/EP_FDDC_Aug_2026_04_Dr_Ajay_Jaysingh_Khopade_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 01 Sep 2026 00:35:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Ajay, Jaysingh, Khopade, Site, Head, R&amp;D, and, Head-Formulation, and, Analytical, R&amp;D, Sun, Pharmaceutical, Industries</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="422" src="https://cdn.expresspharma.in/wp-content/uploads/2026/08/31221233/EP_FDDC_Aug_2026_04_Dr_Ajay_Jaysingh_Khopade_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/08/31221233/EP_FDDC_Aug_2026_04_Dr_Ajay_Jaysingh_Khopade_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/31221233/EP_FDDC_Aug_2026_04_Dr_Ajay_Jaysingh_Khopade_750-300x169.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p></p>
<hr>
<p><strong>Speaker in this video:</strong><br>
Dr Ajay Jaysingh Khopade, Site Head R&D, VP and Head-Formulation and Analytical R&D, Sun Pharmaceutical Industries</p>
<p><strong>Topic:</strong> Beyond generics: Creating a competitive edge through innovation</p>
<p><strong>Key Highlights:</strong><br>
[1] Volume is no longer enough. Differentiation will define the next era of Indian pharma. </p>
<p>[2] Complex formulations and specialty products deliver stronger margins and lasting competitive advantage. </p>
<p>[3] Success demands the right mix of product innovation, process excellence and regulatory strategy. Innovation must improve patient outcomes, not just advance science. </p>
<p>[4] Moving beyond generics is a long-term investment with high-value rewards</p>
<p>The post <a href="https://www.expresspharma.in/dr-ajay-jaysingh-khopade-site-head-rd-vp-and-head-formulation-and-analytical-rd-sun-pharmaceutical-industries-06-aug-2026-ahd/">Dr Ajay Jaysingh Khopade, Site Head R&D, VP and Head-Formulation and Analytical R&D, Sun Pharmaceutical Industries</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Ms Ritu Laddha, Sr VP &amp;amp; Cluster Head, Zydus Lifesciences</title>
<link>https://edusehat.com/en/ms-ritu-laddha-sr-vp-cluster-head-zydus-lifesciences</link>
<guid>https://edusehat.com/en/ms-ritu-laddha-sr-vp-cluster-head-zydus-lifesciences</guid>
<description><![CDATA[ 
FDD Conclave 2026 | 6th August 2026 | Ahmedabad Connect
The post Ms Ritu Laddha, Sr VP &amp; Cluster Head, Zydus Lifesciences appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/08/31221241/EP_FDDC_Aug_2026_06_Ritu_Laddha_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 01 Sep 2026 00:35:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Ritu, Laddha, Cluster, Head, Zydus, Lifesciences</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="422" src="https://cdn.expresspharma.in/wp-content/uploads/2026/08/31221241/EP_FDDC_Aug_2026_06_Ritu_Laddha_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/08/31221241/EP_FDDC_Aug_2026_06_Ritu_Laddha_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/31221241/EP_FDDC_Aug_2026_06_Ritu_Laddha_750-300x169.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p></p>
<hr>
<p><strong>Speaker in this video:</strong><br>
Ms Ritu Laddha, Sr VP & Cluster Head, Zydus Lifesciences</p>
<p><strong>Topic:</strong> Reimagining pain therapy: Oral-to-intranasal product innovation</p>
<p><strong>Key Highlights:</strong><br>
[1] Intranasal drug delivery can provide much faster pain relief than oral medicines. Zydus developed an intranasal version of Cyclobenzaprine to improve speed and patient outcomes. </p>
<p>[2] Preclinical studies and human studies showed significantly faster absorption and higher drug exposure with the nasal formulation.</p>
<p>[3] The innovation demonstrated strong efficacy, good tolerability, and patent potential for next-generation pain therapy.</p>
<p>The post <a href="https://www.expresspharma.in/ms-ritu-laddha-sr-vp-cluster-head-zydus-lifesciences-06-aug-2026-ahd/">Ms Ritu Laddha, Sr VP & Cluster Head, Zydus Lifesciences</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Panel Discussion: AI, talent and technology: The new FR&amp;amp;D toolkit</title>
<link>https://edusehat.com/en/panel-discussion-ai-talent-and-technology-the-new-frd-toolkit</link>
<guid>https://edusehat.com/en/panel-discussion-ai-talent-and-technology-the-new-frd-toolkit</guid>
<description><![CDATA[ 
FDD Conclave 2026 | 6th August 2026 | Ahmedabad Connect 
The post Panel Discussion: AI, talent and technology: The new FR&amp;D toolkit appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/08/31222135/EP_FDDC_Aug_2026_07_PD_AI_talent_technology_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 01 Sep 2026 00:35:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Panel, Discussion:, AI, talent, and, technology:, The, new, FR&amp;D, toolkit</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="422" src="https://cdn.expresspharma.in/wp-content/uploads/2026/08/31222135/EP_FDDC_Aug_2026_07_PD_AI_talent_technology_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/08/31222135/EP_FDDC_Aug_2026_07_PD_AI_talent_technology_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/31222135/EP_FDDC_Aug_2026_07_PD_AI_talent_technology_750-300x169.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p></p>
<hr>
<p><strong>Panellists in this video:</strong><br>
<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2666.png" alt="♦" class="wp-smiley"> Dr Tushar N Mehta, VP – Respiratory and Advanced Analytical R&D, Amneal Pharmaceuticals (MODERATOR)<br>
<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2666.png" alt="♦" class="wp-smiley"> Mr Nilesh Malaviya, Head – Formulation Development, Alembic Pharmaceuticals<br>
<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2666.png" alt="♦" class="wp-smiley"> Dr Sanju Dhawan, Sr Director GPRD & Site Leader, Baxter Pharmaceuticals India<br>
<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2666.png" alt="♦" class="wp-smiley"> Dr Dhaval Pethani, Co-Founder and CTO, Cutyx Research LLP<br>
<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2666.png" alt="♦" class="wp-smiley"> Dr Prabhat Shrivastava, Associate Director and Vertical Head (Formulation and Packaging Development), Piramal Pharma Solutions, Ahmedabad<br>
<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2666.png" alt="♦" class="wp-smiley"> Dr Vinod Venkatpurwar, Sr GM, Formulation Development, Cadila Pharmaceuticals<br>
<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2666.png" alt="♦" class="wp-smiley"> Dr Ajay Vairale, Sr GM, Cadila Pharmaceuticals<br>
<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2666.png" alt="♦" class="wp-smiley"> Dr Sunny P Desai, Sr Manager (Site Lead) – MS&T (Technology Transfer), Zydus Lifesciences</p>
<p><strong>Key Highlights:</strong><br>
[1] AI is transforming formulation development from trial-and-error to predict-and-design, enabling faster, smarter decisions.</p>
<p>[2] Manufacturability and scale-up must be built into product development from the pre-formulation stage, not addressed at the end.</p>
<p>[3] Digital twins, AI models and electronic lab notebooks can reduce scale-up failures, eliminate repetitive work and speed up technology transfer.</p>
<p>[4] AI is only as powerful as the quality of the data behind it. A strong digital foundation is the first step towards successful AI adoption.</p>
<p>[5] The real value of AI lies in rethinking systems, with connected data, traceable workflows and integrated digital processes.</p>
<p>[6] AI should augment, not replace scientists. Human expertise, judgement and accountability remain central to every development decision.</p>
<p>[7] Successful AI adoption depends on strong governance, ethical use and protecting confidential organisational data.</p>
<p>[8] The future belongs to AI-enabled scientists who understand both the potential and the limitations of AI, and use it to bring medicines to patients faster.</p>
<p>The post <a href="https://www.expresspharma.in/panel-discussion-ai-talent-and-technology-the-new-frd-toolkit-06-aug-2026-ahd/">Panel Discussion: AI, talent and technology: The new FR&D toolkit</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Dr Richa Dayaramani, Scientist Grade F, NIPER Ahmedabad</title>
<link>https://edusehat.com/en/dr-richa-dayaramani-scientist-grade-f-niper-ahmedabad</link>
<guid>https://edusehat.com/en/dr-richa-dayaramani-scientist-grade-f-niper-ahmedabad</guid>
<description><![CDATA[ 
FDD Conclave 2026 | 6th August 2026 | Ahmedabad Connect 
The post Dr Richa Dayaramani, Scientist Grade F, NIPER Ahmedabad appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/08/31222138/EP_FDDC_Aug_2026_08_Dr_Richa_Dayaramani_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 01 Sep 2026 00:35:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Richa, Dayaramani, Scientist, Grade, NIPER, Ahmedabad</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="422" src="https://cdn.expresspharma.in/wp-content/uploads/2026/08/31222138/EP_FDDC_Aug_2026_08_Dr_Richa_Dayaramani_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/08/31222138/EP_FDDC_Aug_2026_08_Dr_Richa_Dayaramani_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/31222138/EP_FDDC_Aug_2026_08_Dr_Richa_Dayaramani_750-300x169.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p></p>
<hr>
<p><strong>Speaker in this video:</strong><br>
Dr Richa Dayaramani, Scientist Grade F, NIPER Ahmedabad</p>
<p><strong>Topic:</strong> Injectables and specialty formulations: Driving the next wave of growth</p>
<p><strong>Key Highlights:</strong><br>
[1] As biologics and GLP-1 therapies grow, companies must build capabilities in advanced drug delivery and injectable technologies. </p>
<p>[2] Formulation is becoming a key differentiator. The more complex the formulation, the greater the opportunity to create value and stay ahead of competition. </p>
<p>[3] Patient convenience is shaping innovation. Future formulations must support self-administration through devices like pre-filled syringes and wearable injectors. </p>
<p>[4] Success will depend on getting the entire ecosystem right, from formulation and device compatibility to manufacturing and execution.</p>
<p>The post <a href="https://www.expresspharma.in/dr-richa-dayaramani-scientist-grade-f-niper-ahmedabad-06-aug-2026-ahd/">Dr Richa Dayaramani, Scientist Grade F, NIPER Ahmedabad</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Panel Discussion: Ahmedabad’s innovation edge: Where science meets scale</title>
<link>https://edusehat.com/en/panel-discussion-ahmedabads-innovation-edge-where-science-meets-scale</link>
<guid>https://edusehat.com/en/panel-discussion-ahmedabads-innovation-edge-where-science-meets-scale</guid>
<description><![CDATA[ 
FDD Conclave 2026 | 6th August 2026 | Ahmedabad Connect 
The post Panel Discussion: Ahmedabad’s innovation edge: Where science meets scale appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/08/31222141/EP_FDDC_Aug_2026_09_PD_Ahmedabads_innovation_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 01 Sep 2026 00:35:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Panel, Discussion:, Ahmedabad’s, innovation, edge:, Where, science, meets, scale</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="422" src="https://cdn.expresspharma.in/wp-content/uploads/2026/08/31222141/EP_FDDC_Aug_2026_09_PD_Ahmedabads_innovation_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/08/31222141/EP_FDDC_Aug_2026_09_PD_Ahmedabads_innovation_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/31222141/EP_FDDC_Aug_2026_09_PD_Ahmedabads_innovation_750-300x169.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p></p>
<hr>
<p><strong>Panellists in this video:</strong><br>
<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2666.png" alt="♦" class="wp-smiley"> Mr Naresh Kumar Gaur, Consultant, Pharma Manufacturing Operations (MODERATOR)<br>
<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2666.png" alt="♦" class="wp-smiley"> Dr Madhusudhan Bommagani, President – FR&D, Cadila Pharmaceuticals<br>
<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2666.png" alt="♦" class="wp-smiley"> Dr Mukesh Patel, MD, QualiHeal Pharmaceuticals<br>
<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2666.png" alt="♦" class="wp-smiley"> Ms Anshu Rathore, AVP-Pharma & Regulatory, Molkem Labs<br>
<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2666.png" alt="♦" class="wp-smiley"> Mr Gopal Thakur, Sr Manager, Immacule Life Sciences<br>
<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2666.png" alt="♦" class="wp-smiley"> Mr Abhikumar Turakhiya, Sr GM and Head – Formulation R&D, Avance Research<br>
<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2666.png" alt="♦" class="wp-smiley"> Dr Kashyap Nagariya, Assistant Division Head, Otsuka Pharmaceutical India</p>
<p><strong>Key Highlights:</strong><br>
[1] Ahmedabad’s growing pharma ecosystem is supported by a large pool of skilled talent from pharmacy universities and colleges across the city and Gujarat.</p>
<p>[2] The availability of local technical and digital support, including software, automation and equipment expertise, gives Ahmedabad an advantage for pharma manufacturing and R&D.</p>
<p>[3] Ahmedabad is seeing a growing presence of CMOs and CDMOs, creating opportunities for technology transfer, cost efficiencies and faster market access.</p>
<p>[4] Gujarat’s government-backed skill-development initiatives are helping strengthen the talent pipeline for the pharmaceutical industry.</p>
<p>[5] Ahmedabad’s pharma industry needs to move beyond conventional generics towards complex products, biologics and other value-added offerings.</p>
<p>[6] The city’s strong manufacturing base and business acumen can be leveraged to build a stronger position in pharma innovation and product development.</p>
<p>[7] Greater commitment to quality, alongside Ahmedabad’s existing manufacturing strength, will be critical to strengthening its position as a global pharma hub.</p>
<p>The post <a href="https://www.expresspharma.in/panel-discussion-ahmedabads-innovation-edge-where-science-meets-scale-06-aug-2026-ahd/">Panel Discussion: Ahmedabad’s innovation edge: Where science meets scale</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>BioE3 at 2: From policy push to industry scale</title>
<link>https://edusehat.com/en/bioe3-at-2-from-policy-push-to-industry-scale</link>
<guid>https://edusehat.com/en/bioe3-at-2-from-policy-push-to-industry-scale</guid>
<description><![CDATA[ 
Podcast with Dr. Rahul Warke, Ph.D., Director, Research and Development (Microbiology) HiMedia Laboratories Ltd
The post BioE3 at 2: From policy push to industry scale appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/08/31160627/EP_Excl_Intv_Dr_Rahul_Warke_PhD_HiMedia_Labs_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 31 Aug 2026 21:00:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>BioE3, From, policy, push, industry, scale</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="422" src="https://cdn.expresspharma.in/wp-content/uploads/2026/08/31160627/EP_Excl_Intv_Dr_Rahul_Warke_PhD_HiMedia_Labs_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/08/31160627/EP_Excl_Intv_Dr_Rahul_Warke_PhD_HiMedia_Labs_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/31160627/EP_Excl_Intv_Dr_Rahul_Warke_PhD_HiMedia_Labs_750-300x169.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p></p>
<hr>
<p>Two years ago, the BioE3 Policy set out to strengthen India’s biotechnology ecosystem and create new opportunities for industry.</p>
<p>As we mark its second anniversary, Dr Rahul Warke, Director, Research & Development (Microbiology), HiMedia Laboratories, speaks to Lakshmipriya Nair, Assistant Editor, Express Pharma, about HiMedia’s experience as one of the beneficiaries of the policy and what it means for industry.</p>
<p>What has the policy changed on the ground? Is it helping companies invest in R&D and scale up? And what more does industry need to turn India’s biotech potential into real opportunities?</p>
<p>Dr Warke shares his perspective on the journey so far and what comes next.</p>
<p>The post <a href="https://www.expresspharma.in/bioe3-at-2-from-policy-push-to-industry-scale/">BioE3 at 2: From policy push to industry scale</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Teva Pharmaceuticals to acquire BioXcel assets for up to $125m</title>
<link>https://edusehat.com/en/teva-pharmaceuticals-to-acquire-bioxcel-assets-for-up-to-125m</link>
<guid>https://edusehat.com/en/teva-pharmaceuticals-to-acquire-bioxcel-assets-for-up-to-125m</guid>
<description><![CDATA[ The agreement arises as part of BioXcel Therapeutics’ voluntary Chapter 11 proceedings in the US Bankruptcy Court for the District of Delaware, initiating a court-supervised sale of the 
The post Teva Pharmaceuticals to acquire BioXcel assets for up to $125m appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/08/PT-31-08-2026-shutterstock_2426123175.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 31 Aug 2026 17:25:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Teva, Pharmaceuticals, acquire, BioXcel, assets, for, 125m</media:keywords>
<content:encoded><![CDATA[<p>The agreement arises as part of BioXcel Therapeutics’ voluntary Chapter 11 proceedings in the US Bankruptcy Court for the District of Delaware, initiating a court-supervised sale of the company’s main assets.</p>
<p>The proposed transaction would see Teva obtain worldwide rights to Igalmi (dexmedetomidine) sublingual film, a prescription medicine, and the investigational BXCL501.</p>
<p>BXCL501 is currently being reviewed by the US Food and Drug Administration (FDA) for potential at-home use in treating acute agitation linked to schizophrenia or bipolar I or II disorder in adults.</p>
<p>Teva has been designated as the “stalking horse bidder”, setting the initial offer for the assets in the Section 363 auction process under the US Bankruptcy Code.</p>
<p>Should Teva not prevail as the successful bidder, the company would receive a break-up fee and reimbursement of certain expenses, as outlined in the agreement.</p>
<p>The upfront consideration for the assets totals $57.5m, with up to a further $67.5m in contingent payments linked to FDA approval timing and specified sales milestones.</p>
<p>Teva business development executive vice-president Evan Lippman said: “Business development plays a critical role in accelerating our Pivot to Growth strategy. This opportunity strengthens our neuroscience portfolio and reflects our disciplined approach to pursuing innovative assets with a clear strategic fit, the potential to make a meaningful difference for patients and attractive long-term growth potential, while balancing risk and value creation.”</p>
<p>Igalmi remains available commercially during this process.</p>
<p>BioXcel Therapeutics is seeking to facilitate the sale of substantially all its assets through the auction process, aiming to maximise stakeholder value.</p>
<p>The company has also secured $19m in debtor-in-possession financing from existing lenders to maintain operations and support the court process.</p>
<p>BioXcel Therapeutics intends to continue supporting patients, prescribers, and commercial partners during the proceedings.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/teva-to-acquire-bioxcel-assets/">Teva Pharmaceuticals to acquire BioXcel assets for up to $125m</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>AusperBio raises $120m to progress hepatitis B therapies</title>
<link>https://edusehat.com/en/ausperbio-raises-120m-to-progress-hepatitis-b-therapies</link>
<guid>https://edusehat.com/en/ausperbio-raises-120m-to-progress-hepatitis-b-therapies</guid>
<description><![CDATA[ The round was led by an undisclosed strategic investor. New investor RA Capital Management also participated, along with existing investors that included HanKang Capital, Qiming Venture Partners and 
The post AusperBio raises $120m to progress hepatitis B therapies appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/08/PT-2-28-08-2026-shutterstock_2327782841-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 31 Aug 2026 17:25:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>AusperBio, raises, 120m, progress, hepatitis, therapies</media:keywords>
<content:encoded><![CDATA[<p>The round was led by an undisclosed strategic investor.</p>
<p>New investor RA Capital Management also participated, along with existing investors that included HanKang Capital, Qiming Venture Partners and CDH Investments.</p>
<p>With this funding, AusperBio’s total capital raised since 2024 has reached $360m.</p>
<p>The funds are intended to further the advancement of AHB-137, an antisense oligonucleotide therapy for CHB, including its Phase III registrational programme and preparations for commercial readiness.</p>
<p>Additionally, the proceeds will accelerate the development of AHB-171, a hepatocyte-targeted small interfering ribonucleic acid (siRNA) therapeutic candidate, and next-generation combination treatment approaches aimed at providing a functional cure for CHB.</p>
<p>AusperBio co-founder and CEO Dr Guofeng Cheng said: “This financing represents an important inflection point for AusperBio as we advance AHB-137 toward potential commercialisation while developing next-generation therapies for CHB.</p>
<p>“We are grateful for the continued confidence of our existing investors and pleased to welcome RA Capital to AusperBio. We look forward to building on this momentum to advance our strategy toward functional cure and unlock new opportunities across our oligonucleotide platforms.”</p>
<p>AHB-137 is being tested in a Phase III trial in China after earlier global Phase I and several Phase II studies.</p>
<p>It is designed to suppress hepatitis B surface antigen production, inhibit viral deoxyribonucleic acid (DNA) replication, and promote immune reactivation as part of efforts for a functional cure.</p>
<p>AHB-171 is the first clinical candidate using the company’s Au-HALO liver-targeting delivery platform and is intended to selectively suppress viral gene expression.</p>
<p>AusperBio is developing targeted oligonucleotide therapeutics and delivery technologies focused initially on CHB and aims to broaden its pipeline to address other diseases.</p>
<p>In July 2024, AusperBio Therapeutics and Ausper Biopharma secured breakthrough therapy designation in China for their investigational drug, AHB-137, to treat CHB.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/ausperbio-120m-hepatitis-b-therapies/">AusperBio raises $120m to progress hepatitis B therapies</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Lannett launches generic Advair Diskus in US</title>
<link>https://edusehat.com/en/lannett-launches-generic-advair-diskus-in-us</link>
<guid>https://edusehat.com/en/lannett-launches-generic-advair-diskus-in-us</guid>
<description><![CDATA[ 
Aurobindo Pharma USA subsidiary introduces fluticasone propionate and salmeterol inhalation powder in two strengths
The post Lannett launches generic Advair Diskus in US appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 31 Aug 2026 17:25:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Lannett, launches, generic, Advair, Diskus</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Lannett Company LLC, a wholly owned subsidiary of Aurobindo Pharma USA, Inc., has launched the generic equivalent of Advair Diskus (fluticasone propionate and salmeterol inhalation powder), a product of GSK plc, in the US market.</span></p>
<p><span>The product has been launched in 100/50 mcg and 250/50 mcg strengths.</span></p>
<p><span>The launch is the first product from Lannett’s inhalation pipeline to be commercialised in the US, reflecting the company’s focus on expanding its portfolio of complex and differentiated inhalation products.</span></p>
<p><span>Advair Diskus in combination therapy is indicated for the treatment of asthma and chronic obstructive pulmonary disease (COPD).</span></p>
<p>The post <a href="https://www.expresspharma.in/lannett-launches-generic-advair-diskus-in-us/">Lannett launches generic Advair Diskus in US</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>MetaG1 launches scientific discussion platform for pharma and life sciences</title>
<link>https://edusehat.com/en/metag1-launches-scientific-discussion-platform-for-pharma-and-life-sciences</link>
<guid>https://edusehat.com/en/metag1-launches-scientific-discussion-platform-for-pharma-and-life-sciences</guid>
<description><![CDATA[ 
Bengaluru-based initiative aims to preserve expert discussions on evidence, methods and problem-solving as searchable, attributable knowledge
The post MetaG1 launches scientific discussion platform for pharma and life sciences appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2019/09/18134232/digital-healthcare.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 31 Aug 2026 17:25:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>MetaG1, launches, scientific, discussion, platform, for, pharma, and, life, sciences</media:keywords>
<content:encoded><![CDATA[<div><img width="888" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2019/09/18134232/digital-healthcare.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2019/09/18134232/digital-healthcare.jpg 888w, https://cdn.expresspharma.in/wp-content/uploads/2019/09/18134232/digital-healthcare-300x135.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2019/09/18134232/digital-healthcare-768x346.jpg 768w" sizes="auto, (max-width: 888px) 100vw, 888px"></div><p><span>MetaG1 Research Consortium has announced the controlled public launch of a scientific community connecting agriculture, biotechnology, pharmaceutical research and life sciences.</span></p>
<p><span>The Bengaluru-based initiative addresses the dispersion of expert insights across conferences, private messages, email exchanges and social media discussions. MetaG1 provides a structured environment where scientific questions, evidence, methods, disagreements and proposed solutions can be examined and preserved as an accessible professional record.</span></p>
<p><span>MetaG1 is an initiative of CropG1 Agro Research & Development, Bengaluru, and operates under its own identity and community governance.</span></p>
<p><span>Agriculture, pharmaceutical research and biotechnology work with different products, applications and regulatory environments, but face related scientific challenges including biological variability, reproducibility, formulation, stability, safety, evidence standards, manufacturing, scale-up and translation from controlled studies to practical performance.</span></p>
<p><span>MetaG1 enables specialists to examine these challenges across disciplinary boundaries while retaining the scientific and regulatory context of each sector.</span></p>
<p><span>Initial areas of discussion include agriculture and biologicals, covering efficacy, formulation, shelf life, field performance, resistance management, adoption and evidence required to strengthen grower confidence. Pharma and biotechnology discussions cover discovery, translational research, manufacturing, quality, safety, regulatory science and movement from laboratory evidence to practical application.</span></p>
<p><span>The platform also focuses on cross-disciplinary collaboration by identifying complementary expertise and developing focused research, institutional and commercial collaborations.</span></p>
<p><span>MetaG1 also seeks to address how professional reputation is built. The platform enables contributors to establish credibility through a persistent, attributable record of the questions they raise, the evidence they share and the problems they help to solve.</span></p>
<p><span>“A person is known by the company he keeps. A student is known by the question he raises. A scientist is known by the problem he solves,” said Dr. Purushottam M. Dewang, Founder MD & Chief Scientific Officer of CropG1 and Convenor of MetaG1 Research Consortium.</span></p>
<p><span>The contribution record is intended to help fellow scientists, institutions and businesses identify expertise and complementary capabilities. Over time, it can support professional recognition, focused collaboration and new research or commercial relationships. MetaG1 describes this as a professional brand-building engine grounded in intellectual contribution.</span></p>
<p><span>MetaG1 discussions begin with clearly framed problems. Contributors can present observations, identify inferences, cite evidence, compare methods, question assumptions and record how understanding develops over time.</span></p>
<p><span>“Scientific discussions gain lasting value when their reasoning, evidence and unresolved questions remain available for examination,” said Dr. Sheetal Dewang, Co-Convenor of MetaG1 Research Consortium. “MetaG1 is designed to preserve that intellectual trail and make it useful to future contributors.”</span></p>
<p><span>Dr. Manjula R, Chief Moderator, said universities, professional bodies, research groups, companies and sector organisations can participate under their own identities and establish governed discussion spaces within MetaG1. Designated subject specialists may steward these areas, define participation boundaries and moderate discussions according to published community standards.</span></p>
<p><span>During the initial launch, visitors can access selected institutional and guidance pages. Registration and participation in working discussions are subject to community approval. MetaG1 said this phased approach will allow it to establish moderation, evidence standards and a founding community before wider expansion.</span></p>
<p>The post <a href="https://www.expresspharma.in/metag1-launches-scientific-discussion-platform-for-pharma-and-life-sciences/">MetaG1 launches scientific discussion platform for pharma and life sciences</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Zydus reports positive Phase II(b) EVIDENCES&#45;X results for Saroglitazar Mg in MASH</title>
<link>https://edusehat.com/en/zydus-reports-positive-phase-iib-evidences-x-results-for-saroglitazar-mg-in-mash</link>
<guid>https://edusehat.com/en/zydus-reports-positive-phase-iib-evidences-x-results-for-saroglitazar-mg-in-mash</guid>
<description><![CDATA[ 
Global trial met its primary endpoint of MASH resolution without worsening of fibrosis at week 52
The post Zydus reports positive Phase II(b) EVIDENCES-X results for Saroglitazar Mg in MASH appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2019/09/05163746/Inspection-Report-1-e1722581430582.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 31 Aug 2026 17:25:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Zydus, reports, positive, Phase, IIb, EVIDENCES-X, results, for, Saroglitazar, MASH</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="399" src="https://cdn.expresspharma.in/wp-content/uploads/2019/09/05163746/Inspection-Report-1-e1722581430582.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2019/09/05163746/Inspection-Report-1-e1722581430582.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2019/09/05163746/Inspection-Report-1-e1722581430582-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>Zydus Lifesciences (Zydus) has announced positive topline results from the completed EVIDENCES-X global Phase II(b) clinical trial evaluating the efficacy and safety of Saroglitazar Magnesium (Saroglitazar Mg) in patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis.</span></p>
<p><span>The prospective, multicentre, randomised, double-blind, placebo-controlled study enrolled 189 subjects who were randomised in a 1:1:1 ratio to receive Saroglitazar 2 mg, Saroglitazar 4 mg or placebo over a treatment period of 52 weeks.</span></p>
<p><span>The study met its primary endpoint of resolution of steatohepatitis with no worsening of fibrosis at week 52, with a treatment difference of 26.5 per cent.</span></p>
<p><span>The study also reported findings across key secondary and exploratory endpoints, including improvements in liver histology parameters and assessments of steatosis, inflammation and ballooning. Detailed results from the EVIDENCES-X trial will be presented at an upcoming Liver Congress and submitted for publication in a peer-reviewed medical journal.</span></p>
<p><span>The EVIDENCES-X trial was led by Prof. Naga Chalasani, M.D., Interim Chair, Department of Medicine, Indiana University School of Medicine, and Prof. Arun J. Sanyal, M.D., Division of Gastroenterology, Virginia Commonwealth University, as co-Principal Investigators. The global study enrolled patients across the United States, Turkey and Argentina.</span></p>
<p><span>Speaking on the development, Dr. Sharvil Patel, Managing Director, Zydus Lifesciences Limited, said, “The successful completion of the EVIDENCES-X Phase II(b) trial and achievement of the primary endpoint marks an important milestone in our MASH development programme. These results reinforce the therapeutic potential of Saroglitazar Mg and our commitment to developing innovative treatment options for patients suffering from chronic liver diseases.”</span></p>
<p><span>Metabolic dysfunction Associated Steatotic Liver Disease (MASLD) and MASH continue to represent significant unmet medical needs globally. It is estimated that approximately 25 per cent of adults worldwide are affected by MASLD, while MASH affects an estimated 5 per cent to 20 per cent of the adult population.</span></p>
<p><span>MASH is characterised by hepatic steatosis, inflammation and hepatocellular injury and can progress to advanced fibrosis, cirrhosis, liver failure, hepatocellular carcinoma and death.</span></p>
<p><span>The results from EVIDENCES-X add to the evidence generated from earlier Phase II studies evaluating Saroglitazar in patients with MASH and MASLD and support the ongoing global development programme for Saroglitazar Mg in chronic liver diseases.</span></p>
<p><span>Saroglitazar Mg was approved by the Drug Controller General of India (DCGI) for the treatment of MASH and MASLD in India in 2020. Saroglitazar Mg remains an investigational compound in the United States and has not been approved by the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for the treatment of MASH or MASLD.</span></p>
<p>The post <a href="https://www.expresspharma.in/zydus-reports-positive-phase-iib-evidences-x-results-for-saroglitazar-mg-in-mash/">Zydus reports positive Phase II(b) EVIDENCES-X results for Saroglitazar Mg in MASH</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Bombay HC directs Maharashtra FDA to withdraw Cipla licence cancellation order</title>
<link>https://edusehat.com/en/bombay-hc-directs-maharashtra-fda-to-withdraw-cipla-licence-cancellation-order</link>
<guid>https://edusehat.com/en/bombay-hc-directs-maharashtra-fda-to-withdraw-cipla-licence-cancellation-order</guid>
<description><![CDATA[ 
Court questions FDA’s handling of proceedings and directs regulator to issue fresh show-cause notice and conduct hearing on a regular working day
The post Bombay HC directs Maharashtra FDA to withdraw Cipla licence cancellation order appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/06/25113229/us-fda-approval-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 31 Aug 2026 13:50:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Bombay, directs, Maharashtra, FDA, withdraw, Cipla, licence, cancellation, order</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/06/25113229/us-fda-approval-1.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/06/25113229/us-fda-approval-1.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/06/25113229/us-fda-approval-1-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>The Bombay High Court has directed the Maharashtra Food and Drug Administration (FDA) to withdraw its licence cancellation order against Cipla Pharma & Life Sciences and restart the proceedings by issuing a fresh show-cause notice and conducting a hearing on a regular working day.</span></p>
<p><span>The FDA had initiated action against Cipla following inspections at the company’s carrying and forwarding facility in Wadki, Pune. The regulator cited packaging issues with Reactin Plus tablets, gaps in purchase and sales documentation, discrepancies between physical and computerised stock records, unauthorised promotional text on artwork and non-compliance with standard product recall procedures.</span></p>
<p><span>The legal proceedings focused on the timeline followed by the FDA under Commissioner Tukaram Mundhe. The FDA issued a show-cause notice to Cipla on August 13, to which the company responded on August 25. The regulator then scheduled a personal hearing for August 26, which was a state public holiday.</span></p>
<p><span>Cipla requested an adjournment as its representatives were unavailable on the holiday. The FDA rejected the request and issued an order cancelling the company’s licence on August 26, with the cancellation taking effect from August 27.</span></p>
<p><span>A Bombay High Court division bench comprising Acting Chief Justice Ravindra Ghuge and Justice Gautam Ankhad questioned the manner in which the FDA had conducted the proceedings, stating what it considered an excessive and disproportionate approach by the regulator. </span></p>
<p><span>Senior Counsel Aabad Ponda, representing Cipla Pharma & Life Sciences, argued that the FDA had violated the principles of natural justice and acted with undue haste by scheduling the personal hearing on a public holiday declared by the Maharashtra state government.</span></p>
<p><span>Ponda argued that corporate offices were closed and Cipla’s representatives were unavailable on the holiday. The company therefore requested an adjournment to a regular business day.</span></p>
<p><span>Additional Government Pleader P. P. Kakade, representing the FDA, argued that the pharmaceutical company did not have a strict statutory right to a hearing. The bench rejected this position, stating that a “shoot first, ask questions later” approach has no place in law.</span></p>
<p><span>The court’s intervention does not clear Cipla of the packaging or record violations cited by the FDA. The regulator has been directed to restart the legal process by issuing a fresh show-cause notice and conducting a hearing on a regular business day.</span></p>
<p>The post <a href="https://www.expresspharma.in/bombay-hc-directs-maharashtra-fda-to-withdraw-cipla-licence-cancellation-order/">Bombay HC directs Maharashtra FDA to withdraw Cipla licence cancellation order</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Maharashtra FDA cancels Cipla C&amp;amp;F drug sale licences in Pune</title>
<link>https://edusehat.com/en/maharashtra-fda-cancels-cipla-cf-drug-sale-licences-in-pune</link>
<guid>https://edusehat.com/en/maharashtra-fda-cancels-cipla-cf-drug-sale-licences-in-pune</guid>
<description><![CDATA[ 
The action follows inspections in June 2026 involving Reactin Plus Tablets, a Schedule H prescription medicine.
The post Maharashtra FDA cancels Cipla C&amp;F drug sale licences in Pune appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2020/04/20125724/letter-HDMA.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 29 Aug 2026 15:15:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Maharashtra, FDA, cancels, Cipla, C&amp;F, drug, sale, licences, Pune</media:keywords>
<content:encoded><![CDATA[<div><img width="880" height="582" src="https://cdn.expresspharma.in/wp-content/uploads/2020/04/20125724/letter-HDMA.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2020/04/20125724/letter-HDMA.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2020/04/20125724/letter-HDMA.jpg 768w, https://cdn.expresspharma.in/wp-content/uploads/2020/04/20125724/letter-HDMA.jpg 880w" sizes="(max-width: 880px) 100vw, 880px"></div><p class="isSelectedEnd">The Maharashtra Food and Drug Administration (FDA) has cancelled the drug sale licences of Cipla Pharma & Life Sciences Ltd’s C&F facility at Wadki, Pune.</p>
<p class="isSelectedEnd">The action follows inspections in June 2026 involving Reactin Plus Tablets, a Schedule H prescription medicine.</p>
<p class="isSelectedEnd">According to the FDA, the packaging carried the claim “Analgesic & Antipyretic” along with promotional material. The regulator considered this non-compliant with the Drugs and Cosmetics Act and Rules.</p>
<p class="isSelectedEnd">The FDA seized Reactin Plus stock worth Rs 11.19 lakh and directed its withdrawal from the market. It said the company did not fully comply with the recall directions.</p>
<p class="isSelectedEnd">A subsequent inspection also found deficiencies in storage and record-keeping, including discrepancies between physical and computerised stock. Medicines were also found stored directly on the floor, according to the FDA.</p>
<p class="isSelectedEnd">The FDA later issued a show-cause notice before cancelling the licences.</p>
<p>Cipla has contested the order. The company said the matter is sub judice and that the order does not allege any concerns over the safety, quality or efficacy of its products.</p>
<p>The post <a href="https://www.expresspharma.in/maharashtra-fda-cancels-cipla-cf-drug-sale-licences-in-pune/">Maharashtra FDA cancels Cipla C&F drug sale licences in Pune</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>FDA to review Kowa Pharmaceuticals’ NDA for glaucoma eye drop K&#45;911</title>
<link>https://edusehat.com/en/fda-to-review-kowa-pharmaceuticals-nda-for-glaucoma-eye-drop-k-911</link>
<guid>https://edusehat.com/en/fda-to-review-kowa-pharmaceuticals-nda-for-glaucoma-eye-drop-k-911</guid>
<description><![CDATA[ The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of 30 April 2027. Also known as bimatoprost grenod or NCX 470, K-911 is 
The post FDA to review Kowa Pharmaceuticals’ NDA for glaucoma eye drop K-911 appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/08/PT-28-08-2026-shutterstock_1884612793.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 28 Aug 2026 17:40:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>FDA, review, Kowa, Pharmaceuticals’, NDA, for, glaucoma, eye, drop, K-911</media:keywords>
<content:encoded><![CDATA[<p>The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of 30 April 2027.</p>
<p>Also known as bimatoprost grenod or NCX 470, K-911 is being developed as a topical ophthalmic monotherapy formulated as a sterile solution.</p>
<p>The treatment is designed to decrease IOP through two mechanisms: nitric oxide to boost outflow through the trabecular meshwork-Schlemm’s canal, and bimatoprost to increase uveoscleral outflow.</p>
<p>The NDA is supported by data from two pivotal Phase III trials, Mont Blanc and Denali, in which K-911 0.1% was compared with latanoprost 0.005%, an established prostaglandin analogue, in individuals with OAG or OHT.</p>
<p>Kowa Pharmaceuticals America stated that achieving and maintaining IOP control remains a significant treatment goal in OAG and OHT, as individual patient needs can vary over time.</p>
<p>Kowa Pharmaceuticals America CEO and president Joe Barna said: “The FDA’s acceptance of the NDA for K-911 marks an important milestone as we work toward bringing a potential new treatment option to people living with open-angle glaucoma or ocular hypertension.</p>
<p>“We’re proud to bring Kowa’s decades of global ophthalmology experience to the US eye care community, and we look forward to working with the FDA throughout the review process.”</p>
<p>In February 2024, Kowa Company and Nicox signed an exclusive licensing agreement for the development, manufacturing and commercialisation of K-911 in Japan.</p>
<p>An additional agreement in July 2025 granted Kowa the rights to develop and commercialise the product in the US and other regions.</p>
<p>Nicox, which discovered and developed K-911 and led the Phase III trials, will continue to provide development support while Kowa oversees regulatory and commercial activities in the US.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/fda-to-review-kowa-nda-k911/">FDA to review Kowa Pharmaceuticals’ NDA for glaucoma eye drop K-911</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Oviya MedSafe to host webinar on pharmacovigilance system for regulatory compliance in India</title>
<link>https://edusehat.com/en/oviya-medsafe-to-host-webinar-on-pharmacovigilance-system-for-regulatory-compliance-in-india</link>
<guid>https://edusehat.com/en/oviya-medsafe-to-host-webinar-on-pharmacovigilance-system-for-regulatory-compliance-in-india</guid>
<description><![CDATA[ 
Webinar will cover pharmacovigilance requirements, system elements and regulatory responsibilities for pharma and biotechnology companies
The post Oviya MedSafe to host webinar on pharmacovigilance system for regulatory compliance in India appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2019/02/20160339/pharmacovigilance3_85431.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 28 Aug 2026 17:40:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Oviya, MedSafe, host, webinar, pharmacovigilance, system, for, regulatory, compliance, India</media:keywords>
<content:encoded><![CDATA[<div><img width="600" height="403" src="https://cdn.expresspharma.in/wp-content/uploads/2019/02/20160339/pharmacovigilance3_85431.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2019/02/20160339/pharmacovigilance3_85431.jpg 600w, https://cdn.expresspharma.in/wp-content/uploads/2019/02/20160339/pharmacovigilance3_85431-300x202.jpg 300w" sizes="(max-width: 600px) 100vw, 600px"></div><p><span>Oviya MedSafe, a pharmacovigilance consulting and drug safety services organisation, has announced a complimentary educational webinar titled “How to Build a Pharmacovigilance System for Regulatory Compliance in India” on 10 September 2026 from 11:00 AM to 1:00 PM IST.</span></p>
<p><span>The webinar comes following regulatory attention to pharmacovigilance in India. On 3 June 2026, the Central Drugs Standard Control Organisation (CDSCO) issued a circular reiterating the requirement under Paragraph 6.11 of Schedule M for licensees to maintain a pharmacovigilance system for collecting, processing and forwarding adverse drug reaction reports associated with drugs manufactured or marketed by the licensee.</span></p>
<p><span>The circular further directed stakeholders to ensure the establishment and maintenance of an effective pharmacovigilance system in compliance with the applicable provisions of the Drugs & Cosmetics Act, 1940, the Rules made thereunder, and the New Drugs and Clinical Trials (NDCT) Rules, 2019. It also noted that compliance may be verified during routine inspections and other regulatory activities.</span></p>
<p><span>Against this backdrop, pharmaceutical and biotechnology companies are evaluating whether their existing arrangements support their regulatory responsibilities and whether their pharmacovigilance systems are sufficiently robust, sustainable and inspection-ready.</span></p>
<p><span>The session will be led by </span><b>Dr J Vijay Venkatraman</b><span>, Managing Director & CEO, Oviya MedSafe Pvt Ltd, who has 25 years of experience spanning clinical medicine, pharmacovigilance, drug safety, regulatory compliance and pharmacovigilance system development.</span></p>
<p><span>Speaking about the initiative, Dr Vijay said; “A pharmacovigilance system is no longer simply a compliance requirement. It is an essential component of patient safety and responsible product stewardship. Many organisations understand the need for pharmacovigilance but are less certain about what constitutes a complete and sustainable system. Through this webinar, we hope to provide practical guidance that will help pharmaceutical and biotechnology companies better understand the key elements of an effective pharmacovigilance framework and their regulatory responsibilities as Marketing Authorisation Holders.”</span></p>
<p><span>The webinar will provide insights into establishing and maintaining an effective pharmacovigilance system, with emphasis on the expectations applicable to pharmaceutical and biotechnology companies manufacturing and/or marketing products in India.</span></p>
<p><span>Topics will include organisational, governance, procedural, quality and system elements that need to be considered when establishing a pharmacovigilance framework. The session will also cover approaches to building a system that can evolve with an organisation’s growth, business needs and regulatory obligations.</span></p>
<p><span>Participation is free of charge and restricted to representatives of pharmaceutical and biotechnology companies manufacturing and/or marketing products in India. Registrations will be reviewed prior to approval, with participation limited to 100 participants.</span></p>
<p><b>Webinar details</b></p>
<p><b>Title:</b><span> How to Build a Pharmacovigilance System for Regulatory Compliance in India</span><span><br>
</span> <b>Date:</b><span> Thursday, 10 September 2026</span><span><br>
</span> <b>Time:</b><span> 11:00 AM to 1:00 PM IST</span><span><br>
</span> <b>Platform:</b><span> Microsoft Teams Webinar</span><span><br>
</span> <b>Speaker:</b><span> Dr J Vijay Venkatraman, Managing Director & CEO, Oviya MedSafe Pvt Ltd</span></p>
<p><b>Registration</b></p>
<p><span>Interested participants may submit a registration request through the registration form.</span></p>
<p><span>https://forms.cloud.microsoft/r/Pb0htB8dM8</span></p>
<p>The post <a href="https://www.expresspharma.in/oviya-medsafe-to-host-webinar-on-pharmacovigilance-system-for-regulatory-compliance-in-india/">Oviya MedSafe to host webinar on pharmacovigilance system for regulatory compliance in India</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>University of Toronto study advances tRNA approach for genetic diseases</title>
<link>https://edusehat.com/en/university-of-toronto-study-advances-trna-approach-for-genetic-diseases</link>
<guid>https://edusehat.com/en/university-of-toronto-study-advances-trna-approach-for-genetic-diseases</guid>
<description><![CDATA[ 
Researchers show engineered tRNA can restore full-length protein production in cystic fibrosis models
The post University of Toronto study advances tRNA approach for genetic diseases appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2022/05/10153511/dna-g0de2cc098_640-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 28 Aug 2026 14:05:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>University, Toronto, study, advances, tRNA, approach, for, genetic, diseases</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2022/05/10153511/dna-g0de2cc098_640-1.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2022/05/10153511/dna-g0de2cc098_640-1.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2022/05/10153511/dna-g0de2cc098_640-1-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>Researchers at the University of Toronto have developed an RNA therapeutic approach that could treat genetic diseases linked to certain disease-causing mutations. The work advances an emerging platform in genetic medicine centred on transfer RNA, or tRNA. The team engineered tRNA to help cells read through premature stop signals and complete the production of full-length proteins that would otherwise be truncated or absent.</span></p>
<p><span>Study lead Bowen Li, associate professor at U of T’s Leslie Dan Faculty of Pharmacy and affiliate scientist at the University Health Network’s Princess Margaret Cancer Centre, said the research could lay the foundation for a class of drugs designed to treat genetic diseases through a common therapeutic strategy.</span></p>
<p><span>“There are so many types of disease-causing mutations – many affecting only a small number of people – that developing a separate gene therapy for every individual mutation is extremely challenging,” says Li, who is also an affiliate scientist at the University Health Network’s Princess Margaret Cancer Centre.</span></p>
<p><span>“With tRNA therapeutics, our goal is to develop a common therapeutic approach that could potentially address the same type of mutation across many different genes and diseases, including rare conditions that currently have few or no effective treatment options.”</span></p>
<p><span>Li and his team focused on “nonsense mutations”. These mutations introduce a premature stop signal into the genetic instructions for making a protein. As a result, cells may produce little or no full-length functional protein, disrupting vital functions.</span></p>
<p><span>Although nonsense mutations are estimated to cause about 11 per cent of inherited genetic disorders, they number in the thousands, including subsets of cystic fibrosis and certain muscular and neurological diseases.</span></p>
<p><span>The study, published in Science on Aug. 27, shows that tRNA can be engineered to suppress disease-causing nonsense mutations and restore full-length protein production across a series of laboratory and preclinical models of cystic fibrosis. The researchers also found that the approach can be combined with existing cystic fibrosis drugs, suggesting the potential for combination therapy.</span></p>
<p><span>“The same type of premature stop signal can occur in many different genes, causing diseases that affect the lungs, brain, muscles and other tissues”, says Li. “Our long-term goal is to develop tRNA medicines that recognize these shared stop signals, so that one therapeutic strategy could potentially be applied across many different genetic diseases.”</span></p>
<p><span>Study co-lead Haissi Cui, assistant professor of chemistry in the Faculty of Arts & Science, pointed the team towards an approach involving the addition of chemical tags found in natural tRNAs. One modification increased the activity and duration of the engineered tRNA.</span></p>
<p><span>“Interdisciplinary collaboration was key to this project,” says Cui. “We used nature as our design guide and found that adding one specific modification made the engineered tRNA more active and longer-lasting. It shows what becomes possible when chemistry and RNA biology come together.”</span></p>
<p><span>Jingan (Charles) Chen, a researcher in Li’s lab and co-lead author of the study, said the next challenge was delivering the tRNAs to the cells that needed them. The team used lipid nanoparticles, the fatty bubbles that carried mRNA in the COVID-19 vaccines, with a redesign for tRNA delivery.</span></p>
<p><span>“No matter how powerful you make those tRNAs, without delivery, they cannot be a drug,” says Chen, a PhD candidate in the Leslie Dan Faculty of Pharmacy and the Institute of Biomedical Engineering.</span></p>
<p><span>“That cargo-specific delivery system is one of the major advances of our study. We used a tailored lipid nanoparticle delivery system that is specifically developed for tRNA.”</span></p>
<p><span>In recent years, cystic fibrosis care has been transformed by drugs called CFTR modulators, such as Trikafta. However, they are not effective for the roughly one in 10 patients whose disease stems from a nonsense mutation.</span></p>
<p><span>Cystic fibrosis leaves cells unable to move salt and water, causing mucus to clog the airways and gut. Modulators repair and activate the misshapen CFTR protein that controls this flow. However, they cannot fix what was never built.</span></p>
<p><span>The U of T researchers tested whether tRNA could change this. The question was whether the CFTR protein would reappear and whether it would function. In human airway cells with two common nonsense mutations, the protein returned and functioned, remaining for more than 40 days. Further preclinical tests pointed in the same direction.</span></p>
<p><span>Research team members Jim Hu and Tanja Gonska, both SickKids scientists with appointments in U of T’s Temerty Faculty of Medicine, provided access to tissue from a cystic fibrosis patient with a complex CFTR genotype containing four mutations, two of them nonsense, that left them unresponsive to existing drugs.</span></p>
<p><span>The samples were grown into miniature models called organoids. Neither the modified tRNA nor Trikafta had much effect on its own, but the patient’s cells responded when the two were used together. The tRNA restored production of the full-length protein and gave Trikafta something to work with.</span></p>
<p><span>Lisa Dolovich, dean of the Leslie Dan Faculty of Pharmacy, said the study forms part of U of T’s tradition of drawing from the body’s own biology to develop treatments, from insulin to the GLP-1 discoveries behind drugs such as Ozempic.</span></p>
<p><span>“This is the kind of foundational research that medical breakthroughs are built on,” Dolovich says. “By tackling the science and the delivery together, we’re closer to turning a discovery into a drug.”</span></p>
<p><span>The researchers say the study demonstrates tRNA’s therapeutic potential. Li’s lab is looking to expand the approach to other organs, each of which will need a specialised delivery system. For the lungs, the team has shown that its particles can survive being turned into a fine mist, a first step towards a treatment that patients could inhale at home.</span></p>
<p><span>The research was supported by the Canadian Institutes of Health Research, the Natural Sciences and Engineering Research Council, Cystic Fibrosis Canada, the Cystic Fibrosis Foundation, the New Frontiers in Research Fund, the Canada Research Chairs Program, the Connaught Fund, the Harrington Discovery Institute and the National Institutes of Health.</span></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/university-of-toronto-study-advances-trna-approach-for-genetic-diseases/">University of Toronto study advances tRNA approach for genetic diseases</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>FDA grants RPDD to ReviR’s RTX&#45;117 for CMT</title>
<link>https://edusehat.com/en/fda-grants-rpdd-to-revirs-rtx-117-for-cmt</link>
<guid>https://edusehat.com/en/fda-grants-rpdd-to-revirs-rtx-117-for-cmt</guid>
<description><![CDATA[ The designation covers CMT as a whole and is not restricted to specific subtypes. The RPDD programme seeks to promote the development of therapies for rare, serious or 
The post FDA grants RPDD to ReviR’s RTX-117 for CMT appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/08/PT-2-27-08-2026-shutterstock_2105266859.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 27 Aug 2026 20:10:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>FDA, grants, RPDD, ReviR’s, RTX-117, for, CMT</media:keywords>
<content:encoded><![CDATA[<p>The designation covers CMT as a whole and is not restricted to specific subtypes.</p>
<p>The RPDD programme seeks to promote the development of therapies for rare, serious or life-threatening conditions that primarily affect children.</p>
<p>Under the programme, if RTX-117 receives approval and fulfils the statutory and programme criteria, ReviR Therapeutics may be eligible to obtain a rare paediatric disease priority review voucher.</p>
<p>This voucher can be used by the company or transferred to another sponsor for priority review of a future marketing application and may offer commercial value to ReviR Therapeutics.</p>
<p>CMT refers to a group of inherited neuromuscular disorders that often begin in childhood or adolescence.</p>
<p>Common symptoms include loss of sensation, muscle wasting, muscle weakness in the legs, pain, skeletal changes and slow motor development.</p>
<p>According to ReviR Therapeutics, there are currently no disease-modifying therapies approved for CMT.</p>
<p>RTX-117 has been developed using the company’s VoyageR AI platform and is intended to target the integrated stress response (ISR) pathway by activating eukaryotic initiation factor 2B (eIF2B), with the aim of restoring normal messenger ribonucleic acid (mRNA) translation and maintaining protein-expression balance.</p>
<p>The therapy is currently undergoing Phase I clinical trials, with completion expected by the end of the year. RTX-117 also holds orphan drug designation from the FDA for CMT and has received clinical trial authorisations in both China and the US.</p>
<p>ReviR Therapeutics chief scientific officer Paul August said: “People living with CMT, particularly children, urgently need more effective disease-modifying treatment options.</p>
<p>“This designation provides additional support for the continued development of RTX-117. As the CMT programme progresses, we will continue to build clinical and translational evidence that may inform our work in additional ISR-related diseases.”</p>
<p>ReviR Therapeutics focuses on developing therapies within neurology, oncology, immunology and inflammation.</p>
<p>The company aims to advance RTX-117 and other small-molecule candidates targeting RNA function across a range of ISR-related and fibrotic diseases.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/fda-designation-revirs-rtx-117/">FDA grants RPDD to ReviR’s RTX-117 for CMT</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>ViiV Healthcare’s Tivicay PD gains FDA approval for paediatric HIV therapy</title>
<link>https://edusehat.com/en/viiv-healthcares-tivicay-pd-gains-fda-approval-for-paediatric-hiv-therapy</link>
<guid>https://edusehat.com/en/viiv-healthcares-tivicay-pd-gains-fda-approval-for-paediatric-hiv-therapy</guid>
<description><![CDATA[ The therapy is indicated for children who are either new to treatment or have prior experience with antiretroviral therapies but have not been treated with integrase strand transfer 
The post ViiV Healthcare’s Tivicay PD gains FDA approval for paediatric HIV therapy appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/08/PT-27-08-2026-shutterstock_2556717557.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 27 Aug 2026 20:10:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>ViiV, Healthcare’s, Tivicay, gains, FDA, approval, for, paediatric, HIV, therapy</media:keywords>
<content:encoded><![CDATA[<p>The therapy is indicated for children who are either new to treatment or have prior experience with antiretroviral therapies but have not been treated with integrase strand transfer inhibitors (INSTIs).</p>
<p>ViiV Healthcare is a global HIV specialist company, majority owned by GSK, with Shionogi as a shareholder.</p>
<p>Tivicay PD’s approval follows a Priority Review by the FDA.</p>
<p>The decision is backed by data from the International Maternal Paediatric Adolescent AIDS Clinical Trials (IMPAACT) 2023 clinical study, funded by the National Institutes of Health (NIH), as well as additional paediatric pharmacokinetic modelling.</p>
<p>The studies indicated that dolutegravir, described as a second-generation INSTI, reached therapeutic levels in term neonates and demonstrated a safety profile similar to that of older children and adults taking the drug.</p>
<p>ViiV Healthcare chief medical officer Jean van Wyk said: “Today’s approval of Tivicay PD expands the options available for paediatric HIV care, giving families and clinicians in the US greater choice from the very beginning of life.</p>
<p>“For ViiV Healthcare, it reflects our commitment to bringing INSTI-based innovation to children and addressing persistent gaps in HIV care.</p>
<p>“This progress has been made possible through vital collaboration with the HIV community, united by a shared focus on ensuring children living with HIV are not left behind.”</p>
<p>Tivicay and Tivicay PD both contain dolutegravir, which is designed to inhibit HIV integrase and block a critical step in the virus’ replication cycle.</p>
<p>IMPAACT, the clinical research network behind the pivotal trial, brings together investigators and partners worldwide.</p>
<p>It studies interventions for HIV and related conditions across different populations.</p>
<p>The NIH, which supported the research, is the primary US federal agency for medical investigation and part of the Department of Health and Human Services.</p>
<p>In February 2025, the European Commission authorised the use of ViiV Healthcare’s Vocabria (cabotegravir long-acting injections) plus Rekambys (rilpivirine long-acting injections) from Johnson & Johnson for treating adolescents with HIV-1.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/viiv-healthcares-tivicay-pd-fda-approval/">ViiV Healthcare’s Tivicay PD gains FDA approval for paediatric HIV therapy</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Aragen Life Sciences files DRHP with SEBI for ₹800 crore IPO</title>
<link>https://edusehat.com/en/aragen-life-sciences-files-drhp-with-sebi-for-800-crore-ipo</link>
<guid>https://edusehat.com/en/aragen-life-sciences-files-drhp-with-sebi-for-800-crore-ipo</guid>
<description><![CDATA[ 
IPO comprises a fresh issue of ₹800 crore and an offer for sale of up to 27,329,192 equity shares
The post Aragen Life Sciences files DRHP with SEBI for ₹800 crore IPO appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2023/08/23105043/IPO.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 27 Aug 2026 20:10:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Aragen, Life, Sciences, files, DRHP, with, SEBI, for, ₹800, crore, IPO</media:keywords>
<content:encoded><![CDATA[<div><img width="713" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2023/08/23105043/IPO.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2023/08/23105043/IPO.jpg 713w, https://cdn.expresspharma.in/wp-content/uploads/2023/08/23105043/IPO-300x168.jpg 300w" sizes="auto, (max-width: 713px) 100vw, 713px"></div><p><span>Aragen Life Sciences has filed its draft red herring prospectus (DRHP) with SEBI for an initial public offering (IPO).</span></p>
<p><span>The IPO comprises a fresh issue of ₹800 crore and an offer for sale (OFS) aggregating up to 27,329,192 equity shares of face value of ₹10 each by selling shareholders.</span></p>
<p><span>The proceeds from the fresh issue are proposed to be utilised towards the repayment and/or pre-payment of borrowings; capital expenditure to be incurred by the company for purchase of new equipment and machinery for the company’s facilities in Hyderabad; capital expenditure to be incurred by one of the company’s material subsidiaries, Aragen Biologics Private Limited, for the facility in Bengaluru, towards purchase of new equipment and machinery; and general corporate purpose, supporting the company’s next phase of expansion.</span></p>
<p><span>Incorporated in 2000, Aragen Life Sciences is a fully integrated contract research, development and manufacturing organisation (CRDMO) serving global innovator companies and emerging firms in the life sciences industry. The company offers solutions across the entire drug development lifecycle spanning contract discovery and pre-clinical research solutions (CRO or Contract Research) and contract development and manufacturing solutions (CDMO) for both small molecules and biologics.</span></p>
<p><span>With more than 25 years of operations, Aragen Life Sciences has become the largest CRDMO among the assessed Indian peers in terms of number of solutions offered across the drug development value chain as of March 31, 2026. The company has also become one of the top three largest Indian CRDMOs in terms of operating revenue among the assessed Indian peers, operating in a global CRDMO market estimated at USD 171 billion in Fiscal 2026.</span></p>
<p><span>The company focuses on life sciences companies that are engaged in new chemical entities (NCEs) and new biological entities (NBEs) and has served as a strategic partner to 591 customers globally in Fiscal 2026, across key markets including the United States, Europe, Japan, India and other APAC markets. Company’s customer base comprises Big Pharma companies, large pharmaceutical companies, small biotechnology companies and mid-sized pharmaceutical companies operating across pharmaceuticals, biotechnology, animal health, agrochemicals and specialty chemicals. Aragen Life Sciences worked with 16 of the Top 20 Big Pharma customers as of March 31, 2026.</span></p>
<p><span>Aragen Life Sciences initiated its CRO business in 2002 and have since grown to operate the second largest CRO solutions platform in India in terms of number of scientific personnel among the assessed Indian peers as of March 31, 2026. The company is one of two Indian CRDMOs among the assessed peers to offer integrated small molecule drug substance and drug product development services, as of March 31, 2026. Aragen Life Sciences was the second CRDMO in India to offer biologics services through an acquisition in 2014 and have since expanded its capabilities to offer integrated “gene-to-GMP’ solutions across the biologics CRDMO value chain. Its biologics CRDMO platform is supported by an integrated US–India delivery model combining cell line development and early-stage research in the United States with cost-efficient development and manufacturing in India.</span></p>
<p>The Company’s workforce comprises 4,362 employees including 3,412 scientific personnel of whom 479 hold PhD degrees as of March 31, 2026. According to the F&S Report, the company had the highest PhD-to-scientific personnel ratio within the Indian CRDMO industry at 14.04% as of March 31, 2026, that demonstrates the strength of research workforce and depth of its scientific expertise.</p>
<p>The company maintained a structured focus on environmental, social and governance (ESG) initiatives and corporate governance practices including sustainability commitments, responsible business conduct and board-led oversight supported by a professional management team. Aragen Life Sciences obtained the Gold EcoVadis Sustainability Rating in Fiscal 2026, placing it among the top 5% of companies globally and has also become a signatory to the Science Based Target Initiative (SBTi) in Fiscal 2023 and became an associate member of Pharmaceutical Supply Chain Initiative (PSCI) in 2022.</p>
<p>The company also recorded the second highest revenue from operations growth between Fiscal 2025 and Fiscal 2026 among the assessed Indian peers, according to the F&S Report. Its revenue from operations, profit for the year, Adjusted EBITDA and adjusted profit for the year increased at a CAGR of 14.64 per cent, 26.86 per cent, 15.63 per cent and 29.91 per cent, respectively, from Fiscal 2024 to reach ₹21,783.92 million, ₹2,576.44 million, ₹5,937.65 million and ₹2,839.85 million, respectively, in Fiscal 2026. While achieving this growth, the company maintained its focus on capital efficiency with ROCE and ROE were 18.18 per cent and 11.96 per cent, respectively.</p>
<p>Axis Capital Limited, Citigroup Global Markets India Private Limited, Goldman Sachs (India) Securities Private Limited and JM Financial Limited are the book running lead managers to the issue.</p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/aragen-life-sciences-files-drhp-with-sebi-for-%E2%82%B9800-crore-ipo/">Aragen Life Sciences files DRHP with SEBI for ₹800 crore IPO</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Jagat Pharma expands nutra portfolio with six wellness supplements</title>
<link>https://edusehat.com/en/jagat-pharma-expands-nutra-portfolio-with-six-wellness-supplements</link>
<guid>https://edusehat.com/en/jagat-pharma-expands-nutra-portfolio-with-six-wellness-supplements</guid>
<description><![CDATA[ 
The range includes Marine Collagen, L-Arginine, BeatsWell, OsteoBalance, Maxx Booster and PCOS Wellness
The post Jagat Pharma expands nutra portfolio with six wellness supplements appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/12/17130345/Nutraceuticals.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 27 Aug 2026 20:10:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Jagat, Pharma, expands, nutra, portfolio, with, six, wellness, supplements</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/12/17130345/Nutraceuticals.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/12/17130345/Nutraceuticals.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/12/17130345/Nutraceuticals-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>Jagat Pharma, a New Delhi-headquartered Ayurvedic and wellness company with more than four decades of experience in natural healthcare, has expanded its nutraceutical portfolio with a range of science-backed wellness supplements.</span></p>
<p>The nutraceutical portfolio includes Marine Collagen, L-Arginine, BeatsWell, OsteoBalance, Maxx Booster, and PCOS Wellness, which are designed to address everyday health needs spanning beauty, vitality, heart health, bone strength, and women’s hormonal wellness.</p>
<p>Best known for its flagship Isotine range of Ayurvedic eye-care products, Jagat Pharma has broadened its footprint beyond eye health into the nutraceutical space. The company said the expanded range reflects its commitment to offering holistic, research-backed solutions that support the body from within.</p>
<p>“Wellness today is no longer just about treating symptoms—it’s about giving the body the consistent nourishment it needs to function at its best,” said Dr. Mandeep Singh Basu, Director, Jagat Pharma. “With this range, we wanted to bring together targeted formulations for some of the most common wellness needs people face — from joint and skin health to heart function, bone strength, and hormonal balance — all backed by quality ingredients and manufactured to the highest safety standards.”</p>
<p>Marine Collagen is made to help boost joint flexibility, skin elasticity, hair strength and bone health. Marine Collagen Capsules are made using marine collagen with Vitamin C, vitamin E and D-biotin. This combination helps with collagen absorption and provides visible and functional benefits from the inside out.</p>
<p>L-Arginine is an amino acid formula designed to support the production of nitric oxide. L-Arginine capsules are intended for those who want to maintain healthy circulation, improve stamina, and enhance immune function and muscle recovery as part of an active lifestyle.</p>
<p>BeatsWell is a daily heart-support supplement containing Arjuna extract, CoQ10, moringa and lycopene to support cardiovascular function, healthy circulation and protection from oxidative stress as a preventative measure for heart wellness.</p>
<p><span>OsteoBalance is a combination of calcium, vitamin D3, magnesium and other nutrients that support bone health. It is formulated to help maintain bone density, joint flexibility and skeletal strength, especially for those experiencing age- or lifestyle-related bone health issues.</span></p>
<p>PCOS Wellness Capsules are made with traditional herbs including Shatavari, Ashoka and Gokhru to help women with PCOS-related symptoms to support hormonal balance, menstrual regularity and overall well-being.</p>
<p>Maxx Booster is formulated with Ayurvedic herbs that support strength, stamina and overall vitality. Ashwagandha, Shilajit and Safed Musli are some of the key ingredients that naturally help to boost energy, reduce stress and increase muscle strength. This medication is effective in supporting healthy testosterone levels; it helps with increased muscular growth, enhanced endurance and prolonged energy throughout the day. It can also be used regularly to help with stress management, immune health and general vigour.</p>
<p>All six products are manufactured at Jagat Pharma’s WHO-GMP-certified facility in Bareilly, Uttar Pradesh, and lab-tested for purity and potency as per the company’s quality standards across its product range.</p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/jagat-pharma-expands-nutra-portfolio-with-six-wellness-supplements/">Jagat Pharma expands nutra portfolio with six wellness supplements</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>McKesson to acquire Precision Medicine Group for $2.25bn</title>
<link>https://edusehat.com/en/mckesson-to-acquire-precision-medicine-group-for-225bn</link>
<guid>https://edusehat.com/en/mckesson-to-acquire-precision-medicine-group-for-225bn</guid>
<description><![CDATA[ McKesson believes that the deal will support its clinical research and biopharmaceutical commercialisation services. Upon completion of the transaction, Precision Medicine Group will operate under McKesson’s oncology and 
The post McKesson to acquire Precision Medicine Group for $2.25bn appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/08/PT-26-08-2026-shutterstock_2583314417.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 26 Aug 2026 19:00:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>McKesson, acquire, Precision, Medicine, Group, for, 2.25bn</media:keywords>
<content:encoded><![CDATA[<p>McKesson believes that the deal will support its clinical research and biopharmaceutical commercialisation services.</p>
<p>Upon completion of the transaction, Precision Medicine Group will operate under McKesson’s oncology and multi-speciality segment.</p>
<p>The acquisition remains subject to customary closing conditions, including regulatory approvals.</p>
<p>Founded as a provider of global clinical research and commercialisation services, Precision Medicine Group serves biotechnology and pharmaceutical companies.</p>
<p>The company offers integrated services and technology-based products that include biomarker intelligence, laboratory services, a global clinical research organisation, market access consulting, and commercialisation support.</p>
<p>McKesson chair and CEO Brian Tyler said: “This acquisition represents another meaningful step in advancing our oncology and multi-speciality strategy and reflects our continued commitment to providing patients with access to the highest quality of care.</p>
<p>“Precision Medicine Group brings complementary capabilities that will enhance our clinical research and commercialisation services, strengthen clinical trial execution, and broaden our clinical service offerings.”</p>
<p>Precision Medicine Group CEO Margaret Keegan said: “Joining McKesson provides a compelling opportunity to extend the impact of our clinical and commercial expertise for the benefit of our customers, partners and patients they serve.</p>
<p>“Together, we will bring a broader set of capabilities to biopharma companies, supporting them through the development and commercialisation process.</p>
<p>“We are excited to join McKesson and advance our shared commitment to enabling innovation and improving patient access.”</p>
<p>McKesson partners with stakeholders across the healthcare sector, including biopharma companies, care providers and pharmacies, to deliver products and services designed to improve patient health outcomes.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/mckesson-to-buy-precision-medicine-group/">McKesson to acquire Precision Medicine Group for $2.25bn</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Jazz secures FDA approval for Ziihera in advanced HER2+ GEA</title>
<link>https://edusehat.com/en/jazz-secures-fda-approval-for-ziihera-in-advanced-her2-gea</link>
<guid>https://edusehat.com/en/jazz-secures-fda-approval-for-ziihera-in-advanced-her2-gea</guid>
<description><![CDATA[ The regimens include Ziihera combined with Tevimbra (tislelizumab-jsgr) and fluoropyrimidine- and platinum-containing chemotherapy for patients with HER2+ immunohistochemistry (IHC) 3+ or IHC 2+/in situ hybridisation (ISH)+. The other 
The post Jazz secures FDA approval for Ziihera in advanced HER2+ GEA appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/08/PT-2-26-08-2026-shutterstock_2198586225.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 26 Aug 2026 19:00:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Jazz, secures, FDA, approval, for, Ziihera, advanced, HER2, GEA</media:keywords>
<content:encoded><![CDATA[<p>The regimens include Ziihera combined with Tevimbra (tislelizumab-jsgr) and fluoropyrimidine- and platinum-containing chemotherapy for patients with HER2+ immunohistochemistry (IHC) 3+ or IHC 2+/in situ hybridisation (ISH)+.</p>
<p>The other regimen includes Ziihera with fluoropyrimidine- and platinum-containing chemotherapy for those with HER2+ IHC 3+.</p>
<p>The decision follows results from the Phase III HERIZON-GEA-01 trial, which demonstrated significant improvements in both progression-free survival and overall survival for patients receiving Ziihera-based treatments.</p>
<p>In the trial, the regimen featuring Ziihera, tislelizumab-jsgr and chemotherapy reduced the risk of death by 28% compared to a trastuzumab-based regimen, resulting in a median overall survival of 26.4 months versus 19.2 months.</p>
<p>Median progression-free survival with the new regimens was 12.4 months, compared to 8.1 months for trastuzumab plus chemotherapy.</p>
<p>The study found these benefits across subgroups defined by region and programmed death-ligand 1 (PD-L1) status.</p>
<p>Jazz Pharmaceuticals research and development executive vice-president and chief medical officer Rob Iannone said: “This approval is a major step forward for people with HER2+ advanced GEA.</p>
<p>“Ziihera is now the first and only bispecific HER2-targeted antibody combined with a PD-1 inhibitor and chemotherapy approved for all HER2+ advanced GEA patients, regardless of PD-L1 status, establishing a new standard of care in first-line treatment.”</p>
<p>The trial identified diarrhoea as the most common adverse reaction, which generally appeared early and was managed with antidiarrheals and dose modifications. Few patients discontinued Ziihera due to side effects.</p>
<p>GEA encompasses cancers of the stomach, gastroesophageal junction, and oesophagus.</p>
<p>Ziihera, a bispecific HER2-directed antibody developed through collaborative efforts between Jazz Pharmaceuticals and BeOne Medicines under licence from Zymeworks, is also indicated in the US for treatment of previously treated unresectable or metastatic HER2+ biliary tract cancer.</p>
<p>In June, Jazz Pharmaceuticals and AbCellera signed a preclinical research, option, and licence agreement for the discovery and development of T-cell-engaging multi-specific antibodies, or T-cell engagers, for gastrointestinal cancers and other solid tumours.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/jazz-fda-approval-ziihera/">Jazz secures FDA approval for Ziihera in advanced HER2+ GEA</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>CBN and PHARMEXCIL sign MoU to regulate controlled substances in pharma exports</title>
<link>https://edusehat.com/en/cbn-and-pharmexcil-sign-mou-to-regulate-controlled-substances-in-pharma-exports</link>
<guid>https://edusehat.com/en/cbn-and-pharmexcil-sign-mou-to-regulate-controlled-substances-in-pharma-exports</guid>
<description><![CDATA[ 
The Central Bureau of Narcotics (CBN), Department of Revenue, Ministry of Finance, and the Pharmaceuticals Export Promotion Council of India (PHARMEXCIL), set up by the Ministry of Commerce and Industry, […]
The post CBN and PHARMEXCIL sign MoU to regulate controlled substances in pharma exports appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/06/07113956/MoU.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 26 Aug 2026 19:00:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>CBN, and, PHARMEXCIL, sign, MoU, regulate, controlled, substances, pharma, exports</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/06/07113956/MoU.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/06/07113956/MoU.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/06/07113956/MoU-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p>The Central Bureau of Narcotics (CBN), Department of Revenue, Ministry of Finance, and the Pharmaceuticals Export Promotion Council of India (PHARMEXCIL), set up by the Ministry of Commerce and Industry, today signed a Memorandum of Understanding (MoU) to promote legitimate pharmaceutical exports while preventing the diversion of controlled substances. The documents were exchanged between Dr Dinesh Bisen, Narcotics Commissioner, representing CBN, and Raja Bhanu, Director General, PHARMEXCIL at the CBN Headquarters, Gwalior.</p>
<p>India is globally recognised as the “Pharmacy of the World”, a leading supplier of active pharmaceutical ingredients (APIs), bulk drugs, formulations, biologics and medical devices. The sector is closely linked to the chemical industry, which supplies the compounds, solvents and catalysts used in drug synthesis. That shared supply chain can be vulnerable to diversion for illicit use if not adequately safeguarded.</p>
<p>CBN is the agency administering the facilitation, regulatory and enforcement provisions of the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985. Its mandate includes supervising the licit cultivation of opium poppy, issuing authorisations for the import and export of narcotic drugs and psychotropic substances, and ensuring that essential chemical inputs are not diverted for illicit use. The framework with PHARMEXCIL extends the Government of India’s National Roadmap of Ease of Doing Business and integrates voluntary compliance mechanisms into the pharmaceutical export ecosystem.</p>
<p>Speaking on the occasion, K. Raja Bhanu, Director General, PHARMEXCIL said, “India today supplies medicines to more than two hundred countries and is the world’s largest provider of generic medicines. That reputation rests on a single, non-negotiable foundation trust: the trust of regulators abroad, of patients who rely on our medicines, and of our own government agencies. Narcotic drugs and psychotropic substances are essential raw materials for our industry, used in anaesthesia and pain management, but we are equally conscious that diversion, even in small measure, can cause serious harm. Through this MoU, PHARMEXCIL commits to act as a genuine industry interface for CBN disseminating regulatory advisories to our exporter members, mobilising their participation in awareness and training programmes, and building a culture of self-regulation that does not wait for enforcement to arrive at the factory gate. Our role remains facilitative, not regulatory. We bring reach into boardrooms and shop floors across the country, and the ability to make lawful compliance simpler and less intimidating. This partnership shows that trade facilitation and regulatory integrity are not competing goals, but complementary ones.”</p>
<p>Under the MoU, the CBN has developed a Voluntary Code of Conduct in close consultation with PHARMEXCIL, setting out recommended practices for the industry. The code remains voluntary and non-binding and is designed not to interfere with normal business operations or create statutory or financial burdens on exporters beyond applicable laws. Member companies will nominate contact persons to coordinate matters associated with the code.”</p>
<p>The two sides will also identify operational bottlenecks and recommend measures to streamline export procedures for compliant exporters. Joint workshops, seminars and awareness campaigns will be organised, in coordination with government institutions including the Central Drugs Standard Control Organisation and Customs where required. The MoU further establishes a framework for the exchange of information needed to meet regulatory objectives, subject to applicable laws and confidentiality obligations.</p>
<p>Both sides also deliberated on a six-month action plan that will prioritise pan-India outreach, stakeholder sensitisation and establishing core areas of institutional and regulatory cooperation.</p>
<p>The MoU reaffirms the Government of India’s commitment to the compliant and sustainable growth of the pharmaceutical sector, supporting export growth through a reduction in dwell time for export authorisations while safeguarding against the misuse of narcotic drugs, psychotropic substances and controlled precursors.</p>
<p>The MoU is the third in a series of agreements signed by CBN with industry bodies. It follows an MoU with the Indian Chemical Council in 2022 covering basic chemical manufacturing and one with CHEMEXCIL in 2025 covering fine and specialty chemicals. The present agreement covers finished pharmaceutical exports.</p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/cbn-and-pharmexcil-sign-mou-to-regulate-controlled-substances-in-pharma-exports/">CBN and PHARMEXCIL sign MoU to regulate controlled substances in pharma exports</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Piramal Pharma strengthens future ready operations with 22.6% emissions reduction</title>
<link>https://edusehat.com/en/piramal-pharma-strengthens-future-ready-operations-with-226-emissions-reduction</link>
<guid>https://edusehat.com/en/piramal-pharma-strengthens-future-ready-operations-with-226-emissions-reduction</guid>
<description><![CDATA[ 
Piramal Pharma, a leading global pharmaceuticals company, released its Sustainability Report 2025–26, showcasing significant progress across its environmental, social and governance (ESG) priorities. Anchored by the theme “Advancing Innovation, Leveraging […]
The post Piramal Pharma strengthens future ready operations with 22.6% emissions reduction appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2022/01/04164456/Piramal.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 26 Aug 2026 19:00:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Piramal, Pharma, strengthens, future, ready, operations, with, 22.6, emissions, reduction</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2022/01/04164456/Piramal.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2022/01/04164456/Piramal.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2022/01/04164456/Piramal-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Piramal Pharma, a leading global pharmaceuticals company, released its Sustainability Report 2025–26, showcasing significant progress across its environmental, social and governance (ESG) priorities. Anchored by the theme “Advancing Innovation, Leveraging Sustainability,” the report highlights how sustainability continues to be integrated into the Company’s strategy, operations and innovation agenda while creating long-term value for patients, customers, communities and stakeholders.</span></p>
<p><b>Key Highlights:</b></p>
<p><b>Climate and responsible 0perations</b></p>
<ul>
<li aria-level="1"><span>Achieved a 22.6% reduction in Scope 1 and Scope 2 greenhouse gas emissions compared to the FY2022 baseline</span></li>
<li aria-level="1"><span>Increased renewable energy usage to 41% of total energy consumption across operations</span></li>
<li aria-level="1"><span>Recycled and reused 2.63 Lakh kilolitres of freshwater, and diverted 65% of total waste for recycling</span></li>
<li aria-level="1"><span>Continued progress against the Company’s Science Based Targets initiative (SBTi)-approved decarbonisation roadmap</span></li>
</ul>
<p><b>Quality and operational excellence</b></p>
<ul>
<li aria-level="1"><span>Successfully completed 38 regulatory inspections, including three USFDA inspections with zero Official Action Indicated (OAI) observations</span></li>
<li aria-level="1"><span>Completed 209 customer audits, reinforcing the Company’s quality and compliance standards across its global manufacturing network</span></li>
<li aria-level="1"><span>Advanced enterprise-wide digital transformation through Catalyst NxGen, SAP S/4HANA implementation and expansion of digital quality systems</span></li>
<li aria-level="1"><span>Announced a US$90 million investment to expand advanced therapeutics capabilities at its Lexington and Riverview facilities</span></li>
</ul>
<p><b>Governance and people</b></p>
<ul>
<li aria-level="1"><span>Maintained zero data breach incidents and zero corruption cases during the reporting period</span></li>
<li aria-level="1"><span>Achieved 100% ESG training completion across employees and 100% Code of Conduct training for the workforce</span></li>
<li aria-level="1"><span>Women represented 30% of the Board and 20.1% of the global workforce, reflecting continued progress on diversity and inclusion</span></li>
<li aria-level="1"><span>Assessed 38% of critical suppliers against sustainability criteria as part of the Company’s responsible supply chain programme</span></li>
</ul>
<p><b>Community impact</b></p>
<ul>
<li aria-level="1"><span>During FY2025–26, Piramal Pharma invested ₹8.98 crore in CSR initiatives, positively impacted nearly 1.8 million people across 112 Aspirational Districts through healthcare and education programmes, and continued to strengthen stakeholder engagement through community development, employee well being and responsible business practices</span><b>.</b></li>
</ul>
<p>Nandini Piramal, Chairperson, Piramal Pharma said<b>, </b><span>“At Piramal Pharma, we see sustainability not simply as a responsibility, but as a catalyst for innovation, resilience and long-term growth. This means investing in cleaner and more efficient operations, strengthening quality and digital capabilities, developing our people and building deeper partnerships across our value chain.</span></p>
<p><span>The progress reflected in this year’s Sustainability Report gives us confidence in the direction we are taking. We believe that innovation and sustainability can reinforce one another, enabling us to make better decisions today while creating greater value for tomorrow.</span></p>
<p><span>As we move forward, our focus will remain on turning our sustainability ambitions into measurable action. Our aspiration is to create a future ready organisation that delivers better health outcomes, builds stronger communities and creates enduring value for all our stakeholders.”</span></p>
<p><span>The Sustainability Report outlines Piramal Pharma’s long-term sustainability framework, built around four strategic pillars Business Resilience, Quality & Excellence, Responsible Operations, and Stakeholder Centricity supported by more than 50 time-bound sustainability targets across 17 material topics. The Company’s sustainability agenda continues to be overseen by its Sustainability and Risk Management Committee, ensuring ESG considerations remain integral to long-term business performance and value creation.</span></p>
<p><span>The Sustainability report follows GRI standards and is aligned with SASB and UNGC frameworks, underscoring PPL’s commitment to sustainable growth, responsible capital allocation, and impactful stakeholder engagement. </span></p>
<p>The post <a href="https://www.expresspharma.in/piramal-pharma-strengthens-future-ready-operations-with-22-6-emissions-reduction/">Piramal Pharma strengthens future ready operations with 22.6% emissions reduction</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Aurigene enters into long&#45;term manufacturing, supply partnership with a leading global pharma company</title>
<link>https://edusehat.com/en/aurigene-enters-into-long-term-manufacturing-supply-partnership-with-a-leading-global-pharma-company</link>
<guid>https://edusehat.com/en/aurigene-enters-into-long-term-manufacturing-supply-partnership-with-a-leading-global-pharma-company</guid>
<description><![CDATA[ 
Aurigene Pharmaceutical Services (“Aurigene”), a wholly owned subsidiary of Dr. Reddy’s Laboratories announced a strategic, long-term Manufacturing and Supply Agreement (MSA) with a leading global pharmaceutical company for the commercial […]
The post Aurigene enters into long-term manufacturing, supply partnership with a leading global pharma company appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123759/Partnership.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 26 Aug 2026 19:00:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Aurigene, enters, into, long-term, manufacturing, supply, partnership, with, leading, global, pharma, company</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123759/Partnership.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123759/Partnership.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123759/Partnership-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p>Aurigene Pharmaceutical Services (“Aurigene”), a wholly owned subsidiary of Dr. Reddy’s Laboratories announced a strategic, long-term Manufacturing and Supply Agreement (MSA) with a leading global pharmaceutical company for the commercial drug-product manufacturing and supply of a diversified portfolio for USA, Europe, Canada and Emerging markets.</p>
<p>The agreement establishes a full-service framework for technical transfer, process development, scale-up, validation, commercial manufacturing and long-term supply. The collaboration highlights Aurigene’s expanding drug product CDMO (Contract Development and Manufacturing Organization) and CMO (Contract Manufacturing Organization) capabilities, particularly in sterile injectables and biologics, complementing its established development and manufacturing expertise across the pharmaceutical value chain.</p>
<p>The initial portfolio comprises 20+ products spanning sterile injectables, biologics and topicals, to be manufactured across facilities in India. The partnership is expected to progress through a phased technology transfer program over the next two to three years, paving the way for commercial manufacturing and supply. At full commercialization, the portfolio is expected to represent an estimated annual volume of approx.18 million units, largely being injectables, with revenues expected to commence from the calendar year 2028.</p>
<p>“We are delighted to enter into this strategic, long-term collaboration,” said Akhil Ravi, Chief Executive Officer, Aurigene Pharmaceutical Services. “This partnership reflects the confidence global innovators place in our integrated drug-product development and manufacturing capabilities of sterile injectables, biologics and topicals, our proven quality and regulatory track record, and our ability to support complex technology transfers and commercial supply. It provides long-term revenue visibility, accelerates the scale-up of our drug-product business, and reinforces our commitment to reliable, high-quality supply to patients worldwide.</p>
<p>The post <a href="https://www.expresspharma.in/aurigene-enters-into-long-term-manufacturing-supply-partnership-with-a-leading-global-pharma-company/">Aurigene enters into long-term manufacturing, supply partnership with a leading global pharma company</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Aurigene enters long&#45;term manufacturing and supply partnership with a global pharma company</title>
<link>https://edusehat.com/en/aurigene-enters-long-term-manufacturing-and-supply-partnership-with-a-global-pharma-company</link>
<guid>https://edusehat.com/en/aurigene-enters-long-term-manufacturing-and-supply-partnership-with-a-global-pharma-company</guid>
<description><![CDATA[ 
The counterparty&#039;s name has not been disclosed in view of confidentiality obligations under the agreement
The post Aurigene enters long-term manufacturing and supply partnership with a global pharma company appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123759/Partnership.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 26 Aug 2026 15:25:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Aurigene, enters, long-term, manufacturing, and, supply, partnership, with, global, pharma, company</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123759/Partnership.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123759/Partnership.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123759/Partnership-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span><span><span><span lang="en-US">Aurigene Pharmaceutical Services, a wholly owned subsidiary of Dr. Reddy’s Laboratories announced a strategic, long-term Manufacturing and Supply Agreement (MSA) with a leading global pharma company for the commercial drug-product manufacturing and supply of a diversified portfolio for US, Europe, Canada and Emerging markets.</span></span></span></span></p>
<p lang="en-US"><span><span><span>The agreement establishes a full-service framework for technical transfer, process development, scale-up, validation, commercial manufacturing and long-term supply. The collaboration highlights Aurigene’s expanding drug product CDMO and CMO capabilities, particularly in sterile injectables and biologics, complementing its established development and manufacturing expertise across the pharma value chain.</span></span></span></p>
<p lang="en-US"><span><span><span>The initial portfolio comprises 20+ products spanning sterile injectables, biologics and topicals, to be manufactured across facilities in India. The partnership is expected to progress through a phased technology transfer program over the next two to three years, paving the way for commercial manufacturing and supply. At full commercialisation, the portfolio is expected to represent an estimated annual volume of approx.18 million units, largely being injectables, with revenues expected to commence from the calendar year 2028.</span></span></span></p>
<p><span>“<span><span><span lang="en-US">We are delighted to enter into this strategic, long-term collaboration,” said </span><span lang="en-US">Akhil Ravi, Chief Executive Officer, Aurigene Pharmaceutical Services.</span><span lang="en-US"> “This partnership reflects the confidence global innovators place in our integrated drug-product development and manufacturing capabilities of sterile injectables, biologics and topicals, our proven quality and regulatory track record, and our ability to support complex technology transfers and commercial supply. It provides long-term revenue visibility, accelerates the scale-up of our drug-product business, and reinforces our commitment to reliable, high-quality supply to patients worldwide.</span></span></span></span></p>
<p lang="en-US"><span><span><span>The counterparty’s name has not been disclosed in view of confidentiality obligations under the agreement.</span></span></span></p>
<p>The post <a href="https://www.expresspharma.in/aurigene-enters-long-term-manufacturing-and-supply-partnership-with-a-global-pharma-company/">Aurigene enters long-term manufacturing and supply partnership with a global pharma company</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Takeda’s Orzeyful secured Japan MHLW approval for narcolepsy type 1</title>
<link>https://edusehat.com/en/takedas-orzeyful-secured-japan-mhlw-approval-for-narcolepsy-type-1</link>
<guid>https://edusehat.com/en/takedas-orzeyful-secured-japan-mhlw-approval-for-narcolepsy-type-1</guid>
<description><![CDATA[ This decision makes Orzeyful the only treatment in Japan currently indicated to address the underlying cause of narcolepsy type 1, also known as narcolepsy with cataplexy, rather than 
The post Takeda’s Orzeyful secured Japan MHLW approval for narcolepsy type 1 appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/08/PT-25-08-2026-shutterstock_1013737744.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 25 Aug 2026 17:55:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Takeda’s, Orzeyful, secured, Japan, MHLW, approval, for, narcolepsy, type</media:keywords>
<content:encoded><![CDATA[<p>This decision makes Orzeyful the only treatment in Japan currently indicated to address the underlying cause of narcolepsy type 1, also known as narcolepsy with cataplexy, rather than targeting individual symptoms.</p>
<p>Orzeyful, an oral orexin receptor 2 agonist, was discovered in Takeda’s laboratories in Japan.</p>
<p>Takeda is preparing to launch the therapy in Japan, aiming to make it available to patients as soon as possible.</p>
<p>Takeda president and CEO Julie Kim said: “Our discovery of the first orexin agonist is a successful representation of Japan-originated science that will directly impact people around the world living with narcolepsy type 1.</p>
<p>“With the potential to redefine narcolepsy type 1 care, Orzeyful is the first validation of our broader orexin strategy, demonstrating how scientific innovation can create new possibilities for patients and drive future growth for Takeda.”</p>
<p>Narcolepsy type 1 is described as a chronic and rare neurological disorder involving a deficiency of orexin.</p>
<p>Symptoms can include excessive daytime sleepiness, cataplexy (sudden loss of muscle tone), disturbed night-time sleep, sleep paralysis, hallucinations, and cognitive issues.</p>
<p>The MHLW approval was supported by results from a clinical programme, including the global Phase III FirstLight (TAK-861-3001) and RadiantLight (TAK-861-3002) trials.</p>
<p>These studies reported that oveporexton improved excessive daytime sleepiness, cataplexy, and other secondary symptoms compared to placebo.</p>
<p>The safety profile was consistent across studies, with the most frequent adverse events being insomnia, urinary urgency, urinary frequency, and excessive saliva.</p>
<p>The Japanese approval is the third for Orzeyful worldwide, following earlier authorisations for the treatment of narcolepsy type 1 in China and the US.</p>
<p>In the US, the classification of Orzeyful as a controlled substance remains under review by the Drug Enforcement Administration.</p>
<p>Last month, Insilico Medicine entered a strategic collaboration agreement with Takeda to deploy its AI-based Pharma.AI platform in the discovery and development of drug candidates.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/takedas-orzeyful-japan-mhlw-approval/">Takeda’s Orzeyful secured Japan MHLW approval for narcolepsy type 1</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Lundbeck’s asedebart receives EC orphan designation in Cushing’s syndrome</title>
<link>https://edusehat.com/en/lundbecks-asedebart-receives-ec-orphan-designation-in-cushings-syndrome</link>
<guid>https://edusehat.com/en/lundbecks-asedebart-receives-ec-orphan-designation-in-cushings-syndrome</guid>
<description><![CDATA[ This regulatory status is designed for therapies targeting rare, life-threatening, or chronically debilitating diseases. Cushing’s syndrome of endogenous origin is a rare endocrine disease caused in most instances 
The post Lundbeck’s asedebart receives EC orphan designation in Cushing’s syndrome appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/08/PT-2-25-08-2026-shutterstock_2029246028.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 25 Aug 2026 17:55:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Lundbeck’s, asedebart, receives, orphan, designation, Cushing’s, syndrome</media:keywords>
<content:encoded><![CDATA[<p>This regulatory status is designed for therapies targeting rare, life-threatening, or chronically debilitating diseases.</p>
<p>Cushing’s syndrome of endogenous origin is a rare endocrine disease caused in most instances by excessive production of adrenocorticotropic hormone (ACTH).</p>
<p>This is often due to a pituitary tumour known as Cushing’s disease, or less frequently from ectopic ACTH-secreting tumours.</p>
<p>Elevated ACTH leads to increased steroid hormone production, particularly cortisol, resulting in a significant disease burden characterised by metabolic, cardiovascular, and neuropsychiatric complications.</p>
<p>Existing medical therapies for Cushing’s syndrome can help manage cortisol levels, but disease control is often difficult and current treatments may have limited efficacy, safety, and tolerability.</p>
<p>Asedebart, developed by Lundbeck, is a humanised anti-ACTH monoclonal antibody that blocks ACTH binding to the melanocortin 2 receptor in the adrenal glands.</p>
<p>This inhibits the hormonal signalling pathway and reduces secretion of glucocorticoids, mineralocorticoids and androgens.</p>
<p>The mechanism is being explored in ongoing proof-of-concept trials in patients with Cushing’s disease and classic congenital adrenal hyperplasia (CAH) to evaluate safety and efficacy.</p>
<p>Lundbeck research and development executive vice-president Johan Luthman said: “Orphan designation in the European Union is an important recognition of both the unmet need in Cushing’s and the scientific rationale behind asedebart.</p>
<p>“The asedebart programme is a good representation of the type of strong targeted mechanism programmes we like to advance in Lundbeck.</p>
<p>“The orphan designation in Cushing’s syndrome for asedebart is also another example of a breakthrough innovation pipeline in neuroendocrine and rare disorders, where several programmes have been granted a number of special regulatory designations in recent years.”</p>
<p>Previous orphan designations have been awarded to asedebart for classic congenital adrenal hyperplasia in the EU, the US, and Japan, as well as for Cushing’s disease in Japan.</p>
<p>Asedebart remains an investigational product and is not approved for marketing in any country.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/lundbecks-asedebart-ec-orphan-designation/">Lundbeck’s asedebart receives EC orphan designation in Cushing’s syndrome</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>BITS Pilani Goa researchers develop pharma polymer&#45;based bioink for 3D&#45;printed skin scaffolds and customised drug delivery</title>
<link>https://edusehat.com/en/bits-pilani-goa-researchers-develop-pharma-polymer-based-bioink-for-3d-printed-skin-scaffolds-and-customised-drug-delivery</link>
<guid>https://edusehat.com/en/bits-pilani-goa-researchers-develop-pharma-polymer-based-bioink-for-3d-printed-skin-scaffolds-and-customised-drug-delivery</guid>
<description><![CDATA[ 
Study demonstrate a single, affordable hydrogel for tissue engineering and 3D-printed chewable tablets
The post BITS Pilani Goa researchers develop pharma polymer-based bioink for 3D-printed skin scaffolds and customised drug delivery appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/08/25151228/BITS-Pilani-Goa-Campus-Research-team-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 25 Aug 2026 17:55:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>BITS, Pilani, Goa, researchers, develop, pharma, polymer-based, bioink, for, 3D-printed, skin, scaffolds, and, customised, drug, delivery</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="450" src="https://cdn.expresspharma.in/wp-content/uploads/2026/08/25151228/BITS-Pilani-Goa-Campus-Research-team-1.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/08/25151228/BITS-Pilani-Goa-Campus-Research-team-1.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/25151228/BITS-Pilani-Goa-Campus-Research-team-1-300x180.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p align="JUSTIFY"><span><span><span><span lang="en-GB">Researchers at the Birla Institute of Technology and Science (BITS) Pilani, K.K. Birla Goa Campus, have developed a pharma polymer-based hydrogel for 3D printing using extrusion-based method which has the potential to be used for skin tissue engineering and customised drug delivery.</span></span></span></span></p>
<p align="JUSTIFY"><span><span><span><span lang="en-GB">The study, published in the </span></span></span><span><span><span lang="en-GB"><i>Journal of Biological Engineering</i></span></span></span><span><span><span lang="en-GB">, explores the use of pharmaceutical grade polymers, such as starch, maltodextrin and sodium alginate, to create hydrogels that display the desired properties needed to be 3D printed. The method could help to solve some of the issues with traditional bioinks: material variability, safety, high costs, and regulatory approvals.</span></span></span></span></p>
<p lang="en-US" align="JUSTIFY"><span><span><span>The research was led by Prof Anasuya Ganguly, along with Hemant Kumar Bankhede, Maheswari Sivaravi, Antara Poi Raiturker, and Prajakta Praveen Bhende from the Department of Biological Sciences, and Prof Asima Shaukat, Assistant Professor, Mamta Keshav Tari, Sagar B Kale from the Department of Chemical Engineering, BITS Pilani, K.K. Birla Goa Campus.</span></span></span></p>
<p lang="en-US" align="JUSTIFY"><img decoding="async" class="aligncenter size-full wp-image-459223" src="https://cdn.expresspharma.in/wp-content/uploads/2026/08/25150650/Hemant-Bankhede-with-the-3D-bio-printer.jpeg" alt="" width="1280" height="720" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/08/25150650/Hemant-Bankhede-with-the-3D-bio-printer.jpeg 1280w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/25150650/Hemant-Bankhede-with-the-3D-bio-printer-300x169.jpeg 300w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/25150650/Hemant-Bankhede-with-the-3D-bio-printer-1024x576.jpeg 1024w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/25150650/Hemant-Bankhede-with-the-3D-bio-printer-768x432.jpeg 768w" sizes="(max-width: 1280px) 100vw, 1280px"></p>
<h6 lang="en-US" align="JUSTIFY"><em>Caption: Hemant Bankhede with the 3D bioprinter</em></h6>
<p lang="en-GB" align="JUSTIFY"><span><span><span><b>Developing a printable hydrogel for skin tissue engineering</b></span></span></span></p>
<p lang="en-GB" align="JUSTIFY"><span><span><span>The researchers formulated a hydrogel designed to exhibit the flow and recovery properties necessary for extrusion-based 3D printing. The material demonstrated shear-thinning behaviour, enabling it to flow under the shear applied during printing and subsequently recover its structure after deposition. The study reported 87 per cent thixotropic recovery, indicating its ability to retain the shape and structural integrity of the printed constructs.</span></span></span></p>
<p lang="en-GB" align="JUSTIFY"><span><span><span>The researchers also evaluated the biological compatibility of the hydrogel using L929 and HaCaT cells, which are relevant to skin tissue engineering. The formulation demonstrated more than 70 per cent cell viability in the tested cell models. The printed scaffolds also showed blood compatibility, with 5.0 per cent haemolysis reported in the study. Confocal microscopy further provided evidence of cell growth on the crosslinked hydrogel.</span></span></span></p>
<p align="JUSTIFY"><span><span><span><span lang="en-GB">Prof. Anasuya Ganguly, Department of Biological Sciences, BITS Pilani, said,</span> “<span lang="en-GB">This study demonstrates that pharmaceutical-grade polymers can be formulated into hydrogels with properties suitable for 3D bioprinting. The findings provide a promising foundation for exploring a single, versatile platform for applications ranging from skin tissue engineering to customised drug delivery.”</span></span></span></span></p>
<p lang="en-GB" align="JUSTIFY"><span><span><span><b>Extending the bioink platform to customised drug delivery</b></span></span></span></p>
<p lang="en-GB" align="JUSTIFY"><span><span><span>The researchers further demonstrated the versatility of the formulation by incorporating glimepiride into the hydrogel and using it to produce 3D-printed customised chewable tablets.</span></span></span></p>
<p lang="en-GB" align="JUSTIFY"><span><span><span>The printed tablets demonstrated 100.4 per cent content uniformity, indicating consistent drug loading, and exhibited a sustained drug-release profile over four hours. The findings demonstrate how 3D bioprinting could offer greater flexibility in designing oral dosage forms and potentially enable customised formulations based on specific therapeutic requirements.</span></span></span></p>
<p align="JUSTIFY"><span><span><span><span lang="en-GB">Prof. Asima Shaukat, Assistant Professor, Department of Chemical Engineering, BITS Pilani, said,</span> “<span lang="en-GB">By using pharma polymers that are already established in drug formulation, this work explores how 3D bioprinting can be applied across tissue engineering and drug delivery. Our focus has been on combining material safety, printability and practical applications within a single platform.”</span></span></span></span></p>
<p lang="en-GB" align="JUSTIFY"><span><span><span><b>Building on pharma polymers for biomedical applications</b></span></span></span></p>
<p lang="en-GB" align="JUSTIFY"><span><span><span>A significant feature of the work is the use of pharma polymers rather than relying exclusively on specialised or animal-derived biomaterials. The researchers’ approach builds on earlier work exploring pharma polymers as potential bioinks for soft-tissue engineering and clean bioprinting.</span></span></span></p>
<p lang="en-GB" align="JUSTIFY"><span><span><span>While the findings are promising, the study represents a research-stage demonstration rather than a clinically approved treatment or commercially available 3D-printed medical product.</span></span></span></p>
<p>The post <a href="https://www.expresspharma.in/bits-pilani-goa-researchers-develop-pharma-polymer-based-bioink-for-3d-printed-skin-scaffolds-and-customised-drug-delivery/">BITS Pilani Goa researchers develop pharma polymer-based bioink for 3D-printed skin scaffolds and customised drug delivery</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>India Pharma Archives launched at IIM Ahmedabad</title>
<link>https://edusehat.com/en/india-pharma-archives-launched-at-iim-ahmedabad</link>
<guid>https://edusehat.com/en/india-pharma-archives-launched-at-iim-ahmedabad</guid>
<description><![CDATA[ 
Developed by IIM Ahmedabad Archives and supported by the Indian Pharmaceutical Alliance, India Pharma Archives captures the people, institutions and milestones behind the evolution of one of India’s most globally significant industries.
The post India Pharma Archives launched at IIM Ahmedabad appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/08/24171642/IPA.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 24 Aug 2026 22:20:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>India, Pharma, Archives, launched, IIM, Ahmedabad</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/08/24171642/IPA.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/08/24171642/IPA.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/24171642/IPA-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>Anupriya Patel, Union Minister of State for Health & Family Welfare and Chemicals & Fertilisers, Government of India, recently launched the India Pharma Archives at the IIMA Healthcare Summit in Ahmedabad. It is the first publicly accessible digital platform capturing 125 years of Indian pharma history, developed by IIM Ahmedabad Archives and supported by the Indian Pharmaceutical Alliance. </span></p>
<p>Also present were Punya Salila Srivastava, Secretary, Ministry of Health and Family Welfare, and Manoj Joshi, Secretary, Department of Pharmaceuticals, along with industry leaders and academicians.</p>
<p>A release from IPA Earlier this year, the landmark coffee-table book – The Alchemy of Cure laid the foundation for the initiative. The India Pharma Archive now expands the story through a growing collection of rare historical material from across the pharma ecosystem, including company histories and archival collections, films and footage, interview transcripts, timelines and advanced search tools—making the industry’s institutional memory accessible to students, researchers, policymakers, historians and industry leaders.</p>
<p align="JUSTIFY">Going beyond a traditional gallery, India Pharma Archives is designed as a living, continuously evolving archive. At its heart are Oral Histories that preserve the lived experiences of first- generation founders – offering a window into the science, entrepreneurship, policy and leadership that shaped the industry.</p>
<p align="JUSTIFY">Dr Sharvil Patel, MD, Zydus Lifesciences and President, IPA, said, “The Indian pharmaceutical industry is a remarkable story of science, entrepreneurship and global impact. The India Pharma Archives celebrates this collective journey and will serve as a platform for new ideas, collaborations, and solutions that address the health challenges of tomorrow.”</p>
<p align="JUSTIFY">Sudarshan Jain, Secretary General, IPA, said, “India Pharma Archives is not only about preserving history; it is about safeguarding the legacy of innovation for future generations. It will serve as a rich educational resource for students, researchers, and policymakers. It will showcase the resilience and breakthroughs that continue to inspire innovation, while reinforcing India’s position as a global leader in pharmaceuticals.”</p>
<p>The post <a href="https://www.expresspharma.in/india-pharma-archives-launched-at-iim-ahmedabad/">India Pharma Archives launched at IIM Ahmedabad</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Johnson &amp;amp; Johnson’s multiple myeloma treatment secures EC approval</title>
<link>https://edusehat.com/en/johnson-johnsons-multiple-myeloma-treatment-secures-ec-approval</link>
<guid>https://edusehat.com/en/johnson-johnsons-multiple-myeloma-treatment-secures-ec-approval</guid>
<description><![CDATA[ This decision provides a new therapeutic option for patients who have received at least one previous treatment. Teclistamab is a bispecific antibody administered via subcutaneous injection. It targets 
The post Johnson &amp; Johnson’s multiple myeloma treatment secures EC approval appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/08/Myeloma-shutterstock_2363195359.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 24 Aug 2026 18:45:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Johnson, Johnson’s, multiple, myeloma, treatment, secures, approval</media:keywords>
<content:encoded><![CDATA[<p>This decision provides a new therapeutic option for patients who have received at least one previous treatment.</p>
<p>Teclistamab is a bispecific antibody administered via subcutaneous injection. It targets B-Cell Maturation Antigen (BCMA) and cluster of differentiation 3 (CD3), prompting an immune response against cancer.</p>
<p>Johnson & Johnson EMEA haematology therapeutic area head Ester in ‘t Groen said: “This new indication for teclistamab plus daratumumab brings forward a new standard of care for patients in Europe living with relapsed or refractory multiple myeloma.</p>
<p>“By combining the complementary mechanisms of teclistamab, a BCMA×CD3 bispecific antibody, with daratumumab, a well-established standard of care that helps modulate the immune system, we can deliver meaningful long-term outcomes earlier in the treatment journey, where they have the greatest opportunity to influence the disease trajectory and redefine expectations for patients.”</p>
<p>The approval is based on findings from the ongoing Phase III MajesTEC-3 study involving patients with r/r MM who have had one to three previous lines of therapy.</p>
<p>The study compared the safety and efficacy of the new treatment regimen to standard care options, specifically investigating the combination of daratumumab with dexamethasone paired with either pomalidomide or bortezomib.</p>
<p>It included 291 participants receiving the teclistamab and daratumumab combination and 296 on the alternative regimens.</p>
<div></div>
<p>Results from the MajesTEC-3 study indicated substantial improvements in progression-free survival and overall survival for those on the new treatment.</p>
<p>Specifically, the likelihood of disease progression or death was reduced by 83.4% compared to standard treatments, according to the study’s hazard ratio of 0.17. More than 90% of patients who were progression-free at six months remained so at three years, suggesting a durable response.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/johnson-johnsons-multiple-myeloma/">Johnson & Johnson’s multiple myeloma treatment secures EC approval</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Gossamer Bio announces $250m in funding to advance seralutinib</title>
<link>https://edusehat.com/en/gossamer-bio-announces-250m-in-funding-to-advance-seralutinib</link>
<guid>https://edusehat.com/en/gossamer-bio-announces-250m-in-funding-to-advance-seralutinib</guid>
<description><![CDATA[ Seralutinib is intended for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The private investment comprises an initial closing, a 
The post Gossamer Bio announces $250m in funding to advance seralutinib appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/08/PH-shutterstock_342896678.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 24 Aug 2026 18:45:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Gossamer, Bio, announces, 250m, funding, advance, seralutinib</media:keywords>
<content:encoded><![CDATA[<p>Seralutinib is intended for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).</p>
<p>The private investment comprises an initial closing, a subsequent closing contingent upon FDA acceptance of a new drug application (NDA) for seralutinib in PAH and warrants exercisable upon FDA approval.</p>
<p>The company plans to submit the NDA by September 2026. The proceeds will help advance seralutinib’s clinical development and potential commercialisation, with net funds expected to sustain operations until 2028.</p>
<p>Gossamer recently regained global rights to seralutinib.</p>
<p>The financing involves key institutional investors, including EcoR1 Capital and RA Capital Management. The initial closing will raise approximately $25m through the sale of pre-funded warrants, priced at $0.14 per share minus a nominal exercise price.</p>
<p>A later closing will unlock a further $125m upon NDA acceptance. The terms stipulate that investors must fulfil this commitment if NDA acceptance occurs as planned. The purchase price for the second set of pre-funded warrants will follow the market’s five-day volume-weighted average price, less their nominal exercise cost.</p>
<p>Gossamer Bio chairman, co-founder and CEO Faheem Hasnain said: “The committed funding structure aligns capital availability with key regulatory milestones and is expected to support the planned submission and review of our NDA.</p>
<p>“We appreciate the support of this group of leading healthcare investors as we work to bring a potentially important new treatment option to patients with PAH.”</p>
<p>Additionally, investors will receive warrants exercisable upon FDA approval. If these are fully exercised at $0.187 per share, Gossamer Bio could secure up to $100m more. The warrants will expire either 30 days after achieving the FDA approval milestone or five years from their issuance.</p>
<p>Leerink Partners and Cantor are serving as joint placement agents for this financing effort.</p>
<p> </p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/gossamer-bio-funding-seralutinib/">Gossamer Bio announces $250m in funding to advance seralutinib</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>LSSSDC SkillVerse 2026 charts a new direction for skill development in the  life sciences sector</title>
<link>https://edusehat.com/en/lsssdc-skillverse-2026-charts-a-new-direction-for-skill-development-in-the-life-sciences-sector</link>
<guid>https://edusehat.com/en/lsssdc-skillverse-2026-charts-a-new-direction-for-skill-development-in-the-life-sciences-sector</guid>
<description><![CDATA[ 
100+ senior leaders from the life sciences industry participate in the national skill summit in Hyderabad
The post LSSSDC SkillVerse 2026 charts a new direction for skill development in the  life sciences sector appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/08/24110624/LSSSDC-SkillVerse-2026.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 24 Aug 2026 15:10:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>LSSSDC, SkillVerse, 2026, charts, new, direction, for, skill, development, the, life, sciences, sector</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="499" src="https://cdn.expresspharma.in/wp-content/uploads/2026/08/24110624/LSSSDC-SkillVerse-2026.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/08/24110624/LSSSDC-SkillVerse-2026.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/24110624/LSSSDC-SkillVerse-2026-300x200.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/24110624/LSSSDC-SkillVerse-2026-450x300.jpg 450w" sizes="(max-width: 750px) 100vw, 750px"></div><p align="JUSTIFY"><span>Life Sciences Sector Skill Development Council (LSSSDC) recently hosted “SkillVerse 2026 – A National Skill Summit for the Life Sciences Sector” at Le Méridien, Gachibowli, Hyderabad, bringing together more than 100 senior leaders and key stakeholders from the life sciences ecosystem. The summit focused on addressing skill gaps, strengthening training ecosystems, building industry-aligned talent and preparing India’s workforce for the future needs of the rapidly evolving life sciences sector.</span></p>
<p align="JUSTIFY">
</p><p align="JUSTIFY"><span>Organised around the theme “</span><i>Shaping the Skilled Future of Life Sciences</i><span>,” the national summit brought together representatives from the Central and State Governments, pharma and life sciences industries, academia, skill development organisations, policymakers and other ecosystem partners. </span><i>Express Pharma</i><span> was the media partner for this event.</span></p>
<p align="JUSTIFY">
</p><p align="JUSTIFY"><span>The summit commenced with the welcome of dignitaries, followed by the ceremonial lighting of the lamp and the National Anthem. Shri Gautam Bhattacharya, Chief Executive Officer, LSSSDC, delivered the welcome address. Shri Anil Matai, Chairman, LSSSDC and Director General, OPPI, shared his perspectives through a video message.</span></p>
<p align="JUSTIFY">
</p><p align="JUSTIFY"><span>Special addresses were delivered by Shri Aman Sharma, IAS, Department of Pharmaceuticals; Shri Chakravarthi AVPS, LSSSDC Board Member; Ms. Nidhi Satiija, ISS, Director, Ministry of Skill Development & Entrepreneurship (MSDE); Dr. K. Narendran, Deputy Drugs Controller, CDSCO; Dr. Sarvesh Singh, CEO, Telangana Life Sciences; and Prof. Shailendra Saraf, Director, NIPER Hyderabad, among other distinguished speakers.</span></p>
<p align="JUSTIFY">
</p><p align="JUSTIFY"><b>More than 100 senior industry leaders participate</b></p>
<p align="JUSTIFY"><span>A major highlight of SkillVerse 2026 was the participation of more than 100 senior leaders, CXOs, industry experts and decision-makers from the life sciences sector. The summit provided a high-level platform for meaningful dialogue between industry, government, academia and the skill development ecosystem.</span></p>
<p align="JUSTIFY">
</p><p align="JUSTIFY"><span>The industry ecosystem represented at the summit included leading pharmaceutical, biotechnology and life sciences organisations such as Dr. Reddy’s Laboratories, Sun Pharma, Cadila, Biological E, Aurobindo Pharma, Hetero Labs, Granules India, Natco Pharma, MSN Laboratories, Eisai Pharmaceuticals India, Sahajanand Medical Technologies, Alkem Laboratories, Sekhmet Pharmaventures, Cohance Life Sciences, Agappe Diagnostics, Sandoz, Aragen Life Sciences , Bharath Biotech, Biozeen, Sai Life Sciences, Gland Pharma, Vimta Labs, Sai Parenterals.</span></p>
<p align="JUSTIFY"><img decoding="async" class="aligncenter size-full wp-image-459210" src="https://cdn.expresspharma.in/wp-content/uploads/2026/08/24110542/LSSSDC-SkillVerse-2026-2.jpeg" alt="" width="2560" height="1706" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/08/24110542/LSSSDC-SkillVerse-2026-2.jpeg 2560w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/24110542/LSSSDC-SkillVerse-2026-2-300x200.jpeg 300w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/24110542/LSSSDC-SkillVerse-2026-2-1024x682.jpeg 1024w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/24110542/LSSSDC-SkillVerse-2026-2-768x512.jpeg 768w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/24110542/LSSSDC-SkillVerse-2026-2-1536x1024.jpeg 1536w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/24110542/LSSSDC-SkillVerse-2026-2-2048x1365.jpeg 2048w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/24110542/LSSSDC-SkillVerse-2026-2-450x300.jpeg 450w" sizes="(max-width: 2560px) 100vw, 2560px"></p>
<p align="JUSTIFY">
</p><p align="JUSTIFY"><b>Strong representation across government, academia and industry associations</b></p>
<p align="JUSTIFY"><span>The summit witnessed strong representation and participation from key Government Departments and organisations, including the Ministry of Skill Development & Entrepreneurship (MSDE), National Skill Development Corporation (NSDC), Central Drugs Standard Control Organisation (CDSCO), Telangana Life Sciences, Telangana Academy for Skill and Knowledge (TASK), Department of Employment and Training, Government of Andhra Pradesh, Department of Technical Education, Government of Andhra Pradesh, Regional Directorate of Skill Development & Entrepreneurship (RDSDE), Andhra Pradesh Pharmacy Council, Department of Pharmaceuticals and TICEL Bio Park.</span></p>
<p align="JUSTIFY">
</p><p align="JUSTIFY"><span>The academic and knowledge ecosystem was represented by institutions and organisations including IIT Hyderabad, National Institute of Pharmaceutical Education and Research (NIPER), CSIR, GITAM, SRM, Punjab Biotech Incubator, PAGE and VIPER, reflecting the strong commitment of academia and knowledge partners towards building a future-ready life sciences workforce.</span></p>
<p align="JUSTIFY">
</p><p align="JUSTIFY"><span>Industry associations and ecosystem bodies, including FOPE, BDMAI, MDP TG and FABA, also participated in the summit, contributing to discussions on industry requirements, skill development priorities and collaborative models for strengthening the life sciences skill ecosystem.</span></p>
<p align="JUSTIFY">
</p><p align="JUSTIFY"><b>Key discussions on skill gaps and industry needs</b></p>
<p align="JUSTIFY"><span>The first panel discussion, “Identifying Skill Gaps in Life Sciences Sector,” examined the current skill requirements of the industry, changing demands in the employment market and the need to build a workforce that is industry-ready from day one.</span></p>
<p align="JUSTIFY">
</p><p align="JUSTIFY"><span>The second panel, “NeeV Initiatives – Industry-led Models for Strengthening Skill Development Centres (SDCs),” explored practical models for strengthening Skill Development Centres through deeper industry participation, infrastructure support and outcome-oriented training.</span></p>
<p align="JUSTIFY">
</p><p align="JUSTIFY"><b>Government initiatives and industry partnership</b></p>
<p align="JUSTIFY"><span>The third panel discussion on “Government Initiatives for Skilling” focused on aligning government-led skill development programmes with industry requirements, improving training quality and expanding employment opportunities for young talent.</span></p>
<p align="JUSTIFY">
</p><p align="JUSTIFY"><span>The fourth panel, “Future-Ready Workforce for Life Sciences – Preparing for Industry 5.0,” brought together industry experts to discuss emerging skills, advanced technologies, innovation, digital transformation and the human capabilities required to prepare the life sciences workforce for the Industry 5.0 era.</span></p>
<p align="JUSTIFY">
</p><p align="JUSTIFY"><b>Key partnerships to strengthen skill development</b></p>
<p align="JUSTIFY"><span>The summit also witnessed important partnership initiatives aimed at strengthening the skill development ecosystem. An MoU exchange took place between LSSSDC and Biological E Limited for a new Corporate Social Responsibility (CSR)-supported Skill Development Initiative for FY 2026–27.</span></p>
<p align="JUSTIFY">
</p><p align="JUSTIFY"><span>LSSSDC also entered into an understanding with Medical Devices Park to strengthen industry collaboration for multiple skill development initiatives. In addition, Oxygen Pharmatech Private Limited was associated as a Knowledge Partner for various skill development initiatives.</span></p>
<p align="JUSTIFY">
</p><p align="JUSTIFY"><b>Building a future-ready life sciences workforce</b></p>
<p align="JUSTIFY"><span>Speakers and participants unanimously emphasised that as India’s life sciences and pharmaceutical sectors continue to grow rapidly, sustained investment in industry-aligned skilling, industry–academia collaboration, government support and awareness of emerging technologies will be critical.</span></p>
<p align="JUSTIFY">
</p><p align="JUSTIFY"><span>The discussions highlighted that bridging skill gaps can not only improve employment opportunities for young talent but also strengthen India’s ability to compete globally by building a highly skilled, adaptable and future-ready workforce.</span></p>
<p align="JUSTIFY">
</p><p align="JUSTIFY"><b>A strong national platform for collaboration</b></p>
<p align="JUSTIFY"><span>In his concluding remarks, Gautam Bhattacharya, CEO, LSSSDC, outlined key recommendations and the way forward, while thanking the distinguished guests, industry leaders, government representatives, academic institutions, partners and other stakeholders for their valuable participation and support.</span></p>
<p align="JUSTIFY">
</p><p align="JUSTIFY"><span>All participating stakeholders appreciated the LSSSDC team for successfully organising this useful and timely national event for the Life Sciences Sector Skill Ecosystem. Participants acknowledged the summit as a valuable platform for meaningful dialogue, knowledge sharing, collaboration and collective action towards addressing skill gaps and strengthening India’s life sciences talent pipeline.</span></p>
<p align="JUSTIFY">
</p><p align="JUSTIFY"><span>With the shared objectives of “Bridging Skill Gaps – Strengthening Training Ecosystems – Driving Innovation & Future-Ready Talent – Building a Competitive Global Workforce,” SkillVerse 2026 emerged as a significant national platform that brought together industry, government, academia and the wider skill ecosystem to collectively shape the future of talent development in India’s life sciences sector.</span></p>
<p>The post <a href="https://www.expresspharma.in/lsssdc-skillverse-2026-charts-a-new-direction-for-skill-development-in-the-life-sciences-sector/">LSSSDC SkillVerse 2026 charts a new direction for skill development in the  life sciences sector</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Zydus gets final US FDA approval for Ascorbic Acid Injection with 180&#45;Days CGT exclusivity</title>
<link>https://edusehat.com/en/zydus-gets-final-us-fda-approval-for-ascorbic-acid-injection-with-180-days-cgt-exclusivity</link>
<guid>https://edusehat.com/en/zydus-gets-final-us-fda-approval-for-ascorbic-acid-injection-with-180-days-cgt-exclusivity</guid>
<description><![CDATA[ 
The product is primarily used for the short-term treatment of scurvy in adult and paediatric patients aged 5 months and older for whom oral administration is not possible, insufficient or contraindicated
The post Zydus gets final US FDA approval for Ascorbic Acid Injection with 180-Days CGT exclusivity appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2020/08/07111742/US-FDA-stamp-e1722586514279.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 21 Aug 2026 21:50:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Zydus, gets, final, FDA, approval, for, Ascorbic, Acid, Injection, with, 180-Days, CGT, exclusivity</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="399" src="https://cdn.expresspharma.in/wp-content/uploads/2020/08/07111742/US-FDA-stamp-e1722586514279.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2020/08/07111742/US-FDA-stamp-e1722586514279.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2020/08/07111742/US-FDA-stamp-e1722586514279-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p align="JUSTIFY"><span><span><span><span>Zydus </span>Lifesciences announces the receipt of final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Ascorbic Acid Injection USP, 25,000 mg/50 mL (500 mg/mL) and 5,000 mg/10 mL (500 mg/mL). The product is primarily used for the short-term treatment of scurvy in adult and paediatric patients aged 5 months and older for whom oral administration is not possible, insufficient or contraindicated.</span></span></span></p>
<p align="JUSTIFY"><span><span><span>Zydus’ Ascorbic Acid Injection is the generic equivalent of the reference listed drug (RLD), Ascor Injection, 25,000 mg/50 mL (500 mg/mL). The USFDA has designated the ANDA for the product as a Competitive Generic Therapy (CGT). Eligibility for the 180-day exclusivity available to certain competitive generic therapies is determined by the USFDA and, where applicable, the period runs from the date of first commercial marketing of the product.</span></span></span></p>
<p align="JUSTIFY"><span><span><span>The product will be manufactured at the group’s USFDA-approved injectable manufacturing plant at Jarod, near Vadodara in Gujarat, and will be marketed in the US market by Zydus Pharmaceuticals (US) Inc.</span></span></span></p>
<p align="JUSTIFY"><span><span><span>The brand product had annual sales of approximately $11.6 million in the US (IQVIA MAT June-2026).</span></span></span></p>
<p align="JUSTIFY"><span><span><span>The Group now has 448 approvals and has so far filed 513* ANDA with the USFDA. <i>(*As on 30-June-2026)</i></span></span></span></p>
<p align="JUSTIFY">
</p><p>The post <a href="https://www.expresspharma.in/zydus-gets-final-us-fda-approval-for-ascorbic-acid-injection-with-180-days-cgt-exclusivity/">Zydus gets final US FDA approval for Ascorbic Acid Injection with 180-Days CGT exclusivity</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>WellSpan and Johns Hopkins renew partnership for advanced cancer care access</title>
<link>https://edusehat.com/en/wellspan-and-johns-hopkins-renew-partnership-for-advanced-cancer-care-access</link>
<guid>https://edusehat.com/en/wellspan-and-johns-hopkins-renew-partnership-for-advanced-cancer-care-access</guid>
<description><![CDATA[ The development marks the next stage of a partnership that began in 2017 and saw further expansion in 2021. Over the last five years, more than 1,300 WellSpan 
The post WellSpan and Johns Hopkins renew partnership for advanced cancer care access appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/08/PT-2-21-08-2026-shutterstock_2309849697.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 21 Aug 2026 18:15:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>WellSpan, and, Johns, Hopkins, renew, partnership, for, advanced, cancer, care, access</media:keywords>
<content:encoded><![CDATA[<p>The development marks the next stage of a partnership that began in 2017 and saw further expansion in 2021.</p>
<p>Over the last five years, more than 1,300 WellSpan patients at 12 cancer sub-specialties have received support from the partnership, which includes physician consultations, multidisciplinary tumour conferences, and access to subspecialty expertise.</p>
<p>Around 500 WellSpan patients have enrolled in clinical trials that are being by Johns Hopkins Medicine.</p>
<p>WellSpan Health president and CEO Roxanna Gapstur said: “When we expanded this collaboration five years ago, we shared a vision of bringing together the strengths of a leading academic medical centre and a nationally recognised community-based cancer programme to better serve patients across our region.</p>
<p>“Today, that vision continues to deliver meaningful benefits for our patients and it reflects our shared commitment to ensure more people can access world-class cancer care while remaining close to home and surrounded by their support systems.”</p>
<p>Johns Hopkins Health System president and Johns Hopkins Medicine executive vice-president Kevin Sowers said: “Our collaboration with WellSpan Health reflects a shared belief that every patient deserves access to the highest level of cancer expertise, regardless of where they live.</p>
<p>“Over the years, we have built strong clinical and research relationships that support healthcare professionals, advance innovation and improve patient experience.”</p>
<p>The extended collaboration will reach patients in areas, including the Central Susquehanna Valley, where WellSpan is investing in a programme for oncology at WellSpan Evangelical Community Hospital.</p>
<p>Starting this autumn, phased improvements will introduce local oncology, infusion, and eventually radiation oncology and advanced cancer services.</p>
<p>Earlier this year, WellSpan collaborated with Cancer Care Associates of York to support cancer care efforts in York County.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/wellspan-johns-hopkins-advanced-cancer-care/">WellSpan and Johns Hopkins renew partnership for advanced cancer care access</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Charles River and MVC to develop enterovirus vaccine</title>
<link>https://edusehat.com/en/charles-river-and-mvc-to-develop-enterovirus-vaccine</link>
<guid>https://edusehat.com/en/charles-river-and-mvc-to-develop-enterovirus-vaccine</guid>
<description><![CDATA[ Utilising its analytical platforms such as next-generation sequencing (NGS), Charles River will assist with chemistry, manufacturing, and controls (CMC) activities related to the vaccine’s development. The agreement aims 
The post Charles River and MVC to develop enterovirus vaccine appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/08/PT-21-08-2026-shutterstock_2440286495.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 21 Aug 2026 18:15:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Charles, River, and, MVC, develop, enterovirus, vaccine</media:keywords>
<content:encoded><![CDATA[<p>Utilising its analytical platforms such as next-generation sequencing (NGS), Charles River will assist with chemistry, manufacturing, and controls (CMC) activities related to the vaccine’s development.</p>
<p>The agreement aims to accelerate the progression of the new enterovirus vaccine.</p>
<p>It seeks to leverage the global expertise that Charles River provides in areas, including biologics testing, virology, non-clinical development, and regulatory science.</p>
<p>The collaboration is intended to align development with global regulatory expectations and advance the vaccine programme.</p>
<p>Medigen Vaccine Biologics has previously secured approval for its Envacgen Enterovirus 71 Vaccine in Taiwan and Vietnam.</p>
<p>Based on this prior regulatory experience, the company is moving forward with the development of a next-generation vaccine to address broader enterovirus strains.</p>
<p>As part of this process, Charles River has been selected to supply the necessary analytical, testing, and regulatory support.</p>
<p>Charles River global manufacturing corporate senior vice-president Kerstin Dolph said: “We are excited to collaborate with MVC and apply our testing and NGS expertise for vaccine development.</p>
<p>“By leveraging our experience in biologics, analytics, and safety, we are proud to partner with companies like MVC to achieve key milestones and drive innovation in the industry.”</p>
<p>The two companies plan to integrate Charles River’s biologics testing and non-clinical development capabilities with Medigen’s research in order to accelerate development and support investigational new drug (IND)-enabling non-clinical studies.</p>
<p>The partnership also seeks to generate data for global IND applications and future clinical pathways. They have indicated a shared interest in exploring further vaccine development opportunities in response to global infectious diseases.</p>
<p>Charles River has recently enhanced its NGS testing capabilities through the acquisition of Pathoquest. The company’s biologics testing solutions offer expertise and regulatory support across the entire developmental life cycle for clients worldwide.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/charles-river-mvc-enterovirus-vaccine/">Charles River and MVC to develop enterovirus vaccine</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Glenmark launches Calcium Gluconate Injection USP in US</title>
<link>https://edusehat.com/en/glenmark-launches-calcium-gluconate-injection-usp-in-us</link>
<guid>https://edusehat.com/en/glenmark-launches-calcium-gluconate-injection-usp-in-us</guid>
<description><![CDATA[ 
Glenmark introduces three Calcium Gluconate Injection USP presentations for the US market
The post Glenmark launches Calcium Gluconate Injection USP in US appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 21 Aug 2026 14:40:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Glenmark, launches, Calcium, Gluconate, Injection, USP</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Glenmark Pharmaceuticals, USA (Glenmark) has announced the launch of Calcium Gluconate Injection USP in the US in 1,000 mg/10 mL (100 mg/mL) Single-Dose Vials, 5,000 mg/50 mL (100 mg/mL) Single-Dose Vials and 10,000 mg/100 mL (100 mg/mL) Pharmacy Bulk Package.</span></p>
<p><span>Glenmark’s Calcium Gluconate Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, Calcium Gluconate Injection, 1,000 mg/10 mL (100 mg/mL), 5,000 mg/50 mL (100 mg/mL) and 10,000 mg/100 mL (100 mg/mL), of Fresenius Kabi USA, LLC [NDA 208418].</span></p>
<p><span>According to IQVIA sales data for the 12-month period ending June 2026, the Calcium Gluconate Injection, 1,000 mg/10 mL (100 mg/mL), 5,000 mg/50 mL (100 mg/mL) and 10,000 mg/100 mL (100 mg/mL) market achieved annual sales of approximately $69.9 million*.</span></p>
<p><span>Commenting on the launch, Marc Kikuchi, President & Business Head, North America, said, “The launch of Calcium Gluconate Injection USP marks another important step in strengthening Glenmark’s U.S. injectables business and expanding our hospital portfolio. It reflects the disciplined execution of our strategy to build a differentiated and sustainable injectables business – one that addresses institutional needs, supports greater supply resilience and deepens Glenmark’s relevance across the U.S. healthcare system,” he added.</span></p>
<p>The post <a href="https://www.expresspharma.in/glenmark-launches-calcium-gluconate-injection-usp-in-us/">Glenmark launches Calcium Gluconate Injection USP in US</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Lupin signs exclusive licensing agreement for YUVEZZI in Europe</title>
<link>https://edusehat.com/en/lupin-signs-exclusive-licensing-agreement-for-yuvezzi-in-europe</link>
<guid>https://edusehat.com/en/lupin-signs-exclusive-licensing-agreement-for-yuvezzi-in-europe</guid>
<description><![CDATA[ 
VISUfarma to undertake regulatory, commercialisation, marketing and distribution activities for YUVEZZI in 31 European markets
The post Lupin signs exclusive licensing agreement for YUVEZZI in Europe appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/07/22171615/signing-agreement.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 21 Aug 2026 14:40:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Lupin, signs, exclusive, licensing, agreement, for, YUVEZZI, Europe</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/07/22171615/signing-agreement.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/07/22171615/signing-agreement.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/07/22171615/signing-agreement-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>Lupin has announced that VISUfarma B.V. (VISUfarma), a wholly owned subsidiary of Lupin, has entered into an exclusive licensing agreement with Visus Therapeutics Inc., U.S.A., a wholly owned subsidiary of Tenpoint Therapeutics Holding Limited (Tenpoint).</span></p>
<p><span>Under the agreement, VISUfarma will hold exclusive rights to undertake regulatory activities, commercialisation, marketing, promotion, distribution and sale of YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75 per cent/0.1 per cent for the treatment of presbyopia in adults across the European Union, the United Kingdom, Switzerland, Norway and Iceland (Licensed Territories).</span></p>
<p><span>VISUfarma will make a strategic investment in Visus under the agreement. Tenpoint and Visus, individually or collectively, will also be eligible to receive regulatory and commercial milestone payments, as well as tiered royalties based on net sales.</span></p>
<p><span>Vinita Gupta, Chief Executive Officer, Lupin, said, “We are delighted to partner with Tenpoint Therapeutics to bring a novel ophthalmic therapy that advances our Specialty Care strategy. Building on the strategic acquisition of VISUfarma, this partnership further strengthens our vision care franchise and expands our presence across key European markets. The addition of YUVEZZI<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> underscores our commitment to broadening access to differentiated therapies, improving patient outcomes, and reinforcing our leadership in eye care across the Licensed Territories.”</span></p>
<p><span>“This exciting partnership marks an important step for Tenpoint as we continue our work to make YUVEZZI available for the millions of patients with presbyopia and eye care professionals around the world,” said Henric Bjarke, Chief Executive Officer, Tenpoint. “Lupin’s strong commercial operations span major European markets, and its specialty ophthalmology company VISUfarma’s longstanding presence in eyecare makes them an excellent partner. We look forward to working together as we bring YUVEZZI to Europe.”</span></p>
<p><span>YUVEZZI is the first and only approved once-daily, dual-agent eye drop for presbyopia. The addition of YUVEZZI expands Lupin’s ophthalmology portfolio and supports its strategy to expand its specialty care business through therapies addressing patient needs.</span></p>
<p><span>Tenpoint is advancing the commercialisation of YUVEZZI in the United States following its U.S. FDA approval. Tenpoint has submitted an MMA in the UK through the MHRA’s International Recognition Procedure and will continue its plans for regulatory applications for YUVEZZI in other regions. </span></p>
<p>The post <a href="https://www.expresspharma.in/lupin-signs-exclusive-licensing-agreement-for-yuvezzi-in-europe/">Lupin signs exclusive licensing agreement for YUVEZZI in Europe</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy</title>
<link>https://edusehat.com/en/fda-grants-accelerated-approval-to-ultragenyxs-genglycos-gene-therapy</link>
<guid>https://edusehat.com/en/fda-grants-accelerated-approval-to-ultragenyxs-genglycos-gene-therapy</guid>
<description><![CDATA[ The approval covers both adult and paediatric patients aged eight years and above. GSDIa is a rare genetic metabolic disorder caused by a deficiency in the enzyme required 
The post FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/08/PT-2-20-08-2026-shutterstock_2311370891.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 20 Aug 2026 20:40:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>FDA, grants, accelerated, approval, Ultragenyx’s, Genglycos, gene, therapy</media:keywords>
<content:encoded><![CDATA[<p>The approval covers both adult and paediatric patients aged eight years and above.</p>
<p>GSDIa is a rare genetic metabolic disorder caused by a deficiency in the enzyme required for releasing glucose from the liver into the bloodstream.</p>
<p>This deficiency impairs the liver’s ability to manage glucose levels, leading to a risk of severe hypoglycaemia and requiring continuous nutritional monitoring, often involving frequent intake of raw cornstarch as oral glucose replacement.</p>
<p>The FDA granted accelerated approval for Genglycos, also known as DTX401, based on data from a 48-week double-blind, randomised, placebo-controlled Phase III study involving 46 participants who were treated with either DTX401 or a placebo.</p>
<p>The GlucoGene study demonstrated a statistically significant reduction in cornstarch requirements among those who received the gene therapy.</p>
<p>According to the trial’s protocol, participants who completed 48 weeks were able to cross over to the alternate treatment, and follow-up analyses are planned at weeks 96 and 144.</p>
<p>As part of the approval, Ultragenyx will provide two years of efficacy and safety data from an open-label commercial treatment group comprising 50 patients.</p>
<p>This will be conducted alongside 20 control patients who are unable to receive Genglycos due to anti–adeno-associated virus serotype 8 (AAV8) antibodies.</p>
<p>Data collection will occur via the GSDIa Disease Monitoring Program, which will track both new commercial patients and previous trial participants for up to ten years.</p>
<p>Ultragenyx chief medical officer Dr Eric Crombez said: “The approval of Genglycos fulfills our commitment to provide the first therapy that directly targets the root cause of GSDIa.</p>
<p>“The reduced reliance on cornstarch, experienced by patients in our clinical studies, demonstrates this gene therapy’s ability to establish the normal breakdown of glycogen to produce glucose during fasting or episodes of metabolic stress.</p>
<p>“This ability to regulate glucose has alleviated the disease burden and has the potential to mitigate the risk of severe or life-threatening hypoglycaemia for these patients.”</p>
<p>Genglycos is set to be distributed through a network of Qualified Treatment Centers and manufactured at the company’s facility in Bedford, Massachusetts.</p>
<p>In July 2025, Ultragenyx received a complete response letter from the FDA concerning its biologics licence application for UX111 (ABO-102), an adeno-associated virus gene therapy aimed at treating Sanfilippo syndrome type A (MPS IIIA).</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/fda-approval-ultragenyx-genglycos-gene-therapy/">FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>ISHRAE successfully hosts PharmaConnect 2026 – Cleanroom Conclave in Mumbai</title>
<link>https://edusehat.com/en/ishrae-successfully-hosts-pharmaconnect-2026-cleanroom-conclave-in-mumbai</link>
<guid>https://edusehat.com/en/ishrae-successfully-hosts-pharmaconnect-2026-cleanroom-conclave-in-mumbai</guid>
<description><![CDATA[ 
ISHRAE brings pharma, cleanroom and HVAC leaders together to shape the future of sustainable pharma manufacturing
The post ISHRAE successfully hosts PharmaConnect 2026 – Cleanroom Conclave in Mumbai appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/08/20172507/ISHRAE.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 20 Aug 2026 20:40:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>ISHRAE, successfully, hosts, PharmaConnect, 2026, –, Cleanroom, Conclave, Mumbai</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="483" src="https://cdn.expresspharma.in/wp-content/uploads/2026/08/20172507/ISHRAE.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/08/20172507/ISHRAE.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/20172507/ISHRAE-300x193.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/20172507/ISHRAE-210x136.jpg 210w" sizes="(max-width: 750px) 100vw, 750px"></div><p align="JUSTIFY">ISHRAE Thane Chapter, along with ISHRAE Mumbai Chapter, successfully hosted PharmaConnect 2026 – Cleanroom Conclave, a knowledge-sharing and networking platform bringing together professionals from the pharma, biopharma, cleanroom, HVAC, engineering, consultancy and allied industries.</p>
<p align="JUSTIFY">Held at Hotel Ramada, Navi Mumbai, the conclave was organised around the theme “Transcending Frontiers in Pharma: Evolution of Biologics & Facility Adaptation for Next-Gen Sustainable Manufacturing.”</p>
<p align="JUSTIFY">The programme served as a platform for industry leaders, pharma professionals, consultants, technology providers, HVAC experts and facility specialists to discuss the rapidly evolving requirements of the pharma manufacturing ecosystem. The pharmaceutical industry is undergoing significant transformation with the growth of biologics, advanced therapies and next-generation manufacturing technologies — developments that are creating new challenges and opportunities in facility design, cleanroom technology, HVAC systems, contamination control, energy efficiency, sustainability and regulatory compliance.</p>
<p align="JUSTIFY">The gathering was addressed by Tejas Gawde, President, ISHRAE Thane Chapter; Mukesh Suthar, President, ISHRAE Mumbai Chapter; and Manoj Khati, Convener, PharmaConnect 2026, whose remarks set the tone for the event.</p>
<p align="JUSTIFY">PharmaConnect 2026 addressed these emerging requirements through a combination of technical presentations, keynote sessions, expert discussions and a panel discussion, enabling participants to exchange experiences and perspectives.</p>
<p align="JUSTIFY">The event featured eminent industry professionals, including Shyam Khante, President, Shyam Khante & Associates; Ajit Kadam, Director, Spectrum Pharmatech Consultant; and Bhupeshkumar Patil, Associate Vice President, Knexir Consultant, along with other experts from the pharma and engineering ecosystem.</p>
<p align="JUSTIFY">A key highlight of the programme was a panel discussion moderated by Gautam Baliga, which brought together industry experts including Prashant Kavale, Shyam Khante, RV Kulkarni, Adnan Khan and Ajit Kadam. The panel discussed the challenges associated with evolving pharma facilities, sustainability, technology adoption and the changing needs of next-generation manufacturing. The discussion underscored the need for future pharma facilities to balance product quality, patient safety, regulatory compliance, operational reliability, energy efficiency and environmental sustainability.</p>
<p align="JUSTIFY">Speaking on the occasion, the organisers highlighted the need for stronger collaboration between pharmaceutical manufacturers, consultants, technology providers and HVAC professionals to develop facilities that are not only compliant but also energy-efficient, resilient, sustainable and future-ready.</p>
<p align="JUSTIFY"><strong><b>Recognising industry excellence</b></strong></p>
<p align="JUSTIFY">PharmaConnect 2026 also provided an opportunity to recognise and acknowledge the contribution of professionals and organisations supporting the growth and advancement of the pharmaceutical industry. The event witnessed strong participation from professionals across the pharma and allied sectors, creating opportunities for knowledge exchange, professional networking and collaboration.</p>
<p align="JUSTIFY">The success of PharmaConnect 2026 reflects the commitment of ISHRAE Thane Chapter to promoting technical excellence and creating meaningful platforms for interaction between the HVAC&R and pharma industries.</p>
<p align="JUSTIFY"><strong><b>Looking ahead</b></strong></p>
<p align="JUSTIFY">With the pharma industry moving towards biologics, advanced manufacturing technologies and increasingly sustainable operations, the role of cleanroom engineering, HVAC, contamination control and energy-efficient facility design will become even more critical. PharmaConnect 2026 highlighted the importance of bringing stakeholders together to share knowledge, address emerging challenges and explore solutions for the pharma facilities of tomorrow.</p>
<p align="JUSTIFY">ISHRAE Thane Chapter extended its appreciation to all speakers, panelists, sponsors, supporting organisations, delegates and volunteers whose contribution helped make the conclave a successful industry gathering</p>
<p>The post <a href="https://www.expresspharma.in/ishrae-successfully-hosts-pharmaconnect-2026-cleanroom-conclave-in-mumbai/">ISHRAE successfully hosts PharmaConnect 2026 – Cleanroom Conclave in Mumbai</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>SandboxAQ introduces AQPotency for virtual drug screening</title>
<link>https://edusehat.com/en/sandboxaq-introduces-aqpotency-for-virtual-drug-screening</link>
<guid>https://edusehat.com/en/sandboxaq-introduces-aqpotency-for-virtual-drug-screening</guid>
<description><![CDATA[ AQPotency is accessible through Claude via the Model Context Protocol (MCP), as well as through the SandboxAQ website, with plans for listing on Google Cloud’s Marketplace. It enables 
The post SandboxAQ introduces AQPotency for virtual drug screening appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/08/PT-20-08-2026-shutterstock_1924516388.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 20 Aug 2026 17:00:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>SandboxAQ, introduces, AQPotency, for, virtual, drug, screening</media:keywords>
<content:encoded><![CDATA[<p>AQPotency is accessible through Claude via the Model Context Protocol (MCP), as well as through the SandboxAQ website, with plans for listing on Google Cloud’s Marketplace.</p>
<p>It enables drug discovery teams to computationally assess and rank how strongly candidate molecules are likely to interact with specific disease targets.</p>
<p>Unlike established computer methods that require detailed structural data about the target molecule, AQPotency does not rely on existing structural maps.</p>
<p>This capability allows researchers to evaluate potential drug compounds even for targets that lack structural information, which has typically limited access to traditional computational screening.</p>
<p>SandboxAQ stated that early-stage drug discovery often involves selecting which molecules to assess experimentally, a process that can be both costly and time-consuming if unsuitable candidates are chosen.</p>
<p>Existing computational narrowing techniques are described as slow and expensive, and restricted to cases where a detailed structure is available.</p>
<p>AQPotency addresses these shortcomings by providing rapid ranking of molecule-target pairs and delivering results in seconds using standard computing resources.</p>
<p>The model reports both the predicted activity and a confidence assessment, indicating whether a target falls within its reliable performance range.</p>
<p>The tool is also designed to support analysis in the opposite direction.</p>
<p>Researchers can input a molecule and receive a prioritised list of proteins that the compound may interact with, which could be useful when a molecule demonstrates effects whose mechanisms are not yet clear.</p>
<p>SandboxAQ drug discovery vice-president Andrea Bortolato said: “AQPotency has given us and our customers a faster, scalable and reliable way to prioritise compounds in the workflows we already run, without needing a 3D crystal structure of the target. This opens up programmes that structure-based methods simply couldn’t reach.</p>
<p>“The confidence intervals make the output actionable for biopharma companies, and the model has already been successfully used in eight customer programmes with experimentally validated impact.”</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/sandboxaq-aqpotency-virtual-drug-screening/">SandboxAQ introduces AQPotency for virtual drug screening</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Mankind Pharma inks agreement for two insulin analogues in India</title>
<link>https://edusehat.com/en/mankind-pharma-inks-agreement-for-two-insulin-analogues-in-india</link>
<guid>https://edusehat.com/en/mankind-pharma-inks-agreement-for-two-insulin-analogues-in-india</guid>
<description><![CDATA[ 
Partnership with Chongqing Chenan Biopharmaceutical covers Insulin Degludec and Insulin Degludec + Aspart Combination
The post Mankind Pharma inks agreement for two insulin analogues in India appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/07/22171615/signing-agreement.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 20 Aug 2026 17:00:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Mankind, Pharma, inks, agreement, for, two, insulin, analogues, India</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/07/22171615/signing-agreement.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/07/22171615/signing-agreement.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/07/22171615/signing-agreement-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Mankind Pharma has entered into an exclusive in-licensing and marketing agreement with Chongqing Chenan Biopharmaceutical Co., Ltd., China, for the commercialisation of two insulin analogues, Insulin Degludec and Insulin Degludec + Aspart Combination, in India.</span></p>
<p><span>The partnership marks a step in Mankind Pharma’s strategy to strengthen its presence in diabetes care and broaden its portfolio of injectable therapies. The addition of these products will further enhance Mankind Pharma’s position in the injectable diabetes segment, contributing to a more comprehensive portfolio and reinforcing its commitment to addressing the evolving needs of patients.</span></p>
<p><span>The partnership further reinforces the company’s commitment to expanding its diabetes portfolio and bringing a broader range of treatment options to patients in India.</span></p>
<p><span>Commenting on the partnership, Atish Majumdar, Senior President – Sales and Marketing, Mankind Pharma, said, “China is rapidly emerging as a hub for innovative biopharmaceutical assets. Building on our partnerships for Insulin Aspart and Insulin Degludec, we remain focused on expanding our in-licensing pipeline from China. This partnership reinforces our commitment to expanding access to advanced therapies for patients in India while further strengthening our presence in the injectable diabetes segment.”</span></p>
<p><span>The partnership with Chongqing Chenan Biopharmaceutical is also aligned with Mankind Pharma’s broader strategy of leveraging global innovation through strategic partnerships and in-licensing opportunities. China’s developing biopharmaceutical ecosystem presents opportunities for Indian pharmaceutical companies to access differentiated and innovative assets that can complement their existing portfolios.</span></p>
<p>The post <a href="https://www.expresspharma.in/mankind-pharma-inks-agreement-for-two-insulin-analogues-in-india/">Mankind Pharma inks agreement for two insulin analogues in India</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Strides Pharma receives USFDA EIR for Bengaluru facility</title>
<link>https://edusehat.com/en/strides-pharma-receives-usfda-eir-for-bengaluru-facility</link>
<guid>https://edusehat.com/en/strides-pharma-receives-usfda-eir-for-bengaluru-facility</guid>
<description><![CDATA[ 
USFDA classifies inspection outcome as Voluntary Action Indicated following May 2026 cGMP inspection
The post Strides Pharma receives USFDA EIR for Bengaluru facility appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 20 Aug 2026 17:00:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Strides, Pharma, receives, USFDA, EIR, for, Bengaluru, facility</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Strides Pharma Science has announced that its flagship manufacturing facility in Bengaluru, India, has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA), indicating the closure of the inspection conducted at the facility.</span></p>
<p><span>The USFDA conducted a current Good Manufacturing Practices (cGMP) inspection of the facility from May 12 to May 20, 2026. As previously disclosed to the stock exchanges on May 20, 2026, the inspection concluded with the issuance of a Form 483 containing five observations. The company submitted a response addressing all observations within the stipulated timeline.</span></p>
<p><span>Based on the company’s response and the corrective and preventive actions implemented, the USFDA classified the inspection outcome as Voluntary Action Indicated (VAI) and issued the Establishment Inspection Report (EIR), thereby concluding the inspection.</span></p>
<p><span>The facility is Strides’ flagship manufacturing site and serves regulated and other international markets. The facility manufactures pharmaceutical dosage forms, including tablets, capsules and oral liquids, supporting existing commercial products and future growth opportunities.</span></p>
<p><span>The closure of the inspection further strengthens Strides’ regulatory track record and reinforces the company’s commitment to supplying pharmaceutical products to patients across global markets.</span></p>
<p>The post <a href="https://www.expresspharma.in/strides-pharma-receives-usfda-eir-for-bengaluru-facility/">Strides Pharma receives USFDA EIR for Bengaluru facility</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Glenmark receives USFDA approval for Fluticasone Propionate Nasal Spray</title>
<link>https://edusehat.com/en/glenmark-receives-usfda-approval-for-fluticasone-propionate-nasal-spray</link>
<guid>https://edusehat.com/en/glenmark-receives-usfda-approval-for-fluticasone-propionate-nasal-spray</guid>
<description><![CDATA[ 
Fluticasone Propionate Nasal Spray USP is bioequivalent and therapeutically equivalent to Flonase Nasal Spray
The post Glenmark receives USFDA approval for Fluticasone Propionate Nasal Spray appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/06/25113229/us-fda-approval-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 20 Aug 2026 17:00:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Glenmark, receives, USFDA, approval, for, Fluticasone, Propionate, Nasal, Spray</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/06/25113229/us-fda-approval-1.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/06/25113229/us-fda-approval-1.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/06/25113229/us-fda-approval-1-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>Glenmark Pharmaceuticals has announced the receipt of U.S. FDA approval for Fluticasone Propionate Nasal Spray USP, 0.05 mg/spray. Glenmark’s Fluticasone Propionate Nasal Spray USP is bioequivalent and therapeutically equivalent to the reference listed drug, Flonase Nasal Spray, 0.05 mg/spray of Haleon US Holdings LLC [NDA 020121], and will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA.</span></p>
<p><span>According to IQVIA sales data for the 12-month period ending June 2026, the Flonase Nasal Spray market achieved annual sales of approximately $295.2 million.</span></p>
<p><span>Commenting on the approval, Marc Kikuchi, President & Business Head, North America, said, “The approval of Fluticasone Propionate Nasal Spray USP, 0.05 mg/spray marks another step in expanding our respiratory portfolio in the U.S. and builds on the strong foundation we have established in this therapeutic area. We remain committed to broadening access to quality, affordable treatment options that address the evolving needs of patients and healthcare providers.”</span></p>
<p>The post <a href="https://www.expresspharma.in/glenmark-receives-usfda-approval-for-fluticasone-propionate-nasal-spray/">Glenmark receives USFDA approval for Fluticasone Propionate Nasal Spray</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Eppendorf introduces Research 3 neo pipette value packs</title>
<link>https://edusehat.com/en/eppendorf-introduces-research-3-neo-pipette-value-packs</link>
<guid>https://edusehat.com/en/eppendorf-introduces-research-3-neo-pipette-value-packs</guid>
<description><![CDATA[ 
3-pack and 6-pack bundles are now available at a special rate for laboratories worldwide
The post Eppendorf introduces Research 3 neo pipette value packs appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/08/20112444/EP_Eppendorf_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 20 Aug 2026 13:15:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Eppendorf, introduces, Research, neo, pipette, value, packs</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/08/20112444/EP_Eppendorf_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/08/20112444/EP_Eppendorf_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/20112444/EP_Eppendorf_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p>Eppendorf has introduced a new addition to its Eppendorf Research 3 neo single-channel pipette line, launched in 2025. From today, laboratories worldwide can order 3-pack and 6-pack bundles at a special rate, making it easier and more cost-effective to upgrade to the latest Eppendorf pipetting technology.</p>
<p><span>The 3-pack bundles are available in three sets, each designed for common laboratory needs. Option 1 includes 10 µL, 100 µL and 1000 µL pipettes. Option 2 includes 20 µL, 200 µL and 1000 µL pipettes, while Option 3 includes 1000 µL, 5 mL and 10 mL pipettes.</span></p>
<p><span>The 6-pack bundle includes 2.5 µL, 10 µL, 20 µL, 100 µL, 200 µL and 1000 µL pipettes, along with a Pipette Carousel 2 for convenient and safe storage.</span></p>
<p><span>Eppendorf said all multi-packs include an original Eppendorf pipette pen as a bonus item.</span></p>
<p><span>The Research 3 neo pipettes address key pain points for scientists, including faster and easier volume adjustment with a lock to prevent accidental volume changes during pipetting, improved ergonomics with a shorter pipetting button, flexible labelling options, and the reliability and ergonomics Eppendorf is known for.</span></p>
<p><span>Further information about the Eppendorf Research 3 neo pipettes and value packs is available at www.eppendorf.link/research3neo.</span></p>
<p>The post <a href="https://www.expresspharma.in/eppendorf-introduces-research-3-neo-pipette-value-packs/">Eppendorf introduces Research 3 neo pipette value packs</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Invesco Mutual Fund launches India Pharma and Healthcare Fund</title>
<link>https://edusehat.com/en/invesco-mutual-fund-launches-india-pharma-and-healthcare-fund</link>
<guid>https://edusehat.com/en/invesco-mutual-fund-launches-india-pharma-and-healthcare-fund</guid>
<description><![CDATA[ 
The open-ended equity scheme will invest across pharma, healthcare and allied sectors
The post Invesco Mutual Fund launches India Pharma and Healthcare Fund appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2016/08/19172736/doctor-Reu-L-e1532347380500.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 20 Aug 2026 13:15:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Invesco, Mutual, Fund, launches, India, Pharma, and, Healthcare, Fund</media:keywords>
<content:encoded><![CDATA[<div><img width="600" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2016/08/19172736/doctor-Reu-L-e1532347380500.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2016/08/19172736/doctor-Reu-L-e1532347380500.jpg 600w, https://cdn.expresspharma.in/wp-content/uploads/2016/08/19172736/doctor-Reu-L-e1532347380500-300x200.jpg 300w" sizes="(max-width: 600px) 100vw, 600px"></div><p><span>Invesco Mutual Fund has announced the launch of the Invesco India Pharma and Healthcare Fund, an open-ended equity scheme investing in pharma, healthcare and allied sectors.</span></p>
<p><span>The fund seeks to capitalise on India’s evolving healthcare ecosystem, which is being shaped by favourable demographics, expanding healthcare access, rising insurance penetration, growing global pharmaceutical leadership and emerging innovation-driven opportunities across healthcare and life sciences. The scheme will invest across pharmaceutical companies, hospitals, diagnostics, contract development and manufacturing organisations (CDMOs), contract research organisations (CROs), medical devices, healthcare services, insurance and other allied healthcare segments.</span></p>
<p><span>India today occupies a position in the global healthcare ecosystem, supported by its scale, talent pool, manufacturing capabilities and growing innovation footprint. Structural drivers such as increasing healthcare expenditure, ageing demographics, rising lifestyle diseases, expanding health insurance coverage, infrastructure development and growing global outsourcing trends are expected to create long-term opportunities across the healthcare value chain.</span></p>
<p><span>The fund will be managed by Aditya Khemani and will be benchmarked against the BSE Healthcare TRI.</span></p>
<p><span>Speaking at the launch, Aditya Khemani, Head of Equity & Fund Manager, Invesco Mutual Fund, said “India’s healthcare sector is undergoing a structural transformation. The country is not only witnessing rising healthcare consumption driven by favourable demographics and increasing affordability but is also strengthening its position as a global pharmaceutical and healthcare innovation hub. We see attractive opportunities across domestic pharma, hospitals, diagnostics, CDMOs and emerging healthcare segments that can potentially benefit from this multi-year growth cycle. Our investment approach will focus on identifying quality businesses with sustainable competitive advantages and strong growth visibility across the healthcare ecosystem.”</span></p>
<p><span>The minimum lumpsum investment amount during the NFO is ₹1,000 and in multiples of ₹1 thereafter. For SIP investments, the minimum application amount is ₹100 and in multiples of ₹1 thereafter. The fund will charge an exit load of 0.50 per cent for units redeemed or switched out on or before three months from the date of allotment. No exit load will be charged if units are redeemed or switched out after three months.</span></p>
<p><span>The New Fund Offer (NFO) is open for subscription from August 18, 2026 and will close on September 1, 2026.</span></p>
<p>The post <a href="https://www.expresspharma.in/invesco-mutual-fund-launches-india-pharma-and-healthcare-fund/">Invesco Mutual Fund launches India Pharma and Healthcare Fund</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Andelyn Biosciences to develop GM2 gangliosidosis therapy</title>
<link>https://edusehat.com/en/andelyn-biosciences-to-develop-gm2-gangliosidosis-therapy</link>
<guid>https://edusehat.com/en/andelyn-biosciences-to-develop-gm2-gangliosidosis-therapy</guid>
<description><![CDATA[ The partnership aims to progress this gene therapy using Andelyn’s AAV Curator Platform. GM2 gangliosidosis is a rare genetic disorder that leads to the progressive loss of nerve 
The post Andelyn Biosciences to develop GM2 gangliosidosis therapy appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/08/PT-2-19-08-2026-shutterstock_2556717635.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 19 Aug 2026 19:15:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Andelyn, Biosciences, develop, GM2, gangliosidosis, therapy</media:keywords>
<content:encoded><![CDATA[<p>The partnership aims to progress this gene therapy using Andelyn’s AAV Curator Platform.</p>
<p>GM2 gangliosidosis is a rare genetic disorder that leads to the progressive loss of nerve cells in the brain and spinal cord. The most common form begins during infancy, although other forms can appear later in life.</p>
<p>The condition belongs to the group of lysosomal storage disorders and results from genetic mutations that impair lysosomal function, leading to harmful accumulation within cells and severe neurological symptoms.</p>
<p>Andelyn Biosciences will implement a multi-phase programme using its Curator Platform, which features a cell line and a modular approach intended to adapt manufacturing processes to specific programme needs.</p>
<p>Andelyn Biosciences chief commercial officer Matt Niloff said: “We are proud to partner with Queen’s University to advance this gene therapy candidate for the benefit of patients and families facing the challenges of GM2 gangliosidoses.</p>
<p>“Our deep expertise in AAV development and production allows us to support Queen’s University with the scale and quality rigour necessary to bring this life-changing therapy one step closer to reality.”</p>
<p>Queen’s University medical geneticist and department of paediatrics professor Dr Jagdeep Walia said: “This partnership with Andelyn is very strategic as they have the established expertise of producing vectors for many gene therapy programmes.</p>
<p>“Their track record and ability to manufacture the viral vector for the upcoming GM2 programme gives us confidence that the participants in the clinical trial will be receiving the highest quality, safe product.”</p>
<p>In August 2025, Andelyn Biosciences entered a collaboration with Amplo Biotechnology to manufacture adeno-associated virus (AAV) gene therapies to address conditions affecting the neuromuscular junction.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/andelyn-to-develop-gm2-gangliosidosis-therapy/">Andelyn Biosciences to develop GM2 gangliosidosis therapy</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>BeOne Medicines and partners renew Brukinsa access programme for CLL</title>
<link>https://edusehat.com/en/beone-medicines-and-partners-renew-brukinsa-access-programme-for-cll</link>
<guid>https://edusehat.com/en/beone-medicines-and-partners-renew-brukinsa-access-programme-for-cll</guid>
<description><![CDATA[ The renewed agreement is expected to reach approximately 1,000 patients cumulatively by its conclusion. This partnership, which began in 2023, has so far provided Brukinsa to more than 
The post BeOne Medicines and partners renew Brukinsa access programme for CLL appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/08/PT-19-08-2026-shutterstock_2172440175.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 19 Aug 2026 19:15:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>BeOne, Medicines, and, partners, renew, Brukinsa, access, programme, for, CLL</media:keywords>
<content:encoded><![CDATA[<p>The renewed agreement is expected to reach approximately 1,000 patients cumulatively by its conclusion.</p>
<p>This partnership, which began in 2023, has so far provided Brukinsa to more than 300 CLL patients in Armenia, Ethiopia, and Nepal. The figure surpassed the programme’s initial goal by around 150 patients.</p>
<p>The initiative is aimed at improving access to CLL therapy in regions where advanced treatments have previously been limited or unavailable.</p>
<p>Support for the project involves donated Brukinsa from BeOne Medicines and a $1m BeOne Care Foundation grant, which together help underpin patient care, physician involvement, and operational needs for the next two years.</p>
<p>The Max Foundation leads implementation efforts based on its experience with oncology access programmes.</p>
<p>BeOne Medicines co-founder, chairman and CEO John Oyler said: “From the beginning, our goal has been to ensure that where a person lives does not determine whether they can access high-quality cancer care.</p>
<p>“Renewing this partnership with The Max Foundation reflects both the impact we have already achieved together and our commitment to reaching many more patients who otherwise may have limited treatment options.”</p>
<p>The agreement will maintain support in Armenia, Ethiopia, and Nepal, and may include additional countries such as Côte d’Ivoire, Malawi, Mongolia, Mozambique, Togo, and Zambia, depending on future capacity and priorities.</p>
<p>The model includes provisions for ongoing treatment for enrolled patients beyond 2028 if clinically required.</p>
<p>Earlier this month, BeOne Medicines signed a multi-part collaboration with Revolution Medicines to develop and commercialise targeted oncology therapies.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/beone-medicines-partners-renew-brukinsa-programme/">BeOne Medicines and partners renew Brukinsa access programme for CLL</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Dr Ashok Kumar Mittal elected to AIIMS Bathinda governing body</title>
<link>https://edusehat.com/en/dr-ashok-kumar-mittal-elected-to-aiims-bathinda-governing-body</link>
<guid>https://edusehat.com/en/dr-ashok-kumar-mittal-elected-to-aiims-bathinda-governing-body</guid>
<description><![CDATA[ 
Rajya Sabha MP and Lovely Professional University Founder-Chancellor to contribute to the governance of the central healthcare and medical education institution
The post Dr Ashok Kumar Mittal elected to AIIMS Bathinda governing body appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 19 Aug 2026 15:40:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Ashok, Kumar, Mittal, elected, AIIMS, Bathinda, governing, body</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Dr Ashok Kumar Mittal, Rajya Sabha MP and Founder-Chancellor of Lovely Professional University, has been elected by 245 Members of Parliament from the Rajya Sabha as a member of the governing body of the All India Institute of Medical Sciences (AIIMS), Bathinda.</span></p>
<p><span>Dr Mittal is among the Rajya Sabha members recently elected to the governing bodies of various AIIMS institutions across the country. His election to AIIMS Bathinda adds an institutional responsibility to his parliamentary role and places him within the governance framework of a public healthcare and medical education institution in Punjab.</span></p>
<p><span>AIIMS Bathinda combines patient care, medical education and research. Its development is relevant to healthcare capacity and access to medical services in Punjab and the wider region.</span></p>
<p><span>Institutional governance supports healthcare institutions in advancing their academic, clinical and research objectives. In Punjab, medical education, healthcare capacity, research and innovation are areas of focus for developing public healthcare infrastructure.</span></p>
<p><span>Speaking on his election, Dr Ashok Kumar Mittal said, “ I am honoured to have been entrusted with this responsibility, having been elected by 245 Members of the Rajya Sabha. This appointment holds special significance for me: I was previously nominated by the Vice President of India as a member of the School of Planning and Architecture, and of the Jawaharlal Nehru University (JNU) Court — both central institutions located in Delhi. AIIMS Bathinda, though also a central institution, is located in Bathinda, in my own home state of Punjab. ”</span></p>
<p><span>He added, “ The Bathinda region faces a significant health burden linked to water table issues, with cancer being the most serious of these challenges. AIIMS Bathinda, with its clinical experience, its team of doctors, and the infrastructure it is building, can make a major contribution towards addressing the cancer burden faced by the people of Punjab, and particularly by those in the Bathinda region. I am especially glad that, as a member of AIIMS Bathinda, I may be able to contribute meaningfully to the health and well-being of the people of Punjab, and I look forward to strengthening Punjab’s healthcare ecosystem. ”</span></p>
<p><span>He further said, “ Healthcare and education are fundamental pillars of social and economic development. As we work towards a healthier and more developed Punjab, we must continue to strengthen institutions that can deliver quality healthcare while also creating the knowledge, talent and research capabilities needed for the future. My endeavour will be to bring a constructive and public-interest-oriented perspective to this responsibility. ”</span></p>
<p><span>The election comes as healthcare institutions are expected to integrate patient care with medical education, research, technology and innovation. AIIMS Bathinda can contribute to this ecosystem in Punjab.</span></p>
<p><span>Dr Mittal’s participation in the governing body provides an opportunity to contribute his perspective on institution-building and capacity development while supporting objectives related to medical education, healthcare accessibility, research and innovation. No specific initiatives or policy measures have been announced by Dr Mittal in connection with his new role at this stage.</span></p>
<p><span>As Punjab continues to strengthen its healthcare infrastructure and human-resource capabilities, institutions such as AIIMS Bathinda will remain relevant to healthcare access and the development of medical professionals and researchers. Institutional systems, academic excellence and public-oriented healthcare remain areas of focus for the state’s long-term development.</span></p>
<p>The post <a href="https://www.expresspharma.in/dr-ashok-kumar-mittal-elected-to-aiims-bathinda-governing-body/">Dr Ashok Kumar Mittal elected to AIIMS Bathinda governing body</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>India&#45;US pharma ties look beyond generics</title>
<link>https://edusehat.com/en/india-us-pharma-ties-look-beyond-generics</link>
<guid>https://edusehat.com/en/india-us-pharma-ties-look-beyond-generics</guid>
<description><![CDATA[ 
Sergio Gor, US Ambassador to India and Devendra Fadnavis, Maharashatra CM pitch deeper R&amp;D, investment and co-development, at IACC National Convention 2026, reports Lakshmipriya Nair
The post India-US pharma ties look beyond generics appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/08/19122307/EP_US-Indo_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 19 Aug 2026 15:40:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>India-US, pharma, ties, look, beyond, generics</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/08/19122307/EP_US-Indo_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/08/19122307/EP_US-Indo_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/19122307/EP_US-Indo_750-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>India-US pharma ties are entering a new phase. The two countries already have a strong pharma relationship, India supplies 40 per cent of US generic pharma. Now, both sides are looking at what comes next.</span></p>
<p><span>The message came through at the Indo-American Chamber of Commerce (IACC) National Convention 2026 in Mumbai. Sergio Gor, US Ambassador to India and Devendra Fadnavis, Chief Minister, Government of Maharashtra spoke about taking the wider India-US partnership deeper.</span></p>
<p><span>The timing is significant. Gor said trade in goods and services between the two countries has grown 12-fold to $240 billion. The two countries are targeting $500 billion in bilateral trade by 2030.</span></p>
<p><span>“The reason we get 40 per cent of our generic pharma from India, that’s an incredible number, is because we trust India,” said Gor.</span></p>
<p><span>He sees scope to take that trust further. “Simply put, when the US and India work together, we integrate value chains, accelerate breakthroughs in critical technologies, and strengthen supply chain resilience,” he said.</span></p>
<p><b>The bigger opportunity</b></p>
<p><span>Fadnavis wants Maharashtra to play a central role.</span></p>
<p><span>“The next chapter of the India-US partnership must move from strategic convergence to economic execution. And when that happens, Maharashtra wants to be at the center of that story.”</span></p>
<p><span>His message to industry is simple. Do more together.</span></p>
<p><span>He said, “It means moving towards co-investment, co-innovation, co-development and co-creation. It means American technology meeting Indian scale. American capital meeting Indian entrepreneurship. American research meeting Indian talent.”</span></p>
<p><span>For pharma, this could open up new areas of collaboration. Fadnavis pointed to joint research, technology transfer, global capability centres and manufacturing partnerships.</span></p>
<p><span>He also described a bigger ambition for India-US manufacturing.</span></p>
<p><span>“Not merely made in India but increasingly designed together, developed together, manufactured together and taken to the world together.”</span></p>
<p><span>That is a clear step beyond the traditional generics model.</span></p>
<p><span>Gor also made a direct pitch to Indian companies.</span></p>
<p><span>“So here’s my ask of every company in this room. If you’re weighing your next overseas investment, choose the US. Bring your regional project, your R&D center, your manufacturing lines to American soil.</span></p>
<p><span>If you’ve already invested in America, deepen that commitment further. This is the moment.”</span></p>
<p><span>He cited Natco Pharma and Aurobindo Pharma among Indian pharma companies that have expanded their operations in the US.</span></p>
<p><span>He also highlighted Mumbai-based LMAC Packages. The company has partnered with North Carolina-based Aylward to build high-speed pharma packaging equipment.</span></p>
<p><b>So, what will it take?</b></p>
<p><span>Deeper partnerships will need a supportive business environment, Gor said.</span></p>
<p><span>“We need predictable taxation and regulatory frameworks that allow business to thrive. We need candid, trust-based engagement on export controls and technology flows. And we need rock-solid intellectual property protections, giving every innovator in this room the confidence to invest, create and scale without fear.”</span></p>
<p><span>Maharashtra is making its own pitch to US companies.</span></p>
<p><span>“Look at Maharashtra as a platform for your India and global growth. Partner with Maharashtra for your manufacturing. Partner with Mumbai for your financial operations. Utilise our talent for your global capability centers. Utilise our technology ecosystem for innovation. Utilise our healthcare ecosystem for research and medical innovation.”</span></p>
<p><span>Thus, the IACC National Convention brought larger ambition into focus. Anup Acharya, National President, IACC, and Raghavendra Ponkshe, Regional Director–West, IACC, highlighted, the India-US relationship has grown beyond traditional trade and investment.</span></p>
<p><span>IACC has spent decades building bridges between the two business communities. The next chapter, its leadership said, will be about ideas, investment and partnerships.</span></p>
<p><b><i>lakshmipriya.nair@expressindia.com </i></b></p>
<p><b><i>laxmipriyanair@gmail.com </i></b></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/india-us-pharma-ties-look-beyond-generics/">India-US pharma ties look beyond generics</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Fulcrum and Slate Medicines sign merger agreement</title>
<link>https://edusehat.com/en/fulcrum-and-slate-medicines-sign-merger-agreement</link>
<guid>https://edusehat.com/en/fulcrum-and-slate-medicines-sign-merger-agreement</guid>
<description><![CDATA[ The combined organisation, which will operate as Slate Medicines, is expected to be listed on Nasdaq under the “SLTE” ticker symbol. Following completion of the merger, the new 
The post Fulcrum and Slate Medicines sign merger agreement appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/08/PT-18-08-2026-shutterstock_2346589369.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 18 Aug 2026 18:10:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Fulcrum, and, Slate, Medicines, sign, merger, agreement</media:keywords>
<content:encoded><![CDATA[<p>The combined organisation, which will operate as Slate Medicines, is expected to be listed on Nasdaq under the “SLTE” ticker symbol.</p>
<p>Following completion of the merger, the new entity will focus on developing Slate’s pipeline of migraine treatments, with SLTE-1009 as its lead candidate.</p>
<p>This clinical-stage subcutaneous anti- pituitary adenylate cyclase-activating peptide / vasoactive intestinal peptide (PACAP/VIP) monoclonal antibody is intended for the prevention of migraine and other headache disorders.</p>
<p>The financing is expected to support operations through 2029, enabling progress of SLTE-1009 through Phase I studies in healthy volunteers and a Phase II dose-range finding study in patients with migraine.</p>
<p>Also in development is SLTE-2100, a bispecific antibody targeting PACAP/VIP and calcitonin gene-related peptide (CGRP), which remains in the lead optimisation stage.</p>
<p>SLTE-2100 is scheduled to enter clinical trials in the second half of 2027 and has secured funding for a Phase IIa study in migraine.</p>
<p>The transaction, unanimously supported by the boards of both companies, is targeted to close in the fourth quarter of 2026, pending regulatory and shareholder approvals, as well as satisfaction or waiver of customary closing conditions.</p>
<p>Upon completion, pre-merger Fulcrum stockholders are expected to own 5% of the new company while pre-merger Slate stockholders and pre-closing financing investors are expected to hold 95%.</p>
<p>Fulcrum is anticipated to contribute net cash of nearly $20.3m and issue a cash dividend estimated at $270m, to be paid immediately prior to closing, to Fulcrum stockholders.</p>
<p>Slate Medicines CEO Gregory Oakes will lead the merged entity.</p>
<p>Oakes said: “Migraine remains one of the most prevalent and disabling neurological diseases, yet millions of patients continue to be underserved by existing therapies.</p>
<p>“This merger and the related financing are expected to provide the resources to advance SLTE-1009, along with the rest of our pipeline, through potentially meaningful clinical milestones.”</p>
<p>Slate’s management team includes president and chief operating officer Neil Buckley, chief medical officer Dr Roger Cady, and chief financial officer John Umstead.</p>
<p>The new company’s board of directors will include representatives from RA Capital Management, Forbion, Foresite Capital, and a former executive of Verona Pharma.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/fulcrum-slate-medicines-merger-agreement/">Fulcrum and Slate Medicines sign merger agreement</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Faeth’s PIKTOR plus paclitaxel combo gains FDA fast track status</title>
<link>https://edusehat.com/en/faeths-piktor-plus-paclitaxel-combo-gains-fda-fast-track-status</link>
<guid>https://edusehat.com/en/faeths-piktor-plus-paclitaxel-combo-gains-fda-fast-track-status</guid>
<description><![CDATA[ The designation applies specifically to patients whose tumours contain a phosphatidylinositol 3-kinase / protein kinase B / mechanistic target of rapamycin (PI3K/AKT/mTOR) pathway alteration. It also applies to 
The post Faeth’s PIKTOR plus paclitaxel combo gains FDA fast track status appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/08/PT-2-18-08-2026-shutterstock_2342038863.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 18 Aug 2026 18:10:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Faeth’s, PIKTOR, plus, paclitaxel, combo, gains, FDA, fast, track, status</media:keywords>
<content:encoded><![CDATA[<p>The designation applies specifically to patients whose tumours contain a phosphatidylinositol 3-kinase / protein kinase B / mechanistic target of rapamycin (PI3K/AKT/mTOR) pathway alteration.</p>
<p>It also applies to those who have previously undergone platinum-based chemotherapy and an immune checkpoint inhibitor.</p>
<p>Faeth Therapeutics is currently conducting a Phase II trial of this treatment approach, known as Study FTH-PIK-201, in second-line advanced endometrial cancer.</p>
<p>The company anticipates releasing top line results from this trial by the end of this year.</p>
<p>Faeth Therapeutics CEO Anand Parikh said: “Fast track designation for PIKTOR reflects the significant unmet need in advanced endometrial cancer for patients whose disease has progressed despite platinum-based chemotherapy and an immune checkpoint inhibitor.</p>
<p>“We believe PIKTOR’s multi-node approach to the PI3K/AKT/mTOR pathway is well suited to this population as our preclinical data suggests that PIKTOR can resensitise patients to chemotherapy.”</p>
<p>PIKTOR is described as an investigational, all-oral combination therapy and is designed to inhibit several nodes of the PI3K/AKT/mTOR pathway, which, according to published literature, is altered in up to half of all solid tumours.</p>
<p>In addition to the endometrial cancer trial, PIKTOR is being tested in a Phase Ib/II study for hormone receptor positive / human epidermal growth factor receptor 2 negative (HR+/HER2-) advanced breast cancer, referred to as Study FTH-PIK-101.</p>
<p>The first patient in this study was dosed in April, with interim results expected in 2027.</p>
<p>Faeth Therapeutics focuses on multi-node therapies for cancer, with PIKTOR as its leading development programme.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/faeths-combo-fda-fast-track-status/">Faeth’s PIKTOR plus paclitaxel combo gains FDA fast track status</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Godavari Biorefineries secures European patent for pharma composition</title>
<link>https://edusehat.com/en/godavari-biorefineries-secures-european-patent-for-pharma-composition</link>
<guid>https://edusehat.com/en/godavari-biorefineries-secures-european-patent-for-pharma-composition</guid>
<description><![CDATA[ 
Patent covers a pharmaceutical composition combining anti-cancer compounds with a solubilising agent and the process to prepare it
The post Godavari Biorefineries secures European patent for pharma composition appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2020/03/11181405/patent-e1590558369360.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 18 Aug 2026 18:10:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Godavari, Biorefineries, secures, European, patent, for, pharma, composition</media:keywords>
<content:encoded><![CDATA[<div><img width="880" height="447" src="https://cdn.expresspharma.in/wp-content/uploads/2020/03/11181405/patent-e1590558369360.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2020/03/11181405/patent-e1590558369360.jpg 880w, https://cdn.expresspharma.in/wp-content/uploads/2020/03/11181405/patent-300x152.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2020/03/11181405/patent-768x390.jpg 768w" sizes="auto, (max-width: 880px) 100vw, 880px"></div><p><span>Godavari Biorefineries has secured a patent from the European Patent Office for its invention, “Pharmaceutical Composition and a Process to Prepare the Same”. The patent covers a pharmaceutical composition that combines anti-cancer compounds with a solubilising agent, along with the process to prepare it.</span></p>
<p><span>The composition is designed to enhance the solubility and bioavailability of the active compounds, thereby improving their therapeutic potential. It has applications in the treatment of various cancers, including breast and prostate cancers, particularly through oral administration.</span></p>
<p><span>The patent adds to Godavari Biorefineries Limited’s oncology-focused intellectual property portfolio.</span></p>
<p><span>“In oncology research, identifying a promising compound is only one part of the challenge. How that compound is formulated can determine how effectively it can be developed for therapeutic use. Our research has focused on improving the solubility and bioavailability of these compounds, and the grant of this European patent is an important recognition of that work,” said Dr Sangeeta Srivastava, Executive Director, Godavari Biorefineries Limited.</span></p>
<p><span>Commenting on the achievement, Samir Somaiya, Chairman and Managing Director, Godavari Biorefineries Limited said, “Our approach to innovation has always been guided by a larger purpose, to advance health, wellbeing and sustainability while creating lasting value for all. The Sanskrit mantra ‘सर्वे सन्तु निरामयाः’, meaning ‘Health for All’, reflects this purpose and reminds us that the true value of innovation lies in its ability to improve lives. As we look beyond our traditional businesses, our investments in R&D are enabling us to build capabilities in areas where science and technology can address meaningful societal needs. This European patent is an important milestone in that journey, strengthening our intellectual property and opening possibilities for developing solutions with potential applications in healthcare. For us, innovation is meaningful when it creates sustainable opportunities for the business while also contributing to a healthier and more sustainable future for society.”</span></p>
<p><span>The European grant further expands Godavari Biorefineries’ international intellectual property footprint as the company continues to protect its research across major markets worldwide.</span></p>
<p>The post <a href="https://www.expresspharma.in/godavari-biorefineries-secures-european-patent-for-pharma-composition/">Godavari Biorefineries secures European patent for pharma composition</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>An effective methodology for diabetes prediction in the case of class imbalance</title>
<link>https://edusehat.com/en/an-effective-methodology-for-diabetes-prediction-in-the-case-of-class-imbalance</link>
<guid>https://edusehat.com/en/an-effective-methodology-for-diabetes-prediction-in-the-case-of-class-imbalance</guid>
<description><![CDATA[ 
Dr Vincent Hooper highlights how a machine learning methodology can improve diabetes prediction in clinical datasets affected by class imbalance
The post An effective methodology for diabetes prediction in the case of class imbalance appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/08/18140101/EP_GB_Vincent_Hooper_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 18 Aug 2026 18:10:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>effective, methodology, for, diabetes, prediction, the, case, class, imbalance</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/08/18140101/EP_GB_Vincent_Hooper_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/08/18140101/EP_GB_Vincent_Hooper_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/18140101/EP_GB_Vincent_Hooper_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>This article draws on peer-reviewed research conducted at SP Jain School of Global Management and published in </span><i><span>Bioengineering</span></i><span> (2025, 12, 35). The study develops a novel machine learning methodology for diabetes prediction that outperforms existing algorithms when clinical data suffer from class imbalance.</span></p>
<p><b>The clinical stakes of getting prediction right</b></p>
<p><span>Diabetes remains one of the most consequential public health challenges worldwide. According to the International Diabetes Federation’s Diabetes Atlas (11th edition, 2025), an estimated 589 million adults aged 20–79 are living with diabetes, and that figure is projected to reach 853 million by 2050. </span></p>
<p><span>Early detection is critical: when clinicians can identify at-risk individuals before the disease takes hold, lifestyle interventions and targeted treatment can slow or even reverse its progression. Machine learning offers a powerful tool for this purpose, sifting through biological and social indicators to flag patients who might otherwise be missed.</span></p>
<p><span>Yet a persistent technical obstacle undermines many predictive models. Real-world clinical datasets are frequently imbalanced: healthy patients vastly outnumber diabetic ones. In the widely used PIMA Indians Diabetes Dataset, for example, roughly two thirds of observations are non-diabetic. A classifier trained on such data can achieve deceptively high overall accuracy simply by predicting the majority class, while failing to identify the very patients who most need attention. The consequences in a clinical setting are serious: missed diagnoses, delayed treatment, and poorer health outcomes for the most vulnerable.</span></p>
<p><b>A simpler path to better predictions</b></p>
<p><span>Our research, conducted at SP Jain School of Global Management in collaboration with Sofia University, set out to address this class imbalance problem without resorting to computationally expensive deep learning architectures or elaborate feature selection procedures. The methodology we propose introduces two straightforward preprocessing steps—resampling and random shuffling—before applying a standard support vector machine classifier with balanced class weights and k-fold cross validation.</span></p>
<p><span>Resampling supplements the minority class so that both classes are represented more evenly in the training data. Random shuffling then rearranges the order of observations, preventing the model from learning spurious patterns tied to the sequence of the data rather than the genuine relationships among variables. These steps are combined with Python’s built-in balanced class weighting and tested under both standard k-fold and stratified k-fold cross validation. The entire pipeline is simple to implement, fast to execute, and requires no specialist hardware.</span></p>
<p><b>Results that rival deep learning</b></p>
<p><span>The results are striking. Our proposed methodology achieved a classification accuracy of 95.5 per cent on the PIMA dataset, with 100 per cent specificity and over 91 per cent sensitivity. By comparison, the classical approach—shuffling and balanced class weights alone, without resampling—yielded accuracies between 83 and 85 per cent and notably lower sensitivity scores. The proposed methodology also outperformed published results from several other research groups using Random Forest, Naive Bayes, Adaboost, and SHAP-based ensemble methods on the same dataset.</span></p>
<p><span>Perhaps most remarkably, our simple machine learning pipeline came within roughly 2.5 percentage points of the best reported deep neural network accuracies, while achieving a perfect specificity of 100 per cent—a result none of the deep learning benchmarks matched. This means our model correctly identified every non-diabetic patient in the test set, producing zero false positives. In clinical terms, that translates to fewer unnecessary follow-up procedures and reduced patient anxiety, while still detecting over 91 per cent of diabetic cases.</span></p>
<p><b>Why it matters for healthcare</b></p>
<p><span>The practical implications extend well beyond a single dataset. The methodology avoids feature selection, which eliminates an entire source of researcher bias and saves considerable analytical time. It is agnostic to the type of cross validation, performing comparably under both k-fold and stratified k-fold approaches, which suggests robustness across datasets of different sizes and structures. And because it relies on standard Python libraries rather than bespoke deep learning frameworks, it can be deployed in resource-constrained clinical environments where computational infrastructure is limited.</span></p>
<p><span>For public health professionals and policymakers, this work offers an accessible, evidence-based tool for diabetes prescreening. By improving the identification of at-risk individuals, clinicians can allocate preventive resources more effectively, tailor interventions to individual risk profiles, and ultimately reduce the burden of a disease that exacts an enormous toll on patients, families, and health systems.</span></p>
<p><b>Looking ahead</b></p>
<p><span>Future work at SP Jain School of Global Management will extend this methodology to larger diabetes datasets, multiclass classification problems, and datasets with high-dimensional feature spaces. We also plan to incorporate additional evaluation metrics such as the Matthews Correlation Coefficient and nested stratified cross validation to further strengthen model reliability. As artificial intelligence becomes increasingly embedded in healthcare decision-making, ensuring that predictive models are not only accurate but also simple, interpretable, and ethically sound is an imperative that this research directly serves.</span></p>
<p><b><i>This research was conducted at SP Jain School of Global Management, Dubai.</i></b></p>
<p><b>Reference: </b><span>Toleva, B.; Atanasov, I.; Ivanov, I.; Hooper, V. An Effective Methodology for Diabetes Prediction in the Case of Class Imbalance. </span><i><span>Bioengineering</span></i><span> 2025, 12, 35.</span></p>
<p><span>https://doi.org/10.3390/bioengineering12010035</span></p>
<p><span>https://idf.org/news-and-resources/news/idf-diabetes-atlas-11th-edition/</span></p>
<p>The post <a href="https://www.expresspharma.in/an-effective-methodology-for-diabetes-prediction-in-the-case-of-class-imbalance/">An effective methodology for diabetes prediction in the case of class imbalance</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>ACG appoints Lalit Kasliwal as Group Chief Financial Officer</title>
<link>https://edusehat.com/en/acg-appoints-lalit-kasliwal-as-group-chief-financial-officer</link>
<guid>https://edusehat.com/en/acg-appoints-lalit-kasliwal-as-group-chief-financial-officer</guid>
<description><![CDATA[ 
Kasliwal to lead global finance, governance, capital allocation and risk management as ACG expands its international presence
The post ACG appoints Lalit Kasliwal as Group Chief Financial Officer appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/08/18142735/EP_Lalit_Kasliwal_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 18 Aug 2026 18:10:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>ACG, appoints, Lalit, Kasliwal, Group, Chief, Financial, Officer</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/08/18142735/EP_Lalit_Kasliwal_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/08/18142735/EP_Lalit_Kasliwal_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/18142735/EP_Lalit_Kasliwal_750-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>ACG has appointed Lalit Kasliwal as Group Chief Financial Officer, with responsibility for the company’s global finance function across its pharmaceutical and nutraceutical manufacturing businesses.</span></p>
<p><span>In his new role, Kasliwal will lead financial strategy, treasury, governance, capital allocation and risk management to support ACG’s long-term ambitions.</span></p>
<p><span>Kasliwal brings more than 27 years of global leadership experience across financial strategy, treasury, capital allocation and structuring, governance, enterprise transformation and risk management in the pharmaceutical, manufacturing and international trading sectors.</span></p>
<p><span>He joins ACG from Tata International Limited, where he served as Chief Financial Officer and Company Secretary, leading the global finance function for operations across more than 29 countries. Before this, he served as CFO – Group Manufacturing and Head of Group Insurance at Reliance Industries Limited. Earlier in his career, he held senior finance leadership positions with Vedanta Group, including Hindustan Zinc Limited and Sterlite Technologies Limited, Ruia Group and IPCA Laboratories Limited.</span></p>
<p><span>Karan Singh, Managing Director at ACG, commented; “We are delighted to welcome Lalit to ACG. He brings a wealth of global experience, a strong track record of financial leadership and a deep understanding of complex international businesses. His expertise will be invaluable as we continue to strengthen our operations and pursue the next phase of our growth strategy.”</span></p>
<p><span>Lalit Kasliwal added; “I am delighted to be joining ACG at an exciting stage of its global growth journey. I look forward to partnering with colleagues across the organisation to strengthen financial performance, enhance governance and support sustainable long-term value creation for our customers, partners and stakeholders.”</span></p>
<p><span>The appointment comes as ACG continues to expand its global presence and invest in technologies and solutions that support pharmaceutical and nutraceutical manufacturers worldwide.</span></p>
<p>The post <a href="https://www.expresspharma.in/acg-appoints-lalit-kasliwal-as-group-chief-financial-officer/">ACG appoints Lalit Kasliwal as Group Chief Financial Officer</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>ACG appoints Rajesh Bhogavalli as Group Chief Commercial Officer</title>
<link>https://edusehat.com/en/acg-appoints-rajesh-bhogavalli-as-group-chief-commercial-officer</link>
<guid>https://edusehat.com/en/acg-appoints-rajesh-bhogavalli-as-group-chief-commercial-officer</guid>
<description><![CDATA[ 
Rajesh Bhogavalli will lead ACG’s global commercial strategy and support international growth across its pharmaceutical and nutraceutical manufacturing businesses
The post ACG appoints Rajesh Bhogavalli as Group Chief Commercial Officer appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/08/17170233/EP_ACG_Rajesh_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 17 Aug 2026 20:40:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>ACG, appoints, Rajesh, Bhogavalli, Group, Chief, Commercial, Officer</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/08/17170233/EP_ACG_Rajesh_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/08/17170233/EP_ACG_Rajesh_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/17170233/EP_ACG_Rajesh_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>ACG has appointed Rajesh Bhogavalli as Group Chief Commercial Officer as the company continues its international growth, operational excellence and commercial transformation across its pharmaceutical and nutraceutical manufacturing businesses.</span></p>
<p><span>As Group Chief Commercial Officer, Bhogavalli will lead the Group’s global commercial strategy, strengthen strategic partnerships, drive cost-optimisation initiatives and support market expansion.</span></p>
<p><span>Bhogavalli brings more than 30 years’ experience in commercial strategy, global supply chain and business transformation. Before joining ACG, he spent almost 12 years with EPL Limited, formerly Essel Propack Ltd., most recently as President – Supply Chain & Sustainability (Global), leading operations across 11 countries. He has also held senior leadership positions with BASF India and Asian Paints.</span></p>
<p><span>Bhogavalli holds an MBA in Operations Management from IGNOU and an MSc in Physical Chemistry from Andhra University.</span></p>
<p><span>Karan Singh, Managing Director at ACG, said: “We are delighted to welcome Rajesh to ACG. He brings a wealth of global experience, a strong track record in commercial strategy and operations, and a deep understanding of complex international businesses. His expertise will be invaluable as we continue to strengthen our operations and pursue the next phase of our growth strategy.”</span></p>
<p><span>Rajesh Bhogavalli said: “ACG has built an outstanding reputation across the pharmaceutical manufacturing ecosystem, and I’m excited to join the business at such an important stage of its growth. I look forward to further strengthening our commercial strategy, deepening customer relationships and supporting the company’s continued global expansion.”</span></p>
<p><span>The appointment comes as ACG continues to expand its global presence and invest in technologies and solutions that support pharmaceutical and nutraceutical manufacturers worldwide.</span></p>
<p>The post <a href="https://www.expresspharma.in/acg-appoints-rajesh-bhogavalli-as-group-chief-commercial-officer/">ACG appoints Rajesh Bhogavalli as Group Chief Commercial Officer</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Optimus Pharma gets DCGI permission for Tapinarof Cream 1% w/w</title>
<link>https://edusehat.com/en/optimus-pharma-gets-dcgi-permission-for-tapinarof-cream-1-ww</link>
<guid>https://edusehat.com/en/optimus-pharma-gets-dcgi-permission-for-tapinarof-cream-1-ww</guid>
<description><![CDATA[ 
The company has received permission to manufacture and market Tapinarof Cream 1% w/w and the tapinarof bulk drug in India
The post Optimus Pharma gets DCGI permission for Tapinarof Cream 1% w/w appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 17 Aug 2026 20:40:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Optimus, Pharma, gets, DCGI, permission, for, Tapinarof, Cream, ww</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>Optimus Pharma, a subsidiary of Sekhmet Pharmaventures, has become the first company in India to receive permission from the Drugs Controller General of India (DCGI) to manufacture and market Tapinarof Cream 1 per cent w/w and the tapinarof bulk drug.</span></p>
<p><span>Tapinarof Cream 1 per cent w/w is a non-steroidal topical treatment for plaque psoriasis in adults.</span></p>
<p><span>Psoriasis is a chronic, non-communicable skin condition that the World Health Organization estimates affects at least 100 million people worldwide. Indian studies place prevalence in the country between 0.44 and 2.8 percent, with plaque psoriasis the most common presentation. Many patients depend on long-term topical therapy, where options beyond corticosteroids have remained limited. Tapinarof, a topical aryl hydrocarbon receptor agonist, provides a non-steroidal option for the management of plaque psoriasis in adults.</span></p>
<p><span>Optimus’ clinical study in India enrolled 213 patients with moderate-to-severe plaque psoriasis. Tapinarof Cream 1 per cent w/w demonstrated statistically significant superiority over placebo in achieving Physician Global Assessment (PGA) success at Week 12.</span></p>
<p><span>Significant improvements compared with placebo were also observed in the Psoriasis Area and Severity Index (PASI ≥50), percentage reduction in Body Surface Area (%BSA) involvement, the Peak Pruritus Numeric Rating Scale (PP-NRS) and Psoriasis Symptom Diary (PSD) scores. Numerical improvements were observed in higher PASI response rates (PASI ≥75 and PASI ≥90). Additionally, significant improvements were seen in Dermatology Life Quality Index (DLQI) scores.</span></p>
<p><span>Tapinarof Cream 1 per cent w/w was well tolerated in Indian patients, and no immunogenicity concerns were identified during the study.</span></p>
<p><span>Tapinarof Cream 1% w/w and its bulk drug are manufactured at facilities operating cGMP-compliant quality systems. These facilities have undergone inspections by regulatory agencies including the US FDA and European authorities, and are designed to ensure product quality, reliability and patient safety through controls across manufacturing, testing and supply operations.</span></p>
<p><span>With both the bulk drug and the finished formulation produced in-house, Optimus maintains control across the end-to-end manufacturing journey, from drug substance to finished dosage form, supporting consistency, traceability and quality at every stage.</span></p>
<p><span>The approval reflects the company’s capabilities in the development and manufacture of complex and differentiated formulations, enabling early launch through its strategic partners and making products available to Indian patients.</span></p>
<p><span>Sumit Kumar, Chief Commercial Officer, Sekhmet Pharmaventures, said: “The approval for Tapinarof Cream 1 per cent w/w and its bulk drug is a significant milestone for Sekhmet and a testament to the strength of our R&D, regulatory, quality and manufacturing capabilities. The group is backed by more than 250 scientists, reinvests over 12 percent of revenue into R&D, and has filed more than 300 patents and secured over 170 grants. Being the first company in India to receive this permission reflects our commitment to bringing differentiated pharmaceutical products to patients while maintaining the highest standards of quality and compliance.”</span></p>
<p><span>Optimus’ Tapinarof Cream 1 per cent w/w is a prescription-based drug. Patients are advised to consult their doctors for more details.</span></p>
<p>The post <a href="https://www.expresspharma.in/optimus-pharma-gets-dcgi-permission-for-tapinarof-cream-1-w-w/">Optimus Pharma gets DCGI permission for Tapinarof Cream 1% w/w</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>FDA grants fast track status to Phanes’ spevatamig for advanced BTC</title>
<link>https://edusehat.com/en/fda-grants-fast-track-status-to-phanes-spevatamig-for-advanced-btc</link>
<guid>https://edusehat.com/en/fda-grants-fast-track-status-to-phanes-spevatamig-for-advanced-btc</guid>
<description><![CDATA[ The company is evaluating spevatamig in Phase II clinical studies for various gastrointestinal cancers. Spevatamig is a bispecific antibody targeting claudin 18.2 and cluster of differentiation 47 (CD47), 
The post FDA grants fast track status to Phanes’ spevatamig for advanced BTC appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/08/PT-17-08-2026-shutterstock_2518831137.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 17 Aug 2026 17:05:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>FDA, grants, fast, track, status, Phanes’, spevatamig, for, advanced, BTC</media:keywords>
<content:encoded><![CDATA[<p>The company is evaluating spevatamig in Phase II clinical studies for various gastrointestinal cancers.</p>
<p>Spevatamig is a bispecific antibody targeting claudin 18.2 and cluster of differentiation 47 (CD47), designed to function as an innate immunity enhancer (I₂E).</p>
<p>The fast track designation for BTC follows other recent regulatory milestones for spevatamig.</p>
<p>In 2024, the antibody received the designation for metastatic claudin 18.2-positive pancreatic adenocarcinoma, and orphan drug status for metastatic pancreatic cancer in 2022.</p>
<p>Phanes Therapeutics expanded a clinical trial partnership with Merck & Co (MSD) last month to examine spevatamig in combination with pembrolizumab as a first-line treatment for BTC.</p>
<p>The companies began their collaboration in 2023 to study this combination therapy.</p>
<p>Phanes Therapeutics CEO Ming Wang said: “Spevatamig has the potential to be a transformational treatment option for patients with BTC.</p>
<p>“Following the successful completion of enrolment in our Phase II clinical trial of spevatamig in combination with chemotherapy for the front-line treatment of metastatic pancreatic ductal adenocarcinoma, we are making significant progress in the Phase II study of the molecule in BTC.”</p>
<p>The company is conducting three separate Phase II studies of its pipeline assets, notably spevatamig, peluntamig, and mavrostobart.</p>
<p>Both spevatamig and peluntamig are described as first-in-class bispecific antibodies and secured fast track and orphan drug status from the FDA.</p>
<p>The company’s pipeline is built using its PACbody, SPECpair and ATACCbody technology platforms, with the aim of addressing significant unmet needs in cancer treatment.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/fda-fast-track-phanes-spevatamig/">FDA grants fast track status to Phanes’ spevatamig for advanced BTC</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>EMA validates Pfizer and Valneva’s Lyme disease vaccine</title>
<link>https://edusehat.com/en/ema-validates-pfizer-and-valnevas-lyme-disease-vaccine</link>
<guid>https://edusehat.com/en/ema-validates-pfizer-and-valnevas-lyme-disease-vaccine</guid>
<description><![CDATA[ With this validation, the agency will begin its formal assessment of the application. The submission is supported by efficacy and safety data from the Phase III VALOR clinical 
The post EMA validates Pfizer and Valneva’s Lyme disease vaccine appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/08/PT-2-17-08-2026-shutterstock_1385338208.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 17 Aug 2026 17:05:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>EMA, validates, Pfizer, and, Valneva’s, Lyme, disease, vaccine</media:keywords>
<content:encoded><![CDATA[<p>With this validation, the agency will begin its formal assessment of the application.</p>
<p>The submission is supported by efficacy and safety data from the Phase III VALOR clinical trial, which enrolled 9,437 participants aged five years and above across the US, Canada, and Europe.</p>
<p>In the study, PF-07307405 showed efficacy of more than 70% in preventing Lyme disease. The vaccine candidate was found to be well tolerated with no identified safety concerns, according to the companies.</p>
<p>Pfizer senior vice-president and chief vaccines officer Annaliesa Anderson said: “I’m proud of the progress we have made with our Lyme disease vaccine candidate and excited about the opportunity to potentially bring the first vaccine of its kind to Europe. I look forward to collaborating with the EMA as this vaccine candidate advances through the review cycle.”</p>
<p>“Lyme disease remains the most common vector-borne illness in Europe, affecting more than 100,000 people each year. When left untreated, it can lead to serious and potentially long-lasting complications involving the skin, joints, nervous system, and heart.</p>
<p>“We believe vaccination has the potential to provide an important new layer of protection against this debilitating disease and help people continue to enjoy the outdoors with greater confidence.”</p>
<p>Pfizer and Valneva began collaborating on PF-07307405 in April 2020, with the former holding exclusive manufacturing and commercialisation rights if regulatory approval is achieved.</p>
<p>The vaccine is a 6-valent outer surface protein A (OspA)-based protein subunit, targeting six Borrelia OspA serotypes found in North America and Europe.</p>
<p>Currently, no approved human vaccines exist for Lyme disease.</p>
<p>In June 2026, Pfizer received approval from the US Food and Drug Administration for an expanded indication of Hympavzi (marstacimab-hncq) to treat haemophilia A or B.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/ema-pfizer-valnevas-lyme-disease-vaccine/">EMA validates Pfizer and Valneva’s Lyme disease vaccine</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>TCS launches ADD AgentHub for agentic AI in drug development</title>
<link>https://edusehat.com/en/tcs-launches-add-agenthub-for-agentic-ai-in-drug-development</link>
<guid>https://edusehat.com/en/tcs-launches-add-agenthub-for-agentic-ai-in-drug-development</guid>
<description><![CDATA[ 
The platform enables pharmaceutical companies to deploy AI agents across clinical development and pharmacovigilance while maintaining regulatory and audit requirements
The post TCS launches ADD AgentHub for agentic AI in drug development appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 17 Aug 2026 17:05:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>TCS, launches, ADD, AgentHub, for, agentic, drug, development</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Tata Consultancy Services (TCS) has launched TCS ADD AgentHub, a role-based, enterprise-ready and trusted AI platform that enables the use of agentic AI in drug development at scale. The platform is designed to transform clinical trials and pharmacovigilance services while maintaining regulatory and audit requirements.</span></p>
<p><span>Pharmaceutical companies operate in regulated environments and face challenges related to trust, governance and scalability when applying AI across functions. Growing data volumes, fragmented systems and increasing regulatory expectations across clinical development and pharmacovigilance are adding complexities across the R&D value chain.</span></p>
<p><span>TCS ADD AgentHub provides a framework to address these challenges. Within the framework, AI agents can operate with clear roles, defined oversight and built-in auditability. Pharmaceutical companies can custom build their AI agent hub and deploy it across clinical workflows. The platform enables integration with minimal effort to accelerate adoption while maintaining regulatory compliance.</span></p>
<p><span>Built on the TCS ADD framework, TCS ADD AgentHub delivers operational benefits across drug development and drug safety functions. Solutions powered by the platform have demonstrated up to 40 per cent efficiency gains in clinical data management activities, up to 30 per cent reduction in clinical study build effort through metadata-driven automation and up to 30 per cent cost savings in end-to-end safety case processing. AI-powered safety agents can also reduce quality control effort by as much as 50 per cent.</span></p>
<p><span>Built on the TCS ADD agentic AI architecture, TCS ADD AgentHub enables pharmaceutical companies to deploy a Human + AI Operating Model in which AI agents are embedded into enterprise workflows, with humans retaining responsibility for governing and decision-making.</span></p>
<p>Debashis Ghosh, President, Lifesciences and Healthcare, TCS,<span> said, “TCS ADD AgentHub, is a role-based, enterprise-ready, and trusted AI platform that will enable our customers to accelerate drug development using agentic AI at scale. It enables a shift from reactive to proactive, scalable, and audit-ready operations amidst an ever-changing regulatory environment. TCS’ strategy is to move towards autonomous enterprise functions where AI agentic workforce operates alongside humans driving innovation in drug development and improving patient safety.”</span></p>
<p><span>TCS ADD AgentHub supports workflows across clinical development and pharmacovigilance through AI workers for ICSR intake, data entry, coding, review and literature analysis; study design, protocol digitisation and clinical data review; SDTM (Study Data Tabulation Model) transformation; and medical monitoring assistance, among others.</span></p>
<p><span>The platform has an evolving catalogue of AI agents that can be deployed based on specific requirements and the existing landscape. These agents can be deployed progressively with minimal integration and implementation effort. By standardising how AI agents are deployed across these processes, the platform helps organisations improve productivity and enables scientific teams to focus on higher-value work.</span></p>
<p><span>TCS said its “AI-first” culture, exemplified by TCS ADD AgentHub, supports its aspiration to become the world’s largest AI-led technology services company. By leveraging the proprietary cognitive intelligence of the TCS ADD suite, TCS enables tangible, predictive and secure digital ecosystems for its customers.</span></p>
<p>The post <a href="https://www.expresspharma.in/tcs-launches-add-agenthub-for-agentic-ai-in-drug-development-2/">TCS launches ADD AgentHub for agentic AI in drug development</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>75th IPC to be held in New Delhi in December 2026</title>
<link>https://edusehat.com/en/75th-ipc-to-be-held-in-new-delhi-in-december-2026</link>
<guid>https://edusehat.com/en/75th-ipc-to-be-held-in-new-delhi-in-december-2026</guid>
<description><![CDATA[ 
IPC 2026 will focus on transforming India from the Pharmacy of the World to a Pharma Powerhouse by 2047
The post 75th IPC to be held in New Delhi in December 2026 appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2019/09/06161312/Conference.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 17 Aug 2026 17:05:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>75th, IPC, held, New, Delhi, December, 2026</media:keywords>
<content:encoded><![CDATA[<div><img width="888" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2019/09/06161312/Conference.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2019/09/06161312/Conference.jpg 888w, https://cdn.expresspharma.in/wp-content/uploads/2019/09/06161312/Conference-300x135.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2019/09/06161312/Conference-768x346.jpg 768w" sizes="auto, (max-width: 888px) 100vw, 888px"></div><p><span>The 75th Indian Pharmaceutical Congress (IPC) will be held from 18-20 December 2026 at the Yashobhoomi Convention Centre, Sector 25, Dwarka, New Delhi. The Platinum Jubilee edition is being organised by the Indian Pharmaceutical Congress Association (IPCA) and the Indian Pharmacy Graduates’ Association (IPGA).</span></p>
<p><span>The theme of IPC 2026 is “Transforming India from Pharmacy of the World to Pharma Powerhouse @2047”, aligned with the national vision of Viksit Bharat – Viksit Pharmacy.</span></p>
<p><span>According to the event documents, the Congress will bring together scientists, academicians, industry leaders, regulators, healthcare professionals, researchers, policymakers, entrepreneurs and students from India and other countries to exchange knowledge, foster collaborations and discuss the future of pharmaceutical science and the profession.</span></p>
<p><span>The programme will include plenary lectures, keynote addresses, scientific sessions, symposia, workshops, Continuing Professional Development (CPD) programmes, panel discussions and a CEO Conclave. It will also include a pharmaceutical expo, oral and poster presentations, student competitions, innovation challenges, a job fair and career development opportunities.</span></p>
<p><span>The Congress will focus on pharma education, research, industry, healthcare and professional practice. The event documents also identify innovation, advanced research, artificial intelligence, biotechnology, precision medicine, sustainable manufacturing, resilient supply chains and globally harmonised regulatory systems as areas relevant to the sector’s development towards 2047.</span></p>
<p><span>The 75th IPC will also include discussions involving industry, academia, research institutions, government and healthcare professionals. The documents state that the Congress will provide a platform for scientific deliberations, technology exchange, business networking and collaborative partnerships.</span></p>
<p><span>The event will feature PharmaExpo 2026. The documents also list Pharma PowderTech Expo 2026, covering powder processing, particle engineering and pharmaceutical manufacturing technologies. The expo will include areas covering filling, blending, granulation and drying; nutraceutical powder supplement systems; laboratory testing and quality-control equipment; stainless steel equipment and process components; plant engineering and turnkey project solutions; contract manufacturing and processing services; excipients, pharmaceutical ingredients and specialty materials; research, consultancy, validation and regulatory services; and research laboratories, academic institutions, government departments, regulatory organisations, trade organisations, investors, innovators and start-ups.</span></p>
<p><span>The event documents also outline sponsorship opportunities for the 75th IPC. The listed sponsorship categories are Principal Sponsor at Rs 100 lakh, Platinum Sponsor at Rs 75 lakh, Gold Sponsor at Rs 50 lakh and Silver Sponsor at Rs 25 lakh.</span></p>
<p><span>Sponsorship opportunities also include hospitality, scientific sessions, resource persons from abroad, entertainment programmes, delegate kit bags, uniforms and caps for student volunteers, gifts in kit bags, mementos, scientific schedule booklets, stationery for delegates and cosmetics items in kit bags.</span></p>
<p><span>The documents state that the Congress has been held since 1948, with the first Indian Pharmaceutical Congress held at Kota, West Bengal, in December 1948. The IPGA was established in 1971 and has branches across more than 20 states and 10 local chapters, according to the event material.</span></p>
<p><span>The event will be held at Yashobhoomi Convention Centre, Sector 25, Dwarka, New Delhi, from Friday, 18 December to Sunday, 20 December 2026.</span></p>
<p>The post <a href="https://www.expresspharma.in/75th-ipc-to-be-held-in-new-delhi-in-december-2026/">75th IPC to be held in New Delhi in December 2026</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Lupin receives USFDA approval for Pitolisant Tablets</title>
<link>https://edusehat.com/en/lupin-receives-usfda-approval-for-pitolisant-tablets</link>
<guid>https://edusehat.com/en/lupin-receives-usfda-approval-for-pitolisant-tablets</guid>
<description><![CDATA[ 
The approval covers Pitolisant Tablets 4.45 mg and 17.8 mg, bioequivalent to Wakix for the indications in the approved labelling
The post Lupin receives USFDA approval for Pitolisant Tablets appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 17 Aug 2026 17:05:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Lupin, receives, USFDA, approval, for, Pitolisant, Tablets</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>Lupin has received final approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Pitolisant Tablets, 4.45 mg and 17.8 mg.</span></p>
<p><span>The U.S. FDA has approved Lupin’s Pitolisant Tablets, 4.45 mg and 17.8 mg, as bioequivalent to Wakix for the indications in the approved labelling.</span></p>
<p>The post <a href="https://www.expresspharma.in/lupin-receives-usfda-approval-for-pitolisant-tablets/">Lupin receives USFDA approval for Pitolisant Tablets</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>USFDA classifies Aurobindo Pharma’s Raleigh plant as VAI</title>
<link>https://edusehat.com/en/usfda-classifies-aurobindo-pharmas-raleigh-plant-as-vai</link>
<guid>https://edusehat.com/en/usfda-classifies-aurobindo-pharmas-raleigh-plant-as-vai</guid>
<description><![CDATA[ 
The facility received 11 observations during the USFDA inspection conducted from March 24 to April 10, 2025
The post USFDA classifies Aurobindo Pharma’s Raleigh plant as VAI appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2019/08/30121052/usfda-approved-black.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 17 Aug 2026 17:05:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>USFDA, classifies, Aurobindo, Pharma’s, Raleigh, plant, VAI</media:keywords>
<content:encoded><![CDATA[<div><img width="888" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2019/08/30121052/usfda-approved-black.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2019/08/30121052/usfda-approved-black.jpg 888w, https://cdn.expresspharma.in/wp-content/uploads/2019/08/30121052/usfda-approved-black-300x135.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2019/08/30121052/usfda-approved-black-768x346.jpg 768w" sizes="auto, (max-width: 888px) 100vw, 888px"></div><p><span>Aurobindo Pharma said the United States Food and Drug Administration (USFDA) has classified its Raleigh plant in North Carolina, USA, as “Voluntary Action Indicated” (VAI) following an inspection conducted in 2025.</span></p>
<p><span>Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, the company said the USFDA inspected the Raleigh plant from March 24, 2025, to April 10, 2025. The facility is owned by Aurolife Pharma LLC, a wholly owned step-down subsidiary of the company, and is established for manufacturing inhalers, dermatology and transdermal products.</span></p>
<p><span>At the end of the inspection, Form 483 was issued with a total of 11 observations.</span></p>
<p><span>The unit has now received the Establishment Inspection Report (EIR), which classifies the facility as “Voluntary Action Indicated” (VAI). The USFDA has concluded that the inspection is now closed.</span></p>
<p><span>The company said that as the unit is classified as VAI, pending applications for multiple inhalers and other dosage forms filed from the facility can now progress through the USFDA’s review process.</span></p>
<p>The post <a href="https://www.expresspharma.in/usfda-classifies-aurobindo-pharmas-raleigh-plant-as-vai/">USFDA classifies Aurobindo Pharma’s Raleigh plant as VAI</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>CDSCO directs action against unapproved Enclomiphene drug products</title>
<link>https://edusehat.com/en/cdsco-directs-action-against-unapproved-enclomiphene-drug-products</link>
<guid>https://edusehat.com/en/cdsco-directs-action-against-unapproved-enclomiphene-drug-products</guid>
<description><![CDATA[ 
State and UT Drugs Controllers asked to identify manufacturers, marketers, distributors and retailers dealing with Enclomiphene without Central Licensing Authority approval
The post CDSCO directs action against unapproved Enclomiphene drug products appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 17 Aug 2026 13:30:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>CDSCO, directs, action, against, unapproved, Enclomiphene, drug, products</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>The Central Drugs Standard Control Organization (CDSCO), under the Directorate General of Health Services, Government of India, has directed all State and Union Territory (UT) Drugs Controllers to take action against the manufacture and marketing of drug products containing Enclomiphene and its combinations without approval from the Central Licensing Authority (CLA).</span></p>
<p><span>In a letter dated 10 August 2026, issued by the Enforcement & Intelligence Cell of CDSCO, the Directorate said it had been brought to its notice that certain manufacturers were manufacturing and/or marketing drug products containing Enclomiphene and its combinations without obtaining the requisite permission from the CLA, despite such products falling within the definition of a “New Drug” under the New Drugs and Clinical Trials Rules, 2019.</span></p>
<p><span>As per Rule 2(1)(w) read with Rule 19 of the New Drugs and Clinical Trials Rules, 2019, no new drug shall be manufactured for sale or distribution unless it has been granted permission by the CLA.</span></p>
<p><span>Further, under Rule 80 of the Rules, any person intending to manufacture a new drug, whether as an Active Pharmaceutical Ingredient (API) or as a pharmaceutical formulation for sale or distribution, is required to obtain prior permission from the CLA by submitting an application in Form CT-21, along with the prescribed fee specified in the Sixth Schedule.</span></p>
<p><span>The Directorate said it had observed that Enclomiphene and its combinations had not been approved by the CLA for manufacture and marketing in the country.</span></p>
<p><span>Accordingly, it stated that any manufacture, sale, distribution or marketing of such products without prior approval from the CLA would be treated as non-compliance with the provisions of the New Drugs and Clinical Trials Rules, 2019, and the Drugs and Cosmetics Act, 1940.</span></p>
<p><span>The State and UT Drugs Controllers have been requested to immediately identify manufacturers, marketers, distributors and retailers dealing with drug products containing Enclomiphene and its combinations without the requisite approval from the CLA.</span></p>
<p><span>They have also been directed to initiate appropriate regulatory action under the provisions of the Drugs and Cosmetics Act, 1940 and the Rules made thereunder, including cancellation or suspension of manufacturing permissions, wherever applicable.</span></p>
<p><span>The Controllers have further been asked to ensure that such unapproved products are not manufactured, sold, distributed or marketed within their respective jurisdictions.</span></p>
<p><span>CDSCO has also sought an action taken report, including details of manufacturers identified, regulatory action initiated and the present status of compliance, at the earliest.</span></p>
<p>The post <a href="https://www.expresspharma.in/cdsco-directs-action-against-unapproved-enclomiphene-drug-products/">CDSCO directs action against unapproved Enclomiphene drug products</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>LSSSDC to organise Skillverse 2026 National Skill Summit in Hyderabad</title>
<link>https://edusehat.com/en/lsssdc-to-organise-skillverse-2026-national-skill-summit-in-hyderabad</link>
<guid>https://edusehat.com/en/lsssdc-to-organise-skillverse-2026-national-skill-summit-in-hyderabad</guid>
<description><![CDATA[ 
LSSSDC Skillverse 2026 will focus on workforce requirements, Industry 5.0, Global Capability Centres and government initiatives for skill development in the Life Sciences sector
The post LSSSDC to organise Skillverse 2026 National Skill Summit in Hyderabad appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/08/17103445/EP_LSSSDC_Skillverse_2026_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 17 Aug 2026 13:30:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>LSSSDC, organise, Skillverse, 2026, National, Skill, Summit, Hyderabad</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/08/17103445/EP_LSSSDC_Skillverse_2026_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/08/17103445/EP_LSSSDC_Skillverse_2026_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/17103445/EP_LSSSDC_Skillverse_2026_750-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>The Life Sciences Sector Skill Development Council (LSSSDC), operating under the aegis of the Ministry of Skill Development & Entrepreneurship (MSDE), Government of India, will organise ‘LSSSDC Skillverse 2026’, a National Skill Summit for the Life Sciences sector, on 21st August 2026 at Hotel Le Méridien, Hyderabad.</span></p>
<p><span>The summit will bring together CXOs, Managing Directors, CEOs, HR Leaders, Manufacturing Heads, R&D Leaders, CSR Heads, academia, government officials, policymakers, industry associations and skill development experts to deliberate on building a future-ready workforce for India’s Life Sciences ecosystem.</span></p>
<p><span>As India’s Life Sciences industry expands across Pharmaceuticals, Biotechnology, Medical Devices, Clinical Research and Allied Healthcare, the demand for industry-ready talent has become more critical. LSSSDC Skillverse 2026 has been conceptualised as a platform to bridge the gap between industry expectations and workforce capabilities while promoting collaborative solutions for skill development.</span></p>
<p><img decoding="async" class="wp-image-459146 alignleft" src="https://cdn.expresspharma.in/wp-content/uploads/2026/08/17103531/EP_LSSSDC_Skillverse_2026_Full_Invite_900.jpg" alt="" width="424" height="636" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/08/17103531/EP_LSSSDC_Skillverse_2026_Full_Invite_900.jpg 900w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/17103531/EP_LSSSDC_Skillverse_2026_Full_Invite_900-200x300.jpg 200w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/17103531/EP_LSSSDC_Skillverse_2026_Full_Invite_900-683x1024.jpg 683w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/17103531/EP_LSSSDC_Skillverse_2026_Full_Invite_900-768x1152.jpg 768w" sizes="(max-width: 424px) 100vw, 424px"></p>
<p><span>The summit will feature keynote addresses, panel discussions, industry presentations and networking opportunities focused on workforce challenges and emerging opportunities in the sector.</span></p>
<p><span>The key themes of Skillverse 2026 will include identifying skill gaps and workforce requirements in the Life Sciences sector; NeeV initiatives and industry-led models for strengthening Skill Development Centres (SDCs); preparing a future-ready workforce for Industry 5.0; strengthening talent, innovation and global operations in Life Sciences through Global Capability Centres (GCCs); and government initiatives for skill development and workforce transformation.</span></p>
<p><span>The event will provide a platform for industry leaders to share best practices, discuss emerging trends and contribute towards shaping India’s national skilling agenda for the Life Sciences sector.</span></p>
<p><span>Skillverse 2026 reflects LSSSDC’s commitment to creating a skilled, globally competitive workforce by fostering collaboration between industry, academia, government and training institutions. The summit is expected to generate actionable insights and strategic partnerships that will accelerate talent development across the Life Sciences value chain.</span></p>
<p><span>LSSSDC has invited organisations, industry leaders, training institutions and stakeholders from the Life Sciences ecosystem to participate in Skillverse 2026 and contribute towards building a skilled, future-ready workforce for India.</span></p>
<p><span>The event, titled LSSSDC Skillverse 2026 – National Skill Summit for the Life Sciences Sector, will be held on Friday, 21st August 2026 at Hotel Le Méridien, Hyderabad. It is being organised by the Life Sciences Sector Skill Development Council (LSSSDC) under the Ministry of Skill Development & Entrepreneurship (MSDE), Government of India.</span></p>
<p>The post <a href="https://www.expresspharma.in/lsssdc-to-organise-skillverse-2026-national-skill-summit-in-hyderabad/">LSSSDC to organise Skillverse 2026 National Skill Summit in Hyderabad</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>BMS secures FDA accelerated approval for Zenbexus in multiple myeloma</title>
<link>https://edusehat.com/en/bms-secures-fda-accelerated-approval-for-zenbexus-in-multiple-myeloma</link>
<guid>https://edusehat.com/en/bms-secures-fda-accelerated-approval-for-zenbexus-in-multiple-myeloma</guid>
<description><![CDATA[ The combination is intended for patients who have previously received at least one line of therapy that included both a proteasome inhibitor and an immunomodulatory agent. Zenbexus is 
The post BMS secures FDA accelerated approval for Zenbexus in multiple myeloma appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/08/PT-2-14-08-2026-BOTTLE_PILL_75MG_wbg_FINAL.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 14 Aug 2026 17:05:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>BMS, secures, FDA, accelerated, approval, for, Zenbexus, multiple, myeloma</media:keywords>
<content:encoded><![CDATA[<p>The combination is intended for patients who have previously received at least one line of therapy that included both a proteasome inhibitor and an immunomodulatory agent.</p>
<p>Zenbexus is said to be the first cereblon E3 ligase modulator (CELMoD) therapy approved by the FDA for MM treatment. Continued approval for this indication may depend on confirmation of clinical benefit in ongoing trials.</p>
<p>In combination with ZDd, Zenbexus received the agency’s decision following results from the Phase III EXCALIBER-RRMM trial.</p>
<p>The study compared Zenbexus, ZDd (n=207) with daratumumab, bortezomib and dexamethasone (n=213) in patients with relapsed or refractory MM.</p>
<p>After a median follow-up of 16 months, 41% of patients treated with ZDd achieved minimal residual disease (MRD)-negative complete response compared to 21% receiving the comparator regimen.</p>
<p>Safety data indicated that 7.8% of patients discontinued ZDd because of adverse reactions.</p>
<p>Serious infections and severe neutropenia were observed, with neutropenia and infections occurring in 90.2% and 78.9% of patients, respectively.</p>
<p>Fatal adverse reactions occurred in 4.9% of patients treated with Zenbexus, with sepsis as the only event affecting more than one individual. Other observed reactions included upper respiratory tract infection, pneumonia, diarrhoea and fatigue.</p>
<p>Bristol Myers Squibb chief medical officer and development head Cristian Massacesi said: “Today’s approval of Zenbexus represents meaningful progress for patients living with multiple myeloma and underscores the power of our targeted protein degradation platform, particularly our CELMoD programmes.</p>
<p>“As the first approved CELMoD, Zenbexus marks the arrival of a new treatment class and is an important milestone in our efforts to expand what is possible for patients with multiple myeloma. And we believe this is only the beginning.</p>
<p>“This approval validates years of scientific research and strengthens our confidence in the potential of this approach as we continue to advance our innovative pipeline on behalf of patients with significant unmet needs.”</p>
<p>This review was conducted under the FDA’s Project Orbis, enabling concurrent regulatory assessment in several other countries.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/bms-fda-zenbexus-in-multiple-myeloma/">BMS secures FDA accelerated approval for Zenbexus in multiple myeloma</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Xanadu and University of Alberta to develop quantum algorithms for cancer</title>
<link>https://edusehat.com/en/xanadu-and-university-of-alberta-to-develop-quantum-algorithms-for-cancer</link>
<guid>https://edusehat.com/en/xanadu-and-university-of-alberta-to-develop-quantum-algorithms-for-cancer</guid>
<description><![CDATA[ The collaboration aims to develop new quantum algorithms that could accelerate the design of next-generation photosensitisers for photodynamic therapy, a non-invasive treatment approach targeting tumour cells. The project 
The post Xanadu and University of Alberta to develop quantum algorithms for cancer appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/08/PT-14-08-2026-shutterstock_1924512512.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 14 Aug 2026 17:05:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Xanadu, and, University, Alberta, develop, quantum, algorithms, for, cancer</media:keywords>
<content:encoded><![CDATA[<p>The collaboration aims to develop new quantum algorithms that could accelerate the design of next-generation photosensitisers for photodynamic therapy, a non-invasive treatment approach targeting tumour cells.</p>
<p>The project combines Xanadu’s algorithms team and the University of Alberta chemistry professor Alex Brown.</p>
<p>They will work jointly to create a quantum computing framework that addresses the challenges involved in the discovery of novel photosensitisers.</p>
<p>Existing approaches to identifying effective photosensitisers rely on experimental methods or classical simulations, which the partners say are either slow, costly, or limited in their capacity to account for critical molecular interactions.</p>
<p>Recent results released by Xanadu have used quantum computers to simulate light-matter interactions in photosensitiser compounds, focusing on characteristics such as sensitivity to specific wavelengths and the efficiency of triggering cancer cell death.</p>
<p>Xanadu founder and CEO Dr Christian Weedbrook said: “Current methodologies for developing effective photosensitisers are hampered by a variety of hurdles.</p>
<p>“By leveraging early fault-tolerant quantum computers to model critical light-matter interactions within photosensitisers, we are positioning quantum computing as a highly competitive method for accelerating photodynamic drug discovery.”</p>
<p>Brown said: “Photosensitisers are challenging systems because their performance depends on excited-state processes that are difficult to capture accurately with standard computational methods.</p>
<p>“By combining Xanadu’s quantum algorithm expertise with our experience in modelling photodynamic therapy systems, we’re excited to explore how fault-tolerant quantum computing could provide new tools for understanding and designing more effective light-activated cancer treatments.”</p>
<p>The collaboration is intended to strengthen Xanadu’s quantum-based drug design workflow, with the goal of expanding its use to more complex problems in photosensitiser development.</p>
<p>Brown’s role will include identifying mechanisms that influence therapeutic effectiveness in photodynamic therapy.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/xanadu-university-of-alberta-quantum-algorithms-cancer/">Xanadu and University of Alberta to develop quantum algorithms for cancer</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Gulfstream Intelligence launches regulatory intelligence and execution platform</title>
<link>https://edusehat.com/en/gulfstream-intelligence-launches-regulatory-intelligence-and-execution-platform</link>
<guid>https://edusehat.com/en/gulfstream-intelligence-launches-regulatory-intelligence-and-execution-platform</guid>
<description><![CDATA[ 
Platform brings regulatory intelligence, labelling, gap assessments, health authority preparation and submission planning into one environment
The post Gulfstream Intelligence launches regulatory intelligence and execution platform appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/08/09122110/digital-healthcare.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 14 Aug 2026 17:05:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Gulfstream, Intelligence, launches, regulatory, intelligence, and, execution, platform</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/08/09122110/digital-healthcare.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/08/09122110/digital-healthcare.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/08/09122110/digital-healthcare-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Gulfstream Intelligence has announced the launch of a regulatory intelligence and execution platform for pharmaceutical, biotechnology and life science organisations.</span></p>
<p><span>Developed by Gulfstream Life Science, the platform was created by regulatory professionals with more than 25 years of experience in the pharmaceutical and biotechnology industry. Gulfstream Intelligence was developed from experience managing global development programmes, health authority interactions, submissions, labelling, regulatory strategy and regulatory team activities.</span></p>
<p><span>Gulfstream Intelligence said regulatory teams have access to information and technology, but their work can remain disconnected across systems, documents, spreadsheets, email and presentations. Regulatory intelligence may be maintained in one system, submission plans in another and labelling in separate documents and spreadsheets, while health authority preparation, gap assessments and programme decisions may be managed through email, presentations and individual files.</span></p>
<p><span>Gulfstream Intelligence was built to bring these activities together and help regulatory professionals move from finding information to understanding its implications for a programme and determining the actions required.</span></p>
<p><span>The platform brings together global regulatory intelligence and policy, global labelling, global regulatory gap assessments, health authority preparation and simulation, submission planning and critical path management, regulatory document intelligence and decision-ready deliverables.</span></p>
<p><span>The global regulatory intelligence and policy function enables teams to monitor guidance, legislation, policy changes and health authority developments across global markets and assess how these changes may affect development programmes.</span></p>
<p><span>The global labelling function supports the development and lifecycle management of product labelling, including Core Data Sheets and regional labels such as US Prescribing Information, EU Summary of Product Characteristics and Canadian Product Monograph. Teams can compare regional labelling, identify differences, evaluate new safety and efficacy information and maintain consistency between global and local labelling positions.</span></p>
<p><span>The global regulatory gap assessment function enables teams to evaluate programmes and regulatory documentation against regional health authority expectations to identify gaps, risks and actions that may be required before an interaction or submission.</span></p>
<p><span>The health authority preparation and simulation function supports preparation for meetings and interactions with the FDA, EMA, MHRA, PMDA, Health Canada and other global authorities by identifying likely questions, areas of concern and issues that may require additional justification.</span></p>
<p><span>The submission planning and critical path management function enables teams to develop submission plans, timelines, dependencies and deliverables for INDs, BLAs, NDAs, MAAs and other regulatory milestones, while maintaining visibility into activities that may affect submission timelines.</span></p>
<p><span>The regulatory document intelligence function reviews regulatory documents to identify inconsistencies, missing information, potential risks and areas requiring attention. The platform also converts regulatory analysis into structured reports, summaries and editable presentations that can be shared with regulatory teams, development teams and leadership.</span></p>
<p><span>“The problem is not simply finding regulatory information. It is what happens after the information is found,” said Scott Morvay, Founder of Gulfstream Intelligence. “After more than 25 years working in regulatory affairs, we have seen how quickly important context can become disconnected as information moves between systems, documents and teams. We built Gulfstream around the way regulatory professionals actually work, from understanding an issue to deciding what it means for the program and ultimately doing something about it.”</span></p>
<p><span>Gulfstream Intelligence aims to maintain the connection between the regulatory source, professional interpretation of that information, its impact on the development programme, the resulting actions and the final regulatory deliverable.</span></p>
<p><span>For larger pharmaceutical organisations, Gulfstream Intelligence provides a way to maintain continuity across programmes, functions, regions and health authorities. Regulatory intelligence, labelling, health authority preparation, submission planning and document review can remain connected rather than being managed as separate workstreams across multiple systems.</span></p>
<p><span>For emerging and mid-sized biotechnology companies, Gulfstream provides the same capabilities in one environment. The company said this can support regulatory teams managing broad responsibilities with limited internal resources.</span></p>
<p><span>Gulfstream Intelligence was built from the experience of regulatory professionals rather than by adapting a general technology platform to regulatory affairs. The company said this experience informed the platform and how its capabilities work together.</span></p>
<p><span>Gulfstream uses artificial intelligence to assist with research, comparison, analysis, planning and drafting, while qualified regulatory professionals remain responsible for reviewing information, interpreting regulatory requirements and making regulatory decisions.</span></p>
<p><span>“AI can help us work faster, but regulatory affairs is not simply an information problem,” Morvay said. “Experience matters. Judgment matters. Understanding the development program matters. Gulfstream was built to give regulatory professionals better tools to apply that experience.”</span></p>
<p><span>The platform does not replace professional judgment, provide legal advice or independently submit materials to health authorities.</span></p>
<p><span>Gulfstream Intelligence is designed to support regulatory teams throughout development, from monitoring changes in the global regulatory environment and assessing programme readiness to preparing for health authority interactions, developing global labelling and planning submissions.</span></p>
<p><span>As programmes progress, information generated through these activities can remain connected rather than becoming isolated across separate systems and documents. The platform is designed to provide teams with visibility into what has changed, what it means for their programme, what requires attention and what needs to happen next.</span></p>
<p>The post <a href="https://www.expresspharma.in/gulfstream-intelligence-launches-regulatory-intelligence-and-execution-platform/">Gulfstream Intelligence launches regulatory intelligence and execution platform</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Why India’s medicines need integrated authentication, enforceable standards</title>
<link>https://edusehat.com/en/why-indias-medicines-need-integrated-authentication-enforceable-standards</link>
<guid>https://edusehat.com/en/why-indias-medicines-need-integrated-authentication-enforceable-standards</guid>
<description><![CDATA[ 
Triggered by recent high profile operations involving counterfeit semaglutide in the domestic markets and anti-rabies vaccines exported to various countries, India’s regulators are plugging the gaps by expanding the existing QR code mandate and may next require online registration of manufacturers and suppliers of printed pharma packaging materials. However, Ankit Gupta, President, ASPA explains to Viveka Rychowdhury, that as counterfeiters evolve, isolated security measures should be replaced with integrated authentication ecosystems and enforceable standards
The post Why India’s medicines need integrated authentication, enforceable standards appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/08/14133059/EP_GB_Ankit_Gupta_.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 14 Aug 2026 17:05:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Why, India’s, medicines, need, integrated, authentication, enforceable, standards</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/08/14133059/EP_GB_Ankit_Gupta_.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/08/14133059/EP_GB_Ankit_Gupta_.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/14133059/EP_GB_Ankit_Gupta_-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><b>What is the extent of counterfeiting in India’s pharma supply chain? </b></p>
<p><span>Counterfeit medicines continue to pose a significant risk to patient safety and the integrity of India’s pharmaceutical supply chain. According to the CRISILASPA State of Counterfeiting in India 2025 Report, 28 per cent of consumers reported encountering a counterfeit healthcare product at least once during the last 12 months. The report uses the broader category “healthcare products,” which includes pharmaceuticals, OTC medicines, nutraceuticals, and medical devices following a nomenclature update. </span></p>
<p><span>ASPA believes the threat extends beyond economic losses. Counterfeit medicines directly endanger patient safety, undermine treatment outcomes, erode consumer confidence, and damage the reputation of legitimate pharmaceutical manufacturers.</span></p>
<p><b>What are the common modus operandi of such counterfeit operations? </b></p>
<p><span>ASPA observes that counterfeiters have become increasingly sophisticated. Rather than producing obvious imitations, they now: </span></p>
<ul>
<li><span> Closely replicate genuine packaging and labels. </span></li>
<li><span> Attempt to imitate certain security features. </span></li>
<li><span> Exploit fragmented distribution networks. </span></li>
<li><span> Use online marketplaces and e-pharmacies to reach consumers. </span></li>
<li><span> Introduce products containing incorrect ingredients, substandard formulations, harmful substances, or sometimes no active pharmaceutical ingredient at all. </span></li>
</ul>
<p><span>These evolving tactics make visual inspection alone insufficient and reinforce the need for authentication combined with end-to-end traceability.</span></p>
<p><b>What has been the reaction of pharma companies to such incidents? Has it been adequately addressed to prevent future incidents? </b></p>
<p><span>Pharma companies are increasingly strengthening their anti-counterfeiting efforts. ASPA cites examples such as Mankind Pharma, which has adopted authentication and traceability solutions to enhance product security and consumer trust. </span></p>
<p><span>Manufacturers are increasingly viewing authentication not merely as a compliance requirement but as a strategic investment in patient safety and brand protection. </span></p>
<p><span>That said, ASPA’s position is that more needs to be done. Counterfeiters continue to evolve, making isolated security measures insufficient. The association advocates integrated authentication ecosystems combining serialisation, traceability, physical security features, digital verification, and stakeholder collaboration. </span></p>
<p><b>What has been the reaction from policymakers like the CDSCO? </b></p>
<p><span>ASPA welcomes the Government of India’s efforts to strengthen oversight within the pharma packaging ecosystem, including initiatives aimed at improving accountability and traceability. This is a step in the right direction and reflects growing regulatory recognition of the problem. </span></p>
<p><span>At the same time, ASPA believes oversight measures need to evolve into enforceable standards. The association is advocating for the next phase of policy to include mandatory adoption of multi-layered Authentication and Traceability Solutions (ATS) for high-risk drug categories, stricter penal action against counterfeiters and those enabling them, and a national track-and-trace mandate that gives visibility across the entire supply chain, not just at the point of packaging.</span></p>
<p><b>The CDSCO has mandated expansion of QR codes to vaccines. What are ASPA’s views, given that QR codes have proven unsuccessful in preventing counterfeiting? </b></p>
<p><span>ASPA welcomes this as a step in the right direction. Extending QR code requirements to vaccines shows the regulator’s intent to improve traceability in a high stakes category. </span></p>
<p><span>However, the solution is complete only when QR codes are combined with other visible and invisible security features. A standard QR code, on its own, carries the risk of being copied or reprinted by counterfeiters just as easily as the genuine one, since it does not by itself authenticate the product. Layering it with tamper-evident features, holograms, and covert or nonclonable markers is what actually closes that gap and gives both regulators and consumers a way to verify authenticity with confidence.</span></p>
<p><b>At the 69th Drugs Consultative Committee (DCC) meeting, held virtually on last month on June 24, it was recommended to constitute a subcommittee to evaluate the feasibility of the proposal to introduce an online registration framework for manufacturers/suppliers of printed pharma packaging materials used for drugs. Why does ASPA feel that the printer registration initiative is a meaningful first step, but insufficient on its own? </b></p>
<p><span>ASPA sees printer registration as a welcome and meaningful first step. It strengthens oversight, accountability, and transparency at the packaging stage of the supply chain, an area that has traditionally seen limited scrutiny. However, registration of printers does not, by itself, authenticate a product or track it once it leaves the printing facility. Counterfeiters operating outside registered networks can still replicate packaging design. ASPA’s ask is for this initiative to be paired with clear enforcement mechanisms, such as periodic audits of registered printers and a defined compliance timeline, alongside a broader push for product-level authentication so that oversight extends beyond who printed the packaging to whether the product itself can be verified as genuine. </span></p>
<p><b>Where are the gaps even after printer registration is in place? </b></p>
<p><span>The real gap lies beyond the printing stage. Once a product moves through manufacturing, warehousing, distribution, and retail, visibility drops sharply. There is currently no reliable way to confirm that the medicine reaching a patient at the last mile is the same one that left the manufacturing facility. </span></p>
<p><span>This is a supply chain visibility problem as much as a packaging problem. Diverted stock, parallel distribution channels, and unregulated online sellers can all introduce counterfeit or tampered products at any point after packaging, well outside the reach of printer oversight. Closing this gap requires giving every product a verifiable identity that can be checked at each handoff, not just at the point of origin. </span></p>
<p><b>What kind of authentication technology is essential to close those gaps? </b></p>
<p><span>ASPA’s position is that no single technology can eliminate pharma counterfeiting on its own. </span></p>
<p><span>What is needed is a multilayered Authentication and Traceability Solution (ATS): serialisation for unique product identity, secure or non-clonable QR codes, tamper-evident packaging, holograms and covert security features, RFID/NFC for automated tracking, cloud based verification, and AI-enabled monitoring for anomaly detection. </span></p>
<p><span>This “phygital” approach, combining physical security with digital verification, is what allows a product to be authenticated and tracked through its entire lifecycle, rather than relying on any single checkpoint. </span></p>
<p><b>What do such counterfeiting operations mean for India’s credibility as a global pharma exporter? </b></p>
<p><span>Counterfeiting poses a serious threat to India’s reputation as one of the world’s largest pharmaceutical manufacturers and exporters. Even isolated incidents can undermine confidence among international regulators, healthcare providers, and global buyers, leading to increased scrutiny and affecting trust in the country’s pharmaceutical supply chain. </span></p>
<p><span>As the Pharmacy of the World, India must continue strengthening supply chain integrity through robust product authentication, end -to-end traceability, and advanced anti-counterfeiting technologies. These measures will not only safeguard patient safety but also reinforce India’s credibility as a trusted global supplier of high-quality medicines and support seamless international trade. </span></p>
<p> </p>
<p><em><strong>viveka.r@expressindia.com </strong></em></p>
<p><span><em><strong>viveka.roy3@gmail.com</strong></em> </span></p>
<p>The post <a href="https://www.expresspharma.in/why-indias-medicines-need-integrated-authentication-enforceable-standards/">Why India’s medicines need integrated authentication, enforceable standards</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Akeso secures China NMPA authorisation for ivonescimab combo</title>
<link>https://edusehat.com/en/akeso-secures-china-nmpa-authorisation-for-ivonescimab-combo</link>
<guid>https://edusehat.com/en/akeso-secures-china-nmpa-authorisation-for-ivonescimab-combo</guid>
<description><![CDATA[ The decision marks the third NMPA-approved indication for an ivonescimab-containing regimen in the country since the molecule first received authorisation in May 2024. Ivonescimab is described as an 
The post Akeso secures China NMPA authorisation for ivonescimab combo appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/08/PT-2-13-08-2026-shutterstock_2376200217.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 13 Aug 2026 19:35:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Akeso, secures, China, NMPA, authorisation, for, ivonescimab, combo</media:keywords>
<content:encoded><![CDATA[<p>The decision marks the third NMPA-approved indication for an ivonescimab-containing regimen in the country since the molecule first received authorisation in May 2024.</p>
<p>Ivonescimab is described as an investigational bispecific antibody. The latest marketing authorisation is based on data from the HARMONi-6 multi-centre Phase III study that was conducted in China.</p>
<p>Data for the study were generated, managed, and analysed solely by Akeso.</p>
<p>The HARMONi-6 trial compared ivonescimab in combination with platinum-based chemotherapy against a regimen of the programmed cell death protein 1 (PD-1) inhibitor tislelizumab with platinum-based chemotherapy.</p>
<p>It included patients with locally advanced or metastatic squamous NSCLC, regardless of PD-L1 expression.</p>
<p>The study showed that the combination with ivonescimab produced statistically significant and clinically meaningful improvements in both progression-free survival and overall survival when compared to the PD-1 inhibitor-based regimen.</p>
<p>The safety profile observed was said to be consistent with earlier studies of ivonescimab combined with chemotherapy.</p>
<p>Summit Therapeutics chairman and co-CEO Bob Duggan said: “Today’s approval in China marks another extraordinary milestone for ivonescimab and reinforces the strength of the clinical evidence generated to date.</p>
<p>“HARMONi-6 is the first known Phase III study in NSCLC — or any tumour type — to demonstrate a statistically significant and clinically meaningful overall survival benefit over an anti-PD-(L)1 antibody plus chemotherapy regimen in a head-to-head setting.”</p>
<p>Ivonescimab, which is also referred to as SMT112 in Summit Therapeutics’ licence regions, remains an investigational therapy and is not approved by regulatory authorities in the US or Europe.</p>
<p>As noted by Akeso, more than 4,000 patients have been treated with ivonescimab in clinical studies worldwide, and over 70,000 in a commercial setting in China.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/akeso-china-nmpa-ivonescimab-combo/">Akeso secures China NMPA authorisation for ivonescimab combo</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Remepy secures $36m funding for hybrid drug pipeline expansion</title>
<link>https://edusehat.com/en/remepy-secures-36m-funding-for-hybrid-drug-pipeline-expansion</link>
<guid>https://edusehat.com/en/remepy-secures-36m-funding-for-hybrid-drug-pipeline-expansion</guid>
<description><![CDATA[ The proceeds will also be used to fund Remepy’s lead product Hybridopa’s global Phase III clinical trial targeting Parkinson’s disease (PD). It is set to commence in the 
The post Remepy secures $36m funding for hybrid drug pipeline expansion appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/08/PT-13-08-2026-shutterstock_1924512515.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 13 Aug 2026 19:35:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Remepy, secures, 36m, funding, for, hybrid, drug, pipeline, expansion</media:keywords>
<content:encoded><![CDATA[<p>The proceeds will also be used to fund Remepy’s lead product Hybridopa’s global Phase III clinical trial targeting Parkinson’s disease (PD). It is set to commence in the fourth quarter of 2026.</p>
<p>The latest funding brings the total capital raised by the company to $62m.</p>
<p>The Series A round was led by OG Venture Partners and M Ventures, Merck KGaA, Darmstadt, Germany’s corporate strategic venture arm.</p>
<p>Other new and existing backers include NFX, Qumra Capital, Tadmor Group, TechAviv, and Vine Ventures.</p>
<p>Remepy develops Hybrid Drugs through partnerships with pharmaceutical companies.</p>
<p>These drugs combine prescription medicines with personalised, AI-driven therapeutic applications, aiming to integrate pharmacology with adaptive physical, cognitive, and behavioural interventions into a single treatment regimen.</p>
<p>The company stated that the Hybrid Drug model has gained traction, supported by evolving US regulatory frameworks for drug-software combination products.</p>
<p>Remepy recently disclosed a strategic partnership with Merck KGaA, Darmstadt, Germany to develop hybrid drugs for multiple indications, beginning with rare tumours.</p>
<p>Hybridopa, it’s lead programme for Parkinson’s disease, has reported positive Phase IIa clinical data regarding both motor and non-motor symptom improvement.</p>
<p>It remains an investigational product and has not received approval from the US Food and Drug Administration.</p>
<p>Remepy co-CEOs Michal Tsur and Or Shoval said: “We believe medicine is entering a new era, where every breakthrough drug will be paired with personalised intelligence to maximise its impact for every patient.</p>
<p>“Over the past year, we’ve demonstrated that this vision is achievable through clinical validation, peer-reviewed science, regulatory alignment, and partnerships with leading pharmaceutical companies.</p>
<p>“This financing allows us to advance Phase III of Hybridopa for Parkinson’s disease, and expand the hybrid drug model across multiple therapeutic areas.”</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/remepy-36m-funding-hybrid-drug-expansion/">Remepy secures $36m funding for hybrid drug pipeline expansion</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>BASF introduces Floragenist floral active ingredients for skin care</title>
<link>https://edusehat.com/en/basf-introduces-floragenist-floral-active-ingredients-for-skin-care</link>
<guid>https://edusehat.com/en/basf-introduces-floragenist-floral-active-ingredients-for-skin-care</guid>
<description><![CDATA[ 
BASF’s Personal Care business introduces Floragenist Rose and Floragenist Blossom for skin radiance and skin resilience
The post BASF introduces Floragenist floral active ingredients for skin care appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2020/04/30183622/GettyImages-1179214915-e1763466693590.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 13 Aug 2026 16:00:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>BASF, introduces, Floragenist, floral, active, ingredients, for, skin, care</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="338" src="https://cdn.expresspharma.in/wp-content/uploads/2020/04/30183622/GettyImages-1179214915-e1763466693590.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy"></div><p><span>BASF’s Personal Care business has introduced Floragenist, a range of floral active ingredients developed to address consumer demand for natural beauty with performance supported by scientific studies. Floragenist Rose and Floragenist Blossom are derived from Damask Rose (</span><i><span>Rosa damascena</span></i><span>) and Bitter Orange blossom (</span><i><span>Citrus aurantium var. amara</span></i><span>), respectively, and are sourced from Morocco.</span></p>
<p><span>BASF said the ingredients are designed to enhance skin radiance and support the skin’s ability to adapt to daily stress. The botanicals are sourced with traceability and responsible sourcing practices.</span></p>
<p><span>BASF said the development of Floragenist combines its AquaGenesis extraction technology with epigenetic science. AquaGenesis uses coconut water as a natural solvent to extract bioactive compounds without aggressive solvents. According to BASF, the technology preserves phytochemicals while increasing the concentration of key active molecules. Compared with conventional extraction methods, it delivers enhanced levels of flavonoids for skin care applications.</span></p>
<p><span>BASF researchers combined the extraction technology with epigenetic science to develop flower extracts that support the epidermis.</span></p>
<p><span>Floragenist Rose is designed to enhance skin radiance by supporting the skin’s expression of “surface optics” proteins. BASF said these proteins are involved in maintaining skin structure and light-reflecting properties, supporting skin cohesion and visible luminosity. Floragenist Rose also addresses the effects of oxidative stress and supports an even-looking complexion. Clinical studies using VISIA imaging reported a 2.7-fold improvement in the appearance of skin luminosity and a 22 per cent decrease in redness at a concentration of 0.4 per cent of the ingredient compared with the placebo group.</span></p>
<p><span>Floragenist Blossom is designed to support the skin’s adaptive capacity in response to environmental and lifestyle-related stress. BASF said it supports skin resilience by helping the skin express key skin integrity proteins. This contributes to maintaining the skin’s natural barrier function, improving the appearance of epidermal cohesion and helping the skin cope with external stressors such as mechanical stress, over-cleansing and microbial imbalance. An </span><i><span>in vivo</span></i><span> study found that harsh cleansing of skin pre-treated with 0.1 per cent Floragenist Blossom for 28 days resulted in 52 per cent lower variation in transepidermal water loss (TEWL) than placebo.</span></p>
<p><span>BASF said the development of the Floragenist range is guided by the principles of its Responsibly Active programme for cosmetic bioactives, which focuses on transparency, ethical conduct and environmental responsibility. The ingredients are derived from certified organically cultivated Damask Rose and Bitter Orange, hand harvested in Morocco and traceable to the source. BASF said the Damask Rose originates from a supply chain verified against a sustainable sourcing standard, supporting agricultural practices and creating impacts for local communities.</span></p>
<p>The post <a href="https://www.expresspharma.in/basf-introduces-floragenist-floral-active-ingredients-for-skin-care/">BASF introduces Floragenist floral active ingredients for skin care</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>BIRAC showcases biotech and medtech start&#45;ups at Bharatiya Vyapar Mahotsav 2026</title>
<link>https://edusehat.com/en/birac-showcases-biotech-and-medtech-start-ups-at-bharatiya-vyapar-mahotsav-2026</link>
<guid>https://edusehat.com/en/birac-showcases-biotech-and-medtech-start-ups-at-bharatiya-vyapar-mahotsav-2026</guid>
<description><![CDATA[ 
BIRAC’s pavilion features start-ups working on medical devices, rehabilitation systems and assistive technologies at Bharat Mandapam
The post BIRAC showcases biotech and medtech start-ups at Bharatiya Vyapar Mahotsav 2026 appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/08/13142911/EP_BIRAC_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 13 Aug 2026 16:00:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>BIRAC, showcases, biotech, and, medtech, start-ups, Bharatiya, Vyapar, Mahotsav, 2026</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/08/13142911/EP_BIRAC_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/08/13142911/EP_BIRAC_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/13142911/EP_BIRAC_750-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>The Biotechnology Industry Research Assistance Council (BIRAC), a Public Sector Enterprise of the Department of Biotechnology (DBT), Government of India, is showcasing its innovation and start-up ecosystem at a pavilion during the Bharatiya Vyapar Mahotsav (BVM) 2026, being held from August 12–15 at Bharat Mandapam, Pragati Maidan, New Delhi.</span></p>
<p><span>Organised jointly by the Confederation of All India Traders (CAIT) and India Trade Promotion Organisation (ITPO), BVM 2026 brings together traders, MSMEs, manufacturers, institutions, investors and policymakers under the theme “Made in India, Made for India, Made for the World”.</span></p>
<p><span>The BIRAC pavilion allows visitors, investors, industry leaders and the public to engage with biotech and medtech innovators and understand BIRAC’s schemes, funding instruments and infrastructure supporting the development of laboratory research into market-ready products.</span></p>
<p><span>Since its establishment, BIRAC has worked as an interface between India’s scientific research base and industry, supporting the conversion of research into enterprises and products. As an industry–academia interface agency under DBT, BIRAC has developed a network of incubators, bioclusters, accelerators and funding schemes supporting entrepreneurs from proof-of-concept to commercialisation.</span></p>
<p><span>BIRAC’s support includes seed and early-stage funding for validating ideas and developing prototypes, access to risk capital through venture funds and co-investment mechanisms, technology transfer and intellectual property (IP) support, bioincubation infrastructure, and regulatory and market-access support.</span></p>
<p><span>Its bioincubation network provides lab space, mentorship and technical support, including in tier 2 and tier 3 regions. BIRAC also runs social innovation programmes supporting technologies for affordable healthcare, assistive devices, and solutions for underserved and marginalised communities.</span></p>
<p><span>According to BIRAC, these programmes have supported start-ups and MSMEs across therapeutics, diagnostics, medical devices, agri-biotech, industrial biotechnology and clean energy.</span></p>
<p><span>A share of the start-ups featured at the BIRAC pavilion are working on medical technology and social impact, including prosthetics, robotic rehabilitation systems and assistive devices for persons with disabilities.</span></p>
<p><span>“BIRAC’s role has always gone beyond funding — to de-risk the innovation journey for India’s biotech entrepreneurs, connecting them to capital, infrastructure, mentorship and markets at every stage. The start-ups showcased at our pavilion this year, many of them working on assistive technologies and rehabilitation solutions, are a powerful example of how Indian innovation can be both cutting-edge and deeply inclusive. Platforms like the Bharatiya Vyapar Mahotsav allow us to bring these home-grown solutions closer to industry, investors and the public, and to reaffirm BIRAC’s commitment to building a self-reliant, globally competitive Indian bio-economy.” Stated Dr. Dhananjay Kumar Tiwary, Managing Director, BIRAC.</span></p>
<p><span>Reconstructive Healthcare Solutions  (RHS), founded in 2018 by a maxillofacial surgeon, is an ISO 13485-certified medtech company specialising in virtual surgical planning and 3D-printed anatomical models, surgical guides, splints, and dental and orthopaedic implants. Operating from a GMP facility at IMT Faridabad, Haryana, RHS combines imaging, software integration and manufacturing for patient-specific surgical care and healthcare education.</span></p>
<p><span>GenElek Technologies, an IIT Delhi-incubated medical robotics company, develops robotic exoskeletons for gait training and mobility rehabilitation. Its Sencibel Robotic Gait Trainer is a lower-limb robotic exoskeleton with multiple training modes, real-time monitoring and analytics for individuals with neurological and musculoskeletal impairments.</span></p>
<p><span>Exobot Dynamics Pvt. Ltd., incubated at IIT Delhi and backed by BIRAC, AIC, IHFC, SACC, NCPEDP, DST and FICCI-Mercedes Benz, develops upper-limb prosthetics and wearable robotic systems. Its GripX product is a myoelectric prosthetic hand designed for Indian clinical workflows. The company is also developing X1, a bionic hand, as part of its “Human Physical AI” vision.</span></p>
<p><span>Rymo Technologies Pvt. Ltd., founded in 2020, has developed a neuro-rehabilitation ecosystem combining robotics, VR, AI and electrical stimulation. Its product suite includes Mobi-L, Mend, Nudge, Aura XR and Pulse FES. The company said its products have been installed at 779 sites across 612 clinics and hospitals, including AIIMS, Apollo, Sakra and Manipal.</span></p>
<p><span>Translead Medtech Pvt. Ltd., a Bengaluru-based medical device company, has developed Stand at Eaze, an unpowered assistive chair that helps users sit and stand using a compliant hinge mechanism licensed exclusively from biomechanics research at the Indian Institute of Science. The device is CDSCO-registered as a Class A medical device, with clinical evaluation underway at partner hospitals.</span></p>
<p><span>Torchit, a social technology company, develops assistive technologies including the Saarthi Smart Mobility Aid, the Jyoti AI ecosystem, AI Vision Glasses and AI Reader, braille technologies and the Saksharta Inclusive Education Kit. The company works with government bodies, NGOs, hospitals and CSR partners and has impacted over 2 million lives across India and other emerging markets.</span></p>
<p><span>Visitors, media representatives, investors and potential industry partners can connect with BIRAC and the participating start-ups at the BIRAC pavilion at Bharat Mandapam through August 15, 2026, for information on BIRAC’s funding schemes and eligibility for start-ups and SMEs, bioincubation and infrastructure support, technology transfer, licensing and IP-related assistance, regulatory and market-access guidance, and partnership, collaboration and investment opportunities with the participating start-ups.</span></p>
<p>The post <a href="https://www.expresspharma.in/birac-showcases-biotech-and-medtech-start-ups-at-bharatiya-vyapar-mahotsav-2026/">BIRAC showcases biotech and medtech start-ups at Bharatiya Vyapar Mahotsav 2026</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Back to basics: Metal detection in pharmaceutical manufacturing</title>
<link>https://edusehat.com/en/back-to-basics-metal-detection-in-pharmaceutical-manufacturing</link>
<guid>https://edusehat.com/en/back-to-basics-metal-detection-in-pharmaceutical-manufacturing</guid>
<description><![CDATA[ 
Stuart Preston explains how metal detection supports contamination control, product quality and compliance across pharmaceutical manufacturing processes
The post Back to basics: Metal detection in pharmaceutical manufacturing appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/08/13101326/EP_GB_Stuart_Preston.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 13 Aug 2026 12:25:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Back, basics:, Metal, detection, pharmaceutical, manufacturing</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/08/13101326/EP_GB_Stuart_Preston.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/08/13101326/EP_GB_Stuart_Preston.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/13101326/EP_GB_Stuart_Preston-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>In pharmaceutical manufacturing, contamination control begins long before products reach final packaging. Raw materials are blended, milled and granulated before being compressed into tablets or filled into capsules. At each stage, there is potential for metal contamination arising from broken sieves, worn equipment, magnets or foreign material introduced with ingredients.</span></p>
<p><span>Metal detection forms part of the control strategy applied during these processes. By identifying and removing metal contaminated products while they are still in production, it aids compliance with regulations plus supports quality management within validated and documented systems. </span></p>
<p><b>Why are metal detectors used in pharmaceutical production?</b></p>
<p><span>As medications are used directly by individuals, even a small metal contaminant within a tablet, capsule or powder can present a risk to patient safety and product quality. </span><span>Applicable Good Manufacturing Practice (GMP) requirements, including 21 CFR Parts 210 and 211, require manufacturers to establish appropriate controls to prevent contamination and deliver product quality. Where automated systems are used, GAMP 5 (Good Automated Manufacturing Practice) provides guidance on validation and lifecycle management.</span></p>
<p><span>Metal detection provides an automated inspection method capable of identifying stainless steel, ferrous and non-ferrous metal contaminants, including very small particles. In pharmaceutical applications, stainless steel detection sensitivity can reach down to 0.3 mm test spheres, depending on the product and configuration. At this level of sensitivity, inspection plays a vital role in physical contamination control.</span></p>
<p><b>Inspection before compression: powders and granules</b></p>
<p><span>Active Pharmaceutical Ingredients (APIs) and excipients are handled as powders or granules before tableting or encapsulation. During blending, milling or granulation, metal contaminants may be introduced through equipment wear or raw material handling.</span></p>
<p><span>Pharma Gravity Fall (GF-PRO) metal detection systems are designed specifically to inspect these free-flowing materials at vertical transfer points. As powders move by gravity through an enclosed chute, they pass through the detector aperture. If metal contamination is identified, a fast-acting reject mechanism diverts only the affected material from the product stream.</span></p>
<p><span>By positioning inspection before compression, metal contaminated material can be removed early in the process, reducing the likelihood of a full batch being affected.</span></p>
<p><b>Inspection after compression: tablets and capsules</b></p>
<p><span>Once powders have been compressed into tablets or filled into capsules, inspection shifts to the finished dosage form before packaging.</span></p>
<p><span>Tablex-PRO is a pharmaceutical metal detection system from Mettler-Toledo designed specifically for solid-dose applications. It integrates directly with tablet presses or encapsulators and de-dusters, to inspect products immediately after formation. As tablets discharge from these machines, they pass through the metal detector and are automatically separated into accepted and rejected streams.</span></p>
<p><span>Inspection can take place at speeds of up to 300,000 tablets per hour, depending on the application. If a metal contaminant is detected, a minimal number of tablets or capsules are diverted into the reject container by the fast-acting reject device. This rejection approach helps minimise product loss while maintaining tight process control. A lift flap diverter reject mechanism offers straight-line product flow for delicate products; a side diverter reject mechanism is ideal when inspection height space is restricted.</span></p>
<p><span>Blister packs are not typically inspected using conventional metal detectors at this stage because aluminium foil interferes with the detection field. For that reason, inspection is generally focused on unpackaged powders, tablets and capsules.</span></p>
<p><b>How do pharmaceutical metal detectors work?</b></p>
<p><span>Pharmaceutical metal detectors operate using balanced coil technology. A high-frequency electromagnetic field is generated within the inspection aperture. When metal passes through this field, it disturbs the signal and is detected by the system electronics.</span></p>
<p><span>Ultra-high tuned frequency operation, combined with an optimised aperture size, enhances sensitivity particularly for non-magnetic stainless steel contaminants, which can be more difficult to detect. </span></p>
<p><span>When contamination is identified, visual alarms are activated and the reject mechanism diverts the affected product. These events are recorded to provide documented evidence of removal.</span></p>
<p><b>Compliance, validation and lifecycle control</b></p>
<p><span>In pharmaceutical environments, detection capability alone is not sufficient. Inspection systems must operate within validated frameworks and be supported by documented performance. Metal detection equipment is supplied with documentation to support Installation Qualification (IQ), Operational Qualification (OQ) and Performance Qualification (PQ) as part of the wider Equipment Qualification (EQ) process. Ultimately, the EQPac documentation from Mettler-Toledo allows the manufacturer to have a traceable procedure for implementing the metal detection system into their production line. </span></p>
<p><span>Validation and verification activities continue throughout the system lifecycle. Regular sensitivity checks, including Performance Monitoring Routine (PMR) testing, annual performance verification and scheduled revalidation form part of standard site procedures. Systems also maintain controlled records of user access, configuration changes and test results, with reports available via Ethernet or USB to support audit readiness and traceability.</span></p>
<p><span>Trained service engineers can also support installation, validation and ongoing maintenance, helping manufacturers maintain consistent inspection performance over time.</span></p>
<p><b>Design considerations in pharmaceutical environments</b></p>
<p><span>Pharmaceutical production areas are tightly controlled and often space is constrained. Metal detection systems must combine compact design with flexibility to integrate with different tablet presses, de-dusters and transfer points. Adjustable configurations allow the system to accommodate varying tablet sizes and product formats. Flexibility is enhanced with adjustable aperture / reject device height and castors which allow the system to be easily repositioned to integrate with other in-process equipment.</span></p>
<p><span>Hygienic design in pharmaceutical environments focuses on cleanability. Mirror-polished, stainless steel construction, smooth surfaces and simplified strip-down procedures support controlled cleaning processes. Touchscreen interfaces and password-protected access contribute to ease of use and controlled operation.</span></p>
<p><b>Conclusion</b></p>
<p><span>Metal detection remains a core inspection technology within pharmaceutical manufacturing. By inspecting APIs, excipients, tablets and capsules at critical stages, manufacturers can detect and remove metallic contamination before products progress further through production.</span></p>
<p><span>In an industry defined by compliance, documentation and patient protection, metal detection supports reliable inspection, validated performance and controlled process management across the system lifecycle.</span></p>
<p><span>For more information view: </span><a href="https://www.mt.com/md-pharma-basics-pr"><span>www.mt.com/md-pharma-basics-pr</span></a></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/back-to-basics-metal-detection-in-pharmaceutical-manufacturing/">Back to basics: Metal detection in pharmaceutical manufacturing</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Alfasigma signs agreement to acquire Nordic Group</title>
<link>https://edusehat.com/en/alfasigma-signs-agreement-to-acquire-nordic-group</link>
<guid>https://edusehat.com/en/alfasigma-signs-agreement-to-acquire-nordic-group</guid>
<description><![CDATA[ The transaction is structured through a share purchase agreement with SEVER Life Sciences for 100% of Nordic Group and its subsidiaries. While specific financial terms have not been 
The post Alfasigma signs agreement to acquire Nordic Group appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/08/PT-12-08-2026-shutterstock_2401059949.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 12 Aug 2026 18:20:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Alfasigma, signs, agreement, acquire, Nordic, Group</media:keywords>
<content:encoded><![CDATA[<p>The transaction is structured through a share purchase agreement with SEVER Life Sciences for 100% of Nordic Group and its subsidiaries.</p>
<p>While specific financial terms have not been disclosed, the deal is subject to customary conditions, including relevant regulatory clearances.</p>
<p>It will bring Nordic Pharma’s rheumatoid arthritis business, led by the Nordimet methotrexate franchise, into Alfasigma’s rheumatology portfolio.</p>
<p>This portfolio currently includes Jyseleca, approved for second-line treatment in inflammatory and autoimmune diseases such as rheumatoid arthritis and ulcerative colitis, and marketed by Alfasigma in the EU, EEA, and UK.</p>
<p>In addition, the acquisition covers Nordic Pharma’s products in women’s health, critical care, and ophthalmology.</p>
<p>Following the deal, Alfasigma will operate directly in 18 European countries, and extend its commercial activities to Canada and Japan.</p>
<p>The addition of Nordic Pharma will see approximately 265 new employees join Alfasigma.</p>
<p>Alfasigma CEO Francesco Balestrieri said: “Alfasigma is pursuing a deliberate strategy to identify the right opportunities to build our global specialty and rare disease business, focused on areas of significant unmet need in gastroenterology and immunology.</p>
<p>“The acquisition of Nordic Pharma marks a decisive step forward in that journey, strengthening our European presence and expanding our rheumatology portfolio. By combining our portfolios, scientific expertise and talented teams, we are better positioned to deliver meaningful innovation and value for patients and shareholders.”</p>
<p>Nordic Group CEO Charlotte Phelps said: “Alfasigma is the right partner for Nordic Pharma as we enter our next phase of growth. Both companies are patient-focused, rooted in science and entrepreneurial. We look forward to combining our experience to support patients.”</p>
<p>Alfasigma is a privately owned pharmaceutical company headquartered in Italy, distributing products in more than 100 markets and employing around 4,000 people.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/alfasigma-to-buy-nordic-group/">Alfasigma signs agreement to acquire Nordic Group</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Mereo BioPharma and Sentynl Therapeutics sign licensing deal for alvelestat</title>
<link>https://edusehat.com/en/mereo-biopharma-and-sentynl-therapeutics-sign-licensing-deal-for-alvelestat</link>
<guid>https://edusehat.com/en/mereo-biopharma-and-sentynl-therapeutics-sign-licensing-deal-for-alvelestat</guid>
<description><![CDATA[ The arrangement enables Sentynl to acquire exclusive US commercial rights to alvelestat upon exercise of the option while Mereo BioPharma will retain commercial rights outside the US. Under 
The post Mereo BioPharma and Sentynl Therapeutics sign licensing deal for alvelestat appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/08/PT-2-12-08-2026-shutterstock_2535748827.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 12 Aug 2026 18:20:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Mereo, BioPharma, and, Sentynl, Therapeutics, sign, licensing, deal, for, alvelestat</media:keywords>
<content:encoded><![CDATA[<p>The arrangement enables Sentynl to acquire exclusive US commercial rights to alvelestat upon exercise of the option while Mereo BioPharma will retain commercial rights outside the US.</p>
<p>Under the deal, Mereo BioPharma will receive a non-refundable option fee from Sentynl.</p>
<p>If Sentynl exercises the option, Mereo BioPharma will be eligible for $40m in upfront and research and development payments, and up to $435m in regulatory and commercial milestone payments, along with double-digit tiered royalties on net sales in the US.</p>
<p>Sentynl will have a global licence to manufacture the therapy for AATD-LD and provide funding for the Phase III development programme, which might commence in early 2027.</p>
<p>The companies will jointly streamline the Phase III study design during the option period.</p>
<p>Mereo BioPharma CEO Denise Scots-Knight said: “We are very pleased to have the opportunity to partner with Sentynl to advance alvelestat for patients with AATD-LD. We have been preparing alvelestat for a global Phase III study, backed by positive efficacy data from two Phase II studies.</p>
<p>“We believe Sentynl’s commitment to rare diseases and established commercial infrastructure make them the ideal partner for alvelestat and look forward to collaborating with them during the option period, when we plan to refine the global Phase III study design.”</p>
<p>Alvelestat is designed to inhibit neutrophil elastase, an enzyme linked to inflammation and lung tissue damage. Its tolerability and safety have been assessed in trials involving more than 1,000 patients across several respiratory conditions.</p>
<p>The therapy has secured orphan drug designation for AATD-LD from both the European Commission and the US Food and Drug Administration (FDA), along with FDA fast track designation.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/mereo-sentynl-licensing-deal-alvelestat/">Mereo BioPharma and Sentynl Therapeutics sign licensing deal for alvelestat</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>India’s pharma exports rise 6.8% to $8.1 billion in Q1 FY27</title>
<link>https://edusehat.com/en/indias-pharma-exports-rise-68-to-81-billion-in-q1-fy27</link>
<guid>https://edusehat.com/en/indias-pharma-exports-rise-68-to-81-billion-in-q1-fy27</guid>
<description><![CDATA[ 
Pharmexcil data shows growth across formulations, bulk drugs, vaccines and surgical products, with the US remaining the largest export destination
The post India’s pharma exports rise 6.8% to $8.1 billion in Q1 FY27 appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/08/11173227/growth.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 12 Aug 2026 18:20:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>India’s, pharma, exports, rise, 6.8, 8.1, billion, FY27</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/08/11173227/growth.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/08/11173227/growth.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/08/11173227/growth-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>India’s pharmaceutical exports grew by 6.80 per cent to USD 8.10 billion during April–June FY 2026-27, compared with USD 7.58 billion in the corresponding period of the previous financial year, according to data released by the Pharmaceuticals Export Promotion Council of India (Pharmexcil).</span></p>
<p><span>Pharmaceutical shipments increased by 7.13 per cent to USD 2.81 billion in June FY27, compared with USD 2.62 billion in June FY26. June exports were also 6.86 per cent higher than the USD 2.63 billion recorded in May FY27.</span></p>
<p><span>Drug formulations and biologicals contributed USD 5.98 billion during the quarter, accounting for 73.85 per cent of total pharmaceutical exports. The category recorded growth of 4.14 per cent over the corresponding period last year.</span></p>
<p><span>Bulk drugs and drug intermediates, the second-largest export category, grew by 13.84 per cent to USD 1.36 billion. Vaccine exports rose by 35.68 per cent to USD 0.39 billion, while surgical product exports increased by 11.95 per cent to USD 0.21 billion during the quarter.</span></p>
<p><span>NAFTA (North American Free Trade Agreement), Europe, Africa, and Latin America & the Caribbean (LAC) remained the key destinations for India’s pharmaceutical exports during the quarter, collectively accounting for nearly 75 per cent of total pharmaceutical exports. NAFTA accounted for 34.28 per cent of India’s overall pharmaceutical exports.</span></p>
<p><span>The United States remained India’s largest pharmaceutical export destination during April–June FY27, followed by Brazil, the United Kingdom, the Netherlands and France. The top 25 export destinations accounted for nearly 70% of India’s pharmaceutical exports, with shipments valued at USD 5.65 billion. Exports to these 25 countries recorded year-on-year growth of 5.50 per cent during April–June FY27.</span></p>
<p><span>Commenting on the performance, Mr Namit Joshi, Chairman, Pharmexcil, said, “India’s pharmaceutical export performance demonstrates that the sector continues to combine scale in established markets with growing momentum across a wider set of geographies. The United States remains our largest export destination, with shipments valued at USD 2.50 billion and a 30.89 per cent share, while the strong performance of Brazil, the Netherlands, France and several emerging markets reflects the expanding global footprint of Indian pharmaceutical companies. The double-digit growth recorded across Europe, Africa, Latin America, ASEAN and South Asia is particularly important in the present global trade environment. India must continue consolidating its leadership in generics while building a stronger presence in complex generics, biosimilars, peptides and other innovation-led segments. Our ability to combine quality, regulatory credibility, manufacturing scale and market diversification will determine the strength of India’s next phase of pharmaceutical export growth.”</span></p>
<p><span>Mr Bhavin Mehta, Vice Chairman, Pharmexcil, said, “The growth recorded across vaccines, bulk drugs and drug intermediates reflects the increasing depth of India’s capabilities across the pharmaceutical value chain. Vaccine exports increased by 35.68 per cent, while bulk drugs and drug intermediates grew by 13.84 per cent during the quarter. Sustaining this momentum will require continued investments in advanced manufacturing, stronger quality systems, specialised production capabilities and regulatory preparedness. It will also be important to enable Indian MSMEs to upgrade their capabilities, meet international compliance requirements and participate more meaningfully in regulated and emerging global markets.”</span></p>
<p><span>Pharmexcil said it will continue to work with the Government of India, the pharmaceutical industry, overseas regulators and international stakeholders to strengthen market access, regulatory cooperation and the global competitiveness of Indian pharmaceutical exporters.</span></p>
<p><span>The Council will also support efforts to expand India’s presence across established and emerging markets and enable the industry to move towards higher-value and innovation-led pharmaceutical exports.</span></p>
<p>The post <a href="https://www.expresspharma.in/indias-pharma-exports-rise-6-8-to-8-1-billion-in-q1-fy27/">India’s pharma exports rise 6.8% to $8.1 billion in Q1 FY27</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Amgen to open Science and Innovation Center at Genome Valley</title>
<link>https://edusehat.com/en/amgen-to-open-science-and-innovation-center-at-genome-valley</link>
<guid>https://edusehat.com/en/amgen-to-open-science-and-innovation-center-at-genome-valley</guid>
<description><![CDATA[ 
The centre is expected to be operational in 2027 and will join Amgen’s global Research and Development network
The post Amgen to open Science and Innovation Center at Genome Valley appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/08/12101544/EP_Amgen_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 12 Aug 2026 14:45:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Amgen, open, Science, and, Innovation, Center, Genome, Valley</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/08/12101544/EP_Amgen_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/08/12101544/EP_Amgen_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/12101544/EP_Amgen_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Amgen has announced plans to open a new Science and Innovation Center at Genome Valley in Hyderabad. The centre will join Amgen’s global Research and Development network, which consists of seven research laboratories, expanding the company’s research and scientific capabilities.</span></p>
<p><span>The new site reflects Amgen’s focus on fighting diseases by using biology and technology. By integrating scientific capabilities with data and digital innovation, the company aims to accelerate the discovery and development of medicines for patients worldwide.</span></p>
<p><span>“The new center in Genome Valley expands the way we integrate experimental science with data and technology across our global research capabilities and complements our strong U.S.-based Research and Development footprint,” said Jay Bradner, M.D., executive vice president of Research and Development, Artificial Intelligence and Data at Amgen. “By connecting these capabilities, we can learn faster and translate those insights into innovative medicines for patients.”</span></p>
<p><span>“Hyderabad has built one of the world’s strongest life sciences ecosystems, with deep capabilities in pharmaceuticals and vaccines. The next chapter is about taking that strength into discovery and innovation. Amgen’s decision to establish its Science and Innovation Center in Genome Valley reflects Hyderabad’s growing role as a global hub for high-value research, bringing together scientific talent, technology and industry at scale. Our ambition is to make Hyderabad a place where the next generation of medicines and therapies can be discovered, developed and taken to the world.” said Shri D. Sridhar Babu, Hon’ble Minister for Information Technology, Electronics & Communications, Industries & Commerce, and Legislative Affairs, Government of Telangana.</span></p>
<p><span>The centre is expected to be operational in 2027 and will bring together scientists and technologists across discovery chemistry, drug metabolism and pharmacokinetics and precision medicine, working with Amgen’s research sites around the world. This approach is designed to enhance how medicines are discovered and developed, improving speed, precision and efficiency.</span></p>
<p><span>“This new center reflects Amgen’s commitment to advancing scientific excellence, and India will be an important part of our global R&D network” said Som Chattopadhyay, senior vice president of Global Business Solutions and national executive at Amgen. “By expanding Amgen’s global research capabilities through its Hyderabad site, we are enabling deep scientific collaboration and look forward to participating in the local innovation ecosystem.”</span></p>
<p><span>Genome Valley offers scientific expertise and infrastructure, and the new facility will complement Amgen’s existing technology and innovation site in Hyderabad. Together, these sites will enable integration of wet-laboratory science with technology, advancing how the company develops medicines.</span></p>
<p><span>“Hyderabad’s strong life sciences ecosystem and deep STEM expertise enable us to apply advanced technologies at scale,” said Naveen Gullapalli, managing director, Amgen India. “Our new center at Genome Valley will help integrate biotechnology and digital innovation to serve more patients globally.”</span></p>
<p>The post <a href="https://www.expresspharma.in/amgen-to-open-science-and-innovation-center-at-genome-valley/">Amgen to open Science and Innovation Center at Genome Valley</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Zydus’ Sentynl enters option and licence deal for alvelestat</title>
<link>https://edusehat.com/en/zydus-sentynl-enters-option-and-licence-deal-for-alvelestat</link>
<guid>https://edusehat.com/en/zydus-sentynl-enters-option-and-licence-deal-for-alvelestat</guid>
<description><![CDATA[ 
The agreement covers US commercial and global manufacturing rights to Mereo BioPharma’s alvelestat for AATD-LD
The post Zydus’ Sentynl enters option and licence deal for alvelestat appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/05/04131504/handshake.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 12 Aug 2026 14:45:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Zydus’, Sentynl, enters, option, and, licence, deal, for, alvelestat</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/05/04131504/handshake.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/05/04131504/handshake.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/05/04131504/handshake-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Sentynl Therapeutics, a US-based biopharmaceutical company and wholly owned subsidiary of Zydus Lifesciences, and Mereo BioPharma Group, a clinical-stage biopharmaceutical company focused on rare diseases, have entered into an option and licence agreement for the US commercial and global manufacturing rights to alvelestat for AATD-LD.</span></p>
<p><span>Alvelestat is a neutrophil elastase inhibitor being readied for Phase 3 and, if approved, would be the first oral treatment for this rare, progressive genetic lung disease affecting an estimated 50,000-80,000 individuals in the United States.</span></p>
<p><span>The option and licence agreement grants Sentynl the exclusive right to acquire a licence to commercialise alvelestat for AATD-LD in the United States, while Mereo will retain commercial rights in the rest of the world. The agreement also grants Sentynl global rights to manufacture alvelestat for AATD-LD and, on exercise of the option, provides funding for the alvelestat Phase 3 development programme, which could be initiated in early 2027.</span></p>
<p><span>“This partnership marks a pivotal moment for Sentynl’s rare disease strategy. Mereo’s alvelestat is a highly promising, differentiated candidate that meaningfully expands our portfolio and has the potential to address an area of significant unmet need,” said Dr Sharvil P. Patel, Managing Director, Zydus Lifesciences Limited. “AATD-LD has a profound impact on patients’ lives. If approved, alvelestat has the potential to be a meaningful new option that could help their quality of life.”</span></p>
<p><span>“We take great pride in having built a sustainable approach for developing therapies for ultra-rare conditions, and this partnership allows us to expand that strategic focus to a larger population within the rare disease community, enabling us to help more people,” said Matt Heck, Chief Executive Officer of Sentynl Therapeutics. “For patients with AATD-LD, the current standard of care is demanding, often relying on generalized therapies or frequent intravenous treatments. We see a clear opportunity to improve upon that with alvelestat. Mereo has built a strong foundation for this asset, making them an ideal partner as we collaborate during the option period to prepare for the next phase of development.”</span></p>
<p><span>“We are very pleased to have the opportunity to partner with Sentynl to advance alvelestat for patients with AATD-LD. We have been preparing alvelestat for a global Phase 3 study, backed by positive efficacy data from two Phase 2 studies. We believe Sentynl’s commitment to rare diseases and established commercial infrastructure make them the ideal partner for alvelestat and look forward to collaborating with them during the option period, when we plan to refine the global Phase 3 study design,” said Denise Scots-Knight, Chief Executive Officer of Mereo BioPharma.</span></p>
<p><span>Mereo will receive a non-refundable option fee from Sentynl and, on exercise of the option, the company would also receive up to $40 million in upfront and R&D payments until NDA filing. Under the terms, Mereo would also be eligible to receive double-digit tiered royalties on US net sales of alvelestat.</span></p>
<p><span>Mereo will lead the global Phase 3 study and regulatory interactions until the study is completed. During the option period, the companies will collaborate to advance manufacturing and streamline the Phase 3 study design.</span></p>
<p>The post <a href="https://www.expresspharma.in/zydus-sentynl-enters-option-and-licence-deal-for-alvelestat/">Zydus’ Sentynl enters option and licence deal for alvelestat</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Inside Shilpa Medicare’s growth strategy: Quality, digital and global ambitions</title>
<link>https://edusehat.com/en/inside-shilpa-medicares-growth-strategy-quality-digital-and-global-ambitions</link>
<guid>https://edusehat.com/en/inside-shilpa-medicares-growth-strategy-quality-digital-and-global-ambitions</guid>
<description><![CDATA[ 
Dr Vellaian Karuppiah, COO-Management, Shilpa Medicare shares his vision for building a future-ready organisation powered by quality, digital transformation, and operational excellence. In this conversation, he discusses leadership, biosimilars, global markets, and what it takes to earn lasting regulatory trust, in an exclusive interaction with Lakshmipriya Nair 
The post Inside Shilpa Medicare’s growth strategy: Quality, digital and global ambitions appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/08/12122607/EP_Dr_Karuppiah_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 12 Aug 2026 14:45:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Inside, Shilpa, Medicare’s, growth, strategy:, Quality, digital, and, global, ambitions</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/08/12122607/EP_Dr_Karuppiah_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/08/12122607/EP_Dr_Karuppiah_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/12122607/EP_Dr_Karuppiah_750-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><b>You have recently stepped into a new role as COO of Shilpa Medicare – Formulations. What excites you the most, and what are you most careful about? </b></p>
<p><span>Joining Shilpa Medicare at this stage of its evolution is both an exciting opportunity and a significant responsibility. What excites me most is the opportunity to contribute to an organisation that has already established strong scientific capabilities and a differentiated position in oncology and specialty pharma. The global pharma landscape is evolving rapidly, and companies that can consistently combine scientific innovation, manufacturing excellence, and regulatory credibility will emerge as long-term leaders. </span></p>
<p><span>I believe there is tremendous opportunity to further strengthen operational excellence, accelerate commercialisation, improve execution speed, and build an integrated quality culture across the organisation. My focus will be on creating sustainable systems rather than short-term achievements. </span></p>
<p><span>At the same time, I am very conscious that growth should never compromise quality or patient safety. The pharma industry operates on trust. Every product we manufacture ultimately reaches patients whose lives depend on our commitment to quality. Therefore, maintaining regulatory compliance, strengthening our pharma quality system, developing our people, and ensuring robust governance will remain non-negotiable priorities. </span></p>
<p><span>For me, sustainable growth is achieved when scientific excellence, operational excellence, and quality excellence progress together. </span></p>
<p><b>You’ve spent much of your career building scale, strengthening operations, and navigating global regulatory environments. How will that experience shape your leadership approach at Shilpa Medicare – Formulations? </b></p>
<p><span>Throughout my career, I have learned that successful pharma organisations are built on systems rather than individuals. My leadership philosophy has always centered around creating processes that are scalable, predictable, compliant, and continuously improving. </span></p>
<p><span>Global regulatory inspections have taught me that compliance cannot be prepared for just before an inspection—it must be embedded into daily operations. This requires cross-functional collaboration where quality, manufacturing, engineering, supply chain, R&D, regulatory affairs, and commercial teams work towards common objectives. </span></p>
<p><span>My approach will emphasise three pillars: </span></p>
<ul>
<li><b>Operational excellence: </b></li>
</ul>
<p><span>Building highly efficient, data driven manufacturing systems that improve productivity while maintaining the highest quality standards. </span></p>
<ul>
<li><b>Quality culture:</b></li>
</ul>
<p><span>Moving beyond documentation-driven compliance toward a culture where every employee understands their responsibility toward patient safety and product quality.</span></p>
<ul>
<li><b>People development:  </b></li>
</ul>
<p><span>Investing in leadership development, technical competency, and empowering teams to make scientific, evidence-based decisions. Ultimately, my objective is to create an organisation where operational discipline and innovation complement each other rather than compete. </span></p>
<p><b>Biosimilars are getting more competitive. Where do you see real room to differentiate today? </b></p>
<p><span>The biosimilar industry has evolved significantly. Price alone is no longer a sustainable differentiator. True differentiation now lies in delivering consistent quality, regulatory confidence, supply reliability, and patient-centric solutions. </span></p>
<p><span>Manufacturing excellence has become a strategic advantage. Companies that demonstrate robust process controls, strong analytical capabilities, and reliable commercial supply will gain greater confidence from regulators and healthcare providers. </span></p>
<p><span>Another important differentiator is lifecycle management. Developing improved formulations, convenient delivery systems, patient support services, and digital health integration can significantly enhance value beyond the molecule itself. </span></p>
<p><span>Global partnerships will also play an increasingly important role. Collaborations that combine scientific expertise, manufacturing capability, and commercial reach can accelerate market access while reducing development risks. </span></p>
<p><span>Finally, digital manufacturing, artificial intelligence, advanced analytics, and continuous manufacturing technologies will become increasingly important in improving efficiency, reducing costs, and ensuring product consistency.</span></p>
<p><b>When you look at Shilpa Medicare – Formulations three years from now, what do you want it to be known for? What is the one big bet you think will define whether you get there or not? </b></p>
<p><span>Three years from now, I would like Shilpa Medicare Formulations to be recognised globally for three attributes: uncompromising quality, execution excellence, and scientific innovation. </span></p>
<p><span>I envision an organisation known for consistently delivering high-quality oncology and specialty medicines across global markets while maintaining strong regulatory credibility. The one strategic bet that will define this journey is building an integrated culture of operational excellence supported by digital transformation.</span></p>
<p><span>Digital technologies— including electronic quality systems, advanced manufacturing analytics, predictive maintenance, automation, and real-time process monitoring—can transform both compliance and operational performance. However, technology alone is insufficient. Success depends on developing people who understand how to leverage these tools effectively. </span></p>
<p><span>Organisations that successfully combine digital capabilities with strong quality culture will be best positioned for sustainable growth. </span></p>
<p><b>There’s a lot happening in science, be it new therapies or new technologies. How do you decide what is worth investing in and what is just noise? </b></p>
<p><span>Every innovation should ultimately answer one question: Does it create meaningful value for patients, healthcare systems, and the organisation? </span></p>
<p><span>I generally evaluate investments across five dimensions: Scientific differentiation, Unmet medical need, Regulatory feasibility, Commercial sustainability and Operational scalability. </span></p>
<p><span>Not every emerging technology requires immediate adoption. Some technologies generate excitement but lack commercial maturity or practical application. </span></p>
<p><span>Conversely, technologies that improve product quality, manufacturing robustness, regulatory compliance, data integrity, supply reliability, or patient outcomes deserve serious consideration. </span></p>
<p><span>I also believe innovation should not be confined to drug discovery. Process innovation, manufacturing innovation, quality innovation, and digital innovation often generate equally significant competitive advantages. Balanced investment decisions require scientific rigor, business discipline, and long-term strategic thinking. </span></p>
<p><b>As regulatory expectations for oncology and other niche formulations like TDS and ODG rise globally, credibility is becoming a business moat. How do you plan to build that at Shilpa Medicare – Formulations? </b></p>
<p><span>Credibility cannot be built during inspections—it is built every day through disciplined execution. My approach focuses on strengthening the entire Pharmaceutical Quality System rather than isolated compliance initiatives. </span></p>
<p><span>This includes: </span></p>
<ul>
<li><span>Robust quality risk management </span></li>
<li><span>Strong contamination control strategies </span></li>
<li><span>Advanced data integrity practices </span></li>
<li><span>Effective deviation and CAPA systems </span></li>
<li><span>Scientific process validation </span></li>
<li><span>Comprehensive training and competency development </span></li>
<li><span>Continuous process verification </span></li>
<li><span>Transparent quality governance </span></li>
</ul>
<p><span>For specialised formulations such as oncology products, transdermal systems (TDS), and orally disintegrating dosage forms (ODG), manufacturing complexity demands even greater process understanding and contamination control. </span></p>
<p><span>Equally important is leadership behavior. Quality should never be viewed as the responsibility of the QA department alone. Every function—from R&D to Engineering to Manufacturing—must own quality. </span></p>
<p><span>When this culture becomes embedded throughout the organisation, regulatory confidence naturally follows. </span></p>
<p><b>Which markets are you most focused on right now, and why? </b></p>
<p><span>Our focus should remain balanced between highly regulated markets and highgrowth emerging markets. Highly regulated markets such as the US, Europe, Canada, Australia, Japan, and the UK continue to represent significant opportunities because they reward companies with strong quality systems and regulatory excellence. </span></p>
<p><span>At the same time, emerging markets across Asia, Latin America, Africa, and the Middle East continue to experience increasing demand for high-quality, affordable specialty medicines.</span></p>
<p><span>A diversified global presence reduces business risk while creating sustainable long-term growth. Success in these markets will depend not only on obtaining approvals but also on ensuring reliable supply, maintaining regulatory compliance, understanding local healthcare needs, and building long-term partnerships. </span></p>
<p><b>At a strategic level, what do you believe companies like yours should focus on: innovation, partnerships or scale? Why? </b></p>
<p><span>I do not view innovation, partnerships and scale as competing priorities—they are mutually reinforcing. Innovation creates differentiated products and technologies. Partnerships accelerate development, expand market access, and bring complementary capabilities. Scale enables affordability, operational efficiency, and global competitiveness. The companies that will lead the next decade are those capable of integrating all three. </span></p>
<p><span>However, if I had to identify the foundational element, I would say quality-driven innovation. Innovation without quality cannot reach patients. Scale without quality is unsustainable. Partnerships succeed only when built on trust and credibility. </span></p>
<p><span>Ultimately, pharma success is built on a simple principle: delivering safe, effective, high-quality medicines to patients consistently. Everything else—innovation, partnerships, and scale— should strengthen that mission. </span></p>
<p> </p>
<p><em><strong>lakshmipriya.nair@expressindia.com </strong></em></p>
<p><em><strong>laxmipriyanair@gmail.com</strong></em></p>
<p>The post <a href="https://www.expresspharma.in/inside-shilpa-medicares-growth-strategy-quality-digital-and-global-ambitions/">Inside Shilpa Medicare’s growth strategy: Quality, digital and global ambitions</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>BeOne and Revolution Medicines partner for oncology therapies</title>
<link>https://edusehat.com/en/beone-and-revolution-medicines-partner-for-oncology-therapies</link>
<guid>https://edusehat.com/en/beone-and-revolution-medicines-partner-for-oncology-therapies</guid>
<description><![CDATA[ The deal includes joint studies combining BeOne’s cancer pipeline assets with four clinical-stage RAS(ON) inhibitors from Revolution Medicines, alongside a regional rights agreement for select Asian markets. The 
The post BeOne and Revolution Medicines partner for oncology therapies appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/08/PT-2-11-08-2026-shutterstock_2466743483.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 11 Aug 2026 17:20:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>BeOne, and, Revolution, Medicines, partner, for, oncology, therapies</media:keywords>
<content:encoded><![CDATA[<p>The deal includes joint studies combining BeOne’s cancer pipeline assets with four clinical-stage RAS(ON) inhibitors from Revolution Medicines, alongside a regional rights agreement for select Asian markets.</p>
<p>The clinical partnership will focus on developing combination therapies for patients with RAS-addicted cancers.</p>
<p>It will evaluate combinations such as BeOne’s MTA-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitor, BGB-58067, and a trispecific epidermal growth factor receptor × mesenchymal epithelial transition factor × mesenchymal epithelial transition factor (EGFR × MET × MET) antibody, BG-T187.</p>
<p>They will be studied alongside Revolution Medicines’ RAS(ON) inhibitor assets, daraxonrasib; zoldonrasib; elironrasib; and RMC-5127.</p>
<p>Planned studies will explore potential targeted therapy approaches using these combinations.</p>
<p>In a separate component of the arrangement, Revolution Medicines has granted BeOne exclusive rights to develop and commercialise, or solely commercialise, according to territory, its four RAS(ON) inhibitors in certain Asian regions.</p>
<p>The agreement stipulates that Revolution Medicines will receive development and sales milestone payments, along with tiered royalties on net sales from these territories.</p>
<p>Revolution Medicines retains all development and commercial rights for the products outside the licensed regions, notably including Japan and South Korea.</p>
<p>BeOne will also be responsible for funding and conducting a global registrational Phase III trial for one of the Revolution Medicines’ RAS(ON) inhibitors, utilising its internal development resources.</p>
<p>Revolution Medicines will continue to pursue global registrational studies across its broader portfolio.</p>
<p>BeOne co-founder, chairman, and CEO John Oyler said: “We are pleased to enter this collaboration with Revolution Medicines, which gives BeOne the opportunity to evaluate combinations between assets from our oncology pipeline and four promising RAS(ON) inhibitors from Revolution Medicines.</p>
<p>“In parallel, the regional rights transaction allows us to use our global development superhighway capabilities and established commercial presence, with the goal of bringing more medicines to patients with difficult-to-treat cancers.”</p>
<p>In August 2025, BeOne’s investigational Bruton’s tyrosine kinase (BTK) degrader, BGB-16673, received priority medicines (PRIME) designation from the European Medicines Agency to treat Waldenstrom’s macroglobulinemia in individuals previously treated with a BTK inhibitor.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/beone-revolution-medicines-oncology-therapies/">BeOne and Revolution Medicines partner for oncology therapies</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Jazz Pharmaceuticals to acquire Actio Biosciences for $820m upfront</title>
<link>https://edusehat.com/en/jazz-pharmaceuticals-to-acquire-actio-biosciences-for-820m-upfront</link>
<guid>https://edusehat.com/en/jazz-pharmaceuticals-to-acquire-actio-biosciences-for-820m-upfront</guid>
<description><![CDATA[ Unanimously approved by both companies’ boards, the transaction is expected to close by the fourth quarter (Q4) of 2026, pending customary closing conditions. Jazz Pharmaceuticals plans to fund 
The post Jazz Pharmaceuticals to acquire Actio Biosciences for $820m upfront appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/08/PT-11-08-2026-shutterstock_2590137279.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 11 Aug 2026 17:20:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Jazz, Pharmaceuticals, acquire, Actio, Biosciences, for, 820m, upfront</media:keywords>
<content:encoded><![CDATA[<p>Unanimously approved by both companies’ boards, the transaction is expected to close by the fourth quarter (Q4) of 2026, pending customary closing conditions.</p>
<p>Jazz Pharmaceuticals plans to fund the acquisition with a combination of cash on hand and existing financing facilities.</p>
<p>Actio Biosciences’ main clinical asset, ABS-1230, is a small molecule inhibitor targeting the potassium sodium-activated channel subfamily T member 1 (KCNT1) ion channel.</p>
<p>It is being investigated for the treatment of KCNT1+ epilepsy, a rare genetic developmental and epileptic encephalopathy.</p>
<p>KCNT1+ epilepsy typically presents in infancy, resulting in frequent and treatment-resistant seizures and significant developmental delays.</p>
<p>Few patients achieve basic milestones, and the disease can be fatal during childhood. For patients whose disease manifests later, symptoms often include disruptive night-time seizures, along with psychiatric and cognitive complications.</p>
<p>There are currently no therapies approved by the US Food and Drug Administration (FDA) for this condition.</p>
<p>ABS-1230 is currently being studied in the ongoing Phase Ib/IIa KYRON trial, which aims to serve as a registrational study in support of a future new drug application in the US.</p>
<p>The asset has secured FDA fast track, rare paediatric disease and orphan drug product designations, and has been accepted into the FDA’s Rare Disease Evidence Principles programme.</p>
<p>As part of the deal, Actio Biosciences will spin out a new private company focused on genetic rare neurological diseases, retaining certain personnel and assets except for ABS-1230. Jazz Pharmaceuticals will hold a minority equity interest in this new entity.</p>
<p>Jazz Pharmaceuticals president and CEO Renee Gala said: “The acquisition of ABS-1230 represents a highly strategic expansion of our rare epilepsy portfolio, building upon the global success of Epidiolex and deepening our leadership in rare and severe epilepsies.</p>
<p>“The emerging clinical profile of ABS-1230 is highly encouraging, and we look forward to closing the proposed transaction and collaborating with our new Actio Biosciences colleagues to address an urgent patient need.”</p>
<p>Financial advisor for Jazz Pharmaceuticals is Moelis & Company, with Hogan Lovells Cadwalader US serving as legal advisor. Actio Biosciences’ financial advisors are J.P. Morgan Securities and Centerview Partners, with legal counsel from Cooley.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/jazz-pharmaceuticals-to-buy-actio-biosciences/">Jazz Pharmaceuticals to acquire Actio Biosciences for $820m upfront</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>From compliance to circularity: Three ways pharma manufacturers can rethink resource management</title>
<link>https://edusehat.com/en/from-compliance-to-circularity-three-ways-pharma-manufacturers-can-rethink-resource-management</link>
<guid>https://edusehat.com/en/from-compliance-to-circularity-three-ways-pharma-manufacturers-can-rethink-resource-management</guid>
<description><![CDATA[ 
Tiyo Kok Fong highlights how pharmaceutical manufacturers can integrate water management, reuse and solvent recovery to strengthen resource efficiency and operational resilience
The post From compliance to circularity: Three ways pharma manufacturers can rethink resource management appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 11 Aug 2026 17:20:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>From, compliance, circularity:, Three, ways, pharma, manufacturers, can, rethink, resource, management</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2024/12/11161400/EP_Pharma_Workforce_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Access to medication and clean water is a balancing act. As the production and access to medication grow, a new set  of water-related challenges presents itself, such as antimicrobial resistance, ecotoxicity, and emerging contaminants  including residual active pharmaceutical ingredients (APIs), and endocrine disrupting chemicals (EDCs) in surface  waters, groundwater, soil, drinking water, or even within the food chain. </span></p>
<p><span>For pharmaceutical companies looking to improve their environmental, social and governance (ESG) performance,  effective water management within manufacturing processes can serve as a strategic lever to translate typical  challenges into opportunities for environmental sustainability and business resilience. Here are some areas that  decision-makers can consider:  </span></p>
<ol>
<li><span> Water quality and process resilience  </span></li>
</ol>
<p><span>Water is deeply embedded in pharmaceutical manufacturing—not only as a utility, but as a critical raw material  used across production, formulation, dilution, cleaning, and rinsing processes. Depending on the application,  water demand can be substantial: in some cases, producing a single ton of active ingredient may require  hundreds of cubic metres of water across production and cleaning operations. </span></p>
<p><span>This reliance creates a unique operational challenge. Because water readily dissolves, absorbs, and transports  contaminants, maintaining consistent quality standards becomes essential—not just for regulatory compliance,  but for process integrity and product safety. Most pharmacopeias therefore require pharmaceutical  manufacturers to begin with drinking water and further purify it to application-specific standards, such as  purified water or water for injection (WFI). </span></p>
<p><span>For pharmaceutical manufacturers, water security has become a strategic imperative—not merely an  environmental consideration, but a fundamental pillar of operational resilience and long-term business viability.  As a result, pharmaceutical manufacturers devote significant resources to water purification, microbiological  control, and the maintenance of highly controlled water systems. In an industry where water quality directly  affects both product quality and operational continuity, pharmaceutical water control is a continuous, dynamic  process, rather than a static checkpoint.  </span></p>
<ol start="2">
<li><span> Water consumption and reuse  </span></li>
</ol>
<p><span>Water reclamation and reuse are becoming more compelling as rising raw water and discharge tariffs narrow  the cost gap between recycled and fresh water. API manufacturing facilities that generate larger volumes of  wastewater with lower contaminant levels could recycle water for cooling towers, washing applications, and  other ancillary needs.  </span></p>
<p><span>Digital monitoring capabilities are also accelerating the adoption of water reuse initiatives. AI-driven predictive  maintenance flags membrane degradation and system wear before it affects performance, while online  microbial analysis gives operators real-time contamination visibility.  </span></p>
<p><span>Together, these tools give operators a clearer picture of water and wastewater treatment processes, enabling  informed decisions about optimising water consumption. They also support a more connected view of  operations, where water performance is considered alongside energy use and overall process efficiency. Water  reuse and recycling will increasingly become an essential pillar for the long-term viability of operations. </span></p>
<ol start="3">
<li><span> Solvent recovery  </span></li>
</ol>
<p><span>Spent solvents can constitute between 50-80 per cent of the waste of a chemical API plant, and up to 40 per cent of these  solvents can be regenerated through innovative volatile organic chemicals (VOC) treatment technologies.  Recovered solvents can re-enter production or be sold to third parties—converting what was a disposal cost  into a revenue stream. Technologies capable of achieving these recovery rates are well-established and  deployable at API manufacturing scale. </span></p>
<p><span>Maximising these benefits often depends on how recovery processes are integrated with existing production  and waste handling systems, ensuring that efficiencies gained in one area do not introduce trade-offs in  another. </span></p>
<p><span>By approaching these three areas as an integrated system rather than separate compliance tasks, manufacturers can  convert typical challenges into tangible sustainability and commercial gains. </span></p>
<p><span>Looking beyond individual treatment technologies—to how water, waste, and energy systems interact across an  operation—is where that integration becomes most effective. When these capabilities are brought together,  manufacturers gain a more precise and resilient response to both operational demands and environmental pressures,  safeguarding critical resources and supporting environmental security for manufacturers and the communities they  operate in alike. </span></p>
<p><span>These topics will be explored further in a masterclass series by Veolia for pharmaceutical professionals, with a focus on  building water security and operational resilience through integrated approaches to GMP design, microbial control,  validation, and wastewater management. More information and registration details are available here:  </span><span>https://go.watertechnologies.com/Pharmaceutical-Masterclass-RP.html </span></p>
<p>The post <a href="https://www.expresspharma.in/from-compliance-to-circularity-three-ways-pharma-manufacturers-can-rethink-resource-management/">From compliance to circularity: Three ways pharma manufacturers can rethink resource management</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Merck expands Singapore lab for biopharma testing</title>
<link>https://edusehat.com/en/merck-expands-singapore-lab-for-biopharma-testing</link>
<guid>https://edusehat.com/en/merck-expands-singapore-lab-for-biopharma-testing</guid>
<description><![CDATA[ 
Paolo Carli highlights how the expansion will support analytical and biosafety testing services for Asia Pacific biopharma customers
The post Merck expands Singapore lab for biopharma testing appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/08/11134201/EP_Merck_750-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 11 Aug 2026 17:20:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Merck, expands, Singapore, lab, for, biopharma, testing</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/08/11134201/EP_Merck_750-1.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/08/11134201/EP_Merck_750-1.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/11134201/EP_Merck_750-1-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Merck is expanding its Singapore laboratory to strengthen analytical and biosafety testing services for customers across the Asia Pacific region. Biosafety testing is a step in the drug development and manufacturing process, helping to ensure that biologics are safe, effective and compliant with regulatory requirements.</span></p>
<p><span>The expansion builds on Merck’s global testing expertise of more than 75 years and marks a milestone in providing a local contract testing services portfolio for the region’s growing biopharma industry.</span></p>
<p><span>“Localizing these BioReliance testing capabilities means our Asia Pacific biopharma customers can accelerate their development timelines, improve operational efficiency, and meet evolving regulatory and sustainability standards” said Paolo Carli, Head of Advanced Solutions for the Life Science business of Merck. “This investment underscores Merck’s commitment to empowering medicine makers by providing industry-leading analytical and biosafety testing services and technical expertise.”</span></p>
<p><span>Merck’s Singapore laboratory will become the first BioReliance facility in Asia-Pacific to offer both Cell Line Characterization services and GMP next-generation sequencing (NGS) capabilities. It will also offer molecular methods including Blazar®, a proprietary platform for rapid virus detection.</span></p>
<p><span>The expanded facility aims to support the industry’s move towards quality control testing of biologics and 3Rs (Replacement, Reduction, and Refinement of animal use) through molecular methods.</span></p>
<p><span>“Merck’s expansion of the BioReliance lab will bring world-class and next-generation testing services to biopharmaceutical companies in Singapore and the region. We look forward to continuing our partnership with Merck to strengthen Singapore’s ecosystem, build new capabilities within our local workforce, and enable the delivery of innovative therapies to patients,” said Goh Wan Yee, Senior Vice President and Head of Healthcare, Singapore Economic Development Board.</span></p>
<p><span>The Singapore BioReliance® lab was opened in 2018, and the expansion will bring the total lab area to over 1,000 square metres. The expansion is also a step in Merck’s broader strategy to support the region’s life science ecosystem and drive scientific progress.</span></p>
<p>The post <a href="https://www.expresspharma.in/merck-expands-singapore-lab-for-biopharma-testing/">Merck expands Singapore lab for biopharma testing</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Pharma deal value rises 55.2% in July 2026: GlobalData</title>
<link>https://edusehat.com/en/pharma-deal-value-rises-552-in-july-2026-globaldata</link>
<guid>https://edusehat.com/en/pharma-deal-value-rises-552-in-july-2026-globaldata</guid>
<description><![CDATA[ 
The healthcare industry reported 87 deals worth $29.5 billion in July 2026, while VC funding stood at $2.3 billion
The post Pharma deal value rises 55.2% in July 2026: GlobalData appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/08/11173227/growth.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 11 Aug 2026 17:20:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Pharma, deal, value, rises, 55.2, July, 2026:, GlobalData</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/08/11173227/growth.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/08/11173227/growth.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/08/11173227/growth-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>The healthcare industry reported 87 deals worth $29.5 billion in July 2026, compared with the last 12 months’ average of 85 deals worth $29.6 billion, according to GlobalData. Deal value increased by 55.2 per cent in July 2026 compared with July 2025.</span></p>
<p><span>Vertex Pharmaceuticals Inc agreed to acquire Crinetics Pharmaceuticals Inc, a pharmaceutical company focused on developing therapies for endocrine diseases, for $85 per share in cash, representing a total enterprise value of approximately $9.8 billion.</span></p>
<p><span>Eli Lilly and Company agreed to acquire AtaiBeckley Inc, a clinical-stage biopharmaceutical company developing therapeutics for mental health conditions, for up to $3.8 billion.</span></p>
<p><span>Apollo Global Management agreed to obtain a minority stake in Bayer’s long-acting reversible contraceptives (LARC) business for $3.4 billion. These were the three major deals reported in July 2026.</span></p>
<p><span>Venture capital funding decreased by 6.4 per cent in July 2026 compared with July 2025. The healthcare industry reported 83 venture capital (VC) deals worth $2.3 billion in July 2026, compared with the last 12 months’ average of 114 deals worth $3.3 billion.</span></p>
<p><span>Chai Discovery Inc raised $400 million in a Series C financing round to build AI models to accelerate pre-clinical drug discovery by predicting and reprogramming the interactions between molecules.</span></p>
<p><span>AdvanCell Isotopes Pty Ltd, a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer, raised $315 million in a Series D financing round to advance its lead therapy ADVC001 towards registrational development.</span></p>
<p><span>Celea Therapeutics, a clinical-stage biopharmaceutical company dedicated to advancing treatments for people with serious respiratory diseases, raised $180 million in financing to execute its strategy of unlocking the full potential of deupirfenidone for patients. These were the three major VC deals reported in July 2026.</span></p>
<p>The post <a href="https://www.expresspharma.in/pharma-deal-value-rises-55-2-in-july-2026-globaldata/">Pharma deal value rises 55.2% in July 2026: GlobalData</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>India pharma and healthcare funding at $69.8M in July 2026</title>
<link>https://edusehat.com/en/india-pharma-and-healthcare-funding-at-698m-in-july-2026</link>
<guid>https://edusehat.com/en/india-pharma-and-healthcare-funding-at-698m-in-july-2026</guid>
<description><![CDATA[ 
Funding was 34.42% lower than the previous month and 59.71% lower than the same month last year, according to Tracxn
The post India pharma and healthcare funding at $69.8M in July 2026 appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/08/11141334/EP_Tracxn_July_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 11 Aug 2026 17:20:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>India, pharma, and, healthcare, funding, 69.8M, July, 2026</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/08/11141334/EP_Tracxn_July_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/08/11141334/EP_Tracxn_July_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/11141334/EP_Tracxn_July_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>India’s pharma and healthcare sectors recorded total funding of $69.8 million across 18 rounds between July 01 and July 31, 2026, according to data from Tracxn. The data covers the HealthTech, Life Sciences and Healthcare sectors in India.</span></p>
<p><span>Funding was 34.42 per cent lower than the previous month and 59.71 per cent lower than the same month last year. The previous month was June 01 to June 30, 2026, while the same month last year was July 01 to July 31, 2025.</span></p>
<p><span>Stagewise funding in July comprised 12.3 per cent from seed-stage funding, 34.4 per cent from early-stage funding and 53.4 per cent from late-stage funding.</span></p>
<p><span>Funding stood at $57.9 million in August 2025, $128.7 million in September, $159.7 million in October, $27.2 million in November and $162.1 million in December. In January 2026, funding stood at $222.0 million, followed by $50.5 million in February, $220.1 million in March, $291.5 million in April, $116.4 million in May, $106.5 million in June and $69.8 million in July.</span></p>
<p><span>Iswarya Fertility Center accounted for a $37.0 million deal in July, followed by Arp at $10.0 million, Age Care Labs at $9.0 million, Supply6 at $5.0 million, V6 Clinics at $2.0 million, Mandrake Bio at $1.9 million and FibroHeal at $1.5 million.</span></p>
<p><span>Unilever Ventures, Antler and Unicorn India Ventures were the most active VCs. Unilever Ventures participated in one round for Supply6, Antler participated in one round for Mandrake Bio, and Unicorn India Ventures participated in one round for Bioscan Research.</span></p>
<p>The post <a href="https://www.expresspharma.in/india-pharma-and-healthcare-funding-at-69-8m-in-july-2026/">India pharma and healthcare funding at $69.8M in July 2026</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Key challenges in regulating pharma marketing in India</title>
<link>https://edusehat.com/en/key-challenges-in-regulating-pharma-marketing-in-india</link>
<guid>https://edusehat.com/en/key-challenges-in-regulating-pharma-marketing-in-india</guid>
<description><![CDATA[ 
 Dr Suresh R. Saravdekar highlights the need for statutory regulation, mandatory disclosure and stronger oversight of pharmaceutical marketing in India
The post Key challenges in regulating pharma marketing in India appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2022/06/07141645/Dr-Suresh-Saravdekar.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 11 Aug 2026 17:20:02 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Key, challenges, regulating, pharma, marketing, India</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2022/06/07141645/Dr-Suresh-Saravdekar.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2022/06/07141645/Dr-Suresh-Saravdekar.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2022/06/07141645/Dr-Suresh-Saravdekar-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p>India is widely recognised as the “Pharmacy of the World” for its large-scale production of affordable medicines. However, the country’s pharmaceutical marketing regulatory framework has not kept pace with international standards. While medicine quality and patient welfare should remain the primary objectives of healthcare, unethical marketing practices continue to influence prescribing behaviour, raising concerns about transparency, accountability, and rational use of medicines.</p>
<p>The current Uniform Code for Pharmaceutical Marketing Practices (UCPMP) is largely voluntary and lacks statutory backing. As a result, compliance depends mainly on industry self-regulation, with limited legal consequences for violations. In contrast, developed countries such as the United States, France, and the United Kingdom have legally enforceable systems that require public disclosure of financial relationships between pharmaceutical companies and healthcare professionals.</p>
<figure aria-describedby="caption-attachment-459108" class="wp-caption aligncenter"><img decoding="async" class=" wp-image-459108" src="https://cdn.expresspharma.in/wp-content/uploads/2026/08/11153735/ChatGPT-Image-Aug-11-2026-03_31_04-PM.png" alt="" width="411" height="309" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/08/11153735/ChatGPT-Image-Aug-11-2026-03_31_04-PM.png 1448w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/11153735/ChatGPT-Image-Aug-11-2026-03_31_04-PM-300x225.png 300w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/11153735/ChatGPT-Image-Aug-11-2026-03_31_04-PM-1024x768.png 1024w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/11153735/ChatGPT-Image-Aug-11-2026-03_31_04-PM-768x576.png 768w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/11153735/ChatGPT-Image-Aug-11-2026-03_31_04-PM-86x64.png 86w" sizes="(max-width: 411px) 100vw, 411px"><figcaption class="wp-caption-text"><em><strong>                                AI – Generated Image</strong></em></figcaption></figure>
<p> </p>
<p><span>The absence of mandatory disclosure in India makes it difficult for patients to know whether prescribing decisions are influenced by gifts, sponsorships, or other financial incentives. Weak grievance redressal mechanisms, fragmented legal provisions, and limited regulatory oversight further reduce public confidence in the existing system.</span></p>
<p><span>These challenges become even more significant in rural and underserved areas, where shortages of qualified healthcare professionals and limited access to reliable medical information increase the risk of irrational prescribing and unethical promotional practices. Effective regulation should therefore not only address industry conduct but also strengthen patient protection and promote evidence-based healthcare.</span></p>
<p><img decoding="async" class="aligncenter  wp-image-459109" src="https://cdn.expresspharma.in/wp-content/uploads/2026/08/11154216/EP_GB_Sarawadekar_.png" alt="" width="533" height="248" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/08/11154216/EP_GB_Sarawadekar_.png 552w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/11154216/EP_GB_Sarawadekar_-300x140.png 300w" sizes="(max-width: 533px) 100vw, 533px"></p>
<p><b>Why reform is necessary?</b></p>
<p><span>India can substantially improve its regulatory framework through five key reforms:</span></p>
<ul>
<li aria-level="1"><span>Provide statutory backing to the UCPMP by amending the Drugs and Cosmetics Act.</span></li>
<li aria-level="1"><span>Mandate public disclosure of all transfers of value from pharmaceutical companies to healthcare professionals.</span></li>
<li aria-level="1"><span>Establish an independent regulatory authority with adequate investigative and enforcement powers.</span></li>
<li aria-level="1"><span>Strengthen grievance redressal through a transparent national reporting system.</span></li>
<li aria-level="1"><span>Make patient welfare, rational prescribing, and medicine quality the central objectives of pharmaceutical marketing regulation.</span></li>
</ul>
<p><span>These reforms would improve transparency, reduce conflicts of interest, encourage ethical marketing practices, and enhance public trust in the healthcare system. They would also align India more closely with internationally accepted standards while supporting the country’s commitment to Universal Health Coverage.</span></p>
<p><span>As India continues to expand its leadership in global pharmaceutical manufacturing, it must also demonstrate leadership in ethical pharmaceutical governance. A robust and transparent regulatory framework will not only safeguard patients but also strengthen the credibility and long-term sustainability of India’s pharmaceutical industry.</span></p>
<p><span>Ultimately, the success of pharmaceutical marketing regulation should be measured not by the volume of medicines sold, but by its contribution to patient safety, rational prescribing, and the overall quality of healthcare.</span></p>
<p> </p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/key-challenges-in-regulating-pharma-marketing-in-india/">Key challenges in regulating pharma marketing in India</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Amneal completes Kashiv BioSciences acquisition</title>
<link>https://edusehat.com/en/amneal-completes-kashiv-biosciences-acquisition</link>
<guid>https://edusehat.com/en/amneal-completes-kashiv-biosciences-acquisition</guid>
<description><![CDATA[ 
Deal combines Amneal’s commercial scale with Kashiv’s biosimilars research, development and manufacturing capabilities
The post Amneal completes Kashiv BioSciences acquisition appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123851/Acquisition.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 11 Aug 2026 13:45:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Amneal, completes, Kashiv, BioSciences, acquisition</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123851/Acquisition.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123851/Acquisition.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123851/Acquisition-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Amneal Pharmaceuticals has completed its acquisition of Kashiv BioSciences, LLC, creating a fully integrated global biosimilars business with capabilities across research, development, manufacturing and commercialisation. The combination establishes one of the industry’s few fully integrated biosimilars platforms, the company said.</span></p>
<p><span>“The completion of this acquisition marks a pivotal step in Amneal’s strategy to become America’s #1 Affordable Medicines company,” said Chirag Patel, Co-Founder and Co-Chief Executive Officer. “With this acquisition, we have created an integrated biosimilars business that can launch multiple biosimilars each year and extends our growth profile into the next decade.”</span></p>
<p><span>“We are pleased to welcome the Kashiv team to Amneal and thank our shareholders and other stakeholders for their strong support,” said Chintu Patel, Co-Founder and Co-Chief Executive Officer. “This acquisition helps to position Amneal to capitalize on an unprecedented wave of biologic loss of exclusivity. Together, we will pursue this significant opportunity and work to expand patient access to high-quality, affordable biologic medicines.”</span></p>
<p><span>The acquisition combines Kashiv’s biologics research, development and manufacturing capabilities with Amneal’s commercial scale, establishing biosimilars as a major long-term growth pillar within the company’s Affordable Medicines business. The transaction provides Amneal access to the global biosimilars market with more than $300 billion in projected global biologics loss-of-exclusivity over the next decade. The combined portfolio is expected to support a consistent cadence of biosimilar launches for years to come.</span></p>
<p><span>The transaction builds on a relationship between Amneal and Kashiv spanning more than a decade, providing a foundation for integration. Integration planning and related activities are underway and are focused on combining the companies’ development and manufacturing capabilities and advancing the biosimilar pipeline.</span></p>
<p><span>Goldman Sachs & Co. LLC served as financial advisor and Richards, Layton & Finger, P.A. served as legal counsel to the Committee of Independent Directors of the Board of Directors. Simpson Thacher & Bartlett LLP served as legal counsel, among other financial and compliance advisors, to Amneal.</span></p>
<p><span>J.P. Morgan Securities LLC served as financial advisor, Holland & Knight LLP served as legal counsel, and Dhinal Shah Associates served as an advisor in India to Kashiv.</span></p>
<p>The post <a href="https://www.expresspharma.in/amneal-completes-kashiv-biosciences-acquisition/">Amneal completes Kashiv BioSciences acquisition</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Lupin gets US FDA nod for sodium zirconium cyclosilicate</title>
<link>https://edusehat.com/en/lupin-gets-us-fda-nod-for-sodium-zirconium-cyclosilicate</link>
<guid>https://edusehat.com/en/lupin-gets-us-fda-nod-for-sodium-zirconium-cyclosilicate</guid>
<description><![CDATA[ 
The drug is bioequivalent to AstraZeneca’s Lokelma and indicated for hyperkalaemia in adults
The post Lupin gets US FDA nod for sodium zirconium cyclosilicate appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 11 Aug 2026 13:45:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Lupin, gets, FDA, nod, for, sodium, zirconium, cyclosilicate</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>Lupin has received approval from the US Food and Drug Administration (US FDA) for its Abbreviated New Drug Application for Sodium Zirconium Cyclosilicate for Oral Suspension, 5 g/packet and 10 g/packet, the company announced.</span></p>
<p><span>The US FDA has approved Lupin’s Sodium Zirconium Cyclosilicate for Oral Suspension, 5 g/packet and 10 g/packet as bioequivalent to the reference listed drug (RLD) Lokelma for Oral Suspension of AstraZeneca Pharmaceuticals LP. The product is indicated for the treatment of hyperkalaemia in adults.</span></p>
<p><span>Sodium Zirconium Cyclosilicate for Oral Suspension (RLD Lokelma) had estimated annual sales of USD 568 million in the US, according to IQVIA MAT June 2026.</span></p>
<p>The post <a href="https://www.expresspharma.in/lupin-gets-us-fda-nod-for-sodium-zirconium-cyclosilicate/">Lupin gets US FDA nod for sodium zirconium cyclosilicate</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Energenesis and Taiwan Tanabe to develop ENERGI&#45;F703DFU for DFUs</title>
<link>https://edusehat.com/en/energenesis-and-taiwan-tanabe-to-develop-energi-f703dfu-for-dfus</link>
<guid>https://edusehat.com/en/energenesis-and-taiwan-tanabe-to-develop-energi-f703dfu-for-dfus</guid>
<description><![CDATA[ The collaboration will focus on process technology transfer and activities relating to chemistry, manufacturing and controls (CMC) to support a possible new drug application (NDA) in Taiwan for 
The post Energenesis and Taiwan Tanabe to develop ENERGI-F703DFU for DFUs appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/08/PT-10-08-2026-20260806051004EDT_image_1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 10 Aug 2026 19:50:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Energenesis, and, Taiwan, Tanabe, develop, ENERGI-F703DFU, for, DFUs</media:keywords>
<content:encoded><![CDATA[<p>The collaboration will focus on process technology transfer and activities relating to chemistry, manufacturing and controls (CMC) to support a possible new drug application (NDA) in Taiwan for the drug.</p>
<p>Energenesis’ ENERGI-F703DFU is currently in Phase III clinical development in both Taiwan and the US.</p>
<p>The two companies have also stated their intention to discuss future licensing for manufacturing and commercialisation in Taiwan and selected ASEAN markets, should agreements and regulatory approvals be reached.</p>
<p>The initiative combines Energenesis’ ENERGI drug development platform and ongoing clinical programme with Taiwan Tanabe Seiyaku’s capabilities in pharmaceutical development, production, and commercial operations within Taiwan.</p>
<p>Energenesis Biomedical chairman and CEO Dr Han-Min Chen said: “This agreement is an important milestone as ENERGI-F703DFU progresses from late-stage clinical development toward registration and commercial readiness.</p>
<p>“By combining Energenesis’ development expertise with Taiwan Tanabe’s pharmaceutical capabilities, we aim to establish an efficient pathway for a potential Taiwan NDA and prepare for broader access in Asia.</p>
<p>“We remain focused on completing the Phase III programme and generating the evidence required to bring a new treatment option to patients with diabetic foot ulcers.”</p>
<p>The partnership is expected to enhance efficiency in preparing for the registration process in Taiwan, aim to mitigate commercialisation risk, and provide a basis for expanded regional market access.</p>
<p>For Energenesis, working with Taiwan Tanabe is anticipated to supply established local experience in manufacturing, regulatory affairs, and commercial access.</p>
<p>Energenesis Biomedical expects to complete enrolment for the Phase III study in 2027, after which it will progress to data analysis. If the trial reaches its specified endpoints, preparation of a Taiwan NDA would be prioritised.</p>
<p>ENERGI-F703DFU is a topical small-molecule gel that is intended to promote healing of DFUs by modulating cellular energy pathways.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/energenesis-taiwan-tanabe-energi-f703dfu/">Energenesis and Taiwan Tanabe to develop ENERGI-F703DFU for DFUs</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Innovent and Daiichi Sankyo sign deal for Vanflyta in China</title>
<link>https://edusehat.com/en/innovent-and-daiichi-sankyo-sign-deal-for-vanflyta-in-china</link>
<guid>https://edusehat.com/en/innovent-and-daiichi-sankyo-sign-deal-for-vanflyta-in-china</guid>
<description><![CDATA[ Under the contract, Daiichi Sankyo will continue to handle development, manufacturing, and supply of the therapy while Innovent Biologics will lead market promotion and commercialisation activities in China. 
The post Innovent and Daiichi Sankyo sign deal for Vanflyta in China appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/08/PT-2-10-08-2026-shutterstock_789444358.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 10 Aug 2026 19:50:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Innovent, and, Daiichi, Sankyo, sign, deal, for, Vanflyta, China</media:keywords>
<content:encoded><![CDATA[<p>Under the contract, Daiichi Sankyo will continue to handle development, manufacturing, and supply of the therapy while Innovent Biologics will lead market promotion and commercialisation activities in China.</p>
<p>Vanflyta received approval in the country in June 2026 for use in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, as well as for maintenance monotherapy following consolidation chemotherapy.</p>
<p>The indication covers treatment of adult patients with newly diagnosed FLT3-ITD-positive acute myeloid leukaemia (AML) as determined by an appropriate validated diagnostic test. Approval was based on data from the QuANTUM-First trial.</p>
<p>Innovent Biologics executive director and chief commercial officer Vivian Zhang said: “Innovent has continued to expand its product footprint in this field, building a diversified portfolio and strong market presence, including TYVYT (sintilimab injection), Halpryza (rituximab injection), olverembatinib, Fucaso (Equecabtagene Autoleucel Injection), Jaypirca (pirtobrutinib), and the addition of Vanflyta will further enhance our synergistic offerings.”</p>
<p>“Vanflyta will be the 20th product in Innovent’s commercialised product portfolio. Through collaborative efforts, we aim to bring forward innovative medicines to benefit patients with cancer and further strengthen our leadership in oncology.”</p>
<p>Daiichi Sankyo China president Michio Hayashi said: “The partnership with Innovent Biologics reflects our commitment to delivering innovation to patients in China.</p>
<p>“By combining our research and development capabilities with Innovent’s commercial capabilities in China, we believe this collaboration can accelerate access to Vanflyta for patients with newly diagnosed FLT3-ITD-positive AML and ultimately help improve outcomes in this high-risk patient population.”</p>
<p>Last month, Innovent Biologics agreed an exclusive licence deal worth up to $1.1bn with Spero Therapeutics, granting Spero the rights to develop, research, manufacture and commercialise IBI355, also known as SP001, outside Greater China.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/innovent-daiichi-sankyo-vanflyta-china/">Innovent and Daiichi Sankyo sign deal for Vanflyta in China</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Biodeal Pharma raises ₹385 cr growth investment from RMB Capitalworks</title>
<link>https://edusehat.com/en/biodeal-pharma-raises-385-cr-growth-investment-from-rmb-capitalworks</link>
<guid>https://edusehat.com/en/biodeal-pharma-raises-385-cr-growth-investment-from-rmb-capitalworks</guid>
<description><![CDATA[ 
Investment validates Biodeal&#039;s leadership in specialty pharma manufacturing, strengthens its regulated-market platform, and accelerates expansion across nasal drug delivery and global markets
The post Biodeal Pharma raises ₹385 cr growth investment from RMB Capitalworks appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/08/10153412/Biodeal_Pharmaceuticals_Raises____385_Crore_Growth_Investment_from_RMB_Capitalworks.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 10 Aug 2026 19:50:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Biodeal, Pharma, raises, ₹385, growth, investment, from, RMB, Capitalworks</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="483" src="https://cdn.expresspharma.in/wp-content/uploads/2026/08/10153412/Biodeal_Pharmaceuticals_Raises____385_Crore_Growth_Investment_from_RMB_Capitalworks.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/08/10153412/Biodeal_Pharmaceuticals_Raises____385_Crore_Growth_Investment_from_RMB_Capitalworks.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/10153412/Biodeal_Pharmaceuticals_Raises____385_Crore_Growth_Investment_from_RMB_Capitalworks-300x193.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/10153412/Biodeal_Pharmaceuticals_Raises____385_Crore_Growth_Investment_from_RMB_Capitalworks-210x136.jpg 210w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p class="western" align="JUSTIFY"><span>Biodeal Pharmaceuticals announced a growth investment of ₹385 crore from RMB Capitalworks, a joint venture between Rand Merchant Bank and Capitalworks Group. The investment will support the company’s next phase of expansion across specialty pharmaceuticals, manufacturing capabilities, and regulated markets.</span></p>
<p class="western" align="JUSTIFY"><span>Biodeal has built more than two decades of leadership in nasal drug delivery, supported by integrated pharma development and manufacturing capabilities. The investment will support Biodeal’s next phase of expansion, strengthening its positions across Asian markets while accelerating growth across CIS, LATAM, Africa and Europe.</span></p>
<p class="western" align="JUSTIFY"><em><span><span><span><span>“This investment represents much more than capital – it is a strong endorsement of the platform we have built over the past two decades. At Biodeal, we have consistently focused on creating differentiated capabilities in specialty pharmaceuticals, anchored by leadership in nasal drug delivery and a relentless focus on quality and manufacturing excellence. This milestone reflects the strength of what we’ve built and the scale of what lies ahead. We are delighted to welcome RMB Capitalworks as a long-term strategic partner – we chose to partner with them because of the value they bring beyond capital, and their operational expertise, governance philosophy and growth mindset align closely with our vision as we build a globally competitive specialty pharmaceutical company and advance on our path towards a planned public listing</span></span></span></span></em><span><span><span>,” said </span></span></span><strong><span><span><span><span>Anurag Kumar, CMD</span></span></span></span></strong><span><span><span>, </span></span></span><strong><span><span><span><span>Biodeal Pharmaceuticals</span></span></span></span></strong><span><span><span>.</span></span></span></p>
<p class="western" align="JUSTIFY"><em><span><span><span><span><span>“We love founders passionate about building enduring businesses, and we saw that exact fire in Anurag. We work closely with founders to co-create solutions that unlock personal value and provide the long-term financial stability needed to execute ambitious growth plans. Healthcare is a core focus for us, and Biodeal fits our thesis of a differentiated player primed for rapid growth. We are proud to act as true partners, working alongside the Biodeal team to strengthen governance, accelerate expansion, and build a leading pharmaceutical powerhouse</span></span></span></span></span></em><strong><span><span><span><span><span>,”</span></span></span></span></span></strong><span><span><span><span><span> said </span></span></span></span></span><strong><span><span><span><span><span>Anshuman Malur, Managing Partner, RMB Capitalworks.</span></span></span></span></span></strong></p>
<p class="western" align="JUSTIFY"><span>A company release informed, “Biodeal has delivered consistent profitable growth over the past five years, with FY26 revenue estimated to grow 60%+ year-on-year and EBITDA margins expanding further. The company is entering its next phase of growth with a clear ambition; to strengthen its position as a globally trusted specialty pharma partner while advancing confidently on its path towards a planned public listing.”</span></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/biodeal-pharma-raises-%E2%82%B9385-cr-growth-investment-from-rmb-capitalworks/">Biodeal Pharma raises ₹385 cr growth investment from RMB Capitalworks</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Zydus launches REVAHALE, India’s first once&#45;daily nebulised LAMA for COPD</title>
<link>https://edusehat.com/en/zydus-launches-revahale-indias-first-once-daily-nebulised-lama-for-copd</link>
<guid>https://edusehat.com/en/zydus-launches-revahale-indias-first-once-daily-nebulised-lama-for-copd</guid>
<description><![CDATA[ 
REVAHALE (Revefenacin) offers sustained 24-hour bronchodilation through convenient nebulised delivery
The post Zydus launches REVAHALE, India’s first once-daily nebulised LAMA for COPD appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2019/06/24072344/GettyImages-940685570.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 10 Aug 2026 19:50:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Zydus, launches, REVAHALE, India’s, first, once-daily, nebulised, LAMA, for, COPD</media:keywords>
<content:encoded><![CDATA[<div><img width="600" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2019/06/24072344/GettyImages-940685570.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2019/06/24072344/GettyImages-940685570.jpg 600w, https://cdn.expresspharma.in/wp-content/uploads/2019/06/24072344/GettyImages-940685570-300x200.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2019/06/24072344/GettyImages-940685570-450x300.jpg 450w" sizes="(max-width: 600px) 100vw, 600px"></div><p align="JUSTIFY"><span>Zydus Lifesciences (including its subsidiaries and affiliates), an innovation-driven global lifesciences company, launched REVAHALE (Revefenacin), India’s first once-daily nebulised Long-Acting Muscarinic Antagonist (LAMA) indicated for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD).</span></p>
<p align="JUSTIFY">
</p><p align="JUSTIFY"><span>REVAHALE is the first and only LAMA available in India that combines once-daily dosing with nebulised administration, offering a new treatment option for COPD patients who require nebulised therapy. Designed to provide sustained 24-hour bronchodilation with a single daily dose, REVAHALE addresses important challenges associated with inhaler-dependent therapies, particularly among elderly patients and those with severe respiratory impairment.</span></p>
<p align="JUSTIFY">
</p><p align="JUSTIFY"><span>COPD remains a significant public health challenge in India and is a leading cause of morbidity and mortality. While inhaled bronchodilator therapies have transformed disease management, many patients continue to experience difficulties using handheld inhalers, cognitive limitations, severe breathlessness, or an inability to generate sufficient inspiratory effort for effective drug delivery.</span></p>
<p align="JUSTIFY">
</p><p align="JUSTIFY"><span>REVAHALE has been developed to address these unmet needs through a convenient nebulised delivery platform that reduces dependence on inhalation technique and inspiratory flow. The therapy is compatible with standard jet nebulisers, providing flexibility and ease of use for patients and caregivers.</span></p>
<p align="JUSTIFY">
</p><p align="JUSTIFY"><span>Revefenacin is designed to deliver sustained bronchodilation over 24 hours through once-daily administration. Clinical studies have demonstrated significant and sustained improvements in lung function in patients with moderate to very severe COPD, while maintaining a favourable safety profile. Its lung-selective design is intended to maximise bronchodilatory effects in the airways while minimising systemic exposure. </span></p>
<p align="JUSTIFY">
</p><p align="JUSTIFY"><span>By combining once-daily administration, compatibility with standard jet nebulisers and sustained 24-hour bronchodilation, REVAHALE offers a differentiated maintenance treatment option in COPD care.</span></p>
<p align="JUSTIFY">
</p><p>The post <a href="https://www.expresspharma.in/zydus-launches-revahale-indias-first-once-daily-nebulised-lama-for-copd/">Zydus launches REVAHALE, India’s first once-daily nebulised LAMA for COPD</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Evotec and Odyssey collaborate on AI&#45;enabled R&amp;amp;D</title>
<link>https://edusehat.com/en/evotec-and-odyssey-collaborate-on-ai-enabled-rd</link>
<guid>https://edusehat.com/en/evotec-and-odyssey-collaborate-on-ai-enabled-rd</guid>
<description><![CDATA[ This collaboration will focus on utilising Evotec’s data-driven discovery platform alongside its AI data science and advanced screening technologies. It aims to accelerate the discovery and validation of 
The post Evotec and Odyssey collaborate on AI-enabled R&amp;D appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/08/RD-shutterstock_620440031.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 07 Aug 2026 19:15:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Evotec, and, Odyssey, collaborate, AI-enabled, R&amp;D</media:keywords>
<content:encoded><![CDATA[<p>This collaboration will focus on utilising Evotec’s data-driven discovery platform alongside its AI data science and advanced screening technologies.</p>
<p>It aims to accelerate the discovery and validation of new small molecule drug candidates across several disease targets.</p>
<p>By combining Evotec’s screening capabilities, AI-enabled discovery platform and compound libraries with Odyssey’s expertise in autoimmune and inflammatory disease biology, the companies seek to identify validated hit series and advance encouraging therapeutic programmes.</p>
<p>Evotec chief scientific officer Dr Cord Dohrmann said: “Drug discovery increasingly depends on the ability to integrate deep disease biology with advanced experimental and computational approaches to drug discovery.</p>
<p>“This collaboration with Odyssey illustrates well Evotec’s strategy in applying integrated discovery platform technologies to complex disease areas where new approaches are urgently needed.</p>
<p>“Together, we aim to generate differentiated and validated starting points for Odyssey to develop into new therapies for autoimmune and inflammatory diseases.”</p>
<p>This partnership intends to leverage complementary scientific strengths to boost early-stage research and produce new medicines.</p>
<p>Evotec may receive milestone payments based on the delivery of validated hit series successful for targeted diseases, though financial specifics of the agreement remain undisclosed.</p>
<p>Evotec’s expertise covers biologics, small molecules, cell therapies and associated modalities, supported by Molecular Patient Databases, PanOmics and iPSC-based disease modelling platforms.</p>
<p>In a separate development, Niagen Bioscience selected Evotec to support the advancement of NB4168, a small molecule designed for oral pharmaceutical development.</p>
<p>This work will be conducted in collaboration with Niagen Bioscience’s wholly owned subsidiary, NAD Pharmaceuticals, which is focused on developing accelerated ageing and rare genetic disease therapies.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/evotec-odyssey-ai-enabled-rd/">Evotec and Odyssey collaborate on AI-enabled R&D</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Mediar and Ono Pharmaceutical to develop fibro&#45;inflammatory treatments</title>
<link>https://edusehat.com/en/mediar-and-ono-pharmaceutical-to-develop-fibro-inflammatory-treatments</link>
<guid>https://edusehat.com/en/mediar-and-ono-pharmaceutical-to-develop-fibro-inflammatory-treatments</guid>
<description><![CDATA[ These conditions often result in organ failure due to myofibroblast activation, scarring, and tissue inflammation. Ono will work alongside Mediar to utilise its fibrosis-focused discovery platform, expertise in 
The post Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatments appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/08/Research-shutterstock_2709646703.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 07 Aug 2026 19:15:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Mediar, and, Ono, Pharmaceutical, develop, fibro-inflammatory, treatments</media:keywords>
<content:encoded><![CDATA[<p>These conditions often result in organ failure due to myofibroblast activation, scarring, and tissue inflammation.</p>
<p>Ono will work alongside Mediar to utilise its fibrosis-focused discovery platform, expertise in myofibroblast development, and knowledge of fibrosis pathways.</p>
<p>This partnership gives Ono the exclusive option to license worldwide rights to develop and commercialise these therapeutic programmes. The company will also provide an upfront payment to Mediar and support research and development costs.</p>
<p>Ono Pharmaceutical discovery and research corporate officer / executive vice-president Seishi Katsumata said: “Fibro-inflammatory diseases remain areas of significant unmet medical need, and we believe biologics innovation is essential to provide meaningful therapeutic advances.</p>
<p>“Mediar has established deep scientific expertise in fibrosis and antibody discovery. By combining Mediar’s capabilities with Ono’s experience in immunology and inflammation research area, we aim to create novel antibody therapeutics that may offer new treatment options for patients.”</p>
<p>In addition to this collaboration, Mediar will continue progressing its portfolio targeting fibrotic disorders. This includes MTX-474, an EphrinB2-targeting antibody currently in Phase II development for systemic sclerosis.</p>
<p>Additionally, MTX-463, an anti-WISP1 antibody, is being developed in partnership with Eli Lilly and Company for idiopathic pulmonary fibrosis. MTX-439, an anti-SMOC2 antibody, is in Phase I trials for chronic kidney disease-mediated fibrosis.</p>
<p>MTX-474 functions by neutralising the EphrinB2 signalling pathway, which contributes to fibrosis onset and progression.</p>
<p>Similarly, MTX-463 targets the WNT1-inducible signalling pathway protein-1 (WISP1), a crucial factor in fibrosis development. MTX-439 aims to inhibit the activity of SMOC2, a protein linked to the pathogenesis of kidney fibrosis.</p>
<p>Mediar Therapeutics CEO Rahul Ballal said: “This strategic collaboration with Ono is an important milestone for Mediar and reflects the growing recognition that directly targeting the myofibroblast can unlock new therapeutic possibilities in fibrotic diseases.”</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/mediar-ono-pharmaceutical-fibro-inflammatory/">Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatments</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>PayU partners with Marg ERP to streamline digital payments for pharma distributors</title>
<link>https://edusehat.com/en/payu-partners-with-marg-erp-to-streamline-digital-payments-for-pharma-distributors</link>
<guid>https://edusehat.com/en/payu-partners-with-marg-erp-to-streamline-digital-payments-for-pharma-distributors</guid>
<description><![CDATA[ 
The partnership integrates PayU’s payment infrastructure with Marg ERP to enable digital collections and automated reconciliation for distributors, retailers and MSMEs
The post PayU partners with Marg ERP to streamline digital payments for pharma distributors appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/05/04131504/handshake.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 07 Aug 2026 19:15:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>PayU, partners, with, Marg, ERP, streamline, digital, payments, for, pharma, distributors</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/05/04131504/handshake.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/05/04131504/handshake.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/05/04131504/handshake-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>PayU and Marg ERP have announced a strategic partnership to power Marg Pay, Marg ERP’s integrated payments solution for digital payment collection and reconciliation for pharma distributors and MSME retailers.</span></p>
<p><span>The partnership integrates PayU’s payment infrastructure into Marg ERP’s workflow, creating a connected environment for ordering, payments and reconciliation.</span></p>
<p><span>According to the companies, manual payment reconciliation has remained a challenge for pharma distributors and MSME retailers due to the time and errors involved, as well as exposure to cash pilferage. For pharma distribution, the companies said these challenges can translate into working capital risk, revenue loss and customer churn.</span></p>
<p><span>Marg Pay, integrated with PayU’s payment solution, will enable invoicing, collection and reconciliation through digital payment workflows.</span></p>
<p><span>MSME retailers will be able to generate Dynamic QR codes against individual invoices, enabling digital payments to be automatically reconciled within Marg ERP. Distributors will be able to generate payment links against individual invoices, with payments reconciled bill-by-bill and posted directly into the ERP. The companies said this will support faster collections, same-day settlements and operational efficiency.</span></p>
<p><span>“Digital payments are integral to how businesses operate, yet collections and reconciliation remain fragmented and laborious. Together with Marg ERP, we aim to simplify financial administration and bring more predictability to the cash flow of Indian pharma distributors and retailers. This deepens Marg ERP’s role in digitising the pharma sector while expanding PayU’s positioning as an embedded finance aggregator.”, said Vineet Sethi, Chief Growth and Marketing Officer, PayU.</span></p>
<p><span>“Digital payments are no longer just about collecting money, they are about creating smarter financial cash flows for all trades. Through our partnership with PayU, we are strengthening the Marg Pay ecosystem to help distributors, retailers and MSMEs accept payments securely. Not only payment, Marg Pay also facilitates the reconciliation for retailers and distributors accounts automatically. We enable businesses to operate with greater efficiency and confidence”. – Thakur Anup Singh, CMD, Marg ERP Ltd.</span></p>
<p><span>The partnership will also extend to Marg’s eRetail application, which supports B2B ordering, payments and reconciliation.</span></p>
<p>The post <a href="https://www.expresspharma.in/payu-partners-with-marg-erp-to-streamline-digital-payments-for-pharma-distributors/">PayU partners with Marg ERP to streamline digital payments for pharma distributors</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The next move on India’s trade chessboard</title>
<link>https://edusehat.com/en/the-next-move-on-indias-trade-chessboard</link>
<guid>https://edusehat.com/en/the-next-move-on-indias-trade-chessboard</guid>
<description><![CDATA[ 
As tariffs dominate global trade discussions, India&#039;s expanding FTA network promises wider market access for Indian pharma. But will preferential trade agreements translate into sustained export competitiveness? examines Neha Aathavale 
The post The next move on India’s trade chessboard appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2020/03/31173849/Indian-exports.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 07 Aug 2026 15:40:02 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, next, move, India’s, trade, chessboard</media:keywords>
<content:encoded><![CDATA[<div><img width="888" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2020/03/31173849/Indian-exports.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2020/03/31173849/Indian-exports.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2020/03/31173849/Indian-exports.jpg 768w, https://cdn.expresspharma.in/wp-content/uploads/2020/03/31173849/Indian-exports.jpg 888w" sizes="(max-width: 888px) 100vw, 888px"></div><p><span>Few global leaders have kept the world of trade on its toes quite like the United States President Donald Trump. His latest announcement of a phased tariff regime on pharmaceutical imports into the US once again has sent ripples across the Indian pharma industry, triggering discussions on exports, competitiveness and the future of one of India’s largest overseas markets. As explored in this month’s cover story, the development is yet another reminder that in today’s world, trade policy can alter industry sentiment almost overnight </span></p>
<p><span>This feature, however, begins where that conversation leaves off. If tariffs represent one side of the trade equation, Free Trade Agreements (FTAs) represent the other. Every Free Trade Agreement is, in essence, a wager. A wager that easier market access today will deliver economic gains years later. New Delhi has been placing that bet with increasing conviction. Since 2021, India has concluded nine FTAs across 38 countries, signalling a shift in its trade strategy. For pharma, one of the country’s largest export sectors, the expectation is clear. The outcome, however, is far less certain. </span></p>
<p><span>Indian pharma built its global standing long before the current FTA momentum gathered pace. That raises an important question. Can preferential trade agreements fundamentally alter the industry’s competitive position, or do they merely provide an advantage that still has to be earned through quality systems, regulatory credibility, innovation and manufacturing excellence? </span></p>
<p><b>More than a tariff story </b></p>
<p><span>Much of the public discourse around FTAs tends to revolve around tariff concessions. Yet, for pharma, tariffs have rarely been the defining factor in determining export success. In many developed markets, pharma products already attract relatively low or zero import duties under existing WTO commitments. The latest generation of FTAs therefore offers value in a different way: by making trade more predictable, reducing operational friction and creating an environment that encourages long-term commercial relationships. </span></p>
<p><span>For businesses making in vestments that often take years to translate into commercial returns, predictability carries considerable weight. Vivek Valsaraj, CFO, Piramal Pharma, believes the significance of FTAs extends well beyond their impact on duties. “India’s expanding FTA network should be viewed as more than a trade facilitation mechanism. At their core, FTAs bring together interdependent economies, create greater predictability in commercial relationships and provide businesses with the confidence to make long-term investments.” </span></p>
<p><span>That perspective is echoed by Neeraj Bansal, Partner and Head, India Global, KPMG in India, who argues that the real commercial gains increasingly lie in easing the movement of business rather than merely lowering import costs. According to him, agreements such as the India–UAE CEPA, India–Australia ECTA and the India–UK CETA are designed to strengthen regulatory cooperation, improve customs efficiency and enhance policy certainty, making it easier for companies to operate across borders. As India’s pharma exports crossed USD 31 billion in FY26, reducing such business friction is becoming increasingly important as companies expand across regulated and high growth markets. </span></p>
<p><span>For an industry whose global reputation was built on manufacturing scale, cost competitiveness and quality rather than preferential trade access, this distinction is significant. As Dr Vellaian Karuppiah, COO, Shilpa Medicare, points out, “India’s export strength was built on manufacturing scale, cost competitiveness, quality systems and one of the largest bases of regulator-approved facilities outside the US — not on tariff preferences.” In his view, the significance of the latest agreements lies less in tariff reductions and more in the regulatory cooperation, customs facilitation and greater predictability that accompany them, enabling companies to move from opportunistic, priceled exports towards deeper, long-term supply relationships.</span></p>
<p><b>Do FTAs really create a competitive advantage? </b></p>
<p><span>Paradoxically, the biggest value proposition of modern FTAs may have very little to do with tariffs. For the pharma industry, preferential market access has never been the sole determinant of export success. Instead, the debate is increasingly shifting towards what happens beyond the tariff schedule — regulatory cooperation, customs facilitation, institutional cooperation and the ability to reduce the non-tariff frictions that often determine how quickly and efficiently medicines reach global markets. </span></p>
<p><span>It is this distinction that many industry leaders believe is often overlooked. As Bansal highlights, “FTAs should be viewed as enablers rather than standalone growth drivers.” He argues that market access today is increasingly shaped by ease of doing business rather than import duties alone, with provisions that improve regulatory cooperation, customs efficiency and business certainty often delivering greater commercial value than tariff concessions themselves.</span></p>
<p><span>The same sentiment resonates from the manufacturing floor. Dr Karuppiah, believes “Tariff concessions are essentially a one-time reset; the durable advantage sits with the other three,” referring to regulatory compliance, manufacturing excellence and supply-chain resilience. While lower tariffs may create an initial commercial advantage, sustaining that advantage depends on consistently meeting stringent quality standards, navigating regulatory inspections and ensuring uninterrupted supply. </span></p>
<p><span>The commercial implications extend beyond exports to investment decisions themselves. Valsaraj notes, “Tariff benefits are certainly helpful, but in our view, they are only one part of a much larger equation.” In an environment marked by geopolitical shifts and supply-chain realignments, he believes the certainty created by FTAs encourages businesses to make long-term manufacturing investments and forge deeper commercial partnerships. </span></p>
<p><span>That perspective extends to the research-based pharma industry as well. According to Anil Matai, Director General, OPPI, investment decisions are influenced as much by confidence in intellectual property protection, regulatory stability and the ability to commercialise innovation as they are by market access itself. In that sense, FTAs are becoming less about lowering barriers to trade and more about signalling a stable, predictable environment for long-term investment. </span></p>
<p><span>Taken together, the message is clear. FTAs may widen the doorway to international markets, but walking through it still demands capabilities that no trade agreement can confer. For Indian pharma, competitiveness will continue to be earned through quality, regulatory credibility, innovation and execution rather than tariff concessions alone. </span></p>
<p><b>Beyond volume, towards value </b></p>
<p><span>If the last three decades established India as the world’s pharmacy, the next may well determine what kind of pharmacy it becomes. The industry’s global leadership has largely been built on affordable generics, vaccines and cost-efficient manufacturing. Increasingly, however, export growth is expected to come from products where scientific capability, technical complexity and regulatory expertise command a premium over manufacturing scale alone. </span></p>
<p><span>For integrated manufacturers and CDMOs, this shift presents a significant opportunity. Valsaraj, believes “the greatest opportunities are likely to arise in high-value segments where integrated players capable of supporting the full product lifecycle—from development through commercial manufacturing— can differentiate themselves through technical capabilities, quality excellence and execution reliability, rather than cost alone.” He points to growing global demand for sterile injectables, complex formulations, antibody-drug conjugates (ADCs), peptide technologies and integrated CDMO services, particularly across North America, Europe, the UK and Japan. </span></p>
<p><span>Dr Karuppiah, sees a similar shift unfolding within pharma manufacturing. “In plain generics, price competition is intense and a tariff concession is quickly competed away. In complex formulations, injectables, biologics, biosimilars and other specialty segments, the barriers to entry — regulatory, technical and logistical — are far higher, so reduced friction and regulatory cooperation disproportionately help companies that already have depth in these areas.” In other words, FTAs may not fundamentally change the economics of conventional generics, but they could improve market access for companies already positioned in differentiated, higher value segments. </span></p>
<p><span>The opportunity, however, extends beyond expanding exports. It also presents a chance for India to deepen its role within global pharma value chains. According to Matai, “The next opportunity lies in moving up the value chain—from being recognised primarily for scale and affordability to becoming a global centre for innovation-led manufacturing.” He believes this transition will depend on strengthening capabilities in biologics, advanced therapies, specialty medicines, novel drug delivery systems and other technology intensive areas, supported by continued investments in research infrastructure, scientific talent and advanced manufacturing. </span></p>
<p><span>Yet, higher-value exports demand higher-value capabilities. As pharma supply chains become increasingly specialised, manufacturers will need to strengthen automation, digital manufacturing, integrated development capabilities and supplychain resilience. Dr Karuppiah emphasises the importance of backward integration, API and key starting material diversification, digitised and traceable manufacturing, scalable capacity and stronger ESG credentials. Similarly, Valsaraj believes competitive advantage will increasingly depend on advanced manufacturing technologies, integrated development and manufacturing solutions, innovation led capabilities and the ability to serve as reliable long-term partners rather than simply efficient manufacturers. </span></p>
<p><span>On the other hand, Bansal, argues that the companies most likely to benefit from FTAs will be those that view them as part of a broader growth strategy rather than a standalone trade advantage. He believes firms investing in innovation, complex generics, biosimilars and specialty medicines, while combining strong regulatory track records with reliable manufacturing operations and diversified supply chains, will be better positioned to convert preferential market access into sustained business growth. </span></p>
<p><span>Collectively, the experts suggest that the next phase of India’s pharma exports will not be defined by greater volumes alone. Rather, it will depend on whether Indian companies can leverage expanding market access to build deeper capabilities, strengthen innovation and move decisively towards higher-value manufacturing.</span></p>
<p><b>What still needs fixing? </b></p>
<p><span>While FTAs can create favourable conditions for trade, they cannot, on their own, transform India’s pharma export trajectory. Their success will ultimately depend on how effectively they are complemented by domestic reforms that strengthen the industry’s competitiveness, resilience and innovation ecosystem. </span></p>
<p><span>A recurring theme across industry voices is the need to reduce structural vulnerabilities within the supply chain. Dr Karuppiah, believes that reducing dependence on imported APIs and key starting materials remains critical to strengthening supply security. In his view, market access created through FTAs will generate lasting value only if it is supported by continued investment in innovation, quality infrastructure and regulatory credibility at home. </span></p>
<p><span>Adding to it, Matai emphasises that intellectual property protection and stronger incentives for R&D, clinical development, advanced manufacturing and talent development will be essential to support long-term investment. </span></p>
<p><span>Among this discussion, Bansal, offers a note of caution. While FTAs undoubtedly create new opportunities, they also expose Indian companies to stronger global competition and increasingly demanding regulatory expectations around quality, sustainability, data integrity and supply-chain traceability. Companies that assume lower trade barriers will automatically translate into higher exports risk overlooking the execution required to compete in these markets. Instead, he believes the greatest gains will accrue to businesses that combine market access with innovation, operational excellence and a deep understanding of evolving customer and regulatory requirements. </span></p>
<p><b>In brief</b></p>
<p><span>Ultimately, trade agreements, much like tariffs, are ultimately instruments of policy. Their significance lies not merely in what they promise on paper, but in how effectively industry translates those promises into commercial outcomes. As global supply chains continue to evolve and geopolitical considerations increasingly shape pharma trade, India’s expanding FTA network offers an important opportunity. Whether that opportunity becomes a lasting competitive advantage, however, will depend less on the agreements themselves and more on the capabilities, innovation and regulatory credibility that Indian pharma brings to the table.  </span></p>
<p> </p>
<p><em><strong>neha.aathavale@expressindia.com</strong></em></p>
<p><em><strong>nehaaathavale75@gmail.com</strong></em></p>
<p>The post <a href="https://www.expresspharma.in/the-next-move-on-indias-trade-chessboard/">The next move on India’s trade chessboard</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>CDSCO to hold quarterly stakeholder meetings to discuss regulatory framework and procedures</title>
<link>https://edusehat.com/en/cdsco-to-hold-quarterly-stakeholder-meetings-to-discuss-regulatory-framework-and-procedures</link>
<guid>https://edusehat.com/en/cdsco-to-hold-quarterly-stakeholder-meetings-to-discuss-regulatory-framework-and-procedures</guid>
<description><![CDATA[ 
Industry welcome the initiative, with industry bodies calling for structured dialogue on regulatory requirements and implementation.
The post CDSCO to hold quarterly stakeholder meetings to discuss regulatory framework and procedures appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123851/Acquisition.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 07 Aug 2026 12:05:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>CDSCO, hold, quarterly, stakeholder, meetings, discuss, regulatory, framework, and, procedures</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123851/Acquisition.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123851/Acquisition.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/12/03123851/Acquisition-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>The Central Drugs Standard Control Organisation (CDSCO) will organise quarterly stakeholder meetings under the chairmanship of the Drugs Controller General of India (DCGI) to discuss regulatory developments, implementation issues and procedures.</span></p>
<p><span>According to an office order issued by CDSCO on 6 August 2026, the initiative aims to strengthen stakeholder engagement, enhance transparency, improve regulatory compliance and facilitate the dissemination of regulatory developments and stakeholder expectations on regulatory updates.</span></p>
<p><span>The first meeting is scheduled for 24 August 2026 from 2:30 pm to 5:00 pm at the second floor of CDSCO headquarters at FDA Bhawan, New Delhi.</span></p>
<p><span>According to CDSCO, the meetings will provide a platform for interaction between the regulator and stakeholders, including discussions on regulatory updates, implementation issues, regulatory procedures and feedback from industry and other stakeholders.</span></p>
<p><span>CDSCO has asked 12 industry associations to nominate not more than two representatives, comprising the president or chairman and secretary or general secretary, or a senior representative, to participate in the meeting with the DCGI. The associations include the Indian Drug Manufacturers’ Association (IDMA), Organisation of Pharmaceutical Producers of India (OPPI), Bulk Drug Manufacturers Association (India) [BDMA(I)], Federation of Pharma Entrepreneurs (FOPE), Indian Pharmaceutical Alliance (IPA), Federation of Indian Chambers of Commerce and Industry (FICCI), Confederation of Indian Industry (CII), Indian Vaccine Manufacturers Association (IVMA), Himachal Drug Manufacturers Association (HDMA), Laghu Udyog Bharati (LUB), Indian Federation of Animal Health Companies (INFAH) and Veterinary Vaccine India Manufacturers Association (VVIMA).</span></p>
<p><span>The nominated representatives’ names, designations, email IDs and contact numbers, along with brief discussion points not exceeding one page, are to be submitted to CDSCO by 12 August 2026. CDSCO stated that invitations will be issued in the names of the nominated representatives and only those representatives will be permitted to attend the meeting. Subject experts from the respective associations may attend with prior permission.</span></p>
<p><span>Reacting to the development, <strong>Harish Jain, President, Federation of Pharma Entrepreneurs (FOPE), states: </strong></span></p>
<p><span>“ FOPE welcomes the CDSCO’s initiative to institutionalise Quarterly Stakeholder Meetings under the chairmanship of the Drugs Controller General of India. This is a significant step towards making regulatory engagement more structured, transparent and responsive.</span></p>
<p><span>For the pharma industry, particularly MSMEs, timely clarification on regulatory requirements and a predictable implementation framework are extremely important. A regular institutionalised dialogue will help identify practical challenges at the ground level, reduce avoidable ambiguity and facilitate smoother compliance.</span></p>
<p><span>FOPE looks forward to using this platform constructively to present the concerns and suggestions of pharma entrepreneurs and to work closely with CDSCO in strengthening India’s regulatory ecosystem. We believe that effective regulation and ease of doing business must go hand in hand, with patient safety and quality remaining paramount.</span></p>
<p><span>We appreciate the DCGI for creating this forum for continuous stakeholder engagement and look forward to making these quarterly interactions meaningful and outcome-oriented.”</span></p>
<p><strong>Anil Matai, Director General, OPPI:</strong></p>
<p><span>“ OPPI warmly welcomes CDSCO’s initiative to institutionalize Quarterly Stakeholder Meetings under the chairmanship of the Drugs Controller General (India). Structured, recurring engagement of this kind strengthens the trust and transparency that must underpin India’s regulatory ecosystem. As the pharmaceutical industry continues to invest in research-driven and innovative therapies to meet evolving patient needs, a predictable and collaborative regulatory dialogue is essential — it allows industry to align emerging science with regulatory expectations early, rather than navigating them in isolation. We look forward to constructive discussions with CDSCO and believe this platform can meaningfully accelerate the translation of innovation into accessible healthcare solutions for patients across India.” </span></p>
<p>The post <a href="https://www.expresspharma.in/cdsco-to-hold-quarterly-stakeholder-meetings-to-discuss-regulatory-framework-and-procedures/">CDSCO to hold quarterly stakeholder meetings to discuss regulatory framework and procedures</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Power, politics and pharma</title>
<link>https://edusehat.com/en/power-politics-and-pharma</link>
<guid>https://edusehat.com/en/power-politics-and-pharma</guid>
<description><![CDATA[ 
In a world shaped by geopolitics, economic nationalism and heightened scrutiny on quality and resilience, India&#039;s next phase of growth will depend on trust, innovation and strategic agility 
The post Power, politics and pharma appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/08/06141340/EP_DigiMag_CS_Aug_2026_Ft_Image_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 06 Aug 2026 21:25:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Power, politics, and, pharma</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/08/06141340/EP_DigiMag_CS_Aug_2026_Ft_Image_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/08/06141340/EP_DigiMag_CS_Aug_2026_Ft_Image_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/06141340/EP_DigiMag_CS_Aug_2026_Ft_Image_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>On July 21, 2026, US President Donald Trump announced a three-phase tariff regime on generic medicines entering the US, with zero duty until August 2028, a 100 per cent tariff for the following year, and a 200 per cent tariff from 2029 onwards. The announcement sparked immediate concern across India’s pharma industry. Markets reacted swiftly, with stocks such as Dr Reddy’s and Cipla coming under pressure. SBI Research estimated that, with nearly 40 per cent of India’s pharma exports headed to the US, steep tariffs could dent sector earnings in FY26. Dr Reddy’s CEO Erez Israeli reminded investors that shifting generic manufacturing to the US was “a four-to-seven-year industrial undertaking,” not a quick fix. A day later, India’s External Affairs Minister S Jaishankar met US Secretary of State Marco Rubio in Manila as both countries worked towards an interim trade agreement. </span></p>
<p><span>But tariffs are only the trigger. Indian pharma is now operating in a world where geopolitics, trade policy, regulation and supply chain resilience are becoming as important as manufacturing capabilities. The question is no longer whether India can produce medicines at scale. It is whether it can remain competitive in an increasingly volatile global landscape. </span></p>
<p><span>This question formed the backdrop to two recent discussions organised by Express Pharma: the inaugural edition of its virtual thought leadership series, Pharma Frontlines, and a panel discussion on Geopolitics, Trade and Trust at the Chandigarh Pharma Summit. Bringing together industry association leaders, manufacturing heads, supply chain experts, quality professionals and regulatory specialists, the discussions explored how Indian pharma is responding to a rapidly changing global environment. While each conversation approached the issue from a different perspective, both pointed to the same conclusion: the industry’s future will depend not just on what it manufactures, but on how well it manages uncertainty. </span></p>
<p><img decoding="async" class="aligncenter size-full wp-image-459066" src="https://cdn.expresspharma.in/wp-content/uploads/2026/08/06141755/EP_DigiMag_CS_Aug_2026_Inside_Image_02_1000.jpg" alt="" width="1000" height="495" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/08/06141755/EP_DigiMag_CS_Aug_2026_Inside_Image_02_1000.jpg 1000w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/06141755/EP_DigiMag_CS_Aug_2026_Inside_Image_02_1000-300x149.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/06141755/EP_DigiMag_CS_Aug_2026_Inside_Image_02_1000-768x380.jpg 768w" sizes="(max-width: 1000px) 100vw, 1000px"></p>
<p><b>A trade weapon India has faced before </b></p>
<p><span>Pharma and geopolitics have always gone hand in hand, but India has often managed to transform challenges into opportunities. There are several cases in point. </span></p>
<p><span>In 2001, Cipla’s Yusuf Hamied changed the conversation around access to medicines. He offered a triple-antiretroviral cocktail to Médecins Sans Frontières for $350 per patient a year, compared to an originator price of more than $10,000. The move challenged the global patent system and helped shape the WTO’s Doha Declaration. More importantly, it established India as a trusted supplier of affordable medicines.</span></p>
<p><span>India reinforced that trust during the COVID-19 pandemic through the Vaccine Maitri initiative, launched in January 2021, supplying vaccine doses to 94 countries and two UN agencies. The initiative strengthened India’s reputation as a reliable manufacturing partner for the world.</span></p>
<p><span>Today’s challenge, however, is very different. In 2001 and again in 2021, India’s manufacturing strength helped expand access to medicines. Now, that same strength is being tested as countries seek to bring manufacturing closer to home. </span></p>
<p><span>Trade policies are shifting, regulations are becoming more complex, and supply chains are increasingly vulnerable to geopolitical shocks. </span></p>
<p><span>India can still manufacture at scale. But the next phase of growth will depend on how well the industry adapts to this new reality. </span></p>
<p><img decoding="async" class="aligncenter size-full wp-image-459067" src="https://cdn.expresspharma.in/wp-content/uploads/2026/08/06141807/EP_DigiMag_CS_Aug_2026_Inside_Image_01_1000.jpg" alt="" width="1000" height="510" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/08/06141807/EP_DigiMag_CS_Aug_2026_Inside_Image_01_1000.jpg 1000w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/06141807/EP_DigiMag_CS_Aug_2026_Inside_Image_01_1000-300x153.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/06141807/EP_DigiMag_CS_Aug_2026_Inside_Image_01_1000-768x392.jpg 768w" sizes="(max-width: 1000px) 100vw, 1000px"></p>
<p><b>Leadership in an era of uncertainty </b></p>
<p><span>Tariffs dominate the headlines, but industry leaders believe they are only one part of a much larger shift. The bigger question is not whether Indian pharma can absorb higher duties, but how it prepares for a world where trade rules, regulations and geopolitical priorities are constantly evolving.</span></p>
<p><span>For Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance (IPA), understanding the India-US pharma relationship is the starting point. </span></p>
<p><span>India exports over $12 billion worth of medicines to the US, accounting for nearly one-third of its pharma exports. Indian companies also supply almost half of the generic medicines used by American patients. This dependence, Jain says, is often overlooked. “There is a tremendous reliance on the generic drugs, because they ensure accessibility, affordability, and they have played a very important role to improve healthcare outcomes in the US.” </span></p>
<p><span>In other words, the relationship is not one-sided. While India depends on the US as its largest export market, the US healthcare system also depends heavily on Indian manufacturers to keep medicines affordable and accessible.</span></p>
<p><span>Jain also pointed out that Indian companies have not waited for policy changes to strengthen their US presence. Companies such as Sun Pharma, Zydus and Lupin already operate more than 40 manufacturing facilities across 12 US states, reflecting a long-term commitment to the market rather than a short-term response to tariffs. </span></p>
<p><span>Dr TS Parmar, Secretary General, Indian Drug Manufacturers Association (IDMA), widened the discussion beyond bilateral trade. Healthcare, he argues, cannot be viewed through the lens of one country alone. It is, as he describes it, “a composite partnership.” While governments may seek to bring manufacturing back home, globally integrated pharma supply chains cannot be rebuilt overnight. </span></p>
<p><span>For both Jain and Parmar, tariffs are only one part of the challenge. The more significant concern lies in the growing complexity of doing business across multiple regulatory jurisdictions. </span></p>
<p><span>Jain believes non-tariff barriers are likely to become a greater obstacle than tariffs themselves. Indian manufacturing sites continue to undergo separate inspections by regulators in the US, Europe, the UK and Africa, even though many of the requirements overlap. Greater regulatory convergence, he argues, would reduce duplication, lower costs and improve the efficiency of global supply chains. He says, “If there is a regulatory convergence, it would become very, very important.” </span></p>
<p><span>The discussion points to a broader shift in the industry’s priorities. Competitiveness is no longer determined solely by manufacturing efficiency or cost. It increasingly depends on a company’s ability to navigate a complex web of regulations, trade policies and international partnerships. For today’s pharma leaders, managing uncertainty is becoming as important as managing operations.</span></p>
<p><b>When geopolitics reaches the factory floor </b></p>
<p><span>Geopolitical events are now influencing day-to-day operations in ways that would have been difficult to imagine a few years ago. </span></p>
<p><span>Saurabh Sharma, GM-Supply Chain, Sentiss Pharma, describes the shift and says what was once a purely operational function has been pulled into the centre of business strategy. </span></p>
<p><span>He shares how the recent US-Iran conflict disrupted pharma logistics almost overnight. Air cargo operations through Dubai were affected for nearly two weeks, delaying temperature-controlled pharma shipments. He informs that their shipments were stuck for almost two weeks because the flights were not allowed and even a one-degree temperature excursion recorded by data loggers triggered a compliance investigation. </span></p>
<p><span>The experience fundamentally changed the way his company evaluates suppliers. He states, “Choosing the partner is also now becoming very critical.” </span></p>
<p><span>For Sharma, procurement is no longer about securing the lowest price. Companies are evaluating suppliers on the total cost of ownership. As he explains, “It comprises of many things like quality, cost, of course, one factor, then delivery is another factor. Then the compliance is what is the business continuity? What is the financial strength of the supplier?” Thus, compliance history, delivery reliability, financial stability and operational capability have become key metrics. </span></p>
<p><span>His experience reflects a wider transformation across the industry. Supply chains are no longer just sourcing and logistics functions. They have become vital for business continuity, regulatory compliance and an organisation’s ability to respond to disruption. In an era of geopolitical uncertainty, resilience has become as valuable as efficiency. </span></p>
<p><b>The business of being ready </b></p>
<p><span>The growing uncertainty in global trade is forcing pharma companies to make decisions faster than ever before. What once unfolded over months now demands action within days, often based on incomplete information and with significant financial implications.</span></p>
<p><span>Vishnu Mirge, AVP – Site Head, Sun Pharmaceutical Industries, offers a glimpse into how quickly companies now have to respond. Following the US announcement of a 100 per cent tariff on branded formulations, his team took the unusual decision to double production over three months by securing six months’ worth of input-material inventory instead of the usual three. </span></p>
<p><span>This was far more than an operational adjustment. It required rapid financial approvals, close supplier coordination and the confidence to invest ahead of demand. </span></p>
<p><span>For Mirge, the experience reinforced a simple lesson. “If you are agile enough to respond to that demand positively, then that is the success mantra.” </span></p>
<p><span>His example highlights that competitive advantage is no longer determined solely by manufacturing capacity or cost efficiency. Increasingly, it depends on how quickly organisations can assess risks, align cross-functional teams and respond to changing market conditions. </span></p>
<p><span>But responding quickly is only one part of the equation. As supply chains grow more complex and regulatory expectations continue to rise, companies are also rethinking how they approach quality and compliance.</span></p>
<p><span>It is in this context that Dr Sanjit Singh Lamba, Managing Partner, Trillyum Consulting, challenges the industry’s traditional approach to vendor qualification. He states, “We don’t need just a vendor qualification. We need something called continuous vendor verification (CVV). This is something I am driving more and more in companies, that they don’t treat vendor qualification as a paper exercise and then remain quiet for two to three years.” </span></p>
<p><span>His argument reflects a wider industry reality. Nearly 20 per cent of cold-chain pharma material is wasted every year, while first-timepass rates remain at around 80 per cent, Lamba pointed out. As biologics account for a growing share of the industry’s pipeline, these inefficiencies will become even more critical to address. </span></p>
<p><span>Addressing these challenges will require more than stronger processes alone. Technology has an increasingly important role to play but as an enabler rather than a substitute for robust quality systems. </span></p>
<p><span>Taken together, these perspectives reveal how leadership priorities are evolving. Companies are no longer preparing only for the next regulatory inspection or market opportunity. They are building organisations that can anticipate disruption, respond with speed and embed quality across every stage of manufacturing and supply chain operations. </span></p>
<p><b>Reducing dependence, building resilience </b></p>
<p><span>While companies are strengthening agility and quality systems, another strategic priority continues to dominate boardroom discussions, i.e. reducing dependence on China.</span></p>
<p><span>Progress is visible, but industry leaders agree that self-reliance remains a longterm journey rather than an immediate destination. Achieving it will require more than identifying alternate suppliers; it demands a systematic approach to qualification, risk management and long-term partnerships.</span></p>
<p><span>Ravi Bharadwaj, Corporate Quality Head, Ind Swift Laboratories, believes diversifying away from China is achievable, but only with discipline. He opines that successful diversification requires good planning and change management, with supplier qualification backed by comprehensive audits that evaluate suppliers’ capabilities and compliance levels. He cautions that supplier qualification cannot be treated as a one-time exercise, as a supplier that has successfully completed process validation and stability studies may later receive an FDA warning letter, forcing companies to start the qualification process all over again. </span></p>
<p><span>Moreover, supplier qualification is only one part of the challenge. The industry’s continued reliance on China for critical raw materials remains a structural vulnerability with far-reaching implications for cost and supply continuity.</span></p>
<p><span>Dr Saurabh Pandey, Cluster Lead-API ManufacturingToansa-Punjab, Sun Pharmaceutical Industries, points to the scale of the challenge and informs, “Currently, we have around 65 per cent to 70 per cent of the APIs getting imported from China based on the cost pricing. With the recent geopolitical changes, we have seen a 40 per cent increase in the pricing of drugs like paracetamol and azithromycin”. He notes the price shocks this dependence has already produced and cautions that prolonged reliance on a single source “will certainly set up a monopoly in the market, and any amount of instability in China will lead to disruptions, not only in the supplies, but to an increase in the pricing.” </span></p>
<p><img loading="lazy" decoding="async" class="aligncenter  wp-image-459068" src="https://cdn.expresspharma.in/wp-content/uploads/2026/08/06141942/EP_DigiMag_CS_Aug_2026_Inside_Image_03_1000.jpg" alt="" width="642" height="566" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/08/06141942/EP_DigiMag_CS_Aug_2026_Inside_Image_03_1000.jpg 1000w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/06141942/EP_DigiMag_CS_Aug_2026_Inside_Image_03_1000-300x265.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/06141942/EP_DigiMag_CS_Aug_2026_Inside_Image_03_1000-768x677.jpg 768w" sizes="auto, (max-width: 642px) 100vw, 642px"></p>
<p><b>Trust becomes the new currency </b></p>
<p><span>Yet resilience is not built through supply chain diversification alone. In an increasingly regulated global market, trust is as an equally key differentiator. </span></p>
<p><span>If cost and scale defined Indian pharma’s last decade, trust may define its next one, and that trust is often built or broken in the quality function.</span></p>
<p><span>As a result, the role of quality leaders are also being reshaped. Yogesh Sharma, Head-Quality & Compliance, Sun Pharmaceutical Industries, describes how the job itself has been redefined. Five years ago, quality was reactive, teams scrambled only when an inspection was announced, pulling together data to prove there was nothing non-compliant. He explains that today, quality leaders are now measured not only on compliance but also on their ability to act as business partners. Their KPIs reflect their contribution to business deliveries and organisational commitments because the cost of a lapse is no longer just a regulatory problem; it is a commercial one. </span></p>
<p><span>The shift is being reinforced by a regulatory landscape that is evolving just as rapidly. Dr Dr Pardeep Agnihotri, Sr GM – Corporate Regulatory Affairs, CEPH Lifesciences notes that global regulators have raised the bar considerably over the same period, pushing manufacturers toward “a sciencebased, risk-based, and datacentric approach.” He explains that companies are expected to adopt the ALCOA principles, strengthen data integrity and digitalisation, implement comprehensive contamination control strategies (CCS), and ensure facilities remain inspection-ready at all times rather than preparing only for scheduled audits. </span></p>
<p><span>While these expectations have become more demanding, they have also highlighted where India’s strengths and its challenges, lie. Agnihotri argues that India has built genuine strength in costcompetitive manufacturing, API exports, regulatory dossier preparation and CDMO services. At the same time, he points out that gaps remain in data integrity and compliance with evolving regulations. He underscores that quality excellence is an ongoing process, not a one-time milestone. </span></p>
<p><b>The road to 2030 </b></p>
<p><span>As the discussion turned from today’s challenges to tomorrow’s priorities, Prafulla Padhy, Head – Supply Chain Management, Fresenius Kabi Oncology, laid out a vision for where Indian pharma needs to go. He said the industry must move from volume-led manufacturing to innovation, supported by stronger intellectual property protection. He also highlighted the need to strengthen supply chain resilience through indigenous API and KSM manufacturing, improve end-to-end visibility across the supply chain, build quality and compliance so India is recognised as a trusted and reliable partner, adopt more sustainable practices, and make medicines more accessible by reaching tier II and tier III cities as well as rural areas. </span></p>
<p><span>“It’s time for India to move forward in its innovation journey,” he said, “and that’s possible only if we fortify each link in this pharma value chain.” </span></p>
<p><span>His vision brought together many of the themes that had emerged throughout the discussion. Whether it was building resilient supply chains, strengthening quality systems, embracing innovation or expanding access, the underlying message was clear. The pharma value chain is only as strong as its weakest link. </span></p>
<p><span>That is perhaps the defining challenge and opportunity for Indian pharma today. As global trade dynamics shift, the industry’s ability to anticipate change will matter more than ever. </span></p>
<p><span>Thus, success by 2030 will not be determined by how companies respond to disruption, but by how well they prepare for it.  </span></p>
<p> </p>
<p><em><strong>lakshmipriya.nair@expressindia.com</strong></em></p>
<p><em><strong>lakshmipriyanair@gmail.com</strong></em></p>
<p>
</p><p>The post <a href="https://www.expresspharma.in/power-politics-and-pharma/">Power, politics and pharma</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Alteogen signs $365m Hybrozyme licensing deal with pharma company</title>
<link>https://edusehat.com/en/alteogen-signs-365m-hybrozyme-licensing-deal-with-pharma-company</link>
<guid>https://edusehat.com/en/alteogen-signs-365m-hybrozyme-licensing-deal-with-pharma-company</guid>
<description><![CDATA[ The agreement involves access to ALT-B4 (berahyaluronidase alfa), a recombinant human hyaluronidase created with Alteogen’s Hybrozyme platform. This technology is intended to convert biologics typically given via intravenous 
The post Alteogen signs $365m Hybrozyme licensing deal with pharma company appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/08/PT-2-06-08-2026-shutterstock_2210207325.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 06 Aug 2026 17:50:48 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Alteogen, signs, 365m, Hybrozyme, licensing, deal, with, pharma, company</media:keywords>
<content:encoded><![CDATA[<p>The agreement involves access to ALT-B4 (berahyaluronidase alfa), a recombinant human hyaluronidase created with Alteogen’s Hybrozyme platform.</p>
<p>This technology is intended to convert biologics typically given via intravenous infusion into more convenient subcutaneous formulations.</p>
<p>Under the agreement, Alteogen is set to receive an upfront payment and could earn additional amounts through development, regulatory, and sales milestone payments.</p>
<p>The company will also receive royalties on net sales for any product commercialised using this technology.</p>
<p>Alteogen CEO Tae-Yon Chun said: “We are pleased to enter into this licence agreement with a global leader with a long-standing commitment to advancing innovative therapies for patients with serious unmet medical needs.</p>
<p>“We will continue to accelerate the growth of our platform technology through strategic global partnerships.”</p>
<p>ALT-B4, which is provided to the counterparty under the licence, allows biologics normally given intravenously to be converted into subcutaneous formulations.</p>
<p>The technology achieves this by temporarily breaking down hyaluronan in the extracellular matrix, which facilitates faster and more efficient absorption and dispersion of drugs administered together with ALT-B4.</p>
<p>Alteogen operates in the development and commercialisation of biologics, such as antibody-drug conjugates, biobetters, and biosimilars.</p>
<p>Its pipeline includes clinical-stage long-acting therapeutic proteins and next-generation antibody-drug conjugates that use its proprietary NexP-fusion and NexMab platform technologies.</p>
<p>Developed since Alteogen’s founding in 2008, its Hybrozyme technology enables subcutaneous delivery of medicines that are typically administered intravenously.</p>
<p>In March 2025, AstraZeneca entered an exclusive licence agreement with bio-platform company Alteogen, involving the latter’s hyaluronidase utilising Hybrozyme platform technology, ALT-B4, to develop subcutaneous formulations of several oncology assets.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/alteogen-365m-hybrozyme-licensing-deal/">Alteogen signs $365m Hybrozyme licensing deal with pharma company</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Schrödinger and BMS expand partnership to deploy AI for drug discovery</title>
<link>https://edusehat.com/en/schroedinger-and-bms-expand-partnership-to-deploy-ai-for-drug-discovery</link>
<guid>https://edusehat.com/en/schroedinger-and-bms-expand-partnership-to-deploy-ai-for-drug-discovery</guid>
<description><![CDATA[ This initiative builds on an established partnership between the two companies, under which BMS already utilises Schrödinger’s computational platform for drug discovery projects. The new arrangement will extend 
The post Schrödinger and BMS expand partnership to deploy AI for drug discovery appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/08/PT-06-08-2026-shutterstock_2242062077.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 06 Aug 2026 17:50:48 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Schrödinger, and, BMS, expand, partnership, deploy, for, drug, discovery</media:keywords>
<content:encoded><![CDATA[<p>This initiative builds on an established partnership between the two companies, under which BMS already utilises Schrödinger’s computational platform for drug discovery projects.</p>
<p>The new arrangement will extend the use of Schrödinger’s technologies, including Bunsen and the AI-driven synthesis planning platform RetroSynth, throughout BMS’s scientific teams.</p>
<p>The collaboration aims to enable the pharmaceutical company’s researchers to explore chemical space more extensively, prioritise molecular candidates with additional confidence, and support decision-making in the early stages of drug discovery.</p>
<p>Bunsen is an agentic AI co-scientist tailored to perform complex molecular discovery workflows by executing Schrödinger’s computational methods, conducting planning and interpretation tasks, and integrating with other research technologies.</p>
<p>Schrödinger platform chief scientific officer Robert Abel said: “BMS is a long-standing customer and collaborator, and they have been an industry leader in integrating computation into drug discovery.</p>
<p>“We are thrilled they are deploying Bunsen at a large scale. Adopting Bunsen and our computational platform at scale will empower a broader group of scientists to embrace a predict-first computational approach.”</p>
<p>BMS computational sciences vice-president Stephen Johnson said: “Over the past several years, AI has become a key enabler for our scientists, allowing them to scale their creativity and scientific expertise across our research organisation.</p>
<p>“Bunsen is another capability we are adding to that toolkit, one that allows our scientists to think differently about how physics-based tools can be used to navigate molecular design space and accelerate the discovery of innovative medicines for patients.”</p>
<p>Schrödinger reports that its software platform combines AI with physics-based simulation to support hypothesis evaluation and synthetic feasibility in molecular research.</p>
<p>Included in the expanded agreement, RetroSynth is described as enabling high-throughput evaluation of chemical synthesis pathways.</p>
<p>The company’s computational solutions are licensed by customers in the global pharmaceutical, biotechnology, industrial, and academic sectors.</p>
<p>Last month, BMS further established itself on the growing list of big pharma partners who are forging tight collaborations with big tech, as it deepens its collaborations with Nvidia to deploy an AI-enabled supercomputer that it claims is the “most powerful single-owned Nvidia infrastructure in life sciences”.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/schrodinger-bms-ai-drug-discovery/">Schrödinger and BMS expand partnership to deploy AI for drug discovery</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Gland Pharma, Neuland Laboratories enter long&#45;term CDMO partnership for sterile APIs</title>
<link>https://edusehat.com/en/gland-pharma-neuland-laboratories-enter-long-term-cdmo-partnership-for-sterile-apis</link>
<guid>https://edusehat.com/en/gland-pharma-neuland-laboratories-enter-long-term-cdmo-partnership-for-sterile-apis</guid>
<description><![CDATA[ 
The collaboration brings together Neuland’s API development capabilities and Gland Pharma’s sterile manufacturing expertise to support demand for sterile APIs used in microparticle depot products
The post Gland Pharma, Neuland Laboratories enter long-term CDMO partnership for sterile APIs appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/07/22171615/signing-agreement.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 06 Aug 2026 14:15:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Gland, Pharma, Neuland, Laboratories, enter, long-term, CDMO, partnership, for, sterile, APIs</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/07/22171615/signing-agreement.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/07/22171615/signing-agreement.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/07/22171615/signing-agreement-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Gland Pharma and Neuland Laboratories have announced a long-term strategic contract development and manufacturing organisation (CDMO) partnership to manufacture sterile active pharmaceutical ingredients (APIs) for microparticle depot products.</span></p>
<p><span>Under the partnership, Gland Pharma will establish a sterile manufacturing suite for APIs related to microparticle depot products. According to the companies, the collaboration combines Neuland’s complex API development and manufacturing capabilities, including expertise in complex chemistry, process development and custom manufacturing, with Gland Pharma’s sterile manufacturing capabilities and regulatory compliance to serve demand for sterile APIs used in microparticle depot products and other sterile APIs.</span></p>
<p><span>The companies stated that the collaboration expands their existing relationship by creating a manufacturing platform that aligns their capabilities under a long-term partnership. As part of the collaboration, Gland Pharma will expand its sterile manufacturing infrastructure by adding a dedicated suite at its JNPC facility in Visakhapatnam to support Neuland’s demand for sterile APIs.</span></p>
<p><span>According to the companies, the facility will be constructed and operated in compliance with cGMP, USFDA and European Union standards and will be supported by Gland Pharma’s aseptic manufacturing capabilities. Together, the companies will offer a CDMO solution covering development, scale-up, regulatory support and commercial manufacturing of sterile APIs.</span></p>
<p><span>The companies stated that the manufacturing suite will add approximately 1,400 kg of annual capacity, providing manufacturing flexibility across multiple sterile products while supporting future growth.</span></p>
<p><span>According to the companies, the partnership is expected to strengthen global supply by combining Neuland’s development and regulatory capabilities with Gland Pharma’s manufacturing infrastructure.</span></p>
<p><span>Commenting on the development, Srinivas Sadu, Executive Chairman, Gland Pharma, said, “We are pleased to further strengthen our collaboration with Neuland through this strategic partnership. This investment expands our capabilities in sterile API manufacturing and supports increasing customer demand. By leveraging the complementary strengths of both organizations, we will provide a robust and scalable CDMO solution backed by world-class quality, compliance and manufacturing excellence. We believe this partnership creates a strong foundation for sustainable growth and long-term value creation for our customers and both organizations.”</span></p>
<p><span>Saharsh Davuluri, CEO & MD, Neuland Laboratories, said, “Demand for sterile APIs continues to grow as pharmaceutical companies advance increasingly complex injectable therapies. Through this partnership with Gland Pharma, we are combining Neuland’s expertise in complex APIs with Gland’s proven sterile manufacturing capabilities to create a differentiated platform for global customers. Together, we are strengthening our ability to deliver the quality, reliability, and supply assurance that innovators and generic companies expect from their CDMO partners.”</span></p>
<p>The post <a href="https://www.expresspharma.in/gland-pharma-neuland-laboratories-enter-long-term-cdmo-partnership-for-sterile-apis/">Gland Pharma, Neuland Laboratories enter long-term CDMO partnership for sterile APIs</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>IPC recognised as WHO&#45;SEARN Regional Centre of Excellence in Pharmacovigilance</title>
<link>https://edusehat.com/en/ipc-recognised-as-who-searn-regional-centre-of-excellence-in-pharmacovigilance</link>
<guid>https://edusehat.com/en/ipc-recognised-as-who-searn-regional-centre-of-excellence-in-pharmacovigilance</guid>
<description><![CDATA[ 
 Recognition comes during IPC&#039;s participation in the 10th Anniversary Meeting of the South-East Asia Regulatory Network in Nepal
The post IPC recognised as WHO-SEARN Regional Centre of Excellence in Pharmacovigilance appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2019/02/20160339/pharmacovigilance3_85431.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 06 Aug 2026 14:15:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>IPC, recognised, WHO-SEARN, Regional, Centre, Excellence, Pharmacovigilance</media:keywords>
<content:encoded><![CDATA[<div><img width="600" height="403" src="https://cdn.expresspharma.in/wp-content/uploads/2019/02/20160339/pharmacovigilance3_85431.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2019/02/20160339/pharmacovigilance3_85431.jpg 600w, https://cdn.expresspharma.in/wp-content/uploads/2019/02/20160339/pharmacovigilance3_85431-300x202.jpg 300w" sizes="(max-width: 600px) 100vw, 600px"></div><p><span>The Indian Pharmacopoeia Commission (IPC), Ministry of Health & Family Welfare, Government of India, participated in the 10th Anniversary Meeting of the South-East Asia Regulatory Network (SEARN) held in Kathmandu, Nepal, on 4–5 August 2026.</span></p>
<p><span>The meeting brought together representatives of National Regulatory Authorities (NRAs), pharmacopoeias and international organisations from across the South-East Asia Region to mark a decade of regional collaboration and discuss measures to strengthen regulatory systems for ensuring the quality, safety and efficacy of medical products.</span></p>
<p><span>SEARN is a collaborative platform established by the World Health Organization (WHO) South-East Asia Regional Office (SEARO) to strengthen regulatory systems across Member States. Since its inception in 2016, the network has facilitated cooperation among National Regulatory Authorities through knowledge sharing, regulatory convergence, capacity building and reliance mechanisms. It operates through thematic working groups focusing on quality assurance, pharmacovigilance, clinical trials oversight, regulatory preparedness and medical device regulation to improve access to safe, effective and quality-assured medical products across the region.</span></p>
<p><span>The IPC delegation comprised Dr. V. Kalaiselvan, Secretary-cum-Scientific Director; Dr. Jai Prakash, Senior Principal Scientific Officer; Dr. Robin Kumar, Senior Principal Scientific Officer; and Mr. Arvind Kumar Sharma, Scientific Officer.</span></p>
<p><span>During the meeting, IPC highlighted India’s commitment to strengthening the drug regulatory system and promoting access to quality-assured medicines through internationally harmonised standards. The delegation presented IPC’s initiatives in the development and publication of the Indian Pharmacopoeia, the establishment of Indian Pharmacopoeia Reference Substances (IPRS) and Impurity Reference Standards (IMPRS), pharmacovigilance and materiovigilance activities under the Pharmacovigilance Programme of India (PvPI) and Materiovigilance Programme of India (MvPI), capacity-building programmes, and collaborative efforts with national and international stakeholders.</span></p>
<p><span>During the meeting, IPC was recognised as the WHO-SEARN Regional Centre of Excellence in Pharmacovigilance and the Technical Centre in Quality. According to IPC, the recognition acknowledges its contributions to strengthening pharmacovigilance systems, advancing pharmaceutical quality standards and supporting regulatory capacity building across the WHO South-East Asia Region. IPC stated that the designation reinforces its role in pharmacopoeial science and standards and supports collaboration, knowledge sharing and harmonisation among Member States.</span></p>
<p><span>The meeting also provided a platform for the exchange of scientific knowledge, regulatory experiences and discussions on pharmaceutical regulation, including quality assurance, safety, regulatory reliance, digital transformation and regional cooperation. IPC reaffirmed its commitment to supporting collaborative initiatives aimed at strengthening regulatory systems and improving public health outcomes across the South-East Asia Region.</span></p>
<p><span>According to IPC, its participation in the 10th Anniversary Meeting of SEARN, along with its designation as the Regional Centre of Excellence in Pharmacovigilance and Technical Centre in Quality, marks another step in India’s contribution to regional regulatory cooperation. The commission stated that it will continue supporting WHO-SEARN initiatives, regulatory systems and the availability of safe, effective and quality-assured medical products across the South-East Asia Region.</span></p>
<p>The post <a href="https://www.expresspharma.in/ipc-recognised-as-who-searn-regional-centre-of-excellence-in-pharmacovigilance/">IPC recognised as WHO-SEARN Regional Centre of Excellence in Pharmacovigilance</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Phylo and Chugai collaborate to deploy AI platform in drug discovery</title>
<link>https://edusehat.com/en/phylo-and-chugai-collaborate-to-deploy-ai-platform-in-drug-discovery</link>
<guid>https://edusehat.com/en/phylo-and-chugai-collaborate-to-deploy-ai-platform-in-drug-discovery</guid>
<description><![CDATA[ The move aims to address challenges in the sector where analytical work behind research decisions is often slow and dispersed, pushing scientists to use multiple disconnected tools and 
The post Phylo and Chugai collaborate to deploy AI platform in drug discovery appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/08/PT-05-08-2026-shutterstock_1884612508.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 05 Aug 2026 16:45:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Phylo, and, Chugai, collaborate, deploy, platform, drug, discovery</media:keywords>
<content:encoded><![CDATA[<p>The move aims to address challenges in the sector where analytical work behind research decisions is often slow and dispersed, pushing scientists to use multiple disconnected tools and datasets.</p>
<p>This fragmentation can lead to underutilisation of valuable biomedical data.</p>
<p>Under the agreement, Chugai scientists will use Biomni Lab to consolidate AI-driven capabilities and diverse biomedical resources in a single digital workspace.</p>
<p>This integration aims to enable researchers to interact with proprietary data within Chugai’s secure environment, generating new hypotheses and supporting decision-making throughout the drug discovery process.</p>
<p>The platform is expected to be applied across several areas of Chugai’s research, such as single-cell analysis, disease biology, human genetics and target evaluation.</p>
<p>Chugai biological technology department head Sohei Oyama said: “We are excited about the opportunity to work with Phylo and explore the capabilities of Biomni Lab in our research environment.</p>
<p>“As scientific data continues to grow in scale and complexity, scientists need tools designed for the unique challenges of drug discovery research and capable of connecting insights across diverse sources of knowledge.</p>
<p>“We believe Biomni Lab can help our scientists explore scientific questions more effectively and accelerate our drug discovery to create innovative medicines for patients.”</p>
<p>Phylo co-founder and CEO Kexin Huang said: “Our vision is to help biopharma become AI-native, and Biomni Lab is built to make that transition practical for discovery teams today. Chugai’s longstanding track record of R&D innovation makes it an ideal setting to demonstrate how agentic AI can accelerate breakthrough discovery.”</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/phylo-chugai-ai-platform-drug-discovery/">Phylo and Chugai collaborate to deploy AI platform in drug discovery</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>AsymBio to secure $184m to support growth in biologics manufacturing</title>
<link>https://edusehat.com/en/asymbio-to-secure-184m-to-support-growth-in-biologics-manufacturing</link>
<guid>https://edusehat.com/en/asymbio-to-secure-184m-to-support-growth-in-biologics-manufacturing</guid>
<description><![CDATA[ The funds will be used for AsymBio’s principal business operations and drive further expansion of its manufacturing capacity. Asymchem Group will contribute 1.05bn yuan while Hillhouse Qirui will 
The post AsymBio to secure $184m to support growth in biologics manufacturing appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/08/PT-2-05-08-2026-shutterstock_2693401783.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 05 Aug 2026 16:45:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>AsymBio, secure, 184m, support, growth, biologics, manufacturing</media:keywords>
<content:encoded><![CDATA[<p>The funds will be used for AsymBio’s principal business operations and drive further expansion of its manufacturing capacity.</p>
<p>Asymchem Group will contribute 1.05bn yuan while Hillhouse Qirui will invest 177m yuan.</p>
<p>Following the transaction, Asymchem Group’s shareholding in AsymBio is set to rise to 83.4965%.</p>
<p>Hillhouse Qirui’s investment is described as reflecting long-term confidence in both AsymBio and the wider biologics CDMO sector.</p>
<p>The financing round also brings together other unnamed investors and is said to align with Asymchem Group’s strategic approach of providing “one-stop, end-to-end CDMO” services.</p>
<p>The additional capital comes as AsymBio expands its research and development capabilities, good manufacturing practice (GMP) manufacturing lines, and high-containment facilities.</p>
<p>The company states that the new funding will be directed towards supporting the scaling of client programmes and increasing operational efficiency.</p>
<p>Financial results released by AsymBio indicate that the company generated 470m yuan in revenue during 2025, with revenue for the first quarter of 2026 exceeding 140m yuan.</p>
<p>AsymBio operates as a subsidiary of Asymchem Group and focuses on biopharmaceutical CDMO services, ranging from early-stage and process development to toxicology, clinical, and large-scale commercial manufacturing.</p>
<p>The group points to its experience in the production of antibody-drug conjugates (ADCs) and ongoing expansion into novel drug conjugates (NDCs) and various protein-based therapeutics.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/asymbio-growth-biologics-manufacturing/">AsymBio to secure $184m to support growth in biologics manufacturing</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Rx&#45;to&#45;OTC Is only the beginning: Why some brands grow and others don’t</title>
<link>https://edusehat.com/en/rx-to-otc-is-only-the-beginning-why-some-brands-grow-and-others-dont</link>
<guid>https://edusehat.com/en/rx-to-otc-is-only-the-beginning-why-some-brands-grow-and-others-dont</guid>
<description><![CDATA[ 
Vilas Hegade explains why commercial execution determines the success of Rx-to-OTC brands
The post Rx-to-OTC Is only the beginning: Why some brands grow and others don’t appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/08/05114313/EP_Vilas_Hegade_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 05 Aug 2026 16:45:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Rx-to-OTC, only, the, beginning:, Why, some, brands, grow, and, others, don’t</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/08/05114313/EP_Vilas_Hegade_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/08/05114313/EP_Vilas_Hegade_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/05114313/EP_Vilas_Hegade_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>When an Rx product gets approval to move into the OTC market, it’s often seen as a major achievement. And rightly so. Years of scientific work, regulatory effort and planning go into reaching that stage.</span></p>
<p><span>But from what I’ve seen over the years, that’s only the beginning.</span></p>
<p><span>Some brands make the transition and go on to become household names. Others struggle to build momentum, even though they have strong science behind them.</span></p>
<p><span>The difference usually isn’t the product itself.</span></p>
<p><span>It’s what the company does after the switch.</span></p>
<p><span>The real challenge is no longer regulatory. It’s commercial!</span></p>
<p><b>Why good products still struggle</b></p>
<p><span>Many organisations approach an Rx-to-OTC switch using the same thinking they use for prescription brands. That works only up to a point. </span></p>
<p><span>Once a product reaches consumers, the rules change.</span></p>
<p><span>Consumers don’t buy a product because they’ve read a clinical paper. They buy it because they understand what it does, they can find it easily and they trust it enough to choose it over other options.</span></p>
<p><span>This is where many promising brands lose momentum.</span></p>
<p><span>The product may be good. But if it isn’t easy to find, easy to understand or supported in the right places, consumers simply move on.</span></p>
<p><b>Four things successful brands usually get right</b></p>
<p><span>Over the years, I’ve noticed that brands which make a successful transition from Rx to OTC tend to focus on four areas.</span></p>
<ol>
<li><b> They speak the consumer’s language</b></li>
</ol>
<p><span>Healthcare professionals and consumers look at products differently.</span></p>
<p><span>Doctors want evidence.</span></p>
<p><span>Consumers want clarity.</span></p>
<p><span>They want to know what the product does, why it matters and whether they can trust it.</span></p>
<p><span>Simple communication often has a bigger impact than complicated scientific messaging.</span></p>
<ol start="2">
<li><b> They make the product easy to find</b></li>
</ol>
<p><span>Distribution is no longer just about reaching as many outlets as possible.</span></p>
<p><span>It’s about being available where consumers actually shop.</span></p>
<p><span>That includes neighbourhood pharmacies, modern trade, e-commerce and increasingly quick commerce.</span></p>
<p><span>If consumers can’t find the product when they need it, someone else’s brand usually wins.</span></p>
<ol start="3">
<li><b> They build a business, not just a launch</b></li>
</ol>
<p><span>Many companies put enormous effort into launch planning.</span></p>
<p><span>Far fewer keep improving after launch.</span></p>
<p><span>The brands that continue to grow are the ones that keep refining pricing, pack sizes, channel strategy, retail execution and consumer engagement.</span></p>
<p><span>Launching the product is only the first milestone.</span></p>
<p><span>Building the business takes much longer.</span></p>
<ol start="4">
<li><b> They bring everyone together</b></li>
</ol>
<p><span>An OTC business cannot be built by one function alone. Marketing, sales, medical, trade, supply chain and digital teams all have a role to play.</span></p>
<p><span>When these teams work towards the same objective, execution becomes faster and the consumer experience becomes stronger.</span></p>
<p><b>The market has changed</b></p>
<p><span>India’s self-care market is growing steadily. Consumers are becoming more aware of their health, looking for reliable information online and taking a more active role in managing everyday health conditions. At the same time, digital commerce and quick commerce are changing how people discover and buy OTC products. Companies now need to think beyond traditional pharmacy distribution if they want to stay relevant.</span></p>
<p><span>This is why an Rx-to-OTC strategy today looks very different from what it did even a few years ago. Success is no longer decided by one launch event.</span></p>
<p><span>It is built through hundreds of small commercial decisions made every day.</span></p>
<p><b>Three questions every leadership team should ask</b></p>
<p><span>Before approving the next Rx-to-OTC opportunity, I believe every leadership team should pause and ask three simple questions.</span></p>
<ul>
<li aria-level="1"><b>Are we launching an OTC product, or are we building an OTC brand?</b></li>
</ul>
<ul>
<li aria-level="1"><b>Does our distribution strategy reflect how consumers shop today?</b></li>
</ul>
<ul>
<li aria-level="1"><b>Are all our commercial teams working towards the same outcome, or are they still operating in silos?</b></li>
</ul>
<p><span>These questions don’t require complex answers. But they often reveal whether the organisation is truly ready for the journey ahead.</span></p>
<p><b>A final thought</b></p>
<p><span>An Rx-to-OTC switch creates an opportunity but doesn’t guarantee success.</span></p>
<p><span>The brands that grow are rarely those with only the strongest science. They are the ones that understand consumers better, make their products easier to access and keep improving long after the launch is over.</span></p>
<p><span>In the years ahead, I believe the biggest advantage won’t come from making more Rx-to-OTC switches but will come from building organisations that know how to turn those switches into brands people trust and choose again and again.</span></p>
<p>The post <a href="https://www.expresspharma.in/rx-to-otc-is-only-the-beginning-why-some-brands-grow-and-others-dont/">Rx-to-OTC Is only the beginning: Why some brands grow and others don’t</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Diversifying beyond the US market</title>
<link>https://edusehat.com/en/diversifying-beyond-the-us-market</link>
<guid>https://edusehat.com/en/diversifying-beyond-the-us-market</guid>
<description><![CDATA[ 
India&#039;s next export wave will not be won on tariff advantage alone; mutual recognition of standards and regulatory cooperation will play vital roles.
The post Diversifying beyond the US market appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/08/05135526/EP_EditorsNote_Aug_2026_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 05 Aug 2026 16:45:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Diversifying, beyond, the, market</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/08/05135526/EP_EditorsNote_Aug_2026_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/08/05135526/EP_EditorsNote_Aug_2026_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/05135526/EP_EditorsNote_Aug_2026_750-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>On July 21, US President Trump unleashed uncertainty on the tariff front once again. Generics exported to the US will have zero tariff until August 1, 2028, after which tariffs are proposed to increase to 100 per cent from August 2028 and 200 per cent from August 2029. However the two year interim period makes it seem like a negotiation tool. </span></p>
<p><span>As Bharat Celly, Equity Research Analyst at Equirus Securities points out, the proposal runs counter to the intent of the Hatch-Waxman framework, which was designed to reduce drug prices through greater generic competition. Imposing 100–200 per cent tariffs on imported generics could instead raise the cost of low-priced medicines and, in shortage-prone categories, increase the risk of supply disruptions rather than drive reshoring. </span></p>
<p><span>Param Desai, Research analyst – PL Capital points out that President Trump’s term ends in January 2029, while the major tariff impact begins from August 2028, so the eventual implementation remains uncertain if there is a change in administration. </span></p>
<p><span>An Ind-Ra analysis believes that the evolving tariff environment could accelerate consolidation across the generic pharma industry, strengthening the market position of larger and better-capitalised companies. As operating challenges increase, small generic companies may find it difficult to remain competitive due to weaker balance sheets, lower pricing flexibility, and limited ability to undertake significant greenfield investments in the US, particularly where investment paybacks remain unattractive. </span></p>
<p><span>The Ind-Ra report posits that tariff-driven disruptions could create opportunities for partnerships, acquisitions, and strategic investments. Distressed generic assets may become attractive acquisition targets, while Indian pharma companies could increasingly collaborate with US contract manufacturing organisations to establish domestic manufacturing capabilities in a capital efficient manner and meet local sourcing requirements where necessary. </span></p>
<p><span>India has already diversified beyond the US market, through numerous free trade agreements (FTAs). India’s FTA network now includes 15 agreements covering 27 countries, and counting. Though we still haven’t been able to make a trade deal with the US, which is the world’s biggest pharma market, 6Wresearch’s recently released India Export Attractiveness Tracker 2026 makes the point that India’s next export wave will not be won on tariff advantage alone — most of the frictionless doors (Japan, Egypt, Mexico) are already open, and most of the mature markets (US, China, UAE) are now regulatory contests rather than tariff contests. </span></p>
<p><span>For instance, the report points out that the US applies 213 regulatory measures whereas China applies 148 measures on medicines. Both large pharma export markets thus come with a dense regulatory architecture. </span></p>
<p><span>The playbook is therefore twofold: scale fast in the zero-tariff corridors while capacity is uncontested, and invest early in regulatory and standards compliance in the high-value, high-friction markets — because that is where the next $30.1 billion in untapped potential will actually be won.</span></p>
<p><span>According to 6Wresearch’s report, built on UN Comtrade data, generic medicines are the fourth anchor of India’s highest-value future export potential by 2031. Smartphones, polished diamonds, and refined petroleum, lead the list. </span></p>
<p><span>Pharma exports currently make up $39.45 billion, of which medicines make up 44.7 per cent. By 2031, the report projects that medicines alone carry export potential of $23.30 billion, led by the US ($8.67 billion), Switzerland ($3.15 billion), China ($1.81 billion), Japan ($1.45 billion) and Canada ($758.62 million). Human vaccines have an export potential of $209 billion. Within the exports to the US, medicines lead with 9.6 per cent share followed by smartphones (8.8 per cent). </span></p>
<p><span>The pharma sector could scale this to $66.81 billion, with the US alone accounting for $20.13 billion — nearly a third of the total — followed by China ($ 8.79B), Switzerland ($ 5.68B), Japan ($4.23B) and Brazil ($3.36B). </span></p>
<p><span>But the July 21 tariff announcement put this at risk. As the cover story in the August 2026 Express Pharma edition analyses, in a world shaped by geopolitics, economic nationalism and heightened scrutiny on quality and resilience, India’s next phase of growth will depend on trust, innovation and strategic agility. (See story, Power, politics and pharma). </span></p>
<p><span>India will have to work on deepening and expanding current FTAs to increase our export competitiveness. A key part of these measures is mutual recognition of standards and regulatory cooperation. The US tariffs could well be a blessing in disguise if we can look beyond the US and achieve these wins. </span></p>
<p>
</p><p><b>VIVEKA ROYCHOWDHURY, Editor </b></p>
<p><b><i>viveka.r@expressindia.com </i></b></p>
<p><b><i>viveka.roy3@gmail.com </i></b></p>
<p>The post <a href="https://www.expresspharma.in/diversifying-beyond-the-us-market/">Diversifying beyond the US market</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Ecobliss India CMD Chakravarthi AVPS receives Asia Business Leader Award</title>
<link>https://edusehat.com/en/ecobliss-india-cmd-chakravarthi-avps-receives-asia-business-leader-award</link>
<guid>https://edusehat.com/en/ecobliss-india-cmd-chakravarthi-avps-receives-asia-business-leader-award</guid>
<description><![CDATA[ 
Recognition acknowledges his contribution to advancing Indian pharmaceutical capabilities, patient-focused healthcare and pharmaceutical packaging on global platforms
The post Ecobliss India CMD Chakravarthi AVPS receives Asia Business Leader Award appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/08/05103544/EP_AVPS_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 05 Aug 2026 13:10:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Ecobliss, India, CMD, Chakravarthi, AVPS, receives, Asia, Business, Leader, Award</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/08/05103544/EP_AVPS_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/08/05103544/EP_AVPS_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/05103544/EP_AVPS_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Chakravarthi AVPS, Chairman and Managing Director, Ecobliss India Private Limited, has received the CMO Asia Business Leadership & Excellence Award in the category of Asia Business Leader of the Year – Indian Pharma for his contribution to advancing India’s pharmaceutical sector and patient-focused healthcare.</span></p>
<p><span>The award was presented at a ceremony held at the Pan Pacific Singapore on Tuesday evening. The annual recognition honours individuals contributing to industry development across the Asia-Pacific region.</span></p>
<p><span>Chakravarthi shared the recognition with Dr. Anne Phey, Founder & CEO, The School of Leadership; Rohit Gandhi, Group CEO, APAR Technologies Singapore; Munas van Boonstra, APAC Managing Director, TLC Worldwide; Charu Sethi, OpenRouter; and Dr. Tarita Shankar, Chairperson and President Designate, Indira University.</span></p>
<p><span>According to the formal citation, the award recognises Chakravarthi’s leadership in promoting Indian pharmaceutical capabilities on global platforms, patient-focused healthcare solutions, pharmaceutical packaging and international collaborations that support trust in Indian healthcare.</span></p>
<p><span>For more than 25 years, Chakravarthi has represented India at global healthcare, packaging and pharmaceutical conferences, highlighting the country’s focus on quality, innovation and affordable medicines. Under his leadership, Ecobliss India has expanded its presence in medication adherence packaging and patient-focused packaging designs aimed at reducing prescription errors and supporting patient outcomes.</span></p>
<p><span>Reflecting on the recognition, Chakravarthi dedicated the award to the Indian pharmaceutical community, stating that India’s role has expanded beyond manufacturing to becoming a global healthcare partner. He said that healthcare creates impact when treatment adherence is simplified and noted that packaging supports patient safety and health outcomes. He also emphasised that partnerships between governments, academia and industry remain important for advancing medical progress across countries.</span></p>
<p><span>Chakravarthi continues to engage with regulatory and industry organisations, including FOPE, FABA, Pharmexcil, IPA, CII, FTCCI, INBA, LSSSDC, WPO and IIP. Through these organisations, he continues to promote international collaborations and India’s manufacturing capabilities.</span></p>
<p><span>According to the company, the recognition comes as the Indian pharmaceutical sector continues to expand its global presence and strengthen its position in healthcare and patient solutions.</span></p>
<p>The post <a href="https://www.expresspharma.in/ecobliss-india-cmd-chakravarthi-avps-receives-asia-business-leader-award/">Ecobliss India CMD Chakravarthi AVPS receives Asia Business Leader Award</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>SCHOTT charts long&#45;term roadmap for Type I pharmaceutical glass with FIOLAX® Pro</title>
<link>https://edusehat.com/en/schott-charts-long-term-roadmap-for-type-i-pharmaceutical-glass-with-fiolax-pro</link>
<guid>https://edusehat.com/en/schott-charts-long-term-roadmap-for-type-i-pharmaceutical-glass-with-fiolax-pro</guid>
<description><![CDATA[ 
In an exclusive conversation with Sundeep Prabhu, Senior Vice President, Sales &amp; Marketing, SCHOTT India, discusses the evolving needs of the pharmaceutical industry, the role of FIOLAX® Pro in addressing future requirements, and what SCHOTT&#039;s long-term portfolio strategy means for pharmaceutical manufacturers in India
The post SCHOTT charts long-term roadmap for Type I pharmaceutical glass with FIOLAX® Pro appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/08/05105041/EP_Sundeep_Prabhu_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 05 Aug 2026 13:10:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>SCHOTT, charts, long-term, roadmap, for, Type, pharmaceutical, glass, with, FIOLAX®, Pro</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/08/05105041/EP_Sundeep_Prabhu_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/08/05105041/EP_Sundeep_Prabhu_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/05105041/EP_Sundeep_Prabhu_750-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><strong>1. <b>Pharmaceutical primary packaging is undergoing significant transformation globally. What trends are shaping the future of primary packaging materials?</b></strong></p>
<p><span>The pharmaceutical industry is experiencing a period of rapid change. Manufacturers today are expected to ensure the highest levels of patient safety while also improving manufacturing efficiency, meeting increasingly stringent regulatory requirements, and supporting sustainability goals.</span></p>
<p><span>As a result, pharmaceutical primary packaging materials are no longer viewed simply as components. They are becoming strategic enablers of product quality, operational excellence, regulatory compliance, and environmental responsibility. We see growing interest from pharmaceutical companies in solutions that can help them future-proof their operations while maintaining the highest quality standards.</span></p>
<p> </p>
<p><b>2. In its recent communication, SCHOTT highlighted FIOLAX® Pro as the future standard for Type I pharmaceutical glass tubing within its portfolio. What led SCHOTT to take this direction?</b></p>
<p><span>At SCHOTT, continuous innovation has always been part of our commitment to the pharmaceutical industry. As market requirements evolve, we continuously review and strengthen our portfolio to meet future pharmaceutical glass packaging needs.</span></p>
<p><span>FIOLAX® Pro glass tubing is developed to address three fundamental industry requirements – drug safety, manufacturing efficiency, and product carbon footprint reduction with its optional product line FIOLAX® Pro OCF. </span></p>
<p><span>The aim is to provide pharmaceutical companies with a future-ready glass solution that helps address both current and emerging expectations across the value chain.</span></p>
<p> </p>
<p><b>3. What makes FIOLAX® Pro different from conventional FIOLAX® clear?</b></p>
<p><span>FIOLAX® Pro combines advancements in material composition, manufacturing technology, and quality transparency.</span></p>
<p><span>From a safety perspective, it offers a future-proof glass composition with the absence of any heavy metals and supports easy compliance with ICH Q3D requirements. It is designed to deliver minimal drug-container interactions through superior extractables and leachables performance, constant glass composition, and consistently high hydrolytic resistance.</span></p>
<p><span>From an operational standpoint, it supports smooth machinability during converting and fill-finish processes through high cosmetic quality and precise dimensional accuracy. Moreover, the transformation temperature of FIOLAX® pro is quite identical to FIOLAX® clear minimising disruption and simplifying adoption.</span></p>
<p><span>Every product delivery is supported by a digital quality data package enabled by SCHOTT’s perfeXion® process, providing an unprecedented level of quality transparency. </span></p>
<p> </p>
<p><b>4. Sustainability is becoming increasingly important for pharmaceutical manufacturers. How does FIOLAX® Pro address this?</b></p>
<p><span>Sustainability is now a strategic priority for many pharmaceutical companies, and this extends to primary packaging materials and supply chains.</span> <span>In fact, nearly top 20 pharma companies have set strategic SBTi climate targets to reduce their carbon footprint drastically in the upcoming years.</span></p>
<p><span>SCHOTT support these ambitions, with the optional FIOLAX® Pro OCF product line, which will be available first quarter of 2027 with an approx. 50 per cent lower product carbon footprint*. This is enabled by a new electric melting tank technology, powered by 100 per cent of electricity in the production process covered by renewable energy Guarantees of Origin; natural gas is now only used in the separate refining unit and working tank part for technical reasons any longer.</span></p>
<p><span>We believe innovations like these can help pharmaceutical companies advance their sustainability commitments without compromising quality or performance.</span></p>
<p><span>*Calculation of greenhouse gas emissions from cradle-to-gate per kilogram of saleable glass tubing compared to the market average for borosilicate glass tubing [average value according to ecoinvent 3.10; glass tube production, borosilicate // DE. The value currently calculated is based on empirical values and simulation data]. Relevant information about the FIOLAX® Pro OCF product line and the electrical tank can be found in the implementation plan.</span></p>
<p> </p>
<p><b>5. Some pharmaceutical companies are asking how FIOLAX® Pro fits within SCHOTT’s broader FIOLAX® portfolio. Can you clarify</b><span>?</span></p>
<p><span>Certainly. We understand that the right material makes all the difference in pharmaceutical packaging. As industry requirements rise, SCHOTT remains dedicated to advancing innovation and maintaining quality leadership, ensuring we are prepared to meet both current and future needs. Because patient safety starts with us. </span></p>
<p><span>The journey of FIOLAX® Pro clearly demonstrates SCHOTT’s steadfast commitment. The introduction of FIOLAX® Pro does not alter SCHOTT’s commitment to supply reliably. Rather, it further develops our current portfolio and paves the way for the future of SCHOTT’s Type I glass portfolio.</span></p>
<p> </p>
<p><b>6. There is considerable discussion around FIOLAX® Pro in the market. Should pharmaceutical companies view this as a signal that they need to immediately transition away from packaging made out of FIOLAX® clear?</b></p>
<p><span>Not at all. The introduction of FIOLAX® Pro should be viewed as the next evolution step of SCHOTT’s portfolio and our continued commitment to innovation in pharmaceutical primary packaging.</span></p>
<p><span>FIOLAX® Pro is developed to address emerging industry priorities around drug safety, operational efficiency, quality transparency, and sustainability. </span></p>
<p><span>At the same time, FIOLAX® clear remains an established and trusted product used by pharmaceutical manufacturers around the world. </span></p>
<p><span>FIOLAX® Pro will be established as the new standard Type I clear glass for all pharmaceutical applications, gradually succeeding FIOLAX® clear in the long term. But we understand that the pharmaceutical industry operates within long product lifecycles, extensive qualification requirements, and is a highly regulated. Therefore, this evolution will be managed with utmost care and in close partnership with converters and pharmaceutical companies, ensuring sufficient time for qualification, regulatory alignment, and adaptation. Please be assured that this transition is designed to unfold over an extended, decade-scale period, ensuring a seamless and well-supported process that prioritises pharma community requirements and the highest industry standards.</span></p>
<p><span>During this time pharmaceutical companies can continue to rely on FIOLAX® clear with confidence. FIOLAX® clear will be available for years to come, and any transition to FIOLAX® Pro would naturally follow global adoption patterns and will occur gradually over an extended period.</span></p>
<p><span>Our message to the market is simple – pharmaceutical companies should choose the solution that best fits their business, regulatory requirements, and sustainability objectives. For those interested in the benefits offered by FIOLAX® Pro, SCHOTT is ready to support them with comprehensive material in our Technical Dossier now. For companies continuing with FIOLAX® clear, SCHOTT remains fully committed to ensuring reliable supply and long-term partnership.</span></p>
<p> </p>
<p><b>7. How should pharmaceutical companies approach FIOLAX® Pro today?</b></p>
<p><span>Like I already mentioned, FIOLAX® Pro should be viewed as an attractive option for companies that are looking to enhance safety, efficiency, or sustainability within their primary packaging strategy all given by a future-proof glass.</span></p>
<p><span>Every pharmaceutical company has unique technical, regulatory, and commercial requirements. Therefore, decisions regarding qualification and adoption should be driven by individual business needs and long-term plans.</span></p>
<p><span>Our role is to provide pharmaceutical companies with choices on the right basic glass material, technical support by knowledge sharing, and all information necessary to make the best decision for their product needs. We encourage pharmaceutical companies to use the coming years to evaluate FIOLAX® Pro and to define individual qualification and implementation roadmaps. SCHOTT tubing will be happy to extend its support to the pharmaceutical companies, at all times.</span></p>
<p> </p>
<p><b>8. What assurance would you like to give pharmaceutical manufacturers in India or what would be the key take aways from this discussion?</b></p>
<p><span>India is one of the fastest growing pharmaceutical markets globally, and we see increasing interest from Indian pharmaceutical manufacturers in advanced patient care solution such as biosimilars like GLPs, ADCs, etc across pharmaceutical container formats.</span></p>
<p><span>As companies evaluate how to meet rising expectations around product quality, operational performance, regulatory compliance, and sustainability, FIOLAX® Pro pharmaceutical glass offers a compelling path forward. </span></p>
<p><span>I would say that the market should see FIOLAX® Pro as an opportunity. It is a future-oriented solution for companies seeking additional benefits in areas such as safety, efficiency and product carbon footprint reduction. </span></p>
<p><span>Our commitment is to provide all partners along the pharma value chain with reliable supply, clear communication and access to the best technologies available, today and in the future.</span></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/schott-charts-long-term-roadmap-for-type-i-pharmaceutical-glass-with-fiolax-pro/">SCHOTT charts long-term roadmap for Type I pharmaceutical glass with FIOLAX® Pro</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Zydus receives USFDA approval for generic Indocyanine Green for Injection</title>
<link>https://edusehat.com/en/zydus-receives-usfda-approval-for-generic-indocyanine-green-for-injection</link>
<guid>https://edusehat.com/en/zydus-receives-usfda-approval-for-generic-indocyanine-green-for-injection</guid>
<description><![CDATA[ 
Dr Sharvil Patel says the approval expands Zydus’ portfolio of injectable and imaging products and supports its focus on functional dyes and imaging agents
The post Zydus receives USFDA approval for generic Indocyanine Green for Injection appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 05 Aug 2026 13:10:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Zydus, receives, USFDA, approval, for, generic, Indocyanine, Green, for, Injection</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Indocyanine Green for Injection, USP, 25 mg/vial, a sterile lyophilised powder for reconstitution.</span></p>
<p><span>The company stated that Indocyanine Green for Injection is the generic equivalent of the reference listed drug (RLD), IC-Green by Diagnostic Green LLC. The USFDA has designated the application as a Competitive Generic Therapy (CGT). According to the company, eligibility for the 180-day exclusivity available to certain competitive generic therapies is determined by the USFDA and, where applicable, the period begins from the date of first commercial marketing.</span></p>
<p><span>According to Zydus, Indocyanine Green for Injection is an optical imaging agent indicated for fluorescence imaging of vessels, blood flow and tissue perfusion before, during and after vascular, gastrointestinal, organ transplant, plastic, micro and reconstructive surgeries, including general minimally invasive surgical procedures. It is also indicated for fluorescence imaging of extrahepatic biliary ducts, fluorescence imaging of lymph nodes and lymphatic vessels during lymphatic mapping in adults with cervical and uterine cancer, and ophthalmic angiography. The product is indicated for use in adults and, for certain indications, in paediatric patients aged one month and older.</span></p>
<p><span>The product will be manufactured at the group’s USFDA-approved injectable manufacturing facility at Jarod, near Vadodara, Gujarat, and will be marketed in the United States by Zydus Pharmaceuticals (USA).</span></p>
<p><span>Commenting on the development, Dr. Sharvil Patel, Managing Director, Zydus Lifesciences, said, “Indocyanine green sits at the intersection of medicine and imaging science, requiring precise control of chromophore purity, photostability and lyophilisation. Developing and securing approval for such a complex product with our partner reflects the capabilities we have built and our shared commitment to high standards. It also advances our goal of making essential medicines and diagnostics more accessible, while strengthening our presence in the functional dye and imaging agent segment, where we continue to invest.”</span></p>
<p><span>According to the company, the approval adds to its portfolio of injectable and imaging products and reflects a development model combining internal formulation and analytical capabilities with an external partner selected for the programme. Zydus added that it continues to invest in the functional dye and imaging agent segment.</span></p>
<p><span>The product will be supplied as a kit containing single-patient-use vials of Indocyanine Green for Injection, 25 mg, as a sterile lyophilised green powder for reconstitution, together with single-dose vials of Sterile Water for Injection, 10 ml.</span></p>
<p><span>According to IQVIA MAT June 2026 data cited by the company, the reference product recorded annual sales of approximately USD 125.8 million in the United States, reflecting growth of 61.0 per cent, with volumes of 0.64 million units, reflecting growth of 27.1 per cent.</span></p>
<p><span>The company stated that it now has 445 approvals and has filed 513 ANDAs with the USFDA as of 30 June 2026.</span></p>
<p>The post <a href="https://www.expresspharma.in/zydus-receives-usfda-approval-for-generic-indocyanine-green-for-injection/">Zydus receives USFDA approval for generic Indocyanine Green for Injection</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Howden India develops Cancer Care Group Policy; AstraZeneca India adopts cover for employees</title>
<link>https://edusehat.com/en/howden-india-develops-cancer-care-group-policy-astrazeneca-india-adopts-cover-for-employees</link>
<guid>https://edusehat.com/en/howden-india-develops-cancer-care-group-policy-astrazeneca-india-adopts-cover-for-employees</guid>
<description><![CDATA[ 
Amit Agarwal explains how Howden India developed a cancer care policy for employers, while AstraZeneca India integrates it into its employee health benefits
The post Howden India develops Cancer Care Group Policy; AstraZeneca India adopts cover for employees appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/05/04131504/handshake.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 04 Aug 2026 22:40:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Howden, India, develops, Cancer, Care, Group, Policy, AstraZeneca, India, adopts, cover, for, employees</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/05/04131504/handshake.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/05/04131504/handshake.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/05/04131504/handshake-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Howden Insurance Brokers India has developed a Cancer Care Group Policy for employee health protection in India. AstraZeneca India has integrated the policy into its employee well-being programme to provide health benefits that extend beyond conventional insurance coverage.</span></p>
<p><span>According to Howden India, its market assessment found that dedicated group cancer insurance solutions remain largely unavailable, with insurers citing concerns around incidence risk, pricing uncertainty and limited actuarial data.</span></p>
<p><span>The company stated that while the burden of cancer has been recognised, developing an insurance model has remained a challenge because of the condition’s treatment costs and duration. Through collaboration with select insurers, Howden India developed a cancer care group policy that can serve as a model for employer-sponsored, disease-specific insurance solutions in India.</span></p>
<p><span>According to the company, the policy has been designed to make cancer protection more accessible. It stated that as cancer treatment often extends beyond standard hospitalisation timelines, the policy provides dedicated coverage for prolonged treatment pathways, including emerging therapies and oral medications.</span></p>
<p><span>The policy offers sum insured options ranging from ₹15 lakh to ₹30 lakh, with family coverage including parents. It also covers all existing cancer-related claims without a waiting period and includes extended pre- and post-hospitalisation benefits, along with integration with existing Mediclaim policies.</span></p>
<p><span>Commenting on the development, Amit Agarwal, MD & CEO, Howden India, said, “Innovation in insurance is not about creating more products; it is about solving problems that matter. By developing a dedicated cancer care solution, we have shown that complex health risks can be addressed through collaboration, creativity and a willingness to challenge traditional approaches to employee benefits.”</span></p>
<p><span>Praveen Rao Akkinepally, Country President & Managing Director, AstraZeneca India, said, “At AstraZeneca, we are driven by a purpose to transform care, and improving access to life-saving therapies is fundamental to realising that. Health insurance is a critical enabler of equitable healthcare access, particularly in addressing the growing burden of serious illnesses, including cancer. As we continue to advocate for inclusive healthcare in India, we believe meaningful change must begin at home. We are proud to introduce AstraZeneca Cancer Care Cover for our employees and their dependents and hope this starts a broader conversation about redefining employee well-being in today’s context and inspires an innovative and progressive approach to healthcare access across the country.”</span></p>
<p><span>According to Howden India, the Cancer Care Group Policy reflects the company’s focus on developing need-based insurance solutions for corporate clients. The company stated that it will continue working with insurers and employers to expand access to disease-specific coverage models that address healthcare priorities across the Indian workforce.</span></p>
<p>The post <a href="https://www.expresspharma.in/howden-india-develops-cancer-care-group-policy-astrazeneca-india-adopts-cover-for-employees/">Howden India develops Cancer Care Group Policy; AstraZeneca India adopts cover for employees</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Fermenta Biotech lists equity shares on NSE</title>
<link>https://edusehat.com/en/fermenta-biotech-lists-equity-shares-on-nse</link>
<guid>https://edusehat.com/en/fermenta-biotech-lists-equity-shares-on-nse</guid>
<description><![CDATA[ 
Prashant Nagre says the NSE listing strengthens Fermenta’s capital market presence and shareholder engagement
The post Fermenta Biotech lists equity shares on NSE appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/08/04155947/EH_Fermenta_Biotech_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 04 Aug 2026 22:40:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Fermenta, Biotech, lists, equity, shares, NSE</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/08/04155947/EH_Fermenta_Biotech_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/08/04155947/EH_Fermenta_Biotech_750.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/04155947/EH_Fermenta_Biotech_750-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>Fermenta Biotech has announced the listing of its equity shares on the National Stock Exchange of India (NSE).</span></p>
<p><span>Effective 4 August 2026, the company’s 2,94,30,987 equity shares, with a face value of ₹5 each, have been listed and admitted to dealings on the NSE under the symbol </span>FERMENTA and ISIN INE225B01021<span>. The company’s equity shares will continue to remain listed on the BSE under Scrip Code 506414.</span></p>
<p><span>The listing was marked with a bell-ringing ceremony at the NSE’s Exchange Plaza office in Mumbai’s Bandra Kurla Complex. Representatives from the NSE, Fermenta’s Board, senior leadership team and other stakeholders attended the event.</span></p>
<p><span>According to the company, the listing comes during its 75th year. Founded in 1951 and listed on the BSE since 1977, Fermenta has expanded from its pharmaceutical and biotechnology operations to manufacturing Vitamin D3 API, nutritional ingredients, green chemistry products, APIs and customised food premixes. The company serves customers in more than 60 countries.</span></p>
<p><span>Fermenta stated that the NSE listing reflects its growth, expanding customer base and investor interest. According to the company, the listing provides access to shareholders and market participants across both Indian stock exchanges, supporting broader participation, visibility and price discovery.</span></p>
<p><span>Commenting on the development, Prashant Nagre, Managing Director, Fermenta Biotech, said;</span><span>“Fermenta’s listing on the NSE represents a significant milestone in a landmark year for the Company, as we commemorate 75 years of Fermenta and nearly five decades as a publicly listed enterprise, alongside important recognitions in food safety and workplace culture. It reflects a journey shaped by resilience and a path forward defined by innovation, scale and focus. We will continue to enhance our capabilities across nutrition, food fortification, green chemistry and specialised solutions.</span></p>
<p><span>The NSE listing further strengthens our capital-market presence and reaffirms our commitment to transparency, responsible governance and consistent engagement with shareholders. We extend our sincere appreciation to our promoters, Board, shareholders, employees, customers, partners and all other stakeholders for their continued confidence in Fermenta.”</span></p>
<p>The post <a href="https://www.expresspharma.in/fermenta-biotech-lists-equity-shares-on-nse/">Fermenta Biotech lists equity shares on NSE</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Curium to acquire Lantheus in all&#45;cash deal worth up to $8bn</title>
<link>https://edusehat.com/en/curium-to-acquire-lantheus-in-all-cash-deal-worth-up-to-8bn</link>
<guid>https://edusehat.com/en/curium-to-acquire-lantheus-in-all-cash-deal-worth-up-to-8bn</guid>
<description><![CDATA[ The deal will take the Nasdaq-listed Lantheus private. Under the agreement, Curium US will purchase all outstanding shares of Lantheus for $102.50 per share upon closing. Lantheus’ shareholders 
The post Curium to acquire Lantheus in all-cash deal worth up to $8bn appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/08/PT-04-08-2026-shutterstock_329959169.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 04 Aug 2026 19:05:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Curium, acquire, Lantheus, all-cash, deal, worth, 8bn</media:keywords>
<content:encoded><![CDATA[<p>The deal will take the Nasdaq-listed Lantheus private.</p>
<p>Under the agreement, Curium US will purchase all outstanding shares of Lantheus for $102.50 per share upon closing.</p>
<p>Lantheus’ shareholders are also set to receive non-transferable contingent value rights (CVRs) that could provide up to an additional $12.00 per share if certain commercial milestones for the company’s product portfolio are met by 2030. This brings the potential total consideration per share to $114.50.</p>
<p>The offer represents a 38% premium to Lantheus’ 60-day volume-weighted average price, a 29% premium to its 30-day average. It is also 21% above the company’s closing price as of 21 May 2026, the last day before media reports emerged about the potential sale.</p>
<p>The proposed transaction has received unanimous approval from Lantheus’ Board of Directors.</p>
<p>Lantheus executive chair and CEO Mary Anne Heino said: “We believe this transaction is the ultimate validation of what the Lantheus team has built over seven decades of innovation in radiopharmaceuticals.</p>
<p>“Combining strategically with Curium brings together two pioneers with complementary strengths and a shared passion for nuclear medicine. Together, we can broaden and accelerate patient access to life-changing diagnostics and therapeutics and fully realise the differentiated outcomes and value radiopharmaceuticals can deliver.”</p>
<p>If approved and finalised, the new combined entity would operate across oncology, neurology, and cardiology in more than 70 countries. It will integrate Curium’s theranostics capabilities and global manufacturing operations with Lantheus’ US-based radiodiagnostics business.</p>
<p>Curium CEO Renaud Dehareng said: “Lantheus is the ideal partner to accelerate what we have been building at Curium. We have executed a strategy to build an innovative, theragnostic platform by expanding our global manufacturing footprint, advancing our radioligand therapy pipeline across key regions, and positioning Curium to drive the next generation of theragnostic innovation.</p>
<p>“Lantheus’ complementary business accelerates our strategy with a robust US commercial infrastructure, a complementary F18-isotope based prostate diagnostics franchise and marks our entry in the US market for diagnostic solutions targeting Neurology and Echocardiography.</p>
<p>“Together, we will provide meaningful theragnostic options to patients from SPECT and PET diagnostics to targeted radioligand therapy across the globe. This combination unlocks an opportunity that neither company could achieve alone, as it positions us to reach significantly more patients and clinicians globally.”</p>
<p>The transaction will be financed through a mix of debt and equity, with no financial conditions attached. The companies expect the merger to close in the first half of 2027, subject to regulatory and Lantheus’ shareholder approvals.</p>
<p>Until then, Lantheus will continue to operate as an independent, publicly listed company.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/curium-to-buy-lantheus-8bn/">Curium to acquire Lantheus in all-cash deal worth up to $8bn</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>FDA grants breakthrough therapy designation to Lilly’s olomorasib</title>
<link>https://edusehat.com/en/fda-grants-breakthrough-therapy-designation-to-lillys-olomorasib</link>
<guid>https://edusehat.com/en/fda-grants-breakthrough-therapy-designation-to-lillys-olomorasib</guid>
<description><![CDATA[ The designation is specifically for patients whose tumours demonstrate a KRAS G12C mutation confirmed by an FDA-approved test and covers olomorasib administered as a monotherapy. Olomorasib (LY3537982) is 
The post FDA grants breakthrough therapy designation to Lilly’s olomorasib appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/08/PT-2-04-08-2026-shutterstock_2022905333.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 04 Aug 2026 19:05:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>FDA, grants, breakthrough, therapy, designation, Lilly’s, olomorasib</media:keywords>
<content:encoded><![CDATA[<p>The designation is specifically for patients whose tumours demonstrate a KRAS G12C mutation confirmed by an FDA-approved test and covers olomorasib administered as a monotherapy.</p>
<p>Olomorasib (LY3537982) is an investigational inhibitor targeting the KRAS G12C protein and belongs to a class of next-generation therapies under study for various solid tumours.</p>
<p>This marks the second breakthrough therapy designation the experimental drug has received from the US regulator.</p>
<p>In September 2025, the FDA designated olomorasib in combination with Keytruda (pembrolizumab) for the first-line treatment of metastatic or locally advanced non-small cell lung cancer (NSCLC) in patients testing positive for KRAS G12C mutations and a PD-L1 expression of 50% or higher.</p>
<p>Both designations require molecular confirmation through FDA-recognised testing methods.</p>
<p>Breakthrough therapy status is granted to drug candidates that show initial clinical evidence of significant benefits over existing therapies in the treatment of serious conditions.</p>
<p>The FDA’s latest decision for olomorasib was based on preliminary findings from the open-label, multicentre, Phase I/II LOXO-RAS-20001 trial.</p>
<p>This study is assessing safety, tolerability, and early signs of efficacy in people with KRAS G12C-mutant advanced solid tumours, including advanced pancreatic cancers previously exposed to systemic treatment.</p>
<p>Lilly executive vice-president and oncology president Jacob Van Naarden  said: “Pancreatic cancer has historically been one of the most difficult-to-treat cancers and people whose tumours harbour a KRAS G12C mutation face limited options once their disease progresses. This breakthrough therapy designation reflects the early potential we’re seeing with olomorasib in this setting and the critical need for new treatment options.</p>
<p>“With now two breakthrough therapy designations across pancreatic and lung cancers, olomorasib continues to demonstrate broad potential clinical evidence across KRAS G12C-driven tumours and reflects our commitment to bringing meaningful new treatment options to patients living with these cancers.”</p>
<p>LOXO-RAS-20001 includes both a Phase Ia dose escalation stage for monotherapy and a Phase Ib expansion phase looking at olomorasib alone and in combination with other treatments.</p>
<p>According to Lilly, KRAS mutations account for the majority of RAS-associated cancers in humans and appear in 90% of pancreatic cancers, with the G12C subtype estimated in 1% to 2% of patients with this disease.</p>
<p>Recently, Lilly expanded its partnership with Resilience by investing in Ohio-based pharmaceutical manufacturing to boost US production of critical medicines.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/fda-designation-lillys-olomorasib/">FDA grants breakthrough therapy designation to Lilly’s olomorasib</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Dr Reddy’s registers PD&#45;1 inhibitor for recurrent or metastatic nasopharyngeal carcinoma in South Africa</title>
<link>https://edusehat.com/en/dr-reddys-registers-pd-1-inhibitor-for-recurrent-or-metastatic-nasopharyngeal-carcinoma-in-south-africa</link>
<guid>https://edusehat.com/en/dr-reddys-registers-pd-1-inhibitor-for-recurrent-or-metastatic-nasopharyngeal-carcinoma-in-south-africa</guid>
<description><![CDATA[ 
Dr Rashem Mothilal explains how the registration aims to expand access to immunotherapy for patients with recurrent or metastatic nasopharyngeal carcinoma
The post Dr Reddy’s registers PD-1 inhibitor for recurrent or metastatic nasopharyngeal carcinoma in South Africa appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2018/11/20154710/cancer-ThinkstockPhotos-490575333-e1545048577610.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 04 Aug 2026 11:50:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Reddy’s, registers, PD-1, inhibitor, for, recurrent, metastatic, nasopharyngeal, carcinoma, South, Africa</media:keywords>
<content:encoded><![CDATA[<div><img width="600" height="354" src="https://cdn.expresspharma.in/wp-content/uploads/2018/11/20154710/cancer-ThinkstockPhotos-490575333-e1545048577610.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2018/11/20154710/cancer-ThinkstockPhotos-490575333-e1545048577610.jpg 600w, https://cdn.expresspharma.in/wp-content/uploads/2018/11/20154710/cancer-ThinkstockPhotos-490575333-e1545048577610-300x177.jpg 300w" sizes="(max-width: 600px) 100vw, 600px"></div><p><span>According to the Cancer Association of South Africa (CANSA), one in four South Africans will be diagnosed with cancer during their lifetime. While awareness campaigns have helped people recognise the warning signs of breast, prostate and lung cancer, hundreds of rare cancers continue to go largely unnoticed because their symptoms resemble illnesses that people experience without a second thought.</span></p>
<p><span>Addressing an unmet need in oncology care, Dr. Reddy’s Laboratories South Africa has announced the registration of a PD-1 inhibitor for the treatment of recurrent or metastatic nasopharyngeal carcinoma (RM-NPC), a form of head and neck cancer. The registration aims to expand access to cancer treatments for patients living with the disease.</span></p>
<p><span>Unlike chemotherapy, which works by killing rapidly dividing cancer cells and can also affect healthy fast-growing cells such as those in the bone marrow, digestive tract and hair follicles, immunotherapy helps the body’s immune system recognise and fight cancer. It is a form of biological therapy that harnesses the immune system rather than directly attacking cancer cells. According to the company, immunotherapy has changed the treatment landscape for several cancers and has expanded treatment options for patients with certain advanced or difficult-to-treat cancers.</span></p>
<p><span>The World Health Organisation estimates that there are more than 500 rare cancers, many of which receive little public attention. Among them is nasopharyngeal carcinoma (NPC), a form of head and neck cancer in South Africa.</span></p>
<p><span>According to the 2024 </span><i><span>South African Journal of Oncology</span></i><span>, which references GLOBOCAN 2020 data from the International Agency for Research on Cancer (IARC), the disease has a five-year prevalence of 0.88 cases per 100,000 people in South Africa. NPC is frequently diagnosed at an advanced stage, creating challenges for treatment and long-term disease management.</span></p>
<p><span>Despite advances in cancer treatment over the past decade, innovation for recurrent or metastatic nasopharyngeal carcinoma has remained limited, highlighting an unmet need for new therapies.</span></p>
<p><span>“Every cancer patient deserves access to innovative treatment options, regardless of how rare their diagnosis may be,” says Dr. Rashem Mothilal, General Manager, Dr. Reddy’s Laboratories South Africa. “The registration of this immunotherapy represents an important step forward for patients living with recurrent or metastatic nasopharyngeal carcinoma and reflects our commitment to expanding access to advanced oncology treatments in South Africa.”</span></p>
<p><span>Nasopharyngeal carcinoma develops in the tissue behind the nose and above the back of the throat. Early symptoms include persistent nasal congestion, hearing loss, recurrent ear infections and swollen lymph nodes in the neck. These symptoms can be mistaken for other conditions, delaying diagnosis until the disease has reached an advanced stage.</span></p>
<p><span>According to the company, the registration forms part of Dr. Reddy’s broader mission to expand access to cancer therapies and improve outcomes for patients with complex and underserved diseases. It stated that, as cancer care continues to evolve through immunotherapy and precision medicine, access to these innovations remains important in addressing treatment gaps.</span></p>
<p><span>Dr. Reddy’s Laboratories stated that persistent nasal congestion, repeated ear infections, unexplained hearing loss, frequent nosebleeds or swelling in the neck should not be ignored if they continue, worsen or keep returning. While these symptoms are often caused by common conditions, the company encouraged anyone experiencing persistent or unexplained symptoms to consult a healthcare professional. It added that early diagnosis remains one of the most important factors in improving treatment options and outcomes for patients living with nasopharyngeal carcinoma.</span></p>
<p><span>The company stated that access to new treatment options can offer patients living with recurrent or metastatic nasopharyngeal carcinoma improved treatment options and outcomes. It added that expanding access to therapies and promoting awareness of rare cancers can help ensure that patients are not overlooked because of the rarity of their diagnosis.</span></p>
<p>The post <a href="https://www.expresspharma.in/dr-reddys-registers-pd-1-inhibitor-for-recurrent-or-metastatic-nasopharyngeal-carcinoma-in-south-africa/">Dr Reddy’s registers PD-1 inhibitor for recurrent or metastatic nasopharyngeal carcinoma in South Africa</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>IMPACT Therapeutics grants Pharmanovia exclusive $488m rights to senaparib</title>
<link>https://edusehat.com/en/impact-therapeutics-grants-pharmanovia-exclusive-488m-rights-to-senaparib</link>
<guid>https://edusehat.com/en/impact-therapeutics-grants-pharmanovia-exclusive-488m-rights-to-senaparib</guid>
<description><![CDATA[ The agreement covers the use of senaparib as a maintenance monotherapy for adult patients with advanced epithelial high-grade ovarian, fallopian tube, and primary peritoneal cancer. Under the agreement, 
The post IMPACT Therapeutics grants Pharmanovia exclusive $488m rights to senaparib appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/08/PT-2-03-08-2026-shutterstock_2271481515.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 03 Aug 2026 17:40:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>IMPACT, Therapeutics, grants, Pharmanovia, exclusive, 488m, rights, senaparib</media:keywords>
<content:encoded><![CDATA[<p>The agreement covers the use of senaparib as a maintenance monotherapy for adult patients with advanced epithelial high-grade ovarian, fallopian tube, and primary peritoneal cancer.</p>
<p>Under the agreement, IMPACT Therapeutics will receive an upfront payment, near-term regulatory milestone payments, and additional commercial milestones tied to meeting specified sales targets.</p>
<p>The company is also entitled to tiered royalties up to the mid-twenties percent on product net sales.</p>
<p>The deal expands senaparib’s potential availability to all 27 European Union member states, Australia, Iceland, Liechtenstein, New Zealand, Norway, Switzerland, the UK, and a range of territories in the Middle East and North Africa.</p>
<p>The companies anticipate that this partnership will accelerate the availability of senaparib following regulatory approvals.</p>
<p>Senaparib is a poly(ADP-ribose) polymerase 1 and 2 (PARP1/2) inhibitor developed by IMPACT Therapeutics.</p>
<p>The company previously received approval from the National Medical Products Administration of China in January 2025 for the use of senaparib as a first-line maintenance therapy in adult patients with advanced forms of ovarian, fallopian tube, or primary peritoneal cancer.</p>
<p>The product was also added to China’s National Reimbursement Drug List in December 2025.</p>
<p>In Europe, a marketing authorisation application for senaparib as a first-line maintenance therapy in adult patients with advanced ovarian cancer was accepted by the European Medicines Agency in August 2025, and a decision is expected in the second half of 2026.</p>
<p>Pharmanovia brings established expertise and infrastructure to the collaboration, which IMPACT Therapeutics states will assist in making the treatment more widely accessible across the covered regions.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/impact-therapeutics-pharmanovia-exclusive-rights-senaparib/">IMPACT Therapeutics grants Pharmanovia exclusive $488m rights to senaparib</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Ratio Therapeutics secures $70m Series C funding for cancer radiotherapy</title>
<link>https://edusehat.com/en/ratio-therapeutics-secures-70m-series-c-funding-for-cancer-radiotherapy</link>
<guid>https://edusehat.com/en/ratio-therapeutics-secures-70m-series-c-funding-for-cancer-radiotherapy</guid>
<description><![CDATA[ The company said existing investors Duquesne Family Office and Bristol Myers Squibb participated in the round, joined by new investors Catalio Capital Management, Eli Lilly and Company, and 
The post Ratio Therapeutics secures $70m Series C funding for cancer radiotherapy appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/08/PT-03-08-2026-shutterstock_1924512758.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 03 Aug 2026 17:40:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Ratio, Therapeutics, secures, 70m, Series, funding, for, cancer, radiotherapy</media:keywords>
<content:encoded><![CDATA[<p>The company said existing investors Duquesne Family Office and Bristol Myers Squibb participated in the round, joined by new investors Catalio Capital Management, Eli Lilly and Company, and Wasatch Group.</p>
<p>The funding will be used to advance its ATLAS clinical trial, which is assessing its lead candidate [Ac-225]RTX-2358, a fibroblast activation protein (FAP)-targeted radiotherapeutic, for patients with advanced sarcomas.</p>
<p>Further resources will also be directed towards moving a next-generation radioligand therapy candidate into clinical studies.</p>
<p>Ratio Therapeutics plans to expand its discovery pipeline to additional cancer targets and apply its technology to new tumour types that are not currently being addressed.</p>
<p>The company will also use the investment to scale its proprietary radiopharmaceutical technology and manufacturing capabilities to meet both pipeline and anticipated commercial demand.</p>
<p>Ratio Therapeutics CEO Dr Jack Hoppin said: “This financing reflects the confidence our investors and strategic partners have in the progress we have made to date and the opportunities that lie ahead.</p>
<p>“As we march the ATLAS trial forward and prepare for our fifth IND [investigational new drug] filing, these proceeds are instrumental across the development and ultimately the supply of our targeted and PK-optimised radiopharmaceuticals.”</p>
<p>The company’s development portfolio includes [Ac-225]RTX-2358 in the ATLAS Phase I/II trial and next-generation programmes targeting gastrin-releasing peptide receptor (GRPR), as well as additional mono- and bispecific radioligand therapies and imaging agents.</p>
<p>The pipeline assets are based on Ratio’s Trillium pharmacokinetic tuning technology and Macropa chelator platform.</p>
<p>Ratio Therapeutics has also established external validation of its approach through partnership programmes, such as its collaboration with Novartis in somatostatin receptor type 2 (SSTR2) radioligand therapy.</p>
<p>On the manufacturing side, Ratio Therapeutics utilises a hybrid model, combining a vertically integrated site in Utah with outsourcing to external partners and diversified isotope supply.</p>
<p>This approach is designed to provide flexible clinical and potential commercial supply as the company expands its radiopharmaceutical pipeline.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/ratio-therapeutics-70m-funding-cancer-radiotherapy/">Ratio Therapeutics secures $70m Series C funding for cancer radiotherapy</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Eisai launches LEQEMBI in India for early Alzheimer’s disease treatment</title>
<link>https://edusehat.com/en/eisai-launches-leqembi-in-india-for-early-alzheimers-disease-treatment</link>
<guid>https://edusehat.com/en/eisai-launches-leqembi-in-india-for-early-alzheimers-disease-treatment</guid>
<description><![CDATA[ 
 Launch follows CDSCO marketing authorisation for disease-modifying therapy indicated for patients with mild cognitive impairment and mild dementia due to early Alzheimer’s disease
The post Eisai launches LEQEMBI in India for early Alzheimer’s disease treatment appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2016/05/19170812/Alzheimers-reuters-L.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 03 Aug 2026 17:40:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Eisai, launches, LEQEMBI, India, for, early, Alzheimer’s, disease, treatment</media:keywords>
<content:encoded><![CDATA[<div><img width="660" height="440" src="https://cdn.expresspharma.in/wp-content/uploads/2016/05/19170812/Alzheimers-reuters-L.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2016/05/19170812/Alzheimers-reuters-L.jpg 660w, https://cdn.expresspharma.in/wp-content/uploads/2016/05/19170812/Alzheimers-reuters-L-300x200.jpg 300w" sizes="auto, (max-width: 660px) 100vw, 660px"></div><p><span>Eisai, a research and development-based pharmaceutical company headquartered in Japan, has announced the launch of LEQEMBI (lecanemab) in India for the treatment of early Alzheimer’s disease, following marketing authorisation from the Central Drugs Standard Control Organization (CDSCO).</span></p>
<p><span>In India, LEQEMBI is indicated for patients with Mild Cognitive Impairment (MCI) and mild dementia due to early Alzheimer’s disease. The company stated that it marks the introduction of a disease-modifying therapy (DMT) in the country’s Alzheimer’s disease treatment landscape.</span></p>
<p><span>The launch comes amid a growing dementia burden in India, driven by an ageing population, late diagnosis and limited awareness.</span></p>
<p><span>According to estimates cited in the AIIMS–USC LASI study, the estimated dementia prevalence in India among adults aged 60 years and above was 7.4 per cent in 2023. About 8.8 million Indians over the age of 60 are living with dementia. The number is projected to nearly double by 2036, highlighting a significant unmet need.</span></p>
<p><span>LEQEMBI has received approvals in several developed markets, including the United States, Japan and countries across Europe, as well as select developing countries. The company also stated that there is emerging real-world experience indicating the potential value of LEQEMBI in slowing disease progression and improving patient outcomes.</span></p>
<p><span>LEQEMBI (lecanemab) is a humanised monoclonal antibody that selectively targets aggregated amyloid-beta, enabling its clearance while reducing further deposition. It is approved for use in early-stage Alzheimer’s disease, including Mild Cognitive Impairment (MCI) and mild dementia.</span></p>
<p><span>According to the company, LEQEMBI works through a dual mechanism targeting both the removal of existing amyloid-beta plaques and the prevention of new plaque formation, a pathological hallmark of Alzheimer’s disease.</span></p>
<p>The post <a href="https://www.expresspharma.in/eisai-launches-leqembi-in-india-for-early-alzheimers-disease-treatment/">Eisai launches LEQEMBI in India for early Alzheimer’s disease treatment</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Encube Ethicals files DRHP with SEBI for Rs 3,000 crore IPO</title>
<link>https://edusehat.com/en/encube-ethicals-files-drhp-with-sebi-for-rs-3000-crore-ipo</link>
<guid>https://edusehat.com/en/encube-ethicals-files-drhp-with-sebi-for-rs-3000-crore-ipo</guid>
<description><![CDATA[ 
IPO comprises an offer for sale by promoters and investor selling shareholder through the book-building process.
The post Encube Ethicals files DRHP with SEBI for Rs 3,000 crore IPO appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2023/08/23105043/IPO.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 03 Aug 2026 17:40:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Encube, Ethicals, files, DRHP, with, SEBI, for, 3, 000, crore, IPO</media:keywords>
<content:encoded><![CDATA[<div><img width="713" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2023/08/23105043/IPO.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2023/08/23105043/IPO.jpg 713w, https://cdn.expresspharma.in/wp-content/uploads/2023/08/23105043/IPO-300x168.jpg 300w" sizes="(max-width: 713px) 100vw, 713px"></div><p><span>Mumbai-based Encube Ethicals has filed its Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) for its Initial Public Offering (IPO).</span></p>
<p><span>The IPO, with a face value of Re 1 per equity share, comprises an offer for sale of Rs 3,000 crore by promoter Mehul Madhusudan Shah and investor selling shareholder Frontier Investment Holdings Pte. Ltd.</span></p>
<p><span>The issue is being made through the book-building process in accordance with the SEBI (Issue of Capital and Disclosure Requirements) Regulations. Under the issue structure, not more than 50 per cent of the offer is reserved for Qualified Institutional Buyers (QIBs), not less than 15 per cent for Non-Institutional Investors (NIIs), and not less than 35 per cent for Retail Individual Investors (RIIs).</span></p>
<p>The post <a href="https://www.expresspharma.in/encube-ethicals-files-drhp-with-sebi-for-rs-3000-crore-ipo/">Encube Ethicals files DRHP with SEBI for Rs 3,000 crore IPO</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Traceability pays back in many ways</title>
<link>https://edusehat.com/en/traceability-pays-back-in-many-ways</link>
<guid>https://edusehat.com/en/traceability-pays-back-in-many-ways</guid>
<description><![CDATA[ 
S Swaminathan, CEO, GS1 India explains to Express Pharma the broader benefits of the expanded QR code mandate, and how traceability pays back in many ways
The post Traceability pays back in many ways appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/08/03112605/EH_Swami-_750.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 03 Aug 2026 14:00:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Traceability, pays, back, many, ways</media:keywords>
<content:encoded><![CDATA[<div><img width="1280" height="720" src="https://cdn.expresspharma.in/wp-content/uploads/2026/08/03112605/EH_Swami-_750.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/08/03112605/EH_Swami-_750.jpg 1280w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/03112605/EH_Swami-_750-300x169.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/03112605/EH_Swami-_750-1024x576.jpg 1024w, https://cdn.expresspharma.in/wp-content/uploads/2026/08/03112605/EH_Swami-_750-768x432.jpg 768w" sizes="(max-width: 1280px) 100vw, 1280px"></div><p><b>The Union Health Ministry has extended the QR code and barcode mandate to four additional categories of life-saving drugs, building on the existing framework covering the top 300 pharma brands.</b><b> What does the expanded mandate mean for pharmaceutical manufacturers and healthcare providers?</b></p>
<p><span>It simply means more medicines will now carry product identifiers in the form of QR codes, and gradually the entire healthcare system will be covered. For manufacturers, this is about preparing their packaging and data systems to meet the requirement, while for healthcare providers, it gives a simple way to check if a medicine is genuine before it reaches patients. Overall, it is another step toward safer and more transparent supply chains. Verification will now happen at every level – from pharmacies to warehouses to hospitals, making the supply chain safer and more transparent overall.</span></p>
<p><b>Will this expanded mandate eliminate counterfeit medicines, even though QR codes have been digitally copied in the past?</b></p>
<p><span>It is a wrong notion that QR codes alone can stop counterfeiting. QR codes or 2D barcodes are meant for capturing and linking the product with its data. Their role is to connect the physical pack with digital information. When linked to a proper traceability system, they help track the flow of medicines and make it easier to spot irregularities. The mandate builds this foundation, but the real strength comes from how well the codes are implemented and connected to reliable data.</span></p>
<p><b>How much will such mandates add to the average spend of pharma companies on such security features?</b></p>
<p><span>Costs vary widely and there is no single average. The main change is printing 2D codes and adding variable data like batch details and expiry, so the incremental cost is small if serialisation systems already exist. Firms that already export to regulated markets will not need to experience extra expenditure. Smaller manufacturers and first-time adopters will have to bear the initial costs for equipment, software and training etc. Over time, better traceability brings savings from fewer recalls, fewer reprints and smoother operations. </span></p>
<p><b>How can GS1 standards enable end-to-end drug traceability, from manufacturing and distribution to dispensing?</b></p>
<p><span>GS1 standards give every product, shipment and location a unique ID. A product ID on the pack, a shipment ID on the box and a location ID at each facility let everyone record the same facts in the same way. When these IDs are printed as scannable codes and linked to a data record, every movement becomes an accessible and verifiable event. For instance, a medicine can be followed from the production line to the distributor, to the pharmacy and finally dispensed to the patient. Any mismatch or unexpected stop can be monitored. In short, unique IDs plus an end-to-end traceability system create a clear and trusted trail across the whole supply chain.</span></p>
<p><b>Beyond regulatory compliance, what are the other benefits that pharma companies can gain from traceability data?</b></p>
<p><span>Traceability pays back in many ways. Recalls become faster and far more precise, so only affected packs could be pulled back. Inventory becomes visible across the supply chain, reducing expiry losses and stock outs. Companies can spot any diversion and safeguard their brand. Operations run smoother and more efficiently. And when healthcare providers and patients can verify a medicine instantly, trust grows.</span></p>
<p><b>Can you give examples of how global GS1 standards have supported traceability across healthcare supply chains?</b></p>
<p><span>GS1 standards have been instrumental in strengthening healthcare supply chain traceability worldwide. In the European Union, GS1 DataMatrix barcodes are mandated under the ‘Falsified Medicines Directive’ to verify medicines at the point of dispensing. Nigeria uses GS1 serialisation to combat counterfeit drugs through ‘NAFDAC’. In France, hospitals apply GS1 identifiers to track medical devices and medicines, ensuring compliance and patient safety. Similarly, the UK NHS “Scan4Safety” programme leverages GS1 barcodes to reduce errors and improve inventory management. </span></p>
<p><span>Importantly, GS1 2D barcodes are now recommended or mandated in healthcare regulations across more than 70 countries, showing how trusted product identity and interoperability are enabling safer healthcare and more resilient supply chains globally. </span></p>
<p><b>Will digital product identification become the backbone of India’s future pharma compliance ecosystem?</b></p>
<p><span>Yes. Digital IDs give every medicine a digital, scannable identity that works in both physical and digital systems. With a national drug registry and electronic health records coming online, these IDs will let regulators, distributors and pharmacists read the same trusted data at every step. That makes inspections easier and dispensing safer. In short, a unique digital identity is not just a compliance tool; it rather becomes the foundation that links manufacturing, distribution and patient care in a single, reliable system.  </span></p>
<p><b>How can India’s policy makers make these mandates more enforceable and effective?</b></p>
<p><span>The need is to focus on making the data usable, not just mandatory. The healthcare ecosystem requires a unique identification system backed by global standards for trusted product records and for every scan to show accurate information. </span></p>
<p><span>Additionally, it is vital to ensure all participants use the system for warehousing, distribution, point of sale and recalls. Promotion of common standards and registry connectivity should also fall in place so data is interoperable across the chain. We must also support MSMEs with technical help, affordable solutions and capacity building programs. </span></p>
<p>The post <a href="https://www.expresspharma.in/traceability-pays-back-in-many-ways/">Traceability pays back in many ways</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Express Pharma August 2026</title>
<link>https://edusehat.com/en/express-pharma-august-2026</link>
<guid>https://edusehat.com/en/express-pharma-august-2026</guid>
<description><![CDATA[ 
India&#039;s Foremost Pharma &amp; Biotech Magazine ~ Power, Politics And Pharma
The post Express Pharma August 2026 appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/08/01102942/EP-AUG-2026-MAG-COVER.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 01 Aug 2026 15:05:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Express, Pharma, August, 2026</media:keywords>
<content:encoded><![CDATA[<div><img width="200" height="264" src="https://cdn.expresspharma.in/wp-content/uploads/2026/08/01102942/EP-AUG-2026-MAG-COVER.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async"></div><p><em>Power, Politics And Pharma</em><br>
</p><div class="_df_book df-lite" _slug="express-pharma-august-2026" data-title="express-pharma-august-2026" wpoptions="true" thumbtype=""></div>
<hr>
<p><strong>Click to download:</strong> <a href="https://cdn.expresspharma.in/wp-content/uploads/2026/08/01092616/EP_AUGUST_2026.pdf" target="_blank" rel="noopener noreferrer">August 2026 Digital Magazine</a></p>
<p>The post <a href="https://www.expresspharma.in/express-pharma-august-2026/">Express Pharma August 2026</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>miRecule and Rio Biofarma to develop RNA therapeutic delivery technologies</title>
<link>https://edusehat.com/en/mirecule-and-rio-biofarma-to-develop-rna-therapeutic-delivery-technologies</link>
<guid>https://edusehat.com/en/mirecule-and-rio-biofarma-to-develop-rna-therapeutic-delivery-technologies</guid>
<description><![CDATA[ The partnership is intended to jointly advance methods that address one of the main challenges for RNA medicines: delivering treatments to additional tissue types. While existing RNA therapies 
The post miRecule and Rio Biofarma to develop RNA therapeutic delivery technologies appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/07/PT-2-31-07-2026-shutterstock_1884612922.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 31 Jul 2026 21:00:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>miRecule, and, Rio, Biofarma, develop, RNA, therapeutic, delivery, technologies</media:keywords>
<content:encoded><![CDATA[<p>The partnership is intended to jointly advance methods that address one of the main challenges for RNA medicines: delivering treatments to additional tissue types.</p>
<p>While existing RNA therapies have shown progress in liver and muscle targeting, other tissues remain difficult to reach.</p>
<div>
<p>The collaboration seeks to develop delivery approaches that could make RNA therapeutics available to a broader selection of tissues.</p>
<p>Under the agreement, miRecule’s NAVIgGator platform, which is used to design precision RNA medicines, will be combined with RBBL’s capabilities in peptide discovery, development, and manufacturing.</p>
<p>This partnership aims to generate peptide–RNA conjugates suitable for delivering RNA-based treatments to new target tissues. According to the companies, the technology developed through the collaboration will be jointly owned.</p>
<p>The agreement specifies that miRecule will develop oligonucleotide payloads for up to three targets while RBBL will be responsible for manufacturing the resultant products at its facility in Brazil.</p>
<p>Both companies have also outlined opportunities to expand the development of these products in international markets.</p>
<p>To support the advancement of both the collaboration and miRecule’s neuromuscular disease-focused assets, Rio Biofarma Brasil has also made an equity investment in miRecule. However, the financial terms of the collaboration have not been made public.</p>
<p>miRecule CEO Dr Anthony Saleh said: “Working alongside an organisation with the scale, scientific commitment, manufacturing expertise, and global reputation of EMS-RBBL strengthens our ability to bring transformative technologies closer to patients.</p>
<p>“We are excited about the potential of this collaboration to expand the reach of RNA therapies into challenging extra-hepatic tissue targets.”</p>
</div>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/mirecule-rio-biofarma-rna-therapeutic/">miRecule and Rio Biofarma to develop RNA therapeutic delivery technologies</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Resilience and Lilly to increase US medicines production with $750m investment</title>
<link>https://edusehat.com/en/resilience-and-lilly-to-increase-us-medicines-production-with-750m-investment</link>
<guid>https://edusehat.com/en/resilience-and-lilly-to-increase-us-medicines-production-with-750m-investment</guid>
<description><![CDATA[ The investment will support the expansion of Resilience’s advanced manufacturing operations in the Cincinnati region and create at least 400 new jobs. With this initiative, the total number 
The post Resilience and Lilly to increase US medicines production with $750m investment appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/07/PT-31-07-2026-shutterstock_387335098.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 31 Jul 2026 17:05:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Resilience, and, Lilly, increase, medicines, production, with, 750m, investment</media:keywords>
<content:encoded><![CDATA[<p>The investment will support the expansion of Resilience’s advanced manufacturing operations in the Cincinnati region and create at least 400 new jobs.</p>
<p>With this initiative, the total number of jobs generated by Resilience across its Ohio sites will exceed 1,400.</p>
<p>Preparation for the site expansion has commenced, and complete operations are projected to begin in early 2027.</p>
<p>The expanded collaboration builds upon a strategic partnership between the two firms first formed in 2023.</p>
<p>This initiative is in response to growing patient demand for injectable treatments for diabetes and obesity in the US.</p>
<p>Resilience president and CEO William Marth said: “We are proud of what we have built together with Lilly and this new expansion as we scale production of complex medicines in Ohio.</p>
<p>“Our investment reflects our long-term commitment to building one of the largest and most advanced sterile injectable and device assembly and packaging operations in the US, and demonstrates how trusted partnerships, operational excellence, and disciplined execution can strengthen America’s medicine supply.”</p>
<p>Lilly executive vice-president and manufacturing operations president Edgardo Hernandez said: “As demand for our medicines continues to increase, scaling complex manufacturing programmes requires proven technical capability, an uncompromising commitment to quality, and the ability to deliver consistently over time.”</p>
<p>The partnership has so far resulted in the production of more than 150 million doses of medicines for US patients in vial and pre-filled syringe formats.</p>
<p>Resilience operates two facilities in the region, employing nearly 1,000 staff across various functions.</p>
<p>The location in Blue Ash, Ohio, was recently established as Resilience’s global headquarters. The company’s partnerships with REDI Cincinnati, JobsOhio, and Ohio Life Sciences have also supported workforce development efforts in the Cincinnati area.</p>
<p>Prior to this, Eli Lilly and Company entered an agreement with Innovent Biologics for the commercialisation of Verzenios (abemaciclib) in mainland China.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/resilience-lilly-us-medicines-production/">Resilience and Lilly to increase US medicines production with $750m investment</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>SCRMP Nexus 2026 Hyderabad to bring together India’s leading pharma, life sciences leaders</title>
<link>https://edusehat.com/en/scrmp-nexus-2026-hyderabad-to-bring-together-indias-leading-pharma-life-sciences-leaders</link>
<guid>https://edusehat.com/en/scrmp-nexus-2026-hyderabad-to-bring-together-indias-leading-pharma-life-sciences-leaders</guid>
<description><![CDATA[ 
The Society of Clinical Research and Medical Professionals (SCRMP) will host SCRMP Nexus 2026 – Hyderabad Edition on 8 August 2026 at Novotel Hyderabad Airport, bringing together senior leaders from […]
The post SCRMP Nexus 2026 Hyderabad to bring together India’s leading pharma, life sciences leaders appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/07/31120020/EP_SCRMP.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 31 Jul 2026 17:05:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>SCRMP, Nexus, 2026, Hyderabad, bring, together, India’s, leading, pharma, life, sciences, leaders</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/07/31120020/EP_SCRMP.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/07/31120020/EP_SCRMP.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/07/31120020/EP_SCRMP-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>The Society of Clinical Research and Medical Professionals (SCRMP) will host SCRMP Nexus 2026 – Hyderabad Edition on 8 August 2026 at Novotel Hyderabad Airport, bringing together senior leaders from the pharmaceutical, CRO, biotechnology, healthcare and technology sectors to discuss the future of clinical research, pharmacovigilance, regulatory science, medical affairs and AI-driven healthcare.</span></p>
<p><span>The conference is expected to welcome 30+ speakers, 22+ sponsors, 21+ exhibitors, representatives from 75+ organizations and over 130+ delegates, making it one of India’s leading life sciences networking events.</span></p>
<p><span>The scientific programme will feature keynote presentations and panel discussions led by experts from organisations including Government of Telangana Life Sciences, Dr. Reddy’s Laboratories, Bristol Myers Squibb, Sanofi, USP India, Wockhardt, Cipla, AstraZeneca, Novartis, Novo Nordisk, Sandoz, Sun Pharmaceutical Industries, Pfizer, Syneos Health, Accenture, PharmaLex and several other leading organisations.</span></p>
<p><span>Notable speakers include Sarvesh Singh, Dr. Anu Kumar Saini, Dr. Retesh Kumar Bhumbak, Dr. Girish Kapur, Dr. Anitha Kumari, Zoher Jiwani, Dr. Rajeev M. Patil, Dr. Prasad Deshmukh, Dr. Kiran Kandula, Joydeep Sengupta, Gargi Chatterjee, Dr. Neeraj Mehta, Narendra Annamaneni, Dipankar Dey, along with many other industry experts.</span></p>
<p><span>SCRMP extends its sincere appreciation to its Board Members and Organizing Committee—Jayapaul Bonthu, Dr. Bitumani Borah, Ankit Jain, Firoz Momin, Arvind Chauhan, Aparna Kiran Gandham, and Rahul Joshi for their outstanding leadership and invaluable contributions in curating a high-impact scientific programme for SCRMP Nexus 2026 Hyderabad.</span></p>
<p><span>The conference is supported by Pharmacoevidence, Navatio Pharma, ALWIS Solutions, Techsol Life Sciences, MetatronicMind Technologies, THRANA, Advity Research, KnowledgeWorks, Nested Knowledge, AccuScript Consultancy, VictoLabs AI, CRQA, CliniMinds, Premise Bio, PV Analytica, Datafoundry AI, eTrialTrack, Sarjen Systems, Croissance Clinical Research, BioAgile Therapeutics and Inductive Quotient. SCRMP also thanks the Journal of Patient Safety & Epidemiology (JPSE) as the Official Journal Partner and Express Pharma, BioSpectrum and Pharma Now as Official Media Partners.</span></p>
<p><span>Dr. Umama Yezdani, Hon. Founder, SCRMP, said: “SCRMP Nexus was established to create a collaborative platform where industry, academia and healthcare professionals can exchange ideas, build partnerships and accelerate innovation. We look forward to welcoming the life sciences community to Hyderabad for a day of learning, networking and meaningful collaboration.”</span></p>
<p><span>Mohammad Gayoor Khan, Co-Founder & General Secretary, SCRMP, added: “SCRMP Nexus reflects our commitment to strengthening collaboration across the pharmaceutical and healthcare ecosystem. We thank our speakers, sponsors, exhibitors, partners and delegates for supporting this vision and look forward to an engaging conference that inspires innovation and professional excellence.”</span></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/scrmp-nexus-2026-hyderabad-to-bring-together-indias-leading-pharma-life-sciences-leaders/">SCRMP Nexus 2026 Hyderabad to bring together India’s leading pharma, life sciences leaders</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>India to build future&#45;ready drug regulatory framework to accelerate healthcare innovation, Says J P Nadda</title>
<link>https://edusehat.com/en/india-to-build-future-ready-drug-regulatory-framework-to-accelerate-healthcare-innovation-says-j-p-nadda</link>
<guid>https://edusehat.com/en/india-to-build-future-ready-drug-regulatory-framework-to-accelerate-healthcare-innovation-says-j-p-nadda</guid>
<description><![CDATA[ 
India is building a future-ready drug regulatory framework to accelerate healthcare innovation while maintaining the highest standards of patient safety, quality, and efficacy, Union Minister for Health and Family Welfare […]
The post India to build future-ready drug regulatory framework to accelerate healthcare innovation, Says J P Nadda appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/07/31121844/EP_GDRC.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 31 Jul 2026 17:05:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>India, build, future-ready, drug, regulatory, framework, accelerate, healthcare, innovation, Says, Nadda</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/07/31121844/EP_GDRC.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/07/31121844/EP_GDRC.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/07/31121844/EP_GDRC-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>India is building a future-ready drug regulatory framework to accelerate healthcare innovation while maintaining the highest standards of patient safety, quality, and efficacy, Union Minister for Health and Family Welfare J P Nadda said in his virtual address at the inaugural Global Drug Regulatory Conclave (GDRC) 2026. </span></p>
<p><span>Reinforcing this vision, Drugs Controller General of India (DCGI) Dr Rajeev Singh Raghuvanshi announced at the event that the Central Drugs Standard Control Organisation (CDSCO) will roll out the first phase of an end-to-end digital drug regulatory platform within the next 18 months, marking a significant step in modernising India’s pharmaceutical regulatory ecosystem.</span></p>
<p><span>Addressing regulators, policymakers, industry leaders, and delegates from across the globe, Nadda said India’s pharmaceutical industry is evolving from a global supplier of affordable generic medicines to a global center of pharmaceutical innovation. As healthcare advances towards biologics, biosimilars, gene therapies, precision medicine, AI-assisted drug development, and digital therapeutics, he said India’s regulatory framework must evolve in parallel to facilitate innovation while upholding uncompromising standards of safety, quality, and efficacy.</span></p>
<p><span>Highlighting the Government’s ongoing regulatory reforms, Nadda said CDSCO is undergoing a comprehensive transformation driven by transparency, scientific rigour, efficiency, accountability, and digital governance. He added that digital regulatory platforms, risk-based oversight, strengthened inspection systems, and enhanced surveillance are creating a modern regulatory ecosystem that inspires greater global confidence. Calling for deeper international collaboration, he urged regulators to strengthen information sharing, regulatory science partnerships, collaborative inspections, and the convergence of scientific standards to improve global access to safe, effective, and affordable medicines.</span></p>
<p><span>In his opening remarks at the event, Dr Rajeev Singh Raghuvanshi outlined CDSCO’s roadmap for regulatory transformation centered on digitalisation, innovation, quality assurance, and global regulatory convergence. He said the upcoming common digital regulatory platform will integrate the entire pharmaceutical regulatory value chain from research and clinical development to manufacturing, approvals, distribution, and post-market surveillance—bringing together central and state regulators, manufacturers, and other stakeholders into a single digital ecosystem.</span></p>
<p><span>Dr Raghuvanshi said more than 99 percent of CDSCO’s regulatory processes have already been digitised, significantly improving transparency and approval timelines. Building on this, CDSCO is piloting Artificial Intelligence across regulatory processes to create a faster, more agile, and data-driven regulatory system. He also announced that GMP and Certificate of Pharmaceutical Product (COPP) certificates will soon carry QR-code-based digital authentication, enabling overseas regulators to instantly verify their authenticity while reducing verification timelines.</span></p>
<p><span>Highlighting initiatives to strengthen quality and innovation, Dr Raghuvanshi said CDSCO has streamlined its export regulatory framework through a fully digitized export No Objection Certificate (NOC) system, introduced globally aligned regulatory reliance mechanisms, and accelerated approval pathways to enable faster patient access to innovative therapies. Around 25–30 percent of clinical trials are currently being considered for waiver for eligible innovative products. He further highlighted MedTech Mitra, which has already supported more than 800 startups in navigating regulatory pathways, and noted that similar facilitation mechanisms are planned for biologics and other emerging technologies.</span></p>
<p><span>Further, speaking at the event, Mohit Yadav, IFS, Joint Secretary, Department of Commerce, EP (Pharma), said, “For pharmaceuticals, regulation is the true border. Faster, transparent, and predictable pathways can improve patient access without lowering standards. India must build on the trust it has earned through quality manufacturing by deepening regulatory cooperation, reliance, and responsible use of digital and AI-enabled tools.”</span></p>
<p><span>Namit Joshi, Chairman, Pharmexcil, said, “India has earned its position as the pharmacy of the world, and the next step is to become a stronger regulatory partner. As global expectations on quality and compliance continue to evolve, GDRC will bring regulators and industry together to promote harmonised standards, clearer regulatory pathways, and faster access to quality, affordable medicines. It will also help translate policy into consistent compliance across the industry, strengthening confidence in Indian pharmaceuticals across global markets.”</span></p>
<p><span>The Global Drug Regulatory Conclave 2026, organized by the Central Drugs Standard Control Organization (CDSCO) in association with Pharmexcil, brought together global drug regulatory authorities, policymakers, researchers, industry leaders, and international organizations to deliberate on the future of pharmaceutical regulation. The conclave focused on strengthening regulatory cooperation, advancing digital transformation, promoting regulatory science, encouraging innovation, and building resilient global healthcare supply chains that ensure timely access to safe, effective, and affordable medicines.</span></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/india-to-build-future-ready-drug-regulatory-framework-to-accelerate-healthcare-innovation-says-j-p-nadda/">India to build future-ready drug regulatory framework to accelerate healthcare innovation, Says J P Nadda</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Lupin announces US FDA approval and launch of Sugammadex injection</title>
<link>https://edusehat.com/en/lupin-announces-us-fda-approval-and-launch-of-sugammadex-injection</link>
<guid>https://edusehat.com/en/lupin-announces-us-fda-approval-and-launch-of-sugammadex-injection</guid>
<description><![CDATA[ 
Global pharma major Lupin announced that following approval from the United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Application, the company launched Sugammadex Injection, 200 […]
The post Lupin announces US FDA approval and launch of Sugammadex injection appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2020/08/07111742/US-FDA-stamp-e1722586514279.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 31 Jul 2026 17:05:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Lupin, announces, FDA, approval, and, launch, Sugammadex, injection</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="399" src="https://cdn.expresspharma.in/wp-content/uploads/2020/08/07111742/US-FDA-stamp-e1722586514279.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2020/08/07111742/US-FDA-stamp-e1722586514279.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2020/08/07111742/US-FDA-stamp-e1722586514279-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p>Global pharma major Lupin announced that following approval from the United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Application, the company launched Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vial in the United States.</p>
<p>Lupin’s Sugammadex Injection is the bioequivalent to Bridion Injection of Merck, Sharp & Dohme LLC (Merck) and is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery.</p>
<p> </p>
<p> </p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/lupin-announces-us-fda-approval-and-launch-of-sugammadex-injection/">Lupin announces US FDA approval and launch of Sugammadex injection</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>First Amgen Scholars Program in India launches at IIIT Hyderabad</title>
<link>https://edusehat.com/en/first-amgen-scholars-program-in-india-launches-at-iiit-hyderabad</link>
<guid>https://edusehat.com/en/first-amgen-scholars-program-in-india-launches-at-iiit-hyderabad</guid>
<description><![CDATA[ 
Amgen announced the launch of the first Amgen Scholars Program in India at the International Institute of Information Technology Hyderabad (IIIT Hyderabad), bringing the globally respected undergraduate summer research program […]
The post First Amgen Scholars Program in India launches at IIIT Hyderabad appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11142213/Naveen-Gullapalli_Amgen_EP.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 31 Jul 2026 13:25:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>First, Amgen, Scholars, Program, India, launches, IIIT, Hyderabad</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="422" src="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11142213/Naveen-Gullapalli_Amgen_EP.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2024/12/11142213/Naveen-Gullapalli_Amgen_EP.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2024/12/11142213/Naveen-Gullapalli_Amgen_EP-300x169.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Amgen announced the launch of the first Amgen Scholars Program in India at the International Institute of Information Technology Hyderabad (IIIT Hyderabad), bringing the globally respected undergraduate summer research program to India for the first time.</span></p>
<p><span>Supported through a two-year commitment from Amgen through summer 2027, the program reflects the company’s long-standing commitment to advancing science education and inspiring future innovators. The inaugural cohort comprises 10 undergraduate scholars, including students from India, Vietnam, Qatar, and Dubai, creating opportunities for scientific collaboration and exchange across Asia. The students represent universities across Asia and are pursuing undergraduate programs in science, engineering, and related disciplines, reflecting the program’s regional diversity and academic excellence.</span></p>
<p><span>As part of the intensive two-month residential research experience, students will explore artificial intelligence and machine learning applications in fundamental sciences, drug design and discovery, healthcare, cheminformatics, genomics and related areas alongside faculty mentors at IIIT Hyderabad. They will also have an opportunity to participate in seminars, networking events and a regional Amgen Scholars Symposium to be held in Tokyo in August 2026. At the conclusion of the program, each scholar presents their research through a scientific poster presentation. The scholars were selected through a rigorous evaluation by an expert committee at IIIT Hyderabad based on academic excellence, research aptitude, motivation for doctoral studies, and demonstrated interest in applying AI and machine learning to drug discovery.</span></p>
<p><span>“Scientific breakthroughs begin with curious minds and meaningful opportunities to learn,” said Naveen Gullapalli, Managing Director, Amgen India. “We are proud to bring the Amgen Scholars Program to India. We hope to inspire talented students to pursue research careers while helping build the interdisciplinary skills needed to strengthen India’s scientific ecosystem.”</span></p>
<p><span>“We are delighted to serve as the host institution for the first Amgen Scholars Program in India,” said Deva Priyakumar, professor & dean (R&D), IIIT Hyderabad. “The program aligns well with our research-led approach to education and provides undergraduate students with an exceptional opportunity to contribute to cutting-edge research in AI for healthcare and drug discovery while learning from leading faculty.”</span></p>
<p><span>“AI is transforming every stage of biotech research, from understanding disease biology to discovering new medicines,” said Sandeep Shukla, professor & director, IIIT Hyderabad. “This program gives students an opportunity to work on real scientific problems while developing the interdisciplinary research skills needed to address tomorrow’s complex healthcare challenges.”</span></p>
<p><span>Designed to inspire the scientists of tomorrow, the </span><a href="https://www.amgenfoundation.org/science-education/amgen-scholars-program"><span>Amgen Scholars Program</span></a><span> is a long-standing, signature initiative of the Amgen Foundation, providing undergraduates the opportunity to engage in a compelling summer, scientific research experience at some of the world’s leading institutions. This program builds on successful programming in the United States, with over 4,000 US students having benefited from the program. Twenty-six leading institutions across the world currently host the summer research program. More than 6,000 students from over 1,000 colleges and universities have participated to date. Financial support for students is a critical component of the program, which seeks to ensure that eligible students, regardless of their financial status, can participate.  The Amgen Scholars Program seeks to expand research, learning and networking opportunities for students committed to pursuing advanced degrees in STEM. Thousands of program alumni have gone on to complete graduate education and build careers across academia, biotechnology and healthcare in more than 40 countries. </span><a href="http://www.amgenscholars.com/"><span>www.amgenscholars.com</span></a><span>. </span></p>
<p>The post <a href="https://www.expresspharma.in/first-amgen-scholars-program-in-india-launches-at-iiit-hyderabad/">First Amgen Scholars Program in India launches at IIIT Hyderabad</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Arboreal raises ₹230 Crore Series A to scale India’s next&#45;gen ingredient technology platform</title>
<link>https://edusehat.com/en/arboreal-raises-230-crore-series-a-to-scale-indias-next-gen-ingredient-technology-platform</link>
<guid>https://edusehat.com/en/arboreal-raises-230-crore-series-a-to-scale-indias-next-gen-ingredient-technology-platform</guid>
<description><![CDATA[ 
Arboreal Bioinnovations, India’s first specialty food and nutraceutical ingredients technology company, today announced the successful close of its ₹230 crore Series A funding round. EAAA, the alternatives arm of Edelweiss […]
The post Arboreal raises ₹230 Crore Series A to scale India’s next-gen ingredient technology platform appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/06/25101937/funding.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 31 Jul 2026 13:25:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Arboreal, raises, ₹230, Crore, Series, scale, India’s, next-gen, ingredient, technology, platform</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/06/25101937/funding.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/06/25101937/funding.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/06/25101937/funding-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>Arboreal Bioinnovations, India’s first specialty food and nutraceutical ingredients technology company, today announced the successful close of its ₹230 crore Series A funding round. EAAA, the alternatives arm of Edelweiss and Omnivore co-led the funding round, with continued backing from existing investor Rainmatter by Zerodha.</span></p>
<p><span>The transaction represents one of the largest Series A fundraises in India’s specialty food ingredients sector. Arboreal will deploy the capital to expand its manufacturing capacity, strengthen its research and development capabilities, and accelerate the commercialization of its next generation of functional ingredients.</span></p>
<p><span>Arboreal has built a differentiated “contextual innovation” model focused on developing ingredient solutions for the specific nutritional, functional, sensory and commercial requirements of Indian consumers and brands. This approach has enabled hundreds of emerging and challenger brands to launch category-defining products and scale rapidly across the food, beverage and nutraceutical markets.</span></p>
<p><span>The company’s integrated ingredient technology platform brings together ingredient engineering, process research and development, formulation science and precision manufacturing. Arboreal has developed and commercialized proprietary ingredients across next-generation proteins, cocoa-based ingredients, natural zero-calorie sweeteners and functional fibres, with several additional ingredient platforms currently under development.</span></p>
<p><span>Having more than doubled its growth year-on-year, Arboreal’s portfolio of “better-for-you” ingredients and its “ingredient-first innovation” model have supported more than 300 product launches across over 1,100 consumer brands and nutraceutical manufacturers during the past 18 months.</span></p>
<p><span>Swati Pandey, Co-Founder and CEO, Arboreal Bioinnovations, said, “This fundraise is a strong validation of the direction we are taking as a company. It gives us the fuel to accelerate our mission of building clean, science-led solutions that address some of the world’s most pressing nutritional and food challenges, with innovation originating in India and reaching consumers globally.</span></p>
<p><span>Manish Chauhan, Co-Founder and COO, Arboreal Bioinnovations, said, “This fundraise marks an important milestone in Arboreal’s journey from building IP led ingredient technologies to enabling big shifts across categories through ingredient first innovation. The confidence shown by EAAA, Omnivore and Rainmatter validates both the strength of our platform and the opportunity ahead of us. It gives us the ability to invest more deeply in science, manufacturing, talent and long-term innovation, while building a platform capable of creating differentiated ingredients for some of the world’s most important food and nutraceutical brands. We are excited to build Arboreal into a globally respected ingredient technology company from India.</span></p>
<p><span>Ashish Agarwal, Managing Director, Private Equity, EAAA Alternatives, added, ” The investment in Arboreal reflects the core philosophy of our Fund’s strategy – backing businesses with the potential to emerge as category leaders. As the first investment from our Discovery Fund II, we are particularly excited at the long term growth prospects of Arboreal’s next-generation yeast protein products We look forward to working with Swati and Manish as they continue to build category leadership in R&D-led nutraceutical ingredients.”</span></p>
<p><span>Jinesh Shah, Managing Partner at Omnivore, said, “The shift toward clean-label and functional foods requires engineered ingredients that deliver clear health benefits without sacrificing taste or margins. Arboreal fills a critical market gap with locally developed formulations. From sweetener alternatives to novel yeast proteins and collagens, Arboreal’s R&D stack positions them to power the next wave of health and wellness brands.”</span></p>
<p><span>Dinesh Pai, Head of investments at Rainmatter, said, “We all lament that India does not allocate capital for enough R&D. Aside from all the things everyone else shared in their reasoning for the investment, we truly wanted to back Swati and Manish in building a world class R&D team working on food ingredients from India. We believe that they are the right team, with exceptional grit to chase down this problem. Rainmatter exists to back these audacious bets, and this is one of them.</span></p>
<p>The post <a href="https://www.expresspharma.in/arboreal-raises-%E2%82%B9230-crore-series-a-to-scale-indias-next-gen-ingredient-technology-platform/">Arboreal raises ₹230 Crore Series A to scale India’s next-gen ingredient technology platform</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Synlogic and Caldera sign merger agreement</title>
<link>https://edusehat.com/en/synlogic-and-caldera-sign-merger-agreement</link>
<guid>https://edusehat.com/en/synlogic-and-caldera-sign-merger-agreement</guid>
<description><![CDATA[ The companies will become 100%-owned subsidiaries of Caldera Therapeutics, a newly formed holding company. This combined company intends to apply for a listing on the Nasdaq Capital Market 
The post Synlogic and Caldera sign merger agreement appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/07/PT-30-07-2026-shutterstock_1349493995.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 30 Jul 2026 19:10:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Synlogic, and, Caldera, sign, merger, agreement</media:keywords>
<content:encoded><![CDATA[<p>The companies will become 100%-owned subsidiaries of Caldera Therapeutics, a newly formed holding company.</p>
<p>This combined company intends to apply for a listing on the Nasdaq Capital Market under the “CALD” ticker symbol.</p>
<div>
<p>To support the proposed merger, Caldera has arranged an upsized concurrent private placement projected to generate around $278m in gross proceeds.</p>
<p>A syndicate of healthcare institutional investors and mutual funds have committed to the private placement.</p>
<p>Participants include Atlas Venture, Bain Capital Life Sciences, Blackstone Multi-Asset Investing, Janus Henderson Investors, LAV, Omega Funds, Sirenia Capital Management LP, TCGX, venBio Partners, Vivo Capital, Wellington Management, and others.</p>
<p>This financing is planned to support the Phase II clinical development of Caldera’s CLD-423 in ulcerative colitis and Crohn’s disease.</p>
<p>The cash and cash equivalents of the merged company at closing, along with proceeds from the simultaneous private placement, are anticipated to support its operations until 2029. The financing is set to conclude alongside the merger, pending the fulfilment of standard closing conditions.</p>
<p>Following the merger, Caldera Therapeutics will focus on advancing CLD-423, an investigational bispecific antibody intended to simultaneously target TL1A and IL-23p19 pathways for the treatment of inflammatory bowel disease (IBD) and other immune-mediated diseases.</p>
<p>CLD-423 is currently being studied in a Phase I clinical trial in healthy volunteers in Australia, which began in January 2026.</p>
<p>Dosing in the study has concluded, and early unblinded data from single ascending dose cohorts showed the candidate was generally well tolerated and displayed no dose-limiting toxicities.</p>
<p>Caldera CEO Praveen Tipirneni said: “In just over a year, we’ve shown our team’s ability to open up a lead with compelling data from a molecule poised to deliver the next horizon of I&I [immunology and inflammation] therapy.</p>
<p>“These transactions provide the capital and public company platform to advance our vision as we move into Phase II development in IBD and continue exploring the potential of CLD-423 across additional immune-mediated diseases.”</p>
<p>The transaction will see Caldera shareholders hold approximately 62.8% of the combined company, Synlogic shareholders 2.3%, and private placement investors around 34.9%.</p>
<p>The deal and financing remain subject to shareholder approvals and customary closing conditions. Approved by the companies’ board of directors, the transaction is expected to complete by early 2027.</p>
</div>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/synlogic-and-caldera-sign-merger-agreement/">Synlogic and Caldera sign merger agreement</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Amgen’s Repatha receives positive CHMP opinion for broader cardiovascular use</title>
<link>https://edusehat.com/en/amgens-repatha-receives-positive-chmp-opinion-for-broader-cardiovascular-use</link>
<guid>https://edusehat.com/en/amgens-repatha-receives-positive-chmp-opinion-for-broader-cardiovascular-use</guid>
<description><![CDATA[ Repatha is intended for adults with established or high risk of atherosclerotic cardiovascular disease (ASCVD) and aims to reduce the risk by decreasing low-density lipoprotein cholesterol (LDL-C) levels, 
The post Amgen’s Repatha receives positive CHMP opinion for broader cardiovascular use appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/07/PT-2-30-07-2026-shutterstock_2112532703.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 30 Jul 2026 19:10:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Amgen’s, Repatha, receives, positive, CHMP, opinion, for, broader, cardiovascular, use</media:keywords>
<content:encoded><![CDATA[<p>Repatha is intended for adults with established or high risk of atherosclerotic cardiovascular disease (ASCVD) and aims to reduce the risk by decreasing low-density lipoprotein cholesterol (LDL-C) levels, along with the management of other risk factors.</p>
<p>The recommendation is based on data from the Phase III VESALIUS-Cardiovascular (VESALIUS-CV) trial, which involved more than 12,000 patients.</p>
<p>The trial evaluated the effect of adding evolocumab to standard lipid-lowering therapy in adults at high risk but with no previous heart attack or stroke.</p>
<p>It found that Repatha significantly reduced the risk of major adverse cardiovascular events.</p>
<p>Results showed a 25% relative reduction for a composite of coronary heart disease death, myocardial infarction or ischaemic stroke, and a 19% decline in a broader composite endpoint that also included arterial revascularisations.</p>
<p>A 36% reduction in the risk of myocardial infarction was also reported.</p>
<p>Amgen chief medical officer Paul Burton said: “There remains a significant unmet need in Europe, where many patients at high cardiovascular risk are unable to achieve recommended LDL-C levels despite available lipid-lowering therapies.</p>
<p>“The CHMP’s positive opinion reflects the strength of Repatha’s clinical evidence and brings us one step closer to making Repatha available to more patients who may benefit from it.”</p>
<p>In 2015, Repatha was initially approved in the EU for certain adults and paediatric patients with primary hypercholesterolaemia or mixed dyslipidaemia, as well as for reducing cardiovascular risk in adults with established ASCVD.</p>
<p>A final decision from the European Commission (EC) is expected in the coming months.</p>
<p>Burton added: “Repatha is the only PCSK9 inhibitor proven in a Phase III clinical trial to reduce the risk of a first major cardiovascular event. If approved by the EC, this expanded indication has the potential to redefine cardiovascular care for appropriate patients in Europe.”</p>
<p>Earlier this year, Amgen secured approval from the EC for Uplizna (inebilizumab) as an add-on treatment to standard therapy for adults with generalised myasthenia gravis who are anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibody positive.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/amgens-repatha-chmp-broader-cardiovascular/">Amgen’s Repatha receives positive CHMP opinion for broader cardiovascular use</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Biocon Foundation and IISc convene national experts to shape India’s oral cancer elimination strategy</title>
<link>https://edusehat.com/en/biocon-foundation-and-iisc-convene-national-experts-to-shape-indias-oral-cancer-elimination-strategy</link>
<guid>https://edusehat.com/en/biocon-foundation-and-iisc-convene-national-experts-to-shape-indias-oral-cancer-elimination-strategy</guid>
<description><![CDATA[ 
The two-day conference brought together leading oncologists, clinicians, public health experts, researchers, policymakers, artificial intelligence specialists and implementation partners to advance India’s roadmap towards oral cancer elimination. Biocon Foundation, the […]
The post Biocon Foundation and IISc convene national experts to shape India’s oral cancer elimination strategy appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/07/30112333/EP_Biocon-FOundation.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 30 Jul 2026 19:10:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Biocon, Foundation, and, IISc, convene, national, experts, shape, India’s, oral, cancer, elimination, strategy</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/07/30112333/EP_Biocon-FOundation.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/07/30112333/EP_Biocon-FOundation.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/07/30112333/EP_Biocon-FOundation-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p>The two-day conference brought together leading oncologists, clinicians, public health experts, researchers, policymakers, artificial intelligence specialists and implementation partners to advance India’s roadmap towards oral cancer elimination.</p>
<p>Biocon Foundation, the Corporate Social Responsibility (CSR) arm of the Biocon Group, in association with the Indian Institute of Science (IISc) and Translational AI for Networked Universal Health Care (TANUH), commemorated World Head & Neck Cancer Day by hosting the 7th edition of the Oral Cancer Task Force (OCTF) Annual Conference on July 27–28, 2026, at the BITS Pilani, Goa Campus.</p>
<p>The two-day conference brought together leading oncologists, clinicians, public health experts, researchers, policymakers, artificial intelligence specialists and implementation partners to advance India’s roadmap towards oral cancer elimination. This year’s theme, ‘Integrating AI, Research, and Advocacy towards Oral Cancer Elimination,’ underscored the role of artificial intelligence, implementation research and multi-stakeholder collaboration in strengthening oral cancer prevention, early detection and access to timely care.</p>
<p>Kiran Mazumdar-Shaw, Founder & Managing Trustee, Biocon Foundation, and Convenor, OCTF, said, “India has a unique opportunity to redefine the global approach to oral cancer by harnessing the power of artificial intelligence, scientific innovation, and strong public health systems. Through the Oral Cancer Task Force, we are bringing together expertise across sectors to develop scalable, technology-enabled solutions that can drive early detection, improve access to timely treatment, and ultimately save lives. The goal is to ensure that these innovations reach far and wide, making quality cancer care more equitable and accessible.”</p>
<p>Oral Cancer Task Force Members, “Oral cancers are responsible for a humongous amount of mortality and morbidity in India.  Eliminating this scourge necessitates a comprehensive, pragmatic approach that integrates health and technology through tobacco control and cessation, AI-enabled screening and early detection, timely referral pathways, down staging of disease, and quality care across the continuum of care. It is heartening to know that AI-enabled oral cancer screening at the district level has been implemented. This initiative marks a significant step towards AI-assisted approach to improve oral cancer outcomes.”</p>
<p>Established in 2018 by Biocon Foundation, the Oral Cancer Task Force (OCTF) is an independent multidisciplinary platform bringing together clinicians, researchers, public health experts, policymakers and technology partners to reduce the burden of oral cancer through research, innovation, evidence generation, advocacy and policy engagement. Over the years, OCTF has contributed to the development of consensus guidelines for Oral Potentially Malignant Disorders (OPMDs) and Head & Neck Cancers, while advancing technology-enabled screening approaches across India.</p>
<p><strong>Advancing AI-enabled screening at scale</strong></p>
<p>A key highlight of the conference was the progress made under the Centre of Excellence for Artificial Intelligence (AI-CoE), a first-of-its-kind multicentric initiative involving 28 consortium partners with IISc serving as the nodal institution.</p>
<p>The initiative has developed an AI-assisted, mobile phone-based white-light imaging solution that stratifies oral lesions into high- and low-risk categories, enabling early identification of oral cancer. The technology powers Aarogya Aarohan, an AI-enabled mobile application currently deployed across Public Health Centres in Goa. Designed for use by frontline healthcare workers, the application can operate on low-cost smartphones, function offline in low-connectivity settings and support referral workflows across different levels of the healthcare system, making point-of-care screening more accessible and scalable.</p>
<p>Since 2014, Biocon Foundation has screened more than 100,000 individuals across multiple states through a community-based oral cancer screening programme. The Foundation contributed over 30,000 annotated oral lesion images that enabled the development of Aarogya Aarohan in collaboration with IISc and TANUH. The deployment of the application has contributed to a ten-fold increase in screening capacity over the past 18 months while helping identify community-specific intervention strategies.</p>
<p><strong>Driving an integrated strategy for oral cancer elimination</strong></p>
<p>The conference reaffirmed OCTF’s commitment to advancing oral cancer elimination through three strategic priorities:</p>
<ul>
<li aria-level="1">Tobacco cessation through education, awareness and school health programmes</li>
<li aria-level="1">Screening and early detection</li>
<li aria-level="1">Timely diagnosis and initiation of treatment</li>
</ul>
<p>Supported by collaborations across public health, clinical research, artificial intelligence and policy, these efforts aim to build a scalable, evidence-based framework for oral cancer control in India.</p>
<p>The conference featured keynote addresses, expert talks, panel discussions, stakeholder consultations and strategic planning sessions covering AI-assisted screening, integration of AI into clinical workflows, digital innovations for community-based screening, tobacco cessation and improving timely access to treatment. Drawing inspiration from global efforts towards cervical cancer elimination, the deliberations will inform the development of a robust and scalable oral cancer elimination strategy that can be adapted across geographies and health systems.</p>
<p><strong>Consensus guidelines updated</strong></p>
<p>The conference also unveiled the 2026 update to the Indian Clinical Practice Consensus Guidelines for Head & Neck Cancer, developed under the aegis of OCTF. Presented by Dr Kumar Prabhash, the updated guidelines reflect the latest clinical evidence and continue OCTF’s efforts to standardise evidence-based management of head and neck cancers across India. The initiative is coordinated by Dr Neera Gupta, Vice President – Clinical Development & Medical Affairs, Immuneel Therapeutics, and the updated guidelines will continue to be published in the Journal of Cancer Research and Statistics and Treatment.</p>
<p>The conference brought together experts from Tata Memorial Hospital, IISc, the Government of Goa, Biocon Foundation and leading academic, clinical and public health institutions from India and abroad. Keynote speakers and panellists included Dr Srinath Reddy, Dr Shekhar Salkar, Dr Guruprasad Naik, Dr Upendra Bhojani, Dr Sumirtha Gandhi, representatives from the Department of Health Services, Government of Goa, Prof Paturu Kondaiah, Dr Anupama Shetty, Dr Manisha Khorate, Dr Anupama Borkar, Prof Kunal Korgaonkar, Dr Praveen Birur and several other national and international experts.</p>
<p>The conference concluded with a renewed commitment from clinicians, researchers, policymakers and technology partners to accelerate the adoption of AI-enabled, evidence-based approaches for oral cancer prevention, early detection and treatment, strengthening India’s journey towards eliminating oral cancer as a major public health challenge.</p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/biocon-foundation-and-iisc-convene-national-experts-to-shape-indias-oral-cancer-elimination-strategy/">Biocon Foundation and IISc convene national experts to shape India’s oral cancer elimination strategy</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Why clinical governance and doctor&#45;led protocols are becoming increasingly important in aesthetic medicine</title>
<link>https://edusehat.com/en/why-clinical-governance-and-doctor-led-protocols-are-becoming-increasingly-important-in-aesthetic-medicine</link>
<guid>https://edusehat.com/en/why-clinical-governance-and-doctor-led-protocols-are-becoming-increasingly-important-in-aesthetic-medicine</guid>
<description><![CDATA[ 
Aesthetic medicine is no longer a boutique corner of healthcare. The International Society of Aesthetic Plastic Surgery counted close to 38 million surgical and non-surgical aesthetic procedures worldwide, a rise […]
The post Why clinical governance and doctor-led protocols are becoming increasingly important in aesthetic medicine appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/07/30165940/Dr-Priyanka-Sharma-Co-founder-Director-and-Chief-Dermatologist-V6-Clinics.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 30 Jul 2026 19:10:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Why, clinical, governance, and, doctor-led, protocols, are, becoming, increasingly, important, aesthetic, medicine</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/07/30165940/Dr-Priyanka-Sharma-Co-founder-Director-and-Chief-Dermatologist-V6-Clinics.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/07/30165940/Dr-Priyanka-Sharma-Co-founder-Director-and-Chief-Dermatologist-V6-Clinics.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/07/30165940/Dr-Priyanka-Sharma-Co-founder-Director-and-Chief-Dermatologist-V6-Clinics-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p align="LEFT"><span><span><span>Aesthetic medicine is no longer a boutique corner of healthcare. The </span></span></span><span><span><span>International Society of Aesthetic Plastic Surgery</span></span></span><span><span><span> counted close to 38 million surgical and non-surgical aesthetic procedures worldwide, a rise of 42.5 per cent over four years. That is a volume curve most therapeutic specialities would envy. It is also a stress test. When a discipline scales this quickly, the question that decides its future is not how many procedures it can deliver but how safely, consistently and accountably it can deliver them. Growth has arrived. Governance must now catch up.</span></span></span></p>
<p align="LEFT"><span><span><span>The pattern will be familiar to anyone who has watched other sectors industrialise. Demand outruns regulation, capital outruns capability, and operators of wildly uneven quality fill the gap. Injectables administered in salons. Energy devices run without medical oversight. Every such shortcut erodes the one asset on which the entire category depends, which is public trust. How the speciality responds to that erosion will determine whether aesthetic medicine matures into a credible branch of clinical practice or stalls as a consumer fad with a safety problem attached.</span></span></span></p>
<p align="LEFT"><a name="Bookmark"></a><span><span><span><b>The trust deficit that follows fast growth</b></span></span></span></p>
<p align="LEFT"><span><span><span>Trust is the real currency here. A patient choosing a filler, a peel or a laser protocol cannot independently audit the pharmacology or the physics involved. They are buying judgement, and judgement is precisely what clinical governance exists to institutionalise. Governance in this context means defined lines of medical accountability, documented protocols for patient selection and informed consent, adverse event reporting that actually gets reported, regular audit cycles, and credentialing that separates a trained dermatologist or plastic surgeon from an enthusiastic technician with a device. None of this work is glamorous. All of this is what separates medicine from retail.</span></span></span></p>
<p align="LEFT"><span><span><span>Doctor-led protocols are at the centre of that architecture. A protocol written and owned by a qualified physician does three things a marketing-led playbook never will. It screens out patients who should not be treated, arguably the most underrated safety intervention in aesthetics. It standardises technique so that outcomes are reproducible across practitioners and locations rather than dependent on one gifted pair of hands. And it closes the feedback loop, because physicians who own protocols also own complications, and ownership is what drives iteration and improvement. Evidence-based practice, in other words, is not a slogan but an operating system. Nowhere are the stakes of getting that operating system right higher than in the markets growing fastest, and India now sits squarely in that category.</span></span></span></p>
<p align="LEFT"><a name="Bookmark1"></a><span><span><span><b>India’s opportunity arrives with an obligation attached</b></span></span></span></p>
<p align="LEFT"><span><span><span>The national context sharpens the argument considerably. Government data released through the </span></span></span><span><span><span>Press Information Bureau </span></span></span><span><span><span>places India’s medical value travel market at roughly USD 8.7 billion in 2025, projected to reach USD 16.2 billion by 2030, and records 507,244 international patients arriving specifically for medical treatment in 2025. Aesthetic, dermatological and wellness services form a growing slice of that inflow, alongside the far larger domestic market being created by rising incomes, urbanisation and the normalisation of aesthetic care among both women and men.</span></span></span></p>
<p align="LEFT"><span><span><span>India’s pitch to the world rests on a simple proposition, globally benchmarked clinical standards delivered at a competitive cost. That proposition collapses the moment standards become negotiable. Accreditation frameworks such as NABH, rigorous physician credentialing and transparent outcome reporting are not bureaucratic overhead in this reading. They function as the export licence for an entire sector and as the domestic patient’s first line of defence. What the state signals through policy, capital has begun to price.</span></span></span></p>
<p align="LEFT"><a name="Bookmark2"></a><span><span><span><b>What investors are actually underwriting</b></span></span></span></p>
<p align="LEFT"><span><span><span>The investor lens makes the same point in blunter language. Organised aesthetic dermatology in India is consolidating, with clinic chains raising institutional capital and pursuing multi-city expansion, often through partner-led and franchise-style models. Anyone who has sat through diligence on a healthcare asset knows where the sharp questions land. Who owns the medical protocols? What is the verified complication rate? Does quality survive when the founding dermatologist is in one city while the twentieth clinic opens in another? Clinical governance is the answer to every one of those questions, which is why it has quietly shifted from compliance cost to valuation driver.</span></span></span></p>
<p align="LEFT"><span><span><span>A chain that can demonstrate physician-owned protocols, structured training pathways, technology-enabled record-keeping and audited outcomes is effectively buying itself a lower cost of capital and a durable licence to scale. A chain that cannot demonstrate these protocols is one viral complication away from reputational impairment that no marketing budget can repair. Outcome-based care, long the language of hospital medicine, is becoming the language of aesthetic medicine’s terms. sheets as well. And the same logic that reassures an investment committee is, in the end, what protects the individual sitting in the consultation chair.</span></span></span></p>
<p align="LEFT"><span><span><span>Because that is where the argument terminates, with the patient. Aesthetic medicine is unusual in that its consumers are largely healthy people accepting clinical risk in pursuit of quality-of-life gain. That inverts the normal risk calculus of medicine and raises, rather than lowers, the ethical bar. The most credible emerging model treats the patient as a whole system rather than a procedure site. Skin, hair, nutrition, hormonal balance and lifestyle are assessed together. Artificial intelligence and imaging support the physician’s judgement without ever replacing it. Success is measured in outcomes sustained over years, not transactions completed per day. Practices built this way have grasped something the wider category is still learning: that genuine transformation is never only about appearance but about confidence, wellbeing and care that understands the person behind the presenting concern.</span></span></span></p>
<p align="LEFT"><span><span><span>The direction of travel is clear. Regulators are moving, investors are discriminating, and patients are becoming far more sophisticated buyers of medical judgement. The clinics and chains that dominate the next decade will be those that treated clinical governance as a founding principle rather than a retrofit and doctor-led protocols as the product itself rather than the fine print. In aesthetic medicine, as everywhere else in healthcare, the physician-led model is not a constraint on growth. It is the only version of growth worth financing.</span></span></span></p>
<p align="LEFT">
</p><p>The post <a href="https://www.expresspharma.in/why-clinical-governance-and-doctor-led-protocols-are-becoming-increasingly-important-in-aesthetic-medicine/">Why clinical governance and doctor-led protocols are becoming increasingly important in aesthetic medicine</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>RPG Life Sciences announces strategic API initiative to accelerate next phase of growth</title>
<link>https://edusehat.com/en/rpg-life-sciences-announces-strategic-api-initiative-to-accelerate-next-phase-of-growth</link>
<guid>https://edusehat.com/en/rpg-life-sciences-announces-strategic-api-initiative-to-accelerate-next-phase-of-growth</guid>
<description><![CDATA[ 
RPG Life Sciences announced the execution of a Business Transfer Agreement for the transfer of the Company’s Active Pharmaceutical Ingredients (API) business to RPG Active Pharma Limited (“RPG Active Pharma” […]
The post RPG Life Sciences announces strategic API initiative to accelerate next phase of growth appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2020/02/14150622/API.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 30 Jul 2026 19:10:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>RPG, Life, Sciences, announces, strategic, API, initiative, accelerate, next, phase, growth</media:keywords>
<content:encoded><![CDATA[<div><img width="888" height="394" src="https://cdn.expresspharma.in/wp-content/uploads/2020/02/14150622/API.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2020/02/14150622/API.jpg 888w, https://cdn.expresspharma.in/wp-content/uploads/2020/02/14150622/API-300x133.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2020/02/14150622/API-768x341.jpg 768w" sizes="auto, (max-width: 888px) 100vw, 888px"></div><p>RPG Life Sciences announced the execution of a Business Transfer Agreement for the transfer of the Company’s Active Pharmaceutical Ingredients (API) business to RPG Active Pharma Limited (“RPG Active Pharma” or “RPGAP”), a wholly owned subsidiary of RPG Life Sciences, as a going concern on a slump sale basis.</p>
<p>The proposed transfer is part of RPG Life Sciences’ strategy to create a focused API business with dedicated capital, sharper management attention and greater strategic flexibility, while the Company also continues to build its formulations business.</p>
<p>This business has been created at a time when the global pharmaceutical supply chains are undergoing structural realignment and India is increasingly emerging as a preferred destination for reliable, high-quality API manufacturing.</p>
<p>The Company has entered into an investment agreement to forge a strategic partnership with Inv Ascent, a healthcare-focused private equity investor, through an investment in RPG Active Pharma. The partnership brings together RPG Life Sciences’ pharmaceutical experience, manufacturing capabilities and execution track record with lnvAscent’s 20-years’ experience of investing in and scaling pharma businesses. Accordingly, funds managed by lnvAscent will make an initial investment of an<br>
amount upto Rs. 243 er. in RPG Active Pharma.</p>
<p>The agreement envisages investments by the Company and lnvAscent upto Rs. 700 er. in RPGAP in tranches. The investment is expected to provide RPG Active Pharma with the capital and strategic support required to strengthen manufacturing infrastructure, expand the product portfolio, enhance process development capabilities and pursue organic and inorganic growth opportunities.</p>
<p>In addition, the RPG Active Pharma has also executed a Share Purchase Agreement for acquisition of 100% equity share capital of Actis Generics Private Limited – an API manufacturing company based in Visakha patnam. The proposed acquisition is expected to expand RPG Active Pharma’s manufacturing base, broaden its operating platform and support its strategic growth objectives.</p>
<p>The investment by India Life Sciences Fund – a life sciences focused fund – and the proposed acquisition of Actis Generics are intended to establish RPG Active Pharma as a focused API manufacturer for the next phase of RPG Life Sciences’ API growth. RPG AP will focus on augmenting its manufacturing capabilities, expanding its API portfolio and serving customers across domestic and international markets with a strong emphasis on quality, reliability and long-term partnerships. The transactions are subject to customary regulatory approvals and pre-closing conditions.</p>
<p>Commenting on the development, Ashok Nair, Managing Director, RPG Life Sciences, said: “Building a meaningful and scalable presence in AP/s has been a strategic priority for RPG Life Sciences. RPG Active Pharma gives us a focused business to pursue this opportunity with greater speed, discipline and scale. We are pleased to partner with lnvAscent, whose pharma investing experience and long-term partnership approach complements our vision for the business. The proposed acquisition of Actis Generics further strengthens this business and supports our ambition to build a high-quality AP/ business with expanded manufacturing capabilities, a broader product portfolio and the ability to create sustainable value for all stakeholders.”</p>
<p>Commenting on the partnership, Dr Jeevak Gupta, Managing Director, lnvascent, said: “We are excited to partner with RPG Life Sciences in building RPG Active Pharma into a differentiated AP/ business. RPG Life Sciences has established pharmaceutical capabilities, a strong operating foundation and a clear ambition to scale its AP/ business. We believe RPG AP is well positioned to benefit from the long-term growth opportunity in high-quality AP/ manufacturing, and we look forward to supporting the business through capital, strategic guidance and our healthcare sector experience.”</p>
<p>Khaitan & Co. acted as the legal counsel and structuring advisor to RPG group for the investment transaction. o3 Capital acted as an exclusive financial advisor, Quillan Partners acted as legal counsel and Deloitte undertook financial due diligence on the acquisition of Actis by RPG Active Pharma.</p>
<p>The post <a href="https://www.expresspharma.in/rpg-life-sciences-announces-strategic-api-initiative-to-accelerate-next-phase-of-growth/">RPG Life Sciences announces strategic API initiative to accelerate next phase of growth</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>MRG Group announces strategic collaboration with Arica Pharmaceutical</title>
<link>https://edusehat.com/en/mrg-group-announces-strategic-collaboration-with-arica-pharmaceutical</link>
<guid>https://edusehat.com/en/mrg-group-announces-strategic-collaboration-with-arica-pharmaceutical</guid>
<description><![CDATA[ 
MRG Group, a diversified business conglomerate, has announced its strategic collaboration with Arica Pharmaceutical, reinforcing its commitment to supporting India’s rapidly growing healthcare sector while fostering innovation, quality, and community […]
The post MRG Group announces strategic collaboration with Arica Pharmaceutical appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2019/11/20125258/Partnership.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 30 Jul 2026 19:10:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>MRG, Group, announces, strategic, collaboration, with, Arica, Pharmaceutical</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="362" src="https://cdn.expresspharma.in/wp-content/uploads/2019/11/20125258/Partnership.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2019/11/20125258/Partnership.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2019/11/20125258/Partnership-300x145.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p><span>MRG Group, a diversified business conglomerate, has announced its strategic collaboration with Arica Pharmaceutical, reinforcing its commitment to supporting India’s rapidly growing healthcare sector while fostering innovation, quality, and community well-being.</span></p>
<p><b></b><span>The partnership brings together MRG Group’s vision for diversified growth and Arica Pharmaceutical’s expertise in delivering quality healthcare solutions. Established in 2023, Arica Pharmaceutical has built its presence in the pharmaceutical industry with a focus on anti-diabetic, neurosciences, and cardiovascular therapies and is now gearing up to expand into multiple therapeutic categories as part of its long-term growth strategy.</span></p>
<p><span>The collaboration is expected to create opportunities for innovation, business expansion, and initiatives aimed at improving healthcare accessibility while strengthening the pharmaceutical ecosystem in India.</span></p>
<p><span>Speaking on the occasion, </span>Rajjath Goel, Managing Director, MRG Group<span>, said, “</span><span>At MRG Group, we believe meaningful growth is driven by partnerships that create lasting value for society. Our collaboration with Arica Pharmaceutical reflects our commitment to supporting sectors that have a direct impact on people’s lives. We look forward to working together to drive innovation, encourage responsible growth, and contribute towards building a healthier future for India</span><span>.”</span></p>
<p><span>The leadership of Arica Pharmaceutical expressed confidence that the collaboration with MRG Group will further strengthen the company’s expansion plans and accelerate its vision of becoming a trusted healthcare partner through quality products, innovation, and patient-centric solutions.</span></p>
<p><span>The partnership reflects the shared vision of both organizations to promote healthier lifestyles, strengthen communities, and contribute to India’s evolving healthcare landscape.</span></p>
<p><span>As India’s pharmaceutical sector continues to witness robust growth, the collaboration between MRG Group and Arica Pharmaceutical is expected to lay the foundation for future strategic initiatives focused on healthcare innovation, expansion, and sustainable value creation.</span></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/mrg-group-announces-strategic-collaboration-with-arica-pharmaceutical/">MRG Group announces strategic collaboration with Arica Pharmaceutical</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>European Commission authorizes Pfizer and BioNTech XFG&#45;adapted COVID&#45;19 vaccine in the European Union</title>
<link>https://edusehat.com/en/european-commission-authorizes-pfizer-and-biontech-xfg-adapted-covid-19-vaccine-in-the-european-union</link>
<guid>https://edusehat.com/en/european-commission-authorizes-pfizer-and-biontech-xfg-adapted-covid-19-vaccine-in-the-european-union</guid>
<description><![CDATA[ 
Pfizer and BioNTech SE announced that the European Commission (EC) has granted marketing authorization for the companies’ 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, for active immunization to prevent […]
The post European Commission authorizes Pfizer and BioNTech XFG-adapted COVID-19 vaccine in the European Union appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/08/10105104/vaccine-covid-19.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 30 Jul 2026 15:35:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>European, Commission, authorizes, Pfizer, and, BioNTech, XFG-adapted, COVID-19, vaccine, the, European, Union</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/08/10105104/vaccine-covid-19.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/08/10105104/vaccine-covid-19.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/08/10105104/vaccine-covid-19-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Pfizer and BioNTech SE announced that the European Commission (EC) has granted marketing authorization for the companies’ 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The adaptation is based on the recommendation from the Emergency Task Force (ETF) of the European Medicines Agency (EMA) to update COVID-19 vaccines to target the XFG variant of the JN.1 lineage for the 2026-2027 season. The ETF stated that “the evidence suggests that targeting XFG would provide the best protection against COVID-19.”</span></p>
<p><span>The marketing authorization is valid in all 27 European Union (“EU”) Member States, as well as Iceland, Liechtenstein and Norway. Pfizer and BioNTech have already initiated manufacturing of the monovalent XFG-adapted COVID-19 vaccine at risk to ensure supply readiness in anticipation of the respiratory disease season, when the demand for COVID-19 vaccination is expected to increase. EU Member States as well as Norway, will be supplied either via the EC contract or according to individual country government policies.</span></p>
<p><span>The EC approval follows the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommendation from July 23, 2026 based on the cumulative body of evidence previously submitted by Pfizer and BioNTech that includes clinical, non-clinical and real-world data supporting the safety and efficacy of the Pfizer and BioNTech COVID-19 vaccine as well as manufacturing/quality and non-clinical data showing that the monovalent XFG-adapted COVID-19 vaccine generated strong immune responses against currently circulating SARS-CoV-2 lineages, including XFG, XFG.1.1, NB.1.8.1, PQ.17, PQ.2.8.1 and other contemporary lineages.2</span></p>
<p><span>The companies have also submitted data for the updated COVID-19 vaccine to regulatory authorities around the world. The companies are continuing to monitor the evolving epidemiology of COVID-19 in preparation to meet global public health needs.</span></p>
<p><span>The COVID-19 vaccines by Pfizer and BioNTech are based on BioNTech’s proprietary mRNA technology and were developed by both companies. BioNTech is the Marketing Authorization Holder for the Pfizer-BioNTech COVID-19 vaccine and its adapted vaccines in the United States, the EU, the United Kingdom, and other countries, and the holder of emergency use authorizations or equivalents in other countries.</span></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/european-commission-authorizes-pfizer-and-biontech-xfg-adapted-covid-19-vaccine-in-the-european-union/">European Commission authorizes Pfizer and BioNTech XFG-adapted COVID-19 vaccine in the European Union</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Sun Pharma receives approval to manufacture and market semaglutide in Brazil</title>
<link>https://edusehat.com/en/sun-pharma-receives-approval-to-manufacture-and-market-semaglutide-in-brazil</link>
<guid>https://edusehat.com/en/sun-pharma-receives-approval-to-manufacture-and-market-semaglutide-in-brazil</guid>
<description><![CDATA[ 
Sun Pharmaceutical Industries announced that it has received approval from the Brazilian Health Regulatory Agency, ANVISA to manufacture and market semaglutide injection in Brazil for the treatment of adults with […]
The post Sun Pharma receives approval to manufacture and market semaglutide in Brazil appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2021/11/18123517/injection-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 30 Jul 2026 15:35:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Sun, Pharma, receives, approval, manufacture, and, market, semaglutide, Brazil</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2021/11/18123517/injection-1.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2021/11/18123517/injection-1.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2021/11/18123517/injection-1-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span>Sun Pharmaceutical Industries announced that it has received approval from the Brazilian Health Regulatory Agency, ANVISA to manufacture and market semaglutide injection in Brazil for the treatment of adults with inadequately controlled type 2 diabetes mellitus as an adjunct to diet and exercise.</span></p>
<p><span>Sun Pharma plans to launch the product in the next few days in partnership with Hypera Pharma, a leading pharmaceutical company in Brazil. It will be available as a pre‑filled, multi‑dose injectable pen in two strengths (2 mg/1.5 mL and 4 mg/3 mL) allowing flexible, once‑weekly dosing.</span></p>
<p><span>“The approval of semaglutide in Brazil expands access to an evidence-based treatment option for people living with inadequately controlled type 2 diabetes. It reflects the strength of our development and manufacturing capabilities and our commitment to delivering high-quality medicines across global markets,” said Aalok Shanghvi, Chief Operating Officer, Sun Pharma.</span></p>
<p><span>Digvijay Singh, Regional Head, Brazil & LATAM, said, “This approval marks an important step in strengthening our diabetes portfolio in Brazil. We look forward to working closely with our partner to make this treatment option available to patients and support better diabetes care across the country.”</span></p>
<p><span>The semaglutide injectable market in Brazil is approximately USD 413 million (IQVIA, MAT June 2026).</span></p>
<p><span> </span></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/sun-pharma-receives-approval-to-manufacture-and-market-semaglutide-in-brazil/">Sun Pharma receives approval to manufacture and market semaglutide in Brazil</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>CureMeAbroad signs MoUs with Asia Cosmetics and Dr. Brenda’s Clinic</title>
<link>https://edusehat.com/en/curemeabroad-signs-mous-with-asia-cosmetics-and-dr-brendas-clinic</link>
<guid>https://edusehat.com/en/curemeabroad-signs-mous-with-asia-cosmetics-and-dr-brendas-clinic</guid>
<description><![CDATA[ 
CureMeAbroad, a medical tourism discovery and concierge platform operated by Luxora Health Care Experiences, has signed Memoranda of Understanding (MoUs) with Asia Cosmetics in Thailand and Dr. Brenda’s Clinic in […]
The post CureMeAbroad signs MoUs with Asia Cosmetics and Dr. Brenda’s Clinic appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2026/07/30112206/MoU.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 30 Jul 2026 15:35:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>CureMeAbroad, signs, MoUs, with, Asia, Cosmetics, and, Dr., Brenda’s, Clinic</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2026/07/30112206/MoU.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://cdn.expresspharma.in/wp-content/uploads/2026/07/30112206/MoU.jpg 750w, https://cdn.expresspharma.in/wp-content/uploads/2026/07/30112206/MoU-300x160.jpg 300w" sizes="auto, (max-width: 750px) 100vw, 750px"></div><p><span><span><span>CureMeAbroad, a medical tourism discovery and concierge platform operated by Luxora Health Care Experiences, has signed Memoranda of Understanding (MoUs) with Asia Cosmetics in Thailand and Dr. Brenda’s Clinic in Mexico to expand its network of international healthcare providers.</span></span></span></p>
<p><span><span><span>According to the company, the partnerships are intended to facilitate access to cosmetic and aesthetic treatments for patients from the United States, the United Kingdom, Germany, Australia and GCC countries. The collaborations also establish a framework for patient referrals, care coordination, quality standards and post-treatment support.</span></span></span></p>
<p><span><span><span>Commenting on the development, Aditya Oza, CEO and Co-Founder, CureMeAbroad, said, “Patients travelling abroad for cosmetic procedures are making one of the biggest healthcare decisions of their lives, yet many still rely on social media or unverified online recommendations. Our partnerships with Asia Cosmetics and Dr. Brenda’s Clinic give patients access to trusted providers backed by structured care coordination, while enabling our partners to receive a consistent pipeline of well-informed international patients. This is how medical tourism should operate with accountability on both sides.”</span></span></span></p>
<p><span><span><span>Thailand has long been a destination for medical tourism, supported by internationally trained specialists and comparatively lower treatment costs. Mexico has also emerged as a destination for patients, particularly from the United States, seeking cosmetic procedures such as liposuction, rhinoplasty and body contouring due to its proximity and cost advantages.</span></span></span></p>
<p><span><span><span>Dr Jeab, Head, Asia Cosmetics, Thailand, said, “Thailand has become one of the world’s preferred destinations for cosmetic and aesthetic treatments because patients value both quality and trust. Through our partnership with CureMeAbroad, we look forward to welcoming more international patients with a seamless treatment experience backed by transparent communication, personalized care, and internationally accepted clinical standards. Together, we aim to make cross-border healthcare more accessible and reassuring for patients worldwide.”</span></span></span></p>
<p><span><span><span>Under the agreements, CureMeAbroad will coordinate patient services including teleconsultations, treatment planning, travel arrangements, hospital coordination and post-treatment follow-up.</span></span></span></p>
<p><span><span><span>Mikhail Bohra, Co-Founder and CMO, CureMeAbroad, said, “Cosmetic and aesthetic procedures continue to be among the highest enquiry categories on our platform, particularly from patients in the US and Auz. People today are looking for trusted providers as much as affordable treatment. These partnerships allow us to offer verified options in two of the world’s most sought-after cosmetic tourism destinations.”</span></span></span></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/curemeabroad-signs-mous-with-asia-cosmetics-and-dr-brendas-clinic/">CureMeAbroad signs MoUs with Asia Cosmetics and Dr. Brenda’s Clinic</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>ChrysCapital completes acquisition of an Indian subsidiary of a global pharma company</title>
<link>https://edusehat.com/en/chryscapital-completes-acquisition-of-an-indian-subsidiary-of-a-global-pharma-company</link>
<guid>https://edusehat.com/en/chryscapital-completes-acquisition-of-an-indian-subsidiary-of-a-global-pharma-company</guid>
<description><![CDATA[ 
ChrysCapital, one of the biggest private equity firms investing in India, acquired a controlling 70.68% stake in Novartis India Limited (NIL). The transaction marks a defining moment for ChrysCapital and […]
The post ChrysCapital completes acquisition of an Indian subsidiary of a global pharma company appeared first on Express Pharma. ]]></description>
<enclosure url="https://cdn.expresspharma.in/wp-content/uploads/2019/12/04112329/Acquisition.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 30 Jul 2026 15:35:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>ChrysCapital, completes, acquisition, Indian, subsidiary, global, pharma, company</media:keywords>
<content:encoded><![CDATA[<div><img width="888" height="400" src="https://cdn.expresspharma.in/wp-content/uploads/2019/12/04112329/Acquisition.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresspharma.in/wp-content/uploads/2019/12/04112329/Acquisition.jpg 888w, https://cdn.expresspharma.in/wp-content/uploads/2019/12/04112329/Acquisition-300x135.jpg 300w, https://cdn.expresspharma.in/wp-content/uploads/2019/12/04112329/Acquisition-768x346.jpg 768w" sizes="(max-width: 888px) 100vw, 888px"></div><p><span>ChrysCapital, one of the biggest private equity firms investing in India, acquired a controlling 70.68% stake in Novartis India Limited (NIL). The transaction marks a defining moment for ChrysCapital and for the Indian pharmaceutical sector bringing one of India’s longstanding pharmaceutical businesses under dedicated private equity ownership, with the ambition to build a leading branded-generics platform for the Indian market.</span></p>
<p><span>NIL has a legacy spanning several decades and a portfolio of brands that are trusted both by healthcare professionals and patients. NIL operates across key therapeutic areas including pain management, calcium supplementation, gynecology, neurosciences, and transplant immunology through brands such as Voveran, Calcium Sandoz, Tegrital etc. Built on a strong foundation of scientific excellence, physician trust, and nationwide reach, NIL has played a meaningful role in improving healthcare outcomes for millions of patients across the country.</span></p>
<p><span>The acquisition marks ChrysCapital’s first majority-controlled investment in the Indian pharmaceutical sector and reflects the firm’s strong conviction in the long-term growth potential of India’s branded pharmaceuticals market. Building on a proven healthcare investment track record, ChrysCapital aims to leverage its sector expertise and extensive network to support the next phase of growth for NIL and strengthen its position as a leading pharmaceutical business. NIL will adopt a new name and corporate identity to celebrate the company’s separation from its previous owners and the beginning of a new era.</span></p>
<p><span>To support the company’s next phase of growth, NIL has appointed Dr. Vikas Gupta as the CEO and Managing Director. Further, Ramesh Ramadurai, Suchita Sharma and Shashank Sinha have joined as Independent Directors on the Board of NIL.</span></p>
<p><span>“A strong management team is central to any successful organization, and NIL is fortunate to have Dr. Vikas Gupta at the helm – someone who brings both the experience and the vision this business needs. Combined with NIL’s legacy brands and market standing, ChrysCapital believes the foundation for long-term value creation is firmly in place.” – Kshitij Sheth, Managing Director, ChrysCapital Advisors.</span></p>
<p><span>Dr. Vikas Gupta, Chief Executive Officer and Managing Director, NIL, said: “NIL has earned its place in Indian healthcare over many decades. Today we begin a new and exciting chapter in NIL’s history. We carry forward decades of scientific rigour and physician trust – from that strong foundation and with ChrysCapital’s backing we have the resources and focus to grow our portfolio with purpose, reach more patients, and build on what this organization has always stood for.”</span></p>
<p><span>For this transaction, Kotak acted as the exclusive financial advisor to Novartis AG. Freshfields, AZB & Partners advised Novartis AG as legal counsels and Ernst & Young advised Novartis AG on the financial and tax diligence. Shardul Amarchand Mangaldas & Co acted as the legal counsel and Alvarez & Marsal, Dhruva Advisors and Price Waterhouse & Co. were the financial and tax advisors for ChrysCapital.</span></p>
<p><span> </span></p>
<p> </p>
<p>The post <a href="https://www.expresspharma.in/chryscapital-completes-acquisition-of-an-indian-subsidiary-of-a-global-pharma-company/">ChrysCapital completes acquisition of an Indian subsidiary of a global pharma company</a> appeared first on <a href="https://www.expresspharma.in/">Express Pharma</a>.</p>]]> </content:encoded>
</item>

<item>
<title>FDA grants fast track designation for HAYA Therapeutics’ HTX&#45;001</title>
<link>https://edusehat.com/en/fda-grants-fast-track-designation-for-haya-therapeutics-htx-001</link>
<guid>https://edusehat.com/en/fda-grants-fast-track-designation-for-haya-therapeutics-htx-001</guid>
<description><![CDATA[ Targeting long non-coding ribonucleic acid (lncRNA), HTX-001 is being evaluated in a Phase Ia/b clinical trial. The first cohort in this trial was dosed in May. This antisense 
The post FDA grants fast track designation for HAYA Therapeutics’ HTX-001 appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/07/PT-2-29-07-2026-shutterstock_2627023655.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 29 Jul 2026 18:00:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>FDA, grants, fast, track, designation, for, HAYA, Therapeutics’, HTX-001</media:keywords>
<content:encoded><![CDATA[<p>Targeting long non-coding ribonucleic acid (lncRNA), HTX-001 is being evaluated in a Phase Ia/b clinical trial. The first cohort in this trial was dosed in May.</p>
<p>This antisense oligonucleotide has been developed to suppress WISPER, a heart stress-specific lncRNA that is overexpressed in hypertrophic cardiomyopathy, including nHCM.</p>
<p>By targeting this lncRNA in cardiac myofibroblasts, the therapy is intended to facilitate the precise reprogramming of these fibrotic and pathological cell states.</p>
<p>HAYA Therapeutics CEO and co-founder Samir Ounzain said: “HAYA was founded on the belief that the regulatory genome offers a new way to address the underlying biology of disease. This regulatory designation recognises the potential of HTX-001 to offer a differentiated therapeutic approach for patients with nHCM.”</p>
<p>HAYA Therapeutics chief medical officer Jordan Shin said: “Patients with non-obstructive HCM are seeking treatments that go beyond management of symptoms. This designation reflects the urgency of delivering better therapeutic options.</p>
<p>“With our Phase I clinical trial already underway, fast track designation allows us to work more closely with the FDA as we advance HTX-001, our investigational precision RNA-guided therapy designed to reprogramme disease-driving cardiac fibroblasts—the sentinel effector cells that act to drive fibrosis and remodelling in the myocardium.”</p>
<p>The designation seeks to expedite the development and review of drugs intended for serious conditions where there is an unmet medical need.</p>
<p>It may result in more frequent interactions with the FDA and eligibility for various expedited review processes.</p>
<p>HTX-001 has not received approval from the FDA, European Medicines Agency (EMA), or any other regulatory authority. Its safety and potential to provide clinical benefit are yet to be determined.</p>
<p>In May 2025, Haya Therapeutics procured $65m in Series A funding to expedite the clinical development of HTX-001 for treating heart failure.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/fda-fast-track-designation-haya-htx-001/">FDA grants fast track designation for HAYA Therapeutics’ HTX-001</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Eisai and CORE Biomedicine agree on global licence for oncology pipeline</title>
<link>https://edusehat.com/en/eisai-and-core-biomedicine-agree-on-global-licence-for-oncology-pipeline</link>
<guid>https://edusehat.com/en/eisai-and-core-biomedicine-agree-on-global-licence-for-oncology-pipeline</guid>
<description><![CDATA[ The deal grants CORE Biomedicine rights to develop and commercialise a portfolio of cancer therapies originally discovered by Eisai and its affiliates. The licensed assets focus on targeting 
The post Eisai and CORE Biomedicine agree on global licence for oncology pipeline appeared first on Pharmaceutical Business review. ]]></description>
<enclosure url="https://www.pharmaceutical-business-review.com/wp-content/uploads/2026/07/PT-29-07-2026-shutterstock_2664976159.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 29 Jul 2026 18:00:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Eisai, and, CORE, Biomedicine, agree, global, licence, for, oncology, pipeline</media:keywords>
<content:encoded><![CDATA[<p>The deal grants CORE Biomedicine rights to develop and commercialise a portfolio of cancer therapies originally discovered by Eisai and its affiliates.</p>
<p>The licensed assets focus on targeting key molecular drivers implicated in a range of cancers. The portfolio includes multiple programmes covering different targets and biological pathways.</p>
<p>CORE Biomedicine plans to use these assets to support its precision medicine strategy and aims to develop therapies for a broader set of cancer patients.</p>
<p>The company uses a lineage-based approach intended to identify and target oncology drivers beyond genomics, seeking to enable the discovery of therapies for wider patient populations.</p>
<p>CORE Biomedicine co-founder and business development head Dr Douglas McMillin said: “CORE was created to advance an exceptional portfolio of oncology programmes grounded in deep cancer biology, precision medicine and lineage therapeutics.</p>
<p>“We believe these programmes have tremendous potential to address significant unmet medical needs across multiple cancers, and we are committed to advancing them efficiently toward the clinic and ultimately to patients.”</p>
<p>In a separate development, CORE Biomedicine completed a $21m Series A funding round co-led by Elikon Venture and UTokyo Innovation Platform, with involvement from CD Capital, InnoPinnacle Fund, Mitsubishi UFJ Capital, Root Venture Partners, Suzhou Capital Group, Vision Incubate, and YuanBio Venture Capital.</p>
<p>These funds are intended to support the advancement of the company’s lead programmes from discovery to early clinical development.</p>
<p>Additionally, the company’s wholly owned subsidiary, CORE Biomedicine Japan, received a grant through the Strengthening Program for Pharmaceutical Startup Ecosystem, a scheme run by the Japan Agency for Medical Research and Development (AMED).</p>
<p>This initiative is aimed at accelerating research and development activities and fostering collaborations within Japan’s biopharmaceutical sector.</p>
<p>The post <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/news/eisai-core-biomedicine-oncology-pipeline/">Eisai and CORE Biomedicine agree on global licence for oncology pipeline</a> appeared first on <a rel="nofollow" href="https://www.pharmaceutical-business-review.com/">Pharmaceutical Business review</a>.</p>]]> </content:encoded>
</item>

</channel>
</rss>